

Access PPO  
Elect PPO  
Summit PPO  
Options Federal

## 2023 Preauthorization and notification requirements

The following services require notification or preauthorization. Services that require preauthorization will be denied if preauthorization is not obtained. The following list does not include services that will be reviewed post service for medical necessity upon receipt of the claim. Claims reviewed for medical necessity may result in a denial.

Please contact Kaiser Permanente Member Services to verify coverage, preauthorization requirements, or medical necessity review.

### Notification Required

- All inpatient admissions, including emergency admissions, planned admissions, mental health, and withdrawal management services<sup>+</sup>
- Home health care, including home infusion and home dialysis
- Hospice
- Long-term acute care admission
- Skilled nursing facility
- Substance abuse disorder residential admissions<sup>+</sup>

### Preauthorization Required – Durable Medical Equipment, Prostheses, and Supplies

- Bone growth stimulators, electrical and ultrasonic
- Electrical stimulation devices
- Home oxygen
- Mobility assist devices, including wheelchairs and other high-end mobility equipment
- Negative pressure wound therapy pumps
- Oscillatory chest compression devices
- Prosthetic limbs
- Speech-generating devices
- Tumor-treating fields therapy

### Preauthorization Required – Other Services

- Acupuncture, after 8 visits\*
- Advanced imaging, including CT scans and MRI
- Applied behavioral analysis therapy
- Capsule endoscopy
- Cardiac telemetry
- Charged particle radiation therapy
- Clinical trials
- Craniofacial dental
- Elective air transport
- Electroconvulsive therapy
- Experimental and investigational services, including new technology
- Genetic testing, including genetic panels  
Exception: Certain genetic testing does not require prior authorization in the prenatal setting
- Hyperbaric oxygen
- Inpatient rehabilitation
- Manipulative therapy, after 8 visits\*
- Monitored anesthesia care (MAC)
- Neuropsychological testing
- Partial hospitalization, including mental health and chemical dependency
- Platelet-rich plasma
- Repetitive transcranial magnetic stimulation (rTMS)
- Transgender services, when benefit is available
- Ventricular assist devices (VAD)
- Virtual colonoscopy

<sup>+</sup> Concurrent care review required.

\* Visit limits could be higher depending on plan.

## Preauthorization Required – Surgery

---

- Autologous chondrocyte implantation and other cell-based treatments of focal articular cartilage lesions
- Blepharoplasty and brow ptosis repair
- Chemical peels, dermabrasion, microdermabrasion, and laser skin treatment
- Cochlear implant
- Cryosurgical ablation of breast tumors and lesions
- Deep brain stimulation
- Extracranial carotid angioplasty/stenting
- Gastric electrical stimulation
- Gastric reflux surgery
- Image-guided minimally invasive lumbar decompression for spinal stenosis
- Implantable bone conduction and bone-anchored hearing aids
- Keratoprosthesis
- Meniscal allografts and collagen meniscus implants
- Obesity surgery, when benefit is available
- Occipital nerve stimulation
- Orthognathic surgery
- Panniculectomy
- Percutaneous neuromodulation therapy (PNT)
- Plugs for fistula repair
- Posterior tibial nerve stimulation for voiding dysfunction
- Radiofrequency ablation of tumors (RFA)
- Rhinoplasty
- Sacral nerve modulation/stimulation for pelvic floor dysfunction
- Spinal cord stimulation for treatment of pain
- Spinal decompression devices
- Spinal surgery, cervical fusion
- Spinal surgery, lumbar fusion
- Spinal surgery, percutaneous vertebroplasty and vertebral augmentation (such as kyphoplasty)
- Stereotactic radiosurgery and stereotactic body radiation therapy
- Surgeries for snoring, obstructive sleep apnea syndrome, and upper airway resistance syndrome in adults

- Temporomandibular joint (TMJ) surgical interventions
- Transanal endoscopic microsurgery (TEMs)
- Transcatheter aortic valve replacement (TAVR), MitraClip, and left atrial appendage closure
- Transplants
- Reconstructive breast surgery/mastopexy, autologous fat grafting to the breast, and management of breast implants
- Reduction mammoplasty
- Vagus nerve stimulation
- Varicose vein treatment

## Preauthorization Code Check Tool

---

Preauthorization Code Check tool available at [wa-provider.kaiserpermanente.org/home/pre-auth/search](https://wa-provider.kaiserpermanente.org/home/pre-auth/search).

## Preauthorization Required – Office-Administered Injectable Drugs

---

See current list at [kp.org/wa/provider](https://kp.org/wa/provider). Go to "Pharmacy," then "Pharmacy Overview," and click on "Injectable drugs requiring prior authorization."

## Clinical Review Criteria

---

Clinical Review Criteria available at [kp.org/wa/provider](https://kp.org/wa/provider) under "Authorization & Clinical Review."



### Provider questions?

Call Kaiser Permanente  
Provider Assistance Unit  
at **1-888-767-4670**.

### Member questions?

Call Member Services  
at **1-888-901-4636 (TTY 711)**.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### 4Kscore® Test: Predicting the Risk of Aggressive Prostate Cancer

- 4KRK
- Four Kallikrein Markers
- Kallikrein Panel

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>4Kscore® Test: Predicting the Risk of Aggressive Prostate Cancer</b> " for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Prostate Specific Antigen (PSA) is the most widespread test for prostate cancer (PSA) screening. However, it is associated with a high risk of over detection and overtreatment. Since its introduction into practice in the late 1980s, PSA testing has led to a significant increase in the incidence of prostate cancer and migration to an earlier stage at diagnosis. Most men with an elevated PSA either do not have prostate cancer or have a low-risk disease that is unlikely to affect the quality or length of life if left untreated. Between 17% and 50% of men with prostate cancer detected by PSA test have indolent tumors that would not have led to clinical disease. In addition, PSA levels may be elevated by conditions other than cancer such as benign prostatic hyperplasia, and prostatitis. The specificity and sensitivity of the PSA test used alone in detecting prostate cancer range from 20-40% and 70-90% respectively, with an AUC (area under the receiver operating characteristic [ROC] curve) of 0.55-0.71 (depending on the cutoff value used), and a positive predictive value (PPV) of only 25-40%. The low specificity of the PSA

test, results in performance of a large number of unnecessary biopsy procedures with the associated anxiety and complications. It is estimated that more than one million men undergo prostate biopsy every year in the USA, the majority of which are potentially avoidable (Vickers 2010, Bratt 2012, Voigt 2014, Parekh 2015).

Continuous efforts are being made to improve the accuracy of the PSA test and/or develop new biomarkers for prostate cancer screening. PSA density and PSA velocity have been used but were found to only slightly improve the predictive value of PSA, to a level that is insufficient to distinguish between aggressive and indolent forms of prostate cancer. PCA3 and TMPRSS2-ERG fusion biomarkers measured in the urine immediately after a vigorous prostate massage, were also evaluated, but each has its limitations (Punnen 2015, Ferro 2016).

Currently the prediction tools used to preoperatively distinguish between an aggressive and a pathologically insignificant disease incorporate PSA level, clinical stage, as well as biopsy variables such as transrectal ultrasound prostate volume, Gleason grade, number of positive biopsy cores, percentage of cancer in any core sample, total cancer length, and noncancer tissue in biopsy cores. The AUC for the accuracy of these prediction tools ranges from 0.70-0.80 (Carlsson 2013).

The 4Kscore® (4KRC) test (OPKO Lab, Nashville, TN) is a new blood test that has been introduced and evaluated for its ability to accurately predict the risk of aggressive prostate cancer. The test incorporates a panel of four kallikrein protein biomarkers (total PSA [tPSA], free PSA [fPSA], intact PSA [iPSA], and human kallikrein-related peptide 2 [hK2]), together with clinical information (age, and optionally the results of a DRE), in an algorithm that, according to some investigators, provides a percent risk for a high grade cancer (Gleason score  $\geq 7$ ). Tissue kallikrein or kallikrein-related enzymes are a family of 15 secreted serine proteases, the regulatory functions of which are linked to the development of malignancy, neurodegeneration, inflammation and other disorders. Messenger RNA expression of all kallikreins can be detected in the prostate tissue, but KLK2 (also known as human kallikrein2 [hK2]), and KLK3 (also known as PSA) are the most dominant. Some researchers found that in prostate cancer there is a dysregulation and overexpression of both PSA and hK2 and that their levels increase as the prostate cancer becomes more undifferentiated. They also indicate that these kallikreins directly and indirectly contribute to prostate cancer progression and metastasis (Konety 2015, Punnen 2015, McDonald 2016).

Several European studies evaluated the ability of the 4Kscore to distinguish between a pathologically insignificant and an aggressive disease. Based on their analyses, several investigators suggest that 4Kscore test would play an important clinical role as a reflex test before performing an initial prostate biopsy in men with elevated PSA, abnormal DRE results, or after a negative biopsy and persistently higher PSA levels (Punnen 2015). According to the manufacturer, the 4Kscore Test does not provide a diagnosis of prostate cancer; it is designed to help clarify the decision on whether or not to perform a biopsy based on the probability of a patient having aggressive prostate cancer. The test should not be used in isolation to make the decision on the need for biopsy. Other factors such as health status, PSA history medical history, family history of prostate cancer, etc., should all be considered with the 4Kscore risk level into a shared decision-making with the patient.

## Medical Technology Assessment Committee (MTAC)

### 4Kscore Test for Prostate Cancer

#### 03/21/2016: MTAC REVIEW

**Evidence Conclusion:** There is fair evidence from a number of validation studies that 4Kscore test may improve the predictive accuracy of total PSA when used among mainly white men with PSA level  $\geq 3$ ng/mL. As indicated earlier the predictive accuracy of a marker or test does not account for potential harms, and benefits, and may not capture the tradeoffs that the physician and patient face in making a decision about interventions that can carry both benefits and harms. There is insufficient evidence on the clinical utility of the 4Kscore test. There is insufficient evidence to determine the therapeutic impact of the 4Kscore test or the effect of the treatment decision based on the results of the test on the patient outcomes.

**Articles:** The search for studies on the accuracy of the 4Kallikrein panel in predicting high grade prostate cancer, revealed one study that prospectively evaluated the test among men in the USA, and a number of European studies that used retrospective data from several cohorts of screened and unscreened men participating in European Randomized Study of Prostate Cancer (ERSPC) and one cohort from the British ProtecT study. A meta-analysis that pooled the results of seven studies using the ERSPC cohorts was also identified. The search did not reveal any randomized controlled trial that examined the clinical utility of the 4Kscore test, only an observational study that analyzed retrospective data for men receiving the test. The following studies were selected for critical appraisal: Voigt JD, Zappala SM, Vaughan ED, et al. The Kallikrein Panel for prostate cancer screening: its economic impact. *Prostate*. 2014 Feb; 74(3):250-259 [See Evidence Table 1](#). Bryant RJ, Sjoberg



DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate. [See Evidence Table 2](#). Parekh DJ, Punnen S, Sjoberg DD, et al. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep; 68(3):464-470. [See Evidence Table 3](#). biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015 Apr 11; 107. Konety B, Zappala SM, Parekh DJ, et al. The 4Kscore test reduces prostate biopsy rates in community and academic urology practices. Rev Urol. 2015; 17 (4):231-240. [See Evidence Table 4](#).

The use of 4Kscore Test for Prostate Cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## References

Bryant RJ, Sjoberg DD, Vickers AJ, Robinson MC, Kumar R, Marsden L, Davis M, Scardino PT, Donovan J, Neal DE, Lilja H, Hamdy FC. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015 Apr 11;107(7):dju095. doi: 10.1093/jnci/dju095. PMID: 25863334; PMCID: PMC4554254.

Konety B, Zappala SM, Parekh DJ, Osterhout D, Schock J, Chudler RM, Oldford GM, Kernen KM, Hafron J. The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. Rev Urol. 2015;17(4):231-40. PMID: 26839521; PMCID: PMC4735670.

Parekh DJ, Punnen S, Sjoberg DD, Asroff SW, Bailen JL, Cochran JS, Concepcion R, David RD, Deck KB, Dumbadze I, Gambla M, Grable MS, Henderson RJ, Karsh L, Krisch EB, Langford TD, Lin DW, McGee SM, Munoz JJ, Pieczonka CM, Rieger-Christ K, Saltzstein DR, Scott JW, Shore ND, Sieber PR, Waldmann TM, Wolk FN, Zappala SM. A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer. Eur Urol. 2015 Sep;68(3):464-70. doi: 10.1016/j.eururo.2014.10.021. Epub 2014 Oct 27. PMID: 25454615.

Voigt JD, Zappala SM, Vaughan ED, Wein AJ. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate. 2014 Feb;74(3):250-9. doi: 10.1002/pros.22746. Epub 2013 Oct 26. PMID: 24166488.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
<b>81539</b>	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/21/2016	04/05/2016 <sup>MPC</sup> , 02/07/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	09/16/2022

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/05/2016	Created criteria; Added MTAC review

02/07/2017	Medicare is silent; MPC approved to adopt GHC criteria for Medicare members
10/10/2017	Added Medicare instructions for 0010M and 81539
08/08/2018	Removed 0010M
09/01/2020	Added Medicare LCD L37122 and LCA A57337; Removed KPWA Medical Policy statement under Medicare section.
09/16/2022	Removed Medicare LCD L37122 (retired 6/12/22) and LCA A57337 (retired 6/12/22), added KPWA Medical Policy statement under Medicare section.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Applied Behavioral Analysis Therapy (ABA)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual, Chapter 15 - Covered Medical and Other Health Services</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### Non-Medicare Members

- For patients with a Microsoft contract, [click here to view the criteria](#).
- For all other plans where the contract includes coverage for ABA therapy, see below for criteria
- For plans without a benefit, the service is not covered at this time.

#### For all Kaiser Permanente plans with a benefit (except Microsoft)

ABA requires preauthorization for initial and continued therapy. Specific coverage may be defined in the individual member contract. The following criteria must be met:

1. The member has a diagnosis of an Autism Spectrum Disorder (DSM-V code including severity levels) according to WAC 388-823-0500 by a board-certified neurologist; board-certified psychiatrist; a licensed psychologist; an advanced registered nurse practitioner (ARNP) associated with an autism center, developmental center, or center of excellence; a licensed physician associated with an autism center, developmental center, or center of excellence; or a board certified development and behavioral pediatrician
2. The diagnostic assessment must include **All of the following** elements:
  - a. Documentation of formal diagnostic procedures by an experienced clinician (e.g., Autism Diagnostic Interview-Revised, Autism Diagnostic Observation Schedule, diagnostic interview using DSM-V criteria)
  - b. Description of how patient's behaviors are having an impact on development, communication or adjustment such that:
    - i. The member cannot adequately participate in home, school, or community activities; and/ or the member presents a safety risk to self or others, and
    - ii. Less intrusive and/or less intensive behavioral interventions have been tried and have not been successful and/or there is no equally effective alternative strategy available to address the member's behaviors
  - c. Specific evaluations to determine developmental profile using **ONE or more of the following** standard tools:
    - i. Adaptive/Functional skills: Vineland Adaptive Behavior Scales

- ii. Communication skills: Preschool Language Scale-5 (PLS-5), Clinical Evaluation of Language Fundamentals-5 (CELF-5), Verbal Behavior Milestones Assessment and Placement Program (VB-MAPP)
    - iii. Cognitive Assessment (Wechsler scales, Kaufman scales)
    - iv. Social Skills Rating Scales (SSRS), Assessment of Basic Language and Learning Skills (ABLLS), Achenbach System of Empirically Based Assessment (ASEBA)
    - v. Behavior rating scales: ASEBA, Behavior Assessment System for Children, Third Ed. (BASC-3), Gilliam Autism Rating Scale
  - d. Expanded laboratory, documented routine developmental surveillance by providers at every well child visit, screening questionnaire, audiology assessment results, only if indicated.
  - e. There is evidence that the patient can participate in ABA therapy
3. A documented individualized treatment plan (ITP) that includes:
- a. A time-limited ITP that has been developed based on a diagnostic assessment within no more than 12 months of initiating treatment
  - b. ITP is multidisciplinary in nature, member-centered, family-focused, community-based, culturally-competent and least intrusive
  - c. Treatment plans that are templates or generic to a particular program are not acceptable ITP must address behaviors and symptoms that prevent the member from adequately participating in home, school, or community activities and/or present a safety risk to self or others, with a focus on parent training
  - d. The ITP must address behaviors and symptoms that prevent the member from adequately participating in home, school, or community activities and/or present a safety risk to self or others, with a focus on parent training
  - e. The ITP should take into account all school or other community resources available to the patient and provide evidence that the requested services are not redundant to other services already being provided. The ITP should include a review of a school-based IEP (if present) and how the ITP does not duplicate what is on the IEP. The ITP should also include a review of other treatment if present (e.g., outpatient mental health, speech therapy) and how the ITP does not duplicate these community-based resources. Coordination between the ABA provider and school and/or other service providers must take place directly between the providers, and not through parents.
  - f. Coverage of ABA therapy in public or private schools is only provided under the following circumstances:
    - i. Observation and assessment of behavior may take place in the school as part of the ITP assessment with the permission of school personnel
    - ii. ABA may be provided on school property before and after regular school hours with the permission of school personnel
    - iii. ABA may be provided during regular school hours with permission of school, when medically necessary, and the ABA intervention does not duplicate services the school could be expected to provide.
  - g. ABA services do not eliminate the requirement that the school district is to provide appropriate mandatory educational services
  - h. ABA services are not to be used for custodial caregiving services, including respite for caregivers
4. The ITP must include **All of the following**:
- a. The provider must use KP WA required report templates, available at [Applied Behavioral Analysis Treatment for Autism | Kaiser Permanente Washington](#); updates will be posted on the provider site.
  - b. Description of autistic behaviors that are targets for treatment. The targets for treatment should be based on where there is the most significant gap in functioning as measured by developmental and behavioral assessment including **TWO or more of the following**:
    - i. ONE Norm-Referenced assessment is required to be completed during the initial ABA assessment, and to be readministered every 12 months. The provider is to use an instrument that will be suitable for serial measurements over time, and thus to measure functional progress over treatment periods. Some options for norm-based assessment are:
      - Vineland3 Adaptive Behavior Scales
      - Adaptive Behavior Assessment System (ABAS)
      - Pervasive Developmental Disorder Behavior Inventory (PDDBI)

- Social Skills Improvement System (SSIS)
- ii. ONE Criterion-Reference assessment is required to be completed during the initial ABA assessment, and to be updated every 6 months. Some options for this assessment are:
  - The Carolina Curriculum
  - Verbal Behavior Milestones Assessment and Placement Program (VB MAPP)
  - Preschool Language Scale-5 (PLS-5),
  - Promoting Emergence of Advanced Knowledge (PEAK)
  - Accept-Identify-Move (AIM)
  - Assessment of Basic Language and Learning Skills (ABBLS)
  - Essentials for living (EFLs)
  - The Assessment of Functional Living Skills (AFLS) or similar empirically based assessment tool.
- c. A comprehensive description of treatment interventions and techniques specific to each of the targeted behavioral/symptoms
- d. Establishment of baseline data, measurable treatment goals, and criteria for goal attainment and objective measures of progress for each intervention specified (including baseline and targeted goals)
- e. Strategies for generalizing learning skills across persons and situations. Generalization plans are monitored closely as they are key to the patient transitioning to a lower level of care.
- f. A description of parent education, including measurable parenting goals with baseline and criteria for goal attainment, and description of interventions. The parent goals are to include instruction in ABA principles in order to training and support generalization and maintenance of skills. Detailed description of interventions with parents to support their active participation in ABA treatment, including a plan for transferring interventions with the patient from the ABA provider to the parents. An ITP that does not adequately feature parental involvement may be subject to denial.
- g. Strategies for communication and coordinating treatment with other providers and agencies including school-based special education programs, day care, and other health care providers.
- h. Hours requested are itemized for each treatment modality (e.g., parent training, certified behavior technician time, lead behavior therapist, supervision, social skills group, completion of six-month progress report)
- i. Measurable discharge criteria for completing treatment and plans for continued care after a discharge plan from ABA, which include **all of the following**:
  - i. Plans for transition through a continuum of less intensive treatments such that patient's symptoms can be effectively managed at a lower level of care
  - ii. Specific behavioral goals that, when reached, will indicate the patient is adequately participating in home, school, or community activities and/or is no longer presently a safety risk to self or others
- 5. Discharge Criteria - Typically individuals no longer need ABA services if **ONE of the following** is met:
  - a. Patient behaviors and/or symptoms do not prevent them from adequately participating in home, school, or community activities and/or no longer present a safety risk to self or others
  - b. Their behaviors and/or symptoms can be adequately addressed through alternative methods (i.e., school, developmental disability services, parent training)
  - c. Functional and measurable progress toward treatment goals is not occurring as measured by (majority of goals are not being met, there is not significant progress on behaviors and/or symptoms that prevent them from adequately participating in home, school, or community activities, and/or no longer present a safety risk to self or others), improvement is not durable over time, and/or generalizable outside the treatment setting, and there is no reasonable expectation of further progress
- 6. Transition to a lower level of care. Discharge is often not a discrete event, but instead is a transitional process, to prevent relapse of skills. Transition to a lower level of care could include any of the following: lowered number of treatment hours (focused ABA), enhanced focus on training parents or other caregivers, or the use of other treatment modalities e.g., mental health counseling group treatments or other community support activities.
- 7. Coverage of development of the ITP does include time to do baseline assessments, review of past treatment (including IEPs) and development of a plan that includes parent training and coordination with other treatment

providers. Six to 10 hours is usually sufficient for the development of the ITP. If additional time is being requested, clinical documentation to support medical necessity (e.g. more complex cases, or cases in which a complete functional analysis is needed) must be submitted.

8. The amount of treatment is based on medical necessity. As noted in the 2014 Agency for Healthcare Research and Quality update on A Review of Research of Therapies for Children with Autism Spectrum Disorder, early intervention programs (i.e., for children typically, under the age of six) are provided for up to 25 hours a week and can last as long as 12 weeks to 3 years. These services can include direct services to member/identified patient and/or parents by program manager/lead behavioral therapist and/or therapy assistants/behavioral technicians/paraprofessionals, supervision, and the development of a six-month progress report. In the unusual case of very acute and/or unsafe patient behavior, up to 40 hours/week of treatment may be authorized.
9. Fewer hours may be required (5-15 hours per week) for Focused ABA when the primary difficulty is in one targeted area (i.e., social skills deficits).
10. Caregiver coaching is considered best practice and needed for all ABA programs
  - a. Caregiver coaching plans must include baseline behaviors, must have baselines measurable components, and mastery criteria
  - b. Caregiver education must also include the teaching of ABA principles related to the patient goals (i.e., principles of reinforcement, behavior functions, schedules reinforcement, task analysis as a teaching strategy, etc.)
  - c. Monthly meetings (in person or virtual) are required for generalization and maintenance of skills
  - d. The initial caregiver coaching/education plan must be documented
11. Evaluation of progress: Every six months, the provider completes the KP ABA Progress Report. This document is used to review progress in treatment including the following information:
  - a. How patient is progressing towards goals (i.e., what percentage of goals patient has achieved and how these goals have led to functional progress as it pertains to increasing patient's ability to adequately participate in home, school, or community activities, and/or decrease safety risk to self or others
  - b. Progress towards parent goals (how parents have been active participants in the treatment, what percentage of parent goals have been passed, and progress towards transferring interventions with the patient to the parents.
  - c. For goals that have not been met, describe reason for not meeting goals, how goals are being adjusted, and how interventions are being revised to meet goals.
  - d. Any new goals that have been identified (if new goals are identified, include baseline and targeted performance). New goals should be geared towards progress or transition to less intensive interventions.
  - e. A criterion referenced assessment is to be submitted every six months.
  - f. How the patient is progressing towards discharge and/or plans for discharging from care and/or reducing intensity of intervention based on patient progress and/or the implementation of less intensive behavioral interventions. A discharge plan stating that ABA will be needed until he/she no longer meets criteria for ASD is not appropriate. A patient could still meet diagnostic criteria for ASD, but be able to be successfully and safely treated at a lower level of care.
  - g. A brief description of what was done during the past six months to coordinate treatment with school and/or health care providers (i.e., phone call was made to speech therapist to make sure there is common picture communication system; a conference was held with the school to coordinate behavioral interventions for self-injurious behavior). This coordination must take place directly between the ABA provider and any other service providers, and not through the parents
  - h. If functional progress is not occurring (i.e., one or two consecutive ITP's where patient is not meeting majority of goals and not making functional progress towards increased participation in home, school, or community activities and/or is not less of a safety risk to self or others) and there is not a reasonable expectation of further progress, then continuation of ABA services is not considered to be medically necessary
12. Every 12 months standardized (norm-referenced) developmental assessment should be re-administered to assess whether patient continues to be making functional and measurable progress. The provider is to use the same instrument over time as much as possible so scores can be compared over time to measure progress.



13. The following are not considered to be medically necessary ABA services:
- a. More than one program manager/lead behavioral therapist for a member/identified patient at any one time.
  - b. More than one agency/organization providing ABA services for a member/identified patient at any one time.
  - c. If the school has determined that a child is eligible to receive services under an IEP which would overlap with ABA services and the school services are declined or discontinued by the parent.
  - d. Activities and therapy modalities that do not constitute application of applied behavioral analysis techniques for treatment of autism. Examples include (but not limited to):
    - i. Taking the member/identified patient to appointments or activities outside of the home (e.g., recreational activities, eating out, shopping, play activities, medical appointments), except when the member/identified patient has demonstrated a pattern of significant behavioral difficulties during such specific activities
    - ii. Assisting the member/identified patient with academic work or functioning as a tutor, educational or other aide for the member/identified patient in school
    - iii. Provision of services that are part of an IEP and therefore should be provided by school personnel, or other services that schools are obligated to provide
    - iv. Doing housework or chores, or assisting the member/identified patient with housework or chores, except when the member has demonstrated a pattern of significant behavioral difficulties during specific housework or chores, or acquiring the skills to do specific housework or chores is part of the ABA treatment plan for the member/identified patient travel time residing in the member's home and functioning as live-in help (e.g., in an au-pair role)
14. All ABA visits with the patient and/or family should be documented. Documentation should include:
- a. Who was present at the visit?
  - b. Duration of the visit
  - c. What was the targeted behavior during the visit?
  - d. What was the procedure/activity/intervention during visit?
  - e. What was the response to procedure/activity/intervention?
  - f. Intervention format (individual, group, supervision, parent training)
  - g. Graphical or numerical data to track progress/participation
  - h. Signature title, credentials of person completing documentation
  - i. Include targeted behavior, interventions, response, modifications in techniques and plan for next visit with behavior tracking sheets that record and graph data collected for each visit

### **ABA Provider Qualifications and Procedure Codes**

Providers delivering ABA must meet **ALL of the following** qualifications:

1. At a minimum, the lead behavioral therapist, providing treatment and clinical supervision of treatment program must demonstrate that she/he is a board-certified behavior analyst (BCBA).
2. **Either:**
  - A. Individually satisfy **ALL the following** requirements:
    - i. Be a licensed health provider under Title 18, Revised Code of Washington, including but not limited to: speech therapist, occupational therapist, psychologist, pediatrician, neurologist, psychiatrist, mental health counselor, social worker; and
    - ii. Be licensed to practice independently; and
    - iii. Be credentialed and contracted by the Plan; **or**
  - B. Be employed by a Healthcare Delivery Organization that meets **All of the following** requirements:
    - i. Be a hospital, mental health facility, home health agency or in-home agency licensed to provide home health services, or other mental health agency licensed by the Washington Department of Health; **or** a community mental health agency or home health agency licensed by the Washington Department of Social and Health Services; and
    - ii. Be credentialed and contracted by the Plan.
    - iii. Clinical supervision for unlicensed staff providing services must be provided by a lead behavioral therapist as indicated above. Must include, at a minimum bimonthly (once every 60 days) approval and review of the ITP and case review of every member receiving clinical health services; and

- iv. Must include, at a minimum, at least one hour of on-site supervision, with on-site observation for at least one hour for every 40 hours of service to the member.

CPT code	Description
97151	Behavior Identification Assessment, administered by QHP, each 15 minutes of QHP's time face-to-face with patient and/or guardian(s)/caregivers(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan
97152	Behavior Identification Supporting Assessment, administered by one technician under the direction of QHP, face-to-face with the patient, each 15 minutes
97153	Adaptive Behavior Treatment by Protocol, administered by technician under the direction of a QHP, face-to-face with one patient, each 15 minutes
97153 w/HO modifier	
97154	Group Adaptive Behavior Treatment by Protocol, administered by technician under direction of QHP, face-to-face with 2+ patients, each 15 minutes
97155	Adaptive Behavior Treatment with Protocol Modification, administered by QHP, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes
97156	Family Adaptive Behavior Treatment Guidance, administered by QHP (with or without patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes
97157	Multiple-Family Group Adaptive Behavior Treatment Guidance, administered by QHP (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes
97158	Group Adaptive Behavior Treatment with Protocol Modification, administered by QHP face-to-face with multiple patients, each 15 minutes

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Autism is a neurodevelopmental disorder in the category of pervasive developmental disorders (PDD), which is a group of conditions that also include Rhett's disorder, childhood disintegrative disorder, Asperger's disorder, and pervasive developmental disorder not otherwise specified (PDD NOS). Autism is characterized by a triad of deficits involving impaired language development, reciprocal social interaction, and stereotyped repetitive patterns of behaviors and interests. The prevalence estimates released by the CDC based on 2002 data show that approximately one in fifty children in the US is autistic. These estimates indicate a dramatic increase in the recent years, which may be due to an actual increase in the occurrence of the disorder as well as the increased awareness of the disorder among the clinicians. There are no definitive medical tests to indicate the presence of any form of autism spectrum disorders (ASD). Diagnostic assessment includes use of ICD and DSM-IV diagnostic criteria and standardized methods to assess core and co-morbid conditions. Parents usually become aware of developmental problems in their child starting around the age of 18 months, but diagnosis is often not made until 2 years after the expression of parents' concerns. It may sometimes be delayed until close to the age of six (Ospina 2008, Granpeesheh 2009, Levy 2009, Spreckley 2009).

Autism is a lifelong condition with variable clinical course throughout childhood and adolescence. Many adults with autism may still require full-time care. While there is no known cure, the general agreement is that early diagnosis followed by appropriate treatment may improve outcomes in later years for most individuals. Over the past twenty years, a variety of therapies have been proposed to improve the symptoms associated with ASD, many of which have not been validated scientifically. These include pharmacological therapies, complementary therapies as diet modifications and vitamin therapy, speech and language therapy, and psychosocial treatments.

The well-researched treatment programs are based on the principles of applied behavioral analysis (ABA), sometimes called behavioral therapy or behavioral modification. The approach has been outlined by Lovaas and colleagues in the 1980s and, as originally described, involves teaching appropriate behaviors by breaking tasks down into small discrete steps and training in a systematic and precise way called discrete trial training. It is delivered on a 1:1 basis, for 40 hours a week over a three-year period.

The approach of ABA is based on the concept that children with ASD have significant difficulties with learning, being unable to learn through imitation, and listening as normal children do. Its overall goal is to motivate the child to want to be successful. ABA is founded on behavioral principles of learning and motivation, consisting of reinforcement, extinction, stimulus control, and generalization. The basic learning principle at the core of ABA is the idea that the consequences of a behavior can either strengthen or weaken it; behavior that is followed by the presentation of desirable consequences will be strengthened (reinforcement), whereas behavior that is followed by aversive consequences or the removal of desirable consequences will be weakened.

A defining feature of ABA programs is that they are applied consistently. This is accomplished by the use of explicitly written programs for each skill to be taught or maladaptive behavior to be treated, and by having the behavioral analyst train everyone who works with the child to implement it. To increase the likelihood of the generalization of the treatment efforts, it is critical for the therapists and parents to be trained to implement the programs across situations, settings, and people. Typically, teaching trials are repeated until they are mastered. Maladaptive behaviors such as aggression and self-injury are not reinforced, whereas specific, appropriate alternative behaviors are either taught or maintained through positive reinforcement. Each child's program is unique to his/her needs that evolve with the child's progress. Accurate records are kept so that progress can be assessed, and programmatic changes made (Spreckley 2009, Granpeesheh 2009).

Treatment based on APA represents a wide range of early intervention strategies for children with autism. As indicated earlier, the first types of behavioral treatment programs developed, the discrete trial training, were very intensive and structured. Investigators found that children may have difficulty generalizing the information from these very structured sessions to group and community settings. One comprehensive intervention program reviewed by the National Research Council (NRC) was early intensive behavioral intervention (EIBI) based on the UCLA Young Autism Project Model. This is an intensive home-based program using the manual published by Lovaas and involves up to 40 hours of therapy per week for at least 2 years. Other EIBI programs were developed by other researchers (Howlin 2009, Reichow 2009).

Less structured more naturalistic behavior programs e.g. incidental teaching and pivot response training (PRT) have been developed but were not researched in a randomized controlled fashion. Currently, even structured sessions include naturalistic methods for increasing generalization and maintenance. Parent mediated interventions have been reported to be an important aspect of intervention. Overall, structured programs share a common core of set features including: 1. starting the intervention at the earliest possible age (3-4 years), 2. Intervention is intensive (20-40 hours per week), 3. Intervention is individualized, comprehensive, and targeting a wide range of skills, 4. Multiple behavior analytic procedures are used to develop adaptive repertoires, 5. Treatment is delivered in one-to-one format with gradual transition to group activities and natural contexts, 6. Treatment goals are guided by normal developmental sequence, and 7. Parents are, to different extents, trained and become active co-therapists (Levy 2009, Virues-Ortega 2010).

## Medical Technology Assessment Committee (MTAC)

### **ABA Therapy**

#### **04/19/2010: MTAC REVIEW**

**Evidence Conclusion:** There is lack of published well-conducted randomized controlled trials on behavioral interventions for young children with autism. The published trials had their limitations; they had small sample sizes, the majority were not randomized, the participants were frequently diagnosed without using standardized tools, the studies examined different treatments, with different delivery approaches and intensities, over different time spans (ranging from 12 weeks to 2 years) and had different measurement approaches for assessing outcomes. IQ was a major outcome for the majority of studies, and it might not be possible to determine whether an improved IQ results from true improvement of cognitive skills, or better test taking ability. In addition, IQ is not necessarily the main problem in autistic functioning. Autism treatment needs to address every developmental area, all areas of adaptive behavior, and then a whole set of aberrant behavioral responses, involving both positive and negative symptoms (Rogers 2008). A number of systematic reviews and meta-analyses of the

published studies were conducted by several authors. The methodology of the analyses was valid in general, however even a well conducted meta-analysis is only as good as the studies it includes. The studies on intensive behavioral intervention, as indicated earlier, had their limitations and biases and varied widely in the treatments intensity, duration, mode of delivery, and outcome measures; all of which limits generalization of the pooled results. The meta-analyses either pooled the results of controlled studies only or all studies with or without comparison groups. Their results were conflicting, while, Virues-Ortega (2010), Eldevik (2009), Reichow (2009), Howlin (2009) and others show that that ABA /EIBI interventions were associated with improved outcome (primarily measured by IQ) among some children with autism, Ospina (2008) and Spreckley et al (2009) showed no statistically significant additional benefit of APA/EIBI intervention vs. other interventions applied to young children with ASD.

Dawson and colleagues' study (2010), a more recently published randomized controlled trial with valid methodology, can be considered the most rigorous RCT on comprehensive development behavioral intervention. The authors randomized 48 young children to receive Early Start Denver Model (ESDM), a comprehensive behavioral intervention, or to be referred to community providers for intervention commonly available in the community. They were followed up for 2 years and the primary outcome was change in Mullen Scales of Early learning (MSEL) and the Vineland Adaptive Behavior Scales (VABS) composite standard scores. The results of the trial suggest that very young children with autistic disorders may achieve higher cognitive and adaptive scores and improvement in diagnosis after a 2-year comprehensive intervention strategy that includes parental involvement. The study however does not allow determining if the benefits gained would be sustained over time. Conclusions: There is insufficient evidence from well-conducted large randomized comparative trials with long term follow-up to determine which comprehensive treatment approach is best for young children with autism, and in particular the most effective treatment for teaching specific skills given certain profiles and characteristics of the child.

**Articles:** The literature search revealed around 100 articles on ABA/ EIBI for young children with autism. The majority were reviews or articles not related to the current review. There were at least 6 systematic reviews with or without meta-analyses on ABA /EIBI intervention for young children with autism. A small more recent RCT (N=48) on the Early Start Denver Model for toddlers with autism was identified. The search also revealed a systematic review by Clinical Evidence on all interventions for autism including early multidisciplinary interventions based on APA and including home-based, school based, community based or multisite interventions. Three of the meta-analyses on ABA/EIBI for young children were selected for critical appraisal as well as the recently published randomized trial. Dawson G, Rogers S, Munson J, et al. Randomized controlled trial of an intervention for toddlers with autism: The Early Start Denver Model, *Pediatrics* 2010;125:1:e17-e23 See [Evidence Table](#) Eldevik S, Hastings RP, Hughes JC, et al. Meta-analysis of early intensive behavioral intervention for children with autism *J Clin Child Adolesc Psych* 2008;38:439-450 See [Evidence Table](#) Spreckley M, Boyd R. Efficacy of applied behavioral intervention in preschool children with autism for improving cognitive, language, and adaptive behavior: A systematic review and meta-analysis. *J Pediatr* 2009; 154:338-344. See [Evidence Table](#) Virues-Ortega J. Applied behavioral analytic intervention for autism in early childhood: Meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. *Clinical Psychology Review*. 2010 , doi:10.1016/j.cpr.2010.01.008 See [Evidence Table](#)

The use of applied behavioral analysis therapy (ABA), early intensive behavior interventions (EIBI) for the treatment of young children with autism does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## References

- Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, Donaldson A, Varley J. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. *Pediatrics*. 2010 Jan;125(1):e17-23. doi: 10.1542/peds.2009-0958. Epub 2009 Nov 30. PMID: 19948568; PMCID: PMC4951085.
- Eldevik S, Hastings RP, Hughes JC, Jahr E, Eikeseth S, Cross S. Meta-analysis of Early Intensive Behavioral Intervention for children with autism. *J Clin Child Adolesc Psychol*. 2009 May;38(3):439-50. doi: 10.1080/15374410902851739. PMID: 19437303.
- Spreckley M, Boyd R. Efficacy of applied behavioral intervention in preschool children with autism for improving cognitive, language, and adaptive behavior: a systematic review and meta-analysis. *J Pediatr*. 2009 Mar;154(3):338-44. doi: 10.1016/j.jpeds.2008.09.012. Epub 2008 Oct 31. PMID: 18950798.

Virués-Ortega, Javier. Applied behavior analytic intervention for autism in early childhood: Meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes, *Clinical Psychology Review*, Volume 30, Issue 4, 2010, Pages 387-399, ISSN 0272-7358. Doi:10.1016/j.cpr.2010.01.008.  
<https://www.sciencedirect.com/science/article/pii/S0272735810000218>

Washington State Legislature. (2023, February 20). *How do I show that I have autism as an eligible condition?*. WAC 388-823-0500: <https://apps.leg.wa.gov/wac/default.aspx?cite=388-823-0500>

## Applicable Codes

Providers must use the following codes to obtain reimbursement for ABA and ABA-related services

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>97151</b>	Behavior identification assessment, administered by a physician or other qualified health care professional, each 15 minutes of the physician's or other qualified health care professional's time face-to-face with patient and/or guardian(s)/caregiver(s) administering assessments and discussing findings and recommendations, and non-face-to-face analyzing past data, scoring/interpreting the assessment, and preparing the report/treatment plan
<b>97152</b>	Behavior identification-supporting assessment, administered by one technician under the direction of a physician or other qualified health care professional, face-to-face with the patient, each 15 minutes
<b>97153</b>	Adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with one patient, each 15 minutes
<b>97153 (with HO Modifier)</b>	Adaptive behavior treatment by protocol, administered by physician or other qualified health professional, face-to-face with one patient.
<b>97154</b>	Group adaptive behavior treatment by protocol, administered by technician under the direction of a physician or other qualified health care professional, face-to-face with two or more patients, each 15 minutes
<b>97155</b>	Adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, which may include simultaneous direction of technician, face-to-face with one patient, each 15 minutes
<b>97156</b>	Family adaptive behavior treatment guidance, administered by physician or other qualified health care professional (with or without the patient present), face-to-face with guardian(s)/caregiver(s), each 15 minutes
<b>97157</b>	Multiple-family group adaptive behavior treatment guidance, administered by physician or other qualified health care professional (without the patient present), face-to-face with multiple sets of guardians/caregivers, each 15 minutes
<b>97158</b>	Group adaptive behavior treatment with protocol modification, administered by physician or other qualified health care professional, face-to-face with multiple patients, each 15 minutes

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Creation Date	Review Date	Date Last Revised
05/07/2010	05/04/2010 <sup>MDCRPC</sup> , 05/03/2011 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 12/04/2012 <sup>MDCRPC</sup> , 10/03/2013 <sup>MPC</sup> , 12/03/2013 <sup>MPC</sup> , 08/05/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> ,	10/01/2024



	02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	
--	---	--

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
02/07/2017	Revised ABA criteria for commercial members
12/05/2017	MPC approved to delete indication related to school coverage for ABA Therapy (commercial members, except MS)
01/09/2018	MPC approved to modify criteria to remove any language regarding school practices
11/01/2018	Removed the H codes and added the ABA Reimbursable Services
08/06/2019	Revised ABA criteria for commercial members and updated background information to highlight ITP updates
07/06/2021	MPC approved to adopt updates to clinical criteria for Non-Medicare members, with the exception of Microsoft, as there is separately maintained criteria for Microsoft members. Revisions made to clarify requirements, and a new requirement was added for two or more developmental and behavioral assessments used to measure gaps in functioning instead of one. Updated applicable coding to exclude H2017, 0362T, and 0373T. Requires 60-day notice, effective date 10/01/2021.
08/03/2021	Format change: merged separate non-Medicare criteria into main page (Microsoft criteria still a separate document)
01/03/2022	Updated Microsoft SPD language from 2022 document - replaced the terms child or dependent with 'member' throughout.
10/04/2022	MPC approved to modify ABA criteria to clarify coverage language.
11/07/2023	MPC approved to edit language in the current policy to reference WAC 388-823-0500 and align clinical criteria language of provider types with the WAC. MPC should remove lack of parental involvement with ABA treatment from discharge criteria but maintain parent/guardian coaching plan as an integral component of ABA treatment plan requirements.
10/01/2024	MPC approved the criteria updates to the Applied Behavioral Analysis Therapy (ABA) policy to add clarifying language on coverage. 60-day notice required. Effective March 1 <sup>st</sup> , 2024.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Ankle Brachial Index Device

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Ankle Brachial Index Device</b> , for medical necessity determinations. Use the Non-Medicare criteria below.

### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Peripheral artery diseases (PAD) are atherosclerotic diseases resulting in occlusion of peripheral arteries (abdominal aorta, iliac, and lower extremity arteries). The prevalence of lower extremity PAD, around the globe, is estimated at 3 to 12% (Hirsch et al., 2006; Norgren et al., 2007; Olin & Sealove, 2010). Patients may experience rest pain, ulceration, claudication, hospitalizations, and even amputation of limb. PAD may also be asymptomatic. The rate of myocardial infarction, stroke, and cardiovascular mortality is significantly increased with PAD (Olin & Sealove, 2010).

Several risk factors have been identified. However, The American College of Cardiology/American Heart Association (ACC/AHA) guidelines on PAD have recognized specific risk groups with a higher prevalence of PAD. These include age  $\geq 70$  years, age 50 to 69 years with a history of diabetes or smoking, age 40 to 49 with diabetes and at least one other risk factor for atherosclerosis, leg symptoms indicative of claudication with

© 2019, Kaiser Foundation Health Plan of Washington. All Rights Reserved.

[Back to Top](#)

exertion or ischemic pain at rest, abnormal lower extremity pulse examination, known atherosclerosis at other sites (coronary, carotid, renal artery disease) (Hirsch et al., 2006).

Ankle-brachial-index (ABI) using doppler is one of the tests used to diagnose peripheral artery disease (PAD). It measures the ratio of the systolic ankle to brachial pressure. PAD is defined by an ABI  $\leq 0.9$ . However, studies have reported a low utilization of the ABI due to lack of skills to perform the procedure (Mohler et al., 2004). ABI is also incorrectly used in primary care (Davies, Kenkre, & Williams, 2014; Nicolai et al., 2009). In addition, the procedure is time consuming and this might contribute to its low use in busy healthcare centers (Davies et al., 2014; Nicolai et al., 2009). These limitations result in underdiagnosis and undertreatment of PAD.

Several automated ABI devices have been developed to overcome the limitations of Doppler ABI. These encompass devices using oscillometric technology and plethysmographic-based technology. Oscillometric-based devices seem to be less accurate (Verberk, Kollias, & Stergiou, 2012) in computing ABI.

The plethysmographic method is based on reperfusion plethysmography. "A dual-chamber cuff applied to each limb consists of an upper occlusion chamber and a lower detection chamber. When the pressure of the upper occlusion chamber has exceeded arterial systolic pressure, the distal detection chamber detects a gradual decrease in limb volume as a result of blood redistribution in the absence of arterial blood inflow. As the pressure in the occlusion chamber is then incrementally reduced and reaches systolic pressure, arterial blood flow to the limb is restored, which is detected as a volume increase in the lower chamber. The pressure in the upper occlusion chamber at the point when this lower chamber volume increase occurs, is taken as the limb arterial systolic pressure" (Davies & Williams, 2016).

Several manufacturers have developed automated ABI machines using plethysmography technology. Manufactured by Huntleigh Diagnostics, Cardiff, UK, the Dopplex Ability is an automated device that measures ankle-brachial index (ABI) and pulse volume recordings (PVR). It uses air plethysmography technology to perform these assessments (Millen et al., 2018). The Dopplex ability provides fast and easy measurements with a printout of results from integrated software package. ABI's are computed in three minutes (without the need to rest the patient), interpreted and displayed with pulse volume waveforms on LCD panel. The Dopplex ability system includes Dopplex ability automatic machine, one box of disposable sleeves, four pieces set of standard 8½"-14" cuffs, one pack of standard thermal paper, and one set of adhesive paper. The Dopplex ability is intended for wound care for arterial disease before deciding on compression bandaging. It is also considered for PAD detection, and congestive heart disease screening (identification of risk factors) (<https://www.usamedicalsurgical.com/huntleigh-dopplex-ability-automatic-abi-system/>). Other manufacturers include Newman Medical (USA), Enverdis, Skidmore Medical.

## Medical Technology Assessment Committee (MTAC)

### **Ankle-Brachial Index device using plethysmographic method for the diagnosis of peripheral artery disease** **04/08/2019: MTAC REVIEW**

#### **Evidence Conclusion:**

Low evidence suggests that automated ABI device using plethysmographic method (Dopplex Ability) shows:

- moderate agreement with doppler manual method and low reliability
- moderate sensitivity along with high specificity and accuracy for detection of PAD in comparison with the Doppler method as a gold standard
- a conflicting proportion of failing measurements

More studies are needed to clarify whether Dopplex Ability alone can provide enough diagnostic accuracy

**Articles:** PubMed was searched through March 15, 2019. Search terms include ((ABI automated system OR Dopplex Ability)) AND (peripheral artery disease OR PAD). Other terms consist of Automated plethysmography AND ankle-brachial index AND doppler ultrasound. SimpleABI system OR simpleABI automated system OR ABI Doppler system OR ABI automated system was searched. Google scholar was also searched. The search was limited to English language publications and human populations. RCTs and observational studies were included as filter in the search. The reference lists of relevant studies were reviewed to identify additional publications. See [Evidence Table](#).

The use of Ankle-Brachial Index device using plethysmographic method for the diagnosis of peripheral artery disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
No Specific Codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/07/2019	05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	05/07/2019

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
05/07/2019	MPC approved to adopt a non-coverage policy for Ankle Brachial Index Device



## Kaiser Foundation Health Plan of Washington

### *Clinical Review Criteria* Advanced Care at Home

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare & Non-Medicare Members

**Please note that availability of ACAH may be dependent on geography. Also, individual riders/contracts may vary in benefit design impacting member cost shares for services billed.**

- A. To receive advanced care in the home, the member must meet **ALL of the following**:
- The member must be referred into the advanced care program by the managing provider such as in an emergency room setting
  - Advanced Care at Home requires preauthorization based on the member's health status, treatment plan, and home setting or another appropriate care location within the service area
  - The clinical condition must meet inpatient medical necessity criteria, per MCG care inpatient hospitalization guidelines appropriate to the patient's clinical condition
  - The member must consent to receiving advanced care described in the treatment plan
  - The care location, such as the member's residence, must be within 30 minutes ground travel time of an emergency department **AND**
  - The care location, such as the member's residence, must have cell service
- B. Advanced Care at Home is provided through Medically Home, Kaiser Permanente's network provider, and will provide the following services in the member's home or appropriate care location:
- Home visits by RNs, physical therapists, occupational therapists, speech therapists, respiratory therapists, nutritionist, health aides, and other healthcare professionals in accordance with the Advanced Care at Home treatment plan and the provider's scope of practice and licensure.
  - Communication devices to allow the member to contact the medical command center 24 hours a day, 7 days a week. This includes needed communication technology to support reliable connection for communication, and a personal emergency response system alert device to contact the medical command center if the member is unable to get to a phone.
- C. Additional services covered under this benefit include:
- The following equipment necessary to ensure that the patient is monitored appropriately in home: blood pressure cuff/monitor, pulse oximeter, scale, and thermometer
  - Mobile imaging and tests such as X-rays, ultrasounds, and EKGs
  - Safety items when medically necessary, such as shower stools, raised toilet seats, grabbers, long handled shoehorn, and sock aids
  - Meals when medically necessary while patient is receiving advanced care at home

In addition, the following services and items are covered under this benefit when prescribed as part of the Advanced Care at Home treatment plan:

- Durable Medical Equipment
- Medical Supplies

© 2022, Kaiser Foundation Health Plan of Washington. All Rights Reserved.

[Back to Top](#)

- Member transportation to and from network facilities when member transport is medically necessary
- Physician Assistant and Nurse Practitioner house calls
- Emergency Department visits associated with this benefit

**Exclusions:** Private Duty Nursing; housekeeping or meal services not part of the Advanced Care at Home treatment plan; any care provided by or for a family member; any other services rendered in the home which are not specified in the member's Advanced Care at Home treatment plan

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Advanced Care at Home is a personalized, patient-centered program that provides care for patients with certain clinical conditions in their homes, or at another appropriate care location.

Advanced Care at Home services must be associated with an acute episode and the treatment plan may include restorative care associated with the acute episode. The duration of an episode of care (which includes acute and restorative phases) is limited to a total of 30 days.

## Applicable Codes

Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/02/2022	08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 12/03/2024 <sup>MPC</sup>	08/06/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/06/2024	MPC approved the updated changes so that the standard cost-sharing rules will apply based on the type of service billed by qualified providers; 60-day notice required, effective 01/01/2025.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Actigraphy Testing for the Evaluation of Sleep Disorders

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Polysomnography and Other Sleep Studies (L34040)</a>
Local Coverage Article	<a href="#">Billing and Coding: Polysomnography and Other Sleep Studies (A57698)</a> (Actigraphy can be measured as part of a sleep test but will not be paid for separately)

#### For Non-Medicare Members

Refer to [Sleep Studies](#) criteria page

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

#### Background

A sleep disorder (somniphathy) is a medical disorder of the sleep patterns. The international classification of sleep disorders (ICSD)-2 lists over 80 sleep disorders under eight major categories including insomnia, sleep-related breathing disorders, hypersomnia, circadian rhythm sleep disorders, parasomnia, sleep-related movement disorders, and others. It is estimated that 30-40% of Americans have a sleep complaint at any one time and that 10-15% suffer from chronic insomnia (Quan 2006).

The proper diagnosis and management of patients with sleep disorders depends on an accurate clinical history. There is a variety of sleep history questionnaires including the Epworth Sleepiness Scale (ESS) and the Pittsburgh Sleep Quality Index (PSQI). Keeping a sleep-wake diary is a standard procedure used for the subjective assessment of sleep and may give a more complete picture of the individual's sleep patterns and variability from day to day. Sleep diaries are useful for evaluating sleep over extended periods of time in the patient's home environment; they represent an important clinical tool and are often used in behavioral treatment of sleep disorders such as insomnia. However, self-documentation of sleep frequency and duration is prone to bias. The fully attended traditional polysomnography (PSG) is the basic diagnostic procedure and is considered the standard for evaluating sleep disorders. It is an overnight test performed in a sleep laboratory and comprises continuous recording of several physiological variables including airflow, chest/abdominal movements, arterial oxygen saturation, electroencephalography (EEG), electrocardiogram [ECG], electromyography (EMG), and electrooculography (to measure eye movement). The EEG activity, eye movements, and muscle tone reveal the differences between wakefulness and sleep. Some investigators indicate that while the full PSG is widely considered the standard in



clinical practice, it is not a true gold standard as it had not been validated. The use of PSG is limited by its high cost, time consumption, complexity, and considerable utilization of hospital resources. It may be impractical in some cases among whom sleep patterns must be assessed over extended periods of time. Moreover, PSG assesses sleep in an abnormal environment, which can alter its structure. These disadvantages of PSG have led to the search for alternative tools to diagnose and/or monitor sleep disorders in a natural environment (Bar 2003, Buysse 2005 Broughton 1996, Zou 2006, To 2009, Sunwoo 2010, Martin 2011).

Actigraphs, also called actometers or actimeters, were first used to record sleep and wakefulness based on movement in the early 1970s. The term actigraphy refers to methods utilizing miniaturized sensors that translate physical motion into a numeric presentation. Actigraphy simply measures movement, and is one dimensional, whereas polysomnography comprises at least three distinct types of data (EEG, EOG, and EMG), which jointly determine if a patient is asleep or awake. The actigraphy device may be placed on the wrist, ankle, or trunk. The best placement site for the actigraph to obtain the most reliable data is still controversial. In most studies it is worn on the nondominant wrist based on observations that wrist may detect more movements compared with the ankle and trunk, and that placement on the dominant arm detects more movement than the nondominant arm. The actigraphy device includes a small accelerometer that monitors and records the occurrence and degree of motion. It can collect data continuously over an extended period of one week or longer. Autographic data can be displayed and scored manually or downloaded to a computer for display and analysis by software and algorithms that give estimates of sleep-wake and circadian rhythm parameters. The collected data are translated into epochs (typically 30 seconds or 1 minute) of activity. Using validated algorithms, the epochs are scored as sleep or awake. The device interprets the presence of movement as time awake, and absence of movement as sleep time. Some investigators treat PSG and actigraphy measures as equally valid or alternative measures that provide an estimation of the time an individual spends sleeping and awake. However, actigraphy only measures movement; and electrographic sleep-wake status and motor activity/inactivity are not equivalent. Despite the sophisticated algorithms for actigraphy that may potentially estimate the time an individual spent sleeping and awake based on movement, actigraphy just provides an indirect estimate of sleep-wake as it is commonly defined (Broughton 1996, Lotjonen 2003, Ancoli 2003, Flemons 2003, Kuna 2010, Sanchex-Ortuno 2010, Calogiuri 2013).

Actigraphs vary widely in sizes and features and can be expanded to include sensors which monitor light, sound, temperature, and parkinsonian tremors. Some devices are programmable and allow the selection of specific modes of operation while others have only one fixed mode. New devices, scoring algorithms and operating procedures are continuously being developed and updated. Newer devices have the advantage of the small size and light weight making them more convenient for all patients. Different devices have different measuring mechanisms and scoring algorithms, but their results are usually interpreted equally between studies, despite the fact that research found that their accuracy in estimating sleep varies between population groups and from one device to the other (Broughton 1996, Lotjonen 2003, Ancoli 2003, Flemons 2003, Kuna 2010, Meltzer 2012, Blackwell 2011).

Actigraphy was reviewed by MTAC in 2007 and 2011 for detecting obstructive sleep apnea (OSA), and in 2008 for the assessment of sleep disorders, and did not meet the Committee's evaluation criteria. The technology is being re-reviewed for its use for the evaluation of insomnia and circadian rhythm disorders.

## Medical Technology Assessment Committee (MTAC)

### ***Actigraphy in the Treatment of Sleep Disorders***

#### **12/03/2007: MTAC REVIEW**

**Evidence Conclusion:** The studies that evaluated the use of actigraphy for the assessment of sleep apnea did not use the technology alone but embedded/ or combined it with other devices as peripheral arterial tonometers (PAT), or respiratory polygraphs. Watch-PAT 100 was the device most commonly used in the published studies. The actometer estimated the total sleep time while the tests of respiratory function were used to calculate the apnea severity, and apnea hypopnea index (AHI). To date, there are no published controlled trials that would determine whether actigraphy can replace PSG or provide incremental information that would impact patient management decisions or improve health outcomes.

The population sizes of the studies varied from <20 patients to just over 200, and the majority assessed the portable monitors simultaneously with PSG in sleeping laboratories in the presence of sleep clinicians, and not in unattended settings. This would be ideal for testing the ability of the monitors to work but does not assess its performance in the patient's home where it is intended, which in turn may limit extrapolation of the results. Moreover, the studies mainly included patients referred to sleep laboratories for suspected OSA. The high prevalence of the disorder among these patients would affect the sensitivity, specificity and likelihood ratios of the test that would also limit generalization of the results.

**Diagnostic accuracy:** Different algorithms were used for the evaluation of data. The investigators examined multiple respiratory disturbance index (RDI) thresholds for determining abnormal apnea hypopnea index (AHI) and define a positive result. The cutoff for used for AHI was arbitrary and varied between studies. Some investigators question the use of AHI as the correct reference standard. The Watch-PAT does not measure airflow and thus cannot differentiate hypopneas from apneas. Overall the results of the studies show that using PSG as the gold standards, the sensitivity of actigraphs embedded in peripheral arterial tonometers ranged from 82-90%, and specificity ranged from 68-90% depending on severity of the obstructive sleep apnea. The sensitivity tended to be lower, and specificity higher with increasing severity the disorder. The area under the curve (AUC) also varied between studies with severity of sleep apnea, and its measures. It ranged from 0.82 for patients with RDI.>10 in Bar's study, to 0.98 for AHI >30 in Garcia-Diaz study. This latter study also compared the respiratory polygraph (RP) performed in the hospital versus that at home, either with or without the addition of actigraphy. Its results showed that RP performed at the laboratory was more accurate than that done at home, and that the addition of actigraphy did not result in significant improvement but tended to overestimate sleep time. The agreement rate between actigraphy devices and PSG was reported in some studies and ranged from 80% to 93%, also depending on the severity of the obstructive sleep apnea.

**Diagnostic impact:** There is insufficient evidence to determine that actigraphy can provide information that may influence the management decisions for patients diagnosed with obstructive sleep apnea. **Therapeutic impact:** There is insufficient evidence to determine that using actigraphy for the diagnosis of obstructive sleep apnea would improve health outcomes.

**Articles:** The literature search revealed over 500 articles on actigraphy. The majority of the published studies used the technology to investigate patients with insomnia, circadian rhythm sleep disorders, and as an outcome measure to determine response of therapy, mainly melatonin 1. **Diagnostic accuracy** There were no randomized or nonrandomized trials that compared the results of actigraphy used alone, to polysomnography to determine if it can be used as an alternative to PSG in the diagnosis of obstructive sleep apnea. There were several studies that focused on the accuracy and usefulness of actigraphy in evaluating patients with obstructive sleep apnea. These studies, however, did not use actigraphs alone, but combined it with tests of respiratory function in order to calculate the apnea hypopnea index which measures the severity of apnea in these patients. The studies that compared the wrist worn devices with embedded actigraphs used PSG as the gold standard, and reported sensitivity, specificity, likelihood ratios or areas under the receiver operator curves were selected for critical appraisal. 2. **Diagnostic impact** the literature search did not reveal any study that would determine the influence of the technology on management decisions. 3. **Therapeutic impact** No studies on the impact of technology on patient outcomes were identified by the search. *The following studies were critically appraised:*

Ayas NT, Pittman S, MacDonald M, et al. Assessment of a wrist-worn device in the detection of obstructive sleep apnea. *Sleep Medicine* 2003;4:435-442 See [Evidence Table](#). Bar A, Pillar G, Dvir I, et al. Evaluation of a portable device based on peripheral arterial tone for unattended sleep studies. *Chest* 2003;123:695-703 See [Evidence Table](#). Garcia-Diaz E, Quintana-Gallege E, Ruiz A, et al. Respiratory polygraphy with actigraphy in the diagnosis of sleep apnea-hypopnea syndrome. *Chest* 2007; 131:725-732. See [Evidence Table](#). Hedner J, Pillar G, Pittman SD, et al. A novel adaptive wrist actigraphy algorithm for sleep-wake assessment in sleep apnea patients. *Sleep* 2004; 27:1560-1566. See [Evidence Table](#) . Zou D, Grote L, Peker Y, et al. Validation a portable monitoring device for sleep apnea diagnosis in a population-based cohort using synchronized home polysomnography. *Sleep* 2006; 29:367-374. See [Evidence Table](#).

The use of actigraphy in the treatment of obstructive sleep apnea does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 02/04/2008: MTAC REVIEW

### Actigraphy in the Treatment of Sleep Disorders

**Evidence Conclusion:** The published studies that evaluated actigraphy for the assessment of insomnia were conducted on selected groups of patients and used different actigraph models, software, and scoring algorithms. Most studies were conducted in sleep laboratories where recording conditions are standardized, and the artifacts controlled. These controls would be lost when the actigraphy devices are used in the home environment, where it is intended for use. Also, the algorithms that were validated for a specific model, mode of operation, or in a selected population may by not be equally accurate when used with a different brand of device, different gender or age group. The studies reviewed compared actigraphy to PSG, but the authors did not indicate whether the investigators interpreting the results of one test were blinded to the results of the other. The overall results of the studies reviewed, indicate that compared to polysomnography, actigraphy had a high sensitivity (92-98%) but very low specificity (28-48%) in detecting insomnia. It was also found to overestimate the total sleep time and sleep efficiency. Actigraphy tends to overestimate sleep in people with insomnia when they are lying quietly as quiet wakefulness could be miscoded as sleep. Insomnia patients can remain inactive for a period of time attempting to fall asleep. On the other hand, actigraphy may underestimate the amount of sleep and overestimate the duration

awake among those who are asleep but are restless or have large amounts of movements during sleep. The use of actigraphy for the assessment of periodic leg movements in sleep was evaluated in only a few small studies with methodological limitations. It was compared with polysomnography with bilateral anterior tibialis electromyography (BATEMG). However, EMG and leg actigraphy are not interchangeable, and each measures a different event. One records electrical activity of a certain muscle and the other records leg acceleration. Leg activity may be due to movement artifacts produced by obstructive sleep apnea. Kemlink et al (2007) did not exclude patients with suspicious sleep apnea and did not adjust for it in the analysis. In conclusion there is insufficient evidence to determine that actigraphy would replace PSG or add to its value in the diagnosis and management of patients with sleep disorders.

**Articles:** The following questions were considered in screening the published articles:

- 1) What is the diagnostic accuracy of actigraphy in the evaluation of patients with sleep disorders?
- 2) Does the use of actigraphy influence management decisions?
- 3) Does actigraphy lead to better treatment outcomes?

The literature search revealed over 500 articles on actigraphy. Due to the continuing development in the actigraphic devices, operating procedures, software, and scoring algorithms, the literature was screened to identify the more recent studies. Many of these used actigraphy to assess treatment effects or compared results from one actigraphy scoring algorithm to another. Others reported on the use of actigraphy in specific groups as very young infants, children with ADHD, patients with depression, dementia, Parkinson's disease, and others. There were a number of nonrandomized studies that compared actigraphy with other tools for the evaluation of patients with insomnia, periodic leg movement, narcolepsy and other medical disorders other than sleep disorders. The literature search did not reveal any study that would determine the influence of the technology on management decisions or its impact on patient outcome. *The following studies that compared actigraphy with the gold standard of polysomnography were critically appraised:* Kushida CA, Chang A, Gadkary C, et al. comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients. Sleep Medicine 2001;2:389-396. [See Evidence Table 3](#) and [see Evidence Table 4](#). Sivertsen B, Omvik S, Havik OE, et al. A comparison of actigraphy, polysomnography in older adults treated for chronic primary insomnia. Sleep 2006; 29:1353-1358. [See Evidence Table](#). Lichstein K, Stone KC, Donaldson J, et al. Actigraphy validation with insomnia. Sleep 2006; 29:232-239. [See Evidence Table](#). Kemlink D, Pretl M, Sonka K, et al. A comparison of polysomnographic and actigraphic evaluation of periodic limb movement in sleep. Neurol Res 2007; 000:1-5. [See Evidence Table](#). King MA, Jaffre MR, Morrish E, et al. The validation of a new actigraphy system for the measurement of periodic leg movement in sleep. Sleep Medicine 2005; 6:507-513. [See Evidence Table](#).

The use of actigraphy in the treatment of sleep disorders does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

02/04/2011

### **Actigraphy in the Treatment of Sleep Disorders**

**Evidence Conclusion:** Accuracy of actigraphs/portable monitors for the detection of OSA. There were no published studies that compared portable monitors head-to-head. The accuracy of one device cannot be extrapolated to others even from the same class due to the differences in the number and types of signals recorded, sensors used, and the processing of signals. It is unknown which sensors or combinations have the highest sensitivity and specificity. Moreover, differences in scoring, testing environment, and night to night variability in the apnea hypopnea index (AHI) make generalization of results difficult. The studies that evaluated the use of actigraphy for the assessment of sleep apnea did not use the technology alone but embedded or combined it with other devices such as peripheral arterial tonometers (PAT), or respiratory polygraphs. Watch-PAT 100 was the device most commonly used in published studies. The actometer estimated the total sleep time while the tests of respiratory function were used to calculate the apnea severity, and apnea hypopnea index. As indicated in the 2007 review of the technology, the overall results of the studies reviewed showed that using PSG as the gold standards, the sensitivity of actigraphs embedded in peripheral arterial tonometers ranged from 82-90%, and specificity ranged from 68-90% depending on severity of the obstructive sleep apnea. The sensitivity tended to be lower, and specificity higher with increasing severity the disorder. The agreement rate between actigraphy devices and PSG was reported in some studies and ranged from 80% to 93%, also depending on the severity of the obstructive sleep apnea. Therapeutic impact of actigraphs/portable home monitors: In a randomized controlled trial that included 106 subjects with a high likelihood of OSA, Berry and colleagues (Evidence table 1) compared a clinical pathway with the watch-PAT 100 for the diagnosis and unattended autotitrating continuous positive airway pressure (CPAP) for those with an respiratory disturbance index (RDI) > 5 events /hour) to select an effective CPAP, versus standard in-laboratory PSG for diagnosis of OSA and CPAP titration. Using a similar approach, Skomro and colleagues' trial (Evidence table 2) randomized 102 subjects with high a probability of OSA to either home-based diagnosis (using Embletta device that incorporates an actigraph) and auto-CPAP (APAP) or in-laboratory PSG. The in-home study was considered positive if the respiratory

disturbance index (RDI) was  $> 5$ , and patients were offered auto-CPAP therapy for 1 week followed by fixed-pressure CPAP based on the auto-CPAP P95 results. An earlier trial (Mulgrew 2007) compared a type IV portable monitor and APAP titration to in-laboratory PSG in 68 patients (22% of the eligible population) with moderate to severe OSA and followed the patients for 3 months. All three trials showed no statistically significant differences in the Epworth Sleepiness Scale scores, quality of life scores, and other outcome studied between patients in the in-home diagnosis and auto CPAP titration group versus those in-laboratory PSG diagnosis and CPAP titration. These results however, should be interpreted with caution, and may not be generalized to the population at large due to several factors including but not limited to: participants in the studies were highly selected, had high pre-test probability of OSA, were mainly men, those with co-morbidities were excluded, short duration of follow-up, patients and/or providers were not blinded, and most of the participants in the PSG group had split-night PSG, which may lead to different outcomes of CPAP therapy than those derived from a full-night of CPAP titration. In addition, the studies were powered as superiority and not equivalence trials, and lack of significant differences does not necessarily indicate equivalence. Berry and colleagues powered their trial as noninferiority, but only for the compliance outcome. More high-quality randomized trials are needed to compare clinical outcomes of laboratory PSG versus home monitoring for sleep disorders among diverse population groups e.g. ethnic groups, women, the elderly, and patients with cardiopulmonary and neurological diseases as COPD, asthma, heart failure, neuromuscular diseases, and other sleep disorders.

**Articles:** The literature search revealed over 400 articles on actigraphy. The great majority were unrelated to the current review. The technology was frequently used to determine response of therapies for insomnia, mainly melatonin. There were few small validation studies on different portable monitor devices for diagnosing obstructive sleep apnea. There were no head-to-head comparisons between the devices for accuracy in detecting OSA. The search identified two published trials that compared the outcomes of in-laboratory diagnosis and treatment of OSA versus home-based diagnosis and treatment using portable monitoring devices that incorporated an actigraph. Both were critically appraised. Berry RB, Hill G, Thompson L, et al. Portable monitoring and autotitration versus polysomnography for the diagnosis and treatment of sleep apnea. *Sleep* 2008; 31:1423-1431. [See Evidence Table.](#) Skormo RP, Gjevrå J, Reid J, et al. Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. *Chest* 2010; 138:257-263. [See Evidence Table.](#)

The use of actigraphy in the treatment of sleep disorders does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/19/2013: MTAC REVIEW

### Actigraphy in the Treatment of Sleep Disorders

**Evidence Conclusion:** The published studies that evaluated actigraphy for the assessment of insomnia as a primary outcome or in a secondary analysis were conducted on selected groups of patients and used different actigraph models, software, and scoring algorithms. The majority of sleep studies were conducted in sleep laboratories where the recording conditions are standardized, and the artifacts controlled. These controls would be lost when the actigraphy devices are used in the home environment, which is the primary intention for their use. In addition, the authors of the studies that compared actigraphy to PSG did not indicate whether interpretation of the results of one test was blinded to the results of the other. According to Sadeh (2011), a point that deserves attention is that actigraphic validation studies against PSG are all based on “time in bed” period whereas the main advantage of actigraphy is documenting sleep wake patterns continuously over 24-hour periods across days. Generalization of the results of the published studies may be limited to similar devices and population groups as the algorithms that were validated for a specific model, mode of operation, or in a selected population may not be equally accurate when used with a different brand of device, different gender, or age group. The results of the studies previously reviewed for MTAC showed that compared to polysomnography, actigraphy had a high sensitivity (92-98%) but very low specificity (28-48%) in detecting insomnia. These older as well as the more recent studies showed that actigraphy in general underestimates wake and overestimates the total sleep time and sleep efficiency. Individuals with insomnia can remain inactive for a period of time attempting to fall asleep, and actigraphy tends to overestimate sleep in these people as quiet wakefulness could be miscoded as sleep. On the other hand, actigraphy may underestimate the amount of sleep and overestimate the duration awake among those who are asleep but are restless or have large amounts of movements during sleep. A number of studies measured the correlation of actigraphy and PSG sleep outcomes as a measure of validity of actigraphy. These ranged between studies from 0.51-0.93 for total sleep time (TST), 0.48-0.85 for wake time after sleep onset (WASO), 0.36-0.81 for sleep efficiency (SE), and 0.30-0.95 for sleep onset latency (SOL). The MrOS Sleep Study (Blackwell et al, 2011), (Evidence Table 1) was embedded in the Osteoporotic Fractures in Men (MrOS) study and examined whether there was a difference between in home-PSG and actigraphy (using the Sleepwatch-O device) in estimating the total sleep time (TST). The authors used 3 modes for collecting actigraphic data to determine the one that corresponds highest with PSG. These modes were the proportional integration mode (PIM), time above threshold (TAT), and zero crossings mode (ZCM). PIM mode is a measure of

© 2007 Kaiser Foundation Health Plan of Washington. All Rights Reserved. [Back to Top](#)



the activity level or vigor of motion, the TAT mode measures time spent in motion or time spent in active state, and the ZCM measures the frequency of movement. The study had the advantage of including a large population size of community dwelling individuals and the use of in-home PSG as a gold standard. It however, only included men >60 years of age; and the PSG data were collected in 30-minute epochs while the actigraphy data were collected in 1-minute epochs with no synchronization in the clock time. This did not allow direct comparisons for each epoch. In addition, the authors did not explain whether the study participants were asked to complete sleep diaries. The results of the analysis showed that the three actigraphy modes either over-estimated or underestimated sleep and wake compared to PSG. The PIM mode of actigraphy corresponded more closely with PSG estimation of total sleep time (TST) than the TAT or ZCM modes, yet the correlation was weak to moderate. These results, however, may not be generalized to populations in different age groups or to other actigraphy devices. Van Den Berg and colleagues, 2008 (Evidence Table 2) measured the disagreement among actigraphy and sleep diary in estimating the total sleep time (TST) among 969 community dwelling elderly men and women participating in a cohort study that primarily investigated the incidence and risk factors of disabling disease. The participants in this sub study wore an actigraph (Actiwatch model AW4) and kept a sleep diary over a period of 5-7 consecutive days and nights. PSG was not used as the gold standard, but the authors only used the Actiwatch algorithm that was validated against polysomnography. The results of the analysis showed that, the estimated TST in the sleep diaries deviated more than one hour from that measured by actigraphy among 34% of the participants. The level of this disagreement decreased with subjective and actigraphic measures of sleep quality and increased with male gender, poor cognitive function, and functional disability. In a smaller study, Levenson and colleagues 2013 (Evidence Table 3) also compared the accuracy of actigraphy versus sleep diary among a group of older insomniac patients participating in a larger study that examined the effect of behavioral therapy on insomnia in older adults. The study included 119 participants with a mean age of 71.7 years (79 with insomnia confirmed with PSG, and 40 controls who did not undergo a PSG). The participants completed at least 7 nights of sleep diary and actigraphy (using the Minimitter Actiwatch). The results of the analyses indicate that the sleep diary parameters discriminated individuals with insomnia from good sleepers more accurately than actigraphy. The AUC of actigraphy was in the low to moderate range (0.58 for sleep efficiency, and 0.61 for total sleep time, the 95% CI contained the value of 0.5 for many of the parameters). Johnson and colleagues, 2007 (Evidence Table 4) examined the level of agreement between actigraphy and polysomnography among 181 adolescents 12-16 years of age. All participants completed an overnight PSG in a clinical research center. The week prior to the PSG and during the overnight PSG study, they wore a wrist actigraph (Octagonal Sleep watch 2.01) and completed daily sleep logs. Data were digitized in 1-minute epochs and the activity count was calculated and stored based on 1 of 3 data modes: PIM, TAT, and ZCM. The results of the analysis showed significant differences between the assessments of total sleep time by actigraphy vs. PSG. The differences were more pronounced for boys vs. girls and for those with sleep disturbed breathing. In conclusion there is insufficient evidence to determine that actigraphy would replace PSG or add to its value in the diagnosis and management of patients with insomnia or circadian rhythm disorders.

**Articles:** The literature search revealed over 800 articles published on actigraphy and sleep in the last 5 years. The great majority was unrelated to the current review; many reported on the use of actigraphy in specific groups as very young infants, children with ADHD, patients with depression, dementia, Parkinson's disease, and others. There was a lack of published studies on the use of actigraphy in patients with circadian rhythm sleep disorders. The studies that compared the use of actigraphy versus PSG for the evaluation of insomnia were mainly embedded in larger community-based studies conducted among specific age groups and for studying different conditions and/or factors that were not necessarily related to sleep. The following studies with more valid methodology, larger population size, and used actigraphy concurrently with PSG and /or sleep diary were selected for critical review. Blackwell T, Ancoli-Israel S, Redline S, Stone KL; Osteoporotic Fractures in Men (MrOS) Study Group. Factors that may influence the classification of sleep-wake by wrist actigraphy: the MrOS Sleep Study. *J Clin Sleep Med.* 2011;7:357-367 [See Evidence Table](#). Johnson NL, Kirchner HL, Rosen CL, et al. Sleep estimation using wrist actigraphy in adolescents with and without sleep disordered breathing: a comparison of three data modes. *Sleep.* 2007; 30:899-905. [See Evidence Table](#). Levenson JC, Troxel WM, Begley A, et al. A quantitative approach to distinguishing older adults with insomnia from good sleeper controls. *J Clin Sleep Med.* 2013; 9:125-131. [See Evidence Table](#). Van Den Berg JF, Van Rooij FJ, Vos H, et al. Disagreement between subjective and actigraphic measures of sleep duration in a population-based study of elderly persons. *J Sleep Res.* 2008; 17:295-302. [See Evidence Table](#).

The use of actigraphy in the evaluation of obstructive sleep apnea does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
<b>95803</b>	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/20/2007	12/07/2010 <sup>MDCRPC</sup> , 04/05/2011 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 04/01/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 04/05/2016 <sup>MPC</sup> , 02/07/2017 <sup>MPC</sup> , 12/05/2017 <sup>MPC</sup> , 10/02/2018 <sup>MPC</sup> , 10/01/2019 <sup>MPC</sup> , 10/06/2020 <sup>MPC</sup> , 10/05/2021 <sup>MPC</sup> , 10/04/2022 <sup>MPC</sup> , 10/03/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup>	02/07/2017

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description of Change
04/01/2004	Criteria was retired
04/07/2015	Remove criteria from retired status. Medical necessity review will be effective July 5, 2015.
02/07/2017	Medicare is silent; MPC approved to adopt KAISER PERMANENTE criteria for Medicare members



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Acupuncture

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Acupuncture (30.3)</a> <a href="#">Acupuncture for Fibromyalgia (30.3.1)</a> <a href="#">Acupuncture for Osteoarthritis (30.3.2)</a> <a href="#">Acupuncture for Chronic Lower Back Pain (cLBP) (30.3.3)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Medicare Members

Medicare allows up to 12 acupuncture treatments in a 90-day period for chronic low back pain diagnoses.

#### Provider Credential Requirements:

Physicians (as defined in 1861(r)(1)) may furnish acupuncture in accordance with applicable state requirements.

Physician assistants, nurse practitioners/clinical nurse specialists (as identified in 1861(aa)(5)), and auxiliary personnel may furnish acupuncture if they meet all applicable state requirements and have:

A masters or doctoral level degree in acupuncture or Oriental Medicine from a school accredited by the Accreditation Commission on Acupuncture and Oriental Medicine (ACAOM); and current, full, active, and unrestricted license to practice acupuncture in a State, Territory, or Commonwealth (i.e. Puerto Rico) of the United States, or District of Columbia.

Auxiliary personnel furnishing acupuncture must be under the appropriate level of supervision of a physician, physician assistant, or nurse practitioner/clinical nurse specialist required by our regulations at 42 CFR §§ 410.26 and 410.27.

The patient must have a diagnosis of chronic low back pain which meets **ALL** the following:

1. Lasting 12 weeks or longer;
2. Nonspecific in that it has no identifiable systemic cause (i.e., not associated with metastatic, inflammatory, infectious, etc. disease);
3. Not associated with surgery; and
4. Not associated with pregnancy.

An additional eight (8) sessions may be covered for patients with chronic low back pain, as defined in 1-4 above, demonstrating improvement. No more than 20 treatments will be covered annually, *unless otherwise allowed by the member's contract.*

Clinical review criteria for additional visits are based on documentation of baseline PEG\* score at the first visit and are as follows:

1. Documentation of improvement should be sustained across 2 assessments made 1-4 weeks apart and include 1 or more of the following:
  - a. 30% improvement from baseline PEG\* score (documented at visit 10-12)
  - b. ≥ 2-point improvement on a 0 to 10 point scale like the PEG
  - c. Physician attestation of functional improvement and/or analgesic use reduction
2. Treatment must be discontinued if the patient is not improving or is regressing.

All types of acupuncture for any condition other than chronic low back pain are non-covered by Medicare **but may be covered as a supplemental benefit. Please check the member's EOC to confirm.**

\*For more information on the PEG score, review the *Assessment* section of the Clinical Guideline for [Back Pain](#)

### For Non-Medicare Members

Authorizations for covered acupuncture treatments beyond eight visits (per condition that is not specifically excluded by the member contract) require prior approval by the health plan. Clinical review criteria for acupuncture are as follows. The patient must meet **ALL of the following**:

1. The condition has symptoms present on a daily basis resulting in functional limitations (decreased ability to perform activities of daily living) and has not resolved within a typical time frame of a self-limited illness or injury.
2. The patient has an established, documented diagnosis of one of the following:
  - a. Chronic arthritis
  - b. Fibromyalgia (The patient has an established, documented diagnosis of fibromyalgia consistent with the 1990 American College of Rheumatology Criteria.)
  - c. Chronic myofascial pain (Clinical conditions that frequently fall into this category include cervicalgia, chronic neck and back pain, lumbago, muscular tension headaches, plantar fasciitis, and thoracic outlet syndrome.)
  - d. Chronic neuropathic pain
  - e. Chronic headaches
  - f. Dysmenorrhea
  - g. Hyperemesis with pregnancy
  - h. Nausea and vomiting associated with chemotherapy
  - i. Chronic pain secondary to cancer
  - j. Other medical conditions that have responded to an initial course of acupuncture with expectation of continued functional improvement.
3. There is documentation of the patient's baseline measurable functional limitations related directly to one of the above diagnoses.
4. Continued treatment is part of a defined treatment plan with measurable and progressive functional improvement. Maintenance therapy in the absence of progressive functional improvement is not an indication for coverage.
5. Acupuncture is covered for flares of pain when acupuncture has provided clinical improvement in the past.

Review staff will consider each referral request on a case-by-case basis and will consider requests outside the above criteria based on, among other things, clear documentation of objective improvement by the licensed acupuncturist or the patient's personal physician, as well as a detailed treatment plan.

### If requesting these services, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Acupuncture originated in China about 5000 years ago as part of an organized approach to diagnosis and healing that became known as Traditional Chinese Medicine (TCM). According to TCM principles, disease is caused by imbalances in the flow of energy (qi) through 14 major energy pathways, or meridians. Acupuncture seeks to rebalance the flow of qi by inserting special needles at specific points along the meridians. Needling is commonly combined with heat or electricity.

Licensed acupuncturists in Washington must complete a minimum of three years of training at an accredited school. Training includes basic sciences, needling techniques, and herbal medicine.

## Evidence and Source Documents

There is a small body of literature supporting the efficacy of acupuncture. There is also case documentation that supports the value of acupuncture for treatment of specific clinical conditions, particularly chronic pain.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>97810</b>	Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
<b>97811</b>	Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)
<b>97813</b>	Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
<b>97814</b>	Acupuncture, 1 or more needles; with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
11/15/2002	01/05/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 04/01/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	05/05/2020

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/07/2020	MPC approved to endorse the new Medicare Acupuncture criteria (new Medicare policy that went into effect on January 21, 2020).
05/05/2020	MPC approved to adopt updates defining Medicare provider credential requirements; Added new CMS NCD 30.3.3

## Kaiser Foundation Health Plan of Washington

### PATIENT REFERRAL GUIDELINES

#### Heart Transplantation<sup>i</sup>

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Heart Transplants (260.9)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Transplantation may be considered for patients with end-stage or life-threatening disease who have no prospect for prolonged survival, or whose quality of life is severely impaired. The following are current, generally accepted, guidelines for Heart transplantation. These guidelines for referral for transplant evaluation and are not intended as an automatic inclusion or exclusion of a candidate for referral. As such, these should be applied together with careful clinical judgment.

#### 1. GENERAL PRINCIPLES

- 1.1. If clinical parameters of end-stage or life-threatening disease indicate the need for transplantation, then early referral should be made.
- 1.2. Patients with a history of malignancy with a moderate to high risk of recurrence (as determined after consultation with oncologist considering tumor type, response to therapy, and presence or absence of metastatic disease) may be unsuitable candidates for transplantation. Patients with low risk of recurrence may be considered.
- 1.3. Uncontrollable active infection is a contraindication to transplant.
- 1.4. Candidates with a history of substance abuse must be free from alcohol and other substance abuse for six (6) months and have been evaluated by a substance abuse program. The risk of recidivism, which has been documented to negatively impact transplant outcomes, must be addressed and considered to be low <sup>ii</sup>, <sup>iii</sup>, <sup>iv</sup>. Exceptions may be made on a case-by- case basis.
- 1.5. Candidates for thoracic organ (heart, lung and heart/lung) transplants must be free from tobacco use for the previous six (6) months. Routine monitoring may be required. Specific programs for abdominal organs (liver, intestines and kidney) may require abstinence from tobacco products to be actively listed.
- 1.6. Candidates must have adequate social support systems and display a proven record of adherence to medical treatment.
  - 1.6.1. Patient must have a care giver or care givers who are physically and cognitively able to assist the patient with self-care activities and are available to travel within short notice to the KP approved transplant Center of Excellence.
  - 1.6.2. Evidence of non-adherence may be failure to keep appointments, failure to make steady progress in completing pre-transplant evaluation requirements, failure to accurately follow

<sup>i</sup> Note: All patients must be continuously re-evaluated for indications and contraindications. Candidates considered for re-transplantation must be evaluated using the same indications.

medication regimens or failure to accomplish the activities required for maintenance on the waiting list.

- 1.7. Patients must be willing and able to travel within short notice to the KP approved transplant Center of Excellence and, if necessary, return for treatment of complications.
- 1.8. The presence of significant irreversible neurologic dysfunction, active psychological and/or psychiatric conditions, and/or other social behaviors that prevent adherence with a complex medical regimen, are considered contraindications for referral for transplant.
- 1.9. Whenever transplant is considered as an option and discussed with the patient and/or family, consultation with Advanced Life Care Planning/Palliative Care resources is strongly recommended.

## 2. INDICATIONS FOR HEART TRANSPLANT

2.1. End-stage heart disease as evidenced by one or more of the following:

- 2.1.1. Functional class III or IV
- 2.1.2. Not correctable by medical or other surgical therapies
- 2.1.3. A low VO<sub>2</sub> maximum: <sup>ii</sup>
  - 2.1.3.1. ≤14 ml/kg/min in patients not on a beta blocker
  - 2.1.3.2. ≤12 ml/kg/min in patients on a beta blocker <sup>iii</sup>
  - 2.1.3.3. <19 ml/kg/min adjusted for lean body mass in patients with a BMI >30 kg/m<sup>2</sup>
  - 2.1.3.4. Less than 50% of age predicted maximum.
- 2.1.4. A VE/VO<sub>2</sub> >35 in a patient with a sub-maximal cardiopulmonary exercise test (RER <1.05)<sup>2</sup>
- 2.1.5. Cardiac index < 2 L/min/m<sup>2</sup>

2.2. Unable to wean from mechanical or inotropic support.

2.3. Amyloid Cardiomyopathy

- 2.3.1. TTR Amyloid
- 2.3.2. (AL) Amyloidosis without significant extra-cardiac involvement.

2.4. Refractory Life-Threatening Arrhythmias

3. The transplant should only be offered for conditions in which cardiac transplant has proven clinical benefits.

### **CONTRAINDICATIONS FOR HEART TRANSPLANT (In conjunction with the *General Principles* listed above in Section 1 of these guidelines):**

3.1. Significant diseases such as:

- 3.1.1. Severe uncontrolled or poorly controlled hypertension.
- 3.1.2. Clinically significant vascular disease not correctable by intervention.
- 3.1.3. Pulmonary hypertension not reversible by drug manipulation despite maximum tolerated medical management. <sup>iv</sup>
  - 3.1.3.1. Adults: PVR > 4-6 Wood units or transpulmonary gradient > 15 mm Hg
  - 3.1.3.2. Children: PVR > 9 Wood units

3.1.4. Severe pulmonary disease after optimal treatment of severe heart failure. <sup>viii</sup>

3.1.5. Severe hepatic disease after optimal treatment of severe heart failure. <sup>viii</sup>

<sup>i</sup> Journal of Heart & Lung Transplantation, Vol.25 Number 9, pp1024 -1042. Listing Criteria for Heart Transplantation ISHLT Guidelines for the Care of Cardiac Transplant Candidates – 2006.

<sup>iii</sup> Patients on Beta blockers should have a cut-off of ≤12 ml/kg/min, and patients intolerant to beta blockers a VO<sub>2</sub> ≤14 ml/kg/min.

<sup>iv</sup> Circulation; 84 (3), 329 – 337. *Journal of Heart Transplantation* (1990): 526 – 537.

© 1996 Kaiser Foundation Health Plan of Washington. All Rights Reserved.



- 3.1.6. Kidney disease with creatinine clearance <34 ml/kg/min or GFR < 30 ml/min after optimal treatment of heart failure.<sup>v, vi, vii</sup>
- 3.1.7. Active and/or progressive central nervous system disease excluding patients with embolic stroke who have recovered completely.
- 3.1.8. Evidence of cachexia or malnutrition (BMI < 19 kg/m<sup>2</sup> or < 80% ideal body weight).<sup>x</sup>
- 3.1.9. Obesity (BMI>35 kg/m<sup>2</sup> or > 140% ideal body weight) <sup>xi</sup> has been associated with poor outcomes after cardiac transplant.
- 3.1.10. Diabetes with complications resulting in severe end-organ damage.
- 3.1.11. Auto/acquired immune disease with multi-organ manifestation
- 3.1.12. Acute pulmonary embolus
- 3.1.13. Active peptic ulcer disease
- 3.1.14. Severe symptomatic osteoporosis
- 3.1.15. Age over 70 (Carefully selected patients over 70 years of age may be considered for cardiac transplantation)
- 3.1.16. AL Amyloidosis with significant extra-cardiac manifestations
- 3.1.17. Patients with viral hepatitis will require additional evaluation, including hepatology consultation.
- 3.1.18. Any other co-morbid condition that would limit life expectancy or quality of life.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

A heart may be irreversibly damaged by long-lasting heart disease or viral infection. When the heart can no longer adequately work, and a person is at risk of dying, a heart transplant may be appropriate.

Cardiac transplant has become increasingly successful over the past several years. Adult heart transplant recipients have a one-year survival rate of eighty to ninety percent and a five-year survival rate of sixty to seventy percent. Kaiser Permanente contracts have included coverage for heart transplantation for several years. Members with coverage who meet the selection criteria are considered for transplantation.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
33940	Donor cardiectomy (including cold preservation)

<sup>v</sup> Selected patients for possible combined or staged heart/kidney transplant will be evaluated on a case-by-case basis.

<sup>vi</sup> Must have 20mg per kilogram of creatinine in a 24-hour collection period. Creatinine clearance can also be calculated by the Cockcroft-Gault formula.

<sup>vii</sup> The Journal of Heart & Lung Transplantation, Vol. 35, Issue 7, p893-900. Evidence Supports Severe Renal Insufficiency as a relative contraindication to heart transplantation—2016.

<b>33944</b>	Backbench standard preparation of cadaver donor heart allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare aorta, superior vena cava, inferior vena cava, pulmonary artery, and left atrium for implantation
<b>33945</b>	Heart transplant, with or without recipient cardiectomy

**\*\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/1996	07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 12/03/2024 <sup>MPC</sup>	04/06/2021

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MDCRPC</sup> Medical Policy Committee

Revision History	Description
03/05/2019	MPC approved to adopt Kaiser Permanente National Criteria for Heart Transplant
03/03/2020	MPC approved updates for Kaiser Permanente National Transplant Services patient referral guidelines
06/12/2020	Changed "criteria" to guidelines" where appropriate; updated to reflect current patient referral guidelines that were approved 03/03/2020
04/06/2021	Per National Transplant Guidelines: 1.3 added "active"

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Advanced Bronchoscopy Techniques

- Endobronchial ultrasound
- Electromagnetic navigation

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	<p>Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "<b>Endobronchial Ultrasound</b>" for medical necessity determinations. Use the Non-Medicare criteria below.</p> <p>Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "<b>Electromagnetic Navigation Bronchoscopy (ENB)</b>" for medical necessity determinations. Use the Non-Medicare criteria below.</p>

#### For Non-Medicare Members

**Effective until August 1, 2025**

Service	Criteria	
Endobronchial Ultrasound (common CPT 31652, 31653, 31654, C7512)	Kaiser Permanente has elected to use the Endobronchial Ultrasound (A-1049) MCG* Care Guideline for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under <i>Quick Access</i> .	
Electromagnetic Navigation (common CPT 31627, 31654)	Biopsy of Peripheral Lesions	Electromagnetic navigation is covered when performed with biopsy of peripheral lesions.
	Fiducial Marker Placement	Electromagnetic navigation is not covered when used for Fiducial Marker Placement as there is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better

		long-term outcomes than current standard services/therapies.
--	--	--

## Effective August 1, 2025

Service	Criteria	
<b>Endobronchial Ultrasound</b> (common CPT 31652, 31653, 31654, C7512)	Kaiser Permanente has elected to use the Endobronchial Ultrasound (A-1049) MCG* Care Guideline for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under <i>Quick Access</i> .	
<b>Electromagnetic Navigation-Guided Bronchoscopy</b> (common CPT 31627)	Biopsy of Peripheral Lesions	Electromagnetic navigation is covered when performed with biopsy of peripheral lesions not accessible by standard bronchoscopy methods or by a percutaneous transthoracic biopsy approach.
	Fiducial Marker Placement	Electromagnetic navigation is not covered when used for Fiducial Marker Placement as there is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Flexible bronchoscopy (FB) is a minimally invasive procedure that is used for the diagnosis and treatment of lung cancer. Research suggests that the sensitivity of FB is approximately 88% for diagnosing central lesions and 78% for diagnosing peripheral lesions (most commonly defined as lesions that are not visible beyond the visual segmental bronchi). However, the sensitivity of FB is dependent on lesion size. FB does not perform as well for smaller peripheral lesions. It has been estimated that for peripheral lesions less than 2 cm in diameter the sensitivity of FB is approximately 34% (Rivera 2007).

Electromagnetic navigation bronchoscopy (ENB) is a relatively new bronchoscopic tool that combines CT-generated virtual bronchoscopy and electromagnetic tracking of a steerable probe to allow physicians to perform biopsy of peripheral lesion that are not accessible through conventional bronchoscopy. It has also been suggested that mediastinal lymph nodes can be biopsied using ENB. Other uses of ENB include implantation of fiducial markers for radiotherapy, implantation of brachytherapy seeds or catheters, and dye marker placement for surgical resection.

Several ENB systems have received FDA approval. ENB using the superDimensions I Logic™ System (superDimensions, Inc. Minneapolis, MN) is performed in three phases – planning, registration, and navigation and biopsy (Bechara 2011, Schwartz 2010).

1. Planning: A three-dimensional image of the patient's lungs with anatomical landmarks is constructed using previously taken CT scans and proprietary software.

2. Registration: The steerable navigation catheter is inserted through the bronchoscope. The three-dimensional image with anatomical landmarks created in the planning phase is viewed and correlated with the actual image from the video bronchoscope. The position of each landmark is marked using a foot pedal.
3. Navigation and biopsy: The steerable catheter is used to navigate to the lesion. The location of the catheter's tip is displayed on the CT images. Once the catheter reaches the target, it is locked in place, and the working guide is retracted. Once the catheter is in place, any endoscopic tool can be inserted through the channel. This includes transbronchial forceps to biopsy the lesion or guide wire for the placement of fiducial markers.

## Medical Technology Assessment Committee (MTAC)

### Electromagnetic Navigation Bronchoscopy

#### 08/20/2012: MTAC REVIEW

**Evidence Conclusion:** Diagnostic yield: Results from a RCT, a meta-analysis of mainly small case-series, and two case-series suggests that the overall diagnostic yield of ENB is approximately 59 to 85%.

Safety: The pneumothorax rate in the studies ranged from 1.8 to 8%.

Fiducial marker placement: There is insufficient evidence to determine the safety and clinical utility of ENB for the placement of fiducial markers.

**Articles:** Several small observational studies, a randomized controlled trial (RCT), and a meta-analysis were identified that evaluated the use of ENB for diagnosing lung cancer. The meta-analysis and the RCT were selected for review. A few small observational studies were identified that evaluated fiducial marker placement using ENB. The number of patients receiving ENB for the placement ranged from 1 to 12. Due to the small sample size none of these studies were selected for review. A summary of the results from one of the more recent studies is presented below. The following articles were selected for review: Eberhardt R, Anantham D, Ernst A, Feller-Kopman D, Herth F. Multimodality bronchoscopic diagnosis of peripheral lung lesions: a randomized controlled trial. *Am J Respir Crit Care Med*. 2007;176:36-41. See [Evidence Table](#). Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-Analysis of Guided Bronchoscopy for the Evaluation of the Pulmonary Nodule. *Chest*. 2011. See [Evidence Table](#).

The use of ENB for diagnosis does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of ENB for fiducial marker placement does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

##### *Biopsy of peripheral lesions, Fiducial marker placement*

CPT Codes	Description
31627	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed, with computer-assisted, image-guided navigation (list separately in addition to code for primary procedure)

#### Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

##### *Endobronchial Ultrasound*

CPT Codes	Description
31652	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures
31653	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), 3 or more mediastinal and/or hilar lymph node stations or structures
31654	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transendoscopic endobronchial ultrasound (EBUS) during bronchoscopic diagnostic or therapeutic intervention(s) for peripheral lesion(s) (List separately in addition to code for primary procedure[s])

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).



Date Created	Date Reviewed	Date Last Revised
09/04/2012	09/04/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	03/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/26/2020	Added “Kaiser Permanente Medical Policy” statement under Medicare section
02/06/2023	Added CPT code 31627 to criteria page
09/05/2023	MPC approved to adopt Endobronchial Ultrasound, MCG A-1049 for clinical coverage indications. Requires 60-day notice; effective February 1, 2024.
02/22/2024	Updated formatting for clarity.
03/04/2025	MPC approved the proposed criteria update for Advanced Bronchoscopy Techniques, specifically Electromagnetic Navigation-Guided Bronchoscopy, to clarify the policy and ensure alignment with community standards of care. Requires 60-day notice, effective August 1 <sup>st</sup> , 2025.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Air Ambulance

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual Chapter 10 - Ambulance Services</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	<a href="#">Rural Air Ambulance Service Protocols A52917</a>

#### For Non-Medicare Members

##### Air Ambulance Services

Medically appropriate air ambulance transportation is a covered service regardless of the State or region in which it is rendered. However, KPWA will approve claims only if the beneficiary's medical condition is such that transportation by either basic or advanced life support ground ambulance is not appropriate.

There are two categories of air ambulance services: fixed wing (airplane) and rotary wing (helicopter) aircraft. The higher operational costs of the two types of aircraft are recognized with two distinct payment amounts for air ambulance mileage. The air ambulance mileage rate is calculated per actual loaded (patient on board) miles flown and is expressed in statute miles (not nautical miles).

1. Fixed Wing Air Ambulance (FW)
  - a. Fixed wing air ambulance is furnished when the beneficiary's medical condition is such that transport by ground ambulance, in whole or in part, is not appropriate. Generally, transport by fixed wing air ambulance may be necessary because the beneficiary's condition requires rapid transport to a treatment facility, and either great distances or other obstacles, e.g., heavy traffic, preclude such rapid delivery to the nearest appropriate facility. Transport by fixed wing air ambulance may also be necessary because the beneficiary is inaccessible by a ground or water ambulance vehicle.
2. Rotary Wing Air Ambulance (RW)
  - a. Rotary wing air ambulance is furnished when the beneficiary's medical condition is such that transport by ground ambulance, in whole or in part, is not appropriate. Generally, transport by rotary wing air ambulance may be necessary because the beneficiary's condition requires rapid transport to a treatment facility, and either great distances or other obstacles, e.g., heavy traffic, preclude such rapid delivery to the nearest appropriate facility. Transport by rotary wing air ambulance may also be necessary because the beneficiary is inaccessible by a ground or water ambulance vehicle.

##### Coverage Requirements

Air ambulance transportation services, either by means of a helicopter or fixed wing aircraft, may be determined to be covered only if **ALL the following** are met:

1. The vehicle and crew requirements described in [§10.1](#)\* are met; and
2. The beneficiary's medical condition required immediate and rapid ambulance transportation that could not have been provided by ground ambulance; and either

- a. The point of pickup is inaccessible by ground vehicle (this condition could be met in Hawaii, Alaska, and in other remote or sparsely populated areas. or
- b. Great distances or other obstacles are involved in getting the patient to the nearest hospital with appropriate facilities as described in [§10.4.4](#). \*
3. Transport is only to the nearest acute care facility equipped to provide the appropriate treatment for the patient's condition.

### Medical Reasonableness

Medical reasonableness is only established when the beneficiary's condition is such that the time needed to transport a beneficiary by ground, or the instability of transportation by ground, poses a threat to the beneficiary's survival or seriously endangers the beneficiary's health. Following is an advisory list of examples of cases for which air ambulance could be justified. The list is not inclusive of all situations that justify air transportation, nor is it intended to justify air transportation in all locales in the circumstances listed.

1. Intracranial bleeding - requiring neurosurgical intervention;
2. Cardiogenic shock;
3. Burns requiring treatment in a burncenter;
4. Conditions requiring treatment in a Hyperbaric Oxygen Unit;
5. Multiple severe injuries; or
6. Life-threatening trauma.

### Time Needed for Ground Transport

Differing Statewide Emergency Medical Services (EMS) systems determine the amount and level of basic and advanced life support ground transportation available. However, there are very limited emergency cases where ground transportation is available but the time required to transport the patient by ground as opposed to air endangers the beneficiary's life or health. As a general guideline, when it would take a ground ambulance 30-60 minutes or more to transport a beneficiary whose medical condition at the time of pick-up required immediate and rapid transport due to the nature and/or severity of the beneficiary's illness/injury, KPWA will consider air transportation to be appropriate.

### Hospital to Hospital Transport

Air ambulance transport is covered for transfer of a patient from one hospital to another if the medical appropriateness criteria are met, that is, transportation by ground ambulance would endanger the beneficiary's health and the transferring hospital does not have adequate facilities to provide the medical services needed by the patient. Examples of such specialized medical services that are generally not available at all type of facilities may include but are not limited to: burn care, cardiac care, trauma care, and critical care. A patient transported from one hospital to another hospital is covered only if the hospital to which the patient is transferred is the nearest one with appropriate facilities which are not available at the patient's current location. Coverage is not available for transport from a hospital capable of treating the patient because the patient and/or the patient's family prefer a specific hospital or physician.

### Special Coverage Rule

Air ambulance services are not covered for transport to a facility that is not an acute care hospital, such as a nursing facility, physician's office, or a beneficiary's home.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
A0430	Ambulance service, conventional air services, transport, one way (fixed wing)
A0431	Ambulance service, conventional air services, transport, one way (rotary wing)
A0435	Fixed wing air mileage, per statute mile

<b>A0436</b>	Rotary wing air mileage, per statute mile
--------------	---

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/03/2018	04/03/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	04/03/2018

<sup>MPC</sup> Medical Policy Committee

Revision History	Description

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Cardiac Ambulatory Monitoring for Extended Duration

- CardioNet®
- CardioNet ECG Monitor
- eVolution
- Implantable Loop Recorder
- MCOT
- Zio®Patch

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">NCD Manual, Part 1 – Electrocardiographic Services</a> <a href="#">Electrocardiographic Services (20.15)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	For Implantable Loop Recorder requests  Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, for " <b>Implantable Loop Recorder</b> " medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

##### Implantable Loop Recorder

An implantable loop recorder (cardiac event monitor) may be indicated for **1 or more of the following**:

- A. Atrial fibrillation, known or suspected, as indicated by **ALL of the following**:
  - Cryptogenic stroke confirmed by neurology
  - Noninvasive cardiac monitor contraindicated, or results unrevealing or inconclusive after minimum 14-day period
  - Recurrent paroxysmal atrial fibrillation suspected, and test results may impact patient management
- B. Syncope as indicated by **ALL of the following**:
  - i. Cardiac etiology of syncope, suspected, as indicated by **1 or more of the following**:
    - ECG results abnormal (eg, cardiac rhythm other than normal sinus, significant conduction abnormalities, Brugada ECG pattern, long QT syndrome)
    - Family history of sudden death
    - History of chronic heart failure
    - History of structural heart disease (eg, valvular aortic stenosis, congenital heart disease, hypertrophic cardiomyopathy) or severe coronary heart disease
    - Recent history of palpitations, abnormal heart rate, or symptomatic arrhythmia



- Use of medication known to cause malignant arrhythmias (eg, antiarrhythmics, antidepressants, antihistamines)
- ii. Recurrent syncope, suspected
- iii. Test results negative or inconclusive, as indicated by **1 or more of the following**:
  - Electrophysiologic study
  - Non-implantable (external) loop recorder, worn for 14 days at a minimum
  - Tilt table testing

Service	Criteria
CardioNet® CardioNet ECG Monitor eVolution MCOT Zio®Patch	Medical necessity review no longer required.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology notes if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Cardiac rhythm abnormalities are common. Many are harmless, but some cause symptoms such as palpitation, chest pain, pre-syncope and syncope, and others may be a signal for potential stroke or cardiac arrest. Electrocardiographic (ECG) documentation of the cardiac rhythm during symptoms is necessary for making accurate diagnosis, therapeutic decisions, assessing the effectiveness of suppression, and monitoring adverse drug effects. However, symptoms of arrhythmia are often infrequent and episodic, and the underlying heart rhythm may not be detected during physical examination and routine ECG that permits a few seconds of recording. It is thus essential to have extended periods of ECG recording while the patients are pursuing their normal routine (Kowey 2003, Naccarelli 2007, and Saarel 2008).

Devices used:

- *Holter monitors* are portable devices that record heart rhythms continuously for up to 48 hours. These devices are used to record events that occur at least once a day.
- *Non-implantable cardiac event monitors* are portable devices that record heart rhythms intermittently for up to 30 days. These devices capture ECG data before, during and after the time of activation.
- *Standard loop recorders* have just a few minutes of memory. Newer, more sophisticated devices have extended memory features that can store up to several hours of ECG data. Recording can be patient-activated when symptoms occur or automatically triggered based on a computer algorithm designed to detect arrhythmias. These devices are used to record infrequent or irregular events.
- *External mobile cardiovascular telemetry* consists of a monitor that continuously records the electrocardiographic rhythm from external electrodes placed on the patient's body. Segments of the ECG data are automatically (i.e., without patient intervention) transmitted to a remote surveillance location by cellular or landline telephone signal. The transmitted events are triggered automatically by preprogrammed algorithms or by the patient during a symptomatic episode. There is continuous, real-time data analysis in the device and attended surveillance of the transmitted rhythm segments by a surveillance center technician. The surveillance center technician reviews the data and notifies the physician depending on the prescribed criteria. These devices are used to record suspected asymptomatic arrhythmias.

The most commonly used method for extended ECG recording is the Holter monitor which records an ECG continuously for 24 to 48 hours via leads placed on the chest to yield 2 or 3 channels of ECG data. The Holter monitor provides complete rhythm recording and excellent quality tracing. However, it has a diagnostic yield of only 5-28% due to its limited time of recording which is usually too short to capture infrequent arrhythmias. In

addition, some clinically important arrhythmias such as atrial fibrillation may be asymptomatic and pass unnoticed by the Holter recording (Kowey 2003, Naccarelli 2007, Rothman 2007, Saarel 2008).

External patient-activated loop event monitoring (LOOP) devices were found by researchers to improve the diagnostic yield of arrhythmias up to 63%. These may be used for up to 30 days; however, they have limited storage, and require appropriate patient activation during the occurrence of symptoms. Patient activation may be a difficult task for the elderly or those whose arrhythmias cause functional impairment. It was reported that one in four patients does not activate the recorder during symptomatic episodes despite the education received on operating the device. Developments are continuously being made to improve the diagnostic yield of the rhythm monitors. Newer loop recorders continually record and erase so that data gathered from 1 to 4 minutes before, and those recorded 30-60 seconds after activation of the device can be retained. Other loop monitors are automatically activated and start the recording once an abnormal rhythm of any kind is detected, without patient activation. An implantable form of continuous-loop event recorder is also currently available. It is a small device in the size of pacemaker that is implanted subcutaneously to the right or left side of the sternum and is triggered by placing an activator over it. The device has a programmable antegrade and retrograde memory and may be left in place for up to 18 months and can be explanted once the diagnosis is made or battery life has ended. Data from the device however, cannot be transmitted wirelessly (Zimetbaum 1999, Kowey 2003, Naccarelli 2007 Rothman 2007).

Mobile Cardiac Outpatient Telemetry (MCOT, CardioNet®, CardioNet device or recorder) was introduced in 1999 for continuous real-time ambulatory electrographic monitoring and analysis. The device consists of a three-electrode, and a two-channel sensor that transmits wirelessly to a small PDA sized portable monitor which can be clipped to the waist or worn on a strap around the neck. Rhythm strips are recorded continuously and analyzed by an automated arrhythmia analysis algorithm. When an arrhythmia is detected (according to the physicians 'predesignated thresholds) the monitor can transmit the ECG data to the monitoring center utilizing a cellular modem or telephone data line. Patients are monitored for 24 hours/day for up to 30 days, by central station technicians with immediate referral to the prescribing physician for evaluation of rate and rhythm changes and their symptoms. The patient can also initiate the recording and transmission of ECG data if symptoms are felt. MCOT thus potentially improves diagnosis of arrhythmias by allowing continuous monitoring of cardiac rhythm for extended periods of time, detecting asymptomatic arrhythmias, and allowing the patients to submit their symptoms and level of activity from a menu to the device (FDA web page, Rothman 2007, Naccarelli 2007).

The CardioNet ECG monitor was approved by the Food and Drug Administration in 2002 for cardiac monitoring for non-life-threatening arrhythmia detection, its evaluation, and monitoring of antiarrhythmic therapy.

## Medical Technology Assessment Committee (MTAC)

### **Mobile Cardiac Outpatient Telemetry (MCOT)**

#### **06/04/2008: MTAC REVIEW**

**Evidence Conclusion:** There is fair evidence from one RCT with limitations, that CardioNet system may have a higher diagnostic yield compared to the patient-activated external loop device for up to one month. There is no published evidence to date to determine that the device is superior to the auto-triggered loop system that was found to have better diagnostic yield, or to the implanted loop system. There is insufficient evidence to determine the efficacy and safety of the CardioNet system for detecting less frequent syncopal episodes. There is insufficient evidence on the efficacy of CardioNet system in assessing the safety and efficacy of antiarrhythmic agents, or outpatient monitoring for medication titration and dose adjustments.

**Articles:** The search yielded around 50 articles. Many were reviews, or articles that dealt with the analysis of data or feasibility of using the device. Only one randomized controlled study (Rothman 2007) that compared the diagnostic yield of MCOT to the external patient-activated loop event monitoring up to 30 days, was identified. There were a few other relatively small observational prospective and retrospective studies that evaluated the safety and diagnostic yield of the CardioNet system. Rothman and colleagues' RCT were selected for critical appraisal. Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: A prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol 2007; 18:241-247. See [Evidence Table](#).

The use of Mobile Cardiac Outpatient Telemetry (MCOT) in the detection of arrhythmias does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **08/03/2009: MTAC REVIEW**

### **Mobile Cardiac Outpatient Telemetry (MCOT)**

**Evidence Conclusion:** There is fair evidence from one RCT with limitations, that CardioNet system may have a higher diagnostic yield compared to the patient-activated external loop device for up to one month. There is insufficient evidence however to determine that the device is superior to the auto-triggered or the implanted loop systems that were found to have better diagnostic yield than the patient-activated external loop monitors. There is insufficient evidence to determine that CardioNet system improves the management of patients e.g. monitoring for medication titration and dose adjustments. There is insufficient evidence to determine that CardioNet system improves patients' health outcomes.

**Articles:** The search did not reveal any controlled trial on MCOT published after the RCT reviewed earlier in MTAC. Only two relatively small retrospective case series were identified; one reported on the use of MCOT among adult patients with stroke, and the other evaluated its use among children and adolescents with suspected arrhythmias. None were selected for critical appraisal.

The use of Mobile Cardiac Outpatient Telemetry (MCOT) in the detection of arrhythmias does not meet the Kaiser Permanente *Medical Technology Assessment Criteria*.

## **Zio®Patch**

### **12/16/2013: MTAC REVIEW**

**Evidence Conclusion:** There is weak evidence from one small single-center pilot study that Zio®Patch was well tolerated and allowed longer monitoring than Holter monitoring. This resulted in the detection of more AF episodes and cardiac events in symptomatic patients and making changes in the clinical management among more than one fourth of the study participants. There is insufficient published evidence on the use of Zio®Patch for detecting atrial fibrillation and other arrhythmias in asymptomatic patients with AF. There is insufficient evidence to determine the equivalence or superiority of Zio®Patch to any of the other longer-term outpatient ambulatory cardiac rhythm monitors.

**Articles:** The literature search revealed only two published studies on the use of Zio®Patch as a noninvasive monitoring device for arrhythmias in general in one study, and for atrial fibrillation in the other. A retrospective study among 285 patients seen in emergency departments was identified from a review article, but it was not published in a peer review journal; it was only presented in a conference. The two published studies were critically appraised. Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. *Pacing Clin Electrophysiol*. 2013;36:328-333. [See Evidence Table](#), Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. *Am J Cardiol*. 2013; 112:520-524. [See Evidence Table](#).

The use of Zio®Patch the detection of arrhythmias does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Implantable Loop Recorder**

### **BACKGROUND**

Syncope has a complex differential diagnosis. Syncope that remains unexplained after standard evaluation does not appear to be associated with excess mortality (Savage et al., 1985) or serious adverse cardiovascular events (Kapoor, 1990). However, syncope recurrences are associated with fractures, automobile accidents and other complications (Kapoor, 1987).

Standard techniques for diagnosing syncope include history and physical examination, laboratory testing, exercise stress testing, Holter monitoring, tilt table testing and external loop recording. External loop recorders ("King of Hearts" model) store ECG data up to 4 minutes prior to and 1 minute after activation by a patient. They are worn on the wrist or around the waist, generally for up to 1 month.

The implantable loop recorder (ILR) is a new diagnostic tool for unexplained infrequent syncope. The ILR is a 61x19x8mm, recording device produced by Medtronic Reveal. It stores an ECG signal in a circular buffer capable of retaining 21 minutes of uncompressed signal or 42 minutes of compressed signal (can be divided into 1-3 parts). The ILR requires the patient or family member to use a hand-held pager-sized activator to "freeze" the memory buffer during or immediately following an episode of syncope. The device is implanted into the left infraclavicular region. Using local anesthesia, a 2 cm incision is made, a pocket the size and shape of the device is made and the ILR is placed in the pocket. The ILR can monitor patients for up to 14 months. The device is removed after a diagnosis of syncope is made or at the end of battery life.

Medicare approved coverage for this implantable device effective 10/1/1999. Kaiser Permanente added it to the medical criteria subject area at that time.

MTAC reviewed this device at the February 2000 meeting and found the technology appears to be promising and safe for patients whose syncope is undiagnosed but there is not enough evidence to draw conclusions regarding reproducibility, safety and accuracy. The Health Plan Medical Director Group at their February 2000 meeting reviewed the MTAC findings and determined that there was good reason to recommend coverage for patients who had infrequent, undiagnosed episodes of syncope.

## 02/10/1999: MTAC REVIEW

**Evidence Conclusion:** The one study evaluating the potential of the ILR to diagnose unexplained syncope obtained a diagnostic yield of 59% during a mean of 10.5 months of recording. Possible selection bias, conflict of interest on the part of the investigators and a lack of comparison with external loop recorders limit the ability of this study to determine efficacy of the ILR. Two studies evaluating the external loop recorders found point estimates for diagnostic findings of 25% and 36% after approximately one month of recording.

**Articles:** Krahn D, Klein G, Yee R, Takle-Newhouse T, Norris C. Use of an extended monitoring strategy in patients with problematic syncope. *Circulation* 1999; 99: 406-410. See [Evidence Link](#).

The use of implantable loop recorder does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Implantable Loop Recorder - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
33285	Insertion, subcutaneous cardiac rhythm monitor, including programming
HCCP Codes	Description
C1764	Event recorder, cardiac (implantable)
E0616	Implantable cardiac event recorder with memory, activator, and programmer

## External Loop Recorder –

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare - Medical Necessity review no longer required**

CPT® Codes	Description
93228	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional
93229	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional
93270	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; recording (includes connection, recording, and disconnection)
93271	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; transmission and analysis

## External Patient Activated EKG -

**Medicare - Considered not medically necessary**  
**Non-Medicare - Medical Necessity review no longer required**

CPT® Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/17/08	06/04/2008, 08/03/2009, 5/4/2010 <sup>MDCRPC</sup> , 3/1/2011 <sup>MDCRPC</sup> , 1/03/2012 <sup>MDCRPC</sup> , 11/06/2012 <sup>MDCRPC</sup> , 09/03/2013 <sup>MPC</sup> , 03/04/2014 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	12/15/2022

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/05/2016	Added "Following a cryptogenic stroke" as an indication
08/09/2016	Merged Implantable Loop Recorder into one policy as External Loop Recorder
02/01/2017	Medical management approved medical necessity no longer required
03/06/2018	MPC approved commercial criteria for Implantable Loop Recorder effective date 7/1/2018
05/05/2020	Removed deleted codes 33282 and 33284 (ILR)
07/07/2020	MPC approved to adopt updates to the <i>Implantable Loop Recorder</i> clinical indications for Non-Medicare. Requires 60-day notice, effective date 12/01/2020.
08/06/2020	Removed CPT code 33286
05/04/2021	Updated applicable coding
12/15/2022	Updated Medicare Policy to defer to KP non-Medicare criteria for Implantable Loop Recorder. *Per email dated 12/14/2022 from Noridian. <i>Noridian does not have a specific LCD for Implantable Loop Recorders and coverage would be based on medical necessity.</i>
08/08/2023	Removed deleted codes 0497T & 0498T
4/17/2024	Removed deleted code G2066.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Artificial Spinal Discs for Lumbar or Cervical Disc Disease

- Bryan™
- Charité™
- Prestige™ Artificial Discs
- ProDisc-C™
- ProDisc-L™
- Two-level cervical artificial disc replacement for the treatment of cervical degenerative disc disease

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Lumbar Artificial Disc Replacement (LADR) (150.10)</a> Per NCD - this service is not covered for Medicare beneficiaries over 60 years of age.
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance for lumbar artificial disc replacement <b>for Medicare members under 60 years of age</b> or for cervical artificial disc replacement, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>"Artificial Spinal Discs for Lumbar or Cervical Disc Disease"</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

- I. Artificial cervical discs may be considered medically necessary for the following:
  - A. For treatment in adults with symptomatic cervical degenerative disc disease when **ALL** of the following are met:
    1. FDA-approved prosthetic intervertebral discs are used;
    2. Performed at one level or two contiguous levels from C3-C7;
    3. Objective evidence in the clinical record documents cervical radiculopathy and/or myelopathy; and
    4. Patients have failed at least six weeks of conservative management (which may include rest, application of heat/ice, physical therapy, exercise, pain and/or anti-inflammatory medications).
  - B. A subsequent, second-level, anterior total cervical disc replacement using an artificial intervertebral disc following complete decompression may be considered medically necessary in skeletally mature patients with symptomatic cervical disc degeneration when **ALL** of the following are met:
    1. The planned subsequent procedure is at a different cervical level than the initial cervical artificial disc replacement; and
    2. Clinical documentation that the initial cervical artificial disc replacement is fully healed; and
    3. Criteria A, 1-4 are met
- II. Prosthetic intervertebral discs are considered investigational for **ALL** of the following:

- In patients with isolated axial neck pain without cervical radiculopathy or myelopathy;
- When requested adjacent to a prior fusion; or
- At a level of prior surgery
- When more than two levels are requested

### III. Lumbar Disc Disease

Effective until October 1, 2025	Effective October 1, 2025
<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.</p>	<p>Medical necessity review criteria as well as review for Level of Care</p> <p><b>Artificial Spinal Discs for Lumbar Disc Disease</b></p> <p><b>III. Single Level Artificial Lumbar Discs for Degenerative Disc Disease</b></p> <p>Lumbar artificial disc replacement is indicated for patients with discogenic low back pain who meet <b>ALL</b> of the following criteria:</p> <ol style="list-style-type: none"> <li>1. Pain attributable to 1 disc disruption involving L3-4, L4-5, or L5-S1 segments</li> <li>2. Confirmation of pathology at one of the above lumbar disc levels by advanced imaging (MRI) and without severe degenerative changes at adjacent levels</li> <li>3. Primary complaint of axial pain that was unresponsive or incompletely resolved with a facet block</li> <li>4. Presence of symptoms for 6 months or longer, that are not responsive to physician-supervised conservative medical management** over that period</li> </ol> <p>Lumbar disc arthroplasty is <b>NOT</b> indicated in <b>ANY</b> of the following scenarios:</p> <ol style="list-style-type: none"> <li>1. Any case that does not fulfill ALL of the above criteria.</li> <li>2. Presence of symptomatic degenerative disc disease <b>at more than ONE level</b></li> <li>3. Significant facet arthropathy at the index level or signs that the source of pain is primarily facet mediated</li> <li>4. Presence of spinal instability with spondylolisthesis greater than Grade I</li> <li>5. Chronic radiculopathy (unremitting pain with predominance of leg pain symptoms greater than back pain symptoms, extending over a period of at least one year)</li> <li>6. Osteopenia as evidenced by a DEXA bone mineral density T-score less than or equal to -1.0</li> <li>7. Poorly managed psychiatric disorder (any underlying psychiatric disorder, such as depression, should be diagnosed and the management optimized before surgical intervention)</li> <li>8. Age greater than 60 years or less than 18 years</li> <li>9. Presence of infection or tumor</li> </ol> <p><b>Lumbar disc arthroplasty removal and/or revisions</b> Will consider removals and revisions on a case-by-case basis after reviewing medical documentation.</p> <p><b>IV. Artificial Lumbar Discs are considered experimental and investigational for all other indications including but not limited to disc implantation at more than one level.</b></p> <p><b>**Physician-supervised conservative medical management</b> defined as: Patients must have <b>three months</b> of non-operative treatment as demonstrated by a trial of one or more of the following medications:</p> <ul style="list-style-type: none"> <li>• Non-steroidal anti-inflammatory drugs (oral or topical)</li> </ul>

	<ul style="list-style-type: none"> <li>• Acetaminophen</li> <li>• Epidural steroid injection of corticosteroids as appropriate</li> </ul> <p><b>AND</b></p> <ul style="list-style-type: none"> <li>• A trial of <b>ALL</b> of the following physical measures:             <ul style="list-style-type: none"> <li>○ Supervised Physical therapy, attendance at &gt;75% of sessions, minimum of 3 visits</li> <li>○ Flexibility and muscle strengthening exercises</li> <li>○ Reasonable restriction of activities</li> <li>○ If conservative therapy is not appropriate, the medical record must clearly document why such an approach is not reasonable.</li> <li>○ Evaluation and appropriate management of associated cognitive, behavioral or addiction issues when present</li> </ul> </li> </ul>
--	--

**If requesting this service, please send the following documentation to support medical necessity:**

- Specific procedures requested with related procedure/diagnosis codes and identification of disc level(s) for surgery and device to be implanted
- Clinical notes from requesting provider &/or specialist that include a current history and physical exam
- Detailed documentation of extent and response to non-operative conservative therapy or procedural interventions
- Copy of radiologist's report(s) for diagnostic imaging (MRIs, CTs, etc.) completed within the past 12 months

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Degeneration of the intervertebral disc, also known as degenerative disc disease (DDD) is the leading cause of pain and disability among adults in the United States as well as other parts of the world. Disc degeneration can occur at any level of the spine but is most common in the lower neck (cervical disc disease) and in the low back (lumbar disc degeneration). DDD may cause pain in the affected area and may also radiate along the nerves emerging from the spinal canal at that level.

Most DDDs can be treated nonoperatively to relieve the pain. Conservative treatments include physical therapy, nonsteroidal anti-inflammatory medications, and analgesics. Acupuncture, spinal manipulations, axial traction, and muscle relaxants are other alternative therapies that may be used to alleviate the pain and discomfort. A number of patients may not benefit from the non-invasive therapy and resort to surgical treatment. Spinal interbody fusion, a procedure that involves the fusion of two or more vertebrae to eliminate the pain caused by their abnormal motion, has been the surgical standard of care for lumbar DDD for decades. Anterior cervical discectomy combined with fusion (ACDF) is also a well-established treatment for cervical degenerative disc disorders. Interbody fusion reduces the pain caused by the treated segment, however the rigid fusion also leads to a reduction in normal spine motion, and an increase in the biomechanical stress at spinal levels adjacent to the fusion, which in turn accelerates degenerative changes of the discs at these levels (Lee 2004, Mobbs et al, 2007, Sasso 2008, Yang 2008, Heidecke 2008).

Recently arthroplasty performed with artificial discs have emerged as a surgical alternative to interbody fusion. The technology is rapidly developing and offers the promise to restore the normal spinal movement without the kinematic and biochemical issues of fusion. Potential benefits of disc arthroplasty include maintenance of a range of motion, avoidance of adjacent segment degeneration, restoring disc height, correcting spinal misalignment, greater maintenance of maneuverability, and earlier return to previous level of function. On the other hand, potential disadvantages of the artificial disc may include implant migration and material wear (Yang 2008, Burkus 2010, Cepoiu-Martin 2011).

The Charité, the first artificial intervertebral disc used, was developed Germany in the 1950s, but was not commercially available until 1987 after undergoing major design modifications. The third generation Charité

(DePuy Spine) consists of two chromium alloy endplates and a sliding ultra-high molecular weight polyethylene core. The ProDisc-L (Synthes Spine, West Chester, PA) is another disc implant, also developed in Europe, for disc replacement at one level from L3-S1. It has a ball and socket design and is composed of three components; two metal endplates and a plastic inlay. More recently researchers developed artificial disc devices to replace cervical intervertebral discs. These include ProDisc-C (Synthes Spine, West Chester, PA), Bryan Cervical Disc (Medtronic Sofamor Danek, Memphis, TN), and Prestige Cervical Disc (Medtronic Sofamor Danek). ProDisc-C has a similar design to the ProDisc-L, Bryan disc prosthesis has two metal endplates and a polyethylene core, and PRESTIGE has two main pieces of stainless steel that articulate against one another with a ball and trough.

The Prestige ST, ProDisc-C and Bryan artificial disc systems have received US Food and Drug Administration (FDA) premarket application approval as Class III devices in July 2007, December 2007, and May 2009 respectively. FDA clearing of the artificial disc systems required post-approval studies to evaluate the long-term safety and effectiveness of the devices. The post-approval studies are expected to demonstrate 3, 5, 7, and 10-year data for cervical discs.

### **Lumbar**

The Charité® (DePuy) and ProDisc®-L (Synthes Spine) have received approval from the US Food and Drug Administration. The approval was contingent on completion of post-marketing studies to evaluate the longer-term safety and effectiveness of the devices. The post-approval studies are expected to demonstrate the 5-year data for lumbar discs. The Charité® and ProDisc®-L devices are indicated for:

1. Spinal arthroplasty in skeletally mature patients, with pain from degenerative disc disease (DDD).
2. One level of the spine (L3-S1 for the ProDisc-L, L4-S1 for the Charité).
3. Patient may have no more than a grade 1 spondylolisthesis.
4. Patients must have failed to find pain relief after at least 6 months of non-surgical therapies.

Contraindications to total lumbar disc replacement include active infection, allergy to any of the device materials, osteoporosis, marked cervical instability, severe spondylosis, clinically compromised vertebral bodies at the level to be treated, and DDD at more than one level.

Several other contraindications are listed for each of the disc systems. Multilevel total disc replacement and disc replacement with prior spinal fusion are considered off-label uses.

### **Cervical**

The cervical artificial discs are FDA approved for the following:

1. Reconstruction of cervical disc from C3-C7 following single-level discectomy for intractable.
2. Symptomatic cervical disc disease confirmed by imaging.
3. Patient is skeletally mature.
4. Cervical disc disease should have failed at least six weeks of non-operative treatment prior to implantation.

Contraindications to total cervical disc replacement include systemic infection, infection at the operating site, allergy to any of the device materials, osteoporosis, marked cervical instability, severe spondylosis, clinically compromised vertebral bodies at the level to be treated, and symptomatic cervical disc disease (SCDD) at more than one level.

Several other contraindications are listed for each of the disc systems. Multilevel total disc replacement and disc replacement with prior spinal fusion are considered off-label uses.

## **Medical Technology Assessment Committee (MTAC)**

### ***Artificial Disc in the Treatment of Back Pain***

**02/07/2005: MTAC REVIEW**

**Evidence Conclusion:** The trial reviewed on Charité artificial spinal disc was randomized, controlled, and multicenter, but had some limitations. Authors concluded that the clinical outcomes and incidence of major neurological complications at 2 years of follow-up were equivalent to those of BAK fusion. The trial, however, was not designed as an equivalence study. Equivalence trials are planned and analyzed differently from superiority studies, and generally require larger sample sizes. Lack of significant superiority is not necessarily the same as equivalence, and the absence of statistical significance may be due to insufficient power to detect differences between the study groups. The comparison group in this trial was the BAK fusion technique, which was the preferred fusion procedure at the time, but might not be the current up-to-date procedure. Moreover, the 24-

months follow-up period might not sufficient to determine the long-term safety and effectiveness of the implant as well as its impact on other discs and on the bony structures on the back of the spine.

**Articles:** The search yielded 56 articles. The majority were review articles, or reports that dealt with the design, technical aspects and/or evolution of the technology. The search revealed four articles published by the same group of authors reporting on the Charité artificial disc evaluated in a multicenter RCT in the US. The article that reported the results of the trial in all centers was selected for critical appraisal.

The search also revealed a report on the early 6 months results for the first 53 patients randomized in an ongoing multicenter RCT of ProDisc in the United States. The system is not currently FDA approved.

Geisler FH, Blumenthal SL, Guyer RD, et al. Neurological complications of lumbar artificial disc replacement and comparison of clinical results with those related to lumbar arthrodesis in the literature: Results of a multicenter, prospective, randomized investigational device exemption study of Charité intervertebral disc. *L Neurosurg (Spine)* 2004;1:143-154. See [Evidence Table](#).

The use of artificial disc in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Artificial Disc in the Treatment of Back Pain**

#### **10/04/2006: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence that artificial discs approved by the FDA or pending approval are effective, particularly in the long-term. There is only one completed RCT and this is on the Charité device. There are no completed published RCTs on the Prestige or ProDisc devices. The Charité RCT may not have used appropriate equivalence trial methods, including failure to compare the new device to an intervention with proven effectiveness. The safety of the artificial discs after a minimum of 2 years appears similar to that of surgical fusion. Authors of the Charité had financial links to the manufacturer, which could introduce bias.

**Articles:** An April 2005 Blue Cross BlueShield TEC report was identified. In their literature search, they found one completed RCT, the same study included in the first MTAC review. There was also a systematic review (Freeman & Davenport, 2006) that searched the literature through April 2006 and also identified the same single completed RCT. *Literature on individual devices identified through Medline search:*

Charité device: Several additional publications on the RCT previously reviewed by MTAC (Geisler et al., 2004) were identified: Blumenthal et al. (2005) reported updated data on primary outcomes (more patients had reached 24-month follow-up). McAfee et al. (2005) reported on radiographic outcomes e.g. restoration of disc height.

Regan et al. (2006) examined outcomes in the treatment group according to centers' surgical volume. McAfee et al. (2006) reported on the re-operation rate of patients in the RCT as well as other patients, for a total sample size of 688. The updated study on the primary outcomes (Blumenthal et al., 2005) and the study on re-operation rates (McAfee et al., 2006) were critically appraised. The other publications were not evaluated further because they do not add substantially to our ability to evaluate the long-term safety and efficacy of the Charité device. ProDisc device: The RCT identified in the previous MTAC search comparing ProDisc to surgical fusion is still ongoing.

The study is taking place at 19 centers and has an enrollment goal of 500 patients. At the time of the first MTAC review, an article reporting initial findings for 53 patients at one center was identified. A 2005 article was identified that reported additional preliminary findings from the same center, this time for 78 patients. This study was not critically appraised because results from all centers are not yet available. Prestige device (not included in 2005 MTAC review):

There was a 2004 publication reporting on preliminary findings from a randomized controlled trial on Prestige II conducted at four sites in Europe. This study was critically appraised. The article appears to report on all randomized patients, although not all patients had completed the final follow-up. No subsequent publications on outcomes of this RCT were identified. In addition, an older case series with 17 patients using the Prestige I device was identified, but not evaluated further due to the small size and the availability of higher-grade evidence. Blumenthal S et al. A prospective, randomized, multicenter food and drug administration investigational device exemptions study of lumbar total disc replacement with the Charité artificial disc versus lumbar fusion.

*Spine* 2005; 30: 1568-1575. See [Evidence Table](#). McAfee PC et al. Revisability of the Charité artificial disc replacement. *Spine* 2006; 31: 1217-1226. See [Evidence Table](#). Porchet F, Metcalf NH. Clinical outcomes with the Prestige II cervical disc: preliminary results from a prospective randomized clinical trial. *Neurosurgery Focus* 2004; 17: 36-43. See [Evidence Table](#).

The use of artificial disc in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Artificial Disc in the Treatment of Back Pain**

#### **10/01/2007: MTAC REVIEW**



**Evidence Conclusion:** The Prestige cervical disc system was first reviewed by MTAC before final FDA approval. At that time, there was one relatively small published RCT reporting preliminary findings (Porchet & Metcalf, 2004). At the time of data analysis, the investigators did not find a significant difference in pain and disability outcomes at 12 months for patients who underwent either artificial disc replacement or anterior cervical fusion. Limitations of this RCT included insufficient follow-up (only about two-thirds of participants had completed the 12-month follow-up and about 15% had completed the 24-month follow-up), unclear equivalence study methods, and funding from the device manufacturer. A larger multicenter RCT among patients with symptomatic single-level cervical degenerative disc disease (DDD) was identified for the evidence update (Mummanemi et al., 2007). Mummanemi and colleagues randomized 541 patients to receive either the Prestige cervical disc system or anterior cervical discectomy and fusion. Using a composite success measure developed by the investigators that considered efficacy and safety, the Prestige artificial disc system was found to be superior to ACDF in a completer analysis. In an intention to treat analysis with a “worst case scenario” analysis, Prestige was found to be non-inferior to ACDF. Advantages of the Mummanemi study were that it was randomized and there was a high follow-up rate. Disadvantages are that the study was non-blinded, and the authors have financial links with the manufacturer. In conclusion, there is fair evidence from one reasonably valid multicenter RCT that use of the Prestige artificial disc in conjunction with discectomy is at least non-inferior to ACDF in “clinical success” defined as a composite outcome incorporating efficacy and safety. The evidence would be strengthened by longer-term follow-up data and studies conducted by impartial researchers. The Porchet & Metcalf, 2004 study does not add substantially to the body of evidence, especially since only preliminary findings were reported in the published literature.

**Articles:** At the time of the previous MTAC review of artificial discs (October 2006), there was one published randomized controlled trial on the Prestige disc with 55 patients from 4 sites in Europe. The article reported preliminary findings of the RCT (Porchet & Metcalf, 2004). No follow-up publication was identified that reported final results of this RCT. The updated literature search identified a new, larger RCT. This study randomized 541 patients at 32 sites in the United States to discectomy with artificial disc replacement or ACDF (Mummaneni et al., 2007). This was the key study submitted to the FDA for device approval. The Mummaneni et al. RCT was critically appraised: Mummaneni PV, Burkus JK, Haid RW et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled trial. *J Neurosurg Spine* 2007; 6: 198-207. See [Evidence Table](#).

The use of Prestige artificial disc in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Artificial Disc in the Treatment of Back Pain**

### **02/01/2010: MTAC REVIEW**

**Evidence Conclusion:** The published randomized controlled trials on lumbar and cervical artificial disc replacement, reviewed for this report, were all US FDA investigational device exemption (IDE) studies designed to show that artificial disc replacement is at least as good as fusion for lumbar DDD, or ACDF for cervical disc disease (non-inferiority design). Lumbar total disc replacement with artificial intervertebral discs (Charité, and ProDisc-L). The trials on artificial total lumbar disc replacement compared the procedure with interbody fusion among patients 18 to 60 years of age, who had a single level DDD at L4-5 or L5-S1 (Charité) or L3-S1 (ProDisc-L) confirmed radiographically and failed conservative treatment of at least six months. The trials were randomized, controlled and multicenter, but were not blinded and sponsored by the manufacturer which are sources of bias. All trials except the CHARITE IDE trial had a maximum study duration of two years which does not allow determining the long-term efficacy, durability, or safety of total disc replacement or its impact on adjacent risk degeneration.

CHARITE IDE trial (Guyer et al 2009) was the only published RCT with long-term follow-up. However, the five-year outcomes were reported for only 35% of the randomized participants in the original two-year trial (6 of the initial 14 investigational sites refused to participate in the five-year continuation study, and a number of patients were lost to follow-up). This reduces the statistical power of the study which was based on the initial population size. Moreover, the investigational procedure was compared to interbody fusion using the BAK cage technique, which currently is not the best-accepted fusion technique. These, together with non-blinding and other limitations of the original trial make it hard to interpret or generalize the results of the long-term follow-up. The trial on ProDisc-L (Zigler 2007) was also randomized, controlled, and multicenter. However, it had only 2-year follow-up duration which does not allow determining the long-term effectiveness, harms, or durability of the device.

Moreover 11.5% of fusion patients and 9% of ProDisc-L patients were not included in the analysis, which was not based on intention to treat. There is also a concern that the investigators used a revised version of the ODI score that had not been validated.



In conclusion, there is insufficient evidence to determine the long-term efficacy, durability, or safety of artificial disc replacement for patients with lumbar degenerative disc disease, or to determine whether it is associated with the risk of adjacent risk degeneration. Cervical total disc replacement with artificial intervertebral discs (ProDisc-C, Bryan, and PRESTIGE). The trials on artificial total cervical disc replacement compared the procedure in conjunction with discectomy to anterior cervical decompression and fusion (ACDF) among patients between 18 and 60 years of age (>21 years in Bryan disc trial) with radiculopathy or myelopathy from a single-level cervical disc disease From C3 to C7, that failed conservative treatment of at least 6 weeks. The trials were randomized, controlled and multicenter, but were not blinded, the postoperative care was not standardized and left to the discretion of the surgeon, and the majority of the investigators had financial ties to the manufacturer, all of which are sources of bias. Moreover the 2-year follow-up duration insufficient to examine the long-term efficacy, safety, and durability of the artificial disc replacement, or to determine whether it is associated with the risk of adjacent risk degeneration. In conclusion, the short-term results of the trials provide fair evidence that the use of the ProDisc-C, Bryan, or PRESTIGE artificial cervical disc systems in conjunction with discectomy is at least non-inferior to ACDF in “clinical success” defined as a composite outcome incorporating efficacy and safety, among patients with symptomatic single-level cervical disc disease. There is insufficient evidence however, to make any conclusion on whether total intervertebral cervical disc would need revision, would deteriorate with time, or would increase the risk of adjacent segment degenerative disc disease.

**Articles:** *Lumbar artificial disc replacement* the updated literature search identified two randomized controlled trials that compared total lumbar disc replacement with Charité (Guyer 2009) or ProDisc-L (Zigler 2007) systems versus lumbar fusion. Guyer et al reported on 5-year follow up of patients enrolled in the Charité IDE trial that was the key study submitted to the FDA for device approval. Zigler et al’s trial was also the key trial for FDA approval for ProDisc-L. Both RCTs was critically appraised. Guyer RD, McAfee PC, Banco RJ, et al. Prospective, randomized multicenter Food and drug Administration investigational device exemption study of lumbar total disc replacement with the Charité artificial disc and versus lumbar fusion: Five-year follow-up. *Spine J.* 2009; 9:374-386. See [Evidence Table](#). Zigler J, Delamarter R, Spivak JM, et al. Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease. *Spine.* 2007; 22:1155-1162. See [Evidence Table](#). *Cervical artificial disc replacement:* The literature search revealed two RCTs on ProDisc-C total disc replacement as well as two trials on Bryan cervical disc arthroplasty (conducted by the same principle investigators, and published in 5 articles). Two studies, one for each system (Murrey 2009 for ProDisc-C, and Heller 2009 for Bryan cervical disc arthroplasty), were selected for critical appraisal based on the methodological quality of the trial, population size and duration of follow-up. Murrey D, Janssen M, Delamarter R, et al. Results of a prospective, randomized, controlled, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine.* 2009; 9:275-286. See [Evidence Table](#). Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of Bryan cervical disc arthroplasty with anterior cervical decompression and fusion. Clinical and radiographic results of a randomized, controlled, clinical trial. *Spine.* 2009; 34:107-107. See [Evidence Table](#).

The use of artificial spinal discs in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Artificial Disc in the Treatment of Back Pain**

#### **02/13/2012: MTAC REVIEW**

**Evidence Conclusion:** *CERVICAL* The three large published trials on cervical arthroplasty were industry sponsored studies submitted to the U.S. Food and Drug Administration for premarket approval of the devices: Prestige, ProDisc-C, and Bryan cervical disc. All three trials were designed as noninferiority trials i.e. attempting to show that cervical artificial disc replacement is at least as good as ACDF for cervical disc disease. They had similar inclusion and exclusion criteria, similar follow-up schedules, and similar outcome measures and success criteria defined by the FDA. The three trials are still ongoing as the FDA required that the investigators conduct post-approval studies to evaluate the longer-term safety and effectiveness of the devices. The post-approval studies are expected to provide 3, 5, 7, and 10-year data for cervical discs. Each of the three studies compared total replacement with an artificial disc (Prestige, ProDisc-C, or Bryan) in conjunction with discectomy to a single-level anterior cervical decompression and fusion (ACDF) among patients between 18 and 60 years of age (>21 years in Bryan disc trial) with a single level cervical radiculopathy or myelopathy between C- 3 and C-7 that had failed conservative treatment of at least 6 weeks. The trials were relatively large, randomized, controlled, and multicenter, but were not blinded, the postoperative care was not standardized and left to the discretion of the surgeon, and the majority of the investigators had financial ties to the manufacturers who supported the trials, all of which are sources of bias. The 24 months interim analyses of the three trials were previously reviewed by MTAC. The conclusion of the last 2010 MTAC assessment of the technology was as follows, “The short-term

results of the trials provide fair evidence that the use of the ProDisc-C, Bryan, or Prestige artificial cervical disc systems in conjunction with discectomy is at least non-inferior to ACDF in “clinical success” defined as a composite outcome incorporating efficacy and safety, among patients with symptomatic single-level cervical disc disease. There is insufficient evidence however, to make any conclusion on whether total intervertebral cervical disc would need revision, would deteriorate with time, or would increase the risk of adjacent segment degenerative disc disease.” After the last MTAC review of 2010, mid-term follow-up data were published for all three trials: 48 months postoperative data for ProDisc and Bryan artificial discs and 60 months postoperative data for Prestige cervical disc. These mid-term follow-up data were only available for just over two thirds of the population in the Bryan disc trails, and around 50% for each of the 60 months follow-up data for the Prestige disc trials and the 48 months follow-up for ProDisc-C trial. The published results of all three studies show that the one level cervical disc arthroplasty appears to be at least as effective as cervical fusion in up to 2 years of follow-up. The results the extended, mid-term analyses suggest that the outcomes the artificial disc arthroplasty continues to be noninferior to those of fusion. However, the follow-up rates are poor, and the results on sustained effect and durability should be interpreted with caution. The 48 and even 60 months follow-up duration is still insufficient to determine the long-term efficacy, durability, and safety of the system, and the potential risk on adjacent risk degeneration. The trials are still ongoing and long-term results for up to 10 years follow-up are expected. In conclusion, the additional information does not change the conclusions of the previous reports; data on long-term safety and efficacy is still lacking, and there is no evidence to date to determine if one of these three FDA approved artificial discs is superior to the others. A recent update of the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) (November 2011) concluded that artificial intervertebral disc arthroplasty for the treatment of patients with cervical degenerative disc disease does not meet their criteria. The TEC update however did not include Sasso et al’s 2011 article that reports on the 48 months outcomes of all participating centers in the Bryan cervical disc trial. At the time of the TEC review only one center had published the 48-month follow-up results (BCBS 2011). *LUMBAR* As indicated in the last 2010 MTAC review, the published randomized controlled trials on lumbar artificial disc replacement were U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) studies that were designed to show that artificial disc replacement is at least as good as fusion for lumbar DDD. The studies (reviewed in earlier reports) compared the procedure with interbody fusion among patients 18 to 60 years of age, who had a single level DDD at L4-5 or L5-S1 (Charité) or L3-S1 (ProDisc-L) confirmed radiographically and failed conservative treatment of at least six months. The trials were randomized, controlled and multicenter, but were not blinded and sponsored by the manufacturer which are sources of bias. All trials except the Charite IDE trial had a maximum study duration of two years, which does not allow determining the long-term efficacy, durability, or safety of total disc replacement or its impact on adjacent risk degeneration. Charite IDE trial (Guyet et al 2009) was the only published RCT with long-term follow-up. However, the five-year outcomes were reported for only 35% of the randomized participants in the original two-year trial (6 of the initial 14 investigational sites refused to participate in the five-year continuation study, and a number of patients were lost to follow-up). This reduces the statistical power of the study which was based on the initial population size. Moreover, the investigational procedure was compared to interbody fusion using the BAK cage technique, which currently is not the best-accepted fusion technique. These, together with nonblinding and other limitations of the original trial make it hard to interpret or generalize the results of the long-term follow-up. The trial on ProDisc-L (Zigler 2007) was also randomized, controlled, and multicenter. However, it had only 2-year follow-up duration which does not allow determining the long-term effectiveness, harms, or durability of the device. Moreover 11.5% of fusion patients and 9% of ProDisc-L patients were not included in the analysis, which was not based on intention to treat. There is also a concern that the investigators used a revised version of the ODI score that had not been validated. Yajun, et al’s meta-analysis, 2010 (Evidence table 1) pooled the results of five studies involving 837 patients. The meta-analysis had valid methodology and analysis, and according to its reviewers, four of the five trials had good methodological quality. They indicated however, that the studies had limited population sizes and did not indicate that the assessors of the outcomes were blinded. The pooled results of the analysis showed that at 2 years of follow-up the patient functioning ability as measured by the Oswestry Disability Index (ODI) in the total disc replacement (TDR) group was better than the fusion group but, according to the authors a mean difference of 4 Oswestry points is not clinically relevant. There was also a statistically significant but clinically irrelevant difference in the pain score in favor of the TDR. After performing a sensitivity analysis excluding one large study that compared TDR with BAK cages, the difference in ODI, pain, and patient satisfaction were no longer significant. The authors concluded that TDR is not superior to fusion in treating lumbar degenerative disc disease. In conclusion, there is still insufficient published evidence to date, to determine the long-term efficacy, durability, or safety of artificial disc replacement for patients with lumbar degenerative disc disease, or to determine whether it is associated with the risk of adjacent risk degeneration.

**Articles:** *CERVICAL DISC* The literature search revealed four articles reporting on long-term outcomes of three pivotal clinical trials on Prestige ST, ProDisc-C, and Bryan artificial discs (one in a single center, and the other on the entire population studied). The search also identified an RCT on KineflexIC artificial disc with 2-year follow-up,

and a recent meta-analysis (Cheerag, et al. 2011) that pooled the 2-year follow-up results of the three first trials. No trials comparing the three FDA approved artificial disc systems to one another were identified. All three initial studies on Bryan, ProDisc, and Prestige cervical discs initial trials with 2-year outcomes that were submitted to the FDA for premarket approval were previously reviewed by MTAC. The reports on long-term follow-up outcomes of the studies were reviewed and their results added to the last MTAC report to update the findings and conclusions. The meta-analysis was not critically appraised as it does not add more evidence to 24 months interim results of the individual trials. Pooling these results still provide 2-year results when long-term safety, durability, and efficacy are needed. The recent RCT on KineflexIC was also not selected for appraisal as it only provides 24 months data. The following initial trials and more recent publications were critically appraised: Burkus JK, Haid RW, Traynelis VC, et al. Long-term clinical and radiographic outcomes of cervical disc replacement with The Prestige disc: results from a prospective randomized controlled trial. *J Neurosurg Spine* 2010; 13:308-318. See [Evidence Table](#). Delamarter, RB, Murrey D, Janssen ME, et al. Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients *SAS Journal*. 2010; 4:122–128. See [Evidence Table](#). Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of Bryan cervical disc arthroplasty with anterior cervical decompression and fusion. Clinical and radiographic results of a randomized, controlled, clinical trial. *Spine*. 2009; 34:101-107. See [Evidence Table](#). Mummaneni PV, Burkus JK, Haid RW et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled trial. *J Neurosurg Spine* 2007; 6: 198-207. See [Evidence Table](#). Murrey D, Janssen M, Delamarter R, et al. Results of a prospective, randomized, controlled, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine J*. 2009; 9:275-286. See [Evidence Table](#). Sasso RC, Anderson PA, Riew D, et al. Results of cervical arthroplasty compared with anterior discectomy and fusion: Four-year clinical outcomes in a prospective randomized, controlled, trial. *J Bone Joint Surg A*. 2011; 93:1684-1692. See [Evidence Table](#). *LUMBAR* The literature search for studies published after the MTAC 2010 re-review of the technology, did not identify more recent reports on extended follow-up of the key trials on the Charité IDE or ProDisc-L used for the treatment of a single level generative disc disease (DDD). There was a recently published RCT (Delamarter et al 2011) conducted by the same investigators of Pro-disc-L total replacement, but for the treatment of two-level lumbar DDD which the focus of the current review is not. The search also revealed one meta-analysis of studies on artificial lumbar disc replacement for single level DDD, a systematic review, and once case series on with a 2-7 years follow-up of 57 patients who received an artificial Charite III total disc arthroplasty. The meta-analysis was selected for critical appraisal: Yajun W, Yue Z, Xiuxin H. A meta-analysis of artificial total disc replacement versus fusion for lumbar degenerative disc disease. *Eur Spine J*. 2010; 19:1250-1261. See [Evidence Table](#).

The use of cervical artificial disc in the treatment of back pain meeting the *Kaiser Permanente Medical Technology Assessment Criteria* is inconclusive.

The use of artificial lumbar spinal discs in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Two-level cervical artificial disc replacement for the treatment of cervical degenerative disc disease**

### **BACKGROUND**

Degenerative disc disease (DDD) is defined as any changes that occur at any level of the spine. It's the leading cause of pain and disability among adults in the United States as well as other parts of the world. Disc degeneration is most common in the lower neck (cervical disc disease) and in the low back (lumbar disc degeneration). DDD may cause pain in the affected area and may also radiate along the nerves emerging from the spinal canal at that level.

Most DDDs can be treated nonoperatively to relieve the pain. Conservative treatments include physical therapy, nonsteroidal anti-inflammatory medications, and analgesics. Acupuncture, spinal manipulations, axial traction, and muscle relaxants are other alternative therapies that may be used to alleviate the pain and discomfort. A number of patients may not benefit from the non-invasive therapy and resort to surgical treatment. Spinal interbody fusion, a procedure that involves the fusion of two or more vertebrae to eliminate the pain caused by their abnormal motion, has been the surgical standard of care for lumbar DDD for decades. Anterior cervical discectomy combined with fusion (ACDF) is also a well-established treatment for cervical degenerative disc disorders. Interbody fusion reduces the pain caused by the treated segment. However, the rigid fusion also leads to a reduction in normal spine motion, and an increase in the biomechanical stress at spinal levels adjacent to the fusion, which in turn accelerates degenerative changes of the discs at these levels [1-4].

Recently arthroplasty performed with artificial discs have emerged as a surgical alternative to interbody fusion. The technology is rapidly developing and offers the promise to restore the normal spinal movement without the kinematic and biochemical issues of fusion. Potential benefits of disc arthroplasty include maintenance of a range of motion, avoidance of adjacent segment degeneration, restoring disc height, correcting spinal misalignment, greater maintenance of maneuverability, and earlier return to previous level of function. In addition, many trials [5, 6] have shown that cervical disc arthroplasty (CDA) is as safe and effective as ACDF for the treatment of CDD at a single level. On the other hand, potential disadvantages of the artificial disc may include implant migration and material wear [3, 7, 8].

The Charité, the first artificial intervertebral disc used, was developed Germany in the 1950s, but was not commercially available until 1987 after undergoing major design modifications. The third generation Charité™ (DePuy Spine) consists of two chromium alloy endplates and a sliding ultra-high molecular weight polyethylene core. The ProDisc-L (Synthes Spine, West Chester, PA) is another disc implant, also developed in Europe, for disc replacement at one level from L3-S1. It has a ball and socket design and is composed of three components; two metal endplates and a plastic inlay. More recently researchers developed artificial disc devices to replace cervical intervertebral discs. These include ProDisc-C (Synthes Spine, West Chester, PA), Bryan Cervical Disc (Medtronic Sofamor Danek, Memphis, TN), Prestige Cervical Disc (Medtronic Sofamor Danek), Mobi-C Cervical Disc (LDR Spine USA), and Kineflex|C Spinal System (SpinalMotion Inc.). ProDisc-C have a similar design to the ProDisc-L, Bryan disc prosthesis has two metal endplates and a polyethylene core, and Prestige has two main pieces of stainless steel that articulate against one another with a ball and trough.

The Prestige ST, ProDisc-C and Bryan artificial disc systems have received the US Food and Drug Administration (FDA) premarket application approval as Class III devices in July 2007, December 2007, and May 2009 respectively. The Mobi-C has received the US Food and Drug Administration (FDA) premarket application approval on August 2013.

Contraindications to total cervical disc replacement include systemic infection, infection at the operating site, allergy to any of the device materials, osteoporosis, marked cervical instability, severe spondylosis, clinically compromised vertebral bodies at the level to be treated, and symptomatic cervical disc disease (SCDD) at more than one level.

#### 09/21/2016: MTAC REVIEW

##### **Two-level cervical artificial disc replacement for the treatment of cervical degenerative disc disease**

**Evidence Conclusion: Anterior cervical discectomy and fusion (ACDF) versus cervical disc arthroplasty (CDA) for two contiguous levels cervical disc degenerative disease: a meta-analysis of randomized controlled trials** (Zou et al., 2016) (evidence table 1) This meta-analysis of RCT aimed to determine the safety and efficacy of cervical disc arthroplasty (CDA) at two contiguous levels cervical disc degeneration. The search was performed between January 2000 and July 2015. Evaluation of study quality was performed using the Cochrane Collaboration's tool for assessing risk of bias. Mean follow-up of included studies ranged from 20-48 months. CDA group patients showed fewer blood loss, lower post-operative complications, lower reoperation rate and better range of motion at all angles and levels. No significant difference was identified in mean surgical time, neck disability index and neck and arm pain VAS scores. Limitations remain in the variety of artificial intervertebral disc types. Furthermore, there is limited number of articles on artificial cervical disc for 2 levels. Overall, CDA is more effective; the study has valid methodology with some limitations.

**Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial** (Davis et al., 2013) (evidence Table 2) This multicenter RCT, FDA investigational device exemption pivotal trial aimed to compare the Mobi-C cervical artificial disc to anterior discectomy and fusion (ACDF) for treatment of cervical DDD at 2 contiguous levels of the cervical spine. This study shows that the overall study success rates met the non-inferiority margin and provided statistical superiority of the total disc replacement (TDR) treatment over ACDF. Results should be interpreted with caution since several authors had received clinical or research support for this study from LDR, the sponsor. In addition, many other authors had financial ties with LDR.

**Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results** (Davis et al., 2015) (evidence Table 3) This is a 4-year follow-up result of the study performed by the same author in 2013. The follow up in the 2013 study presented earlier is 24 months. The current study follow-up is 48 months.



At 48 months, total disc replacement (TDR) had greater improvement than ACDF in: neck disability index scores, 12-Item Short Form Health Survey Physical Component Summary scores, patient satisfaction, and overall success. In addition, TDR patients had lower subsequent surgery rates and showed a lower rate of adjacent-segment degeneration; TDR also maintained segmental range of motion. The study shows that TDR continue to be safe, effective and superior to ACDF at 48 months for the treatment of degenerative disc disease at 2 contiguous cervical levels.

A systematic review and meta-analysis of RCTs [9] indicated that CDA is more effective and safer than ACDF for the treatment of symptomatic cervical disc disease in mid- to long-term follow-up. However, only one study including 2-level was included in the review. A prospective, randomized study [10] compared the safety and effectiveness of the Bryan Cervical Disc in patients with myelopathy caused by two-level cervical disc disease in Han Nationality. The authors found that the Bryan Cervical Disc replacement was shown to be reliable and safe for the treatment of patients with two-level cervical disc disease.

**Conclusion:**

- Two-level cervical artificial disc replacement shows positive outcomes on the short-term
- There is low evidence to support the effectiveness and safety of two-level cervical artificial disc replacement over anterior cervical discectomy and fusion (ACDF) on the short-term for the treatment of cervical degenerative disc disease
- Studies with longer term follow-up are needed to confirm these findings

**Articles:** The literature revealed a number of articles; the following articles were selected for critical appraisal: Anterior cervical discectomy and fusion (ACDF) versus cervical disc arthroplasty (CDA) for two contiguous levels cervical disc degenerative disease: a meta-analysis of randomized controlled trials (Zou et al., 2016) [See Evidence Table 1](#). Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial (Davis et al., 2013) [See Evidence Table 2](#). Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow-up results (Davis et al., 2015) [See Evidence Table 3](#).

The use of Two-level cervical artificial disc replacement for the treatment of cervical degenerative disc disease does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**10/14/2024: MTAC REVIEW****TWO-LEVEL LUMBAR ARTIFICIAL DISC REPLACEMENT FOR DEGENERATIVE DISC DISEASE****Evidence Conclusion:**

- There is no published evidence, to date, to determine that 2-level total lumbar artificial disc replacement is superior to spinal fusion for the treatment of patients with discogenic pain and 2-level lumbar DDD.
- Low quality evidence from an industry sponsored open-label trial, with short follow-up duration, suggest that total lumbar disc replacement using ProDisc L may be noninferior at 2 years to spinal fusion for the treatment of highly selected patients with discogenic pain and two-level DDD who have failed conservative treatment.
- There is insufficient published evidence to determine that TDR reduces the risk of adjacent-level disc degeneration compared to spinal arthrodesis (the primary goal of the technology)
- There is insufficient published evidence to determine the longer-term efficacy, safety, and durability of the artificial disc implanted including but not limited to implant failure, spinal stenosis, heterotopic ossification, and the health effects of potential metal wear and corrosion, and polyethylene wear debris.
- There is insufficient evidence to determine the long-term net health benefit of TDR compared to spinal fusion for the treatment patients with symptomatic 2-level lumbar DDD.

**Articles:**

The literature search for studies published in full in peer-reviewed medical journals identified; [See Evidence Table](#):

- The pivotal FDA IDE RCT comparing ProDisc-L total disc replacement versus circumferential arthrodesis for the treatment of two-level lumbar DDD (Delamarter, et al 2011 reporting the 24 months results of the trial, and Radcliff, et al 2018 reporting on five-year reoperation rates).
- A retrospective analysis (Trincat, et al, 2014) of data for a series of patients who had undergone two-level lumbar TDR using ProDisc device and completed a minimum follow-up of 2 years, in one center in France.
- A retrospective study (Silvestre, et al 2009) that investigated the results of implanting bisegmental TDR with SB Charite` III artificial disc in patients with DDD who have completed 3-year follow-up after receiving the implant. The analysis also compared, the results of 2-level versus 1-level disc replacement also using SB Charite` III device.

- One RCT (Hoff et al, 2016), three observational studies (Aunoble, et al 2010, Chen, et al, 2015 and Andrieu, et al 2017), and a SR with meta-analysis (Lackey, et al 2016) that assessed the effect of hybrid construct involving fusion and TDR for two- or multilevel level DDD.

#### **Inclusion criteria for the current assessment**

- RCTs that compared FDA approved device for 2-level total disc replacement versus spinal interbody fusion for the treatment of patients with discogenic pain and two-level DDD.

#### **Exclusion criteria for the assessment**

- Prospective or retrospective observational studies with no comparison groups.
- Studies that investigated the efficacy and safety of TDR using a disc device that was withdrawn from the US market and /or has not received FDA clearance for its use.
- Studies that compared one- versus two-level TDR
- Studies that compared the effect of combining TDR and fusion versus a stand-alone procedure.

The use of Two-Level Lumar Artificial Disc Replacmenet for Degenerative Disc Disease does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **10/14/2024: MTAC REVIEW**

#### **LUMBAR DISC ARTHROPLASTY (LUMBAR TOTAL DISC REPLACEMENT) FOR A SINGLE-LEVEL DEGENERATIVE DISC DISEASE**

##### **Evidence Conclusion:**

- Low quality evidence from an industry sponsored open-label trial with limitations, suggest that total lumbar disc replacement using ProDisc-L may be noninferior (for up to 5 years) to spinal fusion for the treatment of highly selected patients with discogenic pain and single-level DDD who have failed conservative treatment.
- There is no published evidence to determine the comparative safety and efficacy of ActivL® lumbar disc and spinal fusion in patients with symptomatic single level DDD.
- There is insufficient published evidence to determine that TDR is superior or noninferior to spinal fusion in reducing adjacent-level disc degeneration (the primary goal of the technology) or preservation of the spinal natural range of motion in patients with a single level LDDD.
- There is insufficient published evidence to determine the longer-term efficacy, safety, and durability of the artificial disc implanted including but not limited to implant failure, spinal stenosis, heterotopic ossification, and the health effects of potential metal wear and corrosion, and polyethylene wear debris.
- There is insufficient evidence to determine the long- term net health benefit of TDR compared to spinal fusion for the treatment patients with symptomatic single- level lumbar DDD.

##### **Articles:**

The literature search for studies published after the 2012 MTAC review of the technology identified the following;

##### **See Evidence Table:**

- Five-year results of a multicenter, FDA investigational device exemption (IDE) study of the ProDisc-L total disc replacement versus circumferential arthrodesis for the treatment of single-level degenerative disc disease. (Zigler, et al 2012).
- Five-year follow-up results (Skold et al, 2013) of a trial conducted in Sweden to compare total disc replacement (using Charite, ProDisc or Maverick devices) versus spinal fusion.
- Two publications (Garcia, et al 2015 and Yue, et al 2019) reporting on 2- & 5-years outcomes (respectively) of a RCT that compared ActivL artificial disc to two control TDR devices (ProDisc-L and Charite') for the treatment of patients with symptomatic single-level lumbar degenerative disc disease (DDD).
- 8-year follow-up a randomized controlled multicenter trial (Furunes, et all 2017) conducted in Norway to compare ProDisc II versus multidisciplinary rehabilitation in patients with discogenic chronic low back.
- Ten systematic reviews with meta-analyses of studies comparing total disc replacement versus spinal fusion for the treatment of lumbar degenerative disc disease. The meta-analyses were overlapping; included studies of discs that were approved by the US FDA as well as others that did not receive FDA approval; half of them pooled the results of RCTs and observational studies together; and all but one MA (Zigler, et al, 2018) combined the result of RCTs investigating 1- or 2-level LDDD.
- One systematic review (Ding, e al 2017) of overlapping meta-analyses published between 2010 and 2015 that compared TDR to fusion for treating LDDD.

The use of Lumbar Disc Arthroplasty (Lumar Total Disc Replacement) for a Single-Level Degenerative Disc Disease does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.



## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**  
**Cervical:**

CPT® or HCPC Codes	Description
22856	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection); single interspace, cervical
22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)
22860	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure)
22861	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
22864	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
0095T	Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)
0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)

**Considered Not Medically Necessary:**

**Lumbar:**

CPT® or HCPC Codes	Description
22857	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); single interspace, lumbar
22862	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar
22865	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar
0164T	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)
0165T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
02/07/2005	04/06/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 03/06/2012 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	05/06/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34866 and L35008

10/04/2016	Added MTAC review
11/01/2016	MPC approved criteria for two contiguous levels from C3-C7
06/04/2020	Removed deleted and inaccurate CPT code 0357T
01/04/2022	Defer to KPWA policy for Medicare members for lumbar disc replacement if younger than 60 years old and for cervical disc replacement for all ages.
05/06/2025	MPC approve criteria for Single Level Artificial Lumbar Discs for Degenerative Disc Disease. 60-day notice required; effective 10/01/2025.

## Clinical Review Criteria

# Patient Referral Guidelines for Use of Mechanical Circulatory Support Devices as a Bridge to Cardiac Transplant

## Artificial Hearts

- AbioCor
- SynCardia

## Ventricular Assistive Devices

- Implanted Ventricular Assist Devices (VAD)
- Percutaneous Left Ventricular Assist Device (PLVAD)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Artificial Hearts and Related Devices (20.9)</a> <a href="#">Ventricular Assist Devices (20.9.1)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	11/01/2023 Noridian retired <a href="#">Percutaneous Endovascular Cardiac Assist Procedures and Devices (A52967)</a> These services still need to meet medical necessity as outlined in the LCA and will require review. LCAs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCAs are not retired because they are incorrect. Therefore, continue to use LCA A52967 for determining medical necessity.

### For Non-Medicare Members

## OVERVIEW

These guidelines have been developed from the major clinical trials. However, acute changes occur in this group of patients and it is often uncertain which parameters are reversible. It is important to know that these are guidelines and should be applied together with careful clinical judgment.

**Devices:** The type of device used is dependent upon the implanting center and the device used by the center. Common devices include Heartmate I, II or III, HeartWare and Total Artificial Heart. Non-durable devices include Impella, ECMO, V-A ECMO. These are common devices and *not* an all-inclusive list.

Inclusion Guidelines (one or more should be present to indicate the patient is ill enough to warrant MCS support):

1. NYHA class III-IV symptoms, and/or intractable ventricular arrhythmia, approved by Kaiser Permanente for, and currently listed by UNOS as a candidate for heart transplant, or are being evaluated as a candidate for transplant.
2. INTERMACS Profile 1, 2, 3, or 4 (see Appendix 1).
3. One or more objective indicators of failing support despite maximum reasonable and tolerated medical therapy may include one or more of the following:

- 3.1. Systemic mean BP < 60mmHg or systolic BP <80 mmHg
- 3.2. Cardiac index < 2.0 L/min/m<sup>2</sup>
- 3.3. Pulmonary capillary wedge pressure (or PA diastolic) > 20 mmHg
- 3.4. A low VO<sub>2</sub> maximum<sup>1</sup>
  - 3.4.1. VO<sub>2</sub> < 12 mL/kg/min on a beta-blocker
  - 3.4.2. VO<sub>2</sub> < 14 mL/kg/min off beta-blockade
  - 3.4.3. VO<sub>2</sub> < 19 mL/kg/min adjusted for lean body mass in patients with a BMI > 30 kg/m.<sup>2</sup>
  - 3.4.4. Less than 50% of age predicted maximum.
- 3.5. A VE/VO<sub>2</sub> > 35 in a patient with a submaximal cardiopulmonary exercise test (RER <1.05)<sup>1</sup>
- 3.6. Inability to wean from other mechanical or inotropic support
- 3.7. Refractory Life-Threatening Arrhythmias

**4. Exclusion guidelines include:**

- 4.1. Severe renal dysfunction unlikely to be reversible such as creatinine > 3.0 mg/dl (unless patient is listed for combined heart/kidney transplant).
- 4.2. Severe hepatic dysfunction unlikely to be reversible such as bilirubin > 5.0 mg/dl,
- 4.3. Infection as evidenced by ongoing fever (T > 38°C), WBC > 15,000/mm<sup>3</sup> or positive blood cultures or specific site of infection (e.g. pneumonia, diverticulitis, pyelonephritis),
- 4.3. Platelet or coagulation disorder likely to compromise survival with the anticoagulation protocol required with the device,
- 4.4. Other conditions which would negate transplant candidacy such as peripheral or cerebral vascular disease, or cancer,
- 4.5. Co-morbidities, which alone may not be considered contraindications to transplantation but, taken together, may make the combination of MCS use and transplantation unreasonable or ill-advised.

**5. Special Considerations:**

- 5.1. Aortic Valve Disease Patients with mechanical prosthetic aortic valve or uncorrected valvular disease, such as severe aortic insufficiency, will require additional surgical intervention at the time of MCS implant.
- 5.2. Right Ventricular Dysfunction Evidence of right-sided cardiac dysfunction may indicate the need for biventricular support.
- 5.3. Pulmonary hypertension not reversible by drug manipulation (PVR >4-6 Wood units or transpulmonary gradient >15mmHg, despite maximum tolerated medical management) is not a contraindication to MCS implantation. Some patients may experience reversal of pulmonary hypertension with MCS implantation and may then become eligible for cardiac transplantation.

**Appendix 1**

## INTERMACS Profiles:

- 1 = Critical cardiogenic shock
- 2 = Progressive decline on Inotropic support
- 3 = Inotrope dependent but stable
- 4 = Resting symptoms on home oral therapy
- 5 = Exertion intolerant
- 6 = Exertion limited
- 7 = Advanced NYHA class III

REVISED BY CMS: AUGUST 6, 2019

ADVISORY COUNCIL APPROVED EFFECTIVE DATE: OCTOBER 24, 2019

### If requesting this service, please send the following documentation to support medical necessity:

- Last 2 Cardiology/Cardiovascular Surgery consults

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### Artificial Hearts

Congestive heart failure is a major health problem affecting more than five million patients in the United States. There is a wide variety of options for medical management of heart failure, but many patients eventually deteriorate and fail to respond to any of the medical therapies and require mechanical circulatory support for survival. In order to provide long-term systemic flow for patients with end-stage heart failure, the National Heart Institute established the artificial heart program in the mid 1960s with the intent to develop a totally implantable mechanical heart.

The AbioCor (Abiomed Inc, Danvers, MA, USA) is the world's first fully implantable total artificial heart. This was first implanted in 2001 at the Jewish Hospital in Louisville, KY. AbioCor is a pneumatically-driven biventricular cardiac support device designed to last at least 18 months. It is made of titanium and Angioflex, a proprietary polyurethane plastic and can produce a flow of up to 8 L/min, sufficient for moderate activity. It is divided into the implantable components and the external drive system. The implanted components consist of the thoracic unit, controller, Transcutaneous Energy Transmission system, and a battery that provides about 30 minutes of power that is designed to allow patients to conduct activities such as taking a shower without an external power source. The external drive system consists of the AbioCor console and support electronics worn or carried by the patient in a waist belt (providing power for 2-4 hours) and an RF communication system for a computer (Samuels 2003, Meyer 2011).

In September 2006, the FDA granted restricted approval of the AbioCor device through the Humanitarian Use Device (HUD) provision. A HUD is a device that the FDA determines is intended to benefit fewer than 4,000 U.S. patients per year. The FDA approval included an agreement by the manufacturer to conduct a post-marketing study, evaluating the AbioCor device in an additional 25 patients. According to the FDA, the AbioCor artificial heart is indicated for use in patients who have both ventricles failing, have end-stage heart disease, are not transplant candidates, are less than 75 years old, are not treatable by single left ventricular heart assist devices for destination therapy, and are not able to be withdrawn from heart support measures. It should not be used for patients who are eligible for a heart transplant, have only left sided heart failure, cannot be successfully treated for blood clotting disorders, or in those where the device will not fit (FDA webpage accessed November 2011).

SynCardia temporary CardioWest™ Total Artificial Heart (TAH), originally developed 30 years ago as the Jarvik TAH and later renamed the CardioWest TAH, continues to be used clinically in over 50 centers within the US and Europe. This is an implantable artificial heart intended to keep hospitalized patients alive while they are waiting for a heart transplant. It is a pulsating bi-ventricular device that is implanted into the chest to replace the patient's left and right ventricles and all four valves of the native heart. The device is sewn to the patient's remaining atria. Hospitalized patients are connected by tubes from the heart through their chest wall to a large power-generating console, which operates and monitors the device. SynCardia was approved by the FDA in 2004 for use only in the

hospital as a "bridge to transplant" for patients waiting for a heart transplant who have both sides of their heart failing (biventricular heart failure), do not respond to other treatments, are at imminent risk of death, and are waiting for a donor heart. The temporary CardioWest™ TAH is should not be used in patients who are not eligible for a heart transplant, do not fit the device, cannot be adequately anticoagulated, or have left sided heart failure only (Meyer 2011, FDA Web page accessed November 2011).

SynCardia temporary CardioWest™ Total Artificial Heart (TAH) has not been previously reviewed by MTAC; AbioCor was reviewed by MTAC in 2007 and did not meet its evaluation criteria. The technology is being reviewed due to the coverage of SynCardia temporary CardioWest™ Total Artificial Heart by other health plans as a bridge to heart transplant.

## Medical Technology Assessment Committee (MTAC)

### AbioCor

#### 04/02/2007: MTAC REVIEW

**Evidence Conclusion:** There are no published empirical studies on the safety and efficacy of the AbioCor permanent total artificial heart. Unpublished data consists of a feasibility study with 14 patients submitted to the FDA by the device manufacturer. The 12 patients who survived the operation experienced multiple serious adverse effects; only 1 was discharged from the hospital.

**Articles:** The Medline search yielded 32 articles. These consisted of reviews/commentaries, several empirical studies on technical aspects of the device or device implantation, case reports and 2 case series reporting on 7 patients. The study submitted to the FDA, which included 14 patients, has not been published.

The use of the AbioCor implantable replacement heart in the treatment of irreversible heart failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 12/19/2011: MTAC REVIEW

### AbioCor

**Evidence Conclusion:** *AbioCor TAH* There is no new published evidence after the initial small feasibility study conducted by the AbioCor manufacturer among 14 patients with end-stage heart failure who were not transplant candidates. *SynCardia temporary CardioWest™ Total Artificial Heart* The published evidence on CardioWest TAH consists of a retrospective study, and a few case series of patients receiving the device as a bridge to transplantation. Due to the eligibility criteria for the implantation, it would be unethical to conduct a randomized trial. The only valid control would be no intervention as the eligible patients for the implant are those who failed medical therapy and are not candidates for left ventricular assist device (LVAD). The results of Copeland and colleagues' case series (Evidence table 1) show that 68% of the critically ill patients who received the CardioWest implant survived to heart transplantation and hospital discharge. Adverse events included bleeding in 20% of cases and device malfunction in 5% of cases. Other complications that occurred at a lower rate included mediastinal infection, fit complications, and stroke. The cause of death was multi-organ failure in 50% of the cases, and sepsis or valve entrapment among the rest. A similar experience was observed in a French study among 42 patients. In this series 12 (28.5%) patients died while receiving device support, and 30 patients (71.5%) underwent transplantation. Actuarial survival rates for the transplanted patients were 90% (n = 25), 81% (n = 14), and 76% (n = 10) at 1, 5, and 10 years, respectively. Causes of death during device support included multi-organ failure (50%), sepsis, acute respiratory distress syndrome, and alveolar hemorrhage. There were no device malfunctions that led to patient death. Adverse events included stroke in 3 patients (7%) and infections in 35 patients (85%) during support.

**Articles:** The literature search for AbioCor total heart transplant did not reveal any study conducted after the initial small feasibility study (Dawling 2003) conducted by the AbioCor manufacturer among 14 patients with end-stage heart failure who were not transplant candidates. The search for SynCardia CardioWest temporary TAH identified a few case series for patients who received the device as a bridge to transplantation, and a retrospective study comparing the device to left ventricular assist devices. The larger case series was selected for critical appraisal. Copeland JG, Smith RG, Arabia FA, et al. Total artificial heart bridge to transplantation: A 9-year experience with 62 patients. *J Heart Lung Transplant* 2004; 23:823-831. See [Evidence Table](#).

The use of the AbioCor implantable replacement heart in the treatment of irreversible heart failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of the SynCardia implantable replacement heart in the treatment of irreversible heart failure does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Background



## **Implanted Ventricular Assist Devices (VAD)**

Heart failure is a clinical condition characterized by the heart's inability to generate a cardiac output sufficient to meet the body's circulation demands. It is a major and growing public health problem responsible for high morbidity and mortality, in addition to the economic impact of medical costs, disability, and loss of employment. According to the Heart Failure Society of America, nearly 5 million people suffer from CHF in the United States and it is responsible for about 200,000 deaths each year (Abraham 1998).

The cause of heart failure in many patients is pump failure due to poor left ventricular systolic function, which is often due to myocardial infarction or dilated cardiomyopathy. In approximately 30% of patients with chronic heart failure, the disease process not only depresses cardiac contractility, but also affects the conduction pathways by causing a delay in the onset of right or left ventricular systole, and in turn the loss of coordination of ventricular contraction. This dyssynchronous pattern of ventricular contraction is believed to reduce the already diminished contractile reserve of the heart (Nelson 2001).

Patients in end-stage heart failure have two primary treatment options:

1. Pharmacological therapy (including digoxin, ACE inhibitors, diuretics and inotropes), and
2. Heart transplantation.

Both treatments have their limitations. Pharmacological therapy is only palliative and improves the short-term survival for patients. Moreover, as the heart failure worsens, medication becomes ineffective in treating the low contractility and pulmonary venous stasis resulting from the increased dilatation of the heart. Cardiac transplantation on the other hand, is limited to the number of available hearts, and the criteria for being a transplant candidate.

In September 1994, the FDA approved the first pneumatically driven left ventricular assist device (LVAD) from TCI for bridging end-stage patients to cardiac transplantation. Patients on these devices had to stay in the hospital connected to a pneumatic console or could go home with extensive home health care support. (FDA News 2002). Four years later, in September 1998, the FDA approved two portable heart assist devices (HeartMate and Novocar LVAS) to support patients outside the hospital while they wait for a transplant. These two devices were approved as a bridge to transplant for patients eligible for heart transplants and waiting for an available heart. Eligible patients were those with irreversible heart failure and a rapidly deteriorating condition. In addition, they had to be on their hospital's transplant list in order to qualify for one of these devices (FDA News, September 1998).

The LVAD does not replace the heart. It works along with the patient's own heart to provide additional strength to the weakened left ventricle to pump blood throughout the body. The portable device consists of a blood pump implanted in the abdominal area and attached to both the left ventricle and the aorta. Blood from the heart flows into the device which then pumps it through the aorta to the rest of the body. The system is also connected by a cable through the skin to a small external computer (the "controller") worn on the waist. The computer can be powered by a base unit that is plugged into the wall or by batteries worn at the waist or, in the case of the HeartMate device, under the arms.

There are risks associated with the surgery to implant the HeartMate, as well as risks and complications with the device itself such as infections, bleeding, thromboembolism, and stroke. Implanting the device requires a major surgery for already seriously sick patients. Moreover, the device requires a percutaneous line that can become a medium for bacterial and fungal infections that are difficult to treat and may require a change of the device, which increases the morbidity and mortality. Another complication reported by Rose et al (2000), is aortic stenosis of variable severity that may be caused by the device. LVAD may also lead to significant changes in the systemic immunologic and thrombostatic functions of the patients (Ites S, 2000). Failure and malfunctioning of the device may also occur which may contribute to higher morbidity, mortality, and cost.

In November 2002, the FDA expanded the use of the HeartMate device to be implanted permanently in certain terminally ill patients; those who have a severe end-stage CHF, are ineligible for heart transplant, and have a body surface area >1.5 sq. m. It required that the manufacturer (Thoratec) conduct a post-approval study to assess the device's long-term safety and effectiveness for permanent use.

## **Percutaneous Left Ventricular Assist Device (PLVAD)**

Cardiogenic shock is a state of inadequate tissue perfusion due to cardiac dysfunction. It occurs in a variety of settings such as myocardial infarction, post-cardiotomy shock, decompensated chronic heart failure, acute valve failure, and myocarditis. Despite the major advances in the treatment and aggressive perfusion strategies, cardiogenic shock is still associated with high in-hospital mortality rates that range from 40% to 80% depending on the clinical circumstances. The Intra-Aortic Balloon Pump (IABP) is the left ventricular mechanical assistance

device most commonly used to stabilize patients in cardiogenic shock. It decreases afterload, increases coronary perfusion, and improves cardiac output. However, IABP pump delivers an output of only 0.5 L/min, lacks active cardiac support, does not decrease infarct size, or improve clinical outcomes of patients with acute ST-segment elevation myocardial infarction. New technologies such as percutaneous left ventricular assist devices (LVADs) have been developed to provide more effective hemodynamic short-term support for the failing heart. The three main indications for percutaneous LVAD support include: 1. Reversible left ventricular failure to provide temporary circulatory support until recovery or revascularization, 2. Large ischemic area at risk to provide temporary circulatory support during high-risk percutaneous or surgical revascularization, and 3. Bridging therapy to provide temporary circulatory support as a bridge to a permanent surgical assist device or heart transplantation (Burkoff 2006, Windecker 2007, Seyfarth 2008, Cheng 2009).

Currently two percutaneous LVADs are available for clinical use: The TandemHeart and the Impella Recover system. The TandemHeart utilizes a drainage cannula placed via transseptal puncture into the left atrium to aspirate oxygenated blood, which is then injected through a transfugal pump into the femoral artery, establishing a left-atrial-to-femoral arterial bypass. The Impella Recover is based on a miniaturized impeller (microaxial pump) that can be advanced into the left ventricle through an arterial vascular system. It has a caged blood flow inlet that is placed retrograde into the left ventricle to aspirate oxygenated blood, which is then injected by means of a microaxial pump into the ascending aorta establishing a left ventricular to aortic by-pass. The TandemHeart requires both venous and arterial femoral access whereas the Impella Recover system requires only femoral arterial access. Currently two Impella Recover systems are available: The Impella Recover LP 2.5 and the Impella Recover LP 5.0 models. The Impella LP 2.5 (Abiomed Europe GmbH, Aachen, Germany) is a catheter suitable for percutaneous implantation, while the Impella Recover LP 5.0 catheter requires surgical cut of the femoral artery for device insertion (Windecker 2007).

The Impella Recover LP 2.5 is a catheter-based, impeller-driven, axial -flow pump. It has a diameter of 6.4 mm at the body of the pump and 7.3 mm diameter at the level of the outflow opening. A small electric motor is built into the device, and a thin 2.8 mm cable leading to the device contains the electrical power supply, which is connected to an external control unit as well as a purge line connected to a purge perfuser. Through this perfuser, heparin (in a glucose solution) is flushed continuously in the motor housing and throughout the pump, and the patient does not need systemic anticoagulation. A pressure sensor within the device continuously monitors pressure differences between inflow and outflow. The pump is inserted percutaneously in the catheterization laboratory via a standard guidewire through the femoral artery into the left ventricle. The circulatory support provided by the device can be adjusted at nine different levels of speed. At its maximal rotation speed of 50,000 rpm, the pump can deliver an output of up to 2.5 liters of blood per minute from the left ventricle into the ascending aorta. This actively unloads the ventricle, increases the cardiac output, and increases both coronary and end-organ perfusion. The Impella pumps are indicated for temporary use (up to 6 hours) however, it has been reported that the device can be safely left in place to support hemodynamics for up to 5 days. (Seyfarth 2008, Vecchio 2008, Cheng 2009, Wiktor 2010).

Impella Recover 2.5 and 5.0 devices (ABIOMED Inc) have both received FDA clearance for circulatory support for periods up to 6 hours. The current review focuses on the use of the Impella Recover 2.5.

## Medical Technology Assessment Committee(MTAC)

### *LVAD in the treatment of End Stage Heart Failure*

#### **08/13/2003: MTAC REVIEW**

**Evidence Conclusion:** The REMATCH trial reviewed was conducted among a highly selected group of patients with end stage heart failure, and contraindication for heart transplantation. The trial compared the patients who received the LVAD to those who were treated medically. The methodology of the trial was generally valid; however, it was not blinded. Blinding in such a trial is not possible, and non-blinding may be a source of observation bias. The authors tried to partly overcome this limitation by using independent blinded observers to measure the outcome events. In this trial survival was higher among patients receiving LVAD vs. those in the optimum medical management group. The difference between the two groups was statistically significant, at one year (NNT=4), but not at 2 years. The two years survival among patients receiving the LVAD was only 22%, and according to the survival graph, the 26 months survival was 8%. The LVAD was associated with serious adverse events. Sepsis and device failure were responsible for the majority of deaths in the LVAD group (41.5%, and 17.1% respectively), and left ventricular dysfunction was the cause of death in 92% of the cases in the medical treatment group. The authors concluded that the quality of life was better among LVAD recipients, however the analysis of QoL was only performed among survivors who were able to complete the questionnaires (35% in the LVAD group, and 18% in the medical treatment group). In conclusion the REMATCH

trial provides some evidence that LVAD may improve survival, however for a short duration, and not without serious adverse events, among a selected group of patients with end stage heart failure, and who are not candidates for heart transplantation. It does not provide evidence that LVAD may be used as an alternative to transplantation, in patients eligible for a heart transplant.

**Articles:** The search yielded 32 articles many of which were reviews, opinion pieces, or dealt with the technical aspects of the procedure. One randomized controlled trial, 5 case series and several case reports were identified. The RCT was selected for critical appraisal. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435-43. See [Evidence Table](#).

The use of LVAD in the treatment of End Stage Heart Failure does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 02/14/2011: MTAC REVIEW

### Percutaneous Cardiac Support Systems

**Evidence Conclusion:** The literature search revealed only one small randomized controlled trial that evaluated the safety and efficacy of the Impella Recover LP 2.5 for the treatment of cardiogenic shock caused by myocardial infarction. The trial compared the Impella device with the IABP, the most commonly used device to treat cardiogenic shock. However, the study was too small, blinding and randomization method were not discussed, and it was only powered to detect the difference between the two devices in hemodynamic improvements. It was not powered to evaluate impact on clinical outcomes. The results of the RCT (Evidence table 1) show that the Impella LP 2.5 resulted in better hemodynamic improvement compared to the IABP. However, this was not translated to an improvement in the 30-day survival of the patients in cardiogenic shock after an acute myocardial infarction.

Patients treated with the Impella device tended to have more device-related bleeding, and more limb ischemia.

**Articles:** The literature search identified one small randomized controlled trial that compared Impella Recover LP 2.5 device to IABP for the treatment of cardiogenic shock, a meta-analysis of RCTs comparing percutaneous LVAD to IABP for the treatment of cardiogenic shock, and three other case series evaluating the feasibility and safety of the device. The meta-analysis (Cheng 2009) pooled the results of three trials; two evaluated the TandemHeart, and the third evaluated the Impella Recover 2.5 device. The RCT that compared Impella Recover LP 2.5 device to IABP for the treatment of cardiogenic shock was selected for critical appraisal. Seyfarth M, Sibbing D, Bauer I, A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52:1584-1588. See [Evidence Table](#).

The use of percutaneous cardiac support systems in the treatment of End Stage Heart Failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Artificial Hearts - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
33927	Implantation of a total replacement heart system (artificial heart) with recipient cardiectomy
33928	Removal and replacement of total replacement heart system (artificial heart)
33929	Removal of a total replacement heart system (artificial heart) for heart transplantation (List separately in addition to code for primary procedure)

**Ventricular Assistive Devices - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
33975	Insertion of ventricular assist device; extracorporeal, single ventricle
33976	Insertion of ventricular assist device; extracorporeal, biventricular
33979	Insertion of ventricular assist device, implantable intracorporeal, single ventricle
33981	Replacement of extracorporeal ventricular assist device, single or biventricular, pump(s), single or

	each pump
<b>33982</b>	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, without cardiopulmonary bypass
<b>33983</b>	Replacement of ventricular assist device pump(s); implantable intracorporeal, single ventricle, with cardiopulmonary bypass
<b>33990</b>	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; arterial access only
<b>33991</b>	Insertion of ventricular assist device, percutaneous including radiological supervision and interpretation; both arterial and venous access, with transseptal puncture
<b>33995</b>	Insertion of ventricular assist device, percutaneous, including radiological supervision and interpretation; right heart, venous access only

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/07/2020	07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/01/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	11/13/2023

Revision History	Description
09/08/2016 (VAD)	Added the LCA A52967
03/12/2020 (VAD)	Added statement for medical director to consult with cardiology re Impella (PLVAD) as needed
04/07/2020	MPC approved to adopt KP National coverage policy. Combined Artificial Heart and Ventricular Assistive Devices criteria. Removed deleted codes 0051T, 0052T and 0053T.
07/07/2020	Added CPT codes 33981, 33982 and 33983
07/06/2021	Coding update, added new CPT code 33995
11/13/2023	Updated Medicare coverage article link A52967 which was retired 11/1/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee



## Kaiser Foundation Health Plan of Washington

### Ambulatory Surgery Center (ASC) - Site of Care Policy

- GI Procedures: Benton, Kitsap, Spokane, Whatcom, King and Thurston Counties
- General Surgery, Plastic Surgery, Orthopedic/Podiatry Procedures: Benton, Kitsap, Spokane, and Whatcom Counties

*(see codes section for applicable codes by county)*

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Background

Surgery may safely be performed in various settings. Some of the common settings used are an inpatient hospital or medical center, an off-campus outpatient hospital or medical center, an on-campus outpatient hospital or medical center, an ambulatory surgical center, or a doctor's office. Costs for surgical procedures may vary among these different settings. To encourage the use of the most safe and appropriate, cost-effective sites of care for certain medically necessary outpatient surgical procedures, prior authorization is required\* to ensure the appropriate site of care for the surgical procedures linked below.

We will review the site of care for medical necessity for certain elective surgical procedures. Site of care is defined as the location where the surgical procedure is performed, such as an off campus-outpatient hospital or medical center, an on campus-outpatient hospital or medical center, an ambulatory surgical center, or an inpatient hospital or medical center.

*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).*

### Policy

#### For Non-Medicare Members

*This will be implemented using a phased approach, starting with Benton, Kitsap, Spokane, and Whatcom counties.*

- I. Certain planned surgical procedures performed in a hospital outpatient department are considered medically necessary for an individual who meets **ANY of the following** criteria:
  - Advanced liver disease (MELD Score > 8)
  - Advance surgical planning determines an individual requires overnight recovery and care following a surgical procedure
  - Anticipated need for transfusion
  - Bleeding disorder requiring replacement factor or blood products or special infusion products to correct a coagulation defect
  - Brittle Diabetes
  - Cardiac arrhythmia (symptomatic arrhythmia despite medication)
  - Chronic obstructive pulmonary disease (COPD) (FEV1 <50%)
  - Coronary artery disease ([CAD]/peripheral vascular disease [PVD]) (ongoing cardiac ischemia requiring medical management recently placed [within 1 year] drug eluting stent)



- Developmental stage or cognitive status warranting use of a hospital outpatient department
  - End stage renal disease ([hyperkalemia above reference range]; peritoneal or hemodialysis)
  - History of cerebrovascular accident (CVA) or transient ischemic attack (TIA) (recent event [< 3 months])
  - History of myocardial infarction (MI) (recent event [< 3 months])
  - Individuals with drug eluting stents (DES) placed within one year or bare metal stents (BMS) or plain angioplasty within 90 days unless acetylsalicylic acid and antiplatelet drugs will be continued by agreement of surgeon, cardiologist and anesthesia
  - Age 15 or younger
  - Ongoing evidence of myocardial ischemia
  - Poorly Controlled asthma (FEV1 < 80% despite medical management)
  - Pregnancy
  - Prolonged surgery (> 3 hours)
  - Resistant hypertension (Poorly Controlled)
  - Severe valvular heart disease
  - Sleep apnea (moderate to severe Obstructive Sleep Apnea (OSA)
  - Uncompensated chronic heart failure (CHF) (NYHA class III or IV)
- II. A planned surgical procedure performed in a hospital outpatient department is considered medically necessary if there is an inability to access an ambulatory surgical center for the procedure due to **ANY one of the following**:
- There is no geographically accessible ambulatory surgical center that has the necessary equipment for the procedure; or
  - There is no geographically accessible ambulatory surgical center available at which the individual's physician has privileges; or
  - An ASC's specific guideline regarding the individual's weight or health conditions that prevents the use of an ASC

When an elective surgery is requested at an inpatient hospital/medical center, this site may be considered medically necessary only when the patient has clinical conditions that places him or her at risk of complications.

Examples include:

- Anesthesia risk
- Cardiovascular, liver, pulmonary, or renal risk
- Morbid obesity
- Pregnancy
- Bleeding disorder
- Anticipated need for transfusions

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific contract and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

### Gastroenterology: (Benton, Kitsap, Spokane, Whatcom counties AND King, and Thurston counties)

CPT® or HCPC Codes	Description
<b>43191</b>	Esophagoscopy, rigid, transoral; diagnostic, including collection of specimen(s) by brushing or washing when performed (separate procedure)
<b>43202</b>	Esophagoscopy, flexible, transoral; with biopsy, single or multiple
<b>43229</b>	Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
<b>43233</b>	Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)
<b>43235</b>	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s)



	by brushing or washing, when performed (separate procedure)
<b>43236</b>	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance
<b>43239</b>	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple
<b>43241</b>	Esophagogastroduodenoscopy, flexible, transoral; with insertion of intraluminal tube or catheter
<b>43242</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)
<b>43245</b>	Esophagogastroduodenoscopy, flexible, transoral; with dilation of gastric/duodenal stricture(s) (eg, balloon, bougie)
<b>43246</b>	Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube
<b>43247</b>	Esophagogastroduodenoscopy, flexible, transoral; with removal of foreign body(s)
<b>43248</b>	Esophagogastroduodenoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) through esophagus over guide wire
<b>43249</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic balloon dilation of esophagus (less than 30 mm diameter)
<b>43251</b>	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
<b>43254</b>	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection
<b>43255</b>	Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method
<b>43259</b>	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis
<b>43270</b>	Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
<b>43450</b>	Dilation of esophagus, by unguided sound or bougie, single or multiple passes
<b>43453</b>	Dilation of esophagus, over guide wire
<b>44360</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
<b>44361</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with biopsy, single or multiple
<b>44376</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)
<b>44377</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; with biopsy, single or multiple
<b>44382</b>	Ileoscopy, through stoma; with biopsy, single or multiple
<b>44386</b>	Endoscopic evaluation of small intestinal pouch (eg, Kock pouch, ileal reservoir [S or J]); with biopsy, single or multiple
<b>44388</b>	Colonoscopy through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
<b>44389</b>	Colonoscopy through stoma; with biopsy, single or multiple
<b>44394</b>	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
<b>45100</b>	Biopsy of anorectal wall, anal approach (eg, congenital megacolon)
<b>45171</b>	Excision of rectal tumor, transanal approach; not including muscularis propria (ie, partial thickness)
<b>45172</b>	Excision of rectal tumor, transanal approach; including muscularis propria (ie, full thickness)
<b>45190</b>	Destruction of rectal tumor (eg, electrodesiccation, electrosurgery, laser ablation, laser resection, cryosurgery) transanal approach
<b>45305</b>	Proctosigmoidoscopy, rigid; with biopsy, single or multiple
<b>45334</b>	Sigmoidoscopy, flexible; with control of bleeding, any method
<b>45335</b>	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance
<b>45340</b>	Sigmoidoscopy, flexible; with transendoscopic balloon dilation

<b>45341</b>	Sigmoidoscopy, flexible; with endoscopic ultrasound examination
<b>45342</b>	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)
<b>45349</b>	Sigmoidoscopy, flexible; with endoscopic mucosal resection
<b>45378</b>	Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
<b>45379</b>	Colonoscopy, flexible; with removal of foreign body(s)
<b>45380</b>	Colonoscopy, flexible; with biopsy, single or multiple
<b>45381</b>	Colonoscopy, flexible; with directed submucosal injection(s), any substance
<b>45382</b>	Colonoscopy, flexible; with control of bleeding, any method
<b>45384</b>	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps
<b>45385</b>	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
<b>45386</b>	Colonoscopy, flexible; with transendoscopic balloon dilation
<b>45388</b>	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
<b>45390</b>	Colonoscopy, flexible; with endoscopic mucosal resection
<b>45391</b>	Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures
<b>45392</b>	Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures
<b>45393</b>	Colonoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed
<b>45398</b>	Colonoscopy, flexible; with band ligation(s) (eg, hemorrhoids)
<b>G0105</b>	Colorectal cancer screening; colonoscopy on individual at high risk
<b>G0121</b>	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk

**General Surgery: (Benton, Kitsap, Spokane, and Whatcom counties)**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>19000</b>	Puncture aspiration of cyst of breast;
<b>19001</b>	Puncture aspiration of cyst of breast; each additional cyst (List separately in addition to code for primary procedure)
<b>19020</b>	Mastotomy with exploration or drainage of abscess, deep
<b>19030</b>	Injection procedure only for mammary ductogram or galactogram
<b>19100</b>	Biopsy of breast; percutaneous, needle core, not using imaging guidance (separate procedure)
<b>19101</b>	Biopsy of breast; open, incisional
<b>19110</b>	Nipple exploration, with or without excision of a solitary lactiferous duct or a papilloma lactiferous duct
<b>19112</b>	Excision of lactiferous duct fistula
<b>19120</b>	Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion (except 19300), open, male or female, 1 or more lesions
<b>19125</b>	Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion
<b>19126</b>	Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure)
<b>19301</b>	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy)
<b>19303</b>	Mastectomy, simple, complete
<b>38520</b>	Biopsy or excision of lymph node(s); open, deep cervical node(s) with excision scalene fat pad
<b>38525</b>	Biopsy or excision of lymph node(s); open, deep axillary node(s)
<b>38530</b>	Biopsy or excision of lymph node(s); open, internal mammary node(s)
<b>38531</b>	Biopsy or excision of lymph node(s); open, inguinofemoral node(s)

<b>45500</b>	Proctoplasty; for stenosis
<b>45505</b>	Proctoplasty; for prolapse of mucous membrane
<b>45520</b>	Perirectal injection of sclerosing solution for prolapse
<b>45541</b>	Proctopexy (e.g., for prolapse); perineal approach
<b>45560</b>	Repair of rectocele (separate procedure)
<b>45900</b>	Reduction of procidentia (separate procedure) under anesthesia
<b>45905</b>	Dilation of anal sphincter (separate procedure) under anesthesia other than local
<b>45910</b>	Dilation of rectal stricture (separate procedure) under anesthesia other than local
<b>45915</b>	Removal of fecal impaction or foreign body (separate procedure) under anesthesia
<b>45990</b>	Anorectal exam, surgical, requiring anesthesia (general, spinal, or epidural), diagnostic
<b>46020</b>	Placement of seton
<b>46030</b>	Removal of anal seton, other marker
<b>46040</b>	Incision and drainage of ischiorectal and/or perirectal abscess (separate procedure)
<b>46045</b>	Incision and drainage of intramural, intramuscular, or submucosal abscess, transanal, under anesthesia
<b>46050</b>	Incision and drainage, perianal abscess, superficial
<b>46060</b>	Incision and drainage of ischiorectal or intramural abscess, with fistulectomy or fistulotomy, submuscular, with or without placement of seton
<b>46080</b>	Sphincterotomy, anal, division of sphincter (separate procedure)
<b>46083</b>	Incision of thrombosed hemorrhoid, external
<b>46200</b>	Fissurectomy, including sphincterotomy, when performed
<b>46220</b>	Excision of single external papilla or tag, anus
<b>46221</b>	Hemorrhoidectomy, internal, by rubber band ligation(s)
<b>46230</b>	Excision of multiple external papillae or tags, anus
<b>46250</b>	Hemorrhoidectomy, external, 2 or more columns/groups
<b>46255</b>	Hemorrhoidectomy, internal and external, single column/group
<b>46257</b>	Hemorrhoidectomy, internal and external, single column/group; with fissurectomy
<b>46258</b>	Hemorrhoidectomy, internal and external, single column/group; with fistulectomy, including fissurectomy, when performed
<b>46260</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups;
<b>46261</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups; with fissurectomy
<b>46262</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups; with fistulectomy, including fissurectomy, when performed
<b>46270</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); subcutaneous
<b>46275</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); inter-sphincteric
<b>46280</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); trans sphincteric, suprasphincteric, extra sphincteric or multiple, including placement of seton, when performed
<b>46285</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); second stage
<b>46288</b>	Closure of anal fistula with rectal advancement flap
<b>46320</b>	Excision of thrombosed hemorrhoid, external
<b>46505</b>	Chemodenervation of internal anal sphincter
<b>46706</b>	Repair of anal fistula with fibrin glue
<b>46707</b>	Repair of anorectal fistula with plug (e.g., porcine small intestine submucosa [SIS])
<b>46750</b>	Sphincteroplasty, anal, for incontinence or prolapse; adult
<b>46753</b>	Graft (Thiersch operation) for rectal incontinence and/or prolapse
<b>46754</b>	Removal of Thiersch wire or suture, anal canal
<b>46760</b>	Sphincteroplasty, anal, for incontinence, adult; muscle transplant
<b>46761</b>	Sphincteroplasty, anal, for incontinence, adult; levator muscle imbrication (Park posterior anal repair)
<b>46900</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; chemical
<b>46910</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; electrodesiccation

<b>46916</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; cryosurgery
<b>46917</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; laser surgery
<b>46922</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; surgical excision
<b>46924</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), extensive (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery)
<b>46930</b>	Destruction of internal hemorrhoid(s) by thermal energy (e.g., infrared coagulation, cautery, radiofrequency)
<b>46940*</b>	Curettage or cautery of anal fissure, including dilation of anal sphincter (separate procedure); initial
<b>46942</b>	Curettage or cautery of anal fissure, including dilation of anal sphincter (separate procedure); subsequent
<b>46945</b>	Hemorrhoidectomy, internal, by ligation other than rubber band; single hemorrhoid column/group
<b>46946</b>	Hemorrhoidectomy, internal, by ligation other than rubber band; 2 or more hemorrhoid columns/groups
<b>46947</b>	Hemorrhoidopexy (e.g., for prolapsing internal hemorrhoids) by stapling
<b>46948</b>	Hemorrhoidectomy, internal, by transanal hemorrhoidal dearterialization, 2 or more hemorrhoid columns/groups, including ultrasound guidance, with mucopexy, when performed
<b>47562</b>	Laparoscopy, surgical; cholecystectomy
<b>47563</b>	Laparoscopy, surgical; cholecystectomy with cholangiography
<b>47564</b>	Laparoscopy, surgical; cholecystectomy with exploration of common duct
<b>49505</b>	Repair initial inguinal hernia, age 5 years or older; reducible
<b>49507</b>	Repair initial inguinal hernia, age 5 years or older; incarcerated or strangulated
<b>49520</b>	Repair recurrent inguinal hernia, any age; reducible
<b>49521</b>	Repair recurrent inguinal hernia, any age; incarcerated or strangulated
<b>49525</b>	Repair inguinal hernia, sliding, any age
<b>49550</b>	Repair initial femoral hernia, any age; reducible
<b>49553</b>	Repair initial femoral hernia, any age; incarcerated or strangulated
<b>49555</b>	Repair recurrent femoral hernia; reducible
<b>49557</b>	Repair recurrent femoral hernia; incarcerated or strangulated
<b>49591</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible
<b>49593</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible
<b>49595</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible
<b>49613</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible
<b>49615</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible
<b>49617</b>	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible
<b>49621</b>	Repair of parastomal hernia, any approach (ie, open, laparoscopic, robotic), initial or recurrent, including implantation of mesh or other prosthesis, when performed; reducible
<b>49623</b>	Removal of total or near total non-infected mesh or other prosthesis at the time of initial or recurrent anterior abdominal hernia repair or parastomal hernia repair, any approach (ie, open, laparoscopic, robotic) (List separately in addition to code for primary procedure)
<b>49650</b>	Laparoscopy, surgical; repair initial inguinal hernia

<b>49651</b>	Laparoscopy, surgical; repair recurrent inguinal hernia
--------------	---

**Plastic surgery:** *(Benton, Kitsap, Spokane, and Whatcom counties)*

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>11950</b>	Subcutaneous injection of filling material (eg, collagen); 1 cc or less
<b>11951</b>	Subcutaneous injection of filling material (eg, collagen); 1.1 to 5.0 cc
<b>11952</b>	Subcutaneous injection of filling material (eg, collagen); 5.1 to 10.0 cc
<b>11954</b>	Subcutaneous injection of filling material (eg, collagen); over 10.0 cc
<b>11960</b>	Insertion of tissue expander(s) for other than breast, including subsequent expansion
<b>11970</b>	Replacement of tissue expander with permanent implant
<b>11971</b>	Removal of tissue expander without insertion of implant
<b>14000</b>	Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less
<b>14001</b>	Adjacent tissue transfer or rearrangement, trunk; defect 10.1 sq cm to 30.0 sq cm
<b>14020</b>	Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10 sq cm or less
<b>14021</b>	Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10.1 sq cm to 30.0 sq cm
<b>14040</b>	Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10 sq cm or less
<b>14041</b>	Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10.1 sq cm to 30.0 sq cm
<b>14060</b>	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less
<b>14061</b>	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less
<b>14301</b>	Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm
<b>14302</b>	Adjacent tissue transfer or rearrangement, any area; each additional 30.0 sq cm, or part thereof (List separately in addition to code for primary procedure)
<b>14350</b>	Filletted finger or toe flap, including preparation of recipient site
<b>19316</b>	Mastopexy
<b>19318</b>	Breast reduction
<b>19325</b>	Breast augmentation with implant
<b>19340</b>	Insertion of breast implant on same day of mastectomy (ie, immediate)
<b>19342</b>	Insertion or replacement of breast implant on separate day from mastectomy
<b>19357</b>	Tissue expander placement in breast reconstruction, including subsequent expansion(s)
<b>19370</b>	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy
<b>19371</b>	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents
<b>19380</b>	Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction)

**Orthopedics/Podiatry:** *(Benton, Kitsap, Spokane, and Whatcom counties)*

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>20200</b>	Biopsy, muscle; superficial
<b>20205</b>	Biopsy, muscle; deep
<b>20206</b>	Biopsy, muscle, percutaneous needle
<b>20220</b>	Biopsy, bone, trocar, or needle; superficial (e.g., ilium, sternum, spinous process, ribs)
<b>20225</b>	Biopsy, bone, trocar, or needle; deep (e.g., vertebral body, femur)
<b>20240</b>	Biopsy, bone, open; superficial (e.g., sternum, spinous process, rib, patella, olecranon process, calcaneus, tarsal, metatarsal, carpal, metacarpal, phalanx)
<b>20245</b>	Biopsy, bone, open; deep (e.g., humeral shaft, ischium, femoral shaft)
<b>20924</b>	Tendon graft, from a distance (eg, palmaris, toe extensor, plantaris)



<b>23130</b>	Acromioplasty or acromionectomy, partial, with or without coracoacromial ligament release
<b>23140</b>	Excision or curettage of bone cyst or benign tumor of clavicle or scapula
<b>23145</b>	Excision or curettage of bone cyst or benign tumor of clavicle or scapula; with autograft (includes obtaining graft)
<b>23150</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus
<b>23155</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus; with autograft (includes obtaining graft)
<b>23156</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus; with allograft
<b>23405</b>	Tenotomy, shoulder area; single tendon
<b>23406</b>	Tenotomy, shoulder area; multiple tendons through same incision
<b>23410</b>	Repair of ruptured musculotendinous cuff (eg, rotator cuff) open; acute
<b>23412</b>	Repair of ruptured musculotendinous cuff (eg, rotator cuff) open; chronic
<b>23415</b>	Coracoacromial ligament release, with or without acromioplasty
<b>23420</b>	Reconstruction of complete shoulder (rotator) cuff avulsion, chronic (includes acromioplasty)
<b>23430</b>	Tenodesis of long tendon of biceps
<b>23440</b>	Resection or transplantation of long tendon of biceps
<b>23450</b>	Capsulorrhaphy, anterior; Putti-Platt procedure or Magnuson type operation
<b>23455</b>	Capsulorrhaphy, anterior; with labral repair (eg, Bankart procedure)
<b>23460</b>	Capsulorrhaphy, anterior, any type; with bone block
<b>23462</b>	Capsulorrhaphy, anterior, any type; with coracoid process transfer
<b>23465</b>	Capsulorrhaphy, glenohumeral joint, posterior, with or without bone block
<b>23466</b>	Capsulorrhaphy, glenohumeral joint, any type multi-directional instability
<b>23480</b>	Osteotomy, clavicle, with or without internal fixation
<b>23485</b>	Osteotomy, clavicle, with or without internal fixation; with bone graft for nonunion or malunion (includes obtaining graft and/or necessary fixation)
<b>23700</b>	Manipulation under anesthesia, shoulder joint, including application of fixation apparatus (dislocation excluded)
<b>23800</b>	Arthrodesis, glenohumeral joint;
<b>23802</b>	Arthrodesis, glenohumeral joint; with autogenous graft (includes obtaining graft)
<b>23930</b>	Incision and drainage, upper arm or elbow area; deep abscess or hematoma
<b>23931</b>	Incision and drainage, upper arm or elbow area; bursa
<b>23935</b>	Incision, deep, with opening of bone cortex (eg, for osteomyelitis or bone abscess), humerus or elbow
<b>24000</b>	Arthrotomy, elbow, including exploration, drainage, or removal of foreign body
<b>24006</b>	Arthrotomy of the elbow, with capsular excision for capsular release (separate procedure)
<b>24100</b>	Arthrotomy, elbow; with synovial biopsy only
<b>24101</b>	Arthrotomy, elbow; with joint exploration, with or without biopsy, with or without removal of loose or foreign body
<b>24102</b>	Arthrotomy, elbow; with synovectomy
<b>24105</b>	Excision, olecranon bursa
<b>24110</b>	Excision or curettage of bone cyst or benign tumor, humerus
<b>24115</b>	Excision or curettage of bone cyst or benign tumor, humerus; with autograft (includes obtaining graft)
<b>24116</b>	Excision or curettage of bone cyst or benign tumor, humerus; with allograft
<b>24120</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process
<b>24125</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process; with autograft (includes obtaining graft)
<b>24126</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process; with allograft
<b>24130</b>	Excision, radial head
<b>24134</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), shaft or distal humerus
<b>24136</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), radial head or neck
<b>24138</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), olecranon process



<b>24140</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis), humerus
<b>24145</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis), radial head or neck
<b>24147</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (e.g., osteomyelitis), olecranon process
<b>24149</b>	Radical resection of capsule, soft tissue, and heterotopic bone, elbow, with contracture release (separate procedure)
<b>24150</b>	Radical resection of tumor, shaft or distal humerus
<b>24152</b>	Radical resection of tumor, radial head or neck
<b>24155</b>	Resection of elbow joint (arthrectomy)
<b>24160</b>	Removal of prosthesis, includes debridement and synovectomy when performed; humeral and ulnar components
<b>24164</b>	Removal of prosthesis, includes debridement and synovectomy when performed; radial head
<b>24200</b>	Removal of foreign body, upper arm or elbow area; subcutaneous
<b>24201</b>	Removal of foreign body, upper arm or elbow area; deep (subfascial or intramuscular)
<b>24220</b>	Injection procedure for elbow arthrography
<b>24300</b>	Manipulation, elbow, under anesthesia
<b>24301</b>	Muscle or tendon transfer, any type, upper arm or elbow, single (excluding 24320-24331)
<b>24305</b>	Tendon lengthening, upper arm or elbow, each tendon
<b>24310</b>	Tenotomy, open, elbow to shoulder, each tendon
<b>24330</b>	Flexor-plasty, elbow (eg, Steindler type advancement);
<b>24331</b>	Flexor-plasty, elbow (eg, Steindler type advancement); with extensor advancement
<b>24332</b>	Tenolysis, triceps
<b>24340</b>	Tenodesis of biceps tendon at elbow (separate procedure)
<b>24341</b>	Repair, tendon or muscle, upper arm or elbow, each tendon or muscle, primary or secondary (excludes rotator cuff)
<b>24342</b>	Reinsertion of ruptured biceps or triceps tendon, distal, with or without tendon graft
<b>24343</b>	Repair lateral collateral ligament, elbow, with local tissue
<b>24344</b>	Reconstruction lateral collateral ligament, elbow, with tendon graft (includes harvesting of graft)
<b>24345</b>	Repair medial collateral ligament, elbow, with local tissue
<b>24346</b>	Reconstruction medial collateral ligament, elbow, with tendon graft (includes harvesting of graft)
<b>24357</b>	Tenotomy, elbow, lateral or medial (e.g., epicondylitis, tennis elbow, golfer's elbow); percutaneous
<b>24358</b>	Tenotomy, elbow, lateral or medial (e.g., epicondylitis, tennis elbow, golfer's elbow); debridement, soft tissue and/or bone, open
<b>24359</b>	Tenotomy, elbow, lateral or medial (eg, epicondylitis, tennis elbow, golfer's elbow); debridement, soft tissue and/or bone, open with tendon repair or reattachment
<b>24360</b>	Arthroplasty, elbow; with membrane (eg, fascial)
<b>24361</b>	Arthroplasty, elbow; with distal humeral prosthetic replacement
<b>24362</b>	Arthroplasty, elbow; with implant and fascia lata ligament reconstruction
<b>24363</b>	Arthroplasty, elbow; with distal humerus and proximal ulnar prosthetic replacement (eg, total elbow)
<b>24365</b>	Arthroplasty, radial head;
<b>24366</b>	Arthroplasty, radial head; with implant
<b>24370</b>	Revision of total elbow arthroplasty, including allograft when performed; humeral or ulnar component
<b>24371</b>	Revision of total elbow arthroplasty, including allograft when performed; humeral and ulnar component
<b>24400</b>	Osteotomy, humerus, with or without internal fixation
<b>24410</b>	Multiple osteotomies with realignment on intramedullary rod, humeral shaft (Sofield type procedure)
<b>24430</b>	Repair of nonunion or malunion, humerus; without graft (eg, compression technique)
<b>24435</b>	Repair of nonunion or malunion, humerus; with iliac or other autograft (includes obtaining graft)
<b>24470</b>	Hemiepiphyseal arrest (eg, cubitus varus or valgus, distal humerus)
<b>24495</b>	Decompression fasciotomy, forearm, with brachial artery exploration

<b>24498</b>	Prophylactic treatment (nailing, pinning, plating or wiring), with or without methylmethacrylate, humeral shaft
<b>25000</b>	Incision, extensor tendon sheath, wrist (eg, deQuervains disease)
<b>25001</b>	Incision, flexor tendon sheath, wrist (eg, flexor carpi radialis)
<b>25085</b>	Capsulotomy, wrist (e.g., contracture)
<b>25100</b>	Arthrotomy, wrist joint; with biopsy
<b>25101</b>	Arthrotomy, wrist joint; with joint exploration, with or without biopsy, with or without removal of loose or foreign body
<b>25105</b>	Arthrotomy, wrist joint; with synovectomy
<b>25107</b>	Arthrotomy, distal radioulnar joint including repair of triangular cartilage, complex
<b>25109</b>	Excision of tendon, forearm and/or wrist, flexor or extensor, each
<b>25110</b>	Excision, lesion of tendon sheath, forearm and/or wrist
<b>25111</b>	Excision, lesion of tendon sheath, forearm and/or wrist
<b>25112</b>	Excision of ganglion, wrist (dorsal or volar); recurrent
<b>25115</b>	Radical excision of bursa, synovia of wrist, or forearm tendon sheaths (eg, tenosynovitis, fungus, Tbc, or other granulomas, rheumatoid arthritis); flexors
<b>25116</b>	Radical excision of bursa, synovia of wrist, or forearm tendon sheaths (eg, tenosynovitis, fungus, Tbc, or other granulomas, rheumatoid arthritis); extensors, with or without transposition of dorsal retinaculum
<b>25118</b>	Synovectomy, extensor tendon sheath, wrist, single compartment
<b>25119</b>	Synovectomy, extensor tendon sheath, wrist, single compartment; with resection of distal ulna
<b>25120</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process)
<b>25125</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process); with autograft (includes obtaining graft)
<b>25126</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process); with allograft
<b>25130</b>	Excision or curettage of bone cyst or benign tumor of carpal bones
<b>25135</b>	Excision or curettage of bone cyst or benign tumor of carpal bones; with autograft (includes obtaining graft)
<b>25136</b>	Excision or curettage of bone cyst or benign tumor of carpal bones; with allograft
<b>25150</b>	Partial excision (craterization, saucerization, or diaphysectomy) of bone (eg, for osteomyelitis); ulna
<b>25151</b>	Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis); radius
<b>25210</b>	Carpectomy; 1 bone
<b>25215</b>	Carpectomy; all bones of proximal row
<b>25230</b>	Radial styloidectomy (separate procedure)
<b>25240</b>	Excision distal ulna partial or complete (e.g., Darrach type or matched resection)
<b>25260</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; primary, single, each tendon or muscle
<b>25263</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; secondary, single, each tendon or muscle
<b>25265</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; secondary, with free graft (includes obtaining graft), each tendon or muscle
<b>25270</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; primary, single, each tendon or muscle
<b>25272</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; secondary, single, each tendon or muscle
<b>25274</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; secondary, with free graft (includes obtaining graft), each tendon or muscle
<b>25275</b>	Repair, tendon sheath, extensor, forearm and/or wrist, with free graft (includes obtaining graft) (e.g., for extensor carpi ulnaris subluxation)
<b>25280</b>	Lengthening or shortening of flexor or extensor tendon, forearm and/or wrist, single, each tendon
<b>25290</b>	Tenotomy, open, flexor or extensor tendon, forearm and/or wrist, single, each tendon
<b>25295</b>	Tenolysis, flexor or extensor tendon, forearm and/or wrist, single, each tendon
<b>25300</b>	Tenodesis at wrist; flexors of fingers
<b>25301</b>	Tenodesis at wrist; extensors of fingers

<b>25310</b>	Radical excision of bursa, synovia of wrist, or forearm tendon sheaths (eg, tenosynovitis, fungus, Tbc, or other granulomas, rheumatoid arthritis); extensors, with or without transposition of dorsal retinaculum
<b>25312</b>	Tendon transplantation or transfer, flexor or extensor, forearm and/or wrist, single; with tendon graft(s) (includes obtaining graft), each tendon
<b>25315</b>	Flexor origin slide (eg, for cerebral palsy, Volkmann contracture), forearm and/or wrist;
<b>25316</b>	Flexor origin slide (eg, for cerebral palsy, Volkmann contracture), forearm and/or wrist; with tendon(s) transfer
<b>25320</b>	Capsulorrhaphy or reconstruction, wrist, open (eg, capsulodesis, ligament repair, tendon transfer or graft) (includes synovectomy, capsulotomy and open reduction) for carpal instability
<b>25332</b>	Arthroplasty, wrist, with or without interposition, with or without external or internal fixation
<b>25335</b>	Centralization of wrist on ulna (eg, radial club hand)
<b>25337</b>	Reconstruction for stabilization of unstable distal ulna or distal radioulnar joint, secondary by soft tissue stabilization (eg, tendon transfer, tendon graft or weave, or tenodesis) with or without open reduction of distal radioulnar joint
<b>25350</b>	Osteotomy, radius; distal third
<b>25355</b>	Osteotomy, radius; middle or proximal third
<b>25360</b>	Osteotomy; ulna
<b>25365</b>	Osteotomy; radius AND ulna
<b>25370</b>	Multiple osteotomies, with realignment on intramedullary rod (Sofield type procedure); radius OR ulna
<b>25375</b>	Multiple osteotomies, with realignment on intramedullary rod (Sofield type procedure); radius AND ulna
<b>25390</b>	Osteoplasty, radius OR ulna; shortening
<b>25392</b>	Osteoplasty, radius AND ulna; shortening (excluding 64876)
<b>25394</b>	Osteoplasty, carpal bone, shortening
<b>25400</b>	Repair of nonunion or malunion, radius OR ulna; without graft (eg, compression technique)
<b>25405</b>	Repair of nonunion or malunion, radius OR ulna; with autograft (includes obtaining graft)
<b>25415</b>	Repair of nonunion or malunion, radius AND ulna; without graft (eg, compression technique)
<b>25420</b>	Repair of nonunion or malunion, radius AND ulna; with autograft (includes obtaining graft)
<b>25430</b>	Insertion of vascular pedicle into carpal bone (eg, Hori procedure)
<b>25431</b>	Repair of nonunion of carpal bone (excluding carpal scaphoid (navicular)) (includes obtaining graft and necessary fixation), each bone
<b>25440</b>	Repair of nonunion, scaphoid carpal (navicular) bone, with or without radial styloidectomy (includes obtaining graft and necessary fixation)
<b>25441</b>	Arthroplasty with prosthetic replacement; distal radius
<b>25442</b>	Arthroplasty with prosthetic replacement; distal ulna
<b>25443</b>	Arthroplasty with prosthetic replacement; scaphoid carpal (navicular)
<b>25444</b>	Arthroplasty with prosthetic replacement; lunate
<b>25445</b>	Arthroplasty with prosthetic replacement; trapezium
<b>25446</b>	Arthroplasty with prosthetic replacement; distal radius and partial or entire carpus (total wrist)
<b>25447</b>	Arthroplasty, interposition, intercarpal or carpometacarpal joints
<b>25449</b>	Revision of arthroplasty, including removal of implant, wrist joint
<b>25450</b>	Epiphyseal arrest by epiphysiodesis or stapling; distal radius OR ulna
<b>25455</b>	Epiphyseal arrest by epiphysiodesis or stapling; distal radius AND ulna
<b>25800</b>	Arthrodesis, wrist; complete, without bone graft (includes radiocarpal and/or intercarpal and/or carpometacarpal joints)
<b>25805</b>	Arthrodesis, wrist; with sliding graft
<b>25810</b>	Arthrodesis, wrist; with iliac or other autograft (includes obtaining graft)
<b>25820</b>	Arthrodesis, wrist; limited, without bone graft (eg, intercarpal or radiocarpal)
<b>25825</b>	Arthrodesis, wrist; with autograft (includes obtaining graft)
<b>25830</b>	Arthrodesis, distal radioulnar joint with segmental resection of ulna, with or without bone graft (eg, Sauve-Kapandji procedure)
<b>26010</b>	Drainage of finger abscess; simple

<b>26011</b>	Drainage of finger abscess; complicated (e.g., felon)
<b>26020</b>	Drainage of tendon sheath, digit and/or palm, each
<b>26040</b>	Fasciotomy, palmar (eg, Dupuytren's contracture); percutaneous
<b>26045</b>	Fasciotomy, palmar (e.g., Dupuytren's contracture); open, partial
<b>26055</b>	Tendon sheath incision (eg, for trigger finger)
<b>26070</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; carpometacarpal joint
<b>26075</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; metacarpophalangeal joint, each
<b>26080</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; interphalangeal joint, each
<b>26100</b>	Arthrotomy with biopsy; carpometacarpal joint, each
<b>26105</b>	Arthrotomy with biopsy; metacarpophalangeal joint, each
<b>26110</b>	Arthrotomy with biopsy; interphalangeal joint, each
<b>26111</b>	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; 1.5 cm or greater
<b>26113</b>	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (e.g., intramuscular); 1.5 cm or greater
<b>26115</b>	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; less than 1.5 cm
<b>26116</b>	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (e.g., intramuscular); less than 1.5 cm
<b>26117</b>	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; less than 3 cm
<b>26118</b>	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; 3 cm or greater
<b>26121</b>	Fasciectomy, palm only, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft)
<b>26123</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft)
<b>26125</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft); each additional digit (List separately in addition to code for primary procedure)
<b>26160</b>	Excision of lesion of tendon sheath or joint capsule (eg, cyst, mucous cyst, or ganglion), hand or finger
<b>26170</b>	Excision of tendon, palm, flexor or extensor, single, each tendon
<b>26180</b>	Excision of tendon, finger, flexor or extensor, each tendon
<b>26200</b>	Excision or curettage of bone cyst or benign tumor of metacarpal
<b>26205</b>	Excision or curettage of bone cyst or benign tumor of metacarpal; with autograft (includes obtaining graft)
<b>26210</b>	Excision or curettage of bone cyst or benign tumor of proximal, middle, or distal phalanx of finger
<b>26215</b>	Excision or curettage of bone cyst or benign tumor of proximal, middle, or distal phalanx of finger; with autograft (includes obtaining graft)
<b>26230</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis); metacarpal
<b>26235</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis); proximal or middle phalanx of finger
<b>26236</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (e.g., osteomyelitis); distal phalanx of finger
<b>26320</b>	Removal of implant from finger or hand
<b>26350</b>	Repair or advancement, flexor tendon, not in zone 2 digital flexor tendon sheath (eg, no man's land); primary or secondary without free graft, each tendon
<b>26352</b>	Repair or advancement, flexor tendon, not in zone 2 digital flexor tendon sheath (eg, no man's land); secondary with free graft (includes obtaining graft), each tendon
<b>26356</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (e.g., no man's land); primary, without free graft, each tendon
<b>26357</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (e.g., no man's land); secondary, without free graft, each tendon
<b>26358</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (eg, no man's land);

	secondary, with free graft (includes obtaining graft), each tendon
<b>26370</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; primary, each tendon
<b>26372</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; secondary with free graft (includes obtaining graft), each tendon
<b>26373</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; secondary without free graft, each tendon
<b>26392</b>	Removal of synthetic rod and insertion of flexor tendon graft, hand or finger (includes obtaining graft), each rod
<b>26410</b>	Repair, extensor tendon, hand, primary or secondary; without free graft, each tendon
<b>26412</b>	Repair, extensor tendon, hand, primary or secondary; with free graft (includes obtaining graft), each tendon
<b>26418</b>	Repair, extensor tendon, finger, primary or secondary; without free graft, each tendon
<b>26420</b>	Repair, extensor tendon, finger, primary or secondary; with free graft (includes obtaining graft) each tendon
<b>26426</b>	Repair of extensor tendon, central slip, secondary (e.g., boutonniere deformity); using local tissue(s), including lateral band(s), each finger
<b>26428</b>	Repair of extensor tendon, central slip, secondary (eg, boutonniere deformity); with free graft (includes obtaining graft), each finger
<b>26432</b>	Closed treatment of distal extensor tendon insertion, with or without percutaneous pinning (e.g., mallet finger)
<b>26433</b>	Repair of extensor tendon, distal insertion, primary or secondary; without graft (e.g., mallet finger)
<b>26434</b>	Repair of extensor tendon, distal insertion, primary or secondary; with free graft (includes obtaining graft)
<b>26437</b>	Realignment of extensor tendon, hand, each tendon
<b>26440</b>	Tenolysis, flexor tendon; palm or finger, each tendon
<b>26442</b>	Tenolysis, flexor tendon; palm and finger, each tendon
<b>26445</b>	Tenolysis, extensor tendon, hand or finger, each tendon
<b>26449</b>	Tenolysis, complex, extensor tendon, finger, including forearm, each tendon
<b>26450</b>	Tenotomy, flexor, palm, open, each tendon
<b>26455</b>	Tenotomy, flexor, finger, open, each tendon
<b>26460</b>	Tenotomy, extensor, hand or finger, open, each tendon
<b>26480</b>	Transfer or transplant of tendon, carpometacarpal area or dorsum of hand; without free graft, each tendon
<b>26483</b>	Transfer or transplant of tendon, carpometacarpal area or dorsum of hand; with free tendon graft (includes obtaining graft), each tendon
<b>26485</b>	Transfer or transplant of tendon, palmar; without free tendon graft, each tendon
<b>26489</b>	Transfer or transplant of tendon, palmar; with free tendon graft (includes obtaining graft), each tendon
<b>26500</b>	Reconstruction of tendon pulley, each tendon; with local tissues (separate procedure)
<b>26502</b>	Reconstruction of tendon pulley, each tendon; with tendon or fascial graft (includes obtaining graft) (separate procedure)
<b>26516</b>	Capsulodesis, metacarpophalangeal joint; single digit
<b>26517</b>	Capsulodesis, metacarpophalangeal joint; 2 digits
<b>26518</b>	Capsulodesis, metacarpophalangeal joint; 3 or 4 digits
<b>26520</b>	Capsulectomy or capsulotomy; metacarpophalangeal joint, each joint
<b>26525</b>	Capsulectomy or capsulotomy; interphalangeal joint, each joint
<b>26540</b>	Repair of collateral ligament, metacarpophalangeal or interphalangeal joint
<b>26541</b>	Reconstruction, collateral ligament, metacarpophalangeal joint, single; with tendon or fascial graft (includes obtaining graft)
<b>26542</b>	Reconstruction, collateral ligament, metacarpophalangeal joint, single; with local tissue (e.g., adductor advancement)
<b>26545</b>	Reconstruction, collateral ligament, interphalangeal joint, single, including graft, each joint
<b>26565</b>	Osteotomy; metacarpal, each
<b>26567</b>	Osteotomy; phalanx of finger, each
<b>26587</b>	Reconstruction of polydactylous digit, soft tissue and bone



<b>26590</b>	Repair macrodactylia, each digit
<b>26591</b>	Repair, intrinsic muscles of hand, each muscle
<b>26593</b>	Release, intrinsic muscles of hand, each muscle
<b>26596</b>	Excision of constricting ring of finger, with multiple Z-plasties
<b>26600</b>	Closed treatment of metacarpal fracture, single; without manipulation, each bone
<b>26605</b>	Closed treatment of metacarpal fracture, single; with manipulation, each bone
<b>26607</b>	Closed treatment of metacarpal fracture, with manipulation, with external fixation, each bone
<b>26608</b>	Percutaneous skeletal fixation of metacarpal fracture, each bone
<b>26615</b>	Open treatment of metacarpal fracture, single, includes internal fixation, when performed, each bone
<b>26641</b>	Closed treatment of carpometacarpal dislocation, thumb, with manipulation
<b>26645</b>	Closed treatment of carpometacarpal fracture dislocation, thumb (Bennett fracture), with manipulation
<b>26650</b>	Percutaneous skeletal fixation of carpometacarpal fracture dislocation, thumb (Bennett fracture), with manipulation
<b>26665</b>	Open treatment of carpometacarpal fracture dislocation, thumb (Bennett fracture), includes internal fixation, when performed
<b>26670</b>	Closed treatment of carpometacarpal dislocation, other than thumb, with manipulation, each joint; without anesthesia
<b>26675</b>	Closed treatment of carpometacarpal dislocation, other than thumb, with manipulation, each joint; requiring anesthesia
<b>26676</b>	Percutaneous skeletal fixation of carpometacarpal dislocation, other than thumb, with manipulation, each joint
<b>26685</b>	Open treatment of carpometacarpal dislocation, other than thumb; includes internal fixation, when performed, each joint
<b>26686</b>	Open treatment of carpometacarpal dislocation, other than thumb; complex, multiple, or delayed reduction
<b>26700</b>	Closed treatment of metacarpophalangeal dislocation, single, with manipulation; without anesthesia
<b>26705</b>	Closed treatment of metacarpophalangeal dislocation, single, with manipulation; requiring anesthesia
<b>26706</b>	Percutaneous skeletal fixation of metacarpophalangeal dislocation, single, with manipulation
<b>26715</b>	Open treatment of metacarpophalangeal dislocation, single, includes internal fixation, when performed
<b>26720</b>	Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; without manipulation, each
<b>26725</b>	Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; with manipulation, with or without skin or skeletal traction, each
<b>26727</b>	Percutaneous skeletal fixation of unstable phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, with manipulation, each
<b>26735</b>	Open treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, includes internal fixation, when performed, each
<b>26740</b>	Closed treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint; without manipulation, each
<b>26742</b>	Closed treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint; with manipulation, each
<b>26746</b>	Open treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint, includes internal fixation, when performed, each
<b>26750</b>	Closed treatment of distal phalangeal fracture, finger or thumb; without manipulation, each
<b>26755</b>	Closed treatment of distal phalangeal fracture, finger or thumb; with manipulation, each
<b>26756</b>	Percutaneous skeletal fixation of distal phalangeal fracture, finger or thumb, each
<b>26765</b>	Open treatment of distal phalangeal fracture, finger or thumb, includes internal fixation, when performed, each
<b>26770</b>	Closed treatment of interphalangeal joint dislocation, single, with manipulation; without anesthesia
<b>26775</b>	Closed treatment of interphalangeal joint dislocation, single, with manipulation; requiring anesthesia



<b>26776</b>	Percutaneous skeletal fixation of interphalangeal joint dislocation, single, with manipulation
<b>26785</b>	Open treatment of interphalangeal joint dislocation, includes internal fixation, when performed, single
<b>26841</b>	Arthrodesis, carpometacarpal joint, thumb, with or without internal fixation
<b>26842</b>	Arthrodesis, carpometacarpal joint, thumb, with or without internal fixation; with autograft (includes obtaining graft)
<b>26843</b>	Arthrodesis, carpometacarpal joint, digit, other than thumb, each;
<b>26844</b>	Arthrodesis, carpometacarpal joint, digit, other than thumb, each; with autograft (includes obtaining graft)
<b>26850</b>	Arthrodesis, metacarpophalangeal joint, with or without internal fixation
<b>26852</b>	Arthrodesis, metacarpophalangeal joint, with or without internal fixation; with autograft (includes obtaining graft)
<b>26860</b>	Arthrodesis, interphalangeal joint, with or without internal fixation
<b>26861</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; each additional interphalangeal joint (List separately in addition to code for primary procedure)
<b>26862</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft)
<b>26863</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft), each additional joint (List separately in addition to code for primary procedure)
<b>26910</b>	Amputation, metacarpal, with finger or thumb (ray amputation), single, with or without interosseous transfer
<b>26951</b>	Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with direct closure
<b>26952</b>	Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with local advancement flaps (V-Y, hood)
<b>27301</b>	Incision and drainage, deep abscess, bursa, or hematoma, thigh or knee region
<b>27310</b>	Arthrotomy, knee, with exploration, drainage, or removal of foreign body (e.g., infection)
<b>27323</b>	Biopsy, soft tissue of thigh or knee area; superficial
<b>27324</b>	Biopsy, soft tissue of thigh or knee area; deep (subfascial or intramuscular)
<b>27330</b>	Arthrotomy, knee; with synovial biopsy only
<b>27331</b>	Arthrotomy, knee; including joint exploration, biopsy, or removal of loose or foreign bodies
<b>27332</b>	Arthrotomy, with excision of semilunar cartilage (meniscectomy) knee; medial or lateral
<b>27333</b>	Arthrotomy, with excision of semilunar cartilage (meniscectomy) knee; medial AND lateral
<b>27334</b>	Arthrotomy, with synovectomy, knee; anterior or posterior
<b>27335</b>	Arthrotomy, with synovectomy, knee; anterior and posterior including popliteal area
<b>27340</b>	Excision, prepatellar bursa
<b>27345</b>	Excision of synovial cyst of popliteal space (e.g., Baker's cyst)
<b>27347</b>	Excision of lesion of meniscus or capsule (e.g., cyst, ganglion), knee
<b>27350</b>	Patellectomy or hemipatellectomy
<b>27372</b>	Removal of foreign body, deep, thigh region or knee area
<b>27380</b>	Suture of infrapatellar tendon; primary
<b>27381</b>	Suture of infrapatellar tendon; secondary reconstruction, including fascial or tendon graft
<b>27385</b>	Suture of quadriceps or hamstring muscle rupture; primary
<b>27386</b>	Suture of quadriceps or hamstring muscle rupture; secondary reconstruction, including fascial or tendon graft
<b>27403</b>	Arthrotomy with meniscus repair, knee
<b>27405</b>	Repair, primary, torn ligament and/or capsule, knee; collateral
<b>27407</b>	Repair, primary, torn ligament and/or capsule, knee; cruciate
<b>27409</b>	Repair, primary, torn ligament and/or capsule, knee; collateral and cruciate ligaments
<b>27418</b>	Anterior tibial tubercleplasty (e.g., Maquet type procedure)
<b>27420</b>	Reconstruction of dislocating patella; (eg, Hauser type procedure)
<b>27422</b>	Reconstruction of dislocating patella; with extensor realignment and/or muscle advancement or release (eg, Campbell, Goldwaite type procedure)
<b>27424</b>	Reconstruction of dislocating patella; with patellectomy

<b>27427</b>	Ligamentous reconstruction (augmentation), knee; extra-articular
<b>27428</b>	Ligamentous reconstruction (augmentation), knee; intra-articular (open)
<b>27429</b>	Ligamentous reconstruction (augmentation), knee; intra-articular (open) and extra-articular
<b>27570</b>	Manipulation of knee joint under general anesthesia (includes application of traction or other fixation devices)
<b>27605</b>	Tenotomy, percutaneous, Achilles tendon (separate procedure); local anesthesia
<b>27606</b>	Tenotomy, percutaneous, Achilles tendon (separate procedure); general anesthesia
<b>27610</b>	Arthrotomy, ankle, including exploration, drainage, or removal of foreign body
<b>27612</b>	Arthrotomy, posterior capsular release, ankle, with or without Achilles tendon lengthening
<b>27620</b>	Arthrotomy, ankle, with joint exploration, with or without biopsy, with or without removal of loose or foreign body
<b>27625</b>	Arthrotomy, with synovectomy, ankle;
<b>27626</b>	Arthrotomy, with synovectomy, ankle; including tenosynovectomy
<b>27630</b>	Excision of lesion of tendon sheath or capsule (eg, cyst or ganglion), leg and/or ankle
<b>27650</b>	Repair, primary, open or percutaneous, ruptured Achilles tendon;
<b>27652</b>	Repair, primary, open or percutaneous, ruptured Achilles tendon; with graft (includes obtaining graft)
<b>27654</b>	Repair, secondary, Achilles tendon, with or without graft
<b>27656</b>	Repair, fascial defect of leg
<b>27658</b>	Repair, flexor tendon, leg; primary, without graft, each tendon
<b>27659</b>	Repair, flexor tendon, leg; secondary, with or without graft, each tendon
<b>27664</b>	Repair, extensor tendon, leg; primary, without graft, each tendon
<b>27665</b>	Repair, extensor tendon, leg; secondary, with or without graft, each tendon
<b>27675</b>	Repair, dislocating peroneal tendons; without fibular osteotomy
<b>27676</b>	Repair, dislocating peroneal tendons; with fibular osteotomy
<b>27680</b>	Tenolysis, flexor or extensor tendon, leg and/or ankle; single, each tendon
<b>27681</b>	Tenolysis, flexor or extensor tendon, leg and/or ankle; multiple tendons (through separate incision[s])
<b>27685</b>	Lengthening or shortening of tendon, leg or ankle; single tendon (separate procedure)
<b>27686</b>	Lengthening or shortening of tendon, leg or ankle; multiple tendons (through same incision), each
<b>27687</b>	Gastrocnemius recession (eg, Strayer procedure)
<b>27690</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); superficial (eg, anterior tibial extensors into midfoot)
<b>27691</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); deep (eg, anterior tibial or posterior tibial through interosseous space, flexor digitorum longus, flexor hallucis longus, or peroneal tendon to midfoot or hindfoot)
<b>27692</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); each additional tendon (List separately in addition to code for primary procedure)
<b>27695</b>	Repair, primary, disrupted ligament, ankle; collateral
<b>27696</b>	Repair, primary, disrupted ligament, ankle; both collateral ligaments
<b>27698</b>	Repair, secondary, disrupted ligament, ankle, collateral (eg, Watson-Jones procedure)
<b>27705</b>	Osteotomy; tibia
<b>27707</b>	Osteotomy; fibula
<b>27709</b>	Osteotomy; tibia and fibula
<b>27720</b>	Repair of nonunion or malunion, tibia; without graft, (e.g., compression technique)
<b>27722</b>	Repair of nonunion or malunion, tibia; with sliding graft
<b>27726</b>	Repair of fibula nonunion and/or malunion with internal fixation
<b>27756</b>	Percutaneous skeletal fixation of tibial shaft fracture (with or without fibular fracture) (e.g., pins or screws)
<b>27792</b>	Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed
<b>27814</b>	Open treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli, or medial and posterior malleoli), includes internal fixation, when performed
<b>27822</b>	Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial

	and/or lateral malleolus; without fixation of posterior lip
<b>27823</b>	Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial and/or lateral malleolus; with fixation of posterior lip
<b>27870</b>	Arthrodesis, ankle, open
<b>27871</b>	Arthrodesis, tibiofibular joint, proximal or distal
<b>28001</b>	Incision and drainage, bursa, foot
<b>28002</b>	Incision and drainage below fascia, with or without tendon sheath involvement, foot; single bursal space
<b>28003</b>	Incision and drainage below fascia, with or without tendon sheath involvement, foot; multiple areas
<b>28005</b>	Incision, bone cortex (e.g., osteomyelitis or bone abscess), foot
<b>28008</b>	Fasciotomy, foot and/or toe
<b>28010</b>	Tenotomy, percutaneous, toe; single tendon
<b>28011</b>	Tenotomy, percutaneous, toe; multiple tendons
<b>28020</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; intertarsal or tarsometatarsal joint
<b>28022</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; metatarsophalangeal joint
<b>28024</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; interphalangeal joint
<b>28035</b>	Release, tarsal tunnel (posterior tibial nerve decompression)
<b>28039</b>	Excision, tumor, soft tissue of foot or toe, subcutaneous; 1.5 cm or greater
<b>28041</b>	Excision, tumor, soft tissue of foot or toe, subfascial (e.g., intramuscular); 1.5 cm or greater
<b>28043</b>	Excision, tumor, soft tissue of foot or toe, subcutaneous; less than 1.5 cm
<b>28045</b>	Excision, tumor, soft tissue of foot or toe, subfascial (e.g., intramuscular); less than 1.5 cm
<b>28046</b>	Radical resection of tumor (eg, sarcoma), soft tissue of foot or toe; less than 3 cm
<b>28047</b>	Radical resection of tumor (e.g., sarcoma), soft tissue of foot or toe; 3 cm or greater
<b>28055</b>	Neurectomy, intrinsic musculature of foot
<b>28060</b>	Fasciectomy, plantar fascia; partial (separate procedure)
<b>28062</b>	Fasciectomy, plantar fascia; radical (separate procedure)
<b>28070</b>	Synovectomy; intertarsal or tarsometatarsal joint, each
<b>28072</b>	Synovectomy; metatarsophalangeal joint, each
<b>28080</b>	Excision, interdigital (Morton) neuroma, single, each
<b>28086</b>	Synovectomy, tendon sheath, foot; flexor
<b>28088</b>	Synovectomy, tendon sheath, foot; extensor
<b>28090</b>	Excision of lesion, tendon, tendon sheath, or capsule (including synovectomy) (eg, cyst or ganglion); foot
<b>28092</b>	Excision of lesion, tendon, tendon sheath, or capsule (including synovectomy) (e.g., cyst or ganglion); toe(s), each
<b>28100</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus
<b>28102</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus; with iliac or other autograft (includes obtaining graft)
<b>28103</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus; with allograft
<b>28104</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus
<b>28106</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus; with iliac or other autograft (includes obtaining graft)
<b>28107</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus; with allograft
<b>28108</b>	Excision or curettage of bone cyst or benign tumor, phalanges of foot
<b>28110</b>	Ostectomy, partial excision, fifth metatarsal head (bunionette) (separate procedure)
<b>28111</b>	Ostectomy, complete excision; first metatarsal head
<b>28112</b>	Ostectomy, complete excision; other metatarsal head (second, third or fourth)
<b>28113</b>	Ostectomy, complete excision; fifth metatarsal head
<b>28114</b>	Ostectomy, complete excision; all metatarsal heads, with partial proximal phalangectomy, excluding first metatarsal (eg, Clayton type procedure)

<b>28116</b>	Ostectomy, excision of tarsal coalition
<b>28118</b>	Ostectomy, calcaneus
<b>28119</b>	Ostectomy, calcaneus; for spur, with or without plantar fascial release
<b>28120</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (e.g., osteomyelitis or bossing); talus or calcaneus
<b>28122</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (eg, osteomyelitis or bossing); tarsal or metatarsal bone, except talus or calcaneus
<b>28124</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (e.g., osteomyelitis or bossing); phalanx of toe
<b>28126</b>	Resection, partial or complete, phalangeal base, each toe
<b>28130</b>	Talectomy (astragalectomy)
<b>28140</b>	Metatarsectomy
<b>28150</b>	Phalangectomy, toe, each toe
<b>28153</b>	Resection, condyle(s), distal end of phalanx, each toe
<b>28160</b>	Hemi phalangectomy or interphalangeal joint excision, toe, proximal end of phalanx, each
<b>28190</b>	Removal of foreign body, foot; subcutaneous
<b>28192</b>	Removal of foreign body, foot; deep
<b>28193</b>	Removal of foreign body, foot; complicated
<b>28200</b>	Repair, tendon, flexor, foot; primary or secondary, without free graft, each tendon
<b>28202</b>	Repair, tendon, flexor, foot; secondary with free graft, each tendon (includes obtaining graft)
<b>28208</b>	Repair, tendon, extensor, foot; primary or secondary, each tendon
<b>28210</b>	Repair, tendon, extensor, foot; secondary with free graft, each tendon (includes obtaining graft)
<b>28220</b>	Tenolysis, flexor, foot; single tendon
<b>28222</b>	Tenolysis, flexor, foot; multiple tendons
<b>28225</b>	Tenolysis, extensor, foot; single tendon
<b>28226</b>	Tenolysis, extensor, foot; multiple tendons
<b>28230</b>	Tenotomy, open, tendon flexor; foot, single or multiple tendon(s) (separate procedure)
<b>28232</b>	Tenotomy, open, tendon flexor; toe, single tendon (separate procedure)
<b>28234</b>	Tenotomy, open, extensor, foot or toe, each tendon
<b>28238</b>	Reconstruction (advancement), posterior tibial tendon with excision of accessory tarsal navicular bone (eg, Kidner type procedure)
<b>28250</b>	Division of plantar fascia and muscle (e.g., Steindler stripping) (separate procedure)
<b>28260</b>	Capsulotomy, midfoot; medial release only (separate procedure)
<b>28261</b>	Capsulotomy, midfoot; with tendon lengthening
<b>28262</b>	Capsulotomy, midfoot; extensive, including posterior talotibial capsulotomy and tendon(s) lengthening (eg, resistant clubfoot deformity)
<b>28264</b>	Capsulotomy, midtarsal (eg, Heyman type procedure)
<b>28270</b>	Capsulotomy; metatarsophalangeal joint, with or without tenorrhaphy, each joint (separate procedure)
<b>28272</b>	Capsulotomy; interphalangeal joint, each joint (separate procedure)
<b>28280</b>	Syndactylization, toes (e.g., webbing or Kelikian type procedure)
<b>28285</b>	Correction, hammertoe (eg, interphalangeal fusion, partial or total phalangectomy)
<b>28286</b>	Correction, cock-up fifth toe, with plastic skin closure (e.g., Ruiz-Mora type procedure)
<b>28288</b>	Ostectomy, partial, exostectomy or condylectomy, metatarsal head, each metatarsal head
<b>28289</b>	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; without implant
<b>28291</b>	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; with implant
<b>28292</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method
<b>28295</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with proximal metatarsal osteotomy, any method
<b>28296</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with distal metatarsal osteotomy, any method

<b>28297</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method
<b>28298</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with proximal phalanx osteotomy, any method
<b>28299</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with double osteotomy, any method
<b>28300</b>	Osteotomy; calcaneus (eg, Dwyer or Chambers type procedure), with or without internal fixation
<b>28302</b>	Osteotomy; talus
<b>28304</b>	Osteotomy, tarsal bones, other than calcaneus or talus;
<b>28305</b>	Osteotomy, tarsal bones, other than calcaneus or talus; with autograft (includes obtaining graft) (eg, Fowler type)
<b>28306</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; first metatarsal
<b>28307</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; first metatarsal with autograft (other than first toe)
<b>28308</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; other than first metatarsal, each
<b>28309</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; multiple (eg, Swanson type cavus foot procedure)
<b>28310</b>	Osteotomy, shortening, angular or rotational correction; proximal phalanx, first toe (separate procedure)
<b>28312</b>	Osteotomy, shortening, angular or rotational correction; other phalanges, any toe
<b>28313</b>	Reconstruction, angular deformity of toe, soft tissue procedures only (e.g., overlapping second toe, fifth toe, curly toes)
<b>28315</b>	Sesamoidectomy, first toe (separate procedure)
<b>28320</b>	Repair, nonunion or malunion; tarsal bones
<b>28322</b>	Repair, nonunion or malunion; metatarsal, with or without bone graft (includes obtaining graft)
<b>28470</b>	Closed treatment of metatarsal fracture; without manipulation, each
<b>28476</b>	Percutaneous skeletal fixation of metatarsal fracture, with manipulation, each
<b>28485</b>	Open treatment of metatarsal fracture, includes internal fixation, when performed, each
<b>28496</b>	Percutaneous skeletal fixation of fracture great toe, phalanx or phalanges, with manipulation
<b>28525</b>	Open treatment of fracture, phalanx or phalanges, other than great toe, includes internal fixation, when performed, each
<b>28666</b>	Percutaneous skeletal fixation of interphalangeal joint dislocation, with manipulation
<b>28675</b>	Open treatment of interphalangeal joint dislocation, includes internal fixation, when performed
<b>28705</b>	Arthrodesis; pantalar
<b>28715</b>	Arthrodesis; triple
<b>28725</b>	Arthrodesis; subtalar
<b>28730</b>	Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse
<b>28735</b>	Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse; with osteotomy (eg, flatfoot correction)
<b>28737</b>	Arthrodesis, with tendon lengthening and advancement, midtarsal, tarsal navicular-cuneiform (eg, Miller type procedure)
<b>28740</b>	Arthrodesis, midtarsal or tarsometatarsal, single joint
<b>28750</b>	Arthrodesis, great toe; metatarsophalangeal joint
<b>28755</b>	Arthrodesis, great toe; interphalangeal joint
<b>28760</b>	Arthrodesis, with extensor hallucis longus transfer to first metatarsal neck, great toe, interphalangeal joint (e.g., Jones type procedure)
<b>28810</b>	Amputation, metatarsal, with toe, single
<b>28820</b>	Amputation, toe; metatarsophalangeal joint
<b>28825</b>	Amputation, toe; interphalangeal joint
<b>29805</b>	Arthroscopy, shoulder, diagnostic, with or without synovial biopsy (separate procedure)
<b>29806</b>	Arthroscopy, shoulder, surgical; capsulorrhaphy
<b>29807</b>	Arthroscopy, shoulder, surgical; repair of SLAP lesion
<b>29819</b>	Arthroscopy, shoulder, surgical; with removal of loose body or foreign body



<b>29820</b>	Arthroscopy, shoulder, surgical; synovectomy, partial
<b>29821</b>	Arthroscopy, shoulder, surgical; synovectomy, complete
<b>29822</b>	Arthroscopy, shoulder, surgical; debridement, limited, 1 or 2 discrete structures (eg, humeral bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps tendon, biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff, bursal side of the rotator cuff, subacromial bursa, foreign body[ies])
<b>29823</b>	Arthroscopy, shoulder, surgical; debridement, extensive, 3 or more discrete structures (eg, humeral bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps tendon, biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff, bursal side of the rotator cuff, subacromial bursa, foreign body[ies])
<b>29824</b>	Arthroscopy, shoulder, surgical; distal claviclectomy including distal articular surface (Mumford procedure)
<b>29825</b>	Arthroscopy, shoulder, surgical; with lysis and resection of adhesions, with or without manipulation
<b>29826</b>	Arthroscopy, shoulder, surgical; decompression of subacromial space with partial acromioplasty, with coracoacromial ligament (ie, arch) release, when performed (List separately in addition to code for primary procedure)
<b>29827</b>	Arthroscopy, shoulder, surgical; with rotator cuff repair
<b>29828</b>	Arthroscopy, shoulder, surgical; biceps tenodesis
<b>29830</b>	Arthroscopy, elbow, diagnostic, with or without synovial biopsy (separate procedure)
<b>29835</b>	Arthroscopy, elbow, surgical; synovectomy, partial
<b>29836</b>	Arthroscopy, elbow, surgical; synovectomy, complete
<b>29837</b>	Arthroscopy, elbow, surgical; debridement, limited
<b>29838</b>	Arthroscopy, elbow, surgical; debridement, extensive
<b>29840</b>	Arthroscopy, wrist, diagnostic, with or without synovial biopsy (separate procedure)
<b>29843</b>	Arthroscopy, wrist, surgical; for infection, lavage and drainage
<b>29844</b>	Arthroscopy, wrist, surgical; synovectomy, partial
<b>29845</b>	Arthroscopy, wrist, surgical; synovectomy, complete
<b>29846</b>	Arthroscopy, wrist, surgical; excision and/or repair of triangular fibrocartilage and/or joint debridement
<b>29847</b>	Arthroscopy, wrist, surgical; internal fixation for fracture or instability
<b>29848</b>	Endoscopy, wrist, surgical, with release of transverse carpal ligament
<b>29860</b>	Arthroscopy, hip, diagnostic with or without synovial biopsy (separate procedure)
<b>29861</b>	Arthroscopy, hip, surgical; with removal of loose body or foreign body
<b>29862</b>	Arthroscopy, hip, surgical; with debridement/shaving of articular cartilage (chondroplasty), abrasion arthroplasty, and/or resection of labrum
<b>29863</b>	Arthroscopy, hip, surgical; with synovectomy
<b>27299</b>	Unlisted procedure, pelvis or hip joint
<b>29916</b>	Arthroscopy, hip, surgical; with labral repair
<b>29870</b>	Arthroscopy, knee, diagnostic, with or without synovial biopsy (separate procedure)
<b>29871</b>	Arthroscopy, knee, surgical; for infection, lavage and drainage
<b>29873</b>	Arthroscopy, knee, surgical; with lateral release
<b>29874</b>	Arthroscopy, knee, surgical; for removal of loose body or foreign body (eg, osteochondritis dissecans fragmentation, chondral fragmentation)
<b>29875</b>	Arthroscopy, knee, surgical; synovectomy, limited (eg, plica or shelf resection) (separate procedure)
<b>29876</b>	Arthroscopy, knee, surgical; synovectomy, major, 2 or more compartments (eg, medial or lateral)
<b>29877</b>	Arthroscopy, knee, surgical; debridement/shaving of articular cartilage (chondroplasty)
<b>29879</b>	Arthroscopy, knee, surgical; abrasion arthroplasty (includes chondroplasty where necessary) or multiple drilling or microfracture
<b>29880</b>	Arthroscopy, knee, surgical; with meniscectomy (medial AND lateral, including any meniscal shaving) including debridement/shaving of articular cartilage (chondroplasty), same or separate compartment(s), when performed
<b>29881</b>	Arthroscopy, knee, surgical; abrasion arthroplasty (includes chondroplasty where necessary) or multiple drilling or microfracture



<b>29882</b>	Arthroscopy, knee, surgical; with meniscus repair (medial OR lateral)
<b>29883</b>	Arthroscopy, knee, surgical; with meniscus repair (medial AND lateral)
<b>29884</b>	Arthroscopy, knee, surgical; with lysis of adhesions, with or without manipulation (separate procedure)
<b>29885</b>	Arthroscopy, knee, surgical; drilling for osteochondritis dissecans with bone grafting, with or without internal fixation (including debridement of base of lesion)
<b>29886</b>	Arthroscopy, knee, surgical; drilling for intact osteochondritis dissecans lesion
<b>29887</b>	Arthroscopy, knee, surgical; drilling for intact osteochondritis dissecans lesion with internal fixation
<b>29888</b>	Arthroscopically aided anterior cruciate ligament repair/augmentation or reconstruction
<b>29889</b>	Arthroscopically aided posterior cruciate ligament repair/augmentation or reconstruction
<b>29891</b>	Arthroscopy, ankle, surgical, excision of osteochondral defect of talus and/or tibia, including drilling of the defect
<b>29892</b>	Arthroscopically aided repair of large osteochondritis dissecans lesion, talar dome fracture, or tibial plafond fracture, with or without internal fixation (includes arthroscopy)
<b>29893</b>	Endoscopic plantar fasciotomy
<b>29894</b>	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; with removal of loose body or foreign body
<b>29895</b>	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; synovectomy, partial
<b>29900</b>	Arthroscopy, metacarpophalangeal joint, diagnostic, includes synovial biopsy
<b>29901</b>	Arthroscopy, metacarpophalangeal joint, surgical; with debridement
<b>29902</b>	Arthroscopy, metacarpophalangeal joint, surgical; with reduction of displaced ulnar collateral ligament (eg, Stenar lesion)
<b>29906</b>	Arthroscopy, subtalar joint, surgical; with debridement
<b>64721</b>	Neuroplasty and/or transposition; median nerve at carpal tunnel

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
02/25/2021	03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	05/02/2023

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/02/2021	MPC approved criteria for Ambulatory Surgery Center Site of Care. Requires 60-day notice; effective July 1, 2021.
04/13/2021	Updated policy effective date to August 1, 2021 with phased approach
05/12/2021	Updated 'site of service' terminology to 'site of care' throughout the policy.
07/27/2021	Updated policy effective date to September 1, 2021 with phased approach
12/15/2022	Moved the ASC list of codes to this criteria page for consolidation.
03/06/2023	Updated applicable codes to include new CPT codes effective 1/1/2023: 49591, 49593, 49595, 49613, 49615, 49617, 49621, 49623
05/02/2023	MPC approved an expansion of the ASC criteria and adoption of SOC restriction for Gastroenterology procedures. GI procedures is applicable to the following counties: **King and Thurston (new counties) and existing counties. This requires a 60-day notice, effective October 1, 2023.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Bone Anchored Hearing System (BAHA)

- BONEBRIDGE Bone Conduction Implant
- Osia®
- Vibrant Soundbridge
- Softband
- Adhear

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Chapter 16, section 100 – “Hearing Aids and Auditory Implants” and section 180 – “Services Related to and Required as a Result of Services Which Are Not Covered Under Medicare.”</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

##### Effective until September 1st, 2025

Kaiser Permanente has elected to use the Bone Anchored Hearing System (BAHS) (KP-0564 09012023) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

##### Effective until September 1st, 2025

Kaiser Permanente has elected to use the Bone Anchored Hearing System (BAHS) (KP-0564 09012025) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*The MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

Service	Criteria Used
Vibrant Soundbridge	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**If requesting these services, please send the following documentation to support medical necessity:**

- Most recent audiogram/hearing test
- Most recent clinical notes from requesting provider &/or specialist (otolaryngology, ENT)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### ***Vibrant Soundbridge System***

The Vibrant Soundbridge System is an implantable alternative to standard hearing aids. It is intended for use in adults with moderate to severe sensorineural hearing loss, who desire an alternative to an acoustic hearing aid. Common limitations of conventional hearing aids are acoustic feedback, sound and voice distortion, and need for frequent servicing and maintenance (FDA documents, Sterkers et al., 2003; Luetje, 2002).

The Soundbridge system consists of a middle-ear implant known as the Vibrating Ossicular Prosthesis (VORP) and an external portion, the amplification system called the Audio Processor. The Audio Processor is about 1.2 inches in diameter and designed to be worn behind or above the ear. It contains a microphone that converts environmental sound to electrical signals. These signals are delivered to the VORP, causing the Floating Mass Transducer (FMT), one of its components, to vibrate. The vibration manually stimulates the auditory ossicles and is perceived by the patient as sound (manufacturer's documents).

Potential adverse effects of the Vibrant Soundbridge include the usual risks of major ear surgery and a possible decrease in residual hearing (FDA documents).

The Vibrant Soundbridge has been available commercially since February 1998 in Europe and received FDA approval in the US in August 2000. The FDA recommends that patients have experience with appropriately fitting conventional hearing aids before using the Vibrant Soundbridge.

### ***Bone Anchored Hearing Aid (BAHA) (Entific Medical Systems)***

The BAHA is an alternative device for hearing-impaired patients who are unable to wear traditional hearing aids. According to the manufacturer, the BAHA can be beneficial to individuals with chronic inflammation or infection of the ear canal, an incomplete ear canal e.g. congenital ear malformation and single-sided hearing loss. The BAHA is based on bone conduction technology, sound transmission without involvement of the skin and soft tissue and thus can be used by individuals with an impaired or diseased external or middle ear (Tjellstrom & Hakansson, 1995).

The BAHA device consists of an implant and an external sound processor attached to a subcutaneous abutment. The implant, a titanium fixture, is implanted behind the ear where it "osseointegrates" or bonds with the living bone. After healing from surgery, a percutaneous abutment is attached to the fixture. The sound processor "snaps" into the abutment. The sound processor, which transmits sound directly via the bone to the inner ear can be connected and disconnected at will (FDA and manufacturer's documents)

The BAHA was developed in Sweden in the 1980s. It was approved by the FDA in August 1996 and was introduced in the US market in January 1997. There are several different models, all of which were considered by the FDA to be Class II devices, substantially equivalent to air conduction hearing aids with digital sound processing.

## Medical Technology Assessment Committee (MTAC)

### ***Vibrant Soundbridge***

#### **06/06/2005: MTAC REVIEW**

**Evidence Conclusion:** There are studies with pre- and post-implantation data, but no controlled studies on the efficacy of either the Vibrant Soundbridge or the BAHA. Data from case series suggest that patients who meet eligibility requirements may experience improvement and hearing from the Vibrant Soundbridge and BAHA. Lack of blinding and lack of a control group limit the validity of case series. The publications are further limited by small sample sizes and/or missing data.

**Articles:** *Vibrant Soundbridge:* Only case series were identified. Most were conducted in Europe where there is longer experience with the device compared to the U.S. Two studies were selected for review: The largest case series, a French study (n=125), and the strongest US study (n=54). The US study was the one used by the FDA

to grant approval. *BAHA*: Only case series were identified, all with sample sizes <100. The two best-case series were reviewed. They were selected based on sample size and length of follow-up. There were two publications on one of the studies, so a total of three articles were reviewed. *The studies that were critically appraised are:* Sterkers O, Boucarra D, Labassi S. A middle ear implant, the Symphonix Vibrant Soundbridge: Retrospective study of the first 125 patients implanted in France. *Otol Neurotol* 2003; 24: 427-436. See [Evidence Table](#) Luetje CM, Brackman D, Balkany TJ et al. Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: A prospective controlled multicenter study. See [Evidence Table](#) Mylanus EA, van der Pouw KC, Snik AFM et al. Intraindividual comparison of the bone-anchored hearing aid and air-conduction hearing aids. *Arch Otolaryngol Head Neck Surg* 1998; 124: 271-276. See [Evidence Table](#) Hol MKS, Snik AFM, Mylanus EAM et al. Long-term results of bone-anchored hearing aid recipients who had previously used air-conduction hearing aids. *Arch Otolaryngol Head Neck Surg* 2005; 131: 321-325. See [Evidence Table](#) Lustig LR, Arts A, Brackmann DE. Hearing rehabilitation using the BAHA bone-anchored hearing aid: Results in 40 patients. *Otol Neurotol* 2001; 22: 328-334. See [Evidence Table](#)

The use of Vibrant Soundbridge or the BAHA in the treatment of hearing loss does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Bone anchored or transcutaneous bone-conduction hearing systems

#### Medicare –

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
69711	Removal or repair of electromagnetic bone conduction hearing device in temporal bone
69714	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy
69715	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
69717	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy
69716	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or resulting in removal of less than 100 sq mm surface area of bone deep to the outer cranial cortex
69718	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
69719	Revision or replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor
69726	Removal, osseointegrated implant, skull; with percutaneous attachment to external speech processor
69727	Removal, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor
69728	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
69729	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
69730	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
HCPC Codes	Description
L8690	Auditory osseointegrated device, includes all internal and external components

<b>L8691</b>	Auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each
<b>L8692</b>	Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment
<b>L8693</b>	Auditory osseointegrated device abutment, any length, replacement only

**Considered Not Medically Necessary:**

<b>CPT® Codes</b>	<b>Description</b>
<b>69710</b>	Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>69710</b>	Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone
<b>69711</b>	Removal or repair of electromagnetic bone conduction hearing device in temporal bone
<b>69714</b>	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy
<b>69715</b>	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
<b>69716</b>	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor
<b>69717</b>	Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor
<b>69718</b>	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
<b>69719</b>	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex
<b>69726</b>	Removal, entire osseointegrated implant, skull; with percutaneous attachment to external speech processor
<b>69727</b>	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex
<b>69728</b>	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
<b>69729</b>	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
<b>69730</b>	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex
<b>HCPC Codes</b>	<b>Description</b>
<b>L8690</b>	Auditory osseointegrated device, includes all internal and external components
<b>L8691</b>	Auditory osseointegrated device, external sound processor, excludes transducer/actuator, replacement only, each
<b>L8692</b>	Auditory osseointegrated device, external sound processor, used without osseointegration, body worn, includes headband or other means of external attachment
<b>L8693</b>	Auditory osseointegrated device abutment, any length, replacement only

**Vibrant Soundbridge - Considered Not Medically Necessary:**



HPCPC Codes	Description
<b>S2230</b>	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear
<b>V5095</b>	Semi-implantable middle ear hearing prosthesis

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Review Dates	Date Last Revised
06/06/2005	09/07/2010 <sup>MDCRPC</sup> , 07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 10/01/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	04/01/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
10/9/2018	Added Adhear to non-coverage statement
04/21/2020	Added applicable CPT codes: 69714, 69715, 69717, 69718
08/04/2020	MPC approved to adopt updates for Non-Medicare, adding clinical indications for BONEBRIDGE (MCG* KP-0564-see KP-0564 v2 eff 01.01.2021). Requires 60-day notice, effective date 01/01/2021.
12/08/2022	Added New CPT Codes applicable for MA and Non-MA.
04/04/2023	MPC approved modification to criteria to include OSIA and clarification to hearing thresholds.
07/02/2024	MPC approved BAHA for the Care Delivery Medical Necessity Review program
04/01/2025	MPC approved the recommended changes for Bone Anchored Hearing System hybrid criteria. 60-day notice required, effective 09/01/2025.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Balloon Dilation of the Eustachian Tube

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Balloon Dilation of the Eustachian Tube</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

##### Eustachian Tube Dilation

Unilateral or bilateral Eustachian tube balloon dilation (ETBD) is considered medically necessary once per lifetime for the treatment of chronic obstructive Eustachian tube dysfunction when **ALL** of the following criteria are met:

- Age 18 years or older
- Patient has had any of the following symptoms continuously for at least 12 months:
  - aural fullness
  - aural pressure
  - otalgia
  - hearing loss
  - autophony
- History of chronic ear disease or intolerance to barometric changes greater than 12 months
- The patient does not have any other causes of aural fullness such as:
  - Temporomandibular joint disorders
  - Extrinsic obstruction of the eustachian tube
  - Superior semicircular canal dehiscence
  - Endolymphatic hydrops
- Prior evaluation of the eustachian tube with nasal endoscopy
- Abnormal result of **BOTH** of the following prior to ETBD:
  - Tympanogram (Type B or C)
  - Tympanic membrane (i.e., retracted membrane, effusion, perforation) on exam
- If applicable, failure to respond to appropriate medical management of potential co-occurring conditions, such as:
  - Allergic rhinitis, rhinosinusitis - 4-6 weeks of a nasal steroid spray, if indicated

- Laryngopharyngeal reflux - Proton pump inhibitor or antacid treatment
- If patient has a history of tympanostomy tube placement, symptoms of Eustachian tube obstruction improved while tubes were patent, or the patient underwent myringotomy without tube placement with symptom relief

**Eustachian tube balloon dilation (ETBD) is considered experimental, investigational or unproven for all other indications.**

**For covered criteria:**

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Eustachian Tube Role, ETD, & Prevalence, & Risk factors: (Anand et al., 2019; Fischer et al., 2020; Juszczak, Aubin-Pouliot, Sharon, & Loftus, 2019; Magro et al., 2021; Shan et al., 2019)

The eustachian tube (ET) is a ciliated epithelial-lined tube that covers the anterior wall of the middle ear and the nasopharynx. The ET has several roles including maintenance of middle ear physiology and function, pressure equalization across the tympanic membrane, clearance of secretions from the middle ear, and protection from pathogens and secretions from the oropharynx. An alteration of the opening or closing of the ET leads to ET dysfunction (ETD).

Categories of ETD vary from obstructive dysfunction to patulous dysfunction. Obstructive dysfunction is an insufficient opening of the ET. Patulous dysfunction is characterized by a patent valve (resulting in equalization of pressure between the middle ear and the nasopharynx).

The prevalence of ETD is estimated at 4.6% among adults in the United States and over 5% in the elderly population. Sinonasal risk factors include self-reported allergic rhinitis and persistent cold/flu.

Presentation & Treatment of ETD: (Swain, Janardan, & Mohanty, 2020)

Signs and symptoms of Eustachian tube dysfunctions consist of fullness of the ear, hearing difficulty, ear pain, tinnitus and vertigo. The medical treatments of ET dysfunction consist of antihistamines, nasal decongestants and oral or nasal steroids. If ETD is recalcitrant, Eustachian tuboplasty may be done. Balloon dilation of the Eustachian tube is a new surgical technique that has garnered interest.

### Rationale

Existing treatments are not efficacious.

Description of the procedure (Magro et al., 2021; Meyer et al., 2018; Swain et al., 2020)

Balloon dilation of the ET (BDET) is a minimally invasive endoscopic procedure for ETD resistant to conservative treatment, in which a balloon is inflated into the Eustachian tube (ET). The procedure is generally performed under general anesthesia. Nevertheless, it can be done in office setting under local anesthesia. It can be unilateral or bilateral.

A balloon catheter is inserted, through the nose, into the ET under nasal endoscopy. The balloon is then inflated by filling it up with saline to a pressure of 10 to 12 bars. The pressure is maintained for 2 minutes. Once the ET is dilated, the balloon is deflated and removed. The goal of the procedure is to dilate the cartilaginous portion of the ET without causing damage.

## Medical Technology Assessment Committee (MTAC)

### ***Balloon Dilation of the Eustachian Tube***

**Date: 10/11/2021**

#### **Evidence Conclusion:**

- Low-quality evidence suggests that eustachian tube balloon dilation is more effective than medical treatment, on the short and long-term, in adult patients with eustachian tube dilation refractory to medical management.

The procedure may be safe as no serious device-related complications are reported. However, more RCTs with longer follow-up are still needed.

- The evidence is insufficient to compare ETBD and tympanoplasty in patients with otitis media and severe ETD.

**Articles:** See [Evidence Table](#)

The use of Balloon Dilation of the Eustachian Tube does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® or HCPCS Codes	Description
69705	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); unilateral
69706	Nasopharyngoscopy, surgical, with dilation of eustachian tube (ie, balloon dilation); bilateral

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
01/27/2022	02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	07/02/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
02/01/2022	MPC approved to adopt MTAC's recommendation of coverage and the clinical review criteria for this medical procedure. Requires 60-day notice, effective date 07/01/2022.
07/02/2024	MPC approved Eustachian Tube Balloon Dilation into the Care Delivery Medical Necessity Review program.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Bariatric Surgery

- Adjustable gastric banding, Laparoscopic or Open (Lap Band)
- Biliopancreatic Diversion with Duodenal Switch (Scopinaro Procedure)
- EndoGastric Solutions StomaphyX™ Endoluminal Fastener
- Endoscopic Sleeve Gastrectomy (ESG)
- Gastric Bypass for GERD
- Gastric Electrical Stimulator
- IntraGastric Balloons
- Mini-Gastric Bypass
- Roux-en-Y Gastric Bypass (RYGB)
- Single Anastomosis Duodeno-Ileal Bypass w/ Sleeve gastrectomy (SADI-S)
- Vertical Banded Gastroplasty (VBG)
- Vertical Sleeve Gastrectomy (VSG)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid Obesity (100.1)</a> —Requires Medical Necessity review AND <a href="#">Level of Care Review</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	<a href="#">Billing and Coding: Bariatric Surgery Coverage (A53028)</a>

#### For Non-Medicare Members (Adult & Pediatric/Adolescent)

Procedure	Criteria
Adjustable gastric banding, Laparoscopic or Open (Lap Band) -Not covered for Federal Plans	Requires <a href="#">Level of Care Review</a> AND medical necessity review using Bariatric Surgery (KP-S-516 10012024) MCG*.
Laparoscopic Vertical Sleeve Gastrectomy (VSG) as Initial Procedure in a Planned Two-Stage Operation for Patients with Severe Morbid Obesity	*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access
Roux-en-Y Gastric Bypass (RYGB)	<b>If requesting this service, please send the following documentation to support medical necessity:</b>
Biliopancreatic Diversion with Duodenal Switch*	<ul style="list-style-type: none"> <li>• Last 2 years of gastroenterology notes</li> <li>• Most recent clinical note from requesting provider</li> </ul>
Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S)*	



Procedure	Criteria
*reserved for patients with a BMI >50	<ul style="list-style-type: none"> <li>Documentation of patient height, weight &amp; comorbid conditions</li> </ul>
EndoGastric Solutions StomaphyX™ Endoluminal Fastener  Endoscopic Sleeve Gastropasty (ESG)  Gastric Bypass for GERD  Transoral Outlet Reduction (TORe)	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.  <b>If requesting review for these services, please send the following documentation:</b> <ul style="list-style-type: none"> <li>Last 6 months of clinical notes from requesting provider &amp;/or specialist</li> </ul>
Intragastric Balloon Device	MCG* A-0970 This is not covered per MCG  <b>If requesting review for these services, please send the following documentation:</b> <ul style="list-style-type: none"> <li>Last 6 months of clinical notes from requesting provider &amp;/or specialist</li> </ul> <p>*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access</p>
Gastric Stimulation (Electrical) <ul style="list-style-type: none"> <li>Morbid Obesity</li> <li>Gastroparesis in pediatric patients</li> </ul>	Kaiser Permanente has elected to use the Gastric Stimulation (Electrical) (A-0395) MCG* Care Guideline for medical necessity determinations. <i>Note:</i> For Gastroparesis in pediatric patients and Morbid Obesity, evidence is non-supportive &/or inconclusive (see evidence summary for further details).  <p>*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access</p>

The following procedures are not covered (benefits are varied and need to be verified): Distal gastric bypass, Mini-gastric bypass

The vertical banded gastroplasty (VBG) is no longer a standard of care and is therefore considered not medically necessary and not covered.

CDC Adult Body Mass Index (BMI) Calculator [View Chart](#)

[https://www.cdc.gov/healthyweight/assessing/bmi/adult\\_bmi/english\\_bmi\\_calculator/bmi\\_calculator.html](https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/english_bmi_calculator/bmi_calculator.html)

Percent of Excess Body Weight Loss Formula

$$\frac{(\text{Initial Weight} - \text{Postop Weight})}{(\text{Initial weight} - \text{Ideal Weight}^*)} \times 100$$
 Ideal weight is defined by the weight corresponding to a BMI of 25 for the person in question.

**\*The MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Evidence and Source Documents

[EndoGastric Solutions](#)  
[Gastric Bypass for GERD](#)  
[Gastric Electrical Stimulator for Obesity](#)  
[Intragastric Balloons](#)  
[Laparoscopic Sleeve Gastrectomy](#)  
[Vertical Sleeve Gastrectomy \(VSG\)](#)

## Background

The NIH has defined overweight as a BMI between 25 kg/m<sup>2</sup> and 29.9 kg/m<sup>2</sup>, and obesity as a BMI of > 30 kg/m<sup>2</sup>. According to national survey data, an estimated one-third of adults in the United States are overweight. Overweight and obesity are associated with an increased risk of mortality. Individuals with a BMI > 30 have a 50-100% increased risk of premature death compared to individuals with a BMI between 20 and 25. In addition, overweight and obesity are associated with an increased risk of coronary heart disease, type 2 diabetes, hypertension, certain cancers and musculoskeletal disorders such as knee osteoarthritis (Surgeon General report: USPSTF).

Lifestyle changes, including diet, exercise, and behavior modification, are generally considered first-line therapy for overweight and obesity. Pharmacotherapy can be used as an adjunctive therapy when lifestyle changes alone are ineffective. Medical management of obesity has been found to be less effective with individuals who are morbidly obese (BMI > 35) than for those with lower BMI, particularly in terms of sustained weight loss. The NIH has stated that bariatric surgery is an option for patients with a BMI > 40 or a BMI > 35 with comorbid conditions, who have failed medical treatment (Fisher and Schauer, 2002; NIH, 1998).

There are two main strategies for surgically inducing weight loss, gastric restriction and intestinal malabsorption. Restrictive procedures mechanically reduce the size of the stomach. This limits the amount of food a patient can consume at a single meal and causes early satiety. Substantial dietary compliance is required, because individuals are still able to consume high-calorie liquids or soft foods. Malabsorption procedures involve bypassing a portion of the intestines which decreases the proportion of nutrients that are absorbed from food. Some types of surgeries use elements of both strategies (Fisher and Schauer, 2002; Southern California-RAND EBPC 2004).

Two currently accepted bariatric surgery methods are Vertical Banded Gastroplasty (VBG) and Roux-en-Y gastric bypass (RYGB). VBG is a restrictive procedure that uses staples to create a narrow gastric inlet or pouch and a non-adjustable band is placed around the new inlet to prevent enlargement. RYGB includes both restrictive and malabsorptive elements. The stomach is reduced to a small gastric pouch, and this pouch is connected to a segment of the jejunum, bypassing the duodenum and proximal small intestine. RYGB can be performed as open surgery or laparoscopically.

Adjustable gastric banding is a restrictive technique, using the Lap-Band System® (Inamed). A small gastric pouch is formed by laparoscopically placing a silicone ring (the Lap-Band) around the upper part of the stomach just below the gastro-esophageal junction. The band is connected via tubing to an access port that is secured beneath the skin of the abdomen. The band has a reservoir that is accessed percutaneously and filled with saline. The size of the band can be adjusted by adding or removing saline. The Lap-Band is removable, either laparoscopically or via an open procedure. In the clinical study presented by the manufacturer to the FDA, 60% of the band removal procedures were laparoscopic. The Lap-Band has been used in Europe and Australia since early 1990s and was approved by FDA in June 2001 (manufacturer's Web site).

## Medical Technology Assessment Committee (MTAC)

### ***Vertical Banded Gastroplasty (VBG) and Roux-en-Y gastric bypass (RYGB)***

**2/10/1999: MTAC REVIEW**

**Evidence Conclusion:** The published scientific evidence consists of several large case series and one randomized controlled trial from multiple institutions published over a 10-year period of time. Vertical Banded Gastroplasty (VBG) Data from 4 case series and 1 RCT totaling 403 patients undergoing VBG with 75-100% follow up at 3 years demonstrates between 15 and 31% weight loss. Reoperation or revisional surgery was required in 3% of patients in one series and 36% in another series. Mortality was 1-3% overall. Roux-en-Y (REY)-Data from 2 case series and 1 RCT totaling 532 patients in the REY groups with 60-86% follow up at 3 years demonstrates that Roux-en-Y gastric restrictive surgery results in between 33 and 35% weight loss. Reoperation or revisional surgery was required in 6% of patients in one series and not reported in the other series. Mortality was 1% overall.

**Articles:** MacLean, LD et al. *Surgery*, 1993;113:380-388. See [Evidence Table](#). Sugerman, HJ, et al. 1989: *Am J Surg*;157 93-100. See [Evidence Table](#).  
Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. *Hypertension* 2000; 36: 20-25. See [Evidence Table](#).

The use of gastric restrictive surgery (VBG or REY) meets the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 12/8/2006: MTAC REVIEW

### Vertical Banded Gastroplasty (VBG) and Roux-en-Y gastric bypass (RYGB)

**Evidence Conclusion:** There is some evidence that Lap-Band surgery is more effective than optimal non-surgical management for patients with BMI between 30-35 kg/m<sup>2</sup> with co-morbidities. This evidence is not conclusive due to the size of the single RCT, and its limitations. Evidence from non-randomized studies suggests that gastric bypass surgery is more effective for weight loss than the Lap-Band technique for patients who meet standard eligibility criteria for bariatric surgery (BMI > 40 kg/m<sup>2</sup> or > 35 kg/m<sup>2</sup> with co-morbidities) and for the subset of patients with BMI > 50 kg/m<sup>2</sup>. Gastric surgery was not associated with more complications than the Lap-Band procedure, and studies generally found a higher reoperation rate after Lap-Band surgery. There may be residual confounding in the non-randomized studies. There are no randomized controlled trials comparing the safety and effectiveness of Lap-Band surgery to either gastric bypass or optimal non-surgical management for adults with BMI > 35 kg/m<sup>2</sup>. There is evidence from one randomized controlled trial that Lap-Band surgery is more effective for weight loss than a non-surgical intervention (i.e. supervised dieting, pharmacotherapy) for patients with BMI between 30-35 kg/m<sup>2</sup> with co-morbidities (O'Brien et al., 2005). However, in the two years of follow-up 4 of the 39 patients who received the Lap-Band experienced prolapse of the posterior gastric wall. In addition, limitations of the study were that it was not blinded, follow-up was only two years, and the nonsurgical intervention was not well described beyond 6 months. The best evidence comparing the Lap-Band and Roux-en-Y gastric bypass comes from two non-randomized comparative studies (Weber et al., 2004; Cottam et al. 2006). Both matched patients who did and did not receive the Lap-Band according to age, sex and BMI. The Weber study included patients with BMI > 40 kg/m<sup>2</sup> or BMI > 35 kg/m<sup>2</sup> who had co-morbidities and the Cottam study did not specify eligibility criteria, but mean BMI was 47 kg/m<sup>2</sup>. Both studies found significantly more weight loss at 2-3 years and fewer co-morbidities in the group that underwent gastric bypass. In the Weber et al. study, the rate of reoperation was somewhat higher in the gastric bypass group than the Lap-Band group during the first 30 days (n=7 vs. n=1), but after 30 days the rate was higher in the Lap-Band group (n=26) than the gastric bypass group (n=4). The Cottam et al. study found a slightly higher rate of major reoperation in the gastric bypass group compared to the Lap-Band group (8% vs. 5%), but this difference was not statistically significant. A third non-randomized study compared the Lap-Band and laparoscopic Roux-en-Y gastric bypass in super morbidly obese patients (BMI > 50 kg/m<sup>2</sup>). Similar to the studies of patients with lower mean BMI, there was greater reduction in BMI and a higher proportion of excess weight loss in patients who received gastric bypass compared to the Lap-Band. There appeared to be a greater reduction in co-morbidities and fewer complications in the gastric bypass group, but numbers were too small to accurately compare the groups in these areas. Reoperations were necessary in 15% of the Lap-Band group and 6.5% of the gastric bypass group. In all of the non-randomized studies, there may be confounding variables, differences between groups that affect the outcome (such as differences in commitment to losing weight). A large case series conducted in Italy (n=1893) provides additional information on the safety of the Lap-Band technique. Reported post-operative mortality was 1 out of 200 procedures (0.5%) and was restricted to patients with preoperative cardiovascular complications. The most common post-operative complications were gastric pouch dilation (5%) and tube port complications (4%). The ideal study would be a randomized controlled trial comparing long-term outcomes of gastric surgery with the Lap-Band and commonly accepted bariatric surgery procedures or optimal non-surgical management. One randomized controlled trial was identified and critically appraised. It compared the Lap-Band to non-surgical treatment. Five non-randomized comparative studies were identified comparing the Lap-Band to gastric bypass. One study conducted in Sweden was excluded because it compared two case series of patients treated at different institutions. A second study was excluded because only preliminary findings were reported: there was 60% follow-up at 1 year and 15% at 2 years. The other three studies were critically appraised. A large case series from Italy (n=1863) was also reviewed to evaluate the long-term safety of Lap-Band surgery.

**Articles:** *Evidence tables were created for the following studies:* O'Brien PE, Dixon JB, Laurie C et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program. *Ann Intern Med* 2005; 144: 625-633. See [Evidence Table](#). Weber M, Miller MK, Bucher T. Laparoscopic gastric bypass is superior to laparoscopic gastric banding for treatment of morbid obesity. *Ann Surg* 2004; 240: 975-983. See [Evidence Table](#). Cottam DR, Atkinson J, Anderson A et al. A case-controlled matched-pair cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band patients in a single US center with three-year follow-up.

*Obesity Surg* 2006; 16: 534-540. See [Evidence Table](#). Browne WB, Julliard K, Castro AE et al. Laparoscopic gastric bypass is superior to adjustable gastric band in super morbidly obese patients. *Arch Surg* 2006; 141: 683-689. See [Evidence Table](#). Angrisani L, Furbette F, Doldi SB et al. Lap-Band adjustable gastric banding system: The Italian experience with 1863 patients operated on over 6 years. *Surg Endosc* 2003; 17: 409-412. See [Evidence Table](#).

The use of adjustable gastric banding and lap-band in the treatment of obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 12/15/2014: MTAC REVIEW

### Vertical Banded Gastroplasty (VBG) and Roux-en-Y gastric bypass (RYGB)

**Evidence Conclusion:** The limited published evidence comparing LAGB to LRYGB or LSG suggest that LAGB is not the most effective surgical procedure for the morbidly obese patients. The literature indicates that LAGB may have shorter operative time, shorter length of hospital stays, and lower rate of early complications; but it is also associated with higher rates of late complications and risk of surgical interventions compared to other bariatric surgery procedures. There is no good published quality evidence to date, to determine the comparative effectiveness of LAGB to LSG or LRYGB on the resolution of co-morbidities and improvement of health-related quality of life.

**Articles:** The literature search for studies published after the 2006 MTAC review, revealed over 500 publications, many of which were unrelated to the current review. Very few small randomized controlled trials compared the effects of one surgical bariatric procedure versus another. The search identified a recently updated Cochrane review (Colquitt et al, 2014) on surgery for weight loss in adults; a meta-analysis that compared LAGB with LSG (Wang et al, 2013), a multicenter retrospective matched cohort study (Dogan et al, 2014) that compared gastric bypass, LAGB and LSG in morbidly obese patients; three systematic reviews with no meta-analyses of RCTs on bariatric surgeries; a comparative effectiveness study of laparoscopic adjustable gastric banding vs. laparoscopic gastric bypass; as well as several cohort studies with no control or comparison groups that reported on short and long-term outcomes of gastric banding and LSG procedures. The two most recent meta-analyses were selected for critical appraisal.

Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. *Cochrane Database Syst Rev*. 2014 Aug 8;8:CD003641. DOI: 10.1002/14651858.CD003641.pub 4. See [Evidence Table 1](#)

Wang S, Li P, Sun XF, et al. Comparison between laparoscopic sleeve gastrectomy and laparoscopic adjustable gastric banding for morbid obesity: a meta-analysis. *Obes Surg*. 2013 Jul; 23(7):980-986. See [Evidence Table 2](#)

The use of LAGB in the treatment of obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### EndoGastric Solutions StomaphyX™ Endoluminal Fastener

#### BACKGROUND

Obesity Surgery the EndoGastric Solutions StomaphyX™ endoluminal fastener and delivery system is a sterile, single-use device for use in transoral tissue approximation and ligation in the GI tract. The system consists of an ergonomic, flexible fastener delivery device and sterile polypropylene fastener implants. The device is introduced into the body through the mouth under endoscopic visualization. Once inside the stomach, the stomach wall is suctioned into the tissue port on the StomaphyX™ creating a large plication. Non-resorbable polypropylene fasteners are then deployed across the fold to hold the tissue in place. Typically, 10 to 20 folds are required depending on the patient's anatomy. The pleats created in the stomach will reduce its size, which would potentially lead to early satiety and weight loss. According to the manufacturer, the StomaphyX™ procedure is incisionless, adjustable, and revisable. It is usually performed as an outpatient procedure, and is intended for individuals who want an alternative to invasive weight loss surgery, or those who have had previous gastric bypass surgery and are regaining weight. The EndoGastric Solutions StomaphyX™ endoluminal fastener and delivery system was cleared for marketing by the FDA in February 2007 for use in endoluminal trans-oral tissue approximation and ligation in the GI tract. The InScope™ Tissue Apposition System is a sterile, single patient used disposable suture system for approximating and securing soft tissue within the gastrointestinal tract. It is intended to perform suturing in conjunction with endoscopes having a working channel of 2.8 mm or larger. The system can be used to treat variety of defects endoscopically including ulcers and perforations (FDA Web site). The InScope™ Tissue Apposition System was cleared by the FDA for marketing in January 2007 to be used for the placement of sutures and approximation of soft tissue. GERD According to the Montreal Consensus, gastroesophageal reflux disease (GERD) is defined as a condition which develops when the reflux of stomach contents cause troublesome symptoms and/or complications. GERD is a mechanical disorder that is caused by a defective lower esophageal sphincter, a gastric emptying disorder, or failed esophageal peristalsis. Typical



symptoms of GERD include heartburn and regurgitation; however, overtime reflux can cause ulceration, Barrett's esophagus, airway disease, and esophageal cancer. It is estimated that 40% of individuals in the United States suffer from GERD on a monthly basis. Current treatment options for GERD include long-term use of acid suppression medications or surgical intervention. While treatment with acid suppressing medications such as proton pump inhibitors and histamine 2-receptor blockers are effective, they do not treat the underlying mechanical disorder. Additionally, not all patients respond to these therapies (Zagol 2011, Stefanidid 2010). Surgery is another treatment option for patients with GERD. According to the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), surgical therapy should be considered in patients with a diagnosis of reflux who (Stefanidid 2010): Have failed medical management (due to inadequate symptom control, severe regurgitation not controlled with acid suppression, or medication side-effects). Opt for surgery despite medical management (due to quality-of-life considerations, lifelong need for medication intake, expense of the medication, etc.). Have complications of GERD (e.g., Barrett's esophagus, peptic stricture). Have extra-esophageal manifestations (asthma, hoarseness, cough, chest pains, aspiration). There are a variety of surgical procedures used for the treatment of GERD. Currently, there is no consensus on the best procedure for all patients. The choice of procedure is often based on anatomic considerations and expertise; however, the laparoscopic Nissen fundoplication has emerged as one of the most widely used techniques. With fundoplication, the gastric fundus is wrapped around the lower end of the esophagus to reduce gastric reflux. The fundal wrap can be either total (360°) or partial (less than 360°). Studies suggest that approximately 90% of patients who undergo Nissen fundoplication achieve symptom relief. Side effects of this procedure include dysphagia, hyperflatulence, inability to belch, bloating, and postsurgery bowel symptoms (AGA 2008, Stefanidid 2010). Transoral incisionless fundoplication using the EsophyX device (EndoGastric Solutions, Inc., Redmond, WA) has been proposed as a less invasive alternative to traditional surgical procedures. This procedure attempts to decrease the reflux of stomach acid into the esophagus through the reconstruction of an anti-reflux barrier. The EsophyX device is inserted transorally, under direct endoscopic visualization, into the stomach and is positioned at the junction of the stomach and the esophagus. Once positioned, the device uses suction and transmural fasteners to facilitate the recreation of the esophageal gastric valve. The result is an omega shaped valve 3-5 cm in length and 200-300° in circumference. This procedure may also reduce hiatal hernias that are less than 2 cm in size through the use of a built-in vacuum invaginator. As this procedure is incisionless and can often be performed on an outpatient basis it is an attractive alternative to conventional surgical procedures (Jafri 2009, Louis 2010). The EsophyX system had been cleared by the FDA for use in transoral tissue approximation, full-thickness plication and ligation in the gastrointestinal tract for the treatment of GERD in patients with symptomatic chronic GERD who require and respond to pharmacological therapy. This device may also be used to narrow the gastroesophageal junction and reduce hiatal hernia ≤2 cm in size in patients with symptomatic chronic GERD. The EsophyX system has not been previously reviewed by the Medical Technology Assessment Committee and is being review based on request from bariatric surgery and a member appeal.

#### 04/09/2008: MTAC REVIEW

##### EndoGastric Solutions Stomaphy X™ Endoluminal Fastener

**Evidence Conclusion:** There is insufficient published evidence to determine the efficacy and safety of the EndoGastric Solutions StomaphyX™ endoluminal fastener for weight loss. There is insufficient published evidence to determine the efficacy and safety of the InScope™ Tissue Apposition System for endoscopic gastric sutures.

**Articles:** The literature search did not reveal any published studies, on the EndoGastric Solutions StomaphyX™ endoluminal fastener and delivery system, or on the InScope™ Tissue Apposition System. Information about the systems was obtained from the FDA and the manufacturer's Web sites.

The use of endoluminal fasteners in the treatment of obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### Vertical Sleeve Gastrectomy (VSG)

##### BACKGROUND

Obesity is a rapidly growing health problem in the United States and worldwide. According to data from the National Health and Nutrition Examination Survey (NHANES), over two thirds of the adults in the US are overweight or obese. Overweight is defined as Body Mass Index [BMI] between 25 and 29 kg/m<sup>2</sup>, and obesity is defined as BMI of 30.0 kg/m<sup>2</sup> or higher. Obesity can be further subdivided into class 1: (BMI 30 to less than 35), class 2: (BMI 35 to less than 40), class 3: severe or morbid obesity (BMI of 40 or higher), and class IV: super obese or super morbid (BMI >50 kg/m<sup>2</sup>). Obesity leads to substantial morbidity, lower social functioning and quality of life, as well as premature mortality. It is associated with development and /or aggravation of many chronic conditions including cardiovascular diseases, hypertension, type 2 diabetes mellitus, sleep apnea, some

forms of cancer, depression, and osteoarthritis (Duval 2006, Ogden 2006, Sturm 2007, Flegal 2012). Diet, behavioral modification, and exercise are the primary recommended treatments for obesity, but were found to have limited success among the morbidly obese. Drug therapy may be indicated for some, but has its side effects, and the majority regain the lost weight over time. Bariatric surgery is considered as an alternative therapy for morbidly obese individuals. Studies showed that bariatric surgery was more effective than behavioral and medical therapy, had long-term control of obesity, and improved comorbidities as type 2 diabetes. There are several surgical techniques for weight loss, but the Roux-en-Y gastric bypass (RYGB) and the adjustable gastric banding (AGB) are the two most commonly performed procedures across the world. However, surgery is a major intervention and may be associated with risk of complications and perioperative mortality. The morbidly obese individuals usually have a higher incidence of co-existing medical problems and are more likely to develop short and long-term complications after bariatric surgery (Karamanakos 2008, Almogly 2004, Fuks 2009). Sleeve gastrectomy (SG), also known as vertical sleeve gastrectomy (VSG), vertical gastrectomy (VG), greater curvature gastrectomy, parietal gastrectomy or vertical gastropasty, was initially described in the late 1980s, as a first step procedure performed before RYGB or biliopancreatic diversion-duodenal switch in the super obese patients with severe comorbidities. It was intended to achieve a significant weight loss prior to performing a more restrictive and malabsorption operation among those at high surgical or anesthesiologic risk. After a period of initial weight loss, the surgical risk would be reduced, and the second definitive surgery could be performed. More recently, SG have been increasingly used as stand-alone operation for the morbidly obese patients due to its technical simplicity and short-term outcomes in weight loss (Lee 2007, Rubin 2008, Akkary 2008, Mellissas 2008, Keuper 2008, Kehagias 2011). Sleeve gastrectomy is a purely restrictive operation with no malabsorptive effects. It involves removing the fundus and greater curvature portion of the stomach leaving a narrow tubular stomach that is approximately the size and shape of a banana. It preserves the integrity of the pylorus and does not include intestinal bypass as part of the technique. The technique is simple, but some components of the surgery can result in serious complications if not performed correctly (Peterli 2009, Gill 2010, Brethauer 2011). There are several mechanisms contributing to the weight loss with SG; removing 80-90% of the stomach and leaving behind only a sleeve restricts the amount of the food that can be ingested and gives the sensation of fullness with minimal oral intake. Hormonal change represented by the decrease in the ghrelin level due to resection of the fundus may be another factor for the weight loss, as well as the accelerated gastric emptying, and the behavioral modification of the patients. The exact underlying mechanism is still unknown, and the long-term effects of the surgery are still under investigation (Rubin 2008, Akkary 2008, Moy 2008, Karamanakos 2008, Brethauer 2011). Sleeve gastrectomy has many potential advantages. Preservation of gastric function including the pylorus eliminates dumping, and being purely restrictive, SG does not result in malabsorption. Moreover, it can be performed laparoscopically (laparoscopic sleeve gastrectomy or LSG) even in the super-obese patients. SG does not require implantation of any artificial device or adjustments as the laparoscopic adjustable gastric band. It can also be performed in patients with disorders which preclude intestinal bypass e.g. anemia or Crohn's disease. However, the procedure is irreversible and has potential complications associated with the relatively long staple line such as bleeding and leakage. Leakage is the most concerning complication after SG and may result from the placement of the final staple line across the gastroesophageal junction or distal esophagus resulting in a staple line disruption. It may also result from mid-sleeve stenosis due to stenosis in the lumen or twisting or kinking of the sleeve at the incisura. Other reported complications associated with the sleeve gastrectomy include pulmonary embolism, subphrenic abscess, liver failure, stricture, wound infection, and need for reoperation. On the long-term, sleeve gastrectomy may potentially lead to gastroesophageal reflux disease due to an increase in the gastric pressure associated with the procedure (Moy 2008, Fuks 2009, Brethauer 2011). The First Report from the American College of Surgeons Bariatric Surgery Center Network indicates that obesity is a life-long disease, and thus short-term safety and efficacy of bariatric surgery should not be the deciding factor for selection of the procedure, and long-term follow-up beyond 1 year is needed; more importantly 5 years or longer. The report also notes that specifically longer-term assessment of the sleeve gastrectomy is critical as the gastric pouch enlargement over time may limit its ultimate effectiveness (Hutter 2011).

#### 04/06/2009: MTAC REVIEW

##### **Vertical Sleeve Gastrectomy (VSG)**

**Evidence Conclusion:** In conclusion, there is insufficient published scientific literature to date to determine the long-term efficacy, safety, and durability of the weight loss associated with sleeve gastrectomy procedure as a stand-alone treatment option for obese patients. There is also insufficient evidence to determine the optimum BMI threshold where SG would be recommended or encouraged.

**Articles:** The search yielded over 130 articles. Many were reviews and opinion pieces. There were three randomized controlled trials; one compared SG with adjustable gastric banding, another compared it with Roux-en-Y gastric bypass, and the third compared two different techniques for sleeve gastrectomy. There were also a number of case series with different population sizes and follow-up durations. Only four were relatively large with



sample sizes over 100, one was conducted in the US and three were conducted overseas. The US series (Lee et al 2007) had the largest sample size, longest follow-up duration, and non-randomized comparison groups. The two RCTs that compared SG with alternative bariatric surgeries were selected for critical appraisal as well as the Lee et al's case series. The citations for the critically appraised studies are:

Himpens J, Dapri G, Cadiere GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy. Results after 1 and 3 years. *Obesity Surgery* 2006; 16:1450-1456. See [Evidence Table](#)

Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide –YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. A prospective, double blind study. *Ann Surg* 2008; 247:401-410. See [Evidence Table](#)

Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for morbid obesity in 216 patients: Report of two-year results. *Surg Endosc* 2007; 21:1810-1816. See [Evidence Table](#)

The use of Vertical Sleeve Gastrectomy for the treatment of obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 2/11/2013: MTAC REVIEW

### Vertical Sleeve Gastrectomy (VSG)

**Evidence Conclusion:** There is some evidence from very few small RCTs, and non-randomized prospective studies that laparoscopic sleeve gastrectomy performed as a stand-alone surgery, leads to short to mid-term significant weight loss, and improvement in comorbidities in obese patients. However, there is insufficient evidence to determine whether the weight loss and resolution of comorbidities will be sustained long-term. There is insufficient evidence to determine the long-term comparative effectiveness and safety of sleeve gastrectomy and Rou-en-Y gastric bypass or adjustable gastric banding for the treatment of obesity and obesity-related comorbidities. There is insufficient evidence to determine the long-term net health outcomes of laparoscopic sleeve gastrectomy. The studies that reported on long-term outcomes were small case series with no comparison or control group. Himpens and colleagues (2010) reported on the results of 6 years follow-up of 53 patients who underwent laparoscopic SG (different population from that in the RCT published by the same group of investigators in 2006). The results showed that after the sixth postoperative year weight gain was observed in 31 cases (75.6%). The mean BMI in this group of patients was  $39.9 \pm 5.9$  at baseline,  $26.6 \pm 4.3$  at 3 years, and  $31.1 \pm 6.2$  at 6 years. New gastroesophageal reflux symptoms were also reported after 6 years; 18% of the patients in the stand-alone SG group reported occasional vomiting, and 23% reported frequent episodes of GERD. In another follow-up of a case series, D'Hondt and colleagues (2012) also reported a trend towards decrease in weight loss by time (median % excess weight loss [EWL] was 78.5% at 12 months, 72% at 24 months, and 54.4% at 72 months). When % EWL above 50% was considered, the total success rate of SG was 92.9% at 1 year, 89.5%, 87%, 85.7%, 64.3% and 54.5% after 2, 3, 4, 5, and 6 years respectively. There is also insufficient evidence to establish criteria for patient selection or an optimum BMI threshold where SG is recommended or encouraged.

**Articles:** The search for studies published after the 2009 MTAC review revealed one RCT comparing laparoscopic sleeve gastrectomy versus laparoscopic Roux-en-Y gastric bypass in patients with BMI <50 kg/m<sup>2</sup>, another very small RCT that compared the effects of the two procedures on the glucose metabolism, two non-randomized prospective comparative studies, and one case control study that compared the outcomes of SG to one or more other bariatric surgery. The literature search also revealed one network meta-analysis and two systematic reviews without meta-analyses that evaluated the different procedures for bariatric surgery, as well as a number of prospective and retrospective case series with or without comparison groups.

The two RCTs and two prospective comparative studies were selected for critical appraisal. The network meta-analysis was not selected for further critical appraisal as it compared changes of BMI levels with different bariatric surgeries vs. standard care and included only two earlier studies on SG. The following studies were critically appraised: Peterli R, Wölnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. *Ann Surg.* 2009; 50:234-241. See [Evidence Table](#)

Kehagias I, Karamanakos SN, Argentou M, et al. Randomized clinical trial of laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the management of patients with BMI<50 kg/m<sup>2</sup>. *Obes Surg.* 2011;21:1650-1656. See [Evidence Table](#)

Leyba JL, Aulestia N, Llopis SN. Laparoscopic Roux-en-Y gastric bypass versus laparoscopic sleeve gastrectomy for the treatment of morbid obesity. A prospective study of 117 patients. *Obes Surg* 2011; 21:212-216. See [Evidence Table](#)

Varela JE. Laparoscopic sleeve gastrectomy versus laparoscopic adjustable gastric banding for the treatment severe obesity in high risk patients. *JSLs* 2011; 15:486-491. See [Evidence Table](#)

The use of Vertical Sleeve Gastrectomy for the treatment of obesity does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Laparoscopic Sleeve Gastrectomy as Initial Procedure in a Planned Two-Stage Operation for Patients with Severe Morbid Obesity**

### **BACKGROUND**

Individuals with BMI >60 are considered to be “super obese.” Super obesity is associated with an increased risk of multiple health problems including arthritis, breathing problems, cancer, depression, diabetes, heart disease, hypertension, venous disorders and death. In addition, surgical treatment for obesity, such as a Roux-en-Y gastric bypass, is believed to be more dangerous in super obese than less obese patients, particularly for individuals who carry their weight in the belly area. Laparoscopic sleeve gastrectomy (LSG) is a bariatric procedure that involves the laparoscopic removal of 70-80% of the left side of the stomach. This results in a stomach that is approximately the size and shape of a banana. LSG is technically simpler than other bariatric procedures including gastric bypass surgery, since it does not require re-routing of the intestines. In addition, the procedure does not require implantation of any artificial device as with other obesity treatments such as the Lap-Band. LSG is most commonly used as the first stage in a two-stage procedure. Patients may be able to lose 80 or more pounds after an LSG, reducing their BMI to the point that a Roux-en-Y gastric bypass or biliopancreatic diversion with duodenal switch can be done more safely. The second operation is generally performed 8-12 months after the LSG. LSG is sometimes performed as a stand-alone procedure, but this application is not yet recognized by the American Society for Bariatric Surgery (ASDS). LSG has not been reviewed previously by MTAC.

### **04/02/2007: MTAC REVIEW**

#### **Laparoscopic Sleeve Gastrectomy as Initial Procedure in a Planned Two-Stage Operation for Patients with Severe Morbid Obesity**

**Evidence Conclusion:** There is insufficient evidence on the safety and efficacy of laparoscopic sleeve gastrectomy for obesity. Only case series were available; there are no randomized controlled trials or cohort studies. The case series were generally small, and the largest series (Cottam et al., 2006) was compromised by a low follow-up rate. Follow-up data 12 months after the stage-one LSG were available for fewer than half of the treated patients. Mean weight loss in 46% of patients with follow-up data was 45± 17%.

**Articles:** The search yielded 6 case series; all but one included fewer than 50 patients. The only published case series with a sample size of >100 patients was critically appraised for MTAC: Cottam D, Qureshi FG, Mattar G et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. *Surg Endosc* 2006; 20: 859-863.

The use of laparoscopic sleeve gastrectomy in the treatment of severe morbid obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Gastric Electrical Stimulator for Obesity**

### **BACKGROUND**

Gastric electric stimulation is a new technique that has been proposed as a treatment for obesity. It involves the application of a small electrical current to the stomach through leads that are implanted in the muscular layer of the gastric wall. Although the exact mechanism of action is not fully understood, it is thought that electrical stimulation of the stomach wall can induce early satiety and reduce appetite. It may also have an effect on hormones related to satiety and/or appetite (Mizrahi 2012, Stamin 2012, Verdam 2012). Currently, no gastric electric stimulation devices are FDA approved for the treatment of obesity. This technology was previously reviewed by the Medical Technology Assessment Committee (MTAC) in 2001 for the treatment of chronic, intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology. It did not meet MTAC criteria for this indication. It has not been previously reviewed for the treatment of obesity. It is being reviewed based on a request from Kaiser Permanente Bariatric Surgery.

### **2/11/2013: MTAC REVIEW**

#### **Gastric Electrical Stimulator for Obesity**

**Evidence Conclusion:** A recent RCT that included 190 obese subjects evaluated the effects of gastric electric stimulation on weight loss. All patients underwent implantation with the gastric electric stimulator. Patients were instructed to consume a diet with a 500 kcal per day deficit and were required to attend monthly support group meetings. Patients in the treatment group had their devices activated. The devices for patients in the control group were kept inactive. After 12 months, there was no significant difference in the percent of excess weight lost between the treatment and the control group. The mean percent of excess weight loss was 11.7 in the treatment group and 11.8 in the control group (P=0.71). Adverse events included: endoscopy-detected gastric lumen lead penetration during the 2-lead implantation procedure (N=26), low battery between month 10 and month 12 (N=22), lead dislodgement (N=2), and pocket infection (N=1). There were no deaths or major complications. Medtronic/Transeurionix sponsored the study (Shikora 2009). An earlier study conducted by the same author also

© 1999, Kaiser Foundation Health Plan of Washington. All Rights Reserved.

found no significant difference in the percent of excess weight loss between treatment (device on) and control (device off) subjects at 6 months; however, due to methodological limitations results from this study should be interpreted with caution (Shikora 2004). Conclusion: Evidence from a RCT suggests that there is no significant difference in the percent of excess weight lost between patients who received treatment with gastric electric stimulation plus a lifestyle intervention and patients who were treatment with lifestyle intervention alone.

**Articles:** The literature search revealed several small, case-series and two randomized controlled trials (RCTs) that evaluated the safety and efficacy of gastric electric stimulation for the treatment of obesity. The RCTs were selected for review. The following studies were selected for review: Shikora SA, Bergenstal R, Bessler M, et al. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. *Surg Obes Relat Dis* 2009; 5:31-7. See [Evidence Table](#) Shikora SA. "What are the yanks doing?" the U.S. experience with implantable gastric stimulation (IGS) for the treatment of obesity - update on the ongoing clinical trials. *Obes Surg* 2004;14 Suppl 1: S40-8. See [Evidence Table](#)

The use of Gastric Electric Stimulation for the Treatment of Obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Gastric Bypass for GERD**

### **BACKGROUND**

Obesity is a rapidly growing health problem in the United States and worldwide. According to the National Health and Nutrition Examination Survey (NHANES), more than one third of the adults and almost 17% of the youths in the US are obese defined as Body Mass Index [BMI] 30.0 kg/m<sup>2</sup> or higher. It is estimated that at least 5% of the total population are morbidly obese (i.e. with BMI >40 kg/m<sup>2</sup>). Obesity is associated with the development and/or aggravation of many chronic conditions including cardiovascular diseases, hypertension, type 2 diabetes mellitus, sleep apnea, some forms of cancer, depression, and osteoarthritis. Obesity may also be a predisposing factor for gastroesophageal reflux disease (GERD); obese patients are nearly three times as likely to experience GERD symptoms as those with normal BMI. However, researchers have found that the prevalence of GERD, even in the setting of severe obesity is <50%, which suggests that severe obesity itself is not sufficient to cause GERD. The mechanism by which obesity may increase gastroesophageal reflux is not fully understood, but several pathophysiologic mechanisms have been proposed to explain the association between the two conditions. Obese individuals may experience extrinsic gastric compression by surrounding adipose tissue leading to the increase in intragastric pressure and subsequent relaxation of the lower esophageal sphincter (LES), as well as anatomical disruption of the gastroesophageal junction. The latter may result in the formation of hiatal hernia which was found to be more prevalent in obese individuals than in those with normal weight (Ortega 2004, Nelson 2005, Duval 2006, Ogden 2012, Sturm 2007, Tai 2009, Prachand 2010, Flegal 2012).

The initial treatment of GERD symptoms involves lifestyle and dietary modification, which are often combined with acid inhibiting therapy. These generally alleviate GERD symptoms, but are usually unsuccessful in morbidly obese patients. If conservative measures fail, surgery is often considered as an alternative approach.

Laparoscopic Nissen fundoplication has been the standard operation for these cases with medically refractory GERD. However, its use is controversial among obese patients due to conflicting results concerning its long-term effectiveness and sustainability. Fundoplication affects only the LES and lower gastroesophageal junction without addressing weight. Bariatric operations, which are intended primarily to induce weight loss in the morbidly obese, are considered as a potential alternative approach for treating GERD in obese patients. The success of these surgeries depends on the technique used. Restrictive techniques such as laparoscopic adjustable gastric banding and sleeve gastrectomy result in weight reduction by reducing the stomach volume leading to early satiety. However, some patients reported persistence or worsening acid reflux symptoms after these surgeries. Malabsorptive techniques such as jejuno-ileal bypass and biliopancreatic diversion result in weight reduction by functional shortening of the digestive tract and/or by diverting gastric juices. The Roux-en-Y gastric bypass (RYGB), a more technically complex operation, has both restrictive and malabsorptive properties and is described by some as a reliable procedure for treating severe GERD in obese individuals. It does not directly affect the cardio-esophageal competence but may prevent GERD through weight loss and physically altering the anatomy of the gastrointestinal tract and preventing acid reflux into the esophagus (Nelson 2005, El-Serag 2008, Ikramuddin 2008, De Groot 2009, Prachand 2010, Reavis 201).

### **2/11/2013: MTAC REVIEW**

#### **Gastric Bypass for GERD**

**Evidence Conclusion:** There is insufficient published evidence from randomized controlled trials to determine the comparative effectiveness and safety of Roux-en-Y gastric bypass (RYGB) surgery and Nissen fundoplication for the treatment of GERD in obese patients. The methodological quality of the published studies is low due to non-randomization of the patients, small population sizes, differences in definitions of obesity and evaluation of

GERD symptoms, lack of objective outcome assessment, as well as other inherent limitations of observational studies. In a non-randomized trial, Braghetto and colleagues (2012) evaluated postoperative results after fundoplication, RYGB, or a combination of the two procedures for the treatment of 139 obese patients with GERD and Barrett's esophagus. The authors did not explain why and how they selected the patients for each operation, and patients were not equally distributed among the different procedures. They noted however, that those with BMI >35 kg/m<sup>2</sup> were selected for RYGB. Compared to the other two groups, patients in the RYGB had significantly higher BMI and weight. Patients underwent careful clinical assessment of symptoms and endoscopic/histological studies at baseline, and at 3-5 years after surgery. Manometric studies and 24-intra-esophageal pH studies were performed in all patients at baseline and among 116 (83%) after surgery. Overall the results of the study showed that the reflux symptoms and erosive esophagitis improved after all three surgeries compared to baseline. The improvement observed was significantly higher in the two approaches that included gastric bypass versus fundoplication alone. The gastric bypass surgery alone did not modify the lower esophageal sphincter (LES) pressure but led to the highest reduction in body weight and BMI. In an earlier very small (N=12) study with data obtained from a prospectively maintained database, Patterson and colleagues (2003) also showed that laparoscopic Roux-en-Y gastric bypass and laparoscopic Nissen Fundoplication were both effective in treating heartburn symptoms and acid reflux in obese patients. The LES resting pressure increased significantly after the fundoplication but not after the RYGB surgeries. Results from a number of other case series show that RYGB resulted in weight loss, improvement of GERD symptoms, regression of esophagitis, and reduction of number of antireflux medications used in obese patients with GERD. The studies did not evaluate the effect of lifestyle and dietary habits of the patients after the surgery, and do not provide sufficient evidence to determine the long-term benefits of gastric bypass in these obese patients with GERD.

**Articles:** The literature search did not reveal any randomized controlled trial that compared gastric bypass surgery to other standard medical or surgical treatment for severe GERD in obese patients. There was one non-randomized prospective study that compared outcomes of three different laparoscopic procedures for the treatment of obese patients with GERD and Barrette's esophagus, a very small study that compared bypass surgery to fundoplication, and another small study that compared vertical banded gastroplasty vs. Roux-en-Y gastric bypass in patients with GERD and morbid obesity. Other published studies on bypass surgery for GERD were all case series with population sizes ranging from less than ten to just over 200 patients. The study that included fundoplication as a comparative surgery as well as 4 relatively large and/or more recent case series were selected for critical appraisal. Braghetto I, Korn O, Csendes A, et al. Laparoscopic treatment of obese patients with gastroesophageal reflux disease and Barrett's esophagus: a prospective study. *Obes Surg* 2012; 22:764-772. See [Evidence Table](#) Frezza EE, Ikramuddin S, Gourash W, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. *Surg Endosc* 2002; 16:1027-1031. See [Evidence Table](#) Nelson LG, Gonzalez R, Haines K, et al. Amelioration of gastroesophageal reflux symptoms following Roux-en-Y gastric bypass for clinically significant obesity. *Am Surg* 2005; 71:950-953. See [Evidence Table](#) Ortega J, Escudero MD, Mora F, yet al. Outcome of esophageal function and 24-hour esophageal pH monitoring after vertical banded gastroplasty and Roux-en-Y gastric bypass. *Obes Surg* 2004; 14:1086-1094. See [Evidence Table](#) Tai CM, Lee YC, Wu MS, et al. The effect of Roux-en-Y gastric bypass on gastroesophageal reflux disease in morbidly obese Chinese patients. *Obes Surg* 2009; 19:565-570. See [Evidence Table](#)

The use of gastric bypass surgery for treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 06/20/2016: MTAC REVIEW

### Roux-en-Y Gastric Bypass (RYGB) Surgery for Obese Patients with Severe Gastroesophageal Reflux Disease (GERD)

#### **Evidence Conclusion:**

- Due to the nature of the published studies, lack of comparison groups and objective outcome assessment, it is hard to determine whether the observed improvement of GERD symptoms were due to a direct effect of gastric bypass and reduction of abdominal pressure, or due to a placebo effect, masking of GERD by the change in diet after surgery, or undervaluation of the disease due to satisfaction with weight loss.
- There is insufficient published evidence to determine the comparative effectiveness and safety of gastric bypass surgery to Nissen fundoplication or other standard medical or endoscopic procedures used for the treatment of severe GERD in morbidly obese patients.
- There is insufficient published evidence to determine the long-term safety and efficacy of gastric bypass surgery in reducing GERD symptoms morbidly obese patients.



- There is insufficient published evidence to determine the effect gastric bypass surgery on the progression or regression of Barrett's esophagus in morbidly obese patients with GERD

**Articles:** The literature search did not reveal any randomized controlled trial that compared gastric bypass surgery to other standard medical or surgical treatment for severe GERD in obese patients with or without Barrett's esophagus. The empirical studies on gastric bypass surgery for patients with GERD were all observational studies that assessed the impact of RGYB on GERD in morbidly obese patients that underwent the surgery either as an initial operation or after a failed fundoplication surgery. The search also identified an analysis using a prospective database (Bariatric Outcomes Longitudinal Database) for patients who underwent bariatric surgery by a participant in the American Society of Metabolic and Bariatric surgery center of Excellence program; a recent meta-analysis that compared RYGB versus laparoscopic sleeve gastrectomy to treat morbid obesity-related comorbidities including GERD; and a number case series on the role of RYGB for failed antireflux surgery. The use of bypass surgery for a failed fundoplication as well as the comparison of different bariatric surgeries were outside the scope of the current review. The largest observational study with the longer follow-up duration was selected for critical appraisal. Madalosso CA, Gurski RR, Callegari-Jacques SM, et al. The Impact of Gastric Bypass Gastroesophageal Reflux Disease in Morbidly Obese Patients. *Ann Surg.* 2016 Jan; 263(1):110-116. See [Evidence Table 1](#).

The use of Roux-en-Y Gastric Bypass (RYGB) Surgery for Obese Patients with Severe Gastroesophageal Reflux Disease (GERD) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Intragastric balloons for the treatment of obesity or morbid obesity***

#### **BACKGROUND**

Obesity is a chronic disease that is strongly associated with numerous conditions including cardiovascular disease (heart failure, stroke, hypertension), diabetes mellitus, sleep apnea, cancers, osteoarthritis and disability [1]. The prevalence of obesity has been increasing and it is projected that, by the year of 2030, 20% of the world's adult population will be obese [1]. Obesity can be categorized based on body mass index (BMI). A body mass index (BMI) between 25 kg/m<sup>2</sup> and 29 kg/m<sup>2</sup> is considered overweight while obesity is defined as BMI greater than 30 kg/m<sup>2</sup> [1]. Moderate and morbid obesity are defined as BMI between 30 to 39.9 kg/m<sup>2</sup> and BMI >40 kg/m<sup>2</sup> respectively [2]. The cause of obesity is multifactorial [3]. First, the chronic imbalance between energy intake and energy expense leads to obesity. Second, interactions between genetic, behaviors, social and environmental factors play a crucial role in the pathogenesis of obesity[3].

Management of obesity includes conservative therapy such as diet modification, physical exercise, psychosocial interventions, pharmacotherapy such as orlistat and bariatric surgery[4]. A study investigating the effect of diet on weight loss [5] showed that hypocaloric diet and exercise alone led to a non-sustainable weight reduction (5%). Similarly, pharmacotherapy results in additional benefits. Bariatric surgery seems to be an alternative method for long term management [6] but can be associated with adverse events. Despite the benefits of these approaches, some patients might not be able to lose weight or sustain weight loss.

For patients who have failed weight reduction with diet and exercise alone, intragastric balloon (IGB) may be an alternative. Performed for the first time in 1980s [7], IGB is a minimally invasive procedure that diminishes the capacity of the stomach resulting in premature satiation and prolonged satiety and subsequently induces weight loss; Other mechanism resides in the regulation of hormone-mediated signal transduction [4, 8]. IGB insertion is a restrictive procedure in which a spherical, saline-filled balloon is endoscopically positioned in the stomach under mild sedation and left inflated for six months [9]. One or two balloons can be inserted and different fill volumes (400-700ml) and fill media have been described. These include air, fluid, combination of air and fluid. Some balloons can be swallowed and do not need to be endoscopically inserted.

Early designs were removed from the market due to severe complication such as migration resulting in intestinal obstruction but the introduction of the dual-balloon from ReShape Medical (San Clemente, CA) is believed to reduce the risks of obstruction and perforation. The ReShape Integrated Dual Balloon System (Reshape Dual Balloon) and ORBERA Intragastric Balloon System were approved by the Food and Drug Administration (FDA) in 2015.

#### **03/21/2016: MTAC REVIEW**

#### ***Intragastric balloons for the treatment of obesity or morbid obesity***

**Evidence Conclusion:** The results indicate that intragastric balloon in combination with diet and exercise may have a short-term effect in reducing weight in obese patients. The findings also indicate that intragastric balloon may be temporarily more effective than diet and exercise. However, the follow-up duration was insufficient to determine the safety and durability of the outcomes. There is insufficient data to determine whether intragastric



balloon is safer and more effective than standard weight loss surgeries or pharmacotherapy. Intra-gastric balloon was reviewed by Interregional New Technology Committee (INTC) which concluded that “based on low-quality evidence of benefit as compared to conventional weight-loss management and lack of long-term evidence regarding safety and efficacy, it could not be concluded whether or not the benefit of intra-gastric balloon outweigh the harms at this time”.

**Articles:** The search identified a meta-analysis [4] and RCTs comparing IGB to diet and exercise and or sham balloon. However, the search did not identify RCTs making direct comparison between IGB and standard weight loss surgeries or pharmacotherapy. The following studies were selected for critical appraisal: Zheng, Y., M. Wang, et al. (2015). "Short-term effects of intra-gastric balloon in association with conservative therapy on weight loss: a meta-analysis." *Journal of translational medicine* 13(1): 1-9. [See Evidence Table 1](#). Ponce, J., G. Woodman, et al. (2015). "The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intra-gastric balloon for the treatment of obesity." *Surgery for Obesity and Related Diseases* 11(4): 874-881. [See Evidence Table 2](#).

The use of Intra-gastric balloons for the treatment of obesity or morbid obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 01/09/2023: MTAC REVIEW

##### ***Bariatric surgery in patients with obesity related medical problems in patients with BMI 35-40***

##### **Evidence Conclusion:**

- Dyslipidemia: Low to moderate quality evidence suggest that bariatric surgery may improve dyslipidemia in patients with BMI 35-40 kg/m<sup>2</sup>.
- Gastroesophageal reflux disease (GERD): Low to moderate evidence suggest that RYGB and SG may be effective in treating GERD in patients with obesity (BMI range 27- ≥60 kg/m<sup>2</sup>), with RYGB showing a better effect.
- Fatty liver or Nonalcoholic fatty liver disease (NAFLD): There is insufficient evidence to draw a firm conclusion for or against the efficacy of bariatric surgery in obese patients (BMI 35-40 kg/m<sup>2</sup>) with NAFLD.

**Articles:** PubMed was searched from 2017 to November 2022. Search terms include bariatric surgery AND obesity AND (GERD OR gastroesophageal reflux disease OR hyperlipidemia OR dyslipidemia OR fatty liver OR comorbidities). Filters: study design (systematic review, meta-analysis, RCTs). The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. PubMed search was also performed for nonalcoholic fatty liver disease from 2010 to 2022. Search terms include non-alcoholic fatty liver disease and bariatric surgery. The search was filtered by systematic review & meta-analysis. Thirty-four articles were yielded, and 10 were selected based on title screening.

#### 01/09/2023: MTAC REVIEW

##### ***Bariatric Surgery in patients with BMI 30-35 kg/m<sup>2</sup> with Type 2 Diabetes mellitus***

##### **Evidence Conclusion:**

Moderate quality evidence from RCTs suggest that bariatric surgeries including Roux-en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding may be safe and effective in adult patients with BMI 30-35 kg/m<sup>2</sup> and type 2 diabetes mellitus over the short and mid-term.

**Articles:** PubMed was searched through 2017 to November 2022. Search terms include (metabolic surgery OR bariatric surgery OR gastric bypass OR Roux-en-Y OR sleeve gastrectomy OR gastric sleeve OR adjustable gastric banding OR adjustable gastric band) AND (obesity OR BMI <35 OR BMI 30 - 35 OR class I obesity OR nonsevere obesity OR nonmorbidly obese OR nonmorbid obesity) AND (type 2 diabetes mellitus OR T2DM OR T2D). Other search terms include obesity AND diabetes AND bariatric surgery. Filters include publication year (2018 to November 2022), age (19 years and above), and study design (systematic review, meta-analysis, RCTs). The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications.

## Hayes Technology Brief

Hayes, Inc. Hayes Technology Brief. Intra-gastric Balloons for Treatment of Obesity. Lansdale, PA: Hayes, Inc; 3/2018

## Applicable Codes

### Adjustable Gastric Banding--

© 1999, Kaiser Foundation Health Plan of Washington. All Rights Reserved.

[Back to Top](#)

**Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)

**Non-Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® /HCPC Codes	Description
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only
43772	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device component only
43773	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only
43774	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components
S2083	Adjustment of gastric band diameter via subcutaneous port by injection or aspiration of saline

**Biliopancreatic Diversion with Duodenal Switch (Scorpinaro Procedure)—  
Single Anastomosis Duodeno-Ileal Bypass with sleeve gastrectomy (SADI-S)**  
\*reserved for patients with BMI >50

**Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

**Non-Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
43775	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy)
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)

**Vertical Banded Gastroplasty (VBG)--**

**Medicare – Considered Not Medically Necessary**

**Non-Medicare - Considered Not Medically Necessary**

CPT® Codes	Description
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty

**Endoscopic Sleeve Gastroplasty--**

**Medicare – Considered Not Medically Necessary**

**Non-Medicare - Considered Not Medically Necessary**

CPT®/HCPC Codes	Description
-----------------	-------------

<b>C9784</b>	Gastric restrictive procedure, endoscopic sleeve gastropasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components
--------------	---

### Vertical Sleeve Gastrectomy (VSG)--

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>43775</b>	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy)
<b>43843</b>	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastropasty

### Lap Band Port Revision--

**Medicare – Considered Not Medically Necessary**

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

<b>CPT® Codes</b>	<b>Description</b>
<b>43886</b>	Gastric restrictive procedure, open; revision of subcutaneous port component only
<b>43887</b>	Gastric restrictive procedure, open; removal of subcutaneous port component only
<b>43888</b>	Gastric restrictive procedure, open; removal and replacement of subcutaneous port component only

### Roux-en-Y Gastric Bypass (RYGB)

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>43644</b>	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)
<b>43645</b>	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption
<b>43846</b>	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy
<b>43847</b>	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
<b>43848</b>	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)

### Transoral Outlet Reduction (TORe)—

**Medicare – Considered Not Medically Necessary**

**Non-Medicare - Considered Not Medically Necessary**

<b>CPT® / HCPC Codes</b>	<b>Description</b>
<b>C9785</b>	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components

### Gastric Electrical Stimulation (GES) for Obesity--

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® Codes	Description
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
43659	Unlisted laparoscopy procedure, stomach
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
95980	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming
95981	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming
95982	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming

#### Intragastric Balloon--

##### Considered Not Medically Necessary:

CPT® or Codes	Description
43290	Esophagogastroduodenoscopy, flexible, transoral; with deployment of intragastric bariatric balloon
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s)

#### Gastric Bypass for GERD--

##### Considered Not Medically Necessary:

CPT® Codes	Description
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption
43848	Revision, open, of gastric restrictive procedure for morbid obesity, other than adjustable gastric restrictive device (separate procedure)

#### EndoGastric Solutions StomaphyX™ Endoluminal Fastener—

##### Considered Not Medically Necessary:

CPT® Codes	Description
No Specific Codes – often submitted as 43289 or 43499	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
02/01/1999	07/06/2010 <sup>MDCRPC</sup> , 05/03/2011 <sup>MDCRPC</sup> , 03/06/2012 <sup>MDCRPC</sup> , 01/08/2013 <sup>MDCRPC</sup> , 03/5/2013 <sup>MDCRPC</sup> , 09/03/2013 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	06/04/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/05/2015	KP-516: Medical policy has been revised to highlight treatment for bariatric complications and repeat bariatric surgical procedure criteria.
09/01/2015	Revised Laparoscopic Sleeve Gastrectomy L34166 and L34157
04/05/2016	Added MTAC Review for Intra gastric Balloons
06/20/2016	Added MTAC Review for Roux-en-Y Gastric Bypass (RYGB) Surgery for Obese Patients with Severe Gastroesophageal Reflux Disease (GERD)
09/28/2017	Added Gastric Electrical Stimulation codes
11/02/2017	PEBB criteria updated
02/14/2017	Added non-covered procedures from CWQI
03/27/2018	Added LCA A53028
04/17/2018	Added Hayes review – Intra gastric Balloons for Treatment of Obesity
10/06/2020	MPC approved the MCG 24 <sup>th</sup> ed. guideline for Intra gastric Balloon Device: A-0970
06/01/2021	MPC approved the updated recommendations to the current hybrid criteria for Bariatric Surgery to lower the qualifying age from 20 to 18 years or older. Requires 60-day notice, effective date 11/01/2021.
08/19/2021	Noted that PEBB is adopting Kaiser Permanente Commercial clinical review criteria for bariatric surgery procedures effective 01/01/2022.
09/07/2021	Removed reference to retired Noridian LCD L34157 as its content was added to LCA A53028 in 2016.
10/05/2021	MPC approved the removal of Vertical Banded Gastroplasty (VBG) from covered procedures. Requires 60-day notice, effective date 03/01/2022.
01/07/2022	Removed PEBB criteria from the commercial plan. PEBB will be using KP criteria effective 01/01/2022.
10/04/2022	MPC approved to adopt Adolescent indications for Bariatric Surgery. 60-day notice required. MPC approved coverage for Biliopancreatic Diversion with Duodenal Switch and Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S). 60-day notice required.
03/16/2023	Added MTAC review for Bariatric Surgery in patients with BMI 30-35 kg/m2 with Type 2 Diabetes mellitus and Bariatric surgery in patients with obesity related medical problems in patients with BMI 35-40.
08/01/2023	MPC approved to adopt added Coronary Artery Disease (CAD) indication for bariatric surgery. Requires 60-day notice, effective date 01/01/2024.
10/20/2023	Updated coding with new codes C9784 and C9785 (effective 7/1/2023)
04/29/2024	MPC approved to adopt modify BMI indications for bariatric surgery in August 2023. Requires 60-day notice with a delayed implementation of Fall 2024, effective date 10/01/2024.
06/04/2024	MPC approved to adopt the 28th edition of MCG for Gastric Stimulation (Electrical) criteria. Requires 60-day notice, effective 11/01/2024.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Basivertebral Nerve Ablation

- Intracept® Intraosseous Nerve Ablation System

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Intraosseous Basivertebral Nerve Ablation (L39644)</a>
Local Coverage Article (LCA)	<a href="#">Billing and Coding: Intraosseous Basivertebral Nerve Ablation (A59468)</a>

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Basivertebral nerve ablation (BVN), such as with the Intracept System (Relieva Medsystems Inc.), is intended to relieve chronic low back pain (CLBP) thought to be due to vertebrogenic causes by inhibiting the transmission of pain signals (Freburger et al., 2009).

The Intracept Procedure is a treatment option for patients who have not had adequate pain relief with conservative therapy. The minimally invasive procedure can be performed in the outpatient setting. Treatment-refractory CLBP and magnetic resonance imaging–detected Modic 1 or Modic 2 changes are listed as key indications by the manufacturer and were inclusion criteria in the identified studies. In the reviewed clinical studies, patients with symptomatic spinal stenosis, radiculopathy, disk protrusion, or spondylolisthesis were excluded.

The Intracept System consists of the Intracept Introducer Cannula, the Intracept Curved Cannula, the Intracept Radiofrequency Probe, and the Intracept Radiofrequency Generator. According to Relieva Medsystems Inc., the cannula is inserted via minimally invasive procedure under fluoroscopic guidance through the pedicle using a transpedicular approach. The Curved Cannula is then passed through the Introducer to create a channel to the trunk of the BVN. Next, the Radiofrequency Probe is inserted via the Curved Cannula and placed at the BVN.

Bipolar radiofrequency (RF) energy is provided using the Radiofrequency Generator to accomplish the thermal ablation of the BVN. The RF destruction of the BVN is intended to stop the transmission of pain.

## Insights

Clinical studies consistently indicate benefits in patient-oriented outcomes after the Intracept System was used to treat chronic low back pain (CLBP) believed to be due to vertebrogenic origin; however, a randomized controlled trial (RCT) did not convincingly indicate advantages over sham. A second RCT did find short-term treatment advantages over continued standard care; however, given the placebo response observed in the sham-controlled RCT, the findings of this open-label study should be interpreted carefully. Although 1 spine specialty society noted Intracept may be considered, no other guidance documents were identified and payer policies are generally unfavorable, possibly due to the lack of comparative research convincingly demonstrating advantages over treatment alternatives.

## Reference

Hayes. Hayes Evolving Evidence Review. Intracept Intraosseous Nerve Ablation System (Relieva Medsystems) for Treatment of Adults with Low Back Pain. Dallas, TX: Hayes; July 9, 2020. Retrieved April 20, 2021 from <https://evidence.hayesinc.com/report/eer.intracptlbp4481>.

## Medical Technology Assessment Committee (MTAC)

### *Intraosseous Radiofrequency Basivertebral Nerve Ablation for the Treatment of Adults with Chronic Vertebrogenic Low Back Pain*

#### 06/24/2022: INTC Review

**Evidence Conclusion:** Low-certainty evidence from two RCTs, two open-label extensions, two prospective case series, and one post-hoc RCT analysis (Total N = 429 patients; 330 patients received Intracept and had data analyzed) demonstrate that the Intracept procedure improved function, pain, and QOL in adults with CLBP (≥6 months) with some patients showing durable and sustained improvements up to 5 years post-procedure. However, these improvements were not significantly different (either statistically or clinically) when compared to sham procedure at 3 months and up to 12 months. Statistically and clinically important differences in these outcomes favoring Intracept were found in one open-label RCT comparing Intracept June 24, 2022 | SCPMG Evidence-Based Medicine Services Page 3 of 35 KAISER PERMANENTE CONFIDENTIAL INFORMATION – internal use only, do not distribute outside of KP to standard care up to 3 months but given the context of no significant differences between Intracept and sham procedure at this timepoint, the results of this RCT must be interpreted with caution. Intracept appears to be relatively safe as no serious adverse events occurred during these clinical trials, but adverse events were not uncommon, with complication rates ranging from 2.7% to 25% among Intracptreated patients across studies. Complications rates were similar between treatment and control arms in comparative RCTs. One of the most common AEs was postoperative leg pain due to a pedicle breach, often at levels L5 or S1. As with all interventional procedures, the experience of the operator and accurate patient selection will correlate with the safety of the procedure. More rigorous RCTs not funded and/or affiliated with the manufacturer and with longer-term comparative data are needed to validate any findings of benefit of the Intracept procedure over sham or standard care. Additionally, trials evaluating the comparative effectiveness of Intracept compared to other minimally invasive procedures are needed to determine its role among several available interventions for CLBP.

**Articles:** The Medical Technology Assessment Team (MTAT) reviewed the evidence on intraosseous radiofrequency basivertebral nerve ablation (i.e., Intracept®) for the treatment of chronic low back pain on June 24, 2022. Based on 2 RCTs of two different comparisons, 2 follow-up open-label extensions of these RCTs, 2 prospective case series, and 1 post-hoc RCT analysis, conclusions are limited by the overall low quantity and quality of the body of evidence.

## Applicable Codes

**Medicare: Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare: Considered Not Medically Necessary**

CPT® or HCPC Codes	Description
--------------------	-------------

<b>64628</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral
<b>64629</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To** verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/21/2021	05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 09/03/2024 <sup>MPC</sup>	01/16/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/04/2021	MPC approved adoption of non-coverage policy for Basivertebral nerve ablation. Requires 60-day notice, effective October 1, 2021.
01/16/2024	Updated Medicare LCD and Billing coding article for NEW coverage policies for Basivertebral Nerve Ablation Effective 1/28/2024.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Eating Disorder

- Anorexia Nervosa
- Binge, Bulimia and Specified Eating Disorders
- Eating Disorders, Unspecified

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### For Non-Medicare Members

Service	Criteria
<b>Anorexia Nervosa</b>	<p><b>Inpatient Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Anorexia Nervosa, Adult: Inpatient Care (B-001-IP) and Anorexia Nervosa, Child or Adolescent: Inpatient Care (B-016-IP) for medical necessity determinations.</p> <p><b>Partial Hospitalization</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Anorexia Nervosa: Partial Hospitalization Program (B-KP-001-PHP v2 eff 12.01.2021) for medical necessity determinations.</p> <p><b>Intensive Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Anorexia Nervosa: Intensive Outpatient Program (B-KP-001-IOP v2 eff 12.01.2021) for medical necessity determinations.</p> <p><b>Acute Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Anorexia Nervosa: Outpatient Care (B-KP-001-AOP v2 eff 12.01.2021) for medical necessity determinations.</p> <p><b>Residential Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Anorexia Nervosa: Residential Care (B-KP-001-RES v2 eff 12.01.2021) for medical necessity determinations.</p>
<b>Binge, Bulimia and Specified Eating Disorders</b>	<p><b>Inpatient Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders, Adult: Inpatient Care (B-005-IP) and Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders, Child or Adolescent: Inpatient Care (B-021-IP) for medical necessity determinations.</p> <p><b>Partial Hospitalization</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders: Partial Hospital Program (B-KP-005-PHP) for medical necessity determinations.</p>

	<p><b>Intensive Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders: Intensive Outpatient Program (B-KP-005-IOP) for medical necessity determinations.</p> <p><b>Acute Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders: Outpatient Care (B-KP-005-AOP) for medical necessity determinations.</p> <p><b>Residential Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Bulimia Nervosa, Binge-Eating Disorder, and Other Specified Feeding or Eating Disorders: Residential Care (B-KP-005-RES) for medical necessity determinations.</p>
<b>Eating Disorders, Unspecified</b>	<p><b>Inpatient Behavioral Health Level of Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Eating Disorders: Inpatient Behavioral Health Level of Care, Adult (B-904-IP) and Eating Disorders: Inpatient Behavioral Health Level of Care, Child or Adolescent (B-913-IP) for medical necessity determinations.</p> <p><b>Partial Hospitalization</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Eating Disorders, Partial Hospital Behavioral Health Level of Care, Adult (B-KP-904-PHP) and Eating Disorders, Partial Hospital Behavioral Health Level of Care, Child or Adolescent (B-KP-913-PHP) for medical necessity determinations.</p> <p><b>Intensive Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Eating Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Adult (B-KP-904-IOP) and Eating Disorders, Intensive Outpatient Program Behavioral Health Level of Care, Child or Adolescent (B-KP-913-IOP) for medical necessity determinations.</p> <p><b>Acute Outpatient</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Eating Disorders, Outpatient Behavioral Health Level of Care, Adult (B-KP-904-AOP) and Eating Disorders, Outpatient Behavioral Health Level of Care, Child or Adolescent (B-KP-913-AOP) for medical necessity determinations.</p> <p><b>Residential Care</b> Kaiser Permanente has elected to use the MCG* Care Guideline: Eating Disorders, Residential Behavioral Health Level of Care, Adult (B-KP-904-RES) and Eating Disorders, Residential Behavioral Health Level of Care, Child or Adolescent (B-KP-913-RES) for medical necessity determinations.</p>

\*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

## **Definitions**

### **Binge Eating**



According to DSM 5:

An episode of binge eating is characterized by both of the following:

1. Eating, in a discrete period of time (e.g. usually less than a 2-hour period), an amount of food that is definitely larger than what most people would eat in a similar period of time under similar circumstances.
2. A sense of lack of control over-eating during the episode (e.g. a feeling that one cannot stop eating or control what or how much one is eating).

The binge-eating episodes are associated with 3 (or more) of the following:

1. Eating much more rapidly than normal
2. Eating until feeling uncomfortably full
3. Eating large amounts of food when not feeling physically hungry
4. Eating alone because of feeling embarrassed by how much one is eating.
5. Feeling disgusted with oneself, depressed, or very guilty afterward.

There is marked distress regarding binge eating.

The bingeing occurs, on average, at least once a week for 3 months, and is not associated with recurrent use of inappropriate compensatory behavior and does not occur exclusively during the course of bulimia nervosa or anorexia nervosa.

### **Overeating**

According to DSM 5 - In Overeating, there is a consumption of excess food, with no engagement in inappropriate compensatory behavior and no excessive concern with body shape and weight characteristics that are seen in bulimia nervosa.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## **Background**

In January 2006, Kaiser Permanente adopted and integrated into its clinical review criteria, the MCG (formerly Milliman) Care Guidelines for determining appropriate levels of care based on symptoms and functional impairment. These criteria are independently developed and based on a review of the scientific literature, expert input, and clinical practice. In addition, the MCG Care Guidelines are updated yearly. Kaiser Permanente Behavioral Health Services operationally defines clinically indicated services as "services for mental health conditions that are having a clinically significant impact on an individual's social, medical, and/or occupational functioning."

Inpatient anorexia nervosa services are provided or authorized with the overall goals of assessing and stabilizing the member's acute symptoms, in order that treatment can be continued effectively in a less restrictive and disruptive level of care. Under specific circumstances (e.g. initiation of ECT), the inpatient level of care may be required for safe administration of certain treatments.

Inpatient anorexia nervosa treatment is utilized when it is the most appropriate and effective level of care that can safely be provided for the member's immediate condition. Service authorization is based on the member's contract and the MCG Care Guidelines for inpatient mental health treatment. When treating children or adolescents, the parents or guardians must be included in both the evaluation and treatment planning processes, except for children age 13 or older who refuse to have a parental figure involved.

## **Applicable Codes**

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
--------------	---------------	-------------------

6/30/2010	7/6/2010 <sup>MDCRPC</sup> , 5/3/2011 <sup>MDCRPC</sup> , 3/6/2012 <sup>MDCRPC</sup> , 1/08/2013 <sup>MDCRPC</sup> , 11/05/2013 <sup>MPC</sup> , 2/04/2014 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	11/05/2024
-----------	---	------------

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/02/2015	Changed documentation of GHC hybrid to MCG
12/01/2015	Revised criteria to reflect approval of MCG 19 <sup>th</sup> Ed.
03/31/2016	Removed 60 day hold notice
02/07/2017	MPC approved to adopt MCG 20 <sup>th</sup> Ed. guidelines for Inpatient & Acute Outpatient Care; MPC approved to adopt hybrid (GHC/MCG) guidelines for Residential, Partial Hospital and Intensive Outpatient
09/05/2017	MPC approved to adopt KP-MCG hybrid criteria for all levels of care
12/05/2017	MPC approved to adopt hybrid (MCG/KP) guidelines for all levels of care
06/02/2020	Removed diagnosis codes
07/06/2021	MPC approved to adopt MCG 25 <sup>th</sup> Edition for Anorexia Nervosa, Bulimia Nervosa, and Eating Disorders for all levels of care: Inpatient (IP), Partial Hospital Program (PHP), Intensive Outpatient Program (IOP), Outpatient Program (AOP) and Residential Behavioral Health (RES).
11/05/2024	Merged Anorexia Nervosa, Binge/Bulimia & Eating Disorders into one policy.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Neuropsychological Testing Psychological Testing

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Chapter 15 of the coverage manual, 80.2 - Psychological Tests and Neuropsychological Tests.</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Service	Criteria
<b>Neuropsychological Testing</b>	<p>Kaiser Permanente has elected to use the MCG* Neuropsychological Testing (B-805-T) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p> <p><b>Exclusions</b> Neuropsychological testing will not be authorized for any of the exclusions found in the member's contract, including learning disabilities.</p>
<b>Psychological Testing</b>	<p>Kaiser Permanente has elected to use the MCG* Psychological Testing (B-807-T) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access</p>

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of PCP or specialty notes that describe the members cognitive deficits

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

In January 2007, Kaiser Permanente adopted and integrated into its clinical review criteria, the MCG Care Guidelines for determining appropriate levels of care based on symptoms and functional impairment. Kaiser Permanente Behavioral Health Services operationally defines clinically indicated services as "services for mental health conditions that are having a clinically significant impact on an individual's social, medical, and/or occupational functioning." The MCG Care Guidelines do not include any criteria regarding neuropsychological testing thus the need to develop these criteria. These criteria are based upon literature from the American Psychological Association as well as the Clinical Neuropsychological Society regarding standards for psychological testing.

### **Explanation to Differentiate Psychological and Neuropsychological Testing**

#### **Psychological Testing**

Psychological tests assess a range of mental abilities and attributes, including achievement, personality, cognitive, and behavioral functioning. They are used to address a variety of questions about people's functioning, diagnostic classification, co-morbidity, and choice of treatment approach. For example, personality tests and inventories evaluate the thoughts, emotions, attitudes, and behavioral traits that contribute to an individual's interpersonal functioning. The results of these tests determine an individual's personality strengths and weaknesses, and may identify certain disturbances in personality, or psychopathology. Basic assessment of memory and intellectual functioning is also part of psychological testing.

Psychological Testing is indicated in the following circumstances:

- Differential diagnosis of behavioral or psychiatric conditions when the member's history and symptomatology are not readily attributable to a particular psychiatric diagnosis and the questions to be answered by testing could not be resolved by a psychiatric/diagnostic interview, observation in therapy, or an assessment for level of care at a mental health or substance abuse facility; or
- Develop treatment recommendations after the member has been tried on various medications and/or psychotherapy, has not progressed in treatment, and continues to be symptomatic.
- A patient has had a recent mild traumatic brain injury (i.e. concussion) and a screening of his/her cognitive status is desired early on after the injury to answer more immediate questions about cognitive and emotional functioning as well as ability to return to accustomed life's activities at that time.
- There has been a recent change in patient's memory (i.e. within past six months) or changes in memory have been present for extended period of time and it is not significant or complex. Psychological testing can clarify /determine extent of memory and cognitive change and impact on functioning.
- Majority of Pre-surgical evaluations (spinal cord stimulator, complex spine surgery, bariatric surgery)

#### **Neuropsychological Testing**

Neuropsychological testing is a sub classification of psychological testing and is a well-established method for evaluating patients who demonstrate complex cognitive or behavioral abnormalities. Areas of brain functioning that are typically assessed are basic motor and sensory-perceptual functions; attention, concentration, speed and efficiency of information processing; learning and memory functions; language and verbal intellectual functions; spatial, perceptual and nonverbal intellectual functions; reasoning and complex problem solving functions; and executive regulatory and monitoring functions. A Neuropsychological evaluation is both a neuro-diagnostic procedure, as well as the most in-depth and comprehensive way of identifying in individual's cognitive strengths and limitations.

Neuropsychological testing is indicated when:

- There is the presence of a significant cognitive deficit, mental status abnormality, behavioral change, or memory loss that requires quantification, monitoring of change, diagnostic clarification, differentiation of cause (e.g., organic cognitive vs. psychiatric disease) and determination of the patient's ability to function.
- There is the presence of a known neurological disease or condition (i.e. dementia, CVA, traumatic brain injury, multiple sclerosis, Parkinson's, etc.) and testing is needed to determine the impact of the disease or condition on brain functioning and the patient's ability to function in his or her personal situation. Patients with mild traumatic brain injury (TBI) should not be referred prior to 3 months post injury as the majority of mild TBI patients recover essentially back to baseline over the initial 3 months post injury period.
- There is a medically complex, not well understood case with memory and cognitive deficits as significant presenting concerns and/or barriers to effective functioning.

- Further assessment of a patient with persisting cognitive symptoms or complaints is needed where a range of previous workups including but not limited to a Neurology consult, brain imaging, Mini-mental State Examination (MMSE), a previous Clinical Psychological evaluation and so forth have been negative or non-contributory.
- As part of pre and post procedure evaluation for deep brain stimulation procedure for Parkinson's Disease

## Summary

When to refer for psychological testing as compared to neuropsychological testing:

- If the primary concern is differential diagnosis (is it bipolar. is it psychosis, is there a personality disorder present), refer for psychological testing
- Majority of pre-surgical evaluation refer for psychological testing.
- There is the presence of cognitive and/or memory concerns and it has not been present for extended period of time (i.e. greater than six months), and there is not the presence of other complicated medical conditions, refer for psychological testing.hcj, t
- If cognitive, memory and behavioral concerns have been present for extended period of time, there are significant medical complications, and/or previous assessments (psychological evaluation, neurology consult) have been unable to clarify diagnosis or functioning status of patient, refer for neuropsychological testing.
- Pre-surgical evaluation for deep brain stimulation for Parkinson's Disease is referred for neuropsychological testing

## Applicable Codes

### Neuropsychological Testing Codes

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
96116	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; first hour
96121	Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, [eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities]), by physician or other qualified health care professional, both face-to-face time with the patient and time interpreting test results and preparing the report; each additional hour (List separately in addition to code for primary procedure)
96132	Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour
96133	Neuropsychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)
96136	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes
96137	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)
96138	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes
96139	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)



<b>96146</b>	Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only
--------------	---

### Psychological Testing Codes

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
<b>90791</b>	Psychiatric diagnostic evaluation
<b>96130</b>	Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; first hour
<b>96131</b>	Psychological testing evaluation services by physician or other qualified health care professional, including integration of patient data, interpretation of standardized test results and clinical data, clinical decision making, treatment planning and report, and interactive feedback to the patient, family member(s) or caregiver(s), when performed; each additional hour (List separately in addition to code for primary procedure)
<b>96136</b>	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; first 30 minutes
<b>96137</b>	Psychological or neuropsychological test administration and scoring by physician or other qualified health care professional, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)
<b>96138</b>	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; first 30 minutes
<b>96139</b>	Psychological or neuropsychological test administration and scoring by technician, two or more tests, any method; each additional 30 minutes (List separately in addition to code for primary procedure)
<b>96146</b>	Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/07/2006	04/06/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	07/17/2024

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
02/02/2016	Adopted MCG 19 <sup>th</sup> Ed. Guidelines (Neuropsych Testing)
04/05/2016	Adopted MCG 19 <sup>th</sup> Edition (Psych Testing)
08/02/2016	Removed LCD (Psych Testing)
12/06/2016	Adopted MCG 20 <sup>th</sup> Ed. Guidelines (Neuropsych Testing)
10/03/2017	Adopted MCG 21 <sup>st</sup> Ed. guidelines (Neuropsych Testing)
11/07/2017	Adopted MCG 21 <sup>st</sup> Edition (Psych Testing)
08/07/2018	Adopted MCG 22 <sup>nd</sup> Ed. Guidelines (Neuropsych Testing)

09/04/2018	Adopted MCG 22 <sup>nd</sup> Edition (Psych Testing)
07/31/2020	Added CPT code 96121 (Psych Testing)
08/04/2020	Added CPT code 96130 (Neuropsych Testing)
09/01/2020	Removed deleted CPT codes 96118-96120 and G0505; Added CPT codes 96136-96139 and 96146 (Psych Testing)
07/17/2024	Merged Neuropsychological Testing and Psychological Testing criteria



## Health Plan

### Clinical Review Criteria

#### Biofeedback

#### Neurofeedback

- Neurofeedback (EEG Biofeedback)
- Neuropsychiatric EEG-Based Assessment Aid (NEBA) – ADHD
- Quantitative EEG (Brain Mapping)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Biofeedback Therapy (30.1)</a> .
Local Coverage Determinations (LCD)	3/14/2007 Noridian retired <a href="#">LCD Biofeedback Therapy Policy (L14443)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L14443 for determining medical necessity.
Local Coverage Article	None
Kaiser Permanente Medical Policy	<p>Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "<b>Attention Deficit Hyperactivity Disorder (ADHD)</b>" for medical necessity determinations. Use the Non-Medicare Criteria below.</p> <p>Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "<b>Quantitative EEG (Brain Mapping)</b>" for medical necessity determinations. Use the Non-Medicare Criteria below.</p>

**\*For FEHB plans:** See the member's contract for specific coverage details

### For Non-Medicare Members

Service	Criteria
Biofeedback	<p>I. Biofeedback is covered for <b>ONE of the following</b>:</p> <p>A. Fecal Incontinence</p>

	<p>B. Tension or migraine headache if pharmacologic treatment inadequate or not indicated, by <b>1 or more</b> of the following:</p> <ul style="list-style-type: none"> <li>▪ Breast-feeding patient</li> <li>▪ History of long-term, frequent, or excessive use of analgesic or medications that can aggravate headache</li> <li>▪ Insufficient or no response to multiple pharmacologic treatment attempts</li> <li>▪ Intolerance of multiple pharmacologic treatment attempts</li> <li>▪ Patient attempting to become pregnant</li> <li>▪ Pregnant patient</li> </ul> <p>II. The following indications for biofeedback are not medically necessary. There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.</p> <ul style="list-style-type: none"> <li>• Abdominal pain, recurrent</li> <li>• Anxiety disorders</li> <li>• Arthritis</li> <li>• Asthma</li> <li>• Autism</li> <li>• Back pain</li> <li>• Bell's palsy</li> <li>• Bruxism and sleep bruxism</li> <li>• Cardiovascular disorders</li> <li>• Chronic fatigue</li> <li>• Chronic pain</li> <li>• Chronic obstructive pulmonary disease (COPD)</li> <li>• Depression</li> <li>• Epilepsy</li> <li>• Facial palsy</li> <li>• Fibromyalgia</li> <li>• Hand hemiplegia</li> <li>• Insomnia</li> <li>• Knee pain</li> <li>• Low back pain</li> <li>• Low vision</li> <li>• Lupus [systemic lupus erythematosus (SLE)]</li> <li>• Motor function after stroke, injury, or lower limb surgery</li> <li>• Movement disorders</li> <li>• Myalgia or muscle pain</li> <li>• Neck pain</li> <li>• Orthostatic hypotension in patients with a spinal cord injury</li> <li>• Post-traumatic stress disorder (PTSD)</li> <li>• Raynaud's disease</li> <li>• Side effects of cancer chemotherapy</li> <li>• Temporomandibular joint disorders</li> <li>• Tinnitus</li> <li>• Vesicoureteral reflux</li> <li>• Voiding dysfunction</li> <li>• Vestibulodysnia, vulvodysnia, vulvar vestibulitis</li> </ul>
<b>Neurofeedback for ADHD (biofeedback)</b>	See MCG* A-0330:

<b>Neuropsychiatric EEG-Based Assessment Aid (NEBA)</b>	<p><b>Biofeedback Inconclusive or Non-Supportive Evidence</b> For attention-deficit hyperactivity disorder in children, evidence is insufficient, conflicting, or poor and demonstrates an incomplete assessment of net benefits vs. harm; additional research is recommended. For adolescents, there is insufficient evidence in the published medical literature to show that this service/therapy provides better outcomes than current standard services/therapy. There was no literature reported for adults with attention-deficit hyperactivity disorder at the time of the review.</p> <p>*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access</p>
<b>EEG, Quantitative (Brain Mapping) for neuropsychiatric disorders</b>	<p>Kaiser Permanente has elected to use the EEG, Quantitative (Brain Mapping) (A-1050) MCG* Care Guideline for medical necessity determinations. This is not covered per MCG*. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under <i>Quick Access</i>.</p>
<b>Biofeedback for the Treatment of Urinary Incontinence</b>	<p>See the <a href="#">Treatment of Urinary Incontinence criteria document</a></p>

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### Biofeedback

Biofeedback is a technique designed to help individuals self-regulate certain physiological processes that are not normally considered to be under voluntary control or responses that are ordinarily easily regulated, but for which regulation has broken down due to trauma or disease. This is achieved through conveying audio and visual information about physiological processes such as blood pressure, heart rate, skin temperature, galvanic skin response (sweating), or muscle tension in real-time to raise awareness of physiological activities and train patients to control them. The goal of biofeedback is that eventually the patient will learn to control physiologic response without the aid of monitors (Kaiser 2011, Roditi 2011).

Different types of biofeedback include (Kaiser 2011, Magnusson 2008, Kapitza 2010):

- Electroencephalography (EEG) biofeedback, which monitors the activity of brain waves linked to different mental states.
- Electrocardiography (EKG) biofeedback, which tracks the patient's heart rate.
- Electromyography (EMG) biofeedback, which uses sensors to measure tension in specific muscles.
- Galvanic skin response biofeedback, which uses sensors to signal anxiety based on the activity of a person's sweat glands and the amount of perspiration on the skin.
- Skin temperature biofeedback, which involves attaching sensors to the fingers or feet to indicate stress when the temperature is low.
- Respiratory biofeedback, which uses sensors to measure breathing.
- Postural biofeedback, which uses sensors to measure body motion.

Biofeedback has been used to treat a variety of medical conditions such as urinary incontinence, ADHD, headaches, anxiety, and back pain.

### Neurobiofeedback & Brain Mapping



Attention Deficit Hyperactivity Disorder (ADHD) is a common chronic neurobehavioral condition affecting approximately 5% of children worldwide. A child with ADHD may present as: 1) predominantly hyperactive, 2) predominantly inattentive, or 3) both hyperactive and inattentive. ADHD is often accompanied by impaired social adjustment, academic problems, and lower adaptive functioning in major life activities which may persist to adolescence and adulthood (Benner-Davis 2007, Gevensleben 2009, Lansbergen 2011).

Medication, particularly psychostimulants, is the primary treatment for ADHD. Psychostimulants work quickly, improve attention, and reduce hyperactivity and impulsivity in about 70% of all children. However, their effect on academic achievement, family relation, and social skills is small. There are also some concerns regarding their side effects, and their long-term benefits have not been established. Behavioral therapy has been shown to reduce ADHD symptoms, but may not be sufficiently effective especially in terms of generalization and long-term effects (Leins 2007, Gevensleben 2009, Lansbergen 2011).

In searching for additional or alternative treatments for children with ADHD, neurofeedback (NF) emerged as a promising option. NF is a type of biofeedback that uses electroencephalography (EEG) to provide a signal that can be used by a person to receive feedback about brain activity. It is based on the rationale that there is a relationship between surface EEG and the underlying thalamocortical mechanism responsible for its rhythms and frequency modulations. Lubar was the first to report on EEG and behavioral changes in a hyperkinetic child. He explained that ADHD children differ from others in that their brain waves tend to be of larger amplitude. Specifically, the EEG shows excess theta activity along with lower amounts of beta activity. This pattern of brain wave activity usually indicates a sleep or daydreaming state, rather than an alert and focused state. The goal of EEG biofeedback training is to alter these abnormal brain waves by decreasing theta waves, while simultaneously increasing beta waves (i.e. theta suppression/beta enhancement). This would potentially help the child acquire self-control over certain brain activity patterns, derive self-regulation strategies, and apply the gained self-regulation skills in daily life (Lubar 1976, Lubar 1991, Bakhshayesh 2011).

In EEG biofeedback training, the therapist explains to the child the connection between what is happening in his/her cortex and what is recorded on the EEG and helps him/her learn how to gain control over the brain activity patterns. The EEG biofeedback equipment is connected to the individual with sensors that are placed on the scalp and ears. Once connected, the brainwave activity can be observed on a computer monitor. Individuals are then taught to play computerized games using their brainwave activity. Changes in the individual's brainwave activity are then fed back to the individual through visual and/or auditory information by the computer. During a typical 45-minute session, the child is seated in front of a computer, electrodes are connected to his head, and then a therapist starts up a videogame or movie on the child's screen and monitors his brain waves on another screen. The child then locks his eyes on the action, concentrating on sending the kind of brain waves that will keep a virtual airplane flying, or perhaps a favorite movie rolling. If his attention wanders or he begins to fidget, the plane slows or the movie screen darkens, and the therapist encourages him to regain focus using techniques such as slow, deep breathing. Children may also practice maintaining learned brainwave states when engaged in school- or work-related tasks (Gevensleben 2009).

In the last three decades many studies compared brain activity using electro-encephalography (EEG) among children with ADHD versus the brain activity of normal controls in an attempt to study the underlying neurophysiology of ADHD; and to investigate subtypes of the disorder and their response to treatment. The EEG frequency bands of most interest in ADHD research are the theta, beta, and alpha bands either alone or in relation to one another such as the theta/beta power or amplitude ratio. Alpha band activity is typically observed during rest when the eyes are closed and is negatively associated with central nervous system arousal. Beta band activity on the contrary, generally accompanies mental activity and concentration. Cortical theta is observed frequently in young children, but in older children and adults, it tends to appear during meditative, drowsy, or sleeping states. Researchers suggest that most children with ADHD display EEG differences in their brain electrical activity as compared to normal children, particularly with respect to their increased frontocentral theta activity primarily during the resting state. This indicates decreased cortical activity that may be associated with underarousal. A theta /beta ratio (TBR) due to increased theta is reported by many investigators as a consistent characteristic of ADHD. Some groups recommend using the TBR during eyes-opened or eye-closed resting condition as an add-on for the diagnosis and monitoring of ADHD. However, it is reported that the true functional significance of this measure is still unknown, and an elevated theta activity may be a nonspecific marker of cortical dysfunction common to other disorders such as epilepsy, bipolar disorder, and polysubstance abuse (Arns 2013, Liechti 2013, Loo 2012).

A number of studies examined the accuracy and diagnostic value of the theta power and TBR in discriminating normal children from children with learning disorders, ADD, and ADHD. In 2005, Boutros and colleagues performed a review and meta-analysis to estimate the strength and effect size of increased theta activity in ADHD patients. Based on their findings they concluded that the increased EEG theta activity in ADHD is promising and should be further developed as a diagnostic test for ADHD. Around the same time another group of investigators (Snyder and Hall, 2006) also

conducted a meta-analysis to investigate the theta and beta powers and their ratio (TBR) and concluded that the pooled results support the finding that an increase in the theta/beta ratio is a commonly observed trait in ADHD relative to normal controls. They however, cautioned that theta/beta ratio trait may arise with other conditions, and that a prospective study covering differential diagnosis would be required to determine generalizability to clinical applications (Arns 2013, Boutros 2005, Loo 2012 Snyder 2006).

Based on this EEG technology, the Neuropsychiatric EEG-Based Assessment Aid (NEBA) System (NEBA Health, Augusta, GA) was developed and recently received Food and Drug Administration (FDA), in July 2013, to help assess ADHD in children and adolescents 6-17 years of age. It is not to be used as a stand-alone diagnostic test, but as a conjunctive tool for diagnosing ADHD. NEBA is a non-invasive test that calculates the ratio of theta and beta waves frequencies in 15-20 minutes (FDA and NEBA websites accessed January 15, 2014).

According to the FDA, the use of the device together with the complete medical and psychological examination, can help confirm an ADHD diagnosis or a clinician's decision that further diagnostic testing should focus on ADHD or other medical or behavioral conditions that lead to symptoms similar to ADHD. The FDA reviewed the NEBA System through a de novo classification process, a regulatory pathway for some low- to moderate-risk medical devices that are not substantially equivalent to an already legally marketed device (FDA website accessed January 15, 2014).

## Evidence and Source Documents

[Biofeedback for Anxiety Disorders](#)

[Biofeedback for Back Pain](#)

[Biofeedback for Migraine and Tension Headaches](#)

[Biofeedback for Treatment of Urinary Incontinence](#)

## Medical Technology Assessment Committee (MTAC)

### ***Biofeedback for Anxiety Disorders***

#### **02/13/2012: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence to determine the safety and efficacy of biofeedback for the treatment of generalized anxiety disorders.

**Articles:** The literature search revealed several studies evaluating biofeedback for the treatment of generalized anxiety disorder. All of the studies had small sample sizes and the majority were published more than 20 years ago. The newest study was a randomized controlled trial that evaluated the efficacy of a biofeedback enhanced virtual reality system. This study was not selected for review as the treatment group contained only 4 subjects (Gorini, 2010). Conclusion: There is insufficient evidence to determine the safety and efficacy of biofeedback for the treatment of generalized anxiety disorders.

The use of biofeedback for anxiety disorders does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Biofeedback for Chronic Back Pain***

#### **02/13/2012: MTAC REVIEW**

**Evidence Conclusion:** The Kaiser review included four randomized controlled trials that ranged in size from 42 to 128 patients. Findings from these trials suggest that pain and disability improved with biofeedback, cognitive behavioral therapy (CBT), biofeedback plus CBT, placebo biofeedback, and rehabilitation; however, no significant differences were found between biofeedback and the other treatments. The body of evidence was limited by heterogeneity in the patient population, biofeedback protocols, and comparator treatments. Additionally, the studies were small with short follow-up periods. Biofeedback vs. CBT alone vs. waitlisted controls (Newton-John 1995) • N=44 • Type of biofeedback: Electromyography biofeedback (EMG). • Both the biofeedback and the CBT groups showed improvement in pain intensity, pain belief, and depression; however, there no significant differences between the two groups. There was no improvement in the waitlisted control group. Biofeedback plus CBT vs. CBT alone vs. waitlisted controls (Glombiewski 2010) • N=128 • Type of biofeedback: EMG • Both the combined group and the CBT alone group showed improvement in pain intensity compared to waitlisted control; however, there no significant differences between the two groups. Active biofeedback vs. placebo biofeedback (Kapitza 2010) • N=42 • Type of biofeedback: Respiratory biofeedback. • There was no significant difference in pain reduction between the two groups. Biofeedback plus rehabilitation vs. rehabilitation alone (Magnusson 2008) • N=47 • Type of biofeedback: Postural biofeedback. • Although the combined group showed improvements in pain, range of motion, and quality of life, the study did not report if they were statistically significantly different from the rehabilitation alone group. Conclusion: There is insufficient evidence to determine the safety and efficacy of biofeedback for the treatment of chronic back pain.

**Articles:** The 2007 American College of Physicians and the American Pain Society (ACP/APS) guideline evaluated the evidence on biofeedback for chronic back pain. The studies evaluating this treatment were of poor quality and therefore they were unable to evaluate the net benefits of biofeedback. The conclusions of the ACP/APS guideline were supported by a 2009 BMJ clinical evidence review (Chou 2009). In 2011, the Kaiser Permanente Medical Technology Assessment Team (MTAT) also reviewed biofeedback for the treatment of chronic back pain. No additional studies were identified after the Kaiser review. The following technology assessments were selected for review: Kaiser Permanente TPMG New Medical Technologies. Biofeedback for chronic neck and low back pain. May 2011.

The use of biofeedback for back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Biofeedback for Migraine and Tension Type Headaches**

#### **02/13/2012: MTAC Review**

**Evidence Conclusion:** A recent meta-analysis that included 94 RCTs and quasi-experimental studies evaluate the efficacy of different types of biofeedback for the treatment of migraine and tension-type headaches. Results from this analysis suggest that biofeedback was more effective than no treatment for headache reduction in patients with migraine headache (small effect size); however, there was no significant difference between biofeedback and placebo or relaxation. For patients with tension-type headache, biofeedback was significantly more effective than no treatment, placebo, and relaxation for headache reduction (small to medium effect size). There was no significant difference between biofeedback treatment modalities for the reduction of migraine headache pain (Nestouric 2008). A meta-analysis is only as good as the studies that it includes. The studies included in the meta-analysis had several limitations. • The majority of the studies included in the meta-analysis were small. The mean number of subjects per study was 40 for migraine studies and 45 for tension-type headache studies. • The type and number of sessions of biofeedback varied. • Several studies failed to describe basic treatment and patient characteristics. • Several studies used unstructured diagnostic systems. Conclusion: Migraine • Results from a recent meta-analysis suggest that biofeedback may be more effective than no treatment, but not placebo or relaxation for headache reduction. Tension-type headaches • Results from a recent meta-analysis suggest that biofeedback may be more effective than no treatment, placebo, and relaxation for headache reduction. • Another recent BMJ Clinical Evidence review found insufficient evidence to determine whether EMG biofeedback is effective for treating chronic tension-type headaches (Krishnan 2009).

**Articles:** Several meta-analyses and randomized controlled trials (RCTs) were identified that evaluated the efficacy of biofeedback for the treatment of migraine and tension-type headaches. The most recent meta-analysis was selected for review. An RCT published after the meta-analysis was also identified that evaluated the efficacy of a pain program that included education and training in pain theory plus EMG and temperature biofeedback compared to the pain program alone. This study was not selected for review due to methodological limitations (i.e., small sample size, high loss to follow-up, power not addressed, and baseline characteristics were not presented) (Mullally 2009). The following study was selected for review: Nestoriuc Y, Martin A, Rief W, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. *Appl Psychophysiology Biofeedback*. 2008; 33:125-140. See [Evidence Table](#).

The use of biofeedback for Migraine and Tension-type Headaches does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Neurofeedback for ADHD**

#### **10/17/2011: MTAC REVIEW**

**Evidence Conclusion:** A number of small randomized and nonrandomized controlled trials included in Arns and colleagues' meta-analysis (evidence table 1) and the pooled results of available data indicate that NF may have some beneficial effects on a number of ADHD measures. However, when compared with stimulant therapy, NF did not prove to have an equivalent or superior effect on ADHD core symptoms. None of the studies monitored potential adverse effects of NF. The small study sizes, their short duration, lack of a valid control group, mixed and multiple interventions used, lack of double-blinding, additional time spent with the therapists for NF, as well as other study methodological limitations make it hard to determine the efficacy of the neurofeedback used alone or in addition to other interventions for the treatment of children with ADHD. Gevensleben and colleagues' trial (evidence table 2) conducted by a group of researchers in a university hospital in Germany, compared NF training to computerized attention skills training. This may be considered as a more valid comparison as it controls for therapist time and attention training. The primary endpoint was improvement in attention and reduced hyperactivity as rated by the parents. No measures of children's academic functioning or classroom performance were collected. The results of the trial showed that symptoms improved in both groups; however, the score of the primary outcome measure (parents' rating of FBB-HKS [a German rating scale]) was significantly higher in children in the NF group. The trial was randomized and controlled, but was not blinded, and the NF training

program was developed by the study group. After the training period 18% of the children were started on a medication. Six months follow-up data, available for only two thirds of the participants, showed that the behavioral improvements were maintained at 6 months, but the difference between the two interventions did not reach a statistically significant level. The investigators attributed the lack of significant difference to insufficient statistical power due to the smaller number of children with follow-up data. They authors concluded that NF training may help some children, but more research is needed to replicate the findings and identify which children with ADHD are more likely to benefit from NF training. Well conducted randomized trials with a sham neurofeedback control, double-blinding, and long-term follow-up are needed to establish the efficacy and safety of neurofeedback in improving the core symptoms of ADHD.

**Articles:** The search revealed one meta-analysis on the efficacy of neurofeedback treatment in ADHD and a number of RCTs that were included in the meta-analysis. Three small RCTs published after the meta-analysis, as well as a report on 6 months follow-up of an earlier RCT were also identified. The meta-analysis as well as the largest trial, which had a more valid design and longer follow-up, were selected for critical appraisal. Arnns M, de Ridder S, Strehl U, et al. Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity; a meta-analysis. Clin EEG Neurosci 2009; 40:180-189. See [Evidence Table](#). Gevensleben H, Holl B, Albrecht B, et al. Is neurofeedback an efficacious treatment for ADHD? A randomized controlled trial. J Child Psychol Psychiatry. 2009; 50:780-789. See [Evidence Table](#). Gevensleben H, Holl B, Albrecht B, et al. Neurofeedback training in children with ADHD: 6-month follow-up of a randomized controlled trial. Eur Child Adolesc Psychiatry 2010; 19:715-724. See [Evidence Table](#).

The use of Neurofeedback for ADHD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 06/20/2016: MTAC REVIEW

### Electroencephalography (EEG) Neurofeedback (NF) for Attention deficit hyperactivity disorder (ADHD)

#### **Evidence Conclusion:**

- The body of evidence is of low quality.
- Variations in the characteristics of EEG-NF protocols, the use of medications while receiving NF treatment, the small sample size, the lack of blinding in a number of studies and the short follow-up periods may have biased the findings.
- Neurofeedback may improve the core symptoms of ADHD in children but did not demonstrate superiority or was not equivalent to pharmacological therapy in reducing ADHD symptoms in children.
- There is insufficient evidence to determine whether Neurofeedback in combination with methylphenidate is effective in reducing the core symptoms of ADHD in children.

**Articles:** The literature revealed a number of articles, but the following articles were selected for critical appraisal: EEG neurofeedback treatments in children with ADHD: an updated meta-analysis of randomized controlled trials (Micoulaud-Franchi et al., 2014) See [Evidence table 1](#). A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder (van Dongen-Boomsma, Vollebregt, Slaats-Willemse, & Buitelaar, 2013) See [Evidence table 2](#). Effects of Neurofeedback versus stimulant Medication in Attention-Deficit/Hyperactivity Disorder: A Randomized pilot study (Meisel, Servera, Garcia-Banda, Cardo, & Moreno, 2014) See [Evidence table 3](#). Effects of Neurofeedback versus stimulant Medication in Attention-Deficit/Hyperactivity Disorder: A Randomized pilot study (Ogrim & Hestad, 2013) See [Evidence table 4](#). A randomised controlled trial of combined EEG feedback and methylphenidate therapy for the treatment of ADHD (Li, Yang, Zhuo, & Wang, 2013) See [Evidence table 5](#).

The use of Electroencephalography (EEG) Neurofeedback (NF) for Attention deficit hyperactivity disorder (ADHD) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Neuropsychiatric EEG-Based Assessment Aid (NEBA)

### 02/10/2014: MTAC REVIEW

**Evidence Conclusion:** There is no published evidence to date to determine the safety, accuracy, or clinical utility of NEBA system in discriminating between children with or without ADHD. The FDA approval was based on a clinical study of 275 children and adolescents with attention and/or behavioral concerns. The study was conducted by the manufacturer of the NEBA system and has not been published in a peer reviewed journal to date. The observational studies on the correlation between the theta/beta ratios (TBR) had their limitations, and their results were inconclusive. In addition (according to Loo, 2012) there are wide variation in EEG instrumentation that can make it very hard to compare or generalize results of studies using different EEG hardware and software.

**Articles:** The literature search did not reveal any published study on the NEBA system; it only identified several observational studies that investigated brain activity using EEG in children with ADHD compared with normal controls, as well as three meta-analyses that pooled the results of a number of these studies.



The use of NEBA does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Biofeedback

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 30 minutes
90876	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 45 minutes
90901	Biofeedback training by any modality
90912	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; initial 15 minutes of one-on-one physician or other qualified health care professional contact with the patient
90913	Biofeedback training, perineal muscles, anorectal or urethral sphincter, including EMG and/or manometry, when performed; each additional 15 minutes of one-on-one physician or other qualified health care professional contact with the patient (List separately in addition to code for primary procedure)
HCPC Codes	Description
E0746	Electromyography (EMG), biofeedback device

### Neuro-biofeedback—

Considered Not Medically Necessary:

CPT® Codes	Description
90875	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 30 minutes
90876	Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); 45 minutes
90901	Biofeedback training by any modality
Dx Codes	Description
F90.0-F90.9	Attention-deficit hyperactivity disorder

### Brain Mapping for neuropsychiatric disorders—

Considered Not Medically Necessary:

CPT® Codes	Description
95961	Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or identify vital brain structures; initial hour of attendance by a physician or other qualified health care professional
95962	Functional cortical and subcortical mapping by stimulation and/or recording of electrodes on brain surface, or of depth electrodes, to provoke seizures or identify vital brain structures; each additional hour of attendance by a physician or other qualified health care professional (List separately in addition to code for primary procedure)
95999	Unlisted neurological or neuromuscular diagnostic procedure
S8040	Topographic brain mapping

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/06/2012	03/06/2012 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	11/05/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/20/2016	Added Electroencephalography (EEG) Neurofeedback (NF) for Attention deficit hyperactivity disorder (ADHD) MTAC review
08/10/2016	Merged NEBA criteria into same document
09/06/2016	Added KPWA policy for Medicare members
05/02/2017	Added indication to cover migraine headaches
10/03/2017	MPC approved to adopt MCG A-0330 summary of findings as criteria language
07/18/2018	Added FEHB language
06/23/2020	Removed deleted CPT code 90911; Added CPT codes 90912 and 90913
12/02/2022	Added Retired LCD L14443
09/05/2023	MPC approved to adopt EEG, Quantitative (Brain Mapping) MCG A-1050. Requires a 60-day notice; effective February 1, 2024.
03/12/2024	Removed urinary conditions from the exclusions list
11/05/2024	Merged Neurofeedback & Brain Mapping with Biofeedback criteria





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Bioimpedance Spectroscopy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Bioimpedance Spectroscopy</b> , for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Bioimpedance Spectroscopy (A-0667) MCG\* for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Lymphedema is a chronic progressive disorder of the lymphatic system characterized by interstitial accumulation of protein rich fluid. This occurs when lymphatic transport is reduced causing lymphatic stasis and subsequent protein accumulation within tissues. Accumulation of protein and fluid in the tissues triggers an inflammatory response and swelling that eventually leads to fibrosis. Primary lymphedema is rare and results from congenital anatomic abnormalities of the lymphatic system such as lymphatic hypoplasia or dysfunction of lymphatic valves. Secondary lymphedema on the other hand, is more common and may result from disease, trauma, surgery, or radiation therapy. In the United States, the most common cause of secondary lymphedema is malignancy and its related treatment, particularly in breast cancer patients treated with axillary surgery and/or

radiation therapy (Warren 2007).

The proportion of women who develop breast cancer-related lymphedema (BCRL) is estimated to range from 3-15% for women who had sentinel node biopsy and up to 49% among those who underwent axillary lymph node dissection. This big variation in reported incidence of lymphedema is due to lack of a standardized assessment and differences in diagnostic criteria. Lymphedema may cause limb swelling, heaviness, pain, pitting of the skin, tightness, inflammation, reduced mobility, and impaired limb function (Taylor 2006, Smoot 2011).

Accurate assessment of lymphedema may facilitate earlier diagnosis and monitoring of treatment response. Physical assessment of BCRL is performed by comparing the affected versus the unaffected arm, or by comparing postoperative with preoperative measurements. Physical measurements used include limb circumferential assessment with a tape measure, and limb volume measurement using water displacement or optoelectrical perometry (also known as infrared volumetry). Circumferential measurement is the most common clinical assessment measure used. Limb circumference is used to calculate volume by assuming either cylindrical or truncated cone geometry. It thus indirectly measures the limb volume and may be confounded by changes in muscle and fat mass. In addition, it may be hard to use for the hand due to its irregular shape. Water volumetry or displacement, in which the limb is lowered in a water tank, has been considered by many as the reference method for determining limb volume. It is a reliable method and provides a way of including volumetric measurements of the hand or foot in the total limb volume measurements. However, water displacement cannot distinguish changes due to fat or muscle from extracellular fluid accumulation. The Perometer is an opto-electrical device that has a square frame in which the extended extremity is placed. The frame emits infrared light and slides up and down scanning the patient's extremity and recording cross sectional information every 3 mm. Limb volume is then calculated based on the assumption that the cross-section is an ellipse or circle. Many investigators consider perometry the modern gold standard for the assessment of limb volume. It is however, bulky in size, not available in most clinics, and cannot be used for bed-ridden patients. In more challenging cases radiologic imaging studies as lymphoscintigraphy, magnetic resonance imaging, or computerized tomography may be necessary to diagnose lymphedema (Sander 2002, Warren 2007, Jain 2010, Czerniec 2010, Smoot 2011).

While circumference and volume measures are reliable measures for changes in limb volume, they are not specific to lymphedema. Bioimpedance analysis (BIA) or bioimpedance spectroscopy (BIS) has been proposed as an alternate method to differentiate the extracellular fluid compartment from the total limb volume. It attempts at measuring lymph volume directly and detecting early increase in the extracellular fluid at a subclinical stage of lymphedema before it manifests as a change limb volume.

BIS is a noninvasive procedure that uses skin electrodes to pass a low-level alternating current through the limb and measures the opposition or impedance to the flow of this current. Current flows along the path of least resistance through the body and thus follows tissues with the highest water content. Tissues as fat and bone act as insulators, while electrolyte body fluids conduct electrical current and as the fluid increases, impedance to current flow decreases, i.e. changes in impedance are inversely proportional to the volume of the extracellular fluid in the extremity the level of impedance is not only a function of the type of tissue, but also the frequency of the current. At low frequencies, cell membranes are non-conductive and current passes only through the extracellular fluid, while at high frequencies, the current passes through cell membranes in addition to the extra- and intracellular fluids. BIS thus gives a measure of electrical impedance and not volume (Warren 2007, Jain 2010, Czerniec 2010).

## Medical Technology Assessment Committee (MTAC)

### *Bioimpedance Lymph Analysis*

#### **06/20/2011: MTAC REVIEW**

**Evidence Conclusion:** The 2010 report prepared for the AHRQ assessed the diagnosis and treatment of secondary lymphedema in general, not specifically for cancer breast-related lymphedema. However, the reviewers indicated that most of the diagnostic studies involved patients with breast cancer. They noted that based on the evidence from the studies reviewed, there does not appear to be a gold standard for grading or measuring the severity of lymphedema. However, based on the extent of use and consistent evidence for reliability and validity, the reviewers of the AHRQ report recommend that measures of limb volume or circumference be considered the gold standard for diagnosing secondary lymphedema. They indicated that

there was very little evidence to allow making conclusions about the reliability of bioimpedance lymph analysis (BIA) which was listed among other tests. BIA was found to have good validity when compared with tape measured circumference or perometry, but lower correlation coefficients than those for the circumference-displacement comparisons. The AHRQ report also indicated that the diagnostic testing studies do not provide sufficient evidence to determine whether any of the test methods would influence the choice of lymphedema treatment or patient outcome. Two more recent studies published after the AHRQ report and critically appraised for this MTAC review do not provide any additional evidence on the accuracy, validity or reliability of BIA, or on its impact on patient management or outcome.

**Articles:** The search revealed a recent comprehensive review on the diagnosis and treatment of secondary lymphedema prepared for the Agency for Healthcare Research and Quality (AHRQ) Technology Assessment (TA) Program in May 2010. The literature search for this AHRQ report was made through January 2010. Two more recent studies that compared the accuracy and/or reliability of BIS to other physical measures used for the assessment of breast cancer-related lymphedema were critically appraised. [Czerniec SA](#), [Ward LC](#), [Refshauge KM](#), et al Assessment of breast cancer-related arm lymphedema--comparison of physical measurement methods and self-report. *Cancer Invest.* 2010; 28:54-62. See [Evidence Table](#). Smoot BJ, Wong JF, Dodd MJ. Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: Area under the curve. *Arch Phys Med Rehabil.* 2011; 92:603-610. See [Evidence Table](#).

The use of bioimpedance lymph analysis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary

CPT® or HCPC Codes	Description
0358T	Bioelectrical impedance analysis whole body composition assessment, with interpretation and report
93702	Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/05/2011	07/05/2011 <sup>MPC</sup> , 05/01/2012 <sup>MPC</sup> , 03/05/2013 <sup>MPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup> , 05/06/2025 <sup>MPC</sup>	01/07/2014

<sup>MPC</sup> Medical Policy Committee

Review History	Description



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Blepharoplasty

- Blepharoptosis
- Brow Lift

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Blepharoplasty, Eyelid Surgery, and Brow Lift (L36286)</a>
Local Coverage Article	<a href="#">Billing and Coding: Blepharoplasty, Eyelid Surgery, and Brow Lift (A57191)</a>

#### For Non-Medicare Members

#### Blepharoplasty, blepharoptosis repair, or brow ptosis repair

Plastic Surgery and/or oculoplastics credentials are preferred for this facial surgery. The above procedures may be medically necessary when **ONE** of following are met:

- I. **Upper eyelid reconstructive blepharoplasty** is considered medically necessary and NOT cosmetic when **ONE of the following** is met:
  - A. Blepharoplasty for the following diagnoses may be considered medically necessary for an affected upper or lower lid without meeting visual loss criteria:
    1. Trichiasis
    2. Ectropion
    3. Entropion
    4. Exposure keratitis
    5. Painful blepharospasm refractory to medical management
  - B. In the absence of one of the conditions listed above **unilateral or bilateral upper lid** may be considered medically necessary for reconstructive purposes when the operative eye **meets ALL of the following** criteria:
    1. Visual field less than 20° above central fixation – (untaped eye) OR limited to 10 to 15 degrees (untaped eye) laterally
    2. Frontal or lateral photograph demonstrates visual field limitation consistent with the visual field examination, AND
    3. Does not have unstable myasthenia gravis or a thyroid condition (No concerns about stability raised by Neurology for myasthenia gravis patients and normal thyroid lab if patient has pre-existing thyroid disease)
    4. **ALL of following** information must be submitted:
      - Visual fields, including physician interpretation
      - MRD1 (marginal reflex distance) measurement
      - Documentation of clinically decreased vision
      - Lateral and full-face photographs

- II. **Upper eyelid ptosis (blepharoptosis) repair** may be considered medically necessary for reconstructive purposes when the operative eye meets **ALL of the following** criteria:
- A. Documented complaints of interference with vision or visual field-related activities causing significant functional impairment (difficulty reading or driving due to eyelid position)
  - B. Photographs demonstrate the eyelid at or below the upper edge of the pupil
  - C. Visual field less than 20° above central fixation
  - D. MRD1 (marginal reflex distance from pupil center to upper eyelid) of 2.0mm or less
  - E. Does not have unstable myasthenia gravis or a thyroid condition
  - F. **ALL of the following** information must be submitted
    - Visual fields, including physician interpretation
    - MRD1 (marginal reflex distance) measurement
    - Documentation of clinical decreased vision
    - Lateral and full-face photographs
- III. **Brow ptosis repair** may be considered medically necessary for reconstructive purposes when **ALL of the following** criteria are met:
- A. Photographs demonstrate the eyebrow is below the super orbital rim
  - B. Visual field less than 20° above central fixation
  - C. MRD1 of 2.0 mm or less
  - D. Cannot be corrected by upper lid blepharoplasty alone
  - E. Frontal or lateral photograph demonstrates visual field limitation consistent with the visual field examination, AND
  - F. Does not have unstable myasthenia gravis or a thyroid condition
  - G. **ALL of the following** information must be submitted:
    - Visual fields, including physician interpretation
    - MRD1 (marginal reflex distance) measurement
    - Documentation of clinically decreased vision
    - Lateral and full-face photographs
- IV. **Blepharoplasty in anophthalmia** is considered medically necessary when the upper eyelid position interferes with the fit of eye prosthesis in the socket.
- V. Blepharoplasty of the lower lids for excessive skin that does not correct a functional issue is considered **cosmetic** under the member benefit.

**If requesting this service, please send the following documentation to support medical necessity:**

- Signed clinical notes supporting a decrease in peripheral vision and/or upper field vision and excessive upper/lower lid skin
- Supporting pre-op lateral and full-face photographs
- Documented subjective patient complaints which justify functional surgery (vision, ptosis, etc.)
- Visual fields, including physician interpretation and recommendations (when applicable)
- MRD1 (marginal reflex distance) measurement (for blepharoptosis or brow ptosis repair)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

This service is covered when it is medically indicated and determined not to be for cosmetic. The Medicare coverage language includes the identification of how to determine medical necessity. This is the language that has been adopted by Kaiser Permanente.

In order to determine coverage, the clinical history submitted by the requesting physician should include the reason for the surgery and the identification of the procedure to be done.

## Evidence and Source Documents

### References:

Kaiser Permanente Coverage Contract Language  
Medicare Coverage Manual /PROW Criteria

Medicare Part B News 180, March 2000, topic 1143 entry #5782, applicable to Washington State. And effective in March 2000 as of publish date.

## Applicable Codes

### Blepharoplasty – Medicare – Considered Not Medically Necessary:

CPT® Codes	Description
15820	Blepharoplasty, lower eyelid;
15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad

### Blepharoplasty – Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
15822	Blepharoplasty, upper eyelid;
15823	Blepharoplasty, upper eyelid; with excessive skin weighting down lid

### Blepharoplasty – Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
15820	Blepharoplasty, lower eyelid;
15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad
15822	Blepharoplasty, upper eyelid;
15823	Blepharoplasty, upper eyelid; with excessive skin weighting down lid

### Blepharoptosis - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
67901	Repair of blepharoptosis; frontalis muscle technique with suture or other material (eg, banked fascia)
67902	Repair of blepharoptosis; frontalis muscle technique with autologous fascial sling (includes obtaining fascia)
67903	Repair of blepharoptosis; (tarso) levator resection or advancement, internal approach
67904	Repair of blepharoptosis; (tarso) levator resection or advancement, external approach
67906	Repair of blepharoptosis; superior rectus technique with fascial sling (includes obtaining fascia)
67908	Repair of blepharoptosis; conjunctivo-tarso-Muller's muscle-levator resection (eg, Fasanella-Servat type)
67909	Reduction of overcorrection of ptosis

### Repair of Brow ptosis - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
------------	-------------



<b>67900</b>	Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)
--------------	--

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/30/1998	05/04/2010 <sup>MDCRPC</sup> , 03/01/2011 <sup>MDCRPC</sup> , 01/03/2012 <sup>MDCRPC</sup> , 11/06/2012 <sup>MDCRPC</sup> , 09/03/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 08/02/2024 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/27/2015	Added new LCD L35536
09/08/2015	Revised LCD to L36281, L34886, L35008
10/04/2016	Added indication: OR limited to 10 to 15 degrees (untapped eye) laterally
06/15/2019	Added indication: Does not have unstable myasthenia gravis or a thyroid condition (No concerns about stability raised by Neurology for myasthenia gravis patients and normal thyroid lab if patient has pre-existing thyroid disease)
07/07/2020	Added Medicare LCA (A57191)
08/04/2020	Added Medicare LCA (A57642); MPC approved to adopt updates to clinical criteria for non-Medicare, separating indications for blepharoplasty and blepharoptosis repair.
02/04/2025	MPC approved to endorse credentialing preferences for Facial Surgery. 60-day notice is not required.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Bone Lengthening

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Bone Lengthening</b> ", for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

Bone lengthening procedures may be considered medically necessary for correction of congenital or post-traumatic limb length discrepancies; and/or angular deformities of the limb (arm, forearm, thigh or leg) when ANY ONE of the following are met:

- Demonstrable non-union or mal-union of long bone with or without bone loss or infection;
- Where lengthening of an amputation stump is needed for proper fitting of a prosthesis;
- Where leg lengthening is needed to equalize leg length discrepancy greater than 6 cm
- For correction of congenital or post-traumatic angular-rotational deformations of the long bones;
- When used for bone defects with or without deformities.

Bone lengthening for conditions other than the above is not medically necessary and, therefore, is not eligible for payment.

Use of a bone-lengthening device for the sole purpose of altering short stature is considered cosmetic; and is therefore, not covered.

Insertion of wires and subsequent osteotomy of the affected limb are performed in the hospital. Removal of the device can be performed in an outpatient setting; thus, hospitalization to remove the bone lengthening device is not medically necessary.

**NOTE:** Non-union/mal-union is defined as not having united within a minimum of three (3) months of the original trauma.

#### **For covered criteria:**

If requesting this service (or these services), please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Hayes Health Technology Assessment

### Limb-Lengthening Surgery for Short Stature

**Synopsis of the Clinical Evidence:** The literature search identified eight uncontrolled studies that evaluated limb-lengthening surgery for short stature. Results of these studies suggest that patients who have a wide variety of causes for short stature can undergo 7 to 10 cm of limb lengthening. Although serious or severe complications can occur during this procedure that may necessitate additional surgery, these complications are rarely life threatening. Since the available studies do not provide evidence that limb-lengthening surgery improves patient health or quality of life, this procedure must be considered elective and cosmetic.

Insights:

The available evidence suggests that limb-lengthening surgery can increase patient height; however, serious and severe complications can arise during this procedure. Since limb-lengthening surgery for short stature is elective and cosmetic, hospitals should not adopt this procedure unless they are willing to arrange for patients to cover the high costs for this procedure without any reimbursement from insurers.

Demand for limb-lengthening surgery for short stature will likely increase slowly due to societal pressures and the paucity of other options for adults to increase their height or apparent height.

Hayes. Hayes Technology Assessment. Limb-Lengthening Surgery for Short Stature. Dallas, TX: Hayes; Jul 2, 2010. Retrieved September 16, 2024, from <https://evidence.hayesinc.com/report/htb.limblength>

## References

- Aquarius R, Van Kampen A, & Verdonshot N. (2007). Rapid pre-tension loss in the Ilizarov external fixator: An in vitro study. *Acta Orthopaedica*, 78(5), 654–660.
- Kristiansen LP, & Steen H. (2002). Reduced lengthening index by use of bifocal osteotomy in the tibia: Comparison of monofocal and bifocal procedures with the Ilizarov external fixator. *Acta Orthopaedica Scandinavica*, 73(1), 93–97. <https://doi.org/10.1080/000164702317281486>
- Kristiansen LP, Steen H, & Reikerås O. (2006). No difference in tibial lengthening index by use of Taylor Spatial Frame or Ilizarov external fixator. *Acta Orthopaedica*, 77(5), 772–777. <https://doi.org/10.1080/17453670610012971>
- Kristiansen LP. (2009). Reconstructive surgery of the human tibia by use of external ring fixator and the Ilizarov method. *Acta Orthopaedica (Supplement)*, 80, 1–43. <https://doi.org/10.1080/000164702317281486>
- Lee DK, Duong ETA, & Chang DG. (2010). The Ilizarov method of external fixation: current intraoperative concepts. *AORN Journal*, 91(3), 326–340. <https://doi.org/10.1016/j.aorn.2009.11.064>
- Moraal JM, Elzinga-Plomp A, Jongmans MJ, Roermund PM, Flikweert PE, Castelein RM, & Sinnema G. (2009). Long-term psychosocial functioning after Ilizarov limb lengthening during childhood: 37 patients followed for 2-14 years. *Acta Orthopaedica*, 80(6), 704–710. <https://doi.org/10.3109/17453670903473024>
- Oostenbroek HJ, Brand R, & van Roermund PM. (2009). Growth rate after limb deformity correction by the Ilizarov method with or without knee joint distraction: lengthening in 30 children followed for at least 2 years. *Acta Orthopaedica*, 80(3), 338–343. <https://doi.org/10.3109/17453670903025345>
- Popkov, A. V., Kononovich, N. A., Filimonova, G. N., Gorbach, E. N., & Popkov, D. A. (2019). Bone Formation and Adaptive Morphology of the Anterior Tibial Muscle in 3-mm Daily Lengthening Using High-Fractional

Automated Distraction and Osteosynthesis with the Ilizarov Apparatus Combined with Intramedullary Hydroxyapatite-Coated Wire. *BioMed Research International*, 1–8. <https://doi.org/10.1155/2019/3241263>

Yanuka M, Krasin E, Goldwirth M, Cohen Z, & Otremski I. (2000). Ankle arthrodesis using the Ilizarov apparatus: Good results in 6 patients. *Acta Orthopaedica Scandinavica*, 71(3), 297–300. <https://doi.org/10.1080/000164700317411915>

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>24420</b>	Osteoplasty, Humerus (e.g., shortening or lengthening) excluding 64876)
<b>25391</b>	Osteoplasty, radius OR ulna; lengthening with autograft
<b>25393</b>	Osteoplasty, radius AND ulna; lengthening with autograft
<b>27466</b>	Osteoplasty, femur; lengthening
<b>27715</b>	Osteoplasty, tibia and fibula, lengthening or shortening
<b>0594T</b>	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/02/2024	04/02/2024 <sup>MPC</sup> , 09/03/2024 <sup>MPC</sup>	

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/02/2024	MPC approved to adopt criteria for Bone Lengthening Medicare and Non-Medicare members. Requires 60-day notice, effective date 09/01/2024.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Osteogenic (Bone) Stimulators

- Non-invasive Electrical Stimulators
- Implantable Electric Stimulators
- Ultrasonic Stimulators

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Osteogenic Stimulators (150.2)</a>
Local Coverage Determinations (LCD)	<a href="#">Osteogenesis Stimulators (L33796)</a>
Local Coverage Article	<a href="#">Osteogenesis Stimulators (A52513)</a>

#### For Non-Medicare Members

##### Electric Bone Growth Stimulators (Non-invasive and Implantable)

Kaiser Permanente has elected to use the Bone Growth Stimulators, Electrical and Electromagnetic (A-0565) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

##### Ultrasonic Bone Growth Stimulators

Kaiser Permanente has elected to use the Bone Growth Stimulators, Ultrasonic (A-0414) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### If requesting these services, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist (Orthopedics/podiatry)
- Copies of last 12 months of x-rays of involved area

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Electrical stimulation has been used as treatment for nonunion of fractures since the early 1950's with a reported success rate of 80-85%. New devices have made the use of this method of treatment more attractive. Bone Stimulators are covered in Kaiser Permanente plans that include coverage for durable medical equipment. The criteria for coverage had previously been part of the Durable Medical Equipment Formulary. The average contracted cost of the device is \$3,000. Because of the renewed attention on this mode of treatment by Kaiser



Permanente orthopedists, the referral management staff requested that clearer criteria be developed for reviewing coverage requests (1/97).

Fracture healing is a highly complex biological process. The healing process is delayed in approximately 10% of the 6 million fractures that occur annually in the United States. A portion of these delayed unions do not heal by 9 months after fracture and are categorized as non-unions (Hadjiargyrou, 1998). There are two types of bone growth stimulators: electric and ultrasonic.

Electrical stimulation has been found to offer a reasonable means of treatment for nonunion that have failed to respond to previous bone grafting over an extended period of time. The effective use of electrical stimulation devices requires an understanding of the various principles and concepts employed by the four types of stimulators currently available. While the exact mechanism of electrically induced osteogenesis is uncertain, current theories indicate that several factors probably are involved, and more than one mechanism may be responsible.

Ultrasound, a form of mechanical energy that is transmitted through and into biological tissues, has a variety of diagnostic and therapeutic clinical applications. Research on the use of ultrasound to accelerate the healing of fractures has been done largely using animal models. For example, a study with rabbits found that bones exposed to ultrasound healed in about half the time as untreated bones. Data from animal models suggest that ultrasound may accelerate healing by increasing the blood flow at the fracture site (Rubin, 2001).

Exogen (Smith and Nephew) manufactures a low-intensity ultrasound device for treating fractures, Sonic Accelerated Fracture Healing System (SAFHS). According to the manufacture, the SAFHS system is a portable, battery-operated device that produces ultrasonic waves of 30 milliwatts per cm<sup>2</sup> (comparable to ultrasound intensity levels used on sonograms for fetal monitoring). Patients apply the ultrasound waves directly to the fracture site.

The FDA approved the use of low-intensity ultrasound for fresh fractures in 1994 based on two randomized controlled trials and Exogen's registry data. In 2000, the FDA extended the use of ultrasound to treating established non-unions.

## Medical Technology Assessment Committee (MTAC)

### Ultrasonic Bone Stimulator

#### 10/10/2001: MTAC REVIEW

**Evidence Conclusion:** *Fresh fractures:* Two of the RCTs (Heckman, Kristiansen) were conducted by some of the same investigators. Both found a significantly shorter time to healing for fractures in patients treated with an ultrasonic bone stimulator healed than those treated with a placebo device. Both studies had similar methodological flaws, the most serious of which was that neither study had a primary intention to treat analysis and about 30% of fractures were not included in the analysis. Both studies include a brief description of a secondary intention-to-treat analysis which found statistically significant differences between the ultrasonic bone stimulation and placebo groups; no point estimates, tables or figures were included to support these analyses. Both studies were funded by Exogen and included co-authored by an Exogen employee which could bias the study design and analysis. A third RCT was conducted by investigators without financial ties to Exogen. That study did not find a significant difference in time to radiographic healing between patients receiving ultrasonic bone stimulation versus placebo. This was a small study which may not have had sufficient statistical power to detect a difference if one existed. The threats to validity in the RCTs limit the ability to draw conclusions about the effect of ultrasonic bone stimulation on health outcomes among patients with fresh fractures. *Non-union fractures:* There were no published articles to evaluate the efficacy of ultrasound treatment to heal non-union fractures.

**Articles:** The search yielded 35 articles. Articles that were opinion pieces, editorials, reviews or on technical aspects of the treatment of fractures with ultrasound were not reviewed. There were 3 RCTs on the use of ultrasound with fresh fractures. Evidence tables were created for these 3 RCTs. There were no published articles on non-union fractures. There was one published abstract by Gebauer, but insufficient information was given in the abstract to evaluate it as evidence. *Citations for the RCTs reviewed:* Emami A, Petren-Mallmin M, Larsson S. No effect of low-intensity ultrasound on healing time of intramedullary fixed tibial fractures. J Orthop Trauma 1999; 13: 252-7. See [Evidence Table](#). Kristiansen TK, Ryabi JP, McCabe J, Frey JJ, Roe LR. Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. J Bone Joint Surg 1997; 79-A: 961-73. See [Evidence Table](#). Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive low-intensity pulsed ultrasound. J Bone Joint Surg 1994; 76-A: 26-34. See [Evidence Table](#)

The use of Ultrasonic Bone Stimulator for treatment of fresh and non-union fractures has been approved by the FDA and therefore meets *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Electrical Bone Growth Stimulator:

**Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met

CPT® or HCPC Codes	Description
20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative)
20975	Electrical stimulation to aid bone healing; invasive (operative)
E0747	Osteogenesis stimulator, electrical, noninvasive, other than spinal applications
E0748	Osteogenesis stimulator, electrical, noninvasive, spinal applications
E0749	Osteogenesis stimulator, electrical, surgically implanted

**Non-Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® or HCPC Codes	Description
20974	Electrical stimulation to aid bone healing; noninvasive (nonoperative)
20975	Electrical stimulation to aid bone healing; invasive (operative)
E0748	Osteogenesis stimulator, electrical, noninvasive, spinal applications
E0749	Osteogenesis stimulator, electrical, surgically implanted

**Non-Medicare:** Considered not medical necessary

CPT® or HCPC Codes	Description
E0747	Osteogenesis stimulator, electrical, noninvasive, other than spinal applications

### Ultrasonic Bone Growth Stimulator:

**Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met

CPT® or HCPC Codes	Description
20979	Low intensity ultrasound stimulation to aid bone healing, noninvasive (nonoperative)
E0760	Osteogenesis stimulator, low intensity ultrasound, noninvasive

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Dates Reviewed	Date Last Revised
--------------	----------------	-------------------

09/25/1997	06/01/2010 <sup>MDCRPC</sup> , 04/05/2011 <sup>MDCRPC</sup> , 02/07/2012 <sup>MDCRPC</sup> , 12/04/2012 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 08/05/2014 <sup>MPC</sup> , 06/02/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 03/07/2017 <sup>MPC</sup> , 01/09/2018 <sup>MPC</sup> , 12/04/2018 <sup>MPC</sup> , 12/03/2019 <sup>MPC</sup> , 12/01/2020 <sup>MPC</sup> , 12/07/2021 <sup>MPC</sup> , 12/06/2022 <sup>MPC</sup> , 12/09/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	01/09/2024
------------	---	------------

Revision History	Description
06/11/2015	CPT codes added
01/08/2019	MPC adopted hybrid criteria for Ultrasonic Bone Growth Stimulators (KP-0414)
04/03/2023	Updated Medicare links
11/6/2023	Updated codes section and Medicare links
01/09/2024	MPC approved to adopt non-hybridized criteria MCG Bone Growth Stimulators Ultrasonic MCG A-0414. Requires 60-day notice, effective June 1st, 2024.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Benign Prostatic Hyperplasia (BPH) Treatments

- Aquablation (Transurethral Waterjet Ablation of the Prostate)
- Rezūm System for the Treatment of LUTS due to BPH
- Prostatic Urethral Lift (PUL or UroLift)
- Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Therapeutic Embolization (20.28)</a>
Local Coverage Determinations (LCD)	<a href="#">Transurethral Waterjet Ablation of the Prostate (L38707)</a>
Local Coverage Article	Urolift: <a href="#">Local Coverage Article: Urolift (A54044)-RETIRED</a> Noridian retired Local Coverage Article (LCA A54044). These services still need to meet medical necessity as outlined in the LCA and will require review. LCAs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCAs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on Kaiser Permanente commercial criteria or literature search.
Medicare Coverage Related to Investigational Device Exemption (IDE) Studies	<b>Prostate Artery Embolization:</b> This procedure is considered experimental and investigational and is <b><i>not recommended</i></b> outside of a clinical trial setting. Procedure is covered when part of an approved Investigational Device Exemption (IDE) trial. There are multiple CMS-approved IDE studies underway <a href="https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies">https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies</a> .
Kaiser Permanente Medical Policy	<b>Rezūm:</b> Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "Rezūm System for the Treatment of LUTS due to BPH," for medical necessity determinations. Use the Non-Medicare criteria below.

## For Non-Medicare Members

Service	Criteria
Transurethral Waterjet Ablation	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
UroLift	<p>Covers prostatic urethral lift (e.g., UroLift) as medically necessary for the treatment of symptomatic benign prostatic hyperplasia (BPH) when <b>ALL of the following</b> criteria are met:</p> <ul style="list-style-type: none"> <li>A. age 50 or above</li> <li>B. prostate volume &lt; 80 cc on ultrasound imaging</li> <li>C. no obstructive median lobe of the prostate identified on cystoscopy</li> <li>D. failure, contraindication or intolerance to at least six months of conventional medical therapy for BPH (e.g., at least one drug trial from one of the following categories: alpha blocker, PDE5 Inhibitor, finasteride/dutasteride)</li> </ul> <p><b>If requesting this service, please send the following documentation to support medical necessity:</b></p> <ul style="list-style-type: none"> <li>• Last 6 months of clinical notes from requesting provider &amp;/or specialist</li> </ul>
Rezūm System for the Treatment of LUTS due to BPH	<p>Water vapor thermal therapy (e.g., Rezūm System) is considered medically necessary for the treatment of symptomatic benign prostatic hyperplasia (BPH) when ALL of the following criteria are met:</p> <ul style="list-style-type: none"> <li>• age 50 years or above</li> <li>• estimated prostate volume ≥ 30 cm<sup>3</sup> and ≤ 80 cm<sup>3</sup></li> <li>• failure, contraindication or intolerance to at least six months of conventional medical therapy for BPH (e.g., at least one drug trial from one of the following categories: alpha blocker, PDE5 Inhibitor, finasteride/dutasteride)</li> </ul> <p><b>If requesting this service, please send the following documentation to support medical necessity:</b></p> <ul style="list-style-type: none"> <li>• Last 6 months of clinical notes from requesting provider &amp;/or specialist</li> </ul>
Prostate artery embolization for benign prostatic hyperplasia (BPH)	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.</p> <p><b>If requesting review for these services, please send the following documentation:</b></p> <ul style="list-style-type: none"> <li>• Last 6 months of clinical notes from requesting provider &amp;/or specialist</li> </ul>
High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer	<p>Please see criteria <a href="#">here</a>.  <i>*Not covered for BPH Treatments</i></p>

## Background

Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common urologic condition that affects 14-30% of men 50 years of age or older. The enlarged prostate is often associated with progressive obstructive lower urinary tract symptoms (LUTS), which may impair the quality of life in older men. Common signs and symptoms of LUTS secondary to BPH include nocturia, frequent or urgent need to urinate, difficulty starting urination, weak urine stream or a stream that stops and starts, dribbling at the end of urination, and inability to completely empty the bladder. The severity of these symptoms varies among patients, but they tend to increase with age (Dixon 2016, Darson 2017, Helo 2017).

The treatment of LUTS depends on the patient's symptoms and level of bother. Therapeutic options include

- Watchful waiting (active surveillance) for patients with mild symptoms of LUTS secondary to BPH and for patients with moderate-to-severe symptoms who are not bothered by their symptoms and are not experiencing complications of BPH.
- Lifestyle modification is initially recommended for patients with bothersome LUTS that begin affecting their quality of life.
- Drug therapy (e.g. alpha-blockers, 5-alpha-reductase inhibitors, muscarinic receptor antagonists and phosphodiesterase 5, inhibitors) is an appropriate and effective treatment for patients with bothersome, moderate to severe LUTS secondary to BPH.
- Surgical intervention is appropriate for patients with moderate-to-severe LUTS, acute urinary retention, or other complications due BPH. Surgery is the most invasive option for BPH management and is generally performed in patients will have failed medical therapy. However, some patients may wish to pursue the most effective therapy as a primary treatment if their symptoms are particularly bothersome (American Urological Association Guideline).

Transurethral resection of the prostate (TURP) and open simple prostatectomy are currently the gold standard surgical interventions. Both are highly effective and provide durable improvement in urinary functional outcomes. However, despite the refinements made in the operative technique, these invasive procedures are associated with perioperative complications and morbidity including bleeding, erectile and ejaculatory dysfunction, urethral stricture, urinary tract infection, and urinary incontinence (Chung 2018, Christidis 2017, Magistro 2017).

Several novel minimally invasive therapies have been developed, or are at different stages of development, with the aim of improving the patients' symptoms and avoiding the adverse outcomes of associated with the more invasive surgeries. Among these therapies are the UroLift System, intraprostatic injectables, temporary implantable nitinol device, image guided robotic waterjet ablation, transurethral microwave therapy (TUMT), convective water vapor energy (WAVE) ablation, prostatic artery embolization, and others. An ideal minimally invasive treatment would be an intervention that can be easily performed in the office or in an outpatient setting, leads to rapid and durable relief of symptoms, is associated with minimal morbidity and recovery time, and preserves the erectile and ejaculatory functions of the patient (Chung 2018, (Magistro 2017).

Rezūm System; NxThera, Inc. Maple Grove, MN) is a minimally invasive transurethral therapy that uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms. Tissue ablation with Rezūm System uses the thermodynamic principle of convection energy transfer in contrast to conductive heat transfer techniques used in the transurethral microwave therapy or transurethral needle ablation. The Rezūm system utilizes radiofrequency (RF) to generate wet thermal energy in the form of water vapor (steam). Once the vapor (103oC) is injected, it disperses through the tissue spaces and immediately changes to liquid releasing and delivering approximately 208 cal of thermal energy in 9 seconds. The target tissue temperature reaches 70o resulting in irreversible and near instantaneous cell death. No thermal effects occur outside the prostate or in the peripheral zone when a transition zone is targeted. In addition, as the vapor is wet thermal energy, there is no charring, desiccation, or carbonization of the treated tissue. The dead tissue will be eventually absorbed by the body through its natural healing response (Dixon 2016, Christidis 2017, Woo 2017 Magistro 2017).

The Rezūm System is composed of a generator containing a radiofrequency power supply to create water vapor from sterile water, and a single use transurethral delivery device that incorporates a standard 4 mm 30o rod lens allowing the procedure to be performed under direct cystoscopic visualization. The tip of the delivery device



contains an 18-gauge polyether ether ketone needle which has 12 small emitter holes spaced around its tip at 120° intervals to allow for circumferential dispersion of water vapor into the prostate tissue. (Darson 2017, Woo 2017).

The procedure is performed in the clinic or out-patient setting, under cystoscopic guidance and oral sedation. Radiofrequency energy is applied to a few drops of water (0.5ml) to create vapor inside a hand-held device. The patient is placed in the lithotomy position and the delivery device is inserted into the urethra; the total penetrating length of the vapor needle is fixed at 10.25mm. Its tip is visually positioned and inserted approximately 1cm distal to the bladder neck. Once the delivery system is within the prostate, the needle is deployed, and a 9-second burst of water vapor is injected into the prostatic tissue. This disperses rapidly and homogeneously through the tissue spaces and immediately condenses to water releasing the energy stored in the vapor into the cell membranes causing cell death and necrosis. The needle is retracted after each treatment and repositioned in 1cm increments distal from the previous site with the objective of creating adjacent overlapping lesions running parallel to the natural slope of the urethra. Usually 1-3 injections are needed for each lateral lobe and 1-2 injections for the median lobe. The total number of injections may vary according to size of the hypertrophied prostate tissue and the length of the urethra (McVary 2016, Woo 2017, Chung 2018).

Potential procedure-related side effects include acute urinary retention, failure of the procedure requiring secondary surgery, posttreatment dysuria, hematuria, frequency & urgency, hematospermia and urinary tract infection. According to the manufacturer, most of these events resolve within 3 weeks of the procedure, but there is a possibility that some may last longer.

## Medical Technology Assessment Committee (MTAC)

### **Convection Radiofrequency Thermal Therapy with Rezūm System (convective water vapor energy [WAVE] ablation) for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hypertrophy** 04/21/2018: MTAC REVIEW

#### **Evidence Conclusion:**

- There is no published evidence to determine the comparative efficacy and safety of convection radiofrequency thermal therapy with the Rezūm System and transurethral resection of the prostate (TURP), open simple prostatectomy, or other noninvasive intervention currently used in practice for relieving bothersome lower urinary tract symptoms secondary to benign prostatic hypertrophy.
- The published literature on Rezūm System consisted of one relatively small randomized sham- controlled trial with a duration of three months after which it was converted to an observational study comparing outcomes to baseline data, as well as a small pilot study and two retrospective analyses with no control groups and overall poor quality.
- The published literature only provides low quality evidence suggesting that treatment with Rezūm System may improve LUTs secondary to BPH compared to sham therapy or no treatment.

**Articles:** The literature search for studies on the efficacy and safety of Rezūm system for the treatment LUTS secondary to BPH, identified one randomized sham-controlled trial that reported three years follow-up results in 4 publications (McVary 2015, 2016 & 2018, and Roehrborn 2017), as well as three pretest- posttest studies (one small pilot study with 2 years follow up results [Dixon 2012, and 2016] and two retrospective analyses [Darson 2017 and Mollengarden 2017]). All 4 studies were critically appraised. [See Evidence Table 1.](#)

The use of Rezūm System (convective water vapor energy [WAVE] ablation) for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hypertrophy does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Rezūm for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)** 03/04/2019: INTC REVIEW

**Evidence Conclusion:** There is insufficient evidence to draw a conclusion on use of Rezūm. The existing evidence is of insufficient quantity and quality.

**Articles:** The published literature on Rezūm System consisted of one relatively small randomized sham-controlled trial with a duration of three months after which it was converted to an observational study comparing outcomes to baseline data, as well as a small pilot study and two retrospective analyses with no control groups and overall poor quality. Two indirect comparisons of Rezūm versus other medical therapy trial data were also reviewed.

The available published literature provided low quality evidence suggesting that treatment with Rezūm System may improve LUTs secondary to BPH compared to sham therapy or no treatment.  
[https://cl.kp.org/pkg/national/cpg/intc/topics/03\\_04\\_191.html](https://cl.kp.org/pkg/national/cpg/intc/topics/03_04_191.html)

### **Prostatic Urethral Lift (PUL or UroLift) for the treatment of benign prostatic hyperplasia (BPH)**

**03/21/2016: MTAC REVIEW**

**Evidence Conclusion:** Conclusion from INTC review - “Urolift may be viable alternative to TURP for patients with LUTS secondary to BPH. Short-term data from low to moderate quality, industry-funded studies conclude that Urolift is effective and safe. The overall quality of the evidence is low to moderate. However, due to concerns regarding risk of bias in these studies, a definitive conclusion regarding the long-term safety and effectiveness of UroLift cannot be made from existing evidence. Additional, high quality studies with longer follow-up are needed to confirm preliminary findings”.

**Articles:** Since the search did not identify new studies, and because INTC evidence review is recent, their review can be adopted. In addition, the search did not find studies comparing PUL to medical management. [See Summary of RCTs.](#)

The use of Prostatic Urethral Lift (PUL or UroLift) for the treatment of benign prostatic hyperplasia (BPH) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Prostatic Urethral Lift (PUL or UroLift) for the treatment of benign prostatic hyperplasia (BPH)**

**06/28/2017: MTAC REVIEW**

**Evidence Conclusion:** One study (C Roehrborn et al., 2016) ([See Evidence Table 1](#)) assessed the long term (4 years) effectiveness and safety of PUL. PUL was compared to sham control. Characteristics of patients were similar. Patients were randomized to either PUL (N=140) or sham control (N=66) at 19 centers in North America and Australia and followed for 4 years. The authors reported that Urolift improved urinary symptoms, preserved sexual and ejaculatory function with minor adverse events. The authors indicated that durability of these effects needs to be confirmed at 5-year follow-up. The risk of bias is unclear for incomplete outcome data and the major limitation is the high attrition rate. The author of the previous study (Claus Roehrborn et al., 2017) ([See Evidence Table 2](#)) confirmed the durability of PUL effects in the 5-year follow-up study. Urinary symptoms (IPSS), BPHII, flow rate (Qmax), QoL, erectile and ejaculation functions were improved and /or preserved with minimal complications. Another abstract was reviewed (Henry Woo). Comparison was made between PUL and sham. This was a crossover study wherein 53 patients were enrolled. Patients were treated with sham, then crossover occurred, and patients were followed for 4 years. Compared to baseline, IPSS, QoL, and BPHII statistically improved at 45%, 49%, and 44% respectively (P<0.001). Flow rate (Qmax) also increased by 50% (P=0.01). Adverse events were mild. Level of evidence: In the first two studies, the risk of bias is unclear for incomplete outcome data and low in other domains of risk of bias assessment; no serious precision or directness issues were identified; findings were consistent; the quality of the study assessed by Modified Jadad Scale is high. The studies provide moderate evidence to support the use of PUL.

Conclusion:

- The long-term effectiveness and safety are based on three articles that compare PUL versus sham over 4 and 5 years. Compared to sham, moderate level of evidence indicates that PUL is effective and durable in patients with LUTS due to BPH on the long-term.
- The technology is also safe with minimal complications.

**Articles:** Three articles were reviewed: Roehrborn, C., Gange, S., Shore, N., Giddens, J., Bolton, D., Cowan, B., Rukstalis, D. (2016). Prospective, randomized, blinded study of Prostatic Urethral Lift (pul): four-year results. *BJU Int*, 117, 19-20. Roehrborn, C., Gange, S., Shore, N., Giddens, J., Bolton, D., Cowan, B., Te, A. (2017). PD27-01. 5 year prospective, randomized, controlled study results on the minimally invasive prostatic urethral lift (PUL). *J Urol*, 197(4), e511. Crossover study on the prostatic urethral lift (pul): 4-year results. Henry Woo, Sydney, Australia; Jack Barkin, Toronto, Canada; Damien Bolton, Heidelberg, Australia; Prem Rashid, Port Macquarie, Australia; Anthony Cantwell, Daytona Beach, FL; William Bogache, Myrtle Beach, SC; Stephen Richardson, Salt Lake City, UT; Ronald Tutrone, Baltimore, MD; James Fagelson, Englewood, CO; Peter Chin, Figtree, Australia

The use of Prostatic Urethral Lift (PUL or UroLift) for the treatment of benign prostatic hyperplasia (BPH) does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Prostate artery embolization for benign prostatic hyperplasia (BPH)**

**10/14/2019: MTAC REVIEW****Evidence Conclusion:**

- Low-quality evidence shows that prostatic artery embolization (PAE) may be less effective than TURP in terms of patient-reported and functional outcomes on the short-term.
- Low-quality evidence suggests that PAE may cause fewer complications than TURP, preserve erectile function, and decrease the duration of hospitalization. More RCTs with enough power and longer follow-up are warranted.
- There is insufficient evidence to compare PAE vs open prostatectomy.

**Articles:** PubMed search was conducted up to August 8, 2019 with the search terms prostate artery embolization. Other search terms included low urinary tract symptoms or LUTS, and benign prostatic hyperplasia or BPH. The search yielded 7 meta-analyses. Of these, four were retained (two meta-analyses with comparative studies and two with noncomparative studies). The other meta-analyses are included in other references because their findings are similar to that of the two meta-analyses of noncomparative studies retained.

In addition, the search yielded 8 RCTs. Of the 8 RCTs, none was retained (RCTs were either included in meta-analysis or were out of scope). Regarding nonrandomized studies, search yielded 18 studies, but none was included due to their inclusion in the meta-analyses of noncomparative studies. The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. [See Evidence Table.](#)

The use of Prostate artery embolization for benign prostatic hyperplasia (BPH) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

***Transurethral Waterjet Ablation (Aquablation, Hydroablation)*****04/10/2023: MTAC REVIEW****Evidence Conclusion:**

- There is insufficient published evidence, to date, to determine that Aquablation therapy is safer and more effective than TURP, robotic simple prostatectomy, or other minimally invasive procedures in improving lower urinary tract symptoms attributed to BPH, in men with small, moderate, or large volume prostates.
- The body of evidence on Aquablation for the treatment of lower urinary tract symptoms due to BPH, consists of a single relatively small randomised controlled study (WATER trial) with limitations, several case series, conducted in different countries, and meta-analyses pooling their results. Except for WATER sub-study and WATER II studies, all the other single arm studies included men with any prostate volume (ranging from 20-154 cc). All were sponsored by PROCEPT BioRobotics the manufacturer of the device used in Aquablation which can bias the research results.
- Though the published literature includes a RCT showing that aquablation is not inferior to TURP, and may be associated with better ejaculatory function and less adverse events in highly selected participants with LUTS/BPH and prostate volume 30-80ml, the study had its limitations and risk of bias, that lowers the certainty of evidence it provides.
- More independent randomized controlled trials are needed to confirm and /or provide more evidence on the comparative safety and efficacy of Aquablation therapy to other surgical or minimally invasive procedures currently used in practice for the treatment of LUTS attributed to BPH, in men with prostate volumes up to 80 cc and in men with larger prostate volumes.

**Articles:** The literature search for published studies comparing transurethral aquablation of the prostate versus TURP, robotic prostatectomy, or other MITs, identified one phase 3 multicenter, international clinical trial (WATER [Gilling et al, 2018, 2019, 2020 and 2022]) that compared Aquablation therapy vs. TURP for the treatment of LUTS/BPH in men with prostate volume 30-80 ml. Other published studies on Aquablation for BPH consisted of several small to relatively small prospective, multicenter, or single center studies without controls or comparison groups, as well as three systematic reviews with meta-analyses (Hwang, et al, 2019, Manfredi, et al, 2022, and Chen, et al, 2022), two network meta-analyses (Sajan, et al, 2022, and Tanneru, et al 2021), that indirectly compared the outcome of different minimally invasive treatments for BPH; and several qualitative systematic reviews.

The search did not identify any RCT that directly compared Aquablation to TURP in men with prostate volume larger than 80 ml, or any RCT that compared Aquablation versus simple prostatectomy, laser ablation of the prostate,

laser enucleation of the prostate, REZUM, or any other minimally invasive therapy in men with prostate volume less or greater than 80 ml.

WATER trial was selected for critical appraisal. The single-arm studies and two meta-analyses (Chen, et al, 2022, and Manfredi et al, 2022) were also reviewed. The Cochrane review (Hwang, et al 2019) only included the WATER trial, and its assessment of the trial is a briefly summarized. The network meta-analyses with no direct comparison between aquablation and other interventions, were excluded from the current review of the technology. [See Evidence Table.](#)

## Hayes Technology Assessment

Aquablation therapy is a minimally invasive procedure that ablates overgrown prostatic tissue in order to restore patency to the urethral passageway. High-velocity saline is sprayed under robotic guidance in order to ablate only the targeted prostatic tissue while sparing all surrounding tissue.

### Conclusion

A low-quality body of mainly single-arm studies suggests Aquablation may improve LUTS associated with BPH at short- to intermediate-term follow-up without impact on sexual function or serious safety issues. One comparative study suggests Aquablation may be comparable to TURP; however substantial uncertainty remains due to the paucity of comparative evidence and the limited long-term evidence regarding the durability and safety of Aquablation. Furthermore, clarity is lacking as to which patient populations are likely to benefit the most from Aquablation therapy.

### Hayes Rating: C

Hayes. Hayes Technology Assessment. *Aquablation for Treatment of Benign Prostatic Hyperplasia*. Dallas, TX: Hayes; March 30, 2021. Retrieved January 18, 2023, from <https://evidence.hayesinc.com/report/htb.aquablation5017>

## Applicable Codes

### Transurethral Waterjet Ablation –

**Medicare – Considered Medically Necessary when the criteria in the applicable policy statements listed above are met**

**Non-Medicare - Considered Not Medically Necessary**

CPT® Codes	Description
<b>0421T</b>	Transurethral waterjet ablation of prostate, including control of post-operative bleeding, including ultrasound guidance, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included when performed)
HCPC Codes	Description
<b>C2596</b>	Probe, image guided, robotic, waterjet ablation

**Urolift - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>52441</b>	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant

<b>52442</b>	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)
<b>HCPC Codes</b>	<b>Description</b>
<b>C9739</b>	Cystourethroscopy, with insertion of transprostatic implant; one to three implants
<b>C9740</b>	Cystourethroscopy, with insertion of transprostatic implant; four or more implants

**Rezüm –**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>53854</b>	Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermotherapy

**Prostate Artery Embolization (PAE) - Considered Not Medically Necessary:**

<b>CPT® Codes</b>	<b>Description</b>
<b>37242</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)
<b>37243</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction
<b>ICD-10 Codes</b>	<b>Description</b>
<b>D29.1</b>	Benign neoplasm of prostate
<b>N35.010- N35.016; N35.1- N35.919</b>	Urethral stricture
<b>N40.0-N40.1</b>	Enlarged prostate (EP)
<b>N40.2-N40.3</b>	Nodular prostate
<b>N42.30</b>	Unspecified dysplasia of prostate
<b>N42.31</b>	Prostatic intraepithelial neoplasia
<b>N42.32</b>	Atypical small acinar proliferation of prostate
<b>N42.39</b>	Other dysplasia of prostate
<b>C61</b>	Malignant neoplasm of prostate

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/03/2019	12/03/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup>	05/23/2024

Revision History	Description
------------------	-------------

12/03/2019	Merged all BPH criteria (Urolift, Rezūm, PAE) into one document
12/03/2019	MPC approved non-coverage policy for Prostate artery embolization (PAE) for benign prostatic hyperplasia (BPH)
05/05/2020	Added diagnosis codes N35.010-N35.92, N40.0-N40.3 and C61 (PAE); Added CPT code 53854 and removed 53899 (Rezūm)
10/06/2020	MPC approved medical necessity criteria for Rezūm. Requires 60-day notice, effective date 3/1/2021.
04/25/2022	Added statement to Medicare section – Medicare covers PAE if part of an IDE study.
02/07/2023	Added 0421T code with Medicare coverage LCD. Added Hayes report.
05/02/2023	Added MTAC review for Transurethral Waterjet Ablation. MPC endorsed MTAC's decision and continued a position of non-coverage.
5/23/2024	Updated Dx code list for PAE procedure



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Brachytherapy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	4/01/2016 Noridian retired Local Coverage Determination <a href="#">LCD Brachytherapy: Non-Intracoronary (L34065)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.
Local Coverage Article	None

#### For Non-Medicare Members

1) Breast Cancer - Brachytherapy as an adjunct to whole breast radiation is covered when recommended by the treating practitioner. Patients eligible for brachytherapy as a sole treatment alternative to whole breast radiation therapy must meet **ALL of the following** criteria:

A. Age ≥ 50\*

**AND**

B. Diagnosis of unifocal invasive ductal cancer with **ALL** of the following:

- a. Tumor size ≤ 3cm
- b. Negative surgical margins at 2mm
- c. Negative nodal status

**OR**

C. Diagnosis of ductal carcinoma in situ (DCIS) with ALL of the following:

- a. Detected on screening
- b. Low to intermediate nuclear grade
- c. Tumor size ≤ 2.5 cm
- d. Resected with margins negative at ≥ 3 mm

\*Age 40-49 meeting requirements above on a case by case basis.

Contraindicated for any of the following:

- A. age < 40
- B. lobular disease
- C. DCIS that does not meet the indications above
- D. EIC
- E. anatomic limitations or
- F. angiolymphatic space invasion

2) High-Dose Rate Brachytherapy for Prostate Cancer

a) High-dose rate (temporary seed implantation) prostate brachytherapy may be considered medically necessary under the following conditions:

- When combined with external beam radiation as a “boost” or
- When used for early stage prostate disease as monotherapy.

**Standard brachytherapy is covered without medical necessity review for:**

Coronary Artery Brachytherapy, Intravascular Coronary Brachytherapy  
Endobronchial Brachytherapy - Lung Cancer  
High-Dose or Low-Dose Brachytherapy for Cervical and Endometrial Cancer  
Prostate Cancer

Procedure	Criteria
AccuBoost peripheral breast brachytherapy	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
Radioactive Seeds for Treatment of Recurrent High-Grade Glioblastoma	

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

## Background

Brachytherapy, also called internal radiation therapy, allows a physician to use a higher total dose of radiation to treat a smaller area and in a shorter time than is possible with external radiation treatment. Brachytherapy involves placing a radioactive material directly inside or next to the tumor. It has been proven to be very effective and safe, providing a good alternative to surgical removal of the prostate, breast, and cervix, while reducing the risk of certain long-term side effects.

There are two types of brachytherapy – temporary and permanent. In temporary brachytherapy, the radioactive material is placed inside or near a tumor for a specific amount of time and then withdrawn. Temporary brachytherapy can be administered at a low-dose rate (LDR) or high-dose rate (HDR). Permanent brachytherapy, also called seed implantation, involves placing radioactive seeds or pellets (about the size of a grain of rice) in or near the tumor and leaving them there permanently. After several weeks or months, the radioactivity level of the implants eventually diminishes to nothing. The inactive seeds then remain in the body, with no lasting effect on the patient.

## Evidence and Source Documents

[Breast Cancer](#)

[Coronary Artery Brachytherapy, Intravascular Coronary Brachytherapy](#)

[Endobronchial Brachytherapy - Lung Cancer](#)

[High-Dose vs. Low-Dose Brachytherapy for Cervical and Endometrial Cancer](#)

[High-Dose Rate Brachytherapy for Prostate Cancer](#)

[Prostate Cancer](#)

[Radioactive Seeds for Treatment of Recurrent High-Grade Glioblastoma](#)

## Medical Technology Assessment Committee (MTAC)

### Breast Cancer Brachytherapy

#### BACKGROUND

In the last two decades, the treatment of early-stage breast cancer has shifted from radical mastectomy to breast conserving therapy (BCT). This involves lumpectomy followed by whole breast external beam radiotherapy (WBRT). Several large randomized controlled trials with long-term follow-up showed that BCT has equivalent survival rates to the modified radical mastectomy among patients with early stage breast cancer. In addition, BCT has better cosmesis and less psychological and emotional trauma for women compared to mastectomy. Researchers believe that whole breast irradiation after lumpectomy reduces local breast recurrence by eliminating residual cancer at the surgical site, as well as occult areas of in-situ or infiltrating cancer in remote areas in the breast. The use of BCT is underutilized in the United States mainly due to the long course of conventional whole-breast radiation therapy, which is typically delivered daily 5 days per week for 5 to 7 weeks. This may be a problem for working women, elderly patients, or those living at a considerable distance from a treatment center. WBRT may also delay or be delayed by the initiation of systemic adjuvant chemotherapy. Investigators also found that treating the entire volume of the breast may deliver small radiation doses to the adjacent tissues leading to acute and chronic toxicity to the skin, heart, lung, and contralateral breast (Fisher 1995, 2002, Baglan 2001, Veronesi 2002, Chen 2007, Cuttino 2007). Recently, accelerated partial breast radiation therapy (APBI) has been proposed as an alternative approach to WBRT. APBI involves the treatment of the lumpectomy bed plus a 1-2 cm margin of breast tissue. This is based on the assumption that the microscopic tumor rarely extends 2 cm beyond the initial resection cavity when the margins are negative on final pathologic examination. Reducing the target allows the delivery of APBI and completing the treatment in less than one week. Several methods for delivering APBI were proposed and/or used. These approaches include multicatheter interstitial brachytherapy, balloon catheter brachytherapy, 3-D CRT (conformal radiation therapy) and intraoperative radiation therapy. These techniques are widely different in terms of radiation delivery, degree of invasiveness, length of treatment, and acceptance by radiation oncologists (Chen 2007, Chao 2007). Breast brachytherapy involves the placement of radioactive sources inside the breast to deliver a relatively high dose of radiation to the tissue immediately surrounding the lumpectomy site, and very little dose to the surrounding normal structure. The interstitial multicatheter system, the most common method used, involves the placement of a number of catheters into the breast to guide the radioactive materials to the intended area. Pellets of iridium-192 are then inserted into the catheters over the course of the treatment. The catheters are briefly connected to a dose-rate brachytherapy machine for internal radiation treatment, which takes about ten minutes each. After the course of treatment is completed the catheters are removed. The procedure requires significant technical expertise, and can be difficult and challenging (Chen 2007, Bovi 2007, Haley 2008, Kacso 2008). Balloon-based brachytherapy Several balloon-based brachytherapy devices were developed as an alternative to the interstitial multicatheter system to be more user-friendly to the clinician and more accessible and better tolerated by the patient. The MammoSite brachytherapy (MSB) system (Hologic, Marlborough, MA) was the first developed balloon-based brachytherapy device. It consists of a small balloon connected to an inflation channel and a catheter for the passage of a high dose rate brachytherapy dose (Iridium-192 [192Ir]). The device is implanted in the lumpectomy cavity during or following breast surgery. The balloon is inflated with sterile saline containing a small amount of radiographic contrast to a size that completely fills the cavity and ensures conformance of the tissue to the balloon. A computed tomography scan is obtained to assess the balloon conformance to the lumpectomy cavity and determine its symmetry, diameter, distance from skin, planning target volume, and the dose distribution. After treatment is completed in several days, the balloon is deflated, and the catheter is removed. The treatment with the MammoSite device generally delivers 34 Gy in 10 fractions (3.4 Gy /fraction twice daily with a minimum of 6 hours between the fractions on the same day). Investigators recommend the system for patients with ductal carcinoma in situ, invasive ductal carcinoma, and primary tumors with a diameter less than 3cm. It may not be suitable for patients with small breast or for tumors located in the upper inner quadrant because of the requirement for skin-to-cavity distances (Bensaleh 2009, Njeh 2010). Xofigo (Xofigo, Inc., Fremont, CA) electronic brachytherapy is a modified form of balloon-based brachytherapy. Similar to MammoSite, Xofigo consists of a balloon catheter that is percutaneously inserted into the lumpectomy cavity. The system uses 50 kiloVolt (kV) X-ray source (an electronic radiation source) rather than radioisotope, such as iridium-192 high dose rate (HDR) source. The x-ray source consists of a miniature x-ray tube that is inserted in the balloon catheter and delivers the radiation therapy to the patient. The system may be operated at variable currents and voltages to change the dose rate and penetration properties. The Xofigo does not require a high-dose rate afterloader unit, or treatment in a shielded vault. Another potential advantage is the lower energy dose deposited in adjacent normal tissues, compared to other forms of balloon brachytherapy. It is unknown if these advantages would be outweighed by a potential harm of fat necrosis as a result of a significant dose inhomogeneity (Strauss 2009, Dickler 2009). SenoRx Contura device (SenoRx, Inc, Aliso Viejo, CA) differs from MammoSite in that it has multiple lumens for passage of 192Ir HDR source. In addition to the central lumen, the Contura balloon has 4

surrounding channels to accommodate the HDR source. The surrounding channels have 5 mm offset around the central channel. The approach provides additional flexibility and has the potential of improving normal tissue sparing. The device includes a port which can be connected to suction to remove seroma fluid or air in an effort to improve conformity (Strauss 2009, Njeh 2010). Image guided radiation therapy: AccuBoost peripheral breast brachytherapy. The AccuBoost® peripheral breast brachytherapy system (Advanced Radiation Therapy of Billerica, MA) was developed to provide a means of delivering partial breast irradiation treatment regimen noninvasively under mammographic image guidance. The AccuBoost system consists of three main components: (1) A conventional mammography unit to immobilize the breast and localize the lumpectomy site. (2) Computed Radiography (CR) system to provide radiographic images of the lumpectomy cavity (and/or implanted fiducial markers) for cavity/ margin localization at the beginning of each fraction. The CR system can also record the exit dose distribution and provide information on the therapeutic dose. (3) AccuBoost Applicators: high dose rate (HDR) Ir192 brachytherapy source remote afterloading system to deliver brachytherapy in a peripheral noninvasive manner. The applicators are made from tungsten in the form of half-cylinders. The patient's breast is compressed to a thickness of 3-8 cm between two mammography paddles and imaged with a radiopaque coordinate grid. The radiation oncologist determines the isocenter coordinates and appropriate applicator size and shape based on the image. The collimating HDR 192Ir brachytherapy applicators are then applied on either side of the breast along a common axis and the brachytherapy dose delivered. The process is repeated along an orthogonal axis to distribute the entrance dose (Rivard 2009, Yang 2009, AccuBoost website). MammoSite, multi-lumen MammoSite, Axxent Electronic brachytherapy, and SenoRx Contura device are all FDA approved to deliver intracavity radiation to the surgical margins following lumpectomy for breast cancer. AccuBoost® system for delivering guided radiation therapy is also FDA approved.

## 06/12/2002: MTAC REVIEW

### Breast Cancer Brachytherapy

**Evidence Conclusion:** The studies reviewed aimed at determining the equivalence between brachytherapy and external beam radiation, yet none of them was designed or analyzed in a fashion to study equivalence, which is a major threat to their validity. The authors set no equivalence boundary but took the lack of statistically significant difference between the two treatments as a proof of equivalence, which could lead to an erroneous judgment. Moreover, the studies were prospective, with a historical control group. The patients were not randomly assigned to the treatment group, and it is not discussed if they were consecutive, which may be a source of selection bias. The cohorts of women treated with brachytherapy were prospectively followed for a variable period of time (median 36 months in Vicini's study, and 74 months in King's study). The follow-up period was as short as a few months among some patients, and the dropout rate in the brachytherapy group was 82% after 5 years in Vicini's study. The reason for this high dropout rate was not discussed. In the two studies, data on the control group were obtained from retrospective chart reviews. Patients in the brachytherapy group received the treatment at either a low- or high-dose rate but were analyzed as one group. There were some differences in the baseline characteristics that were not adjusted for in the analysis of the results. The overall control and cosmetic outcomes of the brachytherapy as a sole treatment after lumpectomy were similar to that achieved by the external beam radiation therapy. However, these results cannot be generalized mainly due to the design of the study as well as the selection, observation and other biases in the studies. Randomized controlled studies with large sample size, power, and longer follow-up periods are needed to determine the long-term benefits and harms of brachytherapy used as a sole treatment after breast conservative therapy.

**Articles:** The search yielded 81 articles. Many were review articles, opinion pieces, or addressed brachytherapy as a boost, not a sole treatment after lumpectomy. The literature did not include any randomized controlled trials, or meta-analyses. There was a number of small case series with no control group, and two prospective studies that compared brachytherapy with external beam irradiation. These two studies were selected for critical appraisal. Vicini FA, Baglan KL, Kestin KL, et al. Accelerated treatment of breast cancer. *J Clin Oncol* 2001; 19:1993-2001. See [Evidence Table](#). King TA, Bolton JS, Kuske RR, et al. Long-term results of wide field brachytherapy as the sole method of radiation therapy after segmental mastectomy for T<sub>is</sub>, 1, 2 breast cancer. *Am J Surg* 2000; 180:299-304. See [Evidence Table](#).

The use of brachytherapy in the treatment of breast cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 02/07/2005: MTAC REVIEW

### Breast Cancer Brachytherapy

**Evidence Conclusion:** Brachytherapy as an adjunct or boost to whole breast radiation therapy:

The two randomized controlled trials reviewed (Polgar 2002, and Poortmans 2004) evaluated brachytherapy for early stage breast cancer with no or limited spread to the axillary lymph nodes. Both trials compared boost to no boost therapy after breast conserving surgery and whole breast external radiation therapy. Different techniques for the boost therapy were used (brachytherapy and electrons in Polgar's trial, and electrons, photon beams, and



interstitial brachytherapy in Poortman's trial). The trials were not blinded, and the patients were randomized to boost or no boost treatment but were not randomized to the different boost techniques used. The latter was selected according to the physicians' preference. Poortman et al's trial was still ongoing, and in this publication the authors did not present a comparison between boost and no boost treatments but compared the outcomes of the different boost techniques used. Polgar et al reported a significant improvement with the boost vs. no boost treatment. The analysis provided however does not indicate that there was a statistically significant improvement as reported by the authors. The boost treatment was also found to be associated with an increased incidence of moderate to severe complications. Brachytherapy as a sole treatment alternative to whole breast radiation therapy. Vicini 2003, and Polgar 2004 were prospective cohort studies with a comparison group. Patients, however, were not randomly assigned to the treatment groups but matched to historical controls from the records or databases. The criteria used to assess the effect of the treatment included the degree of local control, disease free, relapse-free, and cancer free survival, as well as cosmetic outcome, and side effects. These two studies aimed at determining the similarity between brachytherapy and external beam radiation, yet none of them was designed or analyzed in a fashion to study equivalence, which is a major threat to their validity. The authors set no equivalence boundary but took the lack of statistically significant difference between the two treatments as a proof of equivalence, which could lead to an erroneous judgment. In conclusion, interstitial brachytherapy may be a promising treatment, but the studies reviewed do not provided sufficient evidence to conclude that it may be used as an alternative to whole breast radiation therapy after breast conserving surgery. Randomized controlled studies with large sample size, power, and longer follow-up periods are underway to determine the long-term benefits and harms of brachytherapy used as a sole treatment after breast conservative therapy.

**Articles:** The search revealed more than 200 articles. Many were reviews, editorials, or dealt with the technical aspects of the technology. There were several case series, retrospective studies, and small trials. Others compared mastectomy with external beam radiation therapy, and in one trial brachytherapy was compared to WBRT without breast lumpectomy. Studies were selected for review according to the following criteria: 1. Evaluating brachytherapy as an adjunct to whole breast radiation therapy or as a sole treatment after breast-conserving surgery, 2. Prospective design, and 3. Including a comparison or control group. Two large RCTs on the use of brachytherapy as a boost to WBRT were identified and critically appraised. Several studies on the use of brachytherapy as an alternative to WBRT were published after MTAC reviewed the technology in 2002. All evaluated brachytherapy for early stage breast cancer with no or limited spread to axillary lymph nodes. Harms et al (2002), Keisch et al (2003), Perera et al (2003), Richard et al (2004), and Shah et al (2004) studies were case series with no control or comparison groups. These studies mainly evaluated the safety of the treatment rather than efficacy. Only two of the identified studies (Vicini 2003 and Polgar 2004) included a comparison group and were selected for critical appraisal. *Evidence tables were created for the following studies:* *For the use of brachytherapy as an adjunct to whole breast radiation therapy:* Polgar C, Fodor J, Orosz Z, et al. Electron and high dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer. First results of the Randomized Budapest Boost Trial. *Strahlenther Onkol* 2002; 178:1205-1211. See [Evidence Table](#) Poortmans P, Bartelink H, Horiot JC, et al. The influence of the boost technique on local control in breast conserving treatment in the EORTC "boost versus no boost randomized trial. *Radiother Oncol* 2004; 72:25-33. See [Evidence Table](#) *For the use of brachytherapy as a sole treatment alternative to whole breast radiation therapy:* Vicini F, Kestin L, Chen P, et al. Limited field radiation therapy in the management of early-stage breast cancer. *J Natl Cancer Inst* 2003; 95:1205-1211. See [Evidence Table](#) Polgar C, Major T, Fodor J, et al. High dose-rate brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: seven-year results of a comparative study. *Int J Radiat Oncol* 2004; 60:1173-1181 See [Evidence Table](#)

The use of brachytherapy as an adjunct or boost to whole breast radiation therapy in the treatment of breast cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of brachytherapy as a sole treatment alternative to whole breast radiation therapy in the treatment of breast cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/15/2011: MTAC REVIEW

### Breast Cancer Brachytherapy

**Evidence Conclusion:** There is insufficient evidence to date to determine whether accelerated partial breast irradiation delivered by balloon-based brachytherapy or AccuBoost is safe and provides non-inferior or superior local tumor control and survival compared to conventional whole breast irradiation in patients with early stage breast cancer treated with breast conservative therapy. Polgar and colleagues' (2008) RCT, reviewed earlier, and Antonucci et al's study (evidence table 1) had several methodological flaws which limit generalization of their results. Large RCTs with long-term follow-up are needed to determine the equivalence or superiority of accelerated partial breast irradiation therapy to whole breast external beam radiation therapy. A phase 3 trial comparing APBI to whole breast irradiation in over 4,000 women with stage 0, I, or II breast cancer is underway. The trial is jointly conducted by the National Surgical

Adjuvant breast and Bowel Project (NSABP) and the Radiation Therapy Oncology Group (RTOG). Patients in the APBI will be treated using one of three modalities: interstitial brachytherapy, MammoSite brachytherapy, or 3-D conformal EBRT. Outcome measures include overall survival, recurrence free survival, distant disease-free survival, toxicity, cosmesis, and convenience of the care. The primary aim of the trial is determining whether APBI would provide equivalent local breast control as WBRT in early stage breast cancer. Other ongoing trials include the Canadian RAPID trial which is recruiting over 2000 patients to be randomized to either whole breast irradiation or 3-D CRT, and an international phase III large trial supported by the European Brachytherapy Breast Cancer GEC-ESTRO Working Group. This trial will randomize 1170 women between WBRT and APBI using high-dose rate or pulsed-dose rate brachytherapy. The results of these, and a number of other ongoing trials, will provide data on the efficacy and toxicity of partial breast irradiation in the treatment of early stage breast cancer as compared to WBRT. They may also provide data on appropriate candidates for APBI and on the advantages and disadvantages of each method.

**Articles:** Objectives: To determine whether accelerated partial breast irradiation leads to non-inferior or superior local tumor control and survival compared to conventional whole breast irradiation, when used as an adjuvant therapy after lumpectomy in patients with early stage breast cancer. To determine whether the use of balloon-based brachytherapy systems is safe and effective for delivering adjuvant radiation therapy after lumpectomy in patients with early stage breast cancer. To determine whether the image guided radiation therapy using AccuBoost peripheral breast brachytherapy system is safe and effective for delivering adjuvant radiation therapy after lumpectomy in patients with early stage breast cancer.

Screening of articles/selection: The search revealed around 150 articles on accelerated partial breast irradiation (APBI). The majority of the published empirical studies were phase I/II trials with no comparison group, different sizes, and follow-up durations. There were no new randomized trials, published after the last review, on APBI therapy delivered by MammoSite, Axxent, Contura, or AccuBoost systems. The search identified a recently published interim analysis on the acute toxicity in a trial that compared conventional whole breast radiation with APBI plus IMRT, a nonrandomized study that examined the dosimetric advantage of Contura catheter vs. MammoSite, and a small case series of patients treated with Contura catheter. The literature search also revealed a report on four-year outcomes of a prospective study, with no control group, on the efficacy and toxicity of 3-D-CRT to deliver APBI, and a feasibility study with 11 patients treated with intraoperative radiation using the Axxent electronic brachytherapy system. No published clinical studies on AccuBoost system were identified. A recent analysis comparing APBI with WBRT was critically appraised. See [Evidence Table](#). Antonucci JV, Wallace M, Goldstein NS, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. *Int J Radiat Oncol Biol Phys*. 2009;74:447-452. See [Evidence Table](#).

The use of brachytherapy as an adjunct or boost to whole breast radiation therapy in the treatment of breast cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Coronary Artery Brachytherapy Intravascular Coronary Brachytherapy**

### **BACKGROUND**

Percutaneous transluminal coronary angioplasty (PTCA) is a widely used therapy for obstructive coronary artery disease. It is limited however by the high rate of restenosis which occurs in 30-60% of patients after a successful PTCA. The main mechanisms of restenosis include elastic recoil of the vessel, rapid platelet deposition, vascular remodeling and neointimal hyperplasia. Endovascular stents have been shown to reduce stenosis by preventing the elastic recoil and pathological remodeling. However, stents do not prevent the restenosis caused by neointimal hyperplasia, but rather initiate an inflammatory reaction that induces more proliferation than other coronary devices. An effective treatment of restenosis within the stent will be the suppression of this neointimal hyperplasia. Radiation therapy which is known for its antiproliferative effect has been proposed as a treatment for in-stent restenosis. Over the past six years, studies on the use of various techniques to apply intracoronary radiation which is known as intracoronary brachytherapy have been showing encouraging results. Brachytherapy uses a relatively large localized dose of beta or gamma radiation. It does not provide an immediate outcome. If effective, it reduces the rate of restenosis in the vessel in the target area. This effect can be measured by angiograms performed six months after the procedure. Brachytherapy requires a multidisciplinary team to deliver it including an interventionist cardiologist, a radiation oncologist, physicist and safety officer.

### **06/13/2001: MTAC REVIEW**

#### **Coronary Artery Brachytherapy Intravascular Coronary Brachytherapy**

**Evidence Conclusion:** GAMMA-One (Leon et al), beta-WRIST (Waksman et al), SCRIPPS (Teirstein et al), and the START (In press) trials are four of the well-designed RCTs evaluating the use of brachytherapy in the management of in-stent restenosis. There are several other ongoing studies. These trials showed that patients



with in-stent restenosis treated with brachytherapy needed less revascularization than those treated with PTCA or PTCA and stents without radiation. In two of the studies, intracoronary brachytherapy tended to increase the risk of late thrombus formation, but this was statistically insignificant. Although these trials reported that major cardiac events (MACE) were lower among patients who received brachytherapy, none of them had adequate power, or follow-up to detect the difference in myocardial infarction and death rates alone. Brachytherapy may also cause acute damage in the coronary arteries including aneurysm, pseudoaneurysm, arterial dissection, or rupture of the artery. None of these acute complications was reported in any of these trials. In addition, radiation may lead to a long-term damage on the surrounding tissue and have adverse effects on the clinical personnel. These long-term complications are unknown. The longest data available is the three-year follow-up in the SCRIPP trial (Teirstein et al). The nature of radiation needs a long-term follow-up.

**Articles:** The search yielded 79 articles. Many were just reviews and literature. There were eleven articles on randomized controlled studies, more than one publication for each of the major trials, GAMMA-one, beta-WRIST and SCRIPPS. The START trial was still in press. These major randomized controlled studies were evaluated in detail. *Evidence tables were created for the following studies:* Leon MB, Teirstein PS, Moses JW, et al. Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis After Stenting. N Engl J Med 2001; 344: 250-256 See [Evidence Table](#) Teirstein PS, Massulo V, Jani S, Popma JJ, et al. Three-Year Clinical and Angiographic Follow-up After Intracoronary Radiation. Circulation 2000; 101: 360-365. See [Evidence Table](#) Waksman R, White L, Chan RC, et al. Intracoronary Gamma -Radiation Therapy After Angioplasty Inhibits Recurrence In Patients With In-Stent Restenosis. Circulation 2000; 101: 2165-2171 See [Evidence Table](#) The use of Coronary Artery Brachytherapy for the treatment of restenosis of stent passes all *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Endobronchial Brachytherapy - Lung Cancer**

### **BACKGROUND**

Among all types of malignancy, lung cancer is one of the most difficult to manage and is associated with the highest mortality rate. Its incidence is continuously increasing, with no improvement in mortality. 80-85% of the cases is non-small cell lung cancer (NSCLC). Squamous cell carcinoma and adenocarcinoma account for the majority of the NSCLC. Regardless of the histological type, surgery offers the best potential for cure. However, approximately 75% of the patients present with locally advanced non-resectable disease at the time of diagnosis. The treatment options for these patients are chemotherapy and / or external irradiation therapy, which have low survival rates, and high rates of local recurrence. Endobronchial brachytherapy (EBT or EBB) is an additional treatment increasingly used for centrally localized lung cancer. It can be used alone, or with the external radiation therapy (XRT) to boost the total dose of irradiation used. In earlier studies, it was used as a palliative treatment in case of endobronchial recurrence after XRT. In later studies it is used in combination with high-dose of XRT as a potential curative primary treatment in selected cases. With brachytherapy, radioactive sources usually iridium-192 are placed at the tumor site in the involved branch of the tracheobronchial tree. These will deliver a radiation dose that rapidly and progressively declines with the increasing distance from the source. Any adverse effects on normal tissue should be confined to the immediate vicinity of the bronchus, sparing the lung parenchyma and the esophagus. The procedure is done on outpatient basis. Bronchoscopy is performed under topical anesthesia to determine the field of treatment. A guidewire is then placed in the instrumentation channel of the endoscope, and the bronchoscope is removed. An after-loading catheter is passed on the guidewire, the guidewire is removed, and an applicator for placement of the radiation source is inserted in the catheter. Depending on the number of airway branches involved, 1 to 4 catheters may be placed. The position of the catheter is verified by fluoroscopy. The applicator is then connected to the iridium192 afterloading unit and the irradiation source advanced to the intended position under computer control. The application time ranges from 2 to 15 minutes depending on the dose, and length of the irradiated area. After removing the radioactive source, the catheters are removed, and the patient is observed for 30 minutes. High-dose brachytherapy may be delivered in fractionated doses by repeating the procedure at weekly or biweekly intervals, or twice a day until the entire dose is delivered. The dose varies individually and depends on the patient's clinical condition, history, and concurrent use of XRT. Endobronchial brachytherapy may be associated with acute complications. It could lead to fibrotic airway obstruction and may be linked to fatal hemoptysis depending on the dose, dose per fraction and the concurrent use of XRT.

### **08/08/2001: MTAC REVIEW**

#### **Endobronchial Brachytherapy - Lung Cancer**

**Evidence Conclusion:** The RCTs reviewed were conducted to evaluate the effect of endobronchial brachytherapy either used alone, or in addition to external radiation therapy. Langendijk's study found a statistically significant benefit of adding EBT to XRT in treating atelectasis in patients with endobronchial obstruction in the main bronchus. Huber's study did not show any statistical difference between the two treatments. On the other hand, Stout's study found that external irradiation therapy, had a statistically significant better outcome than EBT (used alone) on the patients' survival and palliation of some symptoms. EBT was not found to be associated with a higher rate of fatal hemoptysis in all three trials. The studies had some limitations

including likelihood of observation bias, incomplete data (all three RCTs), premature termination and lack of power (Langendijk). In conclusion, the efficacy and safety of endobronchial brachytherapy cannot be fully determined from the available evidence.

**Articles:** The search yielded 54 articles. Selection was based on study type. There were 3 articles on randomized control trials comparing the effect of external irradiation therapy (XRT) vs. endobronchial brachytherapy (EBT) / XRT + EBT, on patients with non-small cell lung cancer. Reviews, editorials and comments were reviewed, but no evidence tables were created. *The three RCTs selected for critical appraisal were:*

Huber RM, Fischer R, Hautmann H, et al. Does Additional Brachytherapy Improve the Effect of External Irradiation? A Prospective, Randomized Study in Central Lung Tumors. *Int.J.Radiation Oncology Biol. Phys.* 1997; 38 (3): 533-540. See [Evidence Table](#) Langendijk H, Jong JD, Tjwa M, et al. External Irradiation Plus Endobronchial Brachytherapy in Inoperable Non-small Cell Lung Cancer: a Prospective Study. *Radiotherapy and Oncology* 2001; 58: 257-268 See [Evidence Table](#) Stout R, Barber P, Burt P, et al. Clinical and Quality of Life Outcomes in the First United Kingdom Randomized Trial of Endobronchial Brachytherapy Treatment of Inoperable non-small Cell Lung Cancer. *Radiotherapy and Oncology* 2000; 56: 323-327 See [Evidence Table](#)

The use of endobronchial brachytherapy in the treatment of lung cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria 2* for effectiveness.

### **High-Dose Rate Brachytherapy for Prostate Cancer**

#### **BACKGROUND**

Prostate cancer is one of the most common cancers, and the second leading cause of cancer death in men in the United States. The standard management options for localized disease included surgery, radiotherapy, and watchful waiting. However, the optimal treatment is not well defined. Both surgery and radiation therapy are reported to have equivalent outcomes, and each approach has its advantages and disadvantages. Researchers reported that for intermediate and high-risk disease, external beam radiation therapy (EBRT) is the standard treatment, and that there is a dose response for biochemical relapse-free survival. However, dose escalation to >70 Gy is associated with an increase in genitourinary and gastrointestinal side effects. Several techniques have been developed to deliver high doses of radiation to the prostate while sparing surrounding normal tissue. Among these are the three-dimensional conformal radiotherapy (3DCRT), intensity modulated radiation therapy (IMRT), photon therapy, and brachytherapy (Vordermark 2006, Hoskin 2007, Rades 2007). Prostate brachytherapy was introduced in the late 1980s after the development of transrectal ultrasonography and sophisticated treatment planning software. It can be performed as monotherapy or in conjunction with hormone therapy or EBRT. Monotherapy is usually reserved for low-risk cancer, and the combined therapies are used for high-risk disease (Nelson 2007). Interstitial brachytherapy can be delivered using permanent low-dose-rate (LDR) seed implants or temporary high-dose-rate (HDR) implants. The latter entails the temporary placement of higher energy radioactive sources in and near the tumor. An automated machine called an afterloader sequentially moves a high-intensity radioactive source to and from a set of catheters in and around the prostate to deliver a pre-determined radiation dose to the patient's tumor. Following treatment, the radioactive source is withdrawn. Both LDR and HDR have the advantage of conforming high doses of radiation according to the precisely localized target, rapid dose fall-off, and no target movement during treatment. The dose distribution of the LDR mainly depends on the position of the implanted seed, while the HDR uses a steeping source, usually iridium-192, and is thus able to vary both the position and /or dwell time of the source. This has the potential of better target volume coverage and a greater sparing of neighboring organs at risk (Chin 2006). Unlike LDR brachytherapy, HDR brachytherapy usually requires hospitalization of the patient. HDR brachytherapy is also associated with a number of acute and chronic side effects, including urinary urgency and frequency, dysuria, nocturia, urinary retention, urethral stricture, rectal irritation, and impotence.

#### **06/06/2006: MTAC REVIEW**

##### **High-Dose Rate Brachytherapy for Prostate Cancer**

**Evidence Conclusion:** There is insufficient evidence to draw conclusions about the effectiveness and safety of HDR brachytherapy monotherapy compared to an accepted treatment for prostate cancer.

There is some evidence that HDR brachytherapy plus EBRT results in better biochemical control than EBRT alone. Data are from 2 comparative studies, one randomized and one non-randomized; both studies have threats to validity. There is insufficient evidence to determine whether HDR brachytherapy added to EBRT improves disease-specific or overall survival. In the randomized controlled trial, there was no significant increase in overall survival with HDR brachytherapy plus EBRT; data were not reported for disease-specific mortality. In the non-randomized study, there was not a significant difference in disease-specific mortality. Overall survival was significantly higher in the combined treatment group when 5-year outcomes were modeled using Kaplan-Meier analysis—actual patient data on survival were not reported.

There is insufficient evidence on adverse effects associated with HDR brachytherapy plus EBRT. In the RCT, rates of adverse effects did not differ significantly between groups—however, these comparisons were likely

underpowered. In the cohort study, adverse effects were only reported for the HDR brachytherapy plus EBRT group; 29% of patients developed impotence.

**Articles:** Note: Studies were identified using N California report but selection of articles for critical appraisal was re-done for the MTAC report. *HDR brachytherapy monotherapy:* There were no randomized controlled trials or non-randomized controlled trials that compared the safety and effectiveness of HDR brachytherapy monotherapy to a different treatment such as observation, surgery or EBRT. All of the studies were case series. Two publications from a single institution compared series of patients who received either HDR brachytherapy or LDR brachytherapy (Vargas et al., 2005 ; Grills et al., 2004 ). No studies were selected for critical appraisal since none compared HRD brachytherapy to another treatment for prostate cancer. *Combination therapy (HRD brachytherapy plus EBRT):* There was one randomized controlled trial comparing HRD brachytherapy plus EBRT to EBRT alone. There were also two nonrandomized comparison studies and nine case series. One of the non-randomized comparative studies (Jo et al., 2005 ) was a survey that only reported on quality of life, not clinical outcomes and thus this study was excluded from further review. The RCT (Sathya et al., 2005) and the other non-randomized comparison study (Kestin et al., 2000) were critically appraised. *The studies reviewed were:* Sathya JR, Davis IR, Julian JA et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005; 23: 1192-1199. See [Evidence Table](#) Kestin LL, Martinez AA, Stromberg JS et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000; 18: 2869-2880. See [Evidence Table](#)

The use of High-dose rate brachytherapy in the treatment of prostate cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 10/01/2007: MTAC REVIEW

##### High-Dose Rate Brachytherapy for Prostate Cancer

**Evidence Conclusion:** High-dose rate (HDR) brachytherapy for prostate cancer was previously reviewed by MTAC on 6/5/06. The report conclusion indicated that there was insufficient evidence to determine the effectiveness and safety of HDR brachytherapy monotherapy compared to an accepted treatment for prostate cancer. For the current review, the literature search revealed one more recent RCT conducted in the UK (Hoskin 2007), that compared external-beam radiation therapy (EBRT) given as a monotherapy vs. its combination with high-dose rate brachytherapy boost for the treatment of prostate cancer. The primary outcome was biochemical relapse free survival. The secondary outcomes were the overall and relapse-free survival, acute and late toxicity, and quality of life. The study had its advantages and limitations. It was randomized, controlled, had sufficient statistical power, high completeness rate, and analysis was based on intention to treat. However, the authors did not discuss blinding of the investigators to the patient allocation, the 55 Gy dose of external beam radiotherapy is considered suboptimal, and the technique of delivering the EBRT changed along the study. Moreover, the follow-up duration was relatively short, and the primary outcome was biochemical relapse free survival which is a surrogate outcome for overall survival. It is considered acceptable by some investigators, due to the long natural history of the disease. Overall, the results of the trial indicate that the biochemical relapse-free survival was significantly higher among patients in the HDR brachytherapy in combination with external beam radiotherapy group versus those treated with external beam radiotherapy alone. The HDR brachytherapy was also associated with an improved quality of life, without any increase in toxicity. Soumarova and colleagues (2007) compared the acute genitourinary and gastrointestinal toxicity in 97 patients treated with external beam radiotherapy (3D conformal radiotherapy [CRT]) or 3D CRT combined with interstitial conformal HDR brachytherapy for the treatment of histologically verified localized carcinoma of the prostate. The study was prospective but non-randomized: 57 patients received 3D CRT and 40 patients were irradiated with 3D CRT+ HDR brachytherapy. The patients were followed by a radiation oncologist and urologist at 1-3 months intervals, and the acute genitourinary and gastrointestinal toxicities were evaluated using the RTOG criteria. The overall results of the study showed a lower incidence of acute gastrointestinal toxicity in HDR brachytherapy combination therapy group versus those in the 3D CRT monotherapy group. In conclusion the studies published to date do not provide sufficient evidence to determine the efficacy and safety of HDR brachytherapy in the treatment of histologically proven carcinoma of the prostate.

**Articles:** *HDR brachytherapy monotherapy:* The literature search did not reveal any randomized controlled trials or non-randomized controlled trials that compared the safety and effectiveness of HDR brachytherapy monotherapy to no, or a different mode of treatment as surgery or EBRT. All published studies on monotherapeutic brachytherapy for organ confined or locally advanced prostate cancer, were case series with variable sizes and duration of follow-up. None included a comparison or control group and thus were not critically appraised. *HDR brachytherapy in combination with external beam radiotherapy (EBRT):* There was one recent randomized controlled trial (Hoskin 2007) that compared HDR brachytherapy plus EBRT to EBRT alone, and a non-randomized controlled trial (Soumarova 2007) that compared the acute toxicity of EBRT with and without

HDR brachytherapy, as well as several case series. The two studies were reviewed, Hoskin and colleagues RCT was presented in an evidence table.

Hoskin PJ, Motohashi K, Bownes P, et al. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomized phase three trial.

Radiother Oncol 2007; May 24. See [Evidence Table](#)

The use of High-dose rate brachytherapy in the treatment of prostate cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 10/18/2010: MTAC REVIEW

##### High-Dose Rate Brachytherapy for Prostate Cancer

**Evidence Conclusion:** There is insufficient evidence to determine whether HDR brachytherapy given alone or in combination with EBRT is safe and effective for the treatment of prostate cancer.

**Articles:** The literature search did not reveal any randomized controlled trials that addressed the safety and efficacy of HDR brachytherapy. A retrospective cohort study was identified that evaluated the safety and efficacy of HDR brachytherapy given as a monotherapy compared to LDR brachytherapy was selected for review. There were several studies that evaluated the safety and efficacy of HDR brachytherapy combined with EBRT; however, the majority of these were case series. A recent study by Zwahlen and colleagues was selected for review as it was the only study with a control group. The following studies were critically appraised:

Martinez AA, Demanes J, Vargas C, et al. High-dose-rate prostate brachytherapy: An excellent accelerated hypofractionated treatment for favorable prostate cancer. *Am J Clin Oncol* 2009 November 30. See [Evidence Table](#)

Zwahlen DR, Andrianopoulos N, Matheson B, et al. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. *Brachytherapy* 2010; 9:27-35. See [Evidence Table](#)

The use of High-dose rate brachytherapy in the treatment of prostate cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### High-Dose vs. Low-Dose Brachytherapy for Cervical and Endometrial Cancer

##### BACKGROUND

The standard treatment for cervical cancer is external beam radiation therapy (EBRT) combined with intracavity brachytherapy. There is no accepted standard treatment for early endometrial cancer. However, brachytherapy is often used, alone or in combination with EBRT. Intravaginal brachytherapy is believed to be useful for endometrial cancer in part because the vaginal apex is a common site of endometrial cancer recurrence. Brachytherapy refers to internal or local irradiation. In intracavity brachytherapy, radioactive sources are placed in body cavities that are close to the tumor. The relative balance between the two types of radiation treatment (brachytherapy and EBRT) depends on the stage and volume of disease. Generally, as the tumor volume increases, EBRT is favored to achieve a larger volume of homogenous dose (Stitt, 1999). Low-dose rate (LDR) brachytherapy has been available longer and is still used more frequently than high-dose rate (HDR) brachytherapy. There are several potential advantages of HDR brachytherapy, including the ability to treat large clinical patient volume, the lack of need for general anesthesia or bed rest, the ability to individualize treatment, complete radiation protection for staff and the application of multiple fractions on an outpatient basis. Disadvantages of HDR brachytherapy are the higher costs of staffing, equipment and the changing of iridium source every three months. In addition, optimal fractionation schemes for HDR brachytherapy are yet to be well defined and long-term complications are unclear (Stitt, 1999). In a LDR brachytherapy session, instruments need to be in place for 2-3 days. Cervical cancer treatment involves two procedures, approximately one week apart. Radium was used originally, but now cesium-137 is used. In contrast, with HDR brachytherapy, a treatment session takes minutes. Multiple sessions are generally required; five is a common number for treating cervical cancer. For the treatment of endometrial cancer (brachytherapy alone or in combination with EBRT after a hysterectomy), two sessions of about 1 hour each are required. High-dose rate is generally accepted as being between 50-500 cGy/minute (Tewari & DiSaia, 2002; Hogberg et al., 1999).

#### 06/11/2003: MTAC REVIEW

##### High-Dose vs. Low-Dose Brachytherapy for Cervical and Endometrial Cancer

**Evidence Conclusion:** Cervical cancer: With few exceptions, the studies reviewed did not find statistically significant differences in survival between patients receiving HDR and LDR brachytherapy for the treatment of cervical cancer. There were also no significant differences in adverse effects between the HDR and LDR groups. Although the studies suggest that the safety and effectiveness of the two treatments are similar, the studies were not designed as equivalence studies. The lack of a statistically significant finding could be due to a design flaw such as insufficient statistical power or bias. Neither of the RCTs discussed statistical power and both may have



been underpowered to detect differences in survival and/or adverse effects between groups. This is particularly true because the results were reported separately by stage of disease which resulted in a smaller sample size for each comparison. The studies also had several threats to validity. Neither of the RCTs had adequate randomization (one allocated patients by birth month and the other alternated patient assignment to treatment group) which could introduce selection bias. In all three studies, there may have been baseline differences between groups that were not controlled for in the statistical analyses. The studies also differed in the extent of external beam radiation treatment the patients received. Endometrial cancer: There are no studies that specifically compare the safety and effectiveness of HDR and LDR brachytherapy for the treatment of endometrial cancer.

**Articles:** *Cervical cancer:* The search yielded 135 articles. Many of the studies were reviews, opinion pieces or dealt with technical aspects of the procedure. There were four studies that compared the outcomes of patients who received high-dose or low-dose brachytherapy. Two of the studies were randomized and two were non-randomized. The two randomized studies and the prospective non-randomized study were critically appraised: Hareyama M, Sakata K, Oouchi A et al. High-dose versus low-dose-rate intracavity therapy for carcinoma of the uterine cervix. *Cancer* 2002; 94: 117-124. See [Evidence Table](#)  
Teshima T, Inoue T, Ikeda H. High-dose rate and low-dose rate intracavity therapy for carcinoma of the uterine cervix. *Cancer* 1993; 72: 2409-2414. See [Evidence Table](#)  
*Endometrial cancer:* The search yielded 36 articles. No randomized controlled trials were identified. There were no empirical studies comparing low-dose rate and high-dose rate brachytherapy. No articles were critically appraised.

The use of high-dose brachytherapy in the treatment of cervical and endometrial cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Prostate Cancer Brachytherapy**

### **BACKGROUND**

At the December 14, 1994 Committee on Medically Emerging Technologies the efficacy of Transperineal Ultrasound Guided Iodine<sup>125</sup> or Palladium<sup>103</sup> Brachytherapy for Prostate Cancer was originally discussed. Dr. Blasko presented information on the 800 patients for which the procedure was performed. Only 252 of those patients had a minimum follow-up of two years. The conclusion of the committee was that there was inadequate follow-up data supporting the efficacy of Transperineal Ultrasound Guided Iodine<sup>125</sup> or Palladium<sup>103</sup> Brachytherapy for Prostate Cancer. The question of Transperineal Ultrasound Guided Iodine<sup>125</sup> or Palladium<sup>103</sup> Brachytherapy for Prostate Cancer was restated and evaluated at the January 16, 1997 Clinical Policy Committee Meeting. Committee members agreed that there was inadequate evidence to compare the benefits of the three active treatment options but that there was adequate evidence (large case series) to compare the complications of the three options. Among the three active treatment options, it was agreed that brachytherapy appeared to have the lowest rate of complications. Based on this information the Committee recommended to the Clinical Planning and Improvement Council and the Delivery System Operating Team that brachytherapy be added to the list of covered treatment options for localized prostate cancer. This recommendation was accompanied by the stipulation that educational material outlining the treatment options be developed for patient education in order that they can make an informed decision about their treatment course. Not all patients with Prostate Cancer are eligible candidates for Transperineal Ultrasound Guided Iodine<sup>125</sup> or Palladium<sup>103</sup> Brachytherapy for Prostate Cancer. Documentation of the screening criteria used to identification of the eligible candidates is the purpose of this document. In late 2001 the criteria were reviewed by Dr. Nico DeWette and updated based on the current practice and experience with Prostate Seed Implant and Combined Therapy

### **12/14/1994: MTAC REVIEW**

#### **Prostate Cancer Brachytherapy**

**Evidence Conclusion:** he conclusion of the committee was that there was inadequate follow-up data supporting the efficacy of Transperineal Ultrasound Guided Iodine<sup>125</sup> or Palladium<sup>103</sup> Brachytherapy for Prostate Cancer.

### **01/16/1997: MTAC REVIEW**

#### **Prostate Cancer Brachytherapy**

**Evidence Conclusion:** Committee members agreed that there was inadequate evidence to compare the benefits of the three active treatment options but that there was adequate evidence (large case series) to compare the complications of the three options. Among the three active treatment options, it was agreed that brachytherapy appeared to have the lowest rate of complications. Based on this information the Committee recommended to the Clinical Planning and Improvement Council and the Delivery System Operating Team that brachytherapy be added to the list of covered treatment options for localized prostate cancer. This recommendation was

accompanied by the stipulation that educational material outlining the treatment options be developed for patient education in order that they can make an informed decision about their treatment course.

## **2001: MTAC REVIEW**

### **Prostate Cancer Brachytherapy**

**Evidence Conclusion:** In late 2001 the criteria were reviewed by Dr. Nico DeWette and updated based on the current practice and experience with Prostate Seed Implant and Combined Therapy.

**Articles:** Wennberg, John E., Assessing Therapies for Benign Prostatic Hypertrophy and Localized Prostate Cancer (PORT), Agency for Health Care policy and Research, Medical Outcomes and Guidelines Sourcebook, 273-288 Stock et al. Prostate Specific Antigen and Biopsy Results following Interactive Ultrasound Guided Transperineal Brachytherapy for Early Stage Prostate Carcinoma. Cancer. 1996, 77:2386-92 Wallner et al. Tumor Control and Morbidity Following Transperineal Iodine 125 Implantation for Stage T1/T2 Prostatic Carcinoma. Journal of Clinical Oncology. 1996, 14:449-53. Kaye, Keith W., et al. Detailed Preliminary Analysis of <sup>125</sup>Iodine Implantation for Localized Prostate Cancer Using Percutaneous Approach. The Journal of Urology. March 1995. 153: 1020-1025. Blasko, John C., et al., Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. Seminars in Radiation Oncology. 1993: 3(4), 240-249.

### ***Radioactive Seeds for Treatment of Recurrent High-Grade Glioblastoma***

#### **BACKGROUND**

Gliomas are the most common primary tumors of the adult brain. Primary brain tumors are those that arise from brain tissue itself, rather than metastasizing to the brain from another location. One of the most commonly diagnosed types of glioma is glioblastoma multiforme (GBM) which is defined as a Grade 4 (high-grade) astrocytoma. High-grade tumors are by definition, rapidly growing and typically develop at a distinct focus in the brain and become more diffuse in their spread as they progress. Several therapies for high-grade glioblastomas are currently employed. No treatment has been shown to cure these tumors, most likely because tumor cells infiltrate into surrounding tissue and this tumor cell type has been shown to be moderately resistant to chemo and radiation therapy. Treatment for glioblastoma multiforme typically involves surgery to reduce the size of the tumor and external beam radiation therapy. External beam radiotherapy can be delivered using a standard x-ray machine or focused on a small area of three dimensionally localized tissue using stereotactic radiosurgery. Systematic chemotherapy is usually a third line treatment and. One proposed treatment for glioblastoma is the use of stereotactically implanted radioactive seeds (brachytherapy) at the site of the tumor. The potential advantage of brachytherapy is that it allows high dose radiation to be applied directly to the tumor site and may avoid radionecrosis caused by high doses of externally applied radiation and toxic effects of chemotherapy. Glioblastoma is typically associated with a fatal outcome. Brachytherapy for malignant brain tumors has been practiced since the early 1980s. Brachytherapy applied as a boost to external beam radiation therapy has become part of the initial treatment of patients with malignant gliomas. Previous reports on the use of brachytherapy for patients with malignant gliomas have suggested improved survival for some patients. The largest experience to date has been with temporary high-activity brachytherapy implants. However, temporary implants have certain disadvantages compared with permanently implanted seeds, including higher costs and the need for more rigorous radiation safety precautions during the period of implantation.

## **13/13/2000: MTAC REVIEW**

### **Radioactive Seeds for Treatment of Recurrent High-Grade Glioblastoma**

**Evidence Conclusion:** Evidence identification was conducted by searching MEDLINE from 1990-1999 using the terms: glioblastoma, brachytherapy and neoplasm recurrence. The published scientific evidence consists of 4 case series with no comparison group or comparison only to historical controls. Case series do not provide reliable information regarding efficacy as they are subject to bias because they lack control groups that allow elimination of confounding and selection bias. Publication bias can also influence whether negative results are reported in the literature. The studies reviewed in November 2000 have a number of limitations including a small sample size, potential selection bias, lack of a proper control group, and in one of the studies, the fact that different methods variables were used to compare groups of patients. Given these limitations, there is insufficient evidence to draw conclusions about the efficacy and safety of brachytherapy for patients with glioblastoma. It was noted that glioblastoma has the worst prognosis and shortest survival times of any type of primary brain tumor. All treatments serve only to extend survival, usually by a matter of 2-3 months usually at the cost of significant treatment related morbidity. Recent improvement in imaging techniques and more complete surgical resection makes it impossible to use historical control patients as valid comparisons with respect to clinical outcomes.

**Articles:** The search yielded 20 articles. 18 articles were not directly relevant or were review articles, letters, or case reports. Two (2) empirically relevant case series were identified (evidence tables attached). *The articles*



*selected for critical appraisal include:* Patel et al. Permanent Iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. *Neurosurgery* 2000; 46:1123-1130. See [Evidence Table](#)  
 J Clin Oncol 1998;16:2202-12 entitled Iodine 131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant Gliomas: Phase I trial results. See [Evidence Table](#)  
 Shrieve, DC et al, *Neurosurgery*, 1995, 36:275-284 See [Evidence Table](#)  
 Halligan, JB et al, *Int J. Radiation Oncology Biol. Phys.* 1996, 35:541-547 See [Evidence Table](#)  
 Sneed, PK et al, *Seminars in Surgical Oncology*, 1997;13 See [Evidence Table](#)  
 Gaspar, LE, et al. *Int J. Radiation Oncology Biol. Phys.* 1999, 43:977-82 See [Evidence Table](#)  
 Gaspar, LE, et al. *Int J. Radiation Oncology Biol. Phys.* 1999, 43:977-82 See [Evidence Table](#)  
 Koot et al. Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma. *Cancer* 2000;88:2796-802. See [Evidence Table](#)

Radioactive Seeds for Treatment of Recurrent Malignant High-Grade Glioblastoma does not meet *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>19296</b>	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; on date separate from partial mastectomy
<b>19297</b>	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary procedure)
<b>19298</b>	Placement of radiotherapy after loading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance
<b>20555</b>	Placement of needles or catheters into muscle and/or soft tissue for subsequent interstitial radioelement application (at the time of or subsequent to the procedure)
<b>31643</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of catheter(s) for intracavitary radioelement application
<b>41019</b>	Placement of needles, catheters, or other device(s) into the head and/or neck region (percutaneous, transoral, or transnasal) for subsequent interstitial radioelement application
<b>58346</b>	Insertion of Heyman capsules for clinical brachytherapy
<b>61770</b>	Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source
<b>76965</b>	Ultrasonic guidance for interstitial radioelement application
<b>77316</b>	Brachytherapy isodose plan; simple (calculation[s] made from 1 to 4 sources, or remote afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s)
<b>77317</b>	Brachytherapy isodose plan; intermediate (calculation[s] made from 5 to 10 sources, or remote afterloading brachytherapy, 2-12 channels), includes basic dosimetry calculation(s)
<b>77318</b>	Brachytherapy isodose plan; complex (calculation[s] made from over 10 sources, or remote afterloading brachytherapy, over 12 channels), includes basic dosimetry calculation(s)
<b>77750</b>	Infusion or instillation of radioelement solution (includes 3-month follow-up care)
<b>77761</b>	Intracavitary radiation source application; simple
<b>77762</b>	Intracavitary radiation source application; intermediate
<b>77763</b>	Intracavitary radiation source application; complex
<b>77768</b>	Remote afterloading high dose rate radionuclide skin surface brachytherapy, includes basic dosimetry, when performed; lesion diameter over 2.0 cm and 2 or more channels, or multiple lesions
<b>77770</b>	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 1 channel
<b>77771</b>	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes basic dosimetry, when performed; 2-12 channels
<b>77772</b>	Remote afterloading high dose rate radionuclide interstitial or intracavitary brachytherapy, includes

	basic dosimetry, when performed; over 12 channels
<b>77778</b>	Interstitial radiation source application, complex, includes supervision, handling, loading of radiation source, when performed
<b>77789</b>	Surface application of low dose rate radionuclide source
<b>77799</b>	Unlisted procedure, clinical brachytherapy
<b>0395T</b>	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed
<b>HCPC Codes</b>	<b>Description</b>
<b>G0458</b>	Low dose rate (LDR) prostate brachytherapy services, composite rate

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
1998	06/01/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 09/06/2011 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 04/01/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	07/07/2020

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description of change
06/14/2016	Added retired LCD language
05/18/2015	Added AccuBoost to insufficient evidence table
09/08/2015	Revised LCD L34065
11/10/2015	Removed Electronic Brachytherapy for non-melanoma skin cancer. See separate criteria.
04/19/2016	Changed Medicare language as LCD 34065 was retired.
08/11/2016	Revised retired LCD language
06/02/2020	Removed deleted codes 77326, 77327, 77328, 77785, 77786, 77787, 0182T
06/24/2022	Remove codes 55875, 55876, 55920, 57155, 57156
07/07/2020	MPC approved to adopt updates to the clinical indications for Non-Medicare. Requires 60-day notice, effective date 12/01/2020.

**Kaiser Foundation Health Plan  
of Washington*****Clinical Review Criteria***  
**Breast Implant Removal & Re-Implantation**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

**Criteria****For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Breast Reconstruction Following Mastectomy (140.2)</a>
Local Coverage Determinations (LCD)	<a href="#">Plastic Surgery (L37020)</a>
Local Coverage Articles	<a href="#">Plastic Surgery (A57222)</a>

**For Non-Medicare Members****Breast Implant Removal & Re-Implantation**

Plastic Surgery credentials are preferred for breast implant remove & re-implantation. The *above procedures may be medically necessary* when **All of the following** criteria are met:

1. Breast implants were part of a reconstructive procedure meeting [criteria for breast reconstructive surgery](#).
2. **One of the following** clinical symptoms are present:
  - a. Infection related to implant
  - b. Implant extrusion
  - c. Ruptured implant
  - d. Baker Classification\* Class II to IV contracture
  - e. Interference with diagnosis and/or treatment of breast cancer

Additionally, breast implant removal and subsequent re-implantation may be covered if the implants were placed for a diagnosis of breast cancer or other malignancy involving the breast if criteria are met - see [Breast Reconstruction or Breast Prostheses following Mastectomy/Lumpectomy](#).

**\*Baker Classification:**

Class I augmented breast feels as soft as a normal breast

Class II augmented breast is less soft, and implant can be palpated, but is not visible

Class III augmented breast is firm, palpable and the implant (or distortion) is visible

Class IV augmented breast is hard, painful, cold, tender, and distorted

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology notes if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Breast implant removal is medically necessary under limited circumstances.

## Medical Technology Assessment Committee (MTAC)

### Silicone Breast Implant Removal

#### 09/11/1999: MTAC REVIEW

**Evidence Conclusion:** The committee reviewed the available data on the safety of silicone breast implants and concluded: There is no evidence linking silicone breast implants to cancer in women, the elective removal of existing implants is not recommended. There is concern and there may be a relationship between silicone breast implants and the development of connective tissue disease, although there is no epidemiological evidence. Silicone breast implants can impede early detection of breast cancer in cases of cosmetic breast augmentation, but do not in cases of breast reconstruction following extractive surgery.

**Articles:** Committee reviewed the available data on the safety of silicone breast implants and concluded: There is no evidence linking silicone breast implants to cancer in women, the elective removal of existing implants is not recommended. There is concern and there may be a relationship between silicone breast implants and the development of connective tissue disease, although there is no epidemiological evidence. Silicone breast implants can impede early detection of breast cancer in cases of cosmetic breast augmentation, but do not in cases of breast reconstruction following extractive surgery. Capsular contracture does occur in many patients and patients should be advised, before implantation, that it is a possible side effect that is normal and not harmful to their health.

The use of silicone breast implant removal for prevention of breast cancer does not meet the Kaiser Permanente *Medical Technology Assessment Criteria*.

#### 2001: MTAC REVIEW

### Silicone Breast Implant Removal

**Evidence Conclusion:** Evidence update outside of committee process that supported the 1999 outcome.

**Articles:** Intern Med J 2001 Mar31 (2):77-89 Women's health after plastic surgery.

Englert H, Joyner E, McGill N, Chambers P, Horner D, Hunt C, Makaroff J, O'Connor H, Russell N, March L. Westmead Hospital, Sydney, New South Wales, Australia. Laing TJ, Schottenfeld D, Lacey JV Jr, Gillespie BW, Garabrant DH, Cooper BC, Heeringa SG, Alcsér KH, Mayes MD. Department of Internal Medicine, University of Michigan.

No meeting discussion.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
19328	Removal of intact breast implant
19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
3/1999	10/5/2010 <sup>MDCRPC</sup> , 8/2/2011 <sup>MDCRPC</sup> , 4/02/2013 <sup>MDCRPC</sup> , 02/04/2014 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
10/01/2015	Revised LCD Local Coverage Determination (LCD): Non-Covered Services L34886 and L35008
12/19/2017	Added LCD 37020
04/06/2021	Updated LCA to Plastic Surgery (A57222)
04/18/2023	Updated LCA to Plastic Surgery (A57222)
02/04/2025	MPC approved to endorse credentialing preferences for Breast Augmentation. 60-day notice is not required.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Breast Reconstruction or Breast Prostheses

- Following Mastectomy/Lumpectomy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Breast Reconstruction Following Mastectomy (140.2)</a>
Local Coverage Determinations (LCD)	<a href="#">Plastic Surgery (L37020)</a> <a href="#">External Breast Prosthesis (L33317)</a>
Local Coverage Articles	<a href="#">External Breast Prosthesis (A52478)</a>

#### For Non-Medicare Members

#### Breast Reconstruction or Breast Prosthesis

For breast reconstruction or breast prosthesis following a mastectomy or lumpectomy Plastic Surgery credentials are preferred. The above procedures may be medically necessary when criteria in both in A and B are met:

A. **ONE of the following** must be met:

- Medically necessary lumpectomy or complete or partial mastectomy due to disease, injury or illness (such as breast cancer, chronic and severe fibrocystic disease, or infection unresponsive to medical therapy, chest wall surgery, or trauma) resulting in significant deformity

**OR**

- Prophylactic mastectomy to prevent the onset of breast cancer when a clinical determination has been made that there is a high risk for breast cancer

B. And must be **ONE of the following** procedures:

- For the diseased/ injured/affected breast** must meet **ONE of the following:**
  - Tissue/muscle reconstruction procedures (flaps)
  - Capsulotomy
  - Capsulectomy
  - Implantation of tissue expander
  - Implantation of U.S. Food and Drug Administration (FDA) approved internal breast prosthesis
  - Areolar and nipple reconstruction
  - Areolar and nipple tattooing
  - Breast implant removal and subsequent re-implantation
- For the non-diseased/non-injured/unaffected/contralateral breast** to produce symmetry in appearance must meet **ONE of the following:**
  - Breast reduction by mammoplasty or mastopexy
  - Augmentation mammoplasty

- c. Augmentation with implantation of FDA internal breast prosthesis when unaffected breast is smaller than the smallest available internal prosthesis
- d. Areolar and nipple reconstruction
- e. Areolar and nipple tattooing
- f. Breast implant removal and subsequent re-implantation performed to produce a symmetrical appearance when the original implant was in the unaffected breast prior to the disease in the affected breast.
- g. Capsulotomy
- h. Capsulectomy

The following products are covered for breast reconstruction when medically necessity criteria are met:

- 1. Alloderm
- 2. AlloMax
- 3. DermaMatrix
- 4. FlexHD
- 5. Neoform Dermis
- 6. Strattice tissue matrix
- 7. SurgiMend

**Autologous fat injections for post-mastectomy breast reconstruction (autologous fat grafting, autologous fat transfer, breast fat grafting, lipoinjection, lipofilling)**

- A. Autologous fat injection coverage is covered only for breast reconstruction (dimpling and contouring), if medical necessity criteria for breast reconstruction is met.
- B. Total breast reconstruction is not covered using the Brava system (autologous fat injection for complete reconstruction).

**The following are not covered:**

- A. All other bioengineered skin substitutes other than listed above - see Wound Care criteria
- B. Suction lipectomy or ultrasonically assisted suction lipectomy for correction of donor site asymmetry.
- C. Reconstructive surgical revisions are for restoration and not for cosmetic. Ongoing surgery for treatment of natural changes due to age or weight changes is considered cosmetic and not covered.
- D. Breast MRI is not covered for routine surveillance of silicone breast implants. The FDA made a recommendation (not a requirement) when they re-approved silicone implant use that members receive periodic breast MRIs. The FDA did not fund this screening. The choice of silicone vs saline is a patient preference and the use of MRI in this case cannot be described as medically necessary.

**Pulsed electromagnetic field (PEMF) for pain reduction after breast reconstruction surgery**

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies (and/or) provides better long-term outcomes than current standard services/therapies

**External breast prostheses and bras** - If the member has not undergone breast reconstruction, external breast prostheses and bras are covered after a medically necessary mastectomy or a lumpectomy, when surgery results in significant deformity.

- External prosthesis (one silicone every 2 years or one foam every 6 months) Post-mastectomy bras/forms, limited to 2 every 6 months. Replacements within this 6-month period are covered when medically necessary due to a change in the Member's condition.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

While breast reconstructive surgery can be considered a cosmetic procedure, under both state and federal law, carriers must provide coverage for this type of surgery in certain clinical circumstances.

The Women's Health and Cancer Rights Act (WHCRA) of 1988 (also known as Janet's Law) is a federal law that requires Kaiser Permanente plans and carriers offering coverage in connection with group or individual plans to provide benefits for mastectomy-related services, including breast reconstruction surgery. WHCRA states that a Kaiser Permanente plan or carrier (in a manner determined in consultation with the attending physician and the patient), must provide coverage for:

- All stages of reconstruction of the breast on which the mastectomy has been performed;
- Surgery and reconstruction of the other breast to produce a symmetrical appearance; and
- Prostheses and physical complications of mastectomy, including lymphedema.

U.S. Code – Title 29 Chapters - § 1185b, § 300gg-27, and § 300gg-52.

Washington state law also has provisions for the coverage of reconstructive surgery following a mastectomy. Both RCW 48.46.280 (HMOs) and RCW 48.330 (Health Care Service Contractors) require that carriers shall provide coverage for:

- Reconstructive breast surgery resulting from a mastectomy which resulted from disease, illness, or injury.
- All stages of one (1) reconstructive breast reduction on the non-diseased breast to make it equal in size with the diseased breast after definitive reconstructive surgery on the diseased breast has been performed.

In addition to the above statutes, guidance for interpretation of these state statutes is found in Carr v. Blue Cross of Washington and Alaska, 93 Wash. App. 941 (1999).

Kaiser Permanente has developed the criteria above with these laws as a guide.

## Evidence and Source Documents

[Autologous Fat Injections for Post-Mastectomy Breast Reconstruction](#)

[BRAVA® Breast Expansion System](#)

[Pulsed Electromagnetic Field \(PEMF\) for Pain Reduction After Breast Reconstruction Surgery](#)

[SERI® Surgical Scaffold for Breast Reconstruction](#)

## Medical Technology Assessment Committee (MTAC)

### ***Autologous Fat Injections for Post-Mastectomy Breast Reconstruction***

#### **BACKGROUND**

Autologous fat transfer, also known as breast fat grafting (BFG), fat transplantation, lipofilling, or lipoinjection, is a process in which fat cells from one area of the body are transferred to another. Fat transfer was first performed by Neuber in 1893 for the correction of a depressed face scar, and two years later it was performed by Czerny for breast construction after excision of a large fibroadenoma. Since then, several surgeons have used free fat grafts for the reconstruction of breast defects. Autologous fat is considered an ideal injectable agent for soft tissue augmentation; it is easily available for most patients, easy to use, inexpensive, nontoxic, biocompatible, and potentially long lasting, and removable (Mu 2009, Fraser 2011, Bucky 2011). Breast fat grafting is a promising technique to correct contour deformities in breasts reconstructed with either prosthesis or autologous tissues. The value of the procedure is controversial due concerns about its safety and efficacy. The degree of reabsorption of the adipose tissue transplanted is unpredictable. The mechanism underlying the survival of dissected autologous fat after grafting is unknown but is believed to be dependent on revascularization of fat granules. The lipogenic activity may vary by donor site (e.g. abdomen, thigh, and flank), patient age, weight, smoking habits, co-morbidities, condition of recipient site (scarring, radiation, previous surgery) and other factors. One of the main concerns with autogenous fat grafting for the breast is the development of fat necrosis leading to liponecrotic cysts and microcalcifications that could be mistaken for cancerous calcifications. Compression of the breast tissue by the transferred fat may also make it difficult to identify subtle changes in architectural patterns seen with early breast cancer presentation. Another concern relates to the potential oncologic risks of breast fat grafting, as fat transfer into a previous breast-cancer area may potentially stimulate local recurrence. Other complications with autologous fat transfer include edema, hematoma, induration, infection, granuloma formation, oil cyst formation, fat liquefaction, sclerosis and resorption (Pulagam 2006, Mu 2009, Mizuno 2010, Fraser 2011, Bucky 2011, Rietjens 2011, Serra-Renom 2011). After gaining much popularity, the interest in autologous fat transfers waned in the 1950s and 1960s due to low rates of graft survival and the increased use of artificial material. The interest

in autologous fat grafting for aesthetic and reconstructive purposes was renewed in the 1980s with the introduction of liposuction that provided a minimally invasive means of obtaining large amounts of adipose tissue in a semiliquid form. However, the procedure was again discontinued for some time due to concerns over post-operative calcifications and risk of obscuring developing malignant lesions. More recently, autologous fat transfer re-emerged after a number of surgeons introduced "lipomodelling" and used the technique alone or with in combination with other reconstructive procedures. Several harvesting and transplantation techniques have been developed and refined, yet no standard procedures have been adopted by all practitioners. There is no consensus on the ideal cannula, technique for harvesting, processing, or grafting the fat. Harvesting approaches include syringe aspiration and lipoaspiration. Once harvested, the fat is prepared for injection by one of several methods including: washing with physiological buffers, centrifugation for separating the cells from the debris, decantation, or concentrating it using cotton towels or other adsorbent media. For grafting, the fat is injected with a variety of delivery methods using sharp or blunt needles. It is reported that the fat "takes" if it is obtained using atraumatic methods, but it does not acquire the shape of the breast and remains flattened. It is difficult to remodel the grafted fat to acquire the desired cone shape. The procedure is not simple and should be performed by skilled and trained surgeons. It requires careful calculation of the amounts of fat injected at one time, number of injections needed, appropriate sites for injections, and proper administration of the transferred fat (Hyakusoku 2008, Mu 2009, Fraser 2011, Bucky 2011, Parrish 2010). In 1987, the American Society of Plastic and Reconstructive Surgeons (ASPRS) Ad-Hoc committee on New Procedures issued a position statement recommending that autologous fat transfer to the breast be prohibited due to its complications that may compromise breast cancer screening. In 2007, the ASPS and the American Society for Aesthetic Plastic Surgery (ASAPS) again determined that fat grafting for breast augmentation is not recommended due to the lack of clinical data on the efficacy and safety of the procedure, and also because it may interfere with the detection of breast cancer. In 2009, the ASPS Fat Graft Task Force took a more lenient position stating that, "Fat grafting may be considered for breast augmentation and correction of defects associated with medical conditions and previous breast surgeries." This Task Force based the recommendation on low quality evidence from case series, and/or expert opinion and the gave it a B grade. They emphasized that the patients should be made aware of the potential risks and complications of the procedure and indicated that physicians should be cautious when considering high-risk patients (Gutowski 2009, Mizuno 2010).

## 08/15/2001: MTAC REVIEW

### Autologous Fat Injections for Post-Mastectomy Breast Reconstruction

**Evidence Conclusion:** The published studies are limited to case series and case reports which do not provide sufficient evidence to determine the efficacy, safety, and durability of autologous fat transfer for breast reconstruction after a mastectomy. The studies used different techniques, donor site, volume of fat transplant, as well as various outcome measures and follow-up durations. Most of the series included patients undergoing the procedure for breast augmentation, reconstructive surgery after mastectomy, as well as other indications. The largest published series of 880 patients over 10 years was reported by Delay, et al in 2009. The majority (83.4%) of the patient population underwent autologous fat grafting for breast reconstruction, the rest were for correction of congenital deformities, aesthetic breast surgeries, or to correct previous surgeries. The intervention was not compared to another procedure, and the study had several limitations including, but not limited to, lack of reporting inclusion/exclusion criteria, patient characteristics, and lack of clearly defined outcomes and reporting of duration or completeness of follow-up. The authors indicate that the procedure was successful to the patients and surgeons but did not clearly define success other than comparison of photographs. They reported that the incidence of fat necrosis was 15% for the first 50 patients and declined to 3% for the last 100 patients suggesting a surgical learning curve. The authors concluded, "None of the imaging results are likely to confuse the diagnosis of cancer for radiologists who are experienced in breast imaging. Oncologic follow-up (now at 10 years for our first patients) shows no increased risk of local recurrence or of development of a new cancer". Illouz and Sterodimas (2009), reported on a series of 820 consecutive patients who underwent autologous fat transplantation over 25 years. These included patients undergoing the procedure for breast reconstruction after a mastectomy, patients with congenital asymmetry, or women requesting breast augmentation. A total amount of fat transplanted in each breast ranged from 25-900 ml (mean 540 ml), and a mean of 3 sessions (range 1-5) were needed to achieve the desired results. The authors indicated that the majority of patients were satisfied with the results. They did not measure the longevity of the transplantation, did not discuss loss of follow-up, injected fat survival, or necrosis. They indicate that calcifications, cysts, and cancer were not apparent in the first year after the procedure and thought that they may not be directly associated with the procedure. Long-term follow-up data that ranged from 2-25 years (mean 113.3 years) were only available for 28% of the patients. In conclusion, data from published studies do not provide sufficient evidence to determine the components of a successful, consistent, durable, and safe autologous fat transplantation for breast reconstruction. The Breast Reconstruction and Augmentation with Brava Enhanced Autologous Fat Micro Grafting (BRAVA) trial is an ongoing nonrandomized study on fat grafting of the breast post-mastectomy as well as other indications.

**Articles:** Assessment objective: To determine the safety and efficacy of autologous fat grafting for post-mastectomy breast reconstruction. Screening of articles: The literature search revealed around 100 articles on autologous fat grafting for post-mastectomy breast reconstruction and/or augmentation. No published meta-analyses or randomized controlled trials were identified; only case series and case reports. The majority of the published literature was on breast augmentation. The two largest published series of patients who underwent autologous fat transplantation to the breast, mainly for reconstruction after mastectomy, were selected for critical appraisal. Delay E, Garson S, Tousson G, et al. Fat injection to the breast: technique, results, and indications based on 880 procedures over 10 years. *Aesthet Surg J*. 2009; 29:360-376.

See [Evidence Table](#) Illouz YG, Sterodimas A. Autologous fat transplantation to the breast: A personal technique with 25 years of experience *Aesth Plast Surg*. 2009;33:706-715. See [Evidence Table](#)

The use of autologous fat grafting does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **BRAVA® Breast Expansion System**

#### **10/21/2013: MTAC REVIEW**

**Evidence Conclusion:** There is no evidence to permit conclusions concerning the safety and efficacy of the BRAVA Breast Expansion System used in breast reconstructive surgery with fat implants.

**Articles:** A search of PubMed and the National Institute of Health Clinical Trials records was completed for the period through September 2013 for studies on BRAVA® Breast Expansion System used for the treatment of patients following mastectomy for breast cancer. The search strategy used the terms *Brava*, *breast expansion*, *reconstructive surgery*, *fat implants*, *flap surgery* and *mastectomy* with variations. Articles were limited to those published in English language and enrolling human subjects. The search was supplemented by an examination of article bibliographies in addition to the PubMed *related* articles function. Screening of Articles: A literature search was conducted and revealed one publication (funded by the manufacturer) on the use of the Brava system plus autologous fat transfer in breast augmentation. There are no current publications on the use of the BRAVA Breast Expansion System in breast reconstruction. One ongoing clinical trial was discovered (Breast Reconstruction and Augmentation with the BRAVA Enhanced Autologous Fat Micro Grafting) with an estimated completion date of April 2014. No studies were selected for review.

The use of the BRAVA® Breast Expansion System does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Pulsed Electromagnetic Field (PEMF) for Pain Reduction After Breast Reconstruction Surgery**

#### **BACKGROUND**

Pulsed electromagnetic field (PEMF) therapy, also known as electromagnetic therapy, uses an electromagnet to generate electric current, and nonthermal pulsed electromagnetic energy to deliver the current. PEMF utilize generators designed to create radiofrequency signals that are delivered through coils which do not come in direct contact with the skin. The electric current is generated in short bursts into the injured tissue without the production of heat or interfering with nerve or muscle function. Unlike electrical stimulation, FEMF therapy does not involve the use of current, leads, or electrodes. The FEMF devices are noninvasive and can be applied over or as part of the dressing in the wound healing area directly following a procedure for the postoperative management of a surgical wound (Kinney 2005, Gupta 2009, Strauch 2009). The mechanism of action of PEMF on tissue growth and repair is not completely known. In vitro and animal research showed that PEMF can increase blood flow, enhance circulation, induces collagen synthesis, granulocyte infiltration, and inhibit growth of some wound pathogens. The literature also suggests that this modality of therapy can modify the inflammatory process, reduce edema, and enhance tissue repair. The effects of PEMF are immediate and are not limited by pharmacokinetics because the induced currents are instantaneously present when the coil is transmitting into the affected area (Kinney 2005, Gordon 2007, Strauch 2009). Electromagnetic therapy is currently being used in physical medicine, orthopedic and sports injuries, and other musculoskeletal conditions. PEMF therapy use is proposed for other conditions as the reduction of pain and edema after facial surgery, breast surgery, and abdominoplasty. Several trials are currently underway or planned to study the use of PEMF in several other fields of medicine (Kinney 2005, Gupta 2009).

#### **06/18/2012: MTAC REVIEW**

### **Pulsed Electromagnetic Field (PEMF) for Pain Reduction After Breast Reconstruction Surgery**

**Evidence Conclusion:** The overall results of the published small pilot studies show that PEMF therapy may reduce pain and use of pain medication after breast reconstruction surgery. Both trials noted that no adverse events were reported, but neither studied the effect of PEMF on the reduction of postoperative edema, or on the speed and quality of wound repair



**Articles:** The literature search revealed two relatively small randomized controlled trials that evaluated the use of PEMF therapy after breast reconstruction therapy. Both trials were critically appraised.

Hedén P and Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: A double-blind randomized pilot study in breast augmentation patients. *Aesth Plast Surg*.2008; 32:660-666. See [Evidence Table](#)

Rohde C, Chiang A, Adipoju O, et al. Effects of pulsed electromagnetic fields on interleukin-1 $\beta$  and postoperative pain: A double-blind, placebo-controlled, pilot study in breast reduction patients. *Plast Reconstr Surg*.2010; 125:1620-1629. See [Evidence Table](#)

The use of Pulsed electromagnetic field (PEMF) therapy does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **SERI® Surgical Scaffold for Breast Reconstruction**

**04/20/2015: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence to determine the efficacy and safety of SERI surgical scaffold in women undergoing breast reconstructive surgery after mastectomy.

**Articles:** The literature search did not reveal any randomized controlled trials that compared the use of SERI® Surgical Scaffold versus currently used practices or alternative material used for tissue support. To date, the published empirical studies consist of one prospective case series with 139 women undergoing breast reconstruction after mastectomy (SURE-001 study, Fine et al, 2014), a very small retrospective case series, and case reports on the use of SERI® for other indications as abdominoplasty and brachioplasty.

The prospective case series was selected for critical appraisal. Fine NA, Lehfeldt M, Gross JE, et al. SERI Surgical Scaffold, Prospective Clinical Trial of a Silk-Derived Biological Scaffold in Two-Stage Breast Reconstruction: 1-Year Data. *Plast Reconstr Surg*. 2015; 135(2):339-351. See [Evidence Table 1](#)

The use of the SERI® Surgical Scaffold for Breast Reconstruction does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Applicable Codes**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>11970</b>	Replacement of tissue expander with permanent implant
<b>11971</b>	Removal of tissue expander without insertion of implant
<b>15769</b>	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)
<b>15771</b>	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate
<b>15772</b>	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)
<b>19316</b>	Mastopexy
<b>19318</b>	Breast reduction
<b>19325</b>	Breast augmentation with implant
<b>19328</b>	Removal of intact breast implant
<b>19330</b>	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)
<b>19340</b>	Insertion of breast implant on same day of mastectomy (ie, immediate)
<b>19342</b>	Insertion or replacement of breast implant on separate day from mastectomy
<b>19350</b>	Nipple/areola reconstruction
<b>19355</b>	Correction of inverted nipples
<b>19357</b>	Tissue expander placement in breast reconstruction, including subsequent expansion(s)
<b>19361</b>	Breast reconstruction; with latissimus dorsi flap
<b>19364</b>	Breast reconstruction; with free flap (eg, fTRAM, DIEP, SIEA, GAP flap)
<b>19367</b>	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap
<b>19368</b>	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap, requiring separate microvascular anastomosis (supercharging)
<b>19369</b>	Breast reconstruction; with bipedicled transverse rectus abdominis myocutaneous (TRAM) flap
<b>19370</b>	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial

	capsulectomy
<b>19371</b>	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents
<b>19380</b>	Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction)
<b>19396</b>	Preparation of moulage for custom breast implant
<b>HCPC Codes</b>	<b>Description</b>
<b>C1789</b>	Prosthesis, breast (implantable)
<b>L8000</b>	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type
<b>L8001</b>	Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, unilateral, any size, any type
<b>L8002</b>	Breast prosthesis, mastectomy bra, with integrated breast prosthesis form, bilateral, any size, any type
<b>L8015</b>	External breast prosthesis garment, with mastectomy form, post mastectomy
<b>L8020</b>	Breast prosthesis, mastectomy form
<b>L8030</b>	Breast prosthesis, silicone or equal, without integral adhesive
<b>L8031</b>	Breast prosthesis, silicone or equal, with integral adhesive
<b>L8032</b>	Nipple prosthesis, prefabricated, reusable, any type, each
<b>L8033</b>	Nipple prosthesis, custom fabricated, reusable, any material, any type, each
<b>L8035</b>	Custom breast prosthesis, post mastectomy, molded to patient model
<b>L8039</b>	Breast prosthesis, not otherwise specified
<b>L8600</b>	Implantable breast prosthesis, silicone or equal

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/13/2011	08/02/2011 <sup>MDCRPC</sup> , 09/006/2011 <sup>MDCRPC</sup> , 06/05/2012 <sup>MDCRPC</sup> , 07/03/2012 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 04/02/2013 <sup>MDCRPC</sup> , 11/05/2013 <sup>MPC</sup> , 12/03/2013 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/02/2015	MPC approved MTAC recommendation of insufficient evidence for Seri Surgical Scaffolding for Breast Reconstruction
09/01/2015	Added language per that external prosthesis and bras are covered “before, during and after” surgery per WHCRA regs
11/2/2015	Aligned external prosthesis language with contract policy
03/08/2018	Added Plastic Surgery LCD
4/14/2020	Added non-covered statement for routine surveillance of silicone breast implants
07/31/2020	Added CPT codes 15769, 15771 and 15772
04/06/2021	Updated applicable codes
02/07/2023	MPC approved to adopt the modified changes to remove the indication for <i>one reconstructive procedure to produce a symmetrical appearance</i> . Requires 60-Day notice, effective 07/01/2023.

06/12/2023	Removed S codes due to the payment policy that states they are not reimbursable and must be billed with the other codes.
02/04/2025	MPC approved to endorse credentialing preferences for Mastectomy. 60-day notice is not required.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### Bronchial Thermoplasty for Treatment of Severe Bronchial Asthma

- Alair Bronchial Thermoplasty System

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Bronchial Thermoplasty for Treatment of Severe Bronchial Asthma</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the MCG\* (A-0634) for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist (pulmonary/allergy)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Asthma is an increasingly prevalent disease that affects over 20 million people in the United States. It is estimated that 15 -20% of asthma patients have a severe condition despite receiving the new effective therapies. Asthma is characterized by chronic inflammation of the airways, airway wall edema, bronchial hyper responsiveness, and remodeling of the airways that include increased airway smooth muscle mass. Each of these factors alone or in combination can result in recurrent episodes of wheezing, coughing, chest tightness, and breathlessness (Castro 2010, Cox 2011).

Although inflammation of the airways is a main feature of asthma, researchers believe that the contraction of the

excess airway smooth muscles, in response to various asthma triggers, is the main cause of airway constriction and restricted airflow leading to breathing difficulty during asthma attacks. This led to a hypothesis that decreasing the mass and /or contractility of airway smooth muscle would reduce airway bronchoconstriction and ameliorate the symptoms of asthma. Based on this hypothesis, investigators suggested that the application of thermal energy to the airway wall, termed bronchial thermoplasty, can reduce the bronchoconstrictor response in asthma (Cox 2007, Pavord 2007, Wechsler 2008).

Bronchial Thermoplasty (BT) is a device-based approach for severe persistent asthma that involves the application of controlled heat from a radiofrequency (RF) source to the airway wall resulting in a prolonged reduction in airway smooth muscle mass. The Alair System (Asthmatx Inc., Sunnyvale, CA) is the first device designed to use RF to selectively reduce the amount of excess airway smooth muscle in airways distal to the main stem bronchi down to 3 mm in diameter. The Alair system consists of the Alair RF catheter that has an expandable electrode array on the tip, and the Alair RF controller which supplies energy via the catheter to heat the airway wall. The catheter is deployed under direct vision through a compatible flexible bronchoscope, which is navigated to the first target treatment site, typically the most distal airway in the targeted lobe. Once the bronchoscope is inserted in the airways, the catheter is passed through the bronchoscope and its electrode array expanded such that all its sides are in contact with the airway wall. The bronchoscopist steps on a footswitch attached to the RF controller for approximately 10 seconds. This delivers low-power, temperature-controlled RF thermal energy to the treated airway. A single activation of the catheter delivers RF energy over a distance of approximately 5 mm. The catheter is then repositioned so that other adjacent areas of the airways may be treated, following a mapped treatment plan, and avoiding overlap. All visible and reachable airways 3-10 mm in diameter that are distal to the main stem bronchi are treated with a series of contiguous activations. A systematic approach from distal to proximal, working methodologically from airway to airway across the lung being treated is recommended to ensure that all accessible airways are carefully identified and treated only once. BT is performed under conscious sedation in an outpatient setting, and the procedure takes 30-45 minutes to complete. The treatment is administered in three sessions approximately 3 weeks apart. A different region of the lung is treated during each session: one lower lobe in session 1; the second lower lobe in session 2; and both upper lobes in session 3. Depending on the patient size and anatomy, a range of approximately 60-100 energy cycles are performed (Duhamel 2010, Wechsler 2008, Castro 2010).

Patients are selected for BT by an asthma specialist and an experienced bronchoscopist and should not be considered for the procedure if they have acute respiratory infection, known coagulopathy, active respiratory infection, or with asthma exacerbation or changing dose of systemic corticosteroids for asthma (up or down) 14 days before the procedure (Duhamel 2010).

This Alair Bronchial Thermoplasty system received marketing clearance from the U.S. Food and Drug Administration (FDA) in April 2010 for the control of severe persistent asthma in patients 18 years and older whose asthma is not well controlled with inhaled corticosteroids and long acting beta agonists. The FDA approved the system based on data from AIR2 trial and is requiring a five-year post-approval study of the device to study its long-term safety and effectiveness. The FDA list of potential adverse events associated with the use of the device includes: upper respiratory tract infection, throat irritation, pharyngolaryngeal pain, rhinitis, nasopharyngitis, asthma (multiple symptoms), sinusitis, wheezing, dyspnea, airway bleeding, cough, laryngospasm, bronchospasm, bronchitis, excess mucus production, chest discomfort, increased airway reactivity, atelectasis, hemoptysis, bronchial stenosis, bronchiectasis, pneumothorax, and others.

## Medical Technology Assessment Committee (MTAC)

### **Bronchial Thermoplasty**

#### **04/18/2011: MTAC REVIEW**

**Evidence Conclusion:** The Asthma Intervention Research (AIR) trial examined the efficacy of BT in patients with moderate to severe asthma while AIR2 and Research in Severe Asthma (RISA) trials studied the efficacy of the procedure in patients with symptomatic severe asthma despite the use of high doses of inhaled corticosteroids (ICS) and long acting  $\beta_2$  adrenergic agonists (LABA). AIR and RISA trials compared BT in addition to usual care with standard medications versus usual care alone and had no sham control. The AIR2 trial compared the BT to sham therapy, which was an advantage of the trial as it addressed the concern about the placebo effect of bronchial thermoplasty in the control of severe asthma. All three trials were supported by Asthmatx Inc., the manufacturer of Alair Bronchial Thermoplasty System, and the authors had financial ties to the industry and other pharmaceutical companies. The AIR trial conducted by Cox and colleagues ([Evidence Table 1](#)) enrolled 112 patients aged 18 to 65 years with moderate to severe asthma symptoms despite receiving combined therapy with ICS and LABA, and in whom the withdrawal of LABAs resulted in a worsening of asthma control. Eligible patients were randomly allocated to a treatment group that received BT in addition to the standard therapy, or to a control group that only received the standard treatment. Initially the patients were followed up for 12 months after which they were invited to participate in



a 4-year safety study. The primary outcome for the first 12 months was the difference between the BT group and the controls in the change in rate of mild exacerbation between baseline and later time points. The trial results showed a significant difference between the BT group and the controls in the change of mild exacerbations rate from baseline to three months and 12 months. No such significant difference between the two treatment groups was observed for severe exacerbations. The 5-year follow-up of 80% of patients in the BT group showed no increase in rate of hospitalization or emergency department visits for respiratory symptoms in years 2 to 5 compared to year one. The AIR2 trial by Castro and colleagues ([Evidence Table 2](#)) enrolled 288 highly selected patients with severe symptomatic asthma despite treatment with high doses of ICS and LABA. They were randomized in a 2:1 ratio to receive BT or sham therapy in which the controls underwent three bronchoscopies and sham thermoplasty treatment that duplicated the BT procedure except for the delivery of radiofrequency energy. Patients were followed-up for 12 months and the primary outcome was improvement in Asthma Quality of Life Questionnaire (AQLQ) at 6, 9, and 12 months. Both the BT and sham therapy groups experienced a large improvement in the AQLQ that lasted for 12 months. The absolute difference between the two groups was statistically significant but was too small and might not be clinically relevant. Other secondary outcomes including the Asthma Control Questionnaire (ACQ) score, symptom scores, airflow, airway hyper responsiveness, and rescue medication use showed a trend towards more improvement with BT over sham treatment, but none was statistically significant. The authors did not study the effect of BT on step-down of maintenance asthma medications, which according to the national guidelines is the main goal in the long-term management. Both AIR and AIR2 trials show that BT therapy temporarily aggravated asthma symptoms and increased the risk of adverse events some of which required hospitalization.

**Articles:** The literature search revealed around 30 articles on bronchial thermoplasty. The majority were review articles, editorials, and correspondences. Three RCTs conducted by the same group of authors were identified (AIR, AIR2, and RISA trials). RISA trial was too small (N=32), AIR trial had a 5-year follow-up, and AIR2 trial had a sham comparison group. Both AIR and AIR2 trials were selected for critical appraisal. Castro M, Rubin AS, Laviolette M, et al for the AIR2 trial Study group Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. *Am J Respir Crit Care Med*, 2010;18:116-124. See [Evidence Table](#). Cox G, Thompson NC, Rubin AS, et al for the AIR trial Study group. Asthma control during the year after bronchial thermoplasty. *N Engl J Med*. 2007;356:1327-1337 See [Evidence Table](#). Thomson NC, Rubin AS, Niven RM, et al. Long term (5 Year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. *BMC Pulm Med*. 2011;1: 8.

The use of Bronchial Thermoplasty does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
<b>31660</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe
<b>31661</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/04/2011	Added to annual review because of Medicare changes 05/01/2014 <sup>MPC</sup> , 05/06/2014 <sup>MPC</sup> , 03/03/2015 <sup>MPC</sup> , 01/05/2016 <sup>MPC</sup> , 11/01/2016 <sup>MPC</sup> , 09/05/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	08/04/2020

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee  
<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34886 and L35008 Non-Covered Services.
04/07/2016	Removed Medicare coverage language
08/04/2020	Added Kaiser Permanente Medical Policy statement under Medicare section



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Bunionectomy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "Bunionectomy" for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

**Effective until June 1<sup>st</sup>, 2025**

No Medical Necessity Review Required

Requires review for [Ambulatory Surgery Center \(ASC\)/Level of Care](#).

**Effective June 1<sup>st</sup>, 2025**

Kaiser Permanente has elected to use the Bunionectomy (KP-S-260 06012025) MCG\* Care Guideline for medical necessity determinations in addition to a review for [Ambulatory Surgery Center \(ASC\)/Level of Care](#).

For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under *Quick Access*.

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### For covered criteria:

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (podiatry)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

A bunion (also called hallux valgus) is a bony bump that forms on the inside of the big toe joint when the big toe is pushed out of alignment. This can cause the joint to swell, which can lead to pain and difficulty walking.

A Bunionectomy is a surgical procedure designed to correct bunion deformities, which involve a prominent, misaligned bony bump at the base of the big toe. During a bunionectomy, a surgeon removes the bunion, realigns the joint, and balances the muscles around the toe. A surgeon makes a small incision on the side of the foot, removes the bunion, and realigns the bone and soft tissue. The surgeon may use screws, pins, or plates to hold the bones in place. The goal is to permanently remove the bunion and restore normal foot function. A doctor may recommend a bunionectomy if other treatments, like toe spacers, pads, braces, or shoe stretches, don't work. A bunionectomy may also be recommended if walking is extremely painful or if the bunion is debilitating.

## References

- Adverse drug reactions and medication errors. In: Burchum JR, Rosenthal LD, editors. *Lehne's Pharmacology for Nursing Care*. 11th ed. Elsevier; 2022:63-73.
- Attia AK, Heier KA. First metatarsophalangeal arthrodesis for the failed hallux. *Foot and Ankle Clinics* 2022;27(4):723-744. DOI: 10.1016/j.fcl.2022.07.001. [accessed 2025 Jan 28]
- Becker BA, Childress MA. Common foot problems: over-the-counter treatments and home care. *American Family Physician* 2018;98(5):298-303.
- Becker C, et al. Interventions to improve communication at hospital discharge and rates of readmission: a systematic review and meta-analysis. *JAMA Network Open* 2021;4(8):e2119346. DOI:10.1001/jamanetworkopen.2021.19346.
- Buddecke DE, Reese ER, Prusa RD. Revision of malaligned lapidus and nonunited lapidus. *Clinics in Podiatric Medicine and Surgery* 2020;37(3):505-520. DOI: 10.1016/j.cpm.2020.03.010.
- Centers for Medicare and Medicaid Services. "Admissions." 42 CFR 412.3 Washington, DC 2023 Jul [accessed 2025 Jan 28] Accessed at: <https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-412>
- Centers for Medicare and Medicaid Services. "Condition of participation: Discharge planning." 42 CFR Pt. 482.43. Washington, DC 2022 Oct [accessed 2025 Jan 28] Accessed at: <https://www.ecfr.gov/>.
- Centers for Medicare and Medicaid Services. "Hospital services excluded from payment under the hospital outpatient prospective payment system." 42 CFR 419.22 Washington, DC 2023 Jul [accessed 2025 Jan 28] Accessed at: <https://www.ecfr.gov/>.
- Centers for Medicare and Medicaid Services. "Requirements relating to basic benefits." 42 CFR 422.101 Washington, DC 2023 Jun 05 [accessed 2025 Jan 28] Accessed at: <https://www.ecfr.gov/>.
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 1 - Inpatient Hospital Services Covered Under Part A Rev. 10892 [Internet] Centers for Medicare and Medicaid Services. 2021 Aug Accessed at: <https://www.cms.gov/manuals/>. [accessed 2025 Jan 28]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 6 - Hospital Services Covered Under Part B Rev. 10541 [Internet] Centers for Medicare and Medicaid Services. 2020 Dec Accessed at: <http://www.cms.gov/manuals/>. [accessed 2025 Jan 28]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services Rev. 12171 [Internet] Centers for Medicare and Medicaid Services. 2023 Aug 03 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2025 Jan 28]
- Del Vecchio JJ, Ghioldi ME. Evolution of minimally invasive surgery in hallux valgus. *Foot and Ankle Clinics* 2020;25(1):79-95. DOI: 10.1016/j.fcl.2019.10.010.

- Elements of Excellence in Transitions of Care (TOC). TOC Checklist [Internet] National Transitions of Care Coalition. Accessed at: <https://www.ntocc.org>. [accessed 2025 Jan 28]
- Filson R. Musculoskeletal trauma and orthopedic surgery. In: Harding MM, Kwong J, Hagler D, Reinisch C, editors. *Lewis's Medical-Surgical Nursing: Assessment and Management of Clinical Problems*. 12th ed. St. Louis, MO: Mosby; 2023:1638-1672.
- Finney FT, et al. New persistent opioid use following common forefoot procedures for the treatment of hallux valgus. *Journal of Bone and Joint Surgery. American Volume* 2019;101(8):722-729. DOI: 10.2106/JBJS.18.00793.
- Fleischer A, Patel J, Yalla S, Klein E, Landry K, Weil L. Effects of hallux valgus surgery on balance and gait in middle aged and older adults. *Journal of Foot and Ankle Surgery* 2022;61(4):798-801. DOI: 10.1053/j.jfas.2021.11.019.
- Green A. The pediatric foot and ankle. *Pediatric Clinics of North America* 2020;67(1):169-183. DOI: 10.1016/j.pcl.2019.09.007.
- Hester WA, Pedowitz DI. Postoperative considerations in the management of hallux valgus. *Foot and Ankle Clinics* 2020;25(1):141-150. DOI: 10.1016/j.fcl.2019.11.002.
- Hudson T. The role of social determinates of health in discharge practices. *Nursing Clinics of North America* 2021;56(3):369-378. DOI: 10.1016/j.cnur.2021.04.004.
- Hurn SE, Matthews BG, Munteanu SE, Menz HB. Effectiveness of non-surgical interventions for hallux valgus: a systematic review and meta-analysis. *Arthritis Care & Research* 2021;Online. DOI: 10.1002/acr.24603.
- Kadakia AR, Alshouli MT, Barbosa MP, Briggs D, Mutawakkil M. Turf toe, traumatic hallux valgus, and hallux rigidus - what can I do after an metatarsophalangeal fusion? *Clinics in Sports Medicine* 2020;39(4):801-818. DOI: 10.1016/j.csm.2020.07.007.
- Kaiser P, Livingston K, Miller PE, May C, Mahan S. Radiographic evaluation of first metatarsal and medial cuneiform morphology in juvenile hallux valgus. *Foot and Ankle International* 2018;39(10):1223-1228. DOI: 10.1177/1071100718789696.
- Knorr J, Soldado F, Violas P, Sanchez M, Domenech P, de Gauzy JS. Treatment of hallux valgus in children and adolescents. *Orthopaedics & Traumatology, Surgery & Research : OTSR* 2022;108(1S):Online. DOI: 10.1016/j.otsr.2021.103168.
- Lewis TL, Patel K, Shepherd KL, MacInnes P, Ray R, Kokkinakis M. Hallux valgus surgery in children with cerebral palsy: A systematic review. *Foot and Ankle Surgery* 2022;28(4):476-482. DOI: 10.1016/j.fas.2021.12.009.
- Mahan ST, Cidambi EO. Juvenile hallux valgus. *Foot and Ankle Clinics* 2021;26(4):807-828. DOI: 10.1016/j.fcl.2021.07.008.
- Management of patients with dermatologic disorders. In: Hinkle JL, Cheever KH, Overbaugh KJ, editors. *Brunner & Suddarth's Textbook of Medical-Surgical Nursing*. 15th ed. Wolters Kluwer; 2022:1815-1864.
- Management of patients with musculoskeletal disorders. In: Hinkle JL, Cheever KH, Overbaugh KJ, editors. *Brunner & Suddarth's Textbook of Medical-Surgical Nursing*. 15th ed. Wolters Kluwer; 2022:1113-1151.
- Mayer RS, Noles A, Vinh D. Determination of postacute hospitalization level of care. *Medical Clinics of North America* 2020;104(2):345-357. DOI: 10.1016/j.mcna.2019.10.011.
- Medical-surgical nursing. In: Hinkle JL, Cheever KH, Overbaugh KJ, editors. *Brunner & Suddarth's Textbook of Medical-Surgical Nursing*. 15th ed. Wolters Kluwer; 2022:33-55.
- Meyr AJ, et al. The American College of Foot and Ankle Surgeons® clinical consensus statement: hallux valgus. *Journal of Foot and Ankle Surgery* 2022 Mar-Apr;61(2):369-383. DOI: 10.1053/j.jfas.2021.08.011.



- Migliorini F, Eschweiler J, Tingart M, Maffulli N. Revision surgeries for failed hallux valgus correction: A systematic review. *Surgeon* 2021;19(6):e497-e506. DOI: 10.1016/j.surge.2020.11.010.
- Murphy GA. Disorders of the hallux. In: Azar FM, Beaty JH, editors. *Campbell's Operative Orthopaedics*. 14th ed. Philadelphia, PA: Elsevier; 2021:4041-4153.e7.
- Orthopedic surgery. In: Phillips N, Hornacky A, editors. *Berry & Kohn's Operating Room Technique*. 14th ed. St. Louis, MO: Elsevier; 2021:742-769.
- Ostendorf WR. Preparation for safe medication administration. In: Perry AG, Potter PA, Ostendorf WR, editors. *Nursing Interventions and Clinical Skills*. 7th ed. Elsevier; 2020:551-567.
- Premier PINC AI™ Healthcare Database (PHD), 01/01/2021-12/31/2022. Premier, Inc.
- Proprietary health insurance data sources (2021-2022); and Medicare 5% Standard Analytical File (2020-2021).
- Ratliff CR. Inflammation and healing. In: Harding MM, Kwong J, Hagler D, Reinisch C, editors. *Lewis's Medical-Surgical Nursing: Assessment and Management of Clinical Problems*. 12th ed. St. Louis, MO: Mosby; 2023:179-198.
- Saleeby J. Communication and collaboration. In: Perry AG, Potter PA, Ostendorf WR, editors. *Nursing Interventions and Clinical Skills*. 7th ed. Elsevier; 2020:9-21.
- Schipper ON, Day J, Ray GS, Johnson AH. Percutaneous techniques in orthopedic foot and ankle surgery. *Orthopedic Clinics of North America* 2020;51(3):403-422. DOI: 10.1016/j.ocl.2020.02.004.
- Seidenstein AH, Torrez TW, Andrews NA, Patch DA, Conklin MJ, Shah A. Pediatric hallux valgus: An overview of history, examination, conservative, and surgical management. *Paediatrics Child Health* 2022;27(2):75-81. DOI: 10.1093/pch/pxab074.
- Shi GG, Humayun A, Whalen JL, Kitaoka HB. Management of bunionette deformity. *Journal of the American Academy of Orthopedic Surgeons* 2018;26(19):e396-e404. DOI: 10.5435/JAAOS-D-17-00345.
- Shi GG, Whalen JL, Turner NS, Kitaoka HB. Operative approach to adult hallux valgus deformity: principles and techniques. *Journal of the American Academy of Orthopedic Surgeons* 2020;28(10):410-418. DOI: 10.5435/JAAOS-D-19-00324.
- Steinmuller L, Bartlomiejczyk S, Fernandez A, Hemmer J, Galois L. Outpatient surgery of the first ray of the foot: post-operative pain monitoring at home. *Foot (Edinburgh, Scotland)* 2021;46:Online. DOI: 10.1016/j.foot.2020.101748.
- The case manager's roles, functions, and activities. In: Gillingham DC, editor. *Foundations of Case Management*. Blue Bayou Press; 2021:9-14.
- The nursing process in drug therapy and patient safety. In: Tucker RG, editor. *Karch's Focus on Nursing Pharmacology*. 9th ed. Wolters Kluwer; 2023:47-57.
- Transitions of care. In: Gillingham DC, editor. *Foundations of Case Management*. Blue Bayou Press; 2021:137-144.
- Trnka HJ. Managing complications of foot and ankle surgery: hallux valgus. *Foot and Ankle Clinics* 2022;27(2):271-285. DOI: 10.1016/j.fcl.2021.11.015.
- Welck MJ, Al-Khudairi N. Imaging of hallux valgus: how to approach the deformity. *Foot and Ankle Clinics* 2018;23(2):183-192. DOI: 10.1016/j.fcl.2018.01.002.
- York PJ, Wydra FB, Hunt KJ. Injuries to the great toe. *Current Reviews in Musculoskeletal Medicine* 2017;10(1):104-112. DOI: 10.1007/s12178-017-9390-y.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>28292</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with resection of proximal phalanx base, when performed, any method
<b>28295</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with proximal metatarsal osteotomy, any method
<b>28296</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with distal metatarsal osteotomy, any method
<b>28297</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method
<b>28298</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with proximal phalanx osteotomy, any method
<b>28299</b>	Correction, hallux valgus with bunionectomy, with sesamoidectomy when performed; with double osteotomy, any method

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
01/14/2025	01/14/2025 <sup>MPC</sup> ,	01/14/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
01/14/2025	MPC approved to adopt new criteria for Bunionectomy for non-Medicare members. Requires 60-day notice, effective date June 1, 2025.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Capsule Endoscopy

- Given® AGILE Patency System
- M2A™ Capsule Endoscopy
- PillCam™ SB
- Wireless Capsule Enteroscopy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<b>For evaluation of known or suspected colon pathology use LCD: <a href="#">Colon Capsule Endoscopy (CCE) (L38826)</a></b>
Local Coverage Article (LCA)	<b>Billing and Coding: <a href="#">Colon Capsule Endoscopy (CCE) (A58438)</a></b>
KPWA Medical Policy	<b>For known or suspected pathology outside the colon</b> and due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>"Capsule Endoscopy"</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Capsule Endoscopy (KP-0134 08012024) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*The MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente and share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 12 months of clinical notes from requesting provider &/or specialist (gastroenterology)
- Most recent lab works

#### Patency Capsule

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, KPWA will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### **Wireless Endoscopy**

Approximately 5% of patients presenting with obscure gastrointestinal (GI) bleeding do not have a source identified after evaluation with upper endoscopy, colonoscopy and/or barium studies. Enteroscopy, evaluation of the small bowel, is indicated in many of these patients. Push enteroscopy, sonde enteroscopy and intraoperative enteroscopy are commonly used options. Push enteroscopy is relatively easy to perform but is limited by its inability to examine beyond the mid to distal jejunum in most patients. Sonde-type enteroscopes are longer than push enteroscopes and in some cases can examine as far as the terminal ileum. Disadvantages include long procedure times and a steep learning curve to master the technique. Intraoperative enteroscopy was first reported in 1976 and is considered the “gold standard” for evaluating the small bowel for the source of unexplained GI bleeding. However, this is an invasive procedure that requires a laparotomy (Adrain and Kversky, 1996).

The M2A (mouth-to-anus), a pill-sized disposable endoscope, is proposed as an alternative non-invasive tool for identifying obscure GI bleeding. The M2A capsule contains a video camera, lights, transmitter and batteries. It is swallowed by the patient and, as it moves through the digestive tract, it transmits video signals which are stored in a recorder attached to the patient's belt. The M2A moves through the digestive tract with the aid of peristalsis and is then excreted normally by the patient. About five hours of continuous reading is possible. The video can be downloaded from the recorder to a computer workstation with special software (Reporting and Processing of Images and Data, RAPID).

The M2A capsule, manufactured by Given Imaging (Yoqneam, Israel), received FDA approval in August 2001.

M2A capsule endoscopy for unexplained chronic gastrointestinal blood loss or anemia was previously reviewed by MTAC in December 2001. At that time there were no studies of health outcomes and no data on patients with unexplained chronic gastrointestinal blood loss.

#### Iron Deficiency Anemia:

Iron deficiency anemia (IDA) represents a major public health problem. Its estimated prevalence in the US is 2% of adult men and 9-12% of non-Hispanic white women. It is most commonly secondary to chronic occult bleeding from the gastrointestinal tract and is one of the common reasons for referral to gastroenterology clinics (Apostolopoulos 2006, Killip 2007).

Obscure gastrointestinal bleeding (OGIB) is defined as bleeding of unknown origin that persists or recurs after a negative initial endoscopy. OGIB accounts for at 5-10% of all gastrointestinal (GI) bleeds and may be overt or occult. Overt GI bleeding is clearly signified by rectal bleeding, bloody stools, or melena. Occult blood loss, on the other hand, is subtle and may only present as iron deficiency anemia or as a positive fecal occult blood test (Triester 2005, Concha 2007, Estevez 2006).

Diagnosing the cause of OGIB might be clinically challenging, especially when the origin of bleeding is a very small lesion in parts of the small bowel that is not apparent or accessible for direct viewing. Patients with OGIB may undergo multiple diagnostic procedures and invasive testing. Diagnostic work-up may include barium x-ray studies of the bowel, endoscopy, enteroscopy, computed tomography (CT), radionuclide scans, angiography, intraoperative endoscopy, and exploratory surgery.

Evaluation of the small bowel by conventional endoscopy has the advantage of allowing for intervention if the bleeding site is identified, but may be difficult due to the length, motility, tortuosity, looping, and free hanging course of the small bowel. Typically, an endoscope will reach only the proximal small bowel. Enteroscopy is an extension of an upper endoscopy where a longer endoscope that reaches down to the ileum is used. There are different types of enteroscopes including the push type and the sonde-type. Push enteroscopy allows the evaluation of the jejunal mucosa up to 150 cm beyond the ligament of Trietz; however, it is an invasive procedure that requires deep sedation or anesthesia, has a variable diagnostic yield (38-75%), and does not explore lesions in the ileum. Double balloon enteroscopy (DBE) is a modified push enteroscopy that is emerging as an alternative for operative enteroscopy. The balloons grip the intestinal wall allowing further insertion of the scope and the examination of larger areas of the small bowel reaching up to 300 cm in the oral direction. The entire small bowel could be potentially evaluated when a DBE is carried out with oral and anal approaches in conjunction (Lewis 2000, Mitchell 2004, Concha 2007).

Laparotomy with intraoperative enteroscopy is used after all other techniques fail to detect the source of bleeding, when there are adhesions that require lysis via a laparoscopic approach, or and when the risk of bleeding

exceeds the risk of the procedure. It is considered the gold standard for a complete endoscopic evaluation of the small bowel. However, intraoperative endoscopy is invasive, risky, and may cause artifacts that could be falsely identified as the cause of bleeding. Moreover, it was reported that intraoperative endoscopy can examine only 50-80% of the small bowel and detect the source of bleeding in up to 40% of undiagnosed cases (Mitchell 2004).

Other indirect methods for visual examination of the small bowel such as x-ray series and enteroclysis, radioisotope bleeding scans, angiography, computed scans, and MRIs have been found to have low sensitivities in detecting the source of bleeding, especially for vascular lesions which are the most frequent cause of OGIB (Estevez 2006, Leighton 2006).

Capsule endoscopy (M2A video capsule endoscope, Given Imaging Ltd, Yoqneam, Israel) was introduced in 2001 as a noninvasive direct endoscopic technique for visualization of the small bowel. It is a swallowable wireless capsule endoscope 26 mm in length and 11 mm in diameter. The device consists of an optical dome, 4 light emitting electrodes, a sensor, 2 batteries, and a micro transmitter. The capsule acquires and transmits digital images at the rate of 2/second to a sensory array attached to the patient's abdomen. It is able to capture video-images of the mucosal surface of the entire length of the small intestine directly for 7-8 hours. The capsule is propelled forward through the GI tract with the peristaltic movement and is excreted normally by the patient after 8-72 hours. The images can be downloaded from the recorder to a computer workstation with special software (Hara 2005, Eliakim 2007).

The capsule endoscopy is noninvasive and easy to perform. However, it lacks the ability to obtain a tissue sample for biopsy, deliver therapy, or treat pathology when it is found. In addition, it was reported that some lesions could be missed due to rapid or delayed small bowel transit. It might also be difficult to identify the precise location of the pathology when it is discovered. Unlike endoscopy, the lesion cannot be washed, and re-examined, and large amounts of intraluminal bile could be mistaken for blood. Interpretation of the small bowel images is highly subjective, and the potential inter-observer variation may compromise the reliability and accuracy of the technology. Moreover, some investigators have reported that the quality of the images taken by the capsule was not satisfactory, and that the duodenum was not effectively visualized. The 8 hour-battery life of the capsule is estimated to be enough time for 85% of the patients to image the entire small intestine. For the rest, the battery life expires before the capsule reaches the cecum. The major potential complication with capsule endoscopy is the risk of capsule retention due to stenosis, stricture, diverticulum, or fistula. The documented incidence of entrapment is 1%, however a retained capsule may potentially lead to intestinal obstruction, and its retrieval may necessitate surgical extraction (Concha 2007, Mazzarola 2007, Enns 2007).

The PillCam TM, previously marketed as M2A TM, manufactured by Given Imaging (Yoqneam, Israel), received FDA approval in August 2001 for detecting problems in the small bowel in adults and children ten years of age or older. The most common application for capsule endoscopy is the evaluation of obscure gastrointestinal bleeding. The second most studied indication is the evaluation of suspected Crohn's disease. It is also being used to detect polyps, cancers, other causes of chronic inflammation, bleeding, and anemia. Capsule endoscopy is contraindicated in patients with intestinal blockage, strictures or fistulas, pregnant women, patients with swallowing disorders, or those with a cardiac pacemaker or other implanted electromagnetic devices.

### **Patency Capsule**

The capsule endoscopy is relatively noninvasive, easy to perform, well tolerated, and has a low incidence of complications. The most worrisome complication is capsule retention due to stenosis, stricture, diverticulum, or fistula. Overall, the documented incidence of capsule retention or entrapment is as low as 1% but may be higher in some population at risk. Studies reported retention rates of 5-13% in patients with known Crohn's disease, and a rate of 21% in suspected bowel obstruction. A retained or impacted capsule may potentially lead to small bowel ileus, intestinal obstruction, or fragmentation of the capsule with potential toxic hazard. Risk factors for capsule retention include major abdominal surgery, known or suspected Crohn's disease, previous intestinal obstruction, prolonged NSAID use, ischemic bowel disease, radiation injury, and suspected bowel tumors. Retrieval of a retained capsule requires medical, endoscopic or surgical intervention (Sears 2004, Signorelli 2006, Concha 2007, Enns 2007, Caunedo-Alvarez 2008).

Due to the risk of capsule retention, wireless capsule endoscopy is contraindicated in patients with suspected small bowel strictures. In most centers, a radiographic evaluation of the small bowel patency is mandatory before performing a wireless capsule endoscopy in patients with a risk of small bowel strictures. Standard imaging techniques include small bowel (SB) follow-through, barium enema, enteroclysis, or CT enteroclysis. Limitations of these techniques include a tendency to underestimate or overestimate SB strictures. They can identify long or



medium stenosis with great reduction in their lumen size but may not detect a short intestinal stenosis or obstruction, leading to false negative results (Boivin 2005, Caunedo-Alvarez 2008, Karagiannis 2009).

Given Imaging, the manufacturer of the PillCam SB has developed a new system (The Given® Patency Capsule) to identify patients with strictures that may cause retention of the video capsule. The first generation was the M2A patency capsule, which due to the risk of obstruction, was modified to the AGILE Patency Capsule (PC). This consists of a dissolvable capsule and a scanner. The capsule is composed of a lactose body with 5% barium (to induce radiopacity) that surrounds a small radiofrequency identification tag (RFID). The body is coated with an impermeable cellophane membrane with two wax timer plugs located at each end of the capsule. The timer plugs seal the capsule's body, and each has a small window or opening that allows penetration by gastrointestinal (GI) fluids.

The Agile patency capsule (PC) has the same dimensions and shape as the PillCam. Once the patient ingests the capsule, it is propelled through the GI tract by normal peristalsis. The Agile PC is designed to remain intact for 30 hours (40 hours in the first generation). It is assumed that it will be excreted intact if there is no bowel obstruction. In this case a PillCam capsule can be administered. If there is any kind of stricture hindering its passage for more than 30 hours, the patency capsule starts to disintegrate (except for the identification tag), allowing the insoluble outer membrane to collapse and be excreted deformed or in fragments. The persistence of the PC inside the GI tract can be verified by means of radiology or with a radiofrequency emitting external detector device locating the RFID (Signorelli 2006, Caunedo-Alvarez 2008).

It is reported that the Given patency capsule may provide direct evidence of functional patency of the gut lumen, even in those patients showing radiological evidence of small bowel stricture. This information may allow a distinction between rigid fibrotic strictures and flexible ones (Spada 2005, Karagiannis 2009).

The Given® AGILE Patency System received marketing clearance from the U.S. Food and Drug Administration (FDA) in 2006, as an accessory to the PillCam to verify adequate patency of the gastrointestinal tract in patients with known or suspected strictures prior to administration of the PillCam video capsule.

## Medical Technology Assessment Committee (MTAC)

### Capsule Endoscopy

#### 12/12/2001: MTAC REVIEW

**Evidence Conclusion:** There is insufficient published evidence on which to base a conclusion about the effect of M2A capsule endoscopy on health outcomes.

The search yielded 4 articles. One of these was a historical piece, one was a letter to the editor describing the use of the technology with 4 cases. The third was an empirical study conducted in dogs. The fourth was description of the technology including acceptability (e.g. ability to swallow, quality of images, mouth-to-evacuation time) in 10 normal human volunteers. There were no studies of health outcomes and no data on patients with unexplained chronic gastrointestinal blood loss. In addition to the studies found on Medline, there were several published abstracts in the Given Imaging reference list. None of the articles were suitable for critical appraisal.

The use of M2A™ (Given Imaging) capsule in the diagnosis of small bowel lesions/chronic bleed sites does not meet the *Kaiser Permanent Medical Technology Assessment Criteria 2* for effectiveness.

#### 12/10/2003: MTAC REVIEW

### Capsule Endoscopy

**Evidence Conclusion:** The prospective comparative studies that were reviewed suggest that M2A capsule endoscopy has a significantly greater diagnostic yield than push enteroscopy among patients with unexplained gastrointestinal bleeding. The studies did not use the gold standard evaluation tool, an invasive surgical procedure, so diagnostic accuracy (e.g. sensitivity, specificity) cannot be calculated.

**Articles:** The search yielded 23 articles. The ideal study would be an independent, blind comparison of M2A and a gold standard diagnostic test. There were 5 comparative studies in patients with gastrointestinal bleeding. No articles specifically studied use of the M2A for anemia, but patients with anemia suggestive of overt bleeding were included in some of the GI bleeding studies. The methodology was similar in the 5 studies. All compared M2A evaluation with push enteroscopy and none of the studies included evaluation with intraoperative enteroscopy, the invasive "gold standard" procedure. The primary outcome in each study was diagnostic yield (the ability to diagnose the source of bleeding) of the two procedures. All 5 studies included blinded evaluation of test results. Results of the studies were similar; all found a higher rate of diagnostic yield with the M2A. Findings were



statistically significant in 4 of the 5 studies and did not reach statistical significance in the smallest study. Sample sizes ranged from 20 to 60 patients. The two largest studies (n=52, n=60) were critically appraised: Mylonaki M, Fritscher-Ravens A, Swain P. Wireless capsule endoscopy: a comparison with push enteroscopy in patients with gastroscopy and colonoscopy negative gastrointestinal bleeding. *Gut* 2003; 1122-1125. See [Evidence Table](#) Saurin J-C, Delvaux M, Gaudin J-L. et al. Diagnostic value of endoscopic capsule in patients with obscure digestive bleeding: Blinded comparison with video push-enteroscopy. *Endoscopy* 2003; 35: 576-584. See [Evidence Table](#)

The use of M2A™ (Given Imaging) capsule in the diagnosis of small bowel lesions/chronic bleed sites does meet the *Kaiser Permanente Medical Technology Assessment Criteria* for effectiveness.

## 12/03/2007: MTAC REVIEW

### Capsule Endoscopy

**Evidence Conclusion:** Diagnostic accuracy: Triester, Leighton and colleagues' meta-analyses (2005, 2006) as well as the other published meta-analyses compared CE with one or more alternative diagnostic modalities for evaluation the small bowel in patients with OGIB. Triester's meta-analysis included studies either published in full or in the abstract form. The studies compared the performance of CE mainly to push enteroscopy and barium radiography, none of which is considered as a gold standard, nor is able to identify all kinds of lesions in the entire small bowel. The performance of CE and other diagnostic modalities were thus measured as diagnostic yield, which mainly depends on subjective interpretation, rather than sensitivity and specificity. CE was found to be associated with significantly higher incremental yield and number needed to test around 3. A higher yield might indicate that CE is superior to the alternative method but does not assess sensitivity of the test, nor is it able to discriminate the false positive findings. Hartmann and colleagues' 2005, study (not included in the meta-analysis) compared capsule endoscopy to the gold standard of intraoperative enteroscopy. In that study 47 consecutive patients with OGIB and a negative initial work-up underwent both capsule and intraoperative endoscopy. The source of bleeding was located by intraoperative endoscopy in 72.3% of cases and by capsule endoscopy in 74.5%. Compared to the gold standard CE had a sensitivity of 97%, specificity of 85%, positive predictive value of 95% and negative predictive value equal to 86%. CE was not associated with any major adverse events, while one patient died of postoperative peritonitis after laparotomy. Apostolopoulos and colleagues 2006, compared the performance of CE to enteroclysis among 51 patients with unexplained iron deficiency anemia after negative endoscopic evaluation of the upper and lower gastrointestinal tract. This was a highly selected group of patients which may limit generalization of the results. Upper GI series and push enteroscopy were not included among the diagnostic procedures performed. The authors compared the yield of CE with enteroclysis which is not considered as a gold standard, and the results were presented as diagnostic yields not sensitivity and specificity. Its results show that CE had a diagnostic yield of 56.9% vs. 11.8% for the enteroclysis ( $p < .0001$ ). Impact of capsule endoscopy on patient management: The published studies, to date, on the influence of capsule endoscopy on patient management included highly selected groups of patients with wide variations in their baseline characteristics as age, indication of endoscopy, duration of bleeding, number and type of previous investigations undergone, as well as other variables. In addition, the investigators used different diagnostic criteria for the identification of the bleeding pathology, as reflected in the wide range of diagnostic yield. The latter was also influenced with the experience and number of researchers interpreting the CE images. Thus, the published studies with their potential biases and confounding factors, and with the lack of randomized controlled trials, do not provide sufficient evidence to determine that capsule endoscopy would lead to any incremental improvement in the management of patients. Impact of CE on patient outcome: There is insufficient evidence to determine the impact of CE on patient outcome. The published outcome studies were small case series with no control groups. The therapies and interventions received by the patients were not standardized and varied between studies. Patients were treated with medical, endoscopic or surgical interventions and complete resolution of bleeding was achieved in 40-85% of cases. This varied according to study, eligibility criteria, patient characteristics, bleeding condition, condition, and treatment received. Randomized controlled trials with long-term follow-up periods are needed to determine the effect of capsule endoscopy on patient management and outcomes. Assessment objective: To evaluate the diagnostic accuracy for the capsule endoscopy (CE) in identifying the lesion of, IDA or obscure gastrointestinal bleeding (OGIB)? To determine whether CE contributes substantially to improved diagnosis and/or replaces other diagnostic tests or procedures. To determine if diagnosing the source of IDA/OGIB with the CE would influence the management decisions? Would it result in providing more appropriate therapy? To determine whether using CE for locating the source of OGIB would improve the clinical and patient-oriented outcomes? Diagnostic accuracy: There were three meta-analyses (Triester 2005, Triester 2006, and Leighton 2006) that evaluated CE for OGIB and/or Crohn's disease. All three were conducted by the same investigators and the two meta-analyses on OGIB included the same studies. There was also another meta-analysis that compared CE to double-balloon enteroscopy, one study that compared CE with the gold standard intraoperative enteroscopy, and several other studies that compared the performance of CE with other diagnostic

© 2001 Kaiser Foundation Health Plan of Washington. All Rights Reserved. [Back to Top](#)

modalities. Almost all studies investigated the use of CE for patients with OGIB. Two very small studies investigated the use of CE for patients with iron deficiency anemia (IDA) after negative endoscopic evaluation of the upper and lower GI. Apostolopoulos et al 2006 performed CE on 51 out of 253 patients referred for the evaluation of iron deficiency anemia, and Bar-Meir et al 2004, assessed the diagnostic yield of a second CE for 20 patients with severe IDA). Diagnostic/therapeutic impact:

**Articles:** The literature search identified several prospective studies on the influence of capsule endoscopy on management decisions and/or treatment outcomes. All were case series with no control or comparison groups. The largest more recent meta-analysis of studies that compared CE to other diagnostic modalities, the prospective study that compared it with intraoperative endoscopy, the study on its role in investigating unexplained iron deficiency anemia, a case series on its impact on patient management, as well as 4 outcome studies were critically appraised. The four outcome studies were summarized in one table. *The following studies were critically appraised:* Triester SL, Leighton JA, Leontiadis GL, et al. A meta-analysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with obscure gastrointestinal bleeding. *Am J Gastroenterol*; 2005; 100:2407-2418. See [Evidence Table](#) Leighton JA, Triester SL, Sharma VK. Capsule endoscopy: A meta-analysis for use with obscure gastrointestinal bleeding. And Crohn's disease. *Gastrointest Endosc* 2006;16:229-250 See [Evidence Table](#) Hartman D, Schmidt H, Bolz G, et al. A prospective two-center study comparing wireless capsule endoscopy with intraoperative enteroscopy in patients with obscure gastrointestinal bleeding. *Gastrointest Endosc* 2005;61:826-832 See [Evidence Table](#) Apostolopoulos P, Liatos C, Gralnek IM, et al. The role of wireless capsule endoscopy in investigating unexplained iron deficiency anemia after negative endoscopic evaluation of the upper and lower gastrointestinal tract. *Endoscopy* 2006; 38:1127-1132. See [Evidence Table](#) Sidhu R, Sanders DS, Kapur K et al., Capsule endoscopy changes patient management in routine clinical practice. *Dig Dis Sci* 2007; 52:1382-1386. See [Evidence Table](#) Viazis N, Papaxoinis K, Theodoropoulos I, et al. Impact of capsule endoscopy in obscure small-bowel bleeding; defining strict diagnostic criteria for a favorable outcome. *Gastrointest Endosc* 2005; 62:717-722 See [Evidence Table](#) Estevez, Gonzalez-Conde B, Vazquez-Iglesias JL, et al. Diagnostic yield and clinical outcomes after capsule endoscopy in 100 consecutive patients with obscure gastrointestinal bleeding. *Europ J Gastroenterol Hepatol* 2006;18:881-888 See [Evidence Table](#) Neu B, Ell C, May A, et al. Capsule endoscopy versus standard tests in influencing management of obscure digestive bleeding: results from a German multicenter trial. *Am J Gastroenterol*; 2005; 100:1736-1742. See [Evidence Table](#) Pennazio M, Santucci R, Rondonotti E, et al. Outcome of patients with obscure gastrointestinal bleeding after capsule endoscopy: report of 100 consecutive cases. *Gastroenterol* 2004; 26:643-653. See [Evidence Table](#)

The use of M2A™ (Given Imaging) capsule in the diagnosis of unexplained iron deficiency anemia does not meet the *Kaiser Permanente Medical Technology Assessment Criteria* for effectiveness.

#### 4/18/2011: MTAC REVIEW

##### Capsule Endoscopy

**Evidence Conclusion:** There is limited published evidence on the usefulness and safety of Agile patency capsule in identifying patients who can safely undergo capsule endoscopy. There are no published randomized controlled trials, to date, that compared the accuracy of Agile capsule to any of the radiographic methods used to assess small bowel patency prior to capsule endoscopy. The case series by Herrerias and colleagues (2008) examined the ability of the Agile system in determining which patients with known strictures can safely undergo capsule endoscopy (CE). 106 eligible patients with evidence of intestinal stricture ingested the patency capsule and were followed up periodically with scanning devices until the capsule was excreted. The intestinal tract was considered sufficiently patent if the patency capsule was excreted intact without any changes in its original dimensions, or if the radiofrequency identification tag (RFID) was not detected by scanning the patients at 32-38 hours after ingestion. 59 patients (56%) excreted the patency capsules intact and underwent capsule endoscopy with the PillCam video capsule, with no cases of capsule retention. The majority of patients who excreted intact patency capsules still had to undergo fluoroscopy as the capsules were passed after the scheduled 38 hours (over 25% were excreted after 60 hours). A total of 17 patients had adverse events mainly abdominal pain; one patient had intestinal obstruction and underwent surgical resection of the proximal colon and terminal ileum. The authors indicate that no remnants of the capsule were found at surgery. The study may suggest that patients who pass the Agile Patency Capsule intact may be suitable candidates for capsule endoscopy but does not provide sufficient evidence that it is safer and more accurate than other radiographic methods used.

**Articles:** The literature revealed a limited number of articles on the Given Patency System. The published empirical studies were all case series and mainly on the first generation of the patency capsule (M2A Patency Capsule). Only one case series on the newer generation, the Agile Patency System, was identified, and critically appraised. Herrerias J, Leighton JA, Costamagno G, et al. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. *Gastrointest Endosc*. 2008;67:902-909. See [Evidence Table](#)

The use of patency capsule does not meet the *Kaiser Permanente Medical Technology Assessment Criteria* for effectiveness.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>91110</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus through ileum, with interpretation and report
<b>91111</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report
<b>91113</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/12/2001	07/06/2010 <sup>MDCRPC</sup> , 05/03/2011 <sup>MDCRPC</sup> , 03/06/2012 <sup>MDCRPC</sup> , 01/08/2013 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 10/02/2018 <sup>MPC</sup> , 10/01/2019 <sup>MPC</sup> , 10/06/2020 <sup>MPC</sup> , 10/05/2021 <sup>MPC</sup> , 10/04/2022 <sup>MPC</sup> , 10/03/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	03/12/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/05/2015	Slight modifications to the policy were made to include esophageal varices. Also, a notation and to allow approval for NSAIDS if ASA is used for anticoagulation.
08/31/2016	Added retired LCD language
07/11/2017	MPC approved to adopt revised indication
10/05/2021	Added Colon Capsule Endoscopy LCD/LCA for Medicare.
12/08/2022	Added applicable new CPT code to criteria; removed applicable deleted CPT code
03/12/2024	MPC approved the modified hybrid criteria for capsule endoscopy effective August 1 <sup>st</sup> , 2024, 60-day notice required.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Coronary Artery Calcium Score with Computed Tomography (CT)

- Multidetector Computed Tomography (MDCT)
- Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<p>05/13/2016 Noridian retired LCD <a href="#">Multidetector Computed Tomography of the Heart and Great Vessels (L34137)</a>. These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.</p> <p>Per LCD L34137 - ... Until such time as there is more evidence of the medical necessity for quantitative evaluation of coronary calcium, Medicare may not cover the procedure for coronary calcium scoring (75571).</p> <p><a href="#">Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (L39883)</a> (CPT 0623T-0626T)</p>
Local Coverage Articles	<p><a href="#">Billing and Coding: Coronary Computed Tomography Angiography (CCTA) (A57552)</a> <i>Addresses CPT Code 77571</i></p> <p><a href="#">Billing and Coding: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) (A59771)</a> (CPT 0623T-0626T)</p>

#### For Non-Medicare Members

\*Repeat CAC measurement not indicated within less than 5 years.

*Adapted from KPWA ASCVD Primary Prevention Guideline (Oct 2020)*

Coronary artery calcium scoring may be indicated for asymptomatic patients with **1 or more of the following**:

- Intermediate ASCVD risk\* indicated by ALL of the following
  - Age 40-75 without DM and with LDL-C levels  $\geq 70$  mg/dL
  - At a 10-year ASCVD risk\* of  $\geq 7.5\%$  and  $< 20\%$
  - Risk status or decision about statin therapy is uncertain

For these patients, treatment with statin therapy may be withheld or delayed if CAC = 0, except in cigarette smokers and those with a strong family history of premature ASCVD. A CAC score of 1–99 favors statin therapy, especially in those aged  $\geq 55$  years. For any patient, if the CAC score is  $\geq 100$  or  $\geq 75$ th percentile, statin therapy is indicated.

- May be considered in select adults age 40-75 with ALL of the following
  - Borderline elevated ASCVD risk (5-7.4% 10-year ASCVD risk\*)
  - The presence of CAC may change decision-making with regard to statin treatment and intensity of ASCVD risk factor modification

Routine CAC measurement is not recommended for:

- Patients at low ( $< 5\%$  10-year risk) or high ( $\geq 20\%$  10-year risk) ASCVD risk
- Patients who are unlikely to initiate treatment even if CAC is identified

\*[ASCVD Risk Estimator Plus](#) (American College of Cardiology)

**If requesting review for this service, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Documented 10-year ASCVD risk score

\*[ASCVD Risk Estimator Plus](#) (American College of Cardiology)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Coronary heart disease (CHD) remains the leading cause of death among men and women in the United States. It is valuable to detect coronary atherosclerosis early in its course and try to alter its progression by modifying certain identifiable risk factors. The earliest detectable lesion of coronary atherosclerosis is a fatty streak, followed by crescent shaped lipid plaques, which may rupture and produce either progressive stenosis or sudden occlusion with myocardial infarction. It was previously thought that coronary artery calcification was the late result of end stage plaque degeneration. Now it is believed that calcium is present in all stages of plaque formation. Coronary artery calcification occurs in small amounts in the early lesions of atherosclerosis that appear in the second and third decades of life but is found more frequently in advanced lesions in older age (Janowitz 1993). Coronary artery calcium increases with increasing age in men, while women may experience accelerated calcification after menopause (Allison 2004).

The relation of arterial calcification to the probability of plaque rupture is unknown. Some investigators postulate that calcification may actively contribute to the susceptibility of plaque rupture and subsequent events. While others believe that calcification may reflect stabilization and maturation of the plaque that would lead to fewer myocardial infarctions and CHD deaths (Lee 2002). Beckman 2001 reported that although radiographically detected coronary artery calcium can provide an estimate of total coronary plaque burden, calcium does not concentrate exclusively at sites with severe coronary artery stenosis due to arterial remodeling. Other researchers indicated that ultrafast scans cannot detect all calcium and that molecular calcium may go unnoticed. Thus calcium detected by ultrafast scans may represent only the tip of the iceberg (Rumberger 1996). Despite that, some investigators believe coronary artery calcium (CAC) detection may be able to globally define a patient's risk of CHD events.

Now that some believe that calcification can be used as a marker of the atherosclerotic process, and because calcific deposits are radio-opaque, numerous radiographic techniques have been used in the search for a



noninvasive screening test for coronary artery disease. Fluoroscopy was used for decades to detect coronary artery calcium. However, its routine use for identifying patients with coronary artery disease is limited due to its low sensitivity to detect small amounts of coronary calcium that can be observed pathologically in complex atherosclerotic plaques. Conventional computed tomography (CT) have an advantage over fluoroscopy in its improved resolution, which is limited however when moving structures are imaged. This limitation has been overcome by the electron beam computed tomography (EBCT), and multidetector computed tomography (MDCT). Both technologies yield thin slice CT imaging using fast scan speeds that reduce motion artifact. 30-40 adjacent axial scans are usually obtained. The fast time scan allows the entire heart to be imaged over one or two breath holds. Images can be reconstructed to form three-dimensional or cross-sectional images. There are three methods for calcium quantification and scoring: The Agatston method, the volumetric method, and quantification of calcium mass. Agatston method is the most commonly used and is obtained by the summation of areas of the calcified lesions multiplied by a scaling cofactor; an Agatston score of zero indicates absence of coronary calcium, 1-99 is considered low, 10-400 is intermediate, and 400 high (Sanz 2006). Calcium scores can be calculated for a coronary artery segment, a coronary artery, or summed for the whole coronary system.

Ultrafast CT scanners became commercially available in 1983, before the first study of their use was published in 1989. In the 1990s, another form of CT, the helical or spiral computed tomography has been developed. In helical tomography, continuous scanning is performed in combination with a continuous table feed. Thus, the x-ray beam traces a spiral path through the patient. The entire heart can be imaged with 3 mm non-overlapping slices, within one breath hold (30 sec). The initial goal of using cardiac computed tomography was to identify patients at risk of coronary artery disease based on the amount of calcium present. However, in the past 5-10 years these ultrafast scans have been used to: 1) Assist in CHD risk assessment in asymptomatic individuals, and, 2) To assess the likelihood of the presence of CHD in patients who present with atypical symptoms that could be consistent with myocardial ischemia.

The EBCT scanners currently used are produced by GE Imatron, South San Francisco California. They were approved by the FDA as Class II devices.

The use of EBCT for CAC scoring was reviewed by MTAC in 2002 and 2004 and did not meet its evaluation criteria. It is being re-reviewed due to the recent publications of studies with clinically important outcomes.

## Medical Technology Assessment Committee (MTAC)

### ***Ultrafast CT in the Screening and Diagnosis of CAD***

#### **02/11/2002: MTAC REVIEW**

**Evidence Conclusion:** In conclusion, the results of these studies indicate that in a population where CAD is more prevalent, the absence of coronary calcification is more helpful in ruling out CAD than is the detection of calcium in confirming the presence of CAD. Ultrafast CT seems promising, but as yet, there is no evidence that it may substitute angiography, but can be helpful in excluding or increasing the likelihood of significant CAD in certain situations.

**Articles:** The search yielded 39 articles, many of which were review articles, opinion pieces, or dealt with technical aspects of the scan. The search did not reveal any study that evaluated ultrafast scanning as a screening test for coronary heart disease. There were four studies that compared the Ultrafast CT scan with angiography and a few others that did not use a defined gold standard for comparison. There was only one study on the newer helical CT scan. The two studies with the stronger methodology, and larger sample sizes were selected for critical appraisal. Broderick's study that evaluated the performance of the helical CT scan was also reviewed. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease. A multicenter study. *Circulation* 1996; 93:898-904. See [Evidence Table](#). Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 1996; 27:285-90. See [Evidence Table](#). Broderick LS, Shemesh J, Wilensky RL, et al. Measurement of coronary artery calcium with dual-slice helical CT compared with coronary angiography: Evaluation of CT scoring methods, observer variations, and reproducibility. *AJR* 1996; 167:439-444. See [Evidence Table](#).

The use of ultrafast CT in the screening and diagnosis of CAD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **12/08/2004: MTAC REVIEW**

### ***Ultrafast CT in the Screening and Diagnosis of CAD***

**Evidence Conclusion:** A screening test for preclinical coronary artery disease among asymptomatic individuals, and A diagnostic test for coronary artery disease among symptomatic patients. [Use of EBCT for coronary artery](#)

disease screening among asymptomatic individuals: There is insufficient published evidence to determine the value of EBCT (Ultrafast CT) as a screening test for coronary artery disease among asymptomatic individuals. Ideally, a screening test should be highly sensitive in detecting previously undiagnosed disease and should lead to changes in management that improves outcomes. The meta-analysis and observational studies reviewed evaluated EBCT coronary artery calcium as a risk predictor of future coronary events among asymptomatic individuals. These studies suggest that coronary artery calcium detected by EBCT may be an independent predictor for coronary events and may add to the information provided by the Framingham risk score. However, the studies had some threats to validity that may limit generalization of the results. The majority is office-based and included self-referred individuals or others at high risk referred by their primary care physicians for further evaluation. Risk factors were self-reported and not measured in more than one study. Different techniques and scans were used, and there was no established cut-off level for calcium scores. The endpoints included revascularization in several trials, which could have been performed at a higher rate based on the results of the scan. The endpoint in one of the studies was all-cause mortality that might be due to other causes than coronary atherosclerotic diseases. None of these observational studies examined the influence of detecting coronary artery calcification on the management of the individuals, the health benefits, or effect on outcome. There is no evidence that more effective therapy or management could be provided by evaluating CAC score beyond that provided based on FRS. A recent RCT showed that the detection of coronary artery calcium among asymptomatic individuals was not associated with behavior modification or reduction of their cardiac risk scores. This RCT also had its limitations. Use of EBCT as a diagnostic test for coronary artery disease among symptomatic patients: The studies reviewed show that compared to coronary angiography as a gold standard; EBCT scanning had a high sensitivity and low specificity in detecting coronary artery disease among symptomatic patients. The sensitivity ranged from 81% to 99% among the studies reviewed in the meta-analysis, and the more recent study. The sensitivity was inversely related to the calcium score cutoff points. It was highest at a calcium score 0-10 which on the other hand had a specificity as low as 28%, i.e. high false positives which would be associated with further investigations that might be unnecessary. The studies were conducted among symptomatic patients with a high prevalence of coronary disease, and there is a potential of overestimation of the sensitivity, and positive predictive value, which might limit generalization of the results.

**Articles:** The search yielded 39 articles, many of which were review articles, opinion pieces, or dealt with technical aspects of the scan. The search did not reveal any study that evaluated ultrafast scanning as a screening test for coronary heart disease. There were four studies that compared the Ultrafast CT scan with angiography and a few others that did not use a defined gold standard for comparison. There was only one study on the newer helical CT scan. The two studies with the stronger methodology, and larger sample sizes were selected for critical appraisal. Broderick's study that evaluated the performance of the helical CT scan was also reviewed. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease. A multicenter study. *Circulation* 1996; 93:898-904. See [Evidence Table](#). Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 1996; 27:285-90. See [Evidence Table](#). Broderick LS, Shemesh J, Wilensky RL, et al. Measurement of coronary artery calcium with dual-slice helical CT compared with coronary angiography: Evaluation of CT scoring methods, observer variations, and reproducibility. *AJR* 1996; 167:439-444. See [Evidence Table](#).

The use of ultrafast CT in the screening and diagnosis of CAD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 04/02/2007: MTAC REVIEW

##### Ultrafast CT in the Screening and Diagnosis of CAD

**Evidence Conclusion:** There is some evidence that CAC may add a prognostic incremental value to Framingham risk score among selected asymptomatic individuals. Indirect evidence suggests that asymptomatic individuals at intermediate risk might potentially benefit from adding CAC to the risk assessment. The majority of the participants in the studies reviewed were Caucasians which may limit generalization of the results. The studies do not provide an optimal coronary calcium threshold. There is no single cutoff value that defines a high score. The coronary calcification differs according to age, sex, and race. There is no evidence to date that CAC scoring would result in an intervention that would improve CHD related health outcomes among individuals at an increased risk for CHD. The test results may lead to unnecessary invasive procedures, or overtreatment in some patients.

**Articles:** The search yielded around 50 articles. Many were review articles, opinion pieces, or dealt with technical aspects of the scan. Use of EBCT for coronary artery disease screening: The search identified a recent meta-analysis of observational studies (Greenland 2007) and several prospective cohort studies that evaluated EBCT coronary artery calcium (CAC) score as a risk marker predicting the likelihood of future coronary events among asymptomatic patients. It also revealed two articles on the St. Francis Heart Study (Arad, Goodman 2005, and Arad, Spadaro 2005). The first reported on the prospective cohort study, © 2002, Kaiser Foundation Health Plan of Washington. All Rights Reserved. [Back to Top](#)

and the second on the RCT embedded in the cohort. The meta-analysis and the two articles on the St. Francis Heart Study were selected for critical appraisal. Use of EBCT for coronary artery disease diagnosis: The search did not reveal any newly published large valid study on the use of CAC scoring in the detection of coronary artery stenosis among symptomatic patients. *The following articles were critically appraised:* Greenland P, Raggi P, Harrington R, et al. ACC/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment an in evaluation of patients with chest pain. J Am Coll Cardiol. 2007; 49:378-402. See [Evidence Table](#). Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. J Am Coll Cardiol. 2005; 46:158-165. See [Evidence Table](#). Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005; 46:166-172. See [Evidence Table](#).

The use of EBCT in the treatment of coronary artery calcium scoring does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **CORONARY ARTERY CALCIUM (CAC) SCORING WITH COMPUTED TOMOGRAPHY, FOR CARDIOVASCULAR DISEASE RISK ASSESSMENT**

**Date:** 10/12/2020

### **Evidence Conclusion:**

- There is evidence from published long-term large longitudinal population studies indicating that:
  - CAC is strongly associated and in a graded fashion with 10-year risk of incident ASCVD in asymptomatic White, Black, Hispanic and Chinese American men and women 45-84 years of age with no known history of CHD.
  - CAC scoring provides additional predictive information on ASCVD events and mortality, beyond the traditional risk factors, in men and women at different age groups, races, ethnic background, at different levels of risk, and in the presence or absence of comorbid conditions such as diabetes mellitus.
- There is insufficient published evidence, to date, from valid RCTs with long-term follow-up to determine that treatment guided by CAC scoring levels in addition to the traditional risk factors have an impact on patient management and /or health outcomes in asymptomatic adults at intermediate CV risk.

**Articles:** The literature search identified multiple large long-term population-based observational studies conducted in the US and Europe published over the last 20 years, that examined the association between CAC scoring and incidental CVD events and mortality in asymptomatic individual with no known coronary artery disease and its potential utility for CVD risk stratification in asymptomatic population. the largest population cohorts and/or those with longest follow-up duration were included in the review. The search did not identify any recent RCT with important clinical outcomes to determine the impact of CAC on guiding statin therapy an improving outcome in individuals at intermediate ASCVD risk.

The use of Coronary Artery Calcium (CAC) Scoring with Computed Tomography, for Cardiovascular Disease Risk Assessment does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Applicable Codes**

### **Coronary Artery Calcium Score**

#### **Medicare & Non-Medicare:**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>75571</b>	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium
<b>S8092</b>	Electron beam computed tomography (also known as ultrafast CT, cine CT)

### **Artificial Intelligence Enabled CT Based Quantitative Coronary Topography**

**Medicare: Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

**Non-Medicare: Considered Not Medically Necessary - experimental, investigational, or unproven**

CPT® Codes	Description
<b>0623T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report
<b>0624T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission
<b>0625T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography
<b>0626T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/11/2002	Established annual review for Medicare criteria 05/03/2011 <sup>MDCRPC</sup> , 09/06/2011 <sup>MDCRPC</sup> , 07/03/2012 <sup>MDCRPC</sup> , 05/07/2013 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 03/04/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup> , 05/06/2025 <sup>MPC</sup>	02/25/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/01/2015	Revised LCD Multidetector Computed Tomography of the Heart and Great Vessels (L34137)
09/06/2016	Adopted retired LCD policy for Medicare members
04/24/2018	Added Medicare non-coverage language from LCD
03/02/2021	Added October 2020 MTAC Review. MPC approved criteria for Coronary Artery Calcium Scoring for non-Medicare members. The criteria are based on the KPWA ASCVD Primary Prevention Guideline. Removed Electron Beam Computed Tomography (EBCT), Helical or Spiral Computed Tomography, and Ultrafast Computed Tomography from criteria. Requires 60-day notice, effective date 08/01/2021.
09/10/2021	Added additional documentation requirements
02/25/2025	Updated policy to include the new Medicare LCD and billing and coding article for Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA) effective 12/18/2024. Applicable CPT Codes 0623T-0626T.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Cardiac Defibrillators

- Implantable Cardioverter Defibrillator (ICD)
- Subcutaneous implantable Cardioverter Defibrillator (SICD)
- Substernal implantable Cardioverter Defibrillator

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	Medicare Claims Processing Manual, Change Request 11605 – Transmittal 4513, section 19: <b>Extravascular Implantable Cardioverter Defibrillator (EV ICD)</b> <i>*Covered if performed as part of an approved Investigational Device Exemption (IDE) study</i>
National Coverage Determinations (NCD)	Implantable Cardioverter Defibrillator (ICD) requires <a href="#">Level of Care review</a> <b>AND</b> medical necessity review against NCD <a href="#">Implantable Cardioverter Defibrillators (ICD) (20.4)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	Implantable Cardioverter Defibrillator (ICD) requires <a href="#">Level of Care review</a> <b>AND</b> medical necessity review <a href="#">Billing and Coding: Implantable Automatic Defibrillators (A56342)</a>

#### For Non-Medicare Members

Service	Criteria
<b>Subcutaneous Implantable Cardioverter Defibrillator (SICD)</b>	<p>The use of the SICD may be considered medically necessary for all appropriate pacemaker patients who meet the following criteria:</p> <p>A. Have a contraindication to a transvenous ICD due to at least <b>ONE of the following</b>:</p> <ol style="list-style-type: none"> <li>1. Lack of adequate vascular access; or</li> <li>2. The need to preserve existing vascular access due to chronic dialysis; or</li> <li>3. Repeat transvenous ICD placement not indicated due to complications with previous transvenous ICD placement; or</li> <li>4. Congenital heart disease; or</li> <li>5. Increased risk for bacteremia</li> </ol> <p>The use of the SICD is considered investigational when the</p>



	above criteria are not met.
<b>Substernal Implantable Cardioverter Defibrillator</b>	The use of a substernal ICD (CPT Codes 0571T-0580T, 0614T) is considered investigational.
<b>Implantable Cardioverter Defibrillator (ICD)</b>	<p><b>Effective until September 1st, 2025</b></p> <p>Requires <a href="#">Level of Care review</a> <b>AND</b> medical necessity review. Kaiser Permanente has elected to use coverage guidance from Medicare's National Coverage Determination (NCD) <a href="#">Implantable Cardioverter Defibrillators (ICD) (20.4)</a></p> <p><b>Effective September 1<sup>st</sup>, 2025</b></p> <p>Requires <a href="#">Level of Care review</a> <b>AND</b> medical necessity review. Kaiser Permanente has elected to use coverage guidance from Medicare's National Coverage Determination (NCD) <a href="#">Implantable Cardioverter Defibrillators (ICD) (20.4)</a> in addition to the criteria below:</p> <ul style="list-style-type: none"> <li>For AICD requests, (not including VT or VF indications) LVEF should be reassessed after a period on optimal therapy which would include <b>ONE</b> of the following: <ul style="list-style-type: none"> <li>A minimum of 40 days on guideline directed therapy (GDT) after MI</li> <li>A minimum of 90 days on guideline directed therapy after reversing the etiology of cardiomyopathy (eg., revascularization procedure management of uncontrolled tachycardia or other cardiotoxic insult)</li> <li>A minimum of 90 days on guideline directed therapy when a reversible etiology of cardiomyopathy has not been identified</li> </ul> </li> <li>Requests will only be approved when left ventricular systolic ejection function has not responded adequately (LVEF &gt;35%)</li> </ul>

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Cardiovascular disease is the most common cause of death in the Western world, and sudden cardiac death (SCD) accounts for approximately 60% of all cardiovascular mortality. SCD is responsible for ~300,000 annual deaths in the United States; with ventricular fibrillation (VF) accounting for up to one-third of cases (Zipes 1998, Estes 2011, Majithia 2014, Rhyner 2014).

The implantable cardioverter defibrillator (ICD) was developed and introduced to clinical practice around the 1980s to address this issue of fatal SCD from ventricular tachyarrhythmia. The ICD continuously monitors the heart, identifies malignant ventricular tachyarrhythmia, and delivers an electric counter shock to restore normal rhythm. The first defibrillator received FDA approval in 1985 to be used in patients who had survived cardiac arrests. In 2002, the FDA expanded its use to patients with a history of a heart attack and depressed heart function. ICDs are widely used and studies have shown significant mortality benefit in selected patients at increased risk of SCD. However, the use of ICDs may at times be complicated with the implantation procedure, programming, device malfunction, and lead performance deterioration by time. Traditionally, the ICD is implanted transvenously by creating a pocket in the subclavicular areas and gaining vascular access to reach the heart. This approach has its drawbacks and is associated with short- and long-term adverse events. Reported complications associated with ICD systems include lead dislodgement, lead fracture, conductor coil breaks, pneumothorax,

cardiac perforation, pericardial effusion, cardiac tamponade, and systemic infection. Lead malfunction occurs in up to 40% of the transvenous leads at 8 years after implantation. Lead failure either generates inappropriate shocks or impedes appropriate therapy. Extraction of the lead is recommended in cases of lead fracture, malfunction, or other mechanical problems that prevent safe and effective ICD shock therapies. This extraction is complex and can be associated with significant risks including death (Olde Nordkamp 2012, Weiss 2013, Aziz 2014, Chang 2014, Majithia 2014).

The complications associated with the intracardiac leads of the implantable cardioverter defibrillators have led to the development of a totally subcutaneous ICD (S-ICD) with the intention to provide the same protection, but with less procedural and device-related risks. The S-ICD system senses, detects, and treats malignant ventricular tachycardia (VT)/ventricular fibrillation (VF) without requiring vascular access or fluoroscopy. The S-ICD system (model SQ-RX 1010, Cameron Health, Inc., San Clemente, CA) includes a dedicated external programmer, a subcutaneous pulse generator enclosed in a titanium case, and a single subcutaneous electrode containing both sensing and defibrillating components. The lead-electrode is composed of proximal and distal sensing electrodes separated by a shocking coil. The pulse generator is implanted in a subcutaneous pocket created over the fifth intercostal space between the mid and anterior axillary lines. The single lead is tunneled from the xiphoid process to the pocket and to the sternal manubrium joint. Fixation is achieved with the addition of a suture sleeve at the level of the xiphoid and a single suture at the superior parasternal portion of the lead. Implantation of the device relies entirely on anatomic landmarks and does not require fluoroscopy (although some investigators advocate brief screening to verify the final position). The currently used pulse generator weighs 145 g, has a volume of 69 ml, and an estimated 5-year battery life. The greatest advantage of S-ICD is that the lead does not pass through the central veins in the chest, nor is it attached to the tissue within the heart chambers. However, the pulse generator of the S-ICD is approximately twice the volume and weight of the currently used transvenous ICD, which may prevent its use in children, and increase the risk of erosion, discomfort, and infection. In addition, the weight of the device may cause its dislodgement and changes in the shock configuration (Olde Nordkamp 2012, Weiss 2013, Aziz 2014, Chang 2014, Grace 2014, Majithia 2014).

The S-ICD system detects changes in the ventricular rate by using subsurface electrocardiography through a primary, secondary, or alternate vector. The device is programmed to select the vector that best avoids double QRS counting or T-wave oversensing events that could lead to misinterpretation of the rhythm and delivery of inappropriate shock. The heart rate is measured as the average of 4 consecutive sensed intervals. VF is diagnosed when 18 of 24 consecutive sensed events exceed the shock zone limit. Once the system detects a malignant arrhythmia, it delivers up to 80 J shock to terminate the arrhythmia and will automatically reverse polarity if the initial shock fails to terminate the arrhythmia. The mean defibrillation threshold is significantly higher than with transvenous devices, and some investigators suggest that high-energy shocks may be harmful to the myocardium (Aziz 2014, Majithia 2014, Nair 2014).

Unlike the conventional ICD devices, S-ICD is unable to provide long-term bradycardia pacing or antitachycardia pacing due to the absence of an endocardial lead. It is thus not suitable for patients with an indication for antibradycardia pacing or cardiac resynchronization therapy, or for those with a history of repetitive monomorphic ventricular tachycardia that would benefit from antitachycardia pacing. S-ICD may not be used concurrently with unipolar pacemaker as that would interfere with the S-ICD arrhythmia detection. This absence of bradycardia pacing in the S-ICD might lead to more bradycardia related events as syncope or even death. The device may be potentially useful for patients who are not eligible for transvenous ICDs, or are at high risk of complications e.g. subjects with congenital heart disease, complicated vascular anatomy, at high risk of infection, or in patients in whom vascular access is limited or needs to be conserved e.g. for renal dialysis or long-term intravenous drug therapy (Akerstrom 2013, Olde Nordkamp 2012, Chang 2014, Majithia 2014).

S-ICD received US FDA approval in September 2012, "To provide defibrillation therapy for the treatment of life-threatening ventricular tachyarrhythmia in patients who do not have sympathetic bradycardia, incessant (continual) ventricular tachycardia, or spontaneous frequently recurring ventricular tachycardia that is reliably terminated with anti-tachycardia Pacing". The FDA required that a post-approval registry be created to track outcomes of patients and devices for at least 60 months after implantation.

S-ICD has not been previously reviewed by MTAC; it is being reviewed based on a request for the Clinical Review Unit for coverage decision.

## **Medical Technology Assessment Committee (MTAC)**

### ***Subcutaneous Implantable Cardioverter Defibrillator***

## 10/20/2014: MTAC REVIEW

**Evidence Conclusion:** The results of the published observational studies suggest that S-ICD may be accurate in detecting and reversing induced ventricular arrhythmias, however, the incidence of inappropriate therapy was as high as 13.1% (in a mean duration of 11 months in Weiss et al 2013). Inappropriate shock therapy may decrease the quality of life and increase the mortality risk.

The published studies evaluated the accuracy, efficacy and safety of S-ICD in reversing induced rather than spontaneous arrhythmias. The arrhythmia is not always predictable and as seen in one study (Kobe 2013) the S-ICD system had to be changed to transvenous ICD in a patient who needed antitachycardia pacing (ATP) therapy. A group of investigators (Gold and colleague 2012) noted that though there is no reason to suspect that electrograms may differ between induced and spontaneous rhythms of similar rates and regularity, this possibility of this difference cannot be excluded. **Conclusion:** The results of the published literature indicate that: There is some evidence that S-ICD may be accurate in detecting and reversing induced ventricular arrhythmias. There is insufficient evidence to date, to determine the efficacy or effectiveness to S-ICD in terminating spontaneous VT/VF episodes. S-ICD may lead to inappropriate shock therapy in up to 13.1% of cases. There is insufficient evidence to determine the long-term safety of the S-ICD system. There is insufficient evidence to determine that S-ICD is safer or more effective than conventional transvenous ICD. No randomized controlled trial that compared the two devices head to head was published to date. There is insufficient evidence to determine that the use of S-ICD prevents or reduces sudden death from ventricular arrhythmias.

**Articles:** The literature search revealed over 300 citations on subcutaneous implantable cardioverter defibrillator. The majority were reviews or opinion pieces. No published RCTs that compared the safety and efficacy of the S-ICD head to head with the conventional transvenous ICD or other therapeutic interventions were identified; only the published rationale and design of the ongoing PRAETORIAN trial that is comparing the subcutaneous to the transvenous implantable defibrillators. There were a number of published observational studies including those that led to the European approval as well as the pivotal study (Weiss et al, 2013) leading to the US Food and Drug Administration approval. The search also identified a paper documenting the early results from the EFFORTLESS S-ICD Registry that was created to document the clinical, system, and patient-related outcome data from patients implanted with S-ICD in multiple centers in Europe and New Zealand. The pivotal prospective study (Weiss et al, 2013) and a study with a comparison group (Kobe 2013) were selected for critical appraisal: Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. *Circulation*. 2013; 128(9):944-953. See [Evidence Table](#). Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. *Heart Rhythm*. 2013;10 (1):29-36. See [Evidence Table](#).

The use of Subcutaneous Implantable Cardioverter Defibrillator does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## References

- American College of Cardiology. (2022). Guideline-Directed Medical Therapy and Risk of Death With Primary Prevention ICDs. Retrieved from [American College of Cardiology](#)
- American Heart Association. (2022). Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction. *Circulation: Heart Failure*. Retrieved from [American Heart Association](#)
- Centers for Medicare & Medicaid Services (CMS) [website]. Medicare Coverage Database. National Coverage Determinations (NCDs). Updated January 3, 2008. Available at: [http://www.cms.hhs.gov/mcd/index\\_list.asp?list\\_type=ncd](http://www.cms.hhs.gov/mcd/index_list.asp?list_type=ncd). Accessed November 07, 2023.
- Heidenreich, P. A., Bozkurt, B., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. *Circulation*. Retrieved from [American Heart Association](#)
- Russo, A. M., Desai, M. Y., et al. (2025). Newest AUC Provide Clinical Guidance on Cardiac Implantable Electronic Devices. *Cardiology Magazine*. Retrieved from [American College of Cardiology](#)
- Yehya, A., Lopez, J., Sauer, A. J., et al. (2024). Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction. *JACC Heart Fail*. Retrieved from [American College of Cardiology](#)

## Applicable Codes

### Subcutaneous ICD (SICD)

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>33270</b>	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed
<b>33271</b>	Insertion of subcutaneous implantable defibrillator electrode
<b>93260</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; implantable subcutaneous lead defibrillator system
<b>93261</b>	Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable subcutaneous lead defibrillator system
<b>93644</b>	Electrophysiologic evaluation of subcutaneous implantable defibrillator (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)

### Substernal ICD

**Medicare - Considered medically necessary when performed as part of an approved Investigative Device Exemption (IDE) study:**

**Non-Medicare – Considered not medically necessary - experimental, investigational or unproven:**

CPT® or HCPC Codes	Description
<b>0571T</b>	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed
<b>0572T</b>	Insertion of substernal implantable defibrillator electrode
<b>0573T</b>	Removal of substernal implantable defibrillator electrode
<b>0574T</b>	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode
<b>0575T</b>	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional
<b>0576T</b>	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter
<b>0577T</b>	Electrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)
<b>0578T</b>	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
<b>0579T</b>	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results
<b>0580T</b>	Removal of substernal implantable defibrillator pulse generator only
<b>0614T</b>	Removal and replacement of substernal implantable defibrillator pulse generator

## Implantable Cardioverter Defibrillators

Considered medically necessary when criteria in the applicable policy statements listed above are met:

CPT® or HCPC Codes	Description
33216	Insertion of a single transvenous electrode, permanent pacemaker or implantable defibrillator
33217	Insertion of 2 transvenous electrodes, permanent pacemaker or implantable defibrillator
33225	Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)
33230	Insertion of implantable defibrillator pulse generator only; with existing dual leads
33231	Insertion of implantable defibrillator pulse generator only; with existing multiple leads
33240	Insertion of implantable defibrillator pulse generator only; with existing single lead
33249	Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber
C1721	Cardioverter-defibrillator, dual chamber (implantable)
C1722	Cardioverter-defibrillator, single chamber (implantable)
C1882	Cardioverter-defibrillator, other than single or dual chamber (implantable)
93641	Electrophysiologic evaluation of single or dual chamber pacing cardioverter-defibrillator leads including defibrillation threshold evaluation (induction of arrhythmia, evaluation of sensing and pacing for arrhythmia termination) at time of initial implantation or replacement; with testing of single or dual chamber pacing cardioverter-defibrillator pulse generator

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
10/23/2014	11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	04/01/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
07/18/2016	Added NCD 20.4
09/08/2015	Revised LCD L35008
11/07/2017	MPC approved to adopt criteria for SICD
03/01/2022	Added Medicare links and codes related to subcutaneous ICD, noted that substernal ICD is considered investigational for non-Medicare.
11/07/2023	MPC approved adopting Medicare coverage criteria of Defibrillator and Pacemaker placement for commercial members and gold card WPMG Cardiology subject to ongoing audits of compliance with the stated criteria.
04/01/2025	MPC approved the recommendations for cardiac defibrillators criteria for commercial members. 60-day notice required; effective September 1, 2025





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Cardiac Rehabilitation

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Claims Processing Manual Chapter 32, Section 140</a>
National Coverage Determinations (NCD)	<a href="#">Cardiac Rehabilitation Programs for Chronic Heart Failure (20.10.1)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	11/01/2023 Noridian retired <a href="#">LCA A54070 Billing and Coding Outpatient Cardiac Rehabilitation</a> . These services still need to meet medical necessity as outlined in the LCA and will require review. LCAs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCAs are not retired because they are incorrect. Therefore, continue to use LCA A54070 for determining medical necessity.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Cardiac Rehabilitation (KP-0358) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of cardiology notes

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Cardiovascular disease (CVD) is the most common cause of office visits, hospitalizations, and deaths in the United States. In recent years, there has been great progress in pharmacological therapies as well as technology-based diagnostic and therapeutic interventions for CVD. As a consequence, a greater number of patients survive acute events, but with a heavier burden of chronic conditions and clinical needs. In addition to medication and

interventional cardiology, these patients also need structured support to restore their quality of life and to maintain or improve functional capacity.

Cardiac rehabilitation (CR) was initially developed in response to the profound deconditioning caused by the prolonged bed rest that was common in the management of patients following acute cardiac events in the first half of the 20th century. Since then it has developed into multidisciplinary programs to optimize the health of patients with an expanding range of cardiovascular disease (Gordon 2010). CR is a multifactorial, comprehensive intervention defined as the coordinated sum of interventions required to ensure the best physical, psychological, and social conditions so that patients with chronic or post-acute CVD event may, by their own efforts, preserve or resume optimal functioning in society, and through improved health behaviors, slow or reverse progression of disease (Taylor 2004). It is also viewed as the clinical application of preventive care by means of a professional multi-disciplinary integrated approach for comprehensive risk reduction and global long-term care of cardiac patients (Piepoli 2010).

The American Heart Association (AHA), the American College of Cardiology (ACC), and the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) consider cardiac rehabilitation / secondary prevention programs integral to the comprehensive care of patients with CVD. They recommend that all cardiac rehabilitation/secondary prevention programs should contain specific core components that aim at optimizing cardiovascular risk reduction, foster healthy behaviors and compliance with these behaviors, reduce disability, and promote an active lifestyle for patients with cardiovascular disease. The core components include baseline patient assessment, nutritional counseling, risk factor management (weight, blood pressure, lipids, diabetes mellitus and smoking), psychological interventions, physical activity counseling, and exercise training (Balady 2007). The goals of CR consist primarily of mobilizing the patient, optimizing drug therapy, implementing measures of secondary prevention, providing means for understanding the disease through education and advice, facilitating behavior modification, supporting the patient in overcoming the disease, treating psychological disturbances, and improving reintegration into professional life (Farin 2007). It is clearly understood and accepted that an isolated exercise program is not cardiac rehabilitation; however, physical activity and exercise training are considered the core components on which a comprehensive CR program is built (Piepoli 2010).

Most CR programs are held for groups in hospitals, gyms, or community centers. These may be inconvenient to patients (especially women and older patients) who may have problems with accessibility, dislike of groups, and/or work on domestic commitments. Home-based programs were thus introduced as an alternative to traditional CR in an attempt to increase participation rates. These programs have been defined as structured programs with clear objectives to the participants, including monitoring, follow-up, visits, letters, telephone calls from staff, or at least self-monitoring diaries (Dalal 2010).

## Medical Technology Assessment Committee (MTAC)

### **Cardiac Rehabilitation**

#### **12/20/2010: MTAC REVIEW**

**Evidence Conclusion:** There is fair evidence that exercise-based cardiac rehabilitation programs reduces mortality, morbidity, and improves health related quality of life (HRQoL), and modifiable risk factors in low risk patients with coronary heart disease. There is fair evidence that exercise-based cardiac rehabilitation programs reduce hospital admission and improves HRQoL among low- to moderate- risk patients with stable heart failure. There is inconclusive evidence that home-based and center-based CR have similar benefits. The results of trials and meta-analyses comparing the two strategies suggest that they have similar outcomes. However, due to the study designs, a lack of significant statistical differences in the outcomes does not necessarily imply that the two strategies are equivalent.

**Articles:** The literature search revealed at least 15 meta-analyses on cardiac rehabilitation, and a large number of randomized controlled trials, and observational studies. The great majority of the meta-analyses and trials were performed on individual components of the cardiac rehabilitation (CR) program, mainly exercise-based programs, in stable patients post myocardial infarction or coronary revascularization, or in patients with heart failure. Overall, the randomized trials on the comprehensive CR were relatively small and with short duration of follow-up. One trial (Austin 2008), reported on 5 years outcome of patients with heart failure after undergoing a multidisciplinary 8-week CR program. The literature search also revealed 4 recent meta-analyses of RCTs that compared home-based cardiac rehabilitation versus center-based programs for patients with cardiovascular disease. Studies (e.g. HF-ACTION) or meta-analyses (e.g. ExTraMATCH) that examined the safety and efficacy of exercise training or other single components of the program in patients with chronic heart failure or CAD were not included in the current review which evaluates the multidisciplinary cardiac rehabilitation program.

The following meta-analyses of trials on comprehensive CR for patients with heart failure or CHD, that compared and home-based vs. center-based CR as well as the RCT with 5-year follow-up were selected for critical appraisal.

Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systemic review and meta-analysis. *Eur J Heart Fail* 2010; 12:706-715. See [Evidence Table](#). Davidson PM, Cockburn J, Newton PJ, et al. Can a heart specific cardiac rehabilitation program decrease hospitalization and improve outcomes in high-risk patients? *Eur J Cardiovasc Prev Rehabil* 2010; 17:393-402. See [Evidence Table](#). Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: Systematic review and meta-analysis of randomized controlled trials. *Am J Med* 2004; 116:682-692. See [Evidence Table](#). Austin J, Williams WR, Ross L, et al. Five-year follow-up findings from randomized trials of cardiac rehabilitation for heart failure. *Eur J Cardiovasc Prev Rehabil* 2008; 15:162-167. See [Evidence Table](#). Dalal HM, Zawada A, Jolly K, et al. Home based versus center based cardiac rehabilitation: Cochrane systemic review and meta-analysis. *BMJ* 2010;340:C 1133. See [Evidence Table](#).

The use of cardiac rehabilitation facility and home based does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>93797</b>	Physician or other qualified health care professional services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)
<b>93798</b>	Physician or other qualified health care professional services for outpatient cardiac rehabilitation; with continuous ECG monitoring (per session)
<b>G0422</b>	Intensive cardiac rehabilitation; with or without continuous ECG monitoring with exercise, per session
<b>G0423</b>	Intensive cardiac rehabilitation; with or without continuous ECG monitoring; without exercise, per session
<b>S9472</b>	Cardiac rehabilitation program, nonphysician provider, per diem

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/15/1998	06/01/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 11/05/2013 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 03/07/2017 <sup>MPC</sup> , 01/09/2018 <sup>MPC</sup> , 11/05/2019 <sup>MPC</sup> , 11/03/2020 <sup>MPC</sup> , 11/02/2021 <sup>MPC</sup> , 11/01/2022 <sup>MPC</sup> , 11/07/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	11/13/2023

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
06/10/2015	Link for Medicare Pub 100-03 Cardiac Rehabilitation added
09/27/2016	Added NCD 20.31.3 and NCD 20.10.1
11/13/2023	Updated Medicare link for A54070 which was retired 11/1/2023

## **Clinical Review Criteria**

### **Cardiac Contractility Modulation Device**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## **Criteria**

### **For Medicare Members**

<b>Source</b>	<b>Policy</b>
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Cardiac Contractility Modulation Device</b> " for medical necessity determinations. Refer to the Non-Medicare criteria below.

### **For Non-Medicare Members**

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### **If requesting review for this service, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## **Background**

### **Kaiser Interregional New Technologies Committee Assessment**

**Date:** 04/27/2020

There is insufficient evidence regarding the efficacy and safety of Optimizer (cardiac contractility modulation [CCM]) as compared to optimal medical management for heart failure.

Based on the review of 4 randomized trials (n=801) that compared Optimizer CCM plus optimal medical therapy (OMT) versus OMT alone, there is moderate-quality evidence that treatment of heart failure with Optimizer CCM is associated with short-term improvements in quality of life and peak  $\text{Vo}_2$ ; however,

findings for other symptom-related outcomes were mixed and there is a lack of long-term outcomes, including hospitalization and mortality data. Thus, the existing evidence regarding how Optimizer CCM effectively manages heart failure is of insufficient quantity and/or quality.

Heart failure (HF), also referred to as congestive HF, is a chronic, progressive condition that develops due to circumstances that overwork and damage the heart, rendering the heart muscle unable to pump enough blood to meet the body's needs for blood and oxygen. The primary causes of HF include coronary heart disease, high blood pressure, and diabetes. Approximately half of heart failure cases are associated with a reduced ejection fraction (HFrEF), typically defined as a left ventricular ejection fraction (LVEF) <35% or <40%. The impact of heart failure on patient quality of life as well as its economic costs are substantial.

Treatment of HF is focused on symptom relief and typically includes lifestyle modification and oral medications that treat underlying conditions including hypertension, high cholesterol, diabetes, and obesity. Treatment options for patients with severe HFrEF with inadequate response to medications include cardiac resynchronization therapy (CRT), left ventricular assist devices (LVAD), and heart transplantation. However, many patients with moderate to severe HF symptoms—including the 25% to 35% of patients who have HFrEF categorized as NYHA functional class III—do not meet established indications for these options. The Optimizer Smart System (Impulse Dynamics, Inc., Orangeburg, NY, USA) is intended for patients in this treatment “gap.”

The Optimizer Smart System is a pacemaker-sized, rechargeable, implanted device intended to deliver cardiac contractility modulation (CCM) therapy to increase the strength of the heart's ventricular contraction in patients with stage III to IV HF whose LVEF is 25% to 45% despite optimal medical therapy (OMT).

The following clinical question was the subject of the review:

What is the efficacy and safety of the Optimizer Smart System for treatment of heart failure?

A comprehensive search was conducted on March 18, 2020 to identify systematic reviews, technology assessments, and randomized trials addressing the clinical question.

Based on the existing literature:

- The body of evidence on the use of Optimizer CCM for treatment of heart failure consists of 4 randomized trials (n=801) that compared Optimizer CCM plus optimal medical therapy (OMT) versus OMT alone.
- Two early trials employed a sham-control group (FIX-HF-5 Pilot) and a crossover design (FIX-CHF-4), while the 2 more recent trials used a more traditional design. The sham-controlled and crossover trials noted significant placebo effects for several outcomes.
- Moderate-quality evidence suggests that Optimizer CCM plus OMT results in clinically and statistically significant improvements in short-term clinical outcomes including QOL and peak  $\text{Vo}_2$  compared to OMT alone.
- It is unclear if Optimizer CCM has an impact on 6-minute hall-walk (6MHW) distance, NYHA class, ventilatory threshold, hospitalizations, or mortality. The quality of evidence for these outcomes was low due to mixed findings, a lack of between-group differences, insufficient power, and/or inadequate duration of follow-up.
- Moderate-quality evidence suggests that rates of serious adverse events were relatively low and similar between CCM and OMT groups. The implantation procedure and short-term use of the device appear to be relatively safe and comparable to similar interventions (e.g., pacemakers).
- The Optimizer CCM implantation procedure takes about 3 hours to complete, although there was considerable variation across patients and the quality of this evidence is low.



- The main limitations of the included trials are their relatively small sample sizes (801 patients total), lack of long-term follow-up, mixed findings for several key outcome measures (e.g., 6MHW, NYHA class), and lack of a sham control for the 2 most recent trials.
- These promising but preliminary findings suggest that Optimizer CCM is a safe and effective treatment for patients with NYHA class III heart failure with ejection fraction between 25% and 45%. Additional randomized trials are needed to confirm these initial findings and evaluate long-term outcomes.

Among several relevant clinical practice guidelines identified in the evidence search, the European Society of Cardiology (2016) notes that CCM may be considered in selected patients with HF, and NICE (2019) notes that although there are no major safety concerns, the device should only be used in research settings due to the lack of evidence on efficacy.

The committee discussed uncertainty regarding benefits of Optimizer CCM beyond symptomatic improvement. In particular, there is a lack of mortality data. Given the determination of “insufficient evidence,” the plan is to continue participation in clinical trials and to await publication of mortality data prior to considering adopting this technology.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
0408T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes
0409T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only
0410T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only
0411T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)
0416T	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator
0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable cardiac contractility modulation system
HCPC Codes	Description
C1824	Generator, cardiac contractility modulation (implantable)
K1030	External recharging system for battery (internal) for use with implanted cardiac contractility

	modulation generator, replacement only
--	--

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/07/2020	04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup>	10/26/2022

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/07/2020	MPC approved to adopt new non-coverage criteria (Medicare's position)
05/26/2020	Added background from INTC review on 4/27/2020
10/26/2022	Updated applicable codes, including new codes released 01/01/22 and 04/01/22.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Cardiac Electrophysiologic (EP) Procedures

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b><i>"Electrophysiologic Studies and Intracardiac Ablations"</i></b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

#### Electrophysiologic Studies and Intracardiac Ablations

**Effective until October 1<sup>st</sup>, 2025**

Review for [Elective Surgical Procedures \(LOC\)](#) is required. No Medical Necessity Review Required

#### Electrophysiologic Studies and Intracardiac Ablations

**Effective October 1<sup>st</sup>, 2025**

Kaiser Permanente has elected to use the Electrophysiologic Study and Intracardiac Catheter Ablation (KP-M-154 10012025) MCG\* Care Guideline for medical necessity determinations, in addition to the review for [Elective Surgical Procedures \(LOC\)](#).

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### For covered criteria:

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### Electrophysiologic Study (EPS)

An electrophysiologic study (EPS) is a diagnostic test used to evaluate the electrical activity of the heart and identify abnormal heart rhythms (arrhythmias). During an EPS, catheters with electrodes are inserted into the heart through blood vessels. These electrodes send electrical signals and measure the heart's electrical activity to pinpoint the source of arrhythmias. EPS can help determine the effectiveness of medications, the need for a pacemaker or implantable cardioverter defibrillator (ICD), and whether catheter ablation is necessary.

### Intracardiac Catheter Ablation

Intracardiac catheter ablation is a minimally invasive procedure used to treat arrhythmias by destroying the heart tissue causing abnormal electrical signals. During the procedure, catheters are inserted into the heart through blood vessels. Heat (radiofrequency ablation) or cold (cryoablation) energy is used to create tiny scars in the heart tissue, blocking faulty signals and restoring normal heart rhythm. This procedure is often recommended when medications are ineffective or cause significant side effects.

## References

- Adhadek M, Paudel B, Liu K, Ashwath M, Giudici M. Meta-analysis of catheter ablation outcomes in patients with cardiac sarcoidosis refractory ventricular tachycardia. *American Journal of Cardiology* 2022;174:136-142. DOI: 10.1016/j.amjcard.2022.03.038.
- Al-Khatib SM, et al. Risk stratification for arrhythmic events in patients with asymptomatic pre-excitation: a systematic review for the 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* 2016;133(14):e575-e586. DOI: 10.1161/CIR.0000000000000309.
- American Heart Association. (n.d.). Catheter ablation. Retrieved from <https://www.heart.org/en/health-topics/arrhythmia/prevention--treatment-of-arrhythmia>
- Arenal A, et al. Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia. *Journal of the American College of Cardiology* 2022;79(15):1441-1453. DOI: 10.1016/j.jacc.2022.01.050.
- Brugada J, et al. Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. *Europace* 2013;15(9):1337-1382. DOI: 10.1093/europace/eut082. (Reaffirmed 2025 May 20)
- Cleveland Clinic. (n.d.). Catheter ablation. Retrieved from <https://my.clevelandclinic.org/health/treatments/16851-catheter-ablation>
- Cronin EM, et al. 2019 HRS/EHRA/APHRS/LAHS expert consensus statement on catheter ablation of ventricular arrhythmias. *Heart Rhythm* 2020;17(1):e2-e154. DOI: 10.1016/j.hrthm.2019.03.002.
- Dalal AS, Van Hare GF. Disturbances of rate and rhythm of the heart. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, editors. *Nelson Textbook of Pediatrics*. 21st ed. Philadelphia, PA: Elsevier; 2020:2436-2447.e1.
- Hernandez-Madrid A, et al. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. *Europace* 2018;20(11):1719-1753. DOI: 10.1093/europace/eux380. (Reaffirmed 2025 May 20)
- Jentzer JC, et al. Multidisciplinary critical care management of electrical storm: JACC state-of-the-art review. *Journal of the American College of Cardiology* 2023;81(22):2189-2206. DOI: 10.1016/j.jacc.2023.03.424.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. *Journal of the American College of Cardiology* 2023 Nov;online. DOI: 10.1016/j.jacc.2023.08.017. (Reaffirmed 2025 May 20)
- Mayo Clinic. (n.d.). Electrophysiologic study. Retrieved from <https://www.mayoclinic.org/tests-procedures/electrophysiologic-study/about/pac-20384993>
- Miller JM, Ellenbogen KA. Therapy for cardiac arrhythmias. In: Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, editors. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 12th ed. Elsevier; 2022:1208-1244.
- Ommen SR, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 2020;142(25):e558-e631. DOI: 10.1161/CIR.0000000000000937. (Reaffirmed 2025 May 20)
- Page RL, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation* 2015;133(14):e506-e574. DOI: 10.1161/CIR.0000000000000311. (Reaffirmed 2025 May 20)
- Samuel M, et al. Ventricular tachycardia and ICD therapy burden with catheter ablation versus escalated antiarrhythmic drug therapy. *JACC. Clinical Electrophysiology* 2023;9(6):808-821. DOI: 10.1016/j.jacep.2023.01.030.
- Tung R, et al. First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial. *Circulation* 2022;145(25):1839-1849. DOI: 10.1161/CIRCULATIONAHA.122.060039.
- Valderrabano M, et al. Effect of catheter ablation with vein of Marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the VENUS randomized clinical trial. *Journal of the American Medical Association* 2020;324(16):1620-1628. DOI: 10.1001/jama.2020.16195.

## Applicable Codes

### Cardiac Electrophysiological (EP) Studies

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
93619	Comprehensive electrophysiologic evaluation with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording, including insertion and repositioning of multiple electrode catheters, without induction or attempted induction of arrhythmia
93620	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording
93621	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separately in addition to code for primary procedure)
93622	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording (List separately in addition to code for primary procedure)

### Cardiac Catheter Ablation

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
93650	Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement
93653	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including intracardiac electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when performed; with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry
93654	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including intracardiac electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when performed; with treatment of ventricular tachycardia or focus of ventricular ectopy including left ventricular pacing and recording, when performed
93655	Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary procedure)
93656	Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac electrophysiologic 3-dimensional mapping, intracardiac echocardiography including imaging supervision and interpretation, induction or attempted induction of an arrhythmia including left or right atrial pacing/recording, right ventricular pacing/recording, and His bundle recording, when performed

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/06/2025	05/06/2025 <sup>MPC</sup>	05/06/2025

<sup>MPC</sup> Medical Policy Committee



Revision History	Description
05/06/2025	MPC approved to adopt criteria for Electrophysiologic Study and Intracardiac Catheter Ablation based procedures. 60-day notice required; effective date 10/01/2025.

## *Clinical Review Criteria*

### **Implantable Pulmonary Artery Pressure Monitoring Device for Patients with Heart Failure**

- CardioMEMS
- Cordella PA Sensor System (LOWER-PAP)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## **Criteria**

### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management (CAG-00466N)</a> *Implantable Pulmonary Artery Pressure Monitoring Devices are non-covered when furnished outside of a CMS approved CED study.  List of studies that have been determined to meet the requirements for coverage under CED: <a href="#">HERE</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

### **For Non-Medicare Members**

#### **Kaiser Interregional New Technologies Committee**

There is insufficient evidence to determine whether CardioMEMS is a medically appropriate option for patients with NYHA functional class III heart failure. The existing evidence is of insufficient quantity and quality. Patients undergoing IRB clinical trials could be potential candidates if the IRB trial has a well-designed protocol, appropriate informed consent, and structured follow-up.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## **Background**

Heart failure (HF) is a major public health problem in the United States and worldwide. It is estimated that more than six million Americans are currently living with heart failure, and that approximately 550,000 new cases are diagnosed in the US every year. Hospitalization for patients with chronic HF is also on the rise despite the major advances in medical and device therapies. Statistics show that HF is the primary diagnosis in over one million hospitalizations annually, and that patients hospitalized for HF are at high risk for all-cause rehospitalization with a 1-month readmission rate of 25%. The prognosis of these patients is suboptimal especially for those with serial readmissions (Hoppe 2009, Adamson 2011, Go 2013, Yancy 2013, Sandhu 2018).

More than 90% of hospitalizations for worsening HF are due to signs and symptoms of congestion leading to the decompensated state. Investigators found that increases in the intracardiac and pulmonary artery (PA) pressures are the cause of clinical congestion and that these begin several days or weeks before the onset of overt clinical signs and symptoms that are commonly used as indicators of congestion and volume overload leading to hospitalization. Thus, outpatient monitoring of markers for impending hemodynamic decompensation may allow early interventions to reduce both morbidity and hospitalization. Researchers

also found that successful treatment of acutely decompensated HF patients is associated with a decrease in diastolic pressures to values equivalent or below those present at baseline, and that continuous monitoring pressure during treatment may allow the clinicians to tailor the treatment more accurately. Based on these observations, it was hypothesized that ambulatory implantable hemodynamic monitoring (IHM) may provide information that would help avoid discharging patients from the hospital before decreasing the pressure sufficiently and returning the patient to a chronic compensated state. Continuous hemodynamic monitoring after the hospital discharge is also believed to proactively detect signs of congestion and reduce the risk of rehospitalization (Hoppe 2009, Abraham 2011, Adamson 2011, Mooney 2015, Sandhu 2018, Ayyadurai 2019).

Research has thus focused on ambulatory hemodynamic monitoring of chronic HF as a surrogate measure to guide the patients' medical therapy before the onset of acute hemodynamic decompensation. Several implantable systems have been developed to measure various cardiac pressures and tailor medical therapy accordingly "pressure guided therapy". Among these devices is the CardioMEMS HF System, which is the focus of the current review.

The CardioMEMS<sup>TM</sup> HF System (Abbott [previously St Jude Medical], Inc, USA) is a leadless battery-free, permanently implantable pressure measurement system designed to directly measure systolic, diastolic, and mean pulmonary artery pressure (PAP) to help guide heart failure management in an outpatient setting. The design of the system is based on the microelectromechanical principles of resonance whereby an external antenna wand emitting radiofrequency energy can cause varying degrees of oscillations in the sensor depending on the ambient pressure. The CardioMEMS HF System consists of three main components: 1. A miniaturized wireless electromechanical leadless sensor (15mm x 3mm x 2mm) that comprises a coil and capacitor encased in silicone case, with a nitinol wire loop at each end of the sensor to keep the device in place in a pulmonary artery. The capacity and coil of the sensor creates

an electrical circuit that resonates at a given frequency that varies depending on the pulmonary artery pressure 2. A transverse delivery system designed to deploy the implantable sensor in the distal PA; and 3. The Champion Electronics System, which acquires and processes signals from the implantable sensor and wirelessly transfers PA pressure measurements to a secure database to be reviewed and evaluated by the treating physician (Loh 2013, Adamson 2011, Mooney 2015, Ayyaduri 2019, FDA website).

The CardioMEMS sensor is delivered during a standard right heart catheterization procedure and implanted in a descending branch of the pulmonary artery via a delivery catheter. The implanted patients are started on aspirin and clopidogrel for one month followed by aspirin monotherapy. At home, HF patients use a portable electronic unit and a special pillow containing an antenna to take daily sensor readings. The reading takes place when the antenna is held against the body or when the patients lies on the pillow. The pressure readings are then wirelessly transmitted to a secure website and accessed by the clinicians to guide treatment decisions. Automated alerts will be sent to health care providers if pressure readings fall outside of prespecified ranges (Poor Ghaz 2019).

The U.S. Food and drug Administration (FDA) premarket approval (PMA) of CardioMEMS HF System was first rejected in 2011 due to concerns on the validity of the pivotal study results. After discussing additional follow-up data and further analyses of the results provided by the investigators and sponsors, the FDA cautiously approved the system in May 2014 to "*Remotely measure and monitor PA pressure and heart rate in New York Heart Association (NYHA) functional Class III heart failure patients who have been hospitalized for heart failure in the previous year*". According to the FDA, the system may be used by the physician in the hospital or medical office to better manage the patients and potentially reduce HF- related hospitalizations. Continued FDA approval of CardioMEMS HF System is contingent upon the submission of periodic reports at intervals of one year (unless otherwise specified) from the date of approval of the original PMA, as well as conducting two post-approval studies (FDA Website).

The CardioMEMS HF system may not be appropriate for patients with an active infection, history of recurrent deep vein thrombosis or pulmonary embolism, are unable tolerate a right heart catheterization, have congenital heart disease or mechanical right heart valve, with known coagulation disorders, hypersensitivity to aspirin or clopidogrel, with an estimated GFR <25 ml/min and not responsive to diuretics or are on chronic renal dialysis, also for patients who had undergone implantation of CRT-D within the past 3 months, or have BMI >35 kg/m<sup>2</sup> (Ayyaduri 2019).

## **Medical Technology Assessment Committee (MTAC)**

### ***Implantable Pulmonary Artery Pressure Monitoring Device (CardioMEMS HF System) For Patients with Heart Failure***

**Date: 01/13/2020**

**Evidence Conclusion:**

- The CHAMPION trial remains the only published RCT that evaluated CardioMEMS HF device for monitoring NYHA functional class III heart failure patients.
- There is no additional evidence from published RCTs with valid methodology and long-term follow-up that would change the conclusion of the MTAC 2016 evidence review:
  - The results of the CHAMPION study show that previously hospitalized NYHA functional class III heart failure patients who received pressure guided management in addition to the standard care, had statistically significant lower hospital admission rates compared to those managed according to standard of care alone. It is unclear if the hospitalizations prevented in the device-guided management group were among the lower risk patients, and whether it had any impact on mortality.
  - It is hard to make a firm conclusion on the safety and effectiveness of CardioMEMS HF System from one single-blinded randomized trial, with an intermediate endpoint, potential performance bias, strict inclusion/exclusion criteria, conducted under a controlled environment, with a relatively short follow-up period, and funded by the manufacturer of the device that was also responsible for data collection and analysis. In addition, the principal investigators who analyzed, interpreted, and /or wrote the report had financial ties to the manufacturer.
- More RCTs with valid methodology and long-term clinical outcomes are needed to provide stronger evidence on the safety and efficacy of CardioMEMS HF System in monitoring patients with HF.

**Articles:** The updated literature search on CardioMEMS HF System for patients with Heart failure did not identify any RCTs published after the pivotal CHAMPION trial. The search revealed a propensity matched retrospective study, several review articles on pulmonary artery pressure guided management of patients with heart failure, sub-analyses of data from CHAMPION trial, and case series of patients implanted with CardioMEMS. A CardioMEMS post approval study was presented by Shavelle D, MD, in the 2019 annual meeting of the American College of Cardiology but, have not been published, to date, in a peer reviewed journal. The propensity matched study (Abraham et al, 2019) as well as the results of the CardioMEMS post- approval study (Shavelle 2019) \*\* were reviewed and summarized. See [Evidence Table](#).

The use of Implantable Pulmonary Artery Pressure Monitoring Device (CardioMEMS HF System) For Patients with Heart Failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**Applicable Codes**

**Medicare:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare:** Considered Not Medically Necessary

CPT® or HCPC Codes	Description
<b>C2624</b>	Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components
<b>33289</b>	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed
<b>93264</b>	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/05/2016	07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	02/27/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
02/10/2021	Added MTAC review from July 2020 for CardioMems
02/27/2025	Added new Medicare NCD-CAG for Implantable Pulmonary Artery Pressure Monitoring Device for Patients with Heart Failure effective 1/13/25. Implantable Pulmonary Artery Pressure Monitoring Devices are non-covered when furnished outside of a CMS approved CED study.



## *Clinical Review Criteria*

### **Carotid Intima Media Thickness (IMT or CIMT) for Coronary Artery Disease Screening and Monitoring**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## **Criteria**

### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Carotid Intima Media Thickness (IMT or CIMT) for Coronary Artery Disease Screening and Monitoring</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

### **For Non-Medicare Members**

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

### **If requesting review for this service, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## **Background**

Atherosclerosis is a progressive disease that usually starts early in life. It begins with thickening of the vessel wall due to proliferation of smooth muscle cells, and progresses with the accumulation of lipids carbohydrates, calcium deposits, fibrous tissue, and blood products within the lesions resulting in hard calcified plaques (Libby 2000). Acute manifestations of atherosclerosis such as acute myocardial infarction, stroke, or sudden cardiac death are due to thrombosis following rupture of an unstable plaque. It is thus valuable to detect coronary atherosclerosis early in its course and try to alter its progression by modifying certain identifiable risk factors. Several noninvasive imaging techniques to identify and quantify atherosclerosis have evolved in the last decades. These include echocardiography, stress echocardiography with perfusion, MRI, electron beam computed tomography, carotid artery imaging, and others.

B-mode ultrasound is a well-established method to evaluate atherosclerosis of peripheral arteries, and ultrasonographic assessment of easily accessible arteries has been advocated as surrogate markers for less accessible vessels. To consider a test as a surrogate marker, it should have the ability to predict the risk of a disease, and to improve with the improvement of the disease process (Feinstein 2002).

Atherosclerosis predominantly affects the intima of the vessel wall; however, ultrasound imaging cannot discriminate between the intima and media, and is thus applied to the intima-media complex. Carotid artery intima-media thickness (IMT or CIMT) involves a high-resolution ultrasound imaging of the distance between the lumen-intima interface and the media-adventitia interface, reflecting the arterial wall characteristics. It can be measured at several areas along the vessel wall; at the posterior aspect of the common carotid artery, the anterior wall of the internal carotid artery or at the common carotid artery bifurcation. Researchers differ on the choice of wall or segment of the carotid artery to image. It is believed however that imaging from different segments will most likely increase the likelihood of providing more relevant information, based on the fact that atherosclerosis tends to develop in an asymmetric manner. IMT thickness measurements can be calculated as the average of arterial wall thickness, the maximal measured value, or the average of maximal values of different segments. The inter-reader variability is fairly high, and there is no clear cut-off point above which atherosclerosis can be defined. The cut-off points to determine the presence of an atherosclerotic plaque were arbitrarily chosen. It was suggested that an average thickness of the combined intima and media ranging between 0.5 and 1.2 mm is considered to be normal, and that  $\geq 1.2$  mm is used to define the presence of a plaque. It was also reported that the abnormal range of IMT is age dependent, and an IMT  $>1.00$  mm is considered highly abnormal in younger patients and is sometimes used as the cutoff in clinical trials (Feinstein 2002).

The estimated progression of atherosclerosis per year is 0.02 to 0.05 mm (Feinstein 2002). IMT may be a potential useful marker for coronary atherosclerosis, as well as an indicator for its progression or regression, on the condition that the carotid atherosclerosis reflects coronary atherosclerosis. Still the occurrence of an acute event does not only depend on the condition of the coronaries, and carotid IMT does not visualize coronary arteries, and does not provide detailed insight into plaque composition or stability.

## Medical Technology Assessment Committee (MTAC)

### *Carotid IMT in the Evaluation of Risk for CVD or to Monitor the Treatment Effect on CAD*

04/04/2005: MTAC REVIEW

**Evidence Conclusion:** In conclusion, there is evidence for an association between carotid artery IMT and risk of coronary heart disease events, but there is no evidence that measuring carotid IMT, or treating patients based on this measurement would reduce their risk of CVD. There is also insufficient evidence to support the additive value of carotid IMT markers over the global risk assessment strategies using Framingham risk stratification. Use of carotid ITM to monitor effect of treatment on CAD: Several studies evaluated the effect of statins on the progression of atherosclerosis using imaging of carotid ITM thickness as an outcome measure. In these studies, carotid IMT was used a surrogate marker for coronary atherosclerosis. The LIPID trial randomized 522 subjects to receive pravastatin 40 mg/day or placebo in addition to a low-fat diet. Total cholesterol, triglycerides, HDL, and LDL cholesterol were measured at randomization repeatedly during follow-up. Ultrasound scans of the common carotid artery were performed before randomization, and after 2- and 4-years using B-mode ultrasonography. The study showed a regression of the common carotid artery IMT following pravastatin therapy. Carotid IMT was only an intermediate marker, and the relation between the IMT and cardiovascular events was not studied. A change in carotid intima-media thickness does not necessarily indicate a change in cardiovascular risk.

**Articles:** The search revealed 214 articles. The majority were review articles, opinion pieces, or dealt with specific subgroups of patients. As a screening tool/ risk predictor for coronary artery disease: The search did not reveal any randomized controlled trial that evaluated the use of carotid IMT as a screening test for coronary artery disease. There were several prospective studies that investigated carotid IMT as a risk predictor for CHD including two large population based-studies conducted in the USA (ARIC study and CHS). The search also revealed few other studies conducted in Europe (e.g. Rotterdam study in the Netherlands, and KIHd study in Finland). ARIC study and CHS were selected for critical appraisal, as well as Rotterdam study that evaluated the benefit of adding carotid IMT measurement to traditional risk factors used to predict risk of CHD. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid artery wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol.* 1997; 146:483-494. See [Evidence Table](#). O'Leary DH, Polak JF, Kronmal RA, et al, for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. *N Engl J Med.* 1999; 340:14-22. See [Evidence Table](#). Iglesias del Sol A, Moons KGM, Hollander M, et al. Is Carotid Intima-media thickness useful in cardiovascular diseases risk assessment. The Rotterdam Study. *Stroke* 2001; 32:1532-1538. See [Evidence Table](#) As a monitoring tool measure efficacy of a therapeutic intervention: The search revealed several earlier studies conducted in the 1990s to examine the effect of statins and lipid modifying therapy on the progression of atherosclerosis, using changes in the carotid IMT, measured by B-mode Ultrasonography, as their surrogate outcome. Among these studies were ACAPS, BCAPS, KAPS, LIPID, REGRESS, PLAC II as well as others. These studies did not have clinical outcomes, only the intermediate endpoint of carotid IMT. The LIPID trial with a large population size and long follow-up period of 4 years was selected for critical appraisal. MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average or

below-average cholesterol levels on the progression of carotid atherosclerosis. Results of the LIPID atherosclerosis substudy. Circulation. 1998; 97:1784-1790. See [Evidence Table](#). As a diagnostic tool for coronary artery disease: The search revealed at least six studies that investigated the potential use of carotid intima media thickness in the diagnosis of coronary artery disease. In these studies, results of carotid ultrasonography were compared to those of coronary angiography, and/ or exercise tests, or SPECT among symptomatic patients with a suspected CAD. None of these studies was critically appraised as it not the purpose of this review to evaluate the technology as a diagnostic test.

The use of carotid IMT in the evaluation of risk for CVD or to monitor the treatment effect on CAD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/04/2005	04/04/2005, 04/12/2005 <sup>MDCRPC</sup> , Initiated annual review because of Medicare criteria on 05/03/2011 <sup>MDCRPC</sup> , 09/06/2011 <sup>MDCRPC</sup> , 07/03/2012 <sup>MDCRPC</sup> , 05/07/2013 <sup>MDCRPC</sup> , 03/04/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup> , 05/06/2025 <sup>MPC</sup>	05/04/2021

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34886 and L35008 Non-Covered Services.
05/04/2021	Updated applicable codes – removed deleted code 0126T



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Cell-Free Fetal DNA Analysis

- Panorama
- MaterniT21™
- Harmony™
- Verifi™
- QNatal Advanced

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### **Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees (for in-network coverage)**

*Prevention and Invitae/LabCorp Genetics is the preferred labs for genetic testing\*, when the test(s) is/are available at Prevention and LabCorp and medical necessity criteria are met.*

*Prevention test catalog can be found here: [Prevention Test Catalog](#)*

*LabCorp test catalog can be found here: [LabCorp Test Catalog](#)*

*Invitae test catalog can be found here: [Invitae Test Catalog](#)*

*\*Note: This does not affect processing of tumor or other pathology specimens as they are not performed by Invitae.*

**PPO/POS members may use non-preferred labs at the out of network cost share.**

### Exceptions

*For the genetic test(s) listed below, please use the lab specified:*

- **Cell Free Fetal DNA testing –Any of the below labs can be used:**
  - Ariosa Diagnostics, Inc. (81507)
  - LabCorp (81420)
  - Quest-QNatal (81420)
  - Natera: Panorama (81420), Pamorama Twins (0060U)

#### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Molecular Diagnostic Tests (L36256)</a>
Local Coverage Article	None

#### **For Non-Medicare Members**

Kaiser Permanente will cover cell-free fetal DNA testing for trisomies without clinical review for pregnant women regardless of age when performed at Ariosa Diagnostics (CPT code 81507) or at Natera (CPT code 81420) or at Labcorp (CPT code 81420) or at Quest-QNatal (81420).

Prior Authorization will still be required for Non-Invasive Prenatal Testing (NIPT) at any other lab in advance of submitting a claim for payment. For patients who are tested for trisomies using cell-free fetal DNA, the sequential screen and nuchal translucency (NT) ultrasound (76813/76814) should no longer be routinely ordered without clinical indication.

The only codes that Kaiser Permanente will pay for Cell-Free Fetal DNA Analysis for Trisomies are 81420 and 81507.

**Considered not medically necessary:**

Test Name	Criteria Used	Codes
Cell-Free Fetal DNA - Microdeletion Syndromes	A-0848: This service is not covered per MCG guidelines	CPT – 81331 <i>not medically necessary when performed using cell-free fetal DNA</i> , 81422
Cell-Free Fetal DNA - Monogenic Disorders	A-0849: This service is not covered per MCG guidelines	CPT – 81479
Cell-Free Fetal DNA - Sex Chromosome Disorders	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or will provide better long term outcomes than current standard services/therapies.	CPT – 81479

**If requesting review for these services, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

**\*MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Fetal chromosomal abnormalities occur in approximately 1 in 160 live births. Most fetal chromosomal abnormalities are aneuploidies, defined as an abnormal number of chromosomes. The trisomy syndromes are aneuploidies involving 3 copies of 1 chromosome. The most important risk factor for trisomy syndromes is maternal age. The approximate risk of a trisomy 21 (T21; Down syndrome) –affected birth is 1 in 1100 at age 25 to 29. The risk of a fetus with T21 (at 16 weeks of gestation) is about 1 in 250 at age 35 and 1 in 75 at age 40.1

T21 is the most common chromosomal aneuploidy and provides the impetus for current maternal serum screening programs. Other trisomy syndromes include T18 (Edwards syndrome) and T13 (Patau syndrome), which are the next most common forms of fetal aneuploidy, although the percentage of cases surviving to birth is low and survival beyond birth is limited. The prevalence of these other aneuploidies is much lower than the prevalence of T21 and identifying them is not currently the main intent of prenatal screening programs. Also, the clinical implications of identifying T18 and T13 are unclear because survival beyond birth is limited for both conditions.

Standard aneuploidy screening involves combinations of maternal serum markers and fetal ultrasound done at various stages of pregnancy. The detection rate for various combinations of noninvasive testing ranges from 60% to 96% when the false-positive rate is set at 5%. When tests indicate a high risk of a trisomy syndrome, direct karyotyping of fetal tissue obtained by amniocentesis or chorionic villous sampling (CVS) is required to confirm that T21 or another trisomy is present. Both amniocentesis and CVS are invasive procedures and have an associated risk of miscarriage. A new screening strategy that reduces unnecessary amniocentesis and CVS procedures and increases detection of T21, T18, and T13 could improve outcomes. Confirmation of positive



noninvasive screening tests with amniocentesis or CVS is recommended; with more accurate tests, fewer women would receive positive screening results.

Commercial, noninvasive, sequencing-based testing of maternal serum for fetal trisomy syndromes is now available. The test technology involves detection of cell-free fetal DNA fragments present in the plasma of pregnant women. As early as 8 to 10 weeks of gestation, these fetal DNA fragments comprise 6% to 10% or more of the total cell-free fetal DNA in a maternal plasma sample. The tests are unable to provide a result if the fetal fraction is too low (ie, <4%). Fetal fraction can be affected by maternal and fetal characteristics. For example, fetal fraction was found to be lower at higher maternal weights and higher with increasing fetal crown-rump length.

## Medical Technology Assessment Committee (MTAC)

### MaterniT21

#### 08/20/2012: MTAC REVIEW

**Evidence Conclusion:** Kaiser concluded that there is insufficient evidence to determine whether the MaterniT21 prenatal test to detect Down syndrome is medically appropriate for any patient.

**Articles:** In March 2012, Kaiser review MaterniT21 for the detection of trisomy 21. No additional studies were identified since the Kaiser review. The following technology assessment was selected for review: Kaiser Permanente. Sequenom's MaterniT21 prenatal test to detect Down syndrome. March 2012.

[http://cl.kp.org/pkc/national/cpg/intc/materials/MaterniT21toDetectTrisomy21\(G121107\).pdf](http://cl.kp.org/pkc/national/cpg/intc/materials/MaterniT21toDetectTrisomy21(G121107).pdf).

The use of MaterniT21 does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## References

- Advani HV, Barrett AN, Evans MI, Choolani M. Challenges in non-invasive prenatal screening for sub-chromosomal copy number variations using cell-free DNA. *Prenatal Diagnosis* 2017;37(11):1067-1075. DOI: 10.1002/pd.5161.
- Allyse M, et al. Non-invasive prenatal testing: a review of international implementation and challenges. *International Journal of Women's Health* 2015;7:113-126. DOI: 10.2147/IJWH.S67124.
- Badeau M, et al. Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. *Cochrane Database of Systematic Reviews* 2017, Issue 11. Art. No.: CD011767. DOI: 10.1002/14651858.CD011767.pub2.
- Benn P, et al. Position Statement from the Chromosome Abnormality Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. [Internet] International Society for Prenatal Diagnosis. 2015 Feb Accessed at: <https://www.ispdhome.org/>. [accessed 2024 Oct 18]
- Benn P. Non-invasive prenatal testing using cell free DNA in maternal plasma: recent developments and future prospects. *Journal of Clinical Medicine* 2014;3(2):537-565. DOI: 10.3390/jcm3020537.
- Bevilacqua E, et al. Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort. *Ultrasound in Obstetrics & Gynecology* 2021;58(4):597-602. DOI: 10.1002/uog.23699.
- Bianchi DW, et al. DNA sequencing versus standard prenatal aneuploidy screening. *New England Journal of Medicine* 2014;370(9):799-808. DOI: 10.1056/NEJMoa1311037.
- Centers for Medicare and Medicaid Services. "Hospital services excluded from payment under the hospital outpatient prospective payment system." 42 CFR 419.22 Washington, DC 2023 Jul [accessed 2024 Oct 18] Accessed at: <https://www.ecfr.gov/>.
- Centers for Medicare and Medicaid Services. "Requirements relating to basic benefits." 42 CFR 422.101 Washington, DC 2023 Jun 05 [accessed 2024 Oct 18] Accessed at: <https://www.ecfr.gov/>.
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 - Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2024 Oct 18]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 15 - Covered Medical and Other Health Services Rev. 12171 [Internet] Centers for Medicare and Medicaid Services. 2023 Aug 03 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2024 Oct 18]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 16 - General Exclusions From Coverage Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2024 Oct 18]
- Centers for Medicare and Medicaid Services. Medicare Benefit Policy Manual. Chapter 14 - Medical Devices Rev. 198 [Internet] Centers for Medicare and Medicaid Services. 2014 Nov 06 Accessed at:



<https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/>. [accessed 2024 Oct 18] [ Context Link 1 ]

- Chitty LS, et al. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. *Prenatal Diagnosis* 2015;35(7):656-662. DOI: 10.1002/pd.4583.
- Chitty LS, Lo YM. Noninvasive prenatal screening for genetic diseases using massively parallel sequencing of maternal plasma DNA. *Cold Spring Harbor Perspectives in Medicine* 2015;5(9):a023085. DOI: 10.1101/cshperspect.a023085.
- Chiu RW. Noninvasive prenatal testing by maternal plasma DNA analysis: Current practice and future applications. *Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum* 2014;74(244):48-53. DOI: 10.3109/00365513.2014.936681.
- Dar P, et al. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. *American Journal of Obstetrics and Gynecology* 2022;Online. DOI: 10.1016/j.ajog.2022.01.002.
- Dashe JS. Aneuploidy screening in pregnancy. *Obstetrics & Gynecology* 2016;128(1):181-194. DOI: 10.1097/AOG.0000000000001385.
- Deng C, Liu S. Factors affecting the fetal fraction in noninvasive prenatal screening: a review. *Frontiers in Pediatrics* 2022;10:812781. DOI: 10.3389/fped.2022.812781.
- Dondorp W, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. *European Journal of Human Genetics* 2015;23(11):1592. DOI: 10.1038/ejhg.2015.109.
- Drury S, et al. Implementing non-invasive prenatal diagnosis (NIPD) in a National Health Service laboratory; from dominant to recessive disorders. *Advances in Experimental Medicine and Biology* 2016;924:71-75. DOI: 10.1007/978-3-319-42044-8\_14.
- Dugoff L, Mennuti MT, McDonald-McGinn DM. The benefits and limitations of cell-free DNA screening for 22q11.2 deletion syndrome. *Prenatal Diagnosis* 2017;37(1):53-60. DOI: 10.1002/pd.4864.
- Dungan JS, et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine* 2022;Online. DOI: 10.1016/j.gim.2022.11.004. (Reaffirmed 2023 Jan)
- Ferres MA, Hui L, Bianchi DW. Antenatal noninvasive DNA testing: clinical experience and impact. *American Journal of Perinatology* 2014;31(7):577-582. DOI: 10.1055/s-0034-1371706.
- Goldwasser T, Klugman S. Cell-free DNA for the detection of fetal aneuploidy. *Fertility and Sterility* 2018;109(2):195-200. DOI: 10.1016/j.fertnstert.2017.12.019.
- Hanson B, Scotchman E, Chitty LS, Chandler NJ. Non-invasive prenatal diagnosis (NIPD): how analysis of cell-free DNA in maternal plasma has changed prenatal diagnosis for monogenic disorders. *Clinical Science* 2022;136(22):1615-1629. DOI: 10.1042/CS20210380.
- Hardy T. The role of prenatal diagnosis following preimplantation genetic testing for single-gene conditions: A historical overview of evolving technologies and clinical practice. *Prenatal Diagnosis* 2020;40(6):647-651. DOI: 10.1002/pd.5662. [ Context Link 1 ] View abstract...
- Harris S, Reed D, Vora NL. Screening for fetal chromosomal and subchromosomal disorders. *Seminars in Fetal and Neonatal Medicine* 2018;23(2):85-93. DOI: 10.1016/j.siny.2017.10.006.
- Health Quality Ontario. Noninvasive prenatal testing for trisomies 21, 18, and 13, sex chromosome aneuploidies, and microdeletions: A Health Technology Assessment. *Ontario Health Technology Assessment Series* 2019;19(4):1-166.
- Hill M, et al. Non-invasive prenatal diagnosis for cystic fibrosis: detection of paternal mutations, exploration of patient preferences and cost analysis. *Prenatal Diagnosis* 2015;35(10):950-958. DOI: 10.1002/pd.4585. [ Context Link 1 ] View abstract...
- Hudecova I, Chiu RW. Non-invasive prenatal diagnosis of thalassemias using maternal plasma cell free DNA. *Best Practice and Research. Clinical Obstetrics and Gynaecology* 2017;39:63-73. DOI: 10.1016/j.bpobgyn.2016.10.016. [ Context Link 1 ] View abstract...
- Hui L, Bianchi DW. Fetal fraction and noninvasive prenatal testing: What clinicians need to know. *Prenatal Diagnosis* 2020;40(2):155-163. DOI: 10.1002/pd.5620.
- Jenkins LA, Deans ZC, Lewis C, Allen S. Delivering an accredited non-invasive prenatal diagnosis service for monogenic disorders and recommendations for best practice. *Prenatal Diagnosis* 2018;38(1):44-51. DOI: 10.1002/pd.5197. [ Context Link 1 ] View abstract...
- Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ. Uptake of noninvasive prenatal testing at a large academic referral center. *American Journal of Obstetrics and Gynecology* 2014;211(6):651, e1-e7. DOI: 10.1016/j.ajog.2014.06.038.

- Ma D, et al. Haplotype-based approach for noninvasive prenatal diagnosis of congenital adrenal hyperplasia by maternal plasma DNA sequencing. *Gene* 2014;544(2):252-258. DOI: 10.1016/j.gene.2014.04.055. [ Context Link 1 ] View abstract...
- Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. *BJOG: An International Journal of Obstetrics and Gynaecology* 2017;124(1):32-46. DOI: 10.1111/1471-0528.14050. [ Context Link 1 ] View abstract...
- Mahdi Mortazavipour M, Mahdian R, Shahbazi S. The current applications of cell-free fetal DNA in prenatal diagnosis of single-gene diseases: A review. *International Journal of Reproductive Biomedicine* 2022;20(8):613-626. DOI: 10.18502/ijrm.v20i8.11751. [ Context Link 1 ] View abstract...
- Medicare Coverage Database. [Internet] Centers for Medicare and Medicaid Services. Accessed at: <https://www.cms.gov/medicare-coverage-database/search.aspx?> Updated 2023 [accessed 2024 Oct 18]
- Mellis R, Chandler N, Chitty LS. Next-generation sequencing and the impact on prenatal diagnosis. *Expert Review of Molecular Diagnostics* 2018;18(8):689-699. DOI: 10.1080/14737159.2018.1493924.
- Miner MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive prenatal genetic testing: current and emerging ethical, legal, and social issues. *Annual Review of Genomics and Human Genetics* 2015;16:369-398. DOI: 10.1146/annurev-genom-090314-050000.
- Mohan P, et al. Clinical experience with non-invasive prenatal screening for single-gene disorders. *Ultrasound in Obstetrics & Gynecology* 2022;59(1):33-39. DOI: 10.1002/uog.23756.
- Panorama. Non-invasive Prenatal Testing (NIPT) [Internet] Natera, Inc. Accessed at: <https://www.natera.com/womens-health/panorama-nipt-prenatal-screening>. Updated 2023 [accessed 2024 Oct 18]
- Parks M, et al. Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage. *Prenatal Diagnosis* 2016;36(4):312-320. DOI: 10.1002/pd.4781.
- Parks M, et al. Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage. *European Journal of Human Genetics* 2017;25(4):416-422. DOI: 10.1038/ejhg.2016.195.
- Rabinowitz M, Savage M, Pettersen B, Sigurjonsson S, Hill M, Zimmermann B. Noninvasive cell-free DNA-based prenatal detection of microdeletions using single nucleotide polymorphism-targeted sequencing. *Obstetrics & Gynecology* 2014;123 Suppl 1:167S. DOI: 10.1097/01.AOG.0000447172.98639.e5.
- Rabinowitz T, Shomron N. Genome-wide noninvasive prenatal diagnosis of monogenic disorders: Current and future trends. *Computational and Structural Biotechnology Journal* 2020;18:2463-2470. DOI: 10.1016/j.csbj.2020.09.003.
- Rink BD, Norton ME. Screening for fetal aneuploidy. *Seminars in Perinatology* 2016;40(1):35-43. DOI: 10.1053/j.semperi.2015.11.006.
- Rose NC, et al. Screening for fetal chromosomal abnormalities. ACOG Practice Bulletin No. 226. Joint Guideline of the ACOG Obstetrics, Committee on Genetics and Society for Maternal-Fetal Medicine. *Obstetrics and Gynecology* 2020;136(4):e48-e69. DOI: 10.1097/AOG.0000000000004084. (Reaffirmed 2022 Jul)
- Rose NC, et al. Systematic evidence-based review: The application of noninvasive prenatal screening using cell-free DNA in general-risk pregnancies. *Genetics in Medicine* 2022;24(7):1379-1391. DOI: 10.1016/j.gim.2022.03.019.
- Scotchman E, Chandler NJ, Mellis R, Chitty LS. Noninvasive prenatal diagnosis of single-gene diseases: the next frontier. *Clinical Chemistry* 2020;66(1):53-60. DOI: 10.1373/clinchem.2019.304238.
- Scotchman E, Shaw J, Paternoster B, Chandler N, Chitty LS. Non-invasive prenatal diagnosis and screening for monogenic disorders. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* 2020;253:320-327. DOI: 10.1016/j.ejogrb.2020.08.001.
- Shafei N, Hakhamaneshi MS, Houshmand M, Gerayeshnejad S, Fathi F, Sharifzadeh S. Diagnostic value of non-invasive prenatal screening of beta-thalassemia by cell free fetal DNA and fetal NRBC. *Current Molecular Medicine* 2019;19(2):105-111. DOI: 10.2174/1566524019666190226124135.
- Shaffer BL, Norton ME. Cell-free DNA screening for aneuploidy and microdeletion syndromes. *Obstetrics and Gynecology Clinics of North America* 2018;45(1):13-26. DOI: 10.1016/j.ogc.2017.10.001.
- Shaw J, Scotchman E, Chandler N, Chitty L. Non-invasive prenatal testing for aneuploidy, copy number variants and single gene disorders. *Reproduction* 2020;160(5):A1-A11. DOI: 10.1530/REP-19-0591.
- Skotko BG, et al. Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations. *Genetics in Medicine* 2019;21(10):2285-2292. DOI: 10.1038/s41436-019-0485-2.
- Skrzypek H, Hui L. Noninvasive prenatal testing for fetal aneuploidy and single gene disorders. Best Practice and Research. *Clinical Obstetrics and Gynaecology* 2017;42:26-38. DOI: 10.1016/j.bpobgyn.2017.02.007. [ Society for Maternal-Fetal Medicine (SMFM) with the assistance. Norton ME, Biggio JR, Kuller JA, Blackwell SC. SMFM Consult Series #42: The role of ultrasound in women who undergo cell-free DNA screening. *American Journal of Obstetrics and Gynecology* 2017;216(3):B2-B7. DOI: 10.1016/j.ajog.2017.01.005.

- Srinivasan A, Bianchi DW, Huang H, Sehnert AJ, Rava RP. Noninvasive detection of fetal subchromosome abnormalities via deep sequencing of maternal plasma. *American Journal of Human Genetics* 2013;92(2):167-176. DOI: 10.1016/j.ajhg.2012.12.006.
- The NIFTY Test. [Internet] NiftyTest. Accessed at: <https://www.niftytest.com/>. Updated 2022 [created 2014; accessed 2024 Oct 18]
- Van den Oever JM, et al. Noninvasive prenatal diagnosis of Huntington disease: detection of the paternally inherited expanded CAG repeat in maternal plasma. *Prenatal Diagnosis* 2015;35(10):945-949. DOI: 10.1002/pd.4593.
- Van den Veyver IB. Recent advances in prenatal genetic screening and testing. *F1000Research* 2016;5:2591. DOI: 10.12688/f1000research.9215.1.
- Varela-Lema L, Punal-Rioboo J, Ballini L, Emilia-Romagna R. Screening of Fetal Trisomies 21, 18 and 13 by Noninvasive Prenatal Testing. [Internet] EUnetHTA. 2018 Feb Accessed at: <https://www.eunetha.eu/>. [accessed 2024 Oct 18]
- Vora NL, O'Brien BM. Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: proceed with caution. *Obstetrics & Gynecology* 2014;123(5):1097-1099. DOI: 10.1097/AOG.0000000000000237.
- Wou K, Levy B, Wapner RJ. Chromosomal Microarrays for the Prenatal Detection of Microdeletions and Microduplications. *Clinics in Laboratory Medicine* 2016;36(2):261-276. DOI: 10.1016/j.cll.2016.01.017.
- Xiang J, Peng Z. Applications of noninvasive prenatal testing for subchromosomal copy number variations using cell-free DNA. *Clinics in Laboratory Medicine* 2022;42(4):613-625. DOI: 10.1016/j.cll.2022.09.014.
- Xiong L, et al. Non-invasive prenatal testing for fetal inheritance of maternal  $\beta$ -thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study. *BJOG: An International Journal of Obstetrics and Gynaecology* 2018;125(4):461-468. DOI: 10.1111/1471-0528.15045.
- Yaron Y, Jani J, Schmid M, Oepkes D. Current status of testing for microdeletion syndromes and rare autosomal trisomies using cell-free DNA technology. *Obstetrics & Gynecology* 2015;126(5):1095-1099. DOI: 10.1097/AOG.0000000000001091.
- Yatsenko SA, Peters DG, Saller DN, Chu T, Clemens M, Rajkovic A. Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up. *Genetics in Medicine* 2015;17(10):836-838. DOI: 10.1038/gim.2014.197.
- Zaninovic L, Baskovic M, Jezek D, Katusic Bojanac A. Validity and utility of non-invasive prenatal testing for copy number variations and microdeletions: a systematic review. *Journal of Clinical Medicine* 2022;11(12):Online. DOI: 10.3390/jcm11123350.
- Zeevi DA, et al. Proof-of-principle rapid noninvasive prenatal diagnosis of autosomal recessive founder mutations. *Journal of Clinical Investigation* 2015;125(10):3757-3765. DOI: 10.1172/JCI79322.
- Zhang H, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. *Ultrasound in Obstetrics & Gynecology* 2015;45(5):530-538. DOI: 10.1002/uog.14792.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>81420</b>	Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
<b>81507</b>	Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy

**Considered Not Medically Necessary when performed using cell-free fetal DNA:**

CPT® Codes	Description
<b>81331</b>	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (eg, Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
<b>81403</b>	Molecular Pathology Procedure Level 4
<b>81422</b>	Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood
<b>81479</b>	Unlisted molecular pathology procedure

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/04/2012	09/04/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 1, 03/01/2022 <sup>MPC</sup> , 2/03/2013 <sup>MPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	06/13/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34101
07/05/2016	Adopted GHC-0724
04/08/2020	Added temporary change for code 81507 due to COVID-19 pandemic
06/02/2020	Extended temporary change until September 15, 2020 for code 81507 due to COVID-19 pandemic
08/04/2020	Extended temporary change until November 1, 2020 for code 81507 due to COVID-19 pandemic
12/07/2020	Extended temporary change until February 15, 2021 for code 81507 due to COVID-19 pandemic
03/08/2021	Extended temporary change until May 15, 2021 for code 81507 due to COVID-19 pandemic
05/04/2021	Extended temporary change until June 15, 2021 for code 81507 due to COVID-19 pandemic
06/01/2021	Extended temporary change until August 15, 2021 for code 81507 due to COVID-19 pandemic
08/03/2021	MPC approved to permanently eliminate age restrictions on cell-free fetal DNA (NIPT) testing for trisomies for commercial members (81507 and 81420). Prior authorization is still required for this testing at labs other than Ariosa. Requires 60-day notice, effective date January 1, 2022. Extended temporary change until December 31, 2021 for code 81507 due to COVID-19 pandemic.
03/01/2022	Updated applicable codes.
08/16/2022	MCG* A-0847 was removed from the 26 <sup>th</sup> edition; removed from criteria
10/7/2022	Added labcorp as preferred vendor for Cell Free Fetal DNA testing. Noted Prevention as preferred lab for genetic testing.
04/24/2023	Added Quest-QNatal as a preferred vendor for Cell Free Fetal DNA testing.
05/03/2024	Updated list of preferred lab vendors
06/13/2024	Removed MCG* A-0850 (guideline was updated in the 28 <sup>th</sup> ed.); retained position of non-coverage.
10/18/2024	Updated references
12/06/2024	LabCorp acquired Invitae Genetics test. Criteria was updated to reflect acquisition, effective November 15, 2024



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Chronic Cerebrospinal Venous Insufficiency Treatment

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Chronic Cerebrospinal Venous Insufficiency Treatment</b> , for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Criteria will be reviewed using the [Medically Necessary Services policy](#).

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

#### Background

Multiple sclerosis is an autoimmune inflammatory disease of the central nervous system that affects approximately 250,000 to 500,000 people in the United States. Although the cause of multiple sclerosis is unknown, evidence suggests it may be caused by the interplay of genetic and environmental factors. However, it has recently been hypothesized that a phenomenon known as chronic cerebrospinal venous insufficiency (CCSVI) may also play a role in the etiology, pathogenesis, and/or disease progression of multiple sclerosis. This theory suggests that abnormal drainage of venous blood due to stenosis or malformation of the internal jugular and/or azygous veins may be a cause of multiple sclerosis (Ghezzi 2011, Khan 2010, Vedantham 2010).

The evidence pertaining to the association between CCSVI and multiple sclerosis is inconsistent. Depending on the study, the frequency of CCSVI in patients with multiple sclerosis ranged from 0 to 100%. The frequency of CCSVI in controls ranged from 0 to 23%. Different methods of assessing CCSVI may explain some of the variability among these studies. Doppler sonography, venous MRI, and venous angiography have all been used to assess CCSVI; however, it is not clear which is the gold standard (Ghezzi 2011). Additionally, it is not clear if CCSVI is a cause of multiple sclerosis, an effect of multiple sclerosis, or an unrelated finding (Singh 2009, Vedantham 2010). Based on the CCSVI hypothesis balloon angioplasty has been proposed as a treatment for multiple sclerosis patients with CCSVI.

#### Medical Technology Assessment Committee (MTAC)



## Chronic Cerebrospinal Venous Insufficiency Treatment

06/10/2011: MTAC REVIEW

**Evidence Conclusion:** A recent open-label, prospective case-series evaluated the safety of CCSVI endovascular treatment and its influence on clinical outcomes in 65 consecutive patients with multiple sclerosis. No operative or postoperative complications were recorded. After the endovascular treatment, disease severity significantly improved for patients with relapse remitting multiple sclerosis, but not for patients with primary progressive or secondary progressive multiple sclerosis. In patients with relapse remitting multiple sclerosis, significantly more patients were relapse free during the 18 months posttreatment compared to the year preceding endovascular treatment; however, there was no significant difference in annualized relapse rate. Quality of life improved significantly for subjects with relapse remitting and primary progressive multiple sclerosis, but not for subjects with secondary progressive multiple sclerosis. Results from this study should be interpreted with caution as this is a small, open-label study with no comparison group (Zamboni 2009). Another prospective case-series evaluated the safety of endovascular treatment for CCSVI in 331 patients with multiple sclerosis. Overall, three patients experienced major complications. Two patients (1.2% of implanted stents) experienced stent thrombosis and one patient (0.3%) required surgical opening of the femoral vein to remove the angioplastic balloon. Minor complications included: local bleeding from the groin (4 patients, 1.2%), minor gastrointestinal bleeding (1 patient, 0.3%), transient cardiac arrhythmia (2 patients, 0.6%), difficulty removing the angioplastic balloon or delivery system (4 patients, 1.2%), problems with proper placement of the stent (4 patients, 2.3% of implanted stents), unsuccessful catheterization of the stenosed internal jugular vein (4 patients, 1.3%). Long-term complications were not addressed (Ludyga 2010). **Conclusion:** Currently, there is insufficient evidence to determine the safety and efficacy of balloon angioplasty for the treatment of CCSVI in patients with multiple sclerosis. In a recent position statement, the Society of Interventional Radiology also concluded that the current published literature was inconclusive on whether CCSVI is a clinically important factor in the development and/or progression of multiple sclerosis and on whether balloon angioplasty is clinically effective in patients with multiple sclerosis (Vedantham 2010).

**Articles:** To determine the safety and efficacy of balloon angioplasty for the treatment of multiple sclerosis patients with CCSVI. No randomized controlled trials were identified that assessed the safety or efficacy of balloon angioplasty for the treatment of multiple sclerosis patients with CCSVI. The best evidence came from an observational study. This study was selected for review. The following study was critically appraised: Zamboni P, Galeotti R, Menegatti E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. *J Vasc Surg* 2009; 50:1348-1358. See [Evidence Table](#).

The use of chronic cerebrospinal venous insufficiency treatment for multiple sclerosis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered not medically necessary for Multiple Sclerosis:

CPT® or HCPC Codes	Description
37238	Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; initial vein
37239	Transcatheter placement of an intravascular stent(s), open or percutaneous, including radiological supervision and interpretation and including angioplasty within the same vessel, when performed; each additional vein (List separately in addition to code for primary procedure)
37248	Transluminal balloon angioplasty (except dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same vein; initial vein
37249	Transluminal balloon angioplasty (except dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same vein; each additional vein (List separately in addition to code for primary procedure)
<b>With diagnosis code</b>	
G35	Multiple sclerosis

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.



[Criteria](#) | [Codes](#) | [Revision History](#)  
 \*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/05/2011	07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 01/07/2014 <sup>MDCRPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup>	07/02/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34886 and L35008 Non-Covered Services.
07/02/2024	MPC approved to archive policy and add to Medically Necessary Services criteria page, requires 60-day notice, effective 12/01/2024



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Cervical Fusion (Anterior or Posterior)

- **Percutaneous Posterior Cervical Fusion (w/ CAVUX® Cervical Cage, DTRAX® Spinal System, Corus™ Spinal System)**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Cervical Fusion (Anterior or Posterior)</b> " for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

*\*All radiology studies (X-ray, MRI, etc.) must be submitted in a written form: films must be read by a Radiologist.*

**NOTE:** Any operative candidate should be nicotine-free for at least 6 weeks prior to elective surgery (unless there is evidence of cord compression, infection, malignancy, or progressive neurologic deficit). For persons with recent nicotine use, documentation of nicotine cessation should include a lab report (not surgeon summary) showing blood or urine nicotine level of 0, drawn within 6 weeks prior to surgery)

**NOTE:** BMI > 40 is a relative contraindication to fusion in patients without progressive neurologic deficit or cord compression

In addition to the following clinical criteria, this procedure is subject to [Elective Surgical Procedures Level of Care](#) review

#### I. ANTERIOR CERVICAL FUSION FOR DEGENERATIVE DISEASE

Single or multilevel anterior cervical discectomy and fusion (ACDF) is considered medically necessary for treatment of symptomatic degenerative disease when **EITHER of the following** criteria are met:

A. Radiculopathy, must meet **ALL of the following**:

1. Clinical diagnosis of unremitting cervical radiculopathy\*\* (see below), resulting in disability and/or neurological deficit
2. Refractory to at 3 months of standard conservative physician supervised medical management \*\*\* (see below)
3. Complex imaging studies (i.e., CT, MRI, X-ray, Myelogram) demonstrate at least **ONE of the following** at each impacted level being considered for the fusion:
  - Herniated nucleus pulposus
  - Spondylosis such as foraminal stenosis due to an osteophyte causing nerve root compression
  - ligamentous hypertrophy causing impingement (either cord compression or foraminal stenosis)
  - Visible loss of disc height compared to adjacent levels with resultant foraminal stenosis
4. Physical examination findings and imaging studies correlate with each level being considered for the fusion

**OR**

B. Myelopathy, must meet **ALL of the following**:

1. Clinical diagnosis of myelopathy\*(see below)
2. Complex imaging studies (i.e., CT, MRI, Xray, Myelogram) demonstrate structural cord compression associated with cord signal change/myelomalacia on MRI imaging
3. Physical examination findings and imaging studies correlate with each level being considered for the fusion

## II. CERVICAL FUSION FOR INSTABILITY

Single or multilevel cervical fusion is considered medically necessary for **ANY of the following** indications when there is an associated spinal instability:

- Acute spinal fracture and/or dislocation
- Neural compression after spinal fracture
- Traumatic ligamentous disruption
- Epidural compression, fracture or vertebral destruction from spinal tumor or cyst
- Spinal decompression or debridement for infection (e.g., discitis, osteomyelitis, epidural abscess, TB)
- Spinal decompression for myelopathy associated with subluxation in rheumatoid arthritis
- Cervical spinal deformity associated with neurological symptoms of myelopathy\* or radiculopathy\*\* (e.g., sagittal plane angulation of more than 11 degrees between adjacent segments, subluxation of >3.5 mm)
- As an adjunct to cyst excision of synovial facet cysts in the cervical spine
- Atlantoaxial instability (e.g., atlas and axis fracture, nonunion)
- Treatment of cervical spine fracture/dislocation associated with acute cervical radiculopathy\*\* or myelopathy\*
- Multilevel spondylotic myelopathy with kyphosis, when symptoms of myelopathy are present and

- Imaging studies correlate with symptoms and demonstrates cord compression
- Cervical instability from any **ONE of the following**:
  - Klippel-Feil syndrome
  - Down's syndrome
  - Skeletal dysplasia or connective tissue disorder

### III. CERVICAL FUSION FOR IATROGENIC INSTABILITY

Cervical fusion is considered medically necessary for anticipated intraoperative iatrogenic spinal instability of the level or levels involved resulting from **ANY of the following** surgical procedures:

- Removal of 50% or more of the facets bilaterally
- Removal of 75% or more of a single facet
- Following cervical corpectomy\*, as part of a stabilization procedure

**\*Note:** Corpectomy is a procedure in which the at least 50% or more of the body of the vertebrae is removed.

### IV. POSTERIOR CERVICAL FUSION: SPINAL STENOSIS

Posterior cervical fusion is considered medically necessary for the treatment of spinal stenosis with laminectomy when **EITHER of the following** criteria are met:

#### A. Radiculopathy, must meet **ALL of the following**:

1. Clinical diagnosis of unremitting cervical radiculopathy\*\*(see below) resulting in disability and/or neurological deficit
2. Refractory to at 3 months of standard conservative physician supervised medical management \*\*\*
3. Complex imaging studies (i.e., CT, MRI, X-ray, Myelogram) demonstrate at least **ONE of the following** at each impacted level being considered for the fusion:
  - Herniated nucleus pulposus
  - Spondylosis such as foraminal stenosis due to an osteophyte causing nerve root compression
  - ligamentous hypertrophy causing impingement (either cord compression or foraminal stenosis)
  - Visible loss of disc height compared to adjacent levels with resultant foraminal stenosis
4. Physical examination findings and imaging studies correlate with each level being considered for the fusion

**OR**

#### B. Myelopathy, must meet **ALL of the following**:

1. Clinical diagnosis of myelopathy\*
2. Radiographic evidence of **ANY of the following**:
  - Subluxation or translation of more than 3.5 mm on static lateral views or dynamic radiographs
  - Sagittal plane angulation of more than 11 degrees between adjacent segments
  - Structural cord compression associated with cord signal change/myelomalacia on MRI

3. Complex imaging studies (e.g., radiographs, magnetic resonance imaging [MRI], computerized tomography [CT], myelography) that correlates with the clinical symptoms and/or signs

## V. CERVICAL FUSION FOLLOWING PRIOR SPINAL SURGERY:

Cervical fusion is considered medically necessary for treatment of symptomatic adjacent or same segment stenosis following prior cervical surgery, when **EITHER of the following** criteria have been met:

### A. Radiculopathy, must meet **ALL of the following**:

1. Clinical diagnosis of unremitting cervical radiculopathy\*\* resulting in disability and/or neurological deficit
2. Refractory to at 3 months of standard conservative physician supervised medical management \*\*\*
3. Complex imaging studies (i.e., CT, MRI, X-ray, Myelogram) demonstrate at least **ONE of the following** at each impacted level being considered for the fusion:
  - Herniated nucleus pulposus
  - Spondylosis/ foraminal stenosis due such as an osteophyte causing nerve root compression
  - ligamentous hypertrophy causing impingement (either cord compression or foraminal stenosis)
  - Visible loss of disc height compared to adjacent levels with resultant foraminal stenosis
4. Physical examination findings and imaging studies correlate with each level being considered for the fusion

**OR**

### B. Myelopathy, must meet **ALL of the following**:

1. Clinical diagnosis of myelopathy\*
2. Radiographic evidence of **ANY of the following**:
  - Subluxation or translation of more than 3.5 mm on static lateral views or dynamic radiographs
  - Sagittal plane angulation of more than 11 degrees between adjacent segments
  - Structural cord compression associated with cord signal change/myelomalacia on MRI
3. Complex imaging studies (e.g., radiographs, magnetic resonance imaging [MRI], computerized tomography [CT], myelography) that correlates with the clinical symptoms and/or signs

## VI. CERVICAL FUSION FOLLOWING PRIOR SPINAL SURGERY: PSEUDOARTHROSIS

Cervical fusion is considered medically necessary for the treatment of pseudoarthrosis (i.e., nonunion of prior fusion) of the cervical spine at the same level(s) when it has been at least 12 months from the prior surgery and **ALL of the following criteria** are met:

- Mechanical neck pain that correlates to the level of the pseudoarthrosis
- Imaging studies (e.g., radiographs, CT) confirm evidence of a pseudoarthrosis (e.g., lack of bridging bone, dynamic motion on flexion-extension radiographs)



- Failure of three (3) consecutive months of physician-supervised conservative\*\*\* management which includes exercise, nonsteroidal and/or steroidal medications (unless contraindicated), physical therapy **AND**
- Activity lifestyle modification

## VII. CERVICAL FUSION NOT MEDICALLY NECESSARY

Cervical fusion is considered not medically necessary for the following indications:

- anterior or posterior cervical fusion for chronic axial neck pain
- posterior cervical fusion performed with laminectomy in the absence of kyphosis (e.g., degenerative spine) or subluxation/translation of more than 3.5 mm

Isolated cervical facet fusion, with or without instrumentation, including facet joint implants and/or bone graft substitutes used exclusively as a stand-alone stabilization device is considered experimental, investigational, or unproven.

**\*Cervical Myelopathy:** signs suggestive of *spinal cord* involvement:

- Upper limb weakness in more than a single nerve root distribution
- Lower limb weakness
- Loss of dexterity (e.g., clumsiness of hands)
- Bowel or bladder incontinence
- Frequent falls
- Hyperreflexia
- Hoffmann sign (overreaction to flick of the fingernail)
- Increased extremity muscle tone or spasticity
- Spastic Gait/ataxic Gait
- Positive Babinski

**\*\* Radicular pain/suspected radiculopathy** defined as:

- Pain in a *nerve root* distribution (e.g., C6, C7)
- Motor weakness or persistent sensory loss in a radicular distribution (must be in a specific radicular distribution) **OR**
- EMG/NCS confirms acute radiculopathy consistent with the patient's symptoms

**\*\*\*Physician-supervised conservative medical management** defined as: Patients must have three months of non-operative treatment as demonstrated by a trial of **one or more of the following** medications:

- Non-steroidal anti-inflammatory drugs (oral or topical)
- Acetaminophen
- Epidural steroid injection of corticosteroids as appropriate

**AND**

- A trial of **All** of the following physical measures:

- Supervised Physical therapy, attendance at >75% of sessions, minimum of 3 visits
- Flexibility and muscle strengthening exercises
- Reasonable restriction of activities
- If conservative therapy is not appropriate, the medical record must clearly document why such an approach is not reasonable.
- Evaluation and appropriate management of associated cognitive, behavioral or addiction issues when present

Procedure	Criteria
Percutaneous Posterior Cervical Fusion (w/ CAVUX® Cervical Cage, DTRAX® Spinal System, Corus™ Spinal System)	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**For covered criteria:**

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Neck pain occurs in many people and typically involves more than one component of the spine, such as the vertebrae, intervertebral discs, spinal nerves, other anatomic structures such as ligaments, muscles, and joints. Conditions that frequently result in neck pain include soft tissue injury, trauma, infection, herniated disc, degenerative spine conditions, neoplastic conditions, and deformities such as kyphosis. While the cause of neck pain is often multifactorial (e.g., originating from the vertebrae, discs, ligaments, tendons and muscles) the location of pain varies. Axial neck pain occurs along the spine, is of musculoskeletal or soft tissue origin, and is a non-radiating type of pain. The most common cause of axial neck pain is degenerative change to the cervical spine, which occurs as a natural consequence of aging. Radicular pain involves a nerve root, is due to nerve root compression, follows the nerve root distribution, and radiates to one or both upper extremities, and/or into the shoulder area. Radicular pain can include varying degrees of sensory, motor, and/or reflex changes related to nerve root(s) without evidence of myelopathy (North American Spine Society, [NASS], 2013). Myelopathy is a term that describes any neurological deficit related to the spinal cord and is often used to describe loss of function in the upper or lower extremities (NASS, 2013). Depending on the cause of neck pain associated symptoms may include numbness, tingling, weakness, and other types of neurologic dysfunction in the presence of spinal cord compression. Conservative measures for treatment of neck pain include analgesics, muscle relaxants, local injections, physical therapy, cervical bracing and home exercise. Conservative treatment is often effective for alleviating symptoms and typically lasts six to eight weeks. However, conservative therapy is not recommended in the presence of progressive neurological deficits, in the presence of unstable spinal fractures or dislocations, or for progressive spinal deformity. In the absence of progressive neurologic compromise, or when conservative management has been attempted and fails to relieve pain and disability, surgery may be required for conditions with underlying pathology confirmed by physical examination and radiological imaging. When spinal cord compression is present surgical methods to relieve the pressure on the nerves is often necessary and is referred to as decompression surgery.

Decompression typically includes surgical procedures such as discectomy (removal of the disc), laminectomy (removal of the lamina), corpectomy (removal of the vertebral body), or osteotomy (removal of a piece of bone). When performed, these procedures may result in spinal instability. As such, decompression is often performed as part of cervical fusion in order to regain stability of the spine. For example, anterior cervical fusion is usually performed with decompression. Posterior cervical fusion is typically performed with stabilization (using rods, screws) although may be performed with decompression in some instances (NASS, 2014). Instability of the cervical spine can also result from trauma and/or disease, or a combination of all (White, Panjabi, 1980), which may or may not require a decompression. Instability of the cervical spine has been defined by White, Panjabi (1980) and is well-accepted in the medical literature as sagittal plane translation of >3.5 mm, and/or rotation between motion segments of 11°, in addition to other notable factors such as destruction of elements or inability to function, a positive stretch test, spinal cord or nerve root damage, and abnormal disc narrowing (White, Panjabi, 1980). In the absence of instability, evidence in the published peer-reviewed scientific literature does not provide strong support that when used for this indication cervical fusion is clinically effective for reducing pain and disability. 2011; Persson, et al., 1997). Psychological assessment and treatment as part of a multidisciplinary approach to conservative pain management is recommended. Risk factors, such as drug or alcohol abuse and depression may act as a barrier to recovery following spinal fusion (Washington State Department of Labor and Industries, 2002; Hanley, David, 1999; Tang, et al., 2001). Authors have recommended psychological screening, and treatment if applicable, of patients with neck and/or back pain prior to surgery for identification of risk factors that may be associated with chronic disability. Cervical spinal fusion is in many situations an elective surgery, therefore it is strongly recommended that individuals be in the best physical condition prior to undergoing surgery. Modifiable risk factors and the influence on outcomes of spine surgery has been studied, modification of such risk factors can assist with improved patient selection for spine surgery and better postoperative management (Shahrestani, et al., 2021). Along with alcohol and opioid use, tobacco/nicotine increases the risk of perioperative complications, cardiopulmonary complications, pseudoarthrosis and infection (Shahrestani, et al., 2021) furthermore it is well-established that smoking is a preventable cause of morbidity and mortality. Tobacco use in particular is considered a risk factor for poor healing and has been associated with nonunion. Particularly with spinal fusion, tobacco use has been associated with increased risk of pseudoarthrosis (Brown, et al., 1986). The American Academy of Orthopedic Surgeons (AAOS) supports avoidance and cessation of all tobacco products and cigarette smoking due to the harmful impact on musculoskeletal health, as well as overall health (AAOS, 2016).

## Medical Technology Assessment Committee (MTAC)

### ***Percutaneous posterior cervical fusion with the CAVUX Cervical Cage-I or DETRAX System***

#### **BACKGROUND**

**Date: 10/17/2017**

**Evidence Conclusion:** The literature was limited for single-level cervical radiculopathy and studies comparing posterior cervical fusion using DTRAX with standard practice (anterior cervical discectomy and fusion, total disc replacement) were scarce. However, two studies were reviewed. These studies were prospective in design. The aims of these studies were to assess clinical and radiographic outcomes of DTRAX on patients with single level cervical radiculopathy. Patients were enrolled consecutively and underwent surgery using DTRAX. Follow-up occurred at one and two-year post-surgery. Clinical as well as imaging evaluations were also performed. Patients who failed conservative management were recruited and a total of 60 patients were enrolled. Patients' mean age was 53 years with a range of 40 to 75 years. The most common level treated was C5-C6 followed by C6-C7. Clinical outcomes have improved at one and two-year after the surgery. First, neck and arm pain, assessed by VAS, have significantly decreased ( $P<0.0001$  in one study;  $P$ -value not reported in the second study). Second, the neck disability index has significantly decreased ( $P<0.0001$ ). Third, quality of life, measured by both mental and physical component, has improved ( $P<0.0001$ ). Radiographic assessments were equivocal and not consistent. Segmental lordosis did not significantly change 2 years after the surgery; at 1-year post-surgery, this outcome was not reported. In addition, no change was reported for posterior disc height 1 year after surgery, but at 2 years post-surgery, a small decrease was reported ( $P=0.001$ ). Anterior disc height has decreased 1-year post-surgery ( $P<0.01$ ). Fusion rate was high. No major complications were reported; however, the most common procedure-related adverse events were postoperative pain, nausea, pain from the bone graft harvest site. Limitations included the non-randomized nature of the

study, consulting relationship between surgeons and study sponsor, the small sample size, and the short follow-up. For these reasons, the quality of evidence is deemed low. **Other studies and conclusion** ([See Evidence Table 1](#)): Bilateral cervical cage with a posterior approach can increase foraminal area and decompress nerve roots; but studies showing correlation between increased in foraminal area and clinical outcomes are warranted. ([See Evidence Table 1](#)): Posterior bilateral cervical cage led to 6% (N=53) of adjacent segment degeneration 2 years after surgery; 12% of existing degeneration showed moderate progression and long-term adjacent segment degeneration incidence was unknown.

A retrospective study ([See Evidence Table 2](#)) of 10 patients with one-year follow-up, on whom cervical fusion using bilateral posterior cervical cages was performed reported favorable improvements in pain and function in patients with single-level cervical radiculopathy. [See Evidence Table 1 & 2](#)

#### Conclusion:

- Studies were scarce; two studies were reviewed; studies comparing posterior cervical fusion using DTRAX with standard practice (anterior cervical discectomy and fusion, total disc replacement) were not identified
- The quality of evidence is low
- Clinical outcomes have improved at one and two-year post-surgery
- Radiographic findings were not consistent and ambiguous at one and two-year after the procedure
- Adverse events were minimal
- The available evidence is insufficient to recommend for or against the effectiveness and safety of posterior cervical fusion with DTRAX in patients with single level cervical radiculopathy who failed conservative management.

**Articles:** The literature revealed 7 articles, however 4 were relevant, but 2 studies with the largest sample size were extensively reviewed.

The use of Percutaneous posterior cervical fusion with the CAVUX Cervical Cage-I or DETRAX System does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

#### Cervical Fusion: Anterior

CPT® or HCPCS Codes	Description
22548	Arthrodesis, anterior transoral or extraoral technique, clivus-C1-C2 (atlas-axis), with or without excision of odontoid process
22551	Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophyctomy and decompression of spinal cord and/or nerve roots; cervical below C2
22552	Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophyctomy and decompression of spinal cord and/or nerve roots; cervical below C2, each additional interspace (List separately in addition to code for separate procedure)
22554	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below C2
22585	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); each additional interspace (List separately in addition to code for primary procedure)
22808	Arthrodesis, anterior, for spinal deformity, with or without cast; 2 to 3 vertebral segments
22810	Arthrodesis, anterior, for spinal deformity, with or without cast; 4 to 7 vertebral segments
22812	Arthrodesis, anterior, for spinal deformity, with or without cast; 8 or more vertebral segments

#### Cervical Fusion: Posterior

CPT® or HCPCS Codes	Description
22590	Arthrodesis, posterior technique, craniocervical (occiput-C2)

<b>22595</b>	Arthrodesis, posterior technique, atlas-axis (C1-C2)
<b>22600</b>	Arthrodesis, posterior or posterolateral technique, single interspace; cervical below C2 segment
<b>22614</b>	Arthrodesis, posterior or posterolateral technique, single interspace; each additional vertebral segment (List separately in addition to code for primary procedure)
<b>22800</b>	Arthrodesis, posterior, for spinal deformity, with or without cast; up to 6 vertebral segments
<b>22802</b>	Arthrodesis, posterior, for spinal deformity, with or without cast; 7 to 12 vertebral segments

**Considered Experimental, Investigational or Unproven when used to report isolated cervical facet fusion, including facet joint implants and/or bone graft substitutes used exclusively as stand-alone stabilization devices for treatment of facet joint pain:**

<b>CPT® or HCPCS Codes</b>	<b>Description</b>
<b>22899</b>	Unlisted procedure, spine
<b>0219T</b>	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical
<b>0222T</b>	Placement of a posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)

### **Percutaneous Posterior Cervical Fusion**

**Considered Not Medically Necessary**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
No specific codes for percutaneous posterior cervical fusion	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

<b>Date Created</b>	<b>Date Reviewed</b>	<b>Date Last Revised</b>
07/05/2022	07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	12/04/2023

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
07/05/2022	MPC approved to adopt criteria for Cervical Fusion for non-Medicare members. Requires 60-day notice, effective date 12/01/2022.
10/04/2022	MPC approved to include quantifying number of 3 visits for conservative treatment. 60-day notice required.
10/28/2022	Merged criteria set with Percutaneous Cervical Fusion.
12/15/2022	Standardized approach to clinical myelopathy to remove conservative treatment as a prerequisite for surgery.
12/04/2023	Effective 12/05/2023 Lumbar Spinal Fusion will require Level of Care review when procedure is performed as an elective procedure



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Substance Use Disorder

- Office-Based Opioid Agonist Treatment for Opioid Use Disorder
- Methadone Treatment
- SUD Treatments, Level of Care

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Inpatient Hospital Stays for Treatment of Alcoholism (130.1)</a> <a href="#">Outpatient Hospital Services for Treatment of Alcoholism (130.2)</a> <a href="#">Chemical Aversion Therapy for Treatment of Alcoholism (130.3)</a> <a href="#">Excluded Service: Electrical Aversion Therapy for Treatment of Alcoholism (130.4)</a> <a href="#">Treatment of Alcoholism and Drug Abuse in a Freestanding Clinic (130.5)</a> <a href="#">Treatment of Drug Abuse (Chemical Dependency) (130.6)</a> <a href="#">Withdrawal Treatments for Narcotic Addictions (130.7)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
American Society of Addiction Medicine (ASAM)	Kaiser Permanente uses ASAM criteria as a supplement to the above NCDs or LCDs for medical necessity review of residential, inpatient, and detoxification treatment for Medicare members.

#### For Non-Medicare Members

Service	Criteria
<b>Office-Based Opioid Agonist Treatment for Opioid Use Disorder</b>	<p><b>Admission to provider office-based treatment:</b>  <b>ALL of the following</b> met in order to qualify for admission to a provider for office-based treatment (e.g. buprenorphine/naloxone (Suboxone), buprenorphine (Subutex, Sublocade, Probuphine), and naltrexone (Vivitrol)):</p> <ol style="list-style-type: none"> <li>1. The primary use for the office-based opioid management is for treatment of the patient's Opioid Use Disorder (e.g. not as primary treatment of the patient's pain disorder)</li> <li>2. The patient is assessed to be an appropriate candidate for office-based medication maintenance therapy</li> </ol> <p><b>Continued Stay Criteria:</b>  In addition to meeting criteria for admission into office-based opioid use disorder medication treatment, <b>ALL of the following</b> must be met in order to meet criteria for continued stay in office-based opioid use disorder</p>



	<p>medication treatment:</p> <ol style="list-style-type: none"> <li>1. Patient is adhering to their treatment plan, as determined by the physician</li> <li>2. Treatment is primarily for Opioid Use Disorder</li> </ol> <p><b>Discharge Criteria:</b> The patient meets discharge criteria when meeting <b>ONE OR MORE</b> of the following:</p> <ol style="list-style-type: none"> <li>1. Patient is failing office-based opioid use disorder medication treatment provider treatment requirements, as defined by the individual provider.</li> <li>2. Patient voluntarily discontinues office-based opioid use disorder medication treatment.</li> </ol>
<b>Methadone Treatment (H0020)</b>	No medical necessity review required. No prior authorization required for contracted providers for opioid use disorder.
<p><b>For all other SUD treatments</b></p> <p>The following services may be considered medically necessary when criteria are met using ASAM® Criteria:</p> <ul style="list-style-type: none"> <li>• Outpatient Services</li> <li>• Intensive Outpatient</li> <li>• Partial Hospitalization Service</li> <li>• Inpatient Detoxification</li> <li>• Residential Admission &amp; Concurrent Stay</li> <li>• Sub-Acute Detoxification</li> </ul>	<p>Kaiser Permanente uses criteria from the American Society of Addiction Medicine (ASAM) to review for residential, inpatient, and detoxification services for adults and adolescents. ASAM criteria were created to improve access to and quality of care in the treatment of substance use disorders. These criteria match individual patients with the appropriate services to help patients succeed in their recovery. This policy describes which types of substance use disorder treatment may be considered medically necessary when using ASAM criteria.</p>

**\*The ASAM criteria are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed by our Behavioral Health department, you may request a copy of the criteria that is being used to make the coverage determination. Call the Behavioral Health Unit for more information regarding the case under review.

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Kaiser Permanente Mental Health and Wellness Services has adopted American Society of Addiction Medicine (ASAM) criteria to define medical necessity for substance use disorder treatment and to define substance use disorder level of care.

### ASAM placement criteria for both adult and adolescents

Washington State requires the use of ASAM criteria by State-certified chemical dependency treatment providers, when determining placement of patients with substance use disorders (criteria includes placement recommendations related to residential treatment). Clinical recommendations must be documented in writing and must contain objective clinical information. Clinical criteria do not factor in family, employer or legal mandates or requests for treatment. Clinical criteria are intended to evaluate the impact of the substance use disorder on the affected individual (via a bio-psychosocial assessment) and to guide decision making related to care strategies.

### ASAM placement criteria for both adult and adolescents

Washington State requires the use of ASAM criteria by State-certified chemical dependency treatment providers, when determining placement of patients with substance use disorders (criteria includes placement recommendations related to residential treatment). Clinical recommendations must be documented in writing and must contain objective clinical information. Clinical criteria do not factor in family, employer or legal mandates or requests for treatment. Clinical criteria are intended to evaluate the impact of the substance use disorder on the affected individual (via a bio-psychosocial assessment) and to guide decision making related to care strategies.

## Evidence and Source Documents

### References:

The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related and Co-Occurring Conditions, Third Edition (2013)

Copies of the criteria can be obtained at [www.asam.org](http://www.asam.org).

Revised Code of Washington (RCW) 41.05.528

## Applicable Codes

### Methadone for Opioid Use Disorder

#### Medical Necessity Review not required:

CPT® or HCPC Codes	Description
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)

### Substance Use Disorder

#### Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® or HCPC Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
01/09/2006	07/02/2013 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 08/05/2014 <sup>MPC</sup> , 06/02/2015 <sup>MPC</sup> , 04/05/2016 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	10/24/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
01/05/2016	Online version of criteria has been updated with editorial changes
07/11/2017	Minor changes to criteria to note ASAM criteria, 3 <sup>rd</sup> edition
12/31/2020	Adopted ASAM Criteria for non-Medicare per mandated Washington state requirement, effective January
05/26/2021	Adopted ASAM criteria for Medicare members. Requires 60-day notice, effective October 1, 2021.
09/17/2021	Updated Background and References with current information.
10/03/2023	MPC should approve updates to the criteria in order to stop requiring prior-authorization of office-based methadone treatment (H0020) for opioid use disorder. 60-day notice required, effective March 1, 2024.
10/24/2023	Merged all criteria sets that utilize ASAM Criteria: Outpatient Services, Intensive Outpatient/Partial Hospitalization Service, Residential/Inpatient Services, Sub-Acute Detoxification





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Spinal Manipulations – Chiropractic and Osteopathic

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual, Chapter 15 Section 30.5 - Chiropractor's Services and Section 240 Chiropractic Services - General</a>
National Coverage Determinations (NCD)	<a href="#">Manipulation (150.1)</a>
Local Coverage Determinations (LCD)	<a href="#">Chiropractic Services (L34009)</a> 12/31/2019 Noridian retired LCD Chiropractic Services (L34009). These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L34009 for determining medical necessity.
Local Coverage Article	<a href="#">Billing and Coding: Chiropractor Services (A57914)</a>

#### For Non-Medicare Members

When considering clinical information submitted for medical necessity review, the following data elements and corresponding details are evaluated to ensure correlation to the presenting diagnosis and proposed care plan\*:

- Chief Complaint(s)
- Past Medical History
- Mechanism of Onset
- Duration of Symptoms (acute or chronic)
- Evaluation and Re-evaluation findings
- Results of Diagnostic Testing
- Diagnostic Impression
- Complicating Factors (conditions or circumstances that may affect the patient's response to care)
- Prior and/or Concurrent History of Treatment
- Prognosis and Provider Comments

#### Manipulative Therapy\*

In establishing a fundamental need for manipulation, the treating provider must maintain a clinical record that includes an appropriate new and/ or established patient history and physical examination, and a goal-oriented care plan with measurable treatment goals. This collectively will be considered the key components of an evaluation and management service.

Examples of clinically significant improvement include, but are not limited to:

- Corresponding reduction and/or mitigation in subjective symptoms;

- Measured improvement in objective findings (i.e., orthopedic tests, neurologic signs, joint specific and region specific ranges of motion, musculoskeletal asymmetry at rest, palpation of tender and sensitive zones, tissue texture changes, muscle strength metrics); and
- A qualitative and/or quantifiable improvement in the patient's ability to perform specific functional tasks and/or activities of daily living as measured by the Patient-Specific Functional Scale (PSFS) or similar validated patient reported clinical outcome measure. For example, a clinically relevant improvement in the PSFS can be indicated by a change of at least 2 points in the average score of all activities or at least a 3-point change in a single activity over the reported baseline within a 4-week period.

For Manipulative therapy services, Medicare requires the primary diagnosis to be a spinal subluxation diagnosis code, followed by a secondary neuro-musculoskeletal diagnosis code. Medicare mandates that the physical exam must demonstrate a causal relationship between the spine and the patient's presenting complaint, which demonstrates medical necessity for spinal manipulation.

Medical necessity for manipulative therapy services should be supported by three elements of documentation:

- Presence of a spinal subluxation;
- Evidence of the subluxation by X-ray or physical examination; and
- Documentation of the initial and subsequent visits.

Medicare requires the acronym P.A.R.T. (Pain, Asymmetry, Range of Motion, and Tissue/Tone) must be used to describe the examination components indicating that a patient is suffering from a spinal condition amenable to manipulation. At least 2 of the 4 P.A.R.T. criteria must be met, with a least one of them being the "A" or "R" component.

\*Excerpted from Tivity WholeHealth Network [Clinical Criteria to Determine Medical Necessity: Physical Medicine Services](#) (reviewed and updated January, 2021)

**Take home equipment and supplies must follow Kaiser Permanente coverage rules and guidelines.**

See [Devices, Equipment and Supplies](#)

See [Compression Garments](#)

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Spinal manipulation is defined by chiropractors as "a specific form of direct articular manipulation utilizing a short lever and characterized by a dynamic, forceful, high velocity thrust of controlled amplitude" (Janse, 1975, as cited by Coulehan, 1985, p. 355). Chiropractors distinguish between chiropractic adjustments and spinal manipulation. Spinal manipulation is a generic term that refers to techniques used by osteopathic physicians, physiatrists (rehabilitation specialists), physiotherapists, or orthopedic surgeons. Spinal adjustment therapy usually involves more frequent visit than medical treatment for the same condition. (Coulehan, 1985).

Manual manipulation of the spine is composed of four elements: patient positioning, location of applied load, peak velocity of the load that is achieved, and peak load developed. The total displacement of the body segments is believed to be properly controlled by a combination of patient positioning and peak load. Techniques used by chiropractors to augment the manipulation may include mobilization, manual traction, soft-tissue massage, and pressure-point techniques (Haldeman, 1983).

Spinal manipulation and adjunct therapies (physical therapy) have been demonstrated to be effective when delivered alone, but no therapy has been consistently demonstrated to be more effective than the other modalities. A 2011 Cochrane Back Group review of 26 randomized controlled trials with 6070 participants (9 studies with low bias) found high quality evidence that spinal manipulative therapy for low back pain indicates provides clinically relevant, statistically significant short-term effect on pain relief as compared to other interventions, including exercise therapy, standard medical care or physical therapy. (Rubinstein, 26Feb2011) The reviewers note that spinal manipulation appears to be no better or no worse than other existing therapies for

pain relief. This review affirms the 2008 Cochrane Database Review of Spinal Manipulative Therapy for low-back pain results indicating no evidence that spinal manipulative therapy is superior to other standard treatments (physical therapy, exercises, back school, general physician care) for pain relief or improved functional outcomes. (Assendelft, et al., Cochrane Library Review, 8Oct2011)

There is mixed evidence on the clinical effectiveness of adjunct modalities, including physical therapy and rehabilitative services and durable medical equipment and supplies, when delivered concurrently with spinal manipulation.

An April 2010 Cochrane Back Group Review of combined chiropractic interventions demonstrated slightly improved pain and disability for patients with acute and subacute back pain in the short term. No difference was demonstrated for combined chiropractic interventions for chronic lower back pain and for studies that had a mixed population of lower back pain. Any demonstrated differences were small and were only seen in studies with a high risk of bias. For acute and subacute LBP, chiropractic interventions improved short- and medium-term pain (SMD -0.25 (95% CI -0.46 to -0.04) and MD -0.89 (95%CI -1.60 to -0.18)) compared to other treatments, but there was no significant difference in long-term pain (MD -0.46 (95% CI -1.18 to 0.26)). Short-term improvement in disability was greater in the chiropractic group compared to other therapies (SMD -0.36 (95% CI -0.70 to -0.02)). However, the effect was small and all studies contributing to these results had high risk of bias. There was no difference in medium- and long-term disability. (Walker, 14APR2010)

In a randomized controlled trial of chiropractic care (flexion distraction) or physical therapy (exercise program), Cambron found that subjects in both groups had decreased pain and disability regardless of which therapy was utilized ( $p < .002$ ). During the year after care, chiropractic subjects had significantly lower pain scores ( $p = .002$ ) and received fewer visits but experienced no difference in timing of care following intervention when compared to those in physical therapy treatment. Physical therapy subjects attended significantly more health care visits than subjects who received chiropractic care only. (Cambron, Cochrane Register of Controlled Trials, Chiropractic care vs medical care for low back pain: Assessment of long-term follow-up data, 2005).

## Evidence and Source Documents

Hayes Report, Chiropractic Treatment of Low Back Pain, May 26, 1999

Spinal Manipulative Therapy for Chronic Low Back Pain, The Cochrane Library. Rubinstein, SM, van Middelkoop, M, Assendelft, WJJ, de Boer, MR, vanTulder, MW. 8 Oct 2011 online publication.

Walker B, French S, Grant W, Green S, Cochrane Library Review of Combined Chiropractic Interventions for Low Back Pain, 14APR2010 online publication.

Cambron JA, Cochrane Register of Controlled Trials, Chiropractic care vs medical care for low back pain: Assessment of long-term follow-up data, 2005.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
98925	Osteopathic manipulative treatment (OMT); 1-2 body regions involved
98926	Osteopathic manipulative treatment (OMT); 3-4 body regions involved
98927	Osteopathic manipulative treatment (OMT); 5-6 body regions involved
98928	Osteopathic manipulative treatment (OMT); 7-8 body regions involved
98929	Osteopathic manipulative treatment (OMT); 9-10 body regions involved
98940	Chiropractic manipulative treatment (CMT); spinal, 1-2 regions
98941	Chiropractic manipulative treatment (CMT); spinal, 3-4 regions
98942	Chiropractic manipulative treatment (CMT); spinal, 5 regions
98943	Chiropractic manipulative treatment (CMT); extraspinal, 1 or more regions

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).



Date Created	Date Reviewed	Date Last Revised
02/10/2000	10/05/2010 <sup>MDCRPC</sup> , 08/02/2011 <sup>MDCRPC</sup> , 06/05/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	12/21/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/05/2015	The chiropractic policy was modified. The Healthways Clinical Criteria for Chiropractic Services was adopted as GHC policy.
09/08/2015	Revised LCD L34009
09/07/2021	Updated Tivity criteria reference for manipulative therapy.
12/21/2023	Added NCD Manipulation (150.1)

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Cochlear Implant

- Cochlear Implant Device
- Hybrid Cochlear Implant

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Cochlear Implantation (50.3)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Service	Criteria Used
<b>Cochlear Implant</b>	<p>Kaiser Permanente has elected to use the Cochlear Implant (KP-0177 12012022v2) MCG* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p> <p><b>If requesting this service, please send the following documentation to support medical necessity:</b></p> <ul style="list-style-type: none"> <li>• Most recent audiogram/hearing test</li> <li>• Most recent clinical notes from requesting provider &amp;/or specialist (otolaryngology, ENT)</li> </ul>
<b>Cochlear implantation with a hybrid cochlear implant/hearing aid device that includes the hearing aid integrated into the external sound processor of the cochlear implant, including but not limited to the Nucleus® Hybrid™ L24 Cochlear Implant System</b>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies</p>

\*MCG Manuals are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

A cochlear implant is an electronic device that can enable patients with severe to profound hearing loss to perceive sound. Cochlear implants have two main parts:

- 1) An internal device that is implanted under the skin behind the ear; and
- 2) A speech processor that is worn or carried (externally) by the individual.

Sounds are detected by a microphone and transformed into an electrical signal. The speech processor codes the signals into a particular pattern of electrical pulses. The pulses are sent to the implant, which in turn transmits them via the auditory nerve to the brain, which recognizes them as sound. Use of a cochlear implant requires both a surgical procedure to implant the device, and substantial post-implantation therapy to learn or re-learn the sense of hearing. In the United States, approximately 22,000 adults have cochlear implants and about 15,000 children have received them (NIDCD, 2006).

Provision of unilateral cochlear implants is currently standard practice. Although results are often positive, particularly in the ability to understand speech in a quiet situation, normal hearing is not restored. There is increasing interest in bilateral cochlear implants to further improve the ability to patients to detect sound. Potential advantages of bilateral implantation include improvements in:

- Hearing in noise, due to the ability to benefit from a “head shadow effect
- Speech perception, due to the availability of sound information from both ears;
- Sound localization, the ability to correctly identify the directional location of sounds surrounding the listener (Litovsky et al., 2006; Tyler et al., 2003).

A potential problem with bilateral cochlear implants is that bilateral coordination of pulsed signals is not yet possible. Instead, the two implants function independently. This is not likely to be as effective as normal binaural hearing which takes advantages of the integration of binaural acoustical cues. In addition, patients with severe hearing loss may have different patterns of loss on each side, and also may have developed abnormal binaural brain maps (Tyler et al., 2003). Response to bilateral cochlear implants, especially localization ability, may also depend on previous experience with hearing. Adults who have had exposure to binaural stimulation early in life appear to perform better with bilateral cochlear implants than adults who were born without hearing or lost hearing at a very young age (Litovsky et al., 2006).

Experts have pointed out that a challenge in studying the effectiveness of bilateral cochlear implants is that learning may influence an individual’s ability to detect aural cues, either unilateral or bilateral. Studies that evaluate users of bilateral implants without comparing them to experienced users of unilateral users may be limited because they do not include patients who have been able to adapt to listening through one device.

## Medical Technology Assessment Committee (MTAC)

### *Hybrid Cochlear Implant*

#### **BACKGROUND**

Sensorineural hearing loss (SHL) is the most common form of hearing loss occurring when there is damage to the inner ear or the nerve pathway from the inner ear to the brain. Causes are variable and range from aging and heredity, all the way to exposure to loud noises and drugs toxic to the inner ear. SHL typically results in difficulty hearing faint sounds, understanding people with higher-pitched voices, hearing certain speech sounds, and in some cases, hearing high-pitched emergency vehicle sirens or common safety alarms, such as smoke detectors. Any type of hearing loss can be debilitating and can affect people in various ways.

Conventional treatment options for hearing loss are dependent on the type and source of hearing loss. While hearing loss cannot be fully restored, a wide variety of technologies are currently available to improve hearing. These technologies utilize either air or bone conduction to transmit sound. Air conduction hearing aids (ACHA), for example, receive sound waves through a microphone which are then converted to electrical signals and amplified through a speaker in the ear. Alternatively, bone anchored hearing aids (BAHA) transmit sound vibrations directly to the inner ear through the skull, bypassing the outer and middle ear completely. In any case, both technologies come with strengths and limitations.

The Nucleus® Hybrid™ L24 Cochlear Implant System, developed by Cochlear® (Centennial, CO), combines the functions of both ACHA and BAHA in a single device. The device specifically uses acoustic amplification to amplify low frequency hearing, while taking advantage of cochlear implant technology to restore access to the high-frequency hearing allowing a near normal hearing experience. The hybrid technology requires surgical

implantation, similar to that of a standard cochlear implant with the main difference being that the array is shorter and therefore not inserted as far into the cochlear.

The United States Food and Drug Administration (FDA) approved the first hybrid cochlear implant in March of 2014. The Medical Technology and Assessment Committee (MTAC) has not previously assessed hybrid cochlear implants and is currently reviewing the topic to support a coverage decision.

## 08/17/2015: MTAC REVIEW

### Hybrid Cochlear Implant

**Evidence Conclusion:** *Effectiveness:* A multi-centered European study, carried out by Lenarz and colleagues, investigated hearing conservation in 66 patients with significant low-frequency residual hearing using the Nucleus Hybrid L24 cochlear implant. The investigators compared pre- and post-operative performance in speech recognition scores in both quiet and noisy environments were significantly improved for 65% and 73% of subjects, respectively. In addition, the mean speech spatial and quality subscale ratings were significantly improved by 1.2, 1.3 and 1.8 points, respectively ( $p < 0.001$ ). Ultimately, the investigators concluded that the hybrid cochlear implant preserved low-frequency residual hearing and improved speech perception (Lenarz, James et al. 2013).

[Evidence Table 1] A similar study, conducted by Roland et al. in multiple centers across the US, included 50 individuals with severe to profound high-frequency hearing loss. In the same way as the European trial, pre- and post-operative performance was measured on consonant-nucleus-consonant words, AzBio sentence noise as well as self-assessment. At six months, the investigators reported that a majority of the patients had statistically significant improvements in word and sentence recognition leading the investigators to conclude that the Nucleus Hybrid L24 cochlear implant provides significant improvements to hearing (Roland, Gantz et al. 2015). [Evidence Table 2]

**Safety:** The safety profile on these devices is not entirely clear. Both of the included studies detail a number of adverse effects including dizziness, irritation and tinnitus to name a few. Beyond that, the literature reports risk of permanent damage to residual hearing fibers from the surgery and placement of the electrode itself. A larger long-term concern is associated with future changes in hearing in the implanted ear. Specifically, should the patient experience additional hearing loss, will they need additional surgery using a longer standard electrode.

Collectively, the evidence is limited by small sample sizes, lack of randomization and inadequate comparison groups. To add to this, neither of the studies provide a sufficient follow-up period. Finally, both of the studies are sponsored by the device manufacturer leaving the studies open to potential bias. Ultimately, the evidence does not adequately support the safety and effectiveness of the hybrid cochlear implant. The evidence base would benefit from large RCTs with extended follow-up to establish long-term performance and safety.

**Conclusions:** There is insufficient evidence to support the effectiveness of a hybrid cochlear implant with external hearing aid compared with a standard cochlear implant. There is insufficient to establish the safety of hybrid cochlear implant with standard cochlear implant.

**Articles:** The search returned a small variety of publications including retrospective analyses, small single arm prospective studies and one cross-sectional study (Golub, Won et al. 2012; Nguyen, Mosnier et al. 2012; Reiss, Turner et al. 2012; Szyfter, Wróbel et al. 2013; Jurawitz, Büchner et al. 2014). The literature was specifically screened for randomized controlled trials (RCTs) with the overall aim to compare hybrid cochlear implants with conventional cochlear implants. In the absence of RCTs with appropriate comparators, the best available evidence came from two prospective, single arm studies (one of which supported the 2014 FDA approval) were selected for critical appraisal. The following articles were selected for review: Lenarz T, James C, Cuda D, et al. European multi-centre study of the Nucleus Hybrid L24 cochlear implant. *International Journal of Audiology*. 2013; 52:838-848. [See Evidence Table 1](#). Roland JT, Gantz BJ, Waltzman SB, et al. United States multicenter clinical trial of the cochlear nucleus hybrid implant system. *Laryngoscope*. 2015. [See Evidence Table 2](#).

The use of hybrid cochlear implants does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Cochlear Implant - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
69930	Cochlear device implantation, with or without mastoidectomy
H CPC Codes	Description
L8614	Cochlear device, includes all internal and external components
L8619	Cochlear implant, external speech processor and controller, integrated system, replacement

<b>L8627</b>	Cochlear implant, external speech processor, component, replacement
<b>L8628</b>	Cochlear implant, external controller component, replacement

**Hybrid Cochlear Implant - Considered Not Covered:**

Same as listed above and billed with HCPC Code	Description
<b>L8614</b>	Cochlear device, includes all internal and external components

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/20/1995	09/07/2010 <sup>MDCRPC</sup> , 10/05/2010 <sup>MDCRPC</sup> , 07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	02/06/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/07/2020	MPC approved to adopt updates to the Cochlear Implant criteria (KP-0177) Specific changes include but not limited to: <ul style="list-style-type: none"> <li>No longer indicates a need to place one implant at a time and that evidence supports concurrent bilateral implants specifically for adults</li> <li>Added "replacement exclusion" language from commercial contracts</li> </ul> Removed non-applicable CPT codes: 69714, 69715, 69717, 69718
03/02/2021	MPC approved the updated recommendations to the current hybrid criteria for Cochlear Implant to include indications for unilateral sensorineural hearing loss for ages 5 years old and older. Requires 60-day notice, effective date 08/01/2021.
07/05/2022	MPC approved to update the hybrid criteria (KP-0177) to include indications for single-sided deafness and include clarifying language for obsolescence/warranty. Requires 60-day notice, effective date 12/01/2022.
07/02/2024	MPC approved Cochlear Implant into the Care Delivery Medical Necessity Review program.
02/06/2025	Removed MTAC Reviews on Bilateral Cochlear Implants from 2004 and 2006 as it is no longer applicable and covered using KP/MCG Guidelines.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Combined Hydrogen/Methane Breath Test

- Diagnosing Small Intestinal Bacterial Overgrowth (SIBO)
- Fructose or Lactose Intolerance

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Diagnostic Breath Analyses (100.5)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Services	Criteria used
Diagnosing Small Intestinal Bacterial Overgrowth (SIBO)	Hydrogen/methane breath test covered only when ordered by Gastroenterologist for possible SIBO
Fructose or Lactose Intolerance	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Small intestinal bacterial overgrowth (SIBO) is characterized by a malabsorption syndrome due to abnormally large amounts of bacteria within the small intestine (Gasbarrini, et al. 2007). Symptoms include diarrhea, abdominal pain or cramps, nausea, constipation, acid reflux, bloating, flatulence, dehydration and fatigue. SIBO can also cause more severe symptoms including steatorrhea, anemia, bleeding or bruising, night blindness, bone pain, fractures, leaky gut syndrome, autoimmune reactions, weight loss and "failure to thrive". Due largely to uncertainty with regard to definition and detection, the true prevalence of SIBO and its relationship to a number of clinical disorders remains unclear (Dukowicz, et al. 2007).

Direct aspiration and culture of jejunal fluid have traditionally been considered the "gold standard" for SIBO diagnosis. With results expressed as colony-forming units per milliliter of jejunal fluid (cfu/ml), a SIBO diagnosis is



most commonly defined as >105 cfu/ml, however, the thresholds vary throughout the literature (Abu-Shanab and Quigley 2009; Dukowicz, et al. 2007). To add to this, aspiration and culture is expensive, invasive and difficult to perform requiring the passage of a tube under fluoroscopic guidance through the nose, throat, esophagus and stomach. Breath tests, on the other hand, escape these limitations and have been proposed as a simple tool for diagnosing SIBO. Based on the fact that only bacteria in the gastrointestinal tract can ferment unabsorbed carbohydrates and metabolize them into hydrogen and/or methane, the gases are absorbed into the bloodstream and subsequently excreted in the breath (Levitt, et al. 2006; Simren and Stotzer 2006). Put simply, breath tests measure the levels of hydrogen and/or methane gas in a breath (Ghoshal, et al. 2006).

Breath tests can be performed at home or in a clinic and require that the patient fast for 12 hours prior to testing, after which, the patient provides a baseline sample breath. After establishing a baseline measurement, the patient ingests a small amount of substrate, either lactulose or glucose, and subsequently, provides breath samples every 15 minutes for three to five hours. At this time, hydrogen/methane breath tests have not been standardized with protocols differing in dose and concentration of the test substrate, and duration of test time intervals (Bures, et al. 2010). In the same way, there have been no accepted criteria for what constitutes a positive result.

Hydrogen/methane breath tests have not been approved by the Food and Drug Administration (FDA).

## Medical Technology Assessment Committee (MTAC)

### Combined Hydrogen/Methane Breath Test

#### 6/16/2014: MTAC REVIEW

**Evidence Conclusion:** There is insufficient evidence to establish the diagnostic accuracy of the combined hydrogen/methane breath test for diagnosing SIBO. There is insufficient evidence to conclude that the hydrogen breath test is not harmful to patients. There is insufficient evidence to determine the impact of the test on patient management.

**Articles:** There is extensive literature on the use of breath testing to diagnose SIBO with many publications addressing the prevalence of SIBO among patients with irritable bowel syndrome. Generally speaking, there is a greater body of published literature on the use of hydrogen breath testing with less literature specifically addressing the use of methane breath tests and combination hydrogen and methane breath tests. Two studies were identified that assess the utility and accuracy of SIBO. The following studies were selected for critical appraisal: Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth: reliability of jejunal culture and inadequacy of breath hydrogen testing. *Gastroenterology*. 1990;98(2):302-309. See [Evidence Table](#) Ghoshal UC, Ghoshal U, Das K et al. Utility of hydrogen breath tests in diagnosis of small intestinal bacterial overgrowth in malabsorption syndrome, and its relationship with oro-cecal transit time. *Indian J Gastroenterology*. 2006;25(1):6-10. See [Evidence Table](#).

The use of Combined Hydrogen/Methane Breath Test for Diagnosing Small Intestinal Bacterial Overgrowth (SIBO) does not meet the *Kaiser Permanente Medical Technology Testing Criteria*.

### trio-smart® Breath Test for Aiding Diagnosis of Small Intestinal Bacterial Overgrowth (SIBO)

#### 10/25/2023: INTC REVIEW

##### **Evidence Conclusion:**

**There is insufficient evidence regarding the effectiveness and safety of the trio-smart® breath test for aiding diagnosis of small intestinal bacterial overgrowth (SIBO) in patients with gastrointestinal symptoms.**

- The existing evidence regarding how the trio-smart® breath test effectively aids in the diagnosis of SIBO is of insufficient quantity and/or quality.

**Rationale:** In patients with gastrointestinal symptoms, there is no clinical validity or clinical utility evidence on the trio-smart® breath test for aiding diagnosis of SIBO.

##### **Evidence Summary:**

- A Hayes, Inc. Evidence Analysis Research Brief (June 2023) noted that there currently is not enough published peer-reviewed literature to evaluate the evidence related to the trio-smart® breath test for diagnosis of SIBO in a full assessment. There were no relevant clinical validity or clinical utility studies identified in the Hayes, Inc. review of abstracts.

- In our supplemental search of the published literature for studies not identified by Hayes, Inc., we did not find any full-text, peer-reviewed articles addressing the clinical question.
- In the absence of peer-reviewed data, no conclusion is drawn regarding the effectiveness and safety of the trio-smart® breath test in aiding SIBO diagnosis in patients with gastrointestinal symptoms.

## References

- Abu-Shanab A, Quigley EM. Diagnosis of small intestinal bacterial overgrowth: the challenges persist! *Expert Rev Gastroenterol Hepatol*. 2009;3(1):77-87.
- Banik GD, De A, Som S, et al. Hydrogen sulphide in exhaled breath: A potential biomarker for small intestinal bacterial overgrowth in IBS. *J Breath Res*. 2016;10(2):026010.
- Berthold HK, Schober P, Scheurlen C, et al. Use of the lactose-[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test. *J Gastroenterol*. 2009;44(9):944-951.
- Böhmer CJ, Tuynman HA. The effect of a lactose-restricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: a 5-year follow-up study. *Eur J Gastroenterol Hepatol*. 2001;13(8):941-944.
- Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*. 2009;104(Suppl 1):S1-S35.
- Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. *Clin Epidemiol*. 2014;6:71-80.
- Cash BD, Chey WD. Review article: irritable bowel syndrome – an evidence-based approach to diagnosis. *Aliment Pharmacol Ther*. 2004;19(12):1235-1245.
- Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. *Dig Dis Sci*. 2010;55(1):124-130.
- Corazza GR, Menozzi MG, Strocchi A, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. *Gastroenterology*. 1990;98(2):302-309.
- Credentialing Resource Center (CRC). Gastroenterology. Practice Area 138. *Clin Privil White Pap*. 2013;(138):1-20.
- Credentialing Resource Center (CRC). Pediatric gastroenterology. Practice Area 427. *Clin Privil White Pap*. 2014;(427):1-16.
- Drossman DA, Li Z, Andruzzi E, et al. U.S. Householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci*. 1993;38(9):1569-1580.
- Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. *Gastroenterology*. 2016;150(6):1262-1279.e2.
- Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. *Neurogastroenterol Motil*. 2015;27(4):481-489.
- Gasbarrini A, Corazza GR, Gasbarrini G, et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference [correction appears in Aliment Pharmacol Ther. 2010;31(1):166]. *Aliment Pharmacol Ther*. 2009;29(Suppl 1):1-49.
- Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. *Eur J Gastroenterol Hepatol*. 2014;26(7):753-760.

- Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. *Neurogastroenterol Motil*. 2008;20(9):998-1008.
- Hayes, Inc. Evidence Analysis Research Brief. trio-smart® for Diagnosis of Small Intestinal Bacterial Overgrowth. June 2023.
- Kasir R, Zakko S, Zakko P, et al. Predicting a response to antibiotics in patients with the irritable bowel syndrome. *Dig Dis Sci*. 2016;61(3):846-851.
- Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. *Gastroenterology*. 1988;95(4):982-988.
- King CE, Toskes PP. Comparison of the 1-gram [14C]xylose, 10-gram lactulose-H2, and 80-gram glucose-H2 breath tests in patients with small intestine bacterial overgrowth. *Gastroenterology*. 1986;91(6):1447-1451.
- Koza J, Meder A, Swiqtowski M. Small intestinal bacterial overgrowth is diagnosed in some cases of irritable bowel syndrome. *Clin Exp Med Lett*. 2009;50(3):197-198.
- Lacy BE, Fermín M, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. *Gastroenterology* 2016;150:1393-1407.
- Liu JJ, Brenner DM. Updates and Caveats to Breath Testing for Intestinal Overgrowth. *Am J Gastroenterol* . 2022;117(9):1390-1393. doi:10.14309/ajg.0000000000001841
- Long SK, Di Palma JA. Does carbohydrate challenge testing predict clinical response in small intestinal bacterial overgrowth? *South Med J*. 2016;109(5):296-299.
- Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. *Gastroenterology*. 2006;130(5):1480-1491.
- Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. *Aliment Pharmacol Ther*. 2005;22(11-12):1157-1160.
- Mayo Foundation for Education and Research (MFMER). Irritable bowel syndrome. July 31, 2014. Available at: <http://www.mayoclinic.org/diseases-conditions/irritable-bowel-syndrome/basics/definition/con-20024578>. Accessed March 7, 2017.
- Mearin F. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. *Digestion*. 2006;73(Suppl 1):28-37
- Miazga A, Osinski M, Cichy W, Zaba R. Current views on the etiopathogenesis, clinical manifestation, diagnostics, treatment and correlation with other nosological entities of SIBO. *Adv Med Sci*. 2015;60(1):118-124.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Diagnosis of Irritable Bowel Syndrome (IBS). How do doctors diagnose IBS? February 2015. Available at: <https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome/diagnosis>. Accessed March 7, 2017.
- Parker TJ, Woolner JT, Prevost AT, Tuffnell Q, Shorthouse M, Hunter JO. Irritable bowel syndrome: is the search for lactose intolerance justified? *Eur J Gastroenterol Hepatol*. 2001;13(3):219-225.
- Parodi A, Capurso G, Perri F, Cuoco L, Lauritano EC. H2-breath testing for small-intestinal bacterial overgrowth. *Aliment Pharmacol Ther*. 2009a;29(Suppl 1):18-22.

- Parodi A, Dulbecco P, Savarino E, et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. *J Clin Gastroenterol*. 2009b;43(10):962-966.
- Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol*. 2000;95(12):3503-3506.
- Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. *Curr Gastroenterol Rep*. 2016;18(2):8.
- Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. *Scand J Gastroenterol*. 1979;14(3):333-336.
- Riordan SM, McIver CJ, Bolin TD, Duncombe VM. Fasting breath hydrogen concentrations in gastric and small-intestinal bacterial overgrowth. *Scand J Gastroenterol*. 1995;30(3):252-257.
- Riordan SM, McIver CJ, Duncombe VM, Thomas MC, Bolin TD. Evaluation of the rice breath hydrogen test for small intestinal bacterial overgrowth. *Am J Gastroenterol*. 2000;95(10):2858-2864.
- Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. *Am J Gastroenterol*. 1996;91(9):1795-1803.
- Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. *J Gastroenterol Hepatol*. 2011;26(Suppl 3):135-138.
- Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. *J Pediatr*. 2009;155(3):416-420.
- Siddiqui I, Ahmed S, Abid S. Update on diagnostic value of breath test in gastrointestinal and liver diseases. *World J Gastrointest Pathophysiol*. 2016;7(3):256-265.
- Simrén M, Stotzer P-O. Use and abuse of hydrogen breath tests. *Gut*. 2006;55(3):297-303.
- Stotzer PO, Kilander AF. Comparison of the 1-gram (14)C-D-xylose breath test and the 50-gram hydrogen glucose breath test for diagnosis of small intestinal bacterial overgrowth. *Digestion*. 2000;61(3):165-171.
- Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. *Gastroenterology*. 1980;79(2):283-288.
- trio-smart® product website ( More [About trio-smart®](#))
- Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. *Am J Gastroenterol*. 2005;100(7):1566-1570.
- Yuki M, Komazawa Y, Kobayashi Y, et al. Effects of Daikenchuto on abdominal bloating accompanied by chronic constipation: a prospective, single-center randomized open trial. *Curr Ther Res Clin Exp*. 2015;77:58-62.
- Zhao J, Zheng X, Chu H, et al. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients. *Neurogastroenterol Motil*. 2014;26(6):794-802.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>91065</b>	Breath hydrogen or methane test (eg, for detection of lactase deficiency, fructose intolerance,

	bacterial overgrowth, or oro-cecal gastrointestinal transit)
--	--

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/01/2014	07/01/2014 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	11/02/2023

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
12/06/2016	Added language to cover test if ordered only by GI for possible SIBO
11/02/2023	Added October 25, 2023 INTC Review: <i>trio-smart® Breath Test for Aiding Diagnosis of Small Intestinal Bacterial Overgrowth (SIBO)</i>

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Complications of Non-Covered Services

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Benefit Manual Chapter 16, 180 - Services Related to and Required as a Result of Services Which Are Not Covered Under Medicare</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

All services related to the non-covered services are excluded from coverage. However, certain contracts, but not all, have provisions to cover specific complications of non-covered services for acute medical complications. Contracts that have coverage may allow for coverage of specific medically necessary interventions to resolve an acute, potentially life threatening medical complication (not necessarily covering non-acute issues). Refer to the member specific contract language to determine the benefit coverage for non-covered services. Coverage does not include complications that occur during or immediately following the non-covered service. Additional surgeries or other medical services to resolve other acute medical complications resulting from non-covered services shall not be covered.

Examples of -Non-covered complications may include but are not inclusive of the following possible situations:

- A nasal obstruction after cosmetic rhinoplasty
- Desired cosmetic outcomes not achieved
- Scarring of surgical wounds arising from a cosmetic procedure
- Request for removal of breast implants due to contracture or leakage, when placed for cosmetic purposes

All requests that appear to involve complications of a non-covered services, or any from dental services should be sent to the clinical review physicians for review.

#### If requesting these services, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology if applicable



The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Most Kaiser Permanente contracts state “Excluded: non-covered surgical services.” In applying this exclusion guidance was requested by staff making coverage determinations. The above criteria were developed to provide guidance.

Creation Date	Review Dates	Date Last Revised
09/24/2007	04/06/2010 <sup>MDCRPC</sup> , 02/11/2011 <sup>MDCRPC</sup> , 02/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 12/03/2024 <sup>MPC</sup>	08/03/2021

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/01/2015	Revised LCD L34886 and L35008 Non-Covered Services.
11/12/2018	Updated KPWA criteria for Non-Medicare Members
12/5/2018	Revised ALL reviews must go to Medical Director Review
05/07/2019	MPC approved to adopt criteria for complications of non-covered services
08/04/2020	Added Medicare LCA A57642
08/03/2021	Removed retired Medicare LCD L35008 and LCA A57642.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Compression Garments – Stockings/Sleeves

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Surgical Dressings (L33831)</a> <a href="#">Lymphedema Compression Treatment</a> (Must have diagnosis of I89.0, I97.2, I97.89, Q82.0)
Local Coverage Article	<a href="#">Surgical Dressings (A54563)</a> <a href="#">External Breast Prosthesis (A52478)</a> - (Addresses L8010 A mastectomy sleeve (L8010) is denied as noncovered, since it does not meet the definition of a prosthesis) <a href="#">Lymphedema Compression Treatment Items—Correct Coding and Billing</a> (Must have diagnosis of I89.0, I97.2, I97.89, Q82.0) <a href="#">Standard Documentation Article (A55426)</a>
MLN Matters Article	<a href="#">Lymphedema Compression Treatments Items: Implementation</a>

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Graduated Compression Stockings/Sleeves (KP-0336) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

Elastic stockings are generally stockings of 18-20 mm or less and can be purchased over the counter.

**\*The MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 12 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Compression garments are usually made of elastic material and are used to promote venous or lymphatic circulation. Compression garments worn on the legs can help prevent deep vein thrombosis and reduce edema and are useful in a variety of peripheral vascular conditions. Compression garments can come in varying degrees of compression. The higher degrees require a physician's prescription.

## Evidence and Source Documents

### 2/12/1986: LITERATURE SEARCH

**Articles:** The use of JOBST products for the treatment of burns is medically appropriate.

### 12/31/1999: LITERATURE SEARCH

**Articles:** Effective Health Care, NHS Centre for Reviews and Dissemination, University of York, August 1997, Volume 3:4, ISSN: 0965-0288.

Twenty randomized controlled trials evaluated different forms of compression bandaging on venous ulcer healing in a wide range of age groups. Two of these incorporated economic evaluations, 2 compared compression stockings with compression bandages and 2 evaluated intermittent pneumatic compression. Overall, the quality of trials is poor. Six RCT's assessed whether compression therapy was better than no compression. These showed that compression provided by either Unna's boot, 2-layer, 4 layer or short stretch bandages improve healing rates compared to treatment using no compression. One study showed that compression was more cost effective because of faster healing rates saving nursing time. High compression showed the best healing rates. A combination of 2 compression stockings has been shown to increase the rate of healing compared to a short stretch bandage.

Compression stockings have been found to be more effective than drug therapy in the prevention of recurrence of leg ulcers.

White Paper - Kaiser on Benefits of Compression Therapy:

Venous ulcers can be healed, and recurrence prevented through the use of compression therapy (not TED hose). Recommend coverage of two pair a year and patients must wear all day every day. Compression therapy can prevent serious complications of venous insufficiency and reduce treatment costs.

Federal Post-Mastectomy Reconstructive Surgery Mandate: December 21, 1998 AAHP memo:

The Federal post-mastectomy reconstructive surgery mandate was contained in the Women's Health and Cancer Rights Act of 1998 that was included in the FY99 omnibus appropriations act (P.L., 105-277, enacted October 21, 1998). Under the new law most plans and insurers that provide coverage for medical and surgical benefits in connection with a mastectomy are required to provide reconstructive surgery benefits. Coverage includes reconstruction of the breast on which the mastectomy was performed, surgery and reconstruction of the other breast to produce symmetrical appearance, and prostheses and treatment of physical complications at all stages of the mastectomy, including lymphedemas.

Yasuhara MD, Hiroshi et al., A Study of the Advantages of Elastic Stockings for Leg Lymphedema, *International Angiology*, Vol 15:3, 272-277, September 1996 See [Evidence Table](#)

G. Bertelli, et al, An analysis of prognostic factors in response to conservative treatment of postmastectomy lymphedema, *Surgery, Gynecology and Obstetrics*, Volume 175: 455-460, November 1992 See [Evidence Table](#)

Bunce, Ian H et al, Post-mastectomy Lymphedema Treatment and Measurement, *Medical Journal of Australia*, Vol 161: 125-128, July 18, 1994 See [Evidence Table](#)

## Applicable Codes

### Compression Burn Garments

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
A6501	Compression burn garment, bodysuit (head to foot), custom fabricated
A6502	Compression burn garment, chin strap, custom fabricated
A6503	Compression burn garment, facial hood, custom fabricated
A6504	Compression burn garment, glove to wrist, custom fabricated
A6505	Compression burn garment, glove to elbow, custom fabricated
A6506	Compression burn garment, glove to axilla, custom fabricated
A6507	Compression burn garment, foot to knee length, custom fabricated
A6508	Compression burn garment, foot to thigh length, custom fabricated

<b>A6509</b>	Compression burn garment, upper trunk to waist including arm openings (vest), custom fabricated
<b>A6510</b>	Compression burn garment, trunk, including arms down to leg openings (leotard), custom fabricated
<b>A6511</b>	Compression burn garment, lower trunk including leg openings (panty), custom fabricated
<b>A6512</b>	Compression burn garment, not otherwise classified
<b>A6513</b>	Compression burn mask, face and/or neck, plastic or equal, custom fabricated

### **Surgical Dressing Compression Garments**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>A6531</b>	Gradient compression stocking, below knee, 30-40 mmhg, used as a surgical dressing, each
<b>A6532</b>	Gradient compression stocking, below knee, 40-50 mmhg, used as a surgical dressing, each
<b>A6545</b>	Gradient compression wrap, non-elastic, below knee, 30-50 mmhg, used as a surgical dressing, each

### **Compression Garments**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

† not covered by Medicare

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>A6530</b>	Gradient compression stocking, below knee, 18-30 mmhg, each
<b>A6533</b>	Gradient compression stocking, thigh length, 18-30 mmhg, each
<b>A6534</b>	Gradient compression stocking, thigh length, 30-40 mmhg, each
<b>A6535</b>	Gradient compression stocking, thigh length, 40 mmhg or greater, each
<b>A6536</b>	Gradient compression stocking, full length/chap style, 18-30 mmhg, each
<b>A6537</b>	Gradient compression stocking, full length/chap style, 30-40 mmhg, each
<b>A6538</b>	Gradient compression stocking, full length/chap style, 40 mmhg or greater, each
<b>A6539</b>	Gradient compression stocking, waist length, 18-30 mmhg, each
<b>A6540</b>	Gradient compression stocking, waist length, 30-40 mmhg, each
<b>A6541</b>	Gradient compression stocking, waist length, 40 mmhg or greater, each
<b>A6544</b>	Gradient compression stocking, garter belt
<b>A6549</b>	Gradient compression garment, not otherwise specified
<b>L8010†</b>	Breast prosthesis, mastectomy sleeve

### **Stockings/Sleeves**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>A6520</b>	Gradient compression garment, glove, padded, for nighttime use, each
<b>A6521</b>	Gradient compression garment, glove, padded, for nighttime use, custom, each
<b>A6522</b>	Gradient compression garment, arm, padded, for nighttime use, each
<b>A6523</b>	Gradient compression garment, arm, padded, for nighttime use, custom, each
<b>A6524</b>	Gradient compression garment, lower leg and foot, padded, for nighttime use, each
<b>A6525</b>	Gradient compression garment, lower leg and foot, padded, for nighttime use, custom, each
<b>A6526</b>	Gradient compression garment, full leg and foot, padded, for nighttime use, each
<b>A6527</b>	Gradient compression garment, full leg and foot, padded, for nighttime use, custom, each
<b>A6528</b>	Gradient compression garment, bra, for nighttime use, each
<b>A6529</b>	Gradient compression garment, bra, for nighttime use, custom, each
<b>A6552</b>	Gradient compression stocking, below knee, 30-40 mmhg, each
<b>A6553</b>	Gradient compression stocking, below knee, 30-40 mmhg, custom, each
<b>A6554</b>	Gradient compression stocking, below knee, 40 mmhg or greater, each
<b>A6555</b>	Gradient compression stocking, below knee, 40 mmhg or greater, custom, each
<b>A6556</b>	Gradient compression stocking, thigh length, 18-30 mmhg, custom, each
<b>A6557</b>	Gradient compression stocking, thigh length, 30-40 mmhg, custom, each
<b>A6558</b>	Gradient compression stocking, thigh length, 40 mmhg or greater, custom, each

<b>A6559</b>	Gradient compression stocking, full length/chap style, 18-30 mmhg, custom, each
<b>A6560</b>	Gradient compression stocking, full length/chap style, 30-40 mmhg, custom, each
<b>A6561</b>	Gradient compression stocking, full length/chap style, 40 mmhg or greater, custom, each
<b>A6562</b>	Gradient compression stocking, waist length, 18-30 mmhg, custom, each
<b>A6563</b>	Gradient compression stocking, waist length, 30-40 mmhg, custom, each
<b>A6564</b>	Gradient compression stocking, waist length, 40 mmhg or greater, custom, each
<b>A6565</b>	Gradient compression gauntlet, custom, each
<b>A6566</b>	Gradient compression garment, neck/head, each
<b>A6567</b>	Gradient compression garment, neck/head, custom, each
<b>A6568</b>	Gradient compression garment, torso and shoulder, each
<b>A6569</b>	Gradient compression garment, torso/shoulder, custom, each
<b>A6570</b>	Gradient compression garment, genital region, each
<b>A6571</b>	Gradient compression garment, genital region, custom, each
<b>A6572</b>	Gradient compression garment, toe caps, each
<b>A6573</b>	Gradient compression garment, toe caps, custom, each
<b>A6574</b>	Gradient compression arm sleeve and glove combination, custom, each
<b>A6575</b>	Gradient compression arm sleeve and glove combination, each
<b>A6576</b>	Gradient compression arm sleeve, custom, medium weight, each
<b>A6577</b>	Gradient compression arm sleeve, custom, heavy weight, each
<b>A6578</b>	Gradient compression arm sleeve, each
<b>A6579</b>	Gradient compression glove, custom, medium weight, each
<b>A6580</b>	Gradient compression glove, custom, heavy weight, each
<b>A6581</b>	Gradient compression glove, each
<b>A6582</b>	Gradient compression gauntlet, each
<b>A6583</b>	Gradient compression wrap with adjustable straps, below knee, 30-50 mmhg, each
<b>A6584</b>	Gradient compression wrap with adjustable straps, not otherwise specified
<b>A6585</b>	Gradient pressure wrap with adjustable straps, above knee, each
<b>A6586</b>	Gradient pressure wrap with adjustable straps, full leg, each
<b>A6587</b>	Gradient pressure wrap with adjustable straps, foot, each
<b>A6588</b>	Gradient pressure wrap with adjustable straps, arm, each
<b>A6589</b>	Gradient pressure wrap with adjustable straps, bra, each
<b>A6593</b>	Accessory for gradient compression garment or wrap with adjustable straps, not-otherwise specified
<b>A6594</b>	Gradient compression bandaging supply, bandage liner, lower extremity, any size or length, each
<b>A6595</b>	Gradient compression bandaging supply, bandage liner, upper extremity, any size or length, each
<b>A6596</b>	Gradient compression bandaging supply, conforming gauze, per linear yard, any width, each
<b>A6597</b>	Gradient compression bandage roll, elastic long stretch, linear yard, any width, each
<b>A6598</b>	Gradient compression bandage roll, elastic medium stretch, per linear yard, any width, each
<b>A6599</b>	Gradient compression bandage roll, inelastic short stretch, per linear yard, any width, each
<b>A6600</b>	Gradient compression bandaging supply, high density foam sheet, per 250 square centimeters, each
<b>A6601</b>	Gradient compression bandaging supply, high density foam pad, any size or shape, each
<b>A6602</b>	Gradient compression bandaging supply, high density foam roll for bandage, per linear yard, any width, each
<b>A6603</b>	Gradient compression bandaging supply, low density channel foam sheet, per 250 square centimeters, each
<b>A6604</b>	Gradient compression bandaging supply, low density flat foam sheet, per 250 square centimeters, each
<b>A6605</b>	Gradient compression bandaging supply, padded foam, per linear yard, any width, each
<b>A6606</b>	Gradient compression bandaging supply, padded textile, per linear yard, any width, each
<b>A6607</b>	Gradient compression bandaging supply, tubular protective absorption layer, per linear yard, any width, each
<b>A6608</b>	Gradient compression bandaging supply, tubular protective absorption padded layer, per linear yard, any width, each
<b>A6609</b>	Gradient compression bandaging supply, not otherwise specified
<b>A6610</b>	Gradient compression stocking, below knee, 18-30 mmhg, custom, each

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/31/1999	08/03/2010 <sup>MDCRPC</sup> , 06/07/2011 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 12/13/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 01/09/2024 <sup>MPC</sup> , 01/14/2025 <sup>MPC</sup>	08/09/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Date Last Revised	Description
07/28/2015	Codes added and description of elastic stockings
08/26/2015	Added new LCD link
01/27/2016	Added Medicare coverage article
10/03/2017	Revised criteria to include indication: <i>Documented history of venous stasis ulcer within the last 2 years</i>
07/20/2023	Added Medicare Coverage article for External Breast Prostheses as this addresses mastectomy sleeve non-coverage.
12/27/2023	Updated Medicare links related to new DME benefit category for Lymphedema Compression Treatment Garments. Updated coding section with new applicable codes effective 1/1/2024 and description updates.
5/22/2024	Updated Medicare Links
08/09/2024	Added new HCPC codes for Stockings/Sleeves, Effective 1/1/2024





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Continuous Glucose Monitor (CGM)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Home Blood Glucose Monitors (40.2)</a>
Local Coverage Determinations (LCD)	<a href="#">Glucose Monitors (L33822)</a> <a href="#">Implantable Continuous Glucose Monitors (I-CGM) (L38659)</a>
Local Coverage Article	<a href="#">Glucose Monitor – Policy Article (A52464)</a> <a href="#">Billing and Coding: Implantable Continuous Glucose Monitors (I-CGM) (A58138)</a>

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Continuous Glucose Monitoring (KP-0126 01012024) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**MCG\* are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed for heart transplant eligibility, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

\*Note – Requests for an insulin infusion pump used with continuous glucose sensing (HCPCS code E0787 or E0784 + E2103 for Medicare) will only be authorized if the patient meets both criteria for continuous glucose monitor as outlined in this criteria and all criteria outlined in the [Insulin Pump](#) clinical review criteria including that current device is no longer under warranty.

#### Documentation requirements to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist (endocrinology, primary care)
- Last 6 months of lab work
- Last 1-2 months of legible home monitoring logs or a printout of CGM results

#### ORDER FORM

[Request for Approval of Patient-Use Continuous Glucose Monitoring System \(CGMS\)](#)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Diabetes mellitus is one of the leading causes of death in the United States. If poorly controlled, it causes accelerated both large and small artery diseases that predispose patients to a number of late secondary complications including heart disease, stroke, renal, disease, peripheral vascular disease, retinal damage, peripheral nerve damage, and others. Management of diabetes involves maintaining blood glucose levels close to the normal range. Currently, self-monitoring of capillary blood glucose (SMBG), and laboratory testing of HbA1c, to measure longer term glycemic control, are the standard methods for glucose testing. Blood glucose values are influenced by a number of changing variables, including food choices and portions, stress, insulin doses, physical activity, and rate of nutrient absorption. SMBG is important for monitoring and treating fluctuations in blood glucose level, but it provides only a snapshot of glucose status at a given moment, and even compliant diabetics do not do perform it frequently enough to identify all the fluctuations in the blood glucose level, especially those that occur at night (Evert 2009).

In hopes of gaining a more complete picture of blood glucose level, researches have thus developed technologies for monitoring blood glucose concentrations on a continuous basis. Among these are the continuous glucose monitoring systems (CGMS) which are capable of monitoring interstitial glucose levels every 1-5 minutes. These systems consist of a small needle which is inserted in the abdominal subcutaneous fat. On the tip of the needle there is a glucose sensor that measures the glucose levels in the fluid surrounding the fatty tissue. There are two types of CGMS: retrospective systems and real-time systems. Both systems measure glucose concentration during a certain time span; however, these systems differ with regards to when the information is accessed. With the retrospective system data is stored in a monitor to be downloaded for later use while the real-time system continuously provides the actual glucose concentration on a display. It is thought that CGMS may help diabetic patients reach a near normal blood glucose pattern, assist in preventing hypoglycemic events, reduce emergency room visits, and decrease long-term complications by improving glycemic control (Cemeroglu 2010, Chetty 2008, De Block 2008, Girardin 2009, Langendam 2012).

Early generations of CGMS e.g. the GlucoWatch Biographer, and the physician use device MiniMed Continuous Glucose Monitoring System were uncomfortable and difficult to use. In addition, their results could only be determined in a physician's office and when graphed provided useful, but retrospective information about within- and between-day blood glucose variations and the frequency of unrecognized hypoglycemia. When compared with venous plasma glucose values, the interstitial fluid glucose sensor yielded lower values when blood glucose concentrations were rapidly rising. More recent devices were developed to overcome some of the earlier limitations, and several products that provide real-time information on glucose levels to patients rather than requiring data download in a providers' office are now available. These newer systems, however, still measure glucose in the interstitial space, and it takes time for interstitial glucose to achieve equilibrium with blood glucose (Reach, 2008, Cox 2009).

All continuous glucose monitoring devices consist of the same basic components: 1. A disposable short-term glucose sensor (a fine wire about the diameter of two hairs) which is placed under the skin and is worn for 3-7 days depending on the system (3 days for Guardian RT, 5 days for FreeStyle Navigator, or 7 days for DexCom Seven), 2. A reusable transmitter that is wirelessly attached to the sensor and conveys data to a receiver within a 5-10 foot range of the sensor, and 3. A pager-size receiver that displays current glucose values and recent trends. The receiver can be worn on the belt or carried in a pocket or purse. The process is very fast with measurements made every 10 seconds and then aggregated to give a value on the glucose monitor every 1-5 minute. High and low glucose value thresholds can be customized for individual patients and fed into the system. When these thresholds are exceeded, an alarm will sound. The receiver displays directional arrows to show the rate of change in glucose levels, allowing the patient to predict and possibly prevent hypoglycemic episodes. CGMS can be used continuously, as long as the sensors are replaced according to manufacturer recommendations. Continuous readings over a 24-hour period for up to seven days allow the user to detect variations and identify trends. Patients must initialize and calibrate the system whenever a new glucose sensor is inserted. They also need to calibrate it every 8-12 hours and before adjusting insulin therapy (Peters 2009).

Continuous glucose monitors are intended to be used as an adjunct, not a replacement, for self-monitoring of blood glucose. They should not be used to make therapeutic decisions; any readings that indicate hypo- or hyperglycemia events must be verified by SMBG before taking action. CGM systems have several limitations including:

1. They are not suitable for use by all patients and those who are likely to benefit from them are the motivated patients who know the importance of strict metabolic control, participate in the care of their diabetes, and are able to use the technology. Those who have poor control because of reluctance to perform SMBG would not comply with CGMS and will not benefit from its use.

2. Patients need to learn how to use the large amount of data generated by the real-time CGMS.
3. The patients also need to be aware of the limitations of the systems as regards the lag time and calibration issues, and check with a standard blood glucose meter before making medication adjustments. They also need to understand the time of onset and peak of their insulin so that they make appropriate adjustments.
4. The insertion of the sensor under the skin is at times painful, and if it fails to calibrate another one has to be placed. Moreover, it needs to be firmly attached to the skin using tape, which may cause skin irritation or infection, and may become loose especially with sweating and exercise.
5. The functional operability of CGMS is limited to 2-7 days which might not be sufficient to detect recurrent glycemic patterns throughout the day or night.
6. Providers will have to find ways to incorporate the technology into their already busy clinical practice (De Block 2008, Hrabchak 2010, Ives 2010).

As of the current review the FDA-approved CGM real-time systems include:

- Medtronic Guardian Real Time Glucose Monitoring System that records glucose values for up to 3 days.
- Medtronic MiniMed Paradigm Real-Time System which integrates real-time CGM with an insulin delivery device and records glucose values for up to 3 days.
- DexCom SEVEN PLUS records glucose values for up to 7 days.
- Abbott FreeStyle Navigator provides continuous measurement for up to 5 days.
- The iPro Continuous Glucose Monitor (Medtronic, Inc) used only by the health provider and provides an average blood sugar measurement every 5 minutes for 3 days at a time.

The SEVEN PLUS and the FreeStyle Navigator are FDA approved for adults only. Pediatric versions of MiniMed Paradigm and Guardian systems are approved for use in patients 7-17 years. All systems require a prescription.

## Medical Technology Assessment Committee (MTAC)

### Continuous Glucose Monitoring

#### 06/07/2001: MTAC REVIEW

**Evidence Conclusion:** The published evidence is insufficient to draw conclusions about the effect of continuous glucose monitoring on health outcomes. According to MiniMed, a multicenter outcome study is underway.

**Articles:** The literature search yielded 20 articles. Excluding review articles and opinion pieces, articles on other types of glucose monitoring or other aspects of diabetes control, there were two empirical articles, both of which were case series. One article had a sample size of 11 children and the other had a sample size of 9 adults. Due to the small sample sizes, evidence tables were not created.

Continuous Glucose Monitoring for the management of unstable diabetes is approved by the FDA, but does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 02/11/2004: MTAC REVIEW

### Continuous Glucose Monitoring

**Evidence Conclusion:** *Pediatric population* - Three studies with the pediatric population were reviewed. The DirecNet study, a relatively large study with nearly 100 patients, evaluated the accuracy of the CGMS in children during a 24-hour hospital stay. It did not specifically include children with diabetes management problems. The authors found a relatively low accuracy. According to Clarke error grid, 61% of the decisions using the CGMS would lead to clinically correct treatment decisions (Zone A). Newer modified sensors appeared to be more accurate (78% of measurements were in Zone A compared to 58% with older original sensors). The newer sensors were also more reliable than the original sensors, but measurement taken by two new sensors differed from one another by more than 20% about one-fourth of the time. The Ludvigsson study, a randomized cross-over design, focused on changes in HbA1c during three months with the benefit of data from the CGMS and three months without CGMS data. Eligibility included an initial HbA1c  $\geq 6.8\%$ . When each time period was examined separately, there was not a statistically significant benefit from having CGMS data available. When data from both periods were combined, there was a significant decrease in mean HbA1c in the study arm using CGMS data, but not the other arm. The authors did not compare the change in HbA1c in the arm using CGMS data versus the other arm and had several threats to validity including lack of a wash-out period. The Kaufman study included patients with glucose management problems. The study found that data from the CGMS leads to changes in the recommendation for patient management. However, the authors did not discuss the impact of these changes on health outcomes. In summary, the limited evidence suggests that the accuracy of the CGMS in children may not be sufficiently high. The evidence is insufficient to determine the effect of continuous glucose monitoring on improving health outcomes. *Adult population* - There is less published empirical evidence in the adult population and no high-quality studies on accuracy. The best available study (Yogev) was on pregnant women with type 1 diabetes (not on patients with uncontrolled diabetes). In this sample, continuous glucose monitoring detected

hyperglycemia that was not detected by self-blood glucose monitoring in all 34 patients and nocturnal hypoglycemia in 26 (76%) patients. Recommendations to change insulin treatment were made for 24 out of the 34 (70%) patients. However, the authors did not present data on how the change in recommendations affected maternal or neonatal outcomes.

**Articles:** The Medline search yielded 52 articles, some of which were reviews or opinion pieces, were on technical aspects of glucose monitoring or had outcomes unrelated to the accuracy of the glucose monitor e.g. changes in blood glucose with a low glycemic diet. *Pediatric population* - The search yielded 5 empirical articles. One had a sample size of only 9 patients (Caplin, 2003). Another was a case series with 28 patients and appeared to be relatively weak methodologically (e.g. only included 28 out of the 44 children who used the monitor in the analysis, did not discuss management changes following use of the monitor) (Salardi, 2002). The remaining 3 studies, one of which was a randomized cross-over trial, were critically appraised: Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: Results of the diabetes research in children network (DirecNet) accuracy study. *Diabetes Technol Ther* 2003; 5: 781-789. See [Evidence Table](#). Kaufman FR, Gibson LC, Halvorson M. A pilot study of the continuous glucose monitoring system. *Diabetes Care* 2001; 24: 2030-2034. See [Evidence Table](#). Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes; A controlled crossover study. *Pediatrics* 2003; 111: 933-938. See [Evidence Table](#). *Adult population* - The search yielded 4 empirical articles. One was specifically on diabetic patients needing dialysis and included only 8 patients. Two other studies each included only 18 patients. The remaining study, which studied pregnant women with type 1 diabetes, was critically appraised: Yogev Y, Chen R, Ben-Haroush A. Continuous glucose monitoring for the evaluation of gravid women with type 1 diabetes mellitus. *Obstet Gynecol* 2003; 101: 633-638. See [Evidence Table](#).

The use of continuous glucose monitoring in the management of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 08/30/2005: MTAC REVIEW

##### Continuous Glucose Monitoring

**Evidence Conclusion:** The new studies published after our last review of 2/11/2004 were evaluated. There was only one RCT with just over 100 patients (Tanenberg 2004), that compared the hemoglobin A1c values between patients who used the CGMS to those who underwent self-monitoring. The difference between the two groups in the HBA1c was not statistically significant.

**Articles:** Tanenberg R, Bode B, Lane W et al. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: A randomized controlled trial. *Mayo Clin Proc* 2004; 79: 1521-1526. See [Evidence Table](#).

The use of continuous glucose monitoring in the management of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 08/07/2006: MTAC REVIEW

##### Continuous Glucose Monitoring

**Evidence Conclusion:** There are no published studies to date that evaluate the impact of real-time glucose monitor use on diabetic complications. There are also no published studies evaluating the accuracy or effectiveness of the Medtronic MiniMed Guardian RT device, or the consistency of measurements of either the Guardian RT or DexCom STS when multiple devices are worn. One published empirical study on the DexCom STS system was identified. The study evaluated both device accuracy compared to self-monitoring of glucose measurements and impact on short-term glycemic control. In 47 patients, 95% of paired sensor-home monitoring data points over nine days were in Clarke error grid regions A (clinically accurate) or B (acceptable). In addition, compared to a control group (n=44) that used devices but did not receive display information, there was a statistically significant improvement in glycemic control (more time in target glucose range, less time in hypoglycemic and hyperglycemic ranges). Conclusions cannot be drawn about the intermediate or long-term impact of the DexCom STS on glycemic control-- patients were only followed during the nine days devices were worn. Another remaining issue is the 15-30-minute lag time between interstitial glucose readings and blood glucose levels when the blood glucose is rising or falling quickly.

**Articles:** No published empirical studies evaluating the Guardian RT were identified. One published empirical study on the subcutaneous DexCom STS was identified. This was a randomized controlled trial with 91 patients and was critically appraised: Garg S et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. *Diabetes Care* 2006; 29: 44-50. See [Evidence Table](#).

The use of continuous glucose monitoring in the management of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.



**08/04/2008: MTAC REVIEW****Continuous Glucose Monitoring**

**Evidence Conclusion:** *Accuracy/Reliability* the Garg et al. (2006) study, previously reviewed by MTAC, found that the DexCom STS device was reasonably accurate compared to self-monitoring of blood glucose. >95% of 6,767 paired sensor-SMBG data points were in Clarke error grid regions A or B (clinically accurate or acceptable, respectively). An issue identified was the 15-30-minute lag time between interstitial glucose readings and blood glucose levels when the blood glucose is rising or falling quickly. Weinstein et al. (2007) also found >95% of paired sensor-venous blood sample data points were in Clarke error grid regions A or B when the FreeStyle Navigator was tested in an inpatient setting in adults. A smaller study of the FreeStyle Navigator in children (Wilson et al., 2007) identified a lag time, with Navigator readings lagging behind reference values during times of rapid rates of change in glucose levels. Impact: There is insufficient evidence on the impact of real-time continuous glucose monitor use on diabetic complications, hospitalizations and ER visits. There is fair evidence from one RCT (Deiss et al., 2006) that there are greater improvements in HbA1C levels of children and adults when a Guardian RT is worn continuously, but not intermittently, compared to self-monitoring of blood glucose. Limitations of the RCT were that it was sponsored by Medtronic, the device manufacturer, and the process for using glucose monitor data to make changes to patient treatment was not well described. There is insufficient evidence that other commercially available real-time continuous glucose monitors, the DexCom STS or Seven, and the Abbott FreeStyle Navigator, impact glycemic control. Only case series were available. A series of 140 patients (Bailey et al., 2007) found a significant reduction in HbA1c level after 12 weeks of continuous glucose monitoring with the DexCom STS. Significant reductions in HbA1c over 13 weeks were also found in small case series with children who were managed with the FreeStyle Navigator. The available evidence is insufficient to evaluate the impact of real-time continuous glucose monitors on detection of hypoglycemic episodes, larger sample sizes and longer follow-up are required.

**Articles:** No published empirical studies evaluating the Guardian RT were identified. One published empirical study on the subcutaneous DexCom STS was identified. This was a randomized controlled trial with 91 patients and was critically appraised: Garg S et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. *Diabetes Care* 2006; 29: 44-50. See [Evidence Table](#).

The use of continuous glucose monitoring in the management of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**06/21/2010: MTAC REVIEW****Continuous Glucose Monitoring**

**Evidence Conclusion:** There is insufficient evidence to determine the accuracy and reliability of the 7-day continuous glucose monitoring systems. There is fair evidence that the use of CGMSs including the 7 day is associated with a significant reduction in HbA1c levels among highly selected motivated 25 years of age or older patients with type 1 diabetes. There is insufficient evidence to determine whether use of the 7-day real-time continuous glucose monitoring systems leads to better patient-oriented health outcomes (e.g. hospitalizations, ER visits, and microvascular and macro vascular diabetic complications).

Long-term studies are needed to confirm the potential benefits of CGMS in preventing hypo- and hyperglycemic episode, improving the patient's quality of life and potentially reducing the likelihood of complications that may develop.

**Articles:** *Accuracy/Reliability of CGMS:* The literature search revealed the STAR 1 trial (2008) evaluating the MiniMed Paradigm Real-Time System which is sensor augmented insulin pump, the Real Trend study (2009) on the Medtronic MiniMed Paradigm Real-Time System, the MITRE trial (2009) that used the MiniMed CGMS and GlucoWatch which is no longer available commercially and a small study (N=14) by Garg and colleagues (2010) that compared the SEVEN and FreeStyle Navigator CGMS, as well as a meta-analysis of studies published up to March 2007. Impact of CGMS on health outcomes:

The ideal study would be a randomized trial comparing health outcomes in patients managed using a real-time CGMS compared to standard self-monitoring. The literature search did not identify any published RCTs that evaluated the impact of CGMS on hospitalizations, ER visits, microvascular or macrovascular diabetic complications. There was a relatively large trial by the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Group (2008) that used change in the HbA1c as a surrogate outcome for diabetes control. This study was selected for critical appraisal. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Group. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N Engl J Med* 2008;359:1464-176 See [Evidence Table](#).

The use of continuous glucose monitoring in the management of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/20/2012: MTAC REVIEW

### Continuous Glucose Monitoring

**Evidence Conclusion:** For CGM to be considered a useful technology, it needs to be accurate, reliable, and reproducible for reflecting a patient's plasma glucose values, especially in the lower glucose range to help avoid hypoglycemia and allow patients to achieve lower HbA1c with less hypoglycemia. However, current data do not allow this conclusion. Even when taking the average of four sensors worn simultaneously (an impractical approach for everyday use) results vary from the true plasma glucose value by 25 – 50% almost 20% of the time when patients true blood glucose values were less than 70 mg/dL. Additionally, most studies show no or only trivial improvement in HbA1c, that is not sustained overtime. Results from current data suggest that it is unlikely that everyday use of CGM will result in decreased hypoglycemia or lower HbA1c.

**Articles:** No studies were identified that addressed patient-oriented health outcomes. Several meta-analyses and three randomized controlled trials (RCTs) published after the meta-analyses were identified that addressed the effects of CGMS on glycemic control. The most recent meta-analysis, two RCTs, and an observational study published after the meta-analysis were selected for review. The other RCT was not selected for review due to methodological limitations (i.e., not stated if an intent-to-treat analysis was performed, power was not assessed, and baseline characteristic were not similar). The following studies were selected for critical appraisal: Langendam MW, Luijck YM, Hooft L, Devries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. *Cochrane Database Syst Rev.* 2012;1:CD008101. See [Evidence Table](#) Riveline JP, Schaepelynck P, Chaillous L, et al. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study. *Diabetes Care.* 2012; 35:965-971. See [Evidence Table](#). Castle JR, Pitts A, Hanavan K, et al. The accuracy benefit of multiple amperometric glucose sensors in people with type 1 diabetes. *Diabetes Care.* 2012; 35:706-710. See [Evidence Table](#). Mauras N, Beck R, Xing D, et al. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to <10 years. *Diabetes Care.* 2012; 35:204-210. See [Evidence Table](#)

The use of continuous glucose monitoring in the diagnosis of diabetes does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 03/20/2017: MTAC REVIEW

### Continuous Glucose Monitoring

#### **Evidence Conclusion:**

Conclusion:

- Moderate evidence shows that the Continuous Glucose Monitoring system with the use of multiple daily insulin injection may be more effective in HbA1c and glycemic variability in adults with type 1 Diabetes Mellitus than self-monitoring blood glucose on the short term; no major adverse events were reported
- Moderate evidence shows that continuous Glucose Monitoring with the use of insulin pump may be more effective on HbA1c in adults with T1DM than self-monitoring blood glucose on the short term; no statistically significant difference in time spent in hypoglycemia was found
- In patients with T2DM, Hayes conclusion can be adopted: there is conflicting evidence concerning efficacy
- The technology is safe. Studies with longer follow-up are warranted.

**Articles:** Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Polonsky, W. (2017). Effect of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. *JAMA*, 317(4), 371-378. Benkhadra, K., Alahdab, F., Tamhane, S., Wang, Z., Prokop, L. J., Hirsch, I. B., Murad, M. H. (2016). Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. *Clinical Endocrinology*. Gu, W., Liu, Y., Chen, Y., Deng, W., Ran, X., Chen, L. Mu, Y. (2017). Multicentre randomized controlled trial with sensor-augmented pump vs multiple daily injections in hospitalized patients with type 2 diabetes in China: Time to reach target glucose. *Diabetes Metab.* doi: 10.1016/j.diabet.2016.12.009 Lind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Wedel, H. (2017). Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults with Type 1 Diabetes Treated with Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. *JAMA*, 317(4), 379-387. van Beers, C. A., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H., . . . Serne, E. H. (2016). Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. *Lancet Diabetes Endocrinol*, 4(11), 893-902. doi:10.1016/s2213-8587(16)30193-0.

## Applicable Codes

### Continuous Glucose Monitor (not implanted)



**Medicare- Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® or HCPC Codes	Description
A4238	Supply allowance for adjunctive, nonimplanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service
A4239	Supply allowance for nonadjunctive, nonimplanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service
E2102	Adjunctive, nonimplanted continuous glucose monitor (CGM) or receiver
E2103	Nonadjunctive, nonimplanted continuous glucose monitor (CGM) or receiver

**Non-Medicare: Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® or HCPC Codes	Description
A4238	Supply allowance for adjunctive continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service
A4239	Supply allowance for nonadjunctive, nonimplanted continuous glucose monitor (CGM), includes all supplies and accessories, 1 month supply = 1 unit of service
A9276	Sensor; invasive (e.g., subcutaneous), disposable, for use with nondurable medical equipment interstitial continuous glucose monitoring system (CGM), one unit = 1 day supply
A9277	Transmitter; external, for use with nondurable medical equipment interstitial continuous glucose monitoring system (CGM)
A9278	Receiver (monitor); external, for use with nondurable medical equipment interstitial continuous glucose monitoring system (CGM)
E2102	Adjunctive, nonimplanted continuous glucose monitor (CGM) or receiver
E2103	Nonadjunctive, nonimplanted continuous glucose monitor (CGM) or receiver

**Implantable Continuous Glucose Monitors (I-CGM)**

**Medicare- Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare – Considered not medically necessary**

CPT® or HCPC Codes	Description
0446T	Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training
0447T	Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision
0448T	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation

Date Created	Date Reviewed	Date Last Revised
06/07/2001	07/06/2010 <sup>MDCRPC</sup> , 04/05/2011 <sup>MDCRPC</sup> , 07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 09/04/2012 <sup>MDCRPC</sup> , 07/02/2013 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 11/07/2014 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 01/09/2024 <sup>MPC</sup> , 01/14/2025 <sup>MPC</sup>	09/22/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
------------------	-------------

08/04/2015	<ul style="list-style-type: none"> <li>Removal of with a negative C peptide an indication</li> <li>“Criteria for current users and for annual evaluation” was changed to “For ongoing approvals of supplies and/or replacement of current CGM”</li> </ul>
04/03/2018	MPC approved to revise indication to criteria: <i>Patient is motivated, and has monitored and documented blood glucose 4 or more times per day for 2 months (change to 1 month)</i>
08/27/2018	Added Free Style Libre non-coverage language
09/13/2018	Removed Medicare from the Free Style Libre language
03/11/2019	Clinical review is no longer required for 72-hour evaluation
12/03/2019	MPC approved to revise criteria to address pediatric population and avoid delays in receiving a continuous glucose monitor when a pediatric patients’ condition warrants.
11/03/2020	MPC approved to revise hybrid criteria to remove specific qualifiers for hypoglycemia and type I diabetes, removed statement that Freestyle Libre not on formulary for non-Medicare members, updated CGM order form (link in criteria), and added note about combined insulin pump/CGM device
02/16/2022	Updated applicable codes
04/05/2022	MPC approved to update CGM criteria to remove the 4x/day blood glucose checks, added indications for patients with dexterity or visual impairments. Requires 60-day notice, effective date 09/01/2022. Updated applicable codes.
10/26/2022	Updated applicable codes, including new codes released 01/01/22 and 04/01/22.
01/09/2023	Added new HCPC codes A4239 and E2103 effective 1/1/2023.
03/13/2023	Removed reference to code K0554 in the criteria as this code was replaced with code E2103 effective 1/1/23.
08/08/2023	MPC approved changes to the existing CGM criteria to allow providers managing a members diabetes to place this order (including but not limited to primary care, internal medicine, etc.) and relieve the excessive demands on the Diabetes Population care nurses. Requires 60-day notice, effective date 01/01/2024.
09/22/2023	Updated code descriptions and deleted inappropriate codes from I-CGM.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Restorative and Cosmetic Procedures

- Abdominoplasty
- Lipectomy
- Panniculectomy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual Chapter 16 - General Exclusions from Coverage, Section 120</a>
National Coverage Determinations (NCD)	<a href="#">Plastic Surgery to Correct "Moon Face" 140.4</a>
Local Coverage Determinations (LCD)	<a href="#">Plastic Surgery (L37020)</a>
Local Coverage Article	<a href="#">Billing and Coding: Plastic Surgery (A57222)</a>

#### For Non-Medicare Members

**Cosmetic Surgery** is performed to reshape normal structures of the body in order to improve appearance in the absence of a specific functional improvement. Surgery performed to improve on "natural" appearance or performed purely for the purpose of enhancing one's normal appearance is not considered reasonable and necessary.

**Reconstructive Surgery** is performed to restore bodily function or to correct a deformity resulting from disease, injury, trauma, birth defects, congenital anomalies, infections, burns, or previous medical treatment, such as surgery or radiation therapy. The primary goal is to restore function. Reconstructive surgery is reasonable and necessary to improve the functioning of a malformed body part. Please refer to member's contract for specific coverage regarding congenital anomalies.

For the procedures in this policy plastic surgery credentials are preferred and may be medically necessary when the following criteria are met:

#### I. Abdominoplasty

1. Abdominoplasties are not covered as they are considered cosmetic.
2. Diastasis recti treatment - Treatment of diastasis recti is considered cosmetic as the separation/laxity of the muscles of the abdominal wall is not considered a true hernia and the treatment does not address a physical functional condition.

#### II. Panniculectomy: is covered when **ALL of the following** criteria are met:

1. Panniculus hangs below the level of the pubis (documented by photographs)
2. Documentation in the medical record of the presence of significant complications including one or more of the following, requiring at least two office visits for treatment:
  - a. The excess skin is the primary cause of at least one episode of cellulitis requiring systemic (oral or intravenous) antibiotics

OR

b. Transdermal skin ulcerations in the skin folds that are recurrent or refractory to medical treatment.

3. If the procedure is being performed following significant weight loss, in addition to meeting the criteria noted above, there should be evidence that the individual has maintained a stable weight for at least six months. If the weight loss is the result of bariatric surgery, procedure should not be performed until at least 18 months after bariatric surgery.
4. There is a functional deficit (interference with activities of daily living) due to a severe physical deformity or disfigurement resulting from the excess skin.
5. The surgery is expected to restore or improve the functional deficit.
6. BMI must be < 35
7. No diabetes, or diabetes with HbA1c < 7.5
8. Members who use nicotine/tobacco must be actively involved in a nicotine cessation program and must be nicotine/tobacco-free for a minimum of 30 days prior to surgery
9. Not covered when performed in conjunction with abdominal or gynecological procedures (e.g., abdominal hernia repair, hysterectomy, obesity surgery) unless criteria for panniculectomy are met separately
10. Not covered to minimize the risk of hernia formation or recurrence

### III. Liposuction for Lipedema

**Effective until May 1, 2025**

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**Effective May 1, 2025**

1. Liposuction or lipectomy to treat lipedema of the extremities may be considered medically necessary when all of the following are met (A.-G.):
  - a. Surgical interventions are performed by hospital credentialed, board certified plastic surgeon; and
  - b. The individual has a diagnosis of lipedema including all of the following clinical exam findings:
    - i. Bilateral symmetric adiposity that is disproportionately affecting the extremities with minimal involvement of the hands and feet; and .
    - ii. Non-pitting edema; and
    - iii. Pain and tenderness on palpation of the affected areas; and
    - iv. Negative Stemmer sign; and
    - v. Submission of photographs documenting the affected extremities requested for treatment and are consistent with the diagnosis of lipedema; and
  - c. There is documentation of significant physical **functional impairment** (e.g., difficulty ambulating or performing activities of daily living); and
  - d. The individual has not responded to at least three consecutive months of optimal medical management including complex decongestive therapy and compression therapy; and
  - e. For individuals with BMI greater than 35 kg/m<sup>2</sup>, there has been a lack of effect on lipedema-affected areas of weight loss measures as documented in the medical records through nutrition and/or medical interventions with clinic visits over three consecutive months; and
  - f. The plan of care postoperatively is to wear compression garments as instructed to maintain the benefits of treatment; and
  - g. The area requested to be treated has not previously been treated with liposuction or lipectomy.
2. Liposuction or lipectomy to treat lipedema for areas other than extremities (e.g., trunk or back) or when Criterion I. is not met is considered investigational.
3. Lymphatic physiologic surgery with or without a microscope to treat lymphedema (including, but not limited to, lymphatico-lymphatic bypass, lymphatic-venous-lymphaticplasty, lymphovenous bypass, lymphaticovenous anastomosis, autologous lymph node transplantation, lysis of vein adhesions, and vascularized lymph node, omental, or other tissue transfer) is considered investigational.
4. Lymphatic physiologic surgery with or without a microscope performed during nodal dissection (e.g. axillary or groin) or breast reconstruction to prevent lymphedema (including, but not limited to, the Lymphatic Microsurgical Preventing Healing Approach) in individuals who are being treated for breast cancer is considered investigational.
5. Liposuction or lipectomy to treat lymphedema (including, but not limited to, lipectomy, suction-assisted protein lipectomy, liposuction, and lymph-sparing liposuction) is considered investigational.

IV. Procedures to remove excess skin in the arms, buttocks, hips, legs, thighs, or torso are considered cosmetic as these procedures do not address any physical functional condition.

- V. Dental/orthodontic procedures for craniofacial anomalies – for baseline policy for all plans, [click here to view the policy](#).

**See individual links below for the following potentially cosmetic procedures:**

- [Blepharoplasty](#)
- [Dermatology Services](#)
- [Dermal Fillers for Facial Lipoatrophy \(Sculptra/Radiesse\)](#)
- [Reduction Mammoplasty](#)
- [Rhinoplasty](#)
- [Breast Reconstruction](#)
- [Skin Lesions](#)
- [Vein Procedures](#)

**The following are considered cosmetic in nature and non-covered under member's contract:**

- Cervicoplasty ("neck lift")
- Collagen injection
- Hair Transplant
- Canthoplasty ("outer eyelid lift surgery") except in the setting of skin cancer excision

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Kaiser Permanente coverage contracts exclude cosmetic procedures. However, some procedures may be medically necessary when certain clinical criteria have been met. This document has been created to provide guidance to physician's reviewers when reviewer requests to cover potentially cosmetic services.

## Evidence and Source Documents

Member contract

## References

### ***Liposuction for Lipedema***

**April 27, 2020: INTC Review**

**Evidence Conclusion:** There is insufficient evidence regarding the efficacy and safety of liposuction compared to conventional treatments (compression therapy, exercise, or massage) for lipedema. The existing evidence is of insufficient quantity and quality.

The existing body of evidence on the surgical management of lipedema is sparse and limited to six low-quality observational studies, a majority of which were conducted in Germany, among 575 patients and included in two technology assessments. The low-quality evidence reported positive improvements in pain, mobility, bruising, sensitivity to pressure, appearance and quality of life with no report of major complications following liposuction. The diagnostic criteria for the condition is contested and remains unclear.

**Articles:** [Liposuction for Lipedema: Technology Assessment \(kp.org\)](#)

### ***Liposuction for the Treatment of Lipedema***

**April 19, 2022: Hayes Technology Assessment**

Clinical studies: A review of full-text clinical studies suggests minimal support for using liposuction for lipedema. Systematic reviews: A review of full-text systematic reviews suggests no/unclear support for using liposuction for lipedema.

## Insights

Evidence from 3 very poor-quality studies suggests that liposuction leads to clinically significant improvements in quality of life, disability, and pain and reduced need for conservative treatment in women with lipedema at 2 to 3

years of follow-up. Patients enrolled sought treatment at specialized healthcare centers, increasing risk of selection bias in cases reported. No other treatments for lipedema were identified in the literature beyond traditional conservative care with congestive therapy. Nonserious complications were common (e.g., bruising and postoperative bleeding). All 3 studies in this report are retrospective in design and do not compare liposuction treatment to any other intervention. One clinical study comparing the efficacy and safety of liposuction with conservative care is in progress. Clinical practice guidelines and payer policies appear generally supportive of the use of liposuction to treat lipedema.

Hayes. Hayes Technology Assessment. Liposuction for the Treatment of Lipedema. Dallas, TX: Hayes; April 19, 2022. Retrieved September 5, 2024, from <https://evidence.hayesinc.com/report/eer.liposuction4059>

## Applicable Codes

**Panniculectomy - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>15830</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy

**Excision of Excess Skin  
Considered Not Medically Necessary**

CPT® Codes	Description
<b>15832</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh
<b>15833</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg
<b>15834</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip
<b>15835</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock
<b>15836</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm
<b>15837</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand
<b>15838</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad
<b>15839</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area

## Abdominoplasty

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare - Considered Not Medically Necessary**

CPT® Codes	Description
<b>15847</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy), abdomen (eg, abdominoplasty) (includes umbilical transposition and fascial plication) (List separately in addition to code for primary procedure)

## Lipectomy

**Effective until May 1, 2025**

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare - Considered Not Medically Necessary**

CPT® Codes	Description
<b>15876</b>	Suction assisted lipectomy; head and neck
<b>15877</b>	Suction assisted lipectomy; trunk
<b>15878</b>	Suction assisted lipectomy; upper extremity
<b>15879</b>	Suction assisted lipectomy; lower extremity



**Effective May 1, 2025**

**Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare** - Considered Not Medically Necessary

CPT® Codes	Description
15876	Suction assisted lipectomy; head and neck
15877	Suction assisted lipectomy; trunk
15878	Suction assisted lipectomy; upper extremity
15879	Suction assisted lipectomy; lower extremity

**Cervicoplasty** - Considered Not Medically Necessary:

CPT® Codes	Description
15819	Cervicoplasty

**Canthoplasty** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® Codes	Description
67950	Canthoplasty (reconstruction of canthus)

**Otoplasty** - Considered Not Medically Necessary:

CPT® Codes	Description
69300	Otoplasty, protruding ear, with or without size reduction

**Hair Transplant**

**Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare** - Considered Not Medically Necessary

CPT® Codes	Description
15775	Punch graft for hair transplant; 1 to 15 punch grafts
15776	Punch graft for hair transplant; more than 15 punch grafts

**Tissue Expanders** - Considered Not Medically Necessary:

CPT® Codes	Description
11960	Insertion of tissue expander(s) for other than breast, including subsequent expansion
11970	Replacement of tissue expander with permanent implant
11971	Removal of tissue expander without insertion of implant

**Wrinkle Removers** - Considered Not Medically Necessary:

CPT® Codes	Description
15824	Rhytidectomy; forehead
15825	Rhytidectomy; neck with platysmal tightening (platysmal flap, P-flap)

<b>15826</b>	Rhytidectomy; glabellar frown lines
<b>15828</b>	Rhytidectomy; cheek, chin, and neck
<b>15829</b>	Rhytidectomy; superficial musculoaponeurotic system (SMAS) flap

### Collagen Injections - Considered Not Medically Necessary:

<b>CPT® Codes</b>	<b>Description</b>
<b>11950</b>	Subcutaneous injection of filling material (eg, collagen); 1 cc or less
<b>11951</b>	Subcutaneous injection of filling material (eg, collagen); 1.1 to 5.0 cc
<b>11952</b>	Subcutaneous injection of filling material (eg, collagen); 5.1 to 10.0 cc
<b>11954</b>	Subcutaneous injection of filling material (eg, collagen); over 10.0 cc

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

<b>Date Created</b>	<b>Dates Reviewed</b>	<b>Date Last Revised</b>
07/01/2005	07/01/2005 <sup>MDCRPC</sup> , 05/30/2006 <sup>MDCRPC</sup> , 11/20/2006 <sup>MDCRPC</sup> , 12/22/2006 <sup>MDCRPC</sup> , 10/15/2007 <sup>MDCRPC</sup> , 06/09/2008 <sup>MDCRPC</sup> , 04/13/2009 <sup>MDCRPC</sup> , 02/2/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 07/02/2013 <sup>MDCRPC</sup> , 03/04/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 09/03/2024 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
11/01/2015	Changed Medicare links
05/03/2016	Added definitions for Cosmetic vs. Reconstructive Surgery. Added a list of non-covered cosmetic services
12/19/2017	Added LCD 37020
05/18/2020	Added clarifying language to canthoplasty "except in the setting of skin cancer excision"
06/01/2021	Removed reference to retired LCD Cosmetic vs. Reconstructive Surgery (A52729) for Medicare as it was replaced with the Plastic Surgery LCD/LCA. Updated applicable codes.
09/07/2021	MPC approved to adopt updates to the clinical indications for panniculectomy and updated excess skin removal from the arms, buttocks, hips, legs, thighs, or torso to cosmetic/not medically necessary for Non-Medicare members. Requires 60-day notice, effective date February 1, 2022.
11/06/2021	Added clarifying language to Reconstructive Surgery definition "Please refer to member's contract for specific coverage regarding congenital anomalies."
11/07/2023	Make the current policy more explicit and provide a summary of medical evidence justifying a position of non-coverage (no 60-day notice). No Vote Required.
12/21/2023	Added NCD Plastic Surgery to Correct "Moon Face" 140.4
12/03/2024	MPC approved to adopt coverage criteria for Liposuction for Lipedema. 60-day notice required. Effective May 1, 2025.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### Collagen Cross-Linking for the Treatment of Keratoconus

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Collagen Cross-Linking for the Treatment of Keratoconus</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

- A. To qualify for photochemical cross-linkage using riboflavin and Ultraviolet A light **ALL** of the following must be met:
- Has a diagnosis of keratoconus
  - Patient is not older than 50 years old
  - Treatment is limited to a once in a lifetime

#### Notes:

Kaiser Permanente considers epithelium-off photochemical collagen cross-linkage using riboflavin and ultraviolet medically necessary for keratoconus. For any other diagnosis, such as keratectasia, collagen cross-linking is considered experimental and investigational, as the effectiveness has not been established. Epithelium-on (transepithelial) collagen cross-linkage and performance of photochemical collagen cross-linkage in combination with other procedures (CXL-plus) (e.g., intrastromal corneal ring segments, PRK or phakic intra-ocular lens implantation) is considered experimental and investigational.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Keratoconus is a disease of the cornea that is characterized by a gradual thinning and protuberance of the cornea resulting in visual damage. The cause of keratoconus is not known; its prevalence varies from 50 to 230 per 100,000 (Kennedy, Bourne et al. 1986, Heidecke, Burkert et al. 2008) and the association between African Americans and Latinos and keratoconus has been described (Woodward, Blachley et al. 2016). Several risk factors have been identified; these include eye-rubbing, contact lens use, systemic disorders (Down syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta), family history, and environment (asthma, atopic disease) (Gasset, Houde et al. 1978, Rabinowitz 1998, Sugar and Macsai 2012, Woodward, Blachley et al. 2016).

Clinical characteristics include bilateral or unilateral visual impairment, sudden decrease in visual acuity, and/or astigmatism. Patient may also present with difficulty with visual correction and protrusion of the cornea with an indentation of the lower eyelid on downgaze. Disease progression is marked by corneal hydrops. Diagnosis can be done by slit lamp examination when the disease progresses. The mainstay of treatment is the correction of the vision which can be performed with spectacle correction, contact lens, surgical treatments or intrastromal corneal ring, keratectomy, keratoplasty (corneal implantation) and collagen crosslinking (CXL).

Corneal collagen crosslinking aims to slow the progression of keratoconus by increasing covalent bonds in the cornea. During the corneal crosslinking treatment, riboflavin drops saturate the cornea, which is then activated by ultraviolet light. In laboratory and clinical studies this procedure has been shown to strengthen the cornea. CXL is not a cure for keratoconus. The goal of this treatment is to stop the progression of keratoconus and prevent further deterioration in vision. The procedure consists of applying riboflavin every 3-5 minutes for 25-30 minutes and irradiating the cornea with UVA light after removal of the corneal epithelium. Then bandage lens is applied, and assessment of re-epithelialization is performed about one week after the treatment. The intervention lasts one hour to 90 minutes. Although no approval statement was found on the Food and Drug Administration website, Avedro, the manufacturer of Photrex® Viscous, Photrex® and KXL® System indicated that in 2016, the US Food and Drug Administration approved corneal collagen cross-linking using riboflavin and UV for progressive keratoconus (Avedro 2016). Collagen crosslinking is believed to flatten the cornea and improve vision.

## Medical Technology Assessment Committee (MTAC)

### Collagen Cross-Linking for the treatment of Keratoconus

09/19/2016: MTAC REVIEW

**Evidence Conclusion:** Two randomized trials were critically appraised. These studies assessed the efficacy and effectiveness of CXL. Comparison was made between CXL and no treatment or between CXL and riboflavin only. Baseline characteristics were similar between the groups and patients were followed up for one year. The results showed that CXL led to positive outcomes by reducing corneal steepness and asphericity. Adverse events were reported, and these include corneal opacity, eye pain, punctate keratitis, blurry vision, corneal striae and corneal epithelial defect. However, the open label nature of the design, the lack of clarification on how the sequence generation was performed, the lack of information of allocation concealment, the short follow-up (1 year), the small sample size, and the fact that the sponsor of one of the trials was the manufacturer compromise the validity of the studies. The body of evidence is also constituted of prospective and observational studies. The sample size in these studies varied from 13 to 97 and a reduction in keratoconus progression was globally observed. It is worth noted that the follow-up period varied from 6 to 24 months. No meaningful conclusion can be reached because these studies are non-comparative studies.

#### Conclusion:

The body of evidence is of low quality and there is insufficient evidence to determine whether CXL is effective and safe in stopping the progression of keratoconus as compared to the use of alternative treatments.

#### Articles:

The literature revealed a number of articles; the following articles were selected for critical appraisal:

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus (NCT00647699)

<https://clinicaltrials.gov/ct2/show/results/NCT00647699?term=corneal+collagen+crosslinking&rank=19&sect=X016> See Evidence Table 1 (not peer reviewed). Corneal collagen crosslinking for progressive keratoconus in Saudi Arabia: One-year controlled clinical trial analysis (Khattak, Nakhli et al. 2015) See Evidence Table 2.

The use of Collagen Cross-Linking for the treatment of Keratoconus does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>0402T</b>	Collagen cross-linking of cornea, including removal of the corneal epithelium and intraoperative pachymetry, when performed (Report medication separately)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
10/04/2016	10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	07/07/2020

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
10/04/2016	Created document & added MTAC review
11/01/2016	MPC approved criteria of medical necessity for collagen cross linking for the treatment of keratoconus
07/09/2019	MPC approved to change age indication from 40 years old to 50 years old
07/07/2020	Removed LCD L35008 and added Kaiser Permanente Medical Policy statement for Medicare

## Clinical Review Criteria

### Cardiac CT, Coronary CT Angiography, Calcium Scoring and CT Fractional Flow Reserve

- Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT )/Coronary Plaque Analysis (AI-CPA)
- Cardiovascular Computed Tomography (CVCT)
- Cardiovascular Multislice CT (MSCT)
- Multidetector Row Spiral Computed Tomography (MDCT Scan)
- Multislice Detector Computed Tomography
- Multislice Tomography

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria. **Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<p>(CPT codes 75572, 75573, 75574)</p> <p>Noridian has retired <a href="#">LCD Multidetector Computed Tomography of the Heart and Great Vessels (L34137)</a></p> <p>These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.</p> <p><a href="#">LCD Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease L38615</a> (CPT 75580)</p> <p><a href="#">Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (L39883)</a> (CPT 0623T-0626T)</p>
Local Coverage Article (LCA)	<p><a href="#">LCA Billing and Coding: Non-Invasive Fractional Flow Reserve (FFR) for Ischemic Heart Disease A58097</a> (addresses CPT 75580)</p> <p><a href="#">Billing and Coding: Coronary Computed Tomography Angiography (CCTA) (A57552)</a> (Addresses CPT Code 77571)</p>



[Billing and Coding: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography \(AI-QCT\)/Coronary Plaque Analysis \(AI-CPA\) \(A59771\)](#) (CPT 0623T-0626T)

## For Non-Medicare Members

Source	Policy
<b>Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)</b> (CPT 0623T-0626T)	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
<b>Cardiac CT Angiography (CTA)</b> (CPT 755572, 75573, 75574)	Kaiser Permanente has elected to use the MCG* Care Guideline: Cardiac CT Angiography (CTA) (A-0483) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.
<b>Coronary Artery Calcium Score with Computed Tomography (CT)</b> (CPT 75571, S8092) <ul style="list-style-type: none"> <li>Multidetector Computed Tomography (MDCT)</li> </ul>	<p>*Repeat CAC measurement not indicated within less than 5 years.</p> <p><i>Adapted from KPWA ASCVD Primary Prevention Guideline (Oct 2020)</i></p> <p>Coronary artery calcium scoring may be indicated for asymptomatic patients with <b>1 or more of the following</b>:</p> <ul style="list-style-type: none"> <li>Intermediate ASCVD risk* indicated by ALL of the following <ul style="list-style-type: none"> <li>Age 40-75 without DM and with LDL-C levels <math>\geq 70</math> mg/dL</li> <li>At a 10-year ASCVD risk* of <math>\geq 7.5\%</math> and <math>&lt; 20\%</math></li> <li>Risk status or decision about statin therapy is uncertain</li> </ul> </li> </ul> <p>For these patients, treatment with statin therapy may be withheld or delayed if CAC = 0, except in cigarette smokers and those with a strong family history of premature ASCVD. A CAC score of 1–99 favors statin therapy, especially in those aged <math>\geq 55</math> years. For any patient, if the CAC score is <math>\geq 100</math> or <math>\geq 75</math>th percentile, statin therapy is indicated.</p> <ul style="list-style-type: none"> <li>May be considered in select adults age 40-75 with ALL of the following <ul style="list-style-type: none"> <li>Borderline elevated ASCVD risk (5-7.4% 10-year ASCVD risk*)</li> <li>The presence of CAC may change decision-making with regard to statin treatment and intensity of ASCVD risk factor modification</li> </ul> </li> </ul> <p>Routine CAC measurement is not recommended for:</p> <ul style="list-style-type: none"> <li>Patients at low (<math>&lt; 5\%</math> 10-year risk) or high (<math>\geq 20\%</math> 10-year risk) ASCVD risk</li> <li>Patients who are unlikely to initiate treatment even if CAC is identified</li> </ul> <p><a href="#">*ASCVD Risk Estimator Plus</a> (American College of Cardiology)</p>
<b>Fractional Flow Reserve CT</b> (CPT 75580)	<p>FFR-CT is considered medically necessary when <b>ALL</b> of the following criteria are met:</p> <ul style="list-style-type: none"> <li>Patient has symptoms consistent with myocardial ischemia</li> <li>CCTA has been performed in the preceding 90 days</li> </ul> <p>There is at least one 40%-90% coronary stenosis located in the proximal or middle segment of a major native coronary artery or a named branch thereof which is of uncertain functional significance.</p>

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (cardiology)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

## Background

Coronary artery disease (CAD) is one of the leading causes of morbidity and mortality worldwide. Currently invasive coronary angiography is the gold standard for coronary artery lumen assessment. It provides high spatial resolution and accurately determines the location, extent, and severity of coronary obstructive lesions. It also allows immediate intervention if needed. Coronary angiography, however, is an invasive procedure, has a small risk of serious complications, and requires a period of observation for several hours in a monitoring unit. Moreover, it was reported that nearly 40% of these procedures result in normal findings. This has led to a growing interest in the development less invasive methods for evaluating coronary anatomy, especially in stable patients at low to moderate risk of disease (Vembar 2006, Miller 2008).

Numerous anatomic and functional noninvasive tests for detecting CAD have emerged and are rapidly developing. Among these are stress echocardiography, nuclear perfusion studies, SPECT, magnetic resonance angiography, and others. More recently, computed tomography has been used for the evaluation of CAD. Electron beam computed tomography (EBCT) was initially used to assess coronary artery calcium as a marker of atherosclerosis. The first generation of multislice computed tomography (MSCT), also known as multidetector computed tomography (MDCT) scanners were introduced in the 1990s. The 4-slice scanner was developed to provide noninvasive direct visualization of the coronary arteries and led to significant improvements in spatial resolution compared to EBCT. However, it had motion artifacts, low resolution, long acquisition time, and up to 22% of the segments were non-assessable. The 4-slice CT thus rapidly evolved to 16, 32, 40, and 64-slice CT scanners. The 16-slice scanner has better spatial resolution, faster gantry rotation, and larger coverage resulting in significantly shorter breath hold and less motion artifacts than those with 4-slice. The 64-slice scan generation, introduced in 2004, further improved the resolution, decreased the slice thickness, and reduced the acquisition time to less than 10 seconds. The entire procedure can be performed in approximately ten minutes. Systems with 256 and 320 slices and others with 64 slices but with 2 x-ray tubes (dual –source CT or DSCT) have recently been introduced (Gertz 2006, Vembar 2006, Berman 2006, Min 2009).

With the newer scanners, electrocardiographically synchronized images can be taken through the entire heart in the time of one breath hold. Synchronizing the location of the peak of QRS complex in the ECG with the projection data allows the reconstruction and visualization of anatomy at various phases of the cardiac cycle thus making functional imaging possible (Cademartiri 2005, Vembar 2006, Budoff 2008).

MDCT technology, however, has its limitations; it does not have the ability to correctly identify and differentiate between functionally significant and nonsignificant stenosis, or allow for intervention during the examination if needed. Positive findings frequently require confirmation with selective cardiac catheterization angiography, or stress myocardial perfusion to evaluate the functional significance. One of the difficulties in imaging the coronary vessels is the constant motion of the heart, which leads to artifacts and influences the image quality even with the significant improvements in the technology. Reducing the heart rate to 50-60 bpm with beta-blockers, now routinely used by most investigators, increases the cardiac rest period and reduces, but does not eliminate motion artifacts. To date, it is not possible to perform CT angiography in patients with atrial fibrillation unless it is highly regular.

One other significant problem, even with the most recent generations, is the inability of the MDCT to assess the degree of luminal obstruction within a calcified zone when there is dense calcification of the coronary arteries. This may lead to relatively high rate of false positive results and overestimate the severity of the disease. The use of MDCT is also limited for in-stent visualization, for evaluation of distal anastomosis among patients with

previous bypass graft surgery, and for patients with higher body mass index. Moreover, MDCT requires the administration of contrast material and exposure to ionizing radiation. The radiation dose used is equivalent to 2-3 times the dose typically used during an invasive angiogram. This may be considered a low radiation exposure but might be of concern among women in childbearing age, or younger individuals who may use the test repeatedly. History of severe allergic reactions to an iodinated contrast material or of impaired renal function (creatinine level >1.5 mg/dL) are contraindications to CT coronary angiography (Garcia 2005, De Roos 2006, Leber 2006, Berman 2006, Hoffmann 2006, Rixe 2009, Min 2009).

## Medical Technology Assessment Committee (MTAC)

### **Ultrafast CT in the Screening and Diagnosis of CAD**

#### **02/11/2002: MTAC REVIEW**

**Evidence Conclusion:** In conclusion, the results of these studies indicate that in a population where CAD is more prevalent, the absence of coronary calcification is more helpful in ruling out CAD than is the detection of calcium in confirming the presence of CAD. Ultrafast CT seems promising, but as yet, there is no evidence that it may substitute angiography, but can be helpful in excluding or increasing the likelihood of significant CAD in certain situations.

**Articles:** The search yielded 39 articles, many of which were review articles, opinion pieces, or dealt with technical aspects of the scan. The search did not reveal any study that evaluated ultrafast scanning as a screening test for coronary heart disease. There were four studies that compared the Ultrafast CT scan with angiography and a few others that did not use a defined gold standard for comparison. There was only one study on the newer helical CT scan. The two studies with the stronger methodology, and larger sample sizes were selected for critical appraisal. Broderick's study that evaluated the performance of the helical CT scan was also reviewed. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease. A multicenter study. *Circulation* 1996; 93:898-904. See [Evidence Table](#). Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 1996; 27:285-90. See [Evidence Table](#). Broderick LS, Shemesh J, Wilensky RL, et al. Measurement of coronary artery calcium with dual-slice helical CT compared with coronary angiography: Evaluation of CT scoring methods, observer variations, and reproducibility. *AJR* 1996; 167:439-444. See [Evidence Table](#).

The use of ultrafast CT in the screening and diagnosis of CAD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **12/08/2004: MTAC REVIEW**

### **Ultrafast CT in the Screening and Diagnosis of CAD**

**Evidence Conclusion:** A screening test for preclinical coronary artery disease among asymptomatic individuals, and A diagnostic test for coronary artery disease among symptomatic patients. Use of EBCT for coronary artery disease screening among asymptomatic individuals: There is insufficient published evidence to determine the value of EBCT (Ultrafast CT) as a screening test for coronary artery disease among asymptomatic individuals. Ideally, a screening test should be highly sensitive in detecting previously undiagnosed disease and should lead to changes in management that improves outcomes. The meta-analysis and observational studies reviewed evaluated EBCT coronary artery calcium as a risk predictor of future coronary events among asymptomatic individuals. These studies suggest that coronary artery calcium detected by EBCT may be an independent predictor for coronary events and may add to the information provided by the Framingham risk score. However, the studies had some threats to validity that may limit generalization of the results. The majority is office-based and included self-referred individuals or others at high risk referred by their primary care physicians for further evaluation. Risk factors were self-reported and not measured in more than one study. Different techniques and scans were used, and there was no established cut-off level for calcium scores. The endpoints included revascularization in several trials, which could have been performed at a higher rate based on the results of the scan. The endpoint in one of the studies was all-cause mortality that might be due to other causes than coronary atherosclerotic diseases. None of these observational studies examined the influence of detecting coronary artery calcification on the management of the individuals, the health benefits, or effect on outcome. There is no evidence that more effective therapy or management could be provided by evaluating CAC score beyond that provided based on FRS. A recent RCT showed that the detection of coronary artery calcium among asymptomatic individuals was not associated with behavior modification or reduction of their cardiac risk scores. This RCT also had its limitations. Use of EBCT as a diagnostic test for coronary artery disease among symptomatic patients: The studies reviewed show that compared to coronary angiography as a gold standard; EBCT scanning had a high sensitivity and low specificity in detecting coronary artery disease among symptomatic patients. The sensitivity ranged from 81% to 99% among the studies reviewed in the meta-analysis, and the more recent study.

The sensitivity was inversely related to the calcium score cutoff points. It was highest at a calcium score 0-10 which on the other hand had a specificity as low as 28%, i.e. high false positives which would be associated with further investigations that might be unnecessary. The studies were conducted among symptomatic patients with a high prevalence of coronary disease, and there is a potential of overestimation of the sensitivity, and positive predictive value, which might limit generalization of the results.

**Articles:** The search yielded 39 articles, many of which were review articles, opinion pieces, or dealt with technical aspects of the scan. The search did not reveal any study that evaluated ultrafast scanning as a screening test for coronary heart disease. There were four studies that compared the Ultrafast CT scan with angiography and a few others that did not use a defined gold standard for comparison. There was only one study on the newer helical CT scan. The two studies with the stronger methodology, and larger sample sizes were selected for critical appraisal. Broderick's study that evaluated the performance of the helical CT scan was also reviewed. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease. A multicenter study. *Circulation* 1996; 93:898-904. See [Evidence Table](#). Detrano R, Hsiai T, Wang S, et al. Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography. *J Am Coll Cardiol* 1996; 27:285-90. See [Evidence Table](#). Broderick LS, Shemesh J, Wilensky RL, et al. Measurement of coronary artery calcium with dual-slice helical CT compared with coronary angiography: Evaluation of CT scoring methods, observer variations, and reproducibility. *AJR* 1996; 167:439-444. See [Evidence Table](#).

The use of ultrafast CT in the screening and diagnosis of CAD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Virtual Coronary Angioscopy**

### **04/03/2006: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence to support the use of MSCT as a method of screening for CAD among healthy, low risk populations, or asymptomatic patients with known risk factors. There is insufficient evidence that the technology is as beneficial as catheter angiography in the diagnosis of CAD. There is insufficient evidence to support the use of MSCT scanning in monitoring progress of the disease and its outcome after an intervention, in patients with confirmed disease. There is insufficient evidence that the technology improves health outcomes. A multicenter study (CorE 64), and study with long-term healthcare outcomes conducted by the Medical College of Wisconsin are underway.

**Articles:** The search yielded around 170 articles. Many were review articles, opinion pieces, or dealt with technical aspects of the scan. The search revealed several studies using 4, 8, and 16-slice CT scanners for the detection of coronary artery lesions. A recent meta-analysis of 24 of these studies was also identified, as well as seven studies that used the 64-slice CT angiography for detecting CAD stenosis and comparing the technology with invasive coronary angiography. The meta-analysis and four of the studies on the 64-slice scanners were critically appraised. Fine JJ, Hopkins CB, Ruff N, et al. Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. *Am J Cardiol*. 2006; 97:173-174. See [Evidence Table](#). Leber Aw, Knez A, von Ziegler F, et al. Quantification of obstructive and nonobstructive coronary lesions by 64-slice computed tomography. A comparative study with quantitative coronary angiography and intravascular ultrasound. *J Am Coll Cardiol*. 2005; 46:147-154. See [Evidence Table](#). Raff G L, Gallagher MJ, O'Neill WW, et al. Diagnostic accuracy of noninvasive coronary angiography using 64-slice spiral computed tomography. *J Am Coll Cardiol*. 2005; 46:552-557. See [Evidence Table](#). Ropers D, Rixe J, Anders K, et al. Usefulness of multidetector row spiral computed tomography with 6.4x0.6 mm collimator and 330 –ms rotation for the noninvasive detection of significant coronary artery stenoses. *Am J Cardiol*. 2006; 97:343-348. See [Evidence Table](#). Schuijf JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. *Am Heart J*. 2006; 151:404-411. See [Evidence Table](#).

The use virtual coronary angioscopy of in the evaluation of coronary artery disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **02/05/2007: MTAC REVIEW**

#### **MDCT in the Treatment of Coronary Heart Disease**

**Evidence Conclusion:** The patient-based analysis of the results of the studies, as presented individually or pooled in meta-analyses show high sensitivity and negative predictive values, but lower specificity and positive predictive value of the MDCT angiograms in the diagnosis of CAD in selected patients. This indicates that the test may be useful in excluding CAD and avoiding a conventional angiography among some patients, but at the expense of up to 25% false positive tests among population groups with a high prevalence of CAD. The latter



would overestimate the calculated accuracy and predictive values of the test, and in turn the results may not be generalizable to a broader lower-risk population. There is insufficient evidence to determine whether using the technology to diagnose coronary artery stenosis improves the net health outcomes. The published literature on the use of MDCT angiography in an ER does not provide sufficient evidence to determine the benefits and harms of the test in diagnosing patients presenting with acute chest pain. There are no published data to date on the effect of the using the technology on patient treatment or management decisions. A multicenter study (CorE 64) and a study with long-term healthcare outcomes conducted by the Medical College of Wisconsin are underway.

**Articles:** The search yielded around 55 articles. Many were review articles, opinion pieces, or dealt with technical aspects of the scan. Three meta-analyses published after the last review were identified, as well as several small studies on MDCT with patient sizes ranging from 51 to 129. Four studies (Nikolaou 2006l, Plass 2006, Schuijff 2006, and Muhlenbruch 2006) compared the technology with invasive coronary angiography, Dewey et al, compared the 16-slice scanner with exercise electrocardiography, in one study and MRI in another study using the invasive angiography as the gold standard. Four published studies evaluating the use of MDCT for patients presenting to the ER with acute chest pain were identified. None of the latter studies compared the technology to the gold standard of invasive angiography, and only two used the 64-slice CT scans. All meta-analyses and recent studies were reviewed. The meta-analysis that included the most recent studies that used the newest generations of MSCT (> 16 slices), compared MDCT to invasive coronary angiography, and had a valid methodology was critically appraised. A recent study comparing the 64-slice MDCT with invasive angiography, and another evaluating its use in patients presenting to the emergency room with acute chest pain were also selected for critical appraisal. Hamon M, Biondi-Zoccai GG, Malagutti P, et al. Diagnostic performance multislice spiral computed tomography of coronary arteries as compared with conventional invasive coronary angiography. *J Am Coll Cardiol.* 2006; 48:1896-1910. See [Evidence Table](#). Nikolaou K, Knez A, Rist C, et al. Accuracy of 64-MDCT in the diagnosis of ischemic heart disease. *AJR* 2006; 187:111-117. See [Evidence Table](#). Gallagher MJ, Ross MA, Raff GL, et al. The diagnostic accuracy of 64-slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low-risk chest pain patients. *Ann Emerg Med.* 2006; See [Evidence Table](#).

The use of MDCT in the treatment of coronary heart disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 04/02/2007: MTAC REVIEW

##### **Ultrafast CT in the Screening and Diagnosis of CAD**

**Evidence Conclusion:** There is some evidence that CAC may add a prognostic incremental value to Framingham risk score among selected asymptomatic individuals. Indirect evidence suggests that asymptomatic individuals at intermediate risk might potentially benefit from adding CAC to the risk assessment. The majority of the participants in the studies reviewed were Caucasians which may limit generalization of the results. The studies do not provide an optimal coronary calcium threshold. There is no single cutoff value that defines a high score. The coronary calcification differs according to age, sex, and race. There is no evidence to date that CAC scoring would result in an intervention that would improve CHD related health outcomes among individuals at an increased risk for CHD. The test results may lead to unnecessary invasive procedures, or overtreatment in some patients.

**Articles:** The search yielded around 50 articles. Many were review articles, opinion pieces, or dealt with technical aspects of the scan. Use of EBCT for coronary artery disease screening: The search identified a recent meta-analysis of observational studies (Greenland 2007) and several prospective cohort studies that evaluated EBCT coronary artery calcium (CAC) score as a risk marker predicting the likelihood of future coronary events among asymptomatic patients. It also revealed two articles on the St. Francis Heart Study (Arad, Goodman 2005, and Arad, Spadaro 2005). The first reported on the prospective cohort study, and the second on the RCT embedded in the cohort. The meta-analysis and the two articles on the St. Francis Heart Study were selected for critical appraisal. Use of EBCT for coronary artery disease diagnosis: The search did not reveal any newly published large valid study on the use of CAC scoring in the detection of coronary artery stenosis among symptomatic patients. *The following articles were critically appraised:* Greenland P, Raggi P, Harrington R, et al. ACC/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment an in evaluation of patients with chest pain. *J Am Coll Cardiol.* 2007; 49:378-402. See [Evidence Table](#). Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. *J Am Coll Cardiol.* 2005; 46:158-165. See [Evidence Table](#). Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. *J Am Coll Cardiol.* 2005; 46:166-172. See [Evidence Table](#).

The use of EBCT in the treatment of coronary artery calcium scoring does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 06/01/2009: MTAC REVIEW

### MDCT in the Treatment of Coronary Heart Disease

**Evidence Conclusion:** Use of 64-multidetector computed tomography (MDCT) for the diagnosis of coronary artery stenosis in nonemergent settings: The published studies that evaluated the use of MDCT scanners in the diagnosis of coronary artery stenosis had generally valid methodology but were relatively small and mainly conducted among selected patients with stable conditions who were referred for invasive coronary angiography for a known or suspected CAD. The technology was not assessed for screening healthy, asymptomatic, or low-risk individuals. The meta-analyses that pooled the results of the published studies had some variations in their inclusion/exclusion criteria, but a large number of same studies were included in all. The participants in ACCURACY (Budoff 2008) and CORE-64 (Miller 2008) studies, not included in the meta-analyses, were also patients with suspected symptomatic CAD referred for conventional coronary angiography. ACCURACY excluded patients with a known history of CHD, but no exclusions were made based on coronary artery calcium scoring or BMI. On the other hand, CORE 64 included patients with or without a history of CAD and excluded those with coronary artery calcium score >600 or BMI >40. Only coronary artery segments >1.5 mm was included in the analysis. These two studies as well as the other included in the meta-analyses performed patient-based and vessel-based analyses. Per-segment analyses were also performed in several studies. Accuracy of 64-slice MDCT. The patient-based analysis of the results of the studies, as presented individually or pooled in meta-analyses show high sensitivity (85-99%) and negative predictive values (95-100%), but lower specificity (83-91%) and positive predictive value (64-91%) of the MDCT angiograms in the diagnosis of significant (>50%) stenosis of CAD in selected patients. The technology was less sensitive (75-85%) but more specific (90-96%) in detecting stenosis per vessel. The accuracy of the test varied widely by artery and was highest for the left main artery followed by the left circumflex artery. These results indicate that the test may be useful in excluding CAD and avoiding a conventional angiography among some patients with a suspected disease. This however could be at the expense of more than 20% false positive tests among population groups with a high prevalence of CAD. Impact on management and health outcomes: There was insufficient evidence to determine the effect of 64-slice on patient management or net health outcomes. The published studies to date evaluated MDCT angiography in respect to its accuracy in identifying coronary stenosis, but not its effect on the treatment decisions, patient management, and health outcomes. Use of MDCT to evaluate patients presenting to emergency rooms with acute chest pain. The published literature on the use of MDCT angiography in emergency departments (ED) does not provide sufficient evidence to determine the benefits and harms of the test in diagnosing patients presenting with acute chest pain. Hoffmann 2009 (ROMICAT study), as well as earlier smaller studies that evaluated the use of the technology in the ED, did not compare it to the gold standard of catheter angiography, but used a combination of noninvasive tests and observations as a surrogate gold standard. The ROMICAT study aim was to determine the usefulness of MDCT angiography in patients with acute chest pain who presented to an emergency department and were admitted with low to intermediate risk for acute coronary syndrome. However, the results of the CT angiography findings were not provided to the physicians managing the patients, and thus it is not possible to determine whether the management or outcomes would have been altered based on the CT angiography findings. It is uncertain whether the clinicians would have performed less stress tests, more invasive angiograms, treated the patients more or less aggressively, or discharged the patients earlier had they known the results of the CT angiograms.

**Articles:** The search yielded around 325 articles on CT angiography. Many were review articles, opinion pieces, or dealt with technical aspects of the scan. Six meta-analyses published after the last review were identified. Four evaluated the diagnostic performance of the 64-slice CT scanners, one compared the performance of the 16 vs. the 64-slice scanners and another evaluated all 4, 16-slice, and 64 slice CT scanners. Two of the four meta-analyses on 64-slice scanners were performed by the same group of investigators (Mowatt and colleagues) and included the same studies. The literature search also identified two more recent multicenter studies (ACCURACY, and CORE 64) on the accuracy of the 64-slice CT scans in non-emergent settings, and one study on patients presenting to an emergency department (ROMICAT study). None was included in the meta-analyses. There were no published studies that prospectively compared MDCT to other noninvasive stress testing. The most recent valid meta-analysis that compared the performance of 64-slice scanners to invasive coronary angiography was selected for critical appraisal, as well as the newer studies ACCURACY, CORE 64, and ROMICAT. The references for the studies reviewed are: Mowatt G, Cook JA, Hillis GS, et al. 64-slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. *Heart*. 2008; 94:1386-1393. See [Evidence Table](#). Budoff MJ, Dowe D, Jollis JG, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease. Results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary



Angiography) trial. J Am Coll Cardiol 2008; 52:1724-1732. See [Evidence Table](#). Miller JM, Rochite CE, Dewey M, et al. Diagnostic performance of coronary angiography by 64-Row CT. N Engl J Med 2008;359:2324-2336. See [Evidence Table](#). Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain. The ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol 2009; 53:1642-1650. See [Evidence Table](#).

The use of MDCT in the treatment of coronary heart disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **CORONARY ARTERY CALCIUM (CAC) SCORING WITH COMPUTED TOMOGRAPHY, FOR CARDIOVASCULAR DISEASE RISK ASSESSMENT**

**Date:** 10/12/2020

### **Evidence Conclusion:**

- There is evidence from published long-term large longitudinal population studies indicating that:
  - CAC is strongly associated and in a graded fashion with 10-year risk of incident ASCVD in asymptomatic White, Black, Hispanic and Chinese American men and women 45-84 years of age with no known history of CHD.
  - CAC scoring provides additional predictive information on ASCVD events and mortality, beyond the traditional risk factors, in men and women at different age groups, races, ethnic background, at different levels of risk, and in the presence or absence of comorbid conditions such as diabetes mellitus.
- There is insufficient published evidence, to date, from valid RCTs with long-term follow-up to determine that treatment guided by CAC scoring levels in addition to the traditional risk factors have an impact on patient management and /or health outcomes in asymptomatic adults at intermediate CV risk.

**Articles:** The literature search identified multiple large long-term population-based observational studies conducted in the US and Europe published over the last 20 years, that examined the association between CAC scoring and incidental CVD events and mortality in asymptomatic individual with no known coronary artery disease and its potential utility for CVD risk stratification in asymptomatic population. the largest population cohorts and/or those with longest follow-up duration were included in the review. The search did not identify any recent RCT with important clinical outcomes to determine the impact of CAC on guiding statin therapy an improving outcome in individuals at intermediate ASCVD risk.

The use of Coronary Artery Calcium (CAC) Scoring with Computed Tomography, for Cardiovascular Disease Risk Assessment does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Fractional Flow Reserve Computed Tomography (FFRCT) for CAD**

**MTAT Review: September 2021**

### **Evidence Conclusion:**

The Medical Technology Assessment Team (MTAT) reviewed the evidence on Fractional Flow Reserve Computed Tomography (FFRCT) Software (HeartFlow, Inc.) for Coronary Artery Disease (CAD) on September 7, 2021.

- Overall, there is a large body of literature examining the clinical validity and clinical utility of FFRCT in patients with known or suspected coronary artery disease.
- We identified one systematic review/meta-analysis (Luo, 2021) and two health technology assessments (ECRI; Hayes, Inc.) that addressed the clinical question. •
- A Hayes, Inc. (2020)<sup>1</sup> assessment, which was used as the primary evidence source for this review, included 3 systematic reviews/meta-analyses and 28 additional studies (20 on clinical validity of FFRCT, 8 on clinical utility of FFRCT). Regarding evidence quality, the report noted:
  - The body of evidence concerning FFRCT for detection of HSS in patients with known or suspected CAD is large in size and moderate in quality for clinical validity, but low in quality for clinical utility. Overall quality was determined based on the balance of benefits and harms and was assessed taking into consideration the quality of individual studies; the precision, directness, and consistency of data; and the applicability of data to general practice.
  - It was further noted: The available studies of FFRCT have not provided sufficient evidence that this technique provides information that improves patient management, primarily due to a lack of randomized controlled trials (RCTs).
- Our bridge search identified 7 additional individual studies:
  - One small prospective comparative study<sup>2</sup> (N=42) evaluated the clinical validity (i.e., diagnostic performance) of FFRCT in patients with suspected or known CAD. Consistent with the findings of the Hayes, Inc. review, diagnostic accuracy was better than CCTA alone for evaluation of CAD.

- Two comparative studies (one prospective cohort study<sup>2</sup> and one RCT<sup>3</sup>) and 5 observational studies<sup>4-8</sup> examined clinical utility (total N=4,372).
  - Overall, there were statistically significant correlations between reduced FFRCT values and 1 or more types of ACE.
  - There is recent data available from a large RCT<sup>3</sup> showing that FFRCT led to 22% reduction in ICA use (p=0.01) and no difference in symptoms, quality of life, major adverse cardiac and cerebrovascular events, or use of coronary revascularization vs. no FFRCT in patients with stable chest pain (Curzen, 2021<sup>3</sup>; N=1,400); however, the study had a follow-up period of only 9 months. There remains a need for longer term clinical utility data.
- The studies identified in our search were limited by small sample sizes, lack of randomized studies with adequate follow-up data, and retrospective, non-comparative designs.
- Thus, the results of the studies identified in our bridge search (for both clinical validity and clinical utility) are in line with the findings of the Hayes, Inc. review.

### **Overall Conclusion(s)**

- The quality of the evidence on the clinical validity of FFRCT in patients with known or suspected CAD is moderate. The quality of the evidence on the clinical utility of FFRCT in patients with known or suspected CAD is low.
- Therefore, the overall quality of the body of evidence on FFRCT in patients with known or suspected CAD is low.
- Additional trials with randomized controlled designs or high-quality comparative studies with longterm follow-up periods are needed to determine whether use of FFRCT in patients with known or suspected CAD leads to clinically meaningful changes in treatment decision-making and health outcomes.

## **Hayes Technology Assessment**

### **Noninvasive Computed Fractional Flow Reserve from Computed Tomography (FFRCT) for Diagnosis of Coronary Artery Disease**

*Dec 11, 2020 ; annual review 1/30/2023*

#### **Technology Description**

FFRCT is a noninvasive alternative to FFR testing that involves computer-assisted processing of CCTA images to estimate changes in blood pressure inside coronary arteries that have partial or intermediate stenosis. By using information from CCTA to model fluid dynamics of the coronary arteries, FFRCT seeks to determine whether the stenotic lesion causes an appreciable reduction in blood flow to the heart, which may lead to myocardial ischemia or infarction, and whether the lesion can be treated medically or requires a percutaneous coronary intervention (PCI), such as balloon angioplasty and stenting. FFRCT is an alternative to invasive assessment of FFR that uses a pressure-sensing wire inserted into the coronary arteries. A stenosis with an FFRCT value  $\geq 0.80$  creates a small drop in blood pressure, has a low probability of causing inducible ischemia, and is not considered to need PCI. FFRCT is performed using already obtained CCTA images at a center equipped with the specialized software.

#### **Conclusion**

The available studies have provided consistent evidence that FFRCT is more accurate than CCTA alone for detection of HSS but insufficient evidence to evaluate FFRCT relative to other noninvasive methods such as CCTP, SPECT, PET, and CMR. There is also insufficient evidence to evaluate the clinical utility of FFRCT relative to invasive FFR. The only available study with prospective controls found that FFRCT-guided management reduced the use of unnecessary ICA in a significant proportion of patients with no increased occurrence of adverse clinical outcomes. However, this study did not randomize patients to FFRCT versus invasive testing and it involved only 1 year of follow-up. Studies of FFRCT for prediction of CAD events found correlations between reduced FFRCT and adverse clinical outcomes but had significant shortcomings, such as limited or incomplete use of multivariate analysis to identify independent predictors. FFRCT does not pose any notable safety concerns. Although most studies in the evidence base included patients with stable chest pain and suspected or known CAD, most did not limit the patient population to those with intermediate coronary artery blockages and reported results for all lesions, making it difficult to determine which patients would benefit from testing. Additional studies, particularly of clinical utility, are needed to determine the long-term efficacy and safety of FFRCT for guidance of CAD management in this patient population.

#### **Hayes Rating: C**

Hayes. Hayes Technology Assessment. Noninvasive Computed Fractional Flow Reserve from Computed Tomography (FFRCT) for Diagnosis of Coronary Artery Disease. Dallas, TX: Hayes; January 30, 2023. Retrieved February 21, 2023, from <https://evidence.hayesinc.com/report/dir.noninvasivEFFRCT3647>

## Applicable Codes

### **Cardiac CT Angiography (CTA) and/or Fractional Flow Reserve (FFR)**

**Medicare & Non-Medicare- Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>75572</b>	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)
<b>75573</b>	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)
<b>75574</b>	Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)
<b>75580</b>	Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional

### **Coronary Artery Calcium Score**

**Medicare & Non-Medicare:**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® Codes</b>	<b>Description</b>
<b>75571</b>	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium
<b>S8092</b>	Electron beam computed tomography (also known as ultrafast CT, cine CT)

### **Artificial Intelligence Enabled CT Based Quantitative Coronary Topography**

**Medicare: Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

**Non-Medicare: Considered Not Medically Necessary - experimental, investigational, or unproven**

<b>CPT® Codes</b>	<b>Description</b>
<b>0623T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report
<b>0624T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission
<b>0625T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography
<b>0626T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/27/2006	04/03/2006, 02/05/07, 07/13/2009 <sup>MDCRPC</sup> , 06/01/2010 <sup>MDCRPC</sup> , 04/05/2011 <sup>MDCRPC</sup> , 02/07/2012 <sup>MDCRPC</sup> , 12/04/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 4/1/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup>	03/26/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/01/2015	Revised LCD Multidetector Computed Tomography of the Heart and Great Vessels (L34137)
07/28/2016	Added retired LCD language
07/25/2017	Chest CT angiography no longer requires review
06/02/2020	Removed CPT code 71275 and reference for Chest CT Angiography since it does not require medical necessity review
03/06/2023	Addition of Medicare LCD, LCA links for Non-Invasive Fractional Flow Reserve (FFR) for stable Ischemic Heart Disease and applicable codes for Medicare added 0501-0504T.
08/08/2023	MPC approved clinical indications for Fractional Flow Reserve (FFR). Requires 60-day notice, effective date 01/01/2024.
01/31/2024	Updated CPT codes added new code 75580 effective 1/1/2024 and removed CPT 0501T, 0502T, 0503T, 0504T which were deleted 1/1/2024 and replaced with 75580.
03/26/2025	Merged CT angiography and Cardiac CT angiography policies. Added new Medicare LCD L39883 and Billing and Coding Article A59771 for artificial Intelligence Enabled CT Based Quantitative Coronary Topography (CPT Codes 0623T-0626T).



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Cardiovascular Risk Panel Galectin-3 Blood Assay Test PLAC Test

- Predicting the Risk of Coronary Heart Disease (Lp-PLA2)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Biomarkers in Cardiovascular Risk Assessment (L36362)</a>
Local Coverage Article	<a href="#">Billing and Coding: MoIDX: Biomarkers in Cardiovascular Risk Assessment (A57055)</a>

#### For Non-Medicare Members

Service	Criteria
<b>Cardiovascular Risk Panel</b>	<p>There is insufficient evidence in the published medical literature to show that Cardiovascular Risk Panels provide better long-term outcomes than current standard services/therapies.</p> <p>Cardiovascular risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels*) are considered <b>not medically necessary</b>. Some examples of commercially available cardiovascular risk panels include but are not limited to the following:</p> <ul style="list-style-type: none"> <li>Applied Genetics Cardiac Panel</li> <li>Atherotech® Diagnostics Lab CVD Risk Panel and VAP Lipid Panel</li> <li>Berkeley Heart Lab (a Quest Diagnostics service) Cardio IQ® Lipid Panel</li> <li>Health Diagnostics Cardiac Risk Panel</li> <li>Boston Heart Diagnostics</li> <li>Genova Diagnostics CV Health Plus Genomics Panel</li> <li>Genova Diagnostics CV Health Plus Panel</li> <li>Metametrix Cardiovascular Health Profile</li> <li>Cleveland HeartLab CVD Inflammatory Profile</li> <li>Applied Genetics Cardiac Panel</li> <li>Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel</li> </ul>

	<ul style="list-style-type: none"> <li>• Quest Diagnostics 4myheart</li> <li>• Singulex Cardiac Related Test Panels <ul style="list-style-type: none"> <li>○ Cardiac Dysfunction panel</li> <li>○ Vascular Information and Dysfunction panel</li> <li>○ Dyslipidemia panel</li> <li>○ Cardiometabolic</li> </ul> </li> </ul> <p>* A simple lipid panel is generally composed of the following lipid measures:</p> <ul style="list-style-type: none"> <li>• Total cholesterol</li> <li>• LDL cholesterol</li> <li>• HDL cholesterol</li> <li>• Triglycerides</li> </ul> <p>Certain calculated ratios, such as the total/HDL cholesterol may also be reported as part of a simple lipid panel. Other types of lipid testing, i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a), etc., are not considered to be components of a simple lipid profile.</p>
<ul style="list-style-type: none"> <li>• <b>Galectin-3 Blood Assay Test</b></li> <li>• <b>PLAC Test</b></li> </ul>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies for congestive heart failure (CHF).</p> <p>The use of Galactin-3 for all other indications does not meet medical necessity because its clinical utility has not been established.</p>

**If requesting review for these services, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

## Background

Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate risk of cardiovascular disease. There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine results of multiple markers into one score. While the individual risk factors have in most cases been associated with increased risk of CV disease, it is not clear how the results of individual risk factors impact management changes, so it is also not certain how the panels will impact management decisions. Given the lack of evidence for clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CV risk panels improve outcome.

2010 American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Recommendation for Assessment of Lipoprotein Concentrations, Other Lipoprotein Parameters, and Modified Lipids: "Measurement of lipid parameters, including lipoproteins, apolipoproteins, particle size, and density, beyond standard fasting lipid profile is not recommended for cardiovascular disease risk assessment in asymptomatic adults."

<http://circ.ahajournals.org/content/122/25/e584.full.pdf>



Heart failure (HF) is one of the most frequent and challenging medical disorders. It is a complex progressive disease with high morbidity and mortality. The prognosis of patients with HF is poor despite the advances made in the diagnosis, medical management, and device therapies. It is thus important to diagnose HF early and to identify the patients at higher risk of poor outcomes (Lok 2013, Browners 2014).

Accurate risk stratification of HF patients may help in the decision making for managing the disease; including individualizing the therapeutic approach and the proper use of invasive and costly therapies. However, risk prediction in acute, chronic, and new onset HF remains a challenge. Clinical parameters, such as advanced age, higher New York Heart Association (NYHA) functional class, reduced left ventricular ejection fraction (LVEF), lower body mass index, renal dysfunction, and anemia, have all been associated with poor outcomes in HF, but are not significant predictors of mortality. In recent years efforts were made to find biomarkers that might help in the risk stratification, and prognostication of acute and chronic heart failure. Brain natriuretic peptide (BNP) and its N-terminal part (NT-proBNP) have become well-established markers used in the diagnosis and management of HF patients. Both are released in response to myocyte stretch and provide useful information for HF diagnosis, prognosis, and response to therapy. However, natriuretic peptides only indicate ventricular loading conditions and may not reveal other important mechanisms for HF. Other novel biomarkers from different physio pathological pathways such soluble ST2, growth differentiation factor-15, highly sensitive troponins, and Galectin-3, have recently emerged and are being evaluated for their potential use in adding value to the risk stratification of HF patients. For a biomarker to be useful to a clinician, it should be available, accurate, and reliable. It also should add incremental value to the clinical variables or other established markers, provide prognostic information, have an impact on patient management, and be responsive to interventions (Carrasco-Sanchez 2014, Coburn 2014, Filipe 2014, Gruson 2014, Pouleur 2014, Schmitter 2014, Srivatsan 2014).

Galectin-3 (Gal-3) is a member of a family of proteins comprising soluble  $\beta$ -galactoside-binding lectins that have regulatory roles in fibrogenesis, inflammation, tissue repair, and cell proliferation. It is mainly known for its role as a mediator of tumor growth, progression, and metastases. Gal-3 is also associated with increased age, diabetes, nephropathy, and fibrotic conditions such as liver fibrosis, renal fibrosis, idiopathic lung fibrosis, and chronic pancreatitis. Recently, it has been suggested that Gal-3 may play a role in the pathophysiology of HF through promotion of inflammation, myocardial fibrosis and myocardial remodeling, which are key processes for the development and progression of HF. It was thus suggested that an increased Gal-3 level in the circulation may reflect active and excessive myocardial fibrogenesis in patients with HF and can thus be used as a marker for poor prognosis related to excessive and potential irreversible myocardial fibrosis (Lok 2010, Gullestad 2013, Carrasco-Sanchez 2013, Suarez 2014).

GAL-3 is measured in the circulation by manual or automated assays. The enzyme linked immunosorbent assay manual assay (ELISA) is the most frequently used method in the published studies. Manual assays are, however, laborious and take considerable time for sampling, handling, incubation, and washing steps. More recently, several automated assays with faster delivery of the results, have been developed and are commercially available. A number of manual and automated assays have received FDA approval for measuring circulating Gal-3. Others are still seeking approval. The ARCHITECT Galectin-3 assay, BGM Galectin -3TM are among those approved by the FDA to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

Galectin-3 testing in HF patients has not been previously reviewed by MTAC. It is being reviewed for its use as a prognostic marker in patients with heart failure based on requests from contracted providers for its coverage.

## Medical Technology Assessment Committee (MTAC)

### ***Galectin-3 Blood Assay Test***

**02/09/2015: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence from longitudinal studies with long-term follow-up and serial measurements of Gal-3 to determine that elevated circulating Gal-3 levels are independent prognostic markers for poor outcomes in patients with HF. There is insufficient evidence to determine that Gal-3 adds clinically significant incremental value to established markers and clinical variables. There is insufficient evidence to determine that circulating Gal-3 has an impact on management decisions made for patients with HF.

**Articles:** The literature search revealed over 200 articles on Galectin-3 and heart failure. The great majority were unrelated to the current review. There were several published studies on the prognostic value of Gal-3 in patients with heart failure. These were mainly secondary analyses of data or subsets of data collected for patients

enrolled in large cohort studies or randomized controlled trials that investigated different other therapies or interventions. The search also identified a pooled analysis of the results of 3 trials (Meijers 2014), and a more recent meta-analysis (Chen et al, 2015) that pooled the results of 11 studies. The literature search did not identify any RCT that directly studied the impact of using the plasma levels Gal-3 on the management of patients with HF. The two meta-analyses were selected for critical appraisal (Evidence tables 1 & 2). The characteristics of the studies included in the larger meta-analysis as well as selected studies published in the last 5 years and not included in the meta-analyses were reviewed and summarized in [Evidence Table 3](#). Chen A, Hou W, Zhang Y et al. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. *Int J Cardiol* 2015; 182:168-170. See [Evidence Table 1](#). Meijers WC, Januzzi JL, de Filippi C, et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. *Am Heart J*. 2014 Jun;167(6):853-60.e4. See [Evidence Table 2](#).

The use of Galectin-3 Blood Assay Test does not meet the Kaiser Permanente *Medical Technology Assessment Criteria*.

## Medical Technology Assessment Committee (MTAC)

### PLAC Test in Detecting Risk of Coronary Heart Disease

#### 02/11/2004: MTAC REVIEW

**Evidence Conclusion:** Ballantyne et al's study was nested in a large prospective study. It included both men and women 45-64 years of age. In this sub-study CHD patients were compared to a random sample of 785 subjects (minus 45 cases with CHD), and not to the whole study population. The authors do not provide explanation why they selected such a design. There were several significant differences in the base-line characteristics between the cases, and non- cases. Adjustments were made for several of these variables, not for all. Other variables not adjusted for in the analysis may be potential confounders. Overall, it showed that the highest tertile of Lp-PLA<sub>2</sub> enzyme was associated with a higher CHD risk among patients with LDL cholesterol level <130 mg/dL. Packard's study was a case control nested in the WOSCOPS study. Participants were men 45-64 years of age, with baseline LDL cholesterol level 174 –232 mg/dL. Cases were those who developed a coronary event, and controls were men from the same cohort who did not develop a coronary event during the follow-up. Overall the results showed that lipoprotein-associated phospholipase A<sub>2</sub> was significantly associated with coronary events, independent of the other variables studied. Blake's study on the other hand did not detect a significant association between the enzyme and the risk of cardiovascular events among women. It was also a case control nested in a large trial, "Women's Health Study" that only enrolled women 45 years of age or older. The case control study was small, and the power might have been insufficient to detect a significant association. The different findings between the two studies may also indicate that lipoprotein-associated phospholipase levels may be predictive of coronary events in men but not women. The three studies reviewed examined Lp-PLA<sub>2</sub> as a marker or risk predictor for coronary events but did not study the implication of identifying this risk factor on the management of the patients or in improving the net health outcome.

**Articles:** The search yielded 25 articles, the majority of which were news, review articles, and tutorials. The search did not reveal any RCTs. The studies embedded in larger prospective cohort studies were identified. All three were critically appraised: Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase High sensitivity C-reactive protein, and risk incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. *Circulation* 2004; 109:837-842. See [Evidence Table](#). Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein- associated phospholipase A<sub>2</sub> as an independent predictor of coronary heart disease. *N Engl J Med* 2000; 343:1148-1155. See [Evidence Table](#). Blake GJ, Dada N, Fox JC, et al. A prospective evaluation of lipoprotein- associated phospholipase A<sub>2</sub> levels and the risk of future cardiovascular events in women. *J Am Coll Cardiol* 2001; 38:1302-1306. See [Evidence Table](#).

The use of PLAC Test in detecting risk of coronary heart disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 10/05/2009: MTAC REVIEW

### PLAC Test in Detecting Risk of Coronary Heart Disease

**Evidence Conclusion:** The current evidence suggests that Lp-PLA<sub>2</sub> may be associated with vascular disease risk, but it is insufficient to show the association is causal, that measuring the enzyme level improves risk stratification for CVD, would have any impact on managing patients at high risk, or that inhibition therapy of Lp-PLA<sub>2</sub> enzyme would improve health outcomes.

**Articles:** The search yielded around 33 articles. There was a meta-analysis, and a number of case control studies examining the association between Lp-PLA<sub>2</sub> and CVD. The search also identified one randomized

controlled trial on the effect of a selective Lp-PLA2 inhibitor of the enzyme activity (darapladib) in patients with CHD or risk equivalent, and another small RCT on the effect of the drug on the atherosclerotic plaque. The literature search did not reveal any published studies on the clinical benefits of screening for Lp-PLA2 in optimizing therapy and reducing cardiovascular risk, and/or events. There were also no studies on the diagnostic accuracy of PLAC test in assessing the Lp-PLA2 levels. The meta-analysis on the association between Lp-PLA2 and CVD risk, the ARIC study (FDA approval), and the RCT on the effect of darapladib on the enzyme activity in patients with CHD or risk equivalent were selected for critical appraisal: Garza CA, Montori VM, Connell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc.* 2007; 82:159-165. See [Evidence Table](#). Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase High sensitivity C-reactive protein, and risk incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. *Circulation* 2004; 109:837-842. See [Evidence Table](#). Mohler ER, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein -associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease equivalent. The results of a multicenter, randomized double-blind, placebo-controlled study. *J Am Coll Cardiol* 2008; 51:1632-1641. See [Evidence Table](#).

The use of PLAC Test in detecting risk of coronary heart disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## References

- Balagopal P, de Ferranti SD, Cook et al. AHA scientific statement: nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research and clinical considerations for youth. *Circulation*. 2011;123:2749-2769. doi: 10.1161/CIR.0b013e31821c7c64
- Bays HE, Jones PH, Brown WV, et National lipid association annual summary of clinical lipidology. 2015. *J Clin Lipidol*. 2015;8:S1-S36. doi:10.1016/j.jacl.2014.10.002
- Brunzell JD, Davidson M, Furberg CD, et Lipoprotein management in patients with cardiometabolic risk: consensus conference report from American Diabetes Association and American College of Cardiology Foundation. *J Am Coll Cardiol*. 2008;51(15):1512-1524. doi:10.1016/j.jacc.2008.02.034
- Casas JP, Shah T, Hingorani AD, et C-reactive protein and coronary heart disease: a critical review. *J Intern Med*. 2008;264(4):295–314. doi:10.1111/j.1365-2796.2008.02015.x
- Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoprotein and vascular diseases division working group on best Clin Chem. 2009;55(3):407-419. doi:10.1373/clinchem.2008.118356
- Cromwell WC, Barringer Low-density lipoprotein and apolipoprotein b: clinical use in patients with coronary heart disease. *Curr Cardiol Rep*. 2009;11(6):468-475. doi:10.1007/s11886-009-0067-z
- Davidson MH, Ballantyne CM, Jacobson TA, et Clinical utility of inflammatory markers and advance lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol*. 2011;5(5):338-367. doi:10.1016/j.jacl.2011.07.005
- de Zeeuw D, Parving H, Henning Microalbuminuria as an early marker for cardiovascular disease. *J Am Soc Nephrol*. 2006;17(8):2100-2105. doi: 10.1681/ASN.2006050517
- Dijkstra SC, Brouwer IA, van Rooij FJ, et Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: the Rotterdam Study. *Euro J Heart Fail*. 2009; 11(10):922-928. doi: 10.1093/eurjhf/hfp126
- Elamin MB, Abu Elnour NO, Elamin KB, et Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2011;96(7):1931-1942. doi.org/10.1210/jc.2011-0398
- Elliott P, Chambers JC, Zhang W, et Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. *JAMA*. 2009;302(1):37–48. doi:10.1001/jama.2009.954
- Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Recommendations from the EGAPP Working Group: genomic profiling to assess cardiovascular risk to improve cardiovascular health. *Genet Med*. 2010;12(12):839-843. doi:10.1097/GIM.0b013e3181f872c0
- Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE Comprehensive diabetes management algorithm 2013. *Endo Pract*. 2013;19(2):327-336.
- Greenland P, Alpert JS, Beller GA, et 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary. *J Am Coll Cardiol*. 2010;56(25):2182-2199. doi:10.1016/j.jacc.2010.09.002
- Greenland P, Alpert JS, Beller GA, et 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol*. 2010;56(25): e50-e103. doi:10.1016/j.jacc.2010.09.001

- Handelsman Y, Bloomgarden ZT, Grunberg G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology-clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. *Endo Pract.* 2015;21Suppl 1(Suppl 1):1-87. doi:10.4158/EP15672.GL
- Ho E, Galougahi KK, Liu C, et al. Biological markers of oxidative stress: application to cardiovascular research and practice. *Redox Biol.* 2013;1(1):483-491. doi:10.1016/j.redox.2013.07.006
- Huang JV, Greyson CR, Schwartz PPAR-  $\gamma$  as a therapeutic target in cardiovascular disease: evidence and uncertainty. *J Lipid Res.* 2012;53(9):1738-1754. doi: 10.1194/jlr.R024505
- Ioannidis J, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. *Circ Res.* 2012;110:658-662. doi: 10.1161/RES.0b013e31824da8ad
- Javed Clinical implications of tumor necrosis factor- $\alpha$ , interleukin-6 and resistin in coronary artery disease. *World J CV Dis.* 2014;4(9):416-421. doi:10.4236/wjcd.2014.49052
- Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of Endo Pract. 2012;18(2):269- 293. doi:10.4158/ep.18.2.269
- Kleingraber MC, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease: a systematic Thromb Haemost. 2013;110(2):233-243. doi:10.1160/TH13-01-0032
- Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. *Arterioscler Thromb Vasc Bio.* 2007;27(1):127-133. doi: 10.1161/01.ATV.0000251993.20372.40
- Marai I, Massalha Effect of omega-3 polyunsaturated fatty acids and vitamin D on cardiovascular diseases. *Isr Med Assoc J.* 2014; 16(2):117-121.
- McMahon M, Skaggs BJ, Grossman JM, et al. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. *Arthritis Rheumatol.* 2014;66(1):130-139. doi: 10.1002/art.38204
- McPherson Remnant cholesterol:"non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. *J Am Coll Cardiol.* 2013;61(4):437-439. doi:10.1016/j.jacc.2012.11.009
- Medicare Claims Processing Manual, Pub 100-04, Chapter 18, 100: Preventive and Screening Services, Cardiovascular Disease Screening.
- Medicare National Coverage Determinations (NCD) Manual, Pub 100-03, Chapter 1, 190.23: Lipid Testing.
- Myers GL, editor(s). Emerging biomarkers for primary prevention of cardiovascular disease and stroke. Washington (DC): National Academy of Clinical 2009.
- NACB LMPG Committee Members, Myers GL, Christenson RH, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. *Clin Chem.* 2009;55(2):378-384. doi:10.1373/clinchem.2008.115899
- National Cholesterol Education Program (NCEP). Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report). NIH, NHLBI. NIH Pub. No. 02- 5215. Sept 2002.
- Patel SK, Velkoska E, Burrell Emerging markers in cardiovascular disease: where does angiotensin- converting enzyme 2 fit in? *Clin Exp Pharmacol Physiol.* 2013;40(8):551-559. doi: 10.1111/1440- 1681.12069
- Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease; application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. 2003;107(3):499-511. doi:10.1161/01.cir.0000052939.59093.45
- Pepys C-reactive protein is neither a marker nor a mediator of atherosclerosis. *Nat Clin Pract Nephrol.* 2008;4(5):234–235. doi:10.1038/ncpneph0778
- Ridker PM, Buring JE, Cook NR, Rifai C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. *Circulation.* 2003;107(3):391-397. doi:10.1161/01.cir.0000055014.62083.05
- Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. *N Engl J Med.* 2002;347(20):1557–1565. doi:10.1056/NEJMoa021993
- Romacho T, Sanchez-Ferrer CF, Peiro Visfatin/Nampt: an adipokine with cardiovascular impact. *Mediators Inflamm.* 2013;2013:946427. doi:10.1155/2013/946427
- Rosenson RS, Stein JH, Durrington Lipoprotein(a) and cardiovascular disease. UpToDate®, Freeman MW (Ed). Waltham, MA 2014.
- Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. *Int J Epidemiol.* 2009;38(1):217-231. doi:10.1093/ije/dyn217



- Sie MPS, Sayed-Tabatabaei FAS, Oei HS, et al. Interleukin 6-174 G/C promoter polymorphism and risk of coronary heart disease: results from the Rotterdam Study and a meta-analysis. *Arterioscler Thromb Vasc Biol.* 2006;26(1):212-217. doi:10.1161/01.ATV.0000194099.65024.17
- Targonska-Stepniak B, Majdan Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. *Mediators Inflamm.* 2014;2014:793628. doi:10.1155/2014/793628
- Toth PP, Grabner M, Puneekar RS, et Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis.* 2014;235(2):585-591. doi:10.1016/j.atherosclerosis.2014.05.914
- U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2009;151(7):474-482. doi:10.7326/0003-4819-151-7-200910060-00008
- Varbo A, Benn M, Tybjaerg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol.* 2013;61(4):427-436. doi:10.1016/j.jacc.2012.08.1026
- Vaughan PAI-1 and atherothrombosis. *J Thromb Haemost.* 2005;3(8):1879-1883. doi:10.1111/j.1538-7836.2005.01420.x
- Wang L, Manson JE, Song Y, Sesso Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. *Ann Intern Med.* 2010;152(5):315-323. doi:10.7326/0003-4819-152-5-201003020-00010
- Yano Y, Nakazato M, Toshinai K, et al. Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. *Am J Hypertens.* 2014;27(5):727-733. doi: 10.1093/ajh/hpt232

## Applicable Codes

**Considered Not Medically Necessary when billed as part of a Cardiovascular Risk Panel:**

*\*This is not an all-inclusive list.*

CPT® Codes	Description
81225	CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *8, *17)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
81240	F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G>A variant
81241	F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C)
81400	Molecular pathology procedure, Level 1(eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis)
81401	Molecular pathology procedure, Level 2 (eg, 2-10 SNPs, 1 methylated variant, or 1 somatic variant [typically using nonsequencing target variant analysis], or detection of a dynamic mutation disorder/triplet repeat)
81479	Unlisted molecular pathology procedure (when utilized with a description of KIF6, 9p21, 4q25-AF, LPA Aspirin, LPA-Intron 25)
82163	Angiotensin II
82172	Apolipoprotein, each
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed
82397	Chemiluminescent assay (Leptin)
82542	Column chromatography, includes mass spectrometry, if performed (eg, HPLC, LC, LC/MS, LC/MS-MS, GC, GC/MS-MS, GC/MS, HPLC/MS), non-drug analyte(s) not elsewhere specified, qualitative or quantitative, each specimen [not covered for cardiovascular disease risk]
82610	Cystatin C
82664	Electrophoretic technique, not otherwise classified

82725	Fatty acids, nonesterified [not covered for cardiovascular disease risk]
82777	Galectin-3 [not covered for cardiovascular disease risk]
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)
83090	Homocysteine
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified [adiponectin] [leptin] [interleukin-6 (IL-6)] [tumor necrosis factor alpha (TNF-a)] [Oxidized phospholipids] [interleukin 17] [toll-like receptor 4 (TLR4)]
83525	Insulin, total [not covered for cardiovascular disease risk]
83695	Lipoprotein (a)
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)
83700	Lipoprotein, blood; electrophoretic separation and quantitation
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation)
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed
83719	Lipoprotein, direct measurement; VLDL cholesterol
83876	Myeloperoxidase (MPO)
83880	Natriuretic peptide
85384	Fibrinogen; activity
85385	Fibrinogen; antigen

**Galectin-3 Blood Assay Test****Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
82777	Galectin-3

**PLAC Test****Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
01/25/2017	02/07/2017 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	10/01/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/04/2015	Addendum: Insufficient Evidence for all other indications Addendum: Congestive Heart Failure (CHF) as an indication
02/07/2017	MPC approved to adopt criteria to manage cardiovascular risk panels that are commercially available; 60 day notice effective May 1, 2017
06/07/2018	Added LCD – L36362
06/02/2020	Added LCA Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment (A57055)



06/01/2021	Updated applicable coding – removed deleted codes 0111T and 0126T
12/09/2022	Updated applicable coding – removed deleted codes 0423T
10/01/2024	Merged Galectin-3 Blood Assay Test, CV Risk Panel, PLAC test criteria



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Deep Brain Stimulation

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Deep Brain Stimulation for Essential Tremor and Parkinson's Disease (160.24)</a>
Local Coverage Determinations (LCD)	None

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Deep Brain Stimulation (KP-0403) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies for the following:

- Refractory Obsessive - Compulsive Disorder
- Primary Headache
- Neuropathic Pain (see Background information in KP-0403)

[\(See also Occipital Nerve Stimulation for Primary Headache\)](#)

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (Neurology, Neurosurgery)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Deep-brain stimulation (DBS) was first developed in the late 1980's. DBS involves ongoing electrical stimulation of a particular target in the brain and is designed to block the abnormal firing of neurons. The exact mechanism of action of DBS is not known. DBS has been used since the early 1990s to treat movement disorders such as Parkinson's disease, and, in 1999, the first report was published applying DBS to the treatment of refractory obsessive-compulsive disorder.

DBS consists of an insulated wire lead with four electrodes at its end that are surgically implanted into the affected area of the brain. A wire runs under the skin to a battery-operated pulse generator implanted near the collarbone or in abdomen. The generator is programmed to send continuous low voltage electrical pulses to the brain. It can be turned on or off when the patient swipes a special magnet over the generator. (Movement disorders patients typically turn off the device at night, because tremors usually stop during sleep.) The voltage can be adjusted in relation to the symptoms being treated.

To implant the electrodes, a neurosurgeon uses a stereotactic head frame and magnetic resonance or computed tomography imaging to map the brain and pinpoint the problem area. The patient's scalp is anesthetized before the procedure, but the patient is awake to report side effects while the electrodes are placed. This allows the lead to be placed for maximum effectiveness and minimum side effects.

## Evidence and Source Documents

[Electrical Stimulation of the Thalamus for Essential and Parkinsonian Tremor](#)  
[Globus Pallidus and Subthalamic Nucleus Stimulator Implant- Parkinson's](#)  
[Refractory Obsessive-Compulsive Disorder](#)  
[Primary Headache](#)

## Medical Technology Assessment Committee (MTAC)

### ***Electrical Stimulation of the Thalamus for Essential and Parkinsonian Tremor***

#### BACKGROUND

Essential tremor is the most common form of tremor that affects more than 1 million patients in the US. It is defined as tremor which is postural, usually involving the upper limbs, absent at rest, not exacerbated by movement and not of cerebellar or extrapyramidal origin. One of the symptoms of Parkinson's Disease is tremor. Treatment for mild cases of tremor involves pharmacologic therapy with propranolol or L-dopa for Parkinsonian tremor. Severe debilitating tremor is usually treated with stereotactic surgical thalamic ablation (thalamotomy). However, thalamotomy can result in clinically significant neurologic side effects and once lesioned, no further tremor control is possible. The beneficial effects of thalamic stimulation on tremor were first identified when stimulation was used to localize the electrode prior to making a lesion in the thalamus for tremor control.

Electrical tremor control systems consist of an electrode implanted in the thalamus connected to an implanted radio-frequency pulse generator. The stimulator is programmed for optimal tremor control by a Neurologist and can be turned on or off by the patient using a magnet.

#### 04/19/1999: MTAC REVIEW

#### **Electrical Stimulation of the Thalamus for Essential and Parkinsonian Tremor**

**Evidence Conclusion:** Several case series have been published examining the role of thalamic stimulation in essential tremor and in Parkinson's disease. It is clear that stimulation reduces contralateral upper limb tremor to a clinically significant extent. In essential tremor improvement was noted when performing activities such as writing, drinking and eating. Although quality of life was not formally assessed the degree of change is likely to be clinically important. In Parkinson's disease the utility of reducing tremor is less clear, with no change in ability to write, dress, cut food, or speak. Perioperative complications occur in approximately 10%, and at 12 months neurologic complications related to stimulus intensity are common, each of the following occurring in 2-4%: dystonia, dysarthria, paresthesia, and disequilibrium.

**Articles:** Koller, W, et al, High Frequency Unilateral Thalamic Stimulation in the Treatment of Essential and Parkinsonian Tremor, *Ann Neurol.* 1997, 42:292-299 See [Evidence Table](#). Limousin, JD et al, Multicentre European Study of Thalamic Stimulation in Parkinsonian and Essential Tremor. *J Neurol. Neurosurg Psychiatry.* 1999;66:289-296 See [Evidence Table](#). Ondo, W et al. Unilateral Thalamic Deep Brain Stimulation for Refractory Essential Tremor and Parkinson's Disease Tremor. *Neurology*, 1998;51:1063-1069 See [Evidence Table](#).

Members noted that patients who had debilitating non-tremor symptoms of Parkinson's disease such as rigidity and cogwheel movements would probably not show clinically significant improvements in their ability to eat, write or drink and therefore the benefits of thalamic stimulation would probably not outweigh the harms of this invasive surgical procedure in this population.

Electrical stimulation of the thalamus for the treatment of essential tremor meets GHC Medical Technology Assessment Criteria 1-5 for effectiveness and 6 for appropriateness and is therefore considered to be medically appropriate for patients who have failed maximal medical therapy for controlling their tremor.

Thalamic stimulation for treatment of Parkinsonian tremor also meets GHC Medical Technology Assessment Criteria 1-6 only for patients whose primary functional disability is tremor despite maximal medical therapy.

#### **10/03/2006: MTAC REVIEW**

##### **Electrical Stimulation of the Thalamus for Essential and Parkinsonian Tremor**

**Evidence Conclusion:** The evidence on deep brain stimulation for treating Parkinson's disease consists of two randomized controlled trials. Both studies had results favoring deep brain stimulation. The stronger study methodologically found a statistically significant reduction in motor symptom scores in the group assigned to deep brain stimulation in a double-blind comparison to no stimulation (Deep Brain Stimulation Study Group, 2001). However, Medtronic, the device manufacturer funded the study and was responsible for data collection and analysis. The other randomized controlled trial found more improvement in quality of life and symptom severity scores in patients assigned to neurostimulation compared to medical management (Deuschl et al., 2006). Limitations of the latter study are the study was not blinded and study participants had already failed medical management. The Deuschl study was not funded by Medtronic, but several authors had financial links with the company.

**Articles:** Deuschl G, Schade-Brittinger C, Krack P et al. A randomized trial of deep-brain stimulation for Parkinson's Disease. *N Engl J Med* 2006; 355: 896-908. See [Evidence Table](#).

Evidence updated but not brought to MTAC as no change from previous review outcome.

#### **Globus Pallidus and Subthalamic Nucleus Stimulator Implant**

##### **BACKGROUND**

Deep brain stimulation (DBS) is a technique that is being used to treat symptoms of Parkinson's disease (PD). The main pharmacotherapy for PD is levodopa. Although levodopa is generally initially effective at reducing symptoms of PD, it eventually leads to side effects such as dyskinesias in many patients. Surgeries such as thalamotomy, pallidotomy are other possible treatments. An advantage of DBS is that, unlike other surgeries, it does not create lesions or destroy brain tissue.

Deep brain stimulation involves implanting an electrode into a specific region of the brain using stereotactic neurosurgical techniques. The electrode is connected to a programmable pulse generator that generates high frequency stimulation (>100 Hz) in a target nucleus. The pulse generator is implanted below the clavicle.

Thalamic stimulation, used to treat tremor, is the most well-established application of DBS with Parkinson's patients (thalamic stimulation for tremor met MTAC evaluation criteria in April 1999). Other targets are the internal globus pallidus and subthalamic nucleus which are believed to be effective for treating a wider range of PD symptoms, including bradykinesia, rigidity dystonia and gait disorder, as well as tremor.

Medtronic, Inc. manufactures the device that provides deep brain stimulation (the Activa System). The FDA approved a version of this device in 1997 for stimulation of the thalamus to control Parkinson's tremor and essential tremor. In March 2000, an FDA panel gave a premarket approval with conditions for bilateral DBS for the treatment of other Parkinson's symptoms.

#### **10/10/2001: MTAC REVIEW**

##### **Globus Pallidus and Subthalamic Nucleus Stimulator Implant**

**Evidence Conclusion:** The highest quality evidence consisted of one study that had a double-blind randomized component. In the double-blind randomized assessment, the study found a statistically significant reduction in motor symptom scores during deep-brain stimulation of the subthalamic nucleus or pars interna of the globus pallidus compared to no stimulation. The case series portion of the study found that symptoms improved significantly with stimulation 3- and 6-months post-implantation compared to pre-implantation. There were a substantial number of adverse effects but no comparison with adverse effects with other treatments or no treatment. A limitation of the study was that Medtronic, the device manufacturer, not only funded the study but also was responsible for data collection and analysis.

**Articles:** The search yielded 146 articles, many of which were review articles, opinion pieces, dealt with technical aspects of the procedures or addressed other, similar treatments. There were a number of small studies (n=25 or less), mainly case series; one was an RCT with n=10. The strongest study was published after the formal search was conducted. This study included a randomized double-blind assessment of outcomes and the sample size was over 100. This partially randomized study was critically appraised: Deep-brain stimulation for Parkinson's disease study group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N Engl J Med* 2001;345: 956-63. See [Evidence Table](#).

The use of Globus Pallidus and Subthalamic Nucleus Stimulator Implant in treatment of Parkinson's Symptoms does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Refractory Obsessive-Compulsive Disorder**

### **BACKGROUND**

Obsessive-compulsive disorder is a common psychiatric diagnosis, affecting approximately 3% of people worldwide (Burdick et al., 2009). For initial treatment of OCD, the American Psychiatric Association (APA) recommends cognitive behavioral therapy (CBT), pharmacotherapy with SSRIs, or a combination of the two. For patients who do not respond to monotherapy, the next step is either switching medications, augmenting with another medication, or adding CBT if not already initiated (Harvard Medical Letter, 2009).

Approximately 20-40% of patients have worsening symptoms despite conventional treatment. Surgery is an option for patients who experience severe and incapacitating symptoms in spite of multiple medication trials and/or medication and CBT. Primary surgical approaches are subcaudate tractotomy (creating a lesion beneath the head of the caudate nucleus in the substantial innominata), cingulotomy (radiofrequency ablation of the anterior cingulum), limbic leucotomy (combination of previous two procedures), and anterior capsulotomy (interrupting fibers between the thalamus and the anterior frontal lobe) (Burdwick et al., 2009).

Another potential alternative therapy for treatment-resistant patients is deep brain stimulation (DBS). DBS involves chronic electrical stimulation of a particular target in the brain and is designed to modulate transmission of the neural circuit. The exact mechanism of action of DBS is not known and this is an area of active research. DBS has been used since the early 1990s to treat movement disorders such as Parkinson's disease, and, in 1999, the first report was published applying DBS to the treatment of refractory OCD. The optimal target for DBS in OCD patients is still being determined (Burdwick et al., 2009).

In February 2009, the FDA approved a humanitarian device exemption for a deep brain stimulator for severe OCD by Medtronic (Reclaim device). The humanitarian device exemption is an FDA classification signifying that the technology is used to treat conditions that affect fewer than 4,000 new patients per year. The FDA reviews the safety of the device but does not require that efficacy is established before approval. The FDA decision stipulates that deep brain stimulation is indicated for treatment of OCT in adult patients who have failed at least three SSRIs, and it can be used as an adjunct to medication. DBS is contraindicated in patients exposed to diathermy or MRIs, or who are unable to properly operate the brain stimulator. Medtronic plans to release the product commercially in the United States in mid-2009 (Medtronic website; FDA documents).

The Reclaim device by Medtronic includes a neurostimulator that is implanted subcutaneously in the upper abdominal region. The neurostimulator produces electrical stimulation pulses that are carried to an implanted set of leads via a lead extension. The leads are stereotactically introduced into the target area of the brain and are fixed at the skull with a burr hole cap and ring. The neurostimulator is battery-powered. There are sparse clinical data on battery life. According to Medtronic, the battery is expected to last 6-16 months, or longer depending on the neurostimulator setting used. When the battery is depleted, it can be replaced surgically. The primary clinical data submitted by Medtronic for FDA approval was a case series of 26 patients treated at 3 centers in the US and one in Europe (FDA and Medtronic documents).

### **06/01/2009: MTAC REVIEW**

#### **Deep brain stimulation for the treatment of refractory obsessive-compulsive disorder**

**Evidence Conclusion:** There is insufficient evidence to draw conclusions about the safety and effectiveness of deep brain stimulation for patients with refractory obsessive-compulsive disorder. The empirical literature consists of case series with 10 or fewer patients.

**Articles:** The Medline search limited to a range of clinical trials yielded 10 articles. No additional articles were identified on the manufacturer's Web site. There were no randomized controlled trials or non-randomized comparative studies. The empirical literature consisted of small case series, with sample sizes ranging from 4 to 10. The studies do not meet MTAC criteria for reviewable evidence which requires that studies are published and, for case series, has a minimum sample size of 25.

The use of Deep brain stimulation for the treatment of refractory obsessive-compulsive disorder does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Primary Headache**

### **BACKGROUND**

Headache is a major worldwide health problem disabling millions of people and resulting in considerable economic burden. Up to 40% of patients seen in major headache clinics suffer from chronic daily headache.

Chronic headache disorders include migraine, cluster headache, cervicogenic headache, occipital neuralgia, and other types of primary headache (Maizels 1998, Jasper 2008).

Cluster headache (CH), an excruciating headache syndrome, is the most common type of trigeminal autonomic cephalalgias, and is thought to be the most severe primary headache disorder. 10-20% of CH patients develop a chronic form in which the attacks persist for more than one year without remissions, or with remissions lasting less than a month. Acute treatment for the attacks includes injectable or intranasal triptans or oxygen inhalation. About one percent will become refractory to medical treatment and fulfill the criteria of intractable headaches. These patients may get some relief with attack treatments, but the disorder could be disabling and may be associated with depression and suicidality (Magis 2007, Leroux 2008).

Migraine headache is a chronic headache that affects about 15% of the population and is one of the most common problems seen in emergency departments and doctors' offices. Migraine is believed to result from changes in the brain and surrounding blood vessels. The attacks typically last from 4-72 hours and vary in frequency from daily to less than one per year. Transformed migraines are chronic daily or almost daily headaches (>15/month) that lasts more than 4 hours. There is no cure for migraine, and medications can only help reduce the frequency and severity of disorder (Bigal 2008).

Cervicogenic headache is a chronic hemicranial pain that usually occurs daily. It usually begins at the suboccipital region and spreads anteriorly to the ipsilateral orbital, frontal, and temporal areas. It is typically unilateral but occasionally affects the two sides. It is believed to be due to convergence of upper cervical and trigeminal sensory pathways allowing pain signals to refer from the neck to the trigeminal sensory fields of the head and face. Treatments with pain medication, physical therapy, manipulative treatment, and surgical interventions may provide only some inconsistent temporary relief of pain (Naja 2006).

Various ablative surgical procedures targeting the trigeminal nerve, or the cranial parasympathetic outflow have been tried to treat these patients with intractable headaches. These include gamma knife surgery or root section of the trigeminal nerve, trigeminal tractotomy, microvascular decompression of the trigeminal nerve, glycerol injection of the Gasserian ganglion, and others. However, none of these procedures has a consistent effect, and many are associated with serious complications (Magis 2007).

Electrical stimulation of the brain was first attempted late in the 19th century, but its application for pain control began in the 1960s with spinal cord stimulation. The neurostimulation technique for ablating pain is based on the theory that peripheral nerve stimulation can produce specific focal analgesia and anesthesia. In addition, the technique may alter perception of pain by blocking cell membrane depolarization and axonal conduction with directly applied current (Shealy 1967, Lim 2007, Trentman 2008).

In the early 2000s, neurostimulation therapy emerged as a potential treatment option for a variety of different intractable primary headache disorders. This is an invasive device-based approach that has two broad types:

1. Peripheral therapy that involves branches of the occipital nerve: occipital nerve stimulation (ONS), and supraorbital nerve stimulation.
2. Central which refers to deep-brain stimulation (DBS) approaches e.g. hypothalamic deep brain stimulation used for chronic cluster headache (Schwedt 2009).

The occipital nerve stimulators (ONS) are implanted surgically in a 3-phase procedure: Phase 1. An incision is made over the occipital region at the level of the first cervical vertebra for the subcutaneous implantation of bilateral electrodes. These are tunneled in a cephalad direction so that they come to lie across the path of the greater occipital nerve on each side of the head. Phase 2. Confirmation of the electrode position by testing each separately by an external stimulator. The operator gradually increases the amplitude delivered to the electrodes from 0 to 4 v, and the patient is asked to locate and describe any sensation he /she feels. Correct placement is confirmed by the patient describing a vibrating sensation that radiates at least 4 cm cephalad from the base of the skull, on the side of the tested electrode, and Phase 3. Implantation of the stimulator battery in the pectoral, abdominal, or gluteal region, and connecting it to the electrodes via subcutaneously tunneled leads. The procedure is performed under sedation or general anesthesia, however during the second phase the patients are required to be awake and to be able to identify the position of the occipital electrodes when the electric stimulus is applied. Potential complications of the procedure include lead migration, infection, localized pain, muscle spasm, and lack or loss of effect (Lim 2007, Trentman 2008).

The deep brain stimulation (DBS) of the posterior hypothalamus has been investigated in patients with chronic cluster headaches or SUNCT (short-lasting, unilateral, neuralgiform headache attacks with conjunctival injection and tearing). DBS involves MRI guided stereotactic placement of an electrode into the brain (e.g. thalamus, globus pallidus, or subthalamic nucleus). It is typically implanted unilaterally on the side corresponding to the most



severe symptoms. The use of bilateral stimulation using two electrodes has been investigated in patients with bilateral, severe symptoms. Initially, the electrode(s) is/are attached to a temporary transcutaneous cable to validate treatment effectiveness and, if effective, the patient returns to surgery several days later for permanent subcutaneous implantation of the cable and a radiofrequency-coupled or battery-powered programmable stimulator. After implantation, noninvasive programming of the neurostimulator can be adjusted to control the patient's symptoms. The procedures can be performed only by a highly experienced neurosurgeon and may be associated with a small risk of mortality due to intra-cerebral hemorrhage. Before implantation, all patients must undergo complete preoperative neuroimaging to exclude disorders associated with increased hemorrhagic risk (Leon 2006, Bartsch 2008).

Neither the occipital nerve stimulation nor the deep brain stimulators are approved to date by the U.S. Food and Drug Administration for the treatment or prevention of primary headaches.

## 08/03/2009: MTAC REVIEW

### Deep Brain Stimulation for the Treatment of Primary Headache

**Evidence Conclusion:** The literature on brain stimulation for the treatment of chronic primary headache is limited and does not provide sufficient evidence to determine the efficacy or safety of either occipital or deep brain stimulation therapy for the prevention or treatment of chronic headache. There are no published randomized or nonrandomized controlled trials on the intervention to date. The empirical studies consist of a few very small case series with no comparison groups and a number of case reports. The outcome measures varied between studies as some reported change in pain and others reported on headache frequency intensity, disability and/or medication use. To date all published studies on hypothalamic deep brain stimulation are small case series and case reports with a combined total of 55 participants with refractory chronic cluster headache. Leone et al's series had the largest size (N=16) and follow-up duration (mean 23 months). The results of this study and other case series indicate that this invasive procedure has potential serious complications and is not always effective. Deep brain stimulation was not compared to another treatment or intervention to determine that the benefit observed was no a placebo effect.

**Articles:** The search yielded almost four hundred articles. The majority was review articles, opinion pieces, or dealt with technical aspects the procedure. DBS: The search identified 12 small case series and reports with a total number of 57 patients on deep-brain stimulation for chronic cluster headache. Leone M, Franzini A, Broggi G, et al. Hypothalamic stimulation for intractable cluster headache; long-term experience. *Neurology* 2006;67:150-152. See [Evidence Table](#).

The use of Deep brain stimulation for the treatment of primary headache does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>61863</b>	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; first array
<b>61864</b>	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)
<b>61867</b>	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array
<b>61868</b>	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)
<b>61880</b>	Revision or removal of intracranial neurostimulator electrodes
<b>61885</b>	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array

<b>61886</b>	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays
<b>61888</b>	Revision or removal of cranial neurostimulator pulse generator or receiver
<b>95970</b>	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain, cranial nerve, spinal cord, peripheral nerve, or sacral nerve, neurostimulator pulse generator/transmitter, without programming
<b>95983</b>	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional
<b>95984</b>	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)
<b>HCCP Codes</b>	<b>Description</b>
<b>C1820</b>	Generator, neurostimulator (implantable), with rechargeable battery and charging system
<b>L8679</b>	Implantable neurostimulator, pulse generator, any type
<b>L8681</b>	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
<b>L8686</b>	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
<b>L8687</b>	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
<b>L8688</b>	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
<b>L8689</b>	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only
<b>C1778</b>	Lead, neurostimulator (implantable)
<b>C1787</b>	Patient programmer, neurostimulator
<b>C1816</b>	Receiver and/or transmitter, neurostimulator (implantable)
<b>C1897</b>	Lead, neurostimulator test kit (implantable)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/03/2010	08/03/2010 <sup>MDCRPC</sup> , 06/07/2011 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 05/07/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 04/01/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 09/03/2024 <sup>MPC</sup>	12/19/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/02/2019	MPC approved to adopt indications for Mini-Mental State Examination with score of at least 24 and no evidence of severe depression
12/19/2024	Updated applicable codes



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Dermatology Services

Cosmetic vs Medical for the following:

- Alopecia, Keloids, Laser Treatments, Benign Lesions
- Broad Band UVB Therapy
- Excimer Laser for Vitiligo
- Home Narrow Band UVB Therapy for Psoriasis
- Narrow Band UVB Therapy
- PUVA Therapy
- UV Lights

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Laser Procedures (140.5)</a> <a href="#">Treatment of Psoriasis (250.1)</a> <a href="#">Treatment of Actinic Keratosis (AKs) (250.4)</a> <a href="#">Durable Medical Equipment Reference List (280.1)</a> --(for home phototherapy requests outside of <b>psoriasis diagnosis</b> please defer to <a href="#">Kaiser Permanente Medical Policy</a> below)
Local Coverage Determinations (LCD)	<a href="#">Benign Skin Lesion Removal (Excludes Actinic Keratosis, and Mohs) (L33979)</a> <a href="#">Plastic Surgery (L37020)</a> <a href="#">Mohs Micrographic Surgery (L35704)</a>
Local Coverage Article	<a href="#">Local Coverage Article: Additional Information Required for coverage and pricing for Category III CPT® Codes A55681-RETIRED</a> 06/30/2020 Noridian retired <b>Local Coverage Article (LCA A55681)</b> . These services still need to meet medical necessity as outlined in the LCA and will require review. LCAs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCAs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on Kaiser Permanente commercial criteria or literature search. <b>includes CPT 0479T, 0480T</b>

Kaiser Permanente Medical Policy	<p>For home UVB phototherapy requests other than Psoriasis (see above) such as Eczema, as well as other dermatological conditions:</p> <p>Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>for in office or home UVB Phototherapy use Phototherapy, Skin (KP-0255 v2) MCG</b> for medical necessity determinations.</p>
----------------------------------	---

### For Non-Medicare Members

- 1) The following treatments are considered cosmetic and are therefore not covered:
  - a. Botulinum injections for treatment of wrinkles and facial imperfections (for covered indications for botulinum injections see the pharmacy prior authorization criteria)
  - b. Tattoo removal (CPT 15783)
  - c. Laser treatment of pigmented lesions, rosacea, superficial leg and face veins, cherry angiomas, telangiectasias, spider angiomas, or spider veins/venous ectasias
  - d. Chemical peel (CPT 15788, 15789, 15792, 15793, 17360)
  - e. Micro-dermabrasion (No codes specific for this service)
  - f. Dermabrasion (CPT 15780, 15781, 15782, 15783, 15786)
  - g. Acne scar repair (CPT 15780)
  - h. Tattooing, depigmentation, and melanocyte transplant for vitiligo
- 2) The following treatments are covered and are not considered cosmetic when conditions are met:
  - a. **Alopecia treatment** (applicable codes [HERE](#)) when the alopecia results from **ONE of the following**:
    - Infection (treatment is for the infection)
    - Autoimmune disorder
    - Discoid lupus
    - Low iron stores
    - Folliculitis decalvans

Laser treatment services described in 2b no longer require medical necessity review (CPT: 17000, 17003, 17004, 17106, 17107, 17108, 17110, 17111, and 17250)

- b. **Laser treatment for ONE of the following:**
  - Port wine stain on head or neck
  - Telangiectasias scarring when caused by removal of skin cancer or radiation therapy
  - Facial angiofibroma secondary to tuberous sclerosis
  - Vascular lesions with history of spontaneous bleeding as documented in the patient's medical record
  - Actinic Keratoses (AK) for chemo sensitive agents

c.

<p><b>Effective Until August 1<sup>st</sup>, 2025</b></p> <p><b>Excimer Laser</b> (CPT code 96920, 96921, 96922) is covered when ALL of the following are met:</p> <ol style="list-style-type: none"> <li>1. Member must have ONE of the following conditions: <ol style="list-style-type: none"> <li>a. Vitiligo: vitiligo on the face, neck or hands.</li> <li>b. Psoriasis: scalp, face, neck or hands</li> </ol> </li> <li>2. There must be documentation of the failure of medical management with topical therapy</li> </ol>
<p><b>Effective August 1<sup>st</sup>, 2025</b></p> <p><b>Excimer Laser</b> (CPT code 96920, 96921, 96922) is covered when <b>ONE of the following</b> are met:</p> <ol style="list-style-type: none"> <li>1. Psoriasis involving the scalp, face, neck or hands and documented treatment and failure of at least <b>TWO</b> of the following topical treatments over a consecutive 12-week period, one of which should be a high potency corticosteroid unless contraindicated, or contraindication/intolerance to ALL remaining treatment options: <ul style="list-style-type: none"> <li>• High-potency corticosteroid (e.g., clobetasol propionate, betamethasone dipropionate or fluocinonide);</li> <li>• Topical calcineurin inhibitor (i.e., tacrolimus or pimecrolimus 0.1%)</li> <li>• Vitamin D derivatives (calcipotriene)</li> </ul> </li> </ol>

- Retinoids (e.g., tazarotene)
  - Tar preparations
  - Anthralin
  - Keratolytic agents (e.g., lactic acid, salicylic acid, and urea)
2. Vitiligo involving the face, neck or hands and failure of BOTH of the following, unless contraindicated or not tolerated, over at least 12-week consecutive trial:
- a. Topical corticosteroid
  - b. Topical calcineurin inhibitor (i.e., tacrolimus or pimecrolimus 0.1%)

- d. **Scar/keloid revision:** Kaiser Permanente has elected to use the Scar Revisions (KP-0495) MCG\* for medical necessity determinations. (applicable codes [HERE](#))
- e. **Fractional Laser for burns and traumatic scars:** *Currently not covered due to lack of efficacy per the published medical literature (0479T, 0480T).*
- f. Removal of **benign skin lesions** (seborrheic keratoses, skin tags, milia, molluscum contagiosum, sebaceous (epidermoid) cysts, moles (nevi), acquired hyperkeratosis (keratoderma) and viral warts) are medically necessary and not cosmetic and are covered when **ONE or more of the following** criteria are met (applicable codes [HERE](#)):
1. The clinical diagnosis is uncertain, particularly where malignancy is a realistic consideration based on lesion appearance (non-responsive to conventional treatment or change in appearance).
  2. The lesion has **ONE or more of the following** characteristics:
    - Bleeding
    - Intense itching
    - Pain
    - Has physical evidence of inflammation (purulence, oozing, edema, erythema, etc.)
    - Clinically restricts an orifice or vision
    - Is in an anatomical region subject to recurrent physical trauma and there is documentation of resulting pain, itching, or bleeding
- g. **Laser/intense pulse light treatment** is covered for hair removal when the excess hair is a result of a documented endocrine abnormality confirmed by blood test. (commonly submitted with CPT 17999)
- h. **PUVA:** Kaiser Permanente has elected to use the Skin Phototherapy (PUVA) (KP-0253) MCG\* for medical necessity determinations. (CPT code 96912, 96913)
- i. **UVA:** Kaiser Permanente has elected to use the Phototherapy, Skin (KP-0255 v2) MCG\* for medical necessity determinations. (CPT code 96900, 96910)
- j. **Home narrowband UVB phototherapy** (E0691, E0692, E0693, E0694, A4633) is covered for qualifying conditions per Phototherapy, Skin (KP-0255 v2) MCG\* when:
- The member has durable medical equipment coverage
  - The light is ordered by a dermatology provider
  - Home phototherapy requires initial support/teaching for frequency, dose of treatment to avoid over or undertreatment as well as follow up on a regular basis to ensure correct treatment, as arranged by the ordering provider

**Related criteria:**

[Electronic Brachytherapy for non-melanoma skin cancer](#)  
[Dermal Fillers for Facial Lipoatrophy](#)

\* **MCG Manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the



provider portal under Quick Access.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (dermatology, surgery notes)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

## Background

Dermatology services include a wide array of therapies. Some therapies are purely cosmetic, others are considered from a benefits standpoint to be "medically necessary" and relate to function and/or have an impact on an individual's physical, social and/or mental well-being.

The purpose of expanding the criteria set is to distinguish between dermatology services that are considered purely cosmetic versus those which are seen as medically necessary and are covered in part or whole. The creation of the criteria set incorporated what was previously found in coverage policy and other reference documents.

## Medical Technology Assessment Committee (MTAC)

### **Home Narrowband UVB Phototherapy**

#### **BACKGROUND**

Psoriasis is a chronic skin disease that affects 1-3% of the population. With psoriasis, the life cycle of skin cells is shortened from about a month to a few days. Consequently, cells build up rapidly on the outer layer of skin, forming thick erythematous plaques that are often pruritic. (Mayoclinic.com; BMJ clinical evidence). Treatments for psoriasis include: 1) self-care: baths, avoidance of alcohol, moisturizer; 2) topical medications: corticosteroids, vitamin D analogues, anthralin, retinoids; 3) oral medications: retinoids, methotrexate, azathioprine, cyclosporin, immunomodulator drugs (biologics); 4) phototherapy; 5) combination therapy e.g. phototherapy and oral medications. Phototherapy is one of the more commonly used treatments for psoriasis. The rationale behind phototherapy is that it causes photochemical reactions of endogenous absorbing molecules results in reduction of DNA synthesis that leads to a treatment effect. The therapy was first proposed in the 1920s by Dr. Goeckerman at the Mayo clinic who found a beneficial effect of natural sunlight in combination with coal tar. In the 1970s, it was shown that broadband ultraviolet B (UVB) radiation alone could treat milder clinical forms of psoriasis. After experimentation with different wavelengths, it was found that wavelengths between 311-313 nm were best at balancing the clearing of psoriasis while at the same time minimizing the adverse effect of erythema. The first well-designed lamp that emitted narrow-band radiation at 311-313 nm, the Phillips TL-01 fluorescent lamp, was introduced in 1984 (Kist, 2005; Honigsmann, 2001). The main treatment-limiting side effect of narrowband UVB is erythema, reported by 10-94% of patients depending on treatment regimen and definition of erythema. Other short-term side effects include dry skin with pruritis, blistering, and increased frequency of recurrent herpes simplex outbreaks. Long-term side effects, as with other types of phototherapy, include photo ageing and skin cancer. However, the incidence of skin cancer in patients with psoriasis treated with narrowband UVB is not well known (Kist et al., 2005; Naldi et al., 2005). The recommended initial treatment dose of narrowband UVB is 50-80% of a patient's minimal erythema dose (MED), established through phototesting. This is followed by increases of 10-40%, depending on the aggressiveness of the treatment and the patient's response (Kist, 2005; Honigsmann, 2001). The American Academy of Dermatology guidelines recommend giving up to 20-25 treatments of narrowband UVB, 2-3 times a week (Menter et al., 2008).

#### **10/06/2008: MTAC REVIEW**

#### **Home Narrowband UVB Phototherapy**

**Evidence Conclusion:** There is insufficient evidence to draw conclusions about the safety and effectiveness of home narrowband UV-B phototherapy for patients with psoriasis. There are no published randomized or non-randomized trials that use modern home phototherapy equipment. Findings from an RCT are expected to be published within the next 3-6 months.

**Articles:** A 2006 review article (Koek et al., 2006) on home ultraviolet B phototherapy for psoriasis identified 7 empirical clinical studies, 5 of which were published in English. 3 of the 5 studies in English were published between 1979-1983, before the introduction of the Phillips TL-01 fluorescent lamp. Thus, they did not use currently available phototherapy technology. Both of the more recent studies (Cameron et al., 2002; Feldman et al., 1996) were case series with fewer than 25 patients. One of the 3 older studies (Paul et al., 1983) had a

comparison group, the others were case series. The Paul et al. study, which included 40 patients, compared the efficacy of a Metec-Helarium unit emitting low-intensity selective UV phototherapy (LISUP) at home to 3 times/week in-office UVB therapy. In-office UVB therapy was found to be more effective than home LISUP treatment; 90% (18/20) of patients in the UV-B group experienced clearing of psoriasis compared to 40% (8/20) of patients in the home LISUP group. No additional completed studies were identified that compared home UVB phototherapy to in-office UVB phototherapy or to a different type of treatment. A published protocol for an RCT was identified (Koek et al., 2006). This trial, called the PLUTO study, is a multi-center trial comparing home UVB treatment to in-center UV-B phototherapy in 196 patients with psoriasis. The home phototherapy treatments is Waldmann UV-100 units with TL-01 lamps. According to the lead author (personal communication), a manuscript on the study outcomes is currently under review by the BMJ.

The use of Home narrowband UVB phototherapy in the treatment of psoriasis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 10/05/2009: MTAC REVIEW

### Home Narrowband UVB Phototherapy

**Evidence Conclusion:** PLUTO study (Koek 2009) on home versus outpatient ultraviolet B phototherapy for psoriasis randomized 196 patients (in the Netherlands) with mild to severe psoriasis and clinically eligible for narrowband ultraviolet B phototherapy, to receive the treatment at home or in an outpatient setting. The trial had valid methodology and design as a noninferiority study. The patients and providers were not blinded, however assessment of the severity of and extent of the disease were evaluated by an independent research nurse blinded to the treatment arms. The results of the trial indicate that home phototherapy was not inferior to that provided in outpatient department, mainly for the self-administered psoriasis area and severity index (SAPASI) 50, 75, and 90 (i.e. proportion of patients achieving at least 50%, 75%, or 90% decline of baseline SAPASI at the end of therapy) as well as the psoriasis area and severity index (PASI) 90. However, the possible inferiority of home ultraviolet phototherapy to that provided in an outpatient setting, could not be entirely excluded for the primary outcome of PASI 50, or PASI 75, as the lower limits of the 95% confidence intervals were slightly lower than -15% preset noninferiority margin. The differences observed in SAPASI and PASI results may indicate a bias in the patient's self-assessment. The results of the trial also showed that patients in the home therapy group had a significantly higher mean number of irradiations, but an insignificantly higher cumulative dose at the end of therapy. 87% of the all participants had at least one occurrence of mild erythema, 58% a burning sensation, and 39% severe erythema with no significant differences between the two study groups. No significant differences were observed in the disease specific or generic quality of life among patients treated on outpatient setting or at home. The home therapy however, was associated with a lower burden of treatment and greater patient satisfaction.

**Articles:** A study on home versus outpatient ultraviolet B phototherapy for psoriasis was recently published in BMJ in 2009. Koek MB, Buskens E, vanWeelden H, et al. Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicenter randomized controlled non-inferiority trial (PLUTO study). *BMJ* 2009; 338: b1542 doi10.1136/bmj. b1542

The use of Home narrowband UVB phototherapy in the treatment of psoriasis does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Hayes Technology Assessment

Fractional carbon dioxide (CO<sub>2</sub>) and erbium-doped yttrium aluminum garnet (Er:YAG) lasers are commonly used for treatment of excessive scarring. Laser therapy may be used to improve erythema, texture, pliability, and pain associated with burn and traumatic scars. Fractional laser ablation refers to the process in which a laser beam is split into hundreds of microbeams, which create small thermal injuries to the skin. It is believed that the injury caused by laser induces collagen formation and tissue remodeling. As opposed to ablative lasers, nonablative lasers induce coagulation only and do not cause epidermal injury and tissue vaporization.

## Conclusion

An overall very-low-quality body of evidence is insufficient to draw regarding the efficacy and safety of CO<sub>2</sub> fractional laser ablation or Er:YAG fractional treatment of burn or traumatic scars for functional improvement. Although most of the reviewed studies reported improved scar pliability following fractional laser treatment, this represents a surrogate outcome that does not directly address the primary Key Question. There is a large body of evidence on fractional laser ablation of hypertrophic scars and keloids; however, it primarily addresses cosmetic outcomes. The literature evaluating the impact of fractional laser treatment on functional outcomes is wholly

comprised of case reports, which only supply anecdotal information. Large, well-designed trials of fractional laser treatment that directly address improvement of functional outcomes associated with scarring as a result of burns or trauma are needed.

**Hayes Rating:** D<sup>2</sup> --Insufficient Evidence: For carbon dioxide (CO<sup>2</sup>) fractional laser ablation for functional improvement related to burn or traumatic scars. D<sup>2</sup> --Insufficient Evidence: For Erbium-doped yttrium platinum garnet (Er:YAG) fractional laser treatment for functional improvement related to burn or traumatic scars.

Hayes. Hayes Technology Assessment. *Fractional Laser Treatment of Burn and Traumatic Scars for Functional Improvement*. Dallas, TX: Hayes; May 11, 2021. Retrieved February 03, 2023, from <https://evidence.hayesinc.com/report/htb.fractionallaser4442>

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met (unless otherwise noted):**

### Alopecia Treatment

CPT® or HCPC Codes	Description
15775	Punch graft for hair transplant; 1 to 15 punch grafts
15776	Punch graft for hair transplant; more than 15 punch grafts
96902	Microscopic examination of hairs plucked or clipped by the examiner (excluding hair collected by the patient) to determine telogen and anagen counts, or structural hair shaft abnormality
<b>With Diagnosis Codes</b>	
L63.0	Alopecia (capitis) totalis
L63.1	Alopecia universalis
L63.2	Ophiasis
L63.8	Other alopecia areata
L63.9	Alopecia areata, unspecified
L64.0	Drug-induced androgenic alopecia
L64.8	Drug-induced androgenic alopecia
L64.9	Androgenic alopecia, unspecified
L66.2	Folliculitis decalvans
L66.8	Other cicatricial alopecia
L66.9	Cicatricial alopecia, unspecified

### Benign Skin Lesions

CPT® or HCPC Codes	Description
11200	Removal of skin tags, multiple fibrocutaneous tags, any area; up to and including 15 lesions
11201	Removal of skin tags, multiple fibrocutaneous tags, any area; each additional 10 lesions, or part thereof (List separately in addition to code for primary procedure)
11400	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less
11401	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.6 to 1.0 cm
11402	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 1.1 to 2.0 cm
11403	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm
11404	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 3.1 to 4.0 cm
11406	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter over 4.0 cm
11420	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less

<b>11421</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm
<b>11422</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm
<b>11423</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm
<b>11424</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm
<b>11426</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm
<b>11440</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.5 cm or less
<b>11441</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.6 to 1.0 cm
<b>11442</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 1.1 to 2.0 cm
<b>11443</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 2.1 to 3.0 cm
<b>11444</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 3.1 to 4.0 cm
<b>14446</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter over 4.0 cm
<b>11450</b>	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair
<b>11451</b>	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair
<b>11462</b>	Excision of skin and subcutaneous tissue for hidradenitis, inguinal; with simple or intermediate repair
<b>11463</b>	Excision of skin and subcutaneous tissue for hidradenitis, inguinal; with complex repair
<b>11470</b>	Excision of skin and subcutaneous tissue for hidradenitis, perianal, perineal, or umbilical; with simple or intermediate repair
<b>11471</b>	Excision of skin and subcutaneous tissue for hidradenitis, perianal, perineal, or umbilical; with complex repair
<b>17110</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
<b>17111</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions
<b>With Diagnosis Code</b>	
<b>L82.0</b>	Inflamed seborrheic keratosis
<b>L82.1</b>	Other seborrheic keratosis

#### Excimer Laser (Vitiligo & Psoriasis)

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>96920</b>	Laser treatment for inflammatory skin disease (psoriasis); total area less than 250 sq cm
<b>96921</b>	Laser treatment for inflammatory skin disease (psoriasis); 250 sq cm to 500 sq cm
<b>96922</b>	Laser treatment for inflammatory skin disease (psoriasis); over 500 sq cm

#### Home Narrowband UVB Phototherapy

\*Note: Code E0691 can be ordered more than once (e.g., scalp and hand/foot device) or billed with codes E0692-E0694.

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>E0691</b>	Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection; treatment area 2 sq ft or less
<b>E0692</b>	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 4 ft panel
<b>E0693</b>	Ultraviolet light therapy system panel, includes bulbs/lamps, timer and eye protection, 6 ft panel

<b>E0694</b>	Ultraviolet multidirectional light therapy system in 6 ft cabinet, includes bulbs/lamps, timer, and eye protection
<b>A4633</b>	Replacement bulb/lamp for ultraviolet light therapy system, each

**Fractional Laser for burns and traumatic scars**
**Medicare – Considered not medically necessary**
**Non-Medicare – Considered not medically necessary**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>0479T</b>	Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children
<b>0480T</b>	Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; each additional 100 cm2, or each additional 1% of body surface area of infants and children, or part thereof (List separately in addition to code for primary procedure)

**Laser/Intense Pulse Light Treatment for hair removal**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
No specific codes – <i>commonly submitted with CPT code 17999 Unlisted procedure, skin, mucous membrane and subcutaneous tissue</i>	

**PUVA**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>96912</b>	Photochemotherapy; psoralens and ultraviolet A (PUVA)
<b>96913</b>	Photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4-8 hours of care under direct supervision of the physician (includes application of medication and dressings)

**Scar/Keloid Revision**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15002</b>	Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; first 100 sq cm or 1% of body area of infants and children
<b>15003</b>	Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, trunk, arms, legs; each additional 100 sq cm, or part thereof, or each additional 1% of body area of infants and children (List separately in addition to code for primary procedure)
<b>15004</b>	Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet and/or multiple digits; first 100 sq cm or 1% of body area of infants and children
<b>15005</b>	Surgical preparation or creation of recipient site by excision of open wounds, burn eschar, or scar (including subcutaneous tissues), or incisional release of scar contracture, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet and/or multiple digits; each additional 100 sq cm, or part thereof, or each additional 1% of body area of infants and children (List separately in addition to code for primary procedure)
<b>23921</b>	Disarticulation of shoulder; secondary closure or scar revision
<b>24149</b>	Radical resection of capsule, soft tissue, and heterotopic bone, elbow, with contracture release (separate procedure)
<b>24925</b>	Amputation, arm through humerus; secondary closure or scar revision
<b>25907</b>	Amputation, forearm, through radius and ulna; secondary closure or scar revision
<b>25922</b>	Disarticulation through wrist; secondary closure or scar revision
<b>25929</b>	Transmetacarpal amputation; secondary closure or scar revision



<b>26121</b>	Fasciectomy, palm only, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft)
<b>26123</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft);
<b>26125</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft); each additional digit (List separately in addition to code for primary procedure)
<b>27594</b>	Amputation, thigh, through femur, any level; secondary closure or scar revision
<b>27884</b>	Amputation, leg, through tibia and fibula; secondary closure or scar revision
<b>31830</b>	Revision of tracheostomy scar
<b>67343</b>	Release of extensive scar tissue without detaching extraocular muscle (separate procedure)
<b>With Diagnosis Codes</b>	
<b>L73.0</b>	Acne keloid
<b>L91.0</b>	Hypertrophic scar
<b>L90.5</b>	Scar conditions and fibrosis of skin

**UVA**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>96900</b>	Actinotherapy (ultraviolet light)
<b>96910</b>	Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B

**Considered not medically necessary:**
**Botulinum Injections**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>64611</b>	Chemodenervation of parotid and submandibular salivary glands, bilateral
<b>64612</b>	Chemodenervation of parotid and submandibular salivary glands, bilateral
<b>64615</b>	Chemodenervation of muscle(s); muscle(s) innervated by facial, trigeminal, cervical spinal and accessory nerves, bilateral (eg, for chronic migraine)
<b>64616</b>	Chemodenervation of muscle(s); neck muscle(s), excluding muscles of the larynx, unilateral (eg, for cervical dystonia, spasmodic torticollis)
<b>64617</b>	Chemodenervation of muscle(s); larynx, unilateral, percutaneous (eg, for spasmodic dysphonia), includes guidance by needle electromyography, when performed
<b>64642</b>	Chemodenervation of one extremity; 1-4 muscle(s)
<b>64643</b>	Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (List separately in addition to code for primary procedure)
<b>64644</b>	Chemodenervation of one extremity; 5 or more muscles
<b>64645</b>	Chemodenervation of one extremity; each additional extremity, 5 or more muscles (List separately in addition to code for primary procedure)
<b>64646</b>	Chemodenervation of trunk muscle(s); 1-5 muscle(s)
<b>64647</b>	Chemodenervation of trunk muscle(s); 6 or more muscles

**Tattoo Removal**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15783</b>	Dermabrasion; superficial, any site (eg, tattoo removal)

**Chemical Peel**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15788</b>	Chemical peel, facial; epidermal
<b>15789</b>	Chemical peel, facial; dermal



<b>15792</b>	Chemical peel, nonfacial; epidermal
<b>15793</b>	Chemical peel, nonfacial; dermal
<b>17360</b>	Chemical exfoliation for acne (eg, acne paste, acid)

**Micro-dermabrasion**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>No Specific Codes</b>	

**Dermabrasion**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15780</b>	Dermabrasion; total face (eg, for acne scarring, fine wrinkling, rhytids, general keratosis)
<b>15781</b>	Dermabrasion; segmental, face
<b>15782</b>	Dermabrasion; regional, other than face
<b>15783</b>	Dermabrasion; superficial, any site (eg, tattoo removal)
<b>15786</b>	Abrasion; single lesion (eg, keratosis, scar)
<b>15787</b>	Abrasion; each additional 4 lesions or less (List separately in addition to code for primary procedure)

**Tattooing, Depigmentation, and Melanocyte Transplant for Vitiligo**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>No specific codes</b>	

**Acne Scar Repair**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>11400</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less
<b>11401</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.6 to 1.0 cm
<b>11402</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 1.1 to 2.0 cm
<b>11403</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm
<b>11404</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 3.1 to 4.0 cm
<b>11406</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter over 4.0 cm
<b>15786</b>	Abrasion; single lesion (eg, keratosis, scar)
<b>15787</b>	Abrasion; each additional 4 lesions or less (List separately in addition to code for primary procedure)
<b>With Diagnosis Code</b>	
<b>L70.0</b>	Acne vulgaris
<b>L70.1</b>	Acne conglobata
<b>L70.2</b>	Acne varioliformis
<b>L70.3</b>	Acne tropica
<b>L70.4</b>	Infantile acne
<b>L70.5</b>	Acne excoriee
<b>L70.8</b>	Other acne
<b>L70.9</b>	Acne, unspecified

**Medical Necessity Review not required:**
**Laser treatment (described in 2b):**

CPT® or HCPC Codes	Description
<b>17000</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
<b>17003</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); second through 14 lesions, each (List separately in addition to code for first lesion)
<b>17004</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses), 15 or more lesions
<b>17106</b>	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq cm
<b>17107</b>	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); 10.0 to 50.0 sq cm
<b>17108</b>	Destruction of cutaneous vascular proliferative lesions (eg, laser technique); over 50.0 sq cm
<b>17110</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
<b>17111</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; 15 or more lesions
<b>17250</b>	Chemical cauterization of granulation tissue (ie, proud flesh)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Dates Reviewed	Date Revised
07/25/2002	12/07/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 07/02/2013 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	03/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Review History	Description
05/21/2015	Added CPT codes
09/01/2015	Excimer Laser: added scalp psoriasis as indication
02/02/2016	Home UVB Phototherapy: Add psoriasis as a covered indication
08/02/2016	Home UVB Phototherapy: Add diagnosis of eczema will be reviewed on a case-by-case basis
12/19/2017	Added Plastic Surgery LCD (L37020)
06/17/2019	Added Eczema as an indication to Home Narrowband UVB phototherapy
08/06/2019	Minor changes were made to benign skin lesions criteria to allow removal of warts
12/01/2020	MPC approved to adopt updates to the existing hybrid Phototherapy, Skin criteria, KP-0255, to expand coverage for additional indications including Granuloma annulare and Pityriasis lichenoides chronica for in-office and home phototherapy. Members must have durable equipment coverage and requires initial support/teaching by the ordering provider for home phototherapy. Requires 60-day notice, effective date 05/01/2021.
04/28/2021	Added diagnosis codes covered by Medicare for home phototherapy; removed retired LCD L35008
05/04/2021	Laser treatment services described in 2b in criteria above, and represented by CPT codes: 17000, 17003, 17004, 17106, 17107, 17108, 17110, 17111, and 17250, will no longer require medical necessity review. Requires 60-day notice, effective date October 1, 2021.
03/01/2022	Updated applicable codes.

10/28/2022	Updated Medicare Policy to defer to KP Non-Medicare criteria for phototherapy for skin conditions other than psoriasis.
11/01/2022	Updated Medicare Policy to defer to KP non-Medicare criteria for phototherapy for all skin conditions including home UVB.
02/07/2023	Clarified criteria for Fractional Laser Treatment of Burn and Traumatic Scars for Functional Improvement. Added Hayes Technology Assessment dated May 11, 2021, to references.
04/18/2023	Added retired Medicare Retired Local Coverage Article A55681 for supporting documentation
03/04/2025	MPC approved to adopt updated criteria for Excimer Laser Treatments to clarify and define conservative treatment; 60-day notice required. Effective Date August 1 <sup>st</sup> , 2025.  Added codes listed in criteria sections for better clarity.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Dialysis Services

- Facility
- In Home
- Nocturnal
- Short Daily
- Ultrafiltration for the Treatment of Congestive Heart Failure

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual, Chapter 8 - Outpatient ESRD Hospital, Independent Facility, and Physician/Supplier Claims</a>
National Coverage Determinations (NCD)	<a href="#">Ultrafiltration, Hemoperfusion and Hemofiltration (110.15)</a>
Local Coverage Determinations (LCD)	<a href="#">Frequency of Hemodialysis (L37504)</a>
Local Coverage Article	<a href="#">Billing and Coding: Frequency of Hemodialysis (A55676)</a>

#### For Non-Medicare Members

Service	Criteria
<b>Hemodialysis</b>	<p><b>Standard hemodialysis 3 days a week</b> is covered for members with end stage renal disease. For home dialysis the following additional criteria must be met:</p> <ol style="list-style-type: none"> <li>1. The member is stable on dialysis.</li> <li>2. The member is free of complications and significant concomitant disease that would render home dialysis unsuitable or unsafe.</li> <li>3. The member or caregiver is capable of completing a home dialysis training program and adhering to a prescribed treatment regimen.</li> <li>4. Adequate caregiver is available during dialysis</li> <li>5. Back-up arrangements have been made with the facility-based dialysis center.</li> </ol>
<b>Frequent (Greater Than 3 Days a Week) Hemodialysis, Nocturnal or Short Daily, In Home or Facility</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
<b>Ultrafiltration for the Treatment of Congestive Heart Failure</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

End-stage renal disease (ESRD) is defined as an irreversible decline in kidney function that is severe enough to be fatal without treatment. In 2008, the prevalence of ESRD in the United States was 547,982 (Collins 2011). Treatment options for patients with ESRD include kidney transplantation and dialysis. Kidney transplantation is the preferred treatment for ESRD; however, the demand for kidney transplant exceeds the supply of transplantable organs (Pauly 2009). Of the 547,982 patients with ESRD, approximately 382,343 patients received dialysis (Collins 2011).

Dialysis filters blood to rid the body of harmful wastes, extra salt, and water. There are two types of dialysis peritoneal dialysis and hemodialysis. The majority of patients are treated using hemodialysis; however, there is no consensus on the optimal dose and frequency of hemodialysis. Difference hemodialysis regimens include: conventional hemodialysis, nocturnal hemodialysis, and short-daily hemodialysis (Toussaint 2010).

There are two types of dialysis: 1) Peritoneal dialysis: Removes waste products via the peritoneum, the membrane that lines the inside of the abdomen. The membrane is bathed in a special fluid called dialysate that is placed into the abdomen through a small tube, and after a designated period of time, the fluid is drained and replaced by new fluid. 2) Hemodialysis: Access is through surgical placement of an arteriovenous fistula, generally in the forearm, and less commonly by a venous catheter. After access is established, the fistula is connected to a hemodialysis machine that drains the blood, bathes it in dialysate solution and returns it to the bloodstream.

Conventional hemodialysis consists of three treatment sessions per week, with each session lasting 3 to 5 hours. Treatments can be performed in a dialysis center, hospital, or at home. Although this is a life-saving treatment, mortality in patients with ESRD is still remarkably high. Compared to the general population, mortality is four times higher in patients under 30 receiving dialysis and six times higher in patients over 65. Additionally, patients receiving dialysis often experience hypertension, fluid overload and the attendant cardiac sequelae, anemia, mineral and bone disorders, inflammation, poor nutritional status, poor functional status, and psychological disorders (Bayliss 2009, Ng 2010). Moreover, this approach to dialysis is inconvenient for patients receiving treatment in a dialysis center or hospital, who must travel to a dialysis unit several times a week.

Both nocturnal hemodialysis (typically 6-8 hours, 3-7 nights per week) and short-daily hemodialysis (typically 1.5-3 hours, 4-6 days per week) can take place at home or at a dialysis center. It is thought that increasing the frequency and duration of hemodialysis will lead to less fluid gain leading to improved blood pressure control, increased hemodynamic stability, and increased efficiency of solute clearance. A potential harm is an increased risk of vascular access complications due to more frequent use (Ng 2010, Toussaint 2010).

There are several hemodialysis devices approved by the FDA for home use. Some are large, non-portable devices that require modifications to the home electrical and plumbing systems. These include the Fresenius 2008K and the B. Braun Dialog Plus. Others are smaller and portable. The NxStage System One is specifically designed for home use; it does not require infrastructure changes.

## Medical Technology Assessment Committee (MTAC)

### ***Frequent Home Dialysis***

**08/04/2008: MTAC REVIEW**

#### **Evidence Conclusion:**

Objective 1:

- There is insufficient evidence that home nocturnal dialysis improves important health outcomes compared to in-center dialysis. An RCT found improvement in LV mass and phosphate level, intermediate outcomes, and mixed findings in QOL. There is weak evidence from a single cohort study that nocturnal dialysis lowers the

rate of dialysis-related or cardiovascular-related hospitalizations. In this cohort study, all-cause hospitalizations did not decrease significantly.

- There is insufficient evidence that home short-daily dialysis improves health outcomes compared to in-center dialysis. One statistical analysis found a lower mortality rate with short daily dialysis compared to national rates, but patients may have differed in ways that affect outcomes, and there was potential financial bias.

**Objective 2:**

- There is insufficient evidence that home nocturnal dialysis 6 nights a week improves important health outcomes compared to home hemodialysis 3 times a week.
- There is insufficient evidence that home short-daily dialysis 5 or more times a week improves important health outcomes compared to home hemodialysis 3 times a week

**Articles:** Assessment objectives:

- 1) To determine whether frequent home nocturnal or home short daily dialysis leads to better health outcomes in patients with end-stage renal disease compared to conventional in-center dialysis 3 times a week.
- 2) To determine whether frequent home nocturnal or home short daily dialysis leads to better health outcomes in patients with end-stage renal disease compared to home dialysis 3 times a week.

Important health outcomes are survival, hospitalizations and quality of life.

**Objective 1: Comparison with in-center hemodialysis** One randomized controlled trial (Culleton et al., 2007) and two cohort studies (Bergman et al., 2008; Schwartz et al., 2005) comparing frequent nocturnal home hemodialysis to in-center hemodialysis were identified and critically appraised. Case series were not reviewed due to the availability of higher-grade evidence. The studies on short-daily hemodialysis were all case series. Most were small (<15 patients) and/or included patients who primarily received dialysis in-center and thus were not suitable for critical appraisal. The strongest study identified compared outcomes in 117 patients on short-daily dialysis (84% at home) to outcomes of patients from a national database receiving conventional dialysis (Blagg et al., 2006). The Blagg study was critically appraised. **Objective 2: Comparison with home hemodialysis 3 times a week**

One comparative study was identified, and critically appraised (Mahadevan et al., 2006). This was a small retrospective cohort study comparing outcomes in patients who received home nocturnal dialysis either six nights per week or on alternate nights (3-4 times a week). An RCT by the Frequent Hemodialysis Network (FHN) is underway comparing nocturnal home hemodialysis 3 versus 6 times a week. The study is currently recruiting patients; the estimated completion date is January 2010 (Clinicaltrials.gov). **Studies reviewed include:** Blagg CR, Kjellstrand CM, Ting GO, Young BA. Comparison of survival between short-daily hemodialysis and conventional hemodialysis using the standardized mortality ratio. *Hemodialysis International* 2006; 10: 371-374. See [Evidence Table](#) Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. *JAMA* 2007; 298: 1291-1299. See [Evidence Table](#) Bergman A, Fenton SSA, Richardson RMA, Chan CT. Reduction in cardiovascular related hospitalization with nocturnal home hemodialysis. *Clin Nephrol* 2008; 69: 33-39. See [Evidence Table](#) Schwartz DI, Pierratos A, Richardson RMA et al. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. *Clin Nephrol* 2005; 63: 202-208. See [Evidence Table](#) Mahadevan K, Pellicano R, Reid A et al. Comparison of biochemical, hematological and volume parameters in two treatment schedules of nocturnal home hemodialysis. *Nephrology* 2006; 11: 413-418. See [Evidence Table](#).

The use of home dialysis in the treatment of kidney disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Nocturnal Dialysis**

### **04/18/2011: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence to determine whether nocturnal dialysis leads to better health outcomes in patients with end-stage renal disease compared to conventional dialysis 3 times a week. There is fair evidence that short-daily dialysis leads to improvements in intermediate outcomes such as left ventricle mass and physical-health composite score compared to conventional dialysis 3 times a week. **Articles:** Studies were selected for review if they included at least 25 subjects and assessed the effect of nocturnal or short-daily dialysis on health outcomes. The majority of studies identified were non-randomized, observational studies. As these studies are more prone to bias, they were not selected for review. An RCT that compared the quality of life of patients receiving nocturnal dialysis to conventional dialysis was not selected for review as it did not have adequate power. A recent RCT comparing short-daily dialysis to conventional dialysis was selected for review.

The following study was critically appraised: FHN Trial Group. In-center hemodialysis six times per week versus three times per week. *N Engl J Med* 2010; 363:2287-2300. See [Evidence Table](#)

The use of nocturnal dialysis in the treatment of kidney disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.



## **Frequent Home Dialysis**

### **08/20/2012: MTAC REVIEW**

#### **Evidence Conclusion:**

**Survival** – There is lower quality evidence upon which to draw conclusions about survival with home versus in-center hemodialysis. Three observational studies specifically reported on death or measures of mortality and survival with home hemodialysis compared to in-center hemodialysis. One study had no deaths and therefore found no difference. The two other studies favored home hemodialysis but were either small or had a higher likelihood of residual confounding (Kaiser 2011).

Since the Kaiser review, a recent matched-cohort study was identified that included 11,508 subjects assessed the relative mortality between daily home hemodialysis and thrice-weekly in-center hemodialysis. Results from this study suggest that home hemodialysis may be associated with a reduction in all-cause mortality compared to thrice-weekly in-center hemodialysis (HR 0.87, 95% CI 0.78-0.97, P=0.01). Limitations of the study include: residual confounding, approximately 1 in 4 home hemodialysis patients switched to in-center hemodialysis, more patients in the in-center treatment group were dually eligible for Medicare and Medicaid, and the cause of death was unknown in 10-20% of cases (Weinhandl 2012).

**Hospitalizations** – There is lower quality evidence upon which to draw conclusions about hospitalizations with home versus in-center hemodialysis. One nested-case control study favored home hemodialysis in terms of hospitalizations per patients and two additional studies appeared to possibly favor home hemodialysis but were underpowered (Kaiser 2011).

**Quality of life** – The evidence is of insufficient quantity and quality to draw conclusions on quality of life with home versus in-center hemodialysis. Two small observational studies did not find differences in quality of life with home versus in-center hemodialysis. One study reported that both groups had about the same number of subjects working (Kaiser 2011).

**Change in left ventricular mass** – No studies were identified that evaluated this outcome (Kaiser 2011).

**Blood pressure control** – There is lower quality evidence upon which to draw conclusions. Two studies reported significant decreases in blood pressure measures with home hemodialysis compared to in-center hemodialysis. One study also appeared to favor home hemodialysis in terms of need for antihypertensive medications (Kaiser 2011).

**Nutritional status and serum albumin** – There are lower quality evidence upon which to draw conclusions. Three observational studies reported mixed results on measures of serum albumin, with one study significantly favoring home as compared to in-center hemodialysis. One study found no difference in intradialytic weight gain with home versus in-center hemodialysis (Kaiser 2011).

**Vascular access complications/ Safety** – The studies evaluating vascular access complications have been very small and the results were somewhat mixed. One study evaluated the operations (per patient) due to vascular access and found no significant difference, but the data tended toward favoring home hemodialysis. Another small study appeared to favor in-center, but the study was not adequately powered to evaluate this outcome. In terms of other safety reports, one small study appeared to have more machine malfunctions with home hemodialysis, another study reported that a composite measure of intradialytic adverse events appeared to favor home hemodialysis, but this was not significant (Kaiser 2011).

**Articles:** In March 2011, Kaiser reviewed alternative approaches to hemodialysis. Since the Kaiser review three observational studies were identified. Two studies were excluded as they did not compare in-center hemodialysis to home hemodialysis. The remaining observational study was selected for review.

Several studies were identified that reanalyzed results from the FHN trial; however, they were not selected for review since the FHN trial evaluated whether short-daily in-center hemodialysis improved patient outcomes compared to conventional in-center hemodialysis, and whether nocturnal home hemodialysis improved patient outcomes compared to conventional home hemodialysis. The following article and medical technology assessment were selected for review: Kaiser Permanente. Alternative approaches to hemodialysis: short “daily” and nocturnal. March 2011. The committee voted to accept the Kaiser technology assessment. The studies were insufficient to draw conclusions on clinical benefit as compared to standard forms of dialysis.

## **Frequent Home Dialysis**

### **10/12/2020: MTAC REVIEW**

#### **Evidence Conclusion:**

- There is a lack of high-quality randomized controlled trials assessing the effectiveness of frequent home hemodialysis versus conventional in-center hemodialysis in patients with ESRD.
- The available evidence is of low quality, mainly from uncontrolled studies, and suggests:
  - Home hemodialysis may decrease mortality compared to in-center hemodialysis

- No difference between groups in terms of all-cause mortality, hospitalization, cardiovascular mortality, access survival, and transplantation rate
- Mixed findings regarding quality of life and adverse events.
- Home hemodialysis may be comparable to in-center dialysis in patients with ESRD

The use of frequent home dialysis in the treatment of kidney disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Ultrafiltration in the Treatment of Congestive Heart Failure**

**08/07/2006: MTAC REVIEW**

**Evidence Conclusion:** In conclusion, there is insufficient evidence to date to determine the efficacy and long-term safety of ultrafiltration versus standard care in acute decompensated heart failure, or to determine who would benefit most from the intervention.

**Articles:** The search yielded around 280 articles most of which were review articles, opinion pieces, or dealt with the technical aspects of the procedures. There was one RCT, and several small case series, many of which dated back in the 1980s and 1990s. The RCT and the relevant case series using the new UF device (System 100, CHF Solutions, Minneapolis, Minnesota) were selected for critical appraisal: Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure. The Relief for Acutely fluid-overloaded Patients with Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46:2043-2046. See [Evidence Table](#). MR, Saltzberg M, O'sullivan J, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol 2005;46:2047-2051. See [Evidence Table](#).

The use of ultrafiltration in the treatment of congestive heart failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**06/17/2013: MTAC REVIEW**

### **Ultrafiltration in the Treatment of Congestive Heart Failure**

**Evidence Conclusion:** There is insufficient evidence to support the use of ultrafiltration as a first-line treatment in hospitalized ADHF with volume overload. There is insufficient evidence to determine the safety and efficacy of ultrafiltration in patients with ADHF who are refractory to diuretic therapy.

Results from UNLOAD trial, suggest, but do not provide good evidence, that ultrafiltration may provide better correction of volume overload than IV diuretics (given at the dose used in the trial) in patients hospitalized ADHF who are not resistant to diuretic therapy. The trial had its limitations and does not provide any evidence on the safest and most effective rates of fluid removal, duration of treatment, or the conditions for termination of ultrafiltration. There is evidence from the CARRESS-HF that IV loop diuretic-based therapy adding distal-acting diuretics, IV vasodilator and inotropic agents as needed is superior to ultrafiltration in patients with acute decompensated heart failure and worsening renal function. CARESS-HF results show increased incidence of worsening kidney function in the ultrafiltration group versus the stepped pharmacologic therapy group.

A large ongoing trial (AVOID-HF) (NCT01474200) involving 810 patients in 40 US centers is examining the effect of UF vs. intravenous diuretics in reducing hospitalization in patients with ADHF before worsening renal function.

**Articles:** UNLOAD trial (Costanzo et al 2007, evidence table 1) [See Evidence Table](#). CARRESS-HF (Bart et al 2012, evidence table 2) [See Evidence Table](#)

The use of ultrafiltration in the treatment of congestive heart failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Applicable Codes**

**Standard Hemodialysis - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

**Frequent (Greater Than 3 Days a Week) Hemodialysis, Nocturnal or Short Daily, In Home or Facility - Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
99512	Home visit for hemodialysis
90999	Unlisted dialysis procedure, inpatient or outpatient
E1629	Tablo hemodialysis system for the billable dialysis service

## Ultrafiltration for the Treatment of Congestive Heart Failure

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare - Considered Not Medically Necessary**

CPT® or HCPC Codes	Description
0692T	Therapeutic ultrafiltration

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Creation Date	Review Dates	Date Last Revised
08/04/2008	07/06/2010 <sup>MDCRPC</sup> , 05/03/2011 <sup>MDCRPC</sup> , 03/06/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/30/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	04/17/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
12/09/2015	Added Medicare and Noridian links
10/29/2018	Updated the Medicare links
08/04/2020	Added Medicare LCA A55676; Added CPT codes 90999 and 99512
08/03/2021	Added the October 12, 2020 MTAC review
10/26/2022	Updated applicable codes, including new codes released 01/01/22 and 04/01/22.
04/17/2024	Merged "Ultrafiltration for the Treatment of Congestive Heart Failure" criteria and retitled to Dialysis Services



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Discography (Discogram) for Low Back Pain

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Discography (Discogram) for Low Back Pain</b> , for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Low back pain is a great and growing problem in the Western countries as well as other parts of the world. It is the most common cause of disability in patients younger than 45 years old, and the loss of work, medical and disability costs can add up to at least \$50 billion per year in the United States. Many factors are associated with back pain, but the exact causes of severe pain are unclear especially in the absence of a diagnosed anatomic pathology such as infection, tumor, deformity, or instability (Carragee 2001, 2004, Willems 2007).

Currently, there is no clinical test that could be used as a diagnostic gold standard for discogenic pain, and it is not possible to determine with absolute certainty that a particular disc is the spinal pain generator. Imaging methods such as radiography, magnetic resonance imaging (MRI), and computed tomography (CT) may detect disc degeneration but cannot confirm if it is symptomatic and relevant to the patient's pain syndrome. Plain radiographs provide data on bony alignment and deformity, signs of instability, and the general state of lumbar degeneration. Nuclear medicine scans may exclude tumors, fractures and infection, and magnetic resonance imaging (MRI) is used for the diagnosis of lumbar degenerative disorders. MRI is considered the morphological imaging study of choice in patients with low back pain. It is non-invasive and allows assessment of more levels in one test. MRI findings might also provide some information to indicate that a positive test increases the likelihood of the disc as a source of patients' symptoms, yet the current evidence is insufficient to allow making an accurate prediction (Saal 2002, Hancock 2007, Willems 2007). Surgical exposure can confirm the presence of disc degeneration but cannot definitely confirm that it is the source of discogenic pain.

Lumbar discography was first introduced in the late 1940s as a morphologic test. The term discography used to describe the technology, implies a strictly anatomic evaluation. Discograms do not image pain and hence do not provide insight into which neural pathways mediate discogenic pain. Imaging of intervertebral discs morphology usually does not change within a short interval, but discographic images may change after only 2 weeks. Concerns about the invasiveness of discography, radiation exposure, risk of infection, and the recent advances made in the high-resolution multi-detector CT and MRI of the disc, minimized the role of discography as an imaging tool. However, the frequent recurrence of familiar back pain during the discography led to the use of the test in evaluating lumbar discs as the origin of chronic low back pain, as well as pain in the cervical spine. Currently discography is used as a provocative test alleged to correlate symptoms with pathology (Buenaventura 2007).

Provocative discography is an invasive diagnostic procedure performed by the injection of a nonirritating radio-opaque dye, under x-ray guidance, into the nucleus of one or more lumbar discs. The dye is slowly injected into the center of the nucleus pulposus by a 22-25-gauge needle. The patient must be awake and cooperative and is supposed to be blinded to the time and level of injection. The distribution of the dye is noted, and the patient is asked whether each injection seems painful, and if the pain is similar “concordant” to the usual back pain he experiences. The patient is also asked to rate the pain on a visual analogue scale (VAS) or pain thermometer from 0-10 (or 0 to 5), with 0 denoting no pain and the higher end being unbearable pain. A completely intact disc will retain the dye in a central globular pattern, and is usually not very uncomfortable, even at high pressures. With more advanced disc degeneration on the other hand, patients may experience varying degrees of discomfort and pain as the dye is injected. A post discogram CT scan is often performed, and allows for a more thorough visualization, assessment, and identification of disc abnormalities (Saal 2002, Carragee 2001, Cohen 2005, Rowles 2005).

Discography has always been described as one of the most controversial tests in the management of degenerative painful lumbar spine conditions. Unlike MRI or CT scans, discography is used as a provocative test alleged to correlate symptoms with pathology. It seeks to confirm an impression that the back pain is discogenic and originating from a certain intervertebral disc. Some researchers found that healthy, previously pain free, patients can develop both back and leg pain from a provocative discogram as a result of the injection of irritants at different sites in motion segments. They also found that placement of the needle and injecting contrasts in the annulus fibrosus rather than the nucleus pulposus may induce back pain which should be regarded as false positive discography. Also, pain response to the discograms may vary widely among patients with chronic pain and somatization disorders. According to several investigators, psychological distress and pre-existing chronic pain processes may be stronger predictors of low-back pain than painful disc injections (Saal 2002, Carragee 2004, and Lander 2005).

One of the most feared complications of discography is discitis because of the poor blood supply of the intervertebral discs. Other reported adverse events include injury to the intervertebral disc, headache due to neuroaxial leak of the contrast, convulsions, meningitis, subdural or epidural abscesses, intrathecal hemorrhage, and others. Also, as indicated earlier discography may cause or worsen low back pain especially in patients with somatization disorder (Cohen 2005).

The suggested clinical indications for discography are wide-ranging and highly individualized (Carragee 2004). Guidelines published by specialized groups recommend that discography be reserved for use in patients with equivocal or inconsistent findings from MRI or other tests. Some investigators suggest its use for the evaluation of patients with chronic back pain for whom a surgical intervention is being considered.

Discography is being reviewed by MTAC based on a request from Dr. Kyle Kim. Considered as a procedure, discography is not regulated by the FDA; however, the devices and agents used for the test require FDA approval. Several of these devices and contrast material have been approved by the FDA.

## Medical Technology Assessment Committee (MTAC)

### **Discography**

#### **10/01/2007: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient evidence to determine the reliability of discography in the diagnosis of discogenic pain among patients with chronic low back pain. There is insufficient evidence to determine that discography is accurate for the diagnosis of discogenic pain. There is insufficient evidence to conclude whether or not the use of discography can improve selection of patients, predict or improve surgical outcomes in those with discogenic chronic low back pain.



**Articles:** The search yielded over 500 articles some of which dated back to 1966. There were three systematic reviews of the literature with no meta-analyses, and several small prospective or retrospective studies that aimed at determining the reliability, calculating the diagnostic accuracy, comparing, or correlating the findings of discography with MRI, CT scanning, myelograms or radiographs in symptomatic or asymptomatic patients. The search also revealed several relatively small studies that utilized health outcomes as a method for assessing the efficacy of discography. The ideal study would be a blinded independent comparison of discogram with a gold standard. However, to date, there is no known gold standard for discogenic pain. Some researchers determined the accuracy of discography by comparing it to other diagnostic modalities. Others used surgical findings and pathological disc morphology as their standard to confirm discographic results. These can confirm the presence of disc degeneration but cannot definitely confirm that it is the source of discogenic pain. Other groups suggested using clinical results of fusion as a gold standard to confirm whether the positive discogram injections were in fact true positives. Still many disagree on using a “controversial” treatment as the spinal fusion as a gold standard for a diagnostic test. One study that correlated discogram findings with MRI, and another that sought to measure its efficacy based on health outcomes were presented in evidence tables. Several other studies were grouped in table forms (see appendix tables 1 and 2) and/or discussed in the reviewer’s evidence summary section. The studies critically appraised in evidence tables are Birney TJ, White JJ, Berens D, et al. Comparison of MRI and in the diagnosis of lumbar degenerative disc disease. *J Spinal Disord* 1992;5:417-423 See [Evidence Table](#). Willems PC, Elmans L, Anderson PG, et al. Provocative discography and lumbar fusion. Is preoperative assessment of adjacent discs useful? *Spine* 2007;32:1094-1099 See [Evidence Table](#).

The use of discography in the treatment of lower back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Discography

### 12/14/2011: MTAC REVIEW

**Evidence Conclusion:** In 2007 we reviewed the evidence for lumbar provocative discography, and there was insufficient evidence to determine the benefits of the procedure. A quick literature search did not reveal any good quality or large studies on analgesic discography. The only more recent study discussed in that article is the Cooper et al's study presented in a meeting and not published in a peer reviewed journal.

There was a systematic review with no meta-analysis of studies on lumbar discography (Manchianti 2009) that concluded that the level of evidence on the technology is II-2 (i.e. evidence obtained from at least one properly designed small diagnostic accuracy study). The review indicated that there is a lack of literature, poor methodological quality and very few studies using IASP criteria. Carragee (2006) compared 5-year outcomes of two cohorts: 1 Discography (presumed discogenic pain) cohort, n=30, and 2: Unstable spondylolisthesis cohort of 32 patients used as a control group. The gold standard used for the diagnosis of discogenic pain by discography was clinical outcome after surgical intervention. Outcome measures included VAS for back and leg pain, Modems Lumbar Questionnaires, analgesic usage, work status, reoperation, and complications. The results show a surgical success rate of 27% among the patients with discography positive test, compared to a 72% success rate in the control group. The calculated positive predictive value of discography for achieving at least the minimum acceptable outcome was 43%.

**Articles:** A quick literature search did not reveal any good quality or large studies on analgesic discography. The only more recent study discussed in that article is the Cooper et al's study presented in a meeting and not published in a peer reviewed journal. There was an systematic review with no meta-analysis of studies on lumbar discography (Manchianti 2009) that concluded that the level of evidence on the technology is II-2 (i.e. evidence obtained from at least one properly designed small diagnostic accuracy study). The review indicated that there is a lack of literature, poor methodological quality and very few studies using IASP criteria.

The use of discography in the treatment of lower back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary

CPT® or HCPC Codes	Description
62290	Injection procedure for discography, each level; lumbar
62291	Injection procedure for discography, each level; cervical or thoracic
62292	Injection procedure for chemonucleolysis, including discography, intervertebral disc, single or multiple levels, lumbar



<b>72285</b>	Discography, cervical or thoracic, radiological supervision and interpretation
<b>72295</b>	Discography, lumbar, radiological supervision and interpretation

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
10/18/2007	10/01/2007, 10/15/2007 <sup>MDCRPC</sup> , 1/3/2012 <sup>MDCRPC</sup> , 2/7/2012 <sup>MDCRPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup> , 05/06/2025 <sup>MPC</sup>	05/02/2017

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/02/2017	Adopted KPWA policy for Medicare members

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Device, Equipment and Supplies

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Durable Medical Equipment Reference List (280.1).</a>
Local Coverage Determinations (LCD) Local Coverage Article (LCA)	<p><a href="#">Oxygen and Oxygen Equipment (L33797)</a> "Oxygen reimbursement is a bundled payment. All options, supplies and accessories are considered included in the monthly rental payment for oxygen equipment."</p> <p><a href="#">Oxygen and Oxygen Equipment – Policy Article (A52514)</a> "Oximeters (E0445) and replacement probes (A4606) will be denied as non-covered because they are monitoring devices that provide information to physicians to assist in managing the beneficiary's treatment."</p> <p><a href="#">Patient Lifts (L33799)</a></p> <p><a href="#">Patient Lifts – Policy Article (A52516)</a></p> <p><a href="#">Noridian Non-Covered Items</a> for Light Therapy for Seasonal Affective Disorder</p> <p><i>*Please note that many individual DME items may have their own specific LCD and/or LCA.</i></p>
Kaiser Permanente Medical Policy	<p>PureWick™ Urine Collection System</p> <p>Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "<b>Device, Equipment and Supplies</b>" for medical necessity determinations. Refer to the Non-Medicare criteria below.</p>

[Noridian Jurisdiction D DME Supplier Manual](#)  
[Noridian Same or Similar Chart](#)

Please refer to Kaiser Permanente [payment policy Durable Medical Equipment](#) for reimbursement clarification

#### For Non-Medicare Members

Durable Medical equipment (DME) also known as home medical equipment (HME) may be considered medically necessary when **ALL** of the following criteria are met:

- The patient has a documented physical functional impairment or disability due to disease, trauma, congenital anomaly or prior therapeutic intervention and requires accommodation for basic activities of daily living (ADLs) that can be met by using a DME item; and
- Documentation in the medical record contains a clinical assessment and rationale for the requested DME item (see Required Documentation below); and
- The DME is prescribed by a health care practitioner; and
- It is an item with a published HCPCS code; and
- The piece of equipment meets the definition of DME (see Policy Guidelines) and
- The requested DME item is not considered to be not medically necessary, investigational or unsafe by a regulatory agency, excluded by plan benefits or contract exclusion; and
- When specific criteria exist, the patient has also met those criteria.

The following are considered not medically necessary:

- Accessory add-ons and upgrades when a basic DME item meets the member's functional needs
- Athletic/exercise/physical fitness equipment (e.g. treadmills, stationary bikes)
- Comfort or convenience items (e.g., OTC compression sleeve-like garments/soft brace)
- Comfort or convenience items added to basic equipment
- Deluxe equipment when basic (standard) equipment is available and meets the member's functional needs
- Duplicate equipment (e.g. a rolling walker, when the member has a properly fitted cane)
- Equipment and modifications/upgrades to equipment when used primarily for leisure or recreational activities (e.g. special wheelchair wheels for sport activities, prosthetic adaptations for beach use, skiing and others)
- Equipment used for environmental control or to enhance the environmental surroundings (e.g. air conditioners, air filters, humidifiers, allergy protective pillow/mattress covers, furniture [e.g. recliner chairs, over-bed tables], and others)
- First aid or precautionary equipment (e.g. automatic external defibrillator (AED), portable oxygen to back up an in-home oxygen system)
- Home modifications (e.g. bath grab bars, electronic door openers, elevators, Jacuzzi/whirlpools, ramps,)
- Institutional equipment (e.g. any DME that is used only in a medical facility and is not suitable for use in the home setting)
- Same/similar or back-up DME item(s) not used as the primary device to meet the member's functional needs (ie more than one of the same item of durable medical equipment).
- Devices that do not meet the definition of durable medical equipment (DME), because they are not primarily intended for medical purposes (e.g. desktop/laptop computers, smartphones, tablets, internet, phone services, any modification to a patient's residence for DME use)

\*See below for specific exclusions

## Required Documentation

Documentation from the clinical evaluation should include the following:

- An order/prescription from the physician/health care provider responsible for the patient's care that states the therapeutic purpose of the DME
- Details of the patient's physical functional impairment related to completing activities of daily living (ADLs) without the home medical equipment/DME; and
- The patient's medical condition that requires DME for long term use (i.e. 6-12 months or more) when applicable; and
- What assistive devices (e.g., canes, walkers, manual wheelchairs) the device has been trialed and found to be inadequate/unsafe or contraindicated to completely meet the patients functional needs (when applicable)

**Note:** Even when a provider orders or prescribes DME and deems the equipment necessary for the patient's functional needs, that does not mean that the item meets the criteria as listed in the policy. It also does not guarantee that the item will be considered medically necessary.

## Definition of Terms

**Activities of daily living (ADLs)** – ADLs are self-care activities done daily within a member's place of residence and includes

- Dressing/bathing
- Eating
- Ambulating (walking)
- Toileting
- Transferring
- Hygiene/grooming

**Durable Medical Equipment (DME)** – DME is:

- Primarily and customarily used to serve a medical purpose and
- Not useful to a person in the absence of illness or injury and
- Ordered or prescribed by a physician or other qualified provider and
- Reusable (non-disposable) and
- Designed to withstand repeated use (durable) and
- Not solely for the convenience of the patient or caregiver
- The equipment is not for use exclusively outside the home setting.

Prosthetics are covered if:

1. The device replaces all or part of an internal body organ or
2. Replaces all or part of the function of a permanently inoperative or malfunctioning internal body organ. **AND**
3. When specific medical criteria exist, the patient has also met those criteria.

The following items require review by Clinical Review:

1. Equipment with no HCPCS code
2. Equipment using miscellaneous code \*\*\*\*99, K0108, or L4205 in the absence of specific equipment/prosthetic codes
3. New technology
  - a. Not yet FDA approved
  - b. No specific HCPC for the service
  - c. New FDA approval within 6 months
4. All equipment/prosthetics listed in Clinical Review Criteria
5. Duplicate items of equipment are being requested

Testicular prosthesis is considered medically necessary for replacement of congenitally absent testes, or testes lost due to disease, injury or surgery.

Testicular prosthesis may be covered when associated with transgender services when [clinical criteria](#) is met. Some plans do not cover transgender services.

ExoSyn Energy Storing AFO – CMS coding guidelines can be found here: [Correct Coding - IDEO and ExoSym Energy Storing AFO](#)  
[Medicare LCD L33686 – Ankle-Foot/Knee-Ankle-Foot Orthosis](#)

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

In 2012 Kaiser Permanente plans developed a reference list for DME/prosthetic equipment/devices that would be covered. The criteria above were developed to augment the list in the determination of coverage for DME/prosthetic items in the absence of a specific medical policy document.

## Evidence and Source Documents

Member contract

### Applicable Codes

\*To verify authorization requirements for specific DME items, please use the [Pre-authorization Code Check](#).

**Considered non-covered personal convenience item/not separately reimbursable in the home setting:**

CPT® or HCPC Codes	Description
<b>A4467</b>	Belt, strap, sleeve, garment, or covering, any time <i>*Should use a more specific code</i>
<b>A9270</b>	Noncovered item or service
	Air Conditioners or Cleaners
<b>A9280</b>	Alert or alarm device, not otherwise classified
<b>L3000-L3090</b>	Arch support
<b>E0160</b>	Sitz type bath or equipment, portable, used with or without commode
<b>E0161</b>	Sitz type bath or equipment, portable, used with or without commode, with faucet attachment(s)
<b>E0162</b>	Sitz bath chair
<b>E0235</b>	Paraffin bath unit, portable
<b>A4265</b>	Paraffin, per pound
<b>E0203</b>	Therapeutic lightbox, minimum 10,000 lux, table top model
<b>E0240</b>	Bath/shower chair, with or without wheels, any size
<b>E0241</b>	Bathroom wall rail
<b>E0242</b>	Bathroom rail, floor base
<b>E0243</b>	Toilet rail
	Bed Baths (home type)
<b>E0273</b>	Bed board
	Bed Lifters (bed elevators)
	Beds-Lounges (power or manual)
<b>E0270</b>	Hospital bed, institutional type includes: oscillating, circulating and Stryker frame, with mattress (not on Exclusions list in the General Criteria)
<b>E0462</b>	Rocking bed, with or without side rails
	Dehumidifiers
<b>K1004</b>	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories
	Disposable sheets and bags
<b>A4553</b>	Non-disposable underpads, all sizes
<b>A4554</b>	Disposable underpad, all sizes
	Electric air cleaners
	Electrostatic machines
	Elevators
<b>A9300</b>	Exercise equipment
	Face masks (surgical)
<b>E0218</b>	Fluid circulating cold pad with pump, any type
<b>E0191</b>	Heel or elbow protector, each
<b>A9273</b>	Cold or hot fluid bottle, ice cap or collar, heat and/or cold wrap, any type
	Humidifiers (not associated with PAP equipment, oxygen, IPPB, and Cool Air mist set ups)
<b>A4520</b>	Incontinence garment, any type (e.g., brief, diaper), each
<b>E0221</b>	Infrared heating pad system
<b>A4634</b>	Replacement bulb for therapeutic light box, tabletop model
<b>A4639</b>	Replacement pad for infrared heating pad system, each
<b>E0481</b>	Intrapulmonary percussive ventilation system and related supplies
<b>L8499</b>	Leg cover, realistic (Unlisted procedure for miscellaneous prosthetic services)
<b>A9285</b>	Inversion/Eversion correction device
	Leotards (does not include the burn leotards)

CPT® or HCPC Codes	Description
	Massage devices
<b>A9270</b>	Non-covered service
<b>E0274</b>	Over-bed table
	Parallel bars
<b>E0625</b>	Patient lift, bathroom or toilet, not otherwise classified
<b>E0635</b>	Patient lift, electric with seat or sling
<b>E0640</b>	Patient lift, fixed system, includes all components/accessories
<b>E0639</b>	Patient lift, moveable from room to room with disassembly and reassembly, includes all components/accessories
<b>E0300</b>	Pediatric crib, hospital grade, fully enclosed, with or without top enclosure
	Portable room heaters
<b>A9281</b>	Reaching/grabbing device, any type, any length, each
<b>E0710</b>	Restraints, any type (body, chest, wrist or ankle)
<b>E0700</b>	Safety equipment, device or accessory, any type
	Sauna Baths
<b>E0172</b>	Seat lift mechanism placed over or on top of toilet, any type
	Spare tanks of oxygen
	Speech teaching machines
	Stairway elevators
	Vitrectomy Chair or Support Face Down Positioning Device
<b>E0638 &amp; E0641-E0642</b>	Standing frame/table
<b>A4490-A4510</b>	Surgical stockings
	Telephone alert systems
<b>E0203</b>	Therapeutic light box, minimum 10,000 lux, table top model
<b>E0244</b>	Raised toilet seat
<b>E0245</b>	Tub stool or bench
<b>E0246</b>	Tub rail attachment for transfer
<b>E0247</b>	Transfer bench for tub or toilet with or without commode opening
<b>E0248</b>	Transfer bench, heavy-duty, for tub or toilet with or without commode opening
<b>A4575</b>	Topical hyperbaric oxygen chamber, disposable
<b>E0446</b>	Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories
	Treadmill exercisers
<b>L8510</b>	Voice amplifier
<b>E0249</b>	Pad for water circulating heat unit, for replacement only
<b>E0950</b>	Wheelchair tray
<b>E1310</b>	Whirlpool, nonportable (built-in type)
<b>E1300</b>	Whirlpool, portable (overtub type)
	White Canes
<b>A9282</b>	Wigs
<b>A9286</b>	Hygienic item or device, disposable or non-disposable, any type, each
<b>A4606</b>	Oxygen probe for use with oximeter device, replacement
<b>E0445</b>	Oximeter device for measuring blood oxygen levels noninvasively
<b>E0765</b>	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting
<b>V5275</b>	Ear impression, each
<b>V5281</b>	Assistive listening device, personal FM/DM system, monaural (1 receiver, transmitter, microphone), any type
<b>V5282</b>	Assistive listening device, personal FM/DM system, binaural (2 receivers, transmitter, microphone), any type
<b>V5283</b>	Assistive listening device, personal FM/DM neck, loop induction receiver
<b>V5284</b>	Assistive listening device, personal FM/DM, ear level receiver
<b>V5285</b>	Assistive listening device, personal FM/DM, direct audio input receiver



CPT® or HCPC Codes	Description
V5286	Assistive listening device, personal blue tooth FM/DM receiver
V5287	Assistive listening device, personal FM/DM receiver, not otherwise specified
V5288	Assistive listening device, personal FM/DM transmitter assistive listening device
V5289	Assistive listening device, personal FM/DM adapter/boot coupling device for receiver, any type
V5290	Assistive listening device, transmitter microphone, any type
A7001	Canister, non-disposable, used with suction pump, each <i>*not covered when used with disposable external urine management system</i>
A7002	Tubing, used with suction pump, each <i>*not covered when used with disposable external urine management system</i>
A6590	External urinary catheters; disposable, with wicking material, for use with suction pump, per month
A6591	External urinary catheter; non-disposable, for use with suction pump, per month
E2001	Suction pump, home model, portable or stationary, electric, any type, for use with external urine management system
E0936	Continuous passive motion exercise device other than knee
E0445	Oximeter device for measuring blood oxygen levels noninvasively
A4606	Oxygen probe for use with oximeter device, replacement
L2006	Knee-ankle-foot (KAF) device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), cu

**Codes without payment methodology by Medicare that we no longer reimburse:**

CPT® or HCPC Codes	Description
L2999	Lower extremity orthoses, not otherwise specified <i>*There are more specific codes that should be used</i>
L3999	Upper limb orthosis, not otherwise specified <i>*There are more specific codes that should be used</i>

**Considered medically necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
E2601	General use wheelchair seat cushion, width less than 22 in, any depth
E2602	General use wheelchair seat cushion, width 22 in or greater, any depth
E2603	Skin protection wheelchair seat cushion, width less than 22 in, any depth
E2604	Skin protection wheelchair seat cushion, width 22 in or greater, any dept
E2605	Positioning wheelchair seat cushion, width less than 22 in, any depth
E2606	Positioning wheelchair seat cushion, width 22 in or greater, any depth
E2607	Skin protection and positioning wheelchair seat cushion, width less than 22 in, any depth
E2608	Skin protection and positioning wheelchair seat cushion, width 22 in or greater, any depth

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Creation Date	Review Dates	Date Last Revised
01/22/2004	12/07/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 10/01/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
10/1/2015	Added 2 Noridian links
10/27/2015	Added testicular prosthesis information
02/02/2016	Expanded the policy for DME
09/28/2017	Added A9285 to non-covered
11/16/2017	Added ExoSyn language
02/28/2017	Added A4265 to non-covered list
05/23/2018	Added V codes for assistive listening devices to the non covered list
08/04/2020	Added devices not primarily intended for medical purposes (computers/phones/tablets, etc.) to the not medically necessary section
06/07/2022	MPC approved to add Home Pulse Oximetry codes to the DME list; 60-day notice required
10/26/2022	Retitled non covered item list
10/28/2022	Added E0765; Relief Band Device to the DME non-covered list
05/31/2023	Added Purewick Urinary Collection System to the DME non-covered list
12/09/2023	MPC approved to endorse a position of non-coverage in the ambulatory setting, aligning with CMS payment methodology.
12/13/2024	MPC approved DME billing codes that have been reimbursed historically but will no longer have payment methodology will be listed on DME page: L2999, L3999
11/05/2024	MPC approved to include Light Therapy for SAD to the DME policy
12/19/2024	Updated applicable codes
02/04/2025	Added Vitrectomy Chair to the DME non-covered list; no specific code.

## Clinical Review Criteria Driving Skills Assessment

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	<a href="#">Billing and Coding: Therapy Driving Evaluations (A52772)</a> <i>Medicare does not reimburse evaluations performed solely to assess a beneficiary's ability to drive a vehicle. In order for a service to be covered, the service must have a benefit category in the statute Title 18 of the Social Security Act (SSA), it must not be excluded, and it must be reasonable and necessary. There is no benefit category for driving evaluations.</i>

#### For Non-Medicare Members

Treatments and/or therapies that are intended to specifically improve what are known as Instrumental Activities of Daily Living (IADL) are not covered because they are not considered treatment of disease. This includes driving skills assessments.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

OT is generally covered for members with eligible conditions that require improvement in Activities of Daily Living (ADLs). These include, but may not be limited to bathing, communication, dressing, feeding, grooming, mobility, personal hygiene, self-maintenance, skin management, and toileting.

Treatments and/or therapies that are intended to specifically improve what are known as Instrumental Activities of Daily Living (IADL) are not covered because they are not considered treatment of disease. These include, but are not limited to: community living skills including balancing a checkbook, use of public transportation; home management skills including meal preparation, laundry; leisure activities including hobbies, sports or recreation of all types even if suggested as part of an OT treatment plan; motor vehicle driving evaluations and driving instruction - this includes automobiles, trucks, motorcycles and bicycles; or personal safety preparedness. This does not mean that a driving evaluation might not be helpful for a given patient, rather that the patient or family would be responsible for the cost.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/07/2020	04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	04/07/2020

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
04/07/2020	MPC approved to adopt new non-coverage criteria, effective 08/01/2020.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Dry Needling for Myofascial Pain

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Acupuncture (30.3)</a> <a href="#">Acupuncture for Fibromyalgia (30.3.1)</a> <a href="#">Acupuncture for Osteoarthritis (30.3.2)</a> <a href="#">Acupuncture for Chronic Lower Back Pain (cLBP) (30.3.3)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Myofascial pain syndrome (MPS) is a fairly common form of pain that arises from muscles or related fascia. The syndrome is usually characterized by palpable muscle tenderness and trigger points (myofascial trigger points or MTrPs). These are highly localized, hyperirritable spots in a palpable taut band of skeletal muscle fibers. When compressed, MTrPs can cause local and/or referred tenderness and pain, aggravation of existing pain, and /or autonomic phenomena. They can also contribute to impaired range of motion and increased sensitivity to stretch. Active MTrPs are associated with spontaneous local or referred pain and/or pain on movement, while latent MTrPs require direct stimulation to trigger pain symptoms. Palpating a trigger point or inserting a needle into it may elicit a localized twitch response, a brisk contraction of muscle fibers in and around the MTrPs. Trigger points may develop anywhere in the body in response to sudden injury, muscle overload, or repetitive microtrauma. Frequently affected sites include trapezius, supraspinatus, infraspinatus, teres muscle, lumbar paraspinals, gluteus, and pectoralis muscles. It is postulated that the injured muscle fibers shorten forming taut bands in response to the excessive amounts of calcium released from the damaged fibers or to the excessive amounts of acetyl choline released from the corresponding motor end plate. There are no laboratory or imaging tests to establish the diagnosis of MPS or to locate the trigger points. It has been suggested that spot tenderness, taut band, and pain recognition are the three important criteria for the diagnosis of MTrP, and that referred pain and local twitch response can be confirmatory signs for the diagnosis (Chou 2012, Dıraçoğlu 2012, Furlan 2005, Kietrys 2013, Ay 2010, Tekin 2013 Tough 2009).

The primary goal of treating MPS is to inactivate the trigger points and loosen the taut bands. The most important strategy is to treat the underlying etiological lesion that causes activation of MTrPs. If the underlying pathology is not appropriately and completely treated, the MTrP is inactivated only temporarily not completely. Several treatment modalities have been used to alleviate the chronic myofascial pain, but no single strategy proved to be universally successful. These include the use of non-steroidal anti-inflammatory drugs (NSAIDs), NSAID gel or patch, thermotherapy, massage, physical therapy, spray and stretch techniques, exercise, ischemic compression, laser therapy, acupuncture, or local injections of substances as steroids or lidocaine. Trigger point injection with local anesthetic, saline, steroid, botulinum toxin, or even dry needling is believed to be the most effective method for treating MPS (Ay 2010, Chou 2012, Kalichman 2010).

Dry needling (DN) was initially developed to treat musculoskeletal disorders. It was widely used for the treatment of MTrPs in the last three decades after some investigators indicated that needling effect is distinct from that of the injected substance. Trigger-point DN (also called biomedical acupuncture) is different from acupuncture and is not based on the insertion of needles in traditional acupuncture meridian sites. DN is a procedure in which an acupuncture-like needle is inserted into the skin and muscle in the location of an MTrPs without the use of saline or any other liquid agent or medication. The needle is not left in situ but is removed after the muscle has finished twitching and the trigger point inactivated. This should be followed by exercises, usually stretching or ergonomic adjustments, in order to establish a painless full range of motion. It has been suggested that DN is most effective when local twitch responses are elicited, probably because of rapid depolarization of the involved muscle fibers which manifest as local twitches. The actual mechanism by which DN may produce an effect is being debated and several explanations were postulated. Some investigators explain that the localized twitch response that often occurs may interrupt the motor end-plate noise, producing an analgesic effect, while others suggest that eliciting a localized twitch response and stretching exercises relax the actin-myosin bonds in the tight bands. It is also postulated that the mechanical damage of the muscle fibers and nerve terminations leads to an increase of extracellular potassium, depolarization of nerve fibers, inhibition of central feedback mechanisms, local dilution of nerve-sensitizing substances, increasing vasodilatation, and formation of necrosis in trigger point area. A number of other mechanisms were postulated by different researchers. Adverse events associated with the DN include soreness after needling, local hemorrhages at the needling site, and syncopal responses (Ay 2010, Furlan 2005, Kalichman 2010, Kietrys 2013).

Several schools and theoretical models of DN have been developed during the last three decades. The most common are the radiculopathy (also known as intramuscular stimulation) and MTrP models. Dry needling techniques include superficial or deep needling and needling with or without paraspinal needling. In the superficial needling the needle is only inserted into the tissue overlying the MTrP to a depth of 5-10 mm for 30 seconds. At this level the needle does not necessarily reach the MTrP and local twitches are not expected. In the technique that involved paraspinal needling, needles are inserted at the trigger point as well as in the paraspinal muscle of the same segment that innervates the painful muscles. These last two techniques were the least investigated (Kalichman 2010).

DN is a minimally invasive skilled intervention performed by physical therapists (where allowed by state law) and requires advanced training. The states allowing the procedure to have to follow guidelines for education and competency standards for performing it.

## Medical Technology Assessment Committee (MTAC)

### *Dry Needling for Myofascial Pain*

**02/10/2014: MTAC REVIEW**

**Evidence Conclusion** :There is insufficient published evidence to determine that dry needling has a superior or equivalent effect as acupuncture, other therapies, or injections in reducing pain and improving range of motion (ROM) in patients with myofascial pain syndrome (MPS). The results of trials comparing DN to sham needling are conflicting, and may only provide weak evidence that DN performed by experienced physiatrists may be superior to sham needling in reducing the pain, but not improving the ROM. There is insufficient published evidence to determine the appropriate number of points to be injected. There is insufficient published evidence to determine the duration of pain relief after the injection. There is insufficient evidence to determine whether the patients would need to undergo another needling procedure, and the most appropriate interval between re-injections if needed.

**Articles:** The literature search revealed a number of small randomized controlled trials and 4 systematic reviews with or without meta-analyses (MA) on the use of DN in the management of myofascial pain. Kietrys and colleagues' 2013 meta-analysis examined the effectiveness of DN for the treatment of upper quarter myofascial pain. Tough et al's 2009 MA updated an earlier 2001 MA on the effect of DN on MPS in any location in the body. A Cochrane review (Furlan et al, 2005) pooled the results of studies on acupuncture and DN for low back pain.



The three meta-analyses included the majority of the published RCTs that compared DN to sham needling, physical therapy, or injection of local anesthesia used for the treatment of myofascial syndrome in different locations in the body. The following most recent and larger meta-analysis and selected RCTs included or not included in the meta-analyses were critically appraised. Selection of the RCTs was based on their size, control groups, and methodological quality. Ay S, Evcik D, Tur BS. Comparison of injection methods in myofascial pain syndrome: a randomized controlled trial. *Clin Rheumatol*. 2010; 29:19-23. Dıraçoğlu D, Vural M, Karan A, et al. Effectiveness of dry needling for the treatment of temporomandibular myofascial pain: a double-blind, randomized, placebo-controlled study. *J Back Musculoskelet Rehabil*. 2012; 25:285-290. Irnich D, Behrens N, Gleditsch JM, et al. Immediate effects of dry needling and acupuncture at distant points in chronic neck pain: results of a randomized, double-blind, sham-controlled crossover trial. *Pain*. 2002; 99:83-89. Kietrys DM, Palombaro KM, Azzaretto E, et al. Effectiveness of Dry Needling for Upper-Quarter Myofascial Pain: A Systematic Review and Meta-analysis. *J Orthop Sports Phys Ther*. 2013; 43:620-34. Rayegani SM, Bayat M, Bahrami MH, et al. Comparison of dry needling and physiotherapy in treatment of myofascial pain syndrome. *Clin Rheumatol*. 2013 Dec 19. DOI 10.1007/s10067-013-2448-3. Tough EA, White AR, Cummings TM, et al. Acupuncture and dry needling in the management of myofascial trigger point pain: a systematic review and meta-analysis of randomised controlled trials. *Eur J Pain*. 2009; 13:3-10. Tekin L, Akarsu S, Durmuş O, et al. The effect of dry needling in the treatment of myofascial pain syndrome: a randomized double-blinded placebo-controlled trial. *Clin Rheumatol*. 2013; 32:309-315.

The use of dry needling for myofascial pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Hayes Technology Assessment

For dry needling (DN), typically coupled with exercise or stretching, for the treatment of adults with mechanical neck and/or trapezius muscle pain associated with trigger points (TrPs).

### Conclusion

An overall low-quality body of evidence suggests that DN appears to be safe and may be somewhat effective for the treatment of neck and/or trapezius pain when combined with exercise, but it is unclear whether it provides additional benefits beyond those provided by standard therapy alone.

- Two sham-controlled trials found no difference in improvement in pain or physical function between DN plus exercise relative to sham DN plus exercise. This suggests that DN does not confer benefits beyond those attained by exercise or stretching.
- In 6 studies, DN coupled with exercise resulted in statistically and clinically significant improvement in pain relative to pretreatment levels; findings in 5 of these studies were mixed as to whether use of DN improved physical function relative to baseline.
- In 4 studies, DN coupled with exercise resulted in improved pain and function relative to exercise alone, but there were no differences between DN alone or coupled with exercise and manual therapy relative to manual therapy alone. The clinical significance of these results is unclear.

Additional studies are needed to address the remaining questions regarding the clinical significance of DN treatment, its long-term effectiveness, and its effectiveness versus other standard therapies.

### Hayes Rating: C

Hayes. Hayes Technology Assessment. Dry Needling for Mechanical Neck and/or Trapezius Muscle Pain in Adults. May 18, 2023. Retrieved May 23, 2023, from <https://evidence.hayesinc.com/report/dir.needling2835>

## Applicable Codes

**Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare** - Considered Not Medically Necessary

CPT® Codes	Description
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)

<b>20561</b>	Needle insertion(s) without injection(s); 3 or more muscles
--------------	---

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/01/2014	04/01/2014 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	05/23/2023

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/02/2020	Added NCD's: Acupuncture for Chronic Lower Back Pain (cLBP) (30.3.3) and Acupuncture (30.3)
05/23/2023	Added Hayes Technology Assessment for Dry Needling for Mechanical Neck and/or Trapezius Muscle Pain in Adults

**Kaiser Foundation Health Plan of Washington****Clinical Review Criteria**  
**Radiation Therapy for Palmar Fibromatosis**

- Radiotherapy
- Dupuytren's Contracture

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

**Criteria****For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
KPWA Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, KPWA has chosen to use their own Clinical Review Criteria, " <b>Radiation Therapy for Palmar Fibromatosis</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

**For Non-Medicare Members**

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

**Background**

Dupuytren's contracture (DC) is a fibrotic tissue disorder affecting the hands. It is a benign condition characterized by thickening connective tissue in the palm eventually progressing to the formation of nodules and cords. Symptoms typically occur in both hands and progress gradually over time at variable rates. The lumps or dermal pits can be present for extended periods of time before a cord may develop causing the fingers to contract. The contracture, however, may not become troublesome for years or may never progress at all.

DC has a global prevalence of 3-6% primarily affecting males and Caucasian populations. Most patients will present with symptoms in middle age (Rizzo, Stern et al. 2013). Typically diagnosed upon physical examination, the etiology of DC is unknown, however, there is believed to be a strong genetic component as it most commonly occurs in people of Northern European or Scandinavian ancestry and often runs in families. The literature has also suggested associations with diabetes, seizures, smoking, alcohol, trauma and beta-blockers.

At present, there is no cure for DC. Available treatment options include both invasive and noninvasive modalities and typically focus on managing the disability and preventing progression (NICE 2010). Stretching, massage and splinting are frequently recommended while corticosteroid injections and fasciectomy have been used in more

extreme and developed cases. In any case, most treatment options have limited effectiveness as 20% of patients experience recurrence of symptoms.

Radiation therapy or radiotherapy (RT) is a non-surgical treatment option that is reported to halt or slow the progression of DC in its early stages. Aimed to prevent or postpone the need for surgical intervention, the mechanism for action is unclear, but it is thought to affect the development and growth rate of fibroblasts within the palmar fascia. RT treatment of the affected nodules and cords can be performed with either superficial x-rays or electron beams. The technique is typically carried out over several consecutive visits until the intended radiation dose has been achieved.

## Medical Technology Assessment Committee (MTAC)

### *Radiotherapy for Dupuytren's Contracture*

#### **10/20/2014: MTAC REVIEW**

**Evidence Conclusion:** The most recent study, published by Zirbs and colleagues in September of 2014, included 355 patients with DC who had undergone soft X-ray between 1999 and 2008 at one of two sites in Germany. Participants were asked to respond to a structured questionnaire addressing family history, predisposing factors, occupation, disease characteristics, progression, treatments, effects, side-effects, and satisfaction using a visual analogue scale (VAS). Over half (58%) of patients responded to the questionnaire and, of those, almost 80% reported no progression of symptoms after receiving treatment and were satisfied with therapy. The investigators noted a significantly higher improvement in patients with who had experienced symptoms for less than 20 months, supporting the hypothesis that early stages of DC are treated more effectively. Ultimately, the authors concluded that radiotherapy was well-tolerated and prevented further disease progression in most patients (Zirbs, Anzeneder et al. 2014). In the only RCT identified, Seegenschmiedt and colleagues compared two different radiation techniques with the overall aim of optimizing radiation dose. The study included 129 patients (198 hands) who were randomly assigned to receive one of two RT schedules (30 Gy vs. 21 Gy). Subjective responses, DC stage, nodule number, size and consistency, as well as, cords and finger mobility were assessed at two follow-up appointments. At one year, the investigators reported that objective symptom assessment showed indications of regression in over half (56%) of the hands treated with 30 Gy of radiation. Similarly, of the group treated with 21 Gy of radiation, 53% of hands showed signs of regression. Subjective symptom assessment also indicated regression of DC in both groups with 65% and 53% of patients in groups A and B, respectively. The investigators, however, do not indicate if this difference was significant. Ultimately, the authors conclude that both tested regimens are well accepted and tolerated by patients. (Seegenschmiedt, Olschewski et al. 2001). Betz and colleagues present a case series of 135 patients (208 hands) who were irradiated with orthovoltage in two courses of five daily fractions of 3.0 Gy (total dose of 30 Gy) separated by a six to eight-week interval. The investigators were able to follow-up 76% of hands treated at 13 years and reported complete relief of symptoms in 16% of patients, good relief in 18% and minor relief in 32% patients. Ultimately, the investigators concluded that radiotherapy is effective in prevention of disease progression and improves patient's symptoms in early stage DC. (Betz, Ott et al. 2010). In terms of safety, theoretical adverse events could be anything that we already know to be associated with radiation such as skin dryness, scarring/hand stiffness, and long-term potential for developing radiation induced cancer. The included studies list both acute and chronic symptoms such as dryness and desquamation, skin atrophy, lack of sweating, telangiectasia and sensory affection. Seegenschmiedt and colleagues also detailed a higher acute toxicity in the low-dose group receiving (21Gy) when compared to the medium-dose group (30 Gy) siting the dose-time factor as the cause. In any case, all three studies ultimately concluded that the radiation therapy was well tolerated. On the whole, the body of evidence is limited and should be interpreted with caution. First and foremost, none of the included studies used an adequate comparator. In two of the selected studies no comparison group was used, and in the one study that did make comparisons, no sham group was included. To add to this, each study utilized different radiation doses at different regimens without identifying an ideal or standard dose. The inclusion criteria may also be a limiting factor as all three of the studies included patients who had previously received treatment limiting the ability to exclude the effects of prior treatment. Finally, only one of the studies, by Betz and colleagues, provides adequate follow up (13 years) to assess progression of symptoms and long-term safety. Conclusions: There is insufficient evidence to support the effectiveness of radiation therapy for patients with DC. There is insufficient evidence to support the safety of radiation therapy for the treatment of DC.

**Articles:** The literature was searched for publications assessing the safety and effectiveness of RT for DC. Several publications were revealed, many of which were published in languages other than English (primarily German). There were no randomized controlled trials (RCTs) comparing the effectiveness of RT with surgical intervention or any other medical intervention for that matter. One RCT was discovered that compared the effectiveness of two different radiation doses. In addition, two recent case series were included to address safety. The following articles were selected for critical appraisal: Zirbs M, Bruckbauer AH, Hoffman H, et al., Radiotherapy with soft X-rays in Dupuytren's disease – successful, well-tolerated and satisfying. European

Academy of Dermatology and Venerology. 2014. See [Evidence Table 1](#). Seegenschmiedt MH, Olschewski T, Guntrum F. Radiotherapy optimization in early-stage dupuytren's contracture: first results of a randomized clinical study. Int J Radiation Oncology Biol Phys. 2001; 49(3):785-798. See [Evidence Table 2](#). Betz N, Ott OJ, Adamietz B, et al. Radiotherapy in early-stage Dupuytren's contracture. Strahlenther Onkol. 2010;186(2): 82-90. See [Evidence Table 3](#).

The use of Radiotherapy for Dupuytren's Contracture does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
<b>77401</b>	Radiation treatment delivery, superficial and/or ortho voltage, per day
<b>77412</b>	Radiation treatment delivery, => 1 MeV; complex
<b>With diagnosis code</b>	
<b>M72.0</b>	Palmar fascial fibromatosis [Dupuytren]

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
10/28/2014	11/07/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	4/17/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
12/24/2019	Added guidelines for Medicare members to use commercial criteria.
4/17/2024	Added code 77412. Requires 60-day notice, effective 9/1/2024.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Dynamic Spinal Visualization

- Cineradiography
- Digital Fluoroscopic Video of the Spine
- Dynamic Motion X-ray
- Spine Digital Motion X-ray

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Dynamic Spinal Visualization</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or consulting specialist.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Dynamic spinal visualization addresses different imaging techniques that allow the simultaneous visualization of movement of internal body structures with corresponding external body movement. These include dynamic or digital motion x-rays and video fluoroscopy (also known as digital fluoroscopic video or cineradiography). These imaging technologies use x-rays to create images either on film, video monitor, or computer screen.

Video fluoroscopy is a procedure that uses fluoroscopy to create real-time video images of internal structures of the body. Unlike standard x-rays that take one picture at a time, fluoroscopy provides motion pictures of the body that can be displayed on a video monitor during the procedure and also recorded for further or later evaluation. Digital motion X-ray is a fluoroscopic x-ray that integrates today's digital and optic technology to produce an x-ray movie of the body while in motion. It involves the use of either film x-ray or computer-based x-ray snapshots taken in sequence as the patient moves; to image the cervical spine; for example, patients are asked to perform flexion, extension, right and left lateral flexion and left and right rotation exercises to document range of motion. The



snapshots are then digitized, put in order using a computer program and played on a video monitor creating a moving image of the inside of the body. Both digital motion x-rays and video fluoroscopy can either be examined by the physician with or without using special computer software to evaluate several aspects of the body's structure such as intervertebral flexion and extension, to determine the presence or absence of abnormalities.

The technology has been used for decades in the diagnosis of various conditions, mainly swallowing disorders, and have been proposed for the evaluation of spinal disorders including low back pain, and segmental lumbar spinal instability to determine the presence or absence of abnormalities.

## Medical Technology Assessment Committee (MTAC)

### Dynamic Spinal Visualization

#### 10/17/2011: MTAC REVIEW

**Evidence Conclusion:** There is insufficient published evidence, to date, to determine the clinical utility of dynamic spinal visualization for the diagnosis or management of patients with spinal disorders. The published studies mainly evaluated the spine kinematics and motion patterns of the lumbar segments in symptomatic patients and asymptomatic volunteers. Others studied the correlation of total sequence of movement observed by cineradiography with the conventional radiographs taken at the extremes of spinal motion. No studies examined the effect of using the technology on managing the patients, impact on health outcomes, or an incremental value over conventional imaging methods. Reviews made by other health plans including Blue Cross, Blue Shield, Regence, Anthem, and several others, all came to the same conclusion that dynamic spinal visualization is considered investigational, and that there is insufficient published data to support the use of digital motion x-rays or cineradiography/video fluoroscopy of the spine for any indication.

**Articles:** The literature search revealed a limited number of small studies that compared the spine kinematics in patients with neck or back pain versus asymptomatic controls. No studies evaluating the effect of using the technology on managing the patients with back pain or other spinal disorders were identified.

The use of dynamic spinal visualization does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
76120	Cineradiography/videoradiography, except where specifically included
76125	Cineradiography/videoradiography to complement routine examination (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
11/01/2011	11/01/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 05/07/2024 <sup>MPC</sup> , 05/06/2025 <sup>MPC</sup>	11/01/2011

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description



**Kaiser Foundation Health Plan  
of Washington****Clinical Review Criteria**  
**Electroconvulsive Therapy (ECT)**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

**Criteria****For Medicare Members**

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare National Coverage Determinations Manual, Chapter 1, Part 2 (Section 160.25)</a>
National Coverage Determinations (NCD)	<a href="#">Multiple Electroconvulsive Therapy (MECT) 160.25</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

**For Non-Medicare Members**

Kaiser Permanente has elected to use the MCG\* Care Guideline: Electroconvulsive Therapy (B-802-T) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**Note:** Evaluations for the explicit purpose of Electroconvulsive Therapy (ECT) will also be reviewed against clinical criteria for ECT.

\*MCG are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

**Background**

Electroconvulsive therapy (ECT) is a procedure where electrodes are positioned on the patient's scalp, and a measured electrical current is passed through to the brain, inducing generalized seizure activity. ECT is typically administered by a psychiatrist, with the patient under general anesthesia (provided by an anesthesiologist or anesthetist). The treatments are performed in either an inpatient or outpatient setting, depending on a variety of factors.<sup>1</sup>

ECT is not typically considered the first-line of treatment. It is most often used to treat patients with treatment-resistant depression, after a failure of a number of adequate medication trials over time. However, it may result in therapeutic effect more rapidly than medications and should be considered as a possible first line treatment in life threatening catatonia (e.g. with risk of death due to severe malnutrition/starvation) or in someone who is at extremely high risk of suicide.<sup>2</sup> Patients with severe medical or psychiatric illness often start ECT on an inpatient

basis, and as they improve, might switch to outpatient treatment. Continuation and maintenance ECT are usually provided on an outpatient basis.

The mechanism of action for ECT remains unknown. However, many studies have shown a variety of changes in the central nervous system that might play a significant role in its therapeutic effect, including ECT prompting the release of neurotransmitters, and ECT causing the hypothalamus or pituitary gland to release hormones such as thyroid stimulating hormone and endorphins.<sup>2</sup>

ECT has been found to be an effective and safe mode of treatment for a number of behavioral health disorders/conditions, and is practiced widely in the United States.<sup>1</sup> However, the treatment continues to have some stigma attached because of misperceptions about its use, a lack familiarity with the current treatment procedure and the current level of risk of adverse effects.<sup>2</sup>

There are few contra-indications or relative contra-indications to the treatment, so a pre-treatment medical review is required before initiating treatment.

Risks of ECT are primarily those associated with anesthesia. The mortality rate (about 2 to 4 deaths per 100,000 treatments) is mostly related to cardiopulmonary events, but the mortality rate is less than that reported for normal childbirth, and is associated with the anesthesia risks.<sup>3,4</sup>

Current ECT techniques use anesthesia and brief-pulse electrical stimuli that “virtually eliminate” the past risk of fractures and minimize the risk of developing transient cognitive dysfunction effects. Not all patients who receive ECT will obtain Cognitive dysfunction / memory loss from the treatment; however, when it occurs, it can present during or after the course of ECT. The memory effects from ECT can manifest as an acute confusional state, as anterograde amnesia or as retrograde amnesia.

The acute confusional state is considered a result of both the seizure and the anesthesia. It usually resolves 10-30 minutes after the procedure.<sup>5</sup>

Anterograde amnesia is a decreased ability to retain newly acquired information. It can occur during a course of ECT and usually resolves within 2 weeks after completing the course.<sup>6</sup>

Retrograde amnesia involves forgetting recent memories, forgetting events that occur during the course of ECT and for a period of weeks or months prior to the ECT. Patients tend to retain knowledge about themselves but might forget public knowledge or information about world events. This retrograde amnesia tends to recover more slowly.<sup>7,8</sup>

ECT is most commonly used to treat severe or treatment-resistant depression. ECT has also been shown to be effective for bipolar mood disorders (depression, mania or mixed states), schizoaffective disorder, schizophrenia and catatonia.<sup>2</sup>

ECT has been found to be particularly effective in treating patients with depression with prominent suicidal ideation or patients with psychotic depression. Response rates have been found to range from 50-80% for patients with treatment-resistant depression, and maintenance medication management or maintenance ECT may significantly decrease the relapse rate.<sup>9,10</sup>

For patients with bipolar disorder, ECT has been used for treatment of severe and psychotic depression, especially if refractory to medication management.<sup>11,12</sup>

For patients with schizophrenia or schizoaffective disorders, ECT may be considered when a rapid global improvement with reduction in symptoms is needed.<sup>13</sup> ECT might also be used in the treatment of catatonia.<sup>14</sup>

ECT may be warranted for patients who are in an acutely life-threatening situation (e.g. high risk for suicide attempt, unrelenting self-injury, catatonia, starvation, intractable manic excitement, or neuroleptic malignant syndrome). ECT might also be indicated when patients have a coexisting medical condition, where ECT is considered a safer therapeutic alternative than behavioral medication management (e.g. pregnant or elderly patients), and for patients who have previously responded well to ECT or who are unwilling or unable to take medications.<sup>1,2,15,16,17</sup>

For patients who have obtained a positive therapeutic response with ECT, but who are unable to sustain the response with post-ECT behavioral health medication management, ECT as maintenance treatment may be

considered, and is generally administered with decreased frequency (e.g. weekly, biweekly, monthly), and might be provided as long-term maintenance treatment, when discontinuation or further reduction in the treatments is likely to lead to a relapse.<sup>1,18</sup>

## Evidence and Source Documents

1. Lisanby SH. Electroconvulsive therapy for depression. N Engl J Med. 2007; 357(19):1939.
2. Kellner CH, Greenberg RM, Murrough JW et al. ECT in treatment-resistant depression. Am J Psychiatry. 2012; 169(12):1238.
3. Fink M, Taylor MA. Electroconvulsive Therapy. Evidence and Challenges. JAMA. 2007;298(3):330-332.  
<http://jama.jamanetwork.com/article.aspx?articleid=207945>
4. Abrams R. Electroconvulsive Therapy. 4<sup>th</sup> ed. New York, NY: Oxford University Press; 2002.
5. Tzabazis A, Schmitt HJ, Ihmsen H, et al. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT 2013. 29:189.
6. Fink M, Abrams R, Bailine S., Jaffe R. Ambulatory electroconvulsive therapy: report of a task force of the association for convulsive therapy. Association for Convulsive Therapy. Convuls Ther 1996; 12:42.
7. Lisanby SH, Maddox JH, Prudic J, et al. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000; 57:581.
8. Sobin C., Sackeim HA, Prudic J, et al. Predictors of retrograde amnesia following ECT. Am J Psychiatry 1995; 152:995.
9. Allan CL, Ebmeier KP. The use of ECT and MST in treating depression. International Review of Psychiatry 2011;23(5):400-12.
10. Nordenskjold A, von Knorring L, Engstrom I. Predictors of the short-term responder rate of Electroconvulsive therapy in depressive disorders – a population-based study. BMC psychiatry 2012; 12:115.
11. Versiani M, Cheniaux E, Landeira-Fernandez J. Efficacy and safety of electroconvulsive therapy in the treatment of bipolar disorder: a systematic review. Journal of ECT 2011;27(2):153-64
12. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar disorders 2012;14(6):573-84.
13. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, (verified by Cochrane 2009 Apr), Issue 2. Art. No.: CD000076.
14. Hatta K, Miyakawa K, Ota T., Usui C, Nakamura H, Arai H. Maximal response to electroconvulsive therapy for the treatment of catatonic symptoms. Journal of ECT 2007;23(4):233-5.
15. Oral ET, et al. electroconvulsive therapy in psychiatric practice: a selective review of the evidence. Neuro Endocrinology Letters 2008;29 Suppl 1:11-32.
16. Nielsen RE, Damkier P. Pharmacological treatment of unipolar depression during pregnancy and breast-feeding – a clinical overview. Nordic Journal of Psychiatry 2012;66(3):159-66.
17. Wilkins KM, Ostroff R, Tampi RR. Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. Journal of Geriatric Psychiatry and Neurology 2008;21(1):3-11.
18. Rapinesi C, et al. Prevention of relapse with maintenance electroconvulsive therapy in elderly patients with major depressive episode. Journal of ECT 2013;29(1):61-4.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
<b>90792</b>	Psychiatric diagnostic evaluation with medical services
<b>90870</b>	Electroconvulsive therapy (includes necessary monitoring)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/01/2015	12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	06/03/2024

Revision History	Description
06/05/2018	MPC approved to adopt MCG* B-802-T for ECT
12/21/2023	Added NCD Multiple Electroconvulsive Therapy (MECT) 160.25
06/03/2024	Added code 90792 and language to clarify that evaluations for the explicit purpose of ECT Therapy will also be reviewed against clinical criteria for ECT.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Elective Surgical Procedures (Level of Care Policy)

- Bariatric Surgery
- Cardiac Procedures
- Dermatologic Procedures
- Electrical Stimulation Devices
- ENT Procedures
- GI Procedures
- General Surgery
- Gynecology Procedures
- Neurosurgery Procedures
- Orthopedic Procedures
- Ophthalmology Procedures
- Pain Management
- Pulmonology Procedures
- Restorative and Cosmetic Procedures
- Spine Procedures
- Urology Procedures
- Vascular Surgery
- Wound care

#### A separate Criteria document exists for the following services:

- [Ambulatory Surgery Center \(ASC\) - Site of Care Policy](#): Certain planned procedures are redirected to an ASC setting from a hospital setting.

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
Code of Federal Regulations (CFR)	<a href="#">42 CFR 412.3</a>
CMS Coverage Manuals	<a href="#">Hospital Outpatient Regulations and Notices</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Elective Surgical Procedures</b> " for <i>level of care medical necessity determinations</i> . Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

When requesting Inpatient Level of Care for certain *elective* surgical procedures (not those typically done in an ambulatory surgery center), the request will be reviewed for coverage in the most appropriate, safe, and cost-

effective level of care. A member's clinical presentation may be appropriate for an alternate level of care such as a hospital-based outpatient setting.

Some elective surgical procedures may also be subject to medical necessity review in addition to level of care criteria below:

A planned elective admission for certain surgeries or procedures is considered medically necessary at an inpatient level of care when any of the following criteria is met:

- Medical conditions increasing the risk of major post-operative complications:
  - Advanced liver disease (MELD Score >8)
  - Cognitive status that warrants inpatient stay
  - Severe renal disease (GFR  $\leq$  30mL/min)
  - Severe valvular heart disease
  - Stroke or TIA within the last 3 months
  - Symptomatic chronic lung disease (e.g., asthma, COPD)
  - Symptomatic coronary artery disease or heart failure
  - Unstable medical condition (e.g., poorly controlled diabetes)
- Procedure related factors that may increase the risk of complications:
  - Anesthetic risk
    - [American Society of Anesthesiologists class III or greater](#)
    - Age 85 years or older
    - High risk for thromboembolism
    - [Moderate \(AHI 15-30\) to severe \(AHI >30\) sleep apnea](#)
    - Persistent electrolyte abnormalities unresponsive to treatment (e.g., hyperkalemia, hyponatremia)
    - Risk of postoperative airway compromise (e.g., open neck procedure, airway surgery)
  - Complexity of surgical procedure
    - Complex surgical approach (e.g., unusually extensive dissection needed)
    - Complex post-operative wound care (e.g., complex drain management, open wound, previous local tissue injury resulting from factors such as radiation, previous surgery, impaired circulation, sustained pressure)
    - Difficult approach because of previous operation
    - Extensive or prolonged (longer than the usual time frame) surgery
- The need for preoperative diagnostic studies that cannot be performed as an outpatient
- Procedural related event that may require an inpatient stay as indicated by the following:
  - [Acute Kidney Injury](#)
  - Altered mental status that is severe or persistent
  - Ambulatory or appropriate activity level status is not achieved
  - Conversion to open or complex procedure that requires inpatient care
  - Excessive drainage or bleeding from the operative site
  - [Hemodynamic instability](#)
  - Longer postoperative monitoring or treatment is needed due to preoperative use of drugs (e.g., cocaine, amphetamines)
  - Pain, fever, or vomiting not appropriate for ambulatory or observation level of care
  - Severe complications of procedure (e.g., bowel injury, airway compromise, vascular injury)
  - Unstable clinical status

Procedures that require review for level of care when requested as inpatient including but not limited to:

\*asterisk in this list indicates that the procedure also requires medical necessity review

- Bariatric Procedures
  - Lap Roux-en-Y\*
  - Lap Band \*
  - Lap Gastric Sleeve\*
  - Lap Band Port Revision\*
  - Intra gastric Balloon\*
- Cardiac Procedures
  - Cardiac Catheterization

- Cardiac EP procedures
- Implantable Loop Recorder\*
- Pacemaker/Defibrillator\*
- Revascularization procedures
- Dermatologic procedures
  - Biopsy
  - Mohs Surgery
  - Soft Tissue Excision
- Electrical Stimulation Devices
  - Gastric Electrical Stimulation\*
  - Vagus Nerve Stimulator\*
  - Electrical Nerve Stimulators\*
- ENT Procedures
  - BAHA\*
  - Cochlear Implant\*
  - Laryngoscopy
  - Thyroidectomy\*
  - Parathyroidectomy
  - Other miscellaneous services (salivary gland bx, excision of oral lesions, frenoplasty, etc.)
  - Rhinoplasty\*
  - Tonsillectomy/Adenoidectomy
  - Tympanostomy/Myringotomy
- GI procedures
  - Biopsies
  - Colonoscopies
  - ERCP
  - Esophagoscopy
- General Surgery
  - Appendectomy
  - Lap Appendectomy
  - Lap Cholecystectomy
  - Hernia Repair (non-hiatal)
  - Lumpectomy
  - Lap Nissen Fundoplication or Esophagogastric Fundoplasty
  - Lap Lysis of adhesions
  - Myotomy\*
  - Other laparoscopic procedures (lap ablation, lap biopsies, diagnostic lap)
  - Splenectomy
  - Vascular Access
- Gynecology Procedures
  - Dilation & Curettage (D&C)
  - Lap Hysterectomy
  - Vaginal Hysterectomy
  - Hysteroscopy
  - Anterior or posterior Colporrhaphy
  - Lap Surgical Myomectomy, oophorectomy and/or salpingectomy\*
- Orthopedic Procedures
  - Autologous Chondrocyte Implantation (Carticel)\*
  - Hip Impingement and labrum Surgery\*
  - Removal of foreign body in muscle or tendon sheath
  - Total Knee arthroplasty\*
  - Knee Arthroscopy\*
  - Total Hip Arthroplasty\*
  - Hip Arthroscopy\*
  - Total Shoulder Arthroplasty\*
  - Open Fracture repair
- Ophthalmology Procedures
  - Excision of lesions

- Keratoplasty
- Vitrectomy
- Pain Management
  - Chemodenervation
  - Spinal Injection\*
- Pulmonology Procedures
  - Bronchoscopy
  - Thoracentesis
  - Thoracoscopy
  - Uvulopalatopharyngoplasty (UPP)\*
- Restorative and Cosmetic Procedures
  - Abdominoplasty/Panniculectomy/Lipectomy\*
  - Blepharoplasty, canthopexy, canthoplasty\*
  - Breast Reconstruction\*
- Spine Procedures
  - Lumbar discectomy, foraminotomy, or laminotomy (elective procedure and at a single level)\*
  - Cervical discectomy or microdiscectomy, foraminotomy, laminotomy
  - Cervical laminectomy\*
  - Cervical Artificial Disc Surgery\*
  - Lumbar laminectomy
  - Anterior/Posterior Cervical fusion\*
  - Single level lumbar fusion\*
  - Vertebroplasty/Kyphoplasty\*
- Urology Procedures
  - Artificial Urinary Sphincter
  - Circumcision (>28 days old)
  - Colpopexy
  - Cystourethroscopy
  - Percutaneous Nephrostomy
  - Transurethral Resection of Prostate (TURP)
  - Orchiectomy\*
  - Laparoscopic Nephrectomy\*
  - Pyeloplasty
  - Vesicovaginal Fistula Repair
  - Prostatectomy
  - Bladder sling—Vaginal approach\*
  - Bladder sling—Male\*
  - Urolift
  - Renal endoscopy
- Vascular Surgery
  - Varicose Vein Procedures\*
- Wound care
- All codes on [ASC SOC policy](#)

## **Definitions**

**ASA physical Status Classification System Risk Scoring tool:** The American Society of Anesthesiologists (ASA) physical status classification system was developed to offer clinicians a simple categorization of a patient's physiological status that can be helpful in predicting operative risk. The ASA score is a subjective assessment of a patient's overall health that is based on five classes. Current Definitions and ASA-Approved examples found [HERE](#).

**Apnea Hypopnea Index (AHI):** The number of apneas plus the number of hypopneas during the entire sleeping period, times 60, divided by total sleep time in minutes; unit: event per hour

**Acute Kidney Injury:** Acute Kidney Injury is defined as any of the following:

- Increase in the serum creatinine value of  $\geq 0.3$  mg/dL (26.52 micromol/L) in 48 hours

- Increase in serum creatinine of  $\geq 1.5$  times baseline within the prior 7 days
- Reduction of more than 50% in estimated glomerular filtration rate from baseline
- Urine volume  $< 0.5$  mL/kg/hour for 6 hours (KDIGO, 2021)

**Hemodynamic Instability:**

Hemodynamic instability, as indicated by **1 or more** of the following:

- Vital sign abnormality not readily corrected by appropriate treatment, as indicated by **1 or more** of the following:
  - Tachycardia that persists despite appropriate treatment (eg, volume repletion, treatment of pain, treatment of underlying cause)
  - Hypotension: systolic blood pressure  $< 90$  mm hg or decrease in systolic blood pressure  $> 40$  mm hg
  - Mean arterial pressure less than 70 mm Hg
  - Orthostatic hypotension that persists despite appropriate treatment (eg, volume repletion)
  - Altered level of consciousness
  - Shortness of breath

**If requesting this these services, for inpatient level of care, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Attending provider must provide documentation in the prior authorization request that supports the need to have an overnight stay of greater than 2 midnights.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Surgery may safely be performed in various settings. Some of the common settings used are an inpatient hospital or medical center, an off-campus outpatient hospital or medical center, or an on campus outpatient hospital. Costs for surgical procedures may vary among these different settings. To encourage the use of the most safe and appropriate, cost effective sites of service for certain medically necessary outpatient surgical procedures, prior authorization is required for the site of service for the surgical procedures listed below.

## Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific contract and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

### *Link to Applicable Codes*

- [Bariatric Surgery](#)
- [Cardiac Procedures](#)
- [Dermatologic Procedures](#)
- [Electrical Stimulation Devices](#)
- [ENT Procedures](#)
- [GI Procedures](#)
- [General Surgery](#)
- [Gynecology Procedures](#)
- [Neurosurgery Procedures](#)
- [Orthopedic Procedures](#)
- [Ophthalmology Procedures](#)

- [Pain Management](#)
- [Pulmonology Procedures](#)
- [Restorative and Cosmetic Procedures](#)
- [Spine Procedures](#)
- [Urology Procedures](#)
- [Vascular Surgery](#)
- [Wound care](#)

### Bariatric Surgery Codes—

**Non-Medicare:** Requires review when submitted as an inpatient level of care

**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Laparoscopic Roux-en-Y</b> Requires Medical Necessity Review: <a href="#">Bariatric Surgery criteria</a>				
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	X		X
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	X		X
<b>Lap Band Procedure</b> Requires Medical Necessity Review: <a href="#">Bariatric Surgery criteria</a>				
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)			X
43771	Laparoscopy, surgical, gastric restrictive procedure; revision of adjustable gastric restrictive device component only	X		X
43772	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device component only			X
43773	Laparoscopy, surgical, gastric restrictive procedure; removal and replacement of adjustable gastric restrictive device component only			X
43774	Laparoscopy, surgical, gastric restrictive procedure; removal of adjustable gastric restrictive device and subcutaneous port components			X
<b>Laparoscopic Gastric Sleeve</b> Requires Medical Necessity Review: <a href="#">Bariatric Surgery criteria</a>				
43775	Laparoscopy, surgical, gastric restrictive procedure; longitudinal gastrectomy (ie, sleeve gastrectomy)	X		X
<b>Lap Band Port Revision</b> Requires Medical Necessity Review: <a href="#">Bariatric Surgery criteria</a>				
43887	Gastric restrictive procedure, open; removal of subcutaneous port component only			X
<b>Intragastric Balloon</b> Requires Medical Necessity Review: <a href="#">Bariatric Surgery criteria</a>				
43291	Esophagogastroduodenoscopy, flexible, transoral; with removal of intragastric bariatric balloon(s)			X

### Cardiac Procedure Codes—

**Non-Medicare:** Requires review when submitted as an inpatient level of care

**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Cardiology</b> Requires medical necessity review: <a href="#">Pacemaker Clinical Review Policy</a> , <a href="#">Cardiac Defibrillators Clinical Review Policy</a>				



CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>33264</b>	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; multiple lead system			
<b>33270</b>	Insertion or replacement of permanent subcutaneous implantable defibrillator system, with subcutaneous electrode, including defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters, when performed			<b>X</b>
<b>33271</b>	Insertion of subcutaneous implantable defibrillator electrode <i>*Requires separate medical necessity review with</i>			<b>X</b>
<b>33274</b>	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed			<b>X</b>
<b>33275</b>	Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when performed			<b>X</b>
<b>C1721</b>	Cardioverter-defibrillator, dual chamber (implantable)			<b>X</b>
<b>C1722</b>	Cardioverter-defibrillator, single chamber (implantable)			<b>X</b>
<b>C1779</b>	Lead, pacemaker, transvenous VDD single pass			<b>X</b>
<b>C1785</b>	Pacemaker, dual chamber, rate-responsive (implantable)			<b>X</b>
<b>C1786</b>	Pacemaker, single chamber, rate-responsive (implantable)			<b>X</b>
<b>C1882</b>	Cardioverter-defibrillator, other than single or dual chamber (implantable)			<b>X</b>
<b>C1898</b>	Lead, pacemaker, other than transvenous VDD single pass			<b>X</b>
<b>C2619</b>	Pacemaker, dual chamber, nonrate-responsive (implantable)			<b>X</b>
<b>C2620</b>	Pacemaker, single chamber, nonrate-responsive (implantable)			<b>X</b>
<b>C2621</b>	Pacemaker, other than single or dual chamber (implantable)			<b>X</b>
<b>C7537</b>	Insertion of new or replacement of permanent pacemaker with atrial transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)			<b>X</b>
<b>C7538</b>	Insertion of new or replacement of permanent pacemaker with ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)			<b>X</b>
<b>C7539</b>	Insertion of new or replacement of permanent pacemaker with atrial and ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)			<b>X</b>
<b>C7540</b>	Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator, dual lead system, with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or			<b>X</b>

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
	pacemaker pulse generator (e.g., for upgrade to dual chamber system)			
<b>0823T</b>	Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed			<b>X</b>
<b>0824T</b>	Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed			<b>X</b>
<b>0825T</b>	Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed			<b>X</b>
<b>0826T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless pacemaker system in single-cardiac chamber			<b>X</b>
<b>0518T</b>	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; battery component only			<b>X</b>
<b>0861T</b>	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)			<b>X</b>
<b>0832T</b>	Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)			<b>X</b>
<b>0863T</b>	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only			<b>X</b>
<b>Cardiac Catheterization</b> <i>Requires Medical Necessity Review: <a href="#">Medically Necessary Services</a></i>				
<b>0523T</b>	Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)			<b>X</b>
<b>92928</b>	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch			
<b>92929</b>	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)			
<b>92933</b>	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch			
<b>92934</b>	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed;			

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
	each additional branch of a major coronary artery (List separately in addition to code for primary procedure)			
<b>92937</b>	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel			
<b>92938</b>	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (List separately in addition to code for primary procedure)			
<b>92943</b>	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel			
<b>92944</b>	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (List separately in addition to code for primary procedure)			
<b>92978</b>	Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (List separately in addition to code for primary procedure)			
<b>92979</b>	Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; each additional vessel (List separately in addition to code for primary procedure)			
<b>93451</b>	Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed			
<b>93452</b>	Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed			
<b>93453</b>	Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed			
<b>93454</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation;			
<b>93455</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography			
<b>93456</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization			
<b>93457</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography,			

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
	imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization			
<b>93458</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed			
<b>93459</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography			
<b>93460</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed			
<b>93461</b>	Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography			
<b>93462</b>	Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (List separately in addition to code for primary procedure)			
<b>93505</b>	Endomyocardial biopsy			
<b>93563</b>	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (List separately in addition to code for primary procedure)			
<b>93564</b>	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (List separately in addition to code for primary procedure)			
<b>93565</b>	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective left ventricular or left atrial angiography (List separately in addition to code for primary procedure)			
<b>93566</b>	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (List separately in addition to code for primary procedure)			

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
93567	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supraaortic aortography (List separately in addition to code for primary procedure)			
93568	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (List separately in addition to code for primary procedure)			
93569	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, unilateral (List separately in addition to code for primary procedure)			
93571	Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (List separately in addition to code for primary procedure)			
93572	Intravascular Doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (List separately in addition to code for primary procedure)			
93573	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary arterial angiography, bilateral (List separately in addition to code for primary procedure)			
93574	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary venous angiography of each distinct pulmonary vein during cardiac catheterization (List separately in addition to code for primary procedure)			
93575	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective pulmonary angiography of major aortopulmonary collateral arteries (MAPCAs) arising off the aorta or its systemic branches, during cardiac catheterization for congenital heart defects, each distinct vessel (List separately in addition to code for primary procedure)			
93593	Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone; normal native connections			
93594	Right heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone; abnormal native connections			
93595	Left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone, normal or abnormal native connections			
93596	Right and left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone(s); normal native connections			
93597	<b>Right and left heart catheterization for congenital heart defect(s) including imaging guidance by the proceduralist to advance the catheter to the target zone(s); abnormal native connections</b>			
93598	Cardiac output measurement(s), thermodilution or other indicator dilution method, performed during cardiac catheterization for the			

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
	evaluation of congenital heart defects (List separately in addition to code for primary procedure)			
<b>Cardiovascular System</b>				
<i>Requires Medical Necessity Review: <a href="#">Medically Necessary Services</a></i>				
<b>33241</b>	Removal of implantable defibrillator pulse generator only			
<b>36821</b>	Arteriovenous anastomosis, open; direct, any site (e.g., Cimino type) (separate procedure)			
<b>36901</b>	Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis			
<b>36902</b>	Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis			
<b>37248</b>	Transluminal balloon angioplasty (except dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same vein; initial vein			<b>X</b>
<b>37609</b>	Ligation or biopsy, temporal artery			
<b>Pacemaker Placement/Defibrillator Placement</b>				
<i>Requires Medical Necessity Review: <a href="#">Pacemakers</a></i>				
<b>33206</b>	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial			<b>X</b>
<b>33207</b>	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); ventricular			
<b>33208</b>	Insertion of new or replacement of permanent pacemaker with transvenous electrode(s); atrial and ventricular			
<b>33210</b>	Insertion or replacement of temporary transvenous single chamber cardiac electrode or pacemaker catheter (separate procedure)			
<b>33211</b>	Insertion or replacement of temporary transvenous dual chamber pacing electrodes (separate procedure)			
<b>33212</b>	Insertion of pacemaker pulse generator only; with existing single lead			
<b>33213</b>	Insertion of pacemaker pulse generator only; with existing dual leads			
<b>33214</b>	Upgrade of implanted pacemaker system, conversion of single chamber system to dual chamber system (includes removal of previously placed pulse generator, testing of existing lead, insertion of new lead, insertion of new pulse generator)			<b>X</b>
<b>33215</b>	Repositioning of previously implanted transvenous pacemaker or implantable defibrillator (right atrial or right ventricular) electrode			
<b>33216</b>	Insertion of a single transvenous electrode, permanent pacemaker or implantable defibrillator			<b>X</b>
<b>33217</b>	Insertion of 2 transvenous electrodes, permanent pacemaker or implantable defibrillator			<b>X</b>
<b>33218</b>	Repair of single transvenous electrode, permanent pacemaker or implantable defibrillator			
<b>33220</b>	Repair of 2 transvenous electrodes for permanent pacemaker or implantable defibrillator			



CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
33221	Insertion of pacemaker pulse generator only; with existing multiple leads			
33223	Relocation of skin pocket for implantable defibrillator			
33224	Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, with attachment to previously placed pacemaker or implantable defibrillator pulse generator (including revision of pocket, removal, insertion, and/or replacement of existing generator)			X
33225	Insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (eg, for upgrade to dual chamber system) (List separately in addition to code for primary procedure)			X
33226	Repositioning of previously implanted cardiac venous system (left ventricular) electrode (including removal, insertion and/or replacement of existing generator)			
33227	Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; single lead system			
33228	Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; dual lead system			
33229	Removal of permanent pacemaker pulse generator with replacement of pacemaker pulse generator; multiple lead system			
33230	Insertion of implantable defibrillator pulse generator only; with existing dual leads			X
33231	Insertion of implantable defibrillator pulse generator only; with existing multiple leads			X
33233	Removal of permanent pacemaker pulse generator only			
33234	Removal of transvenous pacemaker electrode(s); single lead system, atrial or ventricular			
33235	Removal of transvenous pacemaker electrode(s); dual lead system			
33240	Insertion of implantable defibrillator pulse generator only; with existing single lead			X
33243	Removal of single or dual chamber implantable defibrillator electrode(s); by thoracotomy	X		
33244	Removal of single or dual chamber implantable defibrillator electrode(s); by transvenous extraction			
33249	Insertion or replacement of permanent implantable defibrillator system, with transvenous lead(s), single or dual chamber			X
33262	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; single lead system			
33263	Removal of implantable defibrillator pulse generator with replacement of implantable defibrillator pulse generator; dual lead system			
<b>Implantable Loop Recorder</b> <i>Requires Medical Necessity Review: <a href="#">Cardiac Ambulatory Monitoring for Extended Duration</a></i>				
33285	Insertion, subcutaneous cardiac rhythm monitor, including programming			X
<b>Cardiac EP procedures</b>				
33265	Endoscopy, surgical; operative tissue ablation and reconstruction of atria, limited (eg, modified maze procedure), without cardiopulmonary bypass	X		

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>33266</b>	Endoscopy, surgical; operative tissue ablation and reconstruction of atria, extensive (eg, maze procedure), without cardiopulmonary bypass	<b>X</b>		
<b>93619</b>	Comprehensive electrophysiologic evaluation with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording, including insertion and repositioning of multiple electrode catheters, without induction or attempted induction of arrhythmia			<b>X</b>
<b>93620</b>	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with right atrial pacing and recording, right ventricular pacing and recording, His bundle recording			<b>X</b>
<b>93621</b>	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left atrial pacing and recording from coronary sinus or left atrium (List separately in addition to code for primary procedure)			<b>X</b>
<b>93622</b>	Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of arrhythmia; with left ventricular pacing and recording (List separately in addition to code for primary procedure)			<b>X</b>
<b>93650</b>	Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement			<b>X</b>
<b>93653</b>	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including intracardiac electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when performed; with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry			<b>X</b>
<b>93654</b>	Comprehensive electrophysiologic evaluation with insertion and repositioning of multiple electrode catheters, induction or attempted induction of an arrhythmia with right atrial pacing and recording and catheter ablation of arrhythmogenic focus, including intracardiac electrophysiologic 3-dimensional mapping, right ventricular pacing and recording, left atrial pacing and recording from coronary sinus or left atrium, and His bundle recording, when performed; with treatment of ventricular tachycardia or focus of ventricular ectopy including left ventricular pacing and recording, when performed			<b>X</b>
<b>93655</b>	Intracardiac catheter ablation of a discrete mechanism of arrhythmia which is distinct from the primary ablated mechanism, including repeat diagnostic maneuvers, to treat a spontaneous or induced arrhythmia (List separately in addition to code for primary procedure)			<b>X</b>
<b>93656</b>	Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac electrophysiologic 3-dimensional mapping, intracardiac echocardiography including imaging supervision and interpretation, induction or attempted induction of an arrhythmia including left or			<b>X</b>

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
	right atrial pacing/recording, right ventricular pacing/recording, and His bundle recording, when performed			
93657	Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)			
<b>Revascularization</b>				
35565	Bypass graft, with vein; iliofemoral	X		
35661	Bypass graft, with other than vein; femoral-femoral	X		
37220	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal angioplasty			
37221	Revascularization, endovascular, open or percutaneous, iliac artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed			
37222	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)			
37223	Revascularization, endovascular, open or percutaneous, iliac artery, each additional ipsilateral iliac vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)			
37224	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty			
37225	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with atherectomy, includes angioplasty within the same vessel, when performed			
37226	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed			
37227	Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed			
37228	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal angioplasty			
37229	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with atherectomy, includes angioplasty within the same vessel, when performed			
37230	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed			
37231	Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed			
37232	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal angioplasty (List separately in addition to code for primary procedure)			

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>37234</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)			
<b>37235</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery, unilateral, each additional vessel; with transluminal stent placement(s) and atherectomy, includes angioplasty within the same vessel, when performed (List separately in addition to code for primary procedure)			
<b>Valvuloplasty, Mitral Valve</b>				
<b>33425</b>	Valvuloplasty, mitral valve, with cardiopulmonary bypass;	<b>X</b>		
<b>33426</b>	Valvuloplasty, mitral valve, with cardiopulmonary bypass; with prosthetic ring	<b>X</b>		
<b>33427</b>	Valvuloplasty, mitral valve, with cardiopulmonary bypass; radical reconstruction, with or without ring	<b>X</b>		

### Dermatologic Procedure Codes—

**Non-Medicare:** Requires review when submitted as an inpatient level of care

**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>MOHS Surgery</b>				
<b>17311</b>	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks			
<b>17312</b>	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)			
<b>17313</b>	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks			
<b>17314</b>	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each			

	additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)			
<b>17315</b>	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)			
<b>Soft Tissue Excision Biopsy</b> <b>Requires Medical Necessity Review: <a href="#">Cardiac Ambulatory Monitoring for Extended Duration</a>; <a href="#">Nasal Cryoablation</a>, <a href="#">Radiofrequency Ablation &amp; Laser Treatments</a></b>				
<b>10120</b>	Incision and removal of foreign body, subcutaneous tissues; simple			
<b>10140</b>	Incision and drainage of hematoma, seroma or fluid collection			
<b>10160</b>	Puncture aspiration of abscess, hematoma, bulla, or cyst			
<b>11200</b>	Removal of skin tags, multiple fibrocutaneous tags, any area; up to and including 15 lesions			
<b>11310</b>	Shaving of epidermal or dermal lesion, single lesion, face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less			
<b>11402</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 1.1 to 2.0 cm			<b>X</b>
<b>11403</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 2.1 to 3.0 cm			<b>X</b>
<b>11404</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 3.1 to 4.0 cm			<b>X</b>
<b>11406</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter over 4.0 cm			<b>X</b>
<b>11420</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less			<b>X</b>
<b>11421</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm			<b>X</b>
<b>11422</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm			<b>X</b>
<b>11423</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm			<b>X</b>
<b>11424</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm			<b>X</b>
<b>11426</b>	Excision, benign lesion including margins, except skin tag (unless listed elsewhere), scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm			<b>X</b>
<b>11440</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.5 cm or less			<b>X</b>
<b>11441</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.6 to 1.0 cm			<b>X</b>
<b>11442</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 1.1 to 2.0 cm			<b>X</b>
<b>11443</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 2.1 to 3.0 cm			<b>X</b>

<b>11444</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 3.1 to 4.0 cm			<b>X</b>
<b>11446</b>	Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter over 4.0 cm			
<b>11450</b>	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair			<b>X</b>
<b>11451</b>	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair			<b>X</b>
<b>11462</b>	Excision of skin and subcutaneous tissue for hidradenitis, inguinal; with simple or intermediate repair			<b>X</b>
<b>11463</b>	Excision of skin and subcutaneous tissue for hidradenitis, inguinal; with complex repair			<b>X</b>
<b>11470</b>	Excision of skin and subcutaneous tissue for hidradenitis, perianal, perineal, or umbilical; with simple or intermediate repair			<b>X</b>
<b>11471</b>	Excision of skin and subcutaneous tissue for hidradenitis, perianal, perineal, or umbilical; with complex repair			<b>X</b>
<b>11601</b>	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm			
<b>11602</b>	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm			
<b>11603</b>	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm			
<b>11604</b>	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm			
<b>11606</b>	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm			
<b>11620</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less			
<b>11621</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm			
<b>11622</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm			
<b>11623</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm			
<b>11624</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm			
<b>11626</b>	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm			
<b>11640</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less			
<b>11641</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm			
<b>11642</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm			
<b>11643</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm			
<b>11644</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm			
<b>11646</b>	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm			
<b>11730</b>	Avulsion of nail plate, partial or complete, simple; single			
<b>11765</b>	Wedge excision of skin of nail fold (eg, for ingrown toenail)			
<b>21550</b>	Biopsy, soft tissue of neck or thorax			
<b>21552</b>	Excision, tumor, soft tissue of neck or anterior thorax, subcutaneous; 3 cm or greater			



<b>21554</b>	Excision, tumor, soft tissue of neck or anterior thorax, subfascial (eg, intramuscular); 5 cm or greater			
<b>21555</b>	Excision, tumor, soft tissue of neck or anterior thorax, subcutaneous; less than 3 cm			
<b>21556</b>	Excision, tumor, soft tissue of neck or anterior thorax, subfascial (eg, intramuscular); less than 5 cm			
<b>21557</b>	Radical resection of tumor (eg, sarcoma), soft tissue of neck or anterior thorax; less than 5 cm			
<b>21920</b>	Biopsy, soft tissue of back or flank; superficial			
<b>21930</b>	Excision, tumor, soft tissue of back or flank, subcutaneous; less than 3 cm			
<b>21931</b>	Excision, tumor, soft tissue of back or flank, subcutaneous; 3 cm or greater			
<b>21932</b>	Excision, tumor, soft tissue of back or flank, subfascial (eg, intramuscular); less than 5 cm			
<b>21933</b>	Excision, tumor, soft tissue of back or flank, subfascial (e.g., intramuscular); 5 cm or greater			
<b>22900</b>	Excision, tumor, soft tissue of abdominal wall, subfascial (eg, intramuscular); less than 5 cm			
<b>22901</b>	Excision, tumor, soft tissue of abdominal wall, subfascial (eg, intramuscular); 5 cm or greater			
<b>22902</b>	Excision, tumor, soft tissue of abdominal wall, subcutaneous; less than 3 cm			
<b>22903</b>	Excision, tumor, soft tissue of abdominal wall, subcutaneous; 3 cm or greater			
<b>23071</b>	Excision, tumor, soft tissue of shoulder area, subcutaneous; 3 cm or greater			
<b>23075</b>	Excision, tumor, soft tissue of shoulder area, subcutaneous; less than 3 cm			
<b>23076</b>	Excision, tumor, soft tissue of shoulder area, subfascial (e.g., intramuscular); less than 5 cm			
<b>24065</b>	Biopsy, soft tissue of upper arm or elbow area; superficial			
<b>24066</b>	Biopsy, soft tissue of upper arm or elbow area; deep (subfascial or intramuscular)			
<b>24071</b>	Excision, tumor, soft tissue of upper arm or elbow area, subcutaneous; 3 cm or greater			
<b>24073</b>	Excision, tumor, soft tissue of upper arm or elbow area, subfascial (eg, intramuscular); 5 cm or greater			
<b>24075</b>	Excision, tumor, soft tissue of upper arm or elbow area, subcutaneous; less than 3 cm			
<b>24076</b>	Excision, tumor, soft tissue of upper arm or elbow area, subfascial (eg, intramuscular); less than 5 cm			
<b>25071</b>	Excision, tumor, soft tissue of forearm and/or wrist area, subcutaneous; 3 cm or greater			
<b>25073</b>	Excision, tumor, soft tissue of forearm and/or wrist area, subfascial (e.g., intramuscular); 3 cm or greater			
<b>25075</b>	Excision, tumor, soft tissue of forearm and/or wrist area, subcutaneous; less than 3 cm			
<b>25076</b>	Excision, tumor, soft tissue of forearm and/or wrist area, subfascial (e.g., intramuscular); less than 3 cm			
<b>27043</b>	Excision, tumor, soft tissue of pelvis and hip area, subcutaneous; 3 cm or greater			
<b>27045</b>	Excision, tumor, soft tissue of pelvis and hip area, subfascial (eg, intramuscular); 5 cm or greater			
<b>27047</b>	Excision, tumor, soft tissue of pelvis and hip area, subcutaneous; less than 3 cm			

<b>27048</b>	Excision, tumor, soft tissue of pelvis and hip area, subfascial (eg, intramuscular); less than 5 cm			
<b>27062</b>	Excision; trochanteric bursa or calcification			
<b>27327</b>	Excision, tumor, soft tissue of thigh or knee area, subcutaneous; less than 3 cm			
<b>27328</b>	Excision, tumor, soft tissue of thigh or knee area, subfascial (eg, intramuscular); less than 5 cm			
<b>27329</b>	Radical resection of tumor (eg, sarcoma), soft tissue of thigh or knee area; less than 5 cm			
<b>27337</b>	Excision, tumor, soft tissue of thigh or knee area, subcutaneous; 3 cm or greater			
<b>27339</b>	Excision, tumor, soft tissue of thigh or knee area, subfascial (eg, intramuscular); 5 cm or greater			
<b>27613</b>	Biopsy, soft tissue of leg or ankle area; superficial			
<b>27614</b>	Biopsy, soft tissue of leg or ankle area; deep (subfascial or intramuscular)			
<b>27618</b>	Excision, tumor, soft tissue of leg or ankle area, subcutaneous; less than 3 cm			
<b>27632</b>	Excision, tumor, soft tissue of leg or ankle area, subcutaneous; 3 cm or greater			
<b>27634</b>	Excision, tumor, soft tissue of leg or ankle area, subfascial (eg, intramuscular); 5 cm or greater			
<b>27638</b>	Excision or curettage of bone cyst or benign tumor, tibia or fibula; with allograft			
<b>27640</b>	Partial excision (craterization, saucerization, or diaphysectomy), bone (eg, osteomyelitis); tibia			
<b>30100</b>	Biopsy, intranasal			
<b>30110</b>	Excision, nasal polyp(s), simple			
<b>30115</b>	Excision, nasal polyp(s), extensive			
<b>30117</b>	Excision or destruction (eg, laser), intranasal lesion; internal approach			<b>X</b>
<b>30118</b>	Excision or destruction (eg, laser), intranasal lesion; external approach (lateral rhinotomy)			
<b>30130</b>	Excision inferior turbinate, partial or complete, any method			
<b>32408</b>	Core needle biopsy, lung or mediastinum, percutaneous, including imaging guidance, when performed			
<b>38221</b>	Diagnostic bone marrow; biopsy(ies)			
<b>38222</b>	Diagnostic bone marrow; biopsy(ies) and aspiration(s)			
<b>38500</b>	Biopsy or excision of lymph node(s); open, superficial			
<b>38505</b>	Biopsy or excision of lymph node(s); by needle, superficial (eg, cervical, inguinal, axillary)			
<b>38510</b>	Biopsy or excision of lymph node(s); open, deep cervical node(s)			
<b>38760</b>	Inguinofemoral lymphadenectomy, superficial, including Cloquet's node (separate procedure)			
<b>40490</b>	Biopsy of lip			
<b>40510</b>	Excision of lip; transverse wedge excision with primary closure			
<b>40520</b>	Excision of lip; V-excision with primary direct linear closure			
<b>40525</b>	Excision of lip; full thickness, reconstruction with local flap (eg, Estlander or fan)			
<b>40530</b>	Resection of lip, more than one-fourth, without reconstruction			
<b>40808</b>	Biopsy, vestibule of mouth			
<b>40814</b>	Excision of lesion of mucosa and submucosa, vestibule of mouth; with complex repair			
<b>40816</b>	Excision of lesion of mucosa and submucosa, vestibule of mouth; complex, with excision of underlying muscle			
<b>41010</b>	Incision of lingual frenum (frenotomy)			
<b>41100</b>	Biopsy of tongue; anterior two-thirds			

<b>41105</b>	Biopsy of tongue; posterior one-third			
<b>41108</b>	Biopsy of floor of mouth			
<b>42100</b>	Biopsy of palate, uvula			
<b>42410</b>	Excision of parotid tumor or parotid gland; lateral lobe, without nerve dissection			
<b>42804</b>	Biopsy; nasopharynx, visible lesion, simple			
<b>42808</b>	Excision or destruction of lesion of pharynx, any method			
<b>42870</b>	Excision or destruction lingual tonsil, any method (separate procedure)			
<b>49180</b>	Biopsy, abdominal or retroperitoneal mass, percutaneous needle			

**Electrical Stimulation Devices—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>Electrical Stimulation</b>				
<i>Requires Medical Necessity Review: <a href="#">Occipital Nerve Stimulation (ONS) for Primary Headache</a>, <a href="#">Electrical Stimulation and Devices</a>, <a href="#">Treatment of Urinary Incontinence</a>, <a href="#">Deep Brain Stimulation</a>, <a href="#">Spinal Cord Stimulator for Pain</a></i>				
<b>64575</b>	Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)			<b>X</b>
<b>64580</b>	Incision for implantation of neurostimulator electrode array; neuromuscular			<b>X</b>
<b>64555</b>	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)			<b>X</b>
<b>64585</b>	Revision or removal of peripheral neurostimulator electrode array			<b>X</b>
<b>64561</b>	Percutaneous implantation of neurostimulator electrode array; sacral nerve (transforaminal placement) including image guidance, if performed			<b>X</b>
<b>64581</b>	Open implantation of neurostimulator electrode array; sacral nerve (transforaminal placement)			<b>X</b>
<b>61867</b>	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array	<b>X</b>		<b>X</b>
<b>63661</b>	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed			
<b>63663</b>	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed			
<b>63650</b>	Percutaneous implantation of neurostimulator electrode array, epidural			<b>X</b>
<b>63655</b>	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural			<b>X</b>
<b>63662</b>	Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed			
<b>63664</b>	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed			
<b>63685</b>	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver			<b>X</b>
<b>63688</b>	Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array			<b>X</b>
<b>Gastric Electrical Stimulation Device</b>				

Requires Medical Necessity Review: <a href="#">Bariatric Surgery</a> , <a href="#">Electrical Stimulation Devices</a> , <a href="#">Occipital Nerve Stimulation (ONS) for Primary Headache</a>				
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum			X
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum			X
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open	X		X
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling			X
64595	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver			X
Vagus Nerve Stimulation Requires Medical Necessity Review: <a href="#">Deep Brain Stimulation</a> , <a href="#">Vagus Nerve Stimulation</a>				
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array			X
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays			X
61888	Revision or removal of cranial neurostimulator pulse generator or rec			X
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve			X
64568	Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator			X
64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator			X

**ENT Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
Adenoidectomy over 12				
42831	Adenoidectomy, primary; age 12 or over			
42836	Adenoidectomy, secondary; age 12 or over			
Bone Anchored Hearing System (BAHA) Requires medical necessity review: <a href="#">Bone Anchored Hearing System (BAHA)</a> , <a href="#">Cochlear Implant</a>				
69710	Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone			X
69711	Removal or repair of electromagnetic bone conduction hearing device in temporal bone			X
69714	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy			X
69715	Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy			X
69716	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor			X
69717	Replacement (including removal of existing device), osseointegrated implant, skull; with percutaneous attachment to external speech processor			X

<b>69718</b>	Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy			<b>X</b>
<b>69719</b>	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex			<b>X</b>
<b>69726</b>	Removal, entire osseointegrated implant, skull; with percutaneous attachment to external speech processor			<b>X</b>
<b>69727</b>	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, within the mastoid and/or involving a bony defect less than 100 sq mm surface area of bone deep to the outer cranial cortex			<b>X</b>
<b>69728</b>	Removal, entire osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex			<b>X</b>
<b>69729</b>	Implantation, osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside of the mastoid and resulting in removal of greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex			<b>X</b>
<b>69730</b>	Replacement (including removal of existing device), osseointegrated implant, skull; with magnetic transcutaneous attachment to external speech processor, outside the mastoid and involving a bony defect greater than or equal to 100 sq mm surface area of bone deep to the outer cranial cortex			<b>X</b>
<b>Cochlear Implant</b> <i>Requires medical necessity review: <a href="#">Cochlear Implant</a></i>				
<b>69930</b>	Cochlear device implantation, with or without mastoidectomy			<b>X</b>
<b>Laryngoscopy</b>				
<b>31525</b>	Laryngoscopy direct, with or without tracheoscopy; diagnostic, except newborn			
<b>31526</b>	Laryngoscopy direct, with or without tracheoscopy; diagnostic, with operating microscope or telescope			
<b>31528</b>	Laryngoscopy direct, with or without tracheoscopy; with dilation, initial			
<b>31529</b>	Laryngoscopy direct, with or without tracheoscopy; with dilation, subsequent			
<b>31530</b>	Laryngoscopy, direct, operative, with foreign body removal;			
<b>31535</b>	Laryngoscopy, direct, operative, with biopsy;			
<b>31536</b>	Laryngoscopy, direct, operative, with biopsy; with operating microscope or telescope			
<b>31540</b>	Laryngoscopy, direct, operative, with excision of tumor and/or stripping of vocal cords or epiglottis;			
<b>31541</b>	Laryngoscopy, direct, operative, with excision of tumor and/or stripping of vocal cords or epiglottis; with operating microscope or telescope			
<b>31545</b>	Laryngoscopy, direct, operative, with operating microscope or telescope, with submucosal removal of non-neoplastic lesion(s) of vocal cord; reconstruction with local tissue flap(s)			
<b>31546</b>	Laryngoscopy, direct, operative, with operating microscope or telescope, with submucosal removal of non-neoplastic lesion(s) of vocal cord; reconstruction with graft(s) (includes obtaining autograft)			
<b>31570</b>	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic;			
<b>31571</b>	Laryngoscopy, direct, with injection into vocal cord(s), therapeutic; with operating microscope or telescope			
<b>31574</b>	Laryngoscopy, flexible; with injection(s) for augmentation (eg, percutaneous, transoral), unilateral			

<b>31575</b>	Laryngoscopy, flexible; diagnostic			
<b>31576</b>	Laryngoscopy, flexible; with biopsy(ies)			
<b>31578</b>	Laryngoscopy, flexible; with removal of lesion(s), non-laser			
<b>31591</b>	Laryngoplasty, medialization, unilateral			
<b>Parathyroidectomy</b>				
<b>60500</b>	Parathyroidectomy or exploration of parathyroid(s);			
<b>60502</b>	Parathyroidectomy or exploration of parathyroid(s); re-exploration			
<b>Rhinoplasty</b>				
<i>Requires medical necessity review: <a href="#">Rhinoplasty</a>, <a href="#">Gender Reaffirming Surgeries</a></i>				
<b>30400</b>	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip			<b>X</b>
<b>30410</b>	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip			<b>X</b>
<b>30420</b>	Rhinoplasty, primary; including major septal repair			<b>X</b>
<b>30430</b>	Rhinoplasty, secondary; minor revision (small amount of nasal tip work)			<b>X</b>
<b>30435</b>	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies)			<b>X</b>
<b>30450</b>	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)			<b>X</b>
<b>30468</b>	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)			<b>X</b>
<b>Tonsillectomy for those aged 12 and older</b>				
<b>42821</b>	Tonsillectomy and adenoidectomy; age 12 or over			
<b>42826</b>	Tonsillectomy, primary or secondary; age 12 or over			
<b>Tympanostomy</b>				
<i>Requires Medical necessity review: <a href="#">Medically Necessary Services</a></i>				
<b>0583T</b>	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia			<b>X</b>
<b>69420</b>	Myringotomy including aspiration and/or eustachian tube inflation			
<b>69421</b>	Myringotomy including aspiration and/or eustachian tube inflation requiring general anesthesia			
<b>69433</b>	Tympanostomy (requiring insertion of ventilating tube), local or topical anesthesia			
<b>69436</b>	Tympanostomy (requiring insertion of ventilating tube), general anesthesia			
<b>ENT (additional codes)</b>				
<i>Requires Medical necessity review: <a href="#">Surgical Treatment of Migraine Headaches</a></i>				
<b>20912</b>	Cartilage graft; nasal septum			
<b>21012</b>	Excision, tumor, soft tissue of face or scalp, subcutaneous; 2 cm or greater			
<b>21013</b>	Excision, tumor, soft tissue of face and scalp, subfascial (eg, subgaleal, intramuscular); less than 2 cm			
<b>21014</b>	Excision, tumor, soft tissue of face and scalp, subfascial (eg, subgaleal, intramuscular); 2 cm or greater			
<b>21029</b>	Removal by contouring of benign tumor of facial bone (eg, fibrous dysplasia)			
<b>21030</b>	Excision of benign tumor or cyst of maxilla or zygoma by enucleation and curettage			
<b>21031</b>	Excision of torus mandibularis			
<b>21040</b>	Excision of benign tumor or cyst of mandible, by enucleation and/or curettage			
<b>21046</b>	Excision of benign tumor or cyst of mandible; requiring intra-oral osteotomy (eg, locally aggressive or destructive lesion[s])			
<b>21048</b>	Excision of benign tumor or cyst of maxilla; requiring intra-oral osteotomy (eg, locally aggressive or destructive lesion[s])			



21315	Closed treatment of nasal bone fracture with manipulation; without stabilization			
21320	Closed treatment of nasal bone fracture with manipulation; with stabilization			
21325	Open treatment of nasal fracture; uncomplicated			
21330	Open treatment of nasal fracture; complicated, with internal and/or external skeletal fixation			
21335	Open treatment of nasal fracture; with concomitant open treatment of fractured septum			
21336	Open treatment of nasal septal fracture, with or without stabilization			
21337	Closed treatment of nasal septal fracture, with or without stabilization			
30120	Excision or surgical planing of skin of nose for rhinophyma			
30124	Excision dermoid cyst, nose; simple, skin, subcutaneous			
30125	Excision dermoid cyst, nose; complex, under bone or cartilage			
30140	Submucous resection inferior turbinate, partial or complete, any method			
30220	Insertion, nasal septal prosthesis (button)			
30310	Removal foreign body, intranasal; requiring general anesthesia			
30520	Septoplasty or submucous resection, with or without cartilage scoring, contouring or replacement with graft			X
30580	Repair fistula; oromaxillary (combine with 31030 if antrotomy is included)			
30620	Septal or other intranasal dermatoplasty (does not include obtaining graft)			
30630	Repair nasal septal perforations			
30801	Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction); superficial			X
30802	Ablation, soft tissue of inferior turbinates, unilateral or bilateral, any method (eg, electrocautery, radiofrequency ablation, or tissue volume reduction); intramural (ie, submucosal)			X
30901	Control nasal hemorrhage, anterior, simple (limited cautery and/or packing) any method			
30903	Control nasal hemorrhage, anterior, complex (extensive cautery and/or packing) any method			
30930	Fracture nasal inferior turbinate(s), therapeutic			
31020	Sinusotomy, maxillary (antrotomy); intranasal			
31030	Sinusotomy, maxillary (antrotomy); radical (Caldwell-Luc) without removal of antrochoanal polyps			
31032	Sinusotomy, maxillary (antrotomy); radical (Caldwell-Luc) with removal of antrochoanal polyps			
31200	Ethmoidectomy; intranasal, anterior			X
31205	Ethmoidectomy; extranasal, total			X
31238	Nasal/sinus endoscopy, surgical; with control of nasal hemorrhage			
31611	Construction of tracheoesophageal fistula and subsequent insertion of an alaryngeal speech prosthesis (eg, voice button, Blom-Singer prosthesis)			
31820	Surgical closure tracheostomy or fistula; without plastic repair			
40810	Excision of lesion of mucosa and submucosa, vestibule of mouth; without repair			
40812	Excision of lesion of mucosa and submucosa, vestibule of mouth; with simple repair			
41110	Excision of lesion of tongue without closure			
41112	Excision of lesion of tongue with closure; anterior two-thirds			
41113	Excision of lesion of tongue with closure; posterior one-third			
41116	Excision, lesion of floor of mouth			

41520	Frenoplasty (surgical revision of frenum, e.g., with Z-plasty)			
42104	Excision, lesion of palate, uvula; without closure			
42106	Excision, lesion of palate, uvula; with simple primary closure			
42140	Uvulectomy, excision of uvula			
42330	Sialolithotomy; submandibular (submaxillary), sublingual or parotid, uncomplicated, intraoral			
42335	Sialolithotomy; submandibular (submaxillary), complicated, intraoral			
42405	Biopsy of salivary gland; incisional			
42408	Excision of sublingual salivary cyst (ranula)			
42415	Excision of parotid tumor or parotid gland; lateral lobe, with dissection and preservation of facial nerve			
42420	Excision of parotid tumor or parotid gland; total, with dissection and preservation of facial nerve			
42425	Excision of parotid tumor or parotid gland; total, en bloc removal with sacrifice of facial nerve			
42440	Excision of submandibular (submaxillary) gland			
42450	Excision of sublingual gland			
42500	Plastic repair of salivary duct, sialodochoplasty; primary or simple			
42650	Dilation salivary duct			
42800	Biopsy; oropharynx			
42810	Excision branchial cleft cyst or vestige, confined to skin and subcutaneous tissues			
49999	Unlisted procedure, abdomen, peritoneum and omentum			X
60200	Excision of cyst or adenoma of thyroid, or transection of isthmus			X
60210	Partial thyroid lobectomy, unilateral; with or without isthmusectomy			X
60212	Partial thyroid lobectomy, unilateral; with contralateral subtotal lobectomy, including isthmusectomy			X
60220	Total thyroid lobectomy, unilateral; with or without isthmusectomy			X
60225	Total thyroid lobectomy, unilateral; with contralateral subtotal lobectomy, including isthmusectomy			X
60240	Thyroidectomy, total or complete			X
60252	Thyroidectomy, total or subtotal for malignancy; with limited neck dissection			X
60254	Thyroidectomy, total or subtotal for malignancy; with radical neck dissection	X		X
60260	Thyroidectomy, removal of all remaining thyroid tissue following previous removal of a portion of thyroid			X
60270	Thyroidectomy, including substernal thyroid; sternal split or transthoracic approach	X		X
60271	Thyroidectomy, including substernal thyroid; cervical approach			X
69000	Drainage external ear, abscess or hematoma; simple			
69100	Biopsy external ear			
69110	Excision external ear; partial, simple repair			
69140	Excision exostosis(es), external auditory canal			
69145	Excision soft tissue lesion, external auditory canal			
69205	Removal foreign body from external auditory canal; with general anesthesia			
69222	Debridement, mastoidectomy cavity, complex (eg, with anesthesia or more than routine cleaning)			
69310	Reconstruction of external auditory canal (meatoplasty) (eg, for stenosis due to injury, infection) (separate procedure)			
69320	Reconstruction external auditory canal for congenital atresia, single stage			
69424	Ventilating tube removal requiring general anesthesia			
69440	Middle ear exploration through postauricular or ear canal incision			

<b>69450</b>	Tympanolysis, transcanal			
<b>69502</b>	Mastoidectomy; complete			
<b>69505</b>	Mastoidectomy; modified radical			
<b>69550</b>	Excision aural glomus tumor; transcanal			
<b>69602</b>	Revision mastoidectomy; resulting in modified radical mastoidectomy			
<b>69610</b>	Tympanic membrane repair, with or without site preparation of perforation for closure, with or without patch			
<b>69620</b>	Myringoplasty (surgery confined to drumhead and donor area)			
<b>69631</b>	Tympanoplasty without mastoidectomy (including canalplasty, atticotomy and/or middle ear surgery), initial or revision; without ossicular chain reconstruction			
<b>69632</b>	Tympanoplasty without mastoidectomy (including canalplasty, atticotomy and/or middle ear surgery), initial or revision; with ossicular chain reconstruction (eg, postfenestration)			
<b>69633</b>	Tympanoplasty without mastoidectomy (including canalplasty, atticotomy and/or middle ear surgery), initial or revision; with ossicular chain reconstruction and synthetic prosthesis (eg, partial ossicular replacement prosthesis [PORP], total ossicular replacement prosthesis [TORP])			
<b>69635</b>	Tympanoplasty with antrotomy or mastoidotomy (including canalplasty, atticotomy, middle ear surgery, and/or tympanic membrane repair); without ossicular chain reconstruction			
<b>69636</b>	Tympanoplasty with antrotomy or mastoidotomy (including canalplasty, atticotomy, middle ear surgery, and/or tympanic membrane repair); with ossicular chain reconstruction			
<b>69641</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); without ossicular chain reconstruction			
<b>69642</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); with ossicular chain reconstruction			
<b>69643</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); with intact or reconstructed wall, without ossicular chain reconstruction			
<b>69644</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); with intact or reconstructed canal wall, with ossicular chain reconstruction			
<b>69645</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); radical or complete, without ossicular chain reconstruction			
<b>69646</b>	Tympanoplasty with mastoidectomy (including canalplasty, middle ear surgery, tympanic membrane repair); radical or complete, with ossicular chain reconstruction			
<b>69650</b>	Stapes mobilization			
<b>69660</b>	Stapedectomy or stapedotomy with reestablishment of ossicular continuity, with or without use of foreign material;			
<b>69661</b>	Stapedectomy or stapedotomy with reestablishment of ossicular continuity, with or without use of foreign material; with footplate drill out			
<b>69662</b>	Revision of stapedectomy or stapedotomy			
<b>69666</b>	Repair oval window fistula			
<b>69801</b>	Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal			
<b>69805</b>	Endolymphatic sac operation; without shunt			
<b>69806</b>	Endolymphatic sac operation; with shunt			

### Gastroenterology Procedure Codes--

**Non-Medicare:** Requires review when submitted as an inpatient level of care

**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPC Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Endoscopic Procedures</b>				
<i>Requires Medical necessity review: <a href="#">Radiofrequency Ablation</a></i>				
<b>G0105</b>	Colorectal cancer screening; colonoscopy on individual at high risk		<b>X</b>	
<b>G0121</b>	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk		<b>X</b>	
<b>43191</b>	Esophagoscopy, rigid, transoral; diagnostic, including collection of specimen(s) by brushing or washing when performed (separate procedure)		<b>X</b>	
<b>43202</b>	Esophagoscopy, flexible, transoral; with biopsy, single or multiple		<b>X</b>	
<b>43229</b>	Esophagoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)		<b>X</b>	<b>X</b>
<b>43233</b>	Esophagogastroduodenoscopy, flexible, transoral; with dilation of esophagus with balloon ( <b>30</b> mm diameter or larger) (includes fluoroscopic guidance, when performed)		<b>X</b>	
<b>43235</b>	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)		<b>X</b>	
<b>43236</b>	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance		<b>X</b>	
<b>43239</b>	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple		<b>X</b>	
<b>43241</b>	Esophagogastroduodenoscopy, flexible, transoral; with insertion of intraluminal tube or catheter		<b>X</b>	
<b>43242</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)		<b>X</b>	
<b>43245</b>	Esophagogastroduodenoscopy, flexible, transoral; with dilation of gastric/duodenal stricture(s) (eg, balloon, bougie)		<b>X</b>	
<b>43246</b>	Esophagogastroduodenoscopy, flexible, transoral; with directed placement of percutaneous gastrostomy tube		<b>X</b>	
<b>43247</b>	Esophagogastroduodenoscopy, flexible, transoral; with removal of foreign body(s)		<b>X</b>	
<b>43248</b>	Esophagogastroduodenoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) through esophagus over guide wire		<b>X</b>	
<b>43249</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic balloon dilation of esophagus (less than 30 mm diameter)		<b>X</b>	
<b>43251</b>	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique		<b>X</b>	
<b>43254</b>	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic mucosal resection		<b>X</b>	
<b>43255</b>	Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method		<b>X</b>	
<b>43259</b>	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis		<b>X</b>	

<b>43270</b>	Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)		<b>X</b>	<b>X</b>
<b>43450</b>	Dilation of esophagus, by unguided sound or bougie, single or multiple passes		<b>X</b>	
<b>43453</b>	Dilation of esophagus, over guide wire		<b>X</b>	
<b>44360</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)		<b>X</b>	
<b>44361</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with biopsy, single or multiple		<b>X</b>	
<b>44376</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)		<b>X</b>	
<b>44377</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, including ileum; with biopsy, single or multiple		<b>X</b>	
<b>44382</b>	Ileoscopy, through stoma; with biopsy, single or multiple		<b>X</b>	
<b>44386</b>	Endoscopic evaluation of small intestinal pouch (eg, Kock pouch, ileal reservoir [S or J]); with biopsy, single or multiple		<b>X</b>	
<b>44388</b>	Colonoscopy through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)		<b>X</b>	
<b>44389</b>	Colonoscopy through stoma; with biopsy, single or multiple		<b>X</b>	
<b>44394</b>	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique		<b>X</b>	
<b>45100</b>	Biopsy of anorectal wall, anal approach (eg, congenital megacolon)		<b>X</b>	
<b>45171</b>	Excision of rectal tumor, transanal approach; not including muscularis propria (ie, partial thickness)		<b>X</b>	
<b>45172</b>	Excision of rectal tumor, transanal approach; including muscularis propria (ie, full thickness)		<b>X</b>	
<b>45190</b>	Destruction of rectal tumor (eg, electrodesiccation, electrosurgery, laser ablation, laser resection, cryosurgery) transanal approach		<b>X</b>	
<b>45305</b>	Proctosigmoidoscopy, rigid; with biopsy, single or multiple		<b>X</b>	
<b>45334</b>	Sigmoidoscopy, flexible; with control of bleeding, any method		<b>X</b>	
<b>45335</b>	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance		<b>X</b>	
<b>45340</b>	Sigmoidoscopy, flexible; with transendoscopic balloon dilation		<b>X</b>	
<b>45341</b>	Sigmoidoscopy, flexible; with endoscopic ultrasound examination		<b>X</b>	
<b>45342</b>	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)		<b>X</b>	
<b>45349</b>	Sigmoidoscopy, flexible; with endoscopic mucosal resection		<b>X</b>	
<b>45378</b>	Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)		<b>X</b>	
<b>45379</b>	Colonoscopy, flexible; with removal of foreign body(s)		<b>X</b>	
<b>45380</b>	Colonoscopy, flexible; with biopsy, single or multiple		<b>X</b>	
<b>45381</b>	Colonoscopy, flexible; with directed submucosal injection(s), any substance		<b>X</b>	
<b>45382</b>	Colonoscopy, flexible; with control of bleeding, any method		<b>X</b>	
<b>45384</b>	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps		<b>X</b>	
<b>45385</b>	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique		<b>X</b>	
<b>45386</b>	Colonoscopy, flexible; with transendoscopic balloon dilation		<b>X</b>	
<b>45388</b>	Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)		<b>X</b>	

<b>45390</b>	Colonoscopy, flexible; with endoscopic mucosal resection		<b>X</b>	
<b>45391</b>	Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures		<b>X</b>	
<b>45392</b>	Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures		<b>X</b>	
<b>45393</b>	Colonoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed		<b>X</b>	
<b>45398</b>	Colonoscopy, flexible; with band ligation(s) (eg, hemorrhoids)		<b>X</b>	
<b>ERCP</b>				
<b>43260</b>	Endoscopic retrograde cholangiopancreatography (ERCP); diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>43261</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with biopsy, single or multiple			
<b>43262</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with sphincterotomy/papillotomy			
<b>43263</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with pressure measurement of sphincter of Oddi			
<b>43264</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with removal of calculi/debris from biliary/pancreatic duct(s)			
<b>43265</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with destruction of calculi, any method (eg, mechanical, electrohydraulic, lithotripsy)			
<b>43273</b>	Endoscopic cannulation of papilla with direct visualization of pancreatic/common bile duct(s) (List separately in addition to code(s) for primary procedure)			
<b>43274</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with placement of endoscopic stent into biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent			
<b>43275</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with removal of foreign body(s) or stent(s) from biliary/pancreatic duct(s)			
<b>43276</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with removal and exchange of stent(s), biliary or pancreatic duct, including pre- and post-dilation and guide wire passage, when performed, including sphincterotomy, when performed, each stent exchanged			
<b>43277</b>	Endoscopic retrograde cholangiopancreatography (ERCP); with trans-endoscopic balloon dilation of biliary/pancreatic duct(s) or of ampulla (sphincteroplasty), including sphincterotomy, when performed, each duct			
<b>Esophagoscopy</b>				
<b>43195</b>	Esophagoscopy, rigid, transoral; with balloon dilation (less than 30 mm diameter)			
<b>43197</b>	Esophagoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>43200</b>	Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>43211</b>	Esophagoscopy, flexible, transoral; with endoscopic mucosal resection			



<b>43212</b>	Esophagoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)			
<b>43213</b>	Esophagoscopy, flexible, transoral; with dilation of esophagus, by balloon or dilator, retrograde (includes fluoroscopic guidance, when performed)			
<b>43214</b>	Esophagoscopy, flexible, transoral; with dilation of esophagus with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)			
<b>43215</b>	Esophagoscopy, flexible, transoral; with removal of foreign body(s)			
<b>43216</b>	Esophagoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps			
<b>43217</b>	Esophagoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique			
<b>43220</b>	Esophagoscopy, flexible, transoral; with transendoscopic balloon dilation (less than 30 mm diameter)			
<b>43226</b>	Esophagoscopy, flexible, transoral; with insertion of guide wire followed by passage of dilator(s) over guide wire			
<b>43227</b>	Esophagoscopy, flexible, transoral; with control of bleeding, any method			
<b>43231</b>	Esophagoscopy, flexible, transoral; with endosurologic ultrasound examination			
<b>43232</b>	Esophagoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)			
<b>43237</b>	Esophagogastroduodenoscopy, flexible, transoral; with endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures			
<b>43238</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures)			
<b>43240</b>	Esophagogastroduodenoscopy, flexible, transoral; with transmural drainage of pseudocyst (includes placement of transmural drainage catheter[s]/stent[s], when performed, and endoscopic ultrasound, when performed)			
<b>43243</b>	Esophagogastroduodenoscopy, flexible, transoral; with injection sclerosis of esophageal/gastric varices			
<b>43244</b>	Esophagogastroduodenoscopy, flexible, transoral; with band ligation of esophageal/gastric varices			
<b>43250</b>	Esophagogastroduodenoscopy, flexible, transoral; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps			
<b>43253</b>	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided transmural injection of diagnostic or therapeutic substance(s) (eg, anesthetic, neurolytic agent) or fiducial marker(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)			
<b>43266</b>	Esophagogastroduodenoscopy, flexible, transoral; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)			
<b>Gastroenterology Procedures (add'l codes)</b>				
<b>G0104</b>	Colorectal cancer screening; flexible sigmoidoscopy			
<b>G0106</b>	Colorectal cancer screening; alternative to G0104, screening sigmoidoscopy, barium enema			

<b>G0120</b>	Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema			
<b>G0122</b>	Colorectal cancer screening; barium enema			
<b>44340</b>	Revision of colostomy; simple (release of superficial scar) (separate procedure)			
<b>44364</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique			
<b>44369</b>	Small intestinal endoscopy, enteroscopy beyond second portion of duodenum, not including ileum; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique			
<b>44380</b>	Ileoscopy, through stoma; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>44381</b>	Ileoscopy, through stoma; with transendoscopic balloon dilation			
<b>44385</b>	Endoscopic evaluation of small intestinal pouch (eg, Kock pouch, ileal reservoir [S or JJ]); diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>44391</b>	Colonoscopy through stoma; with control of bleeding, any method			
<b>44392</b>	Colonoscopy through stoma; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps			
<b>44408</b>	Colonoscopy through stoma; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed			
<b>44705</b>	Preparation of fecal microbiota for instillation, including assessment of donor specimen			
<b>45330</b>	Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)			
<b>45331</b>	Sigmoidoscopy, flexible; with biopsy, single or multiple			
<b>45332</b>	Sigmoidoscopy, flexible; with removal of foreign body(s)			
<b>45333</b>	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps			
<b>45337</b>	Sigmoidoscopy, flexible; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed			
<b>45338</b>	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique			
<b>45346</b>	Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)			
<b>45347</b>	Sigmoidoscopy, flexible; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)			
<b>45350</b>	Sigmoidoscopy, flexible; with band ligation(s) (eg, hemorrhoids)			
<b>45389</b>	Colonoscopy, flexible; with endoscopic stent placement (includes pre- and post-dilation and guide wire passage, when performed)			
<b>46606</b>	Anoscopy; with biopsy, single or multiple			
<b>46607</b>	Anoscopy; with high-resolution magnification (HRA) (eg, colposcope, operating microscope) and chemical agent enhancement, with biopsy, single or multiple			
<b>46610</b>	Anoscopy; with removal of single tumor, polyp, or other lesion by hot biopsy forceps or bipolar cautery			
<b>46612</b>	Anoscopy; with removal of multiple tumors, polyps, or other lesions by hot biopsy forceps, bipolar cautery or snare technique			

46615	Anoscopy; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique			
46700	Anoplasty, plastic operation for stricture; adult			
46940	Curettage or cautery of anal fissure, including dilation of anal sphincter (separate procedure); initial		X	
47000	Biopsy of liver, needle; percutaneous			
49082	Abdominal paracentesis (diagnostic or therapeutic); without imaging guidance			
49083	Abdominal paracentesis (diagnostic or therapeutic); with imaging guidance			
49422	Removal of tunneled intraperitoneal catheter			
49500	Repair initial inguinal hernia, age 6 months to younger than 5 years, with or without hydrocelectomy; reducible			
49900	Suture, secondary, of abdominal wall for evisceration or dehiscence	X		

**General Surgery Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Appendectomy</b>				
44950	Appendectomy; for ruptured appendix with abscess or generalized peritonitis			
<b>Laparoscopic Appendectomy</b>				
44960	Appendectomy; for ruptured appendix with abscess or generalized peritonitis	X		
44970	Laparoscopy, surgical, appendectomy			
<b>Laparoscopic Procedure</b>				
47370	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); radiofrequency			
47371	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical			
49321	Laparoscopy, surgical; with biopsy (single or multiple)			
45400	Laparoscopy, surgical; proctopexy (for prolapse)	X		
49320	Laparoscopy, abdomen, peritoneum, and omentum, diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)			
49329	Unlisted laparoscopy procedure, abdomen, peritoneum and omentum			
<b>Laparoscopic Cholecystectomy</b>				
47562	Laparoscopy, surgical; cholecystectomy		X	
47563	Laparoscopy, surgical; cholecystectomy with cholangiography		X	
47564	Laparoscopy, surgical; cholecystectomy with exploration of common duct		X	
47570	Laparoscopy, surgical; cholecystoenterostomy	X		
<b>Hernia Repair (non-hiatal)—Femoral, inguinal, and umbilical</b>				
49505	Repair initial inguinal hernia, age 5 years or older; reducible		X	
49507	Repair initial inguinal hernia, age 5 years or older; incarcerated or strangulated		X	
49520	Repair recurrent inguinal hernia, any age; reducible		X	
49521	Repair recurrent inguinal hernia, any age; incarcerated or strangulated		X	
49525	Repair inguinal hernia, sliding, any age		X	
49550	Repair initial femoral hernia, any age; reducible		X	
49553	Repair initial femoral hernia, any age; incarcerated or strangulated		X	

49555	Repair recurrent femoral hernia; reducible		X	
49557	Repair recurrent femoral hernia; incarcerated or strangulated		X	
49591	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible		X	
49593	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible		X	
49595	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), initial, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible		X	
49613	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); less than 3 cm, reducible		X	
49615	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); 3 cm to 10 cm, reducible		X	
49617	Repair of anterior abdominal hernia(s) (ie, epigastric, incisional, ventral, umbilical, spigelian), any approach (ie, open, laparoscopic, robotic), recurrent, including implantation of mesh or other prosthesis when performed, total length of defect(s); greater than 10 cm, reducible	X	X	
49621	Repair of parastomal hernia, any approach (ie, open, laparoscopic, robotic), initial or recurrent, including implantation of mesh or other prosthesis, when performed; reducible	X	X	
49623	Removal of total or near total non-infected mesh or other prosthesis at the time of initial or recurrent anterior abdominal hernia repair or parastomal hernia repair, any approach (ie, open, laparoscopic, robotic) (List separately in addition to code for primary procedure)		X	
49650	Laparoscopy, surgical; repair initial inguinal hernia		X	
49651	Laparoscopy, surgical; repair recurrent inguinal hernia		X	
49659	Unlisted laparoscopy procedure, hernioplasty, herniorrhaphy, herniotomy			X
<b>Proctoplasty, Hemorrhoidectomy, fistula repair, and other procedures</b>				
45500	Proctoplasty; for stenosis		X	
45505	Proctoplasty; for prolapse of mucous membrane		X	
45520	Perirectal injection of sclerosing solution for prolapse		X	
45541	Proctopexy (e.g., for prolapse); perineal approach		X	
45560	Repair of rectocele (separate procedure)		X	
45900	Reduction of procidentia (separate procedure) under anesthesia		X	
45905	Dilation of anal sphincter (separate procedure) under anesthesia other than local		X	
45910	Dilation of rectal stricture (separate procedure) under anesthesia other than local		X	
45915	Removal of fecal impaction or foreign body (separate procedure) under anesthesia		X	
45990	Anorectal exam, surgical, requiring anesthesia (general, spinal, or epidural), diagnostic		X	
46020	Placement of seton		X	
46030	Removal of anal seton, other marker		X	
46040	Incision and drainage of ischiorectal and/or perirectal abscess (separate procedure)		X	

<b>46045</b>	Incision and drainage of intramural, intramuscular, or submucosal abscess, transanal, under anesthesia		<b>X</b>	
<b>46050</b>	Incision and drainage, perianal abscess, superficial		<b>X</b>	
<b>46060</b>	Incision and drainage of ischiorectal or intramural abscess, with fistulectomy or fistulotomy, submuscular, with or without placement of seton			
<b>46080</b>	Sphincterotomy, anal, division of sphincter (separate procedure)		<b>X</b>	
<b>46083</b>	Incision of thrombosed hemorrhoid, external		<b>X</b>	
<b>46200</b>	Fissurectomy, including sphincterotomy, when performed		<b>X</b>	
<b>46220</b>	Excision of single external papilla or tag, anus		<b>X</b>	
<b>46221</b>	Hemorrhoidectomy, internal, by rubber band ligation(s)		<b>X</b>	
<b>46230</b>	Excision of multiple external papillae or tags, anus		<b>X</b>	
<b>46250</b>	Hemorrhoidectomy, external, 2 or more columns/groups		<b>X</b>	
<b>46255</b>	Hemorrhoidectomy, internal and external, single column/group		<b>X</b>	
<b>46257</b>	Hemorrhoidectomy, internal and external, single column/group; with fissurectomy		<b>X</b>	
<b>46258</b>	Hemorrhoidectomy, internal and external, single column/group; with fistulectomy, including fissurectomy, when performed		<b>X</b>	
<b>46260</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups;		<b>X</b>	
<b>46261</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups; with fissurectomy		<b>X</b>	
<b>46262</b>	Hemorrhoidectomy, internal and external, 2 or more columns/groups; with fistulectomy, including fissurectomy, when performed		<b>X</b>	
<b>46270</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); subcutaneous		<b>X</b>	
<b>46275</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); inter-sphincteric		<b>X</b>	
<b>46280</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); trans sphincteric, suprasphincteric, extra sphincteric or multiple, including placement of seton, when performed		<b>X</b>	
<b>46285</b>	Surgical treatment of anal fistula (fistulectomy/fistulotomy); second stage		<b>X</b>	
<b>46288</b>	Closure of anal fistula with rectal advancement flap		<b>X</b>	
<b>46320</b>	Excision of thrombosed hemorrhoid, external		<b>X</b>	
<b>46505</b>	Chemodenervation of internal anal sphincter		<b>X</b>	
<b>46706</b>	Repair of anal fistula with fibrin glue		<b>X</b>	
<b>46707</b>	Repair of anorectal fistula with plug (e.g., porcine small intestine submucosa [SIS])		<b>X</b>	
<b>46750</b>	Sphincteroplasty, anal, for incontinence or prolapse; adult		<b>X</b>	
<b>46753</b>	Graft (Thiersch operation) for rectal incontinence and/or prolapse		<b>X</b>	
<b>46754</b>	Removal of Thiersch wire or suture, anal canal		<b>X</b>	
<b>46760</b>	Sphincteroplasty, anal, for incontinence, adult; muscle transplant		<b>X</b>	
<b>46761</b>	Sphincteroplasty, anal, for incontinence, adult; levator muscle imbrication (Park posterior anal repair)		<b>X</b>	
<b>46900</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; chemical		<b>X</b>	
<b>46910</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; electrodesiccation		<b>X</b>	
<b>46916</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; cryosurgery		<b>X</b>	
<b>46917</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; laser surgery		<b>X</b>	
<b>46922</b>	Destruction of lesion(s), anus (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; surgical excision		<b>X</b>	
<b>46924</b>	Destruction of lesion(s), anus (e.g., condyloma, papilloma, molluscum contagiosum, herpetic vesicle), extensive (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery)		<b>X</b>	



46930	Destruction of internal hemorrhoid(s) by thermal energy (e.g., infrared coagulation, cautery, radiofrequency)		X	
46942	Curettage or cautery of anal fissure, including dilation of anal sphincter (separate procedure); subsequent		X	
46945	Hemorrhoidectomy, internal, by ligation other than rubber band; single hemorrhoid column/group		X	
46946	Hemorrhoidectomy, internal, by ligation other than rubber band; 2 or more hemorrhoid columns/groups			
46947	Hemorrhoidopexy (e.g., for prolapsing internal hemorrhoids) by stapling		X	
46948	Hemorrhoidectomy, internal, by transanal hemorrhoidal dearterialization, 2 or more hemorrhoid columns/groups, including ultrasound guidance, with mucopexy, when performed		X	
<b>Lumpectomy; Partial or Complete Mastectomy</b>				
19300	Mastectomy for gynecomastia			X
19301	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy);		X	
19302	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy			
19303	Mastectomy, simple, complete		X	
19305	Mastectomy, radical, including pectoral muscles, axillary lymph nodes	X		
19306	Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation)	X		
19307	Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle			
<b>Laparoscopic Nissen Fundoplication or Esophagogastric Fundoplasty</b>				
43280	Laparoscopy, surgical, esophagogastric fundoplasty (eg, Nissen, Toupet procedures)			X
43281	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; without implantation of mesh			X
43282	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; with implantation of mesh			X
<b>Lysis of adhesions by laparoscopy (without bowel ischemia, systemic toxicity)</b>				
<b>Laparotomy is Inpatient procedure</b>				
44005	Enterolysis (freeing of intestinal adhesion) (separate procedure)	X		
44180	Laparoscopy, surgical, enterolysis (freeing of intestinal adhesion) (separate procedure)			
<b>Myotomy</b>				
43279	Laparoscopy, surgical, esophagomyotomy (Heller type), with fundoplasty, when performed	X		
43330	Esophagomyotomy (Heller type); abdominal approach	X		
43331	Esophagomyotomy (Heller type); thoracic approach	X		
<b>Per Oral Endoscopic Myotomy (POEM) for Esophageal Achalasia</b>				
<i>Requires Medical Necessity Review: <a href="#">Per Oral Endoscopy Myotomy (POEM) for Esophageal Achalasia</a></i>				
43497	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])			X
<b>Splenectomy</b>				
38100	Splenectomy; total (separate procedure)	X		
38120	Laparoscopy, surgical, splenectomy			
<b>Vascular Access (tunneled catheter, PORT, PICC)</b>				
36010	Introduction of catheter, superior or inferior vena cava			
36215	Selective catheter placement, arterial system; each first order thoracic or brachiocephalic branch, within a vascular family			
36246	Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family			
36556	Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older			



36558	Insertion of tunneled centrally inserted central venous catheter, without subcutaneous port or pump; age 5 years or older			
36561	Insertion of tunneled centrally inserted central venous access device, with subcutaneous port; age 5 years or older			
36563	Insertion of tunneled centrally inserted central venous access device with subcutaneous pump			
36565	Insertion of tunneled centrally inserted central venous access device, requiring 2 catheters via 2 separate venous access sites; without subcutaneous port or pump (eg, Tesio type catheter)			
36566	Insertion of tunneled centrally inserted central venous access device, requiring 2 catheters via 2 separate venous access sites; with subcutaneous port(s)			
36569	Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older			
36571	Insertion of peripherally inserted central venous access device, with subcutaneous port; age 5 years or older			
36573	Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, including all imaging guidance, image documentation, and all associated radiological supervision and interpretation required to perform the insertion; age 5 years or older			
36581	Replacement, complete, of a tunneled centrally inserted central venous catheter, without subcutaneous port or pump, through same venous access			
36582	Replacement, complete, of a tunneled centrally inserted central venous access device, with subcutaneous port, through same venous access			
36589	Removal of tunneled central venous catheter, without subcutaneous port or pump			
36590	Removal of tunneled central venous access device, with subcutaneous port or pump, central or peripheral insertion			
37607	Ligation or banding of angioaccess arteriovenous fistula			

**Gynecology Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Anterior or Posterior Colporrhaphy</b>				
57240	Anterior colporrhaphy, repair of cystocele with or without repair of urethrocele, including cystourethroscopy, when performed			
57250	Posterior colporrhaphy, repair of rectocele with or without perineorrhaphy			
57260	Combined anteroposterior colporrhaphy, including cystourethroscopy, when performed;			
57265	Combined anteroposterior colporrhaphy, including cystourethroscopy, when performed; with enterocele repair			
<b>Colpopexy</b>				
57280	Colpopexy, abdominal approach	X		
57282	Colpopexy, vaginal; extra-peritoneal approach (sacrospinous, iliococcygeus)			
57283	Colpopexy, vaginal; intra-peritoneal approach (uterosacral, levator myorrhaphy)			
57425	Laparoscopy, surgical, colpopexy (suspension of vaginal apex)			
<b>Dilation and Curettage (D&amp;C)</b>				
58120	Dilation and curettage, diagnostic and/or therapeutic (nonobstetrical)			

<b>Hysterectomy</b>				
<b>58552</b>	Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)			
<b>Hysteroscopy</b>				
<i>Requires Medical Necessity Review: <a href="#">Fertility Services</a></i>				
<b>58555</b>	Hysteroscopy, diagnostic (separate procedure)			
<b>58558</b>	Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or polypectomy, with or without D & C			
<b>58559</b>	Hysteroscopy, surgical; with lysis of intrauterine adhesions (any method)			
<b>58560</b>	Hysteroscopy, surgical; with division or resection of intrauterine septum (any method)			<b>X</b>
<b>58561</b>	Hysteroscopy, surgical; with removal of leiomyomata			
<b>58562</b>	Hysteroscopy, surgical; with removal of impacted foreign body			
<b>58563</b>	Hysteroscopy, surgical; with endometrial ablation (eg, endometrial resection, electrosurgical ablation, thermoablation)			
<b>58565</b>	Hysteroscopy, surgical; with bilateral fallopian tube cannulation to induce occlusion by placement of permanent implants			
<b>Laparoscopic Surgical Myomectomy, Oophorectomy, and/or salpingectomy</b>				
<b>19000</b>	Puncture aspiration of cyst of breast;		<b>X</b>	
<b>19001</b>	Puncture aspiration of cyst of breast; each additional cyst (List separately in addition to code for primary procedure)		<b>X</b>	
<b>19020</b>	Mastotomy with exploration or drainage of abscess, deep		<b>X</b>	
<b>19030</b>	Injection procedure only for mammary ductogram or galactogram		<b>X</b>	
<b>19100</b>	Biopsy of breast; percutaneous, needle core, not using imaging guidance (separate procedure)		<b>X</b>	
<b>19101</b>	Biopsy of breast; open, incisional		<b>X</b>	
<b>19110</b>	Nipple exploration, with or without excision of a solitary lactiferous duct or a papilloma lactiferous duct		<b>X</b>	
<b>19112</b>	Excision of lactiferous duct fistula		<b>X</b>	
<b>19120</b>	Excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion (except 19300), open, male or female, 1 or more lesions		<b>X</b>	
<b>19125</b>	Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion		<b>X</b>	
<b>19126</b>	Excision of breast lesion identified by preoperative placement of radiological marker, open; each additional lesion separately identified by a preoperative radiological marker (List separately in addition to code for primary procedure)		<b>X</b>	
<b>38520</b>	Biopsy or excision of lymph node(s); open, deep cervical node(s) with excision scalene fat pad		<b>X</b>	
<b>38525</b>	Biopsy or excision of lymph node(s); open, deep axillary node(s)		<b>X</b>	
<b>38530</b>	Biopsy or excision of lymph node(s); open, internal mammary node(s)		<b>X</b>	
<b>38531</b>	Biopsy or excision of lymph node(s); open, inguinofemoral node(s)		<b>X</b>	
<b>56740</b>	Excision of Bartholin's gland or cyst			
<b>56810</b>	Perineoplasty, repair of perineum, nonobstetrical (separate procedure)			
<b>56821</b>	Colposcopy of the vulva; with biopsy(s)			
<b>57000</b>	Colpotomy; with exploration			
<b>57061</b>	Destruction of vaginal lesion(s); simple (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery)			
<b>57065</b>	Destruction of vaginal lesion(s); extensive (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery)			
<b>57100</b>	Biopsy of vaginal mucosa; simple (separate procedure)			
<b>57130</b>	Excision of vaginal septum			
<b>57135</b>	Excision of vaginal cyst or tumor			

<b>57210</b>	Colpoperineorrhaphy, suture of injury of vagina and/or perineum (nonobstetrical)			
<b>57268</b>	Repair of enterocele, vaginal approach (separate procedure)			
<b>57300</b>	Closure of rectovaginal fistula; vaginal or transanal approach			
<b>57400</b>	Dilation of vagina under anesthesia (other than local)			
<b>57410</b>	Pelvic examination under anesthesia (other than local)			
<b>57415</b>	Removal of impacted vaginal foreign body (separate procedure) under anesthesia (other than local)			
<b>57420</b>	Colposcopy of the entire vagina, with cervix if present;			
<b>57421</b>	Colposcopy of the entire vagina, with cervix if present; with biopsy(s) of vagina/cervix			
<b>57452</b>	Colposcopy of the cervix including upper/adjacent vagina;			
<b>57454</b>	Colposcopy of the cervix including upper/adjacent vagina; with biopsy(s) of the cervix and endocervical curettage			
<b>57456</b>	Colposcopy of the cervix including upper/adjacent vagina; with endocervical curettage			
<b>57461</b>	Colposcopy of the cervix including upper/adjacent vagina; with loop electrode conization of the cervix			
<b>57500</b>	Biopsy of cervix, single or multiple, or local excision of lesion, with or without fulguration (separate procedure)			
<b>57505</b>	Endocervical curettage (not done as part of a dilation and curettage)			
<b>57510</b>	Cautery of cervix; electro or thermal			
<b>57513</b>	Cautery of cervix; laser ablation			
<b>57520</b>	Conization of cervix, with or without fulguration, with or without dilation and curettage, with or without repair; cold knife or laser			
<b>57522</b>	Conization of cervix, with or without fulguration, with or without dilation and curettage, with or without repair; loop electrode excision			
<b>57530</b>	Trachelectomy (cervicectomy), amputation of cervix (separate procedure)			
<b>57700</b>	Cerclage of uterine cervix, nonobstetrical			
<b>57720</b>	Trachelorrhaphy, plastic repair of uterine cervix, vaginal approach			
<b>57800</b>	Dilation of cervical canal, instrumental (separate procedure)			
<b>58100</b>	Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure)			
<b>58545</b>	Laparoscopy, surgical, myomectomy, excision; 1 to 4 intramural myomas with total weight of 250 g or less and/or removal of surface myomas			
<b>58546</b>	Laparoscopy, surgical, myomectomy, excision; 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g			
<b>58661</b>	Laparoscopy, surgical; with removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)			
<b>58662</b>	Laparoscopy, surgical; with fulguration or excision of lesions of the ovary, pelvic viscera, or peritoneal surface by any method			
<b>58670</b>	Laparoscopy, surgical; with fulguration of oviducts (with or without transection)			
<b>58671</b>	Laparoscopy, surgical; with occlusion of oviducts by device (eg, band, clip, or Falope ring)			
<b>58672</b>	Laparoscopy, surgical; with fimbrioplasty			
<b>58673</b>	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)			
<b>58679</b>	Unlisted laparoscopy procedure, oviduct, ovary			
<b>58700</b>	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)	<b>X</b>		
<b>58925</b>	Ovarian cystectomy, unilateral or bilateral			
<b>59150</b>	Laparoscopic treatment of ectopic pregnancy; without salpingectomy and/or oophorectomy			

<b>59151</b>	Laparoscopic treatment of ectopic pregnancy; with salpingectomy and/or oophorectomy			
<b>59200</b>	Insertion of cervical dilator (eg, laminaria, prostaglandin) (separate procedure)			
<b>Laparoscopic Hysterectomy</b>				
<b>58541</b>	Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less			
<b>58542</b>	Laparoscopy, surgical, supracervical hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)			
<b>58543</b>	Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g			
<b>58544</b>	Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)			
<b>58550</b>	Laparoscopy, surgical, with vaginal hysterectomy, for uterus 250 g or less			
<b>58553</b>	Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g			
<b>58554</b>	Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)			
<b>58570</b>	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less			
<b>58571</b>	Laparoscopy, surgical, with total hysterectomy, for uterus 250 g or less; with removal of tube(s) and/or ovary(s)			
<b>58572</b>	Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g			
<b>58573</b>	Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)			
<b>58575</b>	Laparoscopy, surgical, total hysterectomy for resection of malignancy (tumor debulking), with omentectomy including salpingo-oophorectomy, unilateral or bilateral, when performed	<b>X</b>		
<b>Vaginal Hysterectomy</b>				
<b>58260</b>	Vaginal hysterectomy, for uterus 250 g or less			
<b>58262</b>	Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s)			
<b>58263</b>	Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s), with repair of enterocele			
<b>58267</b>	Vaginal hysterectomy, for uterus 250 g or less; with colpo-urethrocystopexy (Marshall-Marchetti-Krantz type, Pereyra type) with or without endoscopic control	<b>X</b>		
<b>58270</b>	Vaginal hysterectomy, for uterus 250 g or less; with repair of enterocele			
<b>58275</b>	Vaginal hysterectomy, with total or partial vaginectomy	<b>X</b>		
<b>58280</b>	Vaginal hysterectomy, with total or partial vaginectomy; with repair of enterocele	<b>X</b>		
<b>58290</b>	Vaginal hysterectomy, for uterus greater than 250 g			
<b>58291</b>	Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)			
<b>58292</b>	Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s), with repair of enterocele			
<b>58294</b>	Vaginal hysterectomy, for uterus greater than 250 g; with repair of enterocele			

**Neurosurgery Procedure Codes-****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC</b>	<b>Requires List</b>
----------------------------	--------------------	------------------------------	---------------------	----------------------

			SOC Review	Medical Necessity Review
<b>Endovascular Occlusion/Embolization</b>				
<i>Requires Medical Necessity Review: <a href="#">Benign Prostatic Hyperplasia (BPH) Treatments</a>, <a href="#">Therasphere and SIR Sphere for Unresectable Hepatocellular Carcinoma</a></i>				
<b>37241</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)			
<b>37242</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (e.g., congenital or acquire arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)			<b>X</b>
<b>37243</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction			<b>X</b>
<b>37244</b>	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for arterial or venous hemorrhage or lymphatic extravasation			
<b>61624</b>	Transcatheter permanent occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method; central nervous system (intracranial, spinal cord)	<b>X</b>		
<b>61626</b>	Transcatheter permanent occlusion or embolization (eg, for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method; non-central nervous system, head or neck (extracranial, brachiocephalic branch)			

**Orthopedic Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Autologous Chondrocyte Implantation (Carticel)</b>				
<i>Requires Medical Necessity Review: <a href="#">Autologous Chondrocyte Implantation for Treatment of Defects in Articular Cartilage of the Knee</a></i>				
<b>J7330</b>	Autologous cultured chondrocytes, implant			<b>X</b>
<b>S2112</b>	Arthroscopy, knee, surgical for harvesting of cartilage (chondrocyte cells)			<b>X</b>
<b>27412</b>	Autologous chondrocyte implantation, knee			<b>X</b>
<b>Bone Debridement</b>				
<b>11044</b>	Debridement, bone (includes epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed); first 20 sq cm or less			
<b>Hip Impingement and Labrum surgery</b>				
<i>Requires Medical Necessity Review: <a href="#">Hip Surgery Procedures for Femoroacetabular Impingement Syndrome</a></i>				
<b>Removal of foreign body in muscle or tendon sheath</b>				

20520	Removal of foreign body in muscle or tendon sheath; simple			
20525	Removal of foreign body in muscle or tendon sheath; deep or complicated			
27299	Unlisted procedure, pelvis or hip joint		X	X
29914	Arthroscopy, hip, surgical; with femoroplasty (i.e., treatment of cam lesion)			X
29915	Arthroscopy, hip, surgical; with acetabuloplasty (i.e., treatment of pincer lesion)			X
29916	Arthroscopy, hip, surgical; with labral repair		X	X
<b>Shoulder Arthroplasty</b>				
Requires Medical Necessity Review: <a href="#">Shoulder Arthroplasty</a>				
23335	Removal of prosthesis, includes debridement and synovectomy when performed; humeral and glenoid components (eg, total shoulder)	X		X
23470	Arthroplasty, glenohumeral joint; hemiarthroplasty			X
23472	Arthroplasty, glenohumeral joint; total shoulder (glenoid and proximal humeral replacement (eg, total shoulder))			X
23473	Revision of total shoulder arthroplasty, including allograft when performed; humeral or glenoid component			X
23474	Revision of total shoulder arthroplasty, including allograft when performed; humeral and glenoid component	X		X
<b>Total Knee Arthroplasty</b>				
Requires Medical Necessity Review: <a href="#">Total Knee Arthroplasty Criteria</a>				
27438	Arthroplasty, patella; with prosthesis			X
27446	Arthroplasty, knee, condyle and plateau; medial OR lateral compartment			X
27447	Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty)			X
27486	Revision of total knee arthroplasty, with or without allograft; 1 component	X		X
27487	Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial component	X		X
27488	Removal of prosthesis, including total knee prosthesis, methylmethacrylate with or without insertion of spacer, knee	X		X
<b>Total Hip Arthroplasty</b>				
Requires Medical Necessity Review: <a href="#">Total Hip Arthroplasty Criteria</a>				
27130	Arthroplasty, acetabular and proximal femoral prosthetic replacement (total hip arthroplasty), with or without autograft or allograft			X
27132	Conversion of previous hip surgery to total hip arthroplasty, with or without autograft or allograft	X		X
27134	Revision of total hip arthroplasty; both components, with or without autograft or allograft	X		X
27137	Revision of total hip arthroplasty; acetabular component only, with or without autograft or allograft	X		X
27138	Revision of total hip arthroplasty; femoral component only, with or without allograft	X		X
27236	Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement	X		X
<b>Orthopedic (additional codes)</b>				
Requires Medical Necessity Review: <a href="#">Tenex</a> , <a href="#">Dermatology</a> , <a href="#">Hip Surgery Procedures for Femoroacetabular Impingement Syndrome</a>				
20200	Biopsy, muscle; superficial		X	
20205	Biopsy, muscle; deep		X	
20206	Biopsy, muscle, percutaneous needle		X	
20220	Biopsy, bone, trocar, or needle; superficial (e.g., ilium, sternum, spinous process, ribs)		X	



<b>20225</b>	Biopsy, bone, trocar, or needle; deep (e.g., vertebral body, femur)		<b>X</b>	
<b>20240</b>	Biopsy, bone, open; superficial (e.g., sternum, spinous process, rib, patella, olecranon process, calcaneus, tarsal, metatarsal, carpal, metacarpal, phalanx)		<b>X</b>	
<b>20245</b>	Biopsy, bone, open; deep (e.g., humeral shaft, ischium, femoral shaft)		<b>X</b>	
<b>20526</b>	Injection, therapeutic (eg, local anesthetic, corticosteroid), carpal tunnel			
<b>20551</b>	Injection(s); single tendon origin/insertion			
<b>20552</b>	Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)			
<b>20553</b>	Injection(s); single or multiple trigger point(s), 3 or more muscles			
<b>20600</b>	Arthrocentesis, aspiration and/or injection, small joint or bursa (eg, fingers, toes); without ultrasound guidance			
<b>20604</b>	Arthrocentesis, aspiration and/or injection, small joint or bursa (eg, fingers, toes); with ultrasound guidance, with permanent recording and reporting			
<b>20605</b>	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); without ultrasound guidance			
<b>20606</b>	Arthrocentesis, aspiration and/or injection, intermediate joint or bursa (eg, temporomandibular, acromioclavicular, wrist, elbow or ankle, olecranon bursa); with ultrasound guidance, with permanent recording and reporting			
<b>20610</b>	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); without ultrasound guidance			
<b>20611</b>	Arthrocentesis, aspiration and/or injection, major joint or bursa (eg, shoulder, hip, knee, subacromial bursa); with ultrasound guidance, with permanent recording and reporting			
<b>20612</b>	Aspiration and/or injection of ganglion cyst(s) any location			
<b>20670</b>	Removal of implant; superficial (eg, buried wire, pin or rod) (separate procedure)			
<b>20680</b>	Removal of implant; deep (eg, buried wire, pin, screw, metal band, nail, rod or plate)			
<b>20693</b>	Adjustment or revision of external fixation system requiring anesthesia (e.g., new pin[s] or wire[s] and/or new ring[s] or bar[s])			
<b>20694</b>	Removal, under anesthesia, of external fixation system			
<b>20924</b>	Tendon graft, from a distance (eg, palmaris, toe extensor, plantaris)		<b>X</b>	
<b>21356</b>	Open treatment of depressed zygomatic arch fracture (eg, Gillies approach)			
<b>23120</b>	Claviculectomy; partial			
<b>23130</b>	Acromioplasty or acromionectomy, partial, with or without coracoacromial ligament release		<b>X</b>	
<b>23140</b>	Excision or curettage of bone cyst or benign tumor of clavicle or scapula		<b>X</b>	
<b>23145</b>	Excision or curettage of bone cyst or benign tumor of clavicle or scapula; with autograft (includes obtaining graft)		<b>X</b>	
<b>23150</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus		<b>X</b>	
<b>23155</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus; with autograft (includes obtaining graft)		<b>X</b>	
<b>23156</b>	Excision or curettage of bone cyst or benign tumor of proximal humerus; with allograft		<b>X</b>	
<b>23405</b>	Tenotomy, shoulder area; single tendon		<b>X</b>	<b>X</b>
<b>23406</b>	Tenotomy, shoulder area; multiple tendons through same incision		<b>X</b>	<b>X</b>
<b>23410</b>	Repair of ruptured musculotendinous cuff (eg, rotator cuff) open; acute		<b>X</b>	
<b>23412</b>	Repair of ruptured musculotendinous cuff (eg, rotator cuff) open; chronic		<b>X</b>	
<b>23415</b>	Coracoacromial ligament release, with or without acromioplasty		<b>X</b>	

<b>23420</b>	Reconstruction of complete shoulder (rotator) cuff avulsion, chronic (includes acromioplasty)		<b>X</b>	
<b>23430</b>	Tenodesis of long tendon of biceps		<b>X</b>	
<b>23440</b>	Resection or transplantation of long tendon of biceps		<b>X</b>	
<b>23450</b>	Capsulorrhaphy, anterior; Putti-Platt procedure or Magnuson type operation		<b>X</b>	
<b>23455</b>	Capsulorrhaphy, anterior; with labral repair (eg, Bankart procedure)		<b>X</b>	
<b>23460</b>	Capsulorrhaphy, anterior, any type; with bone block		<b>X</b>	
<b>23462</b>	Capsulorrhaphy, anterior, any type; with coracoid process transfer		<b>X</b>	
<b>23465</b>	Capsulorrhaphy, glenohumeral joint, posterior, with or without bone block		<b>X</b>	
<b>23466</b>	Capsulorrhaphy, glenohumeral joint, any type multi-directional instability		<b>X</b>	
<b>23480</b>	Osteotomy, clavicle, with or without internal fixation		<b>X</b>	
<b>23485</b>	Osteotomy, clavicle, with or without internal fixation; with bone graft for nonunion or malunion (includes obtaining graft and/or necessary fixation)		<b>X</b>	
<b>23615</b>	Open treatment of proximal humeral (surgical or anatomical neck) fracture, includes internal fixation, when performed, includes repair of tuberosity(s), when performed			
<b>23630</b>	Open treatment of greater humeral tuberosity fracture, includes internal fixation, when performed			
<b>23700</b>	Manipulation under anesthesia, shoulder joint, including application of fixation apparatus (dislocation excluded)		<b>X</b>	
<b>23800</b>	Arthrodesis, glenohumeral joint;		<b>X</b>	<b>X</b>
<b>23802</b>	Arthrodesis, glenohumeral joint; with autogenous graft (includes obtaining graft)		<b>X</b>	<b>X</b>
<b>23930</b>	Incision and drainage, upper arm or elbow area; deep abscess or hematoma		<b>X</b>	
<b>23931</b>	Incision and drainage, upper arm or elbow area; bursa		<b>X</b>	
<b>23935</b>	Incision, deep, with opening of bone cortex (eg, for osteomyelitis or bone abscess), humerus or elbow		<b>X</b>	
<b>24000</b>	Arthrotomy, elbow, including exploration, drainage, or removal of foreign body		<b>X</b>	
<b>24006</b>	Arthrotomy of the elbow, with capsular excision for capsular release (separate procedure)		<b>X</b>	
<b>24100</b>	Arthrotomy, elbow; with synovial biopsy only		<b>X</b>	
<b>24101</b>	Arthrotomy, elbow; with joint exploration, with or without biopsy, with or without removal of loose or foreign body		<b>X</b>	
<b>24102</b>	Arthrotomy, elbow; with synovectomy		<b>X</b>	
<b>24105</b>	Excision, olecranon bursa		<b>X</b>	
<b>24110</b>	Excision or curettage of bone cyst or benign tumor, humerus		<b>X</b>	
<b>24115</b>	Excision or curettage of bone cyst or benign tumor, humerus; with autograft (includes obtaining graft)		<b>X</b>	
<b>24116</b>	Excision or curettage of bone cyst or benign tumor, humerus; with allograft		<b>X</b>	
<b>24120</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process		<b>X</b>	
<b>24125</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process; with autograft (includes obtaining graft)		<b>X</b>	
<b>24126</b>	Excision or curettage of bone cyst or benign tumor of head or neck of radius or olecranon process; with allograft		<b>X</b>	
<b>24130</b>	Excision, radial head		<b>X</b>	
<b>24134</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), shaft or distal humerus		<b>X</b>	
<b>24136</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), radial head or neck		<b>X</b>	

<b>24138</b>	Sequestrectomy (eg, for osteomyelitis or bone abscess), olecranon process		<b>X</b>	
<b>24140</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis), humerus		<b>X</b>	
<b>24145</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis), radial head or neck		<b>X</b>	
<b>24147</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (e.g., osteomyelitis), olecranon process		<b>X</b>	
<b>24149</b>	Radical resection of capsule, soft tissue, and heterotopic bone, elbow, with contracture release (separate procedure)		<b>X</b>	<b>X</b>
<b>24150</b>	Radical resection of tumor, shaft or distal humerus		<b>X</b>	
<b>24152</b>	Radical resection of tumor, radial head or neck		<b>X</b>	
<b>24155</b>	Resection of elbow joint (arthrectomy)		<b>X</b>	
<b>24160</b>	Removal of prosthesis, includes debridement and synovectomy when performed; humeral and ulnar components		<b>X</b>	
<b>24164</b>	Removal of prosthesis, includes debridement and synovectomy when performed; radial head		<b>X</b>	
<b>24200</b>	Removal of foreign body, upper arm or elbow area; subcutaneous		<b>X</b>	
<b>24201</b>	Removal of foreign body, upper arm or elbow area; deep (subfascial or intramuscular)		<b>X</b>	
<b>24220</b>	Injection procedure for elbow arthrography		<b>X</b>	
<b>24300</b>	Manipulation, elbow, under anesthesia		<b>X</b>	
<b>24301</b>	Muscle or tendon transfer, any type, upper arm or elbow, single (excluding 24320-24331)		<b>X</b>	
<b>24305</b>	Tendon lengthening, upper arm or elbow, each tendon		<b>X</b>	
<b>24310</b>	Tenotomy, open, elbow to shoulder, each tendon		<b>X</b>	
<b>24330</b>	Flexor-plasty, elbow (eg, Steindler type advancement);		<b>X</b>	
<b>24331</b>	Flexor-plasty, elbow (eg, Steindler type advancement); with extensor advancement		<b>X</b>	
<b>24332</b>	Tenolysis, triceps		<b>X</b>	
<b>24340</b>	Tenodesis of biceps tendon at elbow (separate procedure)		<b>X</b>	
<b>24341</b>	Repair, tendon or muscle, upper arm or elbow, each tendon or muscle, primary or secondary (excludes rotator cuff)		<b>X</b>	
<b>24342</b>	Reinsertion of ruptured biceps or triceps tendon, distal, with or without tendon graft		<b>X</b>	
<b>24343</b>	Repair lateral collateral ligament, elbow, with local tissue		<b>X</b>	
<b>24344</b>	Reconstruction lateral collateral ligament, elbow, with tendon graft (includes harvesting of graft)		<b>X</b>	
<b>24345</b>	Repair medial collateral ligament, elbow, with local tissue		<b>X</b>	
<b>24346</b>	Reconstruction medial collateral ligament, elbow, with tendon graft (includes harvesting of graft)		<b>X</b>	
<b>24357</b>	Tenotomy, elbow, lateral or medial (e.g., epicondylitis, tennis elbow, golfer's elbow); percutaneous		<b>X</b>	<b>X</b>
<b>24358</b>	Tenotomy, elbow, lateral or medial (e.g., epicondylitis, tennis elbow, golfer's elbow); debridement, soft tissue and/or bone, open		<b>X</b>	
<b>24359</b>	Tenotomy, elbow, lateral or medial (eg, epicondylitis, tennis elbow, golfer's elbow); debridement, soft tissue and/or bone, open with tendon repair or reattachment		<b>X</b>	
<b>24360</b>	Arthroplasty, elbow; with membrane (eg, fascial)		<b>X</b>	
<b>24361</b>	Arthroplasty, elbow; with distal humeral prosthetic replacement		<b>X</b>	
<b>24362</b>	Arthroplasty, elbow; with implant and fascia lata ligament reconstruction		<b>X</b>	
<b>24363</b>	Arthroplasty, elbow; with distal humerus and proximal ulnar prosthetic replacement (eg, total elbow)		<b>X</b>	
<b>24365</b>	Arthroplasty, radial head;		<b>X</b>	
<b>24366</b>	Arthroplasty, radial head; with implant		<b>X</b>	

<b>24370</b>	Revision of total elbow arthroplasty, including allograft when performed; humeral or ulnar component		<b>X</b>	
<b>24371</b>	Revision of total elbow arthroplasty, including allograft when performed; humeral and ulnar component		<b>X</b>	
<b>24400</b>	Osteotomy, humerus, with or without internal fixation		<b>X</b>	
<b>24410</b>	Multiple osteotomies with realignment on intramedullary rod, humeral shaft (Sofield type procedure)		<b>X</b>	
<b>24430</b>	Repair of nonunion or malunion, humerus; without graft (eg, compression technique)		<b>X</b>	
<b>24435</b>	Repair of nonunion or malunion, humerus; with iliac or other autograft (includes obtaining graft)		<b>X</b>	
<b>24470</b>	Hemiepiphyseal arrest (eg, cubitus varus or valgus, distal humerus)		<b>X</b>	
<b>24495</b>	Decompression fasciotomy, forearm, with brachial artery exploration		<b>X</b>	
<b>24498</b>	Prophylactic treatment (nailing, pinning, plating or wiring), with or without methylmethacrylate, humeral shaft		<b>X</b>	
<b>24515</b>	Open treatment of humeral shaft fracture with plate/screws, with or without cerclage			
<b>24516</b>	Treatment of humeral shaft fracture, with insertion of intramedullary implant, with or without cerclage and/or locking screws			
<b>24586</b>	Open treatment of periarticular fracture and/or dislocation of the elbow (fracture distal humerus and proximal ulna and/or proximal radius)			
<b>24615</b>	Open treatment of acute or chronic elbow dislocation			
<b>24665</b>	Open treatment of radial head or neck fracture, includes internal fixation or radial head excision, when performed;			
<b>24666</b>	Open treatment of radial head or neck fracture, includes internal fixation or radial head excision, when performed; with radial head prosthetic replacement			
<b>25000</b>	Incision, extensor tendon sheath, wrist (eg, deQuervains disease)		<b>X</b>	
<b>25001</b>	Incision, flexor tendon sheath, wrist (eg, flexor carpi radialis)		<b>X</b>	
<b>25085</b>	Capsulotomy, wrist (e.g., contracture)		<b>X</b>	
<b>25100</b>	Arthrotomy, wrist joint; with biopsy		<b>X</b>	
<b>25101</b>	Arthrotomy, wrist joint; with joint exploration, with or without biopsy, with or without removal of loose or foreign body		<b>X</b>	
<b>25105</b>	Arthrotomy, wrist joint; with synovectomy		<b>X</b>	
<b>25107</b>	Arthrotomy, distal radioulnar joint including repair of triangular cartilage, complex		<b>X</b>	
<b>25109</b>	Excision of tendon, forearm and/or wrist, flexor or extensor, each		<b>X</b>	
<b>25110</b>	Excision, lesion of tendon sheath, forearm and/or wrist		<b>X</b>	
<b>25111</b>	Excision of ganglion, wrist (dorsal or volar); primary		<b>X</b>	
<b>25112</b>	Excision of ganglion, wrist (dorsal or volar); recurrent		<b>X</b>	
<b>25115</b>	Radical excision of bursa, synovia of wrist, or forearm tendon sheaths (eg, tenosynovitis, fungus, Tbc, or other granulomas, rheumatoid arthritis); flexors		<b>X</b>	
<b>25116</b>	Radical excision of bursa, synovia of wrist, or forearm tendon sheaths (eg, tenosynovitis, fungus, Tbc, or other granulomas, rheumatoid arthritis); extensors, with or without transposition of dorsal retinaculum		<b>X</b>	
<b>25118</b>	Synovectomy, extensor tendon sheath, wrist, single compartment		<b>X</b>	
<b>25119</b>	Synovectomy, extensor tendon sheath, wrist, single compartment; with resection of distal ulna		<b>X</b>	
<b>25120</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process)		<b>X</b>	
<b>25125</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process); with autograft (includes obtaining graft)		<b>X</b>	
<b>25126</b>	Excision or curettage of bone cyst or benign tumor of radius or ulna (excluding head or neck of radius and olecranon process); with allograft		<b>X</b>	

<b>25130</b>	Excision or curettage of bone cyst or benign tumor of carpal bones		<b>X</b>	
<b>25135</b>	Excision or curettage of bone cyst or benign tumor of carpal bones; with autograft (includes obtaining graft)		<b>X</b>	
<b>25136</b>	Excision or curettage of bone cyst or benign tumor of carpal bones; with allograft		<b>X</b>	
<b>25150</b>	Partial excision (craterization, saucerization, or diaphysectomy) of bone (eg, for osteomyelitis); ulna		<b>X</b>	
<b>25151</b>	Partial excision (craterization, saucerization, or diaphysectomy) of bone (e.g., for osteomyelitis); radius		<b>X</b>	
<b>25210</b>	Carpectomy; 1 bone		<b>X</b>	
<b>25215</b>	Carpectomy; all bones of proximal row		<b>X</b>	
<b>25230</b>	Radial styloidectomy (separate procedure)		<b>X</b>	
<b>25240</b>	Excision distal ulna partial or complete (e.g., Darrach type or matched resection)		<b>X</b>	
<b>25260</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; primary, single, each tendon or muscle		<b>X</b>	
<b>25263</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; secondary, single, each tendon or muscle		<b>X</b>	
<b>25265</b>	Repair, tendon or muscle, flexor, forearm and/or wrist; secondary, with free graft (includes obtaining graft), each tendon or muscle		<b>X</b>	
<b>25270</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; primary, single, each tendon or muscle		<b>X</b>	
<b>25272</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; secondary, single, each tendon or muscle		<b>X</b>	
<b>25274</b>	Repair, tendon or muscle, extensor, forearm and/or wrist; secondary, with free graft (includes obtaining graft), each tendon or muscle		<b>X</b>	
<b>25275</b>	Repair, tendon sheath, extensor, forearm and/or wrist, with free graft (includes obtaining graft) (e.g., for extensor carpi ulnaris subluxation)		<b>X</b>	
<b>25280</b>	Lengthening or shortening of flexor or extensor tendon, forearm and/or wrist, single, each tendon		<b>X</b>	
<b>25290</b>	Tenotomy, open, flexor or extensor tendon, forearm and/or wrist, single, each tendon		<b>X</b>	
<b>25295</b>	Tenolysis, flexor or extensor tendon, forearm and/or wrist, single, each tendon		<b>X</b>	
<b>25300</b>	Tenodesis at wrist; flexors of fingers		<b>X</b>	
<b>25301</b>	Tenodesis at wrist; extensors of fingers		<b>X</b>	
<b>25310</b>	Tendon transplantation or transfer, flexor or extensor, forearm and/or wrist, single; each tendon		<b>X</b>	
<b>25312</b>	Tendon transplantation or transfer, flexor or extensor, forearm and/or wrist, single; with tendon graft(s) (includes obtaining graft), each tendon		<b>X</b>	
<b>25315</b>	Flexor origin slide (eg, for cerebral palsy, Volkmann contracture), forearm and/or wrist;		<b>X</b>	
<b>25316</b>	Flexor origin slide (eg, for cerebral palsy, Volkmann contracture), forearm and/or wrist; with tendon(s) transfer		<b>X</b>	
<b>25320</b>	Capsulorrhaphy or reconstruction, wrist, open (eg, capsulodesis, ligament repair, tendon transfer or graft) (includes synovectomy, capsulotomy and open reduction) for carpal instability		<b>X</b>	
<b>25332</b>	Arthroplasty, wrist, with or without interposition, with or without external or internal fixation		<b>X</b>	
<b>25335</b>	Centralization of wrist on ulna (eg, radial club hand)		<b>X</b>	
<b>25337</b>	Reconstruction for stabilization of unstable distal ulna or distal radioulnar joint, secondary by soft tissue stabilization (eg, tendon transfer, tendon graft or weave, or tenodesis) with or without open reduction of distal radioulnar joint		<b>X</b>	
<b>25350</b>	Osteotomy, radius; distal third		<b>X</b>	
<b>25355</b>	Osteotomy, radius; middle or proximal third		<b>X</b>	

<b>25360</b>	Osteotomy; ulna		<b>X</b>	
<b>25365</b>	Osteotomy; radius AND ulna		<b>X</b>	
<b>25370</b>	Multiple osteotomies, with realignment on intramedullary rod (Sofield type procedure); radius OR ulna		<b>X</b>	
<b>25375</b>	Multiple osteotomies, with realignment on intramedullary rod (Sofield type procedure); radius AND ulna		<b>X</b>	
<b>25390</b>	Osteoplasty, radius OR ulna; shortening		<b>X</b>	
<b>25392</b>	Osteoplasty, radius AND ulna; shortening (excluding 64876)		<b>X</b>	
<b>25394</b>	Osteoplasty, carpal bone, shortening		<b>X</b>	
<b>25400</b>	Repair of nonunion or malunion, radius OR ulna; without graft (eg, compression technique)		<b>X</b>	
<b>25405</b>	Repair of nonunion or malunion, radius OR ulna; with autograft (includes obtaining graft)		<b>X</b>	
<b>25415</b>	Repair of nonunion or malunion, radius AND ulna; without graft (eg, compression technique)		<b>X</b>	
<b>25420</b>	Repair of nonunion or malunion, radius AND ulna; with autograft (includes obtaining graft)		<b>X</b>	
<b>25430</b>	Insertion of vascular pedicle into carpal bone (eg, Hori procedure)		<b>X</b>	
<b>25431</b>	Repair of nonunion of carpal bone (excluding carpal scaphoid (navicular)) (includes obtaining graft and necessary fixation), each bone		<b>X</b>	
<b>25440</b>	Repair of nonunion, scaphoid carpal (navicular) bone, with or without radial styloidectomy (includes obtaining graft and necessary fixation)		<b>X</b>	
<b>25441</b>	Arthroplasty with prosthetic replacement; distal radius		<b>X</b>	
<b>25442</b>	Arthroplasty with prosthetic replacement; distal ulna		<b>X</b>	
<b>25443</b>	Arthroplasty with prosthetic replacement; scaphoid carpal (navicular)		<b>X</b>	
<b>25444</b>	Arthroplasty with prosthetic replacement; lunate		<b>X</b>	
<b>25445</b>	Arthroplasty with prosthetic replacement; trapezium		<b>X</b>	
<b>25446</b>	Arthroplasty with prosthetic replacement; distal radius and partial or entire carpus (total wrist)		<b>X</b>	
<b>25447</b>	Arthroplasty, interposition, intercarpal or carpometacarpal joints		<b>X</b>	
<b>25448</b>	Arthroplasty, intercarpal or carpometacarpal joints; suspension, including transfer or transplant of tendon, with interposition, when performed		<b>X</b>	
<b>25449</b>	Revision of arthroplasty, including removal of implant, wrist joint		<b>X</b>	
<b>25450</b>	Epiphyseal arrest by epiphysiodesis or stapling; distal radius OR ulna		<b>X</b>	
<b>25455</b>	Epiphyseal arrest by epiphysiodesis or stapling; distal radius AND ulna		<b>X</b>	
<b>25545</b>	Open treatment of ulnar shaft fracture, includes internal fixation, when performed			
<b>25574</b>	Open treatment of radial AND ulnar shaft fractures, with internal fixation, when performed; of radius OR ulna			
<b>25605</b>	Closed treatment of distal radial fracture (e.g., Colles or Smith type) or epiphyseal separation, includes closed treatment of fracture of ulnar styloid, when performed; with manipulation			
<b>25606</b>	Percutaneous skeletal fixation of distal radial fracture or epiphyseal separation			
<b>25607</b>	Open treatment of distal radial extra-articular fracture or epiphyseal separation, with internal fixation			
<b>25608</b>	Open treatment of distal radial intra-articular fracture or epiphyseal separation; with internal fixation of 2 fragments			
<b>25609</b>	Open treatment of distal radial intra-articular fracture or epiphyseal separation; with internal fixation of 3 or more fragments			
<b>25624</b>	Closed treatment of carpal scaphoid (navicular) fracture; with manipulation			
<b>25628</b>	Open treatment of carpal scaphoid (navicular) fracture, includes internal fixation, when performed			



<b>25645</b>	Open treatment of carpal bone fracture (other than carpal scaphoid [navicular]), each bone			
<b>25652</b>	Open treatment of ulnar styloid fracture			
<b>25800</b>	Arthrodesis, wrist; complete, without bone graft (includes radiocarpal and/or intercarpal and/or carpometacarpal joints)		<b>X</b>	
<b>25805</b>	Arthrodesis, wrist; with sliding graft		<b>X</b>	
<b>25810</b>	Arthrodesis, wrist; with iliac or other autograft (includes obtaining graft)		<b>X</b>	
<b>25820</b>	Arthrodesis, wrist; limited, without bone graft (eg, intercarpal or radiocarpal)		<b>X</b>	
<b>25825</b>	Arthrodesis, wrist; with autograft (includes obtaining graft)		<b>X</b>	
<b>25830</b>	Arthrodesis, distal radioulnar joint with segmental resection of ulna, with or without bone graft (eg, Sauve-Kapandji procedure)		<b>X</b>	
<b>26010</b>	Drainage of finger abscess; simple		<b>X</b>	
<b>26011</b>	Drainage of finger abscess; complicated (e.g., felon)		<b>X</b>	
<b>26020</b>	Drainage of tendon sheath, digit and/or palm, each		<b>X</b>	
<b>26040</b>	Fasciotomy, palmar (eg, Dupuytren's contracture); percutaneous		<b>X</b>	
<b>26045</b>	Fasciotomy, palmar (e.g., Dupuytren's contracture); open, partial		<b>X</b>	
<b>26055</b>	Tendon sheath incision (eg, for trigger finger)		<b>X</b>	
<b>26070</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; carpometacarpal joint		<b>X</b>	
<b>26075</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; metacarpophalangeal joint, each		<b>X</b>	
<b>26080</b>	Arthrotomy, with exploration, drainage, or removal of loose or foreign body; interphalangeal joint, each		<b>X</b>	
<b>26100</b>	Arthrotomy with biopsy; carpometacarpal joint, each		<b>X</b>	
<b>26105</b>	Arthrotomy with biopsy; metacarpophalangeal joint, each		<b>X</b>	
<b>26110</b>	Arthrotomy with biopsy; interphalangeal joint, each		<b>X</b>	
<b>26111</b>	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; 1.5 cm or greater		<b>X</b>	
<b>26113</b>	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (e.g., intramuscular); 1.5 cm or greater		<b>X</b>	
<b>26115</b>	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; less than 1.5 cm		<b>X</b>	
<b>26116</b>	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (e.g., intramuscular); less than 1.5 cm		<b>X</b>	
<b>26117</b>	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; less than 3 cm		<b>X</b>	
<b>26118</b>	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; 3 cm or greater		<b>X</b>	
<b>26121</b>	Fasciectomy, palm only, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft)		<b>X</b>	<b>X</b>
<b>26123</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft)		<b>X</b>	<b>X</b>
<b>26125</b>	Fasciectomy, partial palmar with release of single digit including proximal interphalangeal joint, with or without Z-plasty, other local tissue rearrangement, or skin grafting (includes obtaining graft); each additional digit (List separately in addition to code for primary procedure)		<b>X</b>	<b>X</b>
<b>26160</b>	Excision of lesion of tendon sheath or joint capsule (eg, cyst, mucous cyst, or ganglion), hand or finger		<b>X</b>	
<b>26170</b>	Excision of tendon, palm, flexor or extensor, single, each tendon		<b>X</b>	
<b>26180</b>	Excision of tendon, finger, flexor or extensor, each tendon		<b>X</b>	
<b>26200</b>	Excision or curettage of bone cyst or benign tumor of metacarpal		<b>X</b>	
<b>26205</b>	Excision or curettage of bone cyst or benign tumor of metacarpal; with autograft (includes obtaining graft)		<b>X</b>	

<b>26210</b>	Excision or curettage of bone cyst or benign tumor of proximal, middle, or distal phalanx of finger		<b>X</b>	
<b>26215</b>	Excision or curettage of bone cyst or benign tumor of proximal, middle, or distal phalanx of finger; with autograft (includes obtaining graft)		<b>X</b>	
<b>26230</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis); metacarpal		<b>X</b>	
<b>26235</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (eg, osteomyelitis); proximal or middle phalanx of finger		<b>X</b>	
<b>26236</b>	Partial excision (craterization, saucerization, or diaphysectomy) bone (e.g., osteomyelitis); distal phalanx of finger		<b>X</b>	
<b>26320</b>	Removal of implant from finger or hand		<b>X</b>	
<b>26350</b>	Repair or advancement, flexor tendon, not in zone 2 digital flexor tendon sheath (eg, no man's land); primary or secondary without free graft, each tendon		<b>X</b>	
<b>26352</b>	Repair or advancement, flexor tendon, not in zone 2 digital flexor tendon sheath (eg, no man's land); secondary with free graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26356</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (e.g., no man's land); primary, without free graft, each tendon		<b>X</b>	
<b>26357</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (e.g., no man's land); secondary, without free graft, each tendon		<b>X</b>	
<b>26358</b>	Repair or advancement, flexor tendon, in zone 2 digital flexor tendon sheath (eg, no man's land); secondary, with free graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26370</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; primary, each tendon		<b>X</b>	
<b>26372</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; secondary with free graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26373</b>	Repair or advancement of profundus tendon, with intact superficialis tendon; secondary without free graft, each tendon		<b>X</b>	
<b>26392</b>	Removal of synthetic rod and insertion of flexor tendon graft, hand or finger (includes obtaining graft), each rod		<b>X</b>	
<b>26410</b>	Repair, extensor tendon, hand, primary or secondary; without free graft, each tendon		<b>X</b>	
<b>26412</b>	Repair, extensor tendon, hand, primary or secondary; with free graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26418</b>	Repair, extensor tendon, finger, primary or secondary; without free graft, each tendon		<b>X</b>	
<b>26420</b>	Repair, extensor tendon, finger, primary or secondary; with free graft (includes obtaining graft) each tendon		<b>X</b>	
<b>26426</b>	Repair of extensor tendon, central slip, secondary (e.g., boutonniere deformity); using local tissue(s), including lateral band(s), each finger		<b>X</b>	
<b>26428</b>	Repair of extensor tendon, central slip, secondary (eg, boutonniere deformity); with free graft (includes obtaining graft), each finger		<b>X</b>	
<b>26432</b>	Closed treatment of distal extensor tendon insertion, with or without percutaneous pinning (e.g., mallet finger)		<b>X</b>	
<b>26433</b>	Repair of extensor tendon, distal insertion, primary or secondary; without graft (e.g., mallet finger)		<b>X</b>	
<b>26434</b>	Repair of extensor tendon, distal insertion, primary or secondary; with free graft (includes obtaining graft)		<b>X</b>	
<b>26437</b>	Realignment of extensor tendon, hand, each tendon		<b>X</b>	
<b>26440</b>	Tenolysis, flexor tendon; palm or finger, each tendon		<b>X</b>	
<b>26442</b>	Tenolysis, flexor tendon; palm and finger, each tendon		<b>X</b>	
<b>26445</b>	Tenolysis, extensor tendon, hand or finger, each tendon		<b>X</b>	

<b>26449</b>	Tenolysis, complex, extensor tendon, finger, including forearm, each tendon		<b>X</b>	
<b>26450</b>	Tenotomy, flexor, palm, open, each tendon		<b>X</b>	
<b>26455</b>	Tenotomy, flexor, finger, open, each tendon		<b>X</b>	
<b>26460</b>	Tenotomy, extensor, hand or finger, open, each tendon		<b>X</b>	
<b>26480</b>	Transfer or transplant of tendon, carpometacarpal area or dorsum of hand; without free graft, each tendon		<b>X</b>	
<b>26483</b>	Transfer or transplant of tendon, carpometacarpal area or dorsum of hand; with free tendon graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26485</b>	Transfer or transplant of tendon, palmar; without free tendon graft, each tendon		<b>X</b>	
<b>26489</b>	Transfer or transplant of tendon, palmar; with free tendon graft (includes obtaining graft), each tendon		<b>X</b>	
<b>26500</b>	Reconstruction of tendon pulley, each tendon; with local tissues (separate procedure)		<b>X</b>	
<b>26502</b>	Reconstruction of tendon pulley, each tendon; with tendon or fascial graft (includes obtaining graft) (separate procedure)		<b>X</b>	
<b>26516</b>	Capsulodesis, metacarpophalangeal joint; single digit		<b>X</b>	
<b>26517</b>	Capsulodesis, metacarpophalangeal joint; 2 digits		<b>X</b>	
<b>26518</b>	Capsulodesis, metacarpophalangeal joint; 3 or 4 digits		<b>X</b>	
<b>26520</b>	Capsulectomy or capsulotomy; metacarpophalangeal joint, each joint		<b>X</b>	
<b>26525</b>	Capsulectomy or capsulotomy; interphalangeal joint, each joint		<b>X</b>	
<b>26530</b>	Arthroplasty, metacarpophalangeal joint; each joint			
<b>26535</b>	Arthroplasty, interphalangeal joint; each joint			
<b>26540</b>	Repair of collateral ligament, metacarpophalangeal or interphalangeal joint		<b>X</b>	
<b>26541</b>	Reconstruction, collateral ligament, metacarpophalangeal joint, single; with tendon or fascial graft (includes obtaining graft)		<b>X</b>	
<b>26542</b>	Reconstruction, collateral ligament, metacarpophalangeal joint, single; with local tissue (e.g., adductor advancement)		<b>X</b>	
<b>26545</b>	Reconstruction, collateral ligament, interphalangeal joint, single, including graft, each joint		<b>X</b>	
<b>26565</b>	Osteotomy; metacarpal, each		<b>X</b>	
<b>26567</b>	Osteotomy; phalanx of finger, each		<b>X</b>	
<b>26587</b>	Reconstruction of polydactylous digit, soft tissue and bone		<b>X</b>	
<b>26590</b>	Repair macrodactylia, each digit		<b>X</b>	
<b>26591</b>	Repair, intrinsic muscles of hand, each muscle		<b>X</b>	
<b>26593</b>	Release, intrinsic muscles of hand, each muscle		<b>X</b>	
<b>26596</b>	Excision of constricting ring of finger, with multiple Z-plasties		<b>X</b>	
<b>26600</b>	Closed treatment of metacarpal fracture, single; without manipulation, each bone		<b>X</b>	
<b>26605</b>	Closed treatment of metacarpal fracture, single; with manipulation, each bone		<b>X</b>	
<b>26607</b>	Closed treatment of metacarpal fracture, with manipulation, with external fixation, each bone		<b>X</b>	
<b>26608</b>	Percutaneous skeletal fixation of metacarpal fracture, each bone		<b>X</b>	
<b>26615</b>	Open treatment of metacarpal fracture, single, includes internal fixation, when performed, each bone		<b>X</b>	
<b>26641</b>	Closed treatment of carpometacarpal dislocation, thumb, with manipulation		<b>X</b>	
<b>26645</b>	Closed treatment of carpometacarpal fracture dislocation, thumb (Bennett fracture), with manipulation		<b>X</b>	
<b>26650</b>	Percutaneous skeletal fixation of carpometacarpal fracture dislocation, thumb (Bennett fracture), with manipulation		<b>X</b>	
<b>26665</b>	Open treatment of carpometacarpal fracture dislocation, thumb (Bennett fracture), includes internal fixation, when performed		<b>X</b>	

<b>26670</b>	Closed treatment of carpometacarpal dislocation, other than thumb, with manipulation, each joint; without anesthesia		<b>X</b>	
<b>26675</b>	Closed treatment of carpometacarpal dislocation, other than thumb, with manipulation, each joint; requiring anesthesia		<b>X</b>	
<b>26676</b>	Percutaneous skeletal fixation of carpometacarpal dislocation, other than thumb, with manipulation, each joint		<b>X</b>	
<b>26685</b>	Open treatment of carpometacarpal dislocation, other than thumb; includes internal fixation, when performed, each joint		<b>X</b>	
<b>26686</b>	Open treatment of carpometacarpal dislocation, other than thumb; complex, multiple, or delayed reduction		<b>X</b>	
<b>26700</b>	Closed treatment of metacarpophalangeal dislocation, single, with manipulation; without anesthesia		<b>X</b>	
<b>26705</b>	Closed treatment of metacarpophalangeal dislocation, single, with manipulation; requiring anesthesia		<b>X</b>	
<b>26706</b>	Percutaneous skeletal fixation of metacarpophalangeal dislocation, single, with manipulation		<b>X</b>	
<b>26715</b>	Open treatment of metacarpophalangeal dislocation, single, includes internal fixation, when performed		<b>X</b>	
<b>26720</b>	Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; without manipulation, each		<b>X</b>	
<b>26725</b>	Closed treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb; with manipulation, with or without skin or skeletal traction, each		<b>X</b>	
<b>26727</b>	Percutaneous skeletal fixation of unstable phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, with manipulation, each		<b>X</b>	
<b>26735</b>	Open treatment of phalangeal shaft fracture, proximal or middle phalanx, finger or thumb, includes internal fixation, when performed, each		<b>X</b>	
<b>26740</b>	Closed treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint; without manipulation, each		<b>X</b>	
<b>26742</b>	Closed treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint; with manipulation, each		<b>X</b>	
<b>26746</b>	Open treatment of articular fracture, involving metacarpophalangeal or interphalangeal joint, includes internal fixation, when performed, each		<b>X</b>	
<b>26750</b>	Closed treatment of distal phalangeal fracture, finger or thumb; without manipulation, each		<b>X</b>	
<b>26755</b>	Closed treatment of distal phalangeal fracture, finger or thumb; with manipulation, each		<b>X</b>	
<b>26756</b>	Percutaneous skeletal fixation of distal phalangeal fracture, finger or thumb, each		<b>X</b>	
<b>26765</b>	Open treatment of distal phalangeal fracture, finger or thumb, includes internal fixation, when performed, each		<b>X</b>	
<b>26770</b>	Closed treatment of interphalangeal joint dislocation, single, with manipulation; without anesthesia		<b>X</b>	
<b>26775</b>	Closed treatment of interphalangeal joint dislocation, single, with manipulation; requiring anesthesia		<b>X</b>	
<b>26776</b>	Percutaneous skeletal fixation of interphalangeal joint dislocation, single, with manipulation		<b>X</b>	
<b>26785</b>	Open treatment of interphalangeal joint dislocation, includes internal fixation, when performed, single		<b>X</b>	
<b>26841</b>	Arthrodesis, carpometacarpal joint, thumb, with or without internal fixation		<b>X</b>	
<b>26842</b>	Arthrodesis, carpometacarpal joint, thumb, with or without internal fixation; with autograft (includes obtaining graft)		<b>X</b>	
<b>26843</b>	Arthrodesis, carpometacarpal joint, digit, other than thumb, each;		<b>X</b>	
<b>26844</b>	Arthrodesis, carpometacarpal joint, digit, other than thumb, each; with autograft (includes obtaining graft)		<b>X</b>	

<b>26850</b>	Arthrodesis, metacarpophalangeal joint, with or without internal fixation		<b>X</b>	
<b>26852</b>	Arthrodesis, metacarpophalangeal joint, with or without internal fixation; with autograft (includes obtaining graft)		<b>X</b>	
<b>26860</b>	Arthrodesis, interphalangeal joint, with or without internal fixation		<b>X</b>	
<b>26861</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; each additional interphalangeal joint (List separately in addition to code for primary procedure)		<b>X</b>	
<b>26862</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft)		<b>X</b>	
<b>26863</b>	Arthrodesis, interphalangeal joint, with or without internal fixation; with autograft (includes obtaining graft), each additional joint (List separately in addition to code for primary procedure)		<b>X</b>	
<b>26910</b>	Amputation, metacarpal, with finger or thumb (ray amputation), single, with or without interosseous transfer		<b>X</b>	
<b>26951</b>	Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with direct closure		<b>X</b>	
<b>26952</b>	Amputation, finger or thumb, primary or secondary, any joint or phalanx, single, including neurectomies; with local advancement flaps (V-Y, hood)		<b>X</b>	
<b>27006</b>	Tenotomy, abductors and/or extensor(s) of hip, open (separate procedure)			
<b>27093</b>	Injection procedure for hip arthrography; without anesthesia			
<b>27095</b>	Injection procedure for hip arthrography; with anesthesia			
<b>27235</b>	Percutaneous skeletal fixation of femoral fracture, proximal end, neck			
<b>27245</b>	Treatment of intertrochanteric, peritrochanteric, or subtrochanteric femoral fracture; with intramedullary implant, with or without interlocking screws and/or cerclage	<b>X</b>		
<b>27248</b>	Open treatment of greater trochanteric fracture, includes internal fixation, when performed	<b>X</b>		
<b>27301</b>	Incision and drainage, deep abscess, bursa, or hematoma, thigh or knee region		<b>X</b>	
<b>27310</b>	Arthrotomy, knee, with exploration, drainage, or removal of foreign body (e.g., infection)		<b>X</b>	
<b>27323</b>	Biopsy, soft tissue of thigh or knee area; superficial		<b>X</b>	
<b>27324</b>	Biopsy, soft tissue of thigh or knee area; deep (subfascial or intramuscular)		<b>X</b>	
<b>27330</b>	Arthrotomy, knee; with synovial biopsy only		<b>X</b>	
<b>27331</b>	Arthrotomy, knee; including joint exploration, biopsy, or removal of loose or foreign bodies		<b>X</b>	
<b>27332</b>	Arthrotomy, with excision of semilunar cartilage (meniscectomy) knee; medial or lateral		<b>X</b>	
<b>27333</b>	Arthrotomy, with excision of semilunar cartilage (meniscectomy) knee; medial AND lateral		<b>X</b>	
<b>27334</b>	Arthrotomy, with synovectomy, knee; anterior or posterior		<b>X</b>	
<b>27335</b>	Arthrotomy, with synovectomy, knee; anterior and posterior including popliteal area		<b>X</b>	
<b>27340</b>	Excision, prepatellar bursa		<b>X</b>	
<b>27345</b>	Excision of synovial cyst of popliteal space (e.g., Baker's cyst)		<b>X</b>	
<b>27347</b>	Excision of lesion of meniscus or capsule (e.g., cyst, ganglion), knee		<b>X</b>	
<b>27350</b>	Patellectomy or hemipatellectomy		<b>X</b>	
<b>27372</b>	Removal of foreign body, deep, thigh region or knee area		<b>X</b>	
<b>27380</b>	Suture of infrapatellar tendon; primary		<b>X</b>	
<b>27381</b>	Suture of infrapatellar tendon; secondary reconstruction, including fascial or tendon graft		<b>X</b>	
<b>27385</b>	Suture of quadriceps or hamstring muscle rupture; primary		<b>X</b>	
<b>27386</b>	Suture of quadriceps or hamstring muscle rupture; secondary reconstruction, including fascial or tendon graft		<b>X</b>	



<b>27403</b>	Arthrotomy with meniscus repair, knee		<b>X</b>	
<b>27405</b>	Repair, primary, torn ligament and/or capsule, knee; collateral		<b>X</b>	
<b>27407</b>	Repair, primary, torn ligament and/or capsule, knee; cruciate		<b>X</b>	
<b>27409</b>	Repair, primary, torn ligament and/or capsule, knee; collateral and cruciate ligaments		<b>X</b>	
<b>27416</b>	Osteochondral autograft(s), knee, open (eg, mosaicplasty) (includes harvesting of autograft[s])		<b>X</b>	<b>X</b>
<b>27418</b>	Anterior tibial tubercleplasty (e.g., Maquet type procedure)		<b>X</b>	
<b>27420</b>	Reconstruction of dislocating patella; (eg, Hauser type procedure)		<b>X</b>	
<b>27422</b>	Reconstruction of dislocating patella; with extensor realignment and/or muscle advancement or release (eg, Campbell, Goldwaite type procedure)		<b>X</b>	
<b>27424</b>	Reconstruction of dislocating patella; with patellectomy		<b>X</b>	
<b>27427</b>	Ligamentous reconstruction (augmentation), knee; extra-articular		<b>X</b>	
<b>27428</b>	Ligamentous reconstruction (augmentation), knee; intra-articular (open)		<b>X</b>	
<b>27429</b>	Ligamentous reconstruction (augmentation), knee; intra-articular (open) and extra-articular		<b>X</b>	
<b>27506</b>	Open treatment of femoral shaft fracture, with or without external fixation, with insertion of intramedullary implant, with or without cerclage and/or locking screws	<b>X</b>		
<b>27507</b>	Open treatment of femoral shaft fracture with plate/screws, with or without cerclage	<b>X</b>		
<b>27509</b>	Percutaneous skeletal fixation of femoral fracture, distal end, medial or lateral condyle, or supracondylar or transcondylar, with or without intercondylar extension, or distal femoral epiphyseal separation			
<b>27511</b>	Open treatment of femoral supracondylar or transcondylar fracture without intercondylar extension, includes internal fixation, when performed	<b>X</b>		
<b>27513</b>	Open treatment of femoral supracondylar or transcondylar fracture with intercondylar extension, includes internal fixation, when performed	<b>X</b>		
<b>27514</b>	Open treatment of femoral fracture, distal end, medial or lateral condyle, includes internal fixation, when performed	<b>X</b>		
<b>27519</b>	Open treatment of distal femoral epiphyseal separation, includes internal fixation, when performed	<b>X</b>		
<b>27524</b>	Open treatment of patellar fracture, with internal fixation and/or partial or complete patellectomy and soft tissue repair			
<b>27535</b>	Open treatment of tibial fracture, proximal (plateau); unicondylar, includes internal fixation, when performed	<b>X</b>		
<b>27536</b>	Open treatment of tibial fracture, proximal (plateau); bicondylar, with or without internal fixation	<b>X</b>		
<b>27540</b>	Open treatment of intercondylar spine(s) and/or tuberosity fracture(s) of the knee, includes internal fixation, when performed	<b>X</b>		
<b>27556</b>	Open treatment of knee dislocation, includes internal fixation, when performed; without primary ligamentous repair or augmentation/reconstruction	<b>X</b>		
<b>27557</b>	Open treatment of knee dislocation, includes internal fixation, when performed; with primary ligamentous repair	<b>X</b>		
<b>27558</b>	Open treatment of knee dislocation, includes internal fixation, when performed; with primary ligamentous repair, with augmentation/reconstruction	<b>X</b>		
<b>27566</b>	Open treatment of patellar dislocation, with or without partial or total patellectomy			
<b>27570</b>	Manipulation of knee joint under general anesthesia (includes application of traction or other fixation devices)		<b>X</b>	
<b>27605</b>	Tenotomy, percutaneous, Achilles tendon (separate procedure); local anesthesia		<b>X</b>	



<b>27606</b>	Tenotomy, percutaneous, Achilles tendon (separate procedure); general anesthesia		<b>X</b>	
<b>27610</b>	Arthrotomy, ankle, including exploration, drainage, or removal of foreign body		<b>X</b>	
<b>27612</b>	Arthrotomy, posterior capsular release, ankle, with or without Achilles tendon lengthening		<b>X</b>	
<b>27619</b>	Excision, tumor, soft tissue of leg or ankle area, subfascial (e.g., intramuscular); less than 5 cm			
<b>27620</b>	Arthrotomy, ankle, with joint exploration, with or without biopsy, with or without removal of loose or foreign body		<b>X</b>	
<b>27625</b>	Arthrotomy, with synovectomy, ankle;		<b>X</b>	
<b>27626</b>	Arthrotomy, with synovectomy, ankle; including tenosynovectomy		<b>X</b>	
<b>27630</b>	Excision of lesion of tendon sheath or capsule (eg, cyst or ganglion), leg and/or ankle		<b>X</b>	
<b>27650</b>	Repair, primary, open or percutaneous, ruptured Achilles tendon;		<b>X</b>	
<b>27652</b>	Repair, primary, open or percutaneous, ruptured Achilles tendon; with graft (includes obtaining graft)		<b>X</b>	
<b>27654</b>	Repair, secondary, Achilles tendon, with or without graft		<b>X</b>	
<b>27656</b>	Repair, fascial defect of leg		<b>X</b>	
<b>27658</b>	Repair, flexor tendon, leg; primary, without graft, each tendon		<b>X</b>	
<b>27659</b>	Repair, flexor tendon, leg; secondary, with or without graft, each tendon		<b>X</b>	
<b>27664</b>	Repair, extensor tendon, leg; primary, without graft, each tendon		<b>X</b>	
<b>27665</b>	Repair, extensor tendon, leg; secondary, with or without graft, each tendon		<b>X</b>	
<b>27675</b>	Repair, dislocating peroneal tendons; without fibular osteotomy		<b>X</b>	
<b>27676</b>	Repair, dislocating peroneal tendons; with fibular osteotomy		<b>X</b>	
<b>27680</b>	Tenolysis, flexor or extensor tendon, leg and/or ankle; single, each tendon		<b>X</b>	
<b>27681</b>	Tenolysis, flexor or extensor tendon, leg and/or ankle; multiple tendons (through separate incision[s])		<b>X</b>	
<b>27685</b>	Lengthening or shortening of tendon, leg or ankle; single tendon (separate procedure)		<b>X</b>	
<b>27686</b>	Lengthening or shortening of tendon, leg or ankle; multiple tendons (through same incision), each		<b>X</b>	
<b>27687</b>	Gastrocnemius recession (eg, Strayer procedure)		<b>X</b>	
<b>27690</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); superficial (eg, anterior tibial extensors into midfoot)		<b>X</b>	
<b>27691</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); deep (eg, anterior tibial or posterior tibial through interosseous space, flexor digitorum longus, flexor hallucis longus, or peroneal tendon to midfoot or hindfoot)		<b>X</b>	
<b>27692</b>	Transfer or transplant of single tendon (with muscle redirection or rerouting); each additional tendon (List separately in addition to code for primary procedure)		<b>X</b>	
<b>27695</b>	Repair, primary, disrupted ligament, ankle; collateral		<b>X</b>	
<b>27696</b>	Repair, primary, disrupted ligament, ankle; both collateral ligaments		<b>X</b>	
<b>27698</b>	Repair, secondary, disrupted ligament, ankle, collateral (eg, Watson-Jones procedure)		<b>X</b>	
<b>27700</b>	Arthroplasty, ankle;			
<b>27702</b>	Arthroplasty, ankle; with implant (total ankle)			
<b>27703</b>	Arthroplasty, ankle; revision, total ankle	<b>X</b>		
<b>27705</b>	Osteotomy; tibia		<b>X</b>	
<b>27707</b>	Osteotomy; fibula		<b>X</b>	
<b>27709</b>	Osteotomy; tibia and fibula		<b>X</b>	
<b>27720</b>	Repair of nonunion or malunion, tibia; without graft, (e.g., compression technique)		<b>X</b>	

<b>27722</b>	Repair of nonunion or malunion, tibia; with sliding graft		<b>X</b>	
<b>27726</b>	Repair of fibula nonunion and/or malunion with internal fixation		<b>X</b>	
<b>27756</b>	Percutaneous skeletal fixation of tibial shaft fracture (with or without fibular fracture) (e.g., pins or screws)		<b>X</b>	
<b>27758</b>	Open treatment of tibial shaft fracture (with or without fibular fracture), with plate/screws, with or without cerclage			
<b>27759</b>	Treatment of tibial shaft fracture (with or without fibular fracture) by intramedullary implant, with or without interlocking screws and/or cerclage			
<b>27788</b>	Closed treatment of distal fibular fracture (lateral malleolus); with manipulation			
<b>27792</b>	Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed		<b>X</b>	
<b>27814</b>	Open treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli, or medial and posterior malleoli), includes internal fixation, when performed		<b>X</b>	
<b>27822</b>	Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial and/or lateral malleolus; without fixation of posterior lip		<b>X</b>	
<b>27823</b>	Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial and/or lateral malleolus; with fixation of posterior lip		<b>X</b>	
<b>27826</b>	Open treatment of fracture of weight bearing articular surface/portion of distal tibia (eg, pilon or tibial plafond), with internal fixation, when performed; of fibula only			
<b>27827</b>	Open treatment of fracture of weight bearing articular surface/portion of distal tibia (eg, pilon or tibial plafond), with internal fixation, when performed; of tibia only			
<b>27828</b>	Open treatment of fracture of weight bearing articular surface/portion of distal tibia (eg, pilon or tibial plafond), with internal fixation, when performed; of both tibia and fibula			
<b>27829</b>	Open treatment of distal tibiofibular joint (syndesmosis) disruption, includes internal fixation, when performed			
<b>27832</b>	Open treatment of proximal tibiofibular joint dislocation, includes internal fixation, when performed, or with excision of proximal fibula			
<b>27846</b>	Open treatment of ankle dislocation, with or without percutaneous skeletal fixation; without repair or internal fixation			
<b>27848</b>	Open treatment of ankle dislocation, with or without percutaneous skeletal fixation; with repair or internal or external fixation			
<b>27870</b>	Arthrodesis, ankle, open		<b>X</b>	
<b>27871</b>	Arthrodesis, tibiofibular joint, proximal or distal		<b>X</b>	
<b>28001</b>	Incision and drainage, bursa, foot		<b>X</b>	
<b>28002</b>	Incision and drainage below fascia, with or without tendon sheath involvement, foot; single bursal space		<b>X</b>	
<b>28003</b>	Incision and drainage below fascia, with or without tendon sheath involvement, foot; multiple areas		<b>X</b>	
<b>28005</b>	Incision, bone cortex (e.g., osteomyelitis or bone abscess), foot		<b>X</b>	
<b>28008</b>	Fasciotomy, foot and/or toe		<b>X</b>	
<b>28010</b>	Tenotomy, percutaneous, toe; single tendon		<b>X</b>	
<b>28011</b>	Tenotomy, percutaneous, toe; multiple tendons		<b>X</b>	
<b>28020</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; intertarsal or tarsometatarsal joint		<b>X</b>	
<b>28022</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; metatarsophalangeal joint		<b>X</b>	
<b>28024</b>	Arthrotomy, including exploration, drainage, or removal of loose or foreign body; interphalangeal joint		<b>X</b>	
<b>28035</b>	Release, tarsal tunnel (posterior tibial nerve decompression)		<b>X</b>	

<b>28039</b>	Excision, tumor, soft tissue of foot or toe, subcutaneous; 1.5 cm or greater		<b>X</b>	
<b>28041</b>	Excision, tumor, soft tissue of foot or toe, subfascial (e.g., intramuscular); 1.5 cm or greater		<b>X</b>	
<b>28043</b>	Excision, tumor, soft tissue of foot or toe, subcutaneous; less than 1.5 cm		<b>X</b>	
<b>28045</b>	Excision, tumor, soft tissue of foot or toe, subfascial (e.g., intramuscular); less than 1.5 cm		<b>X</b>	
<b>28046</b>	Radical resection of tumor (eg, sarcoma), soft tissue of foot or toe; less than 3 cm		<b>X</b>	
<b>28047</b>	Radical resection of tumor (e.g., sarcoma), soft tissue of foot or toe; 3 cm or greater		<b>X</b>	
<b>28055</b>	Neurectomy, intrinsic musculature of foot		<b>X</b>	
<b>28060</b>	Fasciectomy, plantar fascia; partial (separate procedure)		<b>X</b>	
<b>28062</b>	Fasciectomy, plantar fascia; radical (separate procedure)		<b>X</b>	
<b>28070</b>	Synovectomy; intertarsal or tarsometatarsal joint, each		<b>X</b>	
<b>28072</b>	Synovectomy; metatarsophalangeal joint, each		<b>X</b>	
<b>28080</b>	Excision, interdigital (Morton) neuroma, single, each		<b>X</b>	
<b>28086</b>	Synovectomy, tendon sheath, foot; flexor		<b>X</b>	
<b>28088</b>	Synovectomy, tendon sheath, foot; extensor		<b>X</b>	
<b>28090</b>	Excision of lesion, tendon, tendon sheath, or capsule (including synovectomy) (eg, cyst or ganglion); foot		<b>X</b>	
<b>28092</b>	Excision of lesion, tendon, tendon sheath, or capsule (including synovectomy) (e.g., cyst or ganglion); toe(s), each		<b>X</b>	
<b>28100</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus		<b>X</b>	
<b>28102</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus; with iliac or other autograft (includes obtaining graft)		<b>X</b>	
<b>28103</b>	Excision or curettage of bone cyst or benign tumor, talus or calcaneus; with allograft		<b>X</b>	
<b>28104</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus		<b>X</b>	
<b>28106</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus; with iliac or other autograft (includes obtaining graft)		<b>X</b>	
<b>28107</b>	Excision or curettage of bone cyst or benign tumor, tarsal or metatarsal, except talus or calcaneus; with allograft		<b>X</b>	
<b>28108</b>	Excision or curettage of bone cyst or benign tumor, phalanges of foot		<b>X</b>	
<b>28110</b>	Ostectomy, partial excision, fifth metatarsal head (bunionette) (separate procedure)		<b>X</b>	
<b>28111</b>	Ostectomy, complete excision; first metatarsal head		<b>X</b>	
<b>28112</b>	Ostectomy, complete excision; other metatarsal head (second, third or fourth)		<b>X</b>	
<b>28113</b>	Ostectomy, complete excision; fifth metatarsal head		<b>X</b>	
<b>28114</b>	Ostectomy, complete excision; all metatarsal heads, with partial proximal phalangectomy, excluding first metatarsal (eg, Clayton type procedure)		<b>X</b>	
<b>28116</b>	Ostectomy, excision of tarsal coalition		<b>X</b>	
<b>28118</b>	Ostectomy, calcaneus		<b>X</b>	
<b>28119</b>	Ostectomy, calcaneus; for spur, with or without plantar fascial release		<b>X</b>	
<b>28120</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (e.g., osteomyelitis or bossing); talus or calcaneus		<b>X</b>	
<b>28122</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (eg, osteomyelitis or bossing); tarsal or metatarsal bone, except talus or calcaneus		<b>X</b>	
<b>28124</b>	Partial excision (craterization, saucerization, sequestrectomy, or diaphysectomy) bone (e.g., osteomyelitis or bossing); phalanx of toe		<b>X</b>	

<b>28126</b>	Resection, partial or complete, phalangeal base, each toe		<b>X</b>	
<b>28130</b>	Talectomy (astragalectomy)		<b>X</b>	
<b>28140</b>	Metatarsectomy		<b>X</b>	
<b>28150</b>	Phalangectomy, toe, each toe		<b>X</b>	
<b>28153</b>	Resection, condyle(s), distal end of phalanx, each toe		<b>X</b>	
<b>28160</b>	Hemi phalangectomy or interphalangeal joint excision, toe, proximal end of phalanx, each		<b>X</b>	
<b>28190</b>	Removal of foreign body, foot; subcutaneous		<b>X</b>	
<b>28192</b>	Removal of foreign body, foot; deep		<b>X</b>	
<b>28193</b>	Removal of foreign body, foot; complicated		<b>X</b>	
<b>28200</b>	Repair, tendon, flexor, foot; primary or secondary, without free graft, each tendon		<b>X</b>	
<b>28202</b>	Repair, tendon, flexor, foot; secondary with free graft, each tendon (includes obtaining graft)		<b>X</b>	
<b>28208</b>	Repair, tendon, extensor, foot; primary or secondary, each tendon		<b>X</b>	
<b>28210</b>	Repair, tendon, extensor, foot; secondary with free graft, each tendon (includes obtaining graft)		<b>X</b>	
<b>28220</b>	Tenolysis, flexor, foot; single tendon		<b>X</b>	
<b>28222</b>	Tenolysis, flexor, foot; multiple tendons		<b>X</b>	
<b>28225</b>	Tenolysis, extensor, foot; single tendon		<b>X</b>	
<b>28226</b>	Tenolysis, extensor, foot; multiple tendons		<b>X</b>	
<b>28230</b>	Tenotomy, open, tendon flexor; foot, single or multiple tendon(s) (separate procedure)		<b>X</b>	
<b>28232</b>	Tenotomy, open, tendon flexor; toe, single tendon (separate procedure)		<b>X</b>	
<b>28234</b>	Tenotomy, open, extensor, foot or toe, each tendon		<b>X</b>	
<b>28238</b>	Reconstruction (advancement), posterior tibial tendon with excision of accessory tarsal navicular bone (eg, Kidner type procedure)		<b>X</b>	
<b>28250</b>	Division of plantar fascia and muscle (e.g., Steindler stripping) (separate procedure)		<b>X</b>	
<b>28260</b>	Capsulotomy, midfoot; medial release only (separate procedure)		<b>X</b>	
<b>28261</b>	Capsulotomy, midfoot; with tendon lengthening		<b>X</b>	
<b>28262</b>	Capsulotomy, midfoot; extensive, including posterior talotibial capsulotomy and tendon(s) lengthening (eg, resistant clubfoot deformity)		<b>X</b>	
<b>28264</b>	Capsulotomy, midtarsal (eg, Heyman type procedure)		<b>X</b>	
<b>28270</b>	Capsulotomy; metatarsophalangeal joint, with or without tenorrhaphy, each joint (separate procedure)		<b>X</b>	
<b>28272</b>	Capsulotomy; interphalangeal joint, each joint (separate procedure)		<b>X</b>	
<b>28280</b>	Syndactylization, toes (e.g., webbing or Kelikian type procedure)		<b>X</b>	
<b>28285</b>	Correction, hammertoe (eg, interphalangeal fusion, partial or total phalangectomy)		<b>X</b>	
<b>28286</b>	Correction, cock-up fifth toe, with plastic skin closure (e.g., Ruiz-Mora type procedure)		<b>X</b>	
<b>28288</b>	Ostectomy, partial, exostectomy or condylectomy, metatarsal head, each metatarsal head		<b>X</b>	
<b>28289</b>	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; without implant		<b>X</b>	
<b>28291</b>	Hallux rigidus correction with cheilectomy, debridement and capsular release of the first metatarsophalangeal joint; with implant		<b>X</b>	
<b>28292</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method		<b>X</b>	
<b>28295</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with proximal metatarsal osteotomy, any method		<b>X</b>	
<b>28296</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with distal metatarsal osteotomy, any method		<b>X</b>	

<b>28297</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method		<b>X</b>	
<b>28298</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with proximal phalanx osteotomy, any method		<b>X</b>	
<b>28299</b>	Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with double osteotomy, any method		<b>X</b>	
<b>28300</b>	Osteotomy; calcaneus (eg, Dwyer or Chambers type procedure), with or without internal fixation		<b>X</b>	
<b>28302</b>	Osteotomy; talus		<b>X</b>	
<b>28304</b>	Osteotomy, tarsal bones, other than calcaneus or talus;		<b>X</b>	
<b>28305</b>	Osteotomy, tarsal bones, other than calcaneus or talus; with autograft (includes obtaining graft) (eg, Fowler type)		<b>X</b>	
<b>28306</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; first metatarsal		<b>X</b>	
<b>28307</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; first metatarsal with autograft (other than first toe)		<b>X</b>	
<b>28308</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; other than first metatarsal, each		<b>X</b>	
<b>28309</b>	Osteotomy, with or without lengthening, shortening or angular correction, metatarsal; multiple (eg, Swanson type cavus foot procedure)		<b>X</b>	
<b>28310</b>	Osteotomy, shortening, angular or rotational correction; proximal phalanx, first toe (separate procedure)		<b>X</b>	
<b>28312</b>	Osteotomy, shortening, angular or rotational correction; other phalanges, any toe		<b>X</b>	
<b>28313</b>	Reconstruction, angular deformity of toe, soft tissue procedures only (e.g., overlapping second toe, fifth toe, curly toes)		<b>X</b>	
<b>28315</b>	Sesamoidectomy, first toe (separate procedure)		<b>X</b>	
<b>28320</b>	Repair, nonunion or malunion; tarsal bones		<b>X</b>	
<b>28322</b>	Repair, nonunion or malunion; metatarsal, with or without bone graft (includes obtaining graft)		<b>X</b>	
<b>28470</b>	Closed treatment of metatarsal fracture; without manipulation, each		<b>X</b>	
<b>28475</b>	Closed treatment of metatarsal fracture; with manipulation, each			
<b>28476</b>	Percutaneous skeletal fixation of metatarsal fracture, with manipulation, each		<b>X</b>	
<b>28485</b>	Open treatment of metatarsal fracture, includes internal fixation, when performed, each		<b>X</b>	
<b>28496</b>	Percutaneous skeletal fixation of fracture great toe, phalanx or phalanges, with manipulation		<b>X</b>	
<b>28515</b>	Closed treatment of fracture, phalanx or phalanges, other than great toe; with manipulation, each			
<b>28525</b>	Open treatment of fracture, phalanx or phalanges, other than great toe, includes internal fixation, when performed, each		<b>X</b>	
<b>28645</b>	Open treatment of metatarsophalangeal joint dislocation, includes internal fixation, when performed			
<b>28666</b>	Percutaneous skeletal fixation of interphalangeal joint dislocation, with manipulation		<b>X</b>	
<b>28675</b>	Open treatment of interphalangeal joint dislocation, includes internal fixation, when performed		<b>X</b>	
<b>28705</b>	Arthrodesis; pantalar		<b>X</b>	
<b>28715</b>	Arthrodesis; triple		<b>X</b>	
<b>28725</b>	Arthrodesis; subtalar		<b>X</b>	
<b>28730</b>	Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse		<b>X</b>	
<b>28735</b>	Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse; with osteotomy (eg, flatfoot correction)		<b>X</b>	

<b>28737</b>	Arthrodesis, with tendon lengthening and advancement, midtarsal, tarsal navicular-cuneiform (eg, Miller type procedure)		<b>X</b>	
<b>28740</b>	Arthrodesis, midtarsal or tarsometatarsal, single joint		<b>X</b>	
<b>28750</b>	Arthrodesis, great toe; metatarsophalangeal joint		<b>X</b>	
<b>28755</b>	Arthrodesis, great toe; interphalangeal joint		<b>X</b>	
<b>28760</b>	Arthrodesis, with extensor hallucis longus transfer to first metatarsal neck, great toe, interphalangeal joint (e.g., Jones type procedure)		<b>X</b>	
<b>28800</b>	Amputation, foot; midtarsal (eg, Chopart type procedure)	<b>X</b>		
<b>28805</b>	Amputation, foot; transmetatarsa			
<b>28810</b>	Amputation, metatarsal, with toe, single		<b>X</b>	
<b>28820</b>	Amputation, toe; metatarsophalangeal joint		<b>X</b>	
<b>28825</b>	Amputation, toe; interphalangeal joint		<b>X</b>	
<b>29800</b>	Arthroscopy, temporomandibular joint, diagnostic, with or without synovial biopsy (separate procedure)			
<b>29804</b>	Arthroscopy, temporomandibular joint, surgical			
<b>29805</b>	Arthroscopy, shoulder, diagnostic, with or without synovial biopsy (separate procedure)		<b>X</b>	<b>X</b>
<b>29806</b>	Arthroscopy, shoulder, surgical; capsulorrhaphy		<b>X</b>	<b>X</b>
<b>29807</b>	Arthroscopy, shoulder, surgical; repair of SLAP lesion		<b>X</b>	<b>X</b>
<b>29819</b>	Arthroscopy, shoulder, surgical; with removal of loose body or foreign body		<b>X</b>	<b>X</b>
<b>29820</b>	Arthroscopy, shoulder, surgical; synovectomy, partial		<b>X</b>	<b>X</b>
<b>29821</b>	Arthroscopy, shoulder, surgical; synovectomy, complete		<b>X</b>	<b>X</b>
<b>29822</b>	Arthroscopy, shoulder, surgical; debridement, limited, 1 or 2 discrete structures (eg, humeral bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps tendon, biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff, bursal side of the rotator cuff, subacromial bursa, foreign body[ies])		<b>X</b>	<b>X</b>
<b>29823</b>	Arthroscopy, shoulder, surgical; debridement, extensive, 3 or more discrete structures (eg, humeral bone, humeral articular cartilage, glenoid bone, glenoid articular cartilage, biceps tendon, biceps anchor complex, labrum, articular capsule, articular side of the rotator cuff, bursal side of the rotator cuff, subacromial bursa, foreign body[ies])		<b>X</b>	<b>X</b>
<b>29824</b>	Arthroscopy, shoulder, surgical; distal claviclectomy including distal articular surface (Mumford procedure)		<b>X</b>	<b>X</b>
<b>29825</b>	Arthroscopy, shoulder, surgical; with lysis and resection of adhesions, with or without manipulation		<b>X</b>	<b>X</b>
<b>29826</b>	Arthroscopy, shoulder, surgical; decompression of subacromial space with partial acromioplasty, with coracoacromial ligament (ie, arch) release, when performed (List separately in addition to code for primary procedure)		<b>X</b>	<b>X</b>
<b>29827</b>	Arthroscopy, shoulder, surgical; with rotator cuff repair		<b>X</b>	<b>X</b>
<b>29828</b>	Arthroscopy, shoulder, surgical; biceps tenodesis		<b>X</b>	<b>X</b>
<b>29830</b>	Arthroscopy, elbow, diagnostic, with or without synovial biopsy (separate procedure)		<b>X</b>	
<b>29834</b>	Arthroscopy, elbow, surgical; with removal of loose body or foreign body			
<b>29835</b>	Arthroscopy, elbow, surgical; synovectomy, partial		<b>X</b>	
<b>29836</b>	Arthroscopy, elbow, surgical; synovectomy, complete		<b>X</b>	
<b>29837</b>	Arthroscopy, elbow, surgical; debridement, limited		<b>X</b>	
<b>29838</b>	Arthroscopy, elbow, surgical; debridement, extensive		<b>X</b>	
<b>29840</b>	Arthroscopy, wrist, diagnostic, with or without synovial biopsy (separate procedure)		<b>X</b>	
<b>29843</b>	Arthroscopy, wrist, surgical; for infection, lavage and drainage		<b>X</b>	
<b>29844</b>	Arthroscopy, wrist, surgical; synovectomy, partial		<b>X</b>	
<b>29845</b>	Arthroscopy, wrist, surgical; synovectomy, complete		<b>X</b>	



<b>29846</b>	Arthroscopy, wrist, surgical; excision and/or repair of triangular fibrocartilage and/or joint debridement		<b>X</b>	
<b>29847</b>	Arthroscopy, wrist, surgical; internal fixation for fracture or instability		<b>X</b>	
<b>29848</b>	Endoscopy, wrist, surgical, with release of transverse carpal ligament		<b>X</b>	
<b>29860</b>	Arthroscopy, hip, diagnostic with or without synovial biopsy (separate procedure)		<b>X</b>	<b>X</b>
<b>29861</b>	Arthroscopy, hip, surgical; with removal of loose body or foreign body		<b>X</b>	<b>X</b>
<b>29862</b>	Arthroscopy, hip, surgical; with debridement/shaving of articular cartilage (chondroplasty), abrasion arthroplasty, and/or resection of labrum		<b>X</b>	<b>X</b>
<b>29863</b>	Arthroscopy, hip, surgical; with synovectomy		<b>X</b>	<b>X</b>
<b>29866</b>	Arthroscopy, knee, surgical; osteochondral autograft(s) (eg, mosaicplasty) (includes harvesting of the autograft[s])		<b>X</b>	<b>X</b>
<b>29867</b>	Arthroscopy, knee, surgical; osteochondral allograft (eg, mosaicplasty)		<b>X</b>	<b>X</b>
<b>29870</b>	Arthroscopy, knee, diagnostic, with or without synovial biopsy (separate procedure)		<b>X</b>	
<b>29871</b>	Arthroscopy, knee, surgical; for infection, lavage and drainage		<b>X</b>	<b>X</b>
<b>29873</b>	Arthroscopy, knee, surgical; with lateral release		<b>X</b>	
<b>29874</b>	Arthroscopy, knee, surgical; for removal of loose body or foreign body (eg, osteochondritis dissecans fragmentation, chondral fragmentation)		<b>X</b>	
<b>29875</b>	Arthroscopy, knee, surgical; synovectomy, limited (eg, plica or shelf resection) (separate procedure)		<b>X</b>	
<b>29876</b>	Arthroscopy, knee, surgical; synovectomy, major, 2 or more compartments (eg, medial or lateral)		<b>X</b>	
<b>29877</b>	Arthroscopy, knee, surgical; debridement/shaving of articular cartilage (chondroplasty)		<b>X</b>	<b>X</b>
<b>29879</b>	Arthroscopy, knee, surgical; abrasion arthroplasty (includes chondroplasty where necessary) or multiple drilling or microfracture		<b>X</b>	<b>X</b>
<b>29880</b>	Arthroscopy, knee, surgical; with meniscectomy (medial AND lateral, including any meniscal shaving) including debridement/shaving of articular cartilage (chondroplasty), same or separate compartment(s), when performed		<b>X</b>	
<b>29881</b>	Arthroscopy, knee, surgical; with meniscectomy (medial OR lateral, including any meniscal shaving) including debridement/shaving of articular cartilage (chondroplasty), same or separate compartment(s), when performed		<b>X</b>	
<b>29882</b>	Arthroscopy, knee, surgical; with meniscus repair (medial OR lateral)		<b>X</b>	
<b>29883</b>	Arthroscopy, knee, surgical; with meniscus repair (medial AND lateral)		<b>X</b>	
<b>29884</b>	Arthroscopy, knee, surgical; with lysis of adhesions, with or without manipulation (separate procedure)		<b>X</b>	
<b>29885</b>	Arthroscopy, knee, surgical; drilling for osteochondritis dissecans with bone grafting, with or without internal fixation (including debridement of base of lesion)		<b>X</b>	
<b>29886</b>	Arthroscopy, knee, surgical; drilling for intact osteochondritis dissecans lesion		<b>X</b>	<b>X</b>
<b>29887</b>	Arthroscopy, knee, surgical; drilling for intact osteochondritis dissecans lesion with internal fixation		<b>X</b>	
<b>29888</b>	Arthroscopically aided anterior cruciate ligament repair/augmentation or reconstruction		<b>X</b>	
<b>29889</b>	Arthroscopically aided posterior cruciate ligament repair/augmentation or reconstruction		<b>X</b>	
<b>29891</b>	Arthroscopy, ankle, surgical, excision of osteochondral defect of talus and/or tibia, including drilling of the defect		<b>X</b>	
<b>29892</b>	Arthroscopically aided repair of large osteochondritis dissecans lesion, talar dome fracture, or tibial plafond fracture, with or without internal fixation (includes arthroscopy)		<b>X</b>	
<b>29893</b>	Endoscopic plantar fasciotomy		<b>X</b>	

29894	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; with removal of loose body or foreign body		X	
29895	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; synovectomy, partial		X	
29897	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; debridement, limited			
29898	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; debridement, extensive			
29899	Arthroscopy, ankle (tibiotalar and fibulotalar joints), surgical; with ankle arthrodesis			
29900	Arthroscopy, metacarpophalangeal joint, diagnostic, includes synovial biopsy		X	
29901	Arthroscopy, metacarpophalangeal joint, surgical; with debridement		X	
29902	Arthroscopy, metacarpophalangeal joint, surgical; with reduction of displaced ulnar collateral ligament (eg, Stenar lesion)		X	
29906	Arthroscopy, subtalar joint, surgical; with debridement		X	
29999	Unlisted procedure, arthroscopy		X	X
64721	Neuroplasty and/or transposition; median nerve at carpal tunnel		X	

**Ophthalmology Procedures Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Eye/Ocular Adnexa System</b>				
Requires Medical Necessity Review: <a href="#">LASIK</a> , <a href="#">Microinvasive Glaucoma Surgery (MIGS)</a>				
65400	Excision of lesion, cornea (keratectomy, lamellar, partial), except pterygium			
65420	Excision or transposition of pterygium; without graft			
65426	Excision or transposition of pterygium; with graft			
65435	Removal of corneal epithelium; with or without chemocauterization (abrasion, curettage)			
65436	Removal of corneal epithelium; with application of chelating agent (eg, EDTA)			
65710	Keratoplasty (corneal transplant); anterior lamellar			
65730	Keratoplasty (corneal transplant); penetrating (except in aphakia or pseudophakia)			
65750	Keratoplasty (corneal transplant); penetrating (in aphakia)			
65755	Keratoplasty (corneal transplant); penetrating (in pseudophakia)			
65756	Keratoplasty (corneal transplant); endothelial			
65772	Corneal relaxing incision for correction of surgically induced astigmatism			X
65778	Placement of amniotic membrane on the ocular surface; without sutures			
65779	Placement of amniotic membrane on the ocular surface; single layer, sutured			
65780	Ocular surface reconstruction; amniotic membrane transplantation, multiple layers			
65800	Paracentesis of anterior chamber of eye (separate procedure); with removal of aqueous			
65815	Paracentesis of anterior chamber of eye (separate procedure); with removal of blood, with or without irrigation and/or air injection			
65820	Goniotomy			

<b>65850</b>	Trabeculotomy ab externo			
<b>65855</b>	Trabeculoplasty by laser surgery			
<b>65865</b>	Severing adhesions of anterior segment of eye, incisional technique (with or without injection of air or liquid) (separate procedure); goniosynechia			
<b>65875</b>	Severing adhesions of anterior segment of eye, incisional technique (with or without injection of air or liquid) (separate procedure); posterior synechia			
<b>65920</b>	Removal of implanted material, anterior segment of eye			
<b>66020</b>	Injection, anterior chamber of eye (separate procedure); air or liquid			
<b>66170</b>	Fistulization of sclera for glaucoma; trabeculectomy ab externo in absence of previous surgery			
<b>66172</b>	Fistulization of sclera for glaucoma; trabeculectomy ab externo with scarring from previous ocular surgery or trauma (includes injection of antifibrotic agents)			
<b>66179</b>	Aqueous shunt to extraocular equatorial plate reservoir, external approach; without graft			
<b>66180</b>	Aqueous shunt to extraocular equatorial plate reservoir, external approach; with graft			
<b>66183</b>	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach			<b>X</b>
<b>66184</b>	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft			
<b>66185</b>	Revision of aqueous shunt to extraocular equatorial plate reservoir; with graft			
<b>66250</b>	Revision or repair of operative wound of anterior segment, any type, early or late, major or minor procedure			
<b>66682</b>	Suture of iris, ciliary body (separate procedure) with retrieval of suture through small incision (eg, McCannel suture)			
<b>66710</b>	Ciliary body destruction; cyclophotocoagulation, transscleral			
<b>66711</b>	Ciliary body destruction; cyclophotocoagulation, endoscopic, without concomitant removal of crystalline lens			
<b>66761</b>	Iridotomy/iridectomy by laser surgery (eg, for glaucoma) (per session)			
<b>66762</b>	Iridoplasty by photocoagulation (1 or more sessions) (eg, for improvement of vision, for widening of anterior chamber angle)			
<b>66821</b>	Discission of secondary membranous cataract (opacified posterior lens capsule and/or anterior hyaloid); laser surgery (eg, YAG laser) (1 or more stages)			
<b>66825</b>	Repositioning of intraocular lens prosthesis, requiring an incision (separate procedure)			
<b>66840</b>	Removal of lens material; aspiration technique, 1 or more stages			
<b>66850</b>	Removal of lens material; phacofragmentation technique (mechanical or ultrasonic) (eg, phacoemulsification), with aspiration			
<b>66852</b>	Removal of lens material; pars plana approach, with or without vitrectomy			
<b>66982</b>	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; without endoscopic cyclophotocoagulation			
<b>66983</b>	Intracapsular cataract extraction with insertion of intraocular lens prosthesis (1 stage procedure)			

66984	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); without endoscopic cyclophotocoagulation			
66985	Insertion of intraocular lens prosthesis (secondary implant), not associated with concurrent cataract removal			
66986	Exchange of intraocular lens			
66987	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with endoscopic cyclophotocoagulation			
66988	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with endoscopic cyclophotocoagulation			
67005	Removal of vitreous, anterior approach (open sky technique or limbal incision); partial removal			
67010	Removal of vitreous, anterior approach (open sky technique or limbal incision); subtotal removal with mechanical vitrectomy			
67015	Aspiration or release of vitreous, subretinal or choroidal fluid, pars plana approach (posterior sclerotomy)			
67025	Injection of vitreous substitute, pars plana or limbal approach (fluid-gas exchange), with or without aspiration (separate procedure)			
67027	Implantation of intravitreal drug delivery system (eg, ganciclovir implant), includes concomitant removal of vitreous			
67028	Intravitreal injection of a pharmacologic agent (separate procedure)			
67031	Severing of vitreous strands, vitreous face adhesions, sheets, membranes or opacities, laser surgery (1 or more stages)			
67036	Vitrectomy, mechanical, pars plana approach;			
67039	Vitrectomy, mechanical, pars plana approach; with focal endolaser photocoagulation			
67040	Vitrectomy, mechanical, pars plana approach; with endolaser panretinal photocoagulation			
67041	Vitrectomy, mechanical, pars plana approach; with removal of preretinal cellular membrane (eg, macular pucker)			
67042	Vitrectomy, mechanical, pars plana approach; with removal of internal limiting membrane of retina (eg, for repair of macular hole, diabetic macular edema), includes, if performed, intraocular tamponade (ie, air, gas or silicone oil)			
67043	Vitrectomy, mechanical, pars plana approach; with removal of subretinal membrane (eg, choroidal neovascularization), includes, if performed, intraocular tamponade (ie, air, gas or silicone oil) and laser photocoagulation			
67101	Repair of retinal detachment, including drainage of subretinal fluid when performed; cryotherapy			
67105	Repair of retinal detachment, including drainage of subretinal fluid when performed; photocoagulation			
67107	Repair of retinal detachment; scleral buckling (such as lamellar scleral dissection, imbrication or encircling procedure), including, when performed, implant, cryotherapy, photocoagulation, and drainage of subretinal fluid			
67108	Repair of retinal detachment; with vitrectomy, any method, including, when performed, air or gas tamponade, focal endolaser			

	photocoagulation, cryotherapy, drainage of subretinal fluid, scleral buckling, and/or removal of lens by same technique			
67110	Repair of retinal detachment; by injection of air or other gas (eg, pneumatic retinopexy)			
67113	Repair of complex retinal detachment (eg, proliferative vitreoretinopathy, stage C-1 or greater, diabetic traction retinal detachment, retinopathy of prematurity, retinal tear of greater than 90 degrees), with vitrectomy and membrane peeling, including, when performed, air, gas, or silicone oil tamponade, cryotherapy, endolaser photocoagulation, drainage of subretinal fluid, scleral buckling, and/or removal of lens			
67120	Removal of implanted material, posterior segment; extraocular			
67121	Removal of implanted material, posterior segment; intraocular			
67141	Prophylaxis of retinal detachment (eg, retinal break, lattice degeneration) without drainage; cryotherapy, diathermy			
67145	Prophylaxis of retinal detachment (eg, retinal break, lattice degeneration) without drainage; photocoagulation			
67210	Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; photocoagulation			
67218	Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; radiation by implantation of source (includes removal of source)			
67220	Destruction of localized lesion of choroid (eg, choroidal neovascularization); photocoagulation (eg, laser), 1 or more sessions			
67221	Destruction of localized lesion of choroid (eg, choroidal neovascularization); photodynamic therapy (includes intravenous infusion)			
67228	Treatment of extensive or progressive retinopathy (eg, diabetic retinopathy), photocoagulation			
67311	Strabismus surgery, recession or resection procedure; 1 horizontal muscle			
67312	Strabismus surgery, recession or resection procedure; 2 horizontal muscles			
67314	Strabismus surgery, recession or resection procedure; 1 vertical muscle (excluding superior oblique)			
67316	Strabismus surgery, recession or resection procedure; 2 or more vertical muscles (excluding superior oblique)			
67318	Strabismus surgery, any procedure, superior oblique muscle			
67345	Chemodenervation of extraocular muscle			
67400	Orbitotomy without bone flap (frontal or transconjunctival approach); for exploration, with or without biopsy			
67412	Orbitotomy without bone flap (frontal or transconjunctival approach); with removal of lesion			
67414	Orbitotomy without bone flap (frontal or transconjunctival approach); with removal of bone for decompression			
67420	Orbitotomy with bone flap or window, lateral approach (eg, Kroenlein); with removal of lesion			
67445	Orbitotomy with bone flap or window, lateral approach (eg, Kroenlein); with removal of bone for decompression			
67550	Orbital implant (implant outside muscle cone); insertion			
67560	Orbital implant (implant outside muscle cone); removal or revision			
67700	Blepharotomy, drainage of abscess, eyelid			
67800	Excision of chalazion; single			
67801	Excision of chalazion; multiple, same lid			
67805	Excision of chalazion; multiple, different lids			

67808	Excision of chalazion; under general anesthesia and/or requiring hospitalization, single or multiple			
67810	Incisional biopsy of eyelid skin including lid margin			
67825	Correction of trichiasis; epilation by other than forceps (eg, by electrosurgery, cryotherapy, laser surgery)			
67840	Excision of lesion of eyelid (except chalazion) without closure or with simple direct closure			
67875	Temporary closure of eyelids by suture (eg, Frost suture)			
67880	Construction of intermarginal adhesions, median tarsorrhaphy, or canthorrhaphy			
67935	Suture of recent wound, eyelid, involving lid margin, tarsus, and/or palpebral conjunctiva direct closure; full thickness			
67938	Removal of embedded foreign body, eyelid			
67961	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; up to one-fourth of lid margin			
67966	Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; over one-fourth of lid margin			
67971	Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; up to two-thirds of eyelid, 1 stage or first stage			
67973	Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; total eyelid, lower, 1 stage or first stage			
67975	Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; second stage			
68100	Biopsy of conjunctiva			
68110	Excision of lesion, conjunctiva; up to 1 cm			
68115	Excision of lesion, conjunctiva; over 1 cm			
68135	Destruction of lesion, conjunctiva			
68320	Conjunctivoplasty; with conjunctival graft or extensive rearrangement			
68440	Snip incision of lacrimal punctum			
68700	Plastic repair of canaliculi			
68720	Dacryocystorhinostomy (Fistulization of lacrimal sac to nasal cavity)			
68750	Conjunctivorhinostomy (fistulization of conjunctiva to nasal cavity); with insertion of tube or stent			
68761	Closure of the lacrimal punctum; by plug, each			
68801	Dilation of lacrimal punctum, with or without irrigation			
68811	Probing of nasolacrimal duct, with or without irrigation; requiring general anesthesia			
68815	Probing of nasolacrimal duct, with or without irrigation; with insertion of tube or stent			

### Pain Management Codes—

**Non-Medicare:** Requires review when submitted as an inpatient level of care

**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Chemodenervation</b> Requires Medical Necessity Review: <a href="#">Dermatology</a>				



<b>64600</b>	Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch			
<b>64610</b>	Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring			
<b>64642</b>	Chemodenervation of one extremity; 1-4 muscle(s)			<b>X</b>
<b>64644</b>	Chemodenervation of one extremity; 5 or more muscles			<b>X</b>
<b>64646</b>	Chemodenervation of trunk muscle(s); 1-5 muscle(s)			<b>X</b>
<b>64647</b>	Chemodenervation of trunk muscle(s); 6 or more muscles			<b>X</b>
<b>64702</b>	Neuroplasty; digital, 1 or both, same digit			
<b>64718</b>	Neuroplasty and/or transposition; ulnar nerve at elbow			
<b>64719</b>	Neuroplasty and/or transposition; ulnar nerve at wrist			
<b>64774</b>	Excision of neuroma; cutaneous nerve, surgically identifiable			
<b>64776</b>	Excision of neuroma; digital nerve, 1 or both, same digit			
<b>64782</b>	Excision of neuroma; hand or foot, except digital nerve			
<b>64784</b>	Excision of neuroma; major peripheral nerve, except sciatic			
<b>64788</b>	Excision of neurofibroma or neurolemmoma; cutaneous nerve			
<b>64795</b>	Biopsy of nerve			
<b>64831</b>	Suture of digital nerve, hand or foot; 1 nerve			
<b>64835</b>	Suture of 1 nerve; median motor thenar			
<b>65275</b>	Repair of laceration; cornea, nonperforating, with or without removal foreign body			
<b>Spinal Injections</b>				
<b>62270</b>	Spinal puncture, lumbar, diagnostic;			
<b>64418</b>	Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve			
<b>64425</b>	Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves			
<b>64530</b>	Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring			

**Spine Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>Cervical Artificial Disc Surgery</b>				
<i>Requires Medical Necessity Review: <a href="#">Artificial Spinal Discs for Lumbar or Cervical Disc Disease</a></i>				
<b>0098T</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)	<b>X</b>		<b>X</b>
<b>22856</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection); single interspace, cervical			<b>X</b>
<b>22861</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical	<b>X</b>		<b>X</b>
<b>22864</b>	Removal of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical	<b>X</b>		<b>X</b>
<b>Cervical Discectomy or Microdiscectomy, foraminotomy, laminotomy</b>				
<b>63020</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical			
<b>63040</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; cervical			

<b>63043</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional cervical interspace (List separately in addition to code for primary procedure)			
<b>63075</b>	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophylectomy; cervical, single interspace			
<b>63076</b>	Discectomy, anterior, with decompression of spinal cord and/or nerve root(s), including osteophylectomy; cervical, each additional interspace (List separately in addition to code for primary procedure)			
<b>Cervical Laminectomy</b> <i>Requires Medical Necessity Review: <a href="#">Minimally Invasive Lumbar Decompression</a></i>				
<b>0274T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic <i>*Requires separate medical necessity review with <a href="#">Minimally Invasive Lumbar Decompression</a> criteria</i>			<b>X</b>
<b>63045</b>	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; cervical			
<b>63050</b>	Laminoplasty, cervical, with decompression of the spinal cord, 2 or more vertebral segments;	<b>X</b>		
<b>63051</b>	Laminoplasty, cervical, with decompression of the spinal cord, 2 or more vertebral segments; with reconstruction of the posterior bony elements (including the application of bridging bone graft and non-segmental fixation devices [eg, wire, suture, mini-plates], when performed)	<b>X</b>		
<b>63081</b>	Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach with decompression of spinal cord and/or nerve root(s); cervical, single segment	<b>X</b>		
<b>63082</b>	Vertebral corpectomy (vertebral body resection), partial or complete, anterior approach with decompression of spinal cord and/or nerve root(s); cervical, each additional segment (List separately in addition to code for primary procedure)	<b>X</b>		
<b>63185</b>	Laminectomy with rhizotomy; 1 or 2 segments	<b>X</b>		
<b>63190</b>	Laminectomy with rhizotomy; more than 2 segments	<b>X</b>		
<b>63191</b>	Laminectomy with section of spinal accessory nerve	<b>X</b>		
<b>63250</b>	Laminectomy for excision or occlusion of arteriovenous malformation of spinal cord; cervical	<b>X</b>		
<b>63300</b>	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; extradural, cervical	<b>X</b>		
<b>63304</b>	Vertebral corpectomy (vertebral body resection), partial or complete, for excision of intraspinal lesion, single segment; intradural, cervical	<b>X</b>		
<b>Cervical Fusion—Anterior</b> <i>Requires Medical Necessity Review: <a href="#">Cervical Fusion, Lumbar Spinal Fusion</a></i>				
<b>22551</b>	Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophylectomy and decompression of spinal cord and/or nerve roots; cervical below C2			<b>X</b>
<b>22552</b>	Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophylectomy and decompression of spinal cord and/or nerve roots; cervical below C2, each additional interspace (List separately in addition to code for separate procedure)			<b>X</b>

<b>22554</b>	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below C2			<b>X</b>
<b>22585</b>	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); each additional interspace (List separately in addition to code for primary procedure)			<b>X</b>
<b>22858</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophylectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)			<b>X</b>
<b>Cervical Fusion—Posterior</b> <i>Requires Medical Necessity Review: <a href="#">Cervical Fusion</a>, <a href="#">Lumbar Spinal Fusion</a></i>				
<b>22600</b>	Arthrodesis, posterior or posterolateral technique, single interspace; cervical below C2 segment	<b>X</b>		<b>X</b>
<b>22614</b>	Arthrodesis, posterior or posterolateral technique, single interspace; each additional interspace (List separately in addition to code for primary procedure)			<b>X</b>
<b>Lumbar Discectomy, Foraminotomy, or Laminotomy (when elective and not at multiple levels)</b> <i>Requires Medical Necessity Review: <a href="#">Minimally Invasive Lumbar Decompression</a></i>				
<b>62380</b>	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar			<b>X</b>
<b>63030</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, lumbar			
<b>63035</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; each additional interspace, cervical or lumbar (List separately in addition to code for primary procedure)			
<b>63042</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; lumbar			
<b>63044</b>	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional lumbar interspace (List separately in addition to code for primary procedure)			
<b>Lumbar Laminectomy (when elective and without significant comorbid conditions)</b> <i>Requires Medical Necessity Review: <a href="#">Minimally Invasive Lumbar Decompression</a></i>				
<b>0275T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar			<b>X</b>
<b>63005</b>	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), 1 or 2 vertebral segments; lumbar, except for spondylolisthesis			
<b>63012</b>	Laminectomy with removal of abnormal facets and/or pars inter-articularis with decompression of cauda equina and nerve roots for spondylolisthesis, lumbar (Gill type procedure)			
<b>63017</b>	Laminectomy with exploration and/or decompression of spinal cord and/or cauda equina, without facetectomy, foraminotomy or discectomy (eg, spinal stenosis), more than 2 vertebral segments; lumbar			

<b>63047</b>	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; lumbar			
<b>63048</b>	Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; each additional vertebral segment, cervical, thoracic, or lumbar (List separately in addition to code for primary procedure)			
<b>63056</b>	Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; lumbar (including transfacet, or lateral extraforaminal approach) (eg, far lateral herniated intervertebral disc)			
<b>63057</b>	Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; each additional segment, thoracic or lumbar (List separately in addition to code for primary procedure)			
<b>63087</b>	Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic or lumbar; single segment	<b>X</b>		
<b>63088</b>	Vertebral corpectomy (vertebral body resection), partial or complete, combined thoracolumbar approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic or lumbar; each additional segment (List separately in addition to code for primary procedure)	<b>X</b>		
<b>63090</b>	Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic, lumbar, or sacral; single segment	<b>X</b>		
<b>63091</b>	Vertebral corpectomy (vertebral body resection), partial or complete, transperitoneal or retroperitoneal approach with decompression of spinal cord, cauda equina or nerve root(s), lower thoracic, lumbar, or sacral; each additional segment (List separately in addition to code for primary procedure)	<b>X</b>		
<b>63185</b>	Laminectomy with rhizotomy; 1 or 2 segments	<b>X</b>		
<b>63190</b>	Laminectomy with rhizotomy; more than 2 segments	<b>X</b>		
<b>63200</b>	Laminectomy, with release of tethered spinal cord, lumbar	<b>X</b>		
<b>63252</b>	Laminectomy for excision or occlusion of arteriovenous malformation of spinal cord; thoracolumbar	<b>X</b>		
<b>63267</b>	Laminectomy for excision or evacuation of intraspinal lesion other than neoplasm, extradural; lumbar			
<b>63272</b>	Laminectomy for excision of intraspinal lesion other than neoplasm, intradural; lumbar	<b>X</b>		
<b>Single Level Lumbar Fusion</b>				
Requires Medical Necessity review: <a href="#">Lumbar Fusion, Medically Necessary Services</a> , <a href="#">Lumbar Spinal Fusion</a>				
<b>Vertebroplasty/Kyphoplasty</b>				
Requires Medical Necessity Review: <a href="#">Vertebroplasty + Kyphoplasty</a>				
<b>20983</b>	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation			<b>X</b>
<b>22510</b>	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic			<b>X</b>
<b>22511</b>	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral			<b>X</b>

<b>22512</b>	Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure)			<b>X</b>
<b>22513</b>	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic			<b>X</b>
<b>22514</b>	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar			<b>X</b>
<b>22515</b>	Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (eg, kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)			<b>X</b>
<b>22533</b>	Arthrodesis, lateral extracavitary technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar	<b>X</b>		<b>X</b>
<b>22558</b>	Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); lumbar	<b>X</b>		<b>X</b>
<b>22586</b>	Arthrodesis, pre-sacral interbody technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace	<b>X</b>		<b>X</b>
<b>22612</b>	Arthrodesis, posterior or posterolateral technique, single interspace; lumbar (with lateral transverse technique, when performed)			<b>X</b>
<b>22630</b>	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace, lumbar			<b>X</b>
<b>22632</b>	Arthrodesis, posterior interbody technique, including laminectomy and/or discectomy to prepare interspace (other than for decompression), single interspace, lumbar; each additional interspace (List separately in addition to code for primary procedure)			<b>X</b>
<b>22633</b>	Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace (other than for decompression), single interspace, lumbar			<b>X</b>
<b>22634</b>	Arthrodesis, combined posterior or posterolateral technique with posterior interbody technique including laminectomy and/or discectomy sufficient to prepare interspace (other than for decompression), single interspace, lumbar; each additional interspace (List separately in addition to code for primary procedure)			<b>X</b>

**Restorative Cosmetic Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
----------------------------	--------------------	------------------------------	--------------------------------	--

***Abdominoplasty/Panniculectomy/Lipectomy****Requires Medical Necessity Review: [Gender Affirming Surgeries](#), [Restorative and Cosmetic Procedures](#)*



15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy			X
15832	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh			X
15833	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg			X
15834	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip			X
15835	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock			X
15836	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm			X
15837	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand			X
15838	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad			X
15839	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area			X
15847	Excision, excessive skin and subcutaneous tissue (includes lipectomy), abdomen (eg, abdominoplasty) (includes umbilical transposition and fascial plication) (List separately in addition to code for primary procedure)			X
15876	Suction assisted lipectomy; head and neck			X
15877	Suction assisted lipectomy; trunk			X
15878	Suction assisted lipectomy; upper extremity			X
15879	Suction assisted lipectomy; lower extremity			X
<b>Blepharoplasty, Canthopexy, Canthoplasty</b>				
Requires Medical Necessity Review: <a href="#">Blepharoplasty</a> , <a href="#">Gender Affirming Surgeries</a>				
15820	Blepharoplasty, lower eyelid;			X
15821	Blepharoplasty, lower eyelid; with extensive herniated fat pad			X
15822	Blepharoplasty, upper eyelid;			X
15823	Blepharoplasty, upper eyelid; with excessive skin weighting down lid			X
21280	Medial canthopexy (separate procedure)			
21282	Lateral canthopexy			
67950	Canthoplasty (reconstruction of canthus)			X
<b>Breast Reconstruction</b>				
Requires Medical Necessity Review: <a href="#">Breast Reconstruction or Breast Prostheses</a> , <a href="#">Breast Implant Removal &amp; Re-Implantation</a> , <a href="#">Medically Necessary Services</a> , <a href="#">Gynecomastia</a>				
15769	Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia)			X
15771	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate			X
15772	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)			X
15773	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate			X
15774	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)			X
19328	Removal of intact breast implant			X



19330	Removal of ruptured breast implant, including implant contents (eg, saline, silicone gel)			X
19350	Nipple/areola reconstruction			X
19355	Correction of inverted nipples			X
19361	Breast reconstruction; with latissimus dorsi flap	X		X
19364	Breast reconstruction; with free flap (eg, fTRAM, DIEP, SIEA, GAP flap)	X		X
19367	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap	X		X
19368	Breast reconstruction; with single-pedicled transverse rectus abdominis myocutaneous (TRAM) flap, requiring separate microvascular anastomosis (supercharging)	X		X
19369	Breast reconstruction; with bipediced transverse rectus abdominis myocutaneous (TRAM) flap	X		X
19396	Preparation of moulage for custom breast implant			X
21740	Reconstructive repair of pectus excavatum or carinatum; open	X		
21742	Reconstructive repair of pectus excavatum or carinatum; minimally invasive approach (Nuss procedure), without thoracoscopy			
21743	Reconstructive repair of pectus excavatum or carinatum; minimally invasive approach (Nuss procedure), with thoracoscopy			
21750	Closure of median sternotomy separation with or without debridement (separate procedure)	X		
<b>Breast Reconstruction</b>				
<i>Requires Medical Necessity Review: <a href="#">Breast Reconstruction</a>, <a href="#">Breast Reduction (Mammoplasty) Surgery</a></i>				
19316	Mastopexy		X	X
19318	Breast reduction		X	X
19325	Breast augmentation with implant		X	X
19340	Insertion of breast implant on same day of mastectomy (ie, immediate)		X	X
19342	Insertion or replacement of breast implant on separate day from mastectomy		X	X
19357	Tissue expander placement in breast reconstruction, including subsequent expansion(s)		X	X
19370	Revision of peri-implant capsule, breast, including capsulotomy, capsulorrhaphy, and/or partial capsulectomy		X	X
19371	Peri-implant capsulectomy, breast, complete, including removal of all intracapsular contents		X	X
19380	Revision of reconstructed breast (eg, significant removal of tissue, re-advancement and/or re-inset of flaps in autologous reconstruction or significant capsular revision combined with soft tissue excision in implant-based reconstruction)		X	X
<b>Plastic Surgery additional codes</b>				
<i>Requires Medical Necessity Review: <a href="#">Gender Affirming Surgeries</a>, <a href="#">Restorative and Cosmetic Procedures</a></i>				
11950	Subcutaneous injection of filling material (eg, collagen); 1 cc or less		X	X
11951	Subcutaneous injection of filling material (eg, collagen); 1.1 to 5.0 cc		X	X
11952	Subcutaneous injection of filling material (eg, collagen); 5.1 to 10.0 cc		X	X
11954	Subcutaneous injection of filling material (eg, collagen); over 10.0 cc		X	X
11960	Insertion of tissue expander(s) for other than breast, including subsequent expansion		X	X
11970	Replacement of tissue expander with permanent implant		X	X
11971	Removal of tissue expander without insertion of implant		X	X
14000	Adjacent tissue transfer or rearrangement, trunk; defect 10 sq cm or less		X	
14001	Adjacent tissue transfer or rearrangement, trunk; defect 10.1 sq cm to 30.0 sq cm		X	

<b>14020</b>	Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10 sq cm or less		<b>X</b>	
<b>14021</b>	Adjacent tissue transfer or rearrangement, scalp, arms and/or legs; defect 10.1 sq cm to 30.0 sq cm		<b>X</b>	
<b>14040</b>	Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10 sq cm or less		<b>X</b>	
<b>14041</b>	Adjacent tissue transfer or rearrangement, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; defect 10.1 sq cm to 30.0 sq cm		<b>X</b>	
<b>14060</b>	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10 sq cm or less		<b>X</b>	
<b>14061</b>	Adjacent tissue transfer or rearrangement, eyelids, nose, ears and/or lips; defect 10.1 sq cm to 30.0 sq cm		<b>X</b>	
<b>14301</b>	Adjacent tissue transfer or rearrangement, any area; defect 30.1 sq cm to 60.0 sq cm		<b>X</b>	
<b>14302</b>	Adjacent tissue transfer or rearrangement, any area; each additional 30.0 sq cm, or part thereof (List separately in addition to code for primary procedure)		<b>X</b>	
<b>14350</b>	Filleted finger or toe flap, including preparation of recipient sit		<b>X</b>	

**Pulmonary Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>Bronchoscopy</b>				
<i>Requires Medical Necessity Review: <a href="#">Advanced Bronchoscopy Techniques</a></i>				
<b>31622</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; diagnostic, with cell washing, when performed (separate procedure)			
<b>31623</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with brushing or protected brushings			
<b>31624</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage			
<b>31625</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites			
<b>31628</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe			
<b>31630</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with tracheal/bronchial dilation or closed reduction of fracture			
<b>31631</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of tracheal stent(s) (includes tracheal/bronchial dilation as required)			
<b>31652</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]), one or two mediastinal and/or hilar lymph node stations or structures			<b>X</b>
<b>Pulmonary</b>				
<b>32555</b>	Thoracentesis, needle or catheter, aspiration of the pleural space; with imaging guidance			

32557	Pleural drainage, percutaneous, with insertion of indwelling catheter; with imaging guidance			
<b>Thoracoscopy</b>				
32601	Thoracoscopy, diagnostic (separate procedure); lungs, pericardial sac, mediastinal or pleural space, without biopsy			
32604	Thoracoscopy, diagnostic (separate procedure); pericardial sac, with biopsy			
32606	Thoracoscopy, diagnostic (separate procedure); mediastinal space, with biopsy			
32607	Thoracoscopy; with diagnostic biopsy(ies) of lung infiltrate(s) (eg, wedge, incisional), unilateral			
32608	Thoracoscopy; with diagnostic biopsy(ies) of lung nodule(s) or mass(es) (eg, wedge, incisional), unilateral			
32609	Thoracoscopy; with biopsy(ies) of pleura			
32650	Thoracoscopy, surgical; with pleurodesis (eg, mechanical or chemical)	X		
32653	Thoracoscopy, surgical; with removal of intrapleural foreign body or fibrin deposit	X		
32655	Thoracoscopy, surgical; with resection-plication of bullae, includes any pleural procedure when performed	X		
32658	Thoracoscopy, surgical; with removal of clot or foreign body from pericardial sac	X		
32661	Thoracoscopy, surgical; with excision of pericardial cyst, tumor, or mass	X		
32662	Thoracoscopy, surgical; with excision of mediastinal cyst, tumor, or mass	X		
32666	Thoracoscopy, surgical; with therapeutic wedge resection (eg, mass, nodule), initial unilateral	X		
32667	Thoracoscopy, surgical; with therapeutic wedge resection (eg, mass or nodule), each additional resection, ipsilateral (List separately in addition to code for primary procedure)	X		
32674	Thoracoscopy, surgical; with mediastinal and regional lymphadenectomy (List separately in addition to code for primary procedure)	X		
38700	Suprahyoid lymphadenectomy			
38720	Cervical lymphadenectomy (complete)			
38724	Cervical lymphadenectomy (modified radical neck dissection)	X		
38740	Axillary lymphadenectomy; superficial			
38765	Inguinofemoral lymphadenectomy, superficial, in continuity with pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes (separate procedure)	X		
<b>Uvulopalatopharyngoplasty</b>				
<i>Requires Medical Necessity Review: <a href="#">Treatments of Sleep Apnea (Surgical &amp; Non-Surgical)</a></i>				
42145	Palatopharyngoplasty (eg, uvulopalatopharyngoplasty, uvulopharyngoplasty)			X

**Urology Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

CPT® or HCPCS Codes	Description	Medicare IP Only List	Requires ASC SOC Review	Requires Medical Necessity Review
<b>Artificial Urinary Sphincter</b>				
53445	Insertion of inflatable urethral/bladder neck sphincter, including placement of pump, reservoir, and cuff			
<b>Bladder Sling—vaginal approach</b>				
<i>Requires Medical Necessity Review: <a href="#">Treatments for Urinary Incontinence</a></i>				

51840	Anterior vesicourethropepy, or urethropepy (eg, Marshall-Marchetti-Krantz, Burch); simple	X		X
51841	Anterior vesicourethropepy, or urethropepy (eg, Marshall-Marchetti-Krantz, Burch); complicated (eg, secondary repair)	X		X
51845	Abdomino-vaginal vesical neck suspension, with or without endoscopic control (eg, Stamey, Raz, modified Pereyra)			X
51990	Laparoscopy, surgical; urethral suspension for stress incontinence			X
51992	Laparoscopy, surgical; sling operation for stress incontinence (eg, fascia or synthetic)			X
57287	Removal or revision of sling for stress incontinence (eg, fascia or synthetic)			
57288	Sling operation for stress incontinence (eg, fascia or synthetic)			X
57289	Pereyra procedure, including anterior colporrhaphy			X
<b>Bladder Sling—Male</b>				
Requires Medical Necessity Review: <a href="#">Treatments for Urinary Incontinence</a>				
53440	Sling operation for correction of male urinary incontinence (eg, fascia or synthetic)			X
53442	Removal or revision of sling for male urinary incontinence (eg, fascia or synthetic)			X
<b>Circumcision (older than 28 days of age)</b>				
54161	Circumcision, surgical excision other than clamp, device, or dorsal slit; older than 28 days of age			
54162	Lysis or excision of penile post-circumcision adhesions			
54163	Repair incomplete circumcision			
54164	Frenulotomy of penis			
<b>Cystourethroscopy</b>				
52000	Cystourethroscopy (separate procedure)			
52001	Cystourethroscopy with irrigation and evacuation of multiple obstructing clots			
52005	Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service;			
52007	Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; with brush biopsy of ureter and/or renal pelvis			
52010	Cystourethroscopy, with ejaculatory duct catheterization, with or without irrigation, instillation, or duct radiography, exclusive of radiologic service			
52204	Cystourethroscopy, with biopsy(s)			
52214	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands			
52224	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or without biopsy			
52234	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; SMALL bladder tumor(s) (0.5 up to 2.0 cm)			
52235	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; MEDIUM bladder tumor(s) (2.0 to 5.0 cm)			
52240	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; LARGE bladder tumor(s)			
52260	Cystourethroscopy, with dilation of bladder for interstitial cystitis; general or conduction (spinal) anesthesia			
52265	Cystourethroscopy, with dilation of bladder for interstitial cystitis; local anesthesia			
52275	Cystourethroscopy, with internal urethrotomy; male			

52276	Cystourethroscopy with direct vision internal urethrotomy			
52281	Cystourethroscopy, with calibration and/or dilation of urethral stricture or stenosis, with or without meatotomy, with or without injection procedure for cystography, male or female			
52282	Cystourethroscopy, with insertion of permanent urethral stent			
52283	Cystourethroscopy, with steroid injection into stricture			
52285	Cystourethroscopy for treatment of the female urethral syndrome with any or all of the following: urethral meatotomy, urethral dilation, internal urethrotomy, lysis of urethrovaginal septal fibrosis, lateral incisions of the bladder neck, and fulguration of polyp(s) of urethra, bladder neck, and/or trigone			
52287	Cystourethroscopy, with injection(s) for chemodenervation of the bladder			
52300	Cystourethroscopy; with resection or fulguration of orthotopic ureterocele(s), unilateral or bilateral			
52310	Cystourethroscopy, with removal of foreign body, calculus, or ureteral stent from urethra or bladder (separate procedure); simple			
52315	Cystourethroscopy, with removal of foreign body, calculus, or ureteral stent from urethra or bladder (separate procedure); complicated			
52317	Litholapaxy: crushing or fragmentation of calculus by any means in bladder and removal of fragments; simple or small (less than 2.5 cm)			
52318	Litholapaxy: crushing or fragmentation of calculus by any means in bladder and removal of fragments; complicated or large (over 2.5 cm)			
52320	Cystourethroscopy (including ureteral catheterization); with removal of ureteral calculus			
52325	Cystourethroscopy (including ureteral catheterization); with fragmentation of ureteral calculus (eg, ultrasonic or electro-hydraulic technique)			
52327	Cystourethroscopy (including ureteral catheterization); with subureteric injection of implant material			
52330	Cystourethroscopy (including ureteral catheterization); with manipulation, without removal of ureteral calculus			
52332	Cystourethroscopy, with insertion of indwelling ureteral stent (eg, Gibbons or double-J type)			
52341	Cystourethroscopy; with treatment of ureteral stricture (eg, balloon dilation, laser, electrocautery, and incision)			
52344	Cystourethroscopy with ureteroscopy; with treatment of ureteral stricture (eg, balloon dilation, laser, electrocautery, and incision)			
52351	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; diagnostic			
52352	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with removal or manipulation of calculus (ureteral catheterization is included)			
52353	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy (ureteral catheterization is included)			
52354	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with biopsy and/or fulguration of ureteral or renal pelvic lesion			
52356	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with lithotripsy including insertion of indwelling ureteral stent (eg, Gibbons or double-J type)			
<b>Laparoscopic Nephrectomy</b>				
<i>Requires Medical Necessity Review: <a href="#">Kidney/Pancreas Transplant</a> , <a href="#">Kidney Transplant</a></i>				
50543	Laparoscopy, surgical; partial nephrectomy			
50545	Laparoscopy, surgical; radical nephrectomy (includes removal of Gerota's fascia and surrounding fatty tissue, removal of regional lymph nodes, and adrenalectomy)	X		
50546	Laparoscopy, surgical; nephrectomy, including partial ureterectomy	X		
50547	Laparoscopy, surgical; donor nephrectomy (including cold preservation), from living donor	X		X

50548	Laparoscopy, surgical; nephrectomy with total ureterectomy	X		
<b>Orchiectomy</b>				
54520	Orchiectomy, simple (including subcapsular), with or without testicular prosthesis, scrotal or inguinal approach			
54522	Orchiectomy, partial			
54530	Orchiectomy, radical, for tumor; inguinal approach			
54535	Orchiectomy, radical, for tumor; with abdominal exploration			
54690	Laparoscopy, surgical; orchiectomy			
<b>Percutaneous Nephrostomy</b>				
50080	Percutaneous nephrolithotomy or pyelolithotomy, lithotripsy, stone extraction, antegrade ureteroscopy, antegrade stent placement and nephrostomy tube placement, when performed, including imaging guidance; simple (eg, stone[s] up to 2 cm in single location of kidney or renal pelvis, nonbranching stones)			
50081	Percutaneous nephrolithotomy or pyelolithotomy, lithotripsy, stone extraction, antegrade ureteroscopy, antegrade stent placement and nephrostomy tube placement, when performed, including imaging guidance; complex (eg, stone[s] > 2 cm, branching stones, stones in multiple locations, ureter stones, complicated anatomy)			
50432	Placement of nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation			
50433	Placement of nephroureteral catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, new access			
50695	Placement of ureteral stent, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; new access, with separate nephrostomy catheter			
52334	Cystourethroscopy with insertion of ureteral guide wire through kidney to establish a percutaneous nephrostomy, retrograde			
<b>Prostatectomy</b>				
55810	Prostatectomy, perineal radical	X		
55812	Prostatectomy, perineal radical; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	X		
55815	Prostatectomy, perineal radical; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	X		
55842	Prostatectomy, retropubic radical, with or without nerve sparing; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	X		
55845	Prostatectomy, retropubic radical, with or without nerve sparing; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes	X		
55866	Laparoscopy, surgical prostatectomy, retropubic radical, including nerve sparing, includes robotic assistance, when performed			
<b>Pyeloplasty</b>				
50544	Laparoscopy, surgical; pyeloplasty			
<b>Transurethral Resection of the Prostate (TURP)</b>				
52601	Transurethral electrosurgical resection of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)			
52630	Transurethral resection; residual or regrowth of obstructive prostate tissue including control of postoperative bleeding, complete			



	(vasectomy, meatotomy, cystourethroscopy, urethral calibration and/or dilation, and internal urethrotomy are included)			
<b>Urolift</b>				
Requires Medical Necessity Review: <a href="#">Benign Prostatic Hyperplasia (BPH) Treatments</a>				
<b>52441</b>	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant			<b>X</b>
<b>52442</b>	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)			<b>X</b>
<b>C9739</b>	Cystourethroscopy, with insertion of transprostatic implant; one to three implants			<b>X</b>
<b>C9740</b>	Cystourethroscopy, with insertion of transprostatic implant; four or more implants			<b>X</b>
<b>Vesicovaginal Fistula Repair</b>				
<b>57330</b>	Closure of vesicovaginal fistula; transvesical and vaginal approach			
<b>Urology (additional codes)</b>				
Requires Medical Necessity Review: <a href="#">Fertility Services</a>				
<b>50430</b>	Injection procedure for antegrade nephrostogram and/or ureterogram, complete diagnostic procedure including imaging guidance (eg, ultrasound and fluoroscopy) and all associated radiological supervision and interpretation; new access			
<b>50435</b>	Exchange nephrostomy catheter, percutaneous, including diagnostic nephrostogram and/or ureterogram when performed, imaging guidance (eg, ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation			
<b>50575</b>	Renal endoscopy through nephrotomy or pyelotomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; with endopyelotomy (includes cystoscopy, ureteroscopy, dilation of ureter and ureteral pelvic junction, incision of ureteral pelvic junction and insertion of endopyelotomy stent)			
<b>50590</b>	Lithotripsy, extracorporeal shock wave			
<b>50688</b>	Change of ureterostomy tube or externally accessible ureteral stent via ileal conduit			
<b>51040</b>	Cystostomy, cystotomy with drainage			
<b>51050</b>	Cystolithotomy, cystotomy with removal of calculus, without vesical neck resection			
<b>51102</b>	Aspiration of bladder; with insertion of suprapubic catheter			
<b>51600</b>	Injection procedure for cystography or voiding urethrocystography			
<b>51610</b>	Injection procedure for retrograde urethrocystography			
<b>51702</b>	Insertion of temporary indwelling bladder catheter; simple (eg, Foley)			
<b>51710</b>	Change of cystostomy tube; complicated			
<b>51715</b>	Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck			<b>X</b>
<b>51720</b>	Bladder instillation of anticarcinogenic agent (including retention time)			
<b>51726</b>	Complex cystometrogram (ie, calibrated electronic equipment);			
<b>51728</b>	Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure), any technique			
<b>51729</b>	Complex cystometrogram (ie, calibrated electronic equipment); with voiding pressure studies (ie, bladder voiding pressure) and urethral pressure profile studies (ie, urethral closure pressure profile), any technique			
<b>52450</b>	Transurethral incision of prostate			
<b>52500</b>	Transurethral resection of bladder neck (separate procedure)			
<b>52640</b>	Transurethral resection; of postoperative bladder neck contracture			
<b>52648</b>	Laser vaporization of prostate, including control of postoperative bleeding, complete (vasectomy, meatotomy, cystourethroscopy,			

	urethral calibration and/or dilation, internal urethrotomy and transurethral resection of prostate are included if performed)			
<b>53020</b>	Meatotomy, cutting of meatus (separate procedure); except infant			
<b>53200</b>	Biopsy of urethra			
<b>53230</b>	Excision of urethral diverticulum (separate procedure); female			
<b>53260</b>	Excision or fulguration; urethral polyp(s), distal urethra			
<b>53265</b>	Excision or fulguration; urethral caruncle			
<b>53270</b>	Excision or fulguration; Skene's glands			
<b>53400</b>	Urethroplasty; first stage, for fistula, diverticulum, or stricture (eg, Johanssen type)			
<b>53405</b>	Urethroplasty; second stage (formation of urethra), including urinary diversion			
<b>53450</b>	Urethromeatoplasty, with mucosal advancement			
<b>53500</b>	Urethrolisis, transvaginal, secondary, open, including cystourethroscopy (eg, postsurgical obstruction, scarring)			
<b>53605</b>	Dilation of urethral stricture or vesical neck by passage of sound or urethral dilator, male, general or conduction (spinal) anesthesia			
<b>53665</b>	Dilation of female urethra, general or conduction (spinal) anesthesia			
<b>54001</b>	Slitting of prepuce, dorsal or lateral (separate procedure); except newborn			
<b>54055</b>	Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; electrodesiccation			
<b>54057</b>	Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; laser surgery			
<b>54060</b>	Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), simple; surgical excision			
<b>54065</b>	Destruction of lesion(s), penis (eg, condyloma, papilloma, molluscum contagiosum, herpetic vesicle), extensive (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery)			
<b>54100</b>	Biopsy of penis; (separate procedure)			
<b>54110</b>	Excision of penile plaque (Peyronie disease);			
<b>54150</b>	Circumcision, using clamp or other device with regional dorsal penile or ring block			
<b>54300</b>	Plastic operation of penis for straightening of chordee (eg, hypospadias), with or without mobilization of urethra			
<b>54360</b>	Plastic operation on penis to correct angulation			
<b>54450</b>	Foreskin manipulation including lysis of preputial adhesions and stretching			
<b>54512</b>	Excision of extraparenchymal lesion of testis			
<b>54600</b>	Reduction of torsion of testis, surgical, with or without fixation of contralateral testis			
<b>54620</b>	Fixation of contralateral testis (separate procedure)			
<b>54640</b>	Orchiopexy, inguinal or scrotal approach			
<b>54830</b>	Excision of local lesion of epididymis			
<b>54840</b>	Excision of spermatocele, with or without epididymectomy			
<b>54860</b>	Epididymectomy; unilateral			
<b>55000</b>	Puncture aspiration of hydrocele, tunica vaginalis, with or without injection of medication			
<b>55040</b>	Excision of hydrocele; unilateral			
<b>55041</b>	Excision of hydrocele; bilateral			
<b>55060</b>	Repair of tunica vaginalis hydrocele (Bottle type)			
<b>55100</b>	Drainage of scrotal wall abscess			
<b>55110</b>	Scrotal exploration			
<b>55120</b>	Removal of foreign body in scrotum			
<b>55250</b>	Vasectomy, unilateral or bilateral (separate procedure), including postoperative semen examination(s)			
<b>55400</b>	Vasovasostomy, vasovasorrhaphy			<b>X</b>

<b>55500</b>	Excision of hydrocele of spermatic cord, unilateral (separate procedure)			
<b>55520</b>	Excision of lesion of spermatic cord (separate procedure)			
<b>55540</b>	Excision of varicocele or ligation of spermatic veins for varicocele; with hernia repair			
<b>55700</b>	Biopsy, prostate; needle or punch, single or multiple, any approach			
<b>57105</b>	Biopsy of vaginal mucosa; extensive, requiring suture (including cysts)			
<b>57295</b>	Revision (including removal) of prosthetic vaginal graft; vaginal approach			
<b>57511</b>	Cautery of cervix; cryocautery, initial or repeat			
<b>58353</b>	Endometrial ablation, thermal, without hysteroscopic guidance			

**Vascular Procedure Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not apply

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>Varicose Vein Procedures</b>				
<i>Requires Medical Necessity Review: <a href="#">Treatment of Varicose Veins</a></i>				
<b>S2202</b>	Echosclerotherapy			<b>X</b>
<b>36465</b>	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein)			<b>X</b>
<b>36466</b>	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg			<b>X</b>
<b>36468</b>	Injection(s) of sclerosant for spider veins (telangiectasia), limb or trunk			<b>X</b>
<b>36470</b>	Injection of sclerosant; single incompetent vein (other than telangiectasia)			<b>X</b>
<b>36471</b>	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg			<b>X</b>
<b>36473</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated			<b>X</b>
<b>36474</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)			<b>X</b>
<b>36475</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated			<b>X</b>
<b>36476</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)			<b>X</b>
<b>36478</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated			<b>X</b>
<b>36479</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser;			<b>X</b>

	subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)			
<b>36482</b>	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated			<b>X</b>
<b>36483</b>	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)			<b>X</b>
<b>37500</b>	Vascular endoscopy, surgical, with ligation of perforator veins, subfascial (SEPS)			<b>X</b>
<b>37700</b>	Ligation and division of long saphenous vein at saphenofemoral junction, or distal interruptions			<b>X</b>
<b>37718</b>	Ligation, division, and stripping, short saphenous vein			<b>X</b>
<b>37722</b>	Ligation, division, and stripping, long (greater) saphenous veins from saphenofemoral junction to knee or below			<b>X</b>
<b>37735</b>	Ligation and division and complete stripping of long or short saphenous veins with radical excision of ulcer and skin graft and/or interruption of communicating veins of lower leg, with excision of deep fascia			<b>X</b>
<b>37760</b>	Ligation of perforator veins, subfascial, radical (Linton type), including skin graft, when performed, open, 1 leg			<b>X</b>
<b>37761</b>	Ligation of perforator vein(s), subfascial, open, including ultrasound guidance, when performed, 1 leg			<b>X</b>
<b>37765</b>	Stab phlebectomy of varicose veins, 1 extremity; 10-20 stab incisions			<b>X</b>
<b>37766</b>	Stab phlebectomy of varicose veins, 1 extremity; more than 20 incisions			<b>X</b>
<b>37780</b>	Ligation and division of short saphenous vein at saphenopopliteal junction (separate procedure)			<b>X</b>
<b>37785</b>	Ligation, division, and/or excision of varicose vein cluster(s), 1 leg			<b>X</b>

**Wound Care Codes—****Non-Medicare:** Requires review when submitted as an inpatient level of care**Medicare:** Medicare inpatient only procedures indicated with an “X” below, and this policy does not applyRequires Medical Necessity Review: [Dermatology](#)

<b>CPT® or HCPCS Codes</b>	<b>Description</b>	<b>Medicare IP Only List</b>	<b>Requires ASC SOC Review</b>	<b>Requires Medical Necessity Review</b>
<b>10060</b>	Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single			
<b>10061</b>	Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or multiple			
<b>10080</b>	Incision and drainage of pilonidal cyst; simple			
<b>10081</b>	Incision and drainage of pilonidal cyst; complicated			
<b>10121</b>	Incision and removal of foreign body, subcutaneous tissues; complicated			
<b>10180</b>	Incision and drainage, complex, postoperative wound infection			
<b>11000</b>	Debridement of extensive eczematous or infected skin; up to 10% of body surface			
<b>11010</b>	Debridement including removal of foreign material at the site of an open fracture and/or an open dislocation (e.g., excisional debridement); skin and subcutaneous tissues			

<b>11012</b>	Debridement including removal of foreign material at the site of an open fracture and/or an open dislocation (e.g., excisional debridement); skin, subcutaneous tissue, muscle fascia, muscle, and bone			
<b>11042</b>	Debridement, subcutaneous tissue (includes epidermis and dermis, if performed); first 20 sq cm or less			
<b>11750</b>	Excision of nail and nail matrix, partial or complete (e.g., ingrown or deformed nail), for permanent removal			
<b>11755</b>	Biopsy of nail unit (e.g., plate, bed, matrix, hyponychium, proximal and lateral nail folds) (separate procedure)			
<b>11760</b>	Repair of nail bed			
<b>11770</b>	Excision of pilonidal cyst or sinus; simple			
<b>11772</b>	Excision of pilonidal cyst or sinus; complicated			
<b>11900</b>	Injection, intralesional; up to and including 7 lesions			
<b>12001</b>	Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.5 cm or less			
<b>12002</b>	Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or extremities (including hands and feet); 2.6 cm to 7.5 cm			
<b>12011</b>	Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less			
<b>12020</b>	Treatment of superficial wound dehiscence; simple closure			
<b>12031</b>	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 2.5 cm or less			
<b>12032</b>	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 2.6 cm to 7.5 cm			
<b>12034</b>	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 7.6 cm to 12.5 cm			
<b>12035</b>	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); 12.6 cm to 20.0 cm			
<b>12037</b>	Repair, intermediate, wounds of scalp, axillae, trunk and/or extremities (excluding hands and feet); over 30.0 cm			
<b>12041</b>	Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 2.5 cm or less			
<b>12042</b>	Repair, intermediate, wounds of neck, hands, feet and/or external genitalia; 2.6 cm to 7.5 cm			
<b>12051</b>	Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less			
<b>12052</b>	Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.6 cm to 5.0 cm			
<b>13100</b>	Repair, complex, trunk; 1.1 cm to 2.5 cm			
<b>13101</b>	Repair, complex, trunk; 2.6 cm to 7.5 cm			
<b>13120</b>	Repair, complex, scalp, arms, and/or legs; 1.1 cm to 2.5 cm			
<b>13121</b>	Repair, complex, scalp, arms, and/or legs; 2.6 cm to 7.5 cm			
<b>13131</b>	Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 1.1 cm to 2.5 cm			
<b>13132</b>	Repair, complex, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands and/or feet; 2.6 cm to 7.5 cm			
<b>13151</b>	Repair, complex, eyelids, nose, ears and/or lips; 1.1 cm to 2.5 cm			
<b>13152</b>	Repair, complex, eyelids, nose, ears and/or lips; 2.6 cm to 7.5 cm			
<b>13160</b>	Secondary closure of surgical wound or dehiscence, extensive or complicated			
<b>15100</b>	Split-thickness autograft, trunk, arms, legs; first 100 sq. cm or less, or 1% of body area of infants and children (except 15050)			
<b>15120</b>	Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq. cm or less, or 1% of body area of			

	infants and children (except 15050)			
<b>15220</b>	Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; 20 sq. cm or less			
<b>15240</b>	Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands, and/or feet; 20 sq. cm or less			
<b>15576</b>	Formation of direct or tubed pedicle, with or without transfer; eyelids, nose, ears, lips, or intraoral			
<b>15760</b>	Graft; composite (eg, full thickness of external ear or nasal ala), including primary closure, donor area			
<b>15851</b>	Removal of sutures or staples requiring anesthesia (ie, general anesthesia, moderate sedation)			
<b>17000</b>	Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion			<b>X</b>
<b>17004</b>	Destruction (e.g., laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (e.g., actinic keratoses), 15 or more lesions			<b>X</b>
<b>17106</b>	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); less than 10 sq. cm			<b>X</b>
<b>17107</b>	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); 10.0 to 50.0 sq. cm			<b>X</b>
<b>17108</b>	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); over 50.0 sq. cm			<b>X</b>
<b>21011</b>	Excision, tumor, soft tissue of face or scalp, subcutaneous; less than 2 cm			
<b>23030</b>	Incision and drainage, shoulder area; deep abscess or hematoma			
<b>23031</b>	Incision and drainage, shoulder area; infected bursa			
<b>25028</b>	Incision and drainage, forearm and/or wrist; deep abscess or hematoma			
<b>30000</b>	Drainage abscess or hematoma, nasal, internal approach			
<b>30020</b>	Drainage abscess or hematoma, nasal septum			
<b>45005</b>	Incision and drainage of submucosal abscess, rectum			
<b>54700</b>	Incision and drainage of epididymis, testis and/or scrotal space (eg, abscess or hematoma)			

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
11/1/2022	11/01/2022 <sup>MPC</sup> , 11/07/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	05/06/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
11/01/2022	MPC approved the new Elective Surgical Procedures (Level of Care) criteria. Cardiac Catheterization/Pacemaker is the first approved elective procedure to be done on an outpatient basis. 60-day notice is required; effective April 1, 2023.
03/22/2023	Updated effective date to April 25 <sup>th</sup> , 2023.
07/11/2023	MPC approved to expand the scope of our current policy which has been restricted to two procedures to date. Requires 60-day notice. Effective date 12/01/2023
10/06/2023	Effective date changed to 12/05/2023.



05/02/2024	MPC approved Medical necessity review for <a href="#">bladder sling procedures</a> , updated applicable codes section that requires level of care review in addition. 60 day notice required, effective 08/01/2024.
05/10/2024	Added code 27236 to the policy
07/02/2024	MPC approved the addition of all the ASC soc codes to the Level of Care Policy; and MPC approved the expansion of this. 60-day notice required; effective December 1 <sup>st</sup> , 2024
11/18/2024	Removing applicable codes for TAVR, MitraClip, and Watchman device.
03/03/2025	Added indication that Shoulder Arthroscopy codes and Thyroidectomy procedures require Medical Necessity review in addition to LOC review. Deleted duplicate codes.
05/06/2025	MPC approved criteria for Cardiac Catheter EP Based Procedures; add codes that require LOC

## Clinical Review Criteria

### Electrical Stimulation and Devices

- Cranial Electrotherapy Stimulation
- Electrical Stimulation for the Treatment of Dysphagia
- Functional Neuromuscular Stimulation Unit (FNS or ENS)
- Galvanic Stimulation Device
- Gastric Electrical Stimulation (Enterra)
- H-wave Stimulation Device
- Microcurrent Stimulation Device (MENS)
- NESS Stimulators for Foot Drop and Paralyzed Hands
- Neuromuscular Electrical Stimulation Unit (NMES)
- Percutaneous Neuromodulation Therapy (PNT) for Back Pain - Vertis
- Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee
- ReBuilder System
- Transcutaneous Electrical Nerve Stimulation (TENS) Unit
- Transcutaneous Electrical Joint Stimulation Devices (TEJSD)
- WalkAide System for Patients with Foot Drop
- Peripheral Nerve Stimulation

#### A Separate Criteria Document Exists for the Following Devices:

[Central Nervous System Electrical Nerve Stimulator: Spinal Cord Stimulators for Pain, Deep Brain Stimulation](#)  
[Electrical Stimulation for Treatment of Wounds \(Wound Care Treatments\)](#)  
[Hypoglossal Nerve Stimulation \(Treatments for Obstructive Sleep Apnea\)](#)  
[Osteogenic \(Bone\) Stimulators](#)  
[Deep Brain Stimulation](#)  
[Vagus Nerve Stimulation](#)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Electrical Nerve Stimulators 160.7</a> <a href="#">Assessing Patient's Suitability for Electrical Nerve Stimulation Therapy 160.7.1</a> <a href="#">Neuromuscular Electrical Stimulation (NMES) (160.12)</a> <a href="#">Non-Implantable Pelvic Floor Electrical Stimulator (230.8)</a> <a href="#">Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES) (160.13)</a> <a href="#">Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative Pain (10.2)</a> <a href="#">Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP) (160.27)</a>

	Treatment of Motor Function Disorders with Electric Nerve Stimulation (160.2)
Local Coverage Determinations (LCD)	<a href="#">Transcutaneous Electrical Nerve Stimulators (TENS) (L33802)</a> <a href="#">Peripheral Nerve Stimulation (L37360)</a>  <a href="#">Transcutaneous Electrical Joint Stimulation Devices (TEJSD) (L34821)</a> *references code E0762  <a href="#">External upper Limb Tremor Stimulation Therapy (L39591)</a> (References E0734, A4542)
Local Coverage Article	<a href="#">Transcutaneous Electrical Nerve Stimulators (TENS) (A52520)</a>  <a href="#">Transcutaneous Electrical Joint Stimulation Devices (TEJSD) (A52713)</a>

### For Non-Medicare Members

Device	Criteria
<b>TENS unit</b>	<p>Kaiser Permanente has elected to use coverage guidance from Medicare's Local Coverage Determination (LCD) <a href="#">Transcutaneous Electrical Nerve Stimulators L33802</a> and Policy Article <a href="#">Transcutaneous Electrical Nerve Stimulators (TENS) (A52520)</a></p> <p><b>If requesting this service, please send the following documentation to support medical necessity:</b></p> <ul style="list-style-type: none"> <li>• Last 6 months of clinical notes from requesting provider or specialist to include any medications that were tried for pain relief</li> <li>• This service is dependent upon other measures of pain relief having been tried</li> </ul>
<b>External Upper Limb Tremor Stimulator Therapy (e.g., Cala Trio)</b>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies</p>
<b>NMES Unit – Neuromuscular Electrical Stimulation</b>	<p>Must meet <b>ALL of the following:</b></p> <ol style="list-style-type: none"> <li>1) Has durable medical equipment benefit</li> <li>2) Treatment of muscle atrophy where the nerve supply to the muscle is intact, including brain, spinal cord and peripheral nerves and other neurological reasons for disuse atrophy</li> </ol>

Device	Criteria
<b>FES unit – Functional Electrical Stimulation (e.g. Parastep I System)</b>	<p>Must meet <b>ALL of the following</b>:</p> <ol style="list-style-type: none"> <li>1. Has durable medical equipment benefit</li> <li>2. Spinal cord injury patients to achieve walking and not reverse or retard muscle atrophy with all of the following characteristics:               <ol style="list-style-type: none"> <li>a) Persons with intact lower motor units (L1 and below) (both muscle and peripheral nerves);</li> <li>b) Persons with muscle and joint stability for weight bearing at upper and lower extremities that can demonstrate balance and control to maintain an upright support posture independently;</li> <li>c) Persons that demonstrate brisk muscle contraction to NMES and have sensory perception of electrical stimulation sufficient for muscle contraction;</li> <li>d) Persons that possess high motivation, commitment and cognitive ability to use such device for walking;</li> <li>e) Persons that can transfer independently and can demonstrate independent standing tolerance for at least 3 minutes;</li> <li>f) Persons that can demonstrate hand and finger function to manipulate controls;</li> <li>g) Persons with at least 6-month post-recovery spinal cord injury and restorative surgery;</li> <li>h) Persons without hip and knee degenerative disease and no history of long bone fracture secondary to osteoporosis; and</li> <li>i) Persons who have demonstrated a willingness to use the device long-term.</li> <li>j) Persons without one of the following conditions:                   <ol style="list-style-type: none"> <li>i) Cardiac pacemaker;</li> <li>ii) Severe scoliosis or severe osteoporosis;</li> <li>iii) Skin disease or cancer at area of stimulation;</li> <li>iv) Irreversible contracture;</li> <li>v) Autonomic dysreflexia</li> </ol> </li> </ol> </li> </ol>
<b>Gastric Electrical Stimulation for the Treatment of Medically Refractory Diabetic Gastroparesis (Enterra™)</b>	<p>Kaiser Permanente has elected to use the MCG* Gastric Stimulation, Electrical (A-0395) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p> <p><b>If requesting this service, please send the following documentation to support medical necessity:</b></p> <ul style="list-style-type: none"> <li>• Last 2 years of gastroenterology notes</li> <li>• Most recent clinical note from requesting provider</li> </ul>
<b>Gastric Electrical Stimulation for the Treatment of Gastroparesis (other than diabetic gastroparesis)</b>	<p>Kaiser Permanente has elected to use the MCG* Gastric Stimulation, Electrical (A-0395) for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p>
<b>Cranial Electrotherapy Stimulation</b>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies</p>
<b>Electrical Stimulation for the Treatment of Dysphagia</b>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies</p>

Device	Criteria
<b>Galvanic Stimulation Device</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>H-wave Stimulation Device</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>Microcurrent Stimulation Device (MENS)</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>NESS Stimulators for Foot Drop and Paralyzed Hands</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>Percutaneous Neuromodulation Therapy (PNT) for Back Pain - Vertis PNT System</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>ReBuilder System Threshold electrical stimulation</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>Transcutaneous Supraorbital Electrical Nerve Stimulator (e.g., Cefaly, Allive, Relivion HeadA Term)</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>WalkAide System for Patients with Foot Drop</b>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies
<b>Peripheral Nerve Stimulator (i.e., StimRouter, Stimwave, Nalu)</b>	Peripheral nerve stimulation is not covered for any indication at this time. Under evidence review. All requests must be reviewed by the Medical Director.

using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Evidence and Source Documents

[Electrical Stimulation for the Treatment of Dysphagia](#)

[Gastric Electrical Stimulation \(Enterra\)](#)

[Hypoglossal Nerve Stimulation](#)

[NESS Stimulators for Foot Drop and Paralyzed Hands](#)

[Percutaneous Neuromodulation Therapy \(PNT\) for Back Pain - Vertis](#)

[Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee](#)

[ReBuilder System](#)

[WalkAide System for Patients with Foot Drop](#)

## Background

A transcutaneous electrical nerve stimulator (TENS) is a device that utilizes electrical current delivered through electrodes placed on the surface of the skin to decrease the patient's perception of pain by inhibiting the transmission of afferent pain nerve impulses and/or stimulating the release of endorphins.

These are not the same as neuromuscular electrical stimulators (NMES), which are used to directly stimulate muscles and are used to prevent disuse atrophy (not address pain).

The transcutaneous electrical nerve stimulator is a well-established technique with limited effect and efficacy for the control of chronic painful disorders. Patients with chronic pain are best treated with a multi-disciplinary approach that includes increasing their activity. A TENS unit may be useful for a few weeks to assist a patient in becoming more active. It is not recommended for acute pain management as medication is much more effective and is safe for short-term management. It may be used occasionally to assist with pain control in patients with acute pain.

## Medical Technology Assessment Committee (MTAC)

### ***Transcutaneous Electrical Nerve Stimulation (TENS)***

**06/30/1998: MTAC REVIEW**

**Evidence Conclusion:** Jarzem et al., Transcutaneous Electrical Nerve Stimulation for Patients with Chronic Backpain, presented at the annual meeting of the American Academy of Orthopedic Surgeons, San Francisco, 1997. 350 patients with chronic back pain, randomized into 4 groups; (1) daily treatment with conventional TENS; (2) treatment with nu-wave form TENS; (3) treatment with acupuncture TENS; (4) and treatment with sham TENS. In addition, all underwent an identical exercise program by a single therapist, blinded. 26 patients dropped out. All patients improved over time, but there were no significant differences among treatment groups.

### ***Electrical Stimulation for the Treatment of Dysphagia***

#### **BACKGROUND**

Dysphagia is the subjective sensation of difficulty or abnormality of swallowing. The term is derived from the Greek dys for bad or disorder, and phago for eat. Swallowing is a complex sensory-motor behavior that involves more than 25 pairs of muscles, 6 cranial nerves, and 2 cervical nerve roots to transport saliva, ingested solids, and fluids from the oral cavity to the stomach. It consists of three sequential, physiologically interconnected phases: oral preparatory and propulsive phase, pharyngeal phase, and esophageal phase. Dysphagia occurs when there is a problem with any part of this swallowing process. It can affect any age group, and may result from congenital abnormalities, stroke, head injury, neoplasms, and/or other medical conditions. Its incidence is higher in the elderly, in patients who have had strokes, and in patients who are admitted to acute care hospitals or chronic care facilities. Some may have trouble swallowing food, liquids, or saliva, and others are completely unable to swallow. Dysphagia can be a serious health threat due to the risk of aspiration pneumonia, bronchospasm, airway obstruction, pulmonary fibrosis, malnutrition, dehydration, and death (Leelamanit 2002, Blumenfeld 2006, Shaw 2007, Bulow 2008, Humbert 2012, Tan 2013). Functional dysphagia therapy aims at reducing the risk of aspiration and improving the physiology of the impaired swallowing mechanism to restore



function. The traditional therapy incorporates diet modification, position adjustment, speech therapy, and exercise to alter the muscle structure and function. Percutaneous endoscopic gastrostomy tubes are often used in the management of dysphagia. Thermal tactile stimulation by the application of cold to the anterior faucal arch is also being used with some success. Existing treatments for dysphagia are usually unable to restore the complete swallow function among patients with the most severe disorders (Freed, 2001, Miller 2013, Tan 2013).

Transcutaneous electrical stimulation (ES) that involves the application of electric current across the skin to stimulate nerve or muscle tissue during a functional task is commonly used in physical and rehabilitation therapy. It is used to strengthen muscles after surgery, prevent disuse atrophy of denervated muscles, decrease spasticity, and accelerate wound healing. There are several variants of electrical stimulation therapy. Transcutaneous electrical nerve stimulation (TENS) is mainly used in an attempt to alleviate neuropathic or chronic musculoskeletal pains. This can be used on atrophied or denervated muscles but does not cause muscle contraction. Functional electrical stimulation (FES) is the application of electrical current to excitable tissue to supplement or replace function that is lost in neurologically impaired individuals e.g. after spinal cord injury.

Neuromuscular electrical stimulation (NMES) therapy is used on innervated muscles to recruit motor units and increase muscle strength. It selectively targets healthy innervated muscle fibers but does not always stimulate atrophied or denervated muscle. NMES may be considered as a FES in situations when a muscle contraction is facilitated during a functional task (Peckham 2005, Carnaby-Mann 2007, Tan 2013). Over the last 2-3 decades, NMES therapy has been proposed as a treatment option for pharyngeal dysphagia to initiate or re-establish the act of swallowing. The therapy involves the application of electric stimulation through a pair of surface electrodes located on the neck. These are usually placed in one of two configurations: one electrode above the lesser horn of the hyoid bone and the other roughly 4 cm below it, or both electrodes above the lesser hyoid bones bilaterally. Electric pulses are then delivered continuously at 80Hz for duration of 300  $\mu$ s and intensity ranging from 2.5 to 25 mA depending on the patient's tolerance. The therapy is usually given for 60-minutes session every day, 5 days a week until swallowing has been restored or until the patient cannot tolerate it (Steele 2007). NMES has received great interest and raised much controversy since it was introduced. Over 9,000 speech pathologists in the US have been trained to use the technology. However, the underlying neurophysiologic basis for using the procedure that involves surface electrode placement on the external lateral neck is poorly defined. Challenge in designing a neuromuscular stimulation device for swallowing include selecting which muscles to target in the swallowing sequence, designing a device that triggers a chain of successive muscle excitations and inhibitions similar to normal swallowing process. Some scientists have argued that the current intensity delivered by NMES at the submental region is greatest at the skin surface and diminishes with depth through the platysma underlying the skin and subcutaneous fat. The deeper muscles which would pull the hyoid bone up and toward the mandible, and those that elevate the larynx to the hyoid bone, are much less likely to be activated by surface stimulation (Ludlow 2007, Steele 2007). Potential risks of NMES include arrhythmia, hypotension, laryngospasm, burns, glottic closure, and interference with pacemakers. The therapy is contraindicated in patients with pacemakers, superficial metal implants or orthotics, skin breakdown, cancer, history or cardiac disorders, seizures, impaired peripheral conduction system, pregnancy, significant reflux due to use of a feeding tube, or dysphagia due to drug toxicity (Leelamanit 2002, Blumenfeld 2006, Huckabee 2007).

Two NMES devices, the Freed Bioelectric Dysphagia Treatment Device and the Chattanooga VitalStim<sup>TM</sup> system, were cleared by the FDA for marketing in June 2001 and December 2002 respectively. Both are equivalent external electrical stimulation devices intended for re-education of the throat muscles, necessary for pharyngeal contraction, for the treatment of dysphagia from any etiology other than mechanical causes requiring surgery. The therapy treatment sessions last for 60 minutes and are most commonly administered by a speech and language pathologist. The FDA approval came with a warning that: 1. The long-term effects of chronic electric stimulation are unknown, 2. Stimulation should not be applied over the carotid sinus nerves, 3. Improper placement of the electrodes or improper use of recommended frequency, intensity or pulse, may cause laryngeal or pharyngeal spasm which may close the airway or cause difficulty in breathing.

#### 04/14/2004: MTAC REVIEW

##### **Electrical Stimulation for the Treatment of Dysphagia**

**Evidence Conclusion:** The study reviewed provides insufficient evidence on the use of electrical stimulation in patients with dysphagia. It had potential selection and observation bias. The investigators compared electrical stimulation to tactile stimulation in a controlled study where patients were not randomized, but alternately assigned to electric stimulation using the Freed Bioelectric Dysphagia Treatment Device, or thermal tactile stimulation. Overall, the results of the study show that both treatment groups improved, but the final swallow scores were higher among the electrical stimulation group. The study has potential selection and observation biases and does not provide sufficient data on the long-term effectiveness of the treatment.

**Articles:** The search yielded 11 articles on electrical stimulation for the treatment of dysphagia. There was a longitudinal study with a control group, on electrical stimulation for swallowing disorders caused by stroke (Freed et al 2001), and another on effects of electrostimulation on salivary function of Sjogren's syndrome patients (Tala 1992). In the latter study, treatment aimed at increasing the production of saliva by an electrostimulation device

placed on the tongue, which is different from the transcutaneous electric stimulating of the pharyngeal muscles. The search also revealed one case series with 23 patients, four small case reports, and four review articles. A larger study with 892 patients was submitted to the FDA but has not been published in a peer reviewed medical journal to date. *An evidence table was created for the following study:* Freed ML, Freed L, Chatburn RL et al. Electrical stimulation for swallowing disorders caused by stroke. *Respir Care* 2001;46:466-474. See [Evidence Table](#)

The use of electrical stimulation in the treatment of dysphagia does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 08/04/2008: MTAC REVIEW

##### **Electrical Stimulation for the Treatment of Dysphagia**

**Evidence Conclusion:** VitalStim was reviewed earlier by MTAC in April 2004. The best evidence at the time was the Freed et al (2001) nonrandomized controlled trial that compared electrical stimulation to tactile stimulation for the treatment of 110 patients with swallowing disorders caused by stroke. The study had its limitations and biases and did not provide sufficient evidence on the safety and effectiveness of neuromuscular electrical stimulation in treating dysphagia.

**Articles:** There is insufficient published evidence to determine: 1. Whether patients treated with VitalStim will show more improvement in the oral and pharyngeal phases of swallowing compared to the traditional therapies used in the management of dysphagia. 2. If patients treated with VitalStim would have fewer dietary consistency restrictions compared to those receiving traditional means for dysphagia management, or 3. If patients treated with VitalStim would progress more rapidly from nonoral to oral nutrition compared to those receiving traditional means for dysphagia management.

The search yielded just over 30 articles on electrical stimulation for the treatment of dysphagia. Many were reviews and opinion pieces. There was one meta-analysis of non-randomized controlled studies and case series studies, a more recent small randomized controlled trial, and a number of case series on the effect of NMES therapy on improving swallowing. The literature search did not reveal any study on the effect of therapy on dietary restrictions, or progress from nonoral to oral nutrition. The meta-analysis and the RCT were selected for critical appraisal. Carnaby-Mann GD, Crary MA. Examining the evidence on neuromuscular electric stimulation for swallowing. A meta-analysis. *Arch Otolaryngol Head Neck Surg.* 2007;133:564-571. See [Evidence Table](#) Bulow M, Speyer R, Baijens L, et al. Neuromuscular electrical stimulation (NMES) in stroke patients with oral and pharyngeal dysfunction. *Dysphagia* April 2008. See [Evidence Table](#) Bulow M, Speyer R, Baijens L, et al. Neuromuscular electrical stimulation (NMES) in stroke patients with oral and pharyngeal dysfunction. *Dysphagia* April 2008. See [Evidence Table](#)

The use of electrical stimulation in the treatment of dysphagia does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 06/16/2014: MTAC REVIEW

##### **Electrical Stimulation for the Treatment of Dysphagia**

**Evidence Conclusion:** NMES was reviewed earlier by MTAC in 2004 and 2008 and did not pass the evaluation criteria due to the lack of evidence on its safety and efficacy in the management of dysphagia. The best published evidence at the time was the Freed et al (2001) nonrandomized controlled trial that compared electrical stimulation to tactile stimulation for the treatment of 110 patients with swallowing disorders caused by stroke, a very small RCT with 25 patients (Bulow 2008) and a meta-analysis of small nonrandomized studies comprising 225 patients. More recently a number of randomized or quasi randomized RCTs were conducted to assess the efficacy of NMES in patients with dysphagia due to variable etiologies. The studies were small in size, had short follow-up durations, and varied widely in the patient selection, electrode positioning, stimulation protocols, combination with other therapies, and outcome measures. The results of the published trials as well as a meta-analysis of 7 trials are conflicting (evidence tables 1&2). Baijens, et al (2013) found no additional clinical benefit when submental NMES used in addition to the traditional dysphagia therapy in patients with dysphagia secondary to Parkinson's disease. Kushner, et al (2013) reported significantly better outcomes with NMES combined with traditional therapy vs. traditional therapy alone for patients with dysphagia following stroke. On the other hand Tan and colleagues' 2013 meta-analysis of RCTs suggest that NMES may be more effective than traditional therapy in patients with dysphagia due to different etiologies, except for post-stroke dysphagia. The conflicting results of the published studies, different stimulation protocols used, various underlying pathological conditions, and short follow-up durations, makes it hard to determine whether NMES provides additional therapeutic benefit for patients with dysphagia.

**Articles:** The literature search for studies on NMES published after the last 2008 MTAC review, revealed over 50 articles. There were two meta-analyses, 6 small randomized controlled trials, and a number of observational small studies related to the current review. One of the two meta-analyses (Geeganage et al, 2012) assessed feeding

and swallowing treatment strategies including NMES in stroke patients and the other (Tan et al, 2013) evaluated NMES in patients with dysphagia caused by non-stroke conditions. The published RCTs identified by the search examined the effect of NMES on treating dysphagia due to stroke, Parkinson's disease, or cancer. The following meta-analysis and the RCTs were selected for critical appraisal. Baijens LW, Speyer R, Passos VL, et al. Surface electrical stimulation in dysphagic Parkinson patients: a randomized clinical trial. *Laryngoscope*. 2013;123:E38-44. See [Evidence Table](#) Heijnen BJ, Speyer R, Baijens LW, et al. Neuromuscular electrical stimulation versus traditional therapy in patients with Parkinson's disease and oropharyngeal dysphagia: effects on quality of life. *Dysphagia*. 2012; 27:336-345. See [Evidence Table](#) Lim KB1, Lee HJ, Lim SS, et al. Neuromuscular electrical and thermal-tactile stimulation for dysphagia caused by stroke: a randomized controlled trial. *J Rehabil Med*. 2009;41:174-178. See [Evidence Table](#) Long YB, Wu XP. A randomized controlled trial of combination therapy of neuromuscular electrical stimulation and balloon dilatation in the treatment of radiation-induced dysphagia in nasopharyngeal carcinoma patients. *Disabil Rehabil*. 2013;35:450-454 See [Evidence Table](#) Permsirivanich W, Tipchatyotin S, Wongchai M, et al. Comparing the effects of rehabilitation swallowing therapy vs. neuromuscular electrical stimulation therapy among stroke patients with persistent pharyngeal dysphagia: a randomized controlled study. *J Med Assoc Thai*. 2009;92:259-265. See [Evidence Table](#) Ryu JS, Kang JY, Park JY, et al. The effect of electrical stimulation therapy on dysphagia following treatment for head and neck cancer. *Oral Oncol*. 2009;45:665-668. See [Evidence Table](#) Tan C, Liu Y, Li W, et al. Transcutaneous neuromuscular electrical stimulation can improve swallowing function in patients with dysphagia caused by non-stroke diseases: a meta-analysis. *J Oral Rehabil*. 2013; 40:472-480. See [Evidence Table](#) Xia W1, Zheng C, Lei Q, Tang Z, et al. Treatment of post-stroke dysphagia by VitalStim therapy coupled with conventional swallowing training. *J Huazhong Univ Sci Technolog Med Sci*. 2011;31:73-76. See [Evidence Table](#).

The use of electrical stimulation in the treatment of dysphagia does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Gastric Electrical Stimulation for Treatment of Medically Refractory Diabetic Gastroparesis (Enterra™)**

#### **BACKGROUND**

Gastroparesis (GP) is a gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. The most common etiologies of GP are diabetes mellitus, post-surgical often as the result of damage to the vagal nerve, and idiopathic. Other causes include Parkinson's disease, collagen vascular disorder, and any disease process that interferes with the neuromuscular function of the stomach. The characteristic symptoms of gastroparesis include early satiety, nausea, vomiting, bloating, and abdominal pain. These symptoms are typically driven by meal intake but can also be present continually at varying degrees of intensity. A severe gastroparesis can result in impaired quality of life, recurrent hospitalizations, malnutrition, and even death (Velanovich 2008, McCollum 2011). The standard medical management of gastroparesis involves dietary modification, glycemic control, and the use of antiemetic therapy combined with prokinetic agents such as metoclopramide and erythromycin. These therapies are generally effective for the symptomatic relief in the majority of patients with GP. However, some patients do not respond to, or cannot tolerate drug treatment, and may require palliative endoscopic or surgical therapies. Surgical options include feeding jejunostomy tubes, decompressing gastrotomy tubes, pyloroplasty, and gastrectomy as a last resort (McKenna 2008, Velanovich 2008, McCallum 2010). In the last decade, high frequency gastric electrical stimulation (GES) emerged as a potential treatment option for patients with medically refractory gastroparesis. The therapy involves delivering low-energy electrical stimuli in the muscularis propria of the stomach at a frequency significantly higher than the normal gastric slow wave frequency. This is different from gastric pacing that delivers high energy stimuli at a frequency slightly above the intrinsic slow wave activity. The Enterra® Therapy System (Medtronic, Minneapolis, MN), a stimulation device delivering high-frequency GES, was granted Humanitarian Device Exemption by the US Food and Drug Administration in 2000 for patient with chronic drug refractory nausea and vomiting secondary to gastroparesis of diabetes mellitus or idiopathic in origin (O'Grady 2009, Chu 2012). The Enterra® system consists of three main elements: a pair of leads, a pulse generator, and a programming system. The leads and pulse generator are implanted surgically via laparotomy or laparoscopically. The two leads are surgically implanted about 1 cm apart in the muscle wall of the greater curvature of the stomach, approximately 10 cm from the pylorus. They are anchored in place then connected to a pulse generator placed in a subcutaneous pocket created in the abdominal wall generally in the superior quadrant of the abdomen. The pulse generator is controlled by an external programmer that allows for interrogation and programming of stimulation via a radio-telemetry link. The battery life of the pulse generator is 5-10 years depending on the neurostimulator setting. It is sealed in the generator and thus the device must be replaced when the battery is depleted. The leads can be left in place and reused with the new pulse generator. The Enterra system produces intermittent bursts of high-frequency (~14 cycles per second) short duration pulses (~ 330 µs) that are three to four times faster than the native gastric slow wave frequency (Chu 2012, Guerri 2012, Soffer 2012). GES therapy is not without complications; researchers reported that 7-10% of the patients treated with the Enterra® system experience an

adverse event mainly infection of the subcutaneous pocket. Other events include erosion of the abdominal wall by the device, leads dislodgment or penetration through the gastric wall, or tangling of wires in the generator pocket and formation of adhesions (Soffer 2012). This technology was approved by the FDA as a humanitarian device based on data from one study consisting of 33 patients that was not published in the peer-reviewed literature at the time.

## 02/14/2001: MTAC REVIEW

### **Gastric Electrical Stimulation for Treatment of Medically Refractory Diabetic Gastroparesis (Enterra™)**

**Articles:** There are currently no peer-reviewed articles on this technology. Therefore, it is not possible for the MTAC committee to review the Gastric Electrical Stimulation Enterra™ Therapy System at this time. No published evidence found.

The use of Gastric Electrical Stimulation Enterra Therapy System in the treatment of chronic, intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology does not meet the *Kaiser Permanente Medical Technology Assessment Criteria* as there was no published evidence to review.

## 02/11/2013: MTAC REVIEW

### **Gastric Electrical Stimulation for Treatment of Medically Refractory Diabetic Gastroparesis (Enterra™)**

**Evidence Conclusion:** Larger studies with a parallel group design, sufficient power, and long-term follow-up are needed to more accurately determine the efficacy and safety of gastric stimulation therapy for gastroparesis of diabetes mellitus or idiopathic etiology.

**Articles:** The literature search revealed over 100 articles on gastric electrical stimulation in patients with gastroparesis. The majority were review articles, articles on technical aspects of the therapy, or observational studies and case series with no comparison groups. The search identified three randomized controlled trials and two meta-analyses that pooled the results of case series together with the randomized controlled trial. The three RCTs were selected for critical appraisal. Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. *Gastroenterol.* 2003; 125:421-428. See [Evidence Table](#) McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. *Clin Gastroenterol Hepatol.* 2010; 8:947-954. See [Evidence Table](#) Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis: *Gastrointest Endosc.* 2011; 74:496-503. See [Evidence Table](#)

The use of Gastric Electric Stimulation for the Treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **NESS Stimulators for Foot Drop and Paralyzed Hands**

### **BACKGROUND**

Foot drop is a motor deficiency caused by partial or total paralysis of the muscles innervated by the peroneal nerve. It is not a disease but a symptom of an underlying problem. It is often caused by an injury to the peroneal nerve but can also be associated with a variety of conditions such as stroke, dorsiflexor injuries, neuropathies, drug toxicities, or diabetes. The problem may be temporary or permanent depending on the cause. Foot drop is characterized by the lack of voluntary control of ankle dorsiflexion, and subtalar eversion. Patients with foot drop are unable to walk on their heel, flex their ankle, or walk with the normal heel-toe pattern. They usually exhibit an exaggerated or high-stepping walk called steppage gait or foot drop gait in order to compensate for toe drop. This unnatural walking motion may result in subsequent damage to the hip, back or knee (Voigt 2000). Management of patients with foot drop varies and is dependent on the underlying cause. Some patients may be fitted with of ankle-foot orthoses (AFO) brace, which typically limit ankle plantarflexion to enhance foot clearance during swing. Patients may also undergo physical therapy for gait training. Surgery may be an option when the cause of foot drop is muscular or neurologic. Electrical stimulation was first proposed as a treatment for foot drop by Liberson in 1961. Liberson referred to the treatment as “functional electrotherapy” because its purpose was to replace a functional movement that was lost after injury or illness. There has been extensive development of functional stimulation devices since the early 1960s. The first devices were hard-wired surface stimulators, followed by hard-wired implanted electrical stimulators, and then microprocessor-based surface and implanted systems. In the 1990s, artificial and “natural” sensors were developed as a replacement for the foot-switch. More recently, testing has been done on a device in which both the sensor and stimulator are implanted (Lyons et al. 2002). The WalkAide system is an external neuromuscular functional stimulator. It contains a control unit attached to a flexible cuff that contains two electrodes. The unit is placed on the leg below the knee, near the head of the fibula. According to FDA materials, WalkAide stimulates the common peroneal nerve which innervates the muscles that cause dorsiflexion of the ankle. This stimulation is intended to produce a more natural and stable walking stride. It



is indicated for individuals with foot drop due to central nervous system conditions including cerebral palsy, multiple sclerosis, traumatic brain injury, and cerebrovascular accident. It is contraindicated for patients with traumatic accidents to the leg, complications of back, hip or knee surgery, sciatica, peripheral neuropathy, spinal stenosis, post-polio syndrome and Guillain-Barre syndrome. In addition, patients with pacemakers or who experience seizures should not use WalkAide (FDA materials; Innovative Neurotronics website). The Innovative Neurotronics WalkAide System for foot drop was approved by the FDA in August 2005 to address the lack of ankle dorsiflexion in patients who have experienced damage to upper motor neurons or pathways to the spinal cord. The NESS L300 is another electrical stimulation system that received FDA clearance (in 2006) to provide ankle dorsiflexion in individuals with drop foot following an upper motor neuron injury or disease. It has the same intended use and same principal of operation as the WalkAide. The main technological difference however between the two systems, is the RF wireless communications between the components of NESS L300 versus the wired communication in the WalkAide system. NESS L300 is a neuroprosthesis device that consists of four main parts 1. A lower leg orthosis containing electrodes and a controlled stimulation unit, 2. A heel sensor 3. A control unit that is carried in the pocket, mounted on the waist, or on a neck strap, and 4. PDA to be used by the clinician to configure the control unit with functional parameters as appropriate for every patient. The system is intended to provide ankle dorsiflexion in individuals with foot drop following an upper motor neuron injury or disease. During the swing phase of gait, the NESS L300 electrically stimulates muscles in the affected leg to provide dorsiflexion of the foot. According to the manufacturer it may also facilitate muscle reduction, prevent/retard disuse atrophy, maintain or increase joint range of motion and increase local blood flow (FDA materials; Ness 300 website). NESS H200 or Bioness is another new muscle stimulation device developed Bioness Inc. to restore function to paralyzed muscles. It is a brace like apparatus, equipped with electrodes to stimulate and activate muscles that have been affected by stroke, injury, multiple sclerosis or cerebral palsy. The H 200 is worn on the forearm and hand and holds the hand in a functional position. According to the manufacturer, the functional electrical stimulation is used to move affected areas through repetitive exercises which would strengthen the muscles, reduce spasticity, improve blood flow, and increase range of movement. A microprocessor allows the therapist to program the device with a sequence of exercises customized to each patient. The system may be also used in the home setting (Bioness Inc. web page). Stroke is one of the leading causes of disability and impairment in the United States. It is reported that only 12-18% stroke survivors will regain complete functional recovery of the upper extremity, and that about 30% to 66% of those with paretic arms will still have an impaired upper limb function after six months with routine rehabilitation. Arm dysfunction impairs the daily activities of the individual as writing, dressing, bathing, self-care, and in turn reduces the functional independence, occupational performance, and quality of life (de Kroon 2002, Meilink 2008, and Kwakkel 2008). Loss of upper extremity function following stroke is a major rehabilitation challenge. Occupational and physical therapies which are commonly used in the rehabilitation of stroke patients have not always been satisfactory in improving the reaching, grasping, holding, or releasing functions of the paralyzed limb. Investigators are now focusing on therapies that will lead to regaining and improving upper extremity functional activity rather than only minimizing the impairment (Alon 2008). Electrical stimulation (ES) has been studied and used clinically for about 40 years in different neurological conditions such as cerebrovascular accidents, multiple sclerosis, cerebral palsy, and other events. Its use for the upper limb is getting increased attention as a therapeutic modality in poststroke rehabilitation. It provides continuous low voltage stimuli which enable repetitive exercise to the neuromuscular system. ES has two modalities: 1. Therapeutic electrical stimulation (TES) which applies higher frequency (36 Hz) with the aim of activating the reduced muscle strength and preventing or lowering the pain and spasticity of the muscles, and 2. Functional electrical stimulation (FES) which applies lower frequency ES (18 HZ) in order to improve activity during the stimuli. TES includes neuromuscular electrical stimulation (NMES), EMG-triggered electrical stimulation, positional feedback stimulation training (PFST), and transcutaneous electrical nerve stimulation (TENS). These have different indications, mechanisms of action, and are applied by multiple devices with a range of possibilities for the adjustment of stimulation parameter (Berner 2004, Kroon 2002). FES on the other hand, is the application of neuromuscular electrical stimulation concurrently with the training of task specific or functional activity i.e. provoking muscle contraction in order to assist the performance of functional activities during stimulation. In the last decades, several research groups have been working on the development of FES systems for the upper extremity, and currently multiple devices aiming at restoring the upper limb function are commercially available (Snoek 2000, Alon 2008). The NESS H200, formerly known as "The Handmaster", (NESS Ltd Ra'anana, Israel) is a portable, non-invasive, hybrid wrist/hand orthosis and electrical stimulation device that is designed to be used in hemiplegic as well as C5 tetraplegic patients. It provides an instrument for both the treatment at the level of impairment (neuromuscular and articular properties) and disability (functional handgrip with stabilized wrist). The system contains an external control unit connected by a cable to a below the elbow splint. The splint contains a body with front spiral end and a wing which pivots about the body and can be opened by lifting a release handle. Five surface electrodes are attached to the splint and correspond with the motor points in finger and thumb muscles. The control unit allows the user to select from among three exercise modes and three functional modes. The exercise modes provide stimulation to the targeted finger and thumb extensor and flexor muscles. The functional mode provides sequential key grip or palmer grasp and release patterns. The spiral

design of the system allows wrist stabilization in a functional position of 10 -20° of extension. The system is also designed to permit reproducible accurate electrode positioning by the patient. Once fitted into the orthosis, the electrodes remain in position for all subsequent applications and allow consistent replication of the grasp, hold and release hand functions. The patient is provided with a progressive home exercise program and is required to follow a conditioning paradigm using the system's exercise modes. Training periods start at 10 minutes twice daily and gradually increase to 45 minutes 2 times a day (Hara 2008, Snoek 2000). The NESS system and the Handmaster device received FDA clearance in September 2002, and August 2003 respectively, to be used to maintain or increase the range of motion, reduce muscle spasm, prevent retardation of disuse atrophy, muscle reduction, increase local blood circulation, and provide hand active range of motion and function in patients suffering from upper limb paralysis due to C5 spinal cord injury, or hemiplegia due to stroke.

#### **12/03/2007: MTAC REVIEW**

##### **NESS Stimulators for Foot Drop and Paralyzed Hands**

**Evidence Conclusion:** There is insufficient published evidence to determine the efficacy and safety of the Ness L300 system for patients with foot drop. There is insufficient published evidence to determine the efficacy and safety of the Ness H200 system for the restoration of hand movements.

**Articles:** The search did not reveal any published studies, on Bioness, NESS L300, or NESS H200. Information about the devices was obtained from the FDA and/or the manufacturer's Web sites.

The use of the NESS L300 or NESS H200 in the treatment of foot drop or paralyzed hands does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **10/06/2008: MTAC REVIEW**

##### **NESS Stimulators for Foot Drop and Paralyzed Hands**

**Evidence Conclusion:** There is poor evidence to determine that the use of NESS H200 may improve upper extremity function in patients with mild or moderate paresis/paralysis with similar eligibility criteria as those in the trials, compared to standard physical and occupational therapies. There is insufficient evidence to determine whether the benefits observed would persist after therapy is ended. There is insufficient published evidence to determine that the use of NESS H200 would improve function in patients with severe motor loss in the upper extremity. There is insufficient published evidence to determine if the use of NESS H 200 would lead to a faster motor and functional recovery vs. standard therapy alone. There is fair evidence that NESS H200 is safe to use among patients with upper limb impairment due to stroke, and who has eligibility criteria similar to those of the published studies.

**Articles:** Alon G, Levitt AF, McCarthy PA. Functional electrical stimulation (FES) may modify the poor prognosis of stroke survivors with severe motor loss of the upper extremity. *Am J Rehabil Med* 2008;87:627-636 See [Evidence Table](#)

Alon G, Levitt AF, McCarthy PA. Functional electrical stimulation enhancement of upper extremity functional recovery during stroke rehabilitation: A pilot study. *Neurorehabil Neural Repair* 2007;21:207-215 See [Evidence Table](#)

Ring H, and Nechama Rosenthal. Controlled study of neuroprosthetic functional electrical stimulation in sub-acute post-stroke rehabilitation. *J Rehabil Med* 2005;37:32-36 See [Evidence Table](#)

The use of the NESS H200 in the treatment of paralyzed hands does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **Percutaneous Neuromodulation Therapy (PNT) for Back Pain - Vertis PNT System**

##### **BACKGROUND**

The Vertis percutaneous neuromodulation therapy (PNT) system, manufactured by Vertis Neuroscience, is a minimally invasive, nonsurgical therapy. It is based on the premise that chronic back pain is caused by increased sensitization of the nerve cells that transmit pain signals. The Vertis PNT system delivers electrical stimulation to the deep tissues near the spine to alter the "hypersensitivity" of nerve pathways that cause persistent pain. Treatment consists of a series of outpatient treatment sessions performed in a clinic setting. It is intended for use by a physician or other clinician (e.g. physical therapist), not for patient use. The device includes three major components: Control unit - A software driven, five-channel, AC powered nerve stimulator which generates the electrical stimulus, Sterile, needle electrodes, A cable that connects the needles to the control unit. The FDA approved Verdis PNT in September 2001 for the following indications: Symptomatic relief and management of chronic or intractable low back pain and/or as an adjunctive treatment in the management of post-surgical low back pain and post-traumatic low back pain.

#### **10/09/2002: MTAC REVIEW**

##### **Percutaneous Neuromodulation Therapy (PNT) for Back Pain - Vertis PNT System**

**Evidence Conclusion:** There is insufficient evidence to determine the effect of percutaneous neuromodulation therapy on back pain.



**Articles:** There were no published articles evaluating the effect of PNT on back pain. Two articles that were submitted for publication were identified on the manufacturer's website. The manufacturer indicated that the articles are not yet published.

The use of percutaneous neuromodulation therapy in the treatment of back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee***

#### **BACKGROUND**

There are three main types of arthritis that can affect the knee joint: osteoarthritis, rheumatoid arthritis and post-traumatic arthritis. Osteoarthritis, the most common type, is generally a slowly progressing degenerative disease that involves the gradual wearing away of the joint cartilage. Symptoms include pain and swelling. Pain often increases after activities such as walking and stair climbing and is the principal symptom for which patients with osteoarthritis seek medical attention. The main goal of treatment is pain control, although maintaining and/or improving joint function are also goals. A stepwise approach to management of osteoarthritis of the knee is generally recommended. Initial conservative measures include weight reduction, exercise, and the use of supportive devices. Medications, including anti-inflammatories and corticosteroids, can be used to supplement the conservative approaches. For patients who fail medical management, surgical treatments are available. Pulsed electrical stimulation is a potential non-invasive alternative to surgery for patients who do not respond to medical treatment. The BionCare Stimulator has been approved by the FDA as an adjunctive treatment for osteoarthritis of the knee. It is a portable battery-operated device that delivers a low frequency (100 Hz) electrical signal to the knee via skin electrodes. Other types of electrical stimulation including electro-acupuncture, transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) with the Respond Select device have also been used to treat osteoarthritic knee pain.

#### **08/01/2005: MTAC REVIEW**

#### **Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee**

**Evidence Conclusion:** There was one randomized controlled trial on BionCare for treating osteoarthritis (Zizic et al. 1995). The authors reported that the active treatment group had significantly better outcomes than the placebo group two weeks after completing a 4-week treatment period. However, the statistical analysis may have been biased. The authors used a one-sided p-value at  $p < 0.05$ . If they had used the commonly accepted method of dividing the p-value in half for a one-sided p-value (in this case  $p < 0.025$ ), two of the three primary efficacy variables would not have been significant. Another limitation of the study is that, although the authors reported statistically significant differences, the clinical significance is unclear. There was approximately a 10% difference in the change from baseline in patient perception of pain and patient perception of function (approximately 30% change in the treatment group and 20% change in the placebo group for each outcome variable).

**Articles:** The single RCT was published in 1995 and has not been replicated. In addition, no studies were identified that compared BionCare to other treatments such as medication or TENS. Patients in the Zizic study were not required to have failed other treatments. One empirical study on the BionCare system was identified (Zizic, 1995). This was a placebo-controlled randomized controlled trial and was critically appraised. No studies were identified that compared BionCare to other treatments such as exercise or medication, or to different forms of electrical stimulation such as TENS. *The Zizic study was critically appraised:* Zizic TM, Hoffman KC, Holt PA et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. *J Rheumatol* 1995; 22: 1757-1761. See [Evidence Table](#)

The use of Pulsed electrical stimulation in the treatment of osteoarthritis of the knee does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***ReBuilder System***

#### **BACKGROUND**

Peripheral neuropathy is a disorder of the peripheral nervous system characterized by impaired function of sensory, motor and/or autonomic nerves. It results from damage to the cell body, nerve fiber, or to the surrounding myelin sheath of peripheral nerves. Manifestations include pain, numbness, tingling, extreme sensitivity to touch, lack of coordination, muscle weakness or paralysis, and bowel or bladder problems. Treatment relies on addressing the underlying cause and various treatments for pain. ReBuilder is a handheld, battery-powered nerve stimulator that delivers an electrical impulse, similar to a normal nerve signal, to specific regions of the body to alleviate pain, burning, tingling, and numbness from a variety of conditions. The ReBuilder is an FDA class II, neurologic therapeutic medical device that first received FDA 510(k) approval in 1987 for marketing as a TENS unit for pain relief. In 1989, the FDA cleared ReBuilder for other indications. The FDA approval is for the symptomatic relief of chronic intractable pain, post-traumatic and post-surgical pain relief, relaxation of muscle spasms, prevention or retardation of disuse atrophy, increasing local blood circulation,

muscle reeducation, immediate post-surgical stimulation of calf muscles to prevent venous thrombosis, and maintaining or increasing range of motions. The FDA has written warning letters to manufacturer of ReBuilder against marketing the device for any off-label indications, including peripheral neuropathy.

## 12/19/2011: MTAC REVIEW

### ReBuilder System

**Evidence Conclusion:** There is insufficient evidence to determine the safety or efficacy of the ReBuilder System for the treatment of chronic intractable pain for any condition.

**Articles:** The literature studies did not identify any studies that evaluated the ReBuilder System for any indication. The search did identify a 2011 technology assessment from Kaiser Permanente. Their literature search also did not identify any studies that evaluated the safety or efficacy of the ReBuilder System (Kaiser 2011). See [Evidence Table](#).

The use of ReBuilder System does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## WalkAide System for Patients with Foot Drop

### BACKGROUND

Foot drop is defined as a significant weakness in the muscles involved in flexing the ankle and toes (dorsiflexion). The specific muscles affected include the tibialis anterior, extensor hallucis longus and extensor digitorum longus. These muscles allow the toes to swing upward during the beginning of a walking stride and the planting of the heel towards the end of the stride. In patients with foot drop, the foot droops or drags along the ground during the swing phase. The condition is also called steppage gait because patients often raise their thigh excessively high to compensate for toe drop, and they appear as though they are walking up stairs. The unnatural walking motion may result in subsequent damage to the hip, back or knee. Foot drop is associated with a number of conditions such as peripheral nerve injuries, stroke, diabetes, neuropathies and drug toxicity. The causes can be divided into three categories, which may overlap: nerve damage, muscle damage, and/or a skeletal or anatomic abnormality. The conventional treatment for foot drop is the use of ankle-foot orthoses (AFO). These typically limit ankle plantar flexion to enhance foot clearance during swing. Disadvantages of AFOs are that they can be uncomfortable and limiting to wear. Surgery is sometimes beneficial when the cause of foot drop is muscular or neurologic. Electrical stimulation was first proposed as a treatment for foot drop by Liberson in 1961. Liberson referred to the treatment as “functional electrotherapy” because its purpose was to replace a functional movement that was lost after injury or illness. There has been extensive development of functional stimulation devices since the early 1960s. The first devices were hard-wired surface stimulators, followed by hard-wired implanted electrical stimulators, and then microprocessor-based surface and implanted systems. In the 1990s, artificial and “natural” sensors were developed as a replacement for the foot-switch. More recently, testing has been done on a device in which both the sensor and stimulator are implanted (Lyons et al. 2002). The WalkAide system is an external neuromuscular functional stimulator. The system contains a control unit attached to a flexible cuff that contains two electrodes. The unit is placed on the leg below the knee, near the head of the fibula. According to FDA materials, WalkAide stimulates the common peroneal nerve which innervates the muscles that cause dorsiflexion of the ankle. This stimulation is intended to produce a more natural and stable walking stride. WalkAide is indicated for individuals with foot drop due to central nervous system conditions including cerebral palsy, multiple sclerosis, traumatic brain injury and cerebrovascular accident. It is contraindicated for patients with traumatic accidents to the leg, complications of back, hip or knee surgery, sciatica, peripheral neuropathy, spinal stenosis, post-polio syndrome and Guillain-Barre syndrome. In addition, patients with pacemakers or who experience seizures should not use WalkAide (FDA materials; Innovative Neurotronics Web site). The Innovative Neurotronics WalkAide System for foot drop was approved by the FDA in August 2005 to address the lack of ankle dorsiflexion in patients who have experienced damage to upper motor neurons or pathways to the spinal cord.

## 10/02/2006: MTAC REVIEW

### WalkAide System for Patients with Foot Drop

**Evidence Conclusion:** There is insufficient published evidence to determine the efficacy and safety of the Innovative Neurotronics WalkAide System for patients with foot drop. A randomized controlled trial comparing WalkAide to ankle-foot orthoses is underway. The only empirical study identified was a case study, reporting on one patient. The patient used a bionic nerve (BION) implant and a portable BIONic foot drop stimulator that the authors called a “WalkAide2”. It is not clear whether this is the same technology as the Innovative Neurotronics WalkAide system.

**Articles:** There are no published randomized or non-randomized controlled studies. According to ClinicalTrials.gov and the Innovative Neurotronics website, an RCT is underway comparing the Innovative Neurotronics WalkAide System to an ankle-foot orthosis (AFO) in patients with cerebrovascular accident. No data from this study are available at this time.

The use of the WalkAide system in the treatment of foot drop does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### TENS-

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPC Codes	Description
E0720	Transcutaneous electrical nerve stimulation (TENS) device, two-lead, localized stimulation
E0730	Transcutaneous electrical nerve stimulation (TENS) device, four or more leads, for multiple nerve stimulation
E0731	Form-fitting conductive garment for delivery of TENS or NMES (with conductive fibers separated from the patient's skin by layers of fabric)
A4557	Lead wires (e.g., apnea monitor), per pair
A4558	Conductive gel or paste, for use with electrical device (e.g., TENS, NMES), per oz
A4595	Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES)
A4630	Replacement batteries, medically necessary, transcutaneous electrical stimulator, owned by patient

### External Upper Limb Tremor Stimulator Therapy (e.g., Cala Trio)

**Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met

**Non-Medicare** – Considered Not Medically Necessary- experimental, investigational or unproven

HCPC Codes	Description
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist

### NMES/FES--

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPC Codes	Description
E0744	Neuromuscular stimulator for scoliosis
E0745	Neuromuscular stimulator, electronic shock unit
E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified

### Gastric Neurostimulation--

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum
43659	Unlisted laparoscopy procedure, stomach
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open
64590	Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling

<b>64595</b>	Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver
<b>95980</b>	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; intraoperative, with programming
<b>95981</b>	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, without reprogramming
<b>95982</b>	Electronic analysis of implanted neurostimulator pulse generator system (eg, rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient measurements) gastric neurostimulator pulse generator/transmitter; subsequent, with reprogramming
<b>L8679</b>	Implantable neurostimulator, pulse generator, any type
<b>L8680</b>	Implantable neurostimulator electrode, each
<b>L8681</b>	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only
<b>L8695</b>	External recharging system for battery (external) for use with implantable neurostimulator, replacement only

## Electrical Stimulation for the Treatment of Dysphagia

### Considered Not Medically Necessary- experimental, investigational or unproven

<b>CPT® or HCPCS Codes</b>	<b>Description</b>
<b>97014</b>	Application of a modality to 1 or more areas; electrical stimulation (unattended)
<b>97032</b>	Application of a modality to 1 or more areas; electrical stimulation (manual), each 15 minutes
<b>G0283</b>	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care

### Other Electrical Stimulation--

### Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

<b>CPT/HCPC Codes</b>	<b>Description</b>
<b>64575</b>	Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
<b>64580</b>	Incision for implantation of neurostimulator electrode array; neuromuscular
<b>C1820</b>	Generator, neurostimulator (implantable), with rechargeable battery and charging system
<b>C1822</b>	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
<b>L8678</b>	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month
<b>L8682</b>	Implantable neurostimulator radiofrequency receiver
<b>L8683</b>	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver
<b>L8685</b>	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension
<b>L8686</b>	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension
<b>L8687</b>	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension
<b>L8688</b>	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension
<b>C1778</b>	Lead, neurostimulator (implantable)
<b>C1787</b>	Patient programmer, neurostimulator
<b>C1816</b>	Receiver and/or transmitter, neurostimulator (implantable)
<b>C1897</b>	Lead, neurostimulator test kit (implantable)

### Peripheral Nerve Stimulator- i.e., StimRouter--

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Non-Medicare – Considered Not Medically Necessary *\*\*All requests must be reviewed by the Medical Director***

CPT® Codes	Description
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)
64575	Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)

#### Cranial Electrotherapy Stimulation:

**Non-Medicare – Considered Not Medically Necessary**

CPT® Codes	Description
A4596	Cranial electrotherapy stimulation (ces) system supplies and accessories, per month
E0732	Cranial electrotherapy stimulation (ces) system, any type

Galvanic Stimulation Device

H-wave Stimulation Device

Microcurrent Stimulation Device (MENS)

Percutaneous Neuromodulation Therapy (PNT) for Back Pain

Vertis PNT System

ReBuilder System Threshold Electrical Stimulation--

**Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
No specific codes	

**Pulsed Electrical Stimulation for Treatment of Osteoarthritis of the Knee--**

**Considered Not Medically Necessary:**

HCPC Codes	Description
E0762	Transcutaneous electrical joint stimulation device system, includes all accessories

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
06/30/1998	02/02/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 01/03/2012 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 04/02/2013 <sup>MDCRPC</sup> , 01/07/2014 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	12/19/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/14/2016	Added NCD 160.7.1
06/02/2015	TENS: MPC approved recommendation of adopting the MCG hybrid criteria
09/28/2017	Added Gastric Neurostimulation codes
06/28/2018	Removed G0283
07/12/2018	Corrected the FES and NMES criteria
10/03/2018	Added LCD L37360 Peripheral Nerve Stimulator
06/24/2020	Added HCPC code C1823 (ESD)
09/01/2020	Removed HCPC codes A4570, C1823, E0766, E0769, G0281 and G0282. Removed CPT codes 63650, 63655, 63685, 64550, 64565, 95971, 95972, 95973, 95974, 95975, 95976, 95977, 95978 and 95979. Added HCPC code E0762. Removed Hypoglossal Nerve Stimulation indications – noted on <i>Sleep Apnea Treatments</i> criteria.
11/06/2023	Updated Medicare coverage links. Added L34821 transcutaneous Electrical Joint Stimulation Devices (TEJSD)
03/18/2024	Added new LCD External upper Limb Tremor Stimulation Therapy (L39591) (E.g., Cala Trio)
04/02/2024	MPC approved the to adopt the Medicare Local Coverage Determination L33802 for TENS units for commercial members; Requires a 60-day notice. Effective September 1, 2024.
06/04/2024	MPC approved the adoption of the 28th edition of MCG for Gastric Stimulation (Electrical) criteria. Requires 60-day notice, effective November 1 <sup>st</sup> , 2024.
12/19/2024	Updated applicable codes





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Superficial Radiation Therapy (Electronic Brachytherapy for Non-Melanoma Skin Cancer)

- “Xoft” Skin Treatments

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	Noridian retired LCD <a href="#">Brachytherapy: Non-intracoronary (L34065)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for “medical judgment” which could be based on our commercial criteria or literature search.
Local Coverage Article	None
KPWA Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, KPWA has chosen to use their own Clinical Review Criteria, “Superficial Radiation Therapy for Non-Melanoma Skin Cancer,” for medical necessity determinations. Use the Non-Medicare criteria below

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Nonmelanoma skin cancer (NMSC) is the most common malignancy in the Caucasian population and its incidence continues to rise. It is estimated that more than two million Americans are affected by NMSC each year.

Due to ultraviolet light exposure, over 95% of cancers are located in the head and neck region (nose, ears, eyelids, and lips). Basal cell carcinoma (BCC) represents approximately 75-80% of NMSCs and squamous cell carcinoma (SCC) 20-25%. It is reported that half of the patients with NMSC are over 65 years of age and that almost 50% of them may develop a second primary NMSC within 5 years. These cancers have a low mortality rate and are rarely life threatening, but they represent a significant burden on global health care services due to their increasing incidence (Alam 2011, Bhatnagar 2010 & 2013, Benkhalel, 2022).

Treatment options for NMSC include surgery, radiation therapy, chemotherapy, and photodynamic therapy. Surgery is considered the gold standard treatment; it provides the highest cure rates and has satisfactory cosmetic results. Surgical techniques include excision, curettage with electrodesiccation, and Mohs micrographic surgery (MMS). The choice of procedure depends on the histologic type, size, and location of the lesion. Some patients, however, are not suitable candidates for surgery because of their age, health condition, potential disfigurement, or functional defects when the cancer is located in high-risk areas. Radiation therapy has been used for selected skin cancers, typically reserved as a second-line therapy for patients with surgical contraindications or as adjuvant therapy for high-risk lesions. It is also an alternative to surgery for lesions located in areas where surgery may be more difficult, lead to disfigurement, or affect structural function e.g., eyelid, ear, or nose. Radiation therapy techniques used for NMSC include superficial x-rays, orthovoltage x-rays and megavoltage photons, electron beam irradiation, radionuclide-based brachytherapy (BT). (Bhatnagar 2010 & 2013, Frakulli 2015, Linos 2015, Safigholi 2015, Patel 2017, Ramachandran 2017).

Electronic brachytherapy (eBT, EBT, or EBX) is a relatively newer technology administering high-dose-rate brachytherapy (HDR-BT) with the use of a low energy miniaturized electronic X-ray source rather than a radionuclide-based source x-ray source. Potential advantages of EBT over traditional BT include isotope-free delivery, relatively reduced need for shielding, optimal sparing of normal tissues, shorter time of treatment, reduced dose to treating staff, and no radioactive waste. In addition, the EBT systems can be operated in a standard treatment room with minimal shielding due to low energy and no radiation leakage when off (Bhatnagar 2013, Safigholi 2015, Ouhib, 2015, Ramachandran 2017, Goyal 2021, Tang 2022).

Several types of EBT systems are currently available. The main component is a miniature X-ray tube that produces bremsstrahlung (electromagnetic) radiation using electron energies ranging from 20-70keV. Treatment of skin cancers is performed using conical applicators developed by the manufacturers and provided in different sizes (1cm, 2 cm, 3.5 cm, and 5 cm) to ensure adequate coverage of the clinical and planning target volume. Patients are treated with different fractionation regimens depending on the location and depth of the lesion with the most frequent regimen being 40 Gy/8 fx. The therapy is typically delivered twice weekly over 4 weeks (Bhatnagar 2013, Safigholi 2015, Goyal 2021).

## Medical Technology Assessment Committee (MTAC)

### **Electronic Brachytherapy for Non-Melanoma Skin Cancer**

#### **04/21/2014: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient published evidence to determine the safety and efficacy of EBT for the treatment of NMSC. There is an ongoing clinical trial "Electronic Brachytherapy for the Treatment of NMSC" (NLM Identifier NCT01016899) with the objective of recording the recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xofig Axxent Electronic Brachytherapy System. The trial will also evaluate the cosmetic outcomes and skin toxicities related to the treatment.

**Articles:** The literature search for EBT for the treatment of NMSC identified only one study on the use of electronic brachytherapy for the treatment of NMSC. The initial results were reported in 2010 (Bhatnagar A, and Loper A, 2010) and 1-year results were published in 2013 (Bhatnagar A 2013). Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. *Brachytherapy*. 2013; 12(2):134-140. See [Evidence Table](#).

**Evidence Table.** Bhatnagar A, Loper A. The initial experience of electronic brachytherapy for the treatment of non-melanoma skin cancer. *Radiat Oncol*. 2010; 5:87. doi: 10.1186/1748-717X-5-87 See [Evidence Table](#).

The use of electronic brachytherapy for non-melanoma skin cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **03/21/2016: MTAC REVIEW**

### **Electronic Brachytherapy (EBT) for the treatment of non-melanoma skin cancer (NMSC)**

**Evidence Conclusion:** There is insufficient published evidence to determine whether the safety and efficacy outcomes of electronic brachytherapy for NMSC are as good or superior to the outcomes of alternative treatment options. There are no published randomized or non-randomized controlled trials that compared EBT to an alternative therapy for the treatment of NMSC. The available published evidence consists of case series that used

different systems for the delivery of HDR. The largest series (Bhatnagar 2010 & 2013) that used one of the three commercially available devices (the Axxent system, Xofig Inc. Sunnyvale, CA) was reviewed by MTAC earlier in 2014, and did not provide sufficient evidence on the long-term efficacy or safety of the procedure.

The more recent case series identified by the search were small retrospective series with no comparison groups, and do not provide additional evidence to support the use of EBT for NMSC. In a recently published article, Linos and colleagues (2015), expressed their concern regarding the increase in the use of EBT for skin cancer. The authors analyzed Medicare claims data and found that EBT use for skin cancer is increasing rapidly in the Medicare population. They indicated this may be attributable to marketing by the manufacturers, and that there is insufficient long-term data on the efficacy and safety of the therapy to cover the period during which recurrence and radiation sequelae would be expected (Linos, 2015).

**Articles:** The updated literature search for the use of electronic brachytherapy in the treatment of NMSC did not identify any controlled trial that compared the therapy with an alternative mode of treatment. The search only identified a number of small retrospective case series and a systematic review of the observational studies reporting on the outcomes of low-dose or high-dose brachytherapy used for the treatment of NMSC of the eyelid (Frakulli 2015).

The use of electronic brachytherapy for non-melanoma skin cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

Per NCCN Guidelines Version 1.2017 Basal Cell Skin Cancer. P. 11

“There is insufficient long-term efficacy and safety data to support the routine use of electronic surface brachytherapy.”

## 07/08/2024: MTAC REVIEW

### Evidence Conclusion

- There is insufficient published evidence to determine the comparative safety and efficacy of electronic brachytherapy and Mohs surgery in treating patients with NMSC.
- There is insufficient published evidence to determine the net health outcomes of electronic brachytherapy in patients with NMSC.
- Randomized controlled trials with sufficient follow-up duration are needed to determine the comparative long-term safety and efficacy of EBT and MMS in patients with NMSC.

**Articles:** The literature search for studies published after the 2016 MTAC review of the technology, did not identify any RCT that compared electronic brachytherapy to Mohs Surgery for the treatment of patients with nonmelanoma skin cancer. The search only revealed a matched pair cohort study that compared EBT vs. Mohs micrographic surgery for the treatment of early stage NMSC (Patel, et al 2017); a systematic review with meta-analysis of studies evaluating different treatment modalities used for indolent skin cancer (Lee, et al 2019); a small (N=34) prospective study reporting on short term cosmesis and QoL with electronic skin surface brachytherapy for keratinocyte carcinoma (Kuo et al, al 2023); two year outcomes of a small pilot single arm observational study with incomplete follow-up of 26 patients (Ballester-Sánchez, et al, 2017) , retrospective chart reviews; and case series of patients with NMSC treated with EBT. See [Evidence Table](#)

Patel, et al's 2017 matched pair cohort study was selected for critical appraisal. Lee, et al's meta-analysis was not selected for the current review as the authors excluded studies that used electronic brachytherapy due to the lack of long-term data.

The use of electronic brachytherapy for non-melanoma skin cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Hayes Technology Brief

Hayes, Inc. Hayes Technology Brief. Superficial Radiation Therapy for Treatment of Nonmelanoma Skin Cancer. Lansdale, PA: Hayes, Inc.; 3/2018

## Applicable Codes

**Medicare - Considered Not Medically Necessary - experimental, investigational, or unproven**

**Non-Medicare - Considered Not Medically Necessary - experimental, investigational, or unproven**

CPT® Codes	Description
------------	-------------

<b>0394T</b>	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed
<b>77280</b>	Therapeutic radiology simulation-aided field setting; simple
<b>77285</b>	Therapeutic radiology simulation-aided field setting; intermediate
<b>77300</b>	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician
<b>77336</b>	Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment documentation in support of the radiation oncologist, reported per week of therapy
<b>77370</b>	Special medical radiation physics consultation
<b>77401</b>	Radiation treatment delivery, superficial and/or ortho voltage, per day
<b>77412</b>	Radiation treatment delivery, =>1 MeV; complex
<b>G6001</b>	Ultrasonic guidance for placement of radiation therapy fields
<b>With diagnosis Code</b>	
<b>C44.01</b>	Basal cell carcinoma of skin of lip
<b>C44.02</b>	Squamous cell carcinoma of skin of lip
<b>C44.1121</b>	Basal cell carcinoma of skin of right upper eyelid, including canthus
<b>C44.1122</b>	Basal cell carcinoma of skin of right lower eyelid, including canthus
<b>C44.1191</b>	Basal cell carcinoma of skin of left upper eyelid, including canthus
<b>C44.1192</b>	Basal cell carcinoma of skin of left lower eyelid, including canthus
<b>C44.1221</b>	Squamous cell carcinoma of skin of right upper eyelid, including canthus
<b>C44.1222</b>	Squamous cell carcinoma of skin of right lower eyelid, including canthus
<b>C44.1291</b>	Squamous cell carcinoma of skin of left upper eyelid, including canthus
<b>C44.1292</b>	Squamous cell carcinoma of skin of left lower eyelid, including canthus
<b>C44.212</b>	Basal cell carcinoma of skin of right ear and external auricular canal
<b>C44.219</b>	Basal cell carcinoma of skin of left ear and external auricular canal
<b>C44.222</b>	Squamous cell carcinoma of skin of right ear and external auricular canal
<b>C44.229</b>	Squamous cell carcinoma of skin of left ear and external auricular canal
<b>C44.311</b>	Basal cell carcinoma of skin of nose
<b>C44.319</b>	Basal cell carcinoma of skin of other parts of face
<b>C44.321</b>	Squamous cell carcinoma of skin of nose
<b>C44.329</b>	Squamous cell carcinoma of skin of other parts of face
<b>C44.41</b>	Basal cell carcinoma of skin of scalp and neck
<b>C44.42</b>	Squamous cell carcinoma of skin of scalp and neck
<b>C44.510</b>	Basal cell carcinoma of anal skin
<b>C44.511</b>	Basal cell carcinoma of skin of breast
<b>C44.519</b>	Basal cell carcinoma of skin of other part of trunk
<b>C44.520</b>	Squamous cell carcinoma of anal skin
<b>C44.521</b>	Squamous cell carcinoma of skin of breast
<b>C44.529</b>	Squamous cell carcinoma of skin of other part of trunk
<b>C44.612</b>	Basal cell carcinoma of skin of right upper limb, including shoulder
<b>C44.619</b>	Basal cell carcinoma of skin of left upper limb, including shoulder
<b>C44.622</b>	Squamous cell carcinoma of skin of right upper limb, including shoulder
<b>C44.629</b>	Squamous cell carcinoma of skin of left upper limb, including shoulder
<b>C44.712</b>	Basal cell carcinoma of skin of right lower limb, including hip
<b>C44.719</b>	Basal cell carcinoma of skin of left lower limb, including hip
<b>C44.722</b>	Squamous cell carcinoma of skin of right lower limb, including hip
<b>C44.729</b>	Squamous cell carcinoma of skin of left lower limb, including hip

<b>D04.0</b>	Carcinoma in situ of skin of lip
<b>D04.111</b>	Carcinoma in situ of skin of right upper eyelid, including canthus
<b>D04.112</b>	Carcinoma in situ of skin of right lower eyelid, including canthus
<b>D04.121</b>	Carcinoma in situ of skin of left upper eyelid, including canthus
<b>D04.122</b>	Carcinoma in situ of skin of left lower eyelid, including canthus
<b>D04.21</b>	Carcinoma in situ of skin of right ear and external auricular canal
<b>D04.22</b>	Carcinoma in situ of skin of left ear and external auricular canal
<b>D04.39</b>	Carcinoma in situ of skin of other parts of face
<b>D04.4</b>	Carcinoma in situ of skin of scalp and neck
<b>D04.5</b>	Carcinoma in situ of skin of trunk
<b>D04.61</b>	Carcinoma in situ of skin of right upper limb, including shoulder
<b>D04.62</b>	Carcinoma in situ of skin of left upper limb, including shoulder
<b>D04.71</b>	Carcinoma in situ of skin of right lower limb, including hip
<b>D04.72</b>	Carcinoma in situ of skin of left lower limb, including hip
<b>D04.8</b>	Carcinoma in situ of skin of other sites
<b>D07.1</b>	Carcinoma in situ of vulva
<b>D07.4</b>	Carcinoma in situ of penis

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/02/2024	05/06/2014 <sup>MPC</sup> , 03/03/2015 <sup>MPC</sup> , 01/05/2016 <sup>MPC</sup> , 11/01/2016 <sup>MPC</sup> , 09/05/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/07/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	08/06/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description of Change
04/05/2016	Added MTAC review
04/25/2017	Added NCCN Guideline
04/17/2018	Added Hayes Guideline
08/04/2020	Removed deactivated CPT code 0182T and CPT code 77401
04/26/2024	Updated applicable codes by adding: 77280, 77285, 77300, 77336, 77370, 77401 and G6001 with applicable skin cancer diagnosis.
08/02/2024	Added the July 2024 MTAC Review
08/06/2024	MPC approved MTAC's recommendation of insufficient evidence and maintain the policy of non-coverage.
1/10/2025	Updated Medicare Criteria to KPWA Medical Policy due to retired LCD.
4/8/2025	Added CPT code 77412





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Electroretinography

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Electroretinography</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this test provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Liutkevičienė et al., 2012:

During electroretinography (ERG), a total retinal response to light stimulus is recorded. ERG is comprised by a and b-waves which are generated by the outer segments of photoreceptors and Muller cells respectively. B-wave represents activities in the inner retinal layers. Several stimulations and registration techniques help record potentials of various retinal structures: early receptor potential, ERP; standard electroretinogram of full field by ISCEV (International Society for Clinical Electrophysiology of Vision); photopic negative response, PhNR; pattern (alternating contrast) ERG, pERG; multifocal ERG (mfERG).

Detoraki et al., 2016:

#### Multifocal electroretinography (mfERG)

Multifocal electroretinography (mfERG) is an objective evaluation of visual function. It is noninvasive and assesses retinal diseases. During mfERG, several areas of the retina are stimulated but each response is recorded independently. mfERG measures the electrophysiological activity of the retina. Under the influence of light, retinal responses are recorded, permitting diagnosis of retinal abnormality.



The stimulation of the retina is done by hexagonal elements alternating between black and white. Similar to full-field ERG, a corneal electrode records electrical response of the retina which consists of waveforms. The waveforms include three responses: an initial negative response (N1), a positive response (P1) and a second negative response (N2). These responses represent the function of the external layer of the retina (photoreceptors and bipolar cells). The location of the stimulus and anatomical areas correspond to the fovea, parafovea, perifovea, and periphery. mfERG can show the amplitudes of the signal.

Many factors can alter the waveforms. These include unstable electrode contact, poor fixation, continuous blinking, and errors in refraction.

mfERG detects abnormalities of the macula, peri-macular area and the mid peripheral zone of the retina which are not always seen on fundoscopy, such as chloroquine (CQ) or hydroxychloroquine (HCQ) toxicity, siderosis, anorexia nervosa, tilted disk syndrome and keratoconus. mfERG can assess drug-induced retinal toxicity. In addition, mfERG can detect central lesion in all macular diseases (age-related macular degeneration, central serous chorioretinopathy, vitelliform maculopathy, macular hole, juvenile retinoschisis and other diseases). Further, mfERG can estimate the degree of central lesion in early stages of Stargardt's maculopathy and toxic maculopathy. The combination of mfERG and visual evoked potentials (VEPs) is beneficial in the differential diagnosis of retinal and optic nerve diseases.

Another type of mfERG is wide-field (WF)-mfERG that targets peripheral areas of the retina. The testing field of WF-mfERG is 90 degree versus 45 degree for conventional mfERG. WF-mfERG is useful in detecting abnormality of retina in retinitis pigmentosa, retinal vein occlusion, birdshot chorioretinitis and vigabatrin toxicity.

#### Retinal toxicity

Although not frequent, drug-induced ocular toxicity must be detected early to avoid permanent vision loss. There are several medications that can cause ocular toxicity. The most frequent affecting the retina include chloroquine (CQ) and hydroxychloroquine (HCQ), vigabatrin (VGB), deferoxamine, ethambutol, interferon- $\alpha$ , tamoxifen, digoxin, sildenafil, canthaxanthin, amiodarone and nefazodone. Evaluation of retinal toxicity is founded on medical history and ophthalmic examination. However, other investigations including mfERG, optical coherence tomography (OCT), fundus autofluorescence (FAF), perimetry, and fundus angiography are also valuable. The sensitivity and specificity of these tests are not clear. Symptoms of CQ or HCQ retinopathy include blurred vision, photophobia, scotomas, and difficulty reading. The fundus is described as "bull's eye maculopathy".

Whatham 2013:

Full-field ERG stimulates the central and peripheral visual fields with flashlight. Pupils are dilated and response to the stimulation is assessed under dark-adapted and light-adapted conditions. The International Society for Clinical Electrophysiology of Vision (ISCEV) recommends a minimum of 20 minutes dark adaptation to produce a dark adapted (scotopic) state of sensitivity and a minimum of 10 minutes adaptation to a background luminance of 30 cd/m<sup>2</sup> to produce a light-adapted (photopic) state of visual sensitivity. Full-field ERG detects a range of retinal dysfunction, such as rod-cone dystrophy. Full-field ERGs are normal in focal retinal diseases including age-related macular degeneration and Stargardt's disease.

<https://eyewiki.org/Electroretinogram>:

The pattern ERG (PERG) uses the same stimuli, pattern-reversal stimuli, that is used in visual evoked potential (VEP). PERG records retinal ganglion cell activity and may detect optic neuropathies.

One difference between full-field ERG and mfERG is that in full-field ERG, the recording is a massed potential from the whole retina. Multifocal ERGs can map small scotomas in the central 40+ degrees of visual field (Creel, 2019). Full-field ERGs are used to record the global health of the retina, such as in retinitis pigmentosa (Creel, 2019).

## Medical Technology Assessment Committee (MTAC)

### ***Electroretinography (ERG)***

**7/13/2020: MTAC REVIEW**

#### **Evidence Conclusion:**

**HCQ-induced retinopathy:** A systematic review and meta-analysis of studies with high risk of bias shows that mfERG has a high sensitivity and variable specificity. In addition, accuracy of mfERG improves with older age, increased HCQ dose, and longer duration of treatment. mfERG may detect retinal toxicity earlier than other tests.

**Metallic foreign bodies:** There is insufficient evidence to assess ERG and retinal toxicity from metallic foreign bodies. The literature is comprised of case reports and case series. However, the trend from available evidence shows that ERG detected abnormalities in patients with intraocular metallic foreign bodies prior to surgery with improvement after removal of the foreign bodies.

**Retinitis pigmentosa:** Several studies show decreased amplitude of ERG and delayed implicit time in patients with retinitis pigmentosa. This suggests that ERG detects abnormalities in this population. Clinical validity was not reported and comparison with electro-oculogram or visual evoked potential (VEP) was rare. However, there is correlation between mfERG and corresponding mfVEP. Further, ERG may be useful in allowing long-term follow-up of disease progression in retinitis pigmentosa. mfERG may add to the diagnostic information of several patients with retinitis pigmentosa. ERG may distinguish between HCQ-induced retinal toxicity and retinitis pigmentosa. The evidence is comprised of case series and case reports with small sample sizes.

**Cone-Rod dystrophy:** Studies assessing clinical validity were not identified. The evidence is comprised of case reports or case series or retrospective study showing that ERG may detect cone-rod dystrophy and be useful to monitor disease progression.

**Leber's congenital amaurosis, congenital stationary night blindness, achromatopsia:** The evidence is insufficient to assess the accuracy of ERG in these diseases.

**Articles:** See [Evidence Table](#)

The use of Electroretinography (ERG) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Not Medically Necessary- experimental, investigational or unproven:**

CPT® Codes	Description
92273	Electroretinography (ERG), with interpretation and report; full field (ie, ffERG, flash ERG, Ganzfeld ERG)
92274	Electroretinography (ERG), with interpretation and report; multifocal (mfERG)
0509T	Electroretinography (ERG) with interpretation and report, pattern (PERG)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/01/2020	09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	09/01/2020

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/01/2020	MPC approved to endorse a non-coverage policy for electroretinography. Requires 60-day notice, effective date 02/01/2021.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Enteral Formula

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Enteral Nutrition (L38955)</a>
Local Coverage Articles	<a href="#">Enteral Nutrition (A58833)</a>

#### For Non-Medicare Members

**The criteria are for formulas only.** The pumps and associated equipment are considered durable medical equipment and are covered as part of the durable medical equipment benefit.

Elemental formulas are composed of amino acids, fats, sugars, vitamins, and minerals and lack whole or partial protein. An example of an elemental formula is Vivonex. Most formulas are not elemental as they contain complete proteins and complex carbohydrates, examples of which are Ensure or ProSobee.

To qualify for enteral nutritional formula, elemental formula (either replacement or supplemental) or non-elemental formula, the member must meet **ONE of the following**, either I, II, III or IV:

- I. To qualify for Nutritional Replacement Therapy, using an *elemental* formula, members must meet **ONE of the following**:
  - A. Members must have at least **ONE of the following** diagnoses:
    1. Crohn's Disease
    2. Inflammatory Bowel Disease
    3. Short Bowel Syndrome
    4. Eosinophilic gastrointestinal associated disorders
  - B. The member must also meet **ALL of the following**:
    1. Formula is intended for home use
    2. The member is managed by a Gastroenterologist
    3. The member has been evaluated and will be followed by a Registered Dietitian
    4. Elemental total nutritional replacement represents 80 - 100% of diet or 80% or greater of the daily dietary requirements
    5. Alternative approaches, other than use of an elemental formula, have not resulted in adequate nutrition and control of symptoms.
    6. Member must meet **ALL of the following**:
      - a. Able to tolerate oral supplementation
      - b. If unable to tolerate oral supplementation, member must meet **ALL of the following**:
        - The member or caregiver must demonstrate the ability to place a nasogastric tube or manage a surgically placed feeding tube.
        - The member or caregiver must also be able to demonstrate the ability to regulate flow either via gravity drip or pump.

- II. To qualify for Nutritional Supplementation Therapy using an *elemental* formula, members must meet **All of the following**:
- A. Members must have at least **ONE of the following** diagnoses:
    1. Crohn's Disease
    2. Inflammatory Bowel Disease
    3. Short Bowel Syndrome
    4. Cystic Fibrosis involving the intestine
    5. Eosinophilic gastrointestinal associated disorders
  - B. Members must also meet **ALL of the following**:
    1. Intended for home use
    2. Growth failure/retardation or cachexia has been documented
    3. The member is managed by a Gastroenterologist
    4. The member has been evaluated and will be followed by a Registered Dietitian
    5. Other therapies, such as medication, have not resulted in adequate nutrition/weight gain
  - C. Member must meet **ONE of the following**:
    1. Able to tolerate oral supplementation
    2. If unable to tolerate oral supplementation, member must meet **ALL of the following**:
      - a. The member or caregiver must demonstrate the ability to place a nasogastric tube or manage a surgically placed feeding tube.
      - b. The member or caregiver must also be able to demonstrate the ability to regulate flow either via gravity drip or pump.
- III. Oral nutrition or supplements using *non-elemental* formula may be considered medically necessary when used for the treatment of inborn errors of metabolism. Member must meet **ALL of the following**:
- A. Must have **ONE of the following** diagnosis:
    1. Phenylketonuria [PKU]
    2. Maple syrup urine disease (MSUD)
    3. Homocystinuria,
    4. Histidinemia
    5. Tyrosinemia
    6. Glycogen Storage Type II Syndrome (GSD II or Pompe disease)
  - B. Formula is intended for home use (not for use in the hospital or nursing facility)
- IV. *Non-elemental formula* is covered for members who require tube feeding under the following conditions:
- a) Non-function or disease of the structures that normally permit food to reach the small bowel. The condition could either be anatomic (obstruction due to head and neck cancer, reconstructive surgery, etc.) or a motility disorder (e.g., severe dysphagia following a stroke, congenital defects, etc.) **AND**
  - b) Requires tube feeding to maintain weight and strength commensurate with the patient's overall health status **AND**
  - c) The patient's condition is anticipated to be long term in duration, typically at least 3 months (90 days).

\*Elemental formula can be delivered by tube only if indications in I or II above are met

**The following are not covered:**

- Intra-peritoneal nutrition is considered experimental and investigational.

\*Diagnosis Codes that are covered for Eosinophilic Gastrointestinal Associated Diseases

ICD-10

K20.0 Eosinophilic esophagitis

K52.81 Eosinophilic gastritis or gastroenteritis

K52.82 Eosinophilic colitis

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (PCP, GI specialist)
- Last 6 months of radiology notes if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations..

## Background

Until 1996, the only Kaiser Permanente plans that had coverage for enteral therapy were the Medicare plans. In 1996 an appeals case caused Kaiser Permanente to reevaluate the potential inclusion of enteral therapy for all groups. The reevaluation, which included a special work group and the Benefits Committee, concluded that the use of elemental enteral therapy for ineffective GI absorption that represented a major portion of the consumer's calorie intake, should be covered up to the level of replacement of regular cost of food (80% of charges).

This coverage was to be added in 1997 to all plans under dietary formula where enteral nutrition therapy benefit is not in place. Since only subsets of specific consumers are eligible for this coverage, criteria were developed for consistent review of requests.

In 1998, Kaiser Permanente received a request to consider coverage for Glycogen Storage Type II Syndrome supplemental formula. After review of the case and literature, the decision was made to add the disease to the criteria for coverage.

In July 1998 Kaiser Permanente received an update of the Healthy Options criteria for coverage of enteral feedings. In October 2005 the MMA program updated the coverage criteria that are applicable to Healthy Options. Kaiser Permanente criteria were adjusted to reflect the new changes.

## Evidence and Source Documents

03/1998

**Articles:** Definitions: Inflammatory Bowel Disease includes Crohn's Disease of small intestine or colon, Ulcerative Colitis, and overlap syndromes (Non-Specific IBD, Segmental Colitis) An Elemental Diet contains oligo-peptides as the major protein source. Vivonex (lower fat- 2.5%) and Vital HN (higher fat- 8%) are typical elemental diets. Non-elemental diets contain intact proteins from a defined source (such as milk protein, meat or egg)

Growth Retardation/ Failure requires: A pediatric patient (defined as age<18 years, and epiphyses not fused on radiography) and a height per age <5th percentile, or a decrease in growth velocity of  $\geq 2\text{cm/year}$ , or bone age  $> 2\text{ SD}$  below chronologic age Nutritional Replacement Therapy requires  $>90\%$  (and preferable 100%) of the caloric intake be provided by the elemental formula Nutritional Supplementation Therapy requires that  $>50\%$  of the caloric intake is provided by the elemental formula. The use of elemental enteral nutrition in inflammatory bowel disease has progressed from strictly nutritional to therapeutic. Although the mechanism is not fully understood, disease activity and intestinal permeability decrease in patients "fed" with elemental diets, as compared to regular diet or TPN. The therapeutic role is best documented in the management of Crohn's Disease [especially of the small intestine]. The role of this therapy in Ulcerative Pancolitis, Ulcerative Colitis limited to the left colon, nonspecific IBD, and Segmental Colitis is not supported by these data. Nutritional Therapy (whether Replacement or Supplement) is used only in conjunction with other drug therapy (including 5-ASA compounds, corticosteroids, immunosuppressives and antibiotics) not in lieu of these other therapies. The consideration of surgery as primary therapy must be considered in patients with significant strictures complicating nutrition.

### References:

Griffiths et al "Meta-analysis of Enteral Nutrition as a Primary Treatment of Active Crohn's Disease" Gastro 108, 1995

Meta-analysis of enteral nutrition vs. steroids as primary therapy; findings were that steroids were more effective. Also compared composition of diets and found no clear data [not significant power] supporting elemental over polymeric.

Teahon et al "Alterations in Nutritional Status and Disease Activity during Treatment of Crohn's Disease with Elemental Diet" Scand J Gastro 30, 1995

Replacement of diet with Vivonex or similar for 5-week period, 1850-3700 kcal/d. Required significant malnutrition at entry into study. Improvement in inflammatory activity preceded nutritional improvement in most cases.

Fernandez-Banares et al "How Effective is Enteral Nutrition in Inducing Clinical Remission in Active Crohn's Disease? A meta-analysis of the Randomized Clinical Trials" JPEN 19, 1995

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

### Elemental formula

HPC Codes	Description
<b>B4153</b>	Enteral formula, nutritionally complete, hydrolyzed proteins (amino acids and peptide chain), includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4161</b>	Enteral formula, for pediatrics, hydrolyzed/amino acids and peptide chain proteins, includes fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit

### Formula for inborn errors of metabolism

HPC Codes	Description
<b>B4157</b>	Enteral formula, nutritionally complete, for special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4162</b>	Enteral formula, for pediatrics, special metabolic needs for inherited disease of metabolism, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit

### Non-elemental formula

HPC Codes	Description
<b>B4150</b>	Enteral formula, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4152</b>	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4158</b>	Enteral formula, for pediatrics, nutritionally complete with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4159</b>	Enteral formula, for pediatrics, nutritionally complete soy based with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber and/or iron, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4160</b>	Enteral formula, for pediatrics, nutritionally complete calorically dense (equal to or greater than 0.7 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit

### Other specialized formulas

**Not routinely covered; the medical record must document why the specific formula is medically necessary**

**\*Not covered by Medicare**

HPC Codes	Description
<b>B4102*</b>	Enteral formula, for adults, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
<b>B4103*</b>	Enteral formula, for pediatrics, used to replace fluids and electrolytes (e.g., clear liquids), 500 ml = 1 unit
<b>B4105</b>	In-line cartridge containing digestive enzyme(s) for enteral feeding, each
<b>B4149</b>	Enteral formula, manufactured blenderized natural foods with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit
<b>B4154</b>	Enteral formula, nutritionally complete, for special metabolic needs, excludes inherited disease of metabolism, includes altered composition of proteins, fats, carbohydrates, vitamins and/or minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit (i.e., <i>diabetic, renal, post-surgical, ketogenic</i> )
<b>B4155</b>	Enteral formula, nutritionally incomplete/modular nutrients, includes specific nutrients, carbohydrates (e.g., glucose polymers), proteins/amino acids (e.g., glutamine, arginine), fat (e.g., medium chain triglycerides) or combination, administered through an enteral feeding tube, 100 calories = 1 unit



	<i>*almost always taken with another formula unless eating orally and requiring one specific nutrient</i>
--	---

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
7/11/1984	1/5/2010 <sup>MDCRPC</sup> , 11/2/2010 <sup>MDCRPC</sup> , 9/6/2011 <sup>MDCRPC</sup> , 7/3/2012 <sup>MDCRPC</sup> , 5/07/2013 <sup>MDCRPC</sup> , 2/04/2014 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 01/09/2024 <sup>MPC</sup> , 01/14/2025 <sup>MPC</sup>	11/13/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
8/31/2016	Added LCD for Enteral Therapy
12/06/2016	Added Intraperitoneal Nutrition (IPN) to the non-covered list
05/31/2018	Removed the Microsoft link
03/02/2021	MPC approved to amend the current criteria to include indications for non-elemental formula for patients receiving nutrition via tube feeding. Requires 60-day notice, effective date 08/01/2021.
08/13/2021	Added clarifying timeframe to define long term in IV.c. as typically at least 3 months (90 days).
7/28/2023	Updated Medicare policy article link (A58833)
11/13/2023	Updated Medicare LCD link Enteral Nutrition (L38955) and policy article link (A58833).



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Epidural Steroid Injections

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Epidural Steroid Injections for Pain Management (L39242)</a>
Local Coverage Article (LCA)	<a href="#">Billing and Coding: Epidural Steroid Injections for Pain Management (A58995)</a>

#### For Non-Medicare Members

MPC approved to adopt the proposed revisions to the existing ESI criteria to include acknowledge the importance of conservative therapy. Changes include the following:

#### Epidural Steroid Injections (Interlaminar, Caudal, or Transforaminal)

##### Initial Epidural Steroid Injections (ESI)

Initial Epidural Steroid Injections (ESI) are proven and medically necessary when **ALL of the following** criteria are met:

- One of the five indications below:
  - **Suspected Lumbar Radiculopathy defined as:**
    - Lower extremity pain is > or equal to back pain present in nerve root distribution (e.g., L5, S1, etc.) **PLUS, ONE or MORE:**
      - Positive supine straight leg raising test - radicular leg pain reproduced when the leg is extended >30° (e.g., if patient reported pain down the posterior thigh and lateral calf, expectation is a positive SLR test would reproduce that pain and not cause nonspecific pain like calf tightness or low back pain) OR
      - Motor weakness or sensory loss in a radicular distribution (must be in a specific radicular distribution) OR
      - EMG/NCS confirms acute radiculopathy consistent with the patient's symptoms OR
      - Patient's history or advanced imaging consistent with symptoms described
  - **Suspected Cervical Radiculopathy/Radicular pain defined as:**
    - Pain in a *nerve root* distribution (e.g., C6, C7) OR
    - Motor weakness or persistent sensory loss in a radicular distribution (must be in a specific radicular distribution) OR
    - EMG/NCS confirms acute radiculopathy consistent with the patient's symptoms OR
    - Patient's history or advanced imaging consistent with symptoms described
  - **Suspected Thoracic Radiculopathy/Radicular Pain defined as:**

- Band of numbness OR
- Pain or sensitivity in the thoracic dermatomal distribution OR
- Patient's history or advanced imaging consistent with symptoms described
- **Lumbar Radicular Pain (at any level) defined as:**
  - Moderate to severe pain in nerve root distribution (e.g., L5, S1, etc.) **AND**
  - Patient's available history and prior imaging is consistent with radicular pain as the primary etiology
- **Neurogenic claudication** defined as:
  - Bilateral or unilateral leg pain upon standing and walking that is temporarily relieved by forward flexion or sitting or lying down OR
  - The pain of lumbar stenosis is caused by relative ischemia of the lumbar nerve roots when in an upright position
- Treatment of presumed radiculopathy when there has been failure of at least a *4-week trial* of appropriate conservative management **with BOTH of the following:**
  - Physical Therapy\* or home exercise\* **AND**
  - Medications (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs) oral or topical or acetaminophen) unless contraindicated

*\*If conservative therapy is not appropriate, the medical record must clearly document why such approach is not reasonable.*
- MRI or CT with or without Myelography within the past 24-months demonstrates **ONE of the following:**
  - MRI or CT can be waived for the indication of simple lumbar radicular pain without loss of neurologic function (numbness or weakness) of less than six months duration
  - For an indication of *spinal stenosis*: Imaging consistent with moderate to severe spinal stenosis at the level to be treated for patients with a clinical diagnosis of neurogenic claudication
  - For an indication of *radiculopathy*: Imaging consistent with compression or displacement of the corresponding nerve root **OR**, if imaging does not show compression an EMG consistent with acute nerve impingement

**AND**
- None of the contraindications below without documentation of a medically justifiable reason for proceeding \*\*

### **Repeat Epidural Steroid Injections (ESI)**

Repeat Epidural Steroid Injections (ESI) are proven and medically necessary when **the following** criteria are met.

- Pain has returned or deterioration in function has occurred **AND**
- If initial steroid injection was done empirically (without CT or MRI) and patient did not respond adequately, advanced imaging must be done prior to repeat injections **AND**
- Prior injection resulted in less than 50% improvement in pain for two or more weeks and the ESI approach is being changed (intralaminar to transforaminal or vice versa) or a different level is being injected (evidence of nerve root compression by CT, MRI, or EMG is required) **OR**
- Patients condition has declined after patients' initial injection resulted in at least 50% improvement in pain for two or more weeks and **at least ONE of the following:**
  - Increase in the level of function/physical activity (e.g., return to work)
  - Reduction in the use of pain medication and/or additional medical services

**NOTE:** Additional epidural injections are **not** considered medically necessary if these criteria are not met.

### **Epidural Steroid Injection (ESI) Limitations**

- Maximum of four (4) ESI sessions along the spinal column per year.  
Definitions:
  - A year: the 12-month period starting from the date of service of the first approved injection
- Maximum of two (2) transforaminal ESI injections in one date of service

### **\*\*Epidural Steroid Injection (ESI) exclusions/contraindications**

- Anticoagulated
- Axial back pain (isolated to neck, mid-back, or low back pain)
- Back pain in the setting of acute spinal fractures
- Bleeding disorders that are not reversed
- Systemic bacterial or fungal Infection
- Currently on antibiotics/antifungals for an infection
- Currently on high dose steroids
- Demyelinating disease that is causing radicular symptoms
- Local malignancy
- Other CNS processes which predispose to transverse myelitis (case-by-case)
- Uncontrolled Diabetes

**For covered criteria:**

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (including PT notes)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Epidural steroid injections can serve as both a diagnostic and a therapeutic tool for patients with symptoms related to a disc herniation in the spine. Overall, the volume of evidence for the use of therapeutic epidural injections in the treatment of acute and chronic back pain is large. Clinical studies have shown that epidural steroid injections have provided short-term improvement and may be considered in the treatment of selected patients with radicular pain as part of an active therapy program. There is however insufficient evidence to demonstrate that epidural steroid injections are effective in the treatment of back pain in the absence of radicular symptoms.

## References

Washington State Department of Labor & Industries Spinal Injections Coverage Decision. Retrieved 01/26/2023 from [https://lni.wa.gov/patient-care/treating-patients/treatment-guidelines-and-resources/\\_docs/SpinalInjectionsCoverageDecision.pdf](https://lni.wa.gov/patient-care/treating-patients/treatment-guidelines-and-resources/_docs/SpinalInjectionsCoverageDecision.pdf)

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® or HCPCS Codes	Description
<b>62320</b>	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance
<b>62321</b>	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)
<b>62322</b>	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance

<b>62323</b>	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)
<b>62324</b>	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; without imaging guidance
<b>62325</b>	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, cervical or thoracic; with imaging guidance (ie, fluoroscopy or CT)
<b>62326</b>	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance
<b>62327</b>	Injection(s), including indwelling catheter placement, continuous infusion or intermittent bolus, of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)
<b>64479</b>	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), cervical or thoracic, single level
<b>64480</b>	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), cervical or thoracic, each additional level (List separately in addition to code for primary procedure)
<b>64483</b>	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, single level
<b>64484</b>	Injection(s), anesthetic agent(s) and/or steroid; transforaminal epidural, with imaging guidance (fluoroscopy or CT), lumbar or sacral, each additional level (List separately in addition to code for primary procedure)
<b>77003</b>	Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinal diagnostic or therapeutic injection procedures (epidural or subarachnoid) (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/07/2023	03/07/2023 <sup>MPC</sup> , 08/06/2024 <sup>MPC</sup>	07/12/2023

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/07/2023	MPC approved to adopt clinical criteria for Epidural Injections. Requires 60-day notice, effective date 08/01/2023.
06/06/2023	MPC approved to adopt the proposed revisions to the existing ESI criteria to include acknowledge the importance of conservative therapy. 60-day notice required, effective date 11/01/2023
07/12/2023	Updated effective date from 8/1/2023 to 8/14/2023 for the 3/7/2023 approved criteria updates.







## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### Epidural Lysis of Adhesions for Chronic Low-Back Pain

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Epidural Lysis of Adhesions for Chronic Low-Back Pain</b> " for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Estimates for the prevalence of back pain in a lifetime range from 54% to 80%. Chronic persistent back pain is seen in up to 60% of patients five years after the initial episode. Back pain is associated with substantial economic and social costs (Boswell et al., 2005).

Epidural lysis of adhesions (also known as epidural adhesiolysis) is a procedure developed by Dr. Gabor Racz in 1989 to treat chronic low back pain in patients who have failed to respond to conservative treatments. The goals of the procedure are to break down fibrous adhesions in the epidural space and apply medication (i.e. local anesthetics and corticosteroids). Fibrous epidural lesions can develop after surgical laminectomy, or can occur secondary to annular tear, hematoma or infection. The adhesions prevent free movement of structures in the intervertebral foramen and the bony vertebral canal and prevent direct application of medications to structures believed to be the source of pain. The role of fibrous epidural adhesions in causing chronic spinal pain, however, remains controversial (Belozer & Wang, 2004; Manchikanti et al., 2004).

The basic procedure for epidural lysis of adhesions is as follows: A 16-gauge RK needle enters the epidural space and contrast material is injected. Next, an epidurogram is performed to visualize spread of contrast medium

and identify filling defects. If the filling defect corresponds to the area of pain, a specially designed spring-guided reinforced catheter (Racz catheter) is threaded into the filling defect. Lysis of adhesions is carried out by intermittent injections of normal or hypertonic saline through the catheter. After adhesiolysis, local anesthetic and corticosteroids are injected. The original procedure, as described by Racz, requires the catheter to stay in place for 3-days, with additional injections of local anesthetic and steroid occurring on days 2 and 3. The procedure was modified to a 1-day protocol by Manchikanti and colleagues (Heavner et al., 1999).

Patients often undergo multiple adhesiolysis treatments. The American Society of Interventional Pain Physicians (ASIPP) suggests that with a 3-day protocol, patients should be limited to 2 interventions per year and with a 1-day protocol, patients should be limited to 4 interventions per year. Spinal endoscopic adhesiolysis procedures should be limited to a maximum of 2 per year, provided that the patient experienced at least a 50% reduction in pain for at least 2 months (Boswell et al., 2005).

Epidural adhesiolysis can be conducted with a spinal endoscope (called a myeloscope). This allows a 3-dimensional view of the contents of the epidural space. Proponents believe that spinal endoscopy improves the ability to perform appropriate adhesiolysis and provide targeted administration of medications (Belozer & Wang, 2004).

Possible side effects of epidural lysis of adhesions include dural puncture, spinal cord compression, infection and administration of high volumes of fluids which would potentially result in excessive epidural hydrostatic pressures (Boswell et al., 2005). In addition, the FDA has received multiple reports of catheter shearing or unraveling, as recently as April 2005. In most of these cases, sheared catheter pieces were left inside the patient (FDA website).

The Racz epidural catheter received premarket approval from the FDA in 1996.

## Medical Technology Assessment Committee (MTAC)

### *Epidural Lysis of Adhesions*

#### **04/03/2006: MTAC REVIEW**

**Evidence Conclusion:** One RCT evaluated the 3-day procedure for epidural lysis of adhesions. Conclusions cannot be drawn about effectiveness of this treatment from the study because there was no control group that did not receive the treatment. The study compared three alternate ways of performing the procedure. In addition, conclusions cannot be drawn about the relative effectiveness of different ways of performing the procedure since a between-group statistical analysis was not reported. Study validity was limited by a high drop-out rate and no intention to treat analysis, and lack of details about randomization and blinding procedures. Two RCTs evaluated the 1-day procedure for epidural lysis of adhesions. Both were conducted by Manchikanti and colleagues, the group that developed the shortened procedure. One of these was on percutaneous adhesiolysis (Manchikanti et al., 2004) and the other was on spinal endoscopic adhesiolysis (Manchikanti et al., 2005). The studies had similar methodology, and similar findings. Manchikanti et al., 2004 found significantly lower pain in each of two groups receiving epidural adhesiolysis (one received normal saline and the other, hypertonic saline) compared to a no treatment control group at 3, 6 and 12 months. Manchikanti et al., 2005 found significantly lower pain in a group receiving spinal endoscopic adhesiolysis compared to a no treatment control group at 3, 6 and 12 months. In both studies, the authors reported multiple outcomes without specifying primary outcomes or adjusting their p-value for multiple comparisons. Actual p-values were low enough that most of the differences would still have been statistically significant if the p-value had been adjusted. The clinical significance of outcomes using the VAS scale is not clear, but a substantially higher proportion of patients experienced <sup>3</sup>50% pain reliefs. A limitation of the two studies was that patients could choose to be unblinded at 3 months, which could bias responses at 6 and 12 months. 25% of patients in the control group in the Manchikanti et al., 2004 study and 33% of all patients in the Manchikanti et al., 2005 study chose to be unblinded at 3 months.

**Articles:** Three randomized controlled trials were identified and critically appraised. One was on the original 3-day procedure and two were on the 1-day procedure. In addition, one non-randomized controlled trial and several case series were identified. The non-randomized controlled trial was not evaluated further because there were two later RCTs by the same research group on the 1-day procedure. The RCTs were: Heavner JE, Racz GB, Raj P. Percutaneous epidural neuroplasty: Prospective evaluation of 0.9% NaCl versus 10% NaCl with or without hyaluronidase. *Reg Anesthesia Pain Med* 1999; 24: 202-207. See [Evidence Table](#). Manchikanti L, Rivera JJ, Pampati V. et al. One day lumbar epidural adhesiolysis and hypertonic saline neurolysis in treatment of chronic low back pain: A randomized double-blind trial. *Pain Physician* 2004; 7: 177-186. See [Evidence Table](#). Manchikanti L, Boswell MV, Rivera JJ et al. A randomized, controlled trial of spinal endoscopic adhesiolysis in chronic refractory low back and lower extremity pain. *BMC Anesthesiology* 2005; 5:10. See [Evidence Table](#).

The use of Epidural Lysis of Adhesions in the evaluation of chronic low-back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
<b>62263</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days
<b>62264</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/27/2006	04/20/2006 <sup>MDCRPC</sup> , 03/19/2007 <sup>MDCRPC</sup> , 12/17/2007 <sup>MDCRPC</sup> , 09/08/2008 <sup>MDCRPC</sup> , 07/13/2009 <sup>MDCRPC</sup> , 06/01/2010 <sup>MDCRPC</sup> , 04/05/2011 <sup>MDCRPC</sup> , 02/07/2012 <sup>MDCRPC</sup> , 12/04/2012 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 08/05/2014 <sup>MPC</sup> , 06/02/2015 <sup>MPC</sup> , 04/05/2016 <sup>MPC</sup> , 02/07/2017 <sup>MPC</sup> , 12/05/2017 <sup>MPC</sup> , 10/02/2018 <sup>MPC</sup> , 10/01/2019 <sup>MPC</sup> , 10/06/2020 <sup>MPC</sup> , 10/05/2021 <sup>MPC</sup> , 10/04/2022 <sup>MPC</sup> , 10/03/2023 <sup>MPC</sup> , 08/06/2024 <sup>MPC</sup>	09/08/2015

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L34886 and L35008 Non-Covered Services.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### External Trigeminal Nerve Stimulation (eTNS) for ADHD

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source )	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>External Trigeminal Nerve Stimulation (eTNS) for ADHD</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Trigeminal Nerve Stimulation, Transcutaneous: Behavioral Health Care (B-820-T) MCG\* for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Attention-deficit/hyperactivity disorder (ADHD) is the most common behavioral disorder in childhood. It is defined in the DSM-5 as a "*Persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development and negatively impacts directly on social and academic/occupational activities*". The reported

prevalence of ADHD in children varies from 2 to 18 percent depending upon the diagnostic criteria and the population studied. The etiology of the disorder is not fully known, but according to the experts, a combination of genetic, neurological, and environmental factors contributes to its pathogenesis and heterogeneous phenotypes (Felt 2014, Polanczyk 2015, Belanger 2018).

There are three sub-types of ADHD: 1. Predominantly inattentive type (including poor concentration, difficulty completing tasks, ease of distraction, and disorganization); 2. Predominantly hyperactive -impulsive type (e.g. restlessness, persistent fidgeting, impatience, excessive talking, difficulty waiting for turn); and 3. The combined type. Diagnosing a child with ADHD can be challenging due to the lack of specific tests, biomarkers, or symptoms in addition to the common presence of other comorbidities that may affect symptom presentation, increase the severity of the disorder and/ or lead to greater functional impairment. The DSM-5 requires the presence of a sufficient number of core symptoms and functional impairment to diagnose an individual with ADHD. This requires extensive evaluation by a health care professional and involves obtaining information from multiple sources primarily from parents or guardians, teachers, and other school and mental health clinicians involved in the child's care; comprehensive evaluation of the child's symptoms which should include the assessment for other conditions that might coexist with ADHD such as emotional or behavioral disorders (e.g., anxiety, depressive oppositional defiant, and conduct disorders), developmental (e.g. learning and language disorders), and physical conditions (e.g. tics, and sleep apnea) (AAP Guidelines 2011, Felt 2014, Akutagava-Martin 2016, Bélanger 2018).

Treatment of ADHD varies depending on the age of the patient and the presence of comorbidities. It needs to be individualized and is often multimodal requiring the use of both behavioral and pharmacological therapies. The American Academy of Pediatrics guideline recommends behavioral therapy as a first line treatment of preschool aged children (4-5 years of age); FDA- approved medications for ADHD and/or parent- and/or teacher administered behavior therapy as a first line treatment for elementary school-aged children (6–11 years of age); and FDA-approved medications as the first line treatment for adolescents (12-18 years of age). Psychostimulants, are most effective for the treatment of core ADHD symptoms, have generally acceptable adverse effect profiles and may be considered for children aged 6 years and older. Effective behavioral therapies include parent training, classroom management, and peer interventions. Other nonpharmacological interventions such as social, organizational skills, and cognitive training; diet; and exercise should be considered for children with ADHD and other psychiatric and developmental comorbidities (Felt 2014. Feldman 2018).

It is reported that around 70% of patients with ADHD using stimulant medications respond to therapy. In some cases, however, the response may be suboptimal and requires the use of more than one drug. This, in addition to the stigma of using stimulants, its side effects, intolerance, and lack compliance among some children, have led to the investigation of and/or development of alternative non-pharmacological therapies for the potential treatment of ADHD. Among these approaches are EEG-based neurofeedback, computer-based working memory training, and neuromodulation therapy (Grigolon 2019).

Neuromodulation therapy is an evolving therapy that has been, and/or being investigated for the potential treatment of different chronic conditions including pain, spinal cord injuries, epilepsy, movement disorders, and others. It is defined as the "alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". Existing and emerging neuromodulation treatments range from non-invasive techniques such as transcranial magnetic stimulation (TMS) to techniques involving the surgical implantation of devices to alter activity in discrete areas of the nervous system. Among these therapies are deep brain stimulation, hypoglossal nerve stimulation, spinal cord stimulation, vagus nerve stimulation, occipital nerve stimulation and trigeminal nerve stimulation (TNS) (International Neuromodulation Society website).

TNS is a non-invasive neuromodulation technique that has been recently developed for neurological and psychiatric disorders based on the hypothesis that electrical stimulation of the supraorbital branch of the trigeminal nerve modulates cortical and subcortical areas related to neuropsychiatric disorders. The trigeminal nerve carries sensory information from the skin, muscles, and skull to extensive important structures in the brain, including the nucleus solitarius, the locus coeruleus, the vagus nerve and the cerebral cortex. The nerve also sends signals to the anterior cingulate cortex, which is believed to be involved in mood, attention and decision-making (Grigolon 2019, NeuroSigma website, International Neuromodulation Society website).

In April 19, 2019, the FDA granted marketing approval, through a de novo premarket review pathway\*, of the Monarch eTNS System (NeuroSigma) to be used as a non-drug option for the treatment of attention deficit hyperactivity disorder (ADHD) in children 7 to 12 years of age who are not currently taking prescription ADHD medication (FDA website accessed May 9, 2019).



The Monarch eTNS System™ (NeuroSigma, Inc., Los Angeles CA) is a small device, the size of a cell phone, powered by a 9-volt battery. It is connected through a thin wire to a small electrode patch that adheres to a patient's forehead during sleep. The system delivers mild electrical stimulation to the branches of the trigeminal nerve, which sends therapeutic signals to the parts of the brain assumed to be involved with concentration and impulse control. The child wears the patch for an average of eight hours at night and removes it in the morning. The electrical stimulation feels like a tingling sensation on the skin, and the device should be used in the home under the supervision of a caregiver during periods of sleep. The exact mechanism of eTNS is not yet known, but according to some investigators, neuroimaging studies showed that eTNS increases activity in the brain regions that are believed to be important in regulating attention, emotion and behavior. It is reported that the response to eTNS may take up to 4 weeks to become evident, and patients should consult with their health care professional after four weeks of use to assess treatment effects (FDA website).

According to the FDA, “the Monarch eTNS System should not be used in children under seven years of age, in patients with an active implantable pacemaker, with active implantable neurostimulators, or in patients with body-worn devices such as insulin pumps. The eTNS System should also not be used in the presence of radio frequency energy such as magnetic resonance imaging (MRI) as it has not been tested in an MRI machine, or cell phones, because the phone’s low levels of electromagnetic energy may interrupt the therapy. The most common side effects observed with eTNS use are drowsiness, an increase in appetite, trouble sleeping, teeth clenching, headache and fatigue. No serious adverse events were associated with use of the device” (FDA website).

## Medical Technology Assessment Committee (MTAC)

### *External Trigeminal Nerve Stimulation (eTNS) for ADHD*

07/08/2019: MTAC REVIEW

#### **Evidence Conclusion:**

- There is insufficient published evidence to determine the comparative safety and effectiveness eTNS to stimulants and /or behavioral therapies currently used for the treatment of ADHD in children.
- There is low-moderate quality evidence from one relatively small sham-controlled randomized pilot trial that eTNS has more than a placebo short-term effect in improving the severity and frequency of ADHD symptoms examined by ADHD-RS and CGI-I in around 50% of selected children 8-12 years of age during 4 weeks of therapy.
- There is insufficient evidence to determine the sustainability of the observed effect of eTNS after discontinuation of the treatment.
- There is insufficient evidence to determine the long-term safety and efficacy of TNS in the treatment of children with ADHD.
- There is insufficient evidence to determine the optimal duration of TNS therapy i.e. whether it should be used only for 4 weeks, long-term, or periodically applied to the child.
- eTNS therapy is not without side effects; it was associated with an increase in appetite, weight gain, fatigue, headache, drowsiness and other adverse events. The authors noted that the adverse effects were not clinically significant leading to discontinuation of the treatment.
- Long-term RCTs comparing the effectiveness of eTNS to other therapies is needed to determine the equivalence or superiority of TNS to standard therapies, optimal duration of treatment, durability of the observed effect, and whether TNS would have a potential impact on child’s brain development.

**Articles:** The literature search only identified the published pivotal randomized, sham-controlled pilot study on trigeminal nerve stimulation for ADHD (McGough, 2019) and an earlier small observational feasibility study of trigeminal nerve stimulation in youths ADHD (McGough, 2015). Both studies were conducted by the same group of principal investigators who had financial ties with the industry.



McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry*. 2019 Apr; 58(4): 403-411.

McGough JJ, Loo SK, Sturm A, et al. An eight-week, open-trial, pilot feasibility study of trigeminal nerve stimulation in youth with attention-deficit/hyperactivity disorder. *Brain Stimul*. 2015 Mar-Apr; 8(2):299-304. See [Evidence Table](#)

The use of External Trigeminal Nerve Stimulation (eTNS) for ADHD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® /HCPC Codes	Description
<b>E0733</b>	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
Dx Codes	Description
<b>F90.0-F90.9</b>	Attention-deficit hyperactivity disorder

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/06/2019	08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/07/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	08/03/2021

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/06/2019	MPC approved to adopt non-coverage policy
08/03/2021	Added HCPC code K1016 and Dx codes F90.0-F90.9. MPC approved to adopt MCG Care Guideline B-820-T Trigeminal Nerve Stimulation, Transcutaneous: Behavioral Health Care for medical necessity reviews. Requires 60-day notice, effective date January 1, 2022.
04/17/2024	Replaced termed code K1016 with new code E0733 effective 1/1/2024



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

## Expiratory Muscle Training Therapy (EMST150) for Patients with Dysphagia due to Neurologic Diseases or Disorders

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Expiratory Muscle Training Therapy (EMST150) for Patients with Dysphagia due to Neurologic Diseases or Disorders</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Dysphagia is a clinical term that refers to difficulty in swallowing. It may be caused by various pathologies including neuromuscular disorders and diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson disease, and myasthenia gravis. Other etiologies for dysphagia include stroke, traumatic brain injury, head and neck tumors, ageing, generalized weakness, and other non-neurogenic causes. Dysphagia may have a major impact on the quality of life of patients and can lead to malnutrition, dehydration, or aspiration pneumonia (Park 2016).

Dysphagia may occur at any phase of the swallowing process; in the oral phase when impaired lingual movements may lead abnormal bolus formation and manipulation; in the pharyngeal phase due weakening of the pharyngeal constrictors that are crucial for the transfer of the oral bolus from the mouth to the esophagus,

decreased hyoid bone movement, and delayed laryngeal movements leading to pharyngeal residues and aspiration; or in the esophageal stage due to impaired upper esophageal sphincter movements.

Swallowing difficulty in ALS patients may result from weakness and/or spasticity of the muscles of deglutition, including the muscles of mastication, the tongue, lips, pharynx and larynx. In addition, weakness of the respiratory and ventilatory muscles impairs the airway protection by reducing the expiratory pressure needed to produce effective cough. In MS, the swallow coordination can be disrupted by demyelination of the corticobulbar tracts, cerebellar and/or brainstem involvement and the weakness or paresis of the muscles important for the swallow function. Research showed that disruption of the neuromuscular sequencing of pharyngeal and laryngeal events during swallow occurred in up to 90% of individuals with MS. In addition, similar to ALS, the reduced strength of the expiratory muscles not provide sufficient pressure for cough production and airway clearance. The pathophysiology of oropharyngeal dysphasia in Parkinson's disease is not clearly understood but is postulated to be due to dysfunction of the brain stem, degeneration of the substantia nigra, as well as disturbance of nondopaminergic neural networks (Van hooren 2014, Park 2016, Byeon 2016, Plowman 2016, Silverman 2017).

Management of dysphagia can be broadly divided into two approaches: 1. The remedial approach with the goal of improving swallowing function through different exercises; and 2. The compensatory approach that aims at safer swallowing e.g. by controlling the material and viscosity of the food, and the use of specific postural techniques and maneuvers during the food intake. The compensatory approaches, however, have a temporary effect and cannot induce recovery of the damaged swallow network. Investigators have thus focused on the remedial approaches that aim at restoration of function. Different new therapeutic modalities for managing swallowing in neurologic disorders have been developed and introduced to practice in the recent years, such as neuromuscular electrical stimulation, deep brain stimulation, respiratory muscle training, and others (Byeon 2016, Park 2016).

Recently expiratory muscle strength training (EMST) has emerged as a potential remedial therapy for swallowing disorders. It is an exercise program that focuses on increasing the force-generating capacity of the expiratory muscles during breathing with the aim of improving the maximum expiratory pressure, voluntary coughing effectiveness, as well as improving displacement of the hyoid during swallowing. Researchers explained that during the swallowing process suprahyoid muscle contraction in the pharynx pulls the hyoid bone in the anterior superior direction, and that sufficient movement of the hyoid bone in this direction is associated with airway protection and safe swallowing such as opening of the upper esophageal sphincter during swallowing. Neurogenic disorders may result in weakness of the suprahyoid muscles (anterior belly of the digastric, mylohyoid, and geniohyoid muscles) that are important for coughing and breathing out forcefully and swallowing. Weakness of these muscles leads to insufficient movement of the hyoid bone and in turn reduces the cough capacity and airway clearance. Activation of the suprahyoid muscles during EMST is thus believed to be effective in improving swallowing. It was initially investigated in the early 2000s by a team of researchers in Florida as a swallowing rehabilitation intervention in patients with Parkinson's disease (Pitts 2012, Laciuga 2014, Eom 2017, Moon 2017, Park 2016, Pearson 2017, Silverman 2017).

Expiratory muscle training is performed by hand-held resistive or pressure threshold devices. The resistance-based devices rely on adjusting the diameter of the airflow vent holes in the device. Reducing the diameter of the vent holes imposes resistance requiring increases respiratory muscle force. These devices have no threshold for the user to overcome and can be ineffective for strength training if used with inadequate airflow. Pressure-threshold devices on the other hand, rely on the pressure exerted during expiration. The device has a pressure threshold relief valve that opens only when a sufficient expiratory pressure is generated by the user during a forceful expiration into the device.

EMST150 device (Aspire Products, LLC; Gainesville, Florida) is a pressure-threshold handheld calibrated device that includes a one-way, spring-loaded valve with an adjustable external dial. The valve blocks the flow of air until enough pressure is produced. Once the targeted pressure is produced, the valve opens, and air begins to flow through the device. The latter allows adjusting the pressure amount in a range between 0 and 150 cm H<sub>2</sub>O. The pressure-threshold load is based on the patient's maximum expiratory pressure (MEP) obtained through a pressure manometer. During training the pressure threshold device is adjusted incrementally to progressively increase the resistance (progressive overload). The expiratory force must be sufficient to open the spring-loaded valve and allow the air flow. The pressure released valve requires a consistent flow of air to remain open. If the expiratory force is inadequate, the valve will not open and no air will flow through the device. These mechanics may serve as a biofeedback during the use of the device. The "dose" of EMST is typically defined in terms of the number of repetitions per set, with 5 sets completed each day, for 5 days per week with the device resistance set at 75% of the patient's MEP and progressed each week (Pitts 2009, Troche 2010, Brooks 2017).

When training ceases or the body undergoes a long period of detraining (inactivity) following a period of physical training, it loses some or all the positive gains achieved during training. This suggests that training should take place continually to maintain the benefits of an exercise program, particularly in individuals with neurodegenerative disease (<https://emst150.com/faq/>)

EMST is a form of therapy and is not subject to FDA regulations. The technology has not been previously reviewed by MTAC it is being reviewed based on a request from the Clinical Review Unit for decision support.

## Medical Technology Assessment Committee (MTAC)

Date: 07/09/2018 MTAC REVIEW

### ***Expiratory Muscle Training Therapy (EMST150) for Patients with Dysphagia due to Neurologic Diseases or Disorders***

#### **Evidence Conclusion:**

##### **Conclusion:**

- There is no published evidence to date to determine that EMST is superior or equivalent to other remedial or compensatory approaches used to manage swallowing disorders in patients with neurogenic disease or disorders.
- There is low-quality evidence showing that EMST may improve short-term swallowing outcomes, compared to no treatment in selected patients with mild to moderate dysphagia secondary to Parkinson's disease,
- There is low-quality evidence showing that EMST may improve short-term swallowing outcomes in patients with dysphagia secondary to acute/subacute stroke, compared to no active treatment. The benefits observed in the sham therapy groups may suggest that the EMST has a placebo effect, or that dysphagia may improve as a natural recovery of the condition and not due to the intervention.
- The benefits observed in the sham therapy groups in neurogenic conditions other than stroke may also indicate a placebo effect of the EMST, or that expiratory breathing alone without the positive pressure load can improve the MEP.
- There is insufficient evidence to determine whether the short-term benefits observed with EMST therapy compared to sham treatment would last after treatment cessation.
- Adverse outcomes were not reported in any of the trials.

The use of Expiratory Muscle Training Therapy (EMST150) for Patients with Dysphagia due to Neurologic Diseases or Disorders doesn't meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### **Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/07/2018	08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	08/07/2018

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/07/2018	Added MTAC review from 7/9/18 and created document

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Extracorporeal Photopheresis

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Extracorporeal Photopheresis (110.4)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

##### Extracorporeal Photopheresis for Acute and Chronic Graft vs. Host

Medical necessity review no longer required for this service.

##### Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma (CTCL)

Must meet **ALL** of the following:

- The extracorporeal device must be FDA approved;
- The patient has cutaneous t-cell lymphoma that has not responded to other forms of treatment;
- The use is for palliative treatment of associated skin manifestations.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Extracorporeal photopheresis (ECP) is a treatment modality for graft-versus-host disease (GVHD) and cutaneous t-cell lymphoma (CTCL). CTCL refers to several clonal t-cell malignancies that primarily manifest as skin conditions. GVHD is a complication of allogeneic stem cell transplantation.

Extracorporeal photopheresis (ECP) is one of the treatment options for refractory acute and chronic GVHD. ECP involves removing the patient's peripheral blood and separating it into leukocyte-depleted blood and leukocyte-enriched plasma. The leukocyte-depleted blood is returned to the patient. The leukocyte-enriched plasma is exposed to ultraviolet light in the presence of an extracorporeally administered photosensitizing agent, 8-methoxypsoralen (8-MOP). The cells are then re-infused into the patient and die in one-week period. During that week, they are capable of stimulating an anti-idiotypic t suppressor response. The exact mechanism of action of ECP is not known. The Therakos Photopheresis System is FDA approved as a class III medical device specifically for photopheresis (Greinix et al., 2000; Woltz et al., 2006).



There are no agreed-upon standards for the optimal frequency and duration for ECP treatment in patients with chronic GVHD, and there is wide variability in practice. Patients may be treated two or three days a week every two to three weeks for 3 to 30 months (Woltz et al., 2006).

Extracorporeal photopheresis (ECP) is also a treatment option for CTCL. ECP involves removing a portion of the patient's blood and separating into red and white blood cells by centrifugation. The red cells are returned to the patient. The white cells are mixed with a photosensitizing agent, 8-methoxypsoralen or methoxsalen (Uvadex, Therakos), and irradiated with ultraviolet light (UVA light, 320-400 nm). When activated, the photosensitizing agent binds with the cellular DNA of the white cells and accelerates their death. The altered cells are then re-infused into the patient. The intention is that these cells will stimulate an immune response against the damaged pathogenic T cell clones. In the pivotal study upon which FDA approval was based, a case series with 37 patients by Edelson and colleagues, a greater treatment effect was seen in patients with erythrodermic CTCL (later-stage disease) compared to those with plaques or tumors. This distinction has been difficult to confirm in later case series because studies generally include patients at different stages of clinical disease and do not report findings separately by disease stage. The effectiveness of ECP for treating CTCL, particularly Sezary Syndrome, continues to be debated in the literature. Some of the controversies are whether prior treatment with systemic corticosteroids and systemic chemotherapy reduces the effectiveness of ECP and which sub-groups of patients are most likely to benefit from ECP treatment. To date, there have not been any randomized controlled trials comparing ECP to other treatments for CTCL (Apisarnthanarax et al., 2002; Russell-Jones, 2000; FDA Web site; Therakos Web site).

The FDA has approved the photopheresis device UVAR and the photosensitizing Uvadex (both by Therakos) for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other forms of treatment. ECP is covered by Medicare for the same indication.

## Evidence and Source Documents

[Extracorporeal Photopheresis for Acute and Chronic Graft vs. Host Disease](#)

[Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma \(CTCL\)](#)

## Medical Technology Assessment Committee (MTAC)

### ***Extracorporeal Photopheresis in the Treatment of Acute and Chronic Graft Versus Host Disease***

#### **BACKGROUND**

Graft-versus-host disease (GVHD) is a complication of allogeneic stem cell transplantation (SCT). There are two forms of GVHD, acute and chronic. Acute GVHD occurs within the first 100 days of transplantation. In acute GVHD, the T-lymphocytes from the donor recognize tissues or cells in the recipient as foreign and produce a multi-organ (i.e. skin, liver, intestines) autoimmune-like syndrome. The T-lymphocytes use information from genetic markers known as human leukocyte antigens (HLA) to detect differences. Even when donors are matched for HLA markers, GVHD can occur because minor differences in these markers could still exist. Efforts to prevent acute GVHD include using closely matched donors, umbilical cord blood and/or post transplant immunosuppression with drugs including cyclosporine and methotrexate. Acute GVHD is commonly treated with corticosteroids which produce sustained responses in 50-80% of patients depending on the initial severity of disease. Second-line therapy includes different combinations of immunosuppressive agents. Newer treatments include infusion of mesenchymal stem cells (MSC), down-regulation of antigen-presenting cells (APC) and suicide gene transduced T cells (Bacigalupo, 2007). Chronic GVHD can occur after the first 100 days post-transplant, either in patients who experienced acute GVHD or a de novo onset. It is the main cause of late morbidity and mortality after allogeneic SCT. Chronic GVHD generally involves donor T cells expanding and attacking the host's immunologic system; its pathophysiology is poorly understood compared to acute GVHD (Woltz et al., 2006; Perez-Simon et al., 2006). Standard first-line treatment for chronic GVHD includes prednisone alone or in combination with a calcineurin inhibitor such as cyclosporin or tacrolimus. A recent review article (Perez-Simon et al., 2006) states that there is no generally accepted salvage treatment for patients with chronic GVHD who do not respond to prednisone. Treatments that have been used for refractory chronic GVHD include mycophenolate mofetil, anti-interleukin-2a receptor antagonists, sirolimus, pentostatin, CD20 antagonists, tumor necrosis factor- $\alpha$  antagonists and extracorporeal photopheresis. Other, newer treatments include anti-CD25 immunotoxin and inhibition of nuclear factor- $\kappa$ B. The authors of the review article recommend that chronic GVHD patients enter clinical trials for salvage treatment if at all possible. Extracorporeal photopheresis (ECP) is one of the treatment options for refractory acute and chronic GVHD. ECP involves removing the patient's peripheral blood and separating it into leukocyte-depleted blood and leukocyte-enriched plasma. The leukocyte-depleted blood is returned to the patient. The leukocyte-enriched plasma is exposed to ultraviolet light in the presence of an extracorporeally administered photosensitizing agent, 8-methoxypsoralen (8-MOP). The cells are then re-infused into the patient and die in one-week period. During that week, they are capable of stimulating an antidiotypic T

suppressor response. The exact mechanism of action of ECP is not known. The Therakos Photopheresis System is FDA approved as a class III medical device specifically for photopheresis (Greinix et al., 2000; Woltz et al., 2006). There is no generally agreed-upon standards for the optimal frequency and duration for ECP treatment in patients with chronic GVHD, and there is wide variability in practice. Patients may be treated two or three days a week every two to three weeks for 3 to 30 months (Woltz et al., 2006). ECP for acute and chronic graft versus host disease was first reviewed by MTAC in 2002. At that time, the empirical evidence consisted of small case series, with sample sizes varying from 3 to 23. The item failed MTAC evaluation criteria, and the Health Plan Medical Directors decision was to review requests on a case-by-case basis. A new review is being requested due to the length of time since the previous review, and recent changes made to Medicare criteria. Medicare now covers ECP for patients with chronic GVHD whose disease is refractory to standard immunosuppressive drug treatment.

#### **06/12/2002: MTAC REVIEW**

##### **Extracorporeal Photopheresis in the Treatment of Acute and Chronic Graft Versus Host Disease**

**Evidence Conclusion:** There is not enough evidence to permit conclusions on the effectiveness of extracorporeal photopheresis for treating acute or chronic graft-versus-host disease.

**Articles:** The search yielded 16 articles. There were no randomized controlled trials. Seven of the articles were reviews or editorials, two were case reports and seven were small case series (varying in size from n=3 to n=23). Due to the low grade of evidence and the small size of the studies, no evidence tables were created.

The use of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **08/20/2007: MTAC REVIEW**

##### **Extracorporeal Photopheresis in the Treatment of Acute and Chronic Graft Versus Host Disease**

**Evidence Conclusion:** The published studies that evaluated actigraphy for the assessment of insomnia were conducted on selected groups of patients and used different actigraph models, software, and scoring algorithms. Most studies were conducted in sleep laboratories where recording conditions are standardized, and the artifacts controlled. These controls would be lost when the actigraphy devices are used in the home environment, where it is intended for use. Also, the algorithms that were validated for a specific model, mode of operation, or in a selected population may by not be equally accurate when used with a different brand of device, different gender or age group. The studies reviewed compared actigraphy to PSG, but the authors did not indicate whether the investigators interpreting the results of one test were blinded to the results of the other. The overall results of the studies reviewed, indicate that compared to polysomnography, actigraphy had a high sensitivity (92-98%) but very low specificity (28-48%) in detecting insomnia. It was also found to overestimate the total sleep time and sleep efficiency. Actigraphy tends to overestimate sleep in people with insomnia when they are lying quietly as quiet wakefulness could be miscoded as sleep. Insomnia patients can remain inactive for a period of time attempting to fall asleep on the other hand actigraphy may underestimate the amount of sleep and overestimate the duration awake among those who are asleep but are restless or have large amounts of movements during sleep. The use of actigraphy for the assessment of periodic leg movements in sleep was evaluated in only a few small studies with methodological limitations. It was compared with polysomnography with bilateral anterior tibialis electromyography (BATEMG). However, EMG and leg actigraphy are not interchangeable, and each measures a different event. One records electrical activity of a certain muscle and the other records leg acceleration. Leg activity may be due to movement artifacts produced by obstructive sleep apnea. Kemlink et al (2007) did not exclude patients with suspicious sleep apnea and did not adjust for it in the analysis. In conclusion there is insufficient evidence to determine that actigraphy would replace PSG or add to its value in the diagnosis and management of patients with sleep disorders.

**Articles:** No randomized or non-randomized controlled trials were identified. The empirical evidence continues to consist of case series. The largest case series on ECP for acute GVHD (n=59) and for chronic GVHD (n=71) identified in the search were critically appraised. In addition, a case series on ECP in pediatric patients with either acute or chronic GVHD (n=77) was critically appraised. There were additional smaller case series. The studies reviewed include: Greinix HT, Knobler RM, Worel N et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft versus host disease. *Stem Cell Transplant* 2006; 91: 405-408. See [Evidence Table](#). Couriel DR, Hosing C, Saliba R et al. Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD. *Blood* 2006; 107: 3074-3080. See [Evidence Table](#). Messina C, Locatelli F, Lanino e et al. Extracorporeal photochemotherapy for pediatric patients with graft versus host disease after hematopoietic stem cell transplantation. *Br J Hematol* 2003; 122 118-127. See [Evidence Table](#).

The use of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma (CTCL)**

### **BACKGROUND**

Cutaneous T-cell lymphoma (CTCL) refers to several clonal T-cell malignancies that primarily manifest as skin conditions. The classical subsets of CTCL include mycosis fungoides (MF), the most common form, and Sezary Syndrome (SS). MF usually presents as chronic eczematous or psoriasiform patches or plaques whereas SS is characterized by erythroderma and leukemia. SS is sometimes viewed as an advanced form of MF. According to the CTCL disease staging system (stage IA-IVB), patients with Sezary Syndrome have stage IV disease. (Apisarnthanarax et al., 2002; Duvic et al., 2003; Russell-Jones et al., 2000). Therapeutic options differ according to clinical disease stage. Early patch-plaque MF (Stage 1 and IIA) is generally a benign and chronic condition and can be treated with conservative therapies such as topical corticosteroids, retinoids and mechlorethamine (nitrogen mustard). Early stage disease can also be treated with ultraviolet B (UVB) phototherapy or psoralen plus ultraviolet A photochemotherapy (PUVA). Some of the treatments used in early stage disease, such as PUVA or oral bexarotene, are also used for later stage disease but may be less effective. Historically, the most common treatment for late-stage disease (Stage IIB-IVB) is chemotherapy. No single-agent or multi-agent regimen has been shown to be clearly superior to the others. Disadvantages of systemic chemotherapeutic agents are that they have immunosuppressive effects which can lead to opportunistic infections, sepsis or death (Apisarnthanarax et al., 2002). Extracorporeal photopheresis (ECP) is another treatment option for CTCL. ECP involves removing a portion of the patient's blood and separating into red and white blood cells by centrifugation. The red cells are returned to the patient. The white cells are mixed with a photosensitizing agent, 8-methoxypsoralen or methoxsalen (Uvadex, Therakos), and irradiated with ultraviolet light (UVA light, 320-400 nm). When activated, the photosensitizing agent binds with the cellular DNA of the white cells and accelerates their death. The altered cells are then reinfused into the patient. The intention is that these cells will stimulate an immune response against the damaged pathogenic T cell clones. In the pivotal study upon which FDA approval was based, a case series with 37 patients by Edelson and colleagues, a greater treatment effect was seen in patients with erythrodermic CTCL (later-stage disease) compared to those with plaques or tumors. This distinction has been difficult to confirm in later case series because studies generally include patients at different stages of clinical disease and do not report findings separately by disease stage. The effectiveness of ECP for treating CTCL, particularly the following information was used in the development of this document and is provided as background only. Sezary Syndrome continues to be debated in the literature. Some of the controversies are whether prior treatment with systemic corticosteroids and systemic chemotherapy reduces the effectiveness of ECP and which sub-groups of patients are most likely to benefit from ECP treatment. To date, there have not been any randomized controlled trials comparing ECP to other treatments for CTCL (Apisarnthanarax et al., 2002; Russell-Jones, 2000; FDA website; Therakos website). The FDA has approved the photopheresis device UVAR and the photosensitizing Uvadex (both by Therakos) for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other forms of treatment. ECP is covered by Medicare for the same indication. Extracorporeal photopheresis for CTCL has not been reviewed previously by MTAC. ECP for the treatment of graft versus host disease was reviewed by MTAC in June, 2002.

### **06/05/2006: MTAC REVIEW**

#### **Extracorporeal Photopheresis for Cutaneous T-Cell Lymphoma (CTCL)**

**Evidence Conclusion:** There are no randomized controlled trials evaluating the efficacy of extracorporeal photopheresis for treating patients with CTCL. The published literature consists of small, predominantly retrospective case series. The ECP treatment protocol was similar in the case series that were reviewed, generally consisting of treatment every 4 weeks with a tapering off by lengthening treatment intervals in patients who achieved a response. Data from case series suggests that ECP might be helpful for treating skin manifestations of CTCL, the FDA approved indication. However, there are no data on the efficacy of ECP for skin conditions compared to an alternative treatment or no treatment. In the single prospective study, 27/37 patients had a positive response to treatment, defined as at least a 25% reduction in the skin score. 24/29 patients with erythroderma had a positive response after a mean follow-up of 42 weeks (Edelson et al., 1987). A study published 5 years later on the 29 patients with erythroderma (Heald et al., 1992) found that most of the patients had at least some improvement in skin manifestations of CTCL and 6 had a complete remission. It is not possible to draw conclusions about survival after ECP treatment due to the lack of comparative data from RCTs. Predicted median survival using life-table analysis in the Heald/Edelson study was 60 months from time of diagnosis of the erythrodermic state. One of the case series (Fraser-Andrews et al. 1998) included a non-randomized comparison group of patients who did not receive ECP treatment. They did not find a statistically significant difference in median length of survival from time of SS diagnosis in the two groups (39 months in ECP-treated patients vs. 26.5 months in non-ECP treated patients,  $p=0.12$ ). Other than a lack of randomization, limitations of the Fraser-Andrews study was the wide variety of other treatments patients received before, during and after ECP treatment, or instead of ECP treatment. It is difficult to attribute a response to the ECP treatment itself. The limited data on use of ECP for CTCL identified few adverse effects.

**Articles:** No randomized controlled trials were identified. The empirical studies were all case series, each with a sample size of less than 50. Desirable features of case series were prospective design, larger sample size, clear eligibility criteria, longer follow-up and survival included as an outcome. Three studies included survival as an outcome in addition to treatment response, had sample sizes  $n > 25$  and had reasonably long-term follow-up; however, only one of them was prospective. These three studies were critically appraised. The prospective study reporting on patient survival was the original Edelson (1987) study, with follow-up data reported by Heald and colleagues in 1992. Excluded studies include a prospective study that included only 14 patients and a small ( $n = 20$ ) study that included survival as an outcome but was retrospective and did not specify eligibility criteria. *Studies reviewed include:* Heald P, Rook A, Perez M et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. *J Am Acad Dermatol* 1992; 27: 427-433. (Follow-up of Edelson R et al. *NEJM* 1987; 316: 297-303). See [Evidence Table](#). Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous t-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: A 10-year experience at a single institution. *J Am Acad Dermatol* 1996; 35: 946-957. See [Evidence Table](#). Fraser-Andrews E, Seed, P, Whittaker S. et al. Extracorporeal photopheresis in Sezary syndrome. *Arch Dermatol* 1998; 134: 1001-1005. See [Evidence Table](#).

The use of extracorporeal photopheresis in the palliative treatment of cutaneous T-cell lymphoma lesions does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
36522	Photopheresis, extracorporeal

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
06/12/2002	08/03/2010 <sup>MDCRPC</sup> , 06/07/2011 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 11/01/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	08/20/2007

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Facet Joint Procedures for Pain

- Intraarticular (IA) Facet joint Injections
- Medial Branch Blocks (MBB)
- Radiofrequency Ablations (RFA)
- Facet cyst rupture/aspiration

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Facet Joint Interventions for Pain Management (L38803)</a>
Local Coverage Article (LCA)	<a href="#">Billing and Coding: Facet Joint Interventions for Pain Management (A58405)</a>

**Effective until May 1, 2025**

#### For Non-Medicare Members

##### Facet Joint Injections

Kaiser Permanente has elected to use coverage guidance from Noridian Local Coverage Determination (LCD) L38803 [Facet Joint Interventions for Pain Management](#) and [Billing and Coding: Facet Joint Interventions for Pain Management \(A58405\)](#) for Diagnostic Facet Joint Procedures, and therapeutic facet joint procedures.

##### Facet Neurotomy

Kaiser Permanente has elected to use the Facet Neurotomy (KP-0218 12202024) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access

**Effective May 1, 2025**

#### For Non-Medicare Members

##### Facet Joint Injections and Facet Neurotomy

Kaiser Permanente has elected to use coverage guidance from Noridian Local Coverage Determination (LCD) L38803 [Facet Joint Interventions for Pain Management](#) and [Billing and Coding: Facet Joint Interventions for Pain Management \(A58405\)](#) for Diagnostic Facet Joint Procedures, and therapeutic facet joint procedures.

#### For covered criteria:

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (including PT notes)



The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Facet joint injections are used to treat specific etiologies of back pain, generally in the absence of radicular symptoms. Some indications for diagnostic facet joint injections include strong suspicion for the pain of facet joint etiology (focal tenderness over the facet joint, pain in response to hyperextension, rotational movement, or conservative management, or low back pain with normal imaging). Given the natural history of these symptoms, it is recommended that conservative treatments are trialed for at least 3 months prior to consideration of facet injections.

Medial branch block injections are also used for evaluating candidacy for possible facet neuropathy. They involve injection of anesthetic near to the medial branch nerves near the facet joint. These are typically used in preparation and for diagnostic purposes prior to a facet neurotomy.

## Medical Technology Assessment Committee (MTAC)

### Back/Neck Pain

#### 07/14/2004: MTAC REVIEW

**Evidence Conclusion: Back Pain** There is insufficient evidence to conclude that RF neurotomy improves health outcomes among patients with back pain. Two of the three RCTs on back pain that were reviewed (LeClaire; Barendse) did not find a significant benefit of RF neurotomy compared to a sham intervention in the primary analysis. Barendse may have been underpowered to detect a clinically significant difference between groups. The third study (van Kleef, 1999), which included patients with low back pain originating from the lumbar zygapophysial joint, found significantly more clinical successes in the RF neurotomy group. The latter study (n=32), which included a multivariate analysis to adjust for baseline differences, had imprecise estimates with large confidence intervals and only an 8-week follow-up period. All of the studies were limited by small sample sizes. In addition, all of the studies used non-blinded diagnostic blocks and there may have been false positive findings of the location of pain. Long-term safety and efficacy of RF neurotomy for treating back pain was not evaluated.

**Evidence Conclusion: Neck pain** There is insufficient evidence to conclude that RF neurotomy improves health outcomes among patients with neck pain. One of the two RCTs reviewed (Lord) was well designed but had a biased presentation of study results. The authors did not report their primary outcomes, pain and impact of pain on activities of daily living, at the end of the double-blind follow-up period at 3 months. The results they did report were confounded by rescue treatment. The other RCT (van Kleef, 1996) found a significant benefit of RF neurotomy compared to sham intervention for patients with cervicobrachial pain. The study is limited by its short (8-week) follow-up period and small sample size (n=20), which can result in baseline differences between groups. Also, the van Kleef, 1996 study used non-blinded diagnostic blocks and some patients may have been falsely identified with cervicobrachial pain. Long-term safety and efficacy of RF neurotomy for treating neck pain was not evaluated.

**Articles:** The search yielded 23 articles. There was a Cochrane library review from 2003 that reviewed the randomized controlled trials on the topic but did not conduct a quantitative meta-analysis to evaluate the overall effectiveness of the treatment. Seven double-blind sham-controlled RCTs met the inclusion criteria for the Cochrane review. One additional small RCT published after the Cochrane review was identified in the Medline search, but this study was excluded because the patient population had already failed intradiscal electrothermal annuloplasty (IDET). The Cochrane investigators assigned a methodological quality score to each RCT they included. Studies that received a quality score of at least 7 out of 10 were selected for this review. The LeClaire and Barendse articles were by the same research groups but included different study populations. **Back pain:** There were four RCTs on the treatment of back pain. One RCT that had a low methodology score in the Cochrane review was not reviewed. The remaining three RCTs were critically appraised: LeClaire R, Fortin L, Lambert R et al. Radiofrequency facet joint denervation in the treatment of low back pain. *Spine* 2001; 26: 1411-1418. See [Evidence Table](#) van Kleef M, Barendse GAM, Kessels A et al. Randomized trial of radiofrequency



lumbar facet denervation for chronic low back pain. *Spine* 1999; 24: 1937-1942. See [Evidence Table](#) Barendse GAM, van den Berg SGM, Kessels AHF et al. Randomized controlled trial of percutaneous intradiscal radiofrequency thermocoagulation for chronic discogenic back pain. *Spine* 2001; 26: 287-292. See [Evidence Table](#) Lord SM, Barnsley L, Wallis BJ et al. Percutaneous radio-frequency neurotomy for chronic cervical zygapophyseal-joint pain. *N Engl J Med* 1996; 335: 1721-1726. See [Evidence Table](#)

The use of radiofrequency neurotomy in the treatment of chronic neck and back pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 07/29/2005: MTAC REVIEW

### Back Pain/Neck Pain

**Evidence Conclusion:** A PubMed search (2004 to present) yielded 6 articles. Four were review articles and one was a study of electrode placement, not effectiveness. There was one new RCT (Stovner et al. Cephalalgia 2004; 24: 821). The study was not worth critically appraising because it only included 12 patients. It did not find a significant benefit of radiofrequency neurotomy vs. sham treatment for neck pain, but they almost certainly did not have sufficient statistical power.

This review was not taken to the Medical Technology Assessment Committee. The information was not sufficient to warrant a review by the committee.

## References

Centers for Medicare & Medicaid Services. (2022, February). *Facet Joint Interventions for Pain Management*. (L38803). Accessed Oct 23, 2024. <https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38803&ver=12&keyword=medial+branch+block&keywordType=starts&areald=s56&docType=NCA%2CCAL%2CNCD%2CMEDCAC%2CTA%2CMCD%2C6%2C3%2C5%2C1%2CF%2CP&contractOption=all&sortBy=relevance&bc=1>

## Applicable Codes

### Facet Injections & Medial Branch Block

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPCS Codes	Description
64490	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level
64491	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure)
64492	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
64493	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level
64494	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)
64495	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)
77003	Fluoroscopic guidance and localization of needle or catheter tip for spine or paraspinal diagnostic or therapeutic injection procedures (epidural or subarachnoid) (List separately in addition to code for primary procedure)

### Facet Neurotomy

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>64633</b>	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint
<b>64634</b>	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, each additional facet joint (List separately in addition to code for primary procedure)
<b>64635</b>	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint
<b>64636</b>	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, each additional facet joint (List separately in addition to code for primary procedure)

### **Paravertebral Injections**

**Considered Not Medically Necessary - experimental, investigational or unproven:**

CPT® or HCPCS Codes	Description
<b>0213T</b>	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level
<b>0214T</b>	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)
<b>0215T</b>	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)
<b>0217T</b>	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)
<b>0218T</b>	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/07/2023	03/07/2023 <sup>MPC</sup> , 08/06/2024 <sup>MPC</sup>	04/21/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/07/2023	MPC approved to adopt Medicare criteria for non-Medicare members. Requires 60-day notice, effective date 08/01/2023.
7/12/2023	Updated effective date to 8/14/2023
12/7/2024	MPC approved to adopt CMS coverage criteria for Facet Neurotomy. 60-day notice required. Effective 5/1/2025
12/17/2024	Merged RFA Facet neurotomy with Facet injections policy.
04/21/2025	Updated criteria to reflect KPWA's adoption of NCD L8803 and A58405 for facet joint diagnostics effective 5/1/25.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Fertility Services

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

### Non-Medicare Members

Referrals to Reproductive Endocrinology and Infertility (REI) specialists and associated services are not covered as a base benefit and are only eligible for coverage when the member has a sterility and infertility (SI) rider or other evidence of coverage in their contract. **When a Sterility/Infertility (SI) rider is present, initial consultation with an REI specialist is covered without additional criteria review. However, tests and procedures are subject to clinical criteria (as elaborated below).**

Please note that individual riders/contracts may vary in benefit design either excluding or waiving criteria for some services. These may include, but are not limited to, fertility-promoting medications, medications for erectile dysfunction, artificial insemination, in vitro fertilization, long-term cryopreservation, surrogacy services and tubal reanastomosis. The member's rider/contract should be reviewed before making a final coverage determination and supersedes clinical review criteria.

Reproductive services are also subject to lifetime coverage limits which vary by rider/contract and service category.

### Exclusions

*Unless otherwise stated in the members rider/contract, the following services are not covered*

- Reproductive services after voluntary sterilization of a male or female partner (e.g., tubal ligation, vasectomy), including tubal reanastomosis, vas reanastomosis, sperm extraction, artificial insemination and in vitro fertilization
- Long-term cryopreservation (i.e., apart from real-time efforts to conceive)
- Costs related to donor genetic material used for artificial insemination or invitro fertilization
- Services for the purpose of surrogacy
- Routine use of pre-implantation genetic testing (with IVF); medical necessity criteria for pre-implantation genetic testing can be found in a separate clinical criteria - see PGD criteria [here](#)

**The following services are subject to clinical review criteria unless the services have been specifically excluded or the criteria has been waived in the member's rider/contract.**

<b>Definition of Infertility</b>	<p>The definition of infertility is used to determine eligibility for infertility workup (e.g., diagnostic laboratory or imaging studies) apart from other reproductive services enumerated below.</p> <p>Based on Kaiser Permanente policy, a member is considered infertile if they are unable to conceive or produce conception:</p> <ul style="list-style-type: none"> <li>• Inability to achieve conception after frequent unprotected heterosexual intercourse lasting 12 months for members under 35 years of age or 6 months for members 35 years of age and older</li> <li>• Inability to achieve conception after 6 cycles of artificial insemination (of which at least 3 cycles must be medically supervised) for members under 35 years of age or 3 cycles of medically supervised artificial insemination for members 35 years of age and older</li> <li>• A member is not considered “infertile” if they have had a voluntary sterilization (e.g., tubal ligation, vasectomy)</li> </ul> <p><i>*Some members may be eligible for reproductive services without meeting the definition of infertility. Please refer to specific criteria listed below.</i></p>
<b>Pharmaceutical Therapy to Promote Fertility</b>	<ul style="list-style-type: none"> <li>• Both oral and injectable medications to promote ovulation for the purpose of fertility require evidence of coverage (SI rider or contract language) and are covered under the pharmacy benefit subject to any applicable prior auth requirements.</li> <li>• Medications for erectile dysfunction are not covered under this policy but may or may not be covered under the pharmacy benefit subject to any applicable prior auth requirements.</li> </ul>
<b>Artificial insemination (AI)</b>	<p>AI including intravaginal, intracervical, and intrauterine insemination techniques and associated medications, laboratory, imaging, and procedure codes may be covered for the purpose of conception. This includes hysterosalpingogram that would confirm tubal patency necessary for the success of such techniques. Members are eligible for coverage when they have a SI rider that does not specifically exclude these services, have not exceeded their lifetime maximum and meet <b>ONE OR MORE</b> of the following criteria:</p> <ul style="list-style-type: none"> <li>• Natal female member without a male partner (applies to single members and same-sex female couples)</li> <li>• Natal female member’s male partner is unable to participate in natural insemination due to a physical condition. Erectile dysfunction responsive to medical therapy is excluded even when such medication is not a covered benefit.</li> <li>• Inability to achieve conception after frequent unprotected heterosexual intercourse lasting 12 months for members under 35 years of age or 6 months for members 35 years of age and older</li> <li>• Documentation of an infectious disease that would make unprotected heterosexual intercourse unsafe according to the medical opinion of the member’s treating clinician</li> <li>• Documentation of a heritable genetic trait in the male partner (such as an autosomal dominant trait in the male or co-occurrence of an autosomal recessive trait in both partners)</li> </ul>

	would jeopardize the future health of naturally inseminated offspring according to the medical opinion of the member's treating clinician and the member intends to use donor genetic material that does not pose the same risk
<b>In Vitro Fertilization (IVF)</b>	<p>IVF techniques including egg retrieval, fertilization, short-term storage, implantation and associated medications, laboratory, imaging, and procedure codes are eligible for coverage when the member has an SI rider that does not specifically exclude these services, has not exceeded their lifetime maximum and meets <b>ONE OR MORE</b> of the following criteria:</p> <ul style="list-style-type: none"> <li>• Inability to achieve conception after frequent unprotected heterosexual intercourse lasting 12 months for members under 35 years of age or 6 months for members 35 years of age and older</li> <li>• Presence of previously diagnosed male-factor infertility that is reasonably expected to prevent conception (with heterosexual intercourse or artificial insemination). Mild to moderately reduced sperm count and/or motility are not included.</li> <li>• Inability to achieve conception after 6 cycles of artificial insemination (of which at least 3 cycles must be medically supervised) for members under 35 years of age or 3 cycles of medically supervised artificial insemination for members 35 years of age and older</li> <li>• Presence of previously diagnosed female factor infertility that is reasonably expected to prevent conception with heterosexual intercourse or artificial insemination (e.g., fallopian tubes are not patent)</li> <li>• Member has coverage and meets criteria for <a href="#">Preimplantation Genetic Testing</a></li> </ul>
<b>Surgical Procedures of the Fallopian Tube(s) to Promote Fertility</b>	<p>Surgical therapy of the fallopian tube(s) to promote fertility may be covered when the patient has an SI rider or evidence of coverage in their contract and meets <b>ALL</b> of the following criteria:</p> <ul style="list-style-type: none"> <li>• Member meets the definition of infertility above</li> <li>• Imaging (HSG) confirms scarring of the fallopian tube(s) or the patient has undergone prior surgery of the fallopian tube(s) not for the purpose of voluntary sterilization (e.g. ectopic tubal pregnancy)</li> <li>• The member intends to become pregnant once tubal patency is re-established</li> <li>• The member has not had a voluntary tubal ligation for the purpose of sterilization</li> </ul>

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background



Infertility is a common problem. According to the Centers for Disease Control and Prevention (CDC), about 10 percent of U.S. women ages 15 through 44 years have difficulty getting pregnant or staying pregnant.<sup>1</sup>

Both women and men can have problems that cause infertility. About one-third of infertility cases can be connected to the woman. Another third of the cases of infertility can be connected to the man. In the remainder of instances, a cause can't be found.

## Applicable Codes

Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<i><b>Diagnostic services to Evaluate Potential Infertility</b></i>	
<b>54500</b>	Biopsy of testis, needle (separate procedure)
<b>54505</b>	Biopsy of testis, incisional (separate procedure)
<b>54800</b>	Biopsy of epididymis, needle
<b>55200</b>	Vasotomy, cannulization with or without incision of vas, unilateral or bilateral (separate procedure)
<b>55300</b>	Vasotomy for vasograms, seminal vesiculograms, or epididymograms, unilateral or bilateral
<b>55550</b>	Laparoscopy, surgical, with ligation of spermatic veins for varicocele
<b>58340</b>	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography
<b>58345</b>	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography
<b>58350</b>	Chromotubation of oviduct, including materials
<b>58540</b>	Hysteroplasty, repair of uterine anomaly (Strassman type)
<b>58560</b>	Hysteroscopy, surgical; with division or resection of intrauterine septum (any method)
<b>58700</b>	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)
<b>58740</b>	Lysis of adhesions (salpingolysis, ovariolysis)
<b>58752</b>	Tubouterine implantation
<b>58770</b>	Salpingostomy (salpingoneostomy)
<b>58920</b>	Wedge resection or bisection of ovary, unilateral or bilateral
<b>74740</b>	Hysterosalpingography, radiological supervision and interpretation
<b>76831</b>	Saline infusion sonohysterography (SIS), including color flow Doppler, when performed
<b>89300</b>	Semen analysis; presence and/or motility of sperm including Huhner test (post coital)
<b>89310</b>	Semen analysis; motility and count (not including Huhner test)
<b>89320</b>	Semen analysis; volume, count, motility, and differential
<b>89321</b>	Semen analysis; sperm presence and motility of sperm, if performed
<b>89322</b>	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (eg, Kruger)
<b>89325</b>	Sperm antibodies
<b>89329</b>	Sperm evaluation; hamster penetration test
<b>89330</b>	Sperm evaluation; cervical mucus penetration test, with or without spinnbarkeit test
<b>89331</b>	Sperm evaluation, for retrograde ejaculation, urine (sperm concentration, motility, and morphology, as indicated)
<b>G0027</b>	Semen analysis; presence and/or motility of sperm excluding Huhner
<b>Q0115</b>	Postcoital direct, qualitative examinations of vaginal or cervical mucous
<b>S3655</b>	Antisperm antibodies test (immunobead)

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b><i>Intrauterine Insemination (ICI/IUI)</i></b>	
<b>58321</b>	Artificial insemination; intra-cervical
<b>58322</b>	Artificial insemination; intra-uterine
<b>58323</b>	Sperm washing for artificial insemination
<b>89260</b>	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis
<b>89261</b>	Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
<b>89268</b>	Insemination of oocytes
<b>S4035</b>	Stimulated intrauterine insemination (IUI), case rate
<b><i>Advanced Reproductive/Fertilization Services (IVF)</i></b>	
<b>58970</b>	Follicle puncture for oocyte retrieval, any method
<b>58974</b>	Embryo transfer, intrauterine
<b>76948</b>	Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation
<b>89250</b>	Culture of oocyte(s)/embryo(s), less than 4 days;
<b>89251</b>	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos
<b>89253</b>	Assisted embryo hatching, microtechniques (any method)
<b>89254</b>	Oocyte identification from follicular fluid
<b>89255</b>	Preparation of embryo for transfer (any method)
<b>89257</b>	Sperm identification from aspiration (other than seminal fluid)
<b>89258</b>	Cryopreservation; embryo(s)
<b>89259</b>	Cryopreservation; sperm
<b>89264</b>	Sperm identification from testis tissue, fresh or cryopreserved
<b>89272</b>	Extended culture of oocyte(s)/embryo(s), 4-7 days
<b>89335</b>	Cryopreservation, reproductive tissue, testicular
<b>89337</b>	Cryopreservation, mature oocyte(s)
<b>89352</b>	Thawing of cryopreserved; embryo(s)
<b>89353</b>	Thawing of cryopreserved; sperm/semen, each aliquot
<b>89354</b>	Thawing of cryopreserved; reproductive tissue, testicular/ovarian
<b>89356</b>	Thawing of cryopreserved; oocytes, each aliquot
<b>S4011</b>	In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
<b>S4015</b>	Complete in vitro fertilization cycle, not otherwise specified, case rate
<b>S4016</b>	Frozen in vitro fertilization cycle, case rate
<b>S4017</b>	Incomplete cycle, treatment cancelled prior to stimulation, case rate
<b>S4018</b>	Frozen embryo transfer procedure cancelled before transfer, case rate
<b>S4020</b>	In vitro fertilization procedure cancelled before aspiration, case rate
<b>S4021</b>	In vitro fertilization procedure cancelled after aspiration, case rate
<b>S4027</b>	Storage of previously frozen embryos
<b>S4028</b>	Microsurgical epididymal sperm aspiration (MESA)
<b>S4030</b>	Sperm procurement and cryopreservation services; initial visit
<b>S4031</b>	Sperm procurement and cryopreservation services; subsequent visit
<b>S4037</b>	Cryopreserved embryo transfer, case rate
<b>S4040</b>	Monitoring and storage of cryopreserved embryos, per 30 days
<b><i>Zygote Intra-Fallopian Transfer (ZIFT)</i></b>	
<b>58976</b>	Gamete, zygote, or embryo intrafallopian transfer, any method
<b>S4014</b>	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate
<b><i>Gamete Intra-Fallopian Transfer (GIFT)</i></b>	
<b>S4013</b>	Complete cycle, gamete intrafallopian transfer (GIFT), case rate
<b><i>Intracytoplasmic Sperm Injection (ICSI); or Ovum Microsurgery</i></b>	
<b>55870</b>	Electroejaculation
<b>89280</b>	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes
<b>89281</b>	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes
<b><i>Sterilization Reversal Services</i></b>	

<b>55400</b>	Vasovasostomy, vasovasorrhaphy
<b>58750</b>	Tubotubal anastomosis
<b>58760</b>	Fimbrioplasty
<b>58672</b>	Laparoscopy, surgical; with fimbrioplasty
<b>58673</b>	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)

**Considered Not Covered:**

*Unless otherwise stated in the members rider/contract, the following services are generally not covered*

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>89342</b>	Storage (per year); embryo(s)
<b>89343</b>	Storage (per year); sperm/semen
<b>89344</b>	Storage (per year); reproductive tissue, testicular/ovarian
<b>89346</b>	Storage (per year); oocyte(s)
<b>S4023</b>	Donor egg cycle, incomplete, case rate
<b>S4025</b>	Donor services for in vitro fertilization (sperm or embryo), case rate
<b>S4026</b>	Procurement of donor sperm from sperm bank

\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS)

<b>Creation Date</b>	<b>Review Date</b>	<b>Date Last Revised</b>
1/25/2019	02/05/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	08/22/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
02/05/2019	MPC approved to adopt coverage for KP I&F and SBG plans
06/04/2019	Added SEIU has no requirements regarding: age, duration of time, or gender per SEIU contract
05/05/2020	Information regarding the SI-AO rider for SIEU cryopreservation (Effective 8/1/2020) was added
01/04/2022	Added definition of infertility from KP policy document. Listed groups that are no longer requiring a diagnosis of infertility for members to access benefit as of 01/01/2022.
12/16/2022	Updated criteria to include indication for, “A member is not considered “infertile” if they have had a voluntary sterilization.”
06/06/2023	MPC approved to adopt the proposed changes to Fertility Services criteria definition of infertility with additional indications for AI and IVF. Renamed title of criteria to “Fertility Services” (formerly Infertility Services). Requires 60-day notice, effective 11/1/2023.
8/22/2023	Updated applicable codes

## Clinical Review Criteria

### Hip Surgery Procedures for Femoroacetabular Impingement Syndrome

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Kaiser Permanente Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Hip Surgery Procedures for Femoroacetabular Impingement Syndrome</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

### For Non-Medicare Members

Service	Criteria
Hip surgery for labral tear repair	Labral repair (29916) alone does not require review. When a diagnosis of labral tear has been confirmed with imaging, FAI procedures (29914 and/or 29915) may be covered as part of the repair.
Hip surgery procedures for Femoroacetabular impingement Syndrome (FAI)	<p>Femoroacetabular impingement (FAI) may be medically necessary in skeletally mature patients when all of the following criteria are met:</p> <ul style="list-style-type: none"> <li>Mechanical symptoms of the hip (e.g., catching, locking, or giving way) associated with moderate-to-severe, groin-dominant hip pain with duration of at least 6 months that is worsened by flexion activities (e.g., squatting or prolonged sitting) and significantly limits activities.</li> <li>Documentation of <b>one or more</b> of the following positive provocative tests for intra-articular hip pathology on physical examination: <ul style="list-style-type: none"> <li>a. Anterior impingement sign (i.e., hip or groin pain with forced hip flexion, adduction, and internal rotation)</li> <li>b. FABER test (i.e., hip or groin pain with forced flexion, abduction, and external rotation).</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>c. Fitzgerald test (i.e., hip or groin pain with extension, internal rotation, and adduction from forced hip flexion, abduction, and external rotation or with extension, external rotation, and abduction from forced hip flexion, adduction, and internal rotation)</li> <li>▪ Imaging (X-rays, MRI or CT scans) confirms <b>one or more</b> of the following:             <ul style="list-style-type: none"> <li>a. cam impingement (alpha angle greater than 50 degrees)</li> <li>b. pincer impingement (acetabular retroversion or coxa profunda) (center edge angle greater than or equal to 40 degrees), or</li> <li>c. pistol grip deformity (non-spherical femoral head shape); <i>and</i></li> </ul> </li> <li>▪ Failure to respond to all available conservative treatment options, or documentation that conservative therapy is contraindicated, including: activity modification (e.g., restriction of athletic pursuits and avoidance of symptomatic motion), pharmacological intervention (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), and physical therapy. The treatment should be for at least 12 weeks in the past year with at least 6 weeks of formal physical therapy.</li> <li>▪ Positive but transient response to an image-guided intra-articular hip injection with local anesthetic with or without corticosteroid.</li> </ul> <p>Presence of one or more of the following is considered a contraindication to FAI procedures:</p> <ul style="list-style-type: none"> <li>▪ Tönnis grade 2 osteoarthritis (i.e., small cysts in femoral head or acetabulum with moderate joint space narrowing [i.e., &lt; 2mm wide on plain radiographs of the pelvis] and moderate loss of femoral head sphericity)</li> <li>▪ Tönnis grade 3 osteoarthritis (i.e., large cysts in the femoral head or acetabulum, severe joint space narrowing [e.g., bone-on-bone] or obliteration of the joint space, and severe deformity and loss of sphericity of the femoral head)</li> <li>▪ Joint space narrowing on plain radiograph of less than 2 mm wide anywhere along the source; <i>and</i></li> <li>▪ Generalized joint laxity especially in diseases connected with hypermobility of the joints, such as Marfan syndrome and Ehlers-Danlos syndrome; <i>and</i></li> <li>▪ Osteogenesis imperfecta.</li> </ul>
--	---

**If requesting review for these services, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Femoroacetabular impingement (FAI) syndrome is a recently recognized diagnosis in primarily younger individuals where relatively minor abnormalities in the joint (orientation or morphology) are thought to cause

friction/impingement and pain. It is theorized that FAI starts the breakdown of cartilage, leading to osteoarthritis. There are two types of FAI: cam impingement (non-spherical femoral head or abnormality at the head-neck junction) and pincer impingement (deep or retroverted acetabulum resulting in over coverage of the femoral head). Proponents believe that surgical correction of the impinging deformities will alleviate the symptoms and retard the progression of OA degeneration. Surgery to correct FAI includes arthroscopy, open dislocation of the hip, and arthroscopy combined with a mini-open approach. The purpose of the surgery is to remove abnormal outgrowths of bone and damaged cartilage, and to reshape the femoral neck to ensure that there is sufficient clearance between the rim of the acetabulum and the neck of the femur.

## Medical Technology Assessment Committee (MTAC)

### Femoroacetabular Impingement Syndrome

#### 06/17/2013: MTAC REVIEW

**Evidence Conclusion:** There is no new evidence that would change or add to the recommendations of the HTA review as regards the conservative or surgical treatment of femoroacetabular impingement. The results of these non-randomized observational studies as well as other published retrospective series with or without a comparison group should be interpreted with caution. Due to the nature of the study design, they are subject to selection bias, observation bias, confounding and other limitations, and only provide the lowest grade of evidence.

**Articles:** Larson CM, Givens R, Stone RM, et al. Arthroscopic debridement versus refixation of the acetabular labrum associated with femoroacetabular impingement. Mean 3.5 –year follow-up. *Am J Sports Med.* 2012; 40:1015-1021. Larson and colleagues (2012) reported on outcomes of two cohorts of patients with femoroacetabular impingement who were treated with either arthroscopic debridement or refixation of the acetabular labrum in one center, but at different time periods. The mean follow-up ranged between 24 and 72 months with a mean of 42 months. The results indicate that the labral fixation was associated with better Harris Hip Scores (HHS), Short Form-12 (SF-12) and visual analog scale (VAS) for pain outcomes compared to arthroscopic focal debridement. Zingg PO, Ulbrich EJ, Buehler TC, et al. Surgical hip dislocation versus hip arthroscopy for femoroacetabular impingement. Clinical and morphological short-term results. *Arch Orthop Trauma Surg.* 2013; 133:69-79. Zingg and colleagues (2013) compared surgical hip dislocation versus hip arthroscopy in 38 patients presenting with clinically FAI that was morphologically verified with plain radiographs and MRI. In 28 of the 38 participants the selection of the procedure was based on the patient's decision, and only 10 agreed to be randomly allocated to either procedure. There were statistically significant differences in the morphological pathology (in terms of acetabular coverage angle, and head-neck offset ratio) between the two groups at baseline. The primary outcome of the study was the alpha angle on a cross-table view. The results of the study showed that patients in the hip arthroscopy group had faster recovery and better short-term outcomes compared to those treated with surgical hip dislocation. However, the hip arthroscopy showed some overcorrection of the cam deformity and limited frequency of labrum refixations, which the authors indicate that they may lead to negative impact on long-term outcomes.

The use of FIS does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

Per the Washington State Health Care Authority Health Technology Clinical Committee (HTCC) coverage determination following Femoroacetabular Impingement Syndrome re-review (adopted 1/17/2020):

*Hip surgery for femoroacetabular impingement syndrome is not a covered benefit.*

## Applicable Codes

**Considered not medically necessary:**

CPT® Codes	Description
27299	Unlisted procedure, pelvis or hip joint
29914	Arthroscopy, hip, surgical; with femoroplasty (i.e., treatment of cam lesion)
29915	Arthroscopy, hip, surgical; with acetabuloplasty (i.e., treatment of pincer lesion)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS



codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/06/2013	02/04/2013 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	07/02/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/06/2017	Adopted KP policy for Medicare members
04/07/2020	Removed generic service code 27299 and added more specific codes 29914, 29915 and 29916
04/29/2020	Added CPT codes 27299 and 29862 and ICD-10 codes M25.851, M25.852 and M25.859
04/26/2021	Removed CPT code 29862 and ICD-10 codes M25.851, M25.852 and M25.859
11/06/2021	Removed CPT code 29916
04/05/2022	Added the Washington Health Care Authority HTCC decision from January 2020.
01/09/2024	MPC approved to revise the FAI policy to allow for FAI procedures to be authorized when a separate procedure for labral repair is indicated. 60-day notice is not required.
07/02/2024	MPC approved the proposed criteria for the FAI procedure to cover with indications. 60-day notice required; effective December 1, 2024.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Foot Care

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">CMS Internet Only Manual (IOM), Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, Section 290</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Wound and Ulcer Care (L38904)</a>
Local Coverage Article	<a href="#">Billing and coding: Routine Foot Care (A57957)</a> <a href="#">Coverage of Foot Care Services (A52918)</a>
Noridian Coverage Resources	<a href="#">Article – Jurisdiction F – Medicare Part B: Podiatry:</a>  Access the below podiatry related information from this page. <ul style="list-style-type: none"> <li>• <a href="#">Conditions that May Justify Foot Care Coverage</a></li> <li>• <a href="#">Exclusions from Foot Care Coverage</a></li> <li>• <a href="#">Foot Care for Patients with Chronic Disease</a></li> <li>• <a href="#">Lower Extremity Wound Care</a></li> <li>• <a href="#">Therapeutic Shoes for Persons with Diabetes: Decision-Making and Ordering</a></li> </ul>

#### For Non-Medicare Members

- I. For the purpose of the Clinical Review Criteria foot care\* is defined as:
  - A. Cutting or removal of corns or calluses;
  - B. Trimming, cutting, clipping, or debriding of nails;
  - C. Other hygienic and preventative maintenance care, such as cleaning and soaking the feet, the use of skin creams to maintain skin tone of either ambulatory or bedfast patients, and any other service performed in the absence of localized illness, injury, or symptoms involving the foot;
  - D. Asymptomatic foot care is not typically a covered service unless certain complications are present. It is not provided more frequently than every 60 days. The criteria below identify when foot care is covered. They are divided into sections of foot care for the asymptomatic and symptomatic foot.
- II. Kaiser Permanente covers foot care services as medically necessary when **EITHER** of the following criteria is met:
  - A. The foot care services that are associated with systemic conditions that are significant enough to result in severe circulatory insufficiency and/or areas of severe desensitization in the lower extremities, including, but not limited to, **ANY** of the following:
    - Marked diabetic neuropathy documented on physical exam\*
    - Peripheral vascular disease\*

- Marked peripheral neuropathy documented on physical exam\*
- Non-traumatic partial amputation of a foot

\*For neuropathies chart must record the physical findings of severe loss of sensation such that non-professional services might pose a danger to the patient. For peripheral vascular disease, the diagnosis and severity must have been confirmed by a vascular surgery evaluation.

- B. In the absence of a systemic condition, treatment of mycotic nails may be covered.
- The treatment of mycotic nails for an **ambulatory** patient is covered only when the physician attending the patient's mycotic condition documents that (1) there is clinical evidence of mycosis of the toenail, and (2) the patient has marked limitation of ambulation, pain, or secondary infection resulting from the thickening and dystrophy of the infected toenail plate.
  - The treatment of mycotic nails for a **non-ambulatory** patient is covered only when the physician attending the patient's mycotic condition documents that (1) there is clinical evidence of mycosis of the toenail, and (2) the patient suffers from pain or secondary infection resulting from the thickening and dystrophy of the infected toenail plate.

### III. Exclusions

- A. General diagnoses such as arteriosclerotic heart disease, circulatory problems, vascular disease, and venous insufficiency are not sufficient to permit coverage of routine foot care. Likewise, incapacitating injuries or illness such as rheumatoid arthritis, CVA, fractured hip and blindness which make trimming the nails difficult, **are not** diagnoses for which routine foot care is payable.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Asymptomatic foot care or routine foot care is usually not covered for members in the absence of localized illness, injury or symptoms involving the foot. Most Kaiser Permanente coverage contracts exclude routine foot care coverage. Kaiser Permanente developed criteria consistent with the Medicare those published by Medicare.

#### *Foot care includes:*

- Cutting or removal of corns or calluses
- Trimming, cutting, clipping, or debriding of nails
- Other hygienic and preventative maintenance care, such as cleaning and soaking the feet, the use of skin creams to maintain skin tone of either ambulatory or bedfast patients, and any other service performed in the absence of localized illness, injury, or symptoms involving the foot.
- Debridement of nails is a procedure that is needed to remove excessive material (reduce thickness and length) from a dystrophic nail but not a non-dystrophic nail. In contrast, trimming of nails is a procedure that may be directed at either type of nail.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
11055	Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); single lesion
11056	Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); 2 to 4 lesions
11057	Paring or cutting of benign hyperkeratotic lesion (eg, corn or callus); more than 4 lesions
11719	Trimming of nondystrophic nails, any number
11720	Debridement of nail(s) by any method(s); 1 to 5
11721	Debridement of nail(s) by any method(s); 6 or more

<b>G0127</b>	Trimming of dystrophic nails, any number
<b>G0247</b>	Routine foot care by a physician of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (LOPS) to include the local care of superficial wounds (i.e., superficial to muscle and fascia) and at least the following, if present: (1) local care of superficial wounds, (2) debridement of corns and calluses, and (3) trimming and debridement of nails
<b>S0390</b>	Routine foot care; removal and/or trimming of corns, calluses and/or nails and preventive maintenance in specific medical conditions (e.g., diabetes), per visit

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
06/27/1997	08/03/2010 <sup>MDCRPC</sup> , 06/07/2011 <sup>MDCRPC</sup> , 04/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 04/04/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	12/05/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/04/2015	Editorial changes were made to criteria
9/1/2015	Changed LCD hyperlink
09/08/2015	Revised LCD L36107 & L34199
06/07/2016	Revised criteria to simplify guidelines
08/06/2019	Criteria revision regarding need for confirmation and documentation from the appropriate vascular surgeon specialist. An amendment was made to II. A. 4. to read "non-traumatic partial amputation of a foot."
02/02/2021	MPC approved to update criteria for routine foot care services and exclusions.
12/05/2024	Removed historical LCD L24356 and L24366 that have had a Retired status for over 10 years and will no longer be displayed on the MCD Archive. Added Noridian Coverage Resources for Podiatry.



## Clinical Review Criteria Gender Affirming Surgeries

## Kaiser Foundation Health Plan of Washington

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Gender Dysphoria and Gender Reassignment Surgery (140.9)</a> . CMS has deferred to the local MAC for decision coverage (Noridian for Washington State. Currently Noridian has no policy as of 04/05/2022)
Local Coverage Determinations (LCD)	None
Local Coverage Article	CAG-00446N- Gender Dysphoria and Gender Reassignment Surgery
Kaiser Permanente Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Gender Affirming Surgeries</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### Self-Funded Groups:

Coverage may vary for members of self-funded groups and may provide additional exclusions – see member's specific contract or contact member services for specific exceptions and limitations.

Self-Funded Group	Policy
For Microsoft employees	See the member's contract for specific coverage details
For Sound Health and Wellness	See <b>Non-Medicare policy</b> below for coverage details, <b>with the exception of the following exclusions:</b> <ul style="list-style-type: none"> <li>• Facial contouring and other facial reconstructive surgeries; and</li> <li>• Procedures including but not limited to hairline advancement and transplantation; and</li> <li>• Body hair removal (<i>except face/neck and preop genital hair removal</i>); and</li> <li>• Voice modification including speech therapy; and</li> <li>• Collagen injections</li> <li>• Liposuction</li> <li>• Abdominoplasty; and</li> <li>• Other cosmetic procedures are not covered services under the plan</li> </ul> <p>Per the <a href="#">Summary of Material Modifications dated March 31, 2023</a></p>
For Washington State Teamsters Trust	See the member's contract for specific coverage details
For King County employees	See the member's contract for specific coverage details. Coverage

	criteria are based on the <a href="#">Standards of Care</a> published by the World Professional Association for Transgender Health.
--	---

### For Non-Medicare Members:

Members must be enrolled in the Kaiser Permanente of Washington Gender Health Case Management Program to qualify for the gender health services benefit. **To be considered in network all *initial* referrals for gender affirming services including surgical consults (excluding GAHT and/or blockers) must be submitted by the Gender Health Case Management team (Not applicable for options patients utilizing out of network benefit. Out of network provider to place referral and request authorization from the health plan).**

## I. Requirements for hair removal to treat gender dysphoria

Kaiser Permanente of Washington will cover hair removal for members with documented gender dysphoria according to the criteria below with a goal of hair removal to align with identified gender. Member can have either electrolysis or laser hair removal or both. The member must work with the Kaiser Permanente of Washington Gender Health Case Manager to ensure prior authorization is obtained for the service and arrange for either insurance billing or member reimbursement for services.

### Procedures:

#### Facial Hair Removal\*

- 16+ with parental consent or 18+ years old **AND**
- Six months of maximally tolerated Gender Affirming Hormone Therapy (GAHT) (including but not limited to antiandrogens such as spironolactone; T blockers such as leuprolide; and hormones such as: estrogen) appropriate to their desired gender, unless medically contraindicated (e.g., GAHT may be contraindicated when not consistent with members gender identity such as non-binary) **OR**
- In testicular bodied patients, testosterone <100 **OR**
- History of orchiectomy

**NOTE:** Hair removal is not covered for members using exogenous testosterone, as hair growth is expected

#### Body Hair Removal\*

- 16+ with parental consent or 18+ years old **AND**
- Taking Gender Affirming Hormone Therapy (GAHT) (including but not limited to antiandrogens such as spironolactone; T blockers such as leuprolide; and hormones such as: estrogen) appropriate to their desired gender, for 2-3 years unless medically contraindicated (e.g., GAHT may be contraindicated when not consistent with members gender identity such as non-binary) **AND**
- In testicular bodied patients, testosterone <100 **OR**
- History of orchiectomy

**NOTE:** Hair removal is not covered for members using exogenous testosterone, as hair growth is expected

**Preoperative hair removal for genital reconstructive surgery – as indicated based on surgical plan, see element IV below.**

Note: Patients who have not had gender reassignment surgery (gonadectomy or vaginoplasty) should continue hormone/anti-androgen therapy unless contraindicated during and after hair removal to prevent recurrence.

## II. **Mastectomy** (i.e., initial mastectomy, with nipple sparing or tattooing) for members assigned female at birth.

Plastic Surgery credentials are preferred for Mastectomy. Mastectomy may be medically necessary when **ALL of the following** criteria are met:

- Age 18 years or older (Note: age requirement will not be applied to mastectomy for members assigned female at birth if the surgeon, the primary care provider, and the qualified mental health professional unanimously document the medical necessity of earlier intervention)
- Single letter of referral from a qualified mental health professional\*\* within the past 18 months; and the letter



should include:

- i. Gender incongruence is marked and sustained;
  - ii. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
  - iii. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
  - iv. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
  - v. Other possible causes of apparent gender incongruence have been identified and excluded;
  - vi. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- C. The health plan may require a second opinion regarding the patient's stability prior to surgery if in question.
- D. Stable on their gender affirming hormonal treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated). **Note:** a trial of hormone therapy is not a pre-requisite to qualifying for a mastectomy for members.
- E. Patient has already undergone social transition\*\*\* or has a plan to do so after surgery

III. **Breast augmentation** for members assigned male at birth. Plastic Surgery credentials are preferred for Breast Augmentation. Breast Augmentation may be medically necessary when **ALL of the following** criteria are met:

- A. Age 18 years or older (Note: age requirement will not be applied to augmentation for members assigned male at birth if the surgeon, the primary care provider, and the qualified mental health professional unanimously document the medical necessity of earlier intervention)
- B. Single letter of referral from a qualified mental health professional\*\* within the last 18 months; and this letter should include:
- i. Gender incongruence is marked and sustained;
  - ii. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
  - iii. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
  - iv. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
  - v. Other possible causes of apparent gender incongruence have been identified and excluded;
  - vi. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- C. The health plan may require a second opinion regarding the patient's stability prior to surgery if in question; and
- D. **Effective until July 1, 2025**  
Stable on their gender affirming hormonal treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated) and

**Effective July 1, 2025**

Stable on their gender affirming hormonal treatment and 12 months of therapy with oral estrogen, unless medically contraindicated, has failed to result in breast tissue development in the range typical for adult cis-gendered women. Typical breast development includes the presence of breast mounds which extend beyond the circumference of the areolae with or without secondary breast mound formation beneath the areolae. Hypomastia alone does not meet medical necessity for breast augmentation when breast development is within the expected range of cis-gendered women.

- E. Patient has already undergone social transition\*\*\* or has a plan to do so after surgery  
The criteria above apply for only initial augmentation mammoplasty for members assigned male at birth, any additional breast augmentation after an initial mammoplasty is considered a cosmetic procedure, and

therefore, a contract exclusion.

- IV. **Gonadectomy (hysterectomy, oophorectomy or orchiectomy) and Genital Reconstructive Surgery** including, but not limited to: vaginectomy, vulvectomy, colpocleisis, colpectomy, metoidioplasty, vaginoplasty, perineoplasty, colovaginoplasty, penectomy, clitoroplasty, labioplasty, phalloplasty, scrotoplasty, urethroplasty, testicular prosthesis (expanders and implants), penile prosthesis, hair removal in the pubic surgical area for members assigned male at birth, hair removal on the forearm prior to phalloplasty for members assigned female at birth, mons resection. Plastic Surgery, Urology and/or Gynecology Credentials are preferred for genital reconstructive surgery. Genital reconstructive surgery may be medically necessary when **ALL of the following** criteria are met :
- A. Age 18 years and older; and
  - B. One referral letter from a qualified mental health professional\*\* within the last 18 months; and this letter should include:
    - i. Gender incongruence is marked and sustained;
    - ii. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
    - iii. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
    - iv. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
    - v. Other possible causes of apparent gender incongruence have been identified and excluded;
    - vi. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
  - C. The health plan may require a second opinion regarding the patient's stability prior to surgery if in question; and
  - D. Stable on their gender affirming hormonal treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated); and
  - E. Twelve months of living in a gender role that is congruent with their gender identity (real life experience) Patient has undergone social transition\*\*\* and has been living in gender congruent identity for at least twelve months

**Note: Orchiectomy procedure may be subject to [Elective Surgical Procedures Level of Care](#) review in addition to the above clinical criteria being met.**

- V. **Gender affirming voice modification surgery**
- Otolaryngology credentials are preferred for gender affirming voice modification surgery. Gender affirming voice modification surgery may be medically necessary when the following criteria are met:
- A. Pitch lowering surgery (e.g., Type III thyroplasty) is considered medically necessary if the voice fails to deepen below speaking F0 150Hz after 1.5 years of consistent masculinization hormone therapy
- OR**
- B. Pitch elevation surgery is considered medically necessary when speaking  $F_0 < 150\text{Hz}$
- AND**
- A. **ALL of the following** are met:
    - i. Age 18 years of age or older
    - ii. The health plan may require a second opinion regarding the patient's stability prior to surgery if in question; and
    - iii. Patient has already undergone social transition\*\*\* or has a plan to do so after surgery
    - iv. Stable on their gender affirming hormonal treatment regime (which may include at least 6 months of hormone treatment or a longer period if required to achieve the desired surgical result, unless hormone therapy is either not desired or is medically contraindicated)
    - v. Single letter of referral from a qualified mental health professional\*\* in support of the requested procedure(s) in the last 18 months; and the letter should include:
      - Gender incongruence is marked and sustained;
      - Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical

- intervention in regions where a diagnosis is necessary to access health care;
- Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
- Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
- Other possible causes of apparent gender incongruence have been identified and excluded;
- Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- vi. Established with a Speech Language Pathologist (SLP) with experience working with Transgender patients for voice therapy and has engaged with voice therapy techniques with consistent follow-up, documented as attendance at  $\geq 75\%$  of sessions for at least 6 months
- vii. Voice/speech therapy has been ineffective – member has ongoing voice complaints including inability to reliably maintain speaking F0 above 150 Hz (feminizing) or speaking F0 below 150Hz (masculinizing)
- viii. Member agrees to follow-up post-operatively with their surgeon and voice therapist/SLP on a regular cadence (1 week, 1 month, 3 months, 6 months, 1 year, 2 years, etc.)
- ix. Patient has none of the following contraindications:
  - No active laryngeal pathology, except for muscle tension
  - No medical diagnoses that would impair wound healing
  - No medical diagnoses that would seriously impair breathing or swallowing
  - No planned upcoming surgeries within 2 months after pitch modification surgery

VI. **Gender affirming facial surgery**– Plastic Surgery, Otolaryngology, or Occuplastics (in the case of blepharoplasty) credentials are preferred for gender affirming facial surgery. Gender affirming facial surgery may be medically necessary when **ALL of the following** criteria are met

- A. Member is at least 18 years old; and
- B. One referral letter from a qualified mental health professional\*\* in the last 18 months; and this letter should include:
  - i. Gender incongruence is marked and sustained
  - ii. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
  - iii. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
  - iv. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
  - v. Other possible causes of apparent gender incongruence have been identified and excluded;
  - vi. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- C. Twelve months of living in a gender role that is congruent with their gender identity (real life experience) Patient has undergone social transition\*\*\* and has been living in gender congruent identity for at least twelve months

With regard to requested gender affirming facial surgery– must meet **ALL** of the following:

- D. For each requested procedure, documentation from an ABMS board-certified facial surgeon (Facial Plastic Surgery, Plastic Surgery, or Oral Maxillofacial Surgery) that the member experiences dysphoria specifically associated with that facial element is required (e.g., documentation of dysphoria related to a stereotypically masculine nose for a requested rhinoplasty); AND
- E. The goal of each procedure is to alter or reshape the facial feature to an appearance that is within the range of normal for the member's identified gender, as determined by an ABMS board-certified facial surgeon (Facial Plastic Surgery, Plastic Surgery, or Oral Maxillofacial Surgery)

Procedures for gender affirming facial surgery may include (but are not limited to): mandible contouring, brow lift, and forehead reduction, layrngochrondroplasty among others. See below for a list of common procedures\* which may or may not be covered for a particular patient.

Procedures intended solely to reduce the appearance of aging that will not result in significant improvement of

the condition being treated are considered not medically necessary.

\*Procedures considered for gender affirming facial surgery when medical necessity criteria in the applicable policy statement listed above are met – this list represents common procedures; others will be reviewed on a case-by-case basis:

*Typically covered:*

- Brow lift
- Hairline advancement
- Lip lift
- Mandible contouring
- Forehead reduction and contouring
- Tracheal Shave

*Sometimes covered:*

- Rhinoplasty

*Typically not covered:*

- Blepharoplasty
- Lip augmentation
- Cheek implants
- Facelift

## VII. **Gender affirming body contouring procedures**

*Plastic Surgery credentials are preferred for gender affirming body contouring. Gender affirming body contouring may be medically necessary when **ALL of the following** criteria are met:*

- A. Age 18 years or older
- B. Single letter of referral from a qualified mental health professional\*\* within the last 18 months ; and this letter should include:
  - i. Gender incongruence is marked and sustained;
  - ii. Meets diagnostic criteria for gender incongruence prior to gender-affirming surgical intervention in regions where a diagnosis is necessary to access health care;
  - iii. Demonstrates capacity to consent for the specific gender-affirming surgical intervention;
  - iv. Understands the effect of gender-affirming surgical intervention on reproduction and they have explored reproductive options;
  - v. Other possible causes of apparent gender incongruence have been identified and excluded;
  - vi. Mental health and physical conditions that could negatively impact the outcome of gender-affirming surgical intervention have been assessed, with risks and benefits have been discussed;
- C. Twelve months of living in a gender role that is congruent with their gender identity (real life experience). Patient has undergone social transition\*\*\* and has been living in gender congruent identity for at least twelve months.
- D. The request is for gender-affirming body contouring performed by a surgeon with experience in gender health to target areas that affect gender perception for **ONE of the following**:
  - i. For patients on the transmasculine spectrum, this includes liposuction to the hips and thighs; OR
  - ii. For patients on the transfeminine spectrum, this includes liposuction to the waist, sides and back of your abdomen (flanks). There may also be fat grafting to the hips and buttock
- E. Unless medically contraindicated, the patient has completed at least 12 months of continuous hormone therapy as appropriate to the members gender goals, to allow stable body fat redistribution to occur
- F. Patient has a stable BMI between 20-30, as surgery is most likely to be successful in this BMI range
- G. The request is not to alter/augment the appearance of body areas that are within the normal range for the patient's gender identity (using implants or fat transfer)
- H. The request is not for cosmetic purposes only - procedure must affirm gender identity
- I. The request is not for liposuction to the belly or flanks alone as this is considered a cosmetic procedure
- J. The request is not for any areas that require skin removal. Some procedures that require skin removal are considered cosmetic. They are not related to gender identity and are not gender-affirming body contouring procedures. Examples include:
  - Abdominoplasty ("tummy tuck")
  - Brachioplasty (arm lift)
  - Thigh Lift

VIII. The following Procedures are **not covered** as part of this benefit:

- Abdominoplasty
- Calf implants
- Collagen injections

K. Cryopreservation of fertilized embryos

- Drugs for hair loss or growth
- Facials
- Hair implant
- Mastopexy
- Neck tightening
- Pectoral implants
- Reversal of prior genital surgery or reversal of surgery to revise secondary sex characteristics
- Sperm preservation in advance of hormone treatment or gender surgery
- Ultrasonic Assisted Lymphatic Massage
- All other cosmetic procedures that do not meet medical necessity

**\*\*Characteristics of a Qualified Mental Health Professional for:**

1. Master's degree or equivalent in a clinical behavioral science field granted by an institution accredited by the appropriate national accrediting board. The professional should also have documented credentials from the relevant licensing board or equivalent; and
2. Competence in using the Diagnostic Statistical Manual of Mental Disorders and/or the International Classification of Disease for diagnostic purposes; and
3. Ability to recognize and diagnose co-existing mental health concerns and to distinguish these from gender dysphoria;
4. Knowledgeable about gender nonconforming identities and expressions, and the assessment and treatment of gender dysphoria; and
5. Continuing education in the assessment and treatment of gender dysphoria. This may include attending relevant professional meetings, workshops, or seminars; obtaining supervision from a mental health professional with relevant experience; or participating in research related to gender nonconformity and gender dysphoria.

**\*\*\*Social Transition:** (e.g., name change, pronoun change, communication of affirmed gender identity to others) in place or judged by clinician to be unnecessary (e.g., nonbinary gender identity). This requirement is based on evidence of mental health benefits from social transition and lack of evidence to support gender affirming surgical therapy in the absence of social transition. Coverage may still be considered after additional mental health evaluation and/or explanation of not pursuing social transition.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Gender Dysphoria refers to discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth. Gender dysphoria is only experienced by some gender-nonconforming people.

Transgender individuals usually present to the medical profession with a sophisticated understanding of their identity, and a desired course of treatment, including hormone therapy and potentially gender-realignment surgery. The therapeutic approach to gender dysphoria consists of three elements: hormones, real life experience and, finally, surgery for some patients.

The use of hormone therapy and surgery for gender transition/affirmation is based on many years of experience treating transgender people. Research on hormone therapy is providing us with more and more information on the safety and efficacy of hormone therapy, but all of the long-term consequences and effects of hormone therapy may not be fully understood. Therefore, a careful diagnosis, differential diagnosis, and exploration of identity is absolutely vital to the patient's best interest and the patient provider relationship. A vital part of the long-term

diagnostic therapy is the so-called real-life experience, in which the patient lives as a member of the desired gender continually and in all social spheres in order to accumulate necessary experience.

Hormone therapy and gender-realignment surgery are superficial changes in comparison to the major psychological adjustments necessary in affirming gender identity. One aspect of treatment should concentrate on the psychological adjustment, with hormone therapy and gender-realignment surgery being viewed as confirmatory procedures dependent on adequate psychological adjustment. Many providers and organizations are moving to an informed consent model for hormones, but surgery still needs involvement of psychology and psychiatry. Psychiatric care may need to be continued for many years after gender-realignment surgery. The overall success of treatment depends partly on the technical success of the surgery, but more crucially on the psychological adjustment of the patient, and the support from family, friends, employers and the medical profession.

## Evidence and Source Documents

There was no evidence review conducted for these criteria. They were developed in response to the Washington State RCW for the coverage of gender affirming services.

## Interregional New Technologies Committee

### *Voice Surgery for Transgender Females*

INTC Review: June 4, 2021

#### Evidence Conclusion:

The body of evidence evaluating the effectiveness and safety of voice surgery in transgender women (male-to-female) is very low-quality. For efficacy, outcomes demonstrated benefit for acoustic measures, and quality of life/patient satisfaction. For safety, very few complications were reported, and none were major or life-threatening. However, it is difficult to draw definitive conclusions because the majority of studies are methodologically poor, with high risk of bias, and the confidence in the findings of these studies is limited. Most studies are pre-post, and there is only one non-randomized, comparative study. The quality of studies is further limited by small sample size, short-term follow-up, heterogeneity in patient characteristics, and variation in surgical technique and vocal rest time. Variation in lack of standardization for measuring outcomes also increases risk of bias. Use of concomitant voice therapy in some studies may have introduced confounding, which could have artificially inflated efficacy measures. Future comparative studies with stringent inclusion/exclusion criteria, larger sample sizes, longer follow-up, and standardized outcome measures will clarify these findings.

## References

Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline. The Endocrine Society, 2009

Hayes. Hayes Technology Assessment. Combination Facial Feminization Surgery in Patients with Gender Dysphoria. Dallas, TX: Hayes; June 14, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.facial5500>

Hayes. Hayes Technology Assessment. Female-to-Male Gender-Affirming Surgical Procedures for Adolescents With Gender Dysphoria. Dallas, TX: Hayes; May 13, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.affirming5504>

Hayes. Hayes Technology Assessment. Feminizing Voice and Communication Therapy for Gender Dysphoria. Dallas, TX: Hayes; Oct 1, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.speech5347>

Hayes. Hayes Technology Assessment. Gender-Affirming Body-Contouring Procedures in Patients with Gender Dysphoria. Dallas, TX: Hayes; Sept 20, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.contouring5376>

Hayes. Hayes Technology Assessment. Gender-Affirming Hair Removal for Patients With Gender Dysphoria. Dallas, TX: Hayes; June 14, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.hairremoval5593>

Hayes. Hayes Technology Assessment. Hair Removal Procedures Before Gender Affirming Surgery in Patients with Gender Dysphoria. Dallas, TX: Hayes; June 25, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.affirming5499>



Hayes. Hayes Technology Assessment. Male-to-Female Gender-Affirming Surgical Procedures for Adolescents With Gender Dysphoria. Dallas, TX: Hayes; May 15, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.affirming5499>

Hayes. Hayes Technology Assessment. Masculinizing Voice and Communication Therapy for Gender Dysphoria. Dallas, TX: Hayes; Sept 20, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/eer.masculinizing5362>

Hayes. Hayes Technology Assessment. Sex Reassignment Surgery for the Treatment Of Gender Dysphoria. Dallas, TX: Hayes; Jul 27, 2024. Retrieved October 21, 2024 from: <https://evidence.hayesinc.com/report/dir.sex707>

Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 8th Version. The World Professional Association for Transgender Health (WPATH)

Wylie C Hembree, Peggy T Cohen-Kettenis, Louis Gooren, Sabine E Hannema, Walter J Meyer, M Hassan Murad, Stephen M Rosenthal, Joshua D Safer, Vin Tangpricha, Guy G T'Sjoen, Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 11, 1 November 2017, Pages 3869–3903, <https://doi.org/10.1210/jc.2017-01658>

## Applicable Codes (not all-inclusive) – all requests require clinical review

### Members Assigned Male at Birth:

CPT® or HCPC Codes	Description
55970	Intersex Surgery; male to female
15830	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy
With diagnosis codes	
F64.0	Transsexualism
F64.1	Dual role transvestism
F64.2	Gender identity disorder of childhood
F64.8	Other gender identity disorders
F64.9	Gender identity disorder, unspecified

### Members Assigned Female at Birth:

CPT® or HCPC Codes	Description
55980	Intersex Surgery; female to male
With diagnosis codes	
F64.0	Transsexualism
F64.1	Dual role transvestism
F64.2	Gender identity disorder of childhood
F64.8	Other gender identity disorders
F64.9	Gender identity disorder, unspecified

### Electrolysis:

CPT® or HCPC Codes	Description
17380	Electrolysis epilation, each 30 minutes

### Gender Affirming Facial Surgery

#### Forehead Recontouring/Augmentation:

CPT® or HCPC Codes	Description
21137	Reduction forehead; contouring only
21138	Reduction forehead; contouring and application of prosthetic material or bone graft (includes obtaining autograft)
21139	Reduction forehead; contouring and setback of anterior frontal sinus wall

**Brow Lift:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15824</b>	Rhytidectomy; forehead
<b>67900</b>	Repair of brow ptosis (supraciliary, mid-forehead or coronal approach)

**Hairline Correction/Scalp Advancement:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15839</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area

**Jaw Contouring:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>21299</b>	Unlisted craniofacial and maxillofacial procedure
<b>21209</b>	Osteoplasty, facial bones; reduction

**Body Contouring:**

<b>CPT® Codes</b>	<b>Description</b>
<b>15771</b>	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate
<b>15772</b>	Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure)
<b>15773</b>	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate
<b>15774</b>	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)
<b>15830</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); abdomen, infraumbilical panniculectomy
<b>15832</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); thigh
<b>15833</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); leg
<b>15834</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); hip
<b>15835</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); buttock
<b>15836</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); arm
<b>15837</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); forearm or hand
<b>15838</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad
<b>15839</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); other area
<b>15847</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy), abdomen (e.g., abdominoplasty) (includes umbilical transposition and fascial plication) (List separately in addition to code for primary procedure)
<b>15876</b>	Suction assisted lipectomy; head and neck
<b>15877</b>	Suction assisted lipectomy; trunk
<b>15878</b>	Suction assisted lipectomy; upper extremity
<b>15879</b>	Suction assisted lipectomy; lower extremity

**Chin Augmentation:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>21120</b>	Genioplasty; augmentation (autograft, allograft, prosthetic material)
<b>21121</b>	Genioplasty; sliding osteotomy, single piece
<b>21122</b>	Genioplasty; sliding osteotomies, 2 or more osteotomies (e.g., wedge excision or bone wedge reversal for asymmetrical chin)

<b>21123</b>	Genioplasty; sliding, augmentation with interpositional bone grafts (includes obtaining autografts)
<b>21296</b>	Reduction of masseter muscle and bone (e.g., for treatment of benign masseteric hypertrophy); intraoral approach

**Fat Transfer:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15773</b>	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate
<b>15774</b>	Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure)

**Rhinoplasty:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>30400</b>	Rhinoplasty, primary; lateral and alar cartilages and/or elevation of nasal tip
<b>30410</b>	Rhinoplasty, primary; complete, external parts including bony pyramid, lateral and alar cartilages, and/or elevation of nasal tip
<b>30420</b>	Rhinoplasty, primary; including major septal repair
<b>30430</b>	Rhinoplasty, secondary; minor revision (small amount of nasal tip work)
<b>30435</b>	Rhinoplasty, secondary; intermediate revision (bony work with osteotomies)
<b>30450</b>	Rhinoplasty, secondary; major revision (nasal tip work and osteotomies)

**Blepharoplasty:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15820</b>	Blepharoplasty, lower eyelid;
<b>15821</b>	Blepharoplasty, lower eyelid; with extensive herniated fat pad
<b>15822</b>	Blepharoplasty, upper eyelid;
<b>15823</b>	Blepharoplasty, upper eyelid; with excessive skin weighting down lid

**Dermal Filler:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>11950</b>	Subcutaneous injection of filling material (eg, collagen); 1 cc or less
<b>11951</b>	Subcutaneous injection of filling material (e.g., collagen); 1.1 to 5.0 cc
<b>11952</b>	Subcutaneous injection of filling material (e.g., collagen); 5.1 to 10.0 cc
<b>11954</b>	Subcutaneous injection of filling material (e.g., collagen); over 10.0 cc

**Suction Assisted Lipectomy:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15876</b>	Suction assisted lipectomy; head and neck

**Rhytidectomy:**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>15829</b>	Rhytidectomy; superficial musculoaponeurotic system (SMAS) flap
<b>15838</b>	Excision, excessive skin and subcutaneous tissue (includes lipectomy); submental fat pad

**Voice Modification Surgery**

CPT® or HCPC Codes	Description
<b>No specific codes – commonly submitted with CPT code 31599 Unlisted procedure, larynx</b>	

**\*Note:** Codes list is not all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/15/2010	01/04/2011 MDCRPC, 11/01/2011 MDCRPC, 09/04/2012 MDCRPC, 07/02/2013 MDCRPC, 05/06/2014 MPC, 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	02/04/2025

MDCRPC Medical Director Clinical Review and Policy Committee

MPC Medical Policy Committee

Revision History	Description
11/2/2015	Added Providence Health & Services and link to Sound Health & Wellness Policy & ICD-10 codes
03/08/2016	Added PEBB link
09/02/2016	Added FtM Mastectomy criteria for adolescents 16 years and older
11/01/2016	MPC approved revised indication for Electrolysis
10/02/2017	Removed the requirement for testosterone treatment for members 16-18
02/06/2018	Added criteria for M-F breast augmentation
05/01/2018	Added facials and ultrasonic assisted lymphatic massage to the non-covered list
06/05/2018	Changed the mastectomy and breast augmentation criteria
06/11/2018	Added coverage language for facial hair removal
07/10/2018	Added coverage and revised criteria language for facial hair removal
10/02/2018	Updated evaluation criteria under genital reconstructive surgery requirements
12/04/2018	Added MtF criteria to add coverage for Laryngochondroplasty (Tracheal Shave)
04/12/2019	Added Mons Resection code to genital reconstructive surgery
01/22/2020	Minor changes to Facial Hair removal criteria
05/4/2020	Added the following procedures to section V "Requirements for genital reconstruction surgery": vulvectomy, colpocleisis and perineoplasty
12/18/2020	MPC approved to adopt clinical criteria for Facial Harmonization and updated exclusions for the non-covered list.
02/19/2021	Included non-binary patients for facial hair removal and mastectomy indications.
10/04/2021	Updated terminology from female to male and male to female to assigned male at birth or assigned female at birth.
03/01/2022	MPC approved changes to criteria for hair removal, including the addition of criteria for coverage of body hair removal and updates to facial hair removal criteria.
04/05/2022	MPC approved to adopt coverage for voice modification surgery.
05/02/2023	Updated self-funded SHWT policy coverage details statement
05/08/2023	Updated additional exclusions provided by SHWT
06/06/2023	MPC has approved revisions to the clinical criteria for Gender Affirming Services, ensuring alignment with the updated guidelines from the World Professional Association for Transgender Health (WPATH). Requires 60-day notice, effective date 11/01/2023
12/04/2023	Effective 12/5/2023 Orchiectomy procedure may be subject to Elective Surgical Procedure Level of Care Review
10/01/2024	MPC approved the adoption of proposed changes to the Gender Affirming Services criteria for body contouring; 60-day notice required. Effective March 1, 2025. Updated references.
02/04/2025	MPC approved to endorse credentialing preferences for Mastectomy, Breast Augmentation, Gonadectomy/Genital Reconstruction, Voice Modification, Facial Surgery, and Body Contouring. 60-day notice is not required.

02/04/2025	MPC approved the proposed updates to Breast Augmentation Criteria concerning "Gender Affirming Hormonal Treatment Regime." 60-day notice required; effective July 1, 2025.
------------	--



## Kaiser Foundation Health Plan of Washington

### *Clinical Review Criteria*

### **Genetic Screening and Testing Genetic Panels using Next Generation Sequencing (germline/blood testing, excluding Advanced Cancer)**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### ***Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees (for in-network coverage).***

*Prevention and Invitae/LabCorp Genetics are the preferred labs for genetic testing\*, when the test(s) is/are available at Prevention or LabCorp and medical necessity criteria are met.*

LabCorp's test catalog can be found here: [LabCorp Test Catalog](#)  
Prevention test catalog can be found here: [Prevention Test Catalog](#)  
Invitae test catalog can be found here: [Invitae Test Catalog](#)

\*Note: This does not affect processing of tumor or other pathology specimens as they are not performed by LabCorp

**PPO/POS members may use non-preferred labs at the out of network cost share.**

#### **Exceptions**

For the genetic test(s) listed below, please use the lab specified/refer to the link attached:

- **Cell Free Fetal DNA testing – Any of these labs can be used:**
  - Ariosa (Bioreference) Diagnostics, Inc. (81507) or
  - LabCorp (81420)
  - Quest-QNatal (81420)
  - Natera: Panorama (81420), Pamorama Twins (0060U)
- **Next Generation Sequencing for Advanced Cancer —Any of these labs can be used:**
  - CellNetix SymGene Panel
  - Oncoplex (University of Washington)
  - Caris Life Sciences
- **Prenatal Chromosomal Microarray (samples typically obtained via amniocentesis/CVS)— Any of these labs can be used:**
  - Prevention
  - LabCorp
  - Quest (ClariSure Oligo-SNP-81229)
  - Natera (Anora-81229)
- **Fetal diagnostic testing in cases of recurrent intrauterine fetal demise (definition)— Any of these labs can be used:**
  - Prevention
  - LabCorp
- **Pregnancy Carrier Screening or Preconception Counseling— Any of these labs can be used:**
  - Prevention



- Labcorp (Inheritest® 100 PLUS Panel, Inheritest® 300 PLUS panel, Inheritest® 500 PLUS Panel, Inheritest® High Frequency, Inheritest® CF/SMA panel, Core panel, or or Inheritest® 14-gene panel)
- Quest (Prenatal Carrier Panel or QHerit expanded carrier screen)
- Natera (Horizon basic (84999), 4 expanded (84999), or 14 or greater panels (81443))
- Non-prenatal Chromosomal Microarray (sample obtained by blood draw)— **Any of these labs can be used:**
  - Prevention
  - Invitae/LabCorp Genetics

## Related Policies:

[Genetic Panel Testing](#)

[Pharmacogenomic Testing](#)

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<p><a href="#">Next Generation Sequencing (NGS) (90.2)</a> (Applies to diagnostic lab tests using NGS for somatic (acquired) and germline (inherited) breast and ovarian cancer.)</p> <p><a href="#">Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)</a></p> <p><b><a href="#">FDA-approved Companion Diagnostic tests</a></b> (not all-inclusive)  FoundationFocus™ CDxBRCA Assay (Foundation Medicine, Inc.)  FoundationOne CDx (Foundation Medicine, Inc.)  FoundationOne Liquid CDx (Foundation Medicine, Inc.)  Guardant360® CDx (Guardant Health, Inc.)  Guardant360 TissueNext (Guardant Health, Inc.)  Oncomine™ Dx Target Test (Thermo Fisher Scientific, Inc.)  Praxis™ Extended RAS Panel (Illumina, Inc.)  MSK-IMPACT™ (Memorial Sloan Kettering Cancer Center's (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets))</p> <p><a href="#">Chimeric Antigen Receptor (CAR) T-cell Therapy (110.24)</a></p> <p><a href="#">Histocompatibility Testing (190.1)</a></p>

Local Coverage Determinations or Articles (LCD/LCA)	<p>9/30/2015 - Noridian retired <a href="#">LCD for Genetic Testing (L24308)</a>. These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for “medical judgment” which could be based on our commercial criteria or literature search.</p> <p><a href="#">MoIDX: Molecular Diagnostic Tests (MDT) (L36256)</a>  <a href="#">MoIDX: Testing of Multiple Genes (A58121)</a></p> <p><a href="#">MoIDX: Next-Generation Sequencing for Solid Tumors (L38121)</a>          (Applies to diagnostic lab tests using NGS for solid tumors.)</p> <p><a href="#">MoIDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (L39469)</a></p> <p><a href="#">MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (L38649)</a></p> <p><a href="#">Billing and Coding: MoIDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (A58187)</a></p> <p><a href="#">Billing and Coding: MoIDX: Next-Generation Sequencing for Solid Tumors (A57905)</a></p> <p><a href="#">Billing and Coding: MoIDX: Targeted and Comprehensive Genomic Profile Testing in Cancer (A56518)</a></p> <p><a href="#">Billing and Coding: MoIDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis (A59522)</a></p> <p><a href="#">MoIDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test (L37891)</a></p> <p><a href="#">MoIDX: Melanoma Risk Stratification Molecular Testing (L37748)</a></p> <p><a href="#">MoIDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (L39003)</a></p> <p><a href="#">MoIDX: myPath Melanoma Assay (L37881) <b>RETIRED</b></a></p> <p><a href="#">MoIDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma (L39375)</a></p> <p><a href="#">MoIDX: Oncotype DX® Breast Cancer for (DCIS) Genomic Health™ (L36947)</a></p> <p><a href="#">MoIDX: Pigmented Lesion Assay (L38153)</a></p> <p><a href="#">MoIDX: Repeat Germline Testing (L38353)</a></p> <p><a href="#">ProMark Risk Score (L36706)</a></p>
---	---

	<a href="#">MoIDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (L39040)</a>
Decision Memo	<a href="#">Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451)</a>
Kaiser Permanente Medical Policy	<b>Transthyretin (TTR) Amyloidosis Testing</b> Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Transthyretin Amyloidosis - TTR Gene</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

### General Coverage Rules – LCD 24308 (retired)

1. Genetic tests for cancer are only a covered benefit for a beneficiary with a personal history of an illness, injury, or signs/symptoms thereof (i.e. clinically affected). A person with a personal history of a relevant cancer is a clinically affected person, even if the cancer is considered cured. Genetic testing is considered a non-covered screening test for patients unaffected by a relevant illness, injury, or signs/symptoms thereof.

2. Predictive or pre-symptomatic genetic tests and services, in the absence of past or present illness in the beneficiary, are not covered under national Medicare rules. For example, Medicare does not cover genetic tests based on family history alone.

527

3. A covered genetic test must be used to manage a patient. Medicare does not cover a genetic test for a clinically affected individual for purposes of family planning, disease risk assessment of other family members, when the treatment and surveillance of the beneficiary will not be affected, or in any other circumstance that does not directly affect the diagnosis or treatment of the beneficiary.

4. The results of the genetic test must potentially affect at least one of the management options considered by the referring physician in accordance with accepted standards of medical care (e.g. surgery, the extent of surgery, a change in surveillance, hormonal manipulation, or a change from standard therapeutic or adjuvant chemotherapy).

5. Pre-test genetic counseling must be provided by a qualified and appropriately trained practitioner.

6. An informed consent form signed by the patient prior to testing which includes a statement that he/she agree to post-test counseling is required. This consent form must be available on request by Medicare.

7. Genetic analysis must be provided through a laboratory which meets the American Society of Clinical Oncology (ASCO) recommended requirements:

The MoIDX Program has determined certain gene tests do not meet Medicare's medical necessary requirements, and that the inclusion of these genes will result in an entire panel to be denied. MoIDX has determined that testing for the below genes is a statutorily excluded service. Unless indicated otherwise, panels that include these genes will be denied. Please see the individual Test Coding and Billing Guidelines for each gene.

Palmetto GBA is the Medicare contractor for Molecular Diagnostic Testing – this site has the most up to date Medicare coverage guidelines for genetic testing.

[MoIDX® Program \(Administered by Palmetto GBA\)](#)

**Local Coverage Decisions and Articles (LCD/LCA)** *not all-inclusive – refer to the MoIDX® Program link above*

ID	Title	Codes (not all-inclusive)
L36163	08/20/2022 Noridian retired LCD <a href="#">MoIDX: BRCA1 and BRCA2 Genetic Testing</a> These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36163 for determining medical necessity, along with L36256 <a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a> .	81162, 81163, 81164, 81165, 81166, 81167, 81212, 81215, 81216, 81217, 81432, 81433, 0102U, 0103U, 0129U
L36386	<a href="#">MoIDX: Breast Cancer Assay: Prosigna</a>	81520
L37824	<a href="#">MoIDX: Breast Cancer Index® Gene Expression Test</a>	81518
L36186	<a href="#">MoIDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease</a>	81206, 81207, 81208, 81219, 81270, 81279, 81338, 81339, 81450, 0027U, 0040U
L36159	<a href="#">MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)</a>	81240, 81241, 81291
L36374	08/20/2022 Noridian retired LCD <a href="#">MoIDX: Genetic Testing for Lynch Syndrome</a> These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36374 for determining medical necessity, along with L36256 <a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a> .	81210, 81288, 81292, 81293, 81294, 81295, 81296, 81297, 81298, 81299, 81300, 81317, 81318, 81319, 81432, 81433, 0101U
L36192	<a href="#">MoIDX: MGMT Promoter Methylation Analysis</a>	81287
L36544	<a href="#">MoIDX: HLA-DQB1*06:02 Testing for Narcolepsy (L36544)</a> <i>*not covered per LCD</i>	81383
L36256	<a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a>	See LCA*: <a href="#">Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT) (A57527)</a> <i>*Presence of a code on this LCA does not indicate coverage</i>

L38333	<a href="#">MoIDX: Blood Product Molecular Antigen Typing</a>	0001U, 0084U
L36329	08/08/2022 Noridian retired LCD <a href="#">MoIDX: ConfirmMDx Epigenetic Molecular Assay</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36329 for determining medical necessity, along with L36256 <a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a>	81551
L38341	<a href="#">MoIDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38341)</a> (Decipher and similar, i.e., Prolaris)  <a href="#">MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (L39007)</a>  <a href="#">Billing and Coding: MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58724)</a>	81541, 81542, 0047U
L36542	01/01/2018 Noridian retired LCD <a href="#">MoIDX: Chromosome 1p/19q Deletion Analysis (L36542)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36452 for determining medical necessity, along with L36256 <a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a> .	
L36891	09/22/2024 Noridian retired LCD <a href="#">MoIDX: Percepta® Bronchial Genomic Classifier</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36891 for determining medical necessity, along with L39680 <a href="#">MoIDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy</a>	81479
L38329	<a href="#">MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (L38329)</a> (DetermaRx™)  <a href="#">Billing and Coding: MoIDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer (A57330)</a>	0288U
L38816	<a href="#">MoIDX: Minimal Residual Disease Testing for Cancer L38816</a>  <a href="#">MoIDX: Minimal Residual Disease Testing for Hematologic Cancers A58997</a> (refers to coverage for ClonoSEQ for specific cancers)	81479, 0340U, 0364U

**For Non-Medicare Members**

Members must meet **ALL the following** criteria:

1. The member is at clinical risk for a genetic condition because of current documented symptoms being displayed or a strong family history of the condition.
2. The test is scientifically valid and can be adequately interpreted.
3. The results will directly affect a member's clinical management or reproductive decisions.
4. After appropriate clinical work-up, and informed consent by the appropriate practitioner, the genetic test is indicated.

Genetic testing is not covered for the medical management of a family member who does not have Kaiser Permanente coverage.

Carrier Screening is limited to once per lifetime.

*For **specific tests listed** below the member must meet the criteria above **AND** the specific test criteria below:*

\*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access

Cardiology	Criteria
Arrhythmogenic Right Ventricular Cardiomyopathy – ARVC Genes	MCG* A-0627
Brugada Syndrome Channelopathy Genes	MCG* A-0594
Catecholaminergic Polymorphic Ventricular Tachycardia – Gene and Gene Panel Testing	MCG* A-0636
Coronary Artery Disease - 9p21 Allele	MCG* A-0657: This is not covered per MCG*
Coronary Artery Disease - KIF6 Gene	MCG* A-0656: This is not covered per MCG*
Coronary Artery Disease Genetic Panel	There is insufficient evidence in the published medical literature to show clinical utility.
Familial Dilated Cardiomyopathy – Gene and Gene Panel Testing	MCG* A-0648
Familial Hypertrophic Cardiomyopathy, Nonsyndromic – Gene and Gene Panel Testing	MCG* A-0633
Thoracic Aortic Aneurysm and Aortic Dissection (Hereditary) - Gene Panels	There is insufficient evidence in the published medical literature to show clinical utility.
Ehlers-Danlos Syndrome (Vascular) - COL3A1 Gene	MCG* A-0910
Loeys-Dietz Syndrome - Gene and Gene Panel Testing	MCG* A-0909
Long QT Syndrome (Hereditary) - Gene and Gene Panel Testing	MCG* A-0918

Endocrinology	Criteria
Diabetes Mellitus, Type 2 - KCNJ11, KCNQ1, PPARG, SLC16A11 and TCF7L2 Genes	MCG* A-0826: This is not covered per MCG*
Diabetes Mellitus (Maturity-Onset Diabetes of the Young) - ABCC8, APPL1, BLK, CEL, GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11, KLF11, NEUROD1, PAX4, and PDX1 Genes	MCG* A-0598



Gastroenterology	Criteria
HLA Testing for Celiac Disease:	1. Is medically appropriate for symptomatic patients <ul style="list-style-type: none"> <li>a. Despite being on a gluten free diet <b>OR</b></li> <li>b. With indeterminate serology/biopsy results</li> </ul> 2. It is not covered for <ul style="list-style-type: none"> <li>a. Asymptomatic people <b>OR</b></li> <li>b. Screening</li> </ul>
Hemochromatosis - HFE Gene	Medical necessity review no longer required.
Pancreatitis, Hereditary – CFTR, CPA1, CTRC, PRSS1, and SPINK1 Genes	MCG* A-0646

Genomic Testing Methods and Technologies	Criteria
Atomoxetine Therapy	MCG* A-0775 *Not covered per MCG
Broad Spectrum Tumor Molecular Profiling – Next Generation Sequencing (NGS)	There is insufficient evidence in the published medical literature to show clinical utility.

Genomic Testing Methods and Technologies	Criteria
Chromosomal Microarray Testing	<ol style="list-style-type: none"> <li>1) Chromosomal microarray testing may be considered medically necessary for genetic evaluation of an individual when <b>ALL</b> of the following criteria are met:               <ol style="list-style-type: none"> <li>a) Testing has been requested following evaluation and genetic counseling by a medical geneticist, pediatric neurologist, or neurodevelopment pediatrician; and</li> <li>b) Results have the potential to affect clinical management of the patient; and</li> <li>c) The patient meets one or more of the following:                   <ul style="list-style-type: none"> <li>• Multiple anomalies not specific to a well-delineated genetic syndrome</li> <li>• Apparently non-syndromic developmental delay/intellectual disability</li> <li>• Autism spectrum disorder</li> <li>• Dysmorphic facial features</li> <li>• Abnormal growth not otherwise explained</li> </ul> </li> </ol> </li> <li>2) Chromosomal microarray testing (CPT 81228, 81229) may be considered medically necessary for patients undergoing invasive prenatal genetic testing (i.e., amniocentesis, chorionic villus sampling (CVS), or fetal tissue sampling), or a patient who has had recurrent (two or more) intrauterine fetal demise. Genetic counseling is required. Prior authorization is not required if done at Labcorp, Natera or Prevention but is required for all other vendors in advance of submitting a claim for payment.</li> <li>3) Chromosomal microarray testing may be considered medically necessary for testing of one or both parents when a chromosomal deletion or duplication has been identified in one or more of their offspring and:               <ol style="list-style-type: none"> <li>a. Parental testing is necessary to guide a reproductive decision, or</li> <li>b. Parental testing is necessary to determine the clinical significance of the chromosome abnormality found in the child, and</li> <li>c. The result is expected to directly affect clinical management of the child</li> </ol> <p>The following are not covered:</p> </li> <li>4) Chromosomal microarray testing to confirm the diagnosis of a disorder or syndrome that is routinely diagnosed based on clinical evaluation alone.</li> </ol>
Clopidogrel Pharmacogenetics - CYP2C19 Gene	MCG* A-0775*Not covered per MCG
Cytochrome P450 Pharmacogenetics - Gene Tests and Gene Panel	MCG* A-0775
Genome-Wide Association Studies	Does not require medical review
Integrated Molecular Pathology Testing (Topographic Genotyping) - PathFinderTG	There is insufficient evidence in the published medical literature to show clinical utility.
MicroRNA Detection - Cancer	There is insufficient evidence in the published medical literature to show clinical utility.
MicroRNA Detection – Heart Failure	There is insufficient evidence in the published medical

Genomic Testing Methods and Technologies	Criteria
	literature to show clinical utility.
MicroRNA Detection - Inflammatory Bowel Disease	There is insufficient evidence in the published medical literature to show clinical utility.
MicroRNA Detection - Ischemic Heart Disease	There is insufficient evidence in the published medical literature to show clinical utility.
MicroRNA Detection – Kidney Disease	There is insufficient evidence in the published medical literature to show clinical utility.
Molecular Profiling	MCG* A-0789: This is not covered per MCG*
Noninvasive Prenatal Testing (Cell-Free Fetal DNA) - Microdeletion Syndromes <i>81331 not medically necessary when performed using cell-free fetal DNA, 81422</i>	MCG* A-0848: This is not covered per MCG*
Noninvasive Prenatal Testing (Cell-Free Fetal DNA) - Monogenic Disorders	MCG* A-0849: This is not covered per MCG*
Noninvasive Prenatal Testing (Cell-Free Fetal DNA) - Sex Chromosome Disorders	There is insufficient evidence in the published medical literature to show clinical utility.
Opioid Pharmacogenetics - CYP450 Polymorphisms, OPRM1 Gene, and Gene Panels	MCG* A-0775 *Not covered per MCG
Septin 9 (SEPT9) DNA Methylation Testing	MCG* A-0706: This is not covered per MCG*
Tacrolimus Pharmacogenetics – CYP3A4 and CYP3A5 Genes	MCG* A-0775 *Not covered per MCG
Tamoxifen Pharmacogenetics – CYP2D6 Gene	MCG* A-0775 *Not covered per MCG
Telomere Analysis	MCG* A-0672: This is not covered per MCG*
Whole Exome Sequencing (WES)	<p>Whole exome sequencing (WES) is considered medically necessary for a phenotypically affected individual when <b>ALL</b> of the following criteria are met:</p> <ol style="list-style-type: none"> <li>Individual has been evaluated by a board-certified medical geneticist (MD) or other board-certified physician specialist with specific expertise in the conditions and relevant genes for which testing is being considered</li> <li>Results have the potential to directly impact clinical decision-making and clinical outcome for the patient</li> <li>A genetic etiology is the most likely explanation for the phenotype as demonstrated by <b>EITHER</b> of the following: <ol style="list-style-type: none"> <li>multiple abnormalities affecting unrelated organ systems OR</li> <li><b>TWO</b> of the following criteria are met: <ol style="list-style-type: none"> <li>abnormality affecting a single organ system</li> <li>significant intellectual disability, symptoms of a complex neurodevelopmental disorder (e.g. self-injurious behavior, reverse sleep-wake cycles), or severe neuropsychiatric condition (e.g. schizophrenia, bipolar disorder, Tourette syndrome)</li> <li>family history strongly implicating a genetic etiology</li> <li>period of unexplained developmental regression (unrelated to autism or epilepsy)</li> <li>dysmorphic facial features</li> <li>abnormal growth not otherwise explained</li> </ol> </li> </ol> </li> <li>No other causative circumstances (e.g. environmental exposures, injury, infection) can explain symptoms</li> <li>Clinical presentation does not fit a well-described syndrome for which single-gene or targeted panel testing is available</li> <li>The differential diagnosis list and/or phenotype warrant testing of multiple genes and <b>ONE</b> of the following:</li> </ol>

Genomic Testing Methods and Technologies	Criteria
	<ul style="list-style-type: none"> <li>a. WES is more practical than the separate single gene tests or panels that would be recommended based on the differential diagnosis</li> <li>b. WES results may preclude the need for multiple and/or invasive procedures, follow-up, or screening that would be recommended in the absence of testing</li> </ul> <p><u>All requests must be approved by a KP geneticist, regardless of whether they have seen the patient.</u></p>

Hematology	Criteria
Alpha Thalassemia - HBA1 and HBA2 Genes	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0808
Beta Thalassemia - HBB Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0815
Fetal and Neonatal Alloimmune Thrombocytopenia - Human Platelet Antigen (HPA) Genotyping	MCG* A-0793
Factor V Leiden Thrombophilia-F5 gene	Does not require medical review
Fanconi Anemia - FANC Genes and Gene Panel Testing	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0683
Hemoglobin C and E – HBB Gene	MCG* A-0604
Hyperhomocysteinemia - MTHFR Gene	MCG* A-0629
Post-Transfusion Purpura - Human Platelet Antigen (HPA) Genotyping	There is insufficient evidence in the published medical literature to show clinical utility.

Hematology	Criteria
Prothrombin Thrombophilia - F2 Gene	Does not require medical review
Sickle Cell Disease - HBB Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0864
Von Willebrand Disease-VWF Gene	MCG* A-0688

Metabolic and Developmental Disorders	Criteria
Angelman Syndrome - UBE3A Gene <i>Note: Guideline indications are related to tests performed using amniocentesis or chorionic villus sampling. Not medically necessary when performed using cell-free fetal DNA (see MCG A-0848).</i>	MCG* A-0708
Ashkenazi Jewish Genetic Panel	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0592
Autism Spectrum Disorders – Gene Panels	MCG* A-0914 This is not covered per MCG*
Beckwith-Wiedemann Syndrome - CDKN1C Gene	MCG* A-0765
Bloom Syndrome - BLM Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0682
Canavan Disease - ASPA Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0595
Deafness and Hearing Loss, Nonsyndromic - Gene and Gene Panel Testing	MCG* A-0823
Deafness and Hearing Loss, Nonsyndromic - GJB2, MT-RNR1, MT-TS1, POU3F4, PRPS1, and SMPX Genes	There is insufficient evidence in the published medical literature to show clinical utility.

Metabolic and Developmental Disorders	Criteria
Developmental Delay - Gene Panels	MCG* A-0925 This is not covered per MCG*
Fragile X-Associated Disorders - FMR1 Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0602
Fragile X-Associated Primary Ovarian Insufficiency - FMR1 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Fragile X-Associated Tremor/Ataxia Syndrome - FMR1 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Gaucher Disease - GBA Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0603
Glycogen Storage Disease, Type 1 G6PC and SLC37A4 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Intellectual Disability - Gene Panels	MCG* A-0923 This is not covered per MCG*
Joubert Syndrome – Gene Testing and Gene Panels	MCG* A-0785
Lesch-Nyhan Syndrome - HPRT1 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Maple Syrup Urine Disease, Type 1 or Type 2 – BCKDHA, BCKDHB, and DBT Genes	MCG* A-0681
Dihydrolipoamide Dehydrogenase Deficiency - DLD	MCG* A-0776
Mucopolidosis IV - MCOLN1 Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0686
Niemann-Pick Disease (Acid Sphingomyelinase Deficiency) - NPC1, NPC2, and SMPD1 Genes	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0611
Noonan Syndrome – Gene and Gene Panel Testing	MCG* A-0915
Prader-Willi Syndrome DNA Methylation Testing <i>Note: Guideline indications are related to tests performed using amniocentesis or chorionic villus sampling. Not medically necessary when performed using cell-free fetal DNA (see MCG A-0848).</i>	MCG* A-0707
Rett Syndrome – CDKL5, FOXP1 and MECP2 Genes	There is insufficient evidence in the published medical literature to show clinical utility.
Tay-Sachs Disease and Variants - HEXA Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0614
Usher Syndrome - ADGRV1 (GPR98), CDH23, CIB2, CLRN1, DFNB31, HARS, MYO7A, PCDH15, USH1C, USH1G, and USH2A Genes	MCG* A-0802
Fabry Disease - GLA Gene	MCG* A-0916

Miscellaneous	Criteria
Autosomal Recessive and X-Linked Disease Carrier Screening - Expanded Gene Panels	MCG* A-0768: This is not covered per MCG*
Familial Mediterranean Fever - MEFV Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Hereditary Hemorrhagic Telangiectasia - ACVRL1, ENG, GDF2, and SMAD4 Genes	MCG* A-0704
Male Infertility - Y Chromosome Microdeletion Analysis	There is insufficient evidence in the published medical literature to show clinical utility.
Malignant Hyperthermia Susceptibility - CACNA1S and RYR1 Genes	There is insufficient evidence in the published medical literature to show clinical utility.

Nephrology	Criteria
------------	----------

Donor-derived cell-free DNA testing (e.g., Allosure)	*Please see separate criteria for <a href="#">Lab Tests for Detectom of Organ Transplantation Rejection</a>
Polycystic Kidney Disease (Autosomal Recessive) – DZIP1L and PKHD1 Genes and Gene Panels	There is insufficient evidence in the published medical literature to show clinical utility.

Neurology	Criteria
Alzheimer Disease – (Early Onset) APP, PSEN1, and PSEN2 Genes	MCG* A-0590
Alzheimer Disease - APOE Genotyping  CPT codes: 81401, 81405, 81406 HCPC: S3852	MCG* KP-0809 06012024
Amyotrophic Lateral Sclerosis (ALS) - SOD1 Gene	Kaiser Permanente has elected to use the Amyotrophic Lateral Sclerosis (ALS) - SOD1 Gene (KP-0591-12012024) MCG* Care Guideline for medical necessity determinations.
Ataxia-Telangiectasia - ATM Gene	MCG* A-0593
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) - NOTCH3 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Charcot-Marie-Tooth Hereditary Neuropathy – Gene and Gene Panel Testing	MCG* A-0691
Epilepsies (Hereditary) - Gene Panels	MCG* A-0905 This is not covered per MCG
Epilepsies, Hereditary - SCN1A Gene	MCG* A-0904
Familial Dysautonomia - ELP1 Gene	Does not require medical review in the prenatal setting. For all other indications refer to MCG* A-0685
Familial Frontotemporal Dementia - C9orf72, GRN, and MAPT Genes	There is insufficient evidence in the published medical literature to show clinical utility.
Friedreich Ataxia - FXN Gene	MCG* A-0907
Huntington Disease - HTT Gene	MCG* A-0605
Muscular Dystrophies (Duchenne, Becker) - DMD Gene	MCG* A-0608
Myotonic Dystrophy – Type 1 - DMPK Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Myotonic Dystrophy, Type 2 - CNBP Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Narcolepsy - HLA Testing	MCG* A-1005 This is not covered per MCG
Nemaline Myopathy – Gene and Gene Panel Testing	MCG* A-0792
Parkinson Disease – Gene Testing and Gene Panels	MCG* A-0671 This is not covered per MCG



Neurology	Criteria
<p>Spinal Muscular Atrophy - SMN1 and SMN2 Genes</p> <p><b>Spinal Muscular Atrophy – Carrier Testing</b></p> <p>References:  American College of Obstetricians and Gynecologists (2017). Carrier screening for genetic conditions. Committee Opinion No. 691. <i>Obstet Gynecol.</i> 129:e41-45. Retrieved 10/20/21 from: <a href="https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions">https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/03/carrier-screening-for-genetic-conditions</a></p> <p>Gregg, A. R., Aarabi, M., Klugman, S., Leach, N. T., Bashford, M. T., Goldwasser, T., Chen, E., Sparks, T. N., Reddi, H. V., Rajkovic, A., &amp; Dungan, J. S. (2021). Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). <i>Genetics in Medicine</i>, 23(10), 1793–1806. Retrieved 10/20/21 from: <a href="https://doi.org/10.1038/s41436-021-01203-z">https://doi.org/10.1038/s41436-021-01203-z</a></p>	<p>Preconception or prenatal carrier testing for spinal muscular atrophy (SMA) with analysis of the SMN1 gene (CPT code <b>81329</b>), as described by the American College of Medical Genetics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG), is considered medically necessary for a prospective biologic parent with the capacity and intention to reproduce. Testing is covered once in a lifetime.</p> <p>Kaiser Permanente will cover carrier testing for SMA (CPT 81329) without prior authorization when performed at a Kaiser Permanente lab, Natera or Prevention. Prior authorization will still be required for SMA carrier testing at any other lab in advance of submitting a claim for payment.</p> <p>All other spinal muscular atrophy genetic testing: Medical necessity review will be required for all other indications for SMN1/SMN2 gene testing using MCG* <b>KP-0659</b>.  <i>Note – this is a KP hybrid, not MCG A-0659</i>  (Includes CPT codes: 81336, 81337, 0236U)</p>
Spinocerebellar Ataxia - Gene Testing and Gene Panels	MCG* A-0908
Transthyretin Amyloidosis - TTR Gene	<p>Transthyretin (TTR) Amyloidosis Testing is covered when <b>ONE</b> of the following are met:</p> <ul style="list-style-type: none"> <li>Clinical diagnosis of ATTR-cardiomyopathy has been made by SPECT imaging (<sup>99m</sup>Tc-PYP) ; OR</li> <li>Positive biopsy demonstrating transthyretin (TTR)-amyloid deposition; OR</li> <li>Has cardiac features suggestive of ATTR-cardiomyopathy; AND <ul style="list-style-type: none"> <li>Is of African American descent; OR</li> <li>Has a first-degree relative with an hATTR diagnosis</li> </ul> </li> </ul>

Oncology	Criteria
Acute Lymphoblastic Leukemia - BCR-ABL1 Fusion Gene Testing	Does not require medical review
Acute Promyelocytic Leukemia - PML-RARA Fusion Gene Testing	Does not require medical review
Breast Cancer - HER2 Testing	MCG* A-0766
Breast Cancer Gene Expression Assays CPT - 81519	See <a href="#">Oncotype Dx</a>
Breast Cancer - PALB2 Gene	MCG* A-0989
Breast or Ovarian Cancer, Hereditary - BRCA1 and BRCA2 Genes CPT 81211, 81212, 81213, 81162	MCG* A-0499
Cancer of Unknown Primary: Gene Expression Profiling – 81540; CancerTYPE ID	MCG* A-0673 This is not covered per MCG
Chronic Eosinophilic	MCG* A-0770

Oncology	Criteria
Leukemia/Hypereosinophilic Syndrome - FIP1L1-PDGFRα Fusion Gene Testing	
Chronic Myelogenous Leukemia - BCR-ABL1 Fusion Gene Testing	Does not require medical review
ClonoSEQ – 0364U	ClonoSEQ is a new test whose current use is confined to clinical trials. It is not currently covered by KPWA
Cologuard	See <a href="#">Fecal DNA Testing</a>
Colon Cancer - Oncotype DX	MCG* A-0651: This is not covered per MCG*
Colon Cancer Gene Expression Assay - GeneFx Colon	MCG* A-0821: This is not covered per MCG*
Colorectal Cancer (Hereditary) – Gene Panel	Kaiser Permanente has elected to use the Colorectal Cancer (Hereditary) – Gene Panel (KP-0774-12012024) MCG* Care Guideline for medical necessity determinations.
Cowden Syndrome - PTEN Gene	MCG* A-0585
DecisionDx - Choroidal/Uveal Melanoma	DecisionDX is covered for dx of choroidal/uveal melanoma
DecisionDx - Cutaneous Melanoma	There is insufficient evidence in the published medical literature to show clinical utility.
Familial Adenomatous Polyposis - APC Gene	MCG* A-0534
Gastric Cancer, Hereditary - CDH1 Gene	MCG* A-0779
Gastrointestinal Stromal Tumor (GIST) - KIT and PDGFRα Genes	Does not require medical review
Ovarian Cancer (Hereditary) - Gene and Gene Panel Testing	MCG* A-0782
Li-Fraumeni Syndrome - TP53 Gene	MCG* A-0584
Lymphoma - T-Cell Antigen Receptor (TCR) Gene Rearrangement Testing	Does not require medical review
Lynch Syndrome - BRAF V600, EPCAM, MLH1, MSH2, MSH6, and PMS2 Genes and Gene Panel	MCG* A-0533
Malignant Melanoma (Uveal), Hereditary - BAP1 Gene	MCG* A-0836: This is not covered per MCG*
Malignant Melanoma (Cutaneous) – BAP1, CDK4 and CDKN2A Genes	MCG* A-0601: This is not covered per MCG*
Melanoma (Cutaneous) - Gene Expression Profiling	MCG* A-0837: This is not covered per MCG*
Melanoma (Uveal) - Gene Expression Profiling	MCG* A-0670: This is not covered per MCG*
Multiple Endocrine Neoplasia (MEN) Syndrome, Type 2 - RET Gene	MCG* A-0842
Multiple Endocrine Neoplasia (MEN) Syndromes - MEN1 Gene	MCG* A-0582
MUTYH-Associated Polyposis - MUTYH Gene	MCG* A-0828
Myelodysplastic Syndromes (Somatic) - Gene Panels	MCG* A-0791: This is not covered per MCG*
Myeloproliferative Neoplasms - JAK2 Genes	Does not require medical review
Myeloproliferative Neoplasms - MPL Gene	Does not require medical review
Neuroblastoma - ALK, MYCN, and PHOX2B Genes and Gene	MCG* A-0610

Oncology	Criteria												
Expression Profiling													
Neurofibromatosis - NF1 Gene	MCG* A-0581												
Neurofibromatosis - NF2 Gene	MCG* A-0846												
Non-Small Cell Lung Cancer – Gene Testing (Somatic or Therapeutic)	MCG* A-0795 Includes indications for: Anaplastic Lymphoma Kinase (ALK) Fusion Gene Testing – medically necessary when indications met EGFR Gene Testing – medically necessary when indications met KRAS Gene Testing – not medically necessary for NSCLC per MCG*												
OVA1- Assessment for Ovarian Cancer	There is insufficient evidence in the published medical literature to show clinical utility.												
Pancreatic Cancer (Hereditary) - Gene Panel	MCG* A-0797												
Paraganglioma-Pheochromocytoma (Hereditary) - Gene Testing and Gene Panel	MCG* A-0798												
Peutz-Jeghers Syndrome - STK11 Gene	MCG* A-0799												
Prostate Cancer - BRCA1 and BRCA2 Genes	MCG* A-0612												
Prostate Cancer – ConfirmMDx (CPT Code 81551)	<p>ConfirmMDx (81551) for men with prior negative biopsy when repeat biopsy is being considered, and the following criteria are met (must be ordered by treating urologist):</p> <ul style="list-style-type: none"> <li>The beneficiary would benefit from treatment of prostate cancer and has greater than 10-year life expectancy</li> <li>Previous biopsy within the past 12 months negative or atypical small acinar proliferation (ASAP)</li> <li>Meets Age/PSA per table below</li> <li>Serial testing not covered (this is a one-time test)</li> <li>Concurrent testing with multiple assays is not medically necessary</li> </ul> <table border="1"> <thead> <tr> <th colspan="2">TABLE 1. Age-Specific PSA Thresholds for Referral to Urology</th></tr> <tr> <th>Age Range (years)</th><th>PSA Threshold</th></tr> </thead> <tbody> <tr> <td>40-49</td><td>&gt;2.5 ng/ml</td></tr> <tr> <td>50-59</td><td>&gt;3.5 ng/ml</td></tr> <tr> <td>60-69</td><td>&gt;4.5 ng/ml</td></tr> <tr> <td>≥70</td><td>&gt;6.5 ng/ml</td></tr> </tbody> </table>	TABLE 1. Age-Specific PSA Thresholds for Referral to Urology		Age Range (years)	PSA Threshold	40-49	>2.5 ng/ml	50-59	>3.5 ng/ml	60-69	>4.5 ng/ml	≥70	>6.5 ng/ml
TABLE 1. Age-Specific PSA Thresholds for Referral to Urology													
Age Range (years)	PSA Threshold												
40-49	>2.5 ng/ml												
50-59	>3.5 ng/ml												
60-69	>4.5 ng/ml												
≥70	>6.5 ng/ml												
Prostate Cancer (Hereditary) – Gene Panel	MCG* A-0854: This is not covered per MCG*												
Prostate Cancer - PCA3 Gene	MCG* A-0855: This is not covered per MCG*												
Prostate Cancer Gene Expression Testing - Decipher	MCG* A-0856: This is not covered per MCG*												
Prostate Cancer Gene Expression	MCG* A-0712: This is not covered per MCG*												

Oncology	Criteria								
<p>Testing - Genomic Prostate Score Prostate Cancer Gene Expression Testing – Prolaris (CPT Code 81541)</p>	<p>Men with confirmed prostate cancer <i>on biopsy</i> may be covered for Prolaris if <b>ALL</b> the following indications are met (must be ordered by treating urologist):</p> <ol style="list-style-type: none"> <li>Must meet NCCN category* <b>(one)</b>: <ul style="list-style-type: none"> <li>low-risk</li> <li>favorable intermediate-risk</li> <li>unfavorable intermediate-risk</li> </ul> </li> <li>who have greater than 10 year life expectancy</li> <li>Meet <b>ONE of the following</b>: <ul style="list-style-type: none"> <li>has not received treatment for prostate cancer and is a candidate for active surveillance <b>or</b> definitive therapy; or</li> <li>has intermediate-risk prostate cancer when deciding whether to add androgen-deprivation therapy to radiation; or</li> <li>is appropriate for conservative management and yet would be eligible for definitive therapy (radical prostatectomy (RP), radiation or brachytherapy), or;</li> <li>is appropriate for radiation therapy and yet would be eligible for the addition of a brachytherapy boost, or;</li> <li>is appropriate for radiation therapy with short-term ADT yet would be eligible for the use of long-term ADT, or;</li> <li>is appropriate for radiation with standard ADT yet would be eligible for systemic therapy intensification using next generation androgen signaling inhibitors or chemotherapy</li> </ul> </li> <li>Patient has not had a prostatectomy (<b><i>The evidence is insufficient for or against the use of Prolaris test in patients with radical prostatectomy and it is not covered</i></b>)</li> </ol> <ul style="list-style-type: none"> <li>Very low risk patients should be considered active surveillance, Prolaris is unlikely to be helpful</li> <li>Serial testing is not covered (this is a one-time test)</li> <li>Concurrent testing with multiple assays is not medically necessary</li> </ul> <p>*NCCN Initial Risk Stratification and Staging workup for Clinically Localized Disease (see Tables)</p> <table border="1" data-bbox="613 1262 1555 1667"> <thead> <tr> <th colspan="2">Initial Risk Stratification and Staging Workup for Clinically Localized Disease</th></tr> <tr> <th colspan="2">Risk Group Clinical/Pathologic Features</th></tr> </thead> <tbody> <tr> <td>Very Low</td><td>           Has all of the following:           <ul style="list-style-type: none"> <li>cT1c</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/ml</li> <li>Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core</li> <li>PSA density &lt;0.15 ng/mL/g</li> </ul> </td></tr> <tr> <td>Low</td><td>           Has all of the following but does not qualify for very low risk:           <ul style="list-style-type: none"> <li>cT1-cT2a</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/mL</li> </ul> </td></tr> </tbody> </table>	Initial Risk Stratification and Staging Workup for Clinically Localized Disease		Risk Group Clinical/Pathologic Features		Very Low	Has all of the following: <ul style="list-style-type: none"> <li>cT1c</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/ml</li> <li>Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core</li> <li>PSA density &lt;0.15 ng/mL/g</li> </ul>	Low	Has all of the following but does not qualify for very low risk: <ul style="list-style-type: none"> <li>cT1-cT2a</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/mL</li> </ul>
Initial Risk Stratification and Staging Workup for Clinically Localized Disease									
Risk Group Clinical/Pathologic Features									
Very Low	Has all of the following: <ul style="list-style-type: none"> <li>cT1c</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/ml</li> <li>Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer in each fragment/core</li> <li>PSA density &lt;0.15 ng/mL/g</li> </ul>								
Low	Has all of the following but does not qualify for very low risk: <ul style="list-style-type: none"> <li>cT1-cT2a</li> <li>Grade Group 1</li> <li>PSA &lt;10 ng/mL</li> </ul>								

Oncology	Criteria																				
	Intermediate	Has all of the following: <ul style="list-style-type: none"><li>No high-risk group features</li><li>No very-high-risk features</li><li>Has one or more intermediate risk factors (IRFs):<ul style="list-style-type: none"><li>cT2b-cT2c</li><li>Grade Group 2 or 3</li><li>PSA 10-20 ng/mL</li></ul></li></ul>	Favorable intermediate	Has all of the following: <ul style="list-style-type: none"><li>1IRF</li><li>Grade Group 1 or 2</li><li>&lt;50% biopsy cores positive (e.g., &lt;6 of 12 cores)</li></ul>																	
			Unfavorable intermediate	Has one ore more of the following: <ul style="list-style-type: none"><li>2 or 3 IRFs</li><li>Grade Group 3</li><li>≥50% biopsy cores positive (e.g., ≥ 6 of 12 cores)</li></ul>																	
	High	Has no very-high-risk features and has exactly one high-risk feature: <ul style="list-style-type: none"><li>cT3a OR</li><li>Grade Group 4 or Grade Group 5 OR</li><li>PSA &gt;20 ng/mL</li></ul>																			
	Very High	Has at least one of the following: <ul style="list-style-type: none"><li>cT3b-cT4</li><li>Primary Gleason pattern 5</li><li>2 or 3 high-risk features</li><li>&gt;4 cores with Grade Group 4 or 5</li></ul>																			
	<table><tr><th>Grade Group</th><th>Gleason Score</th><th>Gleason Pattern</th></tr><tr><td>1</td><td>&lt;6</td><td>&lt;3 + 3</td></tr><tr><td>2</td><td>7</td><td>3 + 4</td></tr><tr><td>3</td><td>7</td><td>4 + 3</td></tr><tr><td>4</td><td>8</td><td>4 + 4, 3 + 5, 5 + 3</td></tr><tr><td>5</td><td>9 or 10</td><td>4 + 5, 5 + 4, 5 + 5</td></tr></table>				Grade Group	Gleason Score	Gleason Pattern	1	<6	<3 + 3	2	7	3 + 4	3	7	4 + 3	4	8	4 + 4, 3 + 5, 5 + 3	5	9 or 10
Grade Group	Gleason Score	Gleason Pattern																			
1	<6	<3 + 3																			
2	7	3 + 4																			
3	7	4 + 3																			
4	8	4 + 4, 3 + 5, 5 + 3																			
5	9 or 10	4 + 5, 5 + 4, 5 + 5																			
<a href="#">*NCCN Initial Risk Stratification and Staging Workup for Clinically Localized Disease</a>																					
Prostate Cancer – SelectMDx (CPT code 0339U)	There is insufficient evidence in the published medical literature to show clinical utility.																				
Proteomics - Ovarian Cancer Biomarker Panel (ROMA)	MCG* A-0858: This is not covered per MCG*																				
Proteomics (VeriStrat)	Epidermal Growth Factor Receptor Testing is covered when: 1) Diagnosis of NSCLC																				
Renal Cancer (Hereditary) - Gene Panel	MCG* A-0801: Considered medically necessary if indications in MCG A-0801 are met.																				
Retinoblastoma - RB1 Gene	MCG* A-0586																				
Thyroid Nodule Gene Expression Testing	<table><tr><th>Test</th><th>Criteria</th></tr><tr><td>Afirma 81546 Thyroseq 0026U</td><td>There is insufficient evidence in the published medical literature to show clinical utility.</td></tr></table>				Test	Criteria	Afirma 81546 Thyroseq 0026U	There is insufficient evidence in the published medical literature to show clinical utility.													
Test	Criteria																				
Afirma 81546 Thyroseq 0026U	There is insufficient evidence in the published medical literature to show clinical utility.																				

Oncology	Criteria
	<p>ThyGeNEXT® Thyroid Oncogene Panel + ThyraMIR Thyroid miRNA Classifier</p> <p>(CPT Codes 0245U+0018U)</p> <p>Molecular profiling of thyroid nodules with indeterminate cytology for ThyGeNext/ThyraMIR is medically necessary when specific criteria are met:</p> <ul style="list-style-type: none"> <li>Thyroid nodule gene expression testing may be indicated when <b>ALL</b> of the following are present: <ul style="list-style-type: none"> <li>Thyroid nodule, as indicated by <b>ALL</b> of the following: <ul style="list-style-type: none"> <li>Diameter of 1 cm or greater on ultrasound</li> <li>Indeterminate cytology on fine needle aspirate, as indicated by <b>1 or more</b> of the following: <ul style="list-style-type: none"> <li>Atypia of undetermined significance (ie, Bethesda System for Reporting Thyroid Cytopathology category III)</li> <li>Follicular lesion of undetermined significance (ie, Bethesda System for Reporting Thyroid Cytopathology category III)</li> <li>Follicular neoplasm or suspicious for follicular neoplasm (ie, Bethesda System for Reporting Thyroid Cytopathology category IV, excluding Hurthle cell type)</li> </ul> </li> </ul> </li> </ul> </li> </ul>
Von Hippel-Lindau Syndrome - VHL Gene	MCG* A-0583
Wilms Tumor - WT1	MCG* A-0615

Ophthalmology	Criteria
Age-Related Macular Degeneration - Gene Panels	MCG* A-0913 This is not covered per MCG
Retinal Disorders - Gene Panels	Retinal Disorders (Hereditary) Gene Panels (KP-0912 07012024)
Retinal Dystrophy - RPE65 Gene	MCG* A-1011

Orthopedics	Criteria
Ankylosing Spondylitis - HLA-B27 Testing	MCG* A-0762
Osteogenesis Imperfecta - Gene and Gene Panel Testing	MCG* A-0796

Pulmonary	Criteria
Alpha-1 Antitrypsin Deficiency - SERPINA1 Gene Ambulatory Care > Genetic Medicine > Pulmonary > Alpha-1 Antitrypsin Deficiency - SERPINA1 Gene (A-1006)	<p>MCG* KP-1006</p> <p><i>Note – this is a KP hybrid, not MCG A-1006</i></p>
Beta2-Agonist Pharmacogenetics- ADRB2 Gene	There is insufficient evidence in the published medical literature to show clinical utility.
Cystic Fibrosis-CFTR Gene and Mutation Panel:	<p>Does not require medical review in the prenatal setting. For all other indications refer to MCG* <b>KP-0597</b></p> <p><i>Note – this is a KP hybrid, not MCG A-0597</i></p>



Pulmonary	Criteria
Cystic Fibrosis Carrier Testing	Preconception or prenatal carrier testing for cystic fibrosis (CF) with targeted mutation analysis of 23 CFTR mutations (CPT code 81220) as described by the American College of Medical Genetics (ACMG) is considered medically necessary for a prospective biologic parent with the capacity and intention to reproduce. Any testing beyond the 23 gene CFTR mutations recommended by ACMG will not be covered as its utility has not been established. Testing is covered only once in a lifetime. ACMG Guideline - Minimum Mutation Panel for Population-Based Carrier Screening Purposes <a href="#">CF 3.3.1.</a>
Congenital Central Hypoventilation Syndrome - PHOX2B Gene	There is insufficient evidence in the published medical literature to show clinical utility.

Risk Prognosticator Test	Criteria
<ul style="list-style-type: none"> <li>BREVAGen™</li> <li>Fibroblast Growth Factor Receptor 3 (FGFR3)</li> <li>OVA1™ Test for the Assessment of Suspected Ovarian Cancer</li> </ul>	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long- term outcomes than current standard services/therapies.
<ul style="list-style-type: none"> <li>MammaPrint Test (Gene-Expression Profiling Test, 70-Gene Prognostic Signature)</li> </ul>	<p>Medically necessary when <b>ALL</b> of the following criteria are met:</p> <ol style="list-style-type: none"> <li>The patient has ER-positive, HER2-negative breast cancer <b>and</b></li> <li>One to three lymph nodes are positive for metastasis <b>and</b></li> <li>The patient is at high clinical risk for recurrence <b>and</b></li> <li>Outcome of testing will guide decision making regarding adjuvant chemotherapy.</li> </ol>

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Any genetic counseling notes if applicable Results of prior genetic testing
- Last 6 months of specialist notes of that is being reviewed (i.e., neurological notes, medical oncology notes, cardiology notes)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Evidence and Source Documents

[Afirma](#)

[Array Comparative Genomic Hybridization \(aCGH\) for the Genetic Evaluation of Patients with Intellectual Disability](#)

[ConfirmMDx for Prostate Cancer \(MDxHealth Inc.\)](#)

[Polaris for Prostate Cancer](#)

[DecisionDx- Melanoma](#)

[HLA Testing for Celiac Disease](#)

[Micro Array for Evaluation of Intellectual Disability](#)

[OVA1 for Assessment of Ovarian Cancer](#)

[Risk Prognosticator Tests](#)

[SelectMDx for Prostate Cancer \(MDxHealth Inc.\)](#)[Thyroid Nodule Gene Expression Testing \(Afirma\)](#)[Whole Genome/Exome Sequencing for Developmental Delay \(DD\)/Intellectual Disability \(ID\)](#)

## Background

Genetic screening is used to identify the genetic disorders or the potential for transmission of genetic disorders in populations at risk for a particular genetic disorder. Genetic screening is only appropriate when the natural history of the disease is understood; the screening tests are valid and reliable; sensitivity, specificity, false-negative, and false-positive rates are acceptable; and effective therapy is available. A sufficient benefit must be derived from a screening program to justify its cost.

## Medical Technology Assessment Committee (MTAC)

### **Afirma**

#### BACKGROUND

Thyroid nodules are clinically identified in 5-7% of the population, and incidentally on ultrasonography in up to 50% of women and 20% of men over the age of 50. Thyroid nodules are typically benign, but 5-15% prove to be malignant. It is thus recommended that any identified nodule measuring one centimeter or more in diameter be diagnostically evaluated. Ultrasound-guided fine needle aspiration (FNA) biopsy is the most widely used method for clinical evaluation of a suspicious thyroid nodule. FNA is a safe and simple outpatient procedure that yields cellular material suitable for cytological analysis. It can identify approximately 50% of malignant nodules and 70% of benign nodules without the need to perform a diagnostic surgery. However, 15-30% of the biopsied nodules have indeterminate cytology and cannot be conclusively diagnosed by FNA biopsy alone. Most patients with indeterminate lesions or lesions suspicious for malignancy, according to the Bethesda classification\* system, are referred to surgery for both diagnostic and therapeutic purposes. Surgery is the recommended and appropriate treatment for thyroid cancer, however 70-75% of the nodules with indeterminate FNA cytology are found to be benign on final surgical pathology. Thus, a large proportion of these patients may undergo unnecessary partial or complete thyroidectomy with its potential surgical complications and risk of long-term morbidity (Alexander 2012, Duick 2012, Walsh 2012, Ali 2013, Labourier 2015, Sacks 2016).

Molecular markers and assays have been investigated for their ability to preoperatively classify the indeterminate thyroid nodules. Each has its performance characteristics and diagnostic values. Ideally a molecular marker or panel of markers is accurate in differentiating benign from malignant in any lesion that is considered suspicious or indeterminate. Molecular tests should also be simple to use, reproducible by the different institutions/laboratories, and cost-effective.

Molecular genetic testing for cytologically indeterminate thyroid nodules fall in two approaches: the “rule in” and the “rule-out” disease approach. Tests that rule-in malignancy (such as BRAF, RAS mutations, RET/PTC and PAX8-PPAry) have high specificity and positive predictive values (PPVs) for malignancy by identifying specific mutations or gene rearrangements known to be present in thyroid cancer. However, they have limited sensitivity and negative predictive values (NPVs) and fail to detect as many as 30% of malignancies. Tests that rule-out the disease on the other hand, should have a high sensitivity and negative predictive value in order to exclude malignancy when the test results are benign. Because a majority of nodules with indeterminate cytology are found to be benign on surgical resection, a test that can preoperatively rule-out malignancy may spare a subset of these patient’s unnecessary diagnostic surgeries (Alexander 2012, Kouniavsky 2012, Ward 2013, Chaudhary 2016, Nishino 2016).

\*2008 Bethesda classification system for thyroid cytology: Class I: Nondiagnostic or unsatisfactory, Class II: Benign, Class III: atypia or follicular lesion of undetermined significance (AUS/FLUS), Class IV: follicular neoplasm or suspicious for follicular neoplasm (FN), Class V: suspicious for malignancy (SUSP) and Class VI: malignant) (Kuo, 2016)

Afirma gene expression classifier (GEC) is a molecular test developed by Veracyte Inc. (San Francisco, CA) with the intention of reducing unnecessary diagnostic surgeries in patients with thyroid nodules with indeterminate FNA cytopathologic results. It represents the “rule-out” approach by preoperatively identifying the benign thyroid nodules and ruling-out malignancy. Afirma GEC uses a proprietary diagnostic algorithm that analyses the mRNA expression of 167 genes to identify the signature of benign thyroid nodules. 142 of the 167 genes are in the main classifier, and 25 genes filter out rare neoplasms. The selected gene profile is based on the gene expression identified from FNAs of surgically proven benign and malignant thyroid nodules. During the Afirma GEC test RNA is extracted from the FNA sample, amplified and hybridized to a custom microarray to examine for gene patterns. These are compared with the GEC proprietary panel, which molecularly classifies them as either ‘benign’ or ‘suspicious’. Insufficient RNA

in the sample leads to 'no result' conclusion in approximately 10% of cases. Nodules with benign results, in addition to clinical judgement, are typically followed up clinically and ultrasonography, while those with suspicious results undergo diagnostic thyroid lobectomy with possible total thyroidectomy (Alexander 2012, Kim 2012, Ward 2013, Kuo 2016, Witt 2016).

Afirma GEC is a proprietary test commercially owned by Veracyte Corporation and is offered through a sole source, which is a Clinical Laboratory Improvement Amendments certified [CLIA] reference laboratory. During a routine FNA of a thyroid nodule, after the aspirates are obtained for cytopathologic examination, two more needle passes are obtained for Afirma analysis and immediately stored in a preservative. These are either 1. Sent to a Veracyte independent industry partner (Thyroid Cytopathology Partners [TCP], Austin, TX) that performs cytopathologic exam of the FNA sample, and only runs the Afirma test for indeterminate diagnoses on cytopathology, or 2. In Thyroid Cytopathology Medical centers designated as "Enabled centers" cytopathology is done in-house and specimens with indeterminate results based on the Bethesda criteria are sent for Afirma GEC testing. Afirma test is run only on nodules with indeterminate cytology. If the cytopathologic evaluation reveals any other diagnosis or is nondiagnostic due to insufficient FNA samples, the preserved samples are discarded. The goal of the test is to identify the benign nodules from among those with indeterminate cytopathology. It is not intended to assist with clinical decision making for patients who have an indication for surgery or meet criteria for surgical interventions (Alexander 2012, Duick 2012, Ward 2013, Kuo 2016, Yip 2016).

### 03/20/2017: MTAC REVIEW

**Evidence Conclusion:** Based on the results of the published studies, some investigators suggest that Afirma GEC may provide useful information in practice settings where the prevalence of malignancy in indeterminate thyroid nodules is 15-21%. At this range and using the sensitivity and specificity data from the multicenter validation study the NPV would be >95% and the PPV >25%. It is suggested that GEC may also provide some useful information with the prevalence of malignancy ranging from 12-25% but is not expected to be useful in altering management if the prevalence is outside this range (Marti 2015, Zhang 2016). The Afirma GEC performance was found to be suboptimal for Hurthle cell neoplasms (HCNs). Wu and colleagues (2016) examined the clinical factors influencing the performance of GEC testing and found that the test has a limited clinical validity for HCNs due to the high rate of false positive results (specificity 22.7-26.1% and PPV 29.2%). Other studies also showed inconsistent and low performance of GEC testing for HCN nodules. In the clinical validation study only 4 of 21 (19%) FNA samples from Hurthle adenomas were classified as benign with GEC.

**Articles:** The updated literature search revealed a number of retrospective analyses performed after the Afirma GEC validation study, a meta-analysis that pooled the results of selected studies, and three retrospective studies on the clinical utility of the test. The study on the analytic validity, the two clinical validation studies as well as two retrospective studies on clinical utility were reviewed earlier by MTAC. The meta-analysis and the more recent studies on the clinical validity and clinical utility of Afirma GEC test were reviewed and their results summarized.

### 04/12/2022: MTAC Review

#### Thyroid Nodule Molecular Testing

**Evidence Conclusion:** Analytical validity: One study showed that Afirma GSC test has a strong analytic performance and is reproducible. Clinical validity: Low quality evidence suggests that: Afirma GSC test has a good diagnostic performance. Comparison to ThyroSeq v3 and ThyraMIR/ThyGeNEXT: the diagnostic performance cannot be ranked due to lack of head-to-head comparisons. Clinical utility: The evidence is insufficient (very low quality) for or against the use of Afirma GSC to reduce unnecessary surgery in patients with indeterminate thyroid nodules.

**Articles:** PubMed was searched through October 26, 2021. The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. Search terms included: (Afirma Genomic Sequencing Classifier OR Genomic Sequencing Classifier OR GSC OR Afirma OR Veracyte) AND (thyroid) through 10/21/21. For Thyroseq v3, search terms included ThyroSeq v3Regarding ThyGeNEXT and ThyraMIR, search terms included Interpace or ThyGeNEXT or ThyraMIR. Afirma GSC: The search yielded several articles. After screening through abstracts and/or full text, 9 studies were retained and reviewed. The studies consisted of 1 analytical validity study, four clinical validity studies, and four clinical utility studies. Thyroseq v3: The search yielded several articles. Studied retained are critically appraised. ThyGeNEXT and ThyraMIR: The search yielded several articles. Studied retained are critically appraised. See Evidence tables.

The use of Thyroid Nodule Molecular Testing does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Intellectual Disability**

### **BACKGROUND**

Intellectual disability, also termed mental retardation or cognitive disability, affects approximately 1-3% of the general population and is defined as a significant impairment in cognitive and adaptive functions, with the age of onset before 18 years. It is a serious and lifelong condition that presents significant challenges to families and to public health. Determining the specific etiology of intellectual disability may help to provide answers related to prognosis, recurrence risk, and treatment. Intellectual disability can be caused by anything that damages or interferes with the growth or maturation of the brain; however, genetic (chromosomal) abnormalities are one of the main causes of intellectual disability (Galasso 2010, Sagoo 2009). Chromosomal abnormalities are deletions and duplications of genomic material and are commonly referred to as copy number variations. Conventional methods for detecting these abnormalities include karyotyping and fluorescent in situ hybridization (FISH). Karyotyping involves visualizing the chromosome for large gains or losses in chromosomal material and is generally the first step in cytogenetic analysis. Karyotyping can detect chromosomal abnormalities such as deletions, duplications, inversions, and translocations across the entire genome; however, it lacks the resolution necessary to detect abnormalities smaller than 3-5 megabases (Mb; 3-5 million base pairs). FISH uses fluorescent-labeled chromosome-specific probes to detect chromosomal abnormalities. FISH can detect submicroscopic abnormalities and is often used in situations where the karyotype is normal, but there is a high clinical suspicion of a deletion syndrome. However, FISH is a targeted method and requires prior knowledge of the chromosome region(s) of interest to request the appropriate FISH test. Additionally, FISH can only screen a limited number of genomic regions at a time (Bremner 2009, Fruhman 2010, Galasso 2010, Gropman 2010). Array comparative genomic hybridization (aCGH) is a more recent technology used to identify copy number variations by comparing patient DNA with reference DNA. It is currently used as an adjunct to conventional methods. There are two types of aCGH: targeted and whole-genome. Targeted arrays are designed to interrogate areas of the genome with known clinically significant abnormalities. Whole genome arrays provide high resolution coverage of the entire genome. This can lead to the discovery of new copy number variations. Compared to conventional methods, aCGH has a higher resolution and is able to simultaneously detect copy number variations in multiple regions of the genome. Additionally, unlike FISH, knowledge of the chromosome region(s) of interest does not need to be determined in advance because a single array assay detects all genomic variants represented on the array. Array CGH is not without limitations. It cannot detect totally balanced translocations or inversions; it performs suboptimally for polyploidy; and has not been optimized for prenatal diagnosis of point mutations. Because aCGH cannot identify the exact location of a duplicated chromosome, further testing with karyotype or FISH may be necessary. Another limitation is the potential to identify novel copy number variants with unknown clinical significance (Fruhman 2010, Moeschler 2008). Array CGH is a laboratory-developed test and is commercially available from several different laboratories. Laboratory-developed tests are licensed under the Clinical Laboratory Improvement Amendments (CLIA) and do not require clearance from the FDA.

The use of Gene Expression Classifier (Afirma®) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **4/18/2011: MTAC REVIEW**

#### **Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Intellectual Disability**

**Evidence Conclusion:** Analytic validity The BCBS review identified several studies that evaluated the sensitivity of aCGH. The sensitivity of aCGH testing compared to conventional methods (karyotype and/or FISH) ranged from 73% to 100%. As false-positive rates were inconsistently reported, specificity could not be determined (BCBS 2009). Clinical validity

**Articles:** No studies were identified that evaluated the impact of conventional methods or aCGH on patient outcomes other than diagnostic yield. Results from the BCBS review suggest that diagnostic yield in patients with intellectual disability ranged from 5 to 16.7%, which represents a significant improvement compared to conventional methods. The number needed to test by aCGH to detect one clinically relevant abnormality ranged from 25 to 6 depending on the diagnostic yield.

The use of Array Comparative Genomic Hybridization (aCGH) for the genetic evaluation of patients with intellectual disability does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **HLA Testing for Celiac Disease**



## BACKGROUND

Celiac disease is a chronic, autoimmune disorder that affects approximately 1% of children and adults in the United States. In individuals with celiac disease, the ingestion of gluten proteins found in wheat, rye, and barley lead to an autoimmune reaction that causes small intestine mucosal injury. Damages in the small intestine can cause gastrointestinal symptoms and interfere with the absorption of nutrients from food. This may lead to malnutrition-related problems such as anemia, vitamin deficiencies, osteoporosis, and neurological disorders. A gluten-free diet typically resolves symptoms and can prevent long-term consequences (Tack 2010). There are a variety of tests available to diagnose celiac disease. The gold-standard for diagnosing celiac disease is a small intestine biopsy. However, this test is not a perfect gold-standard as false positive and false-negative results may occur due to interobserver variability, patchy mucosal damage, low-grade histological abnormalities, and technical limitations. Additionally, histological features are not unique to celiac disease. Serum antibody tests are used as an initial screening tool to detect and support the presence of celiac disease and to select which patients should undergo a biopsy. Two of the most sensitive and specific serological tests for diagnosing celiac disease are tests that assess the presence of IgA autoantibodies against the endomysium of connective tissue (EMA) (sensitivity 62-81%, specificity 80-99%) and against tissue transglutaminase (tTGA) (sensitivity 81-88%, specificity 84-99%). While these tests are accurate, they are not without limitations. For example, the EMA test correlates with the degree of mucosal damage. As such, the sensitivity of this test is lower in patients with milder cases (higher chance of false negative results). Additionally, false negative results may occur in patients with an IgA deficiency and in patients who are already on a gluten-free diet. In patients with an IgA deficiency, serum IgA testing can be replaced by using IgG assays, which are less sensitive than IgA assays. Another test that can be used to rule out the diagnosis of celiac disease is human leukocyte antigen (HLA) genotyping. It has been reported that approximately 90-95% of patients with celiac disease are carriers of the HLA-DQ2 heterodimer and most of the remaining patients carry the HLA-DQ8 heterodimer. Since virtually all patients with celiac disease carry one of these heterodimers, celiac disease is highly unlikely when both are absent. It has been proposed that using HLA genotyping as an initial screening tool may avoid future concerns about the condition and eliminate further diagnostic testing. However, HLA typing is not a perfect solution since around 25-40% of the general population carries either HLA-DQ2 or DQ8, of which the majority never develop the disease. Other situations where HLA genotyping may be useful is when the diagnosis of celiac disease is unclear based on serological and/or histological findings. Additionally, HLA genotyping can be performed in patients who are already on a gluten free diet (Tack 2010, Hadithi 2010).

## 4/18/2011: MTAC REVIEW

### HLA Testing for Celiac Disease

**Evidence Conclusion:** Analytic validity There are a variety of methods used for HLA genotyping. Each of these assays has its advantages and limitations (Monsuur 2008, Lavant 2009). Clinical validity A recent prospective cohort study evaluated the accuracy of serologic tests and HLA-DQ genotyping used alone and in combination for diagnosing celiac disease compared to small intestine biopsy. Results from this study suggest that both tTGA and EMA are sensitive and specific tests for diagnosing celiac disease. HLA-DQ testing was also highly sensitive but was not as specific as serologic testing. The addition of HLA-DQ genotyping to serum antibody tests did not increase test performance compared to serologic testing alone. Results should be interpreted with caution as only 16 patients were diagnosed with celiac disease (Hadithi 2007).

**Articles:** Articles were selected for review if they included at least 25 subjects and assessed the accuracy of HLA genotyping compared to the small intestine biopsy. A prospective cohort study was selected for review. The following study was critically appraised: Hadithi M, von Blomberg ME, Crusius BA, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. *Ann Intern Med* 2007; 147:294-302. See [Evidence Table](#)

The use of HLA testing for celiac disease does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### Micro Array for Evaluation of Intellectual Disability

#### BACKGROUND

Intellectual disability, also termed mental retardation or cognitive disability, affects approximately 1-3% of the general population and is defined as a significant impairment in cognitive and adaptive functions, with the age of onset before 18 years. It is a serious and lifelong condition that presents significant challenges to families and to public health. Determining the specific etiology of intellectual disability may help to provide answers related to prognosis, recurrence risk, and treatment.

Intellectual disability can be caused by anything that damages or interferes with the growth or maturation of the

brain; however, genetic (chromosomal) abnormalities are one of the main causes of intellectual disability (Galasso 2010, Sagoo 2009).

Chromosomal abnormalities are deletions and duplications of genomic material and are commonly referred to as copy number variations. Conventional methods for detecting these abnormalities include karyotyping and fluorescent in situ hybridization (FISH). Karyotyping involves visualizing the chromosome for large gains or losses in chromosomal material and is generally the first step in cytogenetic analysis. Karyotyping can detect chromosomal abnormalities such as deletions, duplications, inversions, and translocations across the entire genome; however, it lacks the resolution necessary to detect abnormalities smaller than 3-5 megabases (Mb; 3-5 million base pairs).

FISH uses fluorescent-labeled chromosome-specific probes to detect chromosomal abnormalities. FISH can detect submicroscopic abnormalities and is often used in situations where the karyotype is normal, but there is a high clinical suspicion of a deletion syndrome. However, FISH is a targeted method and requires prior knowledge of the chromosome region(s) of interest to request the appropriate FISH test. Additionally, FISH can only screen a limited number of genomic regions at a time (Bremner 2009, Fruhman 2010, Galasso 2010, Gropman 2010).

Array comparative genomic hybridization (aCGH) is a more recent technology used to identify copy number variations by comparing patient DNA with reference DNA. It is currently used as an adjunct to conventional methods. There are two types of aCGH: targeted and whole-genome. Targeted arrays are designed to interrogate areas of the genome with known clinically significant abnormalities. Whole genome arrays provide high resolution coverage of the entire genome. This can lead to the discovery of new copy number variations. Compared to conventional methods, aCGH has a higher resolution and is able to simultaneously detect copy number variations in multiple regions of the genome. Additionally, unlike FISH, knowledge of the chromosome region(s) of interest does not need to be determined in advance because a single array assay detects all genomic variants represented on the array. Array CGH is not without limitations. It cannot detect totally balanced translocations or inversions; it performs suboptimally for polyploidy; and has not been optimized for prenatal diagnosis of point mutations. Because aCGH cannot identify the exact location of a duplicated chromosome, further testing with karyotype or FISH may be necessary. Another limitation is the potential to identify novel copy number variants with unknown clinical significance (Fruhman 2010, Moeschler 2008).

Array CGH is a laboratory-developed test and is commercially available from several different laboratories. Laboratory-developed tests are licensed under the Clinical Laboratory Improvement Amendments (CLIA) and do not require clearance from the FDA.

**Date: 07/09/2018 MTAC REVIEW*****Chromosomal microarray for Intellectual Disability (ID)/ Developmental delay (DD)*****BACKGROUND**

Intellectual disability is a disorder marked by deficits in intellectual and adaptive functioning and starts before 18 years of age. Its management requires early diagnosis and extensive supports. Intellectual disability is caused by any conditions disrupting brain development. Of these conditions, genetic abnormalities are the most common known etiologies (Rauch et al., 2012) with Down syndrome being the leading cause. Conventional cytogenetics (karyotype analysis and fluorescence in situ hybridization (FISH)) can identify the cause but detect less than 10% of chromosomal abnormalities in patients with intellectual disability (ID) or developmental delay (DD) (Shaffer, Beaudet, et al., 2007; Shaffer, Bejjani, et al., 2007). Chromosomal microarray analysis (CMA) has become the primary test for most patients with intellectual disability (Miller et al., 2010). CMA includes array-based comparative genomic hybridization (aCGH) or single nucleotide polymorphism (SNP) microarray analysis.

Array-based comparative genomic hybridization (aCGH), also known as oligonucleotide array comparative genomic hybridization utilizes both patient and control genomes. These DNAs are marked with fluorescent dyes and applied to the microarray. This step is followed by hybridization. Hybridization occurs when patient and control DNAs compete to attach to the microarray which is comprised of thousands of DNA segments (bacterial artificial chromosome clones of > 10 kilobases or oligonucleotides of 50–70 base pairs). Fluorescent signals are assessed by a scanner and a computer analyzes the data and generates a plot. This results in the identification of copy number changes (Theisen et al., 2008(Shaffer et al., 2008)). It is believed that the aCGH concurrently detects copy number variants (CNVs) (deletions, duplications), and/or amplifications across the genome. However, the array-based comparative genomic hybridization cannot detect low-level mosaicism or balanced chromosomal rearrangements (Brady & Vermeesch, 2012). The results of the CMA are interpreted as benign with no impact on phenotype, or pathogenic/clinical significant, or uncertain clinical significance. In the latter category, samples from parents are required for assessment of the clinical significance (Miller et al., 2010; Paciorkowski & Fang, 2009). If the CMA does not detect a cause, whole



exome sequencing (WES) may be performed. Single nucleotide polymorphism (SNP) arrays is a variation of DNA sequence that occurs when there is a discrepancy between a single nucleotide and a reference sequence in the same person. Single nucleotide polymorphism is used as the probes. Only the patient sample is hybridized onto the array (Das & Tan, 2013). SNP can detect copy number changes, uniparental disomy, consanguinity, and balanced translocations (Conlin et al., 2010; Schaaf, Wiszniewska, & Beaudet, 2011; Wiszniewska et al., 2014). No FDA regulatory information was found on FDA website on March 12, 2018. However, genetic tests are controlled under the Clinical Laboratory Improvement Amendments (CLIA). The technology is being assessed for the first time on Medical Technology Assessment Committee (MTAC).

### **Evidence Conclusion:**

- **Analytic validity:** Four studies were reviewed and showed high sensitivity and specificity with high concordance in comparison to FISH or karyotyping. This suggests that chromosomal microarray can accurately detect copy number variants in children and adolescents with developmental delay or intellectual disability. The studies were retrospective in design or case series resulting in low evidence.
- **Clinical validity:** Nine studies (please refer to “other studies table” and table 2) in addition to those included in Milliman review (evidence table 1) were evaluated. In children and adolescents with unexplained developmental delay or intellectual disability, chromosomal microarray (aCGH) diagnosed genomic alterations that were not detected by conventional cytogenetic tests including karyotype or FISH. This suggests that the detection rate of chromosomal microarray is higher than conventional cytogenetic tests. However, the studies reviewed were case series or retrospective chart review resulting in low evidence.
- **Clinical utility:** Two studies (please refer to “other studies table” and table 2) in addition to those included in Milliman review (evidence table 1) were evaluated. The clinical utility revolved around referrals to specialists, recommendation for screening of other anomalies, provision of recurrent risk for affected subsequent pregnancies, and avoidance of unnecessary testing. However, the studies were surveys and retrospective review with small sample size resulting in low evidence.
- Milliman Care guidelines indicated that there is a net benefit in evaluating children and adolescents with intellectual disability with chromosomal microarray analysis (CMA). The use of CMA to detect copy number variants affects medical management and this includes referrals to specialists, treatment intervention for special findings, reduction of unnecessary procedures, and screening for associated anomalies. However, the evidence is of low certainty.

The use of Chromosomal microarray for Intellectual Disability (ID)/ Developmental delay (DD) meets the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **04/18/2011: MTAC REVIEW**

#### **Array Comparative Genomic Hybridization (aCGH)**

#### **Evidence Conclusion:**

1. Analytic validity: There is fair evidence that aCGH testing had good sensitivity compared to conventional methods; however, there is insufficient evidence to determine the specificity or reproducibility of this test.
2. Clinical validity: There is fair evidence that aCGH increases diagnostic yield over conventional methods; however, this is an intermediate outcome.
3. Clinical utility: There is insufficient evidence that patients managed with the genetic test had better outcomes than patients managed without the genetic test.

**Articles:** In 2009, Blue Cross and Blue Shield (BCBS) evaluated the use of aCGH for the genetic evaluation of patients with developmental delay/ mental retardation. Studies were selected for review if they were published after the 2009 review and did not support the BCBS recommendations. No studies were identified that would change the BCBS recommendations. The following review was critically appraised: Blue Cross and Blue Shield Association.

Special report: aCGH for the genetic evaluation of patients with developmental delay/mental retardation or autism spectrum disorder. Assessment Program. Volume 23, No. 10. April 2009.

The use of Array Comparative Genomic Hybridization (aCGH) for the genetic evaluation of patients with intellectual disabilities does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Risk Prognosticator Test**

## **BREVAGen**

### **BACKGROUND**

According to the American Cancer Society, breast cancer is the second leading cause of death in women in the United States after lung cancer. Current methods of assessing breast cancer risk include the Breast Cancer Risk Assessment Tool (BCRAT) otherwise known as the Gail model. This model incorporates individual risk factors such as basic demographic information, reproductive history and medical history. Recent genome wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with an increased risk of breast cancer leading to an additional dimension and understanding of risk (Easton, Pooley et al. 2007; Stacey, Manolescu et al. 2007; Stacey, Manolescu et al. 2008). The BREVAGen™ (Phenogen Sciences, Inc., Charlotte, NC) is a risk stratification test for sporadic breast cancer. Intended for use as an adjunct to the Gail model, the test consists of two parts, the first, a series of questions to determine clinical risk and the second, a buccal swab to analyze specific genetic markers. The latter part of the test, includes a panel of seven SNPs associated with breast cancer risk and does not include either of the BRCA mutations.

Ultimately, a patient's risk is calculated by multiplying the product of the individual SNP risks by the Gail model risk. According to the BREVAGen™ website, the test is only suitable for women of European descent aged 35 years or older. No test combining the results of SNP analysis with clinical factors to predict breast cancer risk has been approved or cleared by the U.S. Food and Drug Administration (FDA). BREVAGen™ is offered as a laboratory developed tests and only requires oversight under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The development and use of this laboratory developed test is restricted to laboratories certified as high complexity under CLIA. Under the current regulatory program, CLIA requires that laboratories demonstrate quality systems which includes validation and proficiency testing.

### **12/16/2013: MTAC REVIEW**

#### **BREVAGen**

##### **Evidence Conclusion:**

Conclusion: There is no evidence to determine the analytic validity of the BREVAGen™. There is some evidence to suggest that the addition of the BREVAGen™ panel is superior in determining breast cancer risk compared to Gail score alone. There is no evidence to determine the clinical utility of the BREVAGen™.

**Articles:** A search of PubMed was completed for the period through November 2013 for studies on the accuracy of BREVAGen™ for detecting the absence or presence of certain common genetic variations associated with an increased risk for developing breast cancer. The search strategy used the terms BREVAGen, Breast Cancer Risk Tool, Gail Model, genetic risk, single nucleotide polymorphism, breast cancer, and sporadic with variations. To identify ongoing clinical trials, a search of the National Institute of Health Clinical Trials website was also conducted using the same methodology. Articles were limited to those published in the English language with human subject enrollment. The search was supplemented by an examination of article reference lists in addition to the PubMed related articles function. The literature search for BREVAGen™ revealed one publication that clinically validates the Breast Cancer Risk Model in combination with the genetic and clinical information. The following study was selected for review: Mealiffe ME, Stokowski RP, Rhees BK, et al. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. *Journal of the National Cancer Institute*. 2010;102(21):1618-1627. [See Evidence Table](#).

The use of BREVAGen does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Fibroblast Growth Factor Receptor 3 (FGFR3) for Urothelial Carcinoma**

### **BACKGROUND**

It is estimated that approximately 70,530 new cases of bladder cancer will be diagnosed in the United States in 2010, and 14,680 will die of the disease (Jemal 2010). The most commonly occurring form of bladder cancer in the United States is urothelial carcinoma (also known as transitional cell carcinoma). The clinical spectrum of urothelial carcinoma can be divided into 3 categories: non-muscle-invasive, muscle-invasive, and metastatic disease. This review will focus on non-muscle-invasive urothelial cancer (NMIUC), which makes up approximately 75-80% of urothelial carcinoma. NMIUC includes stage Ta (noninvasive papillary carcinoma), Tis (carcinoma in situ), and T1 (tumor invades subepithelial connective tissue) tumors. The standard treatment for stage Ta, Tis, and T1 tumors is transurethral resection of bladder tumor (TURBT). Depending on prognosis adjuvant intravesical chemotherapy or immunotherapy may also be considered. However, despite treatment a significant number of patients will develop recurrence within 1 to 2 years of the initial treatment. Because of the high risk of recurrence careful surveillance is required for patients with NMIUC (Chou 2010, Cheng 2011, NCCN 2011, Pollard 2010). Assessing the risk of progression and recurrence is important for planning therapy. The risk for tumor progression and recurrence is estimated using factors such as histological grade, stage, depth of invasion, and extent of disease; however, the ability of these factors to predict clinical outcome is limited (Burger 2008, Cheng 2011,

NCCN 2011). Recently, it has been suggested that molecular biomarkers such as fibroblast growth factor receptor 3 (FGFR3) may be useful for predicting clinical outcome and planning therapy. FGFR3 regulates cell growth, differentiation, and angiogenesis. More than 70% of low-grade noninvasive papillary urothelial carcinomas harbor FGFR3 mutations. Studies suggest that urothelial carcinomas that harbor FGFR3 mutations may be associated with improved prognosis (Cheng 2011). The CertNDx molecular grading assay (Predictive Biosciences, Inc.) was designed as a tool to be used in conjunction with clinical and histological parameters to aid in the clinical management of NMIBC. This test uses two biomarkers to determine molecular grade. The first biomarker is FGFR3 and the second is Ki-67, which is a marker of cell proliferation (Cheng 2011). Patients with molecular grade 1 (mG1) have FGFR3 mutations and low Ki-67 levels. Patients with molecular grade 2 (mG2) have FGFR3 mutations with high Ki-67 levels or wild-type FGFR3 and low Ki-67 levels. Patients with molecular grade 3 (mG3) are FGFR3 wild-type and have high Ki-67 levels. Patients with molecular grade 1 have favorable prognosis, patients with molecular grade 2 have intermediate prognosis, and patients with molecular grade 3 have poor prognosis.

#### 10/17/2011: MTAC REVIEW

#### Fibroblast Growth Factor Receptor 3 (FGFR3) for Urothelial Carcinoma

##### **Evidence Conclusion:**

Conclusion: Analytic validity: No studies were identified that addressed the analytic validity of the CertNDx molecular grading assay. Clinical validity: Results from observational studies regarding the prognostic value of molecular grade (FGFR3/Ki-67) are mixed. Clinical utility: No studies were identified that addressed the clinical utility of the CertNDx molecular grading assay.

**Articles:** No studies were identified that addressed the analytic validity or clinical utility of the CertNDx molecular grading assay. Several studies were identified that evaluated the clinical validity of the CertNDx molecular grading assay. The most recent study was selected for review. The following study was critically appraised: Burger M, van der Aa MN, van Oers JM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. *Eur Urol.* 2008;54:835-843. See [Evidence Table](#).

The use of FGFR3 for urothelial carcinoma does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **MammaPrint Test**

##### **BACKGROUND**

Breast cancer affects almost 10% of women in western countries and is a major cause of morbidity and mortality. Most patients with lymph node negative disease may be successfully treated with surgery and local irradiation. Those with more aggressive disease may benefit from adjuvant chemotherapy and hormone therapy which could significantly improve their overall and disease-free survival. It is generally accepted that breast cancer patients with the poorer prognosis would gain the most benefits from systemic adjuvant therapy. The use of this adjuvant therapy is thus one of the most critical treatment decisions during the clinical management of breast cancer patients. Currently those with aggressive breast cancer are identified according to a combination of criteria including age, clinical stage and size of the tumor, histological type and grade of cancer, axillary node status, and hormone-receptor status. The ability of these criteria to predict outcome and disease progression is imperfect. Within a given patient population at a specific predicted risk of recurrence, there are some patients whose actual clinical outcome does not match that predicted by the indicators. As a result, some of those who need adjuvant therapy do not receive it, while others may receive unnecessary toxic therapy (Kallioniemi 2002, DeVigier 2002). To overcome these issues, scientists are attempting to identify more accurate prognostic indicators. Microarray technology is revolutionizing researchers' understanding of cancer biology through the simultaneous study of the expression of tens of thousands of genes. Molecular profiling is the classification of tissue or other specimens for diagnostic, prognostic, and predictive purposes based on multiple gene expression. The potential value of gene expression profiling in assessing the risk of post-surgical breast cancer recurrence has been extensively investigated over the last few years. This has led to important insights in the molecular heterogeneity of cancers by revealing biologically and clinically relevant subtypes of tumors previously indistinguishable by the conventional approaches (Bertucci 2005). Due to the biological heterogeneity of breast cancers, women with the same stage of the disease may vary widely in their response to treatment and prognosis. Several gene expression-based predictors for breast cancer have been developed but have not been used in routine clinical practice. According to researchers, this is mainly due to the limited validation and the limited clinical description of the molecular subtypes. Validation is a major challenge for microarray studies especially those with clinical implications as it requires a large sample size and because the results are influenced by the patient selection and by choice of the methods used to analyze gene expression data (Calza 2006, Hu 2006, Ioannidis 2007). The Amsterdam 70-gene

profile (MammaPrint®) was first developed using supervised gene expression profiling analysis of frozen tumor samples from two distinct patient populations. All were <55 years of age and had lymph node negative disease. 44% had distant metastases within 5 years of completing treatment and 56% did not. By comparing the gene expression profile of patients with or without metastases, a signature 70-gene set that correlated with the outcome was identified and internally validated with the same group (van't Veer 2002), and externally validated in two retrospective groups (Van De Vijver 2002 and Buyse 2006, see evidence tables). MammaPrint® from Agendia is a qualitative in vitro diagnostic test service performed in a single laboratory using the gene expression profile of breast cancer tissue samples to assess a patient's risk for distant metastases. The MammaPrint assay uses a panel of the Amsterdam 70-gene profile described above. It is a microarray-based gene expression analysis of RNA extracted from breast tumor tissue. The MammaPrint® analysis is designed to determine the activity of specific genes in a tissue sample compared to a reference standard. Its index ranges from -1.0 to +1.0. Tumor samples with an index above the threshold of +0.4 are classified as low risk, and those with an index equal to or less than the threshold is classified as high risk. The test requires fresh frozen samples which are shipped to the Agendia reference laboratory in the Netherlands. It is performed for breast cancer patients <61 years old, with Stage I invasive breast cancer or Stage II node negative invasive breast cancer, with tumor size <5 cm. It is indicated for use by physicians as a prognostic marker only, along with other clinicopathological factors. It is not intended for diagnosis, or for predicting or detecting response to therapy, or to help select the optimal therapy for patients (FDA).

## 08/06/2007: MTAC REVIEW

### MammaPrint Test

**Evidence Conclusion:** The identification and validation of gene expression panels to improve risk prediction or treatment outcomes is a multistep process that starts by 1. Identifying the candidate genes (analytic validity), followed by 2. Evaluating the genetic panel associations with risk prediction or treatment outcomes in preliminary performance studies in relevant population (clinical validity), and 3. Determining whether the use of the multigenetic assay would direct the management of patients and improve outcomes (clinical utility). The most reliable method for validation is to derive a prognostic/predictive gene set from a training set and then apply it to a completely independent set, the test set, (Simon 2003, Ionnidis 2006, and Hu 2006). The MammaPrint test was developed based on research performed in the Netherlands Cancer Institute. The training set was derived from a study by van't Veer and colleagues that included 98 women < 55 years of age at diagnosis, with primary breast cancer (34 developed distant metastases within 5 years, 44 were disease free after at least 5 years). All patients were lymph node negative. 5 µg total RNA was isolated from frozen tumor material for each patient. The authors used inkjet-synthesized oligonucleotide microarrays that included 25,000 genes. Following several techniques 5000 genes were selected from the microarray, and then optimized to 70 genes with which a prognosis profile was established. The authors conducted a cross validation and concluded that a classification system based on these 70 genes outperformed all clinical variables in predicting the likelihood of distant metastases within five years. They noted however, that a selection of the patients based on the outcome (distant metastases or disease free in 5 years) was a limitation to the study. The same research team followed the initial study with a validation study (Van De Vijver, 2002) that included 295 women with either lymph node negative or lymph node positive breast cancer. The authors calculated the correlation coefficient of the level of expression of the 70- predictor genes identified in their initial study. They then classified the women with a correlation coefficient > 0.4 as having a good prognosis gene expression signature, and all the others as having a poor prognosis gene expression signature. In this validation set however the authors included 61 patients from the original training group used to derive the RNA expression signature, which could overestimate the relative risk and inflate the discriminating power of the test. The validation study included women < 55 years of age, with small tumors and at stage I or II of the disease which may not represent the entire spectrum of patients with breast cancer. Adjuvant hormone therapy or chemotherapy or both were given to most of the patients with lymph node positive disease. The Translational Research Network of the Breast International group (TRANSBIG) also conducted an independent validation study of the prognostic signatures in a retrospective series of 302 untreated patients in five European countries. The study included only women node negative early stage breast cancer who had not received systemic adjuvant therapy, and thus may not represent the all patients with breast cancer. Its overall results showed that the 70-gene signature provided prognostic information on time to distant metastases and overall survival independent of the other clinical predictors. In conclusion, the selection of the 70- predictor genes were based on analyses of tumors from patients < 55 years of age with lymph node negative cancer who do not represent all women with breast cancer. The test proved to perform well as an independent prediction tool among the selected women studied. This, however, does not necessarily indicate that it would predict treatment response. To date there are no published studies that show if modification of adjuvant therapy based on this test would improve disease free or overall survival. A large randomized controlled trial (Microarray for Node negative Disease may Avoid Chemotherapy [MINDACT]) that will evaluate the clinical utility of MammaPrint is underway. The trial will directly compare the use of prognostic



information provided by the standard clinicopathological criteria vs. the MammaPrint test to decide whether to offer adjuvant chemotherapy to node-negative breast cancer patients. The MINDACT plans to prospectively include 6000 women and follow-them up for a long duration in order to determine 5-year disease free-survival rate.

**Articles:** The literature search revealed multiple articles on molecular and gene-expression profiling in general. For the MammaPrint test in particular, there was a published study on the training set (to develop or derive the predictive classifier or model) by Van't Veer and colleagues, and three validation studies to evaluate the predictive accuracy of the model (Van De Vijver 2002, Buyse 2006, and Glas 2006). All studies were reviewed but only the first two validation studies were critically appraised, Glas, et al's study was not selected for critical appraisal due to patient overlap with the van De Vijver study. It is to be noted that Van De Vijver, van't Veer, and several other principal authors are named inventors on a patent application for the 70-gene signature used in the studies. All studies also had financial ties to the manufacturer. *The following studies were critically appraised:*

Van De Vijver MJ, He YD, van't Veer LJ, et al. A gene expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002;347:1999-2009. See [Evidence Table](#). Buyse M, van't Veer, L, Viale G et al on behalf of the TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node negative breast cancer. *J Natl Cancer Inst* 2006;98:1183-1192. See [Evidence Table](#).

The use of the MammaPrint test in the treatment of recurring cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **OVA1™ Test for the Assessment of Suspected Ovarian Cancer**

#### **BACKGROUND**

In the United States, ovarian cancer is the fifth leading cause of all cancer-related death among women. It is estimated that in 2010, there were 21,880 new cases of ovarian cancer and 13,850 deaths from ovarian cancer (Jemal 2010). The incidence of ovarian cancer increases with age with approximately two thirds of cases being diagnosed in women over the age of 55. Women with a family history of ovarian or breast cancer or who are carriers of the BRCA gene mutations are also at increased risk for ovarian cancer (Clarke-Pearson 2009). For patients with early stage disease, survival rates are greater than 90%; however, they are less than 30% for patients with advanced disease. Because of the lack of specific symptoms during the early stage approximately 70% of cases are diagnosed with advanced disease (Carter 2011). The most commonly used tests for the detection of ovarian cancer are transvaginal ultrasound (TVS) and serum CA-125. Recently, the FDA approved the OVA1™ test (Quest Diagnostics, Inc.) to be used as an adjunct to clinical/radiological evaluations for women planning surgery for an adnexal mass. This test measures the serum levels of 5 potential biochemical markers for ovarian cancer (transferrin, apolipoprotein A1, transferrin, CA-125, and  $\beta_2$ -microglobulin). The results of the test are then interpreted using a proprietary algorithm to yield a single score ranging from 0 to 10 to indicate the likelihood that the adnexal mass is benign or malignant. A high probability for malignancy is defined as a score of at least 5.0 in premenopausal women or 4.4 in postmenopausal women. The goal of the OVA1™ test is to provide additional information to aid in identifying patients who should be referred to a gynecologic oncologist for surgery (Carter 2011, Muller 2010). Studies suggest that women who receive their initial surgical care from an experienced gynecologic oncologist have improved outcomes and greater overall survival. Because of this the National Comprehensive Cancer Network (NCCN) recommends that all patients should undergo surgery by an experienced gynecologic oncologist (NCCN 2011). It is important to emphasize that this test is not approved for ovarian cancer screening and is not intended for use as a standalone test. Another limitation of this test is that assay interference may occur in patients with rheumatoid factor levels of at least 250 IU/mL and triglyceride levels greater than 4.5 g/L (Muller 2010). In 2009, the FDA approved the use of this test for women over the age of 18 with an ovarian adnexal mass for which surgery is planned and have not yet been referred to an oncologist.

#### **10/17/2011: MTAC REVIEW**

### **OVA1™ Test for the Assessment of Suspected Ovarian Cancer**

#### **Evidence Conclusion:**

Conclusion: Analytic validity: No studies were identified that evaluated analytic validity of the OVA1™ test. Clinical validity: Results from a recent observational study suggest that the when added to physician assessment or substituted for CA 125, the OVA1™ test increased the sensitivity and negative predictive value of these assessments but decrease the specificity and positive predictive value. Clinical utility: No studies were identified that evaluated the clinical utility of the OVA1™ test.

**Articles:** No studies were identified that assessed the analytic validity or clinical utility of the OVA1™ test. Two studies were identified that addressed the clinical validity of the OVA1™ test. Both of these studies were selected for review. The following studies were selected for critical appraisal: Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. *Obstet Gynecol* 2011; 117:1289-1297. See [Evidence Table](#). Ware Miller R, Smith A, DeSimone CP, et al. Performance of the

American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. *Obstet Gynecol.* 2011; 117:1298-1306. See [Evidence Table](#).

The use of OVA1 for ovarian tumors does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Hayes Review

### SelectMDx for Prostate Cancer (MDxHealth Inc.)

According to the testing laboratory, the SelectMDx test is a noninvasive, urine-based molecular screening test that, when combined with patient clinical risk factors, can aid physicians in determining if a patient is at higher risk (defined by laboratory as detecting GS  $\geq$  7 prostate cancer upon biopsy) or lower risk for prostate cancer and can avoid biopsy (MDxHealth, 2019a). The test is intended for men who have not been previously diagnosed with prostate cancer. The SelectMDx test requires a first void post-digital rectal examination (DRE) urine sample, which is analyzed for the mRNA level of 2 cancer-related biomarkers, DLX1 and HOXC6 (MDxHealth, 2016; MDxHealth, 2019b).

### Hayes Rating: D2

For use of the SelectMDx for Prostate Cancer test to aid physicians in determining if a patient is at higher risk (defined by laboratory as detecting Gleason score (GS)  $\geq$  7 prostate cancer upon biopsy) or lower risk for prostate cancer and can avoid biopsy.

**Conclusion:** There is insufficient evidence supporting use of the SelectMDx test. Additional studies are needed to demonstrate the clinical validity and, ultimately, clinical utility of the test and whether the test results would improve patient management outcomes, including avoiding unnecessary prostate biopsies.

### Reference

Hayes. Hayes Molecular Test Assessment. SelectMDx for Prostate Cancer (MDxHealth Inc.). Dallas, TX: Hayes; February 25, 2021. Retrieved November 29, 2021 from <https://evidence.hayesinc.com/report/gte.selectmdx3769>

## Thyroid Nodule Gene Expression Testing (Afirma)

### BACKGROUND

Thyroid nodules are very common; they are clinically identified in 5-7% of the population, and incidentally on ultrasonography in up to 50% of women and 20% of men over the age of 50. The thyroid nodules are typically benign, but 5-15% prove to be malignant. It is thus recommended that any identified nodule measuring one centimeter or more in diameter be diagnostically evaluated. Thyroid fine needle aspiration (FNA) biopsy is the most widely used method for clinical evaluation of a suspicious thyroid nodule. FNA is a safe and simple outpatient procedure that yields cellular material suitable for cytological analysis. However, 15-30% of the biopsied nodules has indeterminate cytology and cannot be conclusively diagnosed by FNA biopsy alone. Most patients with indeterminate lesions (defined in the Bethesda System as Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance, suspicious for Follicular or Hurthle Cell neoplasm and suspicious for malignancy) are referred to surgery. Currently, surgery is performed for both diagnostic and therapeutic purposes in these patients with indeterminate aspirates. Surgery has high operative efficacy in removal of thyroid cancer, however approximately three-quarters of the nodules with indeterminate FNA cytology are ultimately found to be benign on final surgical pathology. Thus, a large proportion of patients with indeterminate nodules may undergo unnecessary partial or complete thyroidectomy with its potential surgical complications and risk of long-term morbidity (Alexander 2012, Duick 2012, Walsh 2012, Ali 2013). In an attempt to preoperatively classify the indeterminate thyroid nodules different novel diagnostic tests and molecular markers have been investigated. These include immunohistochemistry, mutation and gene rearrangement testing, and gene expression and microarray analysis. Each has its performance characteristics and diagnostic values. Ideally a molecular marker or panel of markers would be accurate in differentiating benign from malignant in any lesion that is considered suspicious or indeterminate. It should be simple to use, reproducible by all institutions, and cost-effective. Genetic markers associated with malignancy such as mutation markers (e.g. BRAF, RAS) and gene rearrangements (e.g. RET/PTC and PAX8-PPAr<sub>y</sub>) have high specificity and positive predictive values; and when detected they can "rule in" the diagnosis of thyroid cancer. However, they have limited sensitivity and negative predictive values as they fail to detect a large proportion of malignant samples that do not contain one of the mutations or rearrangements being tested, i.e. mutation or rearrangement markers cannot 'rule out' malignancy when not detected ( Alexander 2012, Kouniavsky 2012, Ward 2013). Microarray techniques seek to identify patterns of expressed RNA in the human genome that are predictive of benign or malignant thyroid disease. Unlike single gene mutations or rearrangements, microarray diagnostic tests involve tens to hundreds of expressed genes. The currently available diagnostic



microarray for use in thyroid nodule analysis is the Afirma Gene Expression Classifier (GEC) recently developed by Veracyte, Inc. It is a genomic test designed with the intention of preoperative identification of benign thyroid nodules in patients with indeterminate FNA cytopathological results. The test assesses gene expression from mRNA isolated from thyroid FNA samples by comparing the mRNA expression detected in a thyroid FNA against a panel of 167 molecular genes. It uses a multidimensional algorithm to identify the thyroid FNA samples with a benign gene expression pattern (Alexander 2012, Kim 2012, Ward 2013). Afirma GEC is commercially owned by Veracyte Corporation; South San Francisco, California and is offered through a sole source, Clinical Laboratory Improvement Amendments (CLIA), a certified reference laboratory. Afirma CEC analysis is indicated only for nodules with indeterminate cytology, and is not performed on cytologically benign, malignant, or nondiagnostic (insufficient FNA samples) nodules. The assay classifies nodule as either benign or suspicious for malignancy. With a preoperative identification of a nodule that is benign rather than malignant, observation or ultrasound follow-up could be recommended instead of thyroid surgery, i.e. potentially avoids unnecessary surgery (Alexander 2012, Duick 2012, Ward 2013).

## 10/21/2013: MTAC REVIEW

### Thyroid Nodule Gene Expression Testing (Afirma)

**Evidence Conclusion:** In conclusion, there is insufficient evidence to determine whether Afirma GEC is more accurate than repeat FNA or immunochemical testing in reclassifying cytologically indeterminate thyroid nodules. There is also insufficient evidence to determine the impact of Afirma GEC on clinical management and net health outcomes in patients with indeterminate thyroid nodules.

**Articles:** The literature search for gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology revealed a number of articles on molecular diagnostic tests. Many were reviews, editorials, letters, or were unrelated to the current review. The search identified a study on the analytic validity of the test, two on its clinical validity, and retrospective study on its clinical utility. The following studies were selected for critical appraisal. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. *N Engl J Med*. 2012; 367:705-715. [See Evidence Table](#) Duick DS, Klopfer JP, Diggans JC, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine- needle aspiration cytopathology. *Thyroid*. 2012 22:996-1001. [See Evidence Table](#)

The use of does Afirma® Thyroid FNA Analysis (Gene Expression Classifier) for Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytopathology not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## ConfirmMDx for Prostate Cancer

### BACKGROUND

Prostate cancer is the second most leading cause of cancer in men around the globe (Fitzmaurice et al., 2017). In the United States, one in six men has a lifetime risk of prostate cancer (Siegel, Ward, Brawley, & Jemal, 2011). Prostate cancer screening is subject to controversy due to overdiagnosis, overtreatment, and harms. Major guidelines highlight the importance of informed decision-making. Despite the controversy, prostate specific antigen (PSA) and or digital rectal examination (DRE) can be performed.

After undetermined or abnormal results are reported on prostate cancer screening, more tests such as prostate biopsy is indicated for prostate cancer diagnosis. A high proportion (62%) of initial biopsies are negative and up to 43% will have second/repeat biopsies. Of these repeat biopsies, 26% – 35% will be diagnosed with prostate cancer (Auprich et al., 2012). False negative results are non-negligible since biopsy can miss cancer (Bhindi et al., 2017). In addition, prostate biopsies may result in several complications. As a result, it is crucial to find other ways to avoid or decrease repeat biopsies and predict with accuracy prostate cancer in patients with negative initial biopsies. ConfirmMDx is an assay that evaluates molecular alterations of three genes to detect prostate cancer.

The following description of the test is from the manufacturer website (<https://mdxhealth.com/confirmmdx-physician/>). ConfirmMDx is a tissue test to enhance the detection of previously negative biopsy patients at high risk for clinically significant prostate cancer. It rules out patients with no cancer and prevent them from unnecessary repeat biopsies and screening procedures, thus alleviating stress and reduce complications. According to the manufacturer, ConfirmMDx is believed to be the most significant predictor of patient outcome among all currently available clinical factors.

ConfirmMDx uses methylation-specific PCR (MSP) and epigenetic biomarkers to detect prostate cancer. The MSP, unlike histopathology, can detect DNA methylation changes (molecular alterations) in tissues surrounding cancer foci.

This epigenetic effect is the molecular mechanism by which MSP detects occult prostate cancer in men with negative initial biopsy. ConfirmMDx measures DNA methylation of 3 genes including GSTP1, APC, and RASSF1. In patients with negative prostate biopsies results, the test can enhance accuracy for predicting repeat biopsy outcome in comparison to the standard risk factors (Waterhouse et al., 2019). The test can also indicate the likelihood of detecting Gleason score  $\leq 6$  (low grade) and  $\geq 7$  (high grade) prostate cancer upon repeat biopsy. Patient report indicates if DNA methylation is positive, the likelihood of detecting prostate cancer, probability of detecting Gleason score  $\leq 6$  and  $\geq 7$  prostate cancer on repeat biopsy (<https://mdxhealth.com/wp-content/uploads/2020/07/MDX-C152-ConfirmMDx-Case-Study-1-v3.pdf>).

The test is indicated when there is a need to perform repeat biopsy on patients with initial negative biopsy result (benign, high-grade prostatic intraepithelial neoplasia (HGPIN), or atypical small acinar proliferation (ASAP)) within the past 24 months and high-risk clinical factors for occult prostate cancer. The results of the test should be interpreted in addition to clinical and other laboratory data.

Eligible patients include those with the following biopsy results:

- Negative/benign
- HGPIN (high-grade prostatic intraepithelial neoplasia)
- Atypia (atypical glands suspicious for malignancy)
- ASAP (atypical small acinar proliferation)
- PIA (proliferative inflammatory atrophy, or lesion)

## 07/11/2022: MTAC REVIEW

### ConfirmMDx for Prostate Cancer

#### Evidence Conclusion:

- Analytical validity: Very low-quality study shows that the assay can measure the methylation status of the three genes including GSTP1, APC, and RASSF1.
- Clinical validity: Low quality evidence support ConfirmMDx in ruling out prostate cancer on repeat biopsy.
- Clinical utility: There is insufficient evidence for or against the clinical utility of ConfirmMDx for prostate cancer.
- **Overall, the evidence is insufficient for or against the use of ConfirmMDx.**

**Articles:** PubMed was searched on 03/29/2022 with the search terms ConfirmMDx OR Episcore OR MDxHealth OR (GSTP1 AND APC AND RASSF1 AND prostate) OR (Epigenetic assay AND prostate cancer) with variations. The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. The search yielded a number of articles. Seven studies were reviewed (1 analytical validity study, 4 clinical validity studies, and 2 clinical utility studies). See [Evidence Table](#).

The use of ConfirmMDx for Prostate Cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Hayes Review

### ConfirmMDx for Prostate Cancer (MDxHealth Inc.)

According to the laboratory, ConfirmMDx is for men with a previous histopathologically cancer-negative prostate biopsy within the past 24 months who have clinicopathological risk factors for prostate cancer to (MDxHealth, 2017; MDxHealth, 2018a):

- Identify men at risk for undetected prostate cancer (a false-negative biopsy result).
- Rule out men who are prostate cancer free to prevent unnecessary repeat biopsies and screening procedures, resulting in reduced complications, patient anxiety, and healthcare expenses.

In addition, the ConfirmMDx test result claims to predict the likelihood of (MDxHealth, 2017):

- Detecting Gleason score  $\leq 6$  prostate cancer on repeat biopsy.
- Detecting Gleason score  $\geq 7$  prostate cancer on repeat biopsy.

#### **Hayes Rating: D2**

For use of ConfirmMDx test, using residual prostate biopsy specimens, to: (1) rule out men who are prostate cancer free; and (2) identify men at risk for undetected prostate cancer by predicting the likelihood of detecting Gleason score  $\leq 6$  and  $\geq 7$  prostate cancer on repeat biopsy in men with an initial negative biopsy yet high-risk clinicopathological features suggestive of prostate cancer.

**Conclusion:** There is positive but insufficient evidence supporting the use of the ConfirmMDx test to help rule-out prostate cancer in repeat biopsy and insufficient evidence for the use of the test to predict the likelihood of Gleason score  $\leq 6$  prostate cancer and Gleason score  $\geq 7$  prostate cancer on repeat biopsy. Available studies do not evaluate whether the test results, when used to influence patient repeat biopsy decisions, result in improved patient outcomes in men with high-risk clinicopathological features suggestive of prostate cancer.

**Reference**

Hayes. *Hayes Molecular Test Assessment. ConfirmMDx for Prostate Cancer (MDxHealth Inc.). Dallas, TX: Hayes; February 14, 2021. Retrieved November 29, 2021 from <https://evidence.hayesinc.com/report/gte.confirm2766>*

**Prolaris for Prostate Cancer**

**BACKGROUND**

Prostate cancer is the second most leading cause of cancer in men around the globe (Fitzmaurice et al., 2017). In the United States, one in six men has a lifetime risk of prostate cancer (Siegel, Ward, Brawley, & Jemal, 2011). Its natural history varies and is difficult to predict. Some men have indolent disease that can be safely managed with active surveillance, whereas others have an aggressive cancer and are treated with a variety of therapeutic options. Accurate prediction of disease behavior is critical because radical treatment is associated with high morbidity (J. Cuzick et al., 2012).

Clinical variables including Gleason score, tumor stage, and PSA have been considered at the time of diagnosis to predict disease outcome. However, predictions based on these variables are not accurate, resulting in hesitation among physicians and patients about the best course for initial treatment (J. Cuzick et al., 2012). Tests to make accurate prediction and determine treatment decision are necessary.

**Description:**

Prolaris is a genetic test that measures the growth of tumor cell. In combination with PSA and Gleason score, the test determines the aggressiveness of prostate cancer. PSA and Gleason only show the progression of prostate cancer. However, when these tests are combined to Prolaris test, the aggressive progression of the cancer over the next ten years is determined. The information on the aggressiveness of cancer is specific to each individual.

**Testing process:**

The same tissue from the original biopsy is utilized to run the test. Therefore, additional biopsies are not required. The tissue sample is sent to Myriad to determine the aggressiveness of the prostate cancer. After the test is complete, the results are sent back to the provider. The result is comprised of a personalized Prolaris Score and a 10-year prostate cancer mortality risk and the risk of metastasis.

The Prolaris Molecular Score is computed by measuring the expression of 31 cell cycle progression (CCP) genes (measured by qRT-PCR and normalized by 15 housekeeping genes). Most of the scores range between 1-11. The higher the score, the more aggressive the cancer. Over- and under-expression of the 31 CCP genes results in positive and negative CCP score, respectively (Shangguan et al., 2021).

**Benefits of Prolaris test:**

The benefits are to identify mortality risk, the risk of metastasis, and to help determine the best course of treatment.

Prolaris is supported by NCCN guidelines as a 2A recommendation which is considered standard of care. Prolaris testing is indicated in men who have been diagnosed with localized prostate cancer.

**07/11/2022: MTAC REVIEW**

**PROLARIS FOR PROSTATE CANCER**

**Evidence Conclusion:**

➤ **PROLARIS BIOPSY TEST**

- Low quality evidence shows that CCP testing is reproducible and precise.
- Very low to low quality evidence indicate that CCP & CCR scores may help predict prostate cancer mortality and metastasis. It may help improve risk stratification in men with localized prostate cancer.
- Low quality evidence shows that Prolaris test may influence physician treatment decision.
- Overall, low quality evidence supports Prolaris test to predict prostate cancer related clinical outcomes.

➤ **PROLARIS POST-PROSTATECTOMY**

- The evidence is insufficient for or against the use of Prolaris test in patients with radical prostatectomy.

**Articles:** PubMed was searched through April 11, 2022 with the search terms (Prolaris OR cell cycle progression OR CCP OR cell cycle risk OR CCR) AND (prostate) with variations. The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. See [Evidence Table](#).

The use of Prolaris Prostate Cancer (Biopsy and Post-Prostatectomy) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 04/20/2015: MTAC REVIEW

##### DecisionDx - Melanoma

##### Evidence Conclusion:

##### DecisionDx - Melanoma

##### BACKGROUND

Skin cancer is extremely common accounting for nearly half of all cancers in the United States. Melanoma, the most aggressive type of skin cancer, occurs as a result of abnormal melanocytes, most often caused by over-exposure to ultraviolet radiation from the sun. When detected early, cutaneous melanoma can be surgically excised resulting in a 5-year overall survival rate of 91%-97%. Despite these odds, however, the clinical behavior of cutaneous melanoma is highly variable and some melanomas, that appear less risky, will develop into advanced disease and require extensive treatments such as additional surgery, immunotherapy, targeted therapy, chemotherapy and radiation therapy (ACS 2015). As with all cancers, a primary challenge is predicting prognosis. Conventional methods of melanoma staging are characterized by the American Joint Committee on Cancer (AJCC) TNM System. The TNM system specifically refers to Tumor thickness, spread to nearby lymph Nodes, and Metastasis. Based on history and physical exam, as well as, biopsy, imaging and pathology, the TNM system groups patients with melanoma into stages, 0-IV based on the advanced nature of the disease (Balch, Gershenwald et al. 2009). The stage of the melanoma is an estimate of prognosis and will ultimately guide treatment options. Recently, gene expression profiling (GEP) has been proposed for use in cancer management. The technique specifically analyzes the patterns of genetic material contained in tumor cells and has the potential ability to predict clinical outcomes associated with cancer. One such test, the DecisionDx-Melanoma™, developed by Castle Biosciences Inc. (Friendswood, TX), is described to more accurately classify stage I and II melanoma.

Proposed as an adjunct to conventional staging systems, the DecisionDX-Melanoma test includes 31 genes, 28 of which have previously been associated with melanoma and the remaining three, controls (Winnepeninckx, Lazar et al. 2006). The results of the DecisionDx-Melanoma test is further claimed to stratify stage I and II melanomas into one of two classes; class one identifying patients as low risk of metastasis, or class two indicating high risk.

The developer claims that the information provided by the DecisionDx-Melanoma test enables physicians to tailor, patient specific, surveillance and treatment plans informing, for example, the intensity of surveillance, need for referral to specialists, evaluation of adjuvant treatments and clinical trial eligibility (CastleBiosciencesInc. 2015).

#### 04/20/2015: MTAC REVIEW

##### DecisionDx - Melanoma

**Evidence Conclusion:** Conclusions: There is limited evidence to conclude that the DecisionDx-Melanoma test is valid. There is insufficient evidence to conclude that the DecisionDx-Melanoma test has prognostic accuracy in predicting metastatic risk. There is insufficient evidence to conclude that the DecisionDx-Melanoma test is not harmful to patients. There is insufficient evidence to establish the clinical utility and therapeutic impact of the DecisionDx-Melanoma test.

**Articles:** The literature search was carried out to identify studies relating to the prognostic value of the DecisionDx-Melanoma test. The search revealed a variety of publications discussing the use of GEP and one publication identifying the genes associated with melanoma progression and prognosis (Winnepeninckx, Lazar et al. 2006). No studies were identified in which the DecisionDX-Melanoma was prospectively analyzed and followed-up in populations with Stage I and II melanoma. A search of the NIH Clinical Trials database identified two manufacturer sponsored prospective studies currently in the enrollment stage. The best, currently available, evidence was a development and validation study published by Castle Biosciences, Inc. The following articles were selected for critical appraisal: Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. *Clinical Cancer Research*. 2015;21(1);175-183. See [Evidence Table](#).

The use of DecisionDx-Melanoma does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **OVA1 Assessment for Ovarian Cancer**

## BACKGROUND

Ovarian cancer is the most lethal gynecological malignant worldwide. The five-year overall survival is over 90% in patients with stage I disease and only 20-40% for stages III and IV. Unfortunately, because of the lack of specific symptoms during the early stage approximately 70% of cases present with an advanced stage disease. Detection of ovarian cancer at an early stage would have a significant impact on reducing mortality, however to date; there is no screening or biomarker test that meets the criteria for a beneficial screening test in asymptomatic women with early ovarian cancer (Carter 2011, Cohen 2014, Leung 2014). Serum CA-125, a high molecular weight glycoprotein, remains the most widely used biomarker for the confirmation of diagnosis and management of ovarian cancer. Serum CA-125 however, is more prominently expressed in patients with late stage serous tumors; it is elevated in 50-60% of women with stage I epithelial ovarian cancer, and in 75-90% of patients with advanced stage disease. Elevated circulating CA-125 has also been documented in uterine fibroids, endometriosis, pregnancy, menstruation, benign ovarian neoplasms, liver cirrhosis, and other malignancies making it a less useful marker for the detection of ovarian cancer (Autelitano 2012, Cohen 2014). Improvements have been made in the preoperative diagnosis of ovarian cancer by combining serum CA-125 concentration with ultrasound score and menopausal status, into a Risk of Malignancy Index (RMI) which was found to outperform CA-125 alone in discriminating between a benign and malignant pelvic mass. Over the past two decades diagnostic triage methods incorporating clinical algorithms, serum biomarkers, imaging, or a combination of these techniques have been investigated to improve its diagnostic efficiency in predicting ovarian malignancy in women with adnexal masses. The Risk of malignancy Algorithm (ROMA) and OVA1 test are two algorithms recently developed for the assessment of malignancy risk in these women. These are not screening tests but are potential tools to further triage women to the appropriate provider once the decision for surgical intervention has been made (Autelitano 2012, Bristow 2013, Cohen 2014). Combining multiple variables or markers in a single biomarker assay (in vitro diagnostic multivariate assay [IVDMIA, or MIA]) has the potential advantage of complementing the information provided by a single-valued index. The inclusion of biomarkers in an IVDMIA requires that they are complementary and collectively outperform a single marker with respect to its intended uses. CA-125 remains the best tumor marker, and the selection of additional biomarkers is based mainly on their ability to detect malignancy in cancer patients with low CA-125 level or to reduce false positive results among non-cancer patients with elevated serum CA-125 levels (Zhang 2012). Ova1™ test (developed by Vermillion and licensed to Quest Diagnostics, Inc.) is the first IVDMIA of protein biomarkers cleared by the FDA to be used as an adjunct to clinical and radiological evaluations for women over the age of 18 who have planned to undergo surgery for an adnexal mass and have not been referred to a gynecologic oncologist. Studies suggest that women who receive their initial surgical care from an experienced gynecologic oncologist are more likely to have better outcomes including surgical staging, optimal debulking, and improved median and overall-5-year survival. Ova1™ test is a qualitative test that measures the serum levels of 5 potential biochemical markers for ovarian cancer (CA-125, prealbumin, apolipoprotein A-1,  $\beta$ 2-microglobulin, and transferrin). The results of the test are then interpreted using a proprietary algorithm to yield a single score ranging from 0 to 10 to indicate the likelihood that the adnexal mass is benign or malignant. A high probability for malignancy is defined as a score of  $\geq 5.0$  in premenopausal women or  $\geq 4.4$  in postmenopausal women. The decision for selecting these cutoff values was made to emphasize the need for high sensitivity to minimize the risk of false negative results for patients who actually have a malignant lesion. A limitation to OVA1™ is that all the included markers with the exception of CA-125 are acute phase reactants that may be nonspecific for ovarian cancer. Another limitation is interference of triglyceride levels greater than 4.5g/L or rheumatoid factor levels more than 250IU/mL with the biomarkers assay (Muller 2010, Carter 2011, Zheng 2012, Leung 2014).

### 04/20/2015: MTAC REVIEW

#### **OVA1 Assessment for Ovarian Cancer**

**Evidence Conclusion:** Conclusion: The published studies do not provide sufficient evidence to determine the clinical utility and impact of using OVA1™ assay on health outcomes of women with ovarian tumors.

The use of OVA 1 does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### Date: 07/09/2018 MTAC REVIEW

#### **Whole Genome/Exome Sequencing for Developmental Delay (DD)/Intellectual Disability (ID)**

##### BACKGROUND

Intellectual disability is a disorder marked by deficits in intellectual and adaptive functioning and starts before 18 years of age. Its management requires early diagnosis and extensive supports. Intellectual disability is caused by any conditions disrupting brain development. Of these conditions, genetic abnormalities are the most commonly known etiologies (Rauch et al., 2012) with Down syndrome being the leading cause. Conventional cytogenetics (karyotype analysis and fluorescence in situ hybridization (FISH)) can identify the cause but they detect less than 10% of



chromosomal abnormalities in patients with intellectual disability (ID) or developmental delay (DD) (Shaffer, Beaudet, et al., 2007; Shaffer, Bejjani, et al., 2007). Chromosomal microarray analysis (CMA) has become the primary test for most patients with intellectual disability (Miller et al., 2010). However, if CMA fails to identify the etiology, whole genome/exome sequencing may be considered.

Whole genome sequencing (WGS) is a process that determines the complete DNA sequence of the entire genome. In contrast, whole exome sequencing (WES) determines the DNA sequence of a small part of the genome. The small part which is the coding part of the genome is 1% of the entire genome.

(Biesecker & Green, 2014) Genome and exome sequencing (GES) begins with extraction of DNA from white cells followed by disintegration of DNA and determination of sequences with sequencing instrument. Using computer, the sequences are placed into specific positions in the human genome reference sequence for assessment of similarities and differences. This results in the determination of the specific genotype at each position in the exome or genome. This leads in output file which is filtered for variants that explain the phenotype. Sequencing can be performed on unaffected or affected parents or affected siblings. Clinical GES can detect single-nucleotide substitutions and insertions or deletions of 8 to 10 nucleotides or smaller. However, it is less accurate for other types of genomic variation. GES is indicated in patients with suspicion of mendelian genetic disease. It is also considered when CMA fails to identify the cause of intellectual disability. (Biesecker & Green, 2014)

This review focuses on developmental delay (DD) or intellectual disability (ID).

As this is a laboratory test, no FDA approval is required. Genetic tests are controlled under the Clinical Laboratory Improvement Amendments (CLIA). The technology is being assessed for the first time on Medical Technology Assessment Committee (MTAC).

#### **Evidence Conclusion:**

##### **Conclusion:**

- **Analytical validity:** Studies assessing analytical validity were scarce. Only two studies reported that the performance of WES/WGS was high. However, the evidence is insufficient to draw conclusion on analytical validity.
- **Clinical validity:** Thirteen studies were evaluated. Most studies have included children with moderate to severe intellectual disability/developmental delay. In most studies, WES or WGS was performed in patients on whom previous genetic evaluations (molecular karyotyping, microarray) failed to diagnose the etiology or were negative. The diagnostic yield ranged from 21% to 60% (including new mutations) suggesting higher detection rate than traditional genetic tests including microarray. Nevertheless, the studies provide low evidence and demonstrate that WES/WGS has high detection rate overall and even in children with undiagnosed or unexplained intellectual disability or developmental delay.
- **Clinical utility:** The evidence on clinical utility is conflicting. More studies are warranted.
- Milliman Care Guidelines was reviewed and indicated that the evidence is poor, or conflicting, or insufficient to assess the net benefit of this test versus harm; additional research is recommended.

The use of Whole Genome/Exome Sequencing for Developmental Delay (DD)/Intellectual Disability (ID) doesn't meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Next Generation Sequencing (NGS) - Broad Spectrum Tumor Molecular profiling***

#### **Background**

All cancers begin in cells. A normal become cancerous largely because of mutations in their genes. Often many mutations are needed before a cell becomes a cancer cell. Some gene changes may increase production of a protein that makes cells grow and others may result in the production of a misshape leading to a nonfunctional form of a protein that normally repairs cellular damage. Genetic changes that promote cancer may be inherited (germline) or more commonly acquired (somatic) during a person's lifetime, either because of errors that occur as cells divide or from exposure to DNA-damaging carcinogens. There are many types of DNA genetic changes; these may affect just one unit of DNA (a nucleotide) or involve larger stretches of DNA (NIH, American Cancer Society).

Somatic mutations include point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options. Thus, in some cases, knowledge of the genetic alterations in a cancer patient can help determine a treatment plan as some treatments, particularly targeted therapies, are effective only for people whose cancer cells have specific genetic alterations that cause the cells to grow out of control (Wagle 2011, National Cancer Institute).

In the past decade, investigators have focused on searching for oncogenes and tumor suppressor genes that drive cancer. This is moving systemic cancer treatment away from the paradigm of treating histologically defined disease with cytotoxic chemotherapy, towards the use of molecularly targeted drugs prescribed to selected



subsets of patients across multiple tumor types. Theoretically targeted therapies that inhibit the abnormally activated proteins, are more specific to cancer cells, potentially safer and more efficacious than the cytotoxic agents that target cell replication (Frampton 2013, Uzilov 2016, Tournau 2015, Beaubier 2018).

To deliver personalized cancer targeted therapy, it is essential to use diagnostic tests that would accurately and comprehensively characterize the genomic alterations within individual tumors. Several technologies including Sanger sequencing (SGS, the gold standard), PCR, mass spectrometric genotyping, and other tests are currently used for the clinical assessment of a limited number of oncogenic markers. These tests may not perform parallel investigations of multiple targets and cannot address the increasing number and variety of therapeutically relevant genomic alterations that occur in hundreds of cancer related genes with the amount of material obtained from biopsies (Frampton 2013, Rehm 2013, Arsenic 2015, Beaubier 2018).

Next generation sequencing (NGS), is becoming an attractive clinical diagnostic technology to detect most genomic alterations in the therapeutically relevant cancer genes in a single assay. NGS is not a test, but is an umbrella term for massively parallel DNA sequencing technology. The term NGS is used to emphasize the difference from the initial traditional gold standard single gene-based sequencing approaches that involve sequencing of one DNA strand at a time. NGS encompasses a variety of technologies that permit rapid parallel sequencing of millions of DNA segments, up to the entire genomes. These can perform three main levels of analysis: exome sequencing, genome sequencing, and disease targeted gene panels (Frampton 2013, Regier 2018).

A NGS cancer panel involves a complex 2-step process: 1. Wet bench process, which includes the handling of patient samples, extraction of nucleic acid, fragmentation and barcoding, target enrichment, adaptor ligation, library preparation, and generation of sequence reads. 2. Bioinformatics analysis of sequence data. This includes mapping sequence reads to the human reference genome, variant calling, annotation, and reviewing data in the right clinical context. Each of these steps require separate standards (Behjati 2013, Frampton 2013, McCourt 2013, Rehm 2013, American College of Medical Genetics and Genomics).

The number and scope of genes to be tested depend on the purpose of the test. A companion diagnostic test for standard care would require a limited number of genes, whereas NGS-based tests used for stratifying patients require the interrogation of a broader range of genes. Currently, there are several NGS platforms that perform sequencing of millions of small fragments of DNA in parallel. The platforms use different sequencing technologies, and due to the complexity and amount of sequencing data, and concerns about the reliability of the different NGS panels, several working groups (including the College of American Pathologists (CAP) and the American College of Medical Genetics and Genomics [ACMG]) have issued guidelines for NGS clinical testing. The assays or platforms should have a high-test sensitivity as cancer specimens may have a low percentage of tumor cells, i.e. high level of normal cell contamination. The test should also have a high specificity as a false positive result will have a negative impact on the choice of therapy (Frampton 2013, Kim 2017).

Cancer panel tests are mainly focused on actionable genomic alterations (variants) whose presence may help identify the most promising treatment approach. Different definitions of “actionable variants” have been used by researchers. While the majority defined it as the variant that can be targeted by a currently available drug (either FDA approved, off label use of an FDA approved drug, or a drug under investigation), others expanded the definition to include change in patient management on the prognostic implication or change in risk stratification. It is estimated that as many as one third of actionable changes in tumor analysis may be incorrectly classified as somatic changes. It is thus recommended to use matched tumor-normal DNA for genomic analysis to accurately identify and interpret actionable somatic and genetic changes that would have an important impact on the diagnosis and therapeutic management of cancer patients (Jones 2015, Kim 2017, Tan 2017, Regier 2018).

In recent years, several academic centers have adopted the use of NGS panels at the point of care to study cancer genomics and personalize patient care (precision oncology). However, the application of the NGS technology in the clinical context as a routine test to support the selection of therapy for cancer patients has its challenges. Most of cancer specimens are formalin-fixed paraffin embedded tissue (FFPE) which can degrade the DNA and RNA. This would require the application of robust nucleic acid extraction and sequencing library construction. In addition, many samples available for testing contain limited amount of tissue and in turn a limited amount of nucleic acid. The assays also need to be sensitive enough to detect gene alterations in specimens with a low tumor percentage. The use of the technology requires an infrastructure e.g. computer capacity and storage, as well as the application of rigorous statistical and analytical approaches to validate the accuracy of NGS technology for use in the clinical setting. An additional reported challenge is the personnel expertise required to comprehensively analyze and interpret the subsequent data, as well as skillfully extract and manage the clinically

important information from the volume of data obtained. NGS has the potential to uncover a significant quantity of complex clinically and non-clinically actionable results with wide ranging implications for the patients and their families. Targeted therapies are limited by several factors including the availability, effectiveness and /or specificity of molecular inhibitor (targeted drug therapies) based on patients' genetic information, heterogeneity the disease, resistance to a targeted therapy, and access to the treatment. It has also been reported that targeted therapies may be successful for some tumor types but not for others (Behjati 2013, Frampton 2013, Radovich 2016, Beaubier 2018).

FoundationOne CDx™ (F1CDx, Foundation Medicine, Inc.) a NGS test, was granted marketing approval by the US Food and Drug Administration (FDA) on November 30, 2017 to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The test can also identify which patients with non-small cell lung cancer (NSCLC), melanoma, breast cancer, colorectal cancer, or ovarian cancer may benefit from 15 different FDA-approved targeted treatment options (FDA website).

#### **01/14/2019: MTAC Review**

##### **Evidence Conclusion:**

- As indicated earlier in the report, it is difficult to set standards for assuring the analytical validity of NGS tests due to the amount and complexity of cancer genome sequencing and the different NGS technologies used. In general, however, the published validation studies suggest that NGS tests may have a high analytic validity, and lower clinical validity.
- There is insufficient evidence from published randomized clinical trials to determine that incorporating NGS into cancer care improves patient outcomes, such as treatment response and disease-free survival, or to support the use of molecularly targeted agents outside their indications based on tumor molecular profiling.
- More RCTs are needed to provide evidence on the utility of cancer genomics in clinical practice.

**Articles:** The literature search identified over 1,000 articles on NGS; the great majority of which were reviews, abstracts or articles not related to the current review. The search was filtered and narrowed down according to the inclusion criteria based on PICO. Selected studies comparing the performance of NGS versus Sanger sequencing as well as randomized or nonrandomized studies evaluating the effectiveness and safety of applying the technology to cancer patients were included in the review. See [Evidence Table](#)

The use of Broad-Spectrum Tumor Molecular Profiling - Next Generation Sequencing (NGS) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **Decipher Prostate Genomic Classifier**

##### **10/10/2022: MTAC Review**

##### **Evidence Conclusion:**

##### **Decipher genomic testing using biopsy specimen**

- There is insufficient evidence for or against the analytical validity and clinical utility of Decipher test. Low quality evidence supports the clinical validity of Decipher test. Overall, the evidence is insufficient for or against the use of Decipher genomic testing using biopsy specimen.

##### **Decipher genomic testing using radical prostatectomy specimen**

- Analytical validity: There is a lack of studies.
- Clinical validity: Low quality evidence from retrospective studies demonstrate that the Decipher Genomic Classifier is consistently superior in its prognostic and discriminatory ability in comparison to clinicopathologic variables for metastasis & prostate cancer-specific mortality.
- Clinical utility: Low quality evidence supports the clinical utility of Decipher testing. Decipher may influence treatment recommendations change in post prostatectomy patients with adverse pathologic characteristics.
- Overall, low quality evidence supports the use of Decipher genomic testing using radical prostatectomy specimens.

**Articles:** PubMed was searched through September 2022 with the search terms (Decipher OR genomic classifier OR 22-gene) AND (prostate). The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. The search yielded several studies. See [Evidence Table](#).

The use of Decipher Prostate Genomic Classifier does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Applicable Codes**

**\*Note:** Codes listed in the criteria above may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
1997	10/04/2011 <sup>MDCRPC</sup> , 8/07/2012 <sup>MDCRPC</sup> , 11/06/2012 <sup>MDCRPC</sup> , 04/02/2013 <sup>MDCRPC</sup> , 05/07/2013 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 03/04/2014 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	11/15/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/11/2015	Array-Based Comparative Genomic Hybridization (aCGH): Removed MCG and reactivated GHC insufficient evidence criteria
06/02/2015	MPC approved MTAC recommendation of insufficient evidence for OVA1 & DecisionDx-Melanoma Testing
06/04/2015	Added Cologuard
06/30/2015	Added LCD link for cytogenetic studies
08/27/2015	Add LCD for CYP Genes
09/08/2015	Revised LCD CYP2C19, CYP2D6, CYP2C9 and VKORC, Genetic Testing (L36311), Cytogenetic Studies L34067
10/13/2015	Added Medicare molecular testing LCD
10/27/2015	Added codes that do not need review
11/18/2015	Added Medicare MoIDX links
03/01/2016	Discontinue review for Factor II & V
08/30/2016	Combined Risk Prognosticator Test to Genetic Screening criteria
09/06/2016	Added Prostate Cancer Gene Expression Testing- Oncotype DX MCG A-0712 to criteria
10/24/2016	Changed Veristat to match Pharmacogenomic policy
11/01/2016	MPC approved to accept the genetic testing recommendations from the MCG 20 <sup>th</sup> edition as outlined
01/23/2017	Added LCD 36544 & LCD 36186
04/04/2017	Added MTAC Review
05/16/2017	Added Percepta LCD
08/28/2017	Added ThyGeNEXT Oncogene Panel
09/18/2017	HFE gene – review no longer required
10/03/2017	Adopted MCG 21 <sup>st</sup> ed. guidelines: A-0910, A-0909, A-0916, A-0907, A-0904, A-0908, A-0918, A-0926
10/11/2017	Removed MCG A-0917
12/05/2017	Adopted clinical criteria for Cystic Fibrosis testing
02/06/2018	MPC approved to adopt criteria for Decision Dx- Choroidal/Uveal Melanoma
03/26/2018	Added Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer

04/25/2018	Added language to BRAF testing
05/03/2018	Updated name changes with the MCG 22 <sup>nd</sup> Edition
06/05/2018	MPC approved to adopt MCG* A-0823 and MCG* A-0957
08/07/2018	Added MTAC review from 7/9/18 for Microarray and Whole Exome for DD/ID
10/02/2018	Updated Micro Array for Evaluation of Intellectual Disability criteria
12/04/2018	MPC approved to adopt MCG* A-0598 Diabetes Mellitus (Maturity-Onset Diabetes of the Young)
01/08/2019	MPC approved to adopt criteria for Whole Exome Sequencing
02/05/2019	MPC approved to adopt policy of no coverage for Next Generation Sequencing (NGS) - Broad Spectrum Tumor Molecular profiling; added 01/2019 MTAC review
02/26/2019	Mammaprint: Send all cases to MD for review until criteria has been developed
04/02/2019	MPC approved to adopt criteria for Mammaprint
12/03/2019	MPC approved a non-coverage policy for Donor-derived cell-free DNA testing (e.g., Allosure)
04/07/2020	MPC approved non-coverage policy for CancerTYPE ID
06/02/2020	Added section: "Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees." Requires 60-day notice, effective date 10/01/2020.
10/06/2020	MPC approved to adopt MCG 24 <sup>th</sup> ed. guidelines for the following: Narcolepsy - HLA Testing: A-1005, Transthyretin Amyloidosis - TTR Gene: A-1010, Retinal Dystrophy - RPE65 Gene: A-1011, Breast Cancer- PALB2: A-0989, Alpha-1 Antitrypsin Deficiency - SERPINA1 Gene: KP-1006, Paraganglioma-Pheochromocytoma (Hereditary) - Gene Testing and Gene Panel: A-0798; added exception for NGS for Advanced Cancer (CellNetix lab) to Invitae as preferred lab section. Removed codes section; will defer to pre-authorization code check tool.
05/04/2021	Updated Medicare LCD links, MCG Guideline information, and applicable codes. MPC approved to adopt MCG 25 <sup>th</sup> edition guidelines for the following: Malignant Melanoma (Cutaneous) – BAP1, CDK4, and CDKN2A; Malignant Melanoma (Cutaneous) – BRAF V600 Testing; Renal Cancer (Hereditary) – Gene Panel; and Noonan Syndrome – Gene and Gene Panel Testing. Requires 60-day notice, effective date 10/1/2021.
08/03/2021	Updated Nephrology section, referencing separate criteria for Donor-derived cell-free DNA testing for Kidney Transplant Rejection (e.g., AlloSure).
11/02/2021	MPC approved to expand coverage for Spinal Muscular Atrophy (SMA) Carrier Testing. Requires 60-day notice, effective date 04/01/2022.
12/07/2021	MPC approved to adopt expansion of coverage for Chromosomal Microarray testing to members who are undergoing invasive prenatal genetic testing (i.e., amniocentesis). Requires 60-day notice, effective date 05/01/2022.
12/07/2021	MPC approved to adopt a policy of non-coverage for the ConfirmMDx and SelectMDx genetic tests for prostate cancer. Requires 60-day notice, effective date 05/01/2022.
04/05/2022	MPC approved to adopt MCG* A-0782 with new indications in the 26 <sup>th</sup> edition. Gene/gene panel testing for hereditary ovarian cancer criteria are in the process of being updated and will all be reviewed by the Medical Director on a case-by-case basis until finalized.
06/07/2022	MPC approved to adopt MTAC's recommendation of non-coverage and to continue the existing policy of insufficient evidence.
08/16/2022	MCG* A-0822 and A-0847 were deleted from the 26 <sup>th</sup> edition guidelines; deleted from criteria
09/22/2022	Added Oncoplex (University of Washington) and Caris Life Sciences as preferred lab vendors for NGS
11/01/2022	Updated criteria for Chromosomal Microarray Testing to remain compliant with revisions to the WAC; also updated other related prenatal genetic testing that were mandated to no longer require medical review. Effective immediately to comply with WAC 246-680-010. 60-day notice required.
11/01/2022	MPC approved to adopt criteria for Thyroid Nodule Gene Expression Testing (ThyraMIR/ThyGeNEXT), Prostate Cancer Gene Expression Testing (Prolaris) and Prostate Cancer (ConfirmMDx). Requires 60-day notice, effective date 04/01/2023.
11/14/2022	Added the July 2022 MTAC reviews for ConfirmMDx and Prolaris for Prostate Cancer.

12/06/2022	MPC approved to remove NRAS genetic test from this page as it is currently on pharmacogenomic page. MPC approved to remove BRAF testing from genetic screening page and move to Pharmacogenomic page. Effective immediately.
12/12/2022	Added ClonoSEQ to flag for medical director review.
01/03/2023	Clarified language on ClonoSEQ indications. Added Medicare LCD L38816 and LCA A58997.
01/18/2023	Added the MTAC review for Decipher Prostate Genomic Classifier.
01/25/2023	For Prolaris-clarified use in setting of radical prostatectomy.
04/24/2023	Added Quest-QNatal as a preferred vendor for Cell Free Fetal DNA testing.
08/14/2023	Updated applicable MCG 27 <sup>th</sup> edition guidelines with updated name changes and guidelines that were marked as deleted to <i>“There is insufficient evidence in the published medical literature to show clinical utility.”</i> Please refer to the MCG 27 <sup>th</sup> edition summary of changes for more detail.
12/21/2023	Added NCD 190.1 Histocompatibility Testing
01/09/2024	MPC approved to revise the medical policy for APOE genotyping. Requires 60-day notice, effective date 06/01/2024
02/13/2024	MPC approved the proposed draft criteria abovenfor Retinal Disorders (Hereditary) - Gene Panels MCG KP-0912 (hybrid).
03/22/2024	Updated Medicare links
05/03/2024	Updated list of preferred lab vendors for Preconception or Pregnancy Carrier Screening.
06/03/2024	MCG 28th Edition guidelines have been updated where applicable.
06/04/2024	MPC approved to adopt the MCG policy on Cytochrome P450 testing. Requires 60-day notice; effective November 1, 2024.
07/02/2024	MPC approved to adopt hybrid (MCG/KP) policies on Colorectal Cancer (Hereditary) – Gene Panel and Amyotrophic Lateral Sclerosis (ALS) - SOD1 Gene. Requires 60-day notice; effective December 1, 2024.
11/05/2024	MPC approved clinical criteria for Transthyretin (TTR) Amyloidosis Testing. Requires 60-day notice; effective April 1, 2025.
11/15/2024	LabCorp acquired Invitae Genetics test. Criteria was updated to reflect acquisition, effective November 15, 2024



## ***Clinical Review Criteria***

### **Genetic Panels using Next Generation Sequencing (germline/blood testing, excluding Advanced Cancer)**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

#### ***Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees (for in-network coverage).***

*Prevention and Invitae/LabCorp Genetics are the preferred labs for genetic testing\*, when the test(s) is/are available at Prevention or LabCorp and medical necessity criteria are met.*

*LabCorp's test catalog can be found here: [LabCorp Test Catalog](#)  
Prevention test catalog can be found here: [Prevention Test Catalog](#)  
Invitae test catalog can be found here: [Invitae Test Catalog](#)*

*\*Note: This does not affect processing of tumor or other pathology specimens as they are not performed by LabCorp*

**PPO/POS members may use non-preferred labs at the out of network cost share.**

#### ***Exceptions***

*For the NGS testing for Advanced Cancer, see below:*

- [Next Generation Sequencing for Advanced Cancer](#)

#### **Related Policies:**

[Genetic Screening and Testing](#)

[Pharmacogenomic Testing](#)

## **Criteria**

### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Next Generation Sequencing (NGS) (90.2)</a> (Applies to diagnostic lab tests using NGS for somatic (acquired) and germline (inherited) breast and ovarian cancer.)  <a href="#">Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)</a>  <b>FDA-approved tests (not all-inclusive)</b> FoundationFocus™ CDxBRCA Assay (Foundation Medicine, Inc.) FoundationOne CDx (Foundation Medicine, Inc.) FoundationOne Liquid CDx (Foundation Medicine, Inc.) Guardant360® CDx (Guardant Health, Inc.)



	Oncomine™ Dx Target Test (Thermo Fisher Scientific, Inc.) Praxis™ Extended RAS Panel (Illumina, Inc.) MSK-IMPACT™ (Memorial Sloan Kettering Cancer Center's (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets))
Local Coverage Determinations (LCD)	<p>9/30/2015 - Noridian retired <a href="#">LCD for Genetic Testing (L24308)</a>. These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.</p> <p><a href="#">MoIDX: Next-Generation Sequencing for Solid Tumors (L38121)</a>  (Applies to diagnostic lab tests using NGS for solid tumors.)</p>

### General Coverage Rules – LCD 24308

1. Genetic tests for cancer are only a covered benefit for a beneficiary with a personal history of an illness, injury, or signs/symptoms thereof (i.e. clinically affected). A person with a personal history of a relevant cancer is a clinically affected person, even if the cancer is considered cured. Genetic testing is considered a non-covered screening test for patients unaffected by a relevant illness, injury, or signs/symptoms thereof.
2. Predictive or pre-symptomatic genetic tests and services, in the absence of past or present illness in the beneficiary, are not covered under national Medicare rules. For example, Medicare does not cover genetic tests based on family history alone.
3. A covered genetic test must be used to manage a patient. Medicare does not cover a genetic test for a clinically affected individual for purposes of family planning, disease risk assessment of other family members, when the treatment and surveillance of the beneficiary will not be affected, or in any other circumstance that does not directly affect the diagnosis or treatment of the beneficiary.
4. The results of the genetic test must potentially affect at least one of the management options considered by the referring physician in accordance with accepted standards of medical care (e.g. surgery, the extent of surgery, a change in surveillance, hormonal manipulation, or a change from standard therapeutic or adjuvant chemotherapy).
5. Pre-test genetic counseling must be provided by a qualified and appropriately trained practitioner.
6. An informed consent form signed by the patient prior to testing which includes a statement that he/she agree to post-test counseling is required. This consent form must be available on request by Medicare.
7. Genetic analysis must be provided through a laboratory which meets the American Society of Clinical Oncology (ASCO) recommended requirements:

The MoIDX Program has determined certain gene tests do not meet Medicare's medical necessary requirements, and that the inclusion of these genes will result in an entire panel to be denied. MoIDX has determined that testing for the below genes is a statutorily excluded service. Unless indicated otherwise, panels that include these genes will be denied. Please see the individual Test Coding and Billing Guidelines for each gene.

Palmetto GBA is the Medicare contractor for Molecular Diagnostic Testing – this site has the most up to date Medicare coverage guidelines for genetic testing.

[MoIDX® Program \(Administered by Palmetto GBA\)](#)

**Local Coverage Decisions (LCD)/Articles (LCA)** *not all-inclusive – refer to the MoIDX® Program link above*

ID	Title	Codes (not all-inclusive)
L36163	8/20/2022 Noridian retired LCD <a href="#">MoIDX: BRCA1 and BRCA2 Genetic Testing</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36163 for determining medical necessity, along with L38974 <a href="#">MoIDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer</a> .	81162, 81163, 81164, 81165, 81166, 81167, 81212, 81215, 81216, 81217, 81432, 81445, 81455, 0102U, 0103U, 0129U
L36386	<a href="#">MoIDX: Breast Cancer Assay: Prosigna</a>	81520
L37824	<a href="#">MoIDX: Breast Cancer Index® Gene Expression Test</a>	81518
L36186	<a href="#">MoIDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease</a>	81206, 81207, 81208, 81219, 81450, 0027U
L36159	<a href="#">MoIDX: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)</a>	81240, 81241, 81291
L36374	8/20/2022 Noridian retired LCD <a href="#">MoIDX: Genetic Testing for Lynch Syndrome</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36163 for determining medical necessity, along with L38974 <a href="#">MoIDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer</a> .	81210, 81288, 81292, 81293, 81294, 81295, 81296, 81297, 81298, 81299, 81300, 81301, 81317, 81318, 81319, 81433, 81435, 81436, 0101U
L36192	<a href="#">MoIDX: MGMT Promoter Methylation Analysis</a>	81287
L36544	<a href="#">MoIDX: HLA-DQB1*06:02 Testing for Narcolepsy (L36544)</a> <i>*not covered per LCD</i>	81383
L36256	<a href="#">MoIDX: Molecular Diagnostic Tests (MDT)</a>	*See LCA: <a href="#">Billing and Coding: MoIDX: Molecular Diagnostic Tests (MDT) (A57527)</a>
L38333	<a href="#">MoIDX: Blood Product Molecular Antigen Typing</a>	0001U, 0084U
L36329	08/08/2022 Noridian retired LCD <a href="#">MoIDX: ConfirmMDx Epigenetic. Molecular Assay. MoIDX: Genetic Testing for Lynch Syndrome</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36163 for determining medical necessity, along with L39007 <a href="#">MoIDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer</a> .	81551, 81313 <a href="#">Billing and Coding: MoIDX: Molecular Biomarkers to Risk Stratify Patients at Increased Risk for Prostate Cancer</a>

L38341	<a href="#">MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease</a> (Decipher and similar, i.e., Prolaris)	81541, 81542
L36339	<a href="#">MolDX: NRAS Genetic Testing</a>	81311, 81479
L36557	01/01/2018 Noridian retired LCD <a href="#">MolDX: Chromosome 1p/19q Deletion Analysis (L36557)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36557 for determining medical necessity, along with L36256 <a href="#">MolDX: Molecular Diagnostic Tests (MDT)</a> .	
L36891	09/22/2024 Noridian retired LCD <a href="#">MolDX: Percepta© Bronchial Genomic Classifier</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L36891 for determining medical necessity, along with L39680 <a href="#">MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy</a>	81479

### For Non-Medicare Members

Kaiser Permanente considers genetic testing panels medically necessary when the results are expected to directly affect treatment, management, surveillance or reproductive decisions and when all genes or genetic variants included in the panel have high quality, evidence-based guidelines established to direct clinical management based on results.

**Testing for individual components of a panel may be medically necessary in some clinical situations. Separate clinical criteria for these components may apply.**

Members must meet ALL the following criteria:

1. The member is at clinical risk for a genetic condition because of current documented symptoms being displayed or a strong family history of the condition.
2. The test is scientifically valid and can be adequately interpreted.
3. The results will directly affect a member's clinical management or reproductive decisions.
4. After appropriate clinical work-up, and informed consent by the appropriate practitioner, the genetic test is indicated.

Genetic testing is not covered for the medical management of a family member who does not have Kaiser Permanente coverage.

- 1.) If Kaiser Permanente Clinical criteria for BRCA genetic testing using MCG\* A-0499 are met AND
  - a. Member has had consultation with a medical geneticist or certified genetic counselor who is recommending the test and who has documented the indication for testing, as well as its expected impact on clinical management or surveillance
  - b. One of the following NGS panels can be covered:
    - i. Invitae Breast Cancer STAT Panel
    - ii. Invitae Breast Cancer Guidelines – Based Panel
    - iii. Invitae Breast and Gynecological Cancers Guidelines – Based Panel
    - iv. Prevention – Breast Cancer- High Risk Panel

- 2.) If Kaiser Permanente Clinical Review Criteria for Lynch syndrome genetic testing using MCG\* A-0533 are met AND
  - a. Member has had consultation with a medical geneticist or certified genetic counselor who is recommending the test and who has documented the indication for testing, as well as its expected impact on clinical management or surveillance
  - b. One of the following NGS panels can be covered:
    - i. Invitae Lynch Syndrome Panel
    - ii. Invitae Colorectal Cancer Guidelines – Based Panel
    - iii. Prevention Lynch Syndrome Panel
  
- 3.) If Kaiser Permanente Clinical Review Criteria for both BRCA and Lynch syndrome genetic testing are met
  - a. Member has had consultation with a medical geneticist or certified genetic counselor who is recommending the test and who has documented the indication for testing, as well as its expected impact on clinical management or surveillance
  - b. The following NGS panel can be covered
    - i. Invitae Breast and Gynecological Cancers Guidelines – Based Panel
    - ii. Prevention Hereditary Breast and Ovarian Cancer – High Risk and Lynch Syndrome Panel

**\*If a member has had prior negative BRCA1 & 2 gene testing:** In most cases, further genetic testing would not be considered necessary. However, in cases where there is a very strong personal or family history suggesting a genetic disposition, testing for additional evidence-based cancer susceptibility genes is warranted. One of the Invitae/LabCorp Genetics NGS panels listed in section 1b above could be covered.

#### Criteria for other Genetic Panel Tests:

Refer to the [Genetic Screening and Testing](#) clinical review criteria to see information about review criteria for specific genetic tests *not* described above; please also check [Invitae Test Catalog](#) or [Prevention Test Catalog](#)

\*For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

\*MCG are proprietary and cannot be published and/or distributed. However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### If requesting these services, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology if applicable

The following genetic panels are **not considered medically necessary** because the current scientific evidence is not yet sufficient to establish how test results from all components of these panels should be used to direct treatment decisions. There is also insufficient evidence to establish that use of these genetic panels to guide treatment decisions results in improved patient health outcomes.

This list is not all-inclusive as new genetic panel tests are frequently being developed.

Test	Laboratory
Anser TM ADA for Adalimumab (Humira) Antibodies Anser TM IFX test for Infliximab (Remicade) Antibodies	Prometheus Laboratories <a href="#">See the Medical Policy "Prometheus Lab Testing"</a>
<u>BrainTumor Next®</u>	Ambry Genetics™
<u>BRCANext™ or BRCANext-Expanded™</u>	Ambry Genetics™
<u>BRCAplus®</u>	Ambry Genetics™
BROCA Cancer Risk Panel	University of Washington
<u>CancerNext: Expanded®</u>	Ambry Genetics™
<u>CancerNext™ or CancerNext-Expanded™</u>	Ambry Genetics™

Test	Laboratory
CancerTYPE ID®	Biotheranostics
Cell Search	Veridex
<u>ColoNext®</u>	Ambry Genetics™
<u>ColoNext™</u>	Ambry Genetics™
<u>ColoSeq™</u>	University of Washington
Comprehensive Mitochondrial Nuclear Gene Panel	GeneDx
Counsyl™ Panel	Counsyl Genomics
<u>CustomNext-Cancer®</u>	Ambry Genetics™
Cxbladder	Pacific Edge Laboratory
DetoxiGenomic®	Profile Test Genova®
FirstStepDx PLUS©	Lineagen
FoundationOne™	Foundation Medicine, Inc.
Galleri®	Grail, Inc
Gene Trails AML/MDS Genotyping Panel	Oregon Heath & Science Univ
Gene Trails NSCLC Genotyping Panel	Oregon Heath & Science Univ
Gene Trails Solid Tumor Panel	Oregon Heath & Science Univ
GeneSight® Psychotropic test	Myriad®
Genomind Professional PGx Express	Genomind, Inc.
Guardant360 CDx	Guardant Health
Leigh Syndrome Nuclear Gene Panel	GeneDx
<u>MelanomaNext®</u>	Ambry Genetics™
Monogenic Hypertension Evaluation Panel	Athena Diagnostics
myRisk® Panels	Myriad®
NeurodevelopmentNext™	Ambry Genetics™
OncotypeDx Genomic Prostate Score <b>MCG* A-0712</b>	Genomic Health
<u>PancNext™</u>	Ambry Genetics™
<u>PGLNext®</u>	Ambry Genetics™
Prometheus IBD sgi® Diagnostic (Serology)	Prometheus Laboratories
<u>ProstateNext®</u>	Ambry Genetics™
Proteomics – Ovarian Cancer Markers (OVA1) <b>MCG* A-0709</b>	
Proteomics – Prostate Cancer Markers	
Providence Personalized Medicine Panel, Solid Tumor (ProvSeq 523)	Providence Health and Services - Oregon
RenalNext®	Ambry Genetics™
Signatera™	Natera™
Tempus xG Hereditary Cancer Panel	Tempus labs
Vascular Aneurysm Genetic Panel	University of Washington
X-linked Intellectual Disability Panel	NTD Genetics
X-linked Intellectual Disability Sequencing Panel	Greenwood Genetic Center

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

The emergence of new genetic testing technology, including next generation sequencing and chromosomal microarray, has made possible the ability to examine many genes simultaneously. This in turn has resulted in a proliferation of new genetic testing panels. The intended use for these panels varies.

For example, for hereditary disorders, a clinical diagnosis may already be established, in which case genetic testing is performed to determine the specific causative mutation and a diagnostic genotype. In other cases, the

clinical findings may suggest a number of possible etiologies, in which case genetic testing is performed in the hope of making a specific diagnosis.

For cancer panels, intended uses also differ. Some panels may be intended to identify the presence of a hereditary syndrome predisposing to the development of certain cancers. Other panels look for somatic mutations in a tumor biopsy specimen with the intent of identifying a cancer's primary site of origin and/or identifying a molecular target to help in selecting treatment.

Panels using next generation sequencing technology are currently available in the areas of cancer, cardiovascular disease, neurologic disease, and for prenatal testing and screening. These panels are intuitively attractive to use in clinical care because they can analyze multiple genes quickly and may lead to greater efficiency in the work-up of genetic disorders. It is also possible that in some cases these "bundled" gene tests can be performed more cost efficiently than individual sequencing, although this may not be true in all cases.

On the other hand, the use of newer sequencing techniques is associated with a higher rate of results which may be of uncertain clinical significance and/or for which there are no reliable evidence-based guidelines regarding management or surveillance. This can potentially lead to unnecessary follow-up testing and procedures, which have their own inherent risks and cost.

The design and composition of genetic panel tests are not standardized. The make-up of each panel is determined by the specific laboratory that has developed the test. In addition, the composition of any individual panel is likely to change over time, as new genetic variations are discovered and added to the existing panels.

## Evidence and Source Documents

[Ambry Genetics' Next-Generation Panels \(BreastNext, OvaNext, CancerNext\)](#)  
[Coloseq™ Colon Cancer Panel](#)

## Medical Technology Assessment Committee (MTAC)

### Ambry Genetics' Next-Generation Panels (BreastNext, OvaNext, CancerNext)

#### BACKGROUND

Understanding the underlying genetic contribution to cancer can give insight to individual and familial risk. This is especially important with hereditary cancer since risk-reducing strategies for additional primary cancers can vary based on molecular diagnosis. Identifying an underlying genetic cause can also aid in the diagnostic process since relying on family history alone can be challenging. Numerous genetic mutations are associated with certain types of hereditary cancer. Traditionally, Sanger sequencing has been considered the gold standard in mutation detection and is still the method of choice for most diagnostic labs. However, since multiple genes are implicated in each type of cancer, testing by traditional sequencing can be burdensome and expensive. Advancements in sequencing technologies have made it possible to generate a large amount of data quickly and cost effectively ([Choi, Scholl et al. 2009](#)). Next generation sequencing (NGS) provides investigators with the required capacity to analyze large panels of genes or whole genomes in a single run (panel testing) ([Prevati, Manfrini et al. 2013](#)). As a result, these technologies are enabling new tailor-made approaches to diagnostic testing with an increasing number of commercially available genetic panels ([Walsh, Lee et al. 2010](#); [Michils, Hollants et al. 2012](#)). Ambry Genetics offers four different genetic testing panels for hereditary cancers ([Keiles 2013](#)). These panels address three specific types of cancer that may be inherited including breast, ovarian and colorectal. The mutations included in these panels are associated with varying levels of risk of developing cancer, and only some of the mutations are associated with well-defined cancer syndromes which have established clinical management guidelines ([Burke, Petersen et al. 1997](#)).

TABLE 1: PANEL NAME AND DESCRIPTION	
PANEL NAME	DESCRIPTION
<i>BreastNext™</i>	Next-generation sequencing panel that simultaneously analyzes 16 genes that contribute to increased risk for breast cancer including BRCA1 and BRCA2.
<i>OvaNext™</i>	Next-generation sequencing panel that simultaneously analyzes 21 genes that contribute to increased risk for breast ovarian and/or uterine cancers.
<i>Colonext™</i>	Next-generation sequencing panel that simultaneously analyzes 14 genes that contribute to increased risk for colon cancer.
<i>CancerNext™</i>	Next-generation sequencing panel that simultaneously analyzes 24 genes that contribute to increased risk for breast colon, ovarian, uterine and other cancers.



There is no standardization to the make-up of genetic panels. Composition of the panels is variable, and different commercial products for the same condition may test a different set of genes. The make-up of the specific panels is determined by the specific lab that has developed the test. In addition, the composition of any individual panel is likely to change over time, as new mutations are discovered. The majority of cancer panel tests are laboratory derived tests that are not subject to U.S. Food and Drug Administration (FDA) approval. Labs are subject to Clinical Laboratory Amendment (CLIA) regulations that monitor high-complexity testing.

#### 10/21/2013: MTAC REVIEW

##### **Ambry Genetics' Next-Generation Panels (BreastNext, OvaNext, CancerNext)**

**Evidence Conclusion:** Analytic Validity According to Ambry Genetics, the analytic sensitivity for the 22 genes analyzed on their cancer susceptibility panels by next generation sequencing is 96-99% ([Keiles 2013](#)), however, no publications were found to support these claims. No published literature addressed the analytic validity of the Ambry Genetics' Next-Gen Cancer Panels. Clinical Validity While it may be possible to evaluate the clinical validity of sequencing of individual genes found on these panels, the clinical validity of Ambry Genetics' Next-Gen Cancer Panels, which include mutations associated with unknown or variable cancer risk, is uncertain. No published literature addressed the clinical validity of panel testing for cancer susceptibility with NGS. Clinical Utility Theoretically, identifying an individual with a genetic mutation that indicates a high risk of developing cancer could lead to changes in clinical management and improved health outcomes including modifications in cancer surveillance and treatment guidance. However, identifying mutations that have intermediate or low risk of developing cancer is of limited clinical utility. With potential harms, such as psychological stress and unnecessary prophylactic intervention, the management for patients found to have one of these mutations is not well defined. No published literature addressed the clinical utility of the Ambry Genetics' Next-Gen Cancer Panels. Conclusion There is insufficient evidence to determine the analytic validity, clinical validity or clinical utility of the Ambry's Next-Gen Cancer Panels.

**Articles:** A search of PubMed was completed for the period through August 2013 for studies on the accuracy of NGS for predicting risk of hereditary breast ovarian and colon cancer. The search strategy used the terms *next generation, cancer panel, BreastNext, breast cancer, ColoNext, colon cancer, OvaNext, ovarian cancer and CancerNext* with variations. To identify ongoing clinical trials, a search of the National Institute of Health Clinical Trials website was also conducted using the same methodology. Articles were limited to those published in the English language with human subject enrollment. The search was supplemented by an examination of article bibliographies in addition to the PubMed *related* articles function.

The use of Ambry next generation does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **Coloseq™ Colon Cancer Panel**

##### **BACKGROUND**

Approximately 2% to 5% of colorectal cancer (CRC) can be attributed to inherited syndromes such as Lynch syndrome (also known as hereditary non-polyposis colon cancer), familial adenomatous polyposis (FAP), and MUTYH-associated polyposis. Patients with these syndromes are at higher risk for CRC and, therefore, require more intensive surveillance programs. Lifetime CRC risk is 50-80% for patients with Lynch syndrome, 100% for patients with FAP, and 80% for patients with MUTYH-associated polyposis compared to 5-6% for patients without these syndromes ([Kaz and Brentnall 2006](#); [Jasperson, Tuohy et al. 2010](#)). There are several different strategies used to identify families at high-risk for developing these syndromes, however, genetic testing is the gold standard for diagnosing Lynch syndrome and FAP. To date, clinical diagnostic criteria for MUTYH-associated polyposis have not been fully established; however, genetic testing may be warranted in individuals with more than 10 colorectal adenomas who are negative for APC mutations ([Jasperson, Tuohy et al. 2010](#)). Genetic testing of high-risk families allows for a more accurate diagnosis and more specific targeting of clinical screening and surveillance protocols to gene carriers in the family. Additionally, genetic testing allows for the identification of family members who did not inherit the mutation and therefore do not warrant intensive surveillance programs. Coloseq™ is a comprehensive genetic test for the prediction and diagnosis of hereditary colon cancer that uses next generation sequencing to detect mutations in multiple genes associated with Lynch syndrome, FAP, and MUTYH-associated polyposis. Initially, the panel was developed to include seven genes that have a well-established role in clinical decision making for patients with Lynch or polyposis syndromes. Since then, however, the panel has undergone several evolutions to include four additional genes in June of 2012, two more genes in January of 2013 and, most recently, the addition of six genes in October of 2013. With a total of 19 genes now included, the panels utility has now expanded into the realms of endometrial, breast, and thyroid cancer, to name a few. Coloseq is not approved by the Food and Drug Administration (FDA) but clinical laboratories that develop and validate tests for in-house use are regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

#### 10/16/2013: MTAC REVIEW

## Coloseq™ Colon Cancer Panel

**Evidence Conclusion:** There is insufficient evidence to determine the analytic validity, clinical utility and clinical validity of Coloseq™ for the identification of hereditary colon cancer.

**Articles:** A search of PubMed was completed for the period from April 2012 to November 5<sup>th</sup>, 2013 for studies on the accuracy of ColoSeq™ for detecting hereditary colon cancer. The search strategy used the terms *Coloseq™*, *genetic testing*, *Lynch syndrome*, *familial adenomatous polyposis (FAP)*, *MUTYH-associated polyposis*, and *colon cancer* with variations. To identify ongoing clinical trials, a search of the National Institute of Health Clinical Trials website was also conducted using the same methodology. Selected articles were limited to those published in the English language enrolling human subjects. The search was supplemented by an examination of article reference lists in addition to the PubMed *related articles* function. **Screening of articles:** The literature search for ColoSeq™ revealed one July 2012 publication on the development and validity of the assay (Pritchard, Smith et al. 2012). Due to recent additions (October 2013) to the Coloseq™ cancer panel, this publication is no longer applicable and was not reviewed.

The use of Coloseq™ does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**\*Note:** Codes listed in the criteria above may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
3/04/2014	3/04/2014 <sup>MPC</sup> , 6/3/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	11/15/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/30/2015	Added Medicare LCD links and PROOVE® panels.
08/27/2015	Added LCD 35850 and LCD 35504
09/08/2015	Revised LCD Circulating Tumor Cell Marker Assays LCD L35096 and L34066, Breast Cancer Genetic Assay L35500 and L36316, GeneSight® Assay for Refractory Depression L36324 and L36325, Genetic Testing L34101, LCD for ConfirmMDx Epigenetic Molecular Assay (L36328),
12/06/2016	Added Cx Bladder & My Risk Panel to the non-covered list
05/16/2017	Added Percepta LCD
06/15/2017	Added Invitae Stat Panel coverage
10/19/2017	Added Health Diagnostics to the non-covered panel list
03/26/2018	Added Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer
06/02/2020	Added section: "Preferred Lab for Genetic Testing for Kaiser Permanente non-Medicare enrollees." Requires 60-day notice, effective date 10/01/2020.
10/06/2020	Removed codes section; will defer to pre-authorization code check tool.
05/04/2021	Removed genetic panel tests that are no longer available. Updated Medicare LCD links and applicable codes.
09/27/2022	Added Prevention as a preferred lab vendor for genetic panel testing. Removed Caris and Oncoplex from the non-inclusive list of genetic panel tests. 60-day notice required; effective 03/01/2023.
01/19/2023	Removed Prolaris from the non-covered list. MPC approved to adopt criteria for Prostate Cancer Gene Expression Testing (Prolaris) and Prostate Cancer (ConfirmMDx), effective 4/1/2023- see <a href="#">Genetic Screening Criteria</a> for details.

03/08/2023	Added Signatera to the non-covered panel list
05/15/2023	Updated Medicare Links including—newly retired policies L36163, L36329 and L36374
06/07/2023	Added Tempus xG Hereditary Cancer Panel test to the non-covered list.
11/15/2023	Added ProvSeq 523 test to the non-covered list
12/14/2023	Added multi-gene panel tests from Ambry Genetics™ to the non-covered list
04/16/2024	Removed Horizon from the non-covered list.
10/21/2024	Updated Medicare LCD Links
11/15/2024	LabCorp acquired Invitae Genetics test. Criteria was updated to reflect acquisition, effective November 15, 2024

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Fundoplication Surgery & Treatment of Gastroesophageal Reflux Disease

- CR BARD's Endoscopic Suturing System
- Endoscopic Placement of a Bulking Material at the Lower Esophageal Sphincter
- LINX Reflux Management System
- Stretta Procedure
- Transoral (Endoluminal) Gastroplication or Suturing (Esophyx)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare members

Procedure(s):	CPT Code(s)	CMS Coverage Guidelines – NCD, LCD, LCA	Kaiser Permanente Medical Policy
Fundoplication Surgery	43280, 43281, 43282, 43325, 43328, 43334, 43335, 43336, 43337, 43327, 43332, 43333	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use non-Medicare Clinical Review Criteria, <b>Fundoplication Surgery</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.	<a href="#">Requires Level of Care Review</a> <b>AND</b> Kaiser Permanente has elected to use the Fundoplication and Hiatal Hernia Repair, by Laparoscopy (KP-S-505 02012025) MCG* Care Guideline for medical necessity determinations.
Transesophageal radiofrequency energy <b>Examples:</b> CSM Stretta™ System, or the Stretta procedure	43257	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use non-Medicare Clinical Review Criteria, <b>Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta)</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.	Kaiser Permanente has elected to use the Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta) (A-0209) MCG* Care Guideline for medical necessity determinations. This service is not covered per MCG guidelines.
Transoral incisionless fundoplication (TIF) <b>Examples:</b> Esophyx	43210	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use non-Medicare Clinical Review Criteria, <b>Transoral</b>	<b>Effective until May 1, 2025</b> Kaiser Permanente has elected to use the Transoral (Endoluminal) Gastroplication or Suturing (A-0205) MCG* Care Guideline for medical necessity determinations. This

		<b>(Endoluminal) Gastroplication or Suturing</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.	service is not covered per MCG guidelines.  <b>Effective May 1, 2025</b> Defer to Kaiser Permanente Medical Policy (see below)
LINX® Reflux Management System	43284, 43285	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use non-Medicare Clinical Review Criteria, <b>Implantable Magnetic Esophageal Ring (Linx)</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.	<b>Effective until May 1, 2025</b> Kaiser Permanente has elected to use the Implantable Magnetic Esophageal Ring (Linx) (A-0990) MCG* Care Guideline for medical necessity determinations. This is not covered per MCG guidelines.  <b>Effective May 1, 2025</b> Defer to Kaiser Permanente Medical Policy (see below)
Endoscopic injection of a bulking agent <b>Examples:</b> pyrolytic carbon-coated zirconium oxide spheres (Durasphere®)	43192, 43201	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria of “insufficient evidence” for medical necessity determinations. Use the Non-Medicare criteria below.	Kaiser Permanente Medical Policy of insufficient evidence (see below).
Endoscopic submucosal implantation or injection of a biocompatible polymer <b>Examples:</b> • Enteryx, • polymethylmethacrylate [PMMA] beads (1) the Gatekeeper Reflux Repair system	43192, 43201	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria of “insufficient evidence” for medical necessity determinations. Use the Non-Medicare criteria below.	Kaiser Permanente Medical Policy of insufficient evidence (see below).
Transesophageal endoscopic gastroplasty <b>Examples:</b> • EndoCinch • Plicator • StomaphyX	No specific codes – <i>often submitted using 43499</i>	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria of “insufficient evidence” for medical necessity determinations. Use the Non-Medicare criteria below.	Kaiser Permanente Medical Policy of insufficient evidence (see below).

### For Non-Medicare members

Service	Criteria
Implantable Magnetic Esophageal Ring (LINX® Reflux Management System)	<b>Effective until May 1, 2025</b>

	<p>Kaiser Permanente has elected to use the Implantable Magnetic Esophageal Ring (Linx) (A-0990) MCG* Care Guideline for medical necessity determinations. This is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p> <p><b>Effective May 1, 2025</b></p> <p>Procedure is indicated for typical symptomatic GERD (e.g., heartburn, regurgitation, dental erosions) with <b>ALL</b> of the following:</p> <ul style="list-style-type: none"> <li>Confirmation of diagnosis on endoscopy, ambulatory pH monitoring, or barium swallow study</li> <li>Unresponsive to lifestyle modification*</li> <li>Failure**, contraindication or intolerance of an adequate trial of medical therapy***</li> <li>Documentation supports the need for LINX® versus traditional fundoplication procedures</li> </ul> <p>When the following exclusions are not present:</p> <ul style="list-style-type: none"> <li>Complete failure of the lower esophageal sphincter</li> <li>Dysphagia</li> <li>Previous endoluminal anti-reflux procedure</li> <li>Barrett's esophagus</li> </ul> <p><b>Definitions:</b></p> <p><b>*Lifestyle Modifications</b> include weight loss, avoidance of trigger foods, avoidance of late meals and elevation of the head of the bed.</p> <p><b>**Failure</b> is defined as lack of response of conservative therapy or inadequate response with significant residual functional limitations due to symptoms.</p> <p><b>***An adequate trial of medical therapy</b> would be at least 4 concurrent months of Proton Pump Inhibitor (PPI) use.</p> <p><b>****Paraesophageal Hernia:</b> Unlike a type 1 hiatus hernia (sliding hernia), a paraesophageal hernia is a true hernia with a hernia sac composed of peritoneum and characterized by an upward dislocation of the gastric fundus through a focal defect in the phrenoesophageal membrane . For definition of Type II-IV see below.</p>
Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta)	<p>Kaiser Permanente has elected to use the Radiofrequency Energy Delivery to Gastroesophageal Junction (Stretta) (A-0209) MCG* Care Guideline for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p>
Transoral (Endoluminal) Gastroplication or Suturing (Esophyx)	<p><b>Effective until May 1, 2025</b></p> <p>Kaiser Permanente has elected to use the Transoral (Endoluminal) Gastroplication or Suturing (A-0205) MCG* Care Guideline for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.</p> <p><b>Effective May 1, 2025</b></p>



	<p>Procedure is indicated for typical symptomatic GERD (e.g., heartburn, regurgitation, dental erosions) with <b>ALL</b> of the following:</p> <ul style="list-style-type: none"> <li>Confirmation of diagnosis on endoscopy, ambulatory pH monitoring, or barium swallow study</li> <li>Unresponsive to lifestyle modification*</li> <li>Failure**, contraindication or intolerance of an adequate trial of medical therapy***</li> </ul> <p>When the following exclusions are not present:</p> <ul style="list-style-type: none"> <li>Prior transoral incisionless fundoplication</li> <li>Hiatal hernia greater than 2 cm</li> <li>Esophagitis LA grade &gt;B</li> <li>Barrett's esophagus &gt; 2 cm</li> <li>Achalasia</li> <li>Esophageal ulcer</li> <li>BMI &gt; 35</li> </ul> <p><b>Definitions:</b></p> <p><b>*Lifestyle Modifications</b> include weight loss, avoidance of trigger foods, avoidance of late meals and elevation of the head of the bed.</p> <p><b>**Failure</b> is defined as lack of response of conservative therapy or inadequate response with significant residual functional limitations due to symptoms.</p> <p><b>***An adequate trial of medical therapy</b> would be at least 4 concurrent months of Proton Pump Inhibitor (PPI) use.</p> <p><b>****Paraesophageal Hernia:</b> Unlike a type 1 hiatus hernia (sliding hernia), a paraesophageal hernia is a true hernia with a hernia sac composed of peritoneum and characterized by an upward dislocation of the gastric fundus through a focal defect in the phrenoesophageal membrane . For definition of Type II-IV see below.</p>
Fundoplication Surgery	<p><a href="#">Requires Level of Care Review</a> <b>AND</b> Kaiser Permanente has elected to use the Fundoplication and Hiatal Hernia Repair, by Laparoscopy (KP-S-505 02012025) MCG* Care Guideline for medical necessity determinations.</p>
<ul style="list-style-type: none"> <li>CR BARD's Endoscopic Suturing System (EndoCinch Therapy, Endoluminal Plication)</li> <li>Endoscopic Placement of a Bulking Material at the Lower Esophageal Sphincter</li> </ul>	<p>There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.</p>

**\*The MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist (GI, general surgeon)

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Gastroesophageal reflux disease (GERD) is a common disease worldwide with an estimated prevalence of 10-20% in the Western population. It is defined as a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications. GERD has a wide clinical spectrum ranging from mild reflux symptoms to severe regurgitation but is typically characterized by heartburn and acid regurgitation. Other symptoms of GERD include epigastric pain, dysphagia, chronic cough, chronic laryngitis, and asthma (Vakil 2006, Zhang 2016, Savarino 2017).

Therapeutic approaches to GERD included lifestyle modification, medical therapy with gastric acid secretion inhibitors, and surgical interventions. Proton pump inhibitors (PPIs) are the standard medical therapy and aim at suppressing the normal acid production in the stomach to alleviate the acid reflux symptoms. PPIs can only inhibit gastric acid secretion, but do not prevent reflux nor address the incompetent lower esophageal sphincter (LES). It is reported that up to 40% of the GERD patients fail to respond either partially or completely to PPIs and will continue to have reflux symptoms or endoscopic evidence of esophagitis (Reynolds 2016, Saino 2016, Chen 2017).

Laparoscopic Nissen fundoplication (LNF) is currently the gold standard surgical treatment for patients who fail medical therapy. Nissen fundoplication reconstructs the defective LES to restore its normal function as an anti-reflux barrier. The surgery is safe and very effective in reducing GERD symptoms. However, the procedure is technically demanding and requires significant anatomical disruption to mobilize the gastric fundus and wrap it around the esophagus. It may also be associated with side effects including difficulty swallowing, bloating, early satiety, and inability to vomit or belch. As a result, only very few GERD patients will opt for the surgery (Saino 2015, Reynolds 2016, Zadeh 2018).

The Magnetic sphincter augmentation device (MSA) (LINX®, Torax Medical Shoreview, MN) was introduced in 2008 as a potential less invasive anti-reflux surgical option for patients with uncomplicated GERD who do not respond to PPIs, and still have some LES function. I.e. it is not indicated for patients with complete LES failure or with complicated GERD. The MSA device is a small expandable bracelet-like string of consisting of 10 or more beads with a magnetic core and interlinked with independent titanic wires. The device is laparoscopically placed around the gastroesophageal junction (GEJ) with minimal dissection of the hiatus to preserve the native LES. The magnetic attraction between the beads augments the existing LES barrier function to prevent reflux, and the mobile wires connecting the beads allow the device to expand during swallowing, belching, or vomiting (Reynolds 2017, Siddiqi 2017, Zadeh 2018, Guidozzi 2019).

The LINX® device should not be placed in patients with suspected or known allergies to titanium, stainless steel, nickel or ferrous material, or in those with pacemakers, defibrillators or metallic implants in the abdomen. In addition, it may not be appropriate for patients with a history of dysphagia, previous upper abdominal surgery, previous endoluminal anti-reflux procedures, large sliding hiatal hernia, or Barrett's esophagus. Reported adverse events and complications associated with magnetic sphincter augmentation include inability to belch or vomit, bloating, and dysphagia. The latter is the most common complication of the MSA, and severe cases may require a second surgery for dilatation, and removal of the device if endoscopic dilatation fails. Other reported adverse events include device failure, device migration, device erosion, and ring eroding into the esophageal lumen (Fass 2017, Chen 2017, Zadeh 2018, Guidozzi 2019).

The LINX® Reflux Management System received U.S. Food and Drug Administration (FDA) approval on March 22, 2012 for patients with GERD as defined by abnormal pH testing, and who continue to have chronic symptoms despite the use of a maximum medical therapy.

## Medical Technology Assessment Committee (MTAC)

### ***CR BARD's Endoscopic Suturing System (EndoCinch Therapy, Endoluminal Plication) for the Treatment of GERD***

#### BACKGROUND

Gastroesophageal reflux disease (GERD) is a chronic disorder that affects as many as 14 million Americans. It is primarily caused by transient inappropriate relaxation or abnormally low resting pressure of the lower esophageal sphincter (LES). This intermittently exposes the esophagus to gastric acid and enzymes. GERD usually manifests as heartburn, regurgitation, or dysphagia. Patients may have significant daily symptoms with a substantial effect on their quality of life. Complications of the disease include Barrett's esophagus, esophagitis, laryngeal injury, pneumonia, and esophageal stricture. Current therapy for GERD begins with lifestyle changes and medical treatment, which proved to be effective in more than three fourths of the patients. Pharmacotherapy reduces the frequency, duration and/ or potency of the refluxate. However, the long-term costs are high, and the recurrence of symptoms could be as high as 90% after the cessation of medication. Patients who do not tolerate, or respond

well to medical treatment, as well as those who want to avoid life-long treatment, may be candidates for surgery. Surgical approaches are used to create barriers to the reflux. Nissen fundoplication is the most commonly used surgical procedure with a response rate as high as 90% at 5-year follow-up (Lafullarde, 2001). More recently endoscopic or endoluminal approaches for treating GERD have either been FDA approved or are still under investigation. These various methods can be divided in three broad categories: 1. Methods that attempt to create a fundoplication (plicating techniques), 2. Methods that create a controlled stricture (radio frequency), and 3. Methods that bulk the gastroesophageal junction (injecting bulking agents). The ideal procedure should be safe, effective over a long term, and would not affect future surgical options. Currently, there are three plicating devices: The EndoCinch (C.R. Bard's endoscopic suturing system, the ESD, and the Full-Thickness Plicator. The first two have been approved by the FDA, and the last was not approved to date. Endoluminal plication uses mechanical techniques to hinder reflux by approximation of tissue at or below the gastroesophageal junction. The EndoCinch (CR BARD Endoscopic technologies, Massachusetts, USA) system was the first FDA approved endoscopic sewing machine method for treating GERD. It was developed by Swain CP et al in London UK, in the mid-1980s. In the Bard method, an oroesophageal tube (19.7 mm in diameter and 30 cm long) is placed to facilitate passage of the suturing device. The suture capsule, which is similar to a sewing machine, is attached to an endoscope and loaded with a suture. After placing the suture capsule, under vision, over the selected site at the gastroesophageal junction, suction through the external vacuum line is applied. This pulls a fold of tissue into the capsule cavity, and the needle driver places the suture. Suction is released, and the tissue is withdrawn from the capsule. The procedure is repeated on an adjoining site. Drawing two sutured sites together creates a plication. It is reported that the procedure is technically difficult, has a steep learning curve, and that the results are likely to be operator dependent. Conscious sedation might not be sufficient, and a general anesthesia may be needed. Adverse effects associated with the procedure include pharyngitis, vomiting, abdominal pain, chest pain, mucosal tear, hypoxia, and bleeding. The Bard's Endoscopic Suturing system was FDA approved in March 2000, for the treatment of GERD. The ESD (Wilson-Cook Medical, Winston-Salem, N.C.) another endoscopically assisted endoluminal suturing device was also approved by the FDA for soft-tissue apposition. The Full-Thickness Plicator (Ndo Surgical, Inc, Mansfield, Mass) is another plication device that had not been approved by the FDA at time the search was made.

## 02/13/2003: MTAC REVIEW

### Endocinch Therapy in the Treatment of GERD

**Evidence Conclusion:** The studies reviewed show that the procedure is associated with a reduction in the frequency and severity of heartburn and regurgitation symptoms. Patients had an improved quality of life, and there was a significant reduction in the use of antisecretory medications in two of the studies. However, the procedure was performed on a highly selected group of patients (those with hiatal hernia >3 cm, esophageal stricture and Barrett's esophagus were excluded). Moreover, the follow-up duration of all studies was short, and insufficient to determine the recurrence rate and long term-efficacy of the procedure. Filipi's study was an RCT, yet the patients were randomized to two different suture configurations of the same procedure and not to an alternative treatment. Randomized controlled studies with long-term follow-up are needed to compare the procedure with other medical and surgical anti reflux therapies and assess the sustained effect of the procedure and the long-term relief from symptoms without using antisecretory medications.

**Articles:** The search yielded 12 articles, all on the Bard technique. There was one randomized controlled trial, one case-control study and one case series. The rest were reviews, tutorials, letters or dealt with the technical aspect of the procedure. There were no published studies on the Wilson-Cook ESD, or the Ndo Full-Thickness Plicator. Evidence tables were created for the three studies identified in the search:

Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral flexible endoscopic suturing for treatment of GERD. A multicenter trial. *Gastrintest Endosc* 2001; 53:416-422. See [Evidence Table](#). Mahmoud Z, McMahon BP, Arfin Q, et al. Endocinch therapy for gastro-esophageal reflux disease: a one-year prospective study. *Gut* 2003, 52:34-39. See [Evidence Table](#). Velanovich V, Ben-Menachem T, and Goel S. Case-control comparison of endoscopic gastroplication, with laparoscopic fundoplication in the management of gastroesophageal reflux disease. Early symptomatic outcomes. *Surg laparosc Endosc Percutan Tech* 2002, 12:219-223. See [Evidence Table](#).

The use of Endocinch therapy in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Endoscopic Placement of a Bulking Material at the Lower Esophageal Sphincter for the Treatment of GERD

### BACKGROUND

Gastro-esophageal reflux disease (GERD) is a chronic disorder that affects as many as fourteen million Americans. It is primarily caused by transient inappropriate relaxation or abnormally low resting pressure of the lower esophageal sphincter (LES). This intermittently exposes the esophagus to gastric acid and enzymes. GERD usually manifests as heartburn, regurgitation, or dysphagia. Patients may have significant daily symptoms with a

substantial effect on their quality of life. Complications of the disease include Barrett's esophagus, esophagitis, laryngeal injury, pneumonia, and esophageal stricture. Current therapy for GERD begins with lifestyle changes and medical treatment, which proved to be effective in more than three fourths of the patients. Pharmacotherapy reduces the frequency, duration and/or potency of the refluxate. However, the long-term costs are high, and the recurrence of symptoms could be as high as 90% after the cessation of medication. Patients who do not tolerate, or respond well to medical treatment, as well as those who want to avoid life-long treatment, may be candidates for surgery. Surgical approaches are used to create barriers to the reflux. Nissen fundoplication is the most commonly used surgical procedure with a response rate as high as 90% at 5-year follow-up ((Lafullarde, 2001). More recently endoscopic or endoluminal approaches for treating GERD have either been approved or are still under trial. These various methods can be divided in three broad categories: 1. Methods that create a controlled stricture (radiofrequency), 2. Methods that attempt to create a fundoplication, and 3. Methods that bulk the gastroesophageal junction (injecting bulking agents). The ideal procedure should be safe, effective, with long-term effects, and do not affect future surgical options. Endoscopic injection of an inert material into the submucosa of the distal esophagus has been tried with the intention to impede the reflux. The bulking effect results from both the material injected and the tissue response. Examples of the bulking agents used are bovine collagen, ethylene vinyl alcohol, polytetrafluoroethylene and others. These are injected through long catheters and small gauge needles under endoscopic guidance. In the experiments conducted the resulting improvement in reducing the LES pressure and GERD symptoms were temporary, and did not last long, either due to the biodegradation or migration of the injected material. Other non-biodegradable substances injected into the submucosa or muscle, and with the use of different application techniques are still under trial. These methods are still in the investigational stage and are not approved by the FDA.

## 02/13/2003: MTAC REVIEW

### Bulking Material in the Treatment of GERD

**Evidence Conclusion:** There is insufficient evidence to determine the efficacy and safety of endoscopic injection of bulking material for the treatment of GERD.

**Articles:** The search did not yield any study. Two studies were revealed from review articles. Both were pilot studies with no comparison groups. One included only a series of 15 patients (10 in Brussels and 5 in Rome), and the other was a case series with only ten participants.

The use of bulking material in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Magnetic Sphincter Augmentation – (LINX® Reflux Management System)**

#### BACKGROUND

Gastroesophageal Reflux Disease (GERD) is an extremely common clinical manifestation of excessive reflux of acidic gastric components. Also referred to as chronic acid reflux, GERD is characterized by a chronic, often progressive dysfunction of the lower esophageal sphincter (LES) allowing acids and bile from the stomach to flow back into the esophagus. Common symptoms include heartburn, regurgitation and dysphagia and can adversely impact the quality of life by interfering with daily activities, disturbing sleep, and reducing productivity. Left untreated GERD can lead to more serious complications such as esophageal stricture, Barrett's esophagus and esophageal cancer (Gorecki 2001). Simple diet and lifestyle modifications can ease some of the symptoms associated with GERD, however, more severe or frequent cases may require pharmaceutical treatment with antacids, H<sub>2</sub>-receptor antagonists or proton pump inhibitors (PPIs). Some cases of GERD, however, will not respond to medications and may require surgical intervention. Laparoscopic fundoplication (LF), has long been considered the gold standard of antireflux surgery. The technique involves wrapping the upper part of the stomach (gastric fundus) around the lower end of the esophagus in an effort to reinforce the LES. Although LF has a high success rate, the procedure is non-reversible and has been associated with a variety of potential side-effects such as dysphagia, loss of belching and vomiting and increased flatulence and bloating. The LINX® Reflux Management System, developed by Torax® Medical (St. Paul, MN), was designed to prevent back flow into the esophagus and is suggested as an alternative to anti-reflux surgery. More specifically, the magnetic sphincter augmentation (MSA) device is a series of interlinked magnetic beads implanted laparoscopically at the junction between the esophagus and stomach that acts as a reinforcement of the LES. The device relies on small wires that allow the magnetic beads to expand and allow the flow of foods and liquids into the stomach while preventing reflux at the same time. According to the manufacturer, the LINX Reflux Management System requires less recovery time, provides immediate relief and faster return to solid foods compared with other surgical interventions. To add to this, the device can be removed if side-effects, such as dysphagia, pain and bloating, become unbearable. The LINX® Reflux Management System received US Food and Drug Administration (FDA) approval on March 22, 2012. The device is intended for use in patients with GERD who continue to have



symptoms despite the use of a maximum medical therapy for the treatment of reflux. More specifically, it is intended for use in patients who would be considered candidates for anti-reflux surgery. This topic has not previously been reviewed by the Medical Technology Assessment Committee (MTAC) and is currently under consideration due to coverage decision support.

## 12/15/2014: MTAC REVIEW

### LINK Reflux Management System

**Evidence Conclusion:** A feasibility trial by Lipham and colleagues, included 44 patients and aimed to assess the long-term safety and effectiveness of the LINX Reflux Management System (up to 3.7 years). In this study, patient's baseline measurements were used as the control for comparison with post-implant measurements. In all outcome measures improvements were seen with reduced esophageal acid exposure, improved GERD-HRQL scores and decreases in use of PPIs. As a result, the investigators concluded that sphincter augmentation with LINX provides long-term clinical benefits with no safety issues (Lipham, DeMeester et al. 2012). [Evidence Table 1](#)

In the second study, a pivotal trial by Ganz and colleagues, the investigators sought to evaluate the safety and effectiveness of the LINX Reflux Management System. The study included 100 patients with GERD and assessed esophageal pH as well as manometry and barium esophagography. The investigators report that 64% (95% CI, 54%-73%) of patients achieved success with normalization of esophageal acid exposure, or a  $\geq 50\%$  reduction in exposure at one year. Additional endpoints were also promising with 50% or more improvements seen in 92% of patients on the GERD-Health Related Quality of Life (HRQL) questionnaire. Although the authors concluded that the LINX device resulted in a decreased exposure to esophageal acid, improved reflux symptoms and allowed cessation of PPIs in the majority of patients, they also noted that additional prospective RCTs with appropriate controls are necessary for confirmation. (Ganz, Peters et al. 2013). Finally, the third study, by Riegler and colleagues, evaluated 249 patients who had undergone MSA and LF and completed one-year follow-up. With the overall goal to compare the clinical experience of each procedure, the investigators evaluated patients reflux symptoms, PPI use, side effects and complications. At one year, both groups showed improvement in total GERD-HRQL score (20 vs. 3 in the MSA group and 23 vs. 3.5 in the LF group) and discontinuation of PPIs was higher in the MSA group with 81.8% of patients abstaining and only 63% in the LF group ( $P=0.009$ ). The investigators concluded that both MSA and LF were comparable but that MSA should be considered as the first-line surgical option [Evidence Table 3](#). Adverse events and complications were documented in all three of the critically appraised publications. In addition, a recent publication from Lipham and colleagues provides a safety analysis of the first 1,000 patients treated with the MSA device. The analysis included safety related events collected from the published literature, FDA databases for device related complications and information provided by the manufacturer for over 1,000 patients treated worldwide between February 2007 and July 2013. This paper was not critically appraised, however, the safety data is generally summarized in table one, below. (Lipham, Taiganides et al. 2014).

Table 1. Summary of events by source		
Source of data	# of events included in analysis	Breakout
Clinical literature	32	<ul style="list-style-type: none"> <li>9 device removal</li> <li>20 esophageal dilation</li> <li>3 hospital readmissions</li> </ul>
MAUDE database	20	<ul style="list-style-type: none"> <li>19 device removal (includes US and OUS)</li> <li>1 device erosion</li> </ul>
Manufacturer's database	59	<ul style="list-style-type: none"> <li>8 device removal</li> <li>1 intra/perioperative complication</li> <li>11 hospital readmissions</li> <li>39 esophageal dilation</li> </ul>

Generally speaking, the body of evidence is limited by small sample sizes, short-term follow-up, as well as a lack of randomization and adequate comparators. Selection bias may be an issue in the third study as the selection of intervention was ultimately made by the surgeon at the time of surgery. It should also be noted that the majority of studies assessing the LINX Reflux Management System are either funded by the device manufacturer or authored by consultants to the manufacturer. Ultimately the body of evidence provides insufficient evidence to support the safety and effectiveness of the LINX Reflux Management System. Conclusions: There is insufficient evidence to support the effectiveness of the LINX Reflux Management System in patients with refractory GERD. There is insufficient evidence to support the safety of the LINX Reflux Management System in patients with refractory GERD.

**Articles:** The literature search revealed just over 100 publications relating to treatment of GERD using sphincter augmentation many of which were not directly applicable to the objective at hand. No randomized controlled trials

(RCTs) were revealed comparing the LINX Reflux Management System with alternative surgical interventions such as LF. The FDA's 2012 approval relied on two publications, a pivotal clinical trial and a feasibility study, which were selected for critical appraisal. Post-approval studies of the LINX Reflux Management System, required by the FDA, are currently ongoing. In addition to the pivotal and feasibility trial, two additional studies were considered. The first was a recent observational study comparing MSA to laparoscopic fundoplication (LF) and the latter, a safety analysis of the first 1,000 patients treated with MSA (this study was not critically appraised but discussed in the evidence summary). The following articles were selected for critical appraisal: Lipham JC, DeMeester TR, Ganz RA, et al. The LINX® reflux management system: confirmed safety and efficacy now at 4 years. *Surgical Endoscopy*. 2012; 26:2944-2949. [See Evidence Table 1](#). Ganz RA, Peters JH, Horgan S, et al. Esophageal Sphincter Device for Gastroesophageal reflux disease. *NEJM*. 2013;368(8):719-72. Reigler M, Schoppman, Bonavina L, et al. Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one-year results of a multicenter, prospective observational study. *Surgical Endoscopy*. 2014. [See Evidence Table 3](#).

The use of LINX Reflux Management System does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Stretta Procedure (Electro-Surgical Coagulation-Radiofrequency [RF] Application- Curon Medical Inc's CSM Stretta System) for the Treatment of GERD**

#### **BACKGROUND**

Gastroesophageal reflux disease (GERD) is one of the most common medical disorders in the United States. It is a chronic disorder that is primarily caused by transient inappropriate relaxation or abnormally low resting pressure of the lower esophageal sphincter (LES). This intermittently exposes the esophagus to gastric acid and enzymes. GERD usually manifests as heartburn, regurgitation, or dysphagia. Patients may have significant daily symptoms with a substantial effect on their quality of life. Complications of the disease include Barrett's esophagus, esophagitis, laryngeal injury, pneumonia, and esophageal stricture. Current therapy for GERD begins with lifestyle changes and medical treatment, which proved to be effective in more than three fourths of the patients. Pharmacotherapy reduces the frequency, duration and/ or potency of the refluxate. However, the long-term costs are high, and the recurrence of symptoms could be as high as 90% after the cessation of medication. Patients who do not tolerate, or respond well to medical treatment, as well as those who want to avoid life-long treatment, may be candidates for surgery. Surgical approaches are used to create barriers to the reflux. Nissen fundoplication is the most commonly used surgical procedure with a response rate as high as 90% at 5-year follow-up (Lafullarde, 2001). More recently options include injection therapy to the lower esophageal sphincter, endoscopic sewing procedures, and radiofrequency ablation therapy. The ideal procedure should be safe, effective for a long time, and would not affect future surgical options. This review evaluates the radiofrequency techniques. Radiofrequency (RF) energy has been used for the general surgical application of tissue coagulation for more than 70 years. RF energy leads to collagen shrinkage, and in turn tissue contraction and tightening. Recently RF is being used for different clinical purposes, including its application to the gastroesophageal junction. The Stretta System (Curon Medical, Sunnyvale, CA) consists of a RF control module and a flexible Stretta catheter. The catheter has a 20F soft bougie tip and a balloon, which opens in a surrounding basket. On its widest area after balloon inflation, the catheter has four nickel-titanium needle electrodes (5.5 mm long), which can be extended in the LES muscle. The catheter is introduced transorally and positioned at the Z-line (squamocolumnar junction). It aspirates and irrigates the esophageal lumen with water to prevent surface injury. The four electrodes provide 60 to 300 J of RF energy to each needle, heating the surrounding muscle tissue to the target temperature between 65° and 85° C while cooling the mucosal with its irrigation system. 15 to 25 lesion sets are created in the region from 2 cm proximal to 1 cm distal to the Z-line by rotating the catheter 45 degrees and varying its linear position. The RF-induced burns eventually scar down and create a reflux barrier. The mechanism of action of RF is reported to be a reduction in the frequency of LES relaxations, as well as physical alteration in tissue compliance and wall thickness of the gastroesophageal junction. The Curon Medical Inc.'s CSM Stretta System was approved by the FDA on April 18, 2000. Curon recommends the device for mild or moderate cases of GERD only. The Stretta procedure is reported to be easy to learn and apply. However, there is a concern that if the scars continue to contract, at least some patients will develop a stricture that could be difficult to manage. Other adverse events that may be associated with the procedure include chest pains, fever, mucosal tear, and dysphagia.

#### **12/10/2003: MTAC REVIEW**

#### **Electro-Surgical Coagulation (radio-frequency application) in the treatment of GERD**

**Evidence Conclusion:** Of the studies reviewed, an RCT compared Stretta procedure to sham treatment, and a non-randomized longitudinal study compared it to laparoscopic fundoplication. The third was just a survey from a



registry with no control or comparison group. Corley et al's trial was randomized and controlled however, it was a small study, with a high dropout rate, and some baseline differences between the two groups, that were not adjusted for in the analysis. Moreover, the procedure was compared to a sham treatment and not to another intervention e.g. laparoscopic fundoplication. The follow-up duration might have been insufficient to determine the long-term sustained effects, or potential late harms that could be associated with the procedure. In addition, the patients included in the study were highly selected for the trial and may not represent typical GERD patients. Richard et al's study was not randomized and patients were highly selected for each procedure. It was not blinded, not powered, and the follow-up duration was as short as 2 months for some patients, which is insufficient to determine the long-term durability of benefits or harms of the procedure. Both Corley's and Richard's studies were financially supported by Curon Medical, the manufacturer of the Stretta system. The third study reviewed was a retrospective survey of patients who underwent the Stretta procedure in several centers, with no reference to the inclusion/exclusion criteria, or techniques used for performing the procedure. Overall, the results of the studies show that radiofrequency application to the gastroesophageal junction to selected GERD patients is associated with improvement in symptoms and quality of life compared to sham treatment or laparoscopic fundoplication. The heartburn improvement associated with GERD vs. sham treatment was significant in the per protocol analysis but not with the ITT analysis in Corley's trial.

**Articles:** The search yielded 9 articles. There were no meta-analyses or randomized controlled trials. There were only three empirical studies all of which were case series. One had a very small sample, and only three months follow-up. The other two with relatively larger sample sizes, and longer follow-up duration were selected for critical appraisal. In December 2001, Curon Medical announced the completion of two major clinical trials, one of which is a RCT of the Stretta vs. sham treatment. To date these studies have not been published. *Evidence tables were created for the following studies:* Triadafilapoulos G, DiBaise JK, Nostrant T, et al. The Stretta procedure for the treatment of GERD: 6 and 12-month follow-up of the U.S. open label trial. *Gastrointest Endosc* 2002; 55:149-156. See [Evidence Table](#). Houston H, Khaitan L, and Richards WO. First year experience of patients undergoing the Stretta procedure. *Surg Endosc* 2002, Nov 20. See [Evidence Table](#).

The use of electro-surgical coagulation (radio-frequency application) in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 02/13/2003: MTAC REVIEW

### **Electro-Surgical Coagulation (radio-frequency application) in the treatment of GERD**

**Evidence Conclusion:** The two-case series reviewed show that the Stretta procedure may be a promising treatment for GERD. Patients had significant reduction in the esophageal acid exposure and use of antisecretory medication, as well as significant improvement in their quality of life scores, compared to those before the intervention. However, the studies were case series that provide the lowest grade of evidence. In the studies reviewed, participants were highly selected for the procedure. Only patients with small or no hiatal hernias, no dysphagia, stricture, or Barrett's disease as well as those whose symptoms are controlled by pharmacological treatment were included in the studies. Moreover, the interpreters of the results were not blinded to the treatment, the follow-up duration was insufficient, dropout rate was high, and there were no comparison or control groups. In conclusion, there is insufficient evidence to determine the efficacy of the Stretta procedure in the treatment of GERD. Prospective randomized studies with larger sample sizes, comparison to another intervention or treatment, and a long follow-up duration will be needed.

**Articles:** The search yielded seven review articles and two empirical studies: (1) An RCT comparing radiofrequency ablation to sham treatment, and (2) A longitudinal non-randomized study comparing the procedure to fundoplication. *Evidence tables were created for these two studies as well as a patient registry published prior to 2003 that was not included in the earlier review:* Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: A randomized, sham-controlled trial. *Gastroenterol* 2002; 125:668-672. See [Evidence Table](#). Richards WO, Houston HL, Torquati A, et al. Paradigm shift in the management of gastroesophageal reflux disease. *Ann Surg* 2003; 237:638-649. See [Evidence Table](#). Wolfson HC, and Richards WO. The Stretta procedure for the treatment of GERD: A registry of 558 patients. *J Laparoendosc Adv Surg Tech* 2002; 6:395-402. See [Evidence Table](#).

The use of electro-surgical coagulation (radio-frequency application) in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **EndoGastric Solutions Stomaphy X™ Endoluminal Fastener, InScope™ Tissue Apposition System, Transoral Incisionless Fundoplication**

### **BACKGROUND**

Over the last two decades, several less invasive endoluminal /endoscopic techniques have been developed for the management of GERD. These procedures include radiofrequency ablation (Stretta system), magnetic sphincter augmentation (LINX procedure), and transoral incisionless fundoplication, among others.

Transoral incisionless fundoplication (TIF) using the (EndoGastric Solutions, Inc., Redmond, WA) has been proposed as a less invasive alternative to traditional surgical procedures. Similar to the NF, TIF attempts to decrease the reflux of stomach acid into the esophagus through the reconstruction of an anti-reflux barrier. It involves wrapping a portion of the stomach around the esophagus without requiring any incisions.

TIF is performed in an outpatient setting under general anesthesia, and involves inserting the EsophyX™ device transorally, under direct endoscopic visualization, into the stomach and positioning it at the junction of the stomach and the esophagus. Once positioned, the device uses suction and transmural fasteners to facilitate the recreation of the esophageal gastric valve. The fundus of the stomach is folded up and around the distal esophagus utilizing the tissue mold and chassis of the device. Next, an integrated suction apparatus grasps the distal esophagus and positions it below the diaphragm. H-shaped fasteners, made of polypropylene, are then delivered through apposed layers of esophageal and fundus tissue to anchor the repair. This process is repeated to create a full thickness, partial circumference, and gastroesophageal fundoplication. Approximately 20 fasteners are implanted during the procedure resulting in the recreation of an omega shaped full-thickness gastroesophageal valve from inside the stomach 3-5 cm in length and 200-300° in circumference. This procedure may also reduce hiatal hernias that are < 2 cm in size through the use of a built-in vacuum invaginator (Jafri 2009, Louis 2010, Hunter 2015, Testoni 2014, Trad 2014, Witteman 2015).

TIF 1.0 utilizing the EsophyX™ device was first performed in 2005 and received United States Food and Drug Administration (FDA) initial 510(k) clearance in 2007. The EsophyX device is indicated for endoluminal, transoral tissue approximation, full thickness plication and ligation in the GI tract for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia < 2cm in size in patients with symptomatic chronic gastroesophageal reflux disease (FDA website accessed June 2020).

The EsophyX technology underwent several modifications along the years. Currently, there are three generations of the device; the original EsophyX® device, EsophyX2®, EsophyX Z®. Over the same timeline, four different fundoplication procedures using the EsophyX have emerged. The initial device was used to perform the endoluminal gastro-gastric fundoplication, called “ELF”. The second procedure TIF 1.0, was a longitudinally oriented plication of gastric cardia onto the distal esophagus just proximal to the gastroesophageal junction. The third procedure TIF 2.0, incorporated a rotational wrap of the cardia and fundus around the circumference of the distal esophagus in addition to providing a 2–4 cm length of the wrap over the intra-abdominal distal esophagus. This results in tightening and reinforcing the sling fibers of the proximal stomach (the lower portion of the LES), accentuating the cardiac notch, steepening the angle of His, and reestablishing the flap valve mechanism. The fourth procedure is a combined laparoscopic hiatal hernia repair with transoral incisionless fundoplication 2.0 (HH-TIF). Each of TIF procedures described is markedly different from the others and have different clinical outcomes. The TIF-2 procedure is believed to be the most similar procedure to NF morphologically and physiologically and is accomplished by using the third generation EsophyX® Z, launched in 2015 and cleared by the FDA in 2016 (Chang 2020, Ihde 2020).

Reported adverse events associated with the procedure include gastrointestinal bleeds, esophageal laceration, pleural effusion, mediastinal abscess, and potential failure of the procedure due to the pull on the fastener used to create the valve.

#### **04/09/2008: MTAC REVIEW**

##### **Endoluminar Fasteners**

**Evidence Conclusion:** There is insufficient published evidence to determine the efficacy and safety of the EndoGastric Solutions StomaphyX™ endoluminar fastener for weight loss. There is insufficient published evidence to determine the efficacy and safety of the InScope™ Tissue Apposition System for endoscopic gastric sutures.

**Articles:** The literature search did not reveal any published studies, on the EndoGastric Solutions StomaphyX™ endoluminar fastener and delivery system, or on the InScope™ Tissue Apposition System. Information about the systems was obtained from the FDA and the manufacturer's Web sites.

The use of endoluminal fasteners in the treatment of obesity does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/15/2011: MTAC REVIEW

### Endoluminal Fasteners

**Evidence Conclusion:** Two case-series were selected for review that evaluated the safety and effectiveness of transoral incisionless fundoplication (TIF) for the treatment of GERD. The first study followed 110 subjects for a median of 7 months and the second study followed 86 subjects for 12 months. The primary outcome in both of these studies was GERD Health-Related Quality of Life (GERD-HRQL). Both studies found significant reductions in GERD-HRQL compared to baseline. However, results from these studies should be interpreted with caution as both studies were case-series (lowest-quality evidence). Serious adverse events included two perforations and a post-TIF intraluminal bleeding that required a blood transfusion. Other adverse events included: left shoulder pain, abdominal pain, sore throat, nausea, and epigastric pain (Barnes 2011; Cadière 2008). **Conclusion:** There is insufficient evidence to determine the safety and efficacy of transoral incisionless fundoplication for the treatment of GERD.

**Articles:** To determine the safety and efficacy of transoral incisionless fundoplication using the EsophyX system for the treatment of GERD. Screening of articles: No randomized controlled trials were identified that addressed the safety or efficacy of transoral incisionless fundoplication using the EsophyX system for the treatment of GERD. Studies were not selected for review if they included less than 25 subjects. The largest studies with the longest duration of follow-up were selected for review. The following studies were critically appraised: Barnes WE, Hoddinott KM, Mundy S, Williams M. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. *Surg Innov* 2011; 18:119-129. See [Evidence Table](#). Cadière GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. *World J Surg* 2008; 32:1676-1688. See [Evidence Table](#).

The use of endoluminal fasteners in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 07/13/2020: MTAC REVIEW

### Transoral Incisionless Fundoplication with Esophyx

#### **Conclusion:**

- The published RCTs evaluating the safety and efficacy of TIF 2.0 using EsophyX compared the procedure versus a sham therapy or PPI and not to laparoscopic Nissen fundoplication (LNF), the most appropriate comparator.
- There is no direct published evidence, to date, to determine the safety and effectiveness of TIF 2.0 using EsophyX compared LNF, the gold standard for the management of patients with refractory GERD.
- Indirect comparison suggests the LNF is superior to TIF 2.0 in esophageal acid control, healing of esophagitis and increasing in LES pressure.
- There is insufficient published evidence to determine the effects of TIF using EsophyX on net health outcomes, and whether it will lead to protection from long-term adverse events of GERD and Barrett's esophagus.
- TIF may be superior to sham therapy (i.e. no therapy), but not PPIs in reducing percent time pH <4.
- TIF may be superior to sham therapy in improving the quality of life, but not in reducing the incidence of persistent esophagitis.
- The published studies and MAs indicate that the efficacy of TIF may decrease over time and that most patients may still need to use PPIs, but maybe at a lower dose.
- Open label trials found significant improvements with TIF 2.0 in subjective measures, but no difference in objective outcome measures of pH normalization and esophagitis when compared with PPI therapy. This may suggest a potential placebo effect of TIF 2.0.
- There is insufficient published data to determine the long-term safety of TIF 2.0 using EsophyX in patients with GERD.

#### **Articles:**

The literature search identified 6 RCTs, one non-randomized comparative study, and over 20 noncomparative observational studies published between 2011 and 2018. The search also revealed 4 meta-analyses (MAs) of exclusively RCTs or RCTs together with observational studies. One of the meta-analyses also included a network MA (NMA). Of the published RCTs, only one trial (Svoboda et al, 2011) compared TIF vs. LNF, 2 trials compared TIF to sham therapy, and two compared the procedure to different PPIs. The Svoboda trial was a small trial (N=52) that used 2 generations of the devices and different techniques for the TIF group along the study (Plicator® method for 18 patients, and the EsophyX® in 16 patients). The study was thus not included in any of the published

meta-analyses as combining results of studies using different procedures and generations of the device would lead to incorrect conclusions on effectiveness of the procedure in treating reflux disease.

The meta-analysis with the more valid methodology and most inclusive of published RCTs (Huang et al, 2017) as well as the Richter and colleagues' systematic review with both a direct and network meta-analysis were selected for critical appraisal. The published RCTs that compared TIF 2.0 versus LNF, sham therapy, or PPIs were summarized in a table format. See [Evidence Table](#).

The use of Transoral Incisionless Fundoplication with Esophyx does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 07/08/2019: MTAC REVIEW

#### Magnetic Sphincter Augmentation (MSA) (LINX® Reflux Management System) for Gastroesophageal Reflux Diseases

##### Conclusion:

- There is no published evidence, to date, from randomized controlled trials to determine the comparative safety and effectiveness of MSA and laparoscopic Nissen fundoplication in patients with GERD refractory to maximal medical therapy.
- Low quality evidence from short-term non-randomized comparative observational studies suggest that MSA may be associated with better postoperative ability to belch and vomit and less bloating compared to fundoplication in patients with GERD.
- There is insufficient evidence to determine the long-term safety or effectiveness of MSN in patients with medically refractory GERD.

**Articles:** The literature search for recently published studies after the December 2017 MTAC review did not identify any randomized controlled trial that compared magnetic sphincter augmentation (LINX® Reflux Management System) versus Nissen fundoplication. The search revealed only one RCT that compared MSA versus double-dose PPIs in patients with moderate to severe GERD who failed once daily PPI therapy for 8 weeks (Bell, 2019). One qualitative systematic review (Stanak 2018) and two more recent systematic reviews with meta-analyses (Ailofi 2018, and Guidozzi 2019) that pooled the results of nonrandomized comparative observational studies, were also identified, as well as a small retrospective study (Richards 2018) of patients who underwent the procedure by a single surgeon. The RCT comparing magnetic sphincter augmentation to double-dose PPI was excluded as the aim of the review was to compare the device to Nissen fundoplication the gold standard procedure for patients with GERD-related symptoms despite the use of a maximum medical therapy. The most recent meta-analyses of studies comparing LINX® reflux management system with Nissen fundoplication were reviewed. No evidence tables referenced for this report.

The use of Magnetic Sphincter Augmentation (MSA) in the treatment of GERD does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Haye's Technology Assessment

### Laparoscopic Surgery for Gastroesophageal Reflux Disease Refractory to Medical Therapy

April 21<sup>st</sup>, 2023

Based on a review of full-text clinical practice guidelines and position statements, guidance appears to confer **strong support for** laparoscopic surgery for gastroesophageal reflux disease (GERD) refractory to medical therapy. This level of support includes five guidelines were identified with varying levels of support in favor of laparoscopic surgery for GERD.

Hayes. Hayes Technology Assessment. Laparoscopic Surgery for Gastroesophageal Reflux Disease Refractory to Medical Therapy. Dallas, TX: Hayes; April 21, 2023.

<https://evidence.hayesinc.com/report/earb.laparoscopic1509>

## Applicable Codes

### LINX® Reflux Management System

**Effective until May 1, 2025: Considered Not Medically Necessary**

**Effective May 1, 2025: Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® Codes	Description
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed
43285	Removal of esophageal sphincter augmentation device

**Radiofrequency Energy Delivery to Gastroesophageal Junction/Transesophageal radiofrequency energy (Ex: CSM Stretta) - Considered Not Medically Necessary:**

CPT® Codes	Description
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease

**Transoral (Endoluminal) Gastroplication or Suturing/Transoral incisionless fundoplication (TIF) (Ex: Esophyx)**

**Effective until May 1, 2025:** Considered Not Medically Necessary

**Effective May 1, 2025:** Considered Medically Necessary when criteria in the applicable policy statements listed above are met

CPT® Codes	Description
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed

**Endoscopic placement of a bulking material at the lower esophageal sphincter - Considered Not Medically Necessary:**

CPT® Codes	Description
43192	Esophagoscopy, rigid, transoral; with directed submucosal injection(s), any substance
43201	Esophagoscopy, flexible, transoral; with directed submucosal injection(s), any substance

**CR BARD's Endoscopic Suturing System - Considered Not Medically Necessary:**

CPT® Codes	Description
No specific codes	

**Laparoscopic Fundoplication and Hiatal Hernia Repair**

**Effective February 1, 2025**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

**\*Requires [Elective Surgical Procedure Level of Care Review](#)**

CPT® Codes	Description
43280*	Laparoscopy, surgical, esophagogastric fundoplasty (eg, Nissen, Toupet procedures)
43281*	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; without implantation of mesh
43282*	Laparoscopy, surgical, repair of paraesophageal hernia, includes fundoplasty, when performed; with implantation of mesh

**Transthoracic Fundoplication and Hiatal Hernia Repair**

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
43325	Esophagogastric fundoplasty, with fundic patch (Thal-Nissen procedure)
43328	Esophagogastric fundoplasty partial or complete; thoracotomy



<b>43334</b>	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracotomy, except neonatal; without implantation of mesh or other prosthesis
<b>43335</b>	Repair, paraesophageal hiatal hernia (including fundoplication), via thoracotomy, except neonatal; with implantation of mesh or other prosthesis
<b>43336</b>	Repair, paraesophageal hiatal hernia, (including fundoplication), via thoracoabdominal incision, except neonatal; without implantation of mesh or other prosthesis
<b>43337</b>	Repair, paraesophageal hiatal hernia, (including fundoplication), via thoracoabdominal incision, except neonatal; with implantation of mesh or other prosthesis

### Abdominal Fundoplication and Hiatal Hernia Repair

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

<b>CPT® Codes</b>	<b>Description</b>
<b>43327</b>	Esophagogastric fundoplasty partial or complete; laparotomy
<b>43332</b>	Repair, paraesophageal hiatal hernia (including fundoplication), via laparotomy, except neonatal; without implantation of mesh or other prosthesis
<b>43333</b>	Repair, paraesophageal hiatal hernia (including fundoplication), via laparotomy, except neonatal; with implantation of mesh or other prosthesis

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

<b>Date Created</b>	<b>Date Reviewed</b>	<b>Date Last Revised</b>
02/13/2003	Initiated annual review because of Medicare criteria 05/03/2011 <sup>MDCRPC</sup> , 09/06/2011 <sup>MDCRPC</sup> , 07/03/2012 <sup>MDCRPC</sup> , 05/07/2013 <sup>MDCRPC</sup> , 03/04/2014 <sup>MPC</sup> , 01/06/2015 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 09/03/2024 <sup>MPC</sup>	12/03/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
07/21/2016	Added LINX® Medicare Coverage
10/04/2016	MPC approved to adopt Kaiser Permanente criteria for GERD when Medicare is silent
08/06/2019	Added MTAC review for Magnetic Sphincter Augmentation- LINX® management system for GERD
02/04/2020	MPC approved to adopt Transoral (Endoluminal) Gastroplication or Suturing (Esophyx) MCG A-0205 for medical necessity determinations.
06/02/2020	Removed deleted code C9737 (LINX®)
10/06/2020	Added MTAC Review for Transoral Incisionless Fundoplication with Esophyx. MPC approved to retain existing policy of non-coverage.
10/06/2020	MPC approved MCG 24 <sup>th</sup> ed. guideline for Implantable Magnetic Esophageal Ring (LINX®) A-0990
09/03/2024	MPC approved to adopt coverage for Fundoplication surgery using a hybrid guideline, KP-S-505. 60-day notice required; effective February 1, 2025.
12/03/2024	MPC approved to adopt limited criteria for EsophyX™ and LINX® procedures; 60-day notice required, effective May 1, 2025





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Glaucoma Surgical Procedures

- Canaloplasty
- Microinvasive Glaucoma Surgery (MIGS)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy						
CMS Coverage Manuals	None						
National Coverage Determinations (NCD)	None						
Local Coverage Determinations (LCD)	<table> <tr> <th>Service</th><th>Criteria</th></tr> <tr> <td>Canaloplasty</td><td>No review required for Medicare members</td></tr> <tr> <td>Microinvasive Glaucoma Surgery (MIGS)</td><td>Micro-Invasive Glaucoma Surgery (MIGS) (L38301)</td></tr> </table>	Service	Criteria	Canaloplasty	No review required for Medicare members	Microinvasive Glaucoma Surgery (MIGS)	Micro-Invasive Glaucoma Surgery (MIGS) (L38301)
Service	Criteria						
Canaloplasty	No review required for Medicare members						
Microinvasive Glaucoma Surgery (MIGS)	Micro-Invasive Glaucoma Surgery (MIGS) (L38301)						
Local Coverage Article	<table> <tr> <th>Service</th><th>Criteria</th></tr> <tr> <td>Canaloplasty</td><td>No review required for Medicare members</td></tr> <tr> <td>Microinvasive Glaucoma Surgery (MIGS)</td><td>Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS) (A57864)</td></tr> </table>	Service	Criteria	Canaloplasty	No review required for Medicare members	Microinvasive Glaucoma Surgery (MIGS)	Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS) (A57864)
Service	Criteria						
Canaloplasty	No review required for Medicare members						
Microinvasive Glaucoma Surgery (MIGS)	Billing and Coding: Micro-Invasive Glaucoma Surgery (MIGS) (A57864)						

#### For Non-Medicare Members

Service	Criteria
Canaloplasty	<p>Canaloplasty is covered when all of the following criteria have been met:</p> <ol style="list-style-type: none"> <li>1. Diagnosis of glaucoma with eye pressures inadequately controlled on maximum tolerated topical medications and laser treatment</li> <li>2. Documented risk for greater problems with standard glaucoma surgery (trabeculectomy or valve implant) as defined by one of the following: <ul style="list-style-type: none"> <li>• Myopic diopters greater than 5</li> <li>• Hyperopic diopters greater than 3</li> <li>• Moderate to severe dry eye</li> <li>• Blepharitis</li> </ul> </li> </ol>

	<ul style="list-style-type: none"> <li>• Preservative allergy</li> <li>• Has allergy or side effects preventing the use of one or more of the standard glaucoma eye drops</li> <li>• Had problems with trabeculectomy or glaucoma valve implant surgery in the contralateral eye (such as bleb dysesthesia (chronic eye pain) or need for re-operation)</li> <li>•</li> </ul>
<b>Microinvasive Glaucoma Surgery (MIGS)</b>	<p><b><i>iStent Device and Hydrus</i> – 66989, 66991</b></p> <p>iStent Device and Hydrus will be considered medically necessary when <b>ALL of the following</b> are met:</p> <ol style="list-style-type: none"> <li>1. Only used in conjunction with Cataract Surgery when the individual is currently being treated with an ocular hypotensive medication <b>AND/OR</b> had prior laser trabeculoplasty</li> <li>2. Used to reduce intraocular pressure (IOP) of greater than 21, except when clinical circumstances would support a lower IOP (this rationale should be documented in the note)</li> <li>3. 18 years old or over <b>AND</b></li> <li>4. Mild to Moderate primary open-angle glaucoma defined as how much vision loss via visual field testing</li> <li>5. Eyes do <b>NOT</b> have the following*             <ol style="list-style-type: none"> <li>a. Prior significant trauma</li> <li>b. In eyes with abnormal anterior segment</li> <li>c. In eyes with chronic inflammation</li> <li>d. In glaucoma associated with vascular disorders</li> <li>e. In pseudophakic patients with glaucoma</li> <li>f. In uveitic glaucoma</li> <li>g. In eyes with prior incisional glaucoma surgery or cilioablative procedures</li> <li>h. In eyes with prior laser trabeculoplasty (LT) with selective LT within 90 days prior to screening or prior argon laser trabeculoplasty (ALT) at any time</li> <li>i. In patients with unmedicated IOP greater than 36 mmHg after “washout” of medications</li> <li>j. Plan for implantation of more than two stents</li> <li>k. After complications during cataract surgery, including but not limited to, severe corneal burn, vitreous removal/vitreotomy required, corneal injuries, or complications requiring the placement of an anterior chamber IOL</li> <li>l. When implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract</li> </ol> </li> </ol> <p><u>Contraindicated</u> in the following patients:</p> <ul style="list-style-type: none"> <li>• In eyes with angle-closure glaucoma.</li> <li>• In eyes with traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital anomalies of the anterior chamber (AC) angle.</li> <li>• In patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure</li> </ul> <p>*Exclusions include clinical circumstances that were not tested in the initial FDA approval.</p> <p><b><i>Xen Gel Implant</i> – 0449T, 66183</b></p>

	<p>The use of Xen Gel Implant will be considered medically necessary when <b>ONE of the following</b> are met:</p> <ol style="list-style-type: none"> <li>1. Refractory glaucoma, defined as prior failure of filtering/cilioablative procedure and/or uncontrolled IOP (progressive damage and mean diurnal medicated IOP <math>\geq 20</math> mm Hg) on maximally tolerated medical therapy (i.e., <math>\geq 4</math> classes of topical IOP-lowering medications, or fewer in the case of tolerability or efficacy issues) <b>OR</b></li> <li>2. Previous surgical treatment has failed (angle-based procedures, laser trabeculoplasty) <b>OR</b></li> <li>3. Primary open-angle glaucoma <b>OR</b></li> <li>4. Pseudo-exfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy</li> </ol> <p>Should <b>NOT</b> be used if any of the following are met:</p> <ol style="list-style-type: none"> <li>a. Angle-closure glaucoma where the drainage angle of the eye has not been surgically open</li> <li>b. Glaucoma drainage device previously implanted</li> <li>c. Presence of conjunctival scarring, prior conjunctival surgery or other conjunctival pathologies (e.g., pterygium) in the target quadrant</li> <li>d. Pathologies of the conjunctiva (clear membrane covering the white outer layer of the eye) in the area needed for this implant Active iris neovascularization or neovascularization of the iris within six months of the surgical date (abnormal formation of new blood vessels on the iris)</li> <li>e. Eye inflammation (e.g., conjunctivitis, keratitis, uveitis)</li> <li>f. Artificial lens implanted in the <u>anterior</u> chamber (intraocular lens)</li> <li>g. Presence of intraocular silicone oil</li> <li>h. Vitreous present in the anterior chamber</li> </ol> <p><b>Cypass Device – 0474T</b></p> <p>The Cypass device was taken off the market on 8/29/2018 by the manufacturer due to safety concerns. This device will no longer be covered for Kaiser Permanente members.</p>
--	--

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background Canaloplasty

Glaucoma is a common eye disease caused by elevated intraocular pressure (IOP) that leads to optic nerve damage and visual field loss. Glaucoma is frequently referred to as the “silent thief of sight” because it is not usually associated with ocular or systemic symptoms but can cause irreversible blindness if left undiagnosed and untreated. It is estimated that over 2 million people in the United States have glaucoma, 80,000 of whom are legally blind as the result of the disease (Lee 2005).

Glaucoma has been classically categorized into primary or secondary angle-closure glaucoma (closure of the anterior chamber angle), and primary or secondary open-angle glaucoma (where the anterior chamber angle of the eye remains open). The condition is considered primary if the eye has no pre-existing disease and secondary in an eye with a pre-existing disease. Primary open-angle glaucoma is the most common type in the US. It occurs insidiously and is usually asymptomatic in its early stages. In the later stages, when the optic nerve is damaged, the patient experiences progressive worsening of vision, and eventually peripheral followed by central visual loss (Lee 2005, Rotchford 2005).

The treatment goal for patients with glaucoma is preventing functional vision loss by lowering the IOP to a level where progressive glaucomatous optic neuropathy is stopped, or at least slowed. Conventional treatment usually begins with the use of topical IOP-lowering agents. These include beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic, and prostaglandin analogs. Laser trabeculoplasty has also been used to further lower the IOP to decrease or eliminate the need for antiglaucoma medications. Incisional filtering surgery is considered if the patient's IOP cannot be reduced with the maximal tolerated medical therapy, laser trabeculoplasty or a combination of both. Trabeculectomy is a filtration surgical procedure commonly used to lower the IOP. The procedure involves creating an opening in the anterior chamber angle to allow the aqueous humor flow from the anterior chamber into a space beneath the conjunctiva under the surface of the eye. A successful trabeculectomy procedure is marked by an elevated conjunctival zone, the bleb, where the aqueous gathers in pockets prior to absorption into the surrounding blood vessels and lymphatics. Trabeculectomy with or without antimetabolites can successfully control IOP, but not without risks. It may be associated with numerous intraoperative or postoperative complications including hypotony, bleb leaks, bleb infections /endophthalmitis, hyphaema, loss of visual acuity, increased risk of cataract formation, scar tissue which causes obstruction of the channel created and in turn blocking the drainage of the aqueous humor, and several other complications (Lee 2005, Rotchford 2005, Lewis 2007).

Nonpenetrating glaucoma procedures were first introduced in the late 1950s and early 1960s, and revived in the 1980s and 1990s, as alternatives to standard filtration surgeries for controlling IOP in open-angle glaucoma without penetration of the intraocular space. These procedures include deep sclerectomy with and without an implant, and viscocanalostomy. The latter is performed by several techniques that basically involve the production of superficial and deep scleral flaps, excision of the deep scleral flap to create a scleral reservoir, and unroofing of Schlemm's canal. An ophthalmic viscoelastic device is then injected into the deep scleral lake and toward the cut ends of Schlemm's canal to open it and create a passage from the scleral reservoir to the canal. The superficial scleral flap is then sutured water tight trapping the viscoelastic until healing takes place (Filippopoulos 2008, Green 2007, Nouredin 2006).

Recent advances in technology, ocular ultrasound, and viscoelastics have led to the development of canaloplasty as a promising nonpenetrating surgical technique for lowering the IOP in patients with open-angle glaucoma. The procedure aims at increasing the flow of aqueous humor from the anterior chamber through the trabecular meshwork and Descemet's window into and around the Schlemm's canal and out through the collector channels, thus reducing the IOP by restoring the trabeculocanalicular outflow pathway. The procedure utilizes the full 360 degrees of the canal and outflow system without creating a fistula or need for a bleb. Unlike viscocanalostomy, canaloplasty aims at opening the entire length of the canal rather than opening only a section of it. Canaloplasty uses viscoelastic and specialized flexible microcatheter with an illuminated tip (iScience surgical Ophthalmic Microcannula) to forcibly open the Schlemm's canal (Lewis 2006, 2007, Godfrey 2009).

Similar to viscocanalostomy, canaloplasty is completed under a scleral flap. A one-half thickness parabolic shaped scleral flap is dissected. A deep flap is then dissected down to a depth very close to the ciliary body/choroid and carefully carried forward anteriorly until the Schlemm's canal is unroofed. The canal is identified and intubated with a cannula which has a lighted tip to identify its location as it passes through the canal. The cannula has a lumen to allow for the passage of viscoelastic for dilatation of the canal. Once it has passed the full length of Schlemm's, a 10-0 Prolene suture is tied to the cannula which is then withdrawn leaving the suture in its place. Tying off the suture provides tension that holds the canal open. The scleral flap is then tightly closed as well as the conjunctiva. The procedure is usually performed under special ultrasound imaging to help identify the canal and its instrumentation (Lewis 2006, 2007).

Canaloplasty has a steep learning curve. Identifying and entering the Schlemm's canal, inserting the catheter, placing the tension suture, and providing the right tension in the suture depend on the surgeon's skill and experience. The outcome of the surgery also depends on the selection of the patients; those who had previous trabeculectomies with scarring in the canal are not good candidates. According to the authors of a review article, the ideal candidates would be patients who cannot have a bleb because they wear contact lenses, have a dry

eye, or for cosmetic reasons. The procedure is contraindicated in patients with angle recession, neovascular glaucoma, chronic angle closure, narrow-angle glaucoma, narrow inlets with plateau iris, and in patients with previous surgery which would prevent 360° catheterization of Schlemm's canal (Lewis 2006, Godfrey 2009).

In June 2008 The FDA cleared the iScience Interventional Canaloplasty Microcatheter for marketing for catheterization and vasodilatation of Schlemm's canal to reduce intraocular pressure in adult patients with open angle glaucoma.

## Microinvasive

The term micro-invasive or minimally invasive glaucoma surgery (MIGS) refers to a group of newer surgical procedures that are performed by using an ab interno (from inside the eye) approach via gonioscopic guidance and involve minimal trauma to ocular tissues. In contrast to external filtration surgeries such as trabeculectomy and aqueous tube shunt, these procedures are categorized as internal filtration surgeries. Compared with traditional filtration surgery, MIGS holds the promise of faster recovery time and less severe complications.

It is this potentially improved safety profile that opened up the indications for MIGS to include patients with early-stage glaucoma to reduce the burden of medications and problems with compliance (due to eye drop application difficulty, cost, cosmetic effects, and frequency). Another area of investigation is patients with glaucoma who require cataract surgery. An advantage of ab interno shunts is that they may be inserted into the same incision and at the same time as cataract surgery. In addition, most devices do not preclude subsequent trabeculectomy if needed. Therefore, health outcomes of interest are the IOP achieved, reduction in medication use, ability to convert to trabeculectomy, complications, and device durability.

There are three FDA approved/cleared micro-invasive surgical stents, the iStent Trabecular Micro-Bypass Stent (2011), the CyPass Micro-Stent System (July 2016), and the XEN Glaucoma Treatment System (Nov 2016). The iStent is a small (1 mm x 0.5 mm) L-shaped titanium device that is inserted into Schlemm's canal to augment the natural outflow system. CyPass is a 6.35 mm long fenestrated microstent made of biocompatible polyimide inserted into the supraciliary space, thus using an alternative outflow system. The XEN45 is a 6 mm long porcine-derived gelatin stent inserted into the subconjunctival space, bypassing the natural outflow system.

Both iStent and CyPass were FDA approved for use in combination with cataract surgery to reduce IOP in adults with mild or moderate OAG and a cataract that are currently being treated with medication to reduce IOP. XEN45 was granted FDA clearance for the management of refractory glaucoma, including cases where previous surgical treatment has failed, cases of primary open angle glaucoma, and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy.

## Canaloplasty

### 10/06/2008: MTAC REVIEW

**Evidence Conclusion:** There is insufficient evidence to determine that canaloplasty has the same or better effect than medical treatment in reducing intraocular pressure in adult patients with open angle glaucoma. There is insufficient evidence to determine that canaloplasty has the same or better effect than filtration surgical procedures as trabeculectomy in reducing intraocular pressure in adult patients with open angle glaucoma. There is insufficient evidence to determine that canaloplasty is safer for the patient than filtration surgical interventions as trabeculectomy.

**Articles:** The search yielded only two studies on canaloplasty: Lewis 2007, and Shingleton 2008. Both were prospective case series with no comparison or control groups. Lewis and colleagues reported the interim results of canaloplasty performed on 94 patients with open-angle glaucoma. Shingleton et al reported one-year results of canaloplasty combined with cataract surgery performed on 54 patients with open-angle glaucoma and cataract. The authors of the latter study were co-authors in the first study. Both studies involved the same 14 clinical sites and same group of ophthalmologists. It appears also that there could be an overlap of the patients participating in the two studies. Both reported on one-year results. The published case series with the larger population size was selected for critical appraisal. Lewis R A, von Wolff K, Tetz M, et al. Canaloplasty: Circumferential viscodilation and tensioning of Schlemm's canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults. Interim clinical study analysis. J Cataract Refract Surg 2007; 33:1217-1226. See [Evidence Table](#).

The use of canaloplasty in the treatment of primary open-angle glaucoma does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**10/05/2009: MTAC REVIEW****Canaloplasty**

**Evidence Conclusion:** There is insufficient evidence to determine that canaloplasty is better than or equivalent to medical treatment in reducing intraocular pressure in adult patients with open angle glaucoma. There is insufficient evidence to determine that canaloplasty is better than or equivalent to filtration surgical procedures as trabeculectomy in reducing intraocular pressure in adult patients with open angle glaucoma. There is insufficient evidence to determine that canaloplasty is safer than filtration surgical interventions as trabeculectomy.

**Articles:** The search yielded only one more recent report (Lewis et al 2009) on the 2-year results of the same case series on canaloplasty that was published earlier in 2007 and reviewed by MTAC in 2008. No randomized or nonrandomized controlled trials comparing canaloplasty to another treatment or intervention were identified. The new report by Lewis and colleagues (2009) was critically appraised. Lewis R A, von Wolff K, Tetz M, et al. Canaloplasty: Circumferential viscodilation and tensioning of Schlemm's canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults. Two-year interim clinical study results. J Cataract Refract Surg 2009; 35:814-824 See [Evidence Table](#).

The use of canaloplasty in the treatment of primary open-angle glaucoma does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**07/08/2019: MTAC REVIEW****XEN Gel Implant (XEN® Gel stent) for Glaucoma****Conclusion:**

- There is no published high-quality evidence from randomized controlled trials (to date) to determine the comparative effectiveness and safety of XEN Gel implantation versus trabeculectomy or other minimally invasive procedure used to lower IOP in patients with open angle glaucoma uncontrolled with optimal local medications.
- Low quality evidence from several prospective and retrospective observational studies suggest that XEN Gel implant lowers the IOP and reduces the number of IOP- lowering medication used in selected patients with open angle glaucoma uncontrolled with optimal local medications. The results, however, must be interpreted with caution due to the non-randomized design, potential confounding, and other inherent limitations of observational studies.
- The success rates varied between studies from 37-68% depending on definition of success based on the level of IOP reached, duration of follow up, use of topical medications, and need for revision surgeries.
- XEN Gel implant is associated with intra-and post- operative adverse events (AEs). Many were reported to resolve spontaneously without the need for intervention. However, few were serious and /or required immediate and inevitable interventions.
- More than one third of the eyes require additional surgeries after XEN Gel implant.

**Articles:** The literature search did not identify any randomized controlled trials that compared the safety and efficacy of XEN45 Gel implant versus trabeculectomy or any other surgical procedure. The search revealed 3 systematic reviews with meta-analyses that pooled the results of the different of MIGS procedures, two studies (published in 3 articles on the earlier generations of the implant (XEN140 and XEN 63), around 10 observational studies with pre-post comparisons after XEN45 Gel implant with or without cataract surgery, and one retrospective observational study that compared the results the microstent implant to those of a trabeculectomy procedure.

The meta-analyses of studies on MIGS as well as the studies using the earlier generations of XEN Gel (60 and 140) were excluded. The observational study with a comparison group (Schlenker, 2017) was critically appraised (Evidence table 1) and the larger prospective and retrospective observational studies were summarized in a following table. See [Evidence Table](#).

The use of Xen Gel Implant as a surgical treatment for glaucoma does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**Applicable Codes**



### Canaloplasty

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

**Medicare – Medical Necessity Review not required**

CPT® Codes	Description
66174	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); without retention of device or stent
66175	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); with retention of device or stent

**Xen Gel - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
0449T	Insertion of aqueous drainage device, without extraocular reservoir, internal approach, into the subconjunctival space; initial device
66183	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, external approach

**iStent and Hydrus - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
66989	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1-stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification), complex, requiring devices or techniques not generally used in routine cataract surgery (eg, iris expansion device, suture support for intraocular lens, or primary posterior capsulorrhexis) or performed on patients in the amblyogenic developmental stage; with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more
66991	Extracapsular cataract removal with insertion of intraocular lens prosthesis (1 stage procedure), manual or mechanical technique (eg, irrigation and aspiration or phacoemulsification); with insertion of intraocular (eg, trabecular meshwork, supraciliary, suprachoroidal) anterior segment aqueous drainage device, without extraocular reservoir, internal approach, one or more

**Considered not medically necessary:**

CPT® Codes	Description
0253T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space
0671T	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more

**Cypass (no longer available) - Considered not medically necessary:**

CPT® Codes	Description
0474T	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date	Date Reviewed	Date Last
------	---------------	-----------

Created		Revised
02/06/2018	02/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 08/06/2024 <sup>MPC</sup>	08/02/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/05/2018	MPC approved criteria for commercial members
10/08/2018	Non-coverage language for the Cypass device
11/14/2018	Language regarding iStent added
08/06/2019	MTAC review for Xen Gel was added
11/15/2019	Added all requests for Xen Gel must go to Medical Director for review
04/07/2020	MPC approved to adopt new coverage criteria for Xen Gel & iStent/Hydrus as surgical treatments for glaucoma, effective 08/01/2020.
08/12/2020	Removed Non-Medicare criteria prior to 08/01/2020
01/27/2022	Updated applicable coding (removed deleted codes 0191T, 0376T, added 66989, 66991, 0671T)
11/13/2023	Updated Medicare coverage article link (A57864).
08/02/2024	Merge MIGS & Canaloplasty criteria- Glaucoma Surgical Procedures



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Genicular Nerve Block for Knee Pain

- Coolief Cooled Radiofrequency Ablation for Knee Pain
- Genicular Nerve Ablation
- Genicular Nerve Ablation for Knee Osteoarthritis
- Genicular Nerve Neurolysis
- Thermal Genicular Nerve Radiofrequency Ablation (GNRFA)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Nerve Blockade for Treatment of Chronic Pain and Neuropathy (L35457)</a>
Local Coverage Article	<a href="#">Billing and Coding: Nerve Blockade for Treatment of Chronic Pain and Neuropathy (A52725)</a>
KPWA Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, KPWA has chosen to use their own Clinical Review Criteria, " <b>Genicular Nerve Ablation for Knee Osteoarthritis</b> " for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Service	Criteria
Neurolysis, Genicular Nerve <ul style="list-style-type: none"> <li>• Coolief Cooled Radiofrequency Ablation for Knee Pain</li> <li>• Genicular Nerve Ablation for Knee Osteoarthritis</li> </ul>	MCG* A-1047 For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access
Thermal Genicular Nerve Radiofrequency Ablation (GNRFA)	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies. This procedure requires review if the ablation is being done as an alternative to surgery.  <b>*Note:</b> Genicular nerve ablation can also be done during surgical procedures for anesthesia, such as total knee replacement or ligament and tendon repair and does not require review for those circumstances.

**If requesting review for these services, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Hayes Technology Assessment

A nerve block is a form of regional anesthesia. The genicular nerve is a sensory nerve that innervates the knee. Genicular nerve blocks are performed to relieve pain in patients who may not be candidates for knee surgery or in advance of total knee replacement surgery. In a genicular nerve block procedure, an anesthetic agent, (e.g., lidocaine, bupivacaine, etc.), is injected on the genicular nerve. Genicular nerve blocks may be performed as a diagnostic step to ensure that blocking the nerve provides pain relief. In these cases, after a genicular nerve block demonstrates pain relief, genicular neurotomy or genicular nerve ablation may be performed as a more permanent solution.

**Hayes Rating: D<sup>2</sup>- Insufficient Evidence:** For use genicular nerve blocks combined with a corticosteroid or alone for treatment of pain and loss of function associated with osteoarthritis of the knee or persistent chronic pain following total knee arthroplasty.

This Rating reflects a very-low-quality body of evidence that does not consistently provide proof of benefit. Substantial uncertainty remains due to conflicting evidence and limited follow-up.

Hayes. Hayes Technology Assessment. *Genicular Nerve Block for the Management of Knee Pain*. Dallas, TX: Hayes; June 24, 2020. Retrieved July 13, 2020, from <https://evidence.hayesinc.com/report/htb.genicular3323>

## Background

Osteoarthritis (OA) of the knee is a common chronic degenerative joint disorder and one of the leading causes of physical impairment and decline in the quality of life in older adults in the US and worldwide. It is a progressive condition in which the cartilage between bones in the joint wears away leaving the bones to rub more closely against one another resulting in pain, swelling, stiffness, and loss of function.

Conservative treatment for symptomatic knee OA includes physical therapy, aquatic therapy, weight loss, oral or topical non-steroidal anti-inflammatory drugs, bracing, and orthosis. Intraarticular injection of corticosteroids, hyaluronic acid, and other treatment modalities have also been used to alleviate the pain however, the analgesic effect is short-term with the steroid injection and unproven with some other therapies. Overall, conservative measures may relieve symptoms and improve function in some patients, but they do not restore the normal knee function, reverse the damage, or slow the progression of the disease. Knee joint arthroplasty is the most effective treatment for relieving pain and improving the knee function in patients with severe knee OA, but it is an invasive surgery that may be associated with medical and postsurgical complications. In addition, older individuals with comorbidities might not be good candidates for the surgery and others may be unable or unwilling to undergo the operation (El-Hakim 2018, Jamison 2018, Erdem 2019).

Over the years, researches have been investigating alternative less invasive therapies for the treatment of patients with refractory knee OA. Several existing and new therapies have thus been or are being evaluated for the alleviation of chronic pain in patients with musculoskeletal disorders including knee OA.

Radiofrequency ablation (RFA) is one of these modalities considered for the treatment of patients with symptomatic knee. RFA is a nonsurgical, minimally invasive procedure that uses radio waves to create an electrical current through the body. The created current delivers heat to the targeted tissue resulting in its destruction. Ablation of the nerve tissues disrupts the ability of the nerve to send pain signals. RFA was first used by a German surgeon in 1931 to treat trigeminal neuralgia and three decades later, the first radiofrequency ablation commercial machine was introduced in the market. The indications of RFA have expanded over the years and is currently being used for the treatment of a variety of medical conditions including chronic low back

pain, cardiac arrhythmias, tumors, varicose veins, obstructive sleep apnea, and several other disorders. More recently RFA gained popularity in alleviating pain due to musculoskeletal disorders. In 2010 Choi and colleagues investigated its use for OA knee pain based on the theory that blocking the sensory innervation for a painful structure will result in pain relief (Choi 2011, Gupta 2017).

The knee joint is innervated by the articular branches of various nerves including the femoral, common peroneal, saphenous, tibial and obturator nerves known as the genicular nerves. Several of these nerves can be approached percutaneously under fluoroscopic or ultrasound guidance to identify the anatomical landmarks around the knee and locate the targeted genicular nerves (Choi 2011, Gupta 2017).

Conventional RFA treatment uses a high temperature probe to impair/destroy the targeted nerve fibers that carry the pain signals to the brain. The high heat originating from the RF probe may potentially damage adjacent tissues as the temperature reaches 70-90°C. In addition, it has been reported that the lesion produced by the heat is limited in size and thus may not reach some target areas. To overcome these limitations, two new techniques the (pulsed RFA (p-RFA) and the cooled RFA (C-RFA) have been investigated for GNRFA (Oladeji 2019).

Coolief™ RFA treatment (the focus of the current review) also known as cooled radiofrequency ablation or neurotomy, follows the same method as the conventional RFA neuronal tissue damage, but uses water-cooled technology to safely impair or destroy the sensory nerves. A radiofrequency generator transmits a small current of RF thermal energy through an insulated electrode placed within the tissue. Sterile water circulates continuously inside the Coolief™ probe to cool it and regulate its temperature while it delivers the RF thermal energy. According the investigators of the technology, the circulating water modulates the thermal heat in the tissue to ≈60°C and alters the size, shape, and projection of the lesions compared to conventional RFA. It is postulated that delivering RF energy through water-cooled electrode enables more RF energy to be safely delivered to the targeted nerves creating larger spherical -shaped lesion that increases the area of denervation and minimizes the risk of excessive heating and damaging the adjacent tissues (Gupta 2017, Oladeji 2019, AVANOS report 2019).

The Cooled RFA (CRFA) procedure is performed in an outpatient setting under local anesthesia, conscious sedation and fluoroscopic or ultrasound guidance. It is performed in 2 stages (McCormick 2017, Davis 2018):

1. A diagnostic genicular nerves block procedure: After positioning the patient in a supine position on a fluoroscopy table, a 25-gauge 2.5-3.5-inch Whitacre needle is placed under fluoroscopic guidance at three unique anatomic sites to block the superior lateral, superior medial, and the inferior medial genicular nerves. Accurate placement of the needle is confirmed using fluoroscopy in the AP and lateral planes, then lidocaine is injected in order to numb each genicular nerve. Patients with a positive response (≥50% reduction in pain in the 24hrs following injection) are offered radiofrequency ablation (stage 2) for a more sustained response.
2. Genicular nerve radiofrequency ablation procedure performed under fluoroscopic visualization of the anatomical landmarks for probe placement. The patient is positioned supine on the fluoroscopy table (similar to the diagnostic nerve block procedure), and given conscious sedation, and local anesthesia at each of the 3 anatomic sites for RFA. An introducer needle (50 or 70 mm 17-gauge) is then placed to lesion the 3 genicular nerves after which the internally cooled RFA electrode (Coolief, 4-mm, 18-gauge active tip) is inserted in the introducer needle and its positioning verified with AP and lateral fluoroscopic views. Lidocaine is then injected through the introducer needle to numb the region before the thermal ablation. Each target undergoes CRFA for 150 seconds at a set temperature of 60°C which produces tissue temperature of 77°C-80°C surrounding the electrode. The needles are then removed, and the patients allowed to recover before they are discharged to home.

## Medical Technology Assessment Committee (MTAC)

### *Coolief Cooled Radiofrequency Ablation for Knee and Hip Pain*

10/14/2019: MTAC REVIEW

#### **Evidence Conclusion:**

- There is insufficient published evidence to determine the safety and efficacy of cooled RFA treatment for the management of moderate to severe chronic OA knee pain that is refractory to conservative therapy in patients who are not candidates for surgery.
- There is low to moderate quality evidence from one relatively small RCT showing that genicular RFA using Coolief™ system, performed prior to total knee replacement surgery had no significant effect compared to sham ablation, on reducing post-operative pain, use of pain medications, or improving function.

**Articles:** The literature search for studies on cooled genicular nerve ablation for symptomatic knee osteoarthritis, published after the March 2018 INCT review yielded less than 10 articles including a report on the 12 months follow-up results of the pivotal RCT (Davis et al 2019). The search also identified a RCT comparing the effect of CRFA versus a sham therapy performed prior to TKA, on postoperative pain. Among the other recently published articles was a randomized trial that evaluated the utility of genicular nerve blocks to predict the outcome of genicular nerve cooled radiofrequency ablation in patients with osteoarthritis (McCormick et al, 2018); a cost-effective analysis of CRFA based on Davis et al's trial (Desai 2019); one observational study with no control or comparison group (House et al, 2019), three technical reports, and a case presentation.

[See Evidence Table.](#)

The use of Coolief Cooled Radiofrequency Ablation for Knee and Hip Pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Thermal Genicular Nerve Radiofrequency Ablation (GNRFA) for continued chronic knee pain post total knee replacement***

**07/13/2020: MTAC REVIEW**

#### **Evidence Conclusion:**

There is insufficient published evidence to support the use of genicular RFA for reducing postoperative pain after total knee replacement surgery.

#### **Articles:**

There is a paucity of published literature evaluating the use of thermal genicular nerve ablation for the management of persistent pain after a total knee replacement surgery. The only published randomized controlled trial identified by the literature search was a small double-blinded trial that compared the efficacy of genicular nerves RFA versus analgesic block with corticosteroids in alleviating pain and improving function and QoL in patients with pain after a TKA (Qudsi-Sinclair S et al, 2017 ([Evidence Table 1](#))).

This trial was randomized, controlled, and double-blinded, but had its limitations including the small sample size study (N=30 randomized and 28 included in the analysis), lack of power calculations, randomization method not discussed, and subjective outcomes. There were also some baseline differences between the study groups e.g. their ages, duration of a pain, knee function, QoL, and the use of medication including opioids before the intervention. The differences were not significant, but the numbers may be too small to detect statistically significant differences.

The overall results of the study show the following (details in the evidence table)

- A significant reduction in pain scores in each of the treatment arm compared to baseline values, this was more pronounced in day 1 after each of the two procedures but tended to increase during follow-up.
- At one year the NRS was almost 5 in the RFA group and >5 in the steroid group (a value of 5-10 indicates worst possible pain).
- Knee functioning also improved vs baseline, in each of the treatment arms, but was still considered poor and unsatisfactory according to the values of the KSS and OKS.
- There were no significant differences between the 2 study groups in any of the outcome measures (pain, function, QoL, or patient satisfaction). Lack of significant difference does not necessarily indicate that the two intervention have similar results as indicated by the authors). The power of the study may have been insufficient to detect statistically significant differences.

The use of Thermal Genicular Nerve Radiofrequency Ablation (GNRFA) for continued chronic knee pain post total knee replacement does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Applicable Codes**

**Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
64450	Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch



<b>64454</b>	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed
<b>64624</b>	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed
<b>64640</b>	Destruction by neurolytic agent; other peripheral nerve or branch
<b>ICD-10 Codes</b>	<b>Description</b>
<b>M25.561</b>	Pain in right knee
<b>M25.562</b>	Pain in left knee

### **Non-Medicare - Considered Not Medically Necessary:**

<b>CPT® Codes</b>	<b>Description</b>
<b>64450</b>	Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch
<b>64454</b>	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed
<b>64624</b>	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed
<b>64640</b>	Destruction by neurolytic agent; other peripheral nerve or branch

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

<b>Date Created</b>	<b>Date Reviewed</b>	<b>Date Last Revised</b>
08/07/2018	08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	09/05/2023

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
08/07/2018	MPC approved to adopt policy of non-coverage for GNA.
12/03/2019	Added MTAC review for Coolief RFA and MPC approved a non-coverage policy for this procedure.
05/18/2020	Added comment about procedure being done for anesthesia during other surgical procedures, which does not require review.
06/23/2020	Added CPT codes 64454 and 64624
08/04/2020	Added Medicare LCD L35457, LCA A52725 and ICD-10 codes M25.561 and M25.562. Removed "hip" from non-coverage policy and added MTAC review from July 2020. MPC approved to retain policy of non-coverage for genicular nerve ablation for non-Medicare patients.
09/05/2023	MPC approved to adopt Neurolysis, Genicular Nerve: MCG A-1047.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Gynecomastia

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">Plastic Surgery (L37020)</a>
Local Coverage Article (LCA)	<a href="#">Billing and Coding: Plastic Surgery (A57222)</a>

#### For Non-Medicare Members

Plastic Surgery credentials are preferred for mammoplasty to treat gynecomastia. Surgery may be medically necessary when the following criteria are met:

Kaiser Permanente has elected to use the Mastectomy for Gynecomastia (KP-0273 v2 eff 04.01.2022) MCG\* Care Guideline for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from primary care provider or specialist, addressing the indications described in the medical necessity criteria

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Gynecomastia is a unilateral or bilateral enlargement of the male breast due to benign proliferation of glandular elements. Pubertal gynecomastia resolves without intervention in the majority of cases. Gynecomastia in postpubertal males may be due to persistent pubertal gynecomastia, medications, liver disease, kidney disease, testicular tumors, or endocrine disorders. The cause remains undetermined in about 25% of cases. Male breast cancer is uncommon and usually presents as a discrete breast mass.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
19300	Mastectomy for gynecomastia

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS)

Date Created	Date Reviewed	Date Last Revised
01/05/2016	01/05/2016 <sup>MPC</sup> , 11/01/2016 <sup>MPC</sup> , 09/05/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	02/04/2025

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
12/19/2017	Added Plastic Surgery LCD L37020
08/04/2020	Added Medicare LCA A57222
11/02/2021	MPC approved modifications to the hybrid criteria for non-Medicare members. Requires 60-day notice, effective date 04/01/2022.
02/04/2025	MPC approved to endorse credentialing preferences for Mastectomy. 60-day notice is not required.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Hearing Aids (Excludes Implantable Devices)

A separate criteria document exists for the following devices:

[Cochlear Implant](#)

[Bone Anchored Hearing System \(BAHA\) criteria](#)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual, chapter 16, 100 – Hearing Aids and Auditory Implants</a>
National Coverage Determinations (NCD)	This service is not covered per Medicare Criteria
Local Coverage Determinations (LCD)	Non-Covered Service defer to Kaiser Permanente Medical Policy
Local Coverage Article (LCA)	None
Kaiser Permanente Medical	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b><i>“Hearing Aids (Excludes Implantable Devices)”</i></b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

Please note that individual riders/contracts may vary in benefit design either excluding or waiving criteria for some services. **The member's rider/contract should be reviewed before making a final coverage determination and supersedes clinical review criteria.**

Equipment	Medical Necessity
Prescription Hearing Aids  Hearing Aid devices include: <ul style="list-style-type: none"> <li>Air conduction devices</li> <li>Bone conduction devices</li> </ul>	Hearing aids that are FDA-approved and dispensed by a prescription may be considered medically necessary when the following criteria are met:  <b>For adult patients (19 or older):</b> <ol style="list-style-type: none"> <li>Hearing thresholds 30 dB HL or greater at <b>TWO or more</b> of the following frequencies: 500, 1000, 2000, 3000, or 4000 hertz (Hz)</li> </ol> <b>For pediatric patients:</b> <ol style="list-style-type: none"> <li>Patient is under 18 years old or younger and has been evaluated by otolaryngologist; <b>AND</b></li> <li>Hearing aids have been prescribed by an audiologist or otolaryngologist.</li> </ol>

Hearing Hardware covered under Hearing Services Benefit	<p>To receive your hearing hardware benefit</p> <ul style="list-style-type: none"> <li>You must be examined by a licensed physician (MD or DO) or audiologist (CCC-A or CCCMSPA) before obtaining hearing aids</li> <li>You must purchase a hearing aid device</li> </ul> <p>Benefits are then provided for the following:</p> <ul style="list-style-type: none"> <li>Hearing aids (monaural or binaural) prescribed as a result of an exam</li> <li>The hearing aid instruments</li> <li>Hearing aid rental while the primary unit is being repaired</li> <li>The initial batteries, cords and other necessary ancillary equipment</li> <li>A warranty, when provided by the manufacturer</li> <li>A follow-up consultation within 30 days following delivery of the hearing aids with either the prescribing physician or audiologist</li> <li>Repairs, servicing, and alteration of hearing aid equipment purchased under this benefit</li> </ul>
---	--

Equipment	Investigational
Hearing Aids	Non-implantable intraoral (in the mouth) bone conduction hearing aids (eg, SoundBite™, Hearing System)

Equipment	Non-Covered
Over the Counter (OTC) Hearing Aids	<p>Over the Counter (OTC) hearing assistive listening devices (ALDs)/personal sound amplification products (PSAPs), Wireless Hearing aid Accessories, and Hearables available without a prescription are not covered. These include but are not limited to the following:</p> <ul style="list-style-type: none"> <li>Cyberscience Amplifier</li> <li>NewEar™</li> <li>Eargo</li> <li>BeHear</li> <li>Magic Ear</li> <li>Pocketalker®</li> <li>TV Ears®</li> <li>Ear buds or headphones</li> </ul>
Hearing Hardware Not covered under the Hearing Services Benefit	Batteries or other ancillary equipment other than that obtained upon purchase of the hearing aids

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Traditional hearing aids are externally worn microphones that amplify sound to the ear through an ear mold that fits in the ear canal.

Selection of the hearing aid is based on the results from a complete work-up performed by a hearing professional that includes skilled hearing tests and assessment along with fitting the chosen device. The hearing aid dispensed should meet the hearing requirements of the member in the environments and under the conditions where enhanced hearing is needed.

Effective January 1, 2024, Washington state law has provisions for the coverage of hearing instruments. [House Bill 1222](#) require that large group plan carriers shall provide coverage for hearing instruments.

## Resources

American Speech-Language-Hearing Association. Hearing Aids. 2023a American Speech-LanguageHearing Association. Accessed Sep 01, 2023. Available at URL address: <https://www.asha.org/public/hearing/hearing-aids/>

American Speech-Language-Hearing Association. The audiogram. 2023b American Speech-LanguageHearing Association. Accessed Sep 01, 2023. Available at URL address: <https://www.asha.org/public/hearing/Audiogram/>

Centers for Medicare and Medicaid Services (CMS). Local Coverage Determinations (LCDs) alphabetical index. Accessed Mar 23, 2023. Available at URL address: <https://www.cms.gov/medicarecoverage-database/indexes/lcd-alphabetical-index.aspx>

Centers for Medicare and Medicaid (CMS). Medicare benefit policy manual. Chapter 16 General Exclusions From Coverage. 100 Hearing aids and auditory implants. Revised 11/06/14. Accessed Sep 01, 2023. Available at URL address: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Internet-Only-Manuals-loms-Items/Cms012673.html>

Ferguson, M. A., Kitterick, P. T., Chong, L. Y., Edmondson-Jones, M., Barker, F., & Hoare, D. J. (2017). Hearing aids for mild to moderate hearing loss in adults. Cochrane Database of Systematic Reviews, 2017 (9). DOI: 10.1002/14651858.CD012023.pub2.

Washington State Legislature. Hearing Instruments—Group Health Plan Coverage. July 23, 2023. Accessed on Sept 01, 2023. Available at URL address: <https://lawfilesexxt.leg.wa.gov/biennium/2023-24/Pdf/Bills/Session%20Laws/House/1222-S.SL.pdf?q=20230917191930>

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPCS Codes	Description
<b>V5030</b>	Hearing aid, monaural, body worn, air conduction
<b>V5040</b>	Hearing aid, monaural, body worn, bone conduction
<b>V5050</b>	Hearing aid, monaural, in the ear
<b>V5060</b>	Hearing aid, monaural, behind the ear



V5100	Hearing aid, bilateral, body worn
V5120	Binaural, body
V5130	Binaural, in the ear
V5140	Binaural, behind the ear
V5171	Hearing aid, contralateral routing device, monaural, in the ear (ITE)
V5172	Hearing aid, contralateral routing device, monaural, in the canal (ITC)
V5181	Hearing aid, contralateral routing device, monaural, behind the ear (BTE)
V5211	Hearing aid, contralateral routing system, binaural, ITE/ITE
V5212	Hearing aid, contralateral routing system, binaural, ITE/ITC
V5213	Hearing aid, contralateral routing system, binaural, ITE/BTE
V5214	Hearing aid, contralateral routing system, binaural, ITC/ITC
V5215	Hearing aid, contralateral routing system, binaural, ITC/BTE
V5221	Hearing aid, contralateral routing system, binaural, BTE/BTE
V5242	Hearing aid, analog, monaural, CIC (completely in the ear canal)
V5243	Hearing aid, analog, monaural, ITC (in the canal)
V5244	Hearing aid, digitally programmable analog, monaural, CIC
V5245	Hearing aid, digitally programmable, analog, monaural, ITC
V5246	Hearing aid, digitally programmable analog, monaural, ITE (in the ear)
V5247	Hearing aid, digitally programmable analog, monaural, BTE (behind the ear)
V5248	Hearing aid, analog, binaural, CIC
V5249	Hearing aid, analog, binaural, ITC
V5250	Hearing aid, digitally programmable analog, binaural, CIC
V5251	Hearing aid, digitally programmable analog, binaural, ITC
V5252	Hearing aid, digitally programmable, binaural, ITE
V5253	Hearing aid, digitally programmable, binaural, BTE
V5254	Hearing aid, digital, monaural, CIC
V5255	Hearing aid, digital, monaural, ITC
V5256	Hearing aid, digital, monaural, ITE
V5257	Hearing aid, digital, monaural, BTE
V5258	Hearing aid, digital, binaural, CIC
V5259	Hearing aid, digital, binaural, ITC
V5260	Hearing aid, digital, binaural, ITE
V5261	Hearing aid, digital, binaural, BTE
V5262	Hearing aid, disposable, any type, monaural
V5263	Hearing aid, disposable, any type, binaural
V5264	Ear mold/insert, not disposable, any type
V5265	Ear mold/insert, disposable, any type
V5267	Hearing aid or assistive listening device/supplies/accessories, not otherwise specified
V5275	Ear impression, each
V5298	Hearing aid, not otherwise classified
V5070	Glasses, air conduction
V5080	Glasses, bone conduction
V5150	Binaural, glasses
V5190	Hearing aid, contralateral routing, monaural, glasses
V5230	Hearing aid, contralateral routing system, binaural, glasses

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
--------------	---------------	-------------------

09/05/2023	09/05/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	09/05/2023
------------	---	------------

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/05/2023	MPC approved medical necessity coverage indications for Prescription Hearing Aids. Requires 60-day notice. Effective date 2/01/2024.

## ***Patient Referral Guidelines***

### **Heart/Lung Transplant**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## **Criteria**

### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Heart Transplants (260.9)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

### **For Non-Medicare Members**

#### **Heart Transplant**

Transplantation may be considered for patients with end-stage or life-threatening disease who have no prospect for prolonged survival, or whose quality of life is severely impaired. The following are current, generally accepted, guidelines for Heart transplantation<sup>1</sup>. These guidelines for referral for transplant evaluation are not intended as an automatic inclusion or exclusion of a candidate for referral. As such, these should be applied together with careful clinical judgment.

#### **1. GENERAL PRINCIPLES**

- If clinical parameters of end-stage or life-threatening disease indicate the need for transplantation, then early referral should be made.
- Patients with a history of malignancy with a moderate to high risk of recurrence (as determined after consultation with oncologist considering tumor type, response to therapy, and presence or absence of metastatic disease) may be unsuitable candidates for transplantation. Patients with low risk of recurrence may be considered.
- Uncontrollable active infection is a contraindication to transplant.
- Candidates with a history of substance abuse must be free from alcohol and other substance abuse for six (6) months and have been evaluated by a substance abuse program. The risk of recidivism, which has been documented to negatively impact transplant outcomes, must be addressed and considered to be low<sup>2,3,4</sup>. Exceptions may be made on a case-by-case basis.
- Candidates for thoracic organ (heart, lung and heart/lung) transplants must be free from tobacco use for the previous six (6) months. Routine monitoring may be required. Specific programs for abdominal organs (liver, intestines and kidney) may require abstinence from tobacco products to be actively listed.
- Candidates must have adequate social support systems and display a proven record of adherence to medical treatment.
  1. Patient must have a care giver or care givers who are physically and cognitively able to assist the patient with self-care activities and are available to travel within short notice to the KP approved transplant Center of Excellence.
  2. Evidence of non-adherence may be failure to keep appointments, failure to make steady progress in completing pre-transplant evaluation requirements, failure to accurately follow medication regimens or failure to accomplish the activities required for maintenance on the waiting list.
- Patients must be willing and able to travel within short notice to the KP approved transplant Center of Excellence and, if necessary, return for treatment of complications.

- h. The presence of significant irreversible neurologic dysfunction, active psychological and/or psychiatric conditions, and/or other social behaviors that prevent adherence with a complex medical regimen, are considered contraindications for referral for transplant.
- i. Whenever transplant is considered as an option and discussed with the patient and/or family, consultation with Advanced Life Care Planning/Palliative Care resources is strongly recommended.

### INDICATIONS FOR HEART TRANSPLANT

- a. End-stage heart disease as evidenced by one or more of the following:
    - i. Functional class III or IV
    - ii. Not correctable by medical or other surgical therapies
    - iii. A low VO<sub>2</sub> maximum: [5](#)
      - 1.  $\leq 14$  ml/kg/min in patients not on a beta blocker
      - 2.  $\leq 12$  ml/kg/min in patients on a beta blocker [6](#)
      - 3.  $< 19$  ml/kg/min adjusted for lean body mass in patients with a BMI  $> 30$  kg/m<sup>2</sup>
      - 4. Less than 50% of age predicted maximum.
    - iv. A VE/VCO<sub>2</sub>  $> 35$  in a patient with a sub-maximal cardiopulmonary exercise test (RER  $< 1.05$ )<sup>2</sup>
    - v. Cardiac index  $< 2$  L/min/m<sup>2</sup>
  - b. Unable to wean from mechanical or inotropic support.
  - c. Amyloid Cardiomyopathy
    - i. TTR Amyloid
    - ii. (AL) Amyloidosis without significant extra-cardiac involvement.
  - d. Refractory Life-Threatening Arrhythmias
3. The transplant should only be offered for conditions in which cardiac transplant has proven clinical benefits.
- CONTRAINDICATIONS FOR HEART TRANSPLANT** (In conjunction with the General Principles listed above in Section 1 of these guidelines):

- a. Significant diseases such as:
  - i. Severe uncontrolled or poorly controlled hypertension.
  - ii. Clinically significant vascular disease not correctable by intervention.
  - iii. Pulmonary hypertension not reversible by drug manipulation despite maximum tolerated medical management. [7](#)
    - 1. Adults: PVR  $> 4$ -6 Wood units or transpulmonary gradient  $> 15$  mm Hg
    - 2. Children: PVR  $> 9$  Wood units
  - iv. Severe pulmonary disease after optimal treatment of severe heart failure.[8](#)
  - v. Severe hepatic disease after optimal treatment of severe heart failure.[8](#)
  - vi. Kidney disease with creatinine clearance  $< 34$  ml/kg/min or GFR  $< 30$  ml/min after optimal treatment of heart failure. [8,9,10](#)
  - vii. Active and/or progressive central nervous system disease excluding patients with embolic stroke who have recovered completely.
  - viii. Evidence of cachexia or malnutrition (BMI  $< 19$  kg/m<sup>2</sup> or  $< 80\%$  ideal body weight).[10](#)
  - ix. Obesity (BMI  $> 35$  kg/m<sup>2</sup> or  $> 140\%$  ideal body weight) [11](#) has been associated with poor outcomes after cardiac transplant.
  - x. Diabetes with complications resulting in severe end-organ damage.
  - xi. Auto/acquired immune disease with multi-organ manifestation
  - xii. Acute pulmonary embolus
  - xiii. Active peptic ulcer disease
  - xiv. Severe symptomatic osteoporosis
  - xv. Age over 70 (Carefully selected patients over 70 years of age may be considered for cardiac transplantation)
  - xvi. AL Amyloidosis with significant extra-cardiac manifestations
  - xvii. Patients with viral hepatitis will require additional evaluation, including hepatology consultation.
  - xviii. Any other co-morbid condition that would limit life expectancy or quality of life.

### Footnotes

- 1. Note: All patients must be continuously re-evaluated for indications and contraindications. Candidates considered for re-transplantation must be evaluated using the same indications.
- 2. Liver Transplantation 2006, .12:813-820. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease.
- 3. Liver Transplant Surg., 1997, Vol. 3, 304 – 310. The natural history of alcoholism and its relationship to liver transplantation.
- 4. Alcohol abstinence prior to liver transplantation for Alcoholic Liver Disease (G110807), TPMG New Medical Technology.

5. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. *J Heart Lung Transplant* 2016; 35:1-23. 10.1016/j.healun.2015.10.023
6. Patients on Beta blockers should have a cut-off of  $\leq 12$  ml/kg/min, and patients intolerant to beta blockers a  $VO_2 \leq 14$  ml/kg/min.
7. Circulation; 84 (3), 329 – 337. *Journal of Heart Transplantation* (1990): 526 – 537.
8. Selected patients for combined organ transplant will be evaluated on a case-by-case basis.
9. Must have 20mg per kilogram of creatinine in a 24-hour collection period. Creatinine clearance can also be calculated by the Cockcroft-Gault formula.
10. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. *J Heart Lung Transplant* 2016; 35:1-23. 10.1016/j.healun.2015.10.023
11. Body Mass Index (BMI) = (weight [kg] / height<sup>2</sup> [m<sup>2</sup>]). Percent Ideal Body Weight (PIBW) was calculated as follows: Men IBW = 106 pounds for the first 5 feet of height, add 6 pounds for each additional inch. Women IBW = 100 pounds for the first 5 feet of height add 5 pounds for each additional inch. *Journal of Heart and Lung Transplantation*, Aug 1999, page 752.

## **LUNG TRANSPLANT:**

Transplantation may be considered for patients with end-stage or life-threatening disease who have no prospect for prolonged survival, or whose quality of life is severely impaired. The following are current, generally accepted, guidelines for lung & heart/lung transplantation. These guidelines for referral for transplant evaluation are not intended as an automatic inclusion or exclusion of a candidate for referral, rather should be applied together with careful clinical judgment.

### **1. GENERAL PRINCIPLES**

- a. If clinical parameters of end-stage or life-threatening disease indicate the need for transplantation, early referral should be made.
- b. Patients with a history of malignancy with moderate to high risk of recurrence (as determined after consultation with oncologist considering tumor type, response to therapy, and presence or absence of metastatic disease) may be unsuitable candidates for transplantation. Patients with low risk of recurrence may be considered.
- c. Uncontrollable active infection is a contraindication to transplant.
- d. Candidates with a history of substance abuse must be free from alcohol and other substance abuse for six (6) months and have been evaluated by a substance abuse program. The risk of recidivism, which has been documented to negatively impact transplant outcomes, must be addressed and considered to be low. <sup>4, 5, 6</sup> Exceptions may be made on a case-by-case basis.
- e. Candidates for thoracic organ (heart, lung and heart/lung) transplants must be free from tobacco use for the previous six (6) months. Routine monitoring may be required. Specific programs for abdominal organs (liver, intestines, and kidney) may require abstinence from tobacco products in order to be actively listed.
- f. Candidates must have adequate social support systems and display a proven record of adherence to medical treatment.
  - i. Patients must have a care giver or care givers who are physically and cognitively able to assist the patient with self-care activities and are available to travel within short notice to the KP approved transplant Center of Excellence.
  - ii. Evidence of non-adherence may be failure to keep appointments, failure to make steady progress in completing pre-transplant evaluation requirements, failure to accurately follow medication regimens or failure to accomplish the activities required for maintenance on the waiting list.
- g. Patients must be willing and able to travel within short notice to the KP approved transplant Center of Excellence and, if necessary, return for treatment of complications.
- h. The presence of significant irreversible neurologic dysfunction, active psychological and/or psychiatric conditions, and/or other social behaviors that prevent adherence with a complex medical regimen, are considered contraindications for referral for transplant.
  - i. Evidence of such non-adherence may be failure to keep appointments, failure to make steady progress in completing pre-transplant evaluation requirements, failure to accurately follow medication regimens or failure to accomplish the activities required for maintenance on the waiting list.
- i. Whenever transplant is considered as an option and discussed with the patient and/or family, consultation with Advanced Life Care Planning/Palliative Care resources is strongly recommended.

### **2. INDICATIONS FOR LUNG TRANSPLANT**

- a. Must meet all prerequisites listed in the General Principles section
- b. Any disease state in which transplantation has become an accepted mode of treatment worldwide including

- i. Chronic obstructive pulmonary disease (COPD), which may include asthma, chronic bronchitis, emphysema and/or Alpha 1 antitrypsin deficiency
  - ii. Idiopathic pulmonary fibrosis
  - iii. Sarcoidosis
  - iv. Connective tissue disease-related pulmonary fibrosis
  - v. Eosinophilic granulomatosis
  - vi. Bronchiectasis
  - vii. Cystic fibrosis (CF)
  - viii. Pulmonary hypertension (both primary and secondary)
  - ix. Lymphangiomyomatosis (LAM)
  - x. Interstitial lung disease not otherwise defined.
- c. Patients should be referred for transplant evaluation by a pulmonologist or a cardiologist who has accumulated data defining both the disease as potentially treatable by transplantation and progression is occurring despite maximal medical therapy.
- d. Early referral is strongly encouraged for progressive lung disease with a poor prognosis<sup>7</sup>
- e. Ideally, the patient should be ambulatory with rehabilitation potential.

### 3. CONTRAINDICATIONS FOR LUNG TRANSPLANT

- a. Must meet all prerequisites listed in the General Principles section
- b. Invasive mechanical ventilator support<sup>8</sup>.
- c. Unresolved infection (except in cystic fibrosis and bronchiectasis).
- d. Uncontrolled chronic infection (i.e., HIV with detectable viral load)
- e. Other systemic diseases including but not limited to:
  - i. Diabetes with end organ effects; i.e., renal, cardiac or uncorrectable peripheral vascular disease. Insulin use itself is not a contraindication.
  - ii. Uncontrolled hypertension.
  - iii. Significant neurologic disease impairing cognitive function.
  - iv. Malnutrition<sup>9</sup>
  - v. Obesity >140% ideal body weight or BMI >32 kg/m<sup>2</sup> <sup>10, 11</sup>(with an understanding that a BMI <30 may be necessary for transplantation).
1. May wish to consider initiating transplant workup if patient has pulmonary fibrosis and BMI >32 (but <34) if showing willingness to lose weight.
- vi. Advanced hepatic dysfunction.
- vii. Advanced renal dysfunction (creatinine clearance < 50 ml/min. after maximum therapy). However, patients with underlying cardiopulmonary causes of low creatinine clearance can be considered for transplant on a case-by-case basis.
- viii. Evidence of clinically significant obstructive coronary artery disease and/or LVEF <40%. <sup>12</sup>
- ix. Active or unresolved peptic ulcer disease.
- x. Chronic opiate use: Patients should be seen by a pain management specialist for alternative forms of therapy.
- xi. Uncorrectable bleeding diathesis or clotting disorder

### 4. RELATIVE CONTRAINDICATIONS

- a. Patients with previous thoracotomy and/or sclerosing procedures should be considered on a case by case basis.
- b. Systemic corticosteroid therapy >10 mgs prednisone daily.
- c. Esophageal dysmotility and reflux. Surgical repair may be necessary.<sup>13</sup>
- d. Age >70 for lung transplant referral.
- e. Symptomatic osteoporosis.
- f. Major mechanical chest deformity (such as kyphoscoliosis).
- g. Short stature patients (in USA 4'11" for females and 5'4" for males) are significantly disadvantaged and early consideration of multiple listing is encouraged.

## PATIENT PROFILE FOR COMMON DIAGNOSES LUNG TRANSPLANT REFERRAL GUIDELINES

Any or all of the listed guidelines for each disease entity should raise consideration for lung transplantation evaluation. Clinical correlation is always of primary importance.

### 1. GROUP A – Obstructive Lung Disease <sup>14, 15</sup> (See Table 1Below)

#### 1.1. FEV1 < 25 %



1.2. DLCO < 40%

1.3. Hypoxemia; PO<sub>2</sub> < 55 Hypercapnia; PCO<sub>2</sub> > 51<sup>16</sup>

1.4. Bode Index > 5

## 2. GROUP B – Pulmonary Arterial Hypertension (See Table 1 Below)<sup>17, 18, 19</sup>

2.1. Patients with clinically significant PAH should be evaluated by physicians experienced in treating pulmonary hypertension and have received maximum available pharmacological treatment.

2.2. Possible indications for referral include:

2.2.1. Pericardial Effusion<sup>20</sup>

2.2.2. World Health Organization (WHO) (New York Heart Association) class 3 or 4

2.2.3. Lack of improvement in WHO Class 3 or 4 and/or lack of improvement in 6-minute walk test of < 350 meters, despite maximum pharmacological therapy.

2.3. Definite indications, after maximum pharmacologic treatment for referral include: <sup>21</sup>

2.3.1. Mean RA > 15 mmHg

2.3.2. Cardiac Index < 2L per minute. Untreated, the mean survival for patients with these criteria is 10-11 months.

## 3. GROUP C – Cystic Fibrosis<sup>22</sup>(See table 1 Below)

3.1. FEV<sub>1</sub> < 40%

3.2. PO<sub>2</sub> < 55

3.3. Clinical deterioration, especially in young female patients, as characterized by increasing number of hospitalizations, including recurrent pneumothoraxes, rapid fall of FEV<sub>1</sub>, recurrent major hemoptysis uncontrolled by embolization and/or increasing cachexia should prompt consideration for transplant referral.

3.4. PCO<sub>2</sub> > 51

3.5. Patients with *Burkholderia cepacia* have a relative contraindication.

## 4. GROUP D – Restrictive Lung Disease)<sup>22, 23</sup>(See Table 1 Below)

4.1. Force Vital Capacity < 80%<sup>22</sup>

4.2. Decline in Forced Vital Capacity of ≥10% and/or decline in DLCO ≥ 15% during 6 months of follow-up<sup>22</sup>

4.3. Diffusing Capacity (corrected for alveolar volume) < 60%

4.4. Evidence of interstitial lung disease on HRCT in conjunction with one or more of the above.

Referral to lung transplant program should be considered when a definitive diagnosis of usual interstitial pneumonitis (UIP) or idiopathic pulmonary fibrosis (IPF) is made and may be considered for the diagnosis of fibrotic nonspecific interstitial pneumonitis (NSIP).

## OTHER CONDITIONS

Other conditions for which transplant may be appropriate include the Lung diseases described in Table 1 below.<sup>24</sup>

**Table 1:** Lung allocation score (LAS) primary diagnostic groupings for lung transplant candidates

LAS lung disease diagnosis grouping	
Group A (obstructive lung disease)	<ul style="list-style-type: none"> <li>• Chronic obstructive pulmonary disease (COPD), with or without alpha-1-antitrypsin deficiency, due to chronic bronchitis and/or emphysema</li> <li>• Lymphangioleiomyomatosis (LAM)</li> <li>• Bronchiectasis, including primary ciliary dyskinesia</li> <li>• Sarcoidosis with a mean pulmonary artery (PA) pressure <math>\leq 30</math> mmHg</li> </ul>
Group B (pulmonary vascular disease)	<ul style="list-style-type: none"> <li>• Idiopathic pulmonary arterial hypertension (IPAH, formerly known as primary pulmonary hypertension [PPH])</li> <li>• Eisenmenger's syndrome</li> <li>• Other pulmonary vascular diseases</li> </ul>
Group C (cystic fibrosis or immunodeficiency disorders)	<ul style="list-style-type: none"> <li>• Cystic fibrosis (CF)</li> <li>• Immunodeficiency disorders such as hypogammaglobulinemia</li> </ul>
Group D (restrictive lung disease)	<ul style="list-style-type: none"> <li>• Idiopathic pulmonary fibrosis (IPF)</li> <li>• Pulmonary fibrosis due to other causes</li> <li>• Sarcoidosis with mean PA pressure <math>&gt; 30</math> mmHg</li> <li>• Obliterative bronchiolitis (nonretransplant)</li> </ul>

Source: Revision to policy 3.7.6.1.

## ADDENDUM

### GUIDANCE FOR LUNG TRANSPLANT FOR IRREVERSIBLE PULMONARY FAILURE FROM COVID-19

Background: Transplant has been successful for other conditions, including infections, that lead to irreversible pulmonary failure, so this disease has some familiar aspects within the lung transplant community. Because of the specific conditions surrounding the effects of SARS-CoV-2, and because much of the mechanism underlying the development of lung injury and recovery are still unclear, the following elements are recommended for any consideration for referral of and authorizations for potential candidates for lung transplant. The below represent elements, *IN ADDITION TO THE USUAL CRITERIA PROVIDED IN THE CMS LUNG PATIENT REFERRAL GUIDELINES*:

1. Age under 65 if ECMO has been used as bridge to transplant
2. Disease has progressed in spite of maximal non-invasive ventilatory support
3. No other significant organ dysfunction exists
4. Sufficient time for recovery must be allowed: once on invasive mechanical support or ECMO, referral should not be considered fewer than 4-6 weeks after ventilator-dependent or ECMO-supported pulmonary failure
5. Patients on prolonged O<sub>2</sub> therapy other than mechanical support or ECMO should be given sufficient time to determine irreversibility of the condition (usually three months) and should be ambulatory with good opportunity for rehabilitation.
6. Evidence of irreversible lung disease (bullae, fibrosis) must be present
7. The ability to gain patient, not surrogate, approval for transplant is an essential ethical concept in light of the relatively poor long-term outcomes from lung transplant
8. Ability to do adequate pulmonary rehabilitation while on support for respiratory failure
9. Have 2 negative SARS-CoV-2 PCR tests at least 24 hours apart with one of the samples being a deep respiratory specimen.
10. Transplants should be performed only at lung transplant programs experienced in the highest risk lung transplants including familiarity with transplanting patients with ECMO bridging to transplant. Furthermore, they should have:
  - a. Broad donor pool (represented by low time to transplant measures), and
  - b. Low wait-list mortality

Reference: Cypel M, Keshavjee S. Comment When to consider lung transplantation for COVID-19. *Lancet Respir Med*. 2020;8:944–6. [https://doi.org/10.1016/S2213-2600\(20\)30393-3](https://doi.org/10.1016/S2213-2600(20)30393-3).

#### Footnotes

1. See Addendum 1, New system for lung allocation (enclosed)
2. Orens, JB, et al, 'International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update - A Consensus Report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation', *Journal of Heart and Lung Transplantation*, 25(7), July 2006, 745-755.
3. Weill D, et al. A consensus document for the selection of lung transplant candidates: 2014 An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2015; 34:1-15
4. *Liver Transplantation* 2006, .12:813-820. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease.
5. *Liver Transplant Surg.*, 1997, Vol 3, 304 – 310. The natural history of alcoholism and its relationship to liver transplantation.
6. 6. Alcohol abstinence prior to liver transplantation for Alcoholic Liver Disease (G110807), *TPMG New Medical Technology*
7. *J Thorac Dis.* 2019 Sep; 11(Suppl 14): S1708-S1720.
8. Under acceptable case-by-case circumstances, a patient who has been listed for a lung transplant and previously ambulatory, and now requires mechanical ventilation, may still be a potential candidate for lung transplantation. Patients who have been listed for lung transplant, and require invasive mechanical ventilation, can remain on the transplant list provided that there remains rehabilitation potential. On a carefully selected case-by-case basis, patients who are on invasive mechanical support, and are ambulatory with a potential for rehabilitation, can be listed for lung transplant. *Chest* 2001; 119 (1) 224-227.
9. Any disorder of nutrition causing a lack of necessary or proper food substances in the body or improper absorption and distribution of them (Taber's Cyclopedic Medical Dictionary).
10. *Journal of Heart and Lung Transplantation Vol. 18 (8), August 1999, pg 750-761*
11. *The Journal of Heart and Lung Transplantation* 2010; 29 (9), 1026 – 1033. Impact of Recipient Body Mass Index on Survival after Lung Transplantation.
12. Potential candidate for Heart/Lung transplantation will be evaluated independently.
13. *Annals of Surgery*, 2006. Vol.244 (4) 491-497.
14. Lung Transplantation in Advanced COPD: Is it Worth it? *Semin Respir Crit Care Med.* 2010 June; 31(3): 365-372; Selecting lung transplant candidates: where do current guidelines fall short? *Expert Rev Respir Med.* 2012 February; 6(1): 51-61.
15. *Amer Rev Respir Dis* 140: S92 and S95 1989; *Ann Int Med* 99: 612: 1983; *New England Journal of Medicine*, 1999 340(14), 1081-91
16. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350:1005-12.
17. Applicable to idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, collagen vascular disease limited to the lungs, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis, and drug induced pulmonary hypertension. *CHEST*, 2004, Volume 126 (Supplement 1).
18. *AJRCCM* 201. 184: 159-171 - Thorough review of lung transplantation; *J Heart Lung Transplant.* 2006. 25(7): 745-55. - Consensus report from ISHLT *Pulm Circ.* 2011. April-June. 1(2): 182-191 - PH and lung transplant.
19. *Transplantation.* 2010 Aug 15. 90(3): 298-305. - Suggests that 6MWD  $\leq$  300 m and RAP  $\geq$  14 mm Hg is better predictor of wait list mortality than LAS scoring system.
20. McGoon MD and Miller DP. *Eur Respir Rev.* 2012; 21(123):8-18.
21. *Ann Int Med* 115: 343 1991
22. Weill D, et al. A consensus document for the selection of lung transplant candidates: 2014 An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2015; 34:1-15
23. Nathan, SD., Lung Transplantation- Disease-Specific Considerations for Referral', *CHEST* 2005; 127: 1006-1016.
24. OPTN Policy 10: Allocation of Lungs, 10.1.F.i Lung Disease Diagnosis Groups, Effective Date 9/1/2016

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

This service is covered when it is medically necessary and identified as a benefit in the consumer's coverage contract. Kaiser Permanente adopted the MCG Guideline for medical necessity decision making.

## Evidence and Source Documents

The scientific literature is periodically reviewed, and patient selection criteria are updated when new efficacy data becomes available.

## Kaiser Permanente Committee on Medically Emerging Technology

Transplant, Lung, Double - 7/12/91 - Double lung transplantation is efficacious for appropriately selected patients.

Transplant, Lung, Single - 7/12/91 Single lung transplantation is efficacious for appropriately selected patients.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>33930</b>	Donor cardiectomy-pneumonectomy (including cold preservation)
<b>33933</b>	Backbench standard preparation of cadaver donor heart/lung allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare aorta, superior vena cava, inferior vena cava, and trachea for implantation
<b>33935</b>	Heart-lung transplant with recipient cardiectomy-pneumonectomy
<b>33940</b>	Donor cardiectomy (including cold preservation)
<b>33944</b>	Backbench standard preparation of cadaver donor heart allograft prior to transplantation, including dissection of allograft from surrounding soft tissues to prepare aorta, superior vena cava, inferior vena cava, pulmonary artery, and left atrium for implantation
<b>33945</b>	Heart transplant, with or without recipient cardiectomy

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/1996	09/07/2010 <sup>MDCRPC</sup> , 07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 01/07/2014 <sup>MPC</sup> , 10/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 12/03/2024 <sup>MPC</sup>	01/10/2022

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/05/2019	MPC approved to adopt KP National Criteria for Heart and Lung Transplant
09/03/2019	MPC approved to change General Principles 1.3 to <i>Uncontrollable infection is a contraindication to transplant</i> as recommended by KP National Transplant Services.
03/03/2020	MPC approved the proposed changes from KP National Transplant Services
04/06/2021	Per National Transplant Guidelines: 1.3 added "active" for Heart Transplant and changes to Lung Transplant. *Lung Transplant Guideline requires 60-day notice, effective date September 1, 2021.
01/10/2022	MPC approved the proposed changes from KP National Transplant Services. 60-day notice is not required.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### High-Frequency Chest Wall Oscillation Devices (HFCWO)

- ABI Vest® for Cystic Fibrosis
- Vest® Airway Clearance System

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">High Frequency Chest Wall Oscillation Devices (L33785)</a>
Local Coverage Article (LCA)	<a href="#">High Frequency Chest Wall Oscillation Devices (A52494)</a>

#### For Non-Medicare Members

##### Effective until July 1<sup>st</sup>, 2025

##### A. The member must have **ONE** of the following:

1. A diagnosis of cystic fibrosis.
2. A diagnosis of bronchiectasis:
  - a) Characterized by daily productive cough for at least 6 continuous, months or, frequent (i.e. more than 2/year) exacerbations requiring antibiotic therapy, and
  - b) Confirmed by high resolution, spiral, or standard CT scan
3. Neuromuscular Disorder
  - a) Acid maltase deficiency
  - b) Anterior horn cell diseases, including amyotrophic lateral sclerosis
  - c) Hereditary muscular dystrophy
  - d) Multiple sclerosis
  - e) Myotonic disorders
  - f) Other myopathies
  - g) Paralysis of the diaphragm
  - h) Post-polio
  - i) Quadriplegia regardless of underlying etiology

##### B. And meet **ALL** of the following criteria:

1. Well-documented failure of standard treatments to adequately mobilize retained secretions with all of the following:
  - a) Chest physical therapy and flutter device at least twice daily (when age appropriate)
  - b) A pattern of hospitalizations at least annually or more
  - c) Significantly deteriorating clinical condition
2. Be under the care of a pulmonologist
3. Had a rental trial to confirm compliance before purchase

##### Effective July 1<sup>st</sup>, 2025

##### A. The member has a diagnosis of Cystic Fibrosis **and**

1. Is being managed by a pulmonologist, and
2. Has demonstrated compliance with Chest physical therapy and flutter device at least twice daily (when age appropriate), and
3. HFCWO has been recommended by the pulmonologist

**OR****B. Member meets ALL of the following:**

1. One of the following conditions:
  - i. Diagnosis of bronchiectasis as evidenced by **ALL** of the following:
    - a. Characterized by daily productive cough for at least 6 continuous, months or, frequent (i.e. more than 2/year) exacerbations requiring antibiotic therapy, and
    - b. Confirmed by high resolution, spiral, or standard CT scan
  - ii. Neuromuscular Disorder:
    - a. Acid maltase deficiency
    - b. Anterior horn cell diseases, including amyotrophic lateral sclerosis
    - c. Hereditary muscular dystrophy
    - d. Multiple sclerosis
    - e. Myotonic disorders
    - f. Other myopathies
    - g. Paralysis of the diaphragm
    - h. Post-polio
    - i. Quadriplegia regardless of underlying etiology.
2. And meet **ALL of the following** criteria:
  - a. Well-documented failure of standard treatments to adequately mobilize retained secretions with all of the following:
    - (a) Chest physical therapy and flutter device at least twice daily (when age appropriate)
    - (b) A pattern of hospitalizations at least annually or more
    - (c) Significantly deteriorating clinical condition
3. Be under the care of a pulmonologist
4. Had a rental trial to confirm compliance before purchase

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

**Background**

Conventional chest physical therapy (CPT), also known as percussion and postural drainage (P/PD) has traditionally been the standard of care of secretion clearance methods for patients with excessive or retained lung secretions. Depending on the severity of the disease or the presence of infection, CPT is performed in 1-3 sessions per day, each lasting between 23-30 minutes. These are administered by a physical therapist or a trained caregiver. CPT is labor intensive and time consuming, which could lead to poor compliance.

A number of airway clearing devices have thus been developed for independent use with little or no assistance by others. These include the high-frequency chest wall oscillation (HFCWO), which is an external non-invasive respiratory modality that mobilizes airway secretions from the small peripheral airways. The technique typically produces compression of the chest wall via an inflatable vest linked to an air pulse generator. The generator delivers an intermittent flow to the vest which rapidly compresses and releases the chest wall at a variety of frequencies. Consequently, an oscillation of airflow within the airways is achieved. The researchers believe that the underlying mechanisms include increased airflow-mucous interaction causing a reduction in viscoelasticity, production of airflow bias that promotes a cephalad movement of the mucous, as well as the enhancement and stimulation of ciliary activity (Osman 2010).

HFCWO is most commonly used for assisting mucous secretion in patients with disorders associated with abnormally thick mucous hypersecretion but preserved muscle function such as cystic fibrosis. It has also been advocated as an adjunctive therapy to assist cough clearance in patients with neuromuscular disorders who have relatively normal mucus but weak respiratory muscles (Chaisson 2006, Osman 2010, Finder 2010).

The FDA has cleared several airway clearing systems for delivering high-frequency chest wall oscillation to promote airway clearance and improve bronchial drainage in situations where physicians recommend external



manipulation of the thorax. These systems include the Vest™ Airway Clearance System (also known as the ABI Vest or the ThAIRapy Vest, or the ThAIRapy Bronchial Drainage System), Medpulse Respiratory Vest System, and the FREQUENCER which produces sound wave stimulation to oscillate and loosen mucous secretion in the chest.

HFCWO is most commonly used with cystic fibrosis patients who have abnormally thick secretions. It has also been used for other conditions such as bronchiectasis. Another proposed application is treating patients with neuromuscular disorders, who may have impaired cough and may not be able to clear their airways. An inadequate cough in these patients can lead to atelectasis or pneumonia. Other possible treatments for airway clearance in patients with neuromuscular disorders include percussion and postural drainage (P&PD), the traditional procedure, autogenic drainage, positive expiratory pressure therapy, flutter valve and intrapulmonary percussive ventilation (IPV) (Panitch et al., 2006; Langenderfer, 1998).

Neuromuscular diseases are a heterogeneous group of inherited or acquired disorders characterized by progressive irreversible weakness of functional groups of skeletal muscles including the respiratory muscles necessary for ventilation and cough. Depending on the severity of the disorder, ineffective cough and clearing of respiratory secretions can present as frequent respiratory infections, pneumonias, and atelectasis. As the disorder progresses, the patients may develop spinal deformities, gas exchange abnormalities, sleep disorders, and cardiac dysfunction. These and any concomitant pulmonary disorder can severely compromise the existent muscle weakness and precipitate respiratory failure (Chaisson 2006, Yuan 2010).

The Vest™ Airway Clearance System (Hill-Rom, ST Paul, Minnesota), consists of a 1. Non-stretching inflatable cloth-like vest that covers the entire thorax and provides high frequency chest wall oscillation; 2. Large-bore tubing connects the vest to the air-pulse generator; and 3. An air pulse generator that creates pressure to inflate and deflate the vest against the thorax. The vest is inflated to a constant pressure to maximize the surface area over which high frequency (5-20 Hertz), small volume pressure impulses are transmitted externally to the entire chest area. Pressure pulses are controlled by the patient and applied during expiration. A typical treatment may last for 20-30 minutes and consists of periods of compression separated by huff coughs (Chatburn 2007).

## Medical Technology Assessment Committee (MTAC)

### ThAIRapy/ABI Vest®

#### 12/13/2000: MTAC REVIEW

**Evidence Conclusion:** The scientific evidence does not permit conclusions about the effect of the ThAIRapy/ABI Vest® on health outcomes. The two randomized trials had small sample sizes and threats to validity that make their findings inconclusive. The Arens study did not find differences between patients (n=50) randomized to the ABI Vest® compared to chest physical therapy, but this may have been due to low statistical power (the authors did not discuss statistical power issues). The Kluft study included only 29 individuals, had a brief intervention (4 days total), no “wash-out” period between the ABI vest and chest physical therapy interventions (patients had a different intervention each day), gave nebulized saline to the ABI vest but not the physical therapy group, and examined sputum weight, an intermediate outcome measure. The Warwick and Hansen study, an interrupted time series design had the smallest sample size (n=16) and the validity was seriously threatened by possible selection bias. None of the available studies examined clinical outcomes such as pulmonary exacerbations or hospitalizations and no information was provided on short-term or long-term adverse health outcomes associated with the use of the ABI Vest®.

**Articles:** The search yielded 20 articles. 11 articles were not directly relevant or were review articles. Of the remaining 9 articles, 5 were randomized controlled trials (RCTs). The two RCTs with the largest sample sizes were selected for critical appraisal (the remaining three RCTs all had sample sizes of less than 20 patients). In addition, an interrupted time-series analysis with longer-term follow-up of patients was reviewed. Arens R, Gozal D, Omlin KJ, Vega J, Boyd KP, Keens TG, Woo MS. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. *Am J Respir Crit Care Med* 1994; 150: 1154-7. See [Evidence Table](#). Kluft J, Beker L, Castagininio M, Gaiser J, Chaney H, Fink RJ. A comparison of bronchial drainage treatments in cystic fibrosis. *Pediatr Pulmonol* 1996; 22: 271-74. See [Evidence Table](#). Warwick WJ, Hansen LG. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. *Pediatr Pulmonol* 1991; 11: 265-71. See [Evidence Table](#).

The use of ThAIRapy/ABI Vest® for treatment of cystic fibrosis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ThAIRapy/ABV Vest®

#### 10/08/2003: MTAC REVIEW

**Evidence Conclusion:** There is no published empirical evidence on the use of the Vest™ Airway Clearance System for bronchiectasis. There is no new published evidence on the use of the Vest™ Airway Clearance System for cystic fibrosis. The summary of the evidence on the ABI vest from December 2000 is: “The scientific evidence does not permit conclusions about the effect of the ThAIRapy/ABI vest on health outcomes. The two randomized trials had small sample sizes and threats to validity that make their findings inconclusive. The Arens study did not find differences between patients (n=50) randomized to the ABI vest compared to chest physical therapy, but this may have been due to low statistical power (the authors did not discuss statistical power issues). The Kluff study included only 29 individuals, had a brief intervention (4 days total), no “wash-out” period between the ABI vest and chest physical therapy interventions (patients had a different intervention each day), gave nebulized saline to the ABI vest but not the physical therapy group, and examined sputum weight, an intermediate outcome measure. The Warwick and Hansen study, an interrupted time series design had the smallest sample size (n=16) and the validity was seriously threatened by possible selection bias. None of the available studies examined clinical outcomes such as pulmonary exacerbations or hospitalizations and no information was provided on short-term or long-term adverse health outcomes associated with the use of the ABI vest.”

**Articles:** The search yielded 6 articles. There were no new empirical studies on the Vest™ Airway Clearance System for cystic fibrosis. There were no empirical studies on the Vest™ Airway Clearance System for bronchiectasis.

The use of ThAIRapy/ABI Vest® for treatment of cystic fibrosis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### High Frequency Chest Wall Oscillation

#### 02/04/2008: MTAC REVIEW

**Evidence Conclusion:** There is no empirical evidence on the safety and effectiveness of the Vest™ Airway Clearance System for improving health outcomes in patients with neuromuscular disease.

**Articles:** The search yielded 11 articles. When limited to English language publications and human populations, there were 7 articles. Only 2 of the 7 articles, both of them reviews/opinion pieces, specifically addressed the topic of interest, airway clearance for patients with neuromuscular weakness. The remaining articles were on different, related topics. No empirical studies were identified. One of the review articles (Panitch, 2006) stated that HFCWO has not been studied in patients with neuromuscular disease.

The use of High-frequency chest wall oscillation (HFCWO) for treatment of neuromuscular deficiency does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 10/18/2010: MTAC REVIEW

### High Frequency Chest Wall Oscillation

**Evidence Conclusion:** The evidence on the use of high-frequency chest wall oscillation (HFCWO) therapy in patients with neuromuscular disorders is very limited and insufficient to determine the safety and effectiveness of the Vest™ Airway Clearance System for improving health outcomes in these patients. The published studies to date have very small sample sizes and short follow-up durations. Those with a control group have several threats to their internal validity. Among these are unblinding, including heterogeneous groups of population, potential selection bias, insufficient power to detect significant differences between therapies, relatively high dropout rates, and/or analyses were not based on intention to treat. Additionally, the studies were funded by the manufacturer of the airway clearance systems used.

**Articles:** The majority of published literature on high-frequency chest wall oscillation (HFCWO) was on its use for patients with cystic fibrosis and other obstructive airway diseases. The literature search for studies published after the last MTAC review of the technology for patients with neuromuscular disorders revealed only one small RCT that compared the use of HFCWO to the standard chest physiotherapy among a small group of pediatric population with cerebral palsy or neuromuscular disease. Yuan N, Kane P, Shelton K, et al. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. *J Child Neurol*. 2010; 25:815-821. See [Evidence Table](#)

The use of High-frequency chest wall oscillation (HFCWO) for treatment of neuromuscular deficiency does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPC	Description
------	-------------

Codes	
<b>A7025</b>	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each
<b>A7026</b>	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each
<b>E0480</b>	Percussor, electric or pneumatic, home model
<b>E0483</b>	High frequency chest wall oscillation system, includes all accessories and supplies, each

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Dates Reviewed	Date Last Revised
12/13/2000	12/07/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	02/04/2025

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
01/19/2016	Defined conditions for neuromuscular disorder
02/04/2025	MPC approved criteria updates for HFCWO devices to better align with current medical evidence and community standards of care. 60-day notice required; effective July 1, 2025.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Home Care Services Criteria

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Benefit Policy Manual Chapter 7 Home Health Services.</a>
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Kaiser Permanente has elected to use the MCG\* Home Care Guidelines for medical necessity determinations. \*\* For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

\*\*note - Social Work is to be considered a secondary service and not a primary service

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

The criteria for admission to home health services are based on the federal regulations for the Medicare home health benefit.

### Evidence and Source Documents

Kaiser Permanente Home Care Services Policy HCS-06-1008.

### Applicable Codes

To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).

CPT® or HCPC Codes	Description
--------------------	-------------

**No specific codes**

Date Created	Date Reviewed	Date Last Revised
02/1996	01/05/2010 <sup>MDCRPC</sup> , 11/02/2010 <sup>MDCRPC</sup> , 09/06/2011 <sup>MDCRPC</sup> , 01/03/2012 <sup>MDCRPC</sup> , 11/06/2012 <sup>MDCRPC</sup> , 09/03/2013 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 08/05/2014 <sup>MPC</sup> , 06/02/2015 <sup>MPC</sup> , 04/05/2016 <sup>MPC</sup> , 02/07/2017 <sup>MPC</sup> , 12/05/2017 <sup>MPC</sup> , 10/02/2018 <sup>MPC</sup> , 10/01/2019 <sup>MPC</sup> , 10/06/2020 <sup>MPC</sup> , 10/05/2021 <sup>MPC</sup> , 10/04/2022 <sup>MPC</sup> , 10/03/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	12/05/17

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee<sup>MPC</sup> Medical Policy Committee

Revision History	Description
02/07/2016	MPC approved to adopt MCG guidelines for home health services



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

## High Intensity Focused Ultrasound (HIFU) for the Treatment of Localized Prostate Cancer

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
KPWA Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, KPWA has elected to use <b>MCG* High Intensity Focused Ultrasound (HIFU), Prostate (A-0271)</b> for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

#### For Non-Medicare Members

Kaiser Permanente has elected to use the MCG\* High Intensity Focused Ultrasound (HIFU), Prostate (A-0271) for medical necessity determinations. This service is not covered per MCG guidelines. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist (oncologist, radiologist, primary care provider)
- Most recent imaging

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Prostate cancer is the second most frequently diagnosed cancer across the globe (Wolff et al., 2015). A 2008-2010 data estimated that 15% of men in the United States will be diagnosed with prostate cancer at some point in their lives (Wolff et al., 2015). However, the mortality rate is low because it is a slow growing cancer.



Treatment is based on a number of factors including tumor stage, prostate specific antigen (PSA) value, Gleason score (GS), patient's age, concomitant diseases, life expectancy and patient's preference (Warmuth, Johansson, & Mad, 2010). A wide range of options are available for prostate cancer and these include active surveillance, watchful waiting, radical prostatectomy, hormone therapy, radiotherapy, external beam radiotherapy (EBRT), brachytherapy and chemotherapy (Wolff et al., 2015). High Intensity Focused Ultrasound (HIFU) and cryotherapy are being considered as treatment options.

HIFU is a procedure in which beams target localized tissue without destroying the surrounding tissue and the high energy produced by HIFU leads to coagulative necrosis (Dogra, Zhang, & Bhatt, 2009). Two mechanisms including hyperthermia and acoustic cavitation cause the destruction of the tissue (Kennedy, Ter Haar, & Cranston, 2014). First, high energy is produced and converted to heat as the ultrasound wave disseminates through the tissue. This high energy leads to extreme temperatures surpassing the threshold level of protein denaturation (>43-degree C) resulting in coagulative necrosis. In the surrounding areas of the target zone, temperatures decrease suddenly keeping the outside tissues unaffected. Second, the interaction between ultrasound and micro-bubbles of water in the sonicated tissue result in cavitation. Cavitation may lead to diffusion of energy reinforcing tissue destruction (Stride & Coussios, 2010).

For this procedure, a transducer, covered by a condom through which cooled water is circulated to cool the rectal wall, is inserted into the rectum and several images are taken. The transducers generate very precise small lesions destroying the prostate partially or completely (Cordeiro et al., 2012).

HIFU is non-invasive and non-ionizing technique that is believed to have some advantages over other thermal therapy such as cryotherapy, laser ablation, and photothermal therapy and radiofrequency interstitial tumor ablation (Cordeiro et al., 2012). Two types of systems have been approved by the Food and Drug Administration (FDA). These include the Sonablate 450 (developed by SonaCare Medical) and the Ablatherm HIFU (EDAP TMS SA) both of which received FDA approval in October and November 2015 respectively. HIFU is indicated for primary treatment and salvage treatment for localized prostate cancer.

## Medical Technology Assessment Committee (MTAC)

### *High Intensity Focused Ultrasound (HIFU) for the treatment of localized Prostate Cancer*

**MTAC REVIEW: 06/21/2016**

**Evidence Conclusion:** INTC reviewed the technology in 2008 and concludes that there is insufficient evidence to determine whether the technology is medically appropriate for any patient and that the existing evidence regarding how HIFU treats prostate cancer is of insufficient quantity and quality. In April 2016, INTC conducted another review of the technology and concludes that: "the body of evidence that is available from which to assess the efficacy and safety of HIFU for localized prostate cancer (as primary and salvage therapy) is very low quality. The risk of bias in existing studies is high. Across studies, there is variation and/or lack of information regarding patient selection criteria, how HIFU was delivered, how outcomes were measured, and how long patients were followed"

INTC review can be adopted.

#### **HIFU for Primary and Salvage therapy**

**Systematic Review of the Efficacy and Safety of High-Intensity Focused Ultrasound for the Primary and Salvage Treatment (Warmuth, Johansson, & Mad, 2010)** (evidence table 1) The aim of this study was to assess the efficacy and safety of HIFU in the primary and salvage treatment for prostate cancer. The primary outcomes were the biochemical disease-free survival rate, the negative biopsy rate, overall survival rates, prostate cancer-specific survival rates, adverse events, and QOL. The literature search was performed from 200 to 2010 and included 20 case series (with more than 50 participants) in which 93% of patients were treated with primary therapy and 7% for salvage HIFU. For all HIFU procedures, the biochemical disease-free survival rate was between 78% and 84%, 45%- 84%, and 69% at 1, 5, and 7 years, respectively. The negative biopsy rate was 86% at 3 months and 80% at 15 months. Overall survival rate and prostate-cancer specific survival rate were reported in 1 study and were 90% and 100% at 5 years and 83% and 98% at 8 years, respectively. Adverse events were mainly related to the urinary tract (1-58%), potency (1-77%) and rectum (0-15%). The study has several limitations including the study design lacking control group, long term follow-up was not available and the quality of evidence of included studies was low, surrogate outcomes were used and the central question is whether surrogate outcomes corroborate with overall survival, QOL, and prostate cancer specific survival, and the possibility for publication bias. The evidence is of low quality; therefore, results should be interpreted with caution.

**Ablative therapy for people with localized prostate cancer: a systematic review and economic evaluation (Ramsay et al., 2015)** (evidence table 2) This systematic review indicates that the biochemical failure rate of HIFU was higher (statistically significant) than that of EBRT at 1 year but no statistically significant difference was observed at 5 years. The results also indicate statistically significant lower rate of disease free survival for HIFU compared to EBRT at 1 year. At 4 years, overall survival was better for HIFU compared to EBRT. Compared to RP, there was an increased risk of biochemical failure for HIFU at 1 and 5 years. But this difference was not significant. Also, in term of disease free survival, no statistical significant difference was noted when HIFU was compared to RP at 1 year. At 3 years, the difference was not statistically significant. For urinary incontinence, erectile dysfunction, or bowel problems (not in the table), data were insufficient to reach a conclusion. Results were not statistically significant for dysuria or urinary retention. Nonetheless, high proportion of urethral stricture was observed for HIFU. When comparing HIFU to active surveillance (AS) (not on the table), there was no difference in overall survival or erectile dysfunction. The results are mixed and due to the poor quality of case series included in the review, with the lack of long term findings, the result should be interpreted with caution.

### **HIFU for Salvage therapy**

#### **High intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer (Cordeiro et al., 2012)**

The purpose of this review was to update the available literature on HFU as definitive treatment of prostate cancer and to describe the techniques extensively and give an overview of historical background. Searched was conducted from 200 to December 2011. The search included case series with more than 50 participants assessing efficacy and safety of HIFU. No RCTs were identified and only 33 uncontrolled studies were identified. HIFU as salvage therapy after EBRT was assessed in two case series. The mean age was 68 years with mean preoperative PSA ranged from 6.89 to 7.73 ng/mL and Gleason score (GS) was  $\geq 8$ . Prostate volume preoperatively ranged from 18-21.4 mL; 34-56% received neoadjuvant androgen-deprivation therapy (NADT). Patients were followed for 15-18 months. The negative biopsy rate ranged from 73-80%; patients achieving  $PSA \leq 5$  ng/ml was 61% in one study; the mean PSA Nadir ranged from 1.97-2.38 ng/ml and disease-free survival ranged from 38-53% (30 mos-36mos). In terms of complications, urinary retention represented 7.8%, urinary tract infections (1.4- 3.5%), urinary incontinence (7-31.5%), bladder stenosis (17%), rectal urethral fistula 3 weeks after HIFU (3-6%) and erectile dysfunction was not assessed. The authors concluded that HIFU seems to control cancer on the short to medium term with less adverse events compared to established therapies. There was heterogeneity among the studies; individual studies are case series resulting in low quality evidence. In addition, long term data was not available. Therefore, results should be interpreted with caution.

### **Additional studies**

Subsequent studies (assessing HIFU as primary or salvage therapy) to the systematic reviews aforementioned were non-randomized controlled trial and did not compare HIFU to other treatment options. Accurate conclusions cannot be made from these studies. Summary of additional studies for HIFU as primary therapy: Nine non-RCTs (Aoun et al., 2015; Sebastien Crouzet et al., 2014; Dickinson et al., 2016; Feijoo et al., 2016; Ganzer et al., 2013; Liu & Chiang, 2016; Mearini et al., 2015; Uchida et al., 2015; van Velthoven et al., 2015) were examined and were for the most part observational studies. The sample size ranged from 50 to 1002; follow-up varied from 12 to 108 months. Of the nine studies, only two were comparative (Aoun et al., 2015; Liu & Chiang, 2016) and the findings from these two studies indicate: for Liu, 2016 (HIFU vs. cryoablation), no differences between biochemical recurrence rates were found; for Aoun, 2015 (HIFU vs. brachytherapy), similar survival outcomes were observed with greater biochemical recurrence free survival in the brachytherapy group. Summary of additional studies for HIFU as salvage therapy: Five observational studies (Baco et al., 2014; Sébastien Crouzet et al., 2012; Song et al., 2014; Uddin Ahmed et al., 2012; Yutkin et al., 2014) were examined; the sample size varied from 19 to 290; follow-up ranged from 19.8 months to 51.6 months and there was heterogeneity in the measures of outcomes. The survival rates varied as well.

### **Conclusion:**

- No RCTs comparing HIFU to other treatment options were identified.
- The available evidence is of low quality since it is represented by non-comparative, case series/observational studies.
- The overall concerns are the lack of control group and long-term follow-up, the use of surrogate outcomes raising the question of consistency with overall survival and QOL, and the variations in patient populations and biochemical progression-free survival.
- Conclusion on efficacy and safety of HIFU for the treatment of localized prostate cancer or recurrent localized prostate cancer cannot be drawn at this time.

**Articles:** No RCTs were identified. The following articles are selected for critical appraisal: Systematic Review of the Efficacy and Safety of High-Intensity Focused Ultrasound for the Primary and Salvage Treatment (Warmuth et al., 2010) (evidence table 1) Ablative therapy for people with localized prostate cancer: a systematic review and economic evaluation (Ramsay et al., 2015) (evidence table 2) High intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer (Cordeiro et al., 2012)

The use of High Intensity Focused Ultrasound (HIFU) for the treatment of localized Prostate Cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
<b>55880</b>	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance
<b>C9734</b>	Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (MR) guidance

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
07/05/2016	07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup>	12/19/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/02/2017	Adopted MCG A-0271
05/02/2017	Adopted Non-Medicare policy for Medicare members
03/16/2021	Added new CPT code 55880 effective 1/1/2021
01/07/2022	Removed diagnosis codes for HIFU
12/19/2024	Updated applicable code



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria High-End Imaging Site of Care Medical Policy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

This policy does not apply to Medicare members.

#### For Non-Medicare Members

A high-tech imaging service (i.e., MRI, MRA, CT, CTA, PET, PET CT) must meet applicable medical necessity criteria for coverage. When coverage criteria are met for the requested imaging procedure, this coverage policy is used to help determine the medical necessity of the requested site of care for ambulatory, non-emergent imaging.

A high-tech imaging procedure in a *hospital-based* imaging department or facility is considered medically necessary for an individual with **ANY** of the following indications:

- Less than 13 years of age (PET scan less than 17 years of age)
- Requires obstetrical observation
- Requires perinatology services
- Imaging related to transplantation services at an approved transplantation facility
- Patient is enrolled in an approved clinical trial and trial protocol requires imaging to be done at this site
- Known contrast allergy and use of that contrast agent is planned
- There are no other appropriate alternative sites for the individual to undergo the imaging procedure for **ANY** of the following reasons:
  - A covered surgery or procedure will be performed at a specific hospital and pre-operative or pre-procedure imaging must be done at the same hospital, as the image is an integral component of the procedure and the protocol is unique to the institution or image interpretation requires specialized Radiology expertise not routinely available outside the hospital setting. This is not common. Examples would include epilepsy surgery where ablation of specific areas is planned; or pre TAVR insertion in certain geographies; breast reconstruction involving deep flaps that require unique imaging protocols and specialized Radiology expertise to identify vascular supply. There must be documentation of a medically necessary reason the images cannot be performed at a freestanding facility and transmitted to the hospital and/or surgeon for pre op planning or in the OR.
  - To maintain continuity within an episode of care, hospital-based imaging is medically necessary when performed within 6 weeks of a hospital-based operation or procedure and non-hospital-based imaging is not available in the same care delivery system (e.g., drain management)
  - Moderate or deep sedation or general anesthesia is required for the imaging procedure and freestanding facility providing such sedation is not available
  - Equipment for the size of the individual is only available at a hospital-based imaging facility
  - Individual has a documented diagnosis of claustrophobia requiring open magnetic resonance imaging which is not available in a freestanding facility; or
  - Imaging outside the hospital-based imaging department or facility is expected to adversely impact or delay care.
  - The patient has a pacemaker that requires coordination, monitoring, and a code team onsite during the MRI, which are not available at a nearby freestanding site\*

All other high-tech radiology (imaging) procedures at a hospital-based imaging department or facility are considered not medically necessary (including but not limited to pre-procedural planning for elective procedures, robotic assisted surgeries, etc.). In the absence of one of the above circumstances, it would be expected that non hospital-based locations would be used, such as a clinic or free-standing imaging centers. Hospital-based imaging departments may be authorized if there is no appropriate geographically accessible free-standing imaging center.

\*Kaiser Permanente can provide this at multiple sites

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Hospital-based advanced radiologic imaging procedures are generally more appropriate for individuals whose health status necessitates the availability of more supportive care for the minimization of the risks associated adverse health events.

Certain high-risk medical conditions can necessitate the need for an anesthesiologist to be present during the advanced radiologic imaging for individuals including neonates and children. Children can require specialized pediatric equipment including smaller anesthetic tools such as endotracheal tubes and monitoring equipment. Conversely, large individuals or those with claustrophobia may also require specialized equipment which could include an open magnetic resonance imaging (MRI) as opposed to a traditional MRI scanner.

Examples of advanced radiologic imaging include computed tomography, computed tomography angiography, magnetic resonance imaging, magnetic resonance angiography.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

### Computed Tomography (CT) and Computed Tomographic Angiography (CTA)

CPT® or HCPC Codes	Description
70450	Computed tomography, head or brain; without contrast material
70460	Computed tomography, head or brain; with contrast material(s)
70470	Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections
70496	Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing
70480	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material
70481	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; with contrast material(s)
70482	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material, followed by contrast material(s) and further sections
70486	Computed tomography, maxillofacial area; without contrast material
70487	Computed tomography, maxillofacial area; with contrast material(s)
70488	Computed tomography, maxillofacial area; without contrast material, followed by contrast material(s) and further sections
70490	Computed tomography, soft tissue neck; without contrast material
70491	Computed tomography, soft tissue neck; with contrast material(s)



<b>70492</b>	Computed tomography, soft tissue neck; without contrast material followed by contrast material(s) and further sections
<b>70498</b>	Computed tomographic angiography, neck, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>71250</b>	Computed tomography, thorax, diagnostic; without contrast material
<b>71260</b>	Computed tomography, thorax, diagnostic; with contrast material(s)
<b>71270</b>	Computed tomography, thorax, diagnostic; without contrast material, followed by contrast material(s) and further sections
<b>71271</b>	Computed tomography, thorax, low dose for lung cancer screening, without contrast material(s)
<b>71275</b>	Computed tomographic angiography, chest (noncoronary), with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>72125</b>	Computed tomography, cervical spine; without contrast material
<b>72126</b>	Computed tomography, cervical spine; with contrast material
<b>72127</b>	Computed tomography, cervical spine; without contrast material, followed by contrast material(s) and further sections
<b>72128</b>	Computed tomography, thoracic spine; without contrast material
<b>72129</b>	Computed tomography, thoracic spine; with contrast material
<b>72130</b>	Computed tomography, thoracic spine; without contrast material, followed by contrast material(s) and further sections
<b>72131</b>	Computed tomography, lumbar spine; without contrast material
<b>72132</b>	Computed tomography, lumbar spine; with contrast material
<b>72133</b>	Computed tomography, lumbar spine; without contrast material, followed by contrast material(s) and further sections
<b>72191</b>	Computed tomographic angiography, pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>72192</b>	Computed tomography, pelvis; without contrast material
<b>72193</b>	Computed tomography, pelvis; with contrast material(s)
<b>72194</b>	Computed tomography, pelvis; without contrast material, followed by contrast material(s) and further sections
<b>73200</b>	Computed tomography, upper extremity; without contrast material
<b>73201</b>	Computed tomography, upper extremity; with contrast material(s)
<b>73202</b>	Computed tomography, upper extremity; without contrast material, followed by contrast material(s) and further sections
<b>73206</b>	Computed tomographic angiography, upper extremity, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>73700</b>	Computed tomography, lower extremity; without contrast material
<b>73701</b>	Computed tomography, lower extremity; with contrast material(s)
<b>73702</b>	Computed tomography, lower extremity; without contrast material, followed by contrast material(s) and further section
<b>73706</b>	Computed tomographic angiography, lower extremity, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>74150</b>	Computed tomography, abdomen; without contrast material
<b>74160</b>	Computed tomography, abdomen; with contrast material(s)
<b>74170</b>	Computed tomography, abdomen; without contrast material, followed by contrast material(s) and further sections
<b>74174</b>	Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>74175</b>	Computed tomographic angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>74176</b>	Computed tomography, abdomen and pelvis; without contrast material
<b>74177</b>	Computed tomography, abdomen and pelvis; with contrast material(s)
<b>74178</b>	Computed tomography, abdomen and pelvis; without contrast material in one or both body regions, followed by contrast material(s) and further sections in one or both body regions
<b>75571</b>	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium



<b>75572</b>	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)
<b>75573</b>	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)
<b>75574</b>	Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)
<b>75635</b>	Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing
<b>76380</b>	Computed tomography, limited or localized follow-up study
<b>S8092</b>	Electronic beam computed tomography (also known as ultrafast CT, cine CT)

**Magnetic Resonance Angiography (MRA)**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>70544</b>	Magnetic resonance angiography, head; without contrast material(s)
<b>70545</b>	Magnetic resonance angiography, head; with contrast material(s)
<b>70546</b>	Magnetic resonance angiography, head; without contrast material(s), followed by contrast material(s) and further sequences
<b>70547</b>	Magnetic resonance angiography, neck; without contrast material(s)
<b>70548</b>	Magnetic resonance angiography, neck; with contrast material(s)
<b>70549</b>	Magnetic resonance angiography, neck; without contrast material(s), followed by contrast material(s) and further sequences
<b>72159</b>	Magnetic resonance angiography, spinal canal and contents, with or without contrast material(s)
<b>71555</b>	Magnetic resonance angiography, chest (excluding myocardium), with or without contrast material(s)
<b>74185</b>	Magnetic resonance angiography, abdomen, with or without contrast material(s)
<b>72198</b>	Magnetic resonance angiography, pelvis, with or without contrast material(s)
<b>73225</b>	Magnetic resonance angiography, upper extremity, with or without contrast material(s)
<b>73725</b>	Magnetic resonance angiography, lower extremity, with or without contrast material(s)
<b>C8900</b>	Magnetic resonance angiography with contrast, abdomen
<b>C8901</b>	Magnetic resonance angiography without contrast, abdomen
<b>C8902</b>	Magnetic resonance angiography without contrast followed by with contrast, abdomen
<b>C8909</b>	Magnetic resonance angiography with contrast, chest (excluding myocardium)
<b>C8910</b>	Magnetic resonance angiography without contrast, chest (excluding myocardium)
<b>C8911</b>	Magnetic resonance angiography without contrast followed by with contrast, chest (excluding myocardium)
<b>C8912</b>	Magnetic resonance angiography with contrast, lower extremity
<b>C8913</b>	Magnetic resonance angiography without contrast, lower extremity
<b>C8914</b>	Magnetic resonance angiography without contrast followed by with contrast, lower extremity
<b>C8918</b>	Magnetic resonance angiography with contrast, pelvis
<b>C8919</b>	Magnetic resonance angiography without contrast, pelvis
<b>C8920</b>	Magnetic resonance angiography without contrast followed by with contrast, pelvis
<b>C8931</b>	Magnetic resonance angiography with contrast, spinal canal and contents
<b>C8932</b>	Magnetic resonance angiography without contrast, spinal canal and contents
<b>C8933</b>	Magnetic resonance angiography without contrast followed by with contrast, spinal canal and contents
<b>C8934</b>	Magnetic resonance angiography with contrast, upper extremity
<b>C8935</b>	Magnetic resonance angiography without contrast, upper extremity
<b>C8936</b>	Magnetic resonance angiography without contrast followed by with contrast, upper extremity

**Magnetic Resonance Imaging (MRI)**

<b>CPT® or HCPC Codes</b>	<b>Description</b>
<b>70336</b>	Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)
<b>70540</b>	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)
<b>70542</b>	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; with contrast material(s)
<b>70543</b>	Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences
<b>70551</b>	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material
<b>70552</b>	Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material(s)
<b>70553</b>	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences
<b>70554</b>	Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration
<b>70555</b>	Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing
<b>71550</b>	Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s)
<b>71551</b>	Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); with contrast material(s)
<b>71552</b>	Magnetic resonance (eg, proton) imaging, chest (eg, for evaluation of hilar and mediastinal lymphadenopathy); without contrast material(s), followed by contrast material(s) and further sequences
<b>72141</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; without contrast material
<b>72142</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, cervical; with contrast material(s)
<b>72146</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; without contrast material
<b>72147</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, thoracic; with contrast material(s)
<b>72148</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; without contrast material
<b>72149</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, lumbar; with contrast material(s)
<b>72156</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical
<b>72157</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic
<b>72158</b>	Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar
<b>72195</b>	Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s)
<b>72196</b>	Magnetic resonance (eg, proton) imaging, pelvis; with contrast material(s)
<b>72197</b>	Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences
<b>73218</b>	Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s)
<b>73219</b>	Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; with contrast material(s)
<b>73220</b>	Magnetic resonance (eg, proton) imaging, upper extremity, other than joint; without contrast material(s), followed by contrast material(s) and further sequences
<b>73221</b>	Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s)
<b>73222</b>	Magnetic resonance (eg, proton) imaging, any joint of upper extremity; with contrast material(s)
<b>73223</b>	Magnetic resonance (eg, proton) imaging, any joint of upper extremity; without contrast material(s), followed by contrast material(s) and further sequences

<b>73718</b>	Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s)
<b>73719</b>	Magnetic resonance (eg, proton) imaging, lower extremity other than joint; with contrast material(s)
<b>73720</b>	Magnetic resonance (eg, proton) imaging, lower extremity other than joint; without contrast material(s), followed by contrast material(s) and further sequences
<b>73721</b>	Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material
<b>73722</b>	Magnetic resonance (eg, proton) imaging, any joint of lower extremity; with contrast material(s)
<b>73723</b>	Magnetic resonance (eg, proton) imaging, any joint of lower extremity; without contrast material(s), followed by contrast material(s) and further sequences
<b>74181</b>	Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s)
<b>74182</b>	Magnetic resonance (eg, proton) imaging, abdomen; with contrast material(s)
<b>74183</b>	Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences
<b>76391</b>	Magnetic resonance (eg, vibration) elastography
<b>77046</b>	Magnetic resonance imaging, breast, without contrast material; unilateral
<b>77047</b>	Magnetic resonance imaging, breast, without contrast material; bilateral
<b>77048</b>	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; unilateral
<b>77049</b>	Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral
<b>77084</b>	Magnetic resonance (eg, proton) imaging, bone marrow blood supply
<b>C8903</b>	Magnetic resonance imaging with contrast, breast; unilateral
<b>C8905</b>	Magnetic resonance imaging without contrast followed by with contrast, breast; unilateral
<b>C8906</b>	Magnetic resonance imaging with contrast, breast; bilateral
<b>C8908</b>	Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral

**PET Scan**

<b>CPT® Codes</b>	<b>Description</b>
<b>78811</b>	Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck)
<b>78812</b>	Positron emission tomography (PET) imaging; skull base to mid-thigh
<b>78813</b>	Positron emission tomography (PET) imaging; whole body
<b>78814</b>	Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck)
<b>78815</b>	Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh
<b>78816</b>	Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; whole body
<b>78608</b>	Brain imaging, positron emission tomography (PET); metabolic evaluation
<b>78609</b>	Brain imaging, positron emission tomography (PET); perfusion evaluation
<b>78429</b>	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan
<b>78459</b>	Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study;
<b>78430</b>	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan
<b>78491</b>	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic)
<b>78492</b>	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic)

<b>78431</b>	Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan
<b>78432</b>	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability);
<b>78433</b>	Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan
<b>78434</b>	Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/23/2020	01/05/2021 <sup>MPC</sup> , 01/03/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	05/07/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/26/2021	Clarifying language added to specify that the policy applies to non-emergent, ambulatory high-tech imaging requests.
05/20/2021	Updated policy effective date to 08/01/2021.
07/08/2021	Updated policy effective date to 09/01/2021.
04/25/2022	Updated applicable codes to include related HCPCS codes. Requires a 60-day notice, effective date 09/01/2022.
06/07/2022	MPC approved the updates to the alternative sites section of the criteria; updated MRI codes
07/14/2022	Added clarifying language for pre TAVR insertion in certain geographies
07/11/2023	MPC approved the modifications to the existing HEI Imaging Site of Care criteria to allow continuity of care for patients who have already started treatment at a higher level of care and require imaging within the same healthcare system. Requires 60-day notice. Effective date 12/01/2023.
05/07/2024	MPC approved the addition of PET scan to the High-End Imaging Site of Care criteria, effective October 1 <sup>st</sup> , 2024. 60-day notice required.
09/25/2024	Clarified age intent for PET scans related to this policy.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Hip Arthroscopy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>Hip Arthroscopy</b> ," for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Service	Criteria
Hip Arthroscopy	Reviewed for <a href="#">Site of Care/Level of Care</a> <b>AND</b> Kaiser Permanente has elected to use the MCG* <b>Hip Arthroscopy KP-S-572 02012025</b> for medical necessity determinations.

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service (or these services), please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Hip arthroscopy is a minimally invasive surgical procedure that allows surgeons to view the hip joint without making a large incision through skin and other soft tissues. Using a small camera called an arthroscope, hip arthroscopy is used to diagnose and treat a wide range of hip problems.

The hip joint is a ball-and-socket joint. The top of the femur (thighbone) is the ball that rests in the acetabulum (socket) which creates a smooth frictionless surface that helps the bones glide easily across each other. The acetabulum is surrounded by strong fibrocartilage called the labrum, bands of tissue called ligaments, and a thin membrane called the synovium. The labrum supports the joint by creating stability. The ligaments hold the joint together. The synovium produces synovial fluid that lubricates the hip joint.

Hip arthroscopy may be recommended when there is a painful condition that does not respond to conservative, non-surgical treatment. Non-surgical treatment includes the use of medication, rest, heat or cool therapy, physical therapy or injections to reduce inflammation. (Alaia et al., 2022)

References

Alaia, Mi. J., Byrd, J. W. T., Throckmorton, T. W., Wilderson, R., & Fischer, S. J. (2022, October). Hip arthroscopy - orthoinfo - AAOS. OrthoInfo. <https://orthoinfo.aaos.org/en/treatment/hip-arthroscopy/>

Applicable Codes

Considered Medically Necessary when criteria in the applicable policy statements listed above are met  
Reviewed for MNR and SOC/level of care

CPT® or HCPC Codes	Description
29860	Arthroscopy, hip, diagnostic with or without synovial biopsy (separate procedure)
29861	Arthroscopy, hip, surgical; with removal of loose body or foreign body
29862	Arthroscopy, hip, surgical; with debridement/shaving of articular cartilage (chondroplasty), abrasion arthroplasty, and/or resection of labrum
29863	Arthroscopy, hip, surgical; with synovectomy
27299	Unlisted procedure, pelvis or hip joint
29916	Arthroscopy, hip, surgical; with labral repair
29999	Unlisted procedure, arthroscopy

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions, and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/03/2024	09/03/2024 <sup>MPC</sup> ,	09/03/2024

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/03/2024	MPC approved to adopt coverage for Hip Arthroscopy using KP-S-572 02012025 for medical necessity determinations. 60-day notice is required; effective February 1, 2025.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Prometheus Lab Testing

- Anser™ ADA for Adalimumab (Humira) Antibodies
- Anser™ IFX test for Infliximab (Remicade) Antibodies
- Anser VDZ (Vedolizumab)
- IBD SGI Diagnostic Test

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<a href="#">MoIDX: Prometheus IBD sgi Diagnostic Policy (L37313)</a> This service is not covered per Noridian LCD.
Local Coverage Article	<a href="#">Billing and Coding: MoIDX: Prometheus IBD sgi Diagnostic Policy (A57517)</a>
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance specific to Anser antibody levels for infliximab or adalimumab, Kaiser Permanente has chosen to use their own Clinical Review Criteria, "Prometheus Testing," for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

Service	Criteria
Anser antibody levels for infliximab or adalimumab	Anser antibody levels for infliximab or adalimumab can be approved under <b>ALL of the following</b> conditions: <ol style="list-style-type: none"> <li>1. Ordered by a gastroenterologist</li> <li>2. Is being ordered as a consideration of changing to alternate therapy in the setting of a concern for loss of response</li> </ol>
Homogenous Mobility Shift Assay (HMSA) Anser VDZ (Vedolizumab) Prometheus IBD sgi Diagnostic Test	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

### Background

Many chronic inflammatory diseases are mediated by up-regulation of the pro-inflammatory cytokine tumor necrosis factor-alpha ((TNF)-α. Protein-based drugs that block TNF-α such as Infliximab (IFX), are effective in

reducing the disease activity of these inflammatory disorders. IFX is a chimeric mouse-human monoclonal antibody approved by the FDA for the treatment of patients with Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. IFX is highly effective in inducing and maintaining remission in a large proportion of these patients. However, more than 30% of cases fail to respond to anti-TNF- $\alpha$  therapy, and 20-60% of those who initially respond, lose their clinical response over time despite maintenance treatment. This loss of response (LOR) usually requires escalation of the dose, shortening the interval between doses, change in the anti-TNF agent to regain the clinical remission, or switching to a non-anti-TNF therapy (Wang 2012, Nanda 2013, Wang 2013, FDA web page accessed August 26, 2013).

The reason for loss of response to IFX is still debatable, but the anti-drug antibody formation is believed to play an important role. IFX is a chimeric mouse/human IgG1 molecule and thus the antibodies are primarily directed against the murine fragment. Antibodies to IFX (ATI), also frequently called human antichimeric antibodies (HACAs), are reported to develop in up to approximately 60% of patients depending on the dosing schedule, administration of concurrent steroids or immunomodulators, and the method of measuring the antibodies in the blood. The antibodies can appear as soon as after the first IFX dose and can persist in the blood for up to 4.5 years even after discontinuation of the therapy. ATI may increase the drug clearance in treated patients and/or neutralize its effect. Researchers found that a lower serum IFX levels is associated with a significantly higher risk of loss of clinical response to the drug. This loss of clinical response and remission due to immunogenicity is a potential major limitation to IFX leading to clinical relapse, impaired quality of life, and increased cost of care. Anti-drug antibodies may also cause serum sickness and hypersensitivity reactions. Despite these observed associations, some researchers dispute the clinical relevance of anti-infliximab antibodies and question whether the presence of antibodies to TNF agents is directly correlated to the decreased efficacy. To date, there is insufficient knowledge about the factors influencing the formation of the antibodies, and on whether the immune reaction to IFX can be transient. It is assumed however, that once the antibody is initiated, it cannot be overcome (Afif 2010, Kopylov 2012, Vande Casteele 2013, Nanda 2013, Wang 2013).

It is suggested that accurate monitoring of the serum drug and anti-drug antibody levels should be an important part of therapy in patients receiving anti TNF- $\alpha$  drugs. However, there is no gold standard technique or test for the detection and quantitative measurement of anti-infliximab antibodies (ATI). Anti-drug antibodies and drug levels in the serum are assessed by the bridging ELISA method, or less commonly by the radioimmunoassay (RIA) method. Each of these two methods has its limitations; the main limitation of the bridge ELISA method is its inability to accurately detect the antibodies in the presence of the drug in the circulation due to cross interference between the drug and the assay. This lowers the sensitivity of the test in detecting antibodies in the presence of IFX. Thus, ELISA can accurately measure the anti-drug antibodies only when there is no drug in the circulation, which limits its clinical utility. RIA method is limited by its complexity, safety concerns of handling radioactive material, and prolonged time needed to reach equilibrium for proper management (Wang 2012).

A novel Homogenous Mobility Shift Assay (HMSA) was recently developed and validated by group of researchers In San Diego (Wang and colleagues 2012) to quantitatively measure the induced ATI and IFX levels in serum samples of patients treated with infliximab. The Anser <sup>TM</sup>IFX test is not ELISA-based and is believed to be able to measure both the serum concentrations of infliximab and infliximab antibodies in the presence of serum infliximab. In the HMSA, serum samples are acidified during sample preparation to dissociate drug-anti-drug-antibody (IFX-ATI) complexes, thereby allowing the detection of ATI in the presence of IFX and overcoming the limitation of bridge ELISA (Casteele 2013).

## Medical Technology Assessment Committee (MTAC)

### Homogenous Mobility Shift Assay (HMSA)

#### 10/21/2013: MTAC REVIEW

**Evidence Conclusion: Analytic validity** There is insufficient evidence to determine the analytic validity of the existing tests for measuring the antibodies to IFX. There is no gold standard technique for anti-infliximab antibodies (ATI) measurement and comparing the technical performance and accuracy of ATI assays in detecting ATI in the presence of IFX may be problematic. As indicated in the introduction the ELISA and RIA have their limitations, and there are no standards available for comparison. Several confounding factors can influence the measurement of these antibodies, and in turn the accuracy and reproducibility of the test. **Clinical validity** The results of studies that examined the association between ATI and clinical efficacy of IFX are inconsistent. While some studies showed that detectable levels of ATI using different ELISA methods or RIA were correlated with low concentrations or undetectable trough levels of IFX and higher rates of loss of response to IFX treatment, others showed no significant effect of ATI on loss of response. Two published meta-analyses (Lee et al, 2012 and Nanda et al, 2013) had conflicting results. Both had their limitations and pooled the results of randomized trials together with observational studies. In these studies, ATI was measured at one time point which may not capture

its possible fluctuating, transient, or latent occurrence; different methods and assays, mainly ELISA, were used to measure ATI with no standardization; patients were on different IFX regimes (episodic or maintenance); and immunosuppressants were used among some, but not all patients. Lee et al' (2012), meta-analysis pooled the results of 18 studies to determine the prevalence of ATI, its effect on perfusion reactions and on disease remission rates among IBD patients treated with infliximab. The analysis included 9 RCTs, 5 cohort studies, and 4 retrospective studies with a total of 3,326 patients. The pooled results showed that patients who tested positive for ATI (using ELISA) were at increased risk of infusion reactions (RR= 2.07 [95% CI, 1.61-2.67]), but with no significant difference in the rates of remission compared to those who tested negative for ATI (RR=0.90, 95% CI 0.79-1.02). On the other hand, the pooled results of the more recent meta-analysis (Nanda et al, 2013) of 13 studies involving 1,378 patients with IBD showed that the presence of ATI was associated with lower IFX serum levels and significantly higher risk of loss of clinical response (LOR) to IFX with a pooled risk ratio for LOR = 3.2 (2.0-4.9). The ATI was measured by different methods including double antigen ELISA, antihuman chain ELISA, immunochromatography-based ELISA, fluid-phase RIA, and western blot. The results of the meta-analysis, however, have to be interpreted with caution due to the high risk of bias in the studies included, significant heterogeneity between studies, publication bias, and combining the results of randomized studies together with of observational studies. In addition, there were differences between studies in the method of assessing ATI, IFX dosing regimens, immunosuppressants use, and assessment of clinical response. The Anser IFX (HMSA) Wang and colleagues (2012) developed and validated a homogenous mobility shift assay (HMSA) to measure the serum levels of infliximab (IFX) and antibodies to IFX (ATI). They compared the performance of the newly developed IFX-HMSA to bridge ELISA and measured the ATI levels with the new test in 100 patients with ELISA positive ATI and found a high correlation between the two methods. HMSA identified five false-positive samples from the bridging ELISA method. Intra-and inter-assay precision rates for ATI were <4% and <15% respectively which, are considered high. The cutoff point of the assay was determined using sera of 100 healthy subjects who were naïve to IFX. The mean values of ATI in patient serum samples were significantly higher than those in the drug naïve health controls (mean  $\pm$ SD=9.57+11.43, vs. 0.73  $\pm$  0.29,  $p$ <0.0001). The area under the curve (AUC) was 0.986, the sensitivity was 95% (95% CI, 88.72-98.36%) The authors concluded that the HMSA-IFX method showed a high assay sensitivity, precision and accuracy. However, validation was performed by using bridging ELISA methodology which can only accurately measure the anti-drug antibodies when there is no drug in the circulation.

*Clinical utility-* In a retrospective study, Afif and colleagues (2010) evaluated the clinical utility of measuring Human Anti-Chimeric Antibody (HACA) concentration in patients with IBD treated with infliximab. They used recorded data for 155 patients treated in one center (from 2003-2008) who had ATI and IFX concentrations measured. Testing for IFX and ATI levels was performed by ELISA at the discretion of the treating physician with no systematic strategy and was not done for all patients receiving IFX. 72% of the initial tests were ordered by a single physician, and the assay(s) used were not defined. Indications for testing were mainly due to loss of response (49%), partial response (22%) and autoimmune or delayed hypersensitivity reaction (10%). There was no control or comparison group and according to the authors, the study population represented only a subset of the total population receiving IFX at the clinic, and the clinical response was abstracted through review of patients' charts using predefined clinical criteria. The use of validated instruments as Crohn's disease Activity Index, Harvey-Bradshaw Index and endoscopic improvement could not be obtained retrospectively. 47% of the patients were on immunosuppressives, and 43 patients (29%) had the dose or frequency of IFX increased before testing. 35 patients had positive ATI based on which, the dose was increased in 6 patients, and 12 were put on a different anti-TNF. The overall results suggest that change to another anti-TNF in these ATI positive patients was associated with a significantly higher complete or partial response than those who received a dose escalation (92% vs. 17%). The authors concluded that measurement of ATI and IFX concentrations had an impact on management and was clinically useful. These results have to be interpreted with caution due to the study design and its imitations. In addition, there was no control group to determine whether any change in management in the absence of ATI measurement would have a similar or different clinical outcome. It also to be noted that 29% of the patients had the dose or frequency of IFX increased before testing. A more recent study (Vande Casteele and colleagues, 2013), used the new HMSA to retrospectively measure 1,232 consecutive frozen serum samples of 90 patients with IBD treated in one center from 1999-2011. The HMSA confirmed ATI in 59% of the patients, this was transient (disappeared by time) in 28% and was sustained in 72% of the patients. All treatment decisions to optimize and to stop therapy were based on clinical grounds and C-reactive protein level without knowledge of infliximab trough levels (TLI) or ATI status. The results of the analysis show that 68% of the patients with sustained ATI needed to discontinue IFX treatment vs. 13% with transient ATI (RR 5.1, 95% CI, 1.4-19.0). The overall results suggest, but do not provide good evidence that ATI may be transient, and that optimizing the IFX dose in patients with low-level ATI may be useful. It also indicates that sustained ATI increases the risk of loss of response to IFX. Based on these results, the authors recommended measuring IFX trough levels at week 14 and at time of loss of treatment response, and only measure ATI at consecutive time points when the trough levels of IFX are undetectable or low. These results have to be interpreted with caution due to the nature of the study and

its limitations. In conclusion there is insufficient evidence to determine analytic and clinical validity of HMSA in detecting ATI to IFX. There is also inconclusive evidence to determine that ATI measurement has a significant impact on management of patients treated with infliximab or significant effect on clinical outcomes.

**Articles:** The published literature on the validity and clinical utility of measuring the antibodies to infliximab (ATI) levels among patients treated with IFX agent is limited. The therapeutic effect of IFX and measuring of the drug and antibody levels were mainly studied for patients with inflammatory bowel disease (IBD). The search revealed one study on the development and validation of a HMSA test, two meta-analyses on the impact of anti-IFX among IBD patients, two observational retrospective studies on clinical utility of measuring the anti-chimeric antibody concentration (ACAC), as well two studies that compared different ELISA methods in their ability to detect ATI. The meta-analysis with more valid methodology, the validation study on the new Anser IFX (HMSA) test, and the larger observational study on the clinical utility of detecting ATI were selected for critical appraisal, Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. *Am J Gastroenterol*. 2010; 105: 1133-1139. [See Evidence Table](#). Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. *Am J Gastroenterol*. 2013; 108:962-971. [See Evidence Table](#). Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. *Eur J Gastroenterol Hepatol*. 2012; 24:1078-1085. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. *Am J Gastroenterol*. 2013; 108:40-47. [See Evidence Table](#). Wang SL, Ohrmund L, Hauenstein S, et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. *J Immunol Methods*. 2012; 382:177-188.

The use of Homogenous Mobility Shift Assay (HMSA) (Anser TM IFX test) for Infliximab Antibodies does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Prometheus IBD sgi Diagnostic

### 10/17/2017: MTAC REVIEW

**Evidence Conclusion:** **Analytic validity:** No studies were identified **Clinical validity:** One study (Lawrence et al., 2015) with low evidence was reviewed. Fifty patients with symptoms of IBD and glycogen storage disease (GSD) type Ib were enrolled consecutively. Of 50 patients who were screened using Prometheus IBD, 11 (22%) tested positive for IBD. Of 11 patients who tested positive, 5 were Crohn's Disease, 5 were ulcerative colitis, and one was non-IBD. However, the major limitations included the sample size, lack of reference test (no test had been performed to confirm the diagnosis of IBD), non-randomized design of the study. **Clinical utility:** No studies were identified.

#### Conclusion:

- No studies assessing analytic validity or clinical utility were identified
- Only one study with non-randomized design and small sample size assessed clinical validity
- There is insufficient evidence to support for or against the use of Prometheus IBD sgi Diagnostic test for patients who present with symptoms of IBD

**Articles:** The search yielded 18 articles, none of which were relevant except one study (Lawrence, Chengsupanimit, Brown, & Weinstein, 2015) with low evidence.

The use of Prometheus IBD sgi Diagnostic does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met** (Anser antibody levels for infliximab or adalimumab):

CPT® or HCPC Codes	Description
84999	Unlisted chemistry procedure

**Considered Not Medically Necessary when requested/submitted as a panel** (IBD sgi Diagnostic Test):

CPT® or HCPC Codes	Description
--------------------	-------------

<b>83520</b>	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
<b>82397</b>	Chemiluminescent assay
<b>86140</b>	C-reactive protein;
<b>88346</b>	Immunofluorescence, per specimen; initial single antibody stain procedure
<b>88350</b>	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)
<b>81479</b>	Unlisted molecular pathology procedure

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

<b>Creation Date</b>	<b>Date Reviewed</b>	<b>Date Last Revised</b>
12/03/2013	12/03/2013 <sup>MPC</sup> , 1/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 10/01/2024 <sup>MPC</sup>	02/02/2021

<sup>MPC</sup> Medical Policy Committee

<b>Revision History</b>	<b>Description</b>
05/02/2017	Adopted KPWA medical policy for Medicare members
06/06/2017	MPC approved medical necessity criteria for Anser Antibody testing
02/06/2018	Added MTAC review for Prometheus IBD sgi Diagnostic
02/02/2021	Added Medicare/Noridian LCD and LCA for IBD sgi Diagnostic Test





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Home INR Monitoring

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation Management (190.11)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	<a href="#">Home PT/INR Monitoring (G0249) Billing and Coding (A55756)</a>

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Prothrombin Time (INR) Home Monitoring Device (A-0650) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Documentation of initial start date for warfarin
- Last 6 months of clinical notes from requesting provider &/or specialist (orthopedics, cardiology)

Home testing is usually not recommended for a frequency of more than once a week.

Additional software or hardware required for downloading data from home prothrombin time testing systems to computers for the management of anticoagulation will not be covered because each is considered a convenience item and not medically necessary.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Oral anticoagulation (OAC) therapy is used for the prophylaxis and /or treatment of thromboembolic complications of deep vein thrombosis, embolic stroke, pulmonary embolism, cardiac valve replacement, and atrial fibrillation, as well as postmyocardial infarction. The aim of the therapy is to maintain a level of anticoagulation that will prevent thromboembolic events without increasing the risk of hemorrhagic complications. Warfarin is an oral anticoagulant that interferes with the cyclic interconversion of vitamin K which in turn leads to depletion its dependant coagulation factors including prothrombin. It is estimated that more than a million patients are treated annually with warfarin in the USA (Koerner 1998).

In the USA, almost 40,000 mechanical heart valves are implanted annually. Mechanical valves are associated with a risk of thrombus formation and emboli. This risk is reduced by lifetime treatment with oral anticoagulants. Biologic implants on the other hand, have a lower thrombogenicity and do not require long-term anticoagulation. Thromboembolism, together with anticoagulant-induced hemorrhage, account for three fourths of all complications after mechanical heart valve replacement. These events were found to be associated with the intensity of oral anticoagulation therapy and fluctuation of international normalized ratio (INR) values. (Edmunds 1987).

Atrial fibrillation (AF), a common arrhythmia, is a leading cause of thromboembolism. It is common among the elderly, and its prevalence increases with age (1% among 60-year-old population, 5% among those aged 70-75 and >10% for 80+ years patients. (Ezekowitz 1999). The incidence of ischemic stroke among these patients may be as much as six times higher than among others with no AF. Studies show that oral anticoagulants significantly reduce the rate of stroke among AF patients (Eldor 2002). However, older patients treated with OAC have a higher rate of bleeding mainly due to the slower metabolism of the drug, and its interaction with other underlying chronic health problems. These patients should thus have better monitoring, and more rigorous regulation of the OAC to optimize their therapy, and prevent intracerebral hemorrhages, and other bleeding complications.

The intensity of anticoagulation treatment also needs to be controlled closely due to the narrow therapeutic range of warfarin, the potentially life-threatening effects of both over, and under-dosing, and its interaction with other drugs or foods like leafy green vegetables. Several other factors may affect the patients' response to warfarin control including compliance to therapy, underlying liver or kidney diseases, infections, diet, and others.

Oral anticoagulation therapy has been monitored for almost 50 years with the prothrombin time (PT) test. The test is easy to perform but its results may widely vary between institutions, and even within the same institution. In 1983 the WHO proposed the international normalized ratio (INR) in attempt to standardize PT measurements. The proposal was supported by the International Committee for Standardization in Hematology in 1985, and INR is the current standard for monitoring anticoagulation therapy. It is calculated as:  $INR = \text{patient PT} / \text{mean normal PT}$ . The recommended therapeutic INR range for oral anticoagulant therapy is 2.0-3.0 for the majority of indications. A higher range of 2.5-3.5 is recommended for patients with mechanical heart valves, and when therapy is recommended to prevent recurrent MI (Koerner 1998). Monitoring patients on OAC requires frequent testing, which in turn requires frequent venous punctures, and regular visits to a physicians' office or lab, as well as lab standardization. Patients on a stable OAC are seen every 4-6 weeks. It was found that at this rate of testing, 40-60% of the PT measurements fall in the desired therapeutic range (Hortskotte, 1998).

Patients using long-term OAC usually worry about complications, regular visits to the physician or lab, frequent venous punctures that may be difficult at times, dietary limitations, freedom at traveling, and other concerns that may affect their quality of life. There has always been an interest in developing an accurate faster and easier way to measure PT. Currently several monitors for finger stick testing of PT are available. These include CoaguChek, CoaguChek plus, ProTime Microcoagulation System, and Harmony INR Monitoring System. These monitors require only a finger stick whole blood rather than the citrated venous blood, and the patients can perform it at home. Among the other advantages of these systems is the immediate INR results, and convenience. In theory patient self-testing at home increases the duration when the patient is within the therapeutic INR range, increases compliance, and patient interaction with his physician, and allows better control of OAC, which in turn reduces morbidity and mortality.

Self-management or personal-self testing however is not suitable for everyone. Patients need to operate the machine, and self-sample blood, they have to be free from any major visual problems, tactile dysfunction, or severe tremors to be able to mechanically handle self-testing, they also have to be reliable and complying with the dosage algorithm.

After Joint Replacement Patients undergoing major orthopedic surgery; hip or knee arthroplasty, or hip fracture repair are in the highest risk category for venous thromboembolism (VTE) solely on the basis of the orthopedic procedure itself. Without prophylaxis, the rate of deep vein thrombosis or pulmonary embolism in these patients range from 40% to 84% and is the most common cause of death. It is thus recommended to use some type of prophylaxis for total knee replacement (TKR), total hip replacement (THR), and hip fracture surgery. The currently available methods of thromboprophylaxis include intermittent pneumatic calf compression, elastic compression stockings, or the use of pharmacological agents.

Warfarin is the most commonly used pharmacological agent followed by low molecular weight heparin (LMWH). The American College of Chest Physicians (ACCP) recommends either adjusted-dose warfarin (INR range 2.0 to 3.0); started preoperatively or immediately after the hip or knee replacement, or SC LMWH therapy. The duration of thromboprophylaxis is controversial and varies widely between practices, ranging from 1-12 weeks postoperatively. Studies have shown a peak incidence of postoperative DVT two to three weeks after total hip arthroplasty. This, together with the shorter durations of hospitalization, extending the use of antithrombotic prophylaxis for up to 5 weeks is becoming more common (Schuringa 1999, Geerts 2001, Frederick 2003, He Xing 2008).

The intensity of anticoagulation treatment needs to be controlled closely due to the narrow therapeutic range of warfarin, its interaction with several other drugs and foods, and the potentially life-threatening effects of both over- and under-dosing of the drug. Monitoring patients on oral anticoagulation (OAC) therapy requires frequent testing, which in turn requires frequent venous punctures, laboratory standardization, and regular clinical visits.

There is an ongoing interest in developing a faster and easier way to accurately measure prothrombin time (PT). Currently several home testing systems have received FDA approval for use. These include CoaguChek, CoaguChek plus, ProTime Microcoagulation System, INRatio Prothrombin Time Monitoring System, Harmony INR Monitoring System, AcuSure, and Rubicon. These monitors may be used at home and only require a fingerstick whole blood rather than the citrated venous blood. They also give immediate INR results. In theory, patient self-testing at home increases the duration within the therapeutic INR range, increases compliance, patient interaction with his physician, and allows better control of OAC which reduces morbidity and mortality. Personal self-testing with or without self-management is however is not suitable for everyone. Patients have to be reliable and free from any major visual problems, tactile dysfunction, or severe tremors to be able to mechanically handle self-testing. They also have to comply with the dosage algorithm.

## Medical Technology Assessment Committee (MTAC)

### Home INR Monitoring

#### 08/13/2003: MTAC REVIEW

**Evidence Conclusion:** Ideally the outcomes of randomized controlled studies for the effectiveness of a test should demonstrate its effect in altering treatment and improving the health outcomes. Two important health outcomes, bleeding and thromboembolism, were only studied in ESCAT (Kortke 2001), and time in the therapeutic range, an intermediate outcome, was used in all other studies. Kortke et al, in the ESCAT randomized controlled trial, followed 600 patients with mechanical heart valves for at least 2 years (25-51 months). They evaluated the event rates, as well as time in the therapeutic range. Less than 10% of the randomized sample took part in the 25-30-month follow-up. Patients in the self-management group had significantly less overall grade III complications (severe hemorrhage or thromboembolism) compared to those in the standard care group. The trial also showed that significantly more measurements were in the therapeutic range among patients in the self-management group. Sawicki's RCT in which 84% of the participants had heart valve replacement, also showed that a higher proportion of patients in the self-management group were within the INR target range compared to those in the routine care group. This difference was only statistically significant at three months of follow-up but not after six months. In Watzke's trial, 57% of the patients had mechanical heart replacement, and 24.5 % had atrial fibrillation. It also showed that a higher proportion of measurements among patients in the self-management group were in the therapeutic range vs. those in the standard care group, however the P value was not provided. Eldor's study on elderly patients with atrial fibrillation was too small, nonrandomized and had insufficient power to detect any difference between the groups. In conclusion there is some evidence that selected patients with mechanical heart valve replacement, who self-monitor their PT, and self manage their OAC therapy, have better control of their INR values, than those receiving a standard care. Only one trial with several limitations, showed some benefit in reducing the severe complications associated with OAC treatment. The other studies had insufficient sample sizes, and follow-up durations to study that outcome. It is worth noting that the studies were conducted among selected groups of patients and cannot be generalized to all patients with mechanical heart replacement. There is insufficient evidence to determine the effect of home INR monitoring on patients with atrial fibrillation.

**Articles:** The search yielded 28 articles. Many were reviews and tutorials. Abstracts, and studies conducted to evaluate the accuracy of the portable PT monitoring systems were not reviewed. The purpose of this review is assessing the home use of the monitors for patients with mechanical heart valves, or atrial fibrillation, and not for evaluating the portable systems that have been in use since 1987 (known as point of service). There were three randomized controlled trials, and three non-randomized controlled studies on self-testing/home INR monitoring. Trials conducted among patients with mechanical heart valves, or atrial fibrillation were selected. *The following articles was critically appraised:* Kortke H, and Korfer R. International Normalized Ratio self-management after mechanical heart valve replacement: is an early start advantageous? *Ann Thorac Surg* 2001; 72:44-48. See

[Evidence Table](#) Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation. A randomized controlled trial. *JAMA* 1999; 281:145-150. See [Evidence Table](#) Watzke H.H, Forberg E, Svolba G, et al. A Prospective Controlled Trial Comparing Weekly Self-Testing and Self-dosing with the Standard Management of Patients on Stable Oral Anticoagulation. *Thromb Haemost* 2000; 83: 661-665. See [Evidence Table](#) Eldor A, and Schwartz J. Self-management of oral anticoagulants with a whole blood prothrombin-time monitor in elderly patients with atrial fibrillation. *Pathophysiol Haemost Thromb* 2002; 99-106. See [Evidence Table](#)

The use of Home INR Monitoring in the treatment of anticoagulation for mechanical valves does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/01/2005: MTAC REVIEW

### Home INR Monitoring

**Evidence Conclusion:** Ideally the outcomes of randomized controlled studies for the effectiveness of a test should demonstrate its effect in altering treatment and improving the health outcomes. Clinical endpoints for studies on self-management of anticoagulation therapy would be bleeding and thromboembolic complications. However, time within therapeutic INR range was used by some studies as a surrogate outcome to assess the quality of treatment based on self-management. In ESCAT I study (Koertke 2001) previously reviewed, 1,200 patients 6-11 days after a mechanical heart replacement were randomly divided into two groups: one monitored by family physicians, and the other controlling INR values at home. Patients were followed for at least 2 years (25-51 months) and the primary outcome was the rate of thromboembolic events and hemorrhage, and stability of INR values. Six hundred patients (50% of the randomized sample) were included in the analysis, dropouts and deaths were not included, and analysis was not based on intention to treat. The results of the trial showed that patients in the self-management group had significantly less overall grade III complications (severe hemorrhage or thromboembolism) compared to those in the standard care group. It also showed that significantly more measurements were in the therapeutic range among patients in the self-management group. ESCAT II study (Koertke 2003) was a large (N=3,300), multicenter RCT that randomized patients to two INR targets for self-management. The primary outcomes were the rate of thromboembolic events and hemorrhage, and the stability of INR values. It is an ongoing trial and the published articles only present the interim analysis with data on 55% of the total sample size. The investigators compared the results of the two INR targets for self-management in this trial and included data on thromboembolism and bleeding for the group controlled by general practitioner from ESCAT I study, which is not a valid comparison. ESCAT I was conducted years earlier, in a single center, and on a different group of patients. In this latter study, patients in the self-managed group had a higher mean INR value (3.0) compared ESCAT II study (2.8 for the conventional-dose INR, and 2.4 in the low-dose INR patients with aortic valve replacement). Overall, the interim results of ESCAT II study show that 72% to 74% of the patients in the low and conventional INR range, respectively, were within target range. The bleeding and thromboembolic rates were <1% in each of the two groups. There was no difference between them in the thromboembolic rates, and the difference in the bleeding rates did not reach statistical difference. There is no new evidence to determine the effect of home INR monitoring on patients with atrial fibrillation.

**Articles:** The search yielded 20 newer articles many of which were reviews and editorials. Studies conducted to evaluate the accuracy of the portable PT monitoring systems were excluded. The purpose of this review is to assess the home use of the monitors for patients with mechanical heart valves or atrial fibrillation, and not for evaluating the portable systems that have been in use since 1987 (known as point of service). There were two publications on one large randomized controlled trial (ESCAT II) that compared two INR targets for self-management of anticoagulants after mechanical valve replacement, a small RCT that included patients with different indications for anticoagulation, and small case series with intermediate outcomes. SMART, a large ongoing trial on self-management of anticoagulation was also identified but no results were published to date. The ESCAT II trial was critically appraised: Kortke H, Minami K, Boethig, et al. INR self-management permits lower anticoagulation levels after mechanical heart valve replacement. *Circulation* 2003;108 II:75-78. Kortke H, Zittermann A, Minami K, et al. Low-dose International normalized ratio self-management: A promising tool to achieve low complication rates after mechanical heart valve replacement. *Ann Thorac Surg* 2005; 79:1909-1914.

The use of Home INR Monitoring in the treatment of anticoagulation for mechanical valves does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 08/07/2006: MTAC REVIEW

### Home INR Monitoring

**Evidence Conclusion:** The previous MTAC reviews of home INR monitoring showed some evidence that selected patients with mechanical heart valve replacement who self-monitor and manage their OAC therapy, may have better control of their INR values, than those receiving standard care. All studies were conducted among selected groups of patients and the results might not be generalized to all patients with mechanical heart



replacement. There was insufficient evidence to determine the safety and efficacy of home INR monitoring on clinically important outcomes as thromboembolic events, major hemorrhage, and death. There was also insufficient evidence to determine the benefit of home INR monitoring in patients with atrial fibrillation. Heneghan et al's recent meta-analysis (2006) assessed the effects of self-monitoring with/ or without or self-management of anticoagulation compared with standard monitoring. The meta-analysis had valid methodology, was well-conducted, and 10 out of the 14 studies it included were judged to be of good quality. The authors also performed a sensitivity analysis by excluding the studies with the lowest quality. However, the control groups in the trials received their routine care in different settings. The results of a recent meta-analysis (van Walraven, 2006) showed that the study setting has a major influence on anticoagulation control. Moreover, the majority of the trials included in Heneghan's meta-analysis, provided education and training sessions only to the patients randomized to self-testing, not to the entire study population. Education increases awareness, motivation, and may modify the patient's attitude and behavior. The education and training were given after randomization, and those who could not complete the training sessions or were incapable of self testing and/or self-management either left the study or were transferred to the routine care group. This resulted in a high dropout rate (20% to > 30%) in the intervention groups, and intention to treat analysis was not conducted in all the trials, which could overestimate the observed results. Ideally, training would be performed prior to randomization to eliminate those who are unable to complete it, and/or are incapable of self testing or self-management, from participating in the trial. The results of this meta-analysis indicate that the thromboembolic events, major bleeds, and death rates were significantly lower in the self-monitoring groups versus the controls who were managed by their personal physicians, anticoagulation management clinics, or managed service. Those who both self-tested and self-adjusted their therapy dose had significantly lower thromboembolic events and mortality rates but a non-significant reduction the rate of hemorrhage. The difference in thromboembolic event rates was not significant between the intervention and control groups in the pooled results of the 3 trials conducted among patients with mechanical heart valves. The authors did not report on the difference in major hemorrhage or death rate among these patients, and no subgroup analysis was provided for patients with atrial fibrillation. Kaiser Permanente INTC recalculated some of the results of Heneghan's meta-analysis using ITT analysis, and found no significant differences between the intervention and routine care group in the percent of subjects with a mean INR in the therapeutic range, and in the major hemorrhagic events in the self-management vs. those receiving care in AMS (anticoagulation management services). Fitzmaurice, et al's (2005) study was a relatively large, multicenter, randomized, and controlled trial. However, it had several limitations and potential biases. Less than 25% of the eligible patient agreed to participate in the trial and were actually randomized to the study groups. Training on self-testing was given after randomization and only to the intervention group not to the entire population, which resulted in a higher dropout rate (43%) in the self-management group compared to 11% of those in the routine care group. Those who were considered incapable of self managing withdrew from the trial or were returned to the routine care group. The study population who self-selected to enroll was younger and included more men than the eligible population. Moreover, participants in the intervention group tested their INR more frequently than those in the routine care group (mean every 12 days vs. 38 days) group, and apparently received more care, which is another potential source of bias. Patients in the routine care group were managed in a variety of models including anticoagulation clinics, hospital outpatient clinics, and primary care clinics which may have an influence on their anticoagulation control, and outcomes. Overall the results of this RCT show no significant differences between the intervention and routine care groups in the percent of time spent within therapeutic INR range (primary outcome) or in the rates of serious bleeding, or serious thrombosis. Patients in a target INR of 3.5 had poorer control before and during the study compared to those with target INR of 2.5. However, patients in the intervention group with a 3.5 target INR showed a significant improvement between the pre-study and study periods. No such improvement was observed for those with a 2.5 INR target in either group, or those with a 3.5, target in the routine care group. These results of the Heneghan's meta-analysis and Fitzmaurice's RCT may not be generalizable to all patients treated with long-term oral anticoagulants. The study participants were highly motivated, mainly younger, willing to take and complete a structured training course on self-management, and capable of performing self-testing correctly and reliably.

**Articles:** The search revealed 7 newer randomized trials that were published after the last review, as well as a meta-analysis of RCTs that assessed the effects of self-monitoring or self-management of anticoagulation compared with standard monitoring. Only three of the recent RCTs were relevant (Fitzmaurice 2005, Voler 2005, and Menedez-Jandula 2005). The latter two were included in the meta-analysis. Studies conducted to compare two home INR monitors, or to evaluate the accuracy of the portable PT monitoring systems were excluded. The purpose of this review is to assess the home use of the monitors for patients receiving long-term anticoagulation treatment, and not for evaluating the portable systems that have been in use since 1987 (known as point of service). Two ongoing trials were also identified: 1. Self-Management of Anticoagulation, a Randomized Trial (SMART) which is a large multicenter trial on self-management of anticoagulation and, 2. The Home INR Study (THINRS) with more than 400 patients from VA Medical Centers with atrial fibrillation and/or mechanical heart valve who are expected to be anticoagulated indefinitely. The trial compares anticoagulation (AC) management using home monitoring devices to high quality management implemented by an AC service. It will have a

minimum of 2 years of follow-up, and the primary outcome is event rates (stroke, bleeding or death). Heneghan's (2006) meta-analysis and the RCT that was not included in the meta-analysis were critically appraised. Heneghan C, Alanzo-Coello P, Garcia-Alamino JM et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. *Lancet* 2006; 367:404-11. See [Evidence Table](#) Fitzmaurice DA, Murray ET, McCahon D, et al. Self-management of oral anticoagulation: randomized trial. *BMJ* 2005;331:1057- See [Evidence Table](#)

The use of Home INR Monitoring in the treatment of anticoagulation for mechanical valves does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 12/01/2008: MTAC REVIEW

### Home INR Monitoring

**Evidence Conclusion:** There is insufficient evidence to determine that: Home INR monitoring after joint replacement surgery increases the percentage of time spent within the therapeutic INR range, compared to routine care. Home INR monitoring, vs. routine care, after joint replacement surgery is effective in reducing the deep vein thrombosis and pulmonary embolic events rates, without increasing hemorrhagic events.

**Articles:** The search did not reveal any RCT that compared outcomes of monitoring of INR post joint replacement at home vs. in the hospital or anticoagulation management centers. There was only one published empirical study on the home prophylaxis with warfarin after hip and knee arthroplasty. Schuringa P, Yen D. Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty. *Can J Surg.* 1999; 42:360-362. See [Evidence Table](#).

The use of Home INR Monitoring in the treatment of anticoagulation for mechanical valves does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT or HCPC® Codes	Description
<b>G0248</b>	Demonstration, prior to initiation of home INR monitoring, for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria, under the direction of a physician; includes: face-to-face demonstration of use and care of the INR monitor, obtaining at least one blood sample, provision of instructions for reporting home INR test results, and documentation of patient's ability to perform testing and report results
<b>G0249</b>	Provision of test materials and equipment for home INR monitoring of patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; includes: provision of materials for use in the home and reporting of test results to physician; testing not occurring more frequently than once a week; testing materials, billing units of service include four tests
<b>G0250</b>	Physician review, interpretation, and patient management of home INR testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets Medicare coverage criteria; testing not occurring more frequently than once a week; billing units of service include four tests

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/10/2002	01/05/2010 <sup>MDCRPC</sup> , 05/04/2010 <sup>MDCRPC</sup> , 03/01/2011 <sup>MDCRPC</sup> , 01/03/2012 <sup>MDCRPC</sup> , 11/06/2012 <sup>MDCRPC</sup> , 09/03/2013 <sup>MPC</sup> , 07/01/2014 <sup>MPC</sup> , 05/05/2015 <sup>MPC</sup> , 03/01/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 11/07/2017 <sup>MPC</sup> , 09/04/2018 <sup>MPC</sup> , 09/03/2019 <sup>MPC</sup> , 09/01/2020 <sup>MPC</sup> , 09/07/2021 <sup>MPC</sup> , 09/06/2022 <sup>MPC</sup> , 09/05/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	09/01/2020



Revision History	Description
09/01/2020	Added Medicare LCA A55756



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Home Oxygen Therapy for Chronic Use

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">Medicare Claims Processing Manual Chapter 20, Section 30.6, Oxygen and Oxygen Equipment</a>
National Coverage Determinations (NCD)	<a href="#">Home Use of Oxygen (240.2)</a> <a href="#">Home Use of Oxygen in Approved Clinical Trials (240.2.1)</a>
National Coverage Analysis (NCA) – Decision Memo	<a href="#">Home Use of Oxygen and Home Oxygen Use to Treat Cluster Headaches (CAG-00296R2)</a>
Local Coverage Determinations (LCD)	<a href="#">Home Use of Oxygen and Oxygen Equipment (L33797)</a>
Local Coverage Article	<a href="#">Oxygen and Oxygen Equipment – Policy Article (A52514)</a>

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Home Oxygen (KP-0343) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider and/or specialist (palliative care, primary care, pulmonary care)
- Most recent Pulse Oximetry documentation and/or most recent at rest &/or activity log

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

In 1986, Kaiser Foundation Health Plan of Washington experienced an increased use of home oxygen and could find no clinical evidence in patient charts that would support the use of oxygen. In addition, once a patient was placed on home oxygen, they were never re-tested to verify continued need of the treatment. In 1989, a task force was initiated to review use and develop clinical indications for use at Kaiser Permanente. The task force reviewed the current literature and adopted the Medicare home oxygen criteria. In addition, they defined several situations where exceptions would be appropriate. The program was initiated for review of all home oxygen requests, and to set up testing and re-testing programs. The program was submitted to Medicare for approval. Medicare not only approved it, but also adopted several of its most critical features such as the re-testing program.

### Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
E0424	Stationary compressed gaseous oxygen system, rental; includes container, contents, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
E0425	Stationary compressed gas system, purchase; includes regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
E0430	Portable gaseous oxygen system, purchase; includes regulator, flowmeter, humidifier, cannula or mask, and tubing
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing
E0433	Portable liquid oxygen system, rental; home liquefier used to fill portable liquid oxygen containers, includes portable containers, regulator, flowmeter, humidifier, cannula or mask and tubing, with or without supply reservoir and contents gauge
E0434	Portable liquid oxygen system, rental; includes portable container, supply reservoir, humidifier, flowmeter, refill adaptor, contents gauge, cannula or mask, and tubing
E0435	Portable liquid oxygen system, purchase; includes portable container, supply reservoir, flowmeter, humidifier, contents gauge, cannula or mask, tubing and refill adaptor
E0439	Stationary liquid oxygen system, rental; includes container, contents, regulator, flowmeter, humidifier, nebulizer, cannula or mask, & tubing
E0440	Stationary liquid oxygen system, purchase; includes use of reservoir, contents indicator, regulator, flowmeter, humidifier, nebulizer, cannula or mask, and tubing
E0441	Stationary oxygen contents, gaseous, 1 month's supply = 1 unit
E0442	Stationary oxygen contents, liquid, 1 month's supply = 1 unit
E0443	Portable oxygen contents, gaseous, 1 month's supply = 1 unit
E0444	Portable oxygen contents, liquid, 1 month's supply = 1 unit
E0447	Portable oxygen contents, liquid, 1 month's supply = 1 unit, prescribed amount at rest or nighttime exceeds 4 liters per minute (LPM)
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate
E1391	Oxygen concentrator, dual delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate, each
E1392	Portable oxygen concentrator, rental
E1405	Oxygen and water vapor enriching system with heated delivery
E1406	Oxygen and water vapor enriching system without heated delivery
K0738	Portable gaseous oxygen system, rental; home compressor used to fill portable oxygen cylinders; includes portable containers, regulator, flowmeter, humidifier, cannula or mask, and tubing

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/15/1985	09/07/2010 <sup>MDCRPC</sup> , 07/05/2011 <sup>MDCRPC</sup> , 05/01/2012 <sup>MDCRPC</sup> , 01/08/2013 <sup>MDCRPC</sup> , 11/05/2013 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 03/07/2017 <sup>MPC</sup> , 11/06/2018 <sup>MPC</sup> , 11/05/2019 <sup>MPC</sup> , 11/03/2020 <sup>MPC</sup> , 11/02/2021 <sup>MPC</sup> , 11/01/2022 <sup>MPC</sup> , 11/07/2023 <sup>MPC</sup> , 02/13/2024 <sup>MPC</sup> , 02/04/2025 <sup>MPC</sup>	03/01/2022

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/01/2022	Updated applicable codes





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Hyperbaric Oxygen Therapy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Hyperbaric Oxygen Therapy (20.29)</a>
Local Coverage Determinations (LCD)	<a href="#">Oxygen and Oxygen Equipment (L33797)</a>
Local Coverage Article	<a href="#">Oxygen and Oxygen Equipment (A52514)</a>

\*Note: It is clinically rare for a patient to require more than 40 hyperbaric treatments for any diagnosis. Requests for more than 40 treatments should be sent to the Medical Director for closer review.

#### For Non-Medicare Members

Hyperbaric oxygen may be indicated with a confirmed diagnosis of **ONE or more of the following:**

1. Chronic severe diabetic ulcer, and need for initial treatment, as indicated by **ALL of the following:**
  - a. Severe wound defined by Wagner grading system, as indicated by **one or more of the following:**
    - Grade 3 Wagner ulcers are deep and involve abscess(es), osteomyelitis (bone infection) and/or joint sepsis
    - Grade 4 Wagner ulcers include gangrene (decay of body tissues) in the forefoot (anterior third of the foot) or heel region(s)
    - Grade 5 Wagner ulcers involve extensive gangrene **AND**
  - b. There is a document plan for initial treatment, which includes **ALL of the following:**
    - Must have complete evaluation and treatment for any underlying peripheral vascular or neuropathic disease. To assess vascular status there must be a documented exam of femoral, popliteal, dorsalis pedis and posterior tibial pulses. If absent or reduced, must have documented ABI Scores. If questionable accuracy of ABI score, due to diabetes, a vascular surgeon consult is needed.
  - c. Minimal to no healing present despite conventional wound treatment for minimum of 30 days, including **ALL of the following:**
    - Documentation of adequate diabetic control and most recent HbA1C
    - Pressure reduction or offloading for at least 8 weeks. (Must have documentation at each visit of the use (or of noncompliance) of walker boot, knee, scooter, or wheelchair)
    - Topical wound treatment. Need documentation regarding what specific products have been used, duration, and effectiveness (i.e., Apligraf, dermagraph, saline, hydrogels, hydrocolloids, alginates, or wound vac)
    - Appropriate wound debridement (practitioner must have appropriate training to perform) and
  - d. Must have formal Infectious Disease consult and treatment for a minimum of 6 weeks for severe wound/bone infection
  - e. Transcutaneous tissue oxygenation (PtcO<sub>2</sub>) levels of **one or more of the following:**
    1. PtcO<sub>2</sub> of 25 mm Hg (3.3 kPa) or greater on room air
    2. PtcO<sub>2</sub> value less than 25 mm Hg (3.3 kPa) on room air that meets **one or more of the following:**

- a. PtcO<sub>2</sub> increase of more than 20 mm Hg (2.7 kPa) while breathing 100% oxygen via face mask at normal atmospheric pressure or
  - b. PtcO<sub>2</sub> increase of greater than 200 mm Hg (26.6 kPa) in chamber during hyperbaric oxygen therapy
2. Chronic severe diabetic ulcer, and need for continued treatment, as indicated by **ALL of the following**:
  - a. Adherent to hyperbaric oxygen therapy
  - b. Documented evidence of improvement after 24 visits and need for continuing improvement after that point
  - c. Plan for no more than 40 total treatments
3. Decompression illness or suspected intravascular gas embolism
4. Anemia, as indicated by **ALL** of the following
  - a. Emergent anemia, as indicated by **1 or more** of the following
    - Active hemolysis with rapidly progressive anemia
    - Active massive hemorrhage
    - Severe signs or symptoms unresponsive to volume replacement (eg, tachycardia, hypotension, chest pain, cognitive impairment)
  - b. Patient unable or unwilling to receive red blood cell transfusions
5. Carbon monoxide (CO) poisoning is unconscious and has a carboxyhemoglobin level over 40%
6. Cyanide poisoning, acute
7. Intracranial abscess
8. Central retinal artery occlusion
9. Gas gangrene (inpatient only)
10. Idiopathic sudden sensorineural hearing loss (will need 20 visits maximum)

#### **KP SSNHL GUIDELINES**

##### **A. Patients presenting with mild to moderate HL:**

- Oral and IT steroid should be discussed with all patients.
- Treatment should be initiated, if possible, within 2 weeks of onset.
- Oral steroid alone should be recommended as initial therapy for mild to moderate HL within 2 weeks of onset but can be offered up to 6 weeks after onset.
- IT steroid should be strongly recommended for salvage for oral steroid failure within 6 weeks of onset
- Combo therapy (oral and IT steroid) should be recommended for those presenting more than 2 weeks after onset and within 6 weeks of onset.
- HBO should not be offered unless there are medical contraindications to oral or IT steroid therapy or special situations ie only hearing ear.
- Patients with > 25% drop in discrimination regardless of the severity of their pure tone loss should be treated as presenting with severe to profound HL patients

##### **B. Patients presenting with severe to profound HL:**

- HBO therapy combined with steroid treatment should be initiated within 2 weeks of onset if possible.
- Combo therapy (oral and IT steroid) should be “strongly” considered within 6 weeks of onset.
- IT steroid should be strongly recommended for salvage for oral steroid failure within 6 weeks of onset
- HBO should not be considered routinely as isolated adjuvant initial or salvage therapy without steroid therapy unless there are medical contraindications to oral or IT steroid therapy or special situations ie only has one hearing ear and that is the ear which is affected by sudden hearing loss.

##### **C. Treatment:**

- Oral Prednisone should be 60mg for at least 7 days.
- IT steroids should be Dexamethasone 10mg/ml up to 3 injections as needed. Treatment intervals – “weekly”
- HBO: 100% at 2-2.5 ATA 10-20 Dives lasting 90 or 60 minutes.

##### **D. Audiogram:**

- Initial, after treatment start consider audiograms prior to additional interventions or if patient reports significant improvement, 6 months after last intervention.

##### **E. Ruling out Retro-cochlear Lesion:**

- MRI (or CT with contrast if MRI contraindicated) required to rule out retro cochlear lesion

##### **F. Routine Laboratory Testing:**

Not recommended

11. Clostridial and non-clostridial myonecrosis: Plan of care indicates use will be in conjunction with other medical/surgical therapies and will not interfere with or delay surgical debridement. (Provided for hospital inpatient only)



12. Necrotizing soft tissue infections (provided for hospital inpatient only)
13. **Osteoradionecrosis as indicated by ONE or more of the following:**
  - a. Mandibular/maxillary osteoradionecrosis (diagnosis is typically made by a clinical exam with exposed bone, and/or by imaging). History of previous radiation therapy to the mandible or maxilla of at least 5,000-7,000 rads
  - b. Osteoradionecrosis in other sites, as an adjunct to conventional treatment. Osteoradionecrosis presents some months/years after radiation (sternum, long bones)
  - c. 30 pre/10 post treatments
14. Open or closed crush injury, compartment syndrome, or acute traumatic ischemias (see <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147240/>)
15. Femoral necrosis (see <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147240/>)
16. Skin grafts and flaps (compromised) (see <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147240/>)
17. Soft tissue radionecrosis as an adjunct to conventional treatment: Typically, bowel, bladder, larynx or wounds in area of prior radiation therapy. Must wait 6 months post completion of radiation therapy. Requires visualization of the damaged area with serial exams to monitor progress (e.g., cystoscopy, laryngoscopy, sigmoidoscopy). Additional health plan review if 30 treatments are exceeded. (40 max). Total radiation dose and field must be documented. Must have **ONE of the following:**
  - a. Radiation-induced proctitis diagnosed by sigmoidoscopy
  - b. Radiation-induced hemorrhagic cystitis diagnosed by cystoscopy
  - c. Radiation-induced head and neck soft tissue injury – soft tissue radionecrosis, typically of the larynx, or in a radiated field.
18. Dental extractions must meet **ALL of the following:**
  - a. Clinical plan on file from the dentist/oral surgeon detailing planned extractions timeline
  - b. History of at least 5,000-7,000 rads received to the teeth planned for the extraction
  - c. Initial Request is for 20 treatments prior and 10 after the extractions. If the initial treatment of 20/10 was delivered within prior 5 years, then only 10 more treatments post extractions are required for any additional extractions done within 5 years but not pre-extraction)
19. Chronic refractory osteomyelitis, unresponsive to both conventional medical and surgical treatment. Must have a prior infectious disease consultation and at least 6 weeks of medical management and a surgical consultation regarding debridement. Any hardware should be removed if feasible. Not indicated for acute osteomyelitis. If involves a distal toe, requires physician consultation prior to auth. Any treatments beyond 30 should have physician consultation. Pelvic bone osteomyelitis from decubiti requires debridement and flap surgery and does not respond well to hyperbaric. For osteomyelitis associated with a diabetic foot ulcer, see I. above.

Hyperbaric oxygen pressurization is considered investigational in all other situations.

**\*Note: Topical application of oxygen (CPT A4575) does not meet the definition of HBO therapy and is considered investigational/not medically necessary in all cases. Also, its clinical efficacy has not been established.**

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or consulting specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Hyperbaric oxygen therapy consists of placing a patient inside a pressurized chamber in which the patient breathes 100% oxygen under a pressure of greater than one atmosphere. Generally, there is a gradual increase to approximately two-and-a-half times the normal atmospheric pressure. Patients receive up to 40 treatment sessions lasting between 45 and 300 minutes. There are monoplace chambers for one person and multi-place chambers that can accommodate two or more patients. (Leach et al, 1998; Porter & Brian, 1999).

Hyperbaric oxygen therapy has both a mechanical (pressure) and physiological (oxygen) component. The increased pressure causes compression of gas bubbles in the body and is useful for conditions such as

decompression illness. Breathing 100% oxygen at increased pressure allows more oxygen to reach non-healing tissue and helps to prevent tissue from dying to a lack of oxygen and blood (Porter & Brian, 1999).

Potential adverse events of hyperbaric oxygen therapy include myopia lasting for weeks or months, ruptured middle ear, seizures, lung damage and oxygen toxicity. The most common complication is a lack of pressure equalization on both sides of the eardrum which can cause pain and bleeding into the middle ear. The high concentration of oxygen also presents a fire hazard (Porter & Brian, 1999; oral cancer foundation).

## Evidence and Source Documents

[Hyperbaric Oxygen for Treatment of Radiation Induced Cerebral Necrosis](#)

[Hyperbaric Oxygen Therapy for Prophylactic Treatment after Head and Neck Radiation to Prevent Osteoradionecrosis \(ORN\) of the Mandible](#)

[Hyperbaric Oxygen Therapy for Prophylaxis before Breast Surgery](#)

[Hyperbaric Oxygen Therapy for Treatment of Gastrointestinal Bleeding Related to Radiation Enteritis](#)

## Medical Technology Assessment Committee (MTAC)

### ***Hyperbaric Oxygen for Treatment of Radiation Induced Cerebral Necrosis***

#### BACKGROUND

Many types of cerebral cancer are treated with external beam, stereo tactically focused or implanted radiation. One of the most common and debilitating sequelae of high dose radiation is tissue destruction and necrosis. Radiation-induced necrosis (RIN) manifests itself as headache, ataxia, cranial nerve palsy, seizures, and visual loss. Necrotic tissue had historically been surgically re-sected when anatomically feasible or left untreated. One proposed method of treatment is the use of hyperbaric oxygen therapy (HBOT) which increases tissue oxygen concentration and may stimulate angiogenesis and establish a new blood supply to healthy cerebral tissue. Typically, hyperbaric oxygen is administered by placing patients into a whole-body hyperbaric chamber and exposing them to oxygen concentrations of 2 times normal atmospheric pressure for a period of 2-4 hours, once a day. Treatments are usually repeated usually 20-40 times with symptomatic improvement used as the measure of treatment success.

#### 08/11/1999: MTAC REVIEW

#### **Hyperbaric Oxygen for Treatment of Radiation Induced Cerebral Necrosis**

**Evidence Conclusion:** Evidence identification was conducted by searching MEDLINE from 1996-1999 using terms radiation necrosis, radiation injuries, cerebral necrosis and hyperbaric oxygenation. Dr. Kindwall, the author of a recent review, identified 2 case series (n=10, n=2) as the only published data on hyperbaric oxygen for treating **cerebral** radiation-induced necrosis. The Kaiser Permanente New Technology hotline staff was also unable to identify any additional literature reporting original data. Data from the case series of 10 patients, 8 of whom had biopsy-proven RIN, demonstrated that, with a median follow up of 7 months post HBOT, symptoms completely resolved in 1 patient, improved in 4 patients, did not get worse in 1 patient, and ended up worse in 4 patients. One patient developed ear pain from HBOT and had ear tubes placed and one developed sinusitis and discontinued treatment. Because this study was a case series rather than a randomized trial, it is not possible to determine whether hyperbaric oxygen therapy improves the clinical outcome of patients with radiation-induced cerebral necrosis beyond what would be expected with corticosteroid therapy alone. The best published scientific evidence on treating radiation induced cerebral necrosis with hyperbaric consists of a case series of 10 patients, 8 of whom had biopsy-proven RIN, demonstrated that, with a median follow up of 7 months post HBOT, symptoms completely resolved in 1 patient, improved in 4 patients, did not get worse in 1 patient, and ended up worse in 4 patients. One patient developed ear pain from HBOT and had ear tubes placed and one developed sinusitis and discontinued treatment. Because this study was a case series rather than a randomized trial, it is not possible to determine whether hyperbaric oxygen therapy improves the clinical outcome of patients with radiation-induced cerebral necrosis beyond what would be expected with corticosteroid therapy alone.

**Articles:** Chuba, PJ, et al, Cancer 1997;80:2005-2012

The use of hyperbaric oxygen does not meet *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Hyperbaric Oxygen Therapy for Prophylactic Treatment after Head and Neck Radiation to Prevent Osteoradionecrosis (ORN) of the Mandible***

#### BACKGROUND

Hyperbaric oxygen therapy consists of placing a patient inside a pressurized chamber in which the patient breathes 100% oxygen under a pressure of greater than one atmosphere. Generally, there is a gradual increase to approximately two-and-a-half times the normal atmospheric pressure. Patients receive up to 40 treatment

sessions lasting between 45 and 300 minutes. There are monoplace chambers for one person and multiplace chambers that can accommodate two or more patients. (Leach et al, 1998; Porter & Brian, 1999). Hyperbaric oxygen therapy has both a mechanical (pressure) and physiological (oxygen) component. The increased pressure causes compression of gas bubbles in the body and is useful for conditions such as decompression illness. Breathing 100% oxygen at increased pressure allows more oxygen to reach non-healing tissue and helps to prevent tissue from dying to a lack of oxygen and blood (Porter & Brian, 1999). Potential adverse events of hyperbaric oxygen therapy include myopia lasting for weeks or months, ruptured middle ear, seizures, lung damage and oxygen toxicity. The most common complication is a lack of pressure equalization on both sides of the eardrum that can cause pain and bleeding into the middle ear. The high concentration of oxygen also presents a fire hazard (Porter & Brian, 1999; oral cancer foundation). Osteoradionecrosis (ORN) of the mandible is a potential complication of head and neck irradiation. It is defined as a nonhealing, nonseptic lesion of bone (Clayman, 1997). The underlying cause of ORN is believed to be progressive vascular occlusion and tissue hypoxia after radiation treatment (Porter & Brian, 1999). Three types of ORN have been described. Type 1 occurs when a patient receives radiation therapy within 21 days of tooth extraction or mandibulotomy. Type 2 is induced by trauma. It generally occurs 3-6 years after radiation therapy, usually following a tooth extraction. Type 3 occurs spontaneously 6 months to 2 years after radiation therapy and is associated with higher radiation doses, neutron beam therapy and brachytherapy (Cronje, 1998). Hyperbaric oxygen therapy is generally accepted as a treatment for patients who have ORN. The use of hyperbaric oxygen therapy is also proposed as a prophylactic treatment before dental work to prevent ORN in patients who have had irradiation of the head and neck.

#### **04/09/2003: MTAC REVIEW**

##### **Hyperbaric Oxygen Therapy for Prophylactic Treatment after Head and Neck Radiation to Prevent Osteoradionecrosis (ORN) of the Mandible**

**Evidence Conclusion:** There is weak evidence from one randomized controlled trial (Marx), published in 1985, that prophylactic hyperbaric oxygen treatment of patients with previous head and neck irradiation before tooth removal lowers the incidence of osteoradionecrosis of the mandible compared to patients treated prophylactically with penicillin. The Marx study had a small sample size (n=74) and the methodology was not well described, leaving open the possibility of threats to validity such as selection bias, inadequate randomization and biased assessment of outcomes. The results of the Marx study have not been replicated. Many factors may have changed since 1985 making the findings less relevant including different radiation protocols that alter the likelihood of developing ORN, better alternative prophylactic treatments and better treatments for patients with ORN. Recent authors have questioned the need for prophylactic hyperbaric oxygen treatment before dental surgery for all patients who have received head and neck radiation before dental surgery because the incidence of post-extraction ORN is relatively low and over half of the patients who do develop ORN heal after conservative treatment. The Marx study has also been criticized as including a particularly high-risk group of patients. The incidence of ORN in the Marx study was 30% in the penicillin-treated group compared to a 5.8% incidence in the general population of post-radiation tooth extraction patients and a lower incidence, 2.1% in studies conducted in the 1990s (Clayman, 1997).

**Articles:** The search yielded 35 articles. Many of the articles were reviews or opinion pieces, dealt with technical aspects of the intervention or addressed the treatment of osteoradionecrosis with hyperbaric oxygen rather than prophylaxis. No randomized controlled trials on prophylactic use of hyperbaric oxygen to prevent osteoradionecrosis were included in the search findings. However, an RCT published in 1985 was identified from the reference list of a review article. In addition to the RCT, there were several case reports and small case series (n<30 patients). The RCT was critically appraised: Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis: a randomized prospective clinical trial of hyperbaric oxygen versus penicillin. JADA 1985; 111: 49-54. See [Evidence Table](#).

The use of hyperbaric oxygen in the prevention of osteoradionecrosis of the mandible does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **Hyperbaric Oxygen Therapy for Prophylaxis Before Breast Surgery**

##### **BACKGROUND**

Breast cancer is the most common cancer in women, other than skin cancer, and the second leading cause of cancer death among them. According to the American cancer society, a woman has a 1 in 7 chance of having invasive breast cancer some time during her life. As of the 2004, there are slightly over 2 million women living in the USA who have been treated for breast cancer. Conservative therapy with lumpectomy, axillary dissection, and irradiation, is a frequently used option for treating early breast cancer. This allows the patient to keep her breast and reduce the physical and psychological trauma associated with the modified radical mastectomy. Radiation therapy is also indicated with mastectomy under certain conditions. In both cases, radiotherapy is given in a moderate to high dose and may be associated with mild to severe complications that might have negative

influence on the health and quality of life. Among these complications are arm lymphedema, subcutaneous fibrosis, painful hardening of the breast, shoulder pain rib fracture, damage to the lungs and heart and others (Gothard 2003, Feldmeier 1995). These complications may be due to early reactions to radiation, or late effects that occur after at least 90 days after the start of treatment (Pasquier, 2004). Late injuries are irreversible and progressive in the majority of cases. These may cause cellular depletion, reduction in vascular density, fibrosis and atrophy all of which may result in hypoxia, and in turn delayed healing of the wounds. Conservative measures may be adequate for managing moderate cases with minimal necrosis, but cases of extensive necrosis are more challenging. Hyperbaric oxygen (HBO) was first used for the treatment of radiotherapy patients in the 1950s (Pasquier, 2004). It is defined as the breathing of pure oxygen at pressure exceeding the normal atmospheric pressure of 100 kPa that increases the solubility of oxygen in the blood. HBO treatment is administered within hyperbaric chambers, which are compressed by air (Plafki, 1998) Researchers indicate that hyperbaric oxygen therapy stimulates angiogenesis, osteogenesis, fibroblast activity, and collagen formation in irradiated tissues, which would increase the cellular level of oxygen. It has been reported that HBO therapy is associated with a low complication rate, but that there is uncertainty about the best time to start the treatment, and the number of sessions needed (Plafki, 1998). There is also uncertainty on the efficacy of the treatment for the different complications, what are its side effects, who would respond to treatment, and for which symptoms.

#### **12/08/2004: MTAC REVIEW**

##### **Hyperbaric Oxygen Therapy for Prophylaxis Before Breast Surgery**

**Evidence Conclusion:** There is no evidence to date on the prophylactic use of hyperbaric oxygen therapy before breast surgery in patients with prior radiation therapy. There is also insufficient evidence on the efficacy of HBO therapy in the treatment of late sequelae in women receiving radiation after breast-conserving surgery. The study reviewed was a case series that provide the least grade of evidence. It was small nonrandomized, and with potential selection and observation bias. The results of the study show that patients who received a hyperbaric oxygen therapy had a significant reduction of pain, edema, and erythema compared to those who refused the therapy. There was no significant difference between the groups in the improvement of fibrosis or telangiectasia.

**Articles:** The search yielded 35 articles. Many were review articles, dealt with technical aspects of the therapy, or the use of hyperbaric oxygen for the treatment of radio-induced lesions in different tissues and organs other than the breast. The search did not reveal any study on the use of Hyperbaric Oxygen Therapy for prophylaxis in breast surgery in patients with prior radiation therapy. There was one prospective case series with a control group on the use of hyperbaric oxygen for the treatment of late sequelae of radiation therapy after breast surgery, a smaller series of 21 patients and control group, and a retrospective review of 23 cases.

The case series with a control group was selected for critical appraisal. Carl UM, Feldmeier JJ, Schmitt, et al. Hyperbaric oxygen therapy for late sequelae in women receiving radiation after breast-conserving surgery. *Int J Radiat Oncol Biol Phys.* 2001; 49:1029-31. See [Evidence Table](#).

The use of hyperbaric oxygen for prophylaxis before breast surgery does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **Hyperbaric Oxygen Therapy for Treatment of Gastrointestinal Bleeding Related to Radiation Enteritis**

##### **BACKGROUND**

Hyperbaric oxygen therapy consists of placing a patient inside a pressurized chamber in which the patient breathes 100% oxygen under a pressure of greater than one atmosphere. Generally, there is a gradual increase to approximately two-and-a-half times the normal atmospheric pressure. Patients receive up to 40 treatment sessions lasting between 45 and 300 minutes. There are monoplace chambers for one person and multiplace chambers that can accommodate two or more patients. (Leach et al, 1998; Porter & Brian, 1999). Hyperbaric oxygen therapy has both a mechanical (pressure) and physiological (oxygen) component. The increased pressure causes compression of gas bubbles in the body and is useful for conditions such as decompression illness. Breathing 100% oxygen at increased pressure allows more oxygen to reach non-healing tissue and helps to prevent tissue from dying to a lack of oxygen and blood (Porter & Brian, 1999). Potential adverse events of hyperbaric oxygen therapy include myopia lasting for weeks or months, ruptured middle ear, seizures, lung damage and oxygen toxicity. The most common complication is a lack of pressure equalization on both sides of the eardrum which can cause pain and bleeding into the middle ear. The high concentration of oxygen also presents a fire hazard (Porter & Brian, 1999; oral cancer foundation). The treatment of gastrointestinal bleeding related to radiation enteritis is one possible application of hyperbaric oxygen therapy.

#### **04/09/2003: MTAC REVIEW**

##### **Hyperbaric Oxygen Therapy for Treatment of Gastrointestinal Bleeding Related to Radiation Enteritis**

**Evidence Conclusion:** There is no published evidence on the effectiveness of hyperbaric oxygen therapy for the treatment of gastrointestinal bleeding related to radiation enteritis.

**Articles:** There were no published empirical studies. An abstract of a small case series (n=19) was identified in a review article. The abstract was presented at a professional meeting in 1998 and the study was not subsequently published.

The use of hyperbaric oxygen in the treatment of gastrointestinal bleeding related to radiation enteritis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
99183	Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session
HCP Codes	Description
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30-minute interval

**Considered Not Medically Necessary - experimental, investigational or unproven:**

HCP Codes	Description
A4575	Topical hyperbaric oxygen chamber, disposable

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/1998	01/05/2010 <sup>MDCRPC</sup> , 11/02/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 04/01/2014 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 01/09/2018 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 11/06/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	03/08/2021

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Director Clinical Review and Policy Committee

Revision History	Description
12/01/2015	Added one additional indication: treatment of central retinal artery occlusion
03/07/2017	Revised indication to dental extractions (part c)
08/06/2019	Revised criteria to include indications for open or closed crush injury, compartment syndrome, or acute traumatic ischemia's; femoral necrosis; skin grafts and flaps and added indication for dental extractions: Initial Request is for 20 treatments prior and 10 after the extractions. If the initial treatment of 20/10 was delivered within prior 5 years, then only 10 more treatments post extractions are required for any additional extractions done within 5 yrs. but not pre extraction
09/03/2019	MPC approved to adopt clinical indications for sudden hearing loss
07/07/2020	Removed Revenue code 413; Added Infectious Disease consult and treatment and medical management 6-week requirements
08/04/2020	MPC approved to adopt updates to clinical criteria for Non-Medicare-additional indications for anemia, cyanide poisoning and intracranial abscess. Requires 60-day notice, effective date 01/01/2021. Added Medicare LCA A52514.



03/08/2021	Added clarifying language around Wagner grading system; also clarified requests will be limited to no more than 40 treatments, as well as sudden hearing sensorineural hearing loss
------------	---



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Implanted Infusion Pumps

For [Insulin Pumps](#) See Separate Criteria

- Intra-Arterial Infusion Pump
- Intraspinal Pump
- Intrathecal Pump

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Infusion Pumps (280.14)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	<a href="#">Implanted Infusion Pump for Chronic Pain (A55323)</a>

#### For Non-Medicare Members

The following criteria must be met for each specific type of treatment:

- Chemotherapy for Liver Cancer must meet **ALL of the following**:
  - Is receiving intra-arterial infusion of 5-FuR for the treatment of liver cancer.
  - Must meet **ONE of the following**:
    - Liver cancer for patients with primary hepatocellular carcinoma.
    - Duke's Class D colorectal cancer, in whom the metastases are limited to the liver, and where (1) the disease is unresectable or (2) the patient refuses surgical excision of the tumor.
- Anti-Spasmotic Drugs for Severe Spasticity must meet **ALL of the following**:
  - Use to administer anti-spasmotic drugs intrathecally (e.g., baclofen).
  - The patient has chronic intractable spasticity with a baseline average Ashworth Scale\* score of at least 3 (or a Modified Ashworth Scale\* score of 2), and a Spasm Frequency score\*\* of at least 2.
  - The spasticity is unresponsive to less invasive medical therapy as determined by the following criteria:
    - A 6-week trial, the patient cannot be maintained on noninvasive methods of spasm control, such as oral anti-spasmotic drugs, either because these methods fail to control adequately the spasticity or produce intolerable side effects.
    - The patient has responded favorably to a trial intrathecal dose of the anti-spasmotic drug, e.g., demonstrates at least a 2-point reduction in the Ashworth Scale or Spasm Frequency score for 4 hours following an intrathecal bolus of baclofen.

\*[Ashworth and Modified Ashworth Scale](#) (scale appears in middle of document)

\*\*[Spasm Frequency Score](#)

- Opioid Drugs for Treatment of Chronic Intractable Pain must meet **ALL of the following**:
  - Used to administer opioid drugs intrathecally or epidurally.
  - Patient has severe chronic intractable pain of malignant or nonmalignant origin with a life expectancy of at least 3 months.
  - Patient agrees to a 50% reduction in systemic opiates prior to undergoing an intrathecal opiate trial.
  - Are proven unresponsive to one or more of the following less invasive medical therapies:

- Trial of neuropathic pain medication
  - Trial of nonsteroidal anti-inflammatory drugs (NSAIDs)
  - Trial of physical therapy
  - Trial of behavioral health treatments (e.g., CBT, ACT)
  - The patient's history indicates that he/she would not respond adequately to non-invasive methods of pain control, such as systemic opioids (documentation should include attempts to eliminate physical and behavioral abnormalities which may cause an exaggerated reaction to pain)
- e. No acute psychiatric instability or uncontrolled suicide risk
  - f. No diagnosed substance-related disorder (other than nicotine) or patient currently receiving active treatment for disorder
  - g. A preliminary trial of intraspinal opioid drug administration has been undertaken with a temporary intrathecal/epidural catheter to substantiate adequately acceptable pain relief and degree of side effects (i.e. patient has experienced > 50% reduction in pain and concomitant increase in function) and patient acceptance.

In addition to meeting the appropriate above criteria the patient does not have one of the following contraindications:

1. A known allergy or hypersensitivity to the drug being used (e.g., oral baclofen, morphine, etc.);
2. An infection;
3. Body size at the implant site is insufficient to support the weight and bulk of the device;
4. Other implanted programmable devices since crosstalk between devices may inadvertently change the prescription.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 3 months of clinical notes from requesting provider &/or consulting specialist.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Implantable pumps are designed to provide a continuous infusion of medication to a specific body site. The pumps are used with morphine for malignant pain management, and the drug 5-FuR for liver cancer chemotherapy and Baclofen for intractable spasticity.

About two-thirds of metastatic cancer patients experience moderate-to-severe pain (Smith et al., 2002). Chronic non-malignant pain is also common. One type of non-malignant pain, chronic low back pain, is the second most frequent cause of hospital admissions in the United States (Deer et al., 2004).

Options for initial treatment of chronic pain include exercise, physical therapy, individual counseling, pain education classes, medications such as NSAIDs and complementary/alternative treatments such as massage or acupuncture. Opioids are an option as part of a comprehensive treatment plan if patients fail other therapies (GHC chronic non-malignant pain guideline). A meta-analysis of studies on oral morphine by the Cochrane Collaboration found it to be an effective analgesic for cancer pain (Wiffen et al., 2003). Another Cochrane review on chronic low-back pain found a lack of high-quality evidence and concluded that the benefits of opioids for this type of pain remain uncertain (Deshpande et al., 2007). Disadvantages of opioid analgesics include potential side effects such as nausea and vomiting, constipation, itching and respiratory depression. Moreover, during long-term opioid therapy patients may develop a tolerance leading to a need for higher doses, and patients may become physically dependent on opioids, and experience withdrawal symptoms if the medication is suddenly stopped (Wiffen et al., 2003).

The delivery of pain medication in directly into the fluid that surrounds the spinal cord (intrathecal analgesia) began in the 1970s following the discovery of opioid receptors in the central nervous system. Potential advantages of intrathecal analgesia include the ability to relieve pain in patients with previously intractable pain; the need for a lower milligram dose of opioids compared to systemic administration which may result in fewer side effects; and the ability to easily adjust the dose of opioids. Spinal analgesia was first used to treat chronic cancer-related pain. The use of intrathecal pain pumps for non-malignant pain is more controversial due to the limited

evidence on the ability of opioids to relieve non-malignant pain over the long-term. As with oral opioids, there are concerns about tolerance, dependence and addiction (Williams et al., 2000; Cohen & Dragovich, 2007). Side effects that have been associated with long-term intrathecal morphine therapy include nausea, vomiting, itching urinary retention, constipation, sexual dysfunction and edema (Ruan, 2007).

Chronic pain is a major public health problem in the United States and across the world. It has significant negative effects on patients' functional capacity and quality of life, as well as high direct and indirect costs for the health care system. In a Gallup Survey of "Pain in America" more than 4 out of 10 adults indicated that they experience pain on a daily basis. Chronic pain is a complex phenomenon that is difficult to define. The American Society of Interventional Pain Physicians (ASIPP) defined it as:

1. Pain that persists beyond the usual course of an acute disease or a reasonable time for any injury to heal that is associated with chronic pathologic processes that cause continuous pain or pain at intervals for months or years.
2. Persistent pain that is not amenable to routine pain control methods, and
3. Pain where healing may never occur (Boswell 2007).

Chronic non-cancer pain (CNCP) has also been defined as ongoing pain that lasts over six months, that is due to non-life-threatening causes, and does not respond to available treatment methods (Ghafoor 2007).

A key to successful management of chronic pain is a multidisciplinary approach that optimizes medication use in conjunction with other nonpharmacological therapies including exercise, physical therapy, individual counseling, pain education classes, and complementary/alternative treatments such as massage or acupuncture. When conservative treatments fail, surgery to correct underlying causes is considered. These conservative and surgical therapies provide adequate pain relief for most but not all CNCP patients (Ghafoor 2007).

Intrathecal (IT) analgesia was introduced in the 1970s following the discovery of opioid receptors in the central nervous system and was initially used for malignant pain in patients who have failed to obtain adequate pain relief, or those with adequate analgesia but with intolerable side effects to drug therapy. Currently, it is being used for other indications such as chronic back pain, neuropathy, mixed neuropathic-nociceptive pain, and radicular pain from failed back syndrome. IT analgesia involves the delivery of pain medication directly into the fluid that surrounds the spinal cord to target the pre- and post-synaptic receptors in the dorsal horn of the cord (Koulousakis 2007, Smith 2008, Patel 2009).

There are two types of implantable intrathecal drug delivery systems (IDDS) available in the US. The fixed rate pump allows continuous infusion and bolus dose administration but does not have the option of changing the flow rate. The other, and most common implantable pump is a programmable infusion system which is available in different reservoir sizes. The infusion pumps are typically implanted in the lower abdomen, just beneath the skin. A catheter is inserted into the intrathecal space of the spine, tunneled under the skin and connected to the implanted pump for medication delivery, and to an external programmer that controls infusion rate and records medication concentration, volume, and dosage. A drug is infused over an extended period and may be delivered at a constant or variable rate by calibrating the infusion pump according to the physicians' specification. The pump requires refilling regularly via subcutaneous port injections. A variety of analgesic/co-analgesic agents have been utilized to provide spinal analgesia however, morphine remains the gold standard and is the only opioid approved by the FDA for intrathecal delivery to treat chronic pain. The FDA approved the use of ziconotide, for patients unresponsive to intrathecally delivered morphine. It also approved the use baclofen with the use of implantable infusion pumps for patients with severe spasticity of spinal origin. However, off-label use of other drugs in IT pumps is common (Ghafoor 2007, Koulousakis 2007, Turner 2007).

The implantable infusion pump is an invasive alternative for medication delivery and requires ongoing maintenance and surgeries to periodically replace the pump. It has the potential benefit of providing more effective pain control by administering the analgesic drug directly to the target area, using lower doses of opioids compared to systemic administration, and the ability to adjust the dose of opioids. However, there are many risks and potential harms associated with IT drug therapy. These involve the problems related to the intrathecal drug delivery systems (IDDS), and the adverse events of the medications used. Serious complications that may occur after the intrathecal catheter placement include postoperative subarachnoid hemorrhage, meningitis, catheter tip inflammatory masses, infection, root irritation, reactive arachnoiditis, catheter dislocation, and pump failure. Drug-related side effects consist of dose-independent effects as urinary retention, pruritis, pain due to bolus injection, perspiration, and sedation; and dose-dependent side effects as nausea, constipation, dysphoria, euphoria, sedation, respiratory depression, hypotension, central depression, and tachyphylaxis. As with oral opioids, there are concerns about tolerance, dependence, and addiction. Drug overdose could take place if the pump is

inappropriately used or monitored; and drug withdrawal symptoms may occur with mechanical problems as pump failure or catheter blockage and kinking. There are also reports that patients with CNCP treated with intrathecal opioid therapy experience increased mortality compared to others with similar conditions treated with other therapies. It is thus recommended that pumps for chronic IT opioid application should only be implanted in specialized center. Before implantation the therapeutic effect of IT application should be assessed by a bolus trial or continuous injection via an external pump, connected to the intrathecal catheter through an implanted port (Cohen 2007, Koulousakis 2007, Smith 2008, Pasutharnchat 2009, Rathmell 2009, Coffey 2009).

In 1991, the Medtronic SynchroMed infusion system was approved by the FDA for the intrathecal delivery of morphine to treat malignant and non-malignant pain. The system consists of a pump that is generally implanted subcutaneously in the lower abdominal wall, a spinal catheter implanted into the lumbar intrathecal space between L1 and L4 and a programmer. The pump can be programmed via telemetry to control infusion modes and flow rates. SynchroMed is the only commercially available pump system that can be programmed outside the body. There are various models that differ in the size of the reservoir and the presence of a side catheter access port. Other implantable infusion pumps that have received FDA premarket approval include the Codman 3000 (Codman), Model 300 Constant Flow Implantable Infusion Pump (Arrow international) and the infused implantable Infusion Pump (Strato/infusaid).

Assessment objectives:

- To determine whether implanted infusion pumps for delivering intrathecal opioids are effective for the control of chronic noncancer pain (CNCP).
- To determine whether the use of implanted infusion pumps for delivering intrathecal opioids improves the quality of life and functioning in patients with CNCP.
- To determine whether the use of implanted infusion pumps for delivering intrathecal opioids are more effective than other non-invasive alternative therapies for pain control in patients with CNCP.
- To determine whether the technology is safe for use in patients with CNCP.

## Medical Technology Assessment Committee (MTAC)

### *Implanted Pain Pumps for the Intrathecal Delivery of Opioids*

#### **08/06/2007: MTAC REVIEW**

**Evidence Conclusion:** Cancer pain: The best evidence on the safety and effectiveness of implanted intrathecal pain pumps is an RCT with 200 patients. Of the 74% of patients with follow-up data at 4 weeks, there was a significantly greater reduction in toxicity, marginally significant reduction in pain and marginally significant increase in clinical success in the group assigned to receive a SynchroMed implantable pain pump in addition to comprehensive medical management (CMM) compared to CMM alone. Estimated survival at 6 months was higher in the group assigned to pain pumps, but the difference did not reach statistical significance. Limitations of the study include lack of blinding which could lead to biased estimates of self-report pain outcomes, funding by the device manufacturer and substantial cross-over (only 70% of the patients evaluated at 4 weeks in the pain pump group actually received implants and 5% of patients in the non-implant group received implants). Non-malignant pain: The evidence on safety and effectiveness is insufficient. There were case series and a cohort study that only compared pre- to post-implant changes, not between-group differences. The studies tended to find a reduction in self-reported pain after pump implantation and a reduction in oral morphine use (1 or 2 year follow-up). There were no comparison interventions and sample sizes were small. Device-related complications were relatively common.

**Articles:** The Medline search yielded one systematic review. This was published by the British Health Technology Assessment (HTA) group in 2000 and they did not identify any high-grade evidence. One randomized controlled trial was identified on malignant pain. Several articles were published based on this trial, the first on study outcomes in 2002. The article presenting the primary study outcomes (Smith et al., 2002) was critically appraised. No randomized controlled trials on non-malignant were identified. There was one non-randomized comparative trial which was critically appraised. (Thimineur et al., 2004). Two uncontrolled studies were also reviewed. Deer et al. (2004) reported data from the National Outcomes Registry for Low Back Pain. This registry was set up to prospectively collect data on patients with chronic low-back pain who underwent screening or a trial or an implanted pain pump. The other study was a prospective series using the Medtronic SynchroMed device (Anderson and Burchiel, 1999). There were other case series that had small sample sizes and/or did not mention whether a commercially available device was used. *Studies selected for critical appraisal were:*

Smith TJ, Staats PS, Deer T et al. for the Implantable Drug Delivery Systems (IDDS) study. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain. *J Clin Oncol* 2002; 20: 4040-4049. See [Evidence Table](#). Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study. *Pain* 2004; 109: 242-249. See [Evidence Table](#). Deer T, Chapple I, Classen A et al. Intrathecal drug delivery for treatment of chronic low

back pain. Am Acad Pain Med 2004; 5: 6-13. See [Evidence Table](#). Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurg 1999; 44: 289-300 See [Evidence Table](#).

The use of implanted pain pumps for the intrathecal delivery of opioids in the treatment of malignant pain meets the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of implanted pain pumps for the intrathecal delivery of opioids in the treatment of non-malignant pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 10/18/2010: MTAC REVIEW

##### **Implanted Pain Pumps for the Intrathecal Delivery of Opioids**

**Evidence Conclusion:** This re-review of the implantable infusion pumps for delivering intrathecal opioids did not identify any studies that would change the conclusion from the 2007 MTAC review of the technology for the control of chronic noncancer pain (CNCP). There is still insufficient published evidence on the safety and effectiveness of the infusion pump for the control of CNCP and/or improving the QoL of the patients. The published studies for this indication were small case series and observational studies with no control groups. Comparisons were made between pre- and post-implant changes, not between differences among groups receiving different therapies or interventions. The studies had multiple threats to validity and may only provide low quality evidence; they are subject to selection and observation bias and did not take into account the placebo effect of the treatment or assess outcome for patients who had not received the therapy. Moreover, the studies did not compare characteristics of patients who completed the study to those who dropped out, did not adjust for the use of additional therapies or other confounding factors, and were funded by the manufacturer. Overall, the results of the published studies indicate a reduction in self-reported pain, reduction in oral morphine use, and /or improvement in quality of life and psychological function. However, there was a significant proportion of side effects associated with the implanted pump, the catheter, and the IT opioid use.

The Washington State Health Technology Assessment (HTA) program reviewed the implantable infusion pump for drug administration to treat chronic non-cancer pain, in August 2008. After reviewing the evidence, the Health Technology Clinical Committee (HTCC) concluded, "The evidence on infusion pumps did not demonstrate net health benefit because weak or unproven evidence of some effectiveness for certain patients was undermined by significant evidence of serious harms and adverse events associated with the implantation of infusion pumps. The committee found that infusion pumps were not proven to be equally or more safe or effective, and the cost, while not a significant factor for this decision was likely equivalent. Based on these evidentiary findings, the committee voted 8 to 2 for non-coverage." Conclusion: There is insufficient published evidence to determine that the use of implanted infusion pumps for delivering intrathecal opioids is effective for the control of chronic non-cancer pain (CNCP). There is insufficient published evidence to determine that the use of implanted infusion pumps for delivering intrathecal opioids improves quality of life and functioning in patients with CNCP. There is insufficient published evidence to determine that the use of implanted infusion pumps for delivering intrathecal opioids is more effective than other non-invasive alternative therapies for pain control in patients with CNCP. There is insufficient published evidence to determine that the use of implanted infusion pumps for delivering intrathecal opioids is safe for use in patients with CNCP.

**Articles:** The available published literature on intrathecal (IT) opioid therapy delivered through implanted pumps for chronic noncancer pain is limited and consists of systematic reviews that did not pool the results in meta-analyses, small case series, and observational cohort studies with no control or comparison groups. The literature search did not identify any meta-analyses or randomized controlled trials that compared IT opioid therapy with other non-invasive therapies published since the 2007 MTAC review. There was one retrospective cohort study (Atli 2010) reporting on 3-years outcome of chronic pain patients receiving IT treatment through implanted pumps, one case series (Shaladi 2007) of 24 patients with osteoporotic vertebral fractures treated with intrathecal morphine infusion, and another series (Duse 2009) reporting on psychological functionality of 30 patients with CNCP. The larger cohort study with a long-term follow-up was selected for critical appraisal: Atli A, Theodore BR, Turk DC, et al. Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. *Pain Medicine* 2010; 11:1010-1016. See [Evidence Table](#).

The use of implanted pain pumps for the intrathecal delivery of opioids in the treatment of non-malignant pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**



CPT® Codes	Description
36260	Insertion of implantable intra-arterial infusion pump (eg, for chemotherapy of liver)
62360	Implantation or replacement of device for intrathecal or epidural drug infusion; subcutaneous reservoir
62361	Implantation or replacement of device for intrathecal or epidural drug infusion; nonprogrammable pump
62362	Implantation or replacement of device for intrathecal or epidural drug infusion; programmable pump, including preparation of pump, with or without programming
HCP Codes	Description
C1772	Infusion pump, programmable (implantable)
C1891	Infusion pump, nonprogrammable, permanent (implantable)
C2626	Infusion pump, nonprogrammable, temporary (implantable)
E0782	Infusion pump, implantable, nonprogrammable (includes all components, e.g., pump, catheter, connectors, etc.)
E0783	Infusion pump system, implantable, programmable (includes all components, e.g., pump, catheter, connectors, etc.)
E0785	Implantable intraspinal (epidural/intrathecal) catheter used with implantable infusion pump, replacement
E0786	Implantable programmable infusion pump, replacement (excludes implantable intraspinal catheter)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
11/23/1999	02/02/2010 <sup>MDCRPC</sup> , 12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 04/01/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 07/02/2024 <sup>MPC</sup>	07/24/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
04/10/2017	Added Coverage Article A55323
07/07/2020	Removed CPT code 36563 and added 36260
09/01/2020	MPC approved to adopt updates to clinical criteria for non-Medicare. Indications added under spasticity and chronic pain sections. Requires 60-day notice, effective 02/01/2021.
04/03/2023	Updating Medicare links.
07/24/2023	Updated Medicare links.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Intensity Modulated Radiation Therapy (IMRT)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	<p><a href="#">Intensity Modulated Radiation Therapy (IMRT) (L34080)</a> – <b>RETIRED</b></p> <p>08/01/2020 Noridian retired Intensity Modulated Radiation Therapy (IMRT) (L34080). These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L34080 for determining medical necessity.</p>
Local Coverage Article	<p>Billing and Coding: <a href="#">Intensity Modulated Radiation Therapy (IMRT) (A58245)</a> <b>RETIRED</b></p> <p>11/01/2023 Noridian retired Billing and Coding: Intensity Modulated Radiation Therapy (IMRT) (A58245). These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an article. Most LCDs are not retired because they are incorrect. Therefore, continue to use LCD L34080 and A58245 for determining medical necessity.</p>

#### For Non-Medicare Members

Kaiser Permanente has elected to use the Intensity Modulated Radiation Therapy (IMRT) (KP-0455 06012023) MCG\* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from oncologist and radiation oncologist

**\*MCG manuals are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Evidence and Source Documents

[Intensity-Modulated Radiation Therapy \(IMRT\) for Head and Neck Cancer](#)

[Intensity Modulated Radiation Therapy \(IMRT\) for Prostate Cancer](#)

## Background

The aim of radical radiotherapy is to deliver a homogenous radiation dose to a tumor target with a minimal dose to surrounding normal tissue. Conventional external beam irradiation (EBRT) has been used to treat prostate cancer for more than thirty years. It partly achieves its goal but leads to irradiation of unnecessarily large volumes of normal tissue. The proximity to the rectum and the bladder has limited the ability to deliver doses > 70Gy to the prostate. This dose may be sufficient for many, but not all prostate cancer cases. The frequent persistence of local residual tumor after EBRT has been a matter of concern. The inability to eradicate some prostate cancers may be related to the lack of tumoricidal doses of radiotherapy on certain resistant clones of tumor cells.

Conformal radiotherapy (CRT) aims at minimizing the volume of normal tissue irradiated by shaping the dose distribution to conform tightly to the shape of the tumor, thus reducing the dose to the normal tissue surrounding it. The three-dimension conformal radiotherapy (3D-CRT) is a further advancement to the 2D dose planning system. It entails direction of multiple beams conformed to the shape of the target from each beam's eye view (BEV). It thus enables a higher degree of certainty of target localization and permits the use of narrow margins around it. Its ultimate goal is to escalate the radiation dose to the target, while maximally excluding the adjacent normal tissue. However, there are situations in which 3D-CRT cannot produce a satisfactory treatment plan because of complex target volume shapes, or close proximity of sensitive normal tissue.

Most recently, an advanced form of 3D-CRT, called intensity modulated radiation therapy (IMRT) was developed to overcome these limitations by adding modulation of beam intensity to beam shaping. In this method intensity modulators, such as multiple leaf collimators (MLC), or beam modifiers are used to divide the treatment beam into a set of small beamlets, the intensity of which vary from 0-100%, independent of all other beamlets. IMRT can achieve any dose distribution, notably an abrupt decrease in the dose at the limit between the tumor volume and the adjacent normal tissue.

The benefits of IMRT will be greatest for patients with tumor targets that are concave, and where normal tissues around it are clinically important. Examples of these are the larynx, pharynx, and thyroid. The main focus for IMRT in the United States has been the prostate, which forms the largest single tumor site treated with IMRT. It is hoped that it will reduce the rectal and bladder doses of irradiation, allow further dose escalation and increase the cure rates.

Special software and computer control systems are necessary to implement IMRT. The planner has to define the anatomical contour of the target volume, the desired dose and the degree of inhomogeneity in the tumor volume. Several target volumes can be distinguished e.g. primary tumor and lymph nodes. The total dose or the dose per session to each target volume can be modulated. IMRT could be used for the whole duration of a radiotherapy treatment, or simply as a boost after more conventional treatment.

## Medical Technology Assessment Committee (MTAC)

***Intensity-Modulated Radiation Therapy (IMRT) for Head and Neck Cancer***

### BACKGROUND

Intensity-modulated radiation therapy (IMRT) is a type of external beam radiation therapy that permits complex three-dimensional shaping of the radiation beams to precisely target the tumor. This allows for a larger dose of

radiation to be applied to the tumor site, while minimizing exposure of the surrounding healthy tissue. Instead of a single, uniform beam as in traditional external beam radiation, IMRT involves the delivery of many small beams of varying intensity. Computer algorithms are used to coordinate the beams and plan the delivery of the radiation dose. Compared to other types of external beam radiation, IMRT is best able to generate concave dose distributions. Head and neck cancers may be particularly suited to treatment with IMRT because these tumors often have concave volumes and because head and neck tumors generally require relatively high doses (i.e. 60-70 Gy) of radiation and are in close proximity to critical tissues and organs that are radiation-sensitive (such as the salivary glands, inner and middle ears, temporomandibular joints, temporal brain and optic nerve). Head and neck cancers may also be good candidates for IMRT because of the relative lack of organ motion compared to other areas of the body. Due to the highly focused radiation dose, lack of motion is important. The most prevalent long-term adverse effect with radiation therapy for head and neck cancers is xerostomia (dry mouth) caused by damage to the salivary glands. This adverse effect may be reduced with IMRT. To date, several thousand patients worldwide have received IMRT treatment; so far, most of this has been for the treatment of prostate cancer. Several centers in the U.S. have been providing IMRT for head and neck cancer, most notably Washington University in St. Louis, the University of California, San Francisco (UCSF) and the University of Michigan (Cozzi & Fogliata, 2002). IMRT is a rapidly evolving technology that experienced clinicians believe will continue to evolve in the near future (Eisbruch, 2002).

#### **04/09/2003: MTAC REVIEW**

##### **Intensity-Modulated Radiation Therapy (IMRT) for Head and Neck Cancer**

**Evidence Conclusion:** There is insufficient evidence to determine the effect of IMRT on health outcomes in patients with head and neck cancer compared to other types of radiation therapy. There is only one published comparative study with clinical outcomes, a retrospective cohort study. This study is limited because only 26 patients received IMRT (14 had post-operative IMRT and 12 had definitive IMRT). Although the findings suggest that there is a higher survival rate and lower rate toxicity rate with IMRT compared to other forms of radiation therapy, the statistics are unreliable due to the small number in the IMRT group. (Percentages are generally considered unstable when the sample size is less than 100). In the Lee case series, actuarial 4-year survival estimates were 98% for local-regional progression-free survival and 66% for distant metastasis-free survival. Two years after IMRT, 32% of patients had Grade I xerostomia and only 1 patient had Grade 2 xerostomia. In the Chao case series, the 2-year actuarial survival estimates was 85% for loco-regional control, (89% after salvage surgery). The case series were limited by lack of comparison groups, variable length of follow-up and inconsistent interventions (e.g. three different IMRT techniques were used over time in the Lee study, and in both case series, some patients had chemotherapy). In addition, each included a heterogeneous patient population in terms of cancer location and stage.

**Articles:** The search yielded 120 articles, many of which were reviews, opinion pieces, dealt with technical aspects of the procedure or addressed treatment planning only. There were no randomized controlled trials comparing clinical outcomes after IMRT versus other forms of radiation therapy. There was one non-randomized comparative clinical study, a retrospective cohort study. The other empirical studies were all case series. The most recent case series from the three major institutions performing IMRT for head and neck cancer (Washington University, UCSF and the University of Michigan) were identified. Two of these institutions had published series of over 50 patients with head and neck cancer who had received IMRT. The comparative study and the two largest case series were critically appraised: Chao KSC, Majhail N, Huang C et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: A comparison with conventional techniques. *Radiother Oncol* 2001; 61: 275-280. See [Evidence Table](#)

The use of IMRT in the treatment of head and neck cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **06/01/2004: MTAC REVIEW**

##### **Intensity-Modulated Radiation Therapy (IMRT) for Head and Neck Cancer**

**Evidence Conclusion:** No new randomized or non-randomized comparative studies were identified. There were updates of earlier case series from two of the major institutions performing IMRT for head and neck cancer, UCSF and Washington University. There were also several new small case series. The new literature does not substantially change the conclusions of the April 2003 MTAC review.

**Articles:** Medline was searched from 2003 to May 2004 using the terms, "intensity-modulated radiation therapy", "IMRT", and "head and neck cancer", with variations. The search was limited to English language publication and human populations. No new randomized or non-randomized comparative studies were identified. There were updates of earlier case series from two of the major institutions performing IMRT for head and neck cancer, UCSF and Washington University. There were also several new small case series. Lee N, Xia P, Quivey JM. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. *Int J. Radiation Oncology Biol Phys* 2002; 53: 12-22. See [Evidence Table](#) Chao KSC, Ozyigit G, Tran BN et al. Patterns

of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. *Int J Radiation Oncology Biol Phys* 2003; 55: 312-321. See [Evidence Table](#)

The use of IMRT in the treatment of head and neck cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### **Intensity Modulated Radiation Therapy (IMRT) for Prostate Cancer**

#### **BACKGROUND**

The aim of radical radiotherapy is to deliver a homogenous radiation dose to a tumor target with a minimal dose to surrounding normal tissue. Conventional external beam irradiation (EBRT) has been used to treat prostate cancer for more than thirty years. It partly achieves this goal but may lead to irradiation of unnecessarily large volumes of normal tissue. The proximity to the rectum and the bladder has limited the ability to deliver doses > 70 Gy to the prostate. This dose may be sufficient for many but not all prostate cancer cases. The frequent persistence of local residual tumor after EBRT has been a matter of concern. The inability to eradicate some prostate cancers may be related to the lack of tumoricidal doses of radiotherapy on certain resistant clones of tumor cells. Conformal radiotherapy (CRT) aims at minimizing the volume of normal tissue irradiated by shaping the dose distribution to conform tightly to the shape of the tumor, thus reducing the dose to the normal tissue surrounding it. The three-dimension conformal radiotherapy (3D-CRT), is a further advancement to the 2D dose planning system. It entails direction of multiple beams conformed to the shape of the target from each beam's eye view (BEV). It thus enables a higher degree of certainty of target localization and permits the use of narrow margins around it. Its ultimate goal is to escalate the radiation dose to the target, while maximally excluding the adjacent normal tissue. However, there are situations in which 3D-CRT cannot produce a satisfactory treatment plan because of complex target volume shapes, or close proximity of sensitive normal tissue. Most recently, an advanced form of 3D-CRT, called intensity modulated radiation therapy (IMRT) was developed to overcome these limitations by adding modulation of beam intensity to beam shaping. In this method intensity modulators, such as multiple leaf collimators (MLC), or beam modifiers are used to divide the treatment beam into a set of small beamlets, the intensity of which vary from 0-100%, independent of all other beamlets. IMRT can achieve any dose distribution, notably an abrupt decrease in the dose at the limit between the tumor volume and the adjacent normal tissue. The benefits of IMRT will be greatest for patients with tumor targets that are concave, and where normal tissues around it are clinically important. Examples of these are the larynx, pharynx, and thyroid. The main focus for IMRT in the United States has been the prostate, which forms the largest single tumor site treated with IMRT. It is hoped that it will reduce the rectal and bladder doses of irradiation, allow further dose escalation and increase the cure rates. Special software and computer control systems are necessary to implement IMRT. The planner has to define the anatomical contour of the target volume, the desired dose and the degree of homogeneity in the tumor volume. Several target volumes can be distinguished e.g. primary tumor and lymph nodes. The total dose or the dose per session to each target volume can be modulated. IMRT could be used for the whole duration of a radiotherapy treatment, or simply as a boost after more conventional treatment. IMRT for prostate cancer was previously reviewed by MTAC in April, 2002. At that time, the evidence consisted of case series on the toxicity of IMRT and the item failed MTAC evaluation criteria.

#### **4/10/02: MTAC REVIEW**

##### **Intensity Modulated Radiation Therapy (IMRT) for Prostate Cancer**

**Evidence Conclusion:** The studies reviewed aimed at determining the toxicity of the high-dose radiation delivered by IMRT. In both studies IMRT was not compared to a low dose conventional treatment, instead it was compared to 3D-CRT, which also uses a high dose irradiation, yet not modulated. Compared to 3D-CRT, IMRT was found to cause significantly lower acute, and late rectal toxicity in Zelefsky's study, and significantly higher acute rectal toxicity in the Shu study. In the two studies reviewed, there was no significant difference between the two treatments in the acute or late bladder toxicity. Both studies were not randomized and non-blinded, there were some variations in the base-line characteristics in the treatment groups, and no adjustments were made for confounding factors. Randomized controlled studies with long-term follow-up are needed to study the effect of IMRT on the outcome of the cancer, as well as the morbidity from the radiation.

**Articles:** The search yielded 55 articles most of which were reviews, case reports, editorials, and letters. The literature did not reveal any randomized controlled studies or meta-analyses.

It also did not reveal any study on the effect of IMRT on the outcome of the prostate cancer. There were 2 articles on studies made to determine the toxicity of IMRT, and compare it to 3D-CRT. *The following articles were critically appraised:* Zelefsky MJ, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. *Radiotherapy and Oncology* 2000;55:241-9. See [Evidence Table](#) Shu H G, et al. Toxicity following high-dose three-dimensional conformal and intensity modulated radiation therapy for clinically localized prostate cancer. *Urology* 2001;57:102-7. See [Evidence Table](#)



The use of intensity modulated radiation in the treatment of prostate cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 2/11/04: MTAC REVIEW

### Intensity Modulated Radiation Therapy (IMRT) for Prostate Cancer

**Evidence Conclusion:** The evidence is limited by the lack of randomized controlled trials, comparison only to 3D-CRT rather than lower-dose standard radiotherapy, inconsistent length of follow-up, lack of actual survival data and potential confounding by androgen deprivation therapy in a substantial proportion of patients. Both studies reported on biochemical survival rates. Three-year actuarial PSA relapse-free survival varied from 81-92% in the Zelefsky study and thirty-month actuarial PSA relapse-free survival was 94% for IMRT and 88% for 3D-CRT (non-significant difference) in the Kuplian study. Change in PSA level is an intermediate outcome and may not be an accurate measure of prognosis. There appeared to be relatively low rates of serious late toxicity, but many patients were not followed up long enough to contribute to this analysis. In the Zelefsky study, 9 of the patients followed for a sufficiently long time (1%) developed grade 3 late toxicity. In the Kuplian study, actuarial grade 3 late rectal toxicity at 30 months was 2% in the IMRT group and 8% in the 3D-CRT group. The evidence is limited by the lack of randomized controlled trials, comparison only to 3D-CRT rather than lower-dose standard radiotherapy, inconsistent length of follow-up, lack of actual survival data and potential confounding by androgen deprivation therapy in a substantial proportion of patients. Both studies reported on biochemical survival rates. Three-year actuarial PSA relapse-free survival varied from 81-92% in the Zelefsky study and thirty-month actuarial PSA relapse-free survival was 94% for IMRT and 88% for 3D-CRT (non-significant difference) in the Kuplian study. Change in PSA level is an intermediate outcome and may not be an accurate measure of prognosis. There appeared to be relatively low rates of serious late toxicity, but many patients were not followed up long enough to contribute to this analysis. In the Zelefsky study, 9 of the patients followed for a sufficiently long time (1%) developed grade 3 late toxicity. In the Kuplian study, actuarial grade 3 late rectal toxicity at 30 months was 2% in the IMRT group and 8% in the 3D-CRT group.

**Articles:** The search yielded 102 articles, many of which were reviews, opinion pieces, dealt with technical aspects of the procedures or were on related procedures. There were no randomized controlled trials. There were three new case series publications by the Memorial Sloan-Kettering Cancer Center research group (led by Zelefsky). The patients included in the three publications overlapped. Two of the articles also included patients who were treated with 3D-CRT, but IMRT and 3D-CRT were not compared in analysis. The Zelefsky case series with the largest number of IMRT cases was critically appraised. In addition, there was a study conducted at the Cleveland Clinic which compared series of patients treated with short-course IMRT and 3D-CRT. There were no studies comparing IMRT to lower dose conventional radiotherapy. *The studies reviewed were:* Zelefsky MJ, Fuks Z, Hunt M et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. *Int J Radiation Oncology Biol Phys* 2002; 53: 1111-1116. See [Evidence Table](#) Kuplian PA, Reddy CA, Carlson TP. et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70Gy at 2.5Gy/Fraction) for localized prostate cancer. *Int J Radiation Oncology Biol Phys* 2002; 53: 904-912. See [Evidence Table](#).

The use of intensity modulated radiation in the treatment of prostate cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
HCPC Codes	Description

<b>G6015</b>	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
<b>G6016</b>	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session
<b>G6017</b>	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/22/2003	07/02/2013 <sup>MPC</sup> , 05/06/2014 <sup>MPC</sup> , 03/03/2015 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 01/05/2016 <sup>MPC</sup> , 11/01/2016 <sup>MPC</sup> , 09/05/2017 <sup>MPC</sup> , 07/10/2018 <sup>MPC</sup> , 07/09/2019 <sup>MPC</sup> , 07/07/2020 <sup>MPC</sup> , 07/06/2021 <sup>MPC</sup> , 07/05/2022 <sup>MPC</sup> , 07/11/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	01/10/2023

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
07/07/2015	MPC approved to reinstate IMRT criteria for medical necessity review. New criteria effective date 11/2015.
09/08/2015	Revised LCD Intensity Modulated Radiation Therapy (IMRT) L34251 and L34080
03/01/2016	Added indication to policy
11/01/2016	MPC approved revised indication for lung cancer
12/05/2017	MPC approved new indication for esophageal cancer
07/07/2020	Added Medicare LCA (A57231); removed deleted CPT code 77418
03/02/2021	MPC approved to expand coverage to the IMRT criteria by including additional indications for coverage which include Cholangiocarcinoma, Gallbladder carcinoma, Gastric cancer, Hepatocellular carcinoma, Liver metastases, Lymphoma with mediastinal involvement, in proximity to lung and heart, Pancreatic cancer; Breast Cancer will still require MD review. Requires 60-day notice, effective date 08/01/2021.
01/10/2023	MPC approved to adopt the revised changes the IMRT criteria to include indications for Breast Cancer (APBI). Requires 60-day notice effective 06/01/2023.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Bone Graft Substitutes & Adjuncts

- InFUSE™ Bone Graft

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article (LCA)	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, " <b>InFUSE™ Bone Graft</b> ," for medical necessity determinations. Use the Non-Medicare criteria below.

See reference: [Technology Assessment for Spinal Fusion for Treatment of Degenerative Disease Affecting the Lumbar Spine](#)

#### For Non-Medicare Members

Service	Criteria
InFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device (Bone Morphogenetic Protein-2)	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies (and/or) provides better long-term outcomes than current standard services/therapies.
Bone Graft Substitutes & Adjuncts	The following Bone Graft Substitutes & Adjuncts but not limited to are considered experimental and investigational, therefore are not covered: <ul style="list-style-type: none"><li>• Celling Biosciences Solum IV allograft</li><li>• Cerament®</li><li>• ChronOS bone graft substitute</li><li>• Equivabone® Graft</li><li>• Healos Sponge</li><li>• Healos® bone graft replacement</li><li>• i-FACTOR™ Peptide-enhanced bone graft</li><li>• InterGro® DBM Fibers</li><li>• Optium® DBM putty</li><li>• OsteoAmp®</li></ul>

	<ul style="list-style-type: none"> <li>• Osteofuse®</li> <li>• OSTEOMATRIX+ Arthrex Quickset™</li> <li>• OsteoVive®</li> <li>• TrueFuse</li> <li>• Vivex (Amendia)</li> <li>• Vivigen Formable®</li> <li>• Vivigen®</li> </ul> <p><b>Note:</b> Products listed above are considered experimental and investigational, this is not an exhausted or comprehensive list</p>
--	--

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Degenerative disc disease (DDD) resulting from wear and tear of the discs between vertebrae can lead to a painful condition that may require spinal fusion (arthrodesis) of the vertebrae on both sides of the degenerative disc. Spinal arthrodesis was introduced over a century ago for treating vertebral fractures, spinal tuberculosis, tumors and severe scoliosis. These indications were later expanded to include spondylolisthesis, spondylosis, intervertebral disc disorders, and discogenic low back pain. Spinal interbody fusion restricts the unstable spinal motion segment and may provide relief from the pain associated with DDD, when all other methods have failed. It involves the removal of the degenerated intervertebral disc and fusion of the adjacent vertebral bodies. This can be achieved through an anterior approach (anterior lumbar interbody fusion or ALIF), posterior fusion (PLIF), or transforaminal approach (TLIF) (Blumenthal 1988, Baskin 2003, Glassman 2005, Papakostidis 2008, Fu 2013, Skovrlj 2014, Noshchenko 2014, Bodalia 2016, Hofstetter 2016).

Vertebral fusions usually use graft material to stimulate the fusion. For decades autogenous iliac crest bone (ICB) has been, and is still considered, the gold standard bone grafting material for its superior osteoinductive and osteogenic properties. However, its harvest may be associated with postoperative complications including persistent pain from the donor site, deep infection, scarring, and other donor site morbidity. Another limitation of using iliac crest bone graft (ICBG) is the relative inadequate supply of graft tissue for multilevel fusions. Spine surgeons have thus been looking for alternative methods to promote spinal fusion. A variety of bone graft materials and substitutes such as local bone, bones from bone banks, demineralized bone matrix, synthetic grafts, platelet gels, and other materials have been introduced into clinical practice, but did not prove to be as effective as ICBG (Blumenthal 1988, Baskin 2003, Glassman 2005, papakostidis 2008, Fu 2013, Skovrlj 2014, Noshchenko 2014, Bodalia 2016, Hofstetter 2016).

Bone morphogenetic protein (BMP), a prototypical osteoinductive protein, was first described by Marshall Urist in 1965. BMPs are members of the superfamily of transforming growth factor-beta and play an important role in embryonic development including bone formation. In the late 1990s recombinant human bone morphogenetic protein type 2, a genetically engineered osteoinductive protein, was tested for use in lumbar fusion among humans in preclinical and clinical studies (Zhang 2014, Hofstetter 2016).

InFUSE® Bone Graft (Medtronic Sofamor Danek, Memphis, TN) is a recombinant human bone morphogenetic protein type-2 (rhBMP-2) applied to an absorbable collagen sponge (ACS) carrier that localizes the protein at the site of implantation and provides a scaffold for the formation of the new bone. The sponge is manufactured from bovine Type I collagen and is designed to resorb over time. InFUSE® Bone Graft is used in conjunction with a proprietary small thimble like titanium lordotic tapered cage (LT-Cage) implant, which is intended to restore the degenerated disc space to its original height. The LT-Cage Devices come in multiple sizes (from XX Small to Large II) to match various patient anatomies. The InFUSE® Bone Graft/LT-Cage® Lumbar Tapered Fusion Device is implanted through an open or laparoscopic anterior surgical approach. The bone graft is prepared immediately prior to its use during surgery\*; the protein solution is soaked into the sponge, which is then inserted into the LT-Cage. After removing the contents of the disc space, two devices are implanted side

by side in the prepared intervertebral disc space. The fusion cage maintains the spacing and temporarily stabilizes the diseased region of the spine while the InFUSE® Bone Graft induces new bone tissue at the site of implantation to fuse this portion of the spine. The fusion process requires several months to complete (Baskin 2003, Glassman 2005, Medtronic website accessed 2017)

\*Once prepared, the InFUSE® Bone Graft contains rhBMP-2 at a concentration of 1.5 mg/mL

In 2002, the US Food and Drug Administration (FDA) approved the use of InFUSE® Bone Graft for anterior interbody fusion as an alternative to the iliac crest bone graft for use in conjunction with lordotic tapered cages (LT-CAGE) lumbar fusion device. According to the FDA, the device is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at a single level from L4-S1. Patients should have had at least six months of nonoperative treatment prior to treatment with the InFUSE Bone Graft. Later the FDA approved rhBMP-2 with other interbody fusion devices (INTER FIX™ Threaded Spinal Fusion Device and INTER FIX™ RP Threaded Fusion Device) also manufactured by Medtronic.

InFUSE® Bone Graft is contraindicated in patients who are pregnant, who may be allergic to any of the materials contained in the device, have an infection in the area of the incision, are skeletally immature, or with an existing or removed tumor in the area.

## Medical Technology Assessment Committee (MTAC)

### **InFuse Bone Graft**

#### **10/08/2003: MTAC REVIEW**

**Evidence Conclusion:** The trial reviewed does not provide sufficient evidence to conclude that InFUSE Bone Graft is equivalent or superior to the standard treatment. It was randomized and controlled; yet the authors compared improvements associated with the InFUSE Bone Graft with the preoperative condition, and not with the standard treatment. The trial shows that both treatments led to significant improvement in the back pain, leg pain, as well as pain associated with activity when compared to the preoperative scores. The two procedures were also associated with post-operative vs. baseline, high neurological success, patient satisfaction and bone fusion. The authors noted that the success rates and pain scores were similar between the two groups, based on the values observed and not on statistical tests of significance. It seems unlikely that there are any significant differences between the two groups, as the numbers, and scores are close. This may suggest that the effect of the two treatments may be similar, but the study isn't conclusive as it may have been underpowered to detect a difference and was not designed as an equivalence trial that requires a larger sample size, and a different method of analysis than superiority trials.

**Articles:** The search revealed 4 randomized controlled studies and one case series. Three of the RCTs were conducted by the same principle investigator and included patients from the same center: one large trial with 279 patients, and two smaller RCTs with 46, and 42 patients. The other trial revealed included only 14 patients. The search also revealed an article where the same principle investigator of the three RCTs pooled data from his trial as well as other 3 unpublished studies, two of which were non-randomized. It had a poor methodology and cannot be categorized as a meta-analysis. The largest of the three RCTs conducted by the same investigator group was selected for critical appraisal. *The following study was critically appraised:* Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. *J Spinal Disord Tech.* 2002; 15:337-49. See [Evidence Table](#).

The use of recombinant human bone morphogenetic protein (rhBMP-2) placed on an absorbable collagen sponge (ACS) in the treatment of degenerative disc disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### **12/07/2009: MTAC REVIEW**

### **InFuse Bone Graft**

**Evidence Conclusion:** There is a lack published material on the use of InFUSE Bone Graft for anterior lumbar interbody fusion, the indication for which the technology received the FDA approval. Glassman and colleagues' trial (2008) had the advantage of comparing rhBMP-2 to iliac crest bone graft in a randomized controlled trial with 2-year follow-up duration. However, the technology was used off-label for a posterolateral lumbar fusion among patients older than 60 years of age. Moreover, the trial was not blinded, and the authors did not discuss

the method of randomization, or clearly describe the inclusion/ exclusion criteria. Non-blinding may be a source of observation bias, especially with the subjective primary outcomes of the trial. The investigators tried to partially overcome this limitation by blinding the orthopedic surgeons who evaluated the radiological outcomes. The authors also did not discuss any power analysis for determining the sample size, and analysis was not based on intention to treat. Overall, the results of the trial show significant improvements in health-related quality of life, as well as the leg, and back pains at one and two years of follow-up among the patients in the two treatment groups, when compared to the preoperative status. There were no significant differences in the primary outcomes between the two interventions. The outcomes may appear similar, but the lack of significant statistical significance does not necessarily imply equivalence. The study was relatively small and might have been unpowered to detect significant differences between the study groups. It was not designed as an equivalence trial that requires a larger sample size and different method of analysis than a superiority trial. Radiographic evaluations at two years showed higher fusion rate with rhBMP-2 vs. ICBG (86.3% and 70.8%, respectively). In conclusion there is insufficient published evidence to conclude that InFUSE Bone Graft is equivalent, noninferior, or superior to the standard iliac crest bone graft in improving functional ability and quality of life of patients with symptomatic degenerative disc disease.

**Articles:** The search revealed over 30 articles on rhBMP-2 /InFUSE Bone Graft. Many were unrelated to the current reviews; others used rhBMP-2 in different formulations or in combination with other elements e.g. ceramic granules. Two articles (Glassman, et al 2005 and 2008) reporting on one- and two-years results of a randomized controlled study comparing the use of rhBMP-2 versus iliac crest bone graft (ICBG) for lumbar spine fusion, were identified as well as a small nonrandomized trial and two case series studies on the use of InFUSE Bone Graft. The RCT with the 2-year follow-up was selected for critical appraisal. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: A randomized, controlled trial in patients over sixty years of age. *Spine*. 2008; 33:2843-9. See [Evidence Table](#).

The use of recombinant human bone morphogenetic protein (rhBMP-2) placed on an absorbable collagen sponge (ACS) in the treatment of degenerative disc disease does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## 06/21/2017: MTAC REVIEW

### InFuse Bone Graft

**Evidence Conclusion:** As indicated in the previous section, the literature search did not identify any more recent RCTs evaluating InFUSE® Bone Graft for ALIF, but a number of qualitative reviews and quantitative meta-analyses of the published trials. All trials were open-label, the great majority was industry sponsored, and the principal authors had financial ties with the industry.

**Efficacy and safety of InFUSE® Bone Graft compared to the gold standard autogenous iliac crest bone graft (ICBG)** Carragee and colleagues (2011) conducted a systematic review and critical analysis of the original peer reviewed industry-sponsored publications and compared their results and conclusions versus the available FDA summaries, follow-up publications, and administrative and organizational database analyses. According to the authors, the systematic review was prompted by complaints to the editorial board of the *Spine Journal* including allegations of research bias, failure to report adverse event recorded by the study surgeons, and discrepancies between FDA summaries and published data. The authors reviewed the results of 13 original industry-sponsored rhBMP-2 publications regarding safety and efficacy, including reports and analyses of 780 patients receiving rhBMP-2 within prospective controlled study protocols. These included studies using anterior, posterior and posterolateral interbody fusion. The estimated rate of adverse events associated with rhBMP-2 use in spinal interbody fusion ranged from 10% to 50% depending on the approach and spinal level of fusion.

- Anterior interbody lumbar with rhBMP-2 was associated with higher rates of implant displacement, subsidence, infection, urogenital events, and retrograde ejaculation versus the controls.
- Posterior lumbar interbody fusion was associated with radiculitis, ectopic bone formation, osteolysis, and poorer global outcomes.
- In posterolateral fusions, the risk of adverse effects associated with rhBMP-2 use was equivalent to or greater than that of iliac crest bone graft harvesting, and 15% to 20% of subjects reported early back pain and leg pain adverse events. Higher doses of rhBMP-2 were associated with a greater apparent risk of new malignancy.
- Anterior cervical fusion with rhBMP-2 had an estimated 40% greater risk of adverse events in the early postoperative period including life-threatening events.

The authors provided evidence showing discrepancy between the FDA documents and the published results of industry-sponsored trials on rhBMP-2. He noted that while the authors of the industry sponsored trials on ALIF, reported no adverse events, the FDA concluded that the original data from the trials indicate that “The incidence of adverse events that were considered device related, including implant displacement/loosening, implant malposition and subsidence were all greater in the investigational [rhBMP-2] groups compared to the control group” (Carragee 2011). Carragee and colleagues summarized the areas of concern regarding the safety and efficacy reported by the industry sponsored trials as follows:

1. Underestimation of adverse events and serious harms associated with rhBMP-2.
2. Presence and magnitude of conflict of interest and potential for reporting bias.
3. Invalid assumption and methodology used for estimating adverse events associated with iliac crest bone grafts, which led to exaggeration of the benefits underestimating the morbidity of rhBMP-2.
4. Significant bias against the selection of the control and techniques used in the PLIF and PLF.

The reviewers concluded that Level I and Level II evidence from original FDA summaries, original published data, and subsequent studies suggest possible study design bias in the original trials, as well as a clear increased risk of complications and adverse events to patients receiving rhBMP-2 in spinal fusion. This risk of adverse events associated with rhBMP-2 is 10 to 50 times the original estimates reported in the industry-sponsored peer-reviewed publications. [Fu and colleagues, 2013 \(Evidence Table 1\)](#) performed a meta-analysis to evaluate the effectiveness and harms of rhBMP-2 in spinal fusion and to assess the reporting bias in industry sponsored journal publications. The authors used data from the literature and individual patient level data of the rhBMP-2 trials (including unpublished data from the trials) provided by the manufacturer through the Yale Open Data Access (YODA) Project. The latter project was sponsored by the manufacturer for an independent review of all published and unpublished data. The analysis included 13 RCTs (12 sponsored by Medtronic) and 31 cohort studies, 47 intervention series, and 35 case series or reports. The primary outcome was the overall success and fusion. The meta-analysis had generally valid methodology, and the studies included were rated by the authors to be of moderate quality. However, all were unblinded; industry sponsored, and according to the authors, had poor ascertainment of harm. The authors analyzed anterior and posterior fusion separately as well as cervical and lumbar fusion. The pooled results of studies comparing rhBMP-2 versus ICBG for ALIF, showed no significant differences in overall success except for very slight improvement in leg pain at 6 weeks with rhBMP-2. There were higher rates to urogenital complications and retrograde ejaculation with rhBMP-2, the difference was not significant but could be due to insufficient power. The cancer risk was significantly higher with rh-BMP-2. The authors of the meta-analysis noted that early journal publications misrepresented the effectiveness and harms through selective reporting, under-reporting, and duplicate publications. They concluded that their technology had no proven advantage over bone graft and may be associated with important harms. [Simmonds et al, 2013 meta-analysis \(Evidence Table 2\)](#) also used data from the YODA project to evaluate the safety and effectiveness of rhBMP-2 compared to ICBG. The analysis included 12 RCTs (11 Medtronic sponsored) for effectiveness plus 35 additional controlled adverse events studies for safety analysis. The primary outcomes were patient centered pain and function, fusion and adverse events. The results of the analysis showed that from 6 months after surgery up to 2-years, rhBMP-2 led to greater pain reduction compared to ICBG. The authors noted however; the difference may not be clinically significant as patients in both treatment groups experienced considerable reduction in pain. Successful fusion rates were found to be higher with rhBMP-2 but there was significant heterogeneity between studies in the relative risk of fusion, and the authors noted that Medtronic definitions of fusion may have been stringent as only 69% of ICBG recipients achieved fusion in 24 months. The authors found no correlation between successful fusion with rhBMP-2 and pain reduction. As regards safety, the analysis showed that pain (which was reported as an outcome and as an adverse effect) was significantly higher with rhBMP-2 shortly after surgery and lower at 24 months, compared to ICBG. Other adverse events including Implant-related events, neurologic events, retrograde ejaculation, vascular events, wound complications, and cancer, all occurred at a higher rate with rh-BMP-2, but the difference did not reach a significant level, which could be attributed to the small number of events. [Zhang and colleagues, 2014 \(Evidence table 3\)](#) conducted a meta-analysis of randomized controlled trials to compare the effectiveness and safety of fusion with BMPs (-2 or -7) versus ICBG for the treatment of degenerative lumbar conditions. The analysis included 19 RCTs involving 1,852 patients. The studies recruited patients with a variety of spinal disorders and different approaches were used for the fusion. In 14 of the 19 trials rhBMP was used off-label. The co-primary outcomes of the analysis were solid fusion rate, clinical outcomes, complications, and reoperation rate. The pooled results showed that the rate of fusion was significantly higher among patients in BMPs group; however, this difference was no longer significant with the



sensitivity analysis that excluded 7 studies with high risk of bias. There were statistically significant differences in the overall success of clinical outcomes, complication rate, blood loss, hospital stay, patient satisfaction, or work status. Significant reductions in the operating time and reoperation rate were found in BMPs. This was a high-quality meta-analysis as regards its methodology, analysis and grading the evidence for each outcome. However, the quality of the results of a meta-analysis relies heavily on the quality of the studies it includes. Due to the nature of the intervention, all published trials evaluating rh-BMP-2 were unblinded, which is a source of bias, especially with subjective outcomes. In addition, there were other limitations to the published studies regarding methods of randomization and allocation procedures. There were variations between the trials in BMP used and the approach for fusion as well the methods and standards used for assessing the bone fusion which. The studies included in the meta-analysis used plain radiography, CT scan, or surgical exploration for evaluating the fusion rate. The authors explained that imaging was used to assess the status of spinal fusion, and that it provides less accurate data compared to direct operative exploration. In addition, the majority of the studies were industry sponsored and some of the authors reported conflict of interest. Overall, the authors concluded that the limited evidence does not show that BMP is superior to ICBG for the treatment of lumbar DDD and that more high-quality trials with long-term outcomes are needed. Other published meta-analyses (Chen, 2012 and Noshchenko, 2014) included the same industry sponsored RCTs, and had similar results showing that rhBMP-2 may lead to slightly higher fusion rates compared to ICBG, but with possible harm and no significant clinical improvement. **Impact of patient characteristics on the effectiveness and harms of rhBMP-2 compared with ICBG.** Laurie and colleagues' (2016) meta-analysis used the data from the YODA project to examine the impact of patient characteristics on the effectiveness and harms of rhBMP-2 as compared with ICBG. The analysis included 10 industry sponsored RCTs involving 1,255 participants. 5 trials used the anterior lumbar approach, 4 used the posterior lumbar, and one used the posterolateral lumbar approach for the interbody fusion with rhBMP-2. The population sizes of the individual trials varied from 10 to 463 participants. The results of the analysis suggest that there may be a differential treatment effect between rhBMP-2 and ICBG according to some patient characteristics. Fusion success was found to be higher with rhBMP-2 vs. ICBG in patients under the age of 60 at 6 months after the surgery and among smokers and normal weight individuals at 24 months postoperatively. No significant differences were observed between the two procedures for overweight or obese patients. The analysis also showed that the rate of device-related adverse events with rhBMP-2 was lower in individuals with no previous back surgery. **Impact of rh-BMP-2 dosing on outcomes** The BMP dose varied widely among the published studies which may indicate that is uncertainty regarding the optimal dose for the spinal fusion procedures. Hofstetter and colleagues' meta-analysis (2016) examined the effect of BMP dosing on successful fusion and morbidity with the common fusion procedures. The analysis included 48 articles involving 5,890 patients. 9 trials were on ALIF, 17 on transforaminal or posterior lumbar interbody fusion (TLIF/PLIF), 7 on anterior cervical discectomy and fusion (ACDF), and 9 trials on posterior lumbar fusion (PLF) supplemented with BMP. The authors performed separate meta-analyses for each procedure. The results of the analyses suggest that there is a wide range in the BMP dosing used for specific spinal fusion procedures (from 2.5mg/level for posterior cervical fusion [PCF] to 10.5mg/level in ACDF). The meta-analysis of studies on ALIF showed a trend toward an association between the likelihood of complications and the dose of BMP. In reports of ALIF supplemented with high doses of BMP (4.3-12.0 mg/level) the rates of endplate resorption and graft subsidence were high. More studies are needed to determine the safe and effective BMP dosing for the different applications.

#### **Conclusion:**

- The published literature does not provide sufficient evidence to determine that rh-BMP-2 has superior or equivalent effectiveness and safety compared standard iliac crest bone graft for adult patients with symptomatic lumbar degenerative disc disease referred to anterior interbody lumbar fusion.
- A number of meta-analyses and systematic reviews, including those using data from the Yale University Open Database Project, suggest that spinal interbody fusion using InFUSE® Bone Graft had a small or no advantage when compared to the standard use of iliac crest bone graft (ICBG), and may be associated with more serious adverse events.

**Articles:** The updated literature search did not reveal any recent trials that examined the efficacy and safety of using InFUSE® Bone Graft for anterior lumbar interbody fusion (ALIF) in patients with symptomatic single level degenerative disc disease from L1-L4. There was a number of systematic reviews with or without meta-analyses as well as several retrospective analyses on the effectiveness and safety of rhBMP-2 for spinal fusion. There were more publications and studies on the use of InFUSE® Bone Graft for cervical interbody fusion, or using the posterior, lateral, or posterolateral approaches for lumbar interbody fusion, all of which are off-label use of



InFUSE® and out of scope for the current review. Two meta-analyses that included individual patient data of the rhBMP-2 trials provided by the manufacturer through the Yale Open Data Access (YODA) project, as well as another meta-analysis of published trials were selected for critical appraisal. Fu R, Selph S, McDonagh M, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. *Ann Intern Med*. 2013 Jun 18; 158(12):890-902. Simmonds MC, Brown JV, Heirs MK, et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data. *Ann Intern Med*. 2013 Jun 18; 158(12):877-889. Zhang H, Wang F, Ding L, Zhang Z, et al. A meta-analysis of lumbar spinal fusion surgery using bone morphogenetic proteins and autologous iliac crest bone graft. *PLoS One*. 2014 Jun 2; 9(6): e97049.

The use of the InFUSE® Bone Graft/LT-Cage® Lumbar Tapered Fusion Device for Anterior Lumbar Interbody Fusion (Recombinant Bone Morphogenetic Protein Type 2 [rhBMP-2]) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary for InFUSE™:

CPT® Codes	Description
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
10/08/2003	10/08/2003 <sup>MPC</sup> , 12/07/2009 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 02/07/2017 <sup>MPC</sup> , 12/05/2017 <sup>MPC</sup> , 10/02/2018 <sup>MPC</sup> , 10/01/2019 <sup>MPC</sup> , 10/06/2020 <sup>MPC</sup> , 10/05/2021 <sup>MPC</sup> , 10/02/2022 <sup>MPC</sup> , 10/03/2023 <sup>MPC</sup> , 06/04/2024 <sup>MPC</sup>	12/06/2022

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/01/2017	Added MTAC second review
07/24/2020	Added code 20930 to criteria
12/06/2022	MPC approved to adopt a non-covered list of bone grafts substitutes and adjuncts. No 60-day notice required.



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Inhaled Nitric Oxide (iNO) Therapy

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Non-Medicare Members

- A. Treatment of pulmonary hypertension (PHN) to reduce risk of chronic lung disease, and respiratory failure in infants born or at near term (>34 weeks)
  - 1. Neonate does not have congenital diaphragmatic hernia, and
  - 2. Conventional therapies such as administration of high concentrations of oxygen, hyperventilation, high-frequency ventilation, the induction of alkalosis, neuromuscular blockade, and sedation have failed or are expected to fail.
  - 3. Treatment of Congenital Diaphragmatic Hernia (CDH)
    - a. iNO is required to stabilize a patient during transition to ECMO (Usually required for a few hours before)
    - b. iNO is required during transition off of ECMO when pulmonary arterial pressures are high (this can be a period of time ranging from hours to several days)
- B. Treatment of pulmonary hypertension in pre-term newborns (≤34 weeks)

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
- C. Treatment of acute respiratory distress syndrome (ARDS) in adults and children

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.
- D. Treatment of Cyanotic Congenital Heart Disease with pulmonary hypertensive crisis (all pediatric patients)
  - 1. The patient is being managed for acute pulmonary hypertension crisis and acute right heart failure with a predisposition to unrestricted over-circulation. OR
  - 2. The patient requires a surgical intervention with increased risk of pulmonary hypertension crisis and is receiving pulmonary vascular therapy AND
    - a. Typical course of treatment 3 days (this may be longer on a case by case basis) to transition to oral medications and wean-off iNO OR
    - b. The patient needs transplant for right heart failure and requires iNO for 1 week to several months.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

#### Treatment of persistent pulmonary hypertension (PPHN) and respiratory failure in infants born or at near term.

Persistent pulmonary hypertension of the newborn (PPHN) is an important cause of cardiorespiratory failure in the near-term neonate (>34 weeks). It occurs when normal cardiopulmonary transition fails to take place after birth;

the newborn's arteries to the lungs remain constricted limiting the amount of blood flow to the lungs and therefore the amount of oxygen into the blood stream. PPHN can occur either as a primary condition of neonatal maladaptation or secondary to other conditions such as pneumonia, sepsis, hyaline membrane disease, meconium aspiration, congenital diaphragmatic hernia, or pulmonary hyperplasia. Causes of PPHN may be variable, but all lead to same physiologic changes; a persistently raised pulmonary vascular resistance that leads to severe hypoxemia due to extra pulmonary shunting. Even with appropriate therapy, the mortality for PPHN remains between 5 and 10% (Gonzales 2009, Finer 2009, Steinhorn 2010).

The goal of therapy of PPHN is to maximize the amount of oxygen transported to the lungs and in turn to the systemic circulation. Conventional therapies include supplemental oxygen with often requires intubation and mechanical ventilation, induction of alkalosis, paralysis, sedation, as well as maintenance of temperature, electrolytes, glucose, and intravascular volume. Infants who fail conventional therapies may require treatment with extracorporeal membrane oxygenation (ECMO). During ECMO, the jugular vein and/or carotid artery is surgically bisected and connected to a heart-lung machine with a cannula to oxygenate the infant's blood. ECMO therapy can be lifesaving, but is highly invasive, labor intensive, and has potential side-effects such as intracranial hemorrhage and ligation of the right common carotid artery (Steinhorn 2010).

Inhaled nitric oxide (iNO) has been investigated for the treatment of PPHN to improve oxidation, reduce the need for ECMO, and decrease mortality. Nitric oxide is a colorless, almost odorless gas that is naturally produced by various human tissues and is involved in several physiologic functions. It is a rapid and potent vasodilator, and because of its small gas molecule, it can be delivered as inhalation therapy to airspaces in close proximity to the pulmonary vascular bed. Once in the blood stream NO binds to hemoglobin and is rapidly inactivated with an estimated half-life of 3-5 seconds. The effect of iNO is limited to the lungs making it a selective pulmonary vasodilator without adverse systemic hemodynamic effect (DiBlasi 2010, Steinhorn 2010).

iNO therapy is not without harmful side effects. When oxygen and nitric oxide mix together, they chemically react to form nitrogen dioxide (NO<sub>2</sub>), which is toxic to the lungs. Nitrogen dioxide concentrations greater than 10 parts per million (ppm) have been known to induce pulmonary edema, alveolar hemorrhage, changes in the surface tension properties of surfactant, and death. NO<sub>2</sub> is dose- dependent and its concentrations should be maintained below 3 ppm by decreasing the iNO concentration if its level increases. Methemoglobinemia (MetHb), which impairs the ability of the hemoglobin molecule to bind with oxygen, is another harmful side effect of iNO therapy. MetHb is dose-dependent and its levels must be carefully monitored. Significant methemoglobinemia has been reported after accidental overdose of iNO, and a level >10% may cause cyanosis, headaches, muscle weakness, and tissue hypoxia. Laboratory and clinical studies have suggested that high doses of inhaled nitric oxide may increase the risk of bleeding, which is a serious concern because of the predisposition of premature newborns to intracranial hemorrhage (Kinsella 2006, Finer 2009, Henry 2012).

The recommended initial dose of iNO is 20 ppm, and the duration of its use is normally less than 5 days but may be maintained for up to 14 days, or until the underlying oxygen desaturation has been resolved. Abrupt discontinuation of the therapy can lead to worsening of PaO<sub>2</sub> and increasing pulmonary artery pressure. The use of iNO was approved by the Food and Drug Administration (FDA) in 1999 for the treatment of term and near-term neonates (>34 weeks) with hypoxic respiratory failure with clinical or echocardiographic evidence of pulmonary hypertension. Using iNO for other medical conditions is considered "off label" usage.

iNO therapy is provided through a delivery system used in conjunction with a ventilator or other breathing gas administration system. Nitric oxide delivery system consists of a nitric oxide administration apparatus, a nitric oxide gas analyzer, and a nitrogen dioxide gas analyzer. INOmax® (INO Therapeutics Inc., Clinton NJ) is a commercially available brand of iNO that received initial Food and Drug Administration approval in 1999 to be used as a vasodilator in conjunction with ventilatory support and other appropriate agents. In 2009, the FDA updated the INOmax safety labeling indicating that in patients with pre-existing left ventricular dysfunction, iNO may increase pulmonary capillary wedge pressure leading to pulmonary edema, even when used for a short time (FDA webpage accessed July 20, 2012).

### **Treatment of pulmonary hypertension in pre-term newborns**

Approximately 8-13% of all babies are born preterm (<37 weeks of gestation) across developed countries. Although survival rates have improved markedly in recent decades, preterm delivery still accounts for more than 75% of all perinatal complications and death. It is estimated that three fourths of preterm infants with birth weight <1000g develop respiratory distress syndrome (RDS), and 30- 40% are still oxygen dependent at a postmenstrual age (gestational age plus chronological age) of 36 weeks. Breathing failure in premature newborns may be complicated by raised pressure within the vessels that carry blood to the lungs (pulmonary hypertension). Those who require assisted ventilation are at high risk of developing long-term medical and neurocognitive impairment

including bronchopulmonary dysplasia (BPD), which is characterized by arrested lung growth, reduced alveolarisation, and dysmorphic vasculature (i.e. the infants' lungs are not fully formed or are not able to make enough surfactant, which is a liquid that coats the inside of the lungs and helps keep them open so an infant can breathe in air once he or she is born). Without surfactant, the lungs collapse, and the infant may not be able to breathe in enough oxygen to support the body's organs. This may lead to neurodevelopmental impairment and damage to other organs (Barrington 2006, Askie 2010, 2011).

Conventional therapy of respiratory failure complicated by pulmonary hypertension in preterm newborn involves respiratory support, which includes assisted ventilation and continued distending pressure, the administration of surfactant, and sedation or muscle relaxation if needed.

iNO has been investigated as a treatment to prevent lung injury in preterm infants based on the findings from experimental studies performed on a variety of fetal animals and/ or premature animal models with hyaline membrane disease and elevated pulmonary artery pressure. These experiments showed that iNO therapy may enhance pulmonary angiogenesis and lung alveolarisation, reduce the pulmonary vascular resistance and improve oxygenation. Studies in full-term infants also showed that iNO may cause selective pulmonary vasodilatation to reduce pulmonary artery pressure and improve ventilation /perfusion mismatch. However, the results of studies conducted among term or near-term infants cannot be extrapolated to the preterm babies because of the difference in pathophysiology of respiratory failure, and the difference in the potential risks of iNO in preterm infants. If iNO therapy leads to a decrease in required ventilation support, it may also lead to a reduction in lung injury and bronchopulmonary dysplasia. However, it is still uncertain which subpopulation of premature infants may profit most from iNO. There is also opposing data on whether exogenous NO is protective or destructive in the presence of hyperoxia. Inhaled nitric oxide has pro-oxidation and antioxidants activities and can potentially worsen lung injury. Preterm infants are also at higher risk of developing intracranial hemorrhage, and there is a concern about the effect of iNO in increasing the bleeding time (Barrington 2006, Love 2012).

Inhaled nitric oxide is provided through a delivery system used in conjunction with a ventilator or other breathing gas administration system. iNO delivery system consists of a nitric oxide administration apparatus, a nitric oxide gas analyzer, and a nitrogen dioxide gas analyzer. INOmax® (INO Therapeutics Inc., Clinton NJ) is a commercially available brand of iNO that received initial Food and Drug Administration approval in 1999 to be used as a vasodilator in conjunction with ventilatory support and other appropriate agents for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The use of iNO for other neonatal medical conditions is considered "off label" use.

### **Treatment of acute respiratory distress syndrome (ARDS) in adults and children**

Acute respiratory distress syndrome (ARDS) is a major source of morbidity and mortality, with a case fatality rate exceeding 30%. ARDS is defined by acute non-cardiogenic pulmonary edema, acute severe hypoxemia irrespective of positive end expiratory pressure, bilateral infiltrates on chest radiography, and a pulmonary artery occlusion pressure  $\leq 18$  in any adult or child more than one month old. Acute lung injury (ALI) is a milder form of the syndrome and both conditions are often referred to as acute hypoxemic respiratory failure (AHRF). They are characterized by an inflammatory process of the alveolar-capillary membrane that may result from a primary lung disease or is secondary to a number of systemic diseases. AHRF results in intrapulmonary shunting with hypoxemia and pulmonary hypertension. Hypoxemia in ARDS is mainly caused by ventilation perfusion mismatch leading to increased pulmonary shunting due to pulmonary vasodilatation in non-ventilated lung regions and vasoconstriction in ventilated areas (Milberg 1995, Afshari 2011, 2012).

Treatment of ARDS/ALI is mainly supportive and aims at improving gas exchange, control of infection, and preventing complications. The optimal therapy involves judicious fluid management, protective mechanical lung ventilation with low tidal volumes and moderate positive end expiratory pressure, multi-organ support, and treatment of the underlying cause, when possible. Pharmacotherapies have a very limited role in the management of ARDS, and to-date there is no effective medical treatment that improves survival for adult patients with the syndrome, although exogenous surfactant is beneficial in the pediatric population (Dushianthan 2011).

In 1991, inhaled nitric oxide (iNO) was shown to be a selective pulmonary vasodilator in patients with pulmonary hypertension, as well as in animals with pulmonary hypertension induced by drugs or hypoxia. Two years later, inhaled nitric oxide was introduced as a potential therapy for ARDS. Nitric oxide is a colorless, odorless gas that rapidly diffuses from alveoli through epithelial cells to gain direct access to the vasculature. Once in the blood stream it binds to hemoglobin and is rapidly inactivated with an estimated half-life of 3-5 seconds. The effect of iNO is limited to the lungs making it a selective pulmonary vasodilator without adverse systemic hemodynamic effects. iNO causes vasodilatation of ventilated lung units and redistribution of pulmonary blood flow away from

non-ventilated lung areas. It decreases pulmonary vascular resistance, improves the ventilation perfusion mismatch, and subsequently reduces the elevated vascular resistance and pulmonary hypertension. It is also believed that iNO may also regulate both the immune and inflammatory responses (oxygenation by redistributing pulmonary blood flow toward ventilated lung units in patients with this condition (Griffiths 2005, DiBlasi 2010, Dushianthan 2011, Pierrakos 2011).

iNO therapy is also associated with harmful side effects. Nitric oxide is unstable in air and when inhaled with high concentrations of oxygen, the gaseous NO slowly forms nitrogen dioxide which is potentially cytotoxic. A NO<sub>2</sub> concentrations higher than 10 parts per million (ppm) has been known to induce pulmonary edema, alveolar hemorrhage, changes in the surface tension properties of surfactant, and death. NO<sub>2</sub> is dose-dependent and its concentration should be maintained at a level below 3 ppm by decreasing the iNO concentration if it goes any higher. Methemoglobinemia (MetHb), which impairs the ability of the hemoglobin molecule to bind with oxygen, is another harmful side effect of iNO therapy. MetHb is dose-dependent and must be carefully monitored as significant methemoglobinemia has been reported after accidental overdose of iNO. A MetHb level >10% may cause cyanosis, headaches, muscle weakness, and tissue. Renal failure has also been reported with iNO use (Kinsella 2006, Finer 2009, Dushianthan 2011, Henry 2012).

Inhaled nitric oxide is provided through a delivery system used in conjunction with a ventilator or other breathing gas administration system. The delivery system consists of a nitric oxide administration apparatus, a nitric oxide gas analyzer, and a nitrogen dioxide gas analyzer. INOmax® (INO Therapeutics Inc., Clinton NJ) is a commercially available brand of iNO that received initial Food and Drug Administration approval in 1999. It was approved for use as a vasodilator, in conjunction with ventilatory support and other appropriate agents for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension. The use of iNO for other neonatal medical conditions and for treatment in the adult patient population is considered "off label" usage.

## Medical Technology Assessment Committee (MTAC)

### *iNO for Treatment of Persistent Pulmonary Hypertension*

**08/20/2012: MTAC REVIEW**

#### **Evidence Conclusion:**

There is fair evidence that inhaled nitric oxide therapy for adult patients with acute respiratory distress syndrome or acute lung injury does not improve survival or other clinical outcomes and may increase the risk of renal impairment. There are insufficient published pediatric trials to determine any benefit or harm of iNO therapy in children with ARDS or ALI.

**Articles:** Treatment of persistent pulmonary hypertension (PPHN) and respiratory failure in infants born or at near term: The literature search revealed a number of randomized controlled studies and a Cochrane review with a meta-analysis that pooled the results of 12 RCTs. The Cochrane review and the RCT published after the meta-analyses were selected for critical appraisal. Finer N and Barrington KJ. Nitric Oxide for respiratory failure in infants born at or near term. *Cochrane Database Syst Rev*. 2006 (updated 2009) Issue 4. Art No. CD000399. [See Evidence Table](#). Gonzalez A, Fabres J, D'Apremont I, et al. Randomized controlled trials of early compared with delayed use of inhaled nitric oxide in newborns with a moderate respiratory failure and pulmonary hypertension. *J Perinatol* 2010; 30:420-424. [See Evidence Table](#). Treatment of pulmonary hypertension in pre-term newborns. The literature search revealed a number of randomized controlled studies published between the late 1990s and 2010 and four meta-analyses that pooled the results of all, or some of these trials including a Cochrane review (Burrington and Finer) first published in 2006 and last updated in 2010, an earlier meta-analysis (Hoehn 2000 updated in 2006) and two more recent meta-analysis (Askie 2011, and Donahue 2011). The Cochrane review and Askie and colleagues' meta-analysis of individual patient data from the same trials included in the Cochrane review were selected for critical appraisal. Askie LM, Ballard RA, Cutter GR, Dani C, et al for the Meta-analysis of Preterm Patients on Inhaled Nitric Oxide (MAPPiNO) Collaboration. Inhaled nitric oxide in preterm infants: An individual -patient data meta-analysis of randomized trials. *Pediatrics*. 2011; 128:729-739. [See Evidence Table](#). Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. *Cochrane Database Syst Rev*. 2010 Dec 8;(12):CD000509. [See Evidence Table](#). Treatment of acute respiratory distress syndrome (ARDS) in adults and children. The literature search revealed a number of randomized controlled studies and two meta-analyses of RCTs (Adhikari 2007, and Afshari (described in 2 publications 2010 and 2011). No trials published after the last meta-analysis were identified by the search. The more recent meta-analysis was selected for critical appraisal. Afshari A, Brok J, Moller AM et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. *Cochrane Database of Systematic Reviews* 2010, Issue 7. Art. No.: CD002787.pub2. [See Evidence Table](#). Afshari A, Brok J, Moller AM et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. A systematic review with meta-analysis and trial sequential analysis. *Anesth Analg* 2011; 112:1411-1421. [See Evidence Table](#).



The use of iNO for Treatment of persistent pulmonary hypertension (PPHN) and respiratory failure in infants born or at near term does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of iNO for treatment of pulmonary hypertension pre- term newborns does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

The use of iNO for treatment of ARDS in adults and children does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
No Specific Codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Review Dates	Date Last Revised
09/04/2012	09/04/2012 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 11/05/2013 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 03/07/2017 <sup>MPC</sup> , 01/09/2018 <sup>MPC</sup> , 12/04/2018 <sup>MPC</sup> , 12/03/2019 <sup>MPC</sup> , 12/01/2020 <sup>MPC</sup> , 12/07/2021 <sup>MPC</sup> , 12/06/2022 <sup>MPC</sup> , 12/09/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	08/06/2013

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Injectable Bulking Agents for Fecal Incontinence

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	<a href="#">Injectable Bulking Agents for the Treatment of Fecal Incontinence (A52923)</a> 12/04/2017 Noridian <b>retired</b> Local Coverage Article (LCA A52923). These services still need to meet medical necessity as outlined in the LCA and will require review. LCAs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCAs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on Kaiser Permanente commercial criteria or literature search.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Fecal incontinence occurs when a person loses the ability to control his/her bowel movements and is unable to retain feces in the rectum. It can be caused by a wide variety of conditions that affect either the anatomy or function of the anal sphincter. Perineal injury during childbirth is a common cause of fecal incontinence in women. It can also be caused by neurological disorders such as spinal injury and multiple sclerosis, or it can result from anorectal surgery. In any case, fecal incontinence is common and, due to its association with considerable physical and social disability, is often under-reported (Tjandra, Chan et al. 2009).

First line treatment for fecal incontinence is usually conservative and includes antidiarrheal medication and pelvic floor muscle training. In patients for whom conservative treatment fails, alternative treatments include surgery to tighten the anal sphincter, sacral nerve stimulation, creation of a new sphincter from other suitable muscles,

implantation of an artificial sphincter or a permanent colostomy. Injectable bulking agents offer an additional, less invasive, second line treatment for fecal incontinence. The concept is to inject a biocompatible material to close the anal canal to avoid fecal incontinence (Siproudhis, Morcet et al. 2007; Maeda, Vaizey et al. 2008; Graf, Mellgren et al. 2011).

At least ten different materials have been used as bulking agents for fecal incontinence including autologous fat, Teflon, bovine glutaraldehyde, cross-linked collagen, carbon coated zirconium beads, polydimethylsiloxane elastomer, dextranomer in nonanimal stabilized hyaluronic acid, hydrogel cross-linked with polyacrylamide, porcine dermal collagen, synthetic calcium hydroxylapatite ceramic microspheres and polyacrylonitrile in cylinder form (Maeda, Laurberg et al. 2013). The material can be injected either via the perianal skin or via the anal mucosa. The procedure may be performed under local, regional or general anesthesia and the injection may be guided by the surgeon's finger in the anal canal or by ultrasound. This treatment is potentially attractive in its simplicity and minimal invasiveness and can be performed in an outpatient setting.

Several injectable bulking agents have been approved by the U.S. Food and Drug Administration (FDA) in recent years for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy.

The Medical Technology Assessment Committee (MTAC) previously reviewed and failed bulking agents for the treatment of GERD in 2003. Currently, the committee has been asked to review the literature on the safety and efficacy of injectable bulking agents for the treatment of fecal incontinence compared to standard treatment for fecal incontinence. This is the first time that bulking agents have been reviewed for this indication. The topic is being reviewed for decision making guidance.

## Medical Technology Assessment Committee (MTAC)

### *Injectable Bulking Agents for Fecal Incontinence*

#### **10/21/2013: MTAC REVIEW**

**Evidence Conclusion:** There is evidence from one large randomized trial to suggest that injectable bulking agents are effective up to 12 months. There is evidence to suggest that injectable bulking agents are reasonably safe in the short term. There is no evidence to permit conclusions about long term safety or efficacy of injectable bulking agents for fecal incontinence.

**Articles:** A literature search was conducted revealing a variety of publications including multiple case-series reports as well as case-control and cohort studies. One recent Cochrane review was also revealed which included five randomized trials measuring the effects of bulking agents versus placebo, bulking agents versus other types of bulking agents and bulking agents versus other minimally invasive interventions. No studies that compared the injection of bulking agent versus conservative treatment were revealed. Four of the studies included reporting of adverse events up to 12 months post treatment. The Cochrane review did not pool the results of the trials due to their heterogeneity. Four of the five trials included in the Cochrane Review were selected for appraisal: Graf W, Mellgren A, Matzel KE, Hull T et al. Efficacy of dextranomer in stabilized hyaluronic acid for treatment of faecal incontinence: a randomized, sham-controlled trial. *Lancet* 2011; **377**(9770):997-1003.

[See Evidence Table 1.](#) Siproudhis, L., J. Morcet, et al. Elastomer implants in faecal incontinence: a blind, randomized placebo-controlled study. *Alimentary Pharmacology & Therapeutics* 2007;**25**(9):1125-1132.

[See Evidence Table 2.](#) Tjandra, J., W. Han, et al. (2004). "Injectable silicone biomaterial for faecal incontinence due to internal sphincter dysfunction is effective." *Diseases of the Colon & Rectum* **47**(12): 2138-2146. [See Evidence Table 3.](#) Tjandra, J, Chan M, et al. Injectable silicone biomaterial (PTQTM) is more effective than carbon-coated beads (Durasphere®) in treating passive faecal incontinence – a randomized trial." *Colorectal Disease* 2009;**11**(4):382-389. [See Evidence Table 4.](#)

The use of Injectable Bulking Agents for Fecal Incontinence does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### **Considered Not Medically Necessary:**

CPT® or HCPC Codes	Description
<b>L8605</b>	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Creation Date	Review Dates	Date Last Revised
12/03/2013	01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 02/05/2019 <sup>MPC</sup> , 02/04/2020 <sup>MPC</sup> , 02/02/2021 <sup>MPC</sup> , 02/01/2022 <sup>MPC</sup> , 02/07/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	12/09/2015

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
09/08/2015	Revised LCD L35008
12/9/2015	Added LCA A52922

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Dermal Fillers for Facial Lipoatrophy

- Sculptra
- Radiesse

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Dermal Injections for the Treatment of Facial Lipodystrophy Syndrome (LDS) (250.5)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

Dermal filler injections are covered when **ALL** of the following criteria are met:

- 1) The member has **ALL** of the following:
  - a) a diagnosis of human immunodeficiency virus (HIV), and
  - b) a diagnosis of facial lipodystrophy/lipoatrophy, grades 3-4\*, related to HIV or highly active antiretroviral therapy (HAART), and

#### AND

- 2) The dermal filler is approved by the Food and Drug Administration for Facial Lipodystrophy Syndrome (LDS), e.g. Sculptra® and Radiesse®.

Multiple sessions may be necessary to complete the therapy, depending upon the severity of the lipodystrophy. The following link provides examples of the Carruthers grading system\*: [www.facialwasting.org](http://www.facialwasting.org).

If the patient has:

- 1) Grade 3 lipodystrophy, up to 4 sessions may be required
- 2) Grade 4 lipodystrophy, up to 8 sessions may be required

\*If additional treatments are desired, the treating provider will need to reevaluate the patient or repeat photos of the patient's face will be required to determine if further treatments are warranted.

Repeat treatment is typically necessary one to two years after the initial therapy, when the patient has regressed to Grade 2 or greater lipoatrophy.

#### CONTRAINDICATIONS

Coagulopathy, active infection (whether or not related to HIV disease), inadequate immune function as determined by HIV provider.

**If requesting review for this service, please send the following documentation:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

HIV-associated lipodystrophy has been reported in the literature starting in the late 1990s. This condition involves loss of subcutaneous fat or fat accumulations in particular regions of the body. It can include fat accumulation around the abdomen, dorsocervical area (buffalo hump) and breast hypertrophy. Regions affected by fat loss (lipoatrophy) include the limbs, buttocks and face, especially the nasolabial regions, the temples and the eye sockets. The condition is different from HIV wasting syndrome that is mainly due to loss of muscle mass. HIV-associated lipodystrophy is also associated with insulin resistance, hyperglycemia and low levels of high-density lipoprotein (HDL) (James et al., 2002).

Although the cause of HIV-associated lipodystrophy is not well understood, some investigators believe there is a link with HIV protease inhibitors (PI). The condition started being reported in the literature around the time that protease inhibitors were introduced and prescribed to HIV-infected patients. In addition, the prevalence of lipodystrophy is higher in HIV-infected patients who received PIs compared to PI-naïve patients (James et al., 2002). Lipoatrophy may be associated with the use of specific nucleosides such as stavudine and didanosine in treatment while lipoaccumulation may be associated with protease inhibitors, especially ritonavir (Dr. Wayne Dodge, personal communication).

The treatment of facial lipoatrophy is the subject of the current MTAC review. There is little published literature on this topic, but anecdotal information suggests that facial lipoatrophy negatively affects HIV-infected individuals' body image and self-esteem and can lead to social and sexual problems. The long-term natural history of lipoatrophy is also not well known. Lipoatrophy does not appear to resolve on its own, or after discontinuation of PIs and other medication (James et al., 2002; Huff, 2004).

Sculptra, an injectable form of poly-L-lactic acid (PLA) is the first FDA-approved treatment for HIV-associated facial lipoatrophy. PLA is a biocompatible, biodegradable substance that is synthetically derived from natural components. It was been used in surgical products such as dissolvable stitches and bone screws. PLA was approved in Europe in 1999 for cosmetic treatment of scars and wrinkles, under the brand name New-Fill. The FDA did not approve Sculptra for the treatment of wrinkles. FDA approval of Sculptra for facial lipoatrophy was based on unpublished data submitted by the manufacturer Dermik Laboratories. A condition of FDA approval was that Dermik agreed to conduct a registry study for five years to evaluate Sculptra's long-term safety (FDA press release; James et al., 2002). Potential limitations of injectable PLA for severe cases of facial lipoatrophy are that large quantities of material are needed to fill the defects and there may be high maintenance costs (Binder & Bloom, 2004).

## Medical Technology Assessment Committee (MTAC)

### *Injectable Poly-L-Lactic Acid (PLA)*

#### **12/08/2004: MTAC REVIEW**

**Evidence Conclusion:** There was one randomized controlled trial with 30 patients (Moyle, 2004) and this compared immediate treatment with PLA to delayed treatment after 12 weeks. The 12-week follow-up is the appropriate point in the study to compare treatment with no treatment. At 12 weeks, there were no significant differences between groups in depression or anxiety scores. A significantly greater proportion of patients in the immediate treatment group perceived "less thinness" in the face. The study was limited by the short follow-up period, small sample size with no statistical power analysis and lack of clear primary outcomes. The other empirical study reviewed was a case series with 50 patients (Valentin, 2003). Although there was no comparison group, advantages of the Valentin study were that there was objective measurement of changes in facial thickness and follow-up was longer, 96 weeks. There was a significant increase in total cutaneous thickness (TCT) of the face after a series of treatments with PLA and the increase in TCT persisted until the 96-week follow-up. There was a significant increase in the quality of life score compared to baseline at the 24- and 48 weeks follow-ups, but not at the 72- or 96-week follow-ups. No serious adverse effects were reported in either study. Safety and efficacy beyond 96 weeks is not known. The generalizability of Valentin study has been criticized because one dermatologist performed all of the injections; it is not known whether there would be similar results

with other dermatologists. In summary, there is some evidence from an uncontrolled case series that treatment with Sculptra can reduce facial lipoatrophy for up to 96 weeks and has no serious adverse effects, when used by a trained dermatologist. There are no good data from controlled studies. The impact on quality of life is less clear. There are no published data on safety and efficacy of Sculptra beyond 96 weeks.

**Articles:** The search yielded 10 articles. Several were reviews or opinion pieces. Three empirical studies were identified. The ideal study would have the following characteristics: Randomized controlled trial, Comparison of Sculptra to alternative treatment, or placebo, Long-term follow-up, sufficiently large sample size, Important outcomes include whether treatment with Sculptra is effective at increasing facial fat and reduces any adverse psychosocial effects. In this case, there is no standard alternate treatment and no other FDA-approved new treatments for HIV-associated facial lipoatrophy. No placebo-controlled studies were identified. There was one randomized controlled trial that compared immediate treatment with PLA to delayed treatment. There was also a case series with 96 weeks' follow-up. Case series can provide important long-term safety data. The RCT and case series were critically appraised. Both used New-Fill, the European version of PLA. The third empirical study was a case report presenting data on 4 patients and was excluded from review. The following studies were critically appraised: Valantin M-A Aubron-Olivier C, Ghosn J et al. Poly lactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. *AIDS* 2003; 17: 2471-2477. See [Evidence Table](#). Moyle GJ, Lysakova L, Brown S et al. A randomized open-label study of immediate versus delayed poly lactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. *HIV Medicine* 2004; 5: 82-87. See [Evidence Table](#).

The use of injectable poly-L-lactic acid (PLA) in the treatment of facial lipoatrophy does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
G0429	Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (LDS) (e.g., as a result of highly active antiretroviral therapy)
Q2026	Injection, Radiesse, 0.1 ml
Q2028	Injection, Sculptra, 0.5 mg

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/08/2004	12/08/2004, 07/06/2010 <sup>MDCRPC</sup> , 05/03/2011 <sup>MDCRPC</sup> , 03/06/2012 <sup>MDCRPC</sup> , 01/08/2013 <sup>MDCRPC</sup> , 11/05/2013 <sup>MPC</sup> , 09/02/2014 <sup>MPC</sup> , 07/07/2015 <sup>MPC</sup> , 05/03/2016 <sup>MPC</sup> , 03/07/2017 <sup>MPC</sup> , 01/09/2018 <sup>MPC</sup> , 12/04/2018 <sup>MPC</sup> , 12/03/2019 <sup>MPC</sup> , 12/01/2020 <sup>MPC</sup> , 12/07/2021 <sup>MPC</sup> , 12/06/2022 <sup>MPC</sup> , 12/09/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	05/04/2021

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/04/2021	MPC approved coverage criteria for non-Medicare members. Requires 60-day notice, effective date 10/01/2021.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Inpatient Rehabilitation

- Admission guidelines

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	<a href="#">See the Medicare Benefit Policy Manual</a> Chapter 1 - Inpatient Hospital Services Covered Under Part A 110 - Inpatient Rehabilitation Facility (IRF) Services
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### For Non-Medicare Members

**Inpatient Rehabilitation Facility (IRF - acute rehabilitation)** admission is indicated by **ALL of the following**:

- 1) No acute hospital care needs.  
The inpatient rehabilitation benefit is not to be used as an alternative to completion of the full course of treatment in the referring hospital. (e.g. for completion of antibiotics or to observe renal failure)
- 2) A preadmission screening assessment must be completed. A preadmission screening assessment is an evaluation of the patient's condition and need for rehabilitation therapy and medical treatment that must be conducted by licensed or certified clinician(s) (Registered Nurse, Physical or Occupational Therapist, Nurse Practitioner, or Medical Doctor) within the 48 hours immediately preceding the IRF admission. A preadmission screening that includes all of the required elements, but that is conducted more than 48 hours immediately preceding the IRF admission, will be accepted as long as an update is conducted in person or by telephone to document the patient's medical and functional status within the 48 hours immediately preceding the IRF admission in the patient's medical record at the IRF.
- 3) There must be documentation in the preadmission screening assessment (a copy of the assessment must be available for review) that includes **ALL of the following**:
  - a) Must indicate the patient's prior level of function (prior to the event or condition that led to the patient's need for intensive rehabilitation therapy),
  - b) Expected level of improvement and
  - c) Expected length of time necessary to achieve that level of improvement.
  - d) Nature and degree of improvement identified with practical goals established for patient's condition
  - e) Conditions that caused the need for rehabilitation,
  - f) Treatments needed (i.e., physical therapy, occupational therapy, speech-language pathology, or prosthetics/orthotics),
  - g) Expected frequency and duration of treatment in the IRF,
  - h) Discharge plan that includes **ALL of the following**:
    - Anticipated discharge destination including documentation that patient will be appropriate for discharge to home or to a community-based environment. (not to a SNF or LTC facility)
  - i) Any anticipated post-discharge treatments and any other information relevant to the care needs of the patient.

- 4) In order for IRF care to be considered reasonable and necessary, the documentation must demonstrate a reasonable expectation that **ALL of the following** criteria will be met at the time of admission to the IRF:
- The patient must require the active and ongoing therapeutic intervention of more than two therapy disciplines (physical therapy, occupational therapy, speech-language pathology, or prosthetics/orthotics), one of which must be physical or occupational therapy.
  - Need for an intensive rehabilitation therapy program that includes **ONE or more** of the following:
    - Therapy at least 3 hours per day for 5 days per week OR
    - Therapy at least 15 hours per week consecutive days
  - Therapy must not exceed the patient's need or tolerance or compromise the patient safety.
  - The patient must reasonably be expected to actively participate in, and benefit significantly from, the intensive rehabilitation therapy program. Also, there should be a reasonable expectation that a measurable, practical improvement in the patient's functional condition can be accomplished within a predetermined and reasonable period of time.
  - Close physician involvement with need for treating rehabilitation physician face-to-face assessment at least 3 days per week (e.g. monitoring of uncontrolled pain, bowel and bladder issues, and complex rehabilitation needs such as adapting mobility devices.)
  - The patient must require an intensive and coordinated interdisciplinary approach to providing rehabilitation
- 5) Document must state why an equivalent outcome will not be achieved in a Skilled Nursing Facility.

The following indications are **not** covered:

- Coma stimulation
- Custodial care
- Routine services for maintenance of medication administration, routine enteral feedings, routine colostomy care, ongoing straight catheterization for chronic conditions.
- Single joint replacement unless the individual has significant comorbidity(ies) resulting in functional deficits which would necessitate an acute inpatient level of rehabilitation in order to achieve a satisfactory outcome within a reasonable time period.

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Inpatient rehabilitation hospital admissions provide intensive rehabilitation to patients with various neurological, musculo-skeletal, orthopedic and other medical conditions following stabilization of their acute medical issues. The inpatient rehabilitation bed is specifically licensed for the rehabilitation services and is sometimes part of an acute hospital or a separate facility.

Rehabilitation hospitals were created to meet a perceived need for facilities which were less costly on a per diem basis than general hospitals, but which provided a higher level of professional therapies such as speech therapy, occupational therapy, and physical therapy than can be obtained in a "skilled nursing care" facility. Prior to admission to an inpatient rehabilitation facility an evaluation is conducted by a physiatrist to determine appropriateness for this level of admission.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/04/2014	02/02/2010 <sup>MDCRPC</sup> , 01/04/2011 <sup>MDCRPC</sup> , 01/03/2012 <sup>MDCRPC</sup> , 02/05/2013 <sup>MPC</sup> , 2/04/2014 <sup>MPC</sup> , 03/04/2014 <sup>MPC</sup> , 02/03/2015 <sup>MPC</sup> , 11/03/2015 <sup>MPC</sup> , 09/06/2016 <sup>MPC</sup> , 07/11/2017 <sup>MPC</sup> , 05/01/2018 <sup>MPC</sup> , 05/07/2019 <sup>MPC</sup> , 05/05/2020 <sup>MPC</sup> , 05/04/2021 <sup>MPC</sup> , 05/03/2022 <sup>MPC</sup> , 05/02/2023 <sup>MPC</sup> , 11/05/2024 <sup>MPC</sup>	06/21/2017

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
06/21/2017	Added a clarifying sentence to 4 d

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Insulin Pump

- InPen System

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Infusion Pumps (280.14)</a>
Local Coverage Determinations (LCD)	<a href="#">External Infusion Pumps (L33794)</a>
Local Coverage Article	<a href="#">External Infusion Pumps – Policy Article (A52507)</a>
Kaiser Permanente Medical Policy	<p><b>For InPen System Requests</b></p> <p>Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, “<a href="#">InPen System</a>” for medical necessity determinations. Refer to the Non-Medicare criteria below.</p>

#### For Non-Medicare Members

##### Initial Insulin Pump:

- I. To qualify for an insulin pump the member must meet **ALL of the following**:
  - A. Patient has Type 1 diabetes of at least six months' duration or Type 2 diabetes requiring a basal/bolus insulin regimen of multiple daily injections using long-acting basal insulin and a rapid-acting analogue
  - B. Referral initiated by a Diabetes specialist\* that will manage therapy with an insulin pump.
  - C. Documentation from the Diabetes specialist\* that includes **ALL of the following**:
    1. Assessment for clinical therapeutic value of an insulin pump.
    2. Assessment of patient pump education and skill training preparation prior to pump start (either one-on-one or within a group).
    3. Assessment of the patient's (or caregiver's) ability to safely and appropriately participate in an insulin-pump self-management plan.
  - D. Has been on a treatment regimen of multiple daily injections (MDI) of insulin that includes a trial of both a long-acting insulin analog and a short-acting insulin analog with a plan for pre-meal short acting insulin dose adjustment for at least 3 – 6 months prior to initiation of the insulin pump.
  - E. Require less than 200 units of total insulin per day prior to pump therapy.
  - F. Has documented logs of glucose self-testing or CGM results - at least 4 times per day during the 1 month prior to consideration of an insulin pump.
  - G. Meets **ONE or more of the following** while on an MDI regimen:
    1. Recent history (within last six months) of significant, recurring hypoglycemia (blood glucose < 70 mg/dl).
    2. Wide fluctuations (well below and above the set glycemic targets) in blood glucose before and after mealtimes, despite appropriate MDI using up to date insulins (analogs) and dose adjustments to affect control.
  - H. Patient has advanced carbohydrate counting skills and actively uses this information for insulin dosing

- I. Patient demonstrates ability to recognize their glucose patterns and safely problem-solve these
- J. Has no other illness that could impede use of the pump (i.e., alcohol/chemical abuse, psychological instability, difficulty with digital dexterity, visual impairment).
- K. Pediatric Patients
  - 1. On a case-by-case basis, upon review by a clinical review medical director, pediatric patients under the age of 13 may waive the 6-month time period, if patient monitoring is occurring per the diabetes management plan outlined by an Endocrinologist.

\*Note – Requests for an insulin infusion pump used with continuous glucose sensing (HCPCS code E0787 or E0784 for Medicare) will only be authorized if the patient meets both criteria for initial or replacement insulin pump as outlined in this criteria and all criteria outlined in the [Continuous Glucose Monitoring](#) clinical review criteria including that current device is no longer under warranty.

### Ongoing Coverage of Pump and Supplies:

To qualify for ongoing coverage of an insulin pump the member must meet **ALL of the following**:

- A. There is documentation that patient monitors glucose at least four times daily, or appropriately uses a continuous glucose monitor.
- B. Patient maintains advanced carbohydrate counting skills and actively uses this information for insulin dosing
- C. Patient maintains ability to recognize their glucose patterns and safely and appropriately problem-solve these, including troubleshooting pump malfunction
- D. Patient does not have other conditions or psychosocial stressors which might impede safe use of an insulin pump
- E. Patient has at least one visit per year with diabetes specialist\* (face-to-face, secure message, or telephone encounter)

### InPen System

To qualify for an InPen System the member must meet **ALL of the following**:

- A. Patient has Type 1 diabetes of at least six months' duration or Type 2 diabetes requiring a basal/bolus insulin regimen of multiple daily injections using long-acting basal insulin and a rapid-acting analogue
- B. Referral initiated by a Diabetes specialist\* that will manage therapy with an InPen System.
- C. Documentation from the Diabetes specialist\* that includes **ALL of the following**:
  - 1. Assessment for clinical therapeutic value of an InPen System.
  - 2. Assessment of patient InPen education and skill training preparation prior to InPen start (either one-on-one or within a group).
  - 3. Assessment of the patient's (or caregiver's) ability to safely and appropriately participate in an InPen System self-management plan.
- D. Has been on a treatment regimen of multiple daily injections (MDI) of insulin that includes a trial of both a long-acting insulin analog and a short-acting insulin analog with a plan for pre-meal short acting insulin dose adjustment for at least 3 – 6 months prior to initiation of the InPen System.
- E. Has documented logs of glucose self-testing or CGM results - at least 4 times per day during the 1 month prior to consideration of an InPen System.
- F. Meets **ONE or more of the following** while on an MDI regimen:
  - 1. Recent history (within last six months) of significant, recurring hypoglycemia (blood glucose < 70 mg/dl).
  - 2. Wide fluctuations (well below and above the set glycemic targets) in blood glucose before and after mealtimes, despite appropriate MDI using up to date insulins (analogs) and dose adjustments to affect control.
- G. Patient has advanced carbohydrate counting skills and actively uses this information for insulin dosing
- H. Patient demonstrates ability to recognize their glucose patterns and safely problem-solve these
- I. Prescriber has documented a need for detailed electronic monitoring the patient's blood glucose levels and insulin dose administered

### Ongoing Coverage of InPen System:

To qualify for ongoing coverage of an InPen System the member must meet **ALL of the following**:

- A. There is documentation that patient monitors glucose at least four times daily, or appropriately uses a continuous glucose monitor.
- B. Patient maintains advanced carbohydrate counting skills and actively uses this information for insulin dosing
- C. Patient maintains ability to recognize their glucose patterns and safely and appropriately problem-solve these, including troubleshooting InPen malfunction
- D. Patient has at least one visit per year with diabetes specialist\* (face-to-face, secure message, or telephone encounter)

## Replacement When Insulin Pump is No Longer under Warranty

The following considerations apply for replacement of an insulin pump that is no longer under warranty:

- A. The warranty for the current device has expired (requests for replacement are not covered when the device is still under warranty). Currently, Medtronic and Tandem have 4-year warranty periods, OmniPod Dash does not have a warranty period. It is recommended to check the manufacturer's website for current information.  
A prior-authorization request from the treating diabetes specialist\* managing the insulin pump to the Kaiser Permanente Pre-Service department is always required when an insulin pump is being replaced.
- B. A face-to-face visit with the treating diabetes specialist\* managing the insulin pump is documented within the past year.
- C. The reason for the replacement request is fully documented in the member's medical treatment plan.
- D. The current pump was previously approved by Kaiser Permanente or the current pump was approved by another non-Medicare plan, and the member meets the medical necessity and coverage criteria for Kaiser Permanente.
- E. Suitability for continuance of pump therapy has been reviewed and confirmed by the Diabetes specialist\*.
- F. The item is not lost or damaged as a result of abuse.

A treating provider may order ongoing pump supplies in the interval between annual visits with the Diabetes specialist\*

\*Diabetes Specialist= Adult or Pediatric Endocrinologist or a provider under his or her direct supervision (eg. PA or ARNP with CDE or BC-ADM certification or Diabetes Team RN-CDE) or a Perinatologist managing a patient with diabetes during pregnancy.

### Documentation requirements to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist (endocrinology, primary care)
- Last 6 months of lab work
- Last 1-2 months of legible home monitoring logs or a printout of CGM results

Links to Request Forms:

[Insulin Pump Request for New Pump Start Form](#)

[Insulin Pump Replacement Request Form](#)

The following information was used in the development of this document and is provided as background only. It is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

In January 1998, the state of Washington passed the Diabetes Cost Reduction Act that requires that major health carriers provide coverage (all, or in part) for diabetes supplies (insulin, syringes, and delivery devices) and education. This new law includes insulin pumps.

Insulin pumps are high technology infusion devices, about the size of a small tape cassette. Flexible tubing connects to the pump that contains the insulin, and then to the patient via a needle that is put in place and changed every 2 to 3 days. The pump itself can then be programmed to deliver 'background' insulin on a continuous basis, and also allow pre-meal "boluses" to accommodate meals. The pump is NOT a system that a patient can just plug into and forget diabetes.

In fact, patients who use the pump have to learn how to program and trouble-shoot the technology, and also learn how to do complex decision-making. This intensive management approach requires multiple daily blood testing, learning how to recognize and use types of food in a very sophisticated way, keeping records, and learning to use the information for complex problem solving. This education is an absolute prerequisite to being on the insulin pump, so special education classes and supervised care are required.

## Medical Technology Assessment Committee (MTAC)

**Insulin Pump Type II Diabetes**  
**04/20/2015: MTAC REVIEW**



**Evidence Conclusion:** There is evidence to support the efficacy of CSII in achieving glycated hemoglobin targets in highly motivated patients with T2DM who have poor glycemic control, who are taking a total daily dose of insulin less than 220 units. There is limited evidence to support the safety of CSII patients with T2DM.

**Articles:** The literature was searched for studies assessing the effectiveness of CSII for glycemic control in patients with T2DM. A variety of publications were revealed including several observational studies and four small randomized controlled trials (RCT) with conflicting results. The best available evidence was a recent RCT comparing CSII with multiple daily injections (MDI). The following articles were selected for critical appraisal: Reznik Y, Cohen O, Aranson R, et al. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (opt2mise): a randomized open-label controlled trial. *The Lancet*. 2014;384(9950):1265-1272. See [Evidence Table 1](#)

The use of Insulin Pump for Type II diabetes does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## **Artificial Pancreas**

### **BACKGROUND**

Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action or both. More specifically, in type 1 diabetes, the pancreas is unable to produce insulin which results in increased blood glucose levels, and ultimately, leads to complications which may affect the eyes, kidneys, nerves, heart and blood vessels. As a result, an essential part of diabetes management is to maintain blood glucose levels to as near normal as possible over all hours of the day. Implementation of this approach requires the individual to be capable of and committed to a day-to-day medical program. It requires ongoing compliance with multiple daily glucose measurements accompanied by appropriate adjustments in insulin dose and insulin injection. Additionally, successful intensive diabetic management requires response to a variety of external factors including changes in diet, exercise, and presence of infection.

Typically, patients self-monitor their blood glucose via fingerprick in an effort to optimize glycemic control, however, this technique is tedious and uncomfortable for the patient. In addition, this technique only provides information about a single point in time making it difficult to recognize trends. In any case, intensive glucose monitoring and insulin therapy can be challenging as they require obtaining, retaining, processing and applying vast amounts of information in the course of everyday life (Watkins, Connell et al. 2000; Boland, Monsod et al. 2001; Brauker 2009).

Evolving technologies such as continuous subcutaneous insulin infusion (CSII), and continuous glucose monitoring (CGM) have allowed patients to safely maintain glycemic goals and prevent other related complications. While there is evidence to support the efficacy of CSII (Misso, Egberts et al. 2010), the reliability and robustness of CGMs leaves much to be desired. Even with the aid of these devices, maintaining blood glucose concentrations within a suggested optimal range is a constant struggle.

Most recent technologic advancements have integrated these components into an Artificial Pancreas Device System (APDS). In addition to CSII and CGM, the APDS incorporates a control algorithm designed to facilitate communication between the different components thus automating the process of maintaining blood glucose concentrations at or near a specified target or range and, ultimately, improving glucose control, preventing complications, and decreasing disease burden. With a wide range of current products available on the market, there is potential for a large variety of different types and designs of ADPSs.

In an effort to help advance the development of the diabetes technologies, the U.S. Food and Drug Administration (FDA), in 2011, established three new product classifications for APDSs including threshold suspend, single hormonal control, and bihormonal control, all of which are regulated as class III device systems (general controls and premarket approval). In September of 2013, Medtronic's MiniMed® 530G was the first system approved under this new product classification. ADPSs have not previously been reviewed by the Medical Technology Assessment Committee (MTAC) and are currently being reviewed due to provider request.

The development of an "artificial pancreas" has been the "holy grail" for management of Type 1 diabetes for several decades. To understand why this is such a difficult task it helps to understand what the normal non-diabetic person's body actually does in response to changes in blood glucose. Within the pancreas we all have 1-2 million groups of cells called the Islets of Langerhans which function together to help maintain the blood glucose levels within a quite narrow range (of around 70-160mg/dl). The islets make two main hormones (insulin from the beta-cells and glucagon from the alpha cells) which work together in concert. These islet cells monitor the blood glucose flowing through them constantly. Whenever the blood goes up (after a meal, for example) the islets

increase the amount of insulin that they are secreting from the beta-cells and decrease the amount of glucagon that they are secreting from the alpha cells. Whenever the blood glucose drops below normal the beta-cells turn off completely (so that no insulin is secreted) and the alpha cells crank out lots of glucagon. Glucagon (as well as other hormones like epinephrine, growth hormone and cortisol) stimulate the liver to release glucose into the blood stream (the liver stores about 300 grams of glucose in the form of a kind of starch called glycogen). The insulin and glucagon are released directly into the portal circulation of blood flowing from the pancreas to the liver. In other words, a non-diabetic person is functioning with millions of blood glucose measurements being done every day with the results connected to a continuously variable secretion of both insulin and glucagon released directly into the blood flowing to the liver. Even though the commercially made components of an “artificial pancreas” may seem very sophisticated they are a very crude and imprecise way of trying to do what the real non-diabetic person’s pancreas can do.

First consider the delivery of insulin. Rather than having both insulin and glucagon being released directly into the blood flowing to the liver we have a continuous subcutaneous infusion of insulin alone. The insulin is absorbed out of the subcutaneous fat into the peripheral systemic circulation and only then gets to the liver. This can give a fairly accurate and stable basal delivery of insulin but when larger amounts of insulin are delivered immediately before meals (bolus insulin delivery) the rate of rise and fall of insulin in the bloodstream is a lot slower than in a healthy non-diabetic person’s body.

Second, consider the measurement of blood glucose. Typically, diabetic patients test the capillary glucose level in their fingertips 2-8 times per day. This can give useful information but does not show the constant rising and falling of blood glucose excursions throughout the day. If needle sensors are placed in the subcutaneous tissue this can give a reading of interstitial fluid glucose (similar to plasma glucose) every 10-20 minutes throughout the day and so can show the trends as the blood glucose rises and falls. Several companies now make these continuous glucose monitoring systems (CGMS). There are two practical issues with CGMS, however: a) the interstitial fluid glucose lags behind the actual plasma glucose by 15-20 minutes and so can give a falsely low or high value if it is measured at times when the blood glucose is rising rapidly (after a meal) or is falling rapidly (after exercise or after injecting a bolus of insulin), and b) the glucose oxidase enzyme system for measuring blood glucose can drift over time and so the readings from a CGMS will be inaccurate unless they are calibrated several times a day by doing a capillary blood glucose test at a time when the blood glucose is expected to be stable (not rising or falling rapidly).

The concept of an “artificial pancreas” is that a person could wear both an insulin pump and a CGMS device and that the insulin pump uses the information from the CGMS to automatically make adjustments to the rate of insulin infusion. The person would not need to worry about testing their blood glucose or of thinking about what they eat and when they exercise but could go about their day-to-day life safe in the knowledge that their blood glucose would stay within normal limits. It is because of the practical limitations of the technology (outlined above) that we are still a long way away from that idealized situation.

## 02/14/2014: MTAC REVIEW

### Artificial Pancreas

#### Evidence Conclusion:

- The results of the published studies suggest that APDS may be effective in reducing hypoglycemia in highly selected, motivated and compliant groups of individuals.
- There is some evidence to support the safety of APDS in highly compliant adult patients.

**Articles:** The search revealed over 500 articles many of which were commentary, discussion, or systematic review articles. Articles were screened for randomized, comparison studies of outcomes between patients using APDS and a control group of patients using currently available technology. The following articles were selected for critical appraisal: Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy for type 1 diabetes. *New England Journal of Medicine*. 2010;**363**(4):311-320. See [Evidence Table](#). Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. *New England Journal of Medicine*. 2013;**369**(3):224-232. See [Evidence Table](#). Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspensions vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes a randomized clinical trial. *JAMA*. 2013; 310:1240-1247. See [Evidence Table](#). Luijck YM, DeVries JH, Zwinderman K, et al. Day and night closed-loop control in adults with type 1 diabetes. *Diabetes Care*. 2013;**36**: 3882-3887. See [Evidence Table](#).

The use of Artificial Pancreas does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Insulin Pump and supplies – Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>E0784</b>	External ambulatory infusion pump, insulin
<b>A4230</b>	Infusion set for external insulin pump, nonneedle cannula type
<b>A4231</b>	Infusion set for external insulin pump, needle type
<b>A4232</b>	Syringe with needle for external insulin pump, sterile, 3 cc
<b>K0552</b>	Supplies for external noninsulin drug infusion pump, syringe type cartridge, sterile, each

**Insulin Pump *used with continuous glucose monitor***

**Medicare - Considered not medically necessary**

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
<b>E0787</b>	External ambulatory infusion pump, insulin, dosage rate adjustment using therapeutic continuous glucose sensing
<b>A4226</b>	Supplies for maintenance of insulin infusion pump with dosage rate adjustment using therapeutic continuous glucose sensing, per week

**Artificial Pancreas -**

**Medicare - Considered not medically necessary**

**Non-Medicare - Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® or HCPC Codes	Description
<b>S1034</b>	Artificial pancreas device system (e.g., low glucose suspend [LGS] feature) including continuous glucose monitor, blood glucose device, insulin pump and computer algorithm that communicates with all of the devices
<b>S1035</b>	Sensor; invasive (e.g., subcutaneous), disposable, for use with artificial pancreas device system
<b>S1036</b>	Transmitter; external, for use with artificial pancreas device system
<b>S1037</b>	Receiver (monitor); external, for use with artificial pancreas device system

**InPen Smart Insulin Pen –**

**Considered medically necessary when criteria in the applicable policy statements listed above are met:**

CPT® or HCPC Codes	Description
No specific codes – often submitted as <i>E1399 Durable medical equipment, miscellaneous</i> or <i>A4211 Supplies for self-administered injections</i>	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
09/1988	12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 12/03/2013 <sup>MPC</sup> , 10/07/2014 <sup>MPCC</sup> , 07/07/2015 <sup>MPC</sup> , 08/04/2015 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 06/07/2016 <sup>MPC</sup> , 01/03/2017 <sup>MPC</sup> , 02/06/2018 <sup>MPC</sup> , 01/08/2019 <sup>MPC</sup> , 01/07/2020 <sup>MPC</sup> , 01/05/2021 <sup>MPC</sup> , 01/04/2022 <sup>MPC</sup> , 01/10/2023 <sup>MPC</sup> , 01/09/2024 <sup>MPC</sup> , 01/14/2025 <sup>MPC</sup>	12/02/2022

Revision History	Description of Change
04/07/2015	Revised C-peptide testing requirement.
04/27/2015	Added MTAC review on Insulin Pump for Type II Diabetes
07/07/2015	Revised criteria to include indications for Type II Diabetes
09/03/2015	Added criteria for Pediatrics – 18 years and under
11/09/2015	Merged Artificial Pancreas criteria with Insulin Pump
02/17/2016	Added HCPCS codes
01/03/2017	Revisions made to insulin pump criteria; combined adult and pediatric into one policy
02/07/2017	MPC approved criteria to manage insulin pumps for pregnant patients
10/08/2018	Updated request form links
11/03/2020	Added note about combined insulin pump/CGM device and documentation requirements to support medical necessity; removed insulin brand names
07/20/2021	Added note about InPen Smart Insulin Pen not currently considered medically necessary pending MTAC review.
11/02/2021	MPC approved to waive the 6-month period typically used to learn how to monitor diet and other factors that impact blood sugar results prior to being eligible for an insulin pump for patients under the age of 13. This will be on a case-by-case basis as approved by a medical director. Requires 60-day notice, effective 04/01/2022.
01/04/2022	Updated required length of time to provide self-testing/CGM logs from 2 months to 1 month for initial insulin pump. MPC approved clinical criteria for the InPen System. 60-day notice is required; effective June 1, 2022.
02/24/2022	Updated applicable codes
07/05/2022	MPC approved to cover the Omnipod 5 system and will apply to the Insulin Pump criteria.
12/02/2022	Updated Medicare Policy to defer to KP Non-Medicare criteria for InPen system requests. Updated Medicare LCD L33794 and LCA A52507 links.

## ***Patient Referral Guidelines***

### **Intestinal and Multi-Visceral Transplantation**

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### **Criteria**

#### **For Medicare Members**

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Intestinal and Multi-Visceral Transplantation (260.5)</a>
Local Coverage Determinations (LCD)	None
Local Coverage Article	None

#### **For Non-Medicare Members**

Transplantation may be considered for patients with end-stage or life-threatening disease who have no prospect for prolonged survival, or whose quality of life is severely impaired. These guidelines for referral for transplant evaluation are not intended as an automatic inclusion or exclusion of a candidate for referral.

Intestinal Transplantation alone may be considered for selected pediatric and adult patients with Short Bowel Syndrome and/or intestinal failure who require chronic Total Parenteral Nutrition (TPN) and have severe complications that lead to serious morbidity and could lead to mortality.

Combined Intestinal/Liver Transplantation may be considered in selected pediatric and adult patients with Short Bowel syndrome and irreversible progressive chronic liver disease when there is no prospect for prolonged survival with conventional therapy.

The following are current, generally accepted, guidelines for Intestinal Transplantation.

#### **1. GENERAL PRINCIPLES**

- 1.1. If clinical parameters of end-stage or life-threatening disease indicate the need for transplantation, then early referral should be made.
- 1.2. Patients with a history of malignancy with a moderate to high risk of recurrence (as determined after consultation with oncologist considering tumor type, response to therapy, and presence or absence of metastatic disease) may be unsuitable candidates for transplantation. Patients with low risk of recurrence may be considered.
- 1.3. Uncontrollable active infection is a contraindication to transplant.
- 1.4. Candidates with a history of substance abuse must be free from alcohol and other substance abuse for six (6) months and have been evaluated by a substance abuse program. The risk of recidivism, which has been documented to negatively impact transplant outcomes, must be addressed and considered to be low<sup>1,2,3</sup>. Exceptions may be made on a case-by-case basis.
- 1.5. Candidates for thoracic organ (heart, lung and heart/lung) transplants must be free from tobacco use for the previous six (6) months. Routine monitoring may be required. Specific programs for abdominal organs (liver, intestines, and kidney) may require abstinence from tobacco products in order to be actively listed.
- 1.6. Candidates must have adequate social support systems and display a proven record of adherence to medical treatment.

- 1.7. Patients must be willing and able to travel within short notice to a KP approved transplant Center of Excellence and, if necessary, return for treatment of complications.
- 1.8. Patient must have a caregiver or caregivers who are physically and cognitively able to assist the patient with self-care activities and are available to travel within short notice to the KP approved transplant Center of Excellence.
- 1.9. The presence of significant irreversible neurologic dysfunction, active psychological and/or psychiatric conditions, and/or other social behaviors that prevent adherence with a complex medical regimen, are considered contraindications for referral for transplant.
- 1.10. Evidence of such nonadherence may be: failure to keep appointments, failure to make steady progress in completing pre-transplant evaluation requirements, failure to accurately follow medication regimens or failure to accomplish the activities required.
- 1.11. Whenever transplant is considered as an option and discussed with the patient and/or family, consultation with Advanced Life Care Planning/Palliative Care resources is strongly recommended.

## **2. INDICATIONS FOR INTESTINAL TRANSPLANT**

### **2.1. Intestinal Transplant**

- 2.1.1. Pediatric or adult patients with irreversible Short Bowel Syndrome or intestinal failure<sup>4</sup>, who have severe complications of TPN, including, but not limited to the following:
  - 2.1.1.1. Lack of vascular access
  - 2.1.1.2. Recurrent central venous catheter-related infections
  - 2.1.1.3. Metallic bone disease
  - 2.1.1.4. Evidence of severe or progressive hepatic dysfunction

### **2.2. Combined intestinal-liver transplant.**

- 2.2.1. Adult and pediatric patients with Short Bowel Syndrome and/or intestinal failure and irreversible progressive chronic liver disease.

## **3. CONTRAINDICATIONS FOR INTESTINAL TRANSPLANT**

- 3.1. Advanced cardiopulmonary disease or any other life limiting disorders, excluding hepatopulmonary syndrome.
- 3.2. Inability to accept the procedure, understand its nature, or cooperate with the treatment protocol.
- 3.3. Patients with HCC, who exceed Region 5<sup>5</sup>/UCSF<sup>4</sup> criteria, should not be sent for intestinal transplant evaluation at this time because they are not medically appropriate. Exceptions may be made on a case by case basis for hepatoblastoma.<sup>5</sup>
- 3.4. Irreversible brain damage or significant neurologic dysfunction.

## **4. RELATIVE CONTRAINDICATIONS FOR INTESTINAL TRANSPLANT**

- 4.1. Relative contraindications include, but not necessarily limited to:
  - 4.1.1. Renal Failure (excluding hepatorenal syndrome)
  - 4.1.2. Portal Vein thrombosis
  - 4.1.3. Active infection outside the hepatobiliary system
  - 4.1.4. Advanced malnutrition
  - 4.1.5. Severe diabetic complications
  - 4.1.6. Multiple abdominal surgeries

### **Footnotes:**

1. Liver Transplantation 2006, .12:813-820. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease.
2. Liver Transplant Surg, 1997, Vol 3, 304 – 310. The natural history of alcoholism and its relationship to liver transplantation.
3. Alcohol abstinence prior to liver transplantation for Alcoholic Liver Disease (G110807), TPMG New Medical Technology



4. May be due, but not necessarily limited, to the following examples:

- a. Volvulus
- b. Atresia
- c. Necrotizing Enterocolitis
- d. Crohn's Disease
- e. Gastroschisis
- f. Superior Mesenteric Artery Thrombosis
- g. Trauma

5. The Region 5 criteria for intestinal patients with HCC is 1 tumor: S5 cm or 2 – 3 lesions, none >3 cm and no vascular invasion. NEJM 1996, 334: 633-699. Pediatr Surg Int. 2016 Oct 11., J Pediatr Surg. 2007 Jan;42(1):184-7., Pediatr Transplant. 2016 Jun;20(4):515-22. doi: 10.1111/petr.12699. Epub 2016 Mar 27.

REVISED BY CLINICAL MANAGEMENT SUBCOMMITTEE: SEPTEMBER 23, 2020

ADVISORY COUNCIL APPROVED AND EFFECTIVE DATE: OCTOBER 22, 2020

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist.

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

Intestinal transplantation is an evolving procedure that was experimentally developed more than 30 years ago. It involves transplantation of a cadaveric intestinal allograft for the purpose of restoring bowel function for patients with irreversible failure. The intestine's massive lymphocyte content and heavy bacterial load provided barriers for nearly three decades. Intestines are more susceptible to rejection and carry higher risk of graft versus host disease (GVHD). The procedure proved to be clinically feasible for humans in the late 1980s but had considerable morbidity and mortality. The initial recipients of the intestinal grafts did poorly because of technical complications, graft rejection and sepsis. Recently better results were reported due to improved surgical techniques, more potent immunosuppressive drugs, and standard prophylaxis for infections and lymphoproliferative disease. Although the purpose of intestinal transplantation is to restore bowel function, patient survival should be considered the primary outcome of interest.

The first long-term success was reported in 1988 when cyclosporin-based immunosuppression was used, yet there were many failures due to rejection. The introduction of FK 506 or Tacrolimus have led to an explosion of the intestinal transplantation activity in the 1990s. It is 100 times more potent than cyclosporin and is somewhat less toxic. Steroids are administered during the early postoperative period and discontinued completely within a month. Since 1990 surgeons at the University of Pittsburgh Medical Center (UPMC) and Children's Hospital of Pittsburgh have performed more than 115 transplants involving the small intestine. This is close to half the total number performed worldwide.

There are three types for intestinal transplantation: small bowel transplantation (SBT), Small bowel/liver transplantation (SB/LT), and multivisceral transplantation (MVT) which is defined as en-bloc transplantation of 3 or more abdominal organs that include liver, stomach, pancreatic-duodenal complexes as well as the intestine with or without the right hemi-colon. Intestinal transplantation is not an alternative to total parenteral nutrition (TPN) but is only intended for selected patients who are predicted to have poor survival on TPN. It should be considered as a life-saving procedure. Patients who can be maintained on long term TPN are not considered for transplantation at the present time.

An isolated intestinal graft is recommended for patients who have fluid and electrolyte loss that cannot be managed by TPN, those with severely limited venous access and/or moderate liver dysfunction secondary to TPN. Combined SB/LT is offered to patients with irreversible liver failure due to TPN, or intestinal/liver failure associated with a hyper-coagulable state that is corrected by a simultaneous liver graft. Multivisceral

transplantation is offered to patients with locally aggressive tumors that can only be removed by a massive evisceration of the abdominal organs. Intestinal transplantation is contraindicated in old age, cardiopulmonary deficiency, AIDS, systemic malignancy and life-threatening infections.

The FDA does not regulate surgical procedures such as intestinal and multivisceral transplantation. However, immunosuppressive drugs are FDA regulated. Tacrolimus, the primary immuno-suppressant used with these transplants was approved by the FDA in April 1994 for rejection prophylaxis in allogenic liver transplantation.

## Medical Technology Assessment Committee (MTAC)

### Intestinal Transplantation

#### 04/10/2002: MTAC REVIEW

**Evidence Conclusion:** The literature reviewed did not reveal any study that compared intestinal transplantation to the long term TPN therapy, and the evidence available does not allow for definitive conclusions. The studies reviewed show that the one- year survival rate of intestinal transplantation varied among studies from 54% to 75%. This dropped to around 42-50% at 5 years. Infection was responsible for more than 40% of the deaths. All studies were case series with limitations including potential selection bias, and lack of control or comparison group. However, it is unlikely that controlled trials, in which outcomes from intestinal/multivisceral transplantation are compared to TPN and medical management, would be conducted. The current use of intestinal transplantation as a rescue therapy for TPN-dependent patients invalidates any comparison with TPN.

**Articles:** Articles were selected based on study type. The search yielded 175 articles most of which were reviews, opinion pieces, editorials, and letters. The literature did not reveal any randomized controlled trials, or meta-analyses, only clinical reports and case series. The articles with the largest size, longest follow-up duration, and with patient survival as the primary outcome of interest were selected for critical appraisal. *Evidence tables were created for the following case series:* Abu-Elmagd K, et al. Clinical intestinal transplantation. *Annals of Surgery* 2001;234(3):404-17. See [Evidence Table](#) Jamieson NV. Adult small intestine transplantation in Europe. *Acta Gastro- Enterologica Belgica* 1999;62(2):239-43. See [Evidence Table](#) Madariaga JR, et al. The long-term efficacy of multivisceral transplantation. *Transplantation proceedings* 2000; 32:1219-20. See [Evidence Table](#).

The use of Intestinal Transplantation in the treatment of irreversible intestinal failure does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
44135	Intestinal allotransplantation; from cadaver donor
44136	Intestinal allotransplantation; from living donor
44137	Removal of transplanted intestinal allograft, complete

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
05/30/2001	04/06/2010 <sup>MDCRPC</sup> , 02/10/2011 <sup>MDCRPC</sup> , 12/06/2011 <sup>MDCRPC</sup> , 10/02/2012 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> , 08/02/2022 <sup>MPC</sup> , 08/01/2023 <sup>MPC</sup> , 12/03/2024 <sup>MPC</sup>	06/12/2020

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision	Description
----------	-------------

History	
04/07/2020	MPC approved to adopt Kaiser Permanente National coverage policy
06/12/2020	Added "Patient Referral Guidelines" to title

## Clinical Review Criteria

### Intraocular Lens Following Cataract Extraction

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Intraocular Lens (80.12)</a>
Local Coverage Determinations (LCD)	<a href="#">Refractive Lenses (L33793)</a> <i>When hydrophilic soft contact lenses (V2520, V2521, V2522, V2523) are used as a corneal dressing, they are denied as noncovered because in this situation they do not meet the definition of a prosthetic device.</i>
Local Coverage Determinations (LCA)	<a href="#">Refractive Lenses (A52499)</a>

### For Non-Medicare Members

#### Accommodative Intraocular Lens

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### Multifocal Intraocular Lens

Multifocal intraocular lenses will not be covered. Standard monofocal intraocular lenses are covered following cataract surgery. The patient may elect to pay for the multifocal lens.

#### Toric Intraocular Lens

Toric intraocular lenses to correct astigmatism are not covered. The purposes of these lenses are to reduce dependence on glasses. Improved vision with glasses is the purpose of standard cataract surgery, the additional benefit of improved vision without glasses is not a covered service.

### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

It is estimated that over 20 million Americans older than 40 years have cataract in at least one eye. It is predicted that this number will increase to 30 million by 2020. The current approach of treating cataracts is to replace the natural crystalline lens of the eye with an artificial intraocular lens (IOL). Traditionally intraocular lenses are monofocal lenses, which can provide excellent distance vision and optical quality, but they do not deliver functional vision at other ranges of distance. After their implantation most patients need spectacles at least for near vision. Bifocal and multifocal IOLs were developed to overcome the lack of accommodation in these pseudophakic patients (i.e. patients with an artificial IOL). They provide good functional distance, near, and

intermediate vision without the use of corrective lenses. However, multifocal and bifocal IOLs may have optical side effects such as decreased contrast sensitivity, glare disability, and halos, which can reduce the retinal image quality and affect the patient's visual performance (Harman 2008, Alio 2010, Alio 2011, Cochener 2011).

### **Accommodative Intraocular Lens**

Positional accommodating IOLs were developed to avoid the optical side effects of the multifocal IOLs and provide some accommodative capability and functional near vision. The basic mechanism of these lenses is the transmission, by haptics (plastic plates or struts), of the contracting forces of the ciliary body to the flexible lens. The design of these IOLs is based on the optic-shift concept i.e. on the axial (backward and forward) movement of the optic resulting from the contraction and relaxation of the ciliary muscle. A hinge between the optic and haptics allows the lens to move forward as the eye focuses on near objects and backward as the eye focuses on distant objects, thereby increasing the dioptric power of the pseudophakic eye. The first developed accommodative IOLs were positional single optic lenses used for both cataract and surgical correction of presbyopia. Among these are the Crystalens™ (Eyeonics, Inc., 1CU [Human Optics Erlangen, Germany], and Tetraflex [KH3500, Lenstec, St Petersburg Florida]) (Marchini 2007).

The Crystalens™ AT-45 IOL is the seventh design of the Crystalens™. It consists of a single biconvex lens with a 4.5 mm optic with two plate haptics each terminating in two polyamide loops that anchor it to the capsular bag. Adjacent to the optic are grooved flexible hinges in the plates that allow forward movement of the optic during accommodative effort to provide near and intermediate vision in pseudophakic patients. The optic is square-edged and is made of silicone to maximize biocompatibility and flexibility and allow easy insertion of the lens through a 3 mm corneal incision. A newer Crystalens™ model (Crystalens HD) has a mechanism of action based on the transitional movement of the lens in anterior and posterior direction due to ciliary muscle contraction and vitreous mass displacement (Macsaï 2006, Cumming 2006).

The Tetraflex (Lenstec) lens is an anteriorly vaulted, single-piece, foldable, accommodating IOL that is implanted using a custom-designed injector system through an incision as small as 3 mm. The lens' optic is 5.75 mm and is made of a highly biocompatible and extremely flexible hydrophilic acrylic material (HEMA). The IOL's two haptics, each with two footplates, sit posteriorly in the peripheral capsular bag (Sheppard 2010).

The 1CU is a foldable single-piece lens with an optic diameter of 5.5 mm and an overall length of 9.8 mm. It is made of a hydrophilic acrylic material and has a biconvex square-edged optic and 4 modified flexible haptics that are designed to bend when constricted by the capsular bag after ciliary muscle contraction. This allows anterior displacement of the optic resulting in an increase in the refractory power (Pallikaris 2011).

The single-optic passive shift IOLs are considered pseudoaccommodative and have limited accommodative ability as their anterior movement is insufficient to provide functionally significant amplitudes of accommodation. The limited optic power of the single optic lenses led to the development of dual-optic devices as the Synchrony (Visiogen, Irvine, California, USA), and the Sarfarazi IOL (developed by FM Sarfarazi of Shenasa Medical LLC, Carlsbad, CA, USA). The configuration of these devices with a high positively-powered mobile anterior optic, connected to a stationary negatively-powered posterior optic, is designed to increase the potential accommodative amplitude (Alio 2009, Sheppard 2010).

Investigators indicate that the way of measuring the range of accommodation in pseudophakic eyes is still unclear. In a recent review article, Pallikaris and colleagues state "Objective measurement of the accommodative capability offered by the accommodative IOLs is extremely difficult to obtain, and different methods such as autorefractometers, retinoscopy, and ultrasound imaging during accommodative effort, ray tracing, or pharmacological stimulation have been developed but the results are sometimes inconsistent... Pseudophakic accommodation, that is, the dynamic component of ocular refractive variation during near vision, and pseudophakic pseudoaccommodation, that is, the depth of focus and the subjective adaption to defocus during near vision, are the two core parts of pseudoaccommodation. Currently there is no consensus in the literature on the percentage of the participation of each part in the phenomenon of pseudoaccommodation. Several different methods are utilized by investigators for the study of the phenomenon thus resulting in different results." (Pallikaris 2011).

### **Multifocal Intraocular Lens**

Bifocal and multifocal intraocular lenses have optical side effects such as glare, halos, and decreased contrast sensitivity, which can reduce the retinal image quality and affect the patient's visual performance. The Array IOL (Advanced Medical Optics [AMO], Santa Ana, CA), one of the first IOLs approved by the FDA (1997) is a typical refractive multifocal IOL. Earlier trials demonstrated that Array IOL improved distance and near visual acuity and reduced spectacle dependency after cataract extraction, but it was also associated with problems as decreased

contrast sensitivity, glare, and halos. Newer generations of multifocal IOLs have been developed with the aim of providing better visual acuities at various distances with less glare and halos and without need for any spectacles. Currently in the United States, multifocal lens options include the ReZoom™ lens (Abbott Medical Optics [AMO] Inc, Santa Ana, CA), ReSTOR® lens (Alcon Laboratories Inc, Fort Worth, TX), and the Tecnis® lens (Abbott Medical Optics Inc, Santa Ana, CA) (Kawamorita 2009).

The ReZoom™ (AMO) is a second-generation multifocal refractive lens that improved on the design of the Array with the aim of decreasing the symptoms of glare and halos. It is a three-piece multifocal lens made of hydrophobic acrylic material and has five refractive optical zones; each zone designed for different light and focal distances: zones 1, 3, and 5 are adjusted for far vision, while zones 2 and 4 are adjusted for near vision. The design of ReZoom is different from the Array in that the second and third zones have been enlarged, and the fourth and fifth zones have been reduced in size. An aspheric transition between zones provides balanced intermediate vision. These changes potentially reduce in night-time glare and improves uncorrected near visual acuity (Forte 2009, Kawamorita 2009, Alio 2011, Kubal 2011, Lichtinger 2012).

The ReSTOR® (Alcon Laboratories Inc) is a diffractive one-piece posterior chamber IOL. It is the first diffractive IOL to be approved by the FDA. ReSTOR® is a biconvex lens made of a soft plastic that can be folded prior to insertion, allowing placement through an incision smaller than the optic diameter of the lens. After surgical insertion into the eye, the lens gently unfolds to restore vision. The supporting arms (haptics) provide for proper positioning of the IOL within the eye. ReSTOR® lens has 12 concentric diffractive rings that cover the central 3.6 mm of the lens. The diffractive portion of the lens is apodized i.e. the height of each diffractive step decreases with increasing distance from the lens center in order to create a smoother transition between focal points. The ReSTOR® is considered a hybrid of diffractive and refractive IOLs with the lens periphery functioning as a refractive zone focusing for distance vision. In 2007, the FDA approved the aspheric version of the ReSTOR® (AcrySof IO, ReSTOR), which has a 10 µm of negative asphericity, while maintaining its apodization and diffractive and refractive components. Recently, a new +3.0 diopter (D) was introduced to improve intermediate vision, which was suboptimal with the +4 D models (Alio 2011, Sood 2011, Zhang 2011, Kubal 2011, Lichtinger 2012).

The Tecnis® Multifocal Intraocular Lens (AMO) is an ultraviolet light-absorbing posterior chamber lens. It was first available as a 3-piece silicone lens (ZM900), then later it became available as a 3-piece acrylic (ZMA00), or a single piece acrylic (ZMB00) lens. The lens is foldable so that it can be inserted into the eye through a very small incision that is actually smaller than the diameter of the lens itself. It has an optical design based on a principle of diffraction similar to the AcrySof ReSTOR® IOL, but with the diffractive rings covering the entire posterior surface of the lens. The rings start very close to the center of the lens and then continue out toward the periphery, usually with an increasing distance between the rings. As a result, the lens achieves its multifocal effects with minimal dependence on the size of the pupil (Sood 2011, Lichtinger 2012).

The ReZoom™, AcrySof ReSTOR 3.0 and 4.0 D, and Tecnis® multifocal intraocular lenses have all received FDA clearance for the visual correction after cataract extraction in adult patients with and without presbyopia.

## Medical Technology Assessment Committee (MTAC)

### *Multifocal Intraocular Lens*

#### **04/11/2001: MTAC REVIEW**

**Evidence Conclusion:** A single well-done RCT provides evidence that multifocal IOL are as effective as monofocal IOL for distance acuity. Patients with multifocal IOL had better uncorrected near VA and distance-corrected near VA than monofocal IOL patients, but similar best-corrected near VA add power. A case series with long-term follow-up showed a high rate of efficacy on visual acuity with multifocal IOL. All studies reviewed indicated that a limitation of multifocal IOL is decreased contrast sensitivity. The cohort study, which had compromised validity, found less contrast sensitivity with multifocal compared to monofocal IOL in daylight and twilight with no glare and twilight with central glare. The benefits of multifocal IOL should be weighed against possible decreases in contrast sensitivity and the efficacy of monofocal IOLs with glasses for near focus.

**Articles:** The search yielded 30 articles. There were 2 RCT articles; these were based on data from the same study. The majority of the articles were case series with small numbers of patients. Evidence tables were created for three studies: The most recent report of RCT data: Javitt JC, Steinert RF. Cataract extraction with multifocal intraocular lens implantation: A multinational clinical trial evaluating clinical, functional and quality-of-life outcomes. *Am Acad Ophthalmol* 2000; 107: 2040-2048. See [Evidence Table](#). A cohort study examining possible adverse effects of multifocal IOL: Winther-Nielsen A, Corydon L, Olsen T. Contrast sensitivity and glare in patients with a diffractive multifocal intraocular lens. *J Cataract Refract Surg* 1993; 19: 254-257. See [Evidence Table](#). A



case series with long-term follow-up data: Slagsvold JE. 3M diffractive multifocal intraocular lens: Eight year follow-up. J Cataract Refract Surg 2000; 26: 402-407. See [Evidence Table](#).

The use of multifocal Intraocular Lens in the treatment of visual correction following cataract surgery does meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 07/2005: MTAC REVIEW

##### Intraocular Lens

**Evidence Conclusion:** *Accommodative Intraocular Lens* The evidence on Crystalens™ is insufficient to draw conclusions about its efficacy and safety compared to standard intraocular lenses. The single published comparative study (Alio et al., 2004) had threats to validity. It was a non-randomized comparison of three case series, one on Crystalens, one on the Array multifocal lens and one on the Twinset bifocal IOL. The study is subject to selection bias because patients were not randomized, and the authors did not control statistically for confounding factors. The study was also non-blinded and thus subject to observation bias. The study had four primary outcomes. Between-group differences were statistically significant for one out of the four outcomes, mean best corrected near acuity, but not for mean uncorrected distance acuity, mean best corrected distance acuity or mean uncorrected near acuity. There were two studies on the 1CU IOL by HumanOptics, a non-FDA approved accommodative IOL. This evidence is also weak. One of the studies (Kuchle et al., 2004) was non-randomized and did not control for confounding factors and is therefore subject to selection bias. The other study (Dogru et al., 2005) was randomized, but the study methodology was not well described, making it impossible to assess validity. There were also validity issues with the statistical analysis in the Dogru study.

**Articles:** *Accommodative Intraocular Lens* There was one study comparing the FDA approved accommodative IOL, Crystalens, to other types of IOLs. There were two studies comparing the non-FDA approved 1CU accommodative IOL (HumanOptics: Erlangen, Germany) to other IOLs. Like Crystalens, the 1CU IOL has a hinge-like design which allows for forward and backward movement. These three empirical studies were critically appraised. In addition, there was a small case series (n=14) reporting on the initial phase of the Crystalens FDA clinical trial. This study was excluded from further review. Evidence tables were created for the following studies: Crystalens™ Alio JL, Tavalato M, De la Hoz F et al. Near vision restoration with refractive lens exchange and pseudoaccommodating and multifocal refractive and diffractive intraocular lens. J cataract Refract Surg 2004; 30: 2494-2503. See [Evidence Table](#). Human Optics 1CU. Dogru M, Honda R, Omoto M. Early visual results with the 1CU accommodating intraocular lens. J Cataract Refract Surg 2005; 31: 895-902. See [Evidence Table](#). Kuchle M, Seitz B, Langenbucher A et al. Comparison of 6-month results of implantation of the 1CU accommodative intraocular lens with conventional intraocular lens. Ophthalmology 2004; 111: 318-324. See [Evidence Table](#).

The use of Accommodative Intraocular Lens in the treatment of visual correction following cataract surgery does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

#### 04/16/2012: MTAC REVIEW

##### Intraocular Lens

**Evidence Conclusion:** *Accommodative Intraocular Lens* Crystalens™: AT-45 The literature search did not reveal any published large good quality RCTs that compared the implantation of the accommodative Crystalens™ with multifocal or monofocal intraocular lenses after cataract extraction. The best published evidence on Crystalens™ comes from the FDA multicenter clinical trial with 12 months follow-up (Evidence table 1). The initial study was a phase II trial that evaluated the efficacy and safety of the Crystalens™ AT-45. It was a prospective cohort study with no control or comparison group. The results of 12 months follow-up of 263 patients receiving the implant in the primary eye showed that the accommodating Crystalens™ AT-45 provided good uncorrected near and distance visual acuity with minimal adverse effects. In a substudy the authors compared contrast sensitivity under mesopic conditions with and without glare in a subgroup of patients who received the Crystalens versus a matched population of 64 patients who received standard IOL. The results of this substudy showed that the difference in contrast sensitivity between the two groups of patients was clinically irrelevant.

ICU (Human Optics) Several randomized and nonrandomized trials compared the performance of 1CU with monofocal and multifocal intraocular lenses (IOLs) (Evidence tables 2-4). The results of the studies showed that distance corrected near vision was significantly better in the 1CU group versus other groups receiving non-accommodating IOLs. Two small studies showed that the accommodative ability of the lens may decrease by time (8 months in Sauder and colleagues' trial and 12 months in Dogru and colleagues' study) leading to a reduction in the near vision acuity. The studies had some limitations and long-term follow-up is needed to determine the long-term safety and efficacy of the lens. In a large prospective, controlled, but non-randomized trial with potential biases (Evidence table 3), Uthoff and colleagues found that 1CU had a minor statistical advantage of half a reading step towards monofocal IOLs measured with subjective methods in near point, defocusing curve, and near visual acuity with BSCVA. They explained that this could be due to the pseudophakic accommodation by the

optic shift or as a result of the additional pseudophakic pseudoaccommodation. The accommodative effect differed between patients and was unpredictable. **Tetraflex:** The prospective nonrandomized US Food and Drug Administration trial (Sanders 2010) on Tetraflex accommodative IOL is ongoing. In this study 255 patients received Tetraflex IOLs and 101 received monofocal IOLs. Interim results of 12 months follow-up of 239 patients in the Tetraflex arm and 96 controls show that the Tetraflex patients read better than the controls at print sizes of 20/80 ( $P=.04$ ), 20/63 ( $P=.01$ ), 20/50 ( $P<.001$ ), 20/40 ( $P=.001$ ), 20/32 ( $P<.001$ ), and 20/25 ( $P=.001$ ). The proportion of patients reading at a speed of  $\geq 80$  words per minute was significantly higher with the Tetraflex IOL ( $P=.003$ ). Ninety-six percent of Tetraflex patients reported never wearing glasses for distance compared with 80% of control patients ( $P<.001$ ). Seventy-five percent of the Tetraflex patients reported that they did not or occasionally needed to wear glasses for near reading small print and/or dim light compared with 46% of control patients ( $P<.001$ ). The trial had its limitations and the study groups were not randomly assigned to type the IOL implanted which is a source of selection bias. They were also not blinded to the IOL received, which is another source of bias especially with subjective outcomes as self-reporting of use of spectacles. Moreover, the reading ability and speed is dependent on many factors in addition to visual acuity. In conclusion, large randomized, controlled, and blinded trials with long-term follow-up are needed to determine the long-term efficacy, durability of benefit, and safety of the accommodative intraocular lenses.

**Multifocal Intraocular Lens:** A Cochrane meta-analysis with valid methodology (Leyland et al, 2008, evidence table 1) pooled the results of ten randomized controlled trials that compared visual outcomes of multifocal IOLs versus monofocal IOL implantation after cataract surgery. There were variations between the studies in population sizes, measures and outcomes reported, as well as follow-up durations. The main pooled results of the analysis showed no significant differences between multifocal and monofocal IOLs in uncorrected distance visual acuity or the proportion of patients achieving distance 6/6 best-corrected distance visual acuity. The uncorrected near vision was improved with the multifocal IOLs, and the rate of freedom from use of glasses was also higher with the multifocal IOLs. Contrast sensitivity was lower among participants receiving multifocal IOL implants who also experienced significantly higher rates of glare and halos. The results of another meta-analysis (Cochener et al 2011, Evidence table 2) that had the limitation of pooling results of observational studies together with randomized controlled trials, also showed that multifocal IOLs provided better uncorrected near visual acuity and less need for spectacles compared to monofocal IOLs. The results of the analysis also showed that diffractive multifocal lenses led to better results than the refractive IOLs, and that ReSTOR® had better uncorrected near visual acuity, uncorrected distance visual acuity, and higher spectacle independence rates compared with other multifocal IOLs. The incidence of halos was higher with multifocal lenses versus monofocal IOLs, but there was no significant difference between the different multifocal IOLs. No sensitivity analysis including only RCTs was made, and the results of the meta-analysis should be interpreted with caution. A more recent randomized controlled trial by Alió and colleagues (2011, Evidence table 3) compared the visual performance of 4 different IOLs: monofocal Acri. Smart, multifocal AcrySof ReSTOR® SN6AD3, multifocal Acri.Lisa 366D, and multifocal ReZoom refractive IOL. The same type of lens was implanted bilaterally in each of the 152 participants (304 eyes). After six months of follow up, the results showed that all patients had postoperative significant improvement in uncorrected and corrected visual acuities. Patients with the ReSTOR® and Acri.Lisa multifocal lens implants had significantly better uncorrected reading acuity than those in the monofocal or the refractive ReZoom™ groups. The monofocal group had the greatest uncorrected reading distance at 1 and 6 months postoperatively. The authors did not evaluate patient satisfaction with the different types of IOLs, nor did they assess the contrast sensitivity, or presence of glare and halos. Studies comparing ReSTOR® +3.0 D versus ReSTOR® +4.0 D were not critically appraised in this report, but their overall results showed better intermediate visual acuity, but more glares with the +3.0 D vs. +4.0 D IOLs. Conclusion: There is good evidence from the published literature that multifocal intraocular lenses improve near visual acuity when compared to monofocal lenses, without compromising distance visual acuity.

There is good evidence that patients undergoing multifocal IOLs implantation have higher rates of spectacle independence compared to those with monofocal lens implants. There is evidence that patients with multifocal IOL implants experience more halos and glare and have lower contrast sensitivity than those with monofocal implants. There is fair evidence that optical outcomes are better with diffractive versus refractive multifocal IOLs, and that improvement in near vision without use of glasses and patient satisfaction are more evident with ReSTOR® compared to other multifocal IOLs. There is insufficient evidence to determine any significant difference in contrast sensitivity, glare, or halos between multifocal IOLs.

**Articles: Accommodative Intraocular Lens** Single optic IOLs - The majority of studies published on the accommodative intraocular lenses evaluated single optic accommodative IOL, mainly the ICU (Humans Optics), and to a lesser extent the Crystalens™ AT-45. The search identified one meta-analysis of RCTs, a small number of controlled randomized and nonrandomized trials, and case series. The larger trials with more valid methodology and longer-term follow-up were selected for critical appraisal. The meta-analysis was not critically appraised as it had a low methodological quality and only included only 5 RCTs with very small sample sizes, along with other nonrandomized, and non-controlled studies published from 1996-2006. Dual optic IOLs - The literature search revealed a small pilot prospective case series with a retrospective control on the Synchrony dual-

optic IOL. Phase III FDA clinical trials are still ongoing. The following studies were critically appraised: Harman FE, Maling S, Kampougeris G, et al. Comparing the 1CU accommodative, multifocal, and monofocal intraocular lenses: a randomized trial. *Ophthalmology*. 2008; 115:993-1001. See [Evidence Table](#). Cumming JS, Colvard DM, Dell SJ, et al. Clinical evaluation of the Crystalens AT-45 accommodating intraocular lens: results of the U.S. Food and Drug Administration clinical trial. *J Cataract Refract Surg*. 2006;32:812-825 See [Evidence Table](#). Mesci C, Erbil HH, Olgun A, et al. Visual performances with monofocal, accommodating, and multifocal intraocular lenses in patients with unilateral cataract. *Am J Ophthalmol*. 2010; 150:609-618. See [Evidence Table](#). Uthoff D, Gulati A, Hepper D. Potentially accommodating 1CU intraocular lens: 1-year results in 553 eyes and literature review. *J Refract Surg*. 2007; 23:159-171. See [Evidence Table](#).

**Multifocal Intraocular Lens** The literature search revealed a large number of studies on multifocal intraocular lenses. The majority were prospective or retrospective observational studies and case series with different population sizes and follow-up durations and no comparison or control groups. There were also a number of published randomized or nonrandomized controlled trials that evaluated the visual function, and /or quality of life after the implantation of monofocal versus multifocal lenses. The search also identified three meta-analyses that pooled the results of trials comparing multifocal versus monofocal intraocular lenses, one meta-analysis of studies compared different IOLs, as well as a pooled analysis of two non-randomized trials that compared outcomes of ReSTOR vs. monofocal IOLs lenses. The most recent meta-analysis comparing outcomes of monofocal versus multifocal lenses, and the meta-analysis that compared different multifocal lenses were selected for critical appraisal. A recent RCT that compared outcomes of one monofocal and three different multifocal IOLs was also critically appraised. Alió JL, Grabner G, Plaza-Puche AB., et al. Postoperative bilateral reading performance with 4 intraocular lens models: six-month results. *Cataract Refract Surg*. 2011; 37:842-852. See [Evidence Table](#). Cochener B, Lafuma A, Khoshnood B, et al. Comparison of outcomes with multifocal intraocular lenses: a meta-analysis. *Clin Ophthalmol*. 2011; 7:45-56. See [Evidence Table](#). Leyland M, Pringle E. Multifocal versus monofocal intraocular lenses after cataract extraction. *Cochrane Database of Systematic Reviews* 2008, issue 4. See [Evidence Table](#).

The use of Accommodative Intraocular Lens in the treatment of visual correction following cataract surgery does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered not medically necessary:

HCCP Codes	Description
V2787	Astigmatism correcting function of intraocular lens
V2788	Presbyopia correcting function of intraocular lens

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
8/1/2005	5/3/2011 <sup>MDCRPC</sup> , 10/4/2011 <sup>MDCRPC</sup> , 6/5/2012 <sup>MDCRPC</sup> , 4/02/2013 <sup>MDCRPC</sup> , 02/04/2014 <sup>MPC</sup> , 12/02/2014 <sup>MPC</sup> , 10/06/2015 <sup>MPC</sup> , 08/02/2016 <sup>MPC</sup> , 06/06/2017 <sup>MPC</sup> , 04/03/2018 <sup>MPC</sup> , 04/02/2019 <sup>MPC</sup> , 04/07/2020 <sup>MPC</sup> , 04/06/2021 <sup>MPC</sup> , 04/05/2022 <sup>MPC</sup> , 04/04/2023 <sup>MPC</sup> , 08/06/2024 <sup>MPC</sup>	08/02/2016

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/02/2016	Added criteria for Toric Intraocular Lens



## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria Intraoperative Neurophysiological Monitoring (IONM)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	Noridian retired <a href="#">LCD Sensory Evoked Potentials &amp; Intraoperative Neurophysiology Monitoring (L34072)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.
Local Coverage Article	None

#### For Non-Medicare Members GENERAL CRITERIA

- Intraoperative neurophysiologic monitoring must be performed by either a licensed physician trained in clinical neurophysiology or a trained technologist who is practicing within the scope of his/her license/certification as defined by state law or appropriate authorities and is working under direct supervision of a physician trained in neurophysiology; AND
- Intraoperative neurophysiologic monitoring must be interpreted by a licensed physician trained in clinical neurophysiology, other than the operating surgeon, who is either in attendance in the operating suite or present by means of a real-time remote mechanism for neurophysiologic monitoring situations and is immediately available; AND
- Monitoring is conducted and interpreted real-time (either on-site or at a remote location) and continuously communicated to the surgical team; AND
- The physician performing, or supervising monitoring must be monitoring no more than three cases simultaneously; AND
- Charges related to intraoperative monitoring will only be reimbursed when billed on a HCFA 1500 claim form for professional charges; AND

- Any charges related to intraoperative monitoring billed on a UB form are not reimbursable.

## INDICATIONS

Intraoperative neuromonitoring may be indicated for a variety of spinal, intracranial, and vascular procedures. The specific type of monitoring indicated for each procedure varies, as outlined in the below criteria and summarized in the following tables. Pre-procedural baseline testing may be separately reported, but only once per operative session.

### Somatosensory-evoked potentials with or without motor-evoked potentials

Intraoperative neuromonitoring using somatosensory-evoked potentials (SSEP), with or without motor-evoked potentials (using electrical stimulation), may be medically necessary during the following procedures:

- Spinal procedures
  - Dorsal rhizotomy
  - Correction of scoliosis
  - Correction of deformity involving traction on the spinal cord
  - Spinal cord tumor removal
  - Surgery due to traumatic injury to spinal cord
  - Surgery for arteriovenous (AV) malformation of spinal cord
- Intracranial procedures
  - Microvascular decompression of cranial nerves
  - Removal of acoustic neuroma, congenital auricular lesions, or cranial base lesions
  - Cholesteatoma, including mastoidotomy or mastoidectomy
  - Vestibular neurectomy for Meniere's
  - Removal of cranial nerve neuromas affecting any of the following nerves:
    - Abducens
    - Facial
    - Glossopharyngeal
    - Hypoglossal
    - Oculomotor
    - Recurrent laryngeal
    - Spinal accessory
    - Superior laryngeal
    - Trochlear
  - Deep brain stimulation
  - Endolymphatic shunting for Meniere's disease
  - Oval or round window graft
  - Removal of cavernous sinus tumors
  - Resection of brain tissue near primary motor cortex and requiring brain mapping
  - Resection of epileptogenic brain tissue or tumor
  - Other intracranial procedures (e.g., aneurysm repair, intracranial AVM)
- Non-cranial vascular procedures
  - Carotid artery surgery
  - Arteriography with test occlusion of carotid artery
  - Deep hypothermic circulatory arrest
  - Distal aortic procedures
  - Surgery of the aortic arch, its branch vessels, or thoracic aorta

### Electroencephalographic monitoring

Intraoperative electroencephalographic (EEG) monitoring may be considered medically necessary for any of the following procedures

- Intracranial procedures
  - Microvascular decompression of cranial nerves



- Removal of acoustic neuroma, congenital auricular lesions, or cranial base lesions
- Cholesteatoma, including mastoidotomy or mastoidectomy
- Vestibular neurectomy for Meniere's
- Removal of cranial nerve neuromas affecting any of the following nerves:
  - Abducens
  - Facial
  - Glossopharyngeal
  - Hypoglossal
  - Oculomotor
  - Recurrent laryngeal
  - Spinal accessory
  - Superior laryngeal
  - Trochlear
- Deep brain stimulation
- Endolymphatic shunting for Meniere's disease
- Oval or round window graft
- Removal of cavernous sinus tumors
- Resection of brain tissue near primary motor cortex and requiring brain mapping
- Resection of epileptogenic brain tissue or tumor
- Other intracranial procedures (e.g., aneurysm repair, intracranial AVM)
- Non-cranial vascular procedures
  - Carotid artery surgery
  - Arteriography with test occlusion of carotid artery

#### Electromyographic monitoring

Intraoperative electromyographic (EMG) monitoring may be considered medically necessary when monitoring is during any of the following procedures:

- Dorsal rhizotomy
- Microvascular decompression of cranial nerves
- Removal of acoustic neuroma, congenital auricular lesions, or cranial base lesions
- Cholesteatoma, including mastoidotomy or mastoidectomy
- Vestibular neurectomy for Meniere's
- Removal of cranial nerve neuromas affecting any of the following nerves:
  - Abducens
  - Facial
  - Glossopharyngeal
  - Hypoglossal
  - Oculomotor
  - Recurrent laryngeal
  - Spinal accessory
  - Superior laryngeal
  - Trochlear

SPINAL PROCEDURES	SSEP (with or without MEP) 95925,95926, 95927,95938 With MEP – 95928, 95929, 95939	EEG 95822 95955	EMG 95860 95861 95867 95868 95870
Dorsal rhizotomy	☑		☑
Correction of scoliosis	☑		



Correction of deformity involving traction on the spinal cord	<input checked="" type="checkbox"/>		
Spinal cord tumor removal	<input checked="" type="checkbox"/>		
Surgery due to traumatic injury to spinal cord	<input checked="" type="checkbox"/>		
Surgery for AV malformation of spinal cord	<input checked="" type="checkbox"/>		

NON-CRANIAL VASCULAR PROCEDURES	SSEP (with or without MEP) 95925,95926, 95927,95938 With MEP – 95928, 95929, 95939	EEG 95822 95955	EMG 95860 95861 95867 95868 95870
Carotid artery surgery	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Arteriography w/ test occlusion of carotid artery	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	
Deep hypothermic circulatory arrest	<input checked="" type="checkbox"/>		
Distal aortic procedures (due to risk of ischemia to spinal cord)	<input checked="" type="checkbox"/>		
Surgery of aortic arch, its branch vessels, or thoracic aorta	<input checked="" type="checkbox"/>		

INTRACRANIAL PROCEDURES*	SSEP (with or without MEP) 95925,95926, 95927,95938 With MEP – 95928, 95929, 95939	EEG 95822 95955	EMG 95860 95861 95867 95868 95870
Microvascular decompression of cranial nerves	☑	☑	☑
Removal of acoustic neuroma, congenital auricular lesions, cranial base lesions	☑	☑	☑
Cholesteatoma, including mastoidotomy or mastoidectomy	☑	☑	☑
Vestibular neurectomy for Meniere's	☑	☑	☑
Removal of cranial nerve neuromas affecting any of following nerves: <i>Abducens</i> <i>Facial</i> <i>Glossopharyngeal</i> <i>Hypoglossal</i> <i>Oculomotor</i> <i>Recurrent laryngeal</i> <i>Spinal accessory</i> <i>Superior laryngeal</i> <i>Trochlear</i>	☑	☑	☑
Deep brain stimulation	☑	☑	
Endolymphatic shunt for Meniere's disease	☑	☑	
Oval or round window graft	☑	☑	
Removal of cavernous sinus tumors	☑	☑	
Resection of brain tissue near primary motor cortex and requiring brain mapping	☑	☑	
Resection of epileptogenic brain tissue or tumor	☑	☑	
Other intracranial vascular procedures (e.g. aneurysm repair, intracranial AV malformation)	☑	☑	

\*Intraoperative brainstem auditory evoked response monitoring may also be appropriate for intracranial procedures in which auditory function is at risk, such as acoustic neuroma resection or brainstem tumor resection.

## EXPERIMENTAL AND INVESTIGATIONAL

IONM is considered experimental/investigational for all indications not meeting the above criteria. Examples of procedures for which there is insufficient evidence to establish net benefit of IONM include, but are not limited to, the following:

- Routine lumbar or cervical laminectomies and fusions
- Spinal cord stimulator implantation
- Thyroid or parathyroid surgery
- Cochlear implantation
- Vagal nerve stimulator implantation
- Spinal injections
- Hip replacement
- Parotid gland surgery

Intraoperative monitoring of visual evoked potentials is experimental and investigational for all indications.

Intraoperative monitoring of motor evoked potentials using transcranial magnetic stimulation is experimental and investigational for all indications.

Nerve conduction studies for intraoperative monitoring purposes are considered experimental and investigational for all indications.

**If requesting these services, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist
- Last 6 months of radiology if applicable

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Background

### **EVIDENCE BASIS**

There is moderate strength of evidence that IONM may identify patients at greater risk of adverse outcomes due to neurological injury among individuals undergoing certain spinal procedures. For surgeries that risk damaging the spinal cord (e.g., scoliosis correction, spinal cord tumor removal), the effectiveness of IONM has been assumed. As such, the evidence base for comparative studies is minimal. However, multiple retrospective and prospective cohort studies indicate that IONM may accurately identify those with postoperative neurological deficits. Less clear is whether knowledge of injury, intraoperatively, can lead to intervention which prevents or reverses said neurological deficits.

A systematic review (Fehlings 2010) concluded that IONM is sensitive and specific for detecting neurological complications during spinal surgery. That review included 14 prospective cohort studies addressing a variety of spinal indications. Across all included studies, IONM was not associated with any serious harms. Authors concluded that IONM can be a valuable tool during spinal surgery when the spinal cord or nerve roots are at risk.

IONM has also been proposed as potentially valuable during thyroid surgery as a means to prevent injury to the recurrent laryngeal nerve. A systematic review (Malik 2016) evaluated 17 studies comparing thyroid surgery with and without IONM. Using pooled data from those studies, authors found no statistically significant difference in recurrent laryngeal nerve palsy (RLNP) between those who had undergone thyroid surgery with or without IONM. Another systematic review (Yang 2017) reported a slightly lower incidence of RLNP among those who had thyroid surgery with IONM, but this difference was not statistically significant.

The American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) released a position statement on IONM in April 2014. The AANS/CNS concluded that there is insufficient evidence to show that the use of IONM mitigates the severity of neurological injury or reduces its incidence. However, the position statement did note that use of IONM may help to diagnose neurological injury during surgery. Later that year, an analysis of all spine surgeries performed from 2007-2011 that were included in the Nationwide Inpatient Sample database was published by James WS, et al. This study included 443,194 spine procedures in which 31,680 cases utilized IONM. Iatrogenic neurological injury was rare, occurring in less than 1% with no difference in cases where IONM was used. In 2015, Hawksworth et al, from the University of Texas Health Sciences Center, published an analysis of their department's spine surgeries completed from 2011-2013, before and after adopting a departmental policy limiting IONM use to intradural procedures and those for spinal deformity correction. While utilization of IONM dropped from 38% of spinal cases to 7%, there was no change in

incidence of neurological injury. In fact, the only observed cases of injury occurred in cases utilizing IONM where the monitoring did not alert the surgeon to the injury.

In 2017, Hadley, et al published, "Guidelines for the Use of Electrophysiological Monitoring for Surgery of the Human Spinal Column and Spinal Cord" which was approved by both the American Association for Neurological Surgeons and the Congress of Neurological Surgeons. This Guideline was based on review of relevant published literature from 1966-2017. Similar to the aforementioned 2014 position statement, this new Guideline found that IONM "has not been shown to be successful in reducing the rate or perioperative neurological deterioration or to improve neurological outcome during spinal surgery procedures." The authors later conclude that because use of IONM during spinal surgery has not been correlated with improvements in neurological outcome that its expense does not appear justified.

In a systematic review on IONM for cervical degenerative myelopathy and radiculopathy, authors concluded that altering of the surgical plan or intraoperative steroid administration based upon IONM monitoring was not shown to decrease the incidence of neurological injury. However, the review concluded that IONM may be sensitive for assessing neurological injury for diagnostic information.

The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) released a position statement in 2014 supporting the use of intraoperative SSEP for certain spinal surgeries, particularly those with increased risk for nerve root or spinal cord injury (including complex, extensive, or lengthy procedures). Authors also stated that intraoperative SSEP was not indicated for routine lumbar or cervical root decompression.

In 2012, the American Academy of Neurology (AAN) and the American Clinical Neurophysiology Society (ACNS) identified 11 studies as part of their evidence-based guidelines process, from which they concluded the IONM is safe and effective for identifying increased risk of adverse outcomes, including paraparesis, paraplegia, and quadriplegia during spinal surgery (Nuwer 2012).

## Medical Technology Assessment Committee (MTAC)

### ***Intraoperative Neurophysiologic Monitoring (IONM)***

#### **08/17/2015: MTAC REVIEW**

**Evidence Conclusion:** The selected studies offer a small sample of the extensive literature currently available relating to IONM. For the most part, the available evidence is descriptive and details the experience of IONM in various surgical settings. In the selected studies, IONM is used to support surgeries in various specialties including neurosurgery (brain and spine), cardiac, and vascular. Population sizes range from 62 to 119 and assessed pre- and post- surgical outcomes such as neurophysiologic alerts during surgery and post-operative neurological deficits. Conclusions from the selected studies conflict with some asserting the utility of IONM technology and others finding minimal utility due to the inability to predict post-operative complications (Schramm, Koht et al. 1990; Linstedt, Maier et al. 1998; Ghariani, Liard et al. 1999; Bose, Sestokas et al. 2004). Surgical procedures and interventions are not always based on scientific evidence and instead, tend to evolve over time. Today, IONM is considered to be a standard of care limiting the ability to carry out methodologically sound comparative studies due to equipoise. Beyond that, the existing literature base is extremely heterogeneous addressing various surgical procedures in different populations with varying and conflicting conclusions. As a result, the evidence is insufficient to be able to determine if IONM is truly effective at detecting and preventing neurologic complications.

**Conclusions:** There is insufficient evidence to establish that IONM, either on-site or remote, reduces the risk of neurologic injuries during surgical procedures. There is insufficient evidence to support the safety of IONM.

**Articles:** The literature search revealed a large number of publications relating to IONM. There were no randomized controlled trials (RCTs) comparing the outcomes of surgeries that employed the use of IONM (either remote or on-site) with those not utilizing the monitoring technique nor were there any studies making a comparison between remote and onsite monitoring. The search yielded a wide variety of observational studies the majority of which had no comparison group. Due to the extensive amount of literature identified, the following studies are a small sample of the available evidence: Bose B, Sestokas AK, Schwartz DM. Neurophysiological monitoring of spinal cord function during instrumented anterior cervical fusion. *The Spine Journal*. 2004;4(2):202-207. [See Evidence Table 1](#). Schramm J, Koht A, Schmidt G, et al. Surgical and electrophysiological observations during clipping of 134 aneurysms with evoked potential monitoring. *Neurosurgery*. 1990;26(1):61-70. [See Evidence Table 1](#). Ghariani S, Liard L, Spaey J, et al. Retrospective study of somatosensory evoked potential monitoring in deep hypothermic circulatory arrest. *The Society of Thoracic Surgeons*. 1999; 67:1915-1918. [See Evidence Table 1](#). Linstedt

U, Maier C, Petry A. Intraoperative monitoring with somatosensory evoked potentials in carotid artery surgery – less reliable in patients with preoperative neurologic deficiency? *Acta Anaesthesiol Scand*. 1998;42(1):13-16. [See Evidence Table 1](#).

The use of Intraoperative Neurophysiologic Monitoring (IONM) does not meet *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

### General Neuromonitoring:

CPT® or HCPC Codes	Description
95940	Continuous intraoperative neurophysiology monitoring in the operating room, one on one monitoring requiring personal attendance, each 15 minutes (List separately in addition to code for primary procedure)
95941	Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby) or for monitoring of more than one case while in the operating room, per hour (List separately in addition to code for primary procedure)
G0453	Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)

### Somatosensory-evoked potentials (SSEP):

**NOTE:** CPTs 95925 and 95926 should not be billed during the same procedure if both upper and lower limbs are monitored; instead, CPT 95938 should be used. CPT 95938 should not be coded in conjunction with either 95925 or 95926. Similarly, 95928 and 95929 should not be billed together; instead 95939 should be used if both upper and lower limbs are monitored.

CPT® or HCPC Codes	Description
95925	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs
95926	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs
95927	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head
95938	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper and lower limbs

### Motor evoked potentials (MEP):

CPT® or HCPC Codes	Description
95928	Central motor evoked potential study (transcranial motor stimulation); upper limbs
95929	Central motor evoked potential study (transcranial motor stimulation); lower limbs
95939	Central motor evoked potential study (transcranial motor stimulation); in upper and lower limbs

### Electroencephalography:

CPT® or HCPC Codes	Description
95822	Electroencephalogram (EEG); recording in coma or sleep only
95955	Electroencephalogram (EEG) during nonintracranial surgery (eg, carotid surgery)

### Electromyography:

CPT® or HCPC	Description
--------------	-------------

Codes	
95860	Needle electromyography; 1 extremity with or without related paraspinal areas
95861	Needle electromyography; 2 extremities with or without related paraspinal areas
95867	Needle electromyography; cranial nerve supplied muscle(s), unilateral
95868	Needle electromyography; cranial nerve supplied muscles, bilateral
95870	Needle electromyography; limited study of muscles in 1 extremity or non-limb (axial) muscles (unilateral or bilateral), other than thoracic paraspinal, cranial nerve supplied muscles, or sphincters

**Considered not medically necessary:**

CPT® or HCPC Codes	Description
95907	Nerve conduction studies; 1-2 studies
95908	Nerve conduction studies; 3-4 studies
95909	Nerve conduction studies; 5-6 studies
95910	Nerve conduction studies; 7-8 studies
95911	Nerve conduction studies; 9-10 studies
95912	Nerve conduction studies; 11-12 studies
95913	Nerve conduction studies; 13 or more studies
95930	Visual evoked potential (VEP) checkerboard or flash testing, central nervous system except glaucoma, with interpretation and report
95937	Neuromuscular junction testing (repetitive stimulation, paired stimuli), each nerve, any 1 method

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
08/27/2015	07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	05/07/2019

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
05/07/2019	MPC approved to adopt KP National criteria for IONM.





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Iontophoresis Phonophoresis

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of an active NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>"Iontophoresis"</b> for medical necessity determinations. Refer to the Non-Medicare criteria below.

#### For Non-Medicare Members

Treatment	Criteria Used
Iontophoresis	Kaiser Permanente has elected to use the Iontophoresis (KP-0617) MCG* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.
Phonophoresis	Kaiser Permanente has elected to use the MCG Phonophoresis guideline (A-0616): this is not covered per MCG* for medical necessity determinations. For access to the MCG Clinical Guidelines criteria, please see the MCG Guideline Index through the provider portal under Quick Access.
For Medication Delivery with Iontophoresis for Temporomandibular Joint (TMJ) Dysfunction and Joint Pain or Devices for use in the member's home	There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

**\*MCG are proprietary and cannot be published and/or distributed.** However, on an individual member basis, Kaiser Permanente can share a copy of the specific criteria document used to make a utilization management decision. If one of your patients is being reviewed using these criteria, you may request a copy of the criteria by calling the Kaiser Permanente Clinical Review staff at 1-800-289-1363 or access the MCG Guideline Index using the link provided above.

**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

## Evidence and Source Documents

[Iontophoresis for Hyperhidrosis using Drionic or Idrostar Devices](#)

[Iontophoresis for Joint Pain](#)

[Medication Delivery with Iontophoresis for Temporomandibular Joint \(TMJ\) Dysfunction](#)

## Background

Iontophoresis is the use of electricity to enhance the percutaneous absorption of a drug or chemical ions. Ions in solution are transferred through the skin by passing DC electrical current between two electrodes. Iontophoresis uses a low current and patients' have little or no sensation during the procedure. Drugs used in iontophoresis should be those that ionize. Drugs used for iontophoresis may include lidocaine hydrochloride (a positive ion forming drug) and dexamethasone sodium phosphate (a negative ion forming drug). Possible advantages include greater convenience and less discomfort compared to injection, less variation in absorption, and fewer side effects compared to oral administration of medication.

## Medical Technology Assessment Committee (MTAC)

[Iontophoresis for Hyperhidrosis using Drionic or Idrostar Devices](#)

### BACKGROUND

Hyperhidrosis or excessive sweating may be classified into primary or essential hyperhidrosis with an unknown cause, and secondary hyperhidrosis which is due to an underlying condition as hyperthyroidism, menopause, obesity, psychiatric disorder, and others. It may be localized in one or several locations of the body, most often in the hands (palmer hyperhidrosis) but may also be planter, axillary, facial, or general. Several methods are used to treat patients with primary hyperhidrosis, or secondary cases with heavy sweating or untreatable conditions. These include the use of antiperspirants, drugs, psychotherapy, surgery, iontophoresis, use of botulinum toxin, alternative medicine, and others. Iontophoresis can be defined as a means of delivering medication to a localized tissue area by applying electrical current to a solution of the medication. It consists of applying low intensity current (15-18 mA) supplied by a D/C generator to the palms and/or soles immersed in an electrolyte solution. The procedure has to be repeated regularly, and the results may vary among patients. The Drionic and Idrostar devices are battery- operated methods of inducing tap water iontophoresis.

### 06/12/2002: MTAC REVIEW

**Iontophoresis for Hyperhidrosis using Drionic or Idrostar Devices**

**Evidence Conclusion:** There is not enough evidence to permit conclusions on the use of either the Drionic or Idrostar device for treating hyperhidrosis.

**Articles:** The search yielded three articles, two of which were reviews, and the third was a small case series with 22 patients with hyperhidrosis treated with the Drionic unit.

The use of Idrostar in the treatment of hyperhidrosis via iontophoresis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### 08/03/2009: MTAC REVIEW

**Iontophoresis in the Treatment of Hyperhidrosis**

**Evidence Conclusion:** There is insufficient evidence to draw conclusions on the safety and efficacy of iontophoresis for treating hyperhidrosis. No published comparative studies were identified. The literature base consists of case series, mostly with fewer than 25 patients and one case series with 112 patients. The larger series reported that about 81% of participants responded to treatment. The criteria provided for response was not clearly defined and there was no long-term follow-up.

**Articles:** Four empirical studies specifically evaluating iontophoresis for hyperhidrosis were identified. There were no randomized or non-randomized controlled studies. All of the empirical studies were case series. Three had fewer than 25 patients and were excluded from further review. The fourth (Karakoc et al., 2002) included 112 patients and was critically appraised. See [Evidence Table](#).

The use of iontophoresis in the treatment of hyperhidrosis does not meet the Kaiser Permanente *Medical Technology Assessment Criteria*.

### ***Iontophoresis for Joint Pain***

#### **BACKGROUND**

Iontophoresis is proposed as a treatment for joint pain. It has been used for various types of tendonitis including epicondylitis, patellar tendonitis, biceps tendonitis, rotator cuff tendonitis and Achilles tendonitis (Winn, unpublished manuscript). Iontophoresis is the use of electricity to enhance the percutaneous absorption of a drug or chemical ions. Ions in solution are transferred through the skin by passing DC electrical current between two electrodes. Iontophoresis uses a low current and patients have little or no sensation during the procedure. Drugs used in iontophoresis should be those that ionize. Dexamethasone sodium phosphate, a negative ion, is a commonly used drug used for iontophoresis treatment of joint pain. Possible advantages include greater convenience and less discomfort compared to injection, less variation in absorption, and fewer side effects compared to oral administration of medication. Common treatments for joint pain include rest, ice after exercise, stretching, bracing and immobilization; medications such as analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) and injection of corticosteroids. A well-done randomized controlled trial (Hay et al., 1999) found that local injection of corticosteroid was more effective for treating lateral epicondylitis than NSAID treatment, but that more than 80% of patients were improved at 12 months regardless of treatment.

#### **10/08/2003: MTAC REVIEW**

#### ***Iontophoresis for Joint Pain***

**Evidence Conclusion:** There is insufficient evidence to conclude that iontophoresis for joint pain is effective compared to the accepted alternatives, corticosteroid injection and NSAID treatment. No studies compared iontophoresis with one of these established treatments. There is some evidence that iontophoresis is not more effective than placebo treatment, although the data are limited. The highest quality study identified was an RCT comparing active iontophoresis with placebo iontophoresis in patients with epicondylitis (Nirschl). This study found a greater effect with active iontophoresis two-days after treatment, but no difference in efficacy after one-month. The study was powered to detect a 20% difference between groups. Another RCT conducted with patients with epicondylitis (Runeson) found no difference in the efficacy of active or placebo iontophoresis 3- and 6-months after treatment. Neither RCT had an intention to treat analysis, but follow-up was much higher in the Nirschl study (90% compared to 64% in the Runeson study). Statistical power was not discussed in the Runeson study. The quality of evidence for conditions other than epicondylitis was low.

**Articles:** The search yielded 12 articles. None of the studies compared iontophoresis to corticosteroid injection or oral medication treatment. There were four RCTs conducted with patients who had epicondylitis. Two studies compared active iontophoresis treatment to placebo treatment and were critically appraised. The two other studies had irrelevant comparison groups and were not reviewed: one compared iontophoresis with two types of active substances and one compared iontophoresis to an experimental treatment, phonophoresis. In addition, there were three controlled studies conducted among patients with other types of tendonitis. All three had weaker methodology than the placebo-controlled epicondylitis studies and were not reviewed. Two did not compare the different treatment groups in analysis and one had a sample size of only 22 patients. *The following studies were critically appraised:*

Nirschl RP, Rodin DM, Ochiai et al. Iontophoretic administration of dexamethasone sodium phosphate for acute epicondylitis. *Am J Sports Med* 2003; 31: 189-195. See [Evidence Table](#). Runeson L, Haker E. Iontophoresis with cortisone in the treatment of lateral epicondylalgia (tennis elbow)- a double blind study. *Scand J Med Sci Sports* 2002; 12: 136-142. See [Evidence Table](#).

The use of iontophoresis in the treatment of joint pain does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Medication Delivery with Iontophoresis for Temporomandibular Joint (TMJ) Dysfunction***

#### **BACKGROUND**

Temporomandibular joint (TMJ) dysfunction is a common condition and involves pain, particularly in the chewing muscles and jaw joint, radiating pain in the face, neck or shoulders, painful clicking sounds in the jaw joint, and restricted jaw movement. Drug therapies for TMJ dysfunction include analgesics, minor tranquilizers or muscle relaxants at bedtime, antidepressants, injections of a local anesthetic and cortisone injections.

Iontophoresis is the use of electricity to enhance the percutaneous absorption of a drug or chemical ions. Ions in solution are transferred through the skin by passing DC electrical current between two electrodes. Iontophoresis uses a low current and patients have little or no sensation during the procedure. Drugs used in iontophoresis should be those that ionize. Drugs used for iontophoresis to treat TMJ include lidocaine hydrochloride (a positive ion forming drug) and dexamethasone sodium phosphate (a negative ion forming drug) (Lark & Gangarosa). Iontophoresis is proposed as an alternative to local anesthetic injections for the treatment of TMJ dysfunction. Possible advantages are less discomfort than interarterial injection and fewer side effects than systemic medications.

## 02/13/2002: MTAC REVIEW

### Iontophoresis in the Treatment of Temporomandibular Joint Syndrome

**Evidence Conclusion:** There is insufficient published scientific evidence on which to base conclusions about the effect of medication delivery with iontophoresis on health outcomes in patients with temporomandibular joint syndrome. Two small RCTs were reviewed, both of which may have had insufficient statistical power to detect clinically important differences between groups; neither of the study discussed statistical power calculations. Shiffman did not compare the randomized groups in analysis. Reid did not find that iontophoresis was more effective than placebo.

**Articles:** The search yielded eight articles. The majority were review articles/opinion pieces. There were two small randomized controlled trials (RCTs) with clinical outcomes. These two articles were critically appraised: Shiffman EL, Braun BL, Lindgren BR. Temporomandibular joint iontophoresis: A double-blind randomized clinical trial. *J Orofacial Pain* 1996; 10: 157-65. See [Evidence Table](#). Reid KJ, Dionne RA, Sicard-Rosenbaum L, Lord D, Dubner RA. Evaluation of iontophoretically applied dexamethasone for painful pathologic temporomandibular joints. *Oral Surg Oral Med Oral Pathol* 1994; 77: 605-9. See [Evidence Table](#).

The use of Iontophoresis in the treatment of temporomandibular joint syndrome does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Iontophoresis -

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met**

CPT® Codes	Description
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes

### Phonophoresis - Considered Not Medically Necessary:

CPT® or HCPC Codes	Description
No specific codes	

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Review Date	Date Revised
02/13/2002	12/07/2010 <sup>MDCRPC</sup> , 10/04/2011 <sup>MDCRPC</sup> , 08/07/2012 <sup>MDCRPC</sup> , 06/04/2013 <sup>MDCRPC</sup> , 08/06/2013 <sup>MPC</sup> , 06/03/2014 <sup>MPC</sup> , 04/07/2015 <sup>MPC</sup> , 02/02/2016 <sup>MPC</sup> , 12/06/2016 <sup>MPC</sup> , 10/03/2017 <sup>MPC</sup> , 08/07/2018 <sup>MPC</sup> , 08/06/2019 <sup>MPC</sup> , 08/04/2020 <sup>MPC</sup> , 08/03/2021 <sup>MPC</sup> ,	08/03/2021

	08/01/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	
MDCRPC Medical Director Clinical Review and Policy Committee		
MPC Medical Policy Committee		

Revision History	Description
09/08/2015	Revised LCD L35008
12/13/2017	Added home unit language
09/03/2019	MPC approved to add clinical indication for Palmar/Plantar Hyperhidrosis
11/05/2019	MPC approved to adopt non coverage criteria for Phonophoresis; adopting MCG A-0616
06/15/2020	60-day notice required for non-coverage of phonophoresis, updated effective date to 10/1/2020
08/04/2020	Added Medicare LCA A57642
08/03/2021	Removed LCD L35008 and LCA A57642; added KPWA medical policy statement under Medicare section.

## Clinical Review Criteria

### Intraoperative Radiation Therapy (IORT)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

## Criteria

### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	4/01/2016 Noridian retired <a href="#">LCD Brachytherapy: Non-Intracoronary (L34065)</a> . These services still need to meet medical necessity as outlined in the LCD and will require review. LCDs are retired due to lack of evidence of current problems, or in some cases because the material is addressed by a National Coverage Decision (NCD), a coverage provision in a CMS interpretative manual or an LCD. Most LCDs are not retired because they are incorrect. The criteria should be still referenced when making an initial decision. However, if the decision is appealed, the retired LCD cannot be specifically referenced. Maximus instead looks for "medical judgment" which could be based on our commercial criteria or literature search.
Local Coverage Article	None

### For Non-Medicare Members

Intraoperative radiation therapy (IORT) may be considered medically necessary in the following situation:

- Rectal cancer with positive or close margins with T4 lesions or recurrent disease.

IORT is considered investigational when used for all other oncologic applications, including but not limited to:

- Breast cancer
- Fibromatosis
- Gastric cancer
- Glioma
- Gynecologic cancers
- Head and neck cancers
- Neuroblastoma
- Pancreatic cancer
- Renal cell cancer
- Soft tissue sarcoma

Some requests may be approved on a case-by-case basis by the Medical Director.



**If requesting this service, please send the following documentation to support medical necessity:**

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage

**Background**

The usual method for delivering radiation is external beam with high-energy photons. However, the external beam doses required to achieve local tumor control can exceed the radiation tolerance of some normal organs and other structures of the body.

Intra-operative radiation therapy (IORT) is being investigated as a technique to deliver a high dose of radiation to a locally advanced tumor while attempting to protect adjacent normal tissues at the time of surgery. It is delivered with applicators and cones attached to the treatment head of high-energy medical linear accelerators. After all or most of the cancer is surgically removed, a large, single-dose of high-energy radiation is aimed directly at the tumor site. Nearby healthy tissue is protected with special shields.

The goal of IORT is to enhance local tumor control. Most patients receiving IORT are concurrently treated with high-dose external beam photon irradiation. The term “intraoperative radiation therapy” may also refer to intra-operative brachytherapy, the temporary or permanent implantation of radioactive seeds. Intra-operative radiation therapy is usually a component of a multi-disciplinary treatment approach for localized cancers that cannot be completely removed or that have a high risk of recurring in nearby tissues.

**Medical Technology Assessment Committee (MTAC)*****Intraoperative Radiation Therapy (IORT) for Breast Cancer*****BACKGROUND**

Breast cancer is the most common cancer in women of all races and ethnicities (not counting skin cancer), and the second most common cause of death from cancer among white, black, Asian/Pacific Islander, and American Indian/Alaska Native women. The American Cancer Society (ACS) estimated that in 2015, 231,840 new cases of invasive breast cancer and 62,570 breast carcinoma in-situ, will be diagnosed among women in the U.S. and that 40,290 will die from breast cancer. The reported five-year relative survival rate is 98.5% for women diagnosed with localized breast cancer. This drops to 84% among women with cancer that has spread to nearby lymph nodes (regional stage) and to 24% in those with metastases in distant lymph nodes and/or other organs (CDC and ACS web pages accessed October 27, 2015). The widespread screening programs and new developments in early detection of cancer have led to an increase in the incidence of early stage breast cancer. Surgical treatment has thus shifted from radical mastectomy to personalized local treatment that preserves the breast and axillary lymph nodes, together with adjuvant therapy. Breast conserving surgery (BCS) followed by postoperative whole breast external beam radiotherapy (EBRT or WBRT) is currently considered the standard treatment for patients with early-stage breast cancer. This approach has been shown to reduce local recurrence (LR) and improve the overall survival. Traditional whole breast EBRT is administered in the postoperative setting as 45-50 Gy in daily fractions for 5 consecutive weeks. An additional external beam boost of 10-16 Gy is often delivered to the tumor bed to improve local control and reduce local recurrence. It is reported that almost one third of the patients undergoing BCS in North America do not receive post-BCS breast radiation therapy and many others choose mastectomy instead, for several reasons including the long course of treatment, comorbidities, advanced age, distance from the radiation therapy facility, inconvenience, and cost (Vaidya, 2010, Esposito 2014, Abbott 2015, Zhang 2015). Accelerated partial breast irradiation (APBI), is a radiation technique that targets partial breast tissue around the tumor cavity with fewer fractions. APBI has emerged in the last 2 decades and is increasingly being accepted as an alternative to whole breast EBRT. It is based on the observation that more than 90% of local recurrences occur at /or near the tumor bed after BCS. There are several techniques for delivering APBI, including multi-catheter interstitial brachytherapy, balloon catheter brachytherapy, 3D- conformal radiation therapy, and intraoperative radiation therapy (IORT). These techniques differ widely in regard to the degree of invasiveness, radiation delivery, operator proficiency, acceptance between radiation oncologists, and length of treatment (Njeh 2010, Vaidya 2010, Abbott 2015, Esposito 2015, Zhang 2015). IORT is an APBI approach that delivers a single dose of irradiation directly to the tumor bed at the time of surgery. Unlike other APBI techniques

that target the index quadrant, IORT specifically targets the tumor cavity. The index quadrant is not demarcated anatomically, whereas the tumor cavity is easily located by the operating surgeon. IORT can be delivered by using low-energy X-rays, electron beam radiation therapy, brachytherapy, high-dose-rate (HDR) after loaders, and other hybrid devices (Esposito 2015). The intrabeam® device (Carl Zeiss, Oberkochen, Germany) is a device used to deliver IORT during surgery after removal of the tumor. It comprises a miniature low-energy X-ray source (50 kVp) that delivers a dose of 20 Gy at the surface of the applicator and 5-5 Gy at 1 cm deep, in 20-40 minutes treatment time. Tungsten-impregnated sheets are used to shield the wound before treatment. Access to the operating room should be controlled and the medical personnel shielded during treatment. The intraoperative electron radiation therapy (IOERT) is another method for delivering IORT that involves the application of electron radiation directly to the tumor bed at the time of surgery. Compared to the X-ray beams, the electron beams have limited penetration into the tissue and faster delivery of the required radiation dose. The IOERT systems are designed to deliver radiation in non-shielded operating theaters. Currently there are three mobile linear accelerators that can be moved easily into an operating room and deliver IOERT (Novac 7®, Liac®, and the Mobetron®). The radiation procedure is completed in 2 minutes delivering a dose of 21 Gy with the depth of 90% isodose ranging from 13-24 mm (Esposito 2015). The advantages of IORT include the reduced treatment visits by delivering a single radiotherapy fraction during surgery, immediate visualization of the operative bed before delivering the radiotherapy, minimizing the possibility of missing the target, shielding the surrounding organs, avoiding treatment delay for patients who may also need to undergo chemotherapy, and reducing healthcare costs. Disadvantages of IORT on the other hand, include longer operating time, reported increased local recurrence compared to EBRT, and lack of final pathological results before delivering the IORT. In patients with positive margins that require re-excision, an IORT boost may be ineffective and may cause complications in re-excision of the margins and difficulty in interpreting the pathology. In addition, IORT requires training of staff, operating room equipment efforts, and expensive devices (Hanna 2014, Esposito 2015).

## 12/21/2015: MTAC REVIEW

### IORT for breast cancer

**Evidence Conclusion:** There are two large published intraoperative radiation therapy (IORT) trials that investigated whether IORT is equivalent (ELIOT) or noninferior (TARGIT-A) to standard EBRT for the treatment of women with early stage breast cancer undergoing breast conservative surgery. The ELIOT trial used electron IORT (using 2 linear accelerators; NOVAC 7 and Liac) and the TARGIT-A trial used a point source low-energy x-rays (50kV maximum) using the Intrabeam device. TARGIT-A trial (Vaidya et al, 2010, 2014), Evidence Table 1 This was a large multicenter trial that examined the noninferiority of IORT to EBRT (within a specified margin of 2.5%) after breast conserving surgery (BCS). 2,232 women 48-75 years of age, with invasive ductal breast cancer undergoing BCS were randomly assigned to receive either a standard regimen of 25-25 fractions (40-56 Gy) EBRT or a single fraction low energy IORT. Randomization was performed either before surgery (pre-pathology entry) or after surgery (post-pathology entry). In the latter group IORT was given after surgery by reopening the wound. 15% of the patients in the IORT group received additional EBRT (the trial protocol allowed recipients of IORT to receive additional EBRT based on unfavorable features found in the pathology [risk adapted policy]). The primary outcome of the trial was pathologically confirmed ipsilateral breast tumor recurrence (IBTR). The initial results of the trial were published in 2010 when only less than one fifth of the participants were followed-up for at least 4 years (median 25 months for all subjects). These results showed that the IBTR rate was 1.2% in the IORT arm and 0.95% the EBRT arm ( $p=0.41$ ). More recent results were published in 2014 after the addition of 1,219 participants, and longer follow-up for the initial cohort. The estimated 5-year risk of local recurrence was 3.3% in the IORT group and 1.3% in the EBRT group ( $p=0.042$ ) (median follow-up was 29 months due to the short follow-up of the additional patients; only 18% of the patients had 5 years of follow-up). The results published in the first report indicate that rate of ipsilateral local recurrence in the IORT group IORT met the noninferiority margin of 2.5% (prespecified by the investigators) for the overall patient population, and for the pre-pathology subgroup, but not for the post-pathology group. However, the incidence of the local recurrence was significantly higher with IORT vs. EBRT. This higher rate was observed at a median follow-up of 29 months which is below the median time when local recurrences are expected, especially when 90% of the women had estrogen receptor positive tumors that tend to recur later. In addition, almost two thirds of the women received adjuvant hormonal therapy which delays recurrence in estrogen receptor positive cases (Silverstein 2014). The results also show that the women who received IORT alone had 3 times the recurrence rate vs. those who received IORT+EBRT (2.7 vs. 0.9%). The authors indicated that the difference was not statistically significant, but no p value was provided. The trial was multicenter, randomized, and controlled. However, it had several methodological limitations, mainly the inadequacy of follow-up duration needed to provide conclusive evidence on the noninferiority of IORT to EBRT. The prespecified non-inferiority margin of 2.5% required a 5-year follow-up for all patients, which was only fulfilled by 20% of the study cohort. Other limitations of the trial include the open-label design (due to the nature of the intervention), and the multiple amendments made to the protocol along the course of the study such as the addition of more participating countries, increasing the population size, changing the start and ending date of the trial, and changing the funding source. In addition, each center participating in the trial managed the EBRT group

according to its institutional guidelines and determined its own criteria for treating patients with IORT given alone or as a boost therapy. [ELIOT trial \(Veronesi, et al 2013\)](#), [Evidence Table 2](#). This was a prospective single-center trial that randomized 1,305 women 48-75 year of age with clinically invasive T1-T2, ≤2.5 cm breast cancer suitable for breast conservative surgery (BCS), to undergo whole breast EBRT delivered over 6 weeks, or receive a single dose of electron beam IORT. The primary outcome of the trial was ipsilateral breast tumor recurrence (IBTR). The results of the analysis show that after a median follow-up of 5.8 years the IBTR fell within the pre-defined equivalence margin of 4.5%, but the rate was significantly higher in the IORT group (4.4% vs. 0.4% in the EBRT group,  $p < 0.0001$ , NNH of 25). The significantly higher rates of IBTR in the IORT group were observed for both the true local recurrence in the index quadrant, and for new ipsilateral breast tumors in other quadrants. The author indicated that the difference may be attributable to the very low recurrence rates in the EBRT group because of the high experience and quality of management. Some investigators raised the question on whether the 4-cm applicator size used in the trial might have been too small to adequately treat microscopic disease that extended beyond the existed tumor. Axillary or other regional lymph node metastasis and locoregional tumor recurrence were also significantly higher in the IORT group (NNH=143 and 22 and respectively). There were no significant differences between the two study arms in the development of contralateral breast metastasis, distant metastasis, or in the 5-year overall survival rate. Subgroup analysis according to patients' risk based on tumor size, grade, receptor status, and nodal positivity, showed that low risk women (69.4% of the study participants) had a 5-year IBTR rate of only 1.5% compared to 11.3% of those with one or more high-risk factors. A multivariate analysis showed that tumors size >2 cm, ≥4 positive lymph nodes, poorly differentiated tumors, and tumors with triple negative subtypes doubled the risk of IBTR. The rate of adverse skin effects (erythema, dryness and hyperpigmentation) was significantly higher in the EBRT group, and the rate of fat necrosis was significantly higher in the IORT group. There were no significant differences between the groups in mammary retraction, pain, or burning. Conclusion: The results of the two large published RCTs show that the rate of local recurrence with IORT was non-inferior (TARGIT-A trial) or equivalent (ELIOT trial) to EBRT. However, these results were based on margins prespecified by the investigators of the trials. The results of both TARGIT-A and ELIOT trials show that the risk of ipsilateral tumor recurrence was significantly higher with the IORT compared to EBRT. The published trials had relatively short follow-up duration and do not provide sufficient evidence to determine the long-term risk of delayed cancer recurrence inside or outside the index quadrant, as well as the long-term efficacy and safety of the therapy. There was significant heterogeneity between the published studies as regards to the study design, patients' ages, tumor size, threshold values, radiation sources and techniques used for delivering the IORT, as well as the follow-up duration. Multivariate analysis of the ELIOT trial results showed that the risk of ipsilateral local recurrence in women receiving IORT was almost double in patients with tumors size >2 cm, ≥4 positive lymph nodes, poorly differentiated tumors, or with triple negative subtypes.

**Articles:** The literature search revealed two large RCTs on IORT (TARGIT-A trial and ELIOT trial) as well as a systematic review and meta-analysis of published studies, and a large number of single institution cohort studies. The two large RCTs and the meta-analysis were selected for critical appraisal. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. *Lancet*. 2010 Jul 10; 376 (9735):91-102. See [Evidence Table 1](#). Vaidya JS, Wenz F, Bulsara M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. *Lancet*. 2014 Feb 15; 383 (9917):603-613. See [Evidence Table 1](#). Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): A randomized controlled equivalence trial. *Lancet Oncol*. 2013 Dec; 14 (13):1269-1277. See [Evidence Table 2](#). Zhang L, Zhou Z, Mei X, et al. Intraoperative Radiotherapy versus Whole-Breast External Beam Radiotherapy in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis. *Medicine (Baltimore)*. 2015 Jul; 94(27):e1143. See [Evidence Table 3](#).

The use of IORT for breast cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
19294	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session

<b>77425</b>	Intraoperative radiation treatment delivery, electrons, single treatment session
<b>77469</b>	Intraoperative radiation treatment management
<b>HCCP Codes</b>	<b>Description</b>
<b>C9726</b>	Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
12/01/2015	12/01/2015 <sup>MPC</sup> , 10/04/2016 <sup>MPC</sup> , 08/01/2017 <sup>MPC</sup> , 06/05/2018 <sup>MPC</sup> , 06/04/2019 <sup>MPC</sup> , 06/02/2020 <sup>MPC</sup> , 06/01/2021 <sup>MPC</sup> , 06/07/2022 <sup>MPC</sup> , 06/06/2023 <sup>MPC</sup> , 04/02/2024 <sup>MPC</sup> , 04/01/2025 <sup>MPC</sup>	04/20/2016

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
01/06/2016	MPC approved the MTAC recommendation of insufficient evidence for IORT for breast cancer
04/20/2016	Changed Medicare language as LCD 34065 was retired.

## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

#### Intraperitoneal Hyperthermic Chemotherapy (IPHC)

- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Intraoperative Chemo Hyperthermic Peritoneal Perfusion (CHPP)
- Intraperitoneal Hyperthermic Chemoperfusion (IHCP)

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	<a href="#">Hyperthermia for Treatment of Cancer (110.1)</a> <i>*Per NCD: Covered in connection with radiation therapy for certain types of malignancies, <u>not covered</u> in connection with chemotherapy</i>
Local Coverage Determinations (LCD)	None

#### For Non-Medicare Members

Service	Criteria Used
Cytoreductive Surgery	Cytoreductive surgery and perioperative hyperthermic intraperitoneal chemotherapy may be considered <b>medically necessary</b> for the treatment of: <ul style="list-style-type: none"> <li>• pseudomyxoma peritonei</li> <li>• diffuse malignant peritoneal mesothelioma</li> <li>• ovarian cancer</li> </ul>
Perioperative Hyperthermic Intraperitoneal Chemotherapy	Cytoreductive surgery and perioperative hyperthermic intraperitoneal chemotherapy is considered <b>investigational</b> for: <ul style="list-style-type: none"> <li>• peritoneal carcinomatosis from colorectal cancer, gastric cancer, or endometrial cancer;</li> <li>• all other indications, including goblet cell tumors of the appendix.</li> </ul>
Intraperitoneal chemotherapy without hyperthermic methodology	Intraperitoneal chemotherapy without hyperthermic methodology is considered standard therapy and is not subject for review and is covered.

#### If requesting this service, please send the following documentation to support medical necessity:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.



## Background

### Colon Cancer

In the United States, approximately 108,070 patients are diagnosed with colon cancer (CRC) per year, and between 10-30% of these patients will develop peritoneal carcinomatosis (PC) at some point after their initial diagnosis. PC is characterized by intraperitoneal spread of tumor nodules in the peritoneum which may occur as a result of growth of the tumor and its invasion through the serosal lining of the bowel lumen, or as result of iatrogenic manipulation during surgical procedures. PC of colorectal origin has poor survival and is the second most frequent cause of death in patients with colorectal cancer (CRC), after metastatic liver disease. It has always been regarded as a terminal condition and was commonly treated only with palliative therapies (Franko 2012, Macri 2010, Ripley 2010, Chua 2012).

Over the last two decades, significant advances made in the field of cytotoxic chemotherapy and biological agents have changed the treatment of PC from a palliative to a potentially curative approach. Modern chemotherapeutic regimens have increased the response rate and median survival of patients with PC. However, few patients experience long-term survival with chemotherapy alone. In the 1980s a multimodal technique was developed to manage PC based on cytoreduction of the primary tumor, peritonectomy, and hyperthermic antitubercular peritoneal perfusion (HIPEC). Theoretically cytoreductive surgery (CRS) treats the macroscopic residual disease and intraperitoneal (IP) chemotherapy treats the microscopic residual disease. IP chemotherapy is based on the principle that a high concentration of chemotherapy within the abdominal cavity will kill the tumor cells on the surface with less diffusion into the tissues and thus are less toxicity. Hyperthermia with IP chemotherapy optimizes the process as heat has direct cytotoxic effects on cancer cells and increases the cytoactivity and penetration of certain cytotoxic drugs (Verwaal 2008, Macri 2010, Ripley 2010, Vaira 2010, Glehen 2010, Mizumato 2012, Chua 2012, Miceli 2012).

HIPEC is achieved by the intraperitoneal administration of a large volume of chemotherapeutic agents in a carrier solution through an open or closed technique. It involves the placement of one inflow and three outflow catheters in the abdominal cavity after the cytoreduction surgery. The cytotoxic agent is applied through the inflow drainage using a roller pump and heat exchanger in a closed system that allows perfusion circulation. The intraperitoneal temperature should reach 41-42°C and is monitored by two sensors placed in the inflow catheter and in the Douglas pouch. At the end of the procedure the solution is drained, and the abdominal wall is closed. There is no standardized procedure for HIPEC and there are variations between the centers in the combinations and/or concentrations for the cytotoxic agents used, as well as the intraabdominal temperature and duration of the treatment which ranges from 30 minutes to 2 hours depending on the protocol of the drug used. The combination therapy of cytoreductive surgery and HIPEC is complex, has a steep learning curve, and is associated with significant morbidity and mortality. Preoperative selection of patients to achieve complete cytoreduction plays a crucial role for the success of therapy regarding the clinical and ontological outcomes as well as the patient quality of life (Glockzin 2009, Mizumato 2012).

There is controversy around the use of cytoreduction therapy and HIPEC for peritoneal surface disease from CRC, and the procedure is not widely accepted despite the Consensus Statement (issued by representatives from the major Peritoneal Surface Malignancy Centers from around the world) on the role of cytoreductive surgery and HIPEC in the management of peritoneal surface malignancies of colonic origin (Esquivel 2007).

### Ovarian Cancer

Ovarian cancer is the fifth leading cause of death in women in the US and the most common cause of death from gynecological cancer in the Western World. It was estimated that around 22,280 women will be diagnosed with ovarian cancer and that 15,500 women will die of the disease in the US in 2012. Approximately two thirds of the women are diagnosed at an advanced stage due to the nonspecific nature of the presenting symptoms of ovarian cancer and its high tendency for early peritoneal spread. Peritoneal carcinomatosis occurs through exfoliation of malignant cells into the peritoneal fluid and their dissemination along the abdominal and pelvic peritoneum. Traditionally these patients with extensive peritoneal carcinomatosis were often labeled as having terminal disease and were only given palliative therapy with no curative intent (Chua 2009, Spiliotis 2011, Chan 2012, de Bree E 2012, Mulier 2012, Siegal 2012, Tentes 2012).

The standard therapy for patients with ovarian cancer is maximal cytoreductive surgery (CRS) followed by systemic chemotherapy with a platinum-based agent and a taxane combination. Ovarian cancer is one of the most chemosensitive tumors, and its response to this initial therapy is high, but the disease often recurs, mostly locoregionally, involving the peritoneum and adjacent intra-abdominal organs. The sensitivity of epithelial ovarian



cancer to chemotherapy and its tendency to remain confined to the peritoneal cavity through much of its natural history, have led the researchers to investigate regional treatment such as intraperitoneal (IP) administration of chemotherapy (IPC). The theoretical benefits include the achievement of a high drug concentration in the peritoneal cavity without the toxic effects of the systemic chemotherapy. IP chemotherapy has been investigated in clinical trials including the Gynecologic Oncology Group (GOG-172) phase III trial that showed approximately 16 months improvement in the median survival of women treated with a combination intravenous (IV) and IP chemotherapy compared to those treated with IV chemotherapy alone, but on the expense of the increased risk of toxicity and catheter-related complications. Based on the results of this as well as other trials, the National Cancer Institute (NCI) issued a clinical announcement in 2006 recommending that women with optimally debulked stage III ovarian cancer and their physicians consider a combination of intravenous (IV) and intraperitoneal chemotherapy (IPC). IPC has limited tissue penetration and may be indicated only following optimal resection of peritoneal disease when there is either no or very small macroscopic disease remaining (<1.0 cm). The use of IPC however, is controversial and is not widely accepted by the medical community as a standard treatment in the management of advanced epithelial ovarian cancer, due to its high toxicity, catheter-related complications, and negative impact on the patients' quality of life (Almadrones 2007, Trimble 2008, Runowicz 2008, Lim 2009, Spiliotis 2011, Tentes 2012, Chan 2012, de Bree 2012).

In the last two decades researchers investigated the synergistic effect of combining regional hyperthermia and intraperitoneal chemotherapy (hyperthermic IPC, or HIPEC) together with the CRS. Theoretically, in addition its tumoricidal effect, hyperthermia increases the permeability of the drug to the tumor cells (up to 5-6 mm compared to 2-3 mm of the conventional IPC). Hyperthermia may also alter the cellular metabolism, and cellular drug pharmacogenetics. A potential advantage of administering HIPEC intraoperatively is providing superior and homogenous exposure of the seroperitoneal surface to the drug and heat before the development of adhesions. The disadvantage of HIPEC compared to IPC is the shorter tumor exposure time and its administration only once during the surgery or at the most twice when a secondary surgery is performed (de Bree 2012).

#### **Other primary peritoneal malignancies or secondary dissemination from gastrointestinal tract or other pelvic organs.**

Primary peritoneal malignancies such as peritoneal mesothelioma or papillary serous carcinoma are rare, but peritoneal dissemination from gastrointestinal tract and ovarian carcinomas are common. In the past these carcinomatosis were regarded as terminal and the patients were only treated with palliative measures. Over the last 30 years however, novel more aggressive treatment strategies that combine cytoreductive surgery with intraperitoneal (IP) chemotherapy were explored. Hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative IP chemotherapy emerged as the most commonly used IP adjuvant therapies. Theoretically cytoreductive therapy treats the macroscopic disease, and intraperitoneal chemotherapy (IP) treats the microscopic disease and the residual or free tumor cells left in the peritoneal cavity after surgery, in order to prevent and control peritoneal dissemination. IP chemotherapy is based on the principle that a high concentration of chemotherapy within the abdominal cavity will kill the tumor cells on the surface with less diffusion into the tissues and less toxicity. Hyperthermia with IP chemotherapy optimizes the process as heat has direct cytotoxic effects on cancer cells and increases the cytotoxicity and penetration of certain cytotoxic drugs. Hyperthermia is also believed to modulate the cells of the innate and adaptive immune system, thereby improving effectiveness (Shen 2009, Glehen 2010, Mizumoto 2012, Sun 2012, MI 2013).

### **Medical Technology Assessment Committee (MTAC)**

#### ***Intraperitoneal Hyperthermic Chemotherapy (IPHC)***

##### **04/02/2007: MTAC REVIEW**

**Evidence Conclusion:** *Prevention of peritoneal carcinomatosis* Two randomized controlled trials from Japan, conducted among patients who underwent surgery for T2-T4 gastric carcinoma with serosal involvement, found a significant benefit from including HIPEC treatment. The study with the stronger methodology (Yonemura et al., 2001) found a higher estimated 5-year survival in the group receiving cytoreduction and HIPEC (61%), compared to two other groups (cytoreduction and normothermic intraperitoneal chemotherapy, 44%; and surgery alone 42%). The other RCT (Fujimoto et al., 1999) had poorly described methodology, and also found a significantly higher estimated survival rate in a group receiving cytoreduction plus HIPEC compared to surgery alone. The first study had a minimum of 2.4 years of follow-up; length of follow-up was not reported in the Fujimoto study. Findings from studies on Japanese gastric cancer may not be generalizable to the United States. *Treatment of peritoneal carcinomatosis* There is evidence from one reasonably valid randomized controlled trial that HIPEC is beneficial as a treatment for peritoneal carcinomatosis (Verwaal et al., 2003). The study, which included 105 patients with histologically proven peritoneal metastases of colorectal adenocarcinoma, compared an experimental treatment (cytoreduction and HIPEC, plus adjuvant chemotherapy) to standard treatment (outpatient chemotherapy, surgery only if necessary). After a median follow-up of 22 months, the survival rate was

significantly higher in the experimental treatment group (56% vs. 39%). Sub-group analyses suggest that survival was lower in patients with extensive residual disease or involvement of more than 5 regions of the abdominal cavity. A case series by the same research group found an estimated one-year survival of 75% and three-year survival of 28% with the experimental treatment. There were no long-term survival data for the standard treatment group. The evidence base would be strengthened with additional comparative studies.

**Articles:** *Prevention of peritoneal carcinomatosis* Three RCTs were identified: all were conducted by Japanese investigators. The two trials with the larger sample sizes (n=139 and n=141) were critically appraised. The third study was smaller (n=82) and had limitations including a non-significant finding with no discussion of statistical power. *Citations for the reviewed studies are as follows:* Yonemura Y, deAretxabala X, Fukimura T et al. Intraoperative chemohyperthermic peritoneal perfusion as a adjuvant to gastric cancer: Final results of a randomized controlled study. *Hepato-Gastroenterology* 2001; 48: 1776-1782. See [Evidence Table](#). Fujimoto S, Takahashi M, Mutou T et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. *Cancer* 1999; 85: 529-534. See [Evidence Table](#). *Treatment of peritoneal carcinomatosis:*

One RCT from the Netherlands was identified and critically appraised (Verwaal et al., 2003). There have also been a number of case series, most had sample sizes under 100. The largest case series was a multicenter study by Glehen et al., 2004 and included 506 patients. This study was limited in that it combined data from different centers that had different protocols and patient populations. All of the centers used perioperative intraperitoneal chemotherapy, but it appears that not all used hyperthermic treatment. As a result, the Glehen article was excluded from further review. The next largest case series available in English was by Verwaal et al., 2005. This article reported long-term follow-up on 117 patients, 48 of whom were included in the 2003 RCT, and was critically appraised. *The two studies reviewed were as follows:* Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003; 21: 3737-3743. See [Evidence Table](#). Verwaal VJ, van Ruth S, Witkamp A et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. *Ann Surg Oncol* 2005; 12: 65-71. See [Evidence Table](#)

The use of intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Intraperitoneal Hyperthermic Chemotherapy (IPHC)***

#### **10/16/2012: MTAC REVIEW**

**Evidence Conclusion:** Verwaal and colleagues (2003, 2008) conducted a randomized controlled trial in one center in the Netherlands to compare the efficacy of cytoreductive surgery (CRS) and HIPEC versus systemic chemotherapy and surgery in the management of peritoneal carcinomatosis of colorectal origin. The study randomized 105 patients younger than 71 years of age, with peritoneal metastases of CRC to undergo CRS in combination with hyperthermic intraperitoneal therapy (HIPEC) or systemic chemotherapy and surgery. The authors published the results after a median of 21.6 months, and later after an extended follow-up of 91 month. The initial results of the trial showed a significantly higher median survival of the patients treated with CRS and HIPEC vs. standard therapy (22.3 months and 12.6 months respectively). After 8-years of follow-up, 9 patients were still alive. This long-term follow-up showed a median progression-free survival of 12.6 months in the CRS and HIPEC group and 7.7 months in the standard therapy group. Subgroup analyses of the results showed that patients with 6-7 regions had a very poor survival (median 5.4 months) compared to those with 0-5 regions (median >29 months), and that survival was significantly higher with success of surgical procedure i.e. complete cytoreduction. The trial had generally valid methodology; it was randomized and controlled. However, it was conducted over a decade ago and significant progress in chemotherapy has been accomplished since then. The systemic therapy with 5-FU and leucovorin used in the control group is outdated, and mitomycin-C, the HIPEC drug used in the experimental group is not the most effective drug for used for CRC. In addition, the experimental group underwent both cytoreduction and HIPEC and it is difficult to determine whether the survival benefit was due to one of the two treatment modalities or their combination, and whether heating of the chemotherapy had an additive effect to the IP therapy.

**Articles:** The search revealed one meta-analysis, one randomized controlled trial with long-term follow-up, and a number of observational studies with or without comparison groups. The randomized trial was selected for critical appraisal. The meta-analysis pooled the results of that RCT together with a retrospective study and was not critically reviewed. Verwaal VJ, van Ruth S, de Bree E, et al Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003;21:3737-3743 See [Evidence Table](#). Verwaal VJ, Bruin S, Boot H, et al 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. *Ann Surg Oncol*.2008; 15:2426-2432 See [Evidence Table](#).

The use of intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of peritoneal carcinomatosis does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

### ***Intraperitoneal Hyperthermic Chemotherapy (IPHC)***

#### **02/11/2013: MTAC REVIEW**

**Evidence Conclusion:** There is insufficient published evidence to determine the efficacy and safety of hyperthermic intraperitoneal chemotherapy for the treatment of patients with ovarian cancer whether as an initial therapy, consolidation therapy, or for the treatment of a persistent or recurrent disease. The published studies on HIPEC for ovarian cancer are all prospective or retrospective case series. The studies included heterogeneous groups of women of different ages, different disease characteristics, stages, and tumor load, previous use of systemic chemotherapy regimens, chemo resistance, and with different indications for HIPEC therapy (primary, consolidation, persistent, or recurrent disease after initial therapy). In addition, the published studies recruited patients over long periods of time and used different HIPEC protocols and chemotherapeutic regimens some of which were outdated by the time the studies were completed and their results published. In a small observational study, Spiliotis and colleagues (2011, evidence table 1) compared survival benefit of HIPEC for ovarian cancer among two case series: one with 24 patients treated with CRS followed by HIPEC and systemic chemotherapy, and the other with 24 were treated with CRS and systemic chemotherapy alone without HIPEC for various reasons not explained by the authors. The results of the study show that the median survival was significantly higher for those who received HIPEC vs. those who did not (19.4 months vs. 11.2 months). The 1-year and 3-year survival rates were also significantly higher among patients treated with HIPEC. Within each of the two groups survival outcomes were better among patients with less extensive peritoneal disease and more complete cytoreduction. Due to the study design, the potential selection bias and confounding, it is difficult to determine whether improved survival was due to HIPEC, successful cytoreduction, or other confounding factors. An earlier observational study (Gori et al, 2005) compared the outcomes of a second look surgery and HIPEC (4-8 weeks after standard CRS and systemic chemotherapy) in 29 patients, to the outcomes for 19 patients who refused the second look and HIPEC. All patients had stage III ovarian cancer and had undergone a primary complete or optimal cytoreductive surgery (residual lesion <2cm) and 6 cycles of systemic chemotherapy. After a median follow-up of 73 months (range 24-134 months) the results showed a higher but statistically insignificant median survival patients treated with HIPEC vs. those who refused to undergo the treatment. The results of a larger retrospective case series with a historical comparison group (Ryu et al 2004, evidence table 2) show that HIPEC may be associated with better disease response and survival in patients with ovarian cancer. However, these results must be interpreted cautiously due to the limitations of the study including but not limited to potential selection bias, confounding, and other inherent limitations of case series and the use of retrospective data. Conclusion: Overall the results of the published observational studies suggest, but do not provide sufficient evidence to conclude, that HIPEC is feasible and may improve survival in women with advanced ovarian cancer. Due to the inherent limitations of the observational studies, it is hard to ascertain the extent at which the reported survival benefit resulted from selection bias, and whether it was due to the intraoperative intraperitoneal therapy, the hyperthermia, the aggressive cytoreduction therapy, the systemic chemotherapy regimens used, or other confounding factors. It is also difficult to determine whether complications occurring after major cytoreduction surgery and HIPEC were due to the surgery itself or the HIPEC. Only well conducted, adequately powered, randomized controlled trials with long-term follow-up may determine the net clinical benefit of incorporating HIPEC in the management of patients with ovarian cancer. Currently, at least three randomized controlled trials are ongoing to investigate the efficacy and safety of adding HIPEC to primary or secondary cytoreductive surgery in women with stage III or relapsing ovarian cancer. Among these trials are the OVIHIPEC trial in the Netherlands, the CHIPOR trial in France, and the HORSE trial in Italy. Their results may answer many questions about the role of HIPEC in treating ovarian cancers, its indications, efficacy, morbidity, and net clinical benefits.

**Articles:** The literature search did not reveal any randomized controlled trial that compared the efficacy of HIPEC to standard therapy for treatment of women with ovarian cancer. The published studies were mainly prospective or retrospective observational studies. The search identified one retrospective review and three case series that compared the outcomes of patients undergoing HIPEC to those who refused to undergo the procedure or did not receive the HIPEC therapy for various other reasons.

Two case series that compared the outcomes of patients who received HIPEC to those of patients who did not were selected for critical appraisal. Spiliotis J, Vaxevanidou A, Sergouniotis F et al. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J Buon 2011; 16:74-75. See [Evidence Table](#). Ryu KS, Kim JH, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004; 94:325–332. See [Evidence Table](#).

The use of intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of ovarian cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

**Intraperitoneal Hyperthermic Chemotherapy (IPHC)****08/19/2013: MTAC REVIEW**

**Evidence Conclusion:** The current review focuses on the safety and efficacy of HIPEC therapy for non-ovarian, non-colorectal cancers with serosal invasion or peritoneal carcinomatosis. Perioperative HIPEC in combination with cytoreductive surgery was evaluated in small, randomized controlled trials and a number of meta-analyses for patients with gastric cancer. The search did not identify any RCTs or large prospective studies that evaluated HIPEC for the treatment of peritoneal mesothelioma, pseudomyxoma peritonei, or for peritoneal carcinomatosis secondary to urinary bladder cancer, or uterine leiomyosarcoma. *HIPEC for Gastric cancer:* Mi DH and colleagues' meta-analysis (2013) pooled the results of 16 trials that examined the effectiveness and safety of radical surgery (RS) combined with HIPEC vs. RS without HIPEC in 1,906 patients with histologically diagnosed, primary, locally advanced gastric cancer with macroscopic serosal invasion, but with no peritoneal or distant metastases. The primary outcome of the analysis was overall survival. The pooled results indicate that compared with surgery alone, the combination of surgery with HIPEC was associated with a significant improvement in survival rate at 1, 2, 3, 5 and 9 years. It was also associated with a significant reduction in recurrence rates at 2, 3, and 5 years. There was however, a significantly higher incidence of abdominal pain with HIPEC. The rates of other adverse events were too small to show a significant difference. Sun and colleagues' meta-analysis (2012) also examined the effectiveness and safety of gastrectomy combined with HIPEC versus gastrectomy alone in patients with advanced gastric cancer with serosal invasion but without distant metastases or peritoneal carcinomatosis. The analysis included 10 trials with a total of 1,062 patients. The primary outcome was overall survival defined as the time from treatment to the last follow-up or death. Similar to Mi et al's analysis, the pooled results indicate that surgery combined with HIPEC may improve the overall survival for patients and prevent peritoneal local recurrence. There pooled results do not show a significantly higher risk of complications associated with HIPEC, but again the numbers were too small to provide sufficient statistical power. The two meta-analyses had had generally valid methodology and analysis. However, they had only 5 trials in common despite almost similar literature search dates. The trials included were small, all were conducted in Asia, and many were performed in the late 1980s and early 1990s and the procedures used may be currently outdated. In addition, there was no standardized agent or dose used for HIPEC; different chemotherapeutic agents were used among the trials and at different doses. The most commonly used agents in the trials were mitomycin C and cisplatin given alone, in combination together, or in combination with other agents. A small phase III RCT (Yang et al, 2011) conducted in Japan, evaluated the efficacy and safety of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal therapy (HIPEC using mitomycin C and cisplatin) for the treatment peritoneal carcinomatosis (PC) from gastric cancer. The study randomized 68 participants to receive CRS combined with open HIPEC or CRS alone. The primary outcome was overall survival. After a median follow-up of 32 months (range 7.5-83.5 months), the results showed that patients in the CRS and HIPEC had significantly better overall survival compared to those who underwent CRS with no HIPEC. The numbers of serious adverse events were higher in the HIPEC group but were too small to allow any conclusion. *HIPEC for diffuse malignant peritoneal mesothelioma (DMPM):* Baratti and colleagues (2009) analyzed data from a prospective database for 70 patients with DMPM who were treated with cytoreduction surgery and HIPEC by the same surgical team from 1996 to 2008 at a cancer institute in Italy. Disease progression was the primary outcome of the study. This occurred among 38 (54.28%) of the participants after a median follow-up of 43 months. The median time to disease progression (TTP) among these patients was 9 months and the median survival from progression was 8 months. Failure pattern was categorized as peritoneal progression, which occurred among 31 (81.58%) patients, liver metastasis in one patient, abdominal lymph node involvement in 2, and pleural seeding in 4 patients. Residual tumor  $\leq 2.2$  mm was the only independent risk factor for disease progression. Progressive disease was treated with second HIPEC in 3 patients, debulking in 4, systemic chemotherapy in 16, and supportive care in 15. A multivariate analysis showed that time to progression  $< 9$  months, poor performance status, and supportive care correlated to reduced survival from progression. These results should be interpreted with caution as the study was small, observational, conducted in a single center, and had no comparison or control group. *HIPEC for Pseudomyxoma peritonei (PMP)* In a retrospective study, Chua and colleagues (2012) reported on the outcome of nearly 2,300 patients from 16 institutions worldwide that were treated with cytoreductive surgery (CRS) and HIPEC over an 18-years period for pseudomyxoma peritonei (PMP) that arose from the appendix. The study was based on data from the Peritoneal Surface Oncology Group International registry. The median survival was 16.3 years, and the median progression-free survival was 8.2 years, with 10-year survival rate of 63% and a 15-year survival rate of 59%. The postoperative mortality rate after cytoreductive surgery and HIPEC was low (2%), but 24% of patients experienced major complications and 10% of patients required surgery for their complications. Data on quality of life were not provided. A multivariate analysis indicated that prior chemotherapy treatment, peritoneal mucinous carcinomatosis (PMCA) histopathological subtype, major postoperative complications, high peritoneal cancer index, and debulking surgery were independent predictors for a poorer progression-free survival. Use of HIPEC was associated with a favorable progression-free survival. Older age, major postoperative complications, debulking surgery, prior chemotherapy treatment, and PMCA histopathological subtype were independent predictors of a poorer overall survival. Elias and colleagues (2010) also conducted a retrospective



analysis of data from a registry with 301 patients with PMP treated with CRS and HIPEC between 1993 and 2007 in 18 French speaking centers in Europe and Canada. The mean follow-up was 88 months, the 5-year and 10-year overall survival rates were 73% and 54.8% respectively. The 5-year disease-free survival was 56%. 4.4 % of the patients died postoperatively, 40% had a grade 3-4 complication. 17.5% of all patients required a re-operation due to complications. These results of these retrospective analyses should be interpreted with caution due to the methodological limitations of retrospective studies, and lack of control groups. Conclusion: There is some evidence from small RCTs conducted in Asia, and meta-analyses pooling their results that cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy may improve the overall survival in patients with advanced gastric cancer without macroscopic peritoneal carcinomatosis or distant metastases. There is insufficient evidence to determine the subgroup of patients with gastric cancer who would benefit most from HIPEC as the effectiveness of HIPEC may depend on size and depth of micrometastases. There is insufficient evidence to determine the optimal regimen for HIPEC. There is insufficient evidence to determine the efficacy of HIPEC in patients with peritoneal carcinomatosis from gastric cancer. There is insufficient evidence to determine the safety of HIPEC or its effect on the quality of life in patients with gastric cancer with or without dissemination to the peritoneum. There is insufficient evidence to determine the safety and efficacy of HIPEC for the treatment of other peritoneal malignancies, whether of a primary origin or peritoneal carcinomatosis secondary to cancer in other organs within the peritoneal cavity.

**Articles:** The literature search for studies on the efficacy and safety of HIPEC in patients with pseudomyxoma peritonei, GI cancers (other than colorectal cancer) identified two recent meta-analyses of RCTs, two older ones, and a phase III RCT on HIPEC for patients with gastric cancer. The search did not reveal any RCTs that evaluated HIPEC for primary peritoneal malignancies, or other peritoneal disseminations from other cancers evaluated in this review. The published studies were mainly small prospective or retrospective case series with no comparison or control groups. The two more recent meta-analyses and the RCT that evaluated the efficacy and safety of HIPEC for gastric carcinoma were selected for critical appraisal.

Mi DH, Li Z, Yang KH, et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomized controlled trials. *Int J Hyperthermia*. 2013; 29:156-167. [See Evidence Table](#). Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. *BMC Cancer*. 2012; 12:526. [See Evidence Table](#). Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. *Ann Surg Oncol*. 2011; 18:1575-1581. [See Evidence Table](#).

The use of intraperitoneal hyperthermic chemotherapy (IPHC) in the treatment of Gastric, DMPM, and PMP cancer does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

**Medicare** – Considered not medically necessary for use of hyperthermia with chemotherapy

**Non-Medicare** - Considered Medically Necessary when criteria in the applicable policy statements listed above are met:

CPT® or HCPC Codes	Description
77605	Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm)
96547	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)
96548	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)
96547	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)
96548	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
04/19/2007	04/02/2007, 04/16/2007 <sup>MDCRPC</sup> , (reinitiated policy document) 11/06/2012 <sup>MDCRPC</sup> , 03/05/2013 <sup>MDCRPC</sup> , 10/01/2013 <sup>MPC</sup> , 01/07/2014 <sup>MPC</sup> , 11/04/2014 <sup>MPC</sup> , 09/01/2015 <sup>MPC</sup> , 07/05/2016 <sup>MPC</sup> , 05/02/2017 <sup>MPC</sup> , 03/06/2018 <sup>MPC</sup> , 03/05/2019 <sup>MPC</sup> , 03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup>	08/09/2024

<sup>MDCRPC</sup> Medical Director Clinical Review and Policy Committee

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
08/02/2016	Removed the diagnosis, Pseudomyxoma Peritonei (PMP), from the non-covered list
05/22/2020	Added CPT codes 77600, 77610, 77615, 77620 and removed 96446.
03/01/2022	Added ovarian cancer to the list of medically necessary diagnoses.
04/25/2024	Updated applicable codes 96547 and 96548 effective 1/1/2024. Removed codes 77600, 77610, 77615, 77620.
08/09/2024	Added new CPT codes, effective 1/1/2024





## Kaiser Foundation Health Plan of Washington

### Clinical Review Criteria

### Intense Pulsed Light (IPL) for Meibomian Gland Dysfunction

**NOTICE:** Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. (Kaiser Permanente) provide these Clinical Review Criteria for internal use by their members and health care providers. The Clinical Review Criteria only apply to Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington Options, Inc. Use of the Clinical Review Criteria or any Kaiser Permanente entity name, logo, trade name, trademark, or service mark for marketing or publicity purposes, including on any website, or in any press release or promotional material, is strictly prohibited.

Kaiser Permanente Clinical Review Criteria are developed to assist in administering plan benefits. These criteria neither offer medical advice nor guarantee coverage. Kaiser Permanente reserves the exclusive right to modify, revoke, suspend or change any or all of these Clinical Review Criteria, at Kaiser Permanente's sole discretion, at any time, with or without notice. **Member contracts differ in health plan benefits. Always consult the patient's Evidence of Coverage or call Kaiser Permanente Member Services at 1-888-901-4636 (TTY 711), Monday through Friday, 8 a.m. to 5 p.m. to determine coverage for a specific medical service.**

### Criteria

#### For Medicare Members

Source	Policy
CMS Coverage Manuals	None
National Coverage Determinations (NCD)	None
Local Coverage Determinations (LCD)	None
Local Coverage Article	None
Kaiser Permanente Medical Policy	Due to the absence of a NCD, LCD, or other coverage guidance, Kaiser Permanente has chosen to use their own Clinical Review Criteria, <b>Intense Pulsed Light (IPL) for Meibomian Gland Dysfunction</b> , for medical necessity determinations. Use the Non-Medicare criteria below.

#### For Non-Medicare Members

There is insufficient evidence in the published medical literature to show that this service/therapy is as safe as standard services/therapies and/or provides better long-term outcomes than current standard services/therapies.

#### If requesting review for this service, please send the following documentation:

- Last 6 months of clinical notes from requesting provider &/or specialist

The following information was used in the development of this document and is provided as background only. It is provided for historical purposes and does not necessarily reflect the most current published literature. When significant new articles are published that impact treatment option, Kaiser Permanente will review as needed. This information is not to be used as coverage criteria. Please only refer to the criteria listed above for coverage determinations.

### Background

Meibomian glands are located in the eyelids and secrete lipids into the surface of the eye. These lipids prevent the tears from evaporating rapidly. Meibomian gland dysfunction (MGD) is an abnormality or obstruction of meibomian glands leading to evaporation of the tears which in turn results in dry eye. Increased evaporative loss results in tear film instability, hyperosmolarity and lacrimal system inflammation (<https://www.uptodate.com/contents/dry-eye-disease>).

Meibomian gland dysfunction affects 70% of the population in some parts of the world (Craig, Chen, & Turnbull, 2015). Risk factors include age (the risk of MGD increases with age), ethnicity (Asians have high risk of MGD), eye makeup, contact lenses. The pathophysiology of MGD is multifactorial; it includes inflammation, bacterial overgrowth, abnormal blood vessel growth around the meibomian gland, and abnormal meibum production (Sabetti, Kheirkhah, Yin, & Dana, 2019).

Clinical symptoms include dryness, red eyes, general irritation, gritty sensation, burning, paradoxical excessive tearing, and decreased visual acuity (<https://www.uptodate.com/contents/dry-eye-disease>).

Treatment of MGD includes artificial tears, heat application, manual gland expression, warm compresses, lubricants with fatty acids, omega-3 supplementation, topical antibiotics, oral antibiotics, corticosteroids, or topical cyclosporine (Craig et al., 2015; Dell, Gaster, Barbarino, & Cunningham, 2017). However, these therapies come with adverse events, are temporarily effective and both physicians and patients are unsatisfied (Craig et al., 2015). IPL has garnered interest due to its concomitant effectiveness on ocular and dermatological manifestations in patients with rosacea. However, the mechanism by which this occurs is not well understood (Rennick & Adcock, 2018).

The most common indication for IPL has been skin disorders such as rosacea and acne. Regarding this treatment, the skin is exposed to the light with wavelengths from 500 to 1200 nm. The targeted tissue absorbed the light. This generates heat which destroys the lesions (Craig et al., 2015). In addition, the wavelengths stimulate melanin and hemoglobin in the skin causing coagulation and ablation of blood vessels ((Gao et al., 2019); Rennick & Adcock, 2018) and suppressing inflammation. IPL can also eliminate bacteria on treated zones of the skin. The theory is that IPL should improve MGD. There are several mechanisms by which IPL enhances MGD: heating, occlusion of abnormal blood vessels, liquefaction of meibum improving secretion and excretion, reduction in epithelial turnover, local photomodulation, activation of fibroblasts, enhancement of collagen synthesis, and destruction of Demodex mites (Sabeti et al., 2019).

The procedure starts with placement of shields over the eyes. This serves as protection from the light. A cooling gel is then applied to the area followed by administration of pulsed light around the eyelids. Manual gland expression is then performed, and normal oil flow is restored in the tear film. The procedure lasts approximately 20 minutes and is performed once a month for four months (<https://www.theeyeinstitute.com/dry-eye/intense-pulsed-light-ipl-treatment/>). Gao et al., 2019 (Gao et al., 2019) applied lidocaine cream for anesthesia for 30 minutes before placing the protective shield and administering IPL. Indications include rosacea, acne, MGD. Other indications include hypertrichosis, benign cavernous hemangiomas, benign venous malformations, telangiectasia, and pigmented lesions. It is also used in the cosmetic industry (Craig et al., 2015). IPL can only be used for patients whose skin is Fitzgerald type four or below (<https://www.reviewofophthalmology.com/article/intense-pulsed-light-for-treating-dry-eye>).

## Medical Technology Assessment Committee (MTAC)

### *Intense Pulsed Light (IPL) for the treatment of meibomian gland dysfunction (MGD)*

#### 01/13/2020: MTAC REVIEW

##### Evidence Conclusion:

The evidence consists of six small randomized controlled trials. One RCT compared intense pulsed light (IPL) to tobramycin/dexamethasone, three RCTs compared IPL plus meibomian gland expression to meibomian gland expression alone, and two other RCTs compared IPL vs sham. Statistically significant reduction of symptoms was found in each study. In addition, IPL appears to be safe as no serious adverse events were reported. However, the studies have small sample size, short follow-up, the risk of bias is not low, power calculations were not consistently provided. High-quality studies with large sample size and long-term follow-up are warranted. The findings are promising.

Overall, the evidence is not sufficient to draw overarching conclusions on the effectiveness and safety of intense pulsed light for the treatment of meibomian gland dysfunction.

**Articles:** PubMed search was conducted up to December 2, 2019 with the search terms (intense pulsed light OR intense-pulsed-light OR intense pulse light OR intense-pulse-light OR IPL) AND (dry eye OR DED OR meibomian OR MGD OR meibomian gland dysfunction). The search was limited to English language publications and human populations. The reference lists of relevant studies were reviewed to identify additional publications. Non-randomized controlled trials were excluded. Only randomized controlled trials were included in the review. The search yielded several articles. However, seven RCTs were retained and reviewed. See [Evidence Table](#).

The use of Intense Pulsed Light (IPL) for the treatment of meibomian gland dysfunction (MGD) does not meet the *Kaiser Permanente Medical Technology Assessment Criteria*.

## Applicable Codes

### Considered Not Medically Necessary:

CPT® Codes	Description
0207T	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral

<b>0507T</b>	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report
<b>0563T</b>	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral
<i>May be submitted with unlisted code 17999 and ICD-10 codes H02.88-H02.88B</i>	Unlisted procedure, skin, mucous membrane and subcutaneous tissue
	Meibomian gland dysfunction of eyelid

**\*Note:** Codes may not be all-inclusive. Deleted codes and codes not in effect at the time of service may not be covered.

**\*\*To verify authorization requirements for a specific code by plan type, please use the [Pre-authorization Code Check](#).**

CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Date Created	Date Reviewed	Date Last Revised
03/03/2020	03/03/2020 <sup>MPC</sup> , 03/02/2021 <sup>MPC</sup> , 03/01/2022 <sup>MPC</sup> , 03/07/2023 <sup>MPC</sup> , 03/12/2024 <sup>MPC</sup> , 03/04/2025 <sup>MPC</sup>	09/11/2020

<sup>MPC</sup> Medical Policy Committee

Revision History	Description
03/03/2020	MPC approved to endorse a non-coverage policy for IPL.
09/11/2020	Added CPT codes 0207T, 0507T, 0563T and 17999 w dx codes H02.88-H02.88B